<SEC-DOCUMENT>0001104659-24-008168.txt : 20240130
<SEC-HEADER>0001104659-24-008168.hdr.sgml : 20240130
<ACCEPTANCE-DATETIME>20240130151656
ACCESSION NUMBER:		0001104659-24-008168
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		63
FILED AS OF DATE:		20240130
DATE AS OF CHANGE:		20240130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evaxion Biotech A/S
		CENTRAL INDEX KEY:			0001828253
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			G7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276505
		FILM NUMBER:		24577750

	BUSINESS ADDRESS:	
		STREET 1:		DR NEERGAARDS VEJ 5F
		CITY:			HOERSHOLM
		STATE:			G7
		ZIP:			2970
		BUSINESS PHONE:		004531262615

	MAIL ADDRESS:	
		STREET 1:		DR NEERGAARDS VEJ 5F
		CITY:			HOERSHOLM
		STATE:			G7
		ZIP:			2970
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>tm2334005-3_f1a.htm
<DESCRIPTION>FORM F-1/A
<TEXT>
<html>
  <head>
    <title>tm2334005-3_f1a - block - 46.760398s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">

          <div style="text-align:center; width:541.31pt; line-height:10pt;font-weight:bold;">
            <font style="letter-spacing:-0.18pt;">As filed with the Securities and Exchange Commission on January 30, 2024</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
          </div>


          <div style="margin-top:1.2pt; text-align:right; width:541.31pt; line-height:9.5pt;font-weight:bold;font-size:8.5pt;">
            <font style="letter-spacing:-0.17pt;">Registration Statement No. 333-276505</font>&#8203;</div>

        <div style="margin-top:1.733pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 1.73333333333333pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:1.9pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 1.9pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3.4pt; text-align:center; width:541.31pt; line-height:15.5pt;font-weight:bold;font-size:15pt;">
          <font style="letter-spacing:-0.3pt;">UNITED STATES </font>
          <br >
          <font style="letter-spacing:-0.3pt;">SECURITIES AND EXCHANGE COMMISSION</font><font style="font-weight:normal;letter-spacing:0.3pt;"> </font>
        </div>
        <div style="margin-top:1.2pt; text-align:center; width:541.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">Washington, D.C. 20549</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:5.7pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 5.7pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="margin-top:4.4pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
            <font style="letter-spacing:-0.18pt;">Amendment No. 1</font>
            <br >
            <font style="letter-spacing:-0.18pt;">to</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
          </div>

        <div style="margin-top:3pt; text-align:center; width:541.31pt; line-height:16pt;font-weight:bold;font-size:15pt;">
          <font style="letter-spacing:-0.3pt;">FORM F-1</font><font style="font-weight:normal;letter-spacing:0.3pt;"> </font>
        </div>
        <div style="margin-top:1.2pt; text-align:center; width:541.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:5.7pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 5.69999999999999pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5.4pt; text-align:center; width:541.31pt; line-height:16pt;font-weight:bold;font-size:15pt;">
          <font style="letter-spacing:-0.3pt;">Evaxion Biotech A/S</font><font style="font-weight:normal;letter-spacing:0.3pt;"> </font>
        </div>
        <div style="margin-top:1.2pt; text-align:center; width:541.31pt; line-height:9pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Exact name of Registrant as specified in its charter) </font>
        </div>
        <div style="margin-top:5.4pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 5.40000000000001pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:541.31pt;margin-top:4.20000000000002pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
          <tr style="line-height:10.8pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;font-weight:bold;font-size:9pt;">
                <font style="letter-spacing:-0.18pt;">The Kingdom of Denmark</font>
              </div>
              <div style="margin-top:1.8pt; text-align:center; line-height:9pt;">
                <font style="letter-spacing:0.16pt;">(State or other jurisdiction of </font>
                <br >
                <font style="letter-spacing:0.16pt;">incorporation or organization)</font><font style="font-size:9pt;">&#8203;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;white-space:nowrap;">
              <div style="text-align:center; line-height:9.49pt;font-size:9pt;">
                <font style="letter-spacing:0.18pt;">&#8199;</font>
                <br >
                <font style="font-size:8pt;letter-spacing:0.16pt;">(Primary Standard Industrial </font>
                <br >
                <font style="font-size:8pt;letter-spacing:0.16pt;">Classification Code Number)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.43pt;">
              <div style="text-align:center;font-weight:bold;font-size:9pt;">
                <font style="letter-spacing:-0.18pt;">Not applicable</font>
              </div>
              <div style="margin-top:1.8pt; text-align:center; line-height:9pt;">
                <font style="letter-spacing:0.16pt;">(IRS Employer </font>
                <br >
                <font style="letter-spacing:0.16pt;">Identification Number)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.7pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">Dr.&#160;Neergaards Vej 5F </font>
          <br >
          <font style="letter-spacing:-0.18pt;">2970 H&#248;rsholm </font>
          <br >
          <font style="letter-spacing:-0.18pt;">Denmark </font>
          <br >
          <font style="letter-spacing:-0.18pt;">Telephone: +45 31 31 97 53</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:1.2pt; text-align:center; width:541.31pt; line-height:9pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font><font style="font-size:8.5pt;">&#8203;<font style="letter-spacing:0.17pt;"> </font></font>
        </div>
        <div style="margin-top:3pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">Christian Kanstrup </font>
          <br >
          <font style="letter-spacing:-0.18pt;">Chief Executive Officer </font>
          <br >
          <font style="letter-spacing:-0.18pt;">Evaxion Biotech A/S </font>
          <br >
          <font style="letter-spacing:-0.18pt;">Dr.&#160;Neergaards Vej 5F </font>
          <br >
          <font style="letter-spacing:-0.18pt;">2970 H&#248;rsholm </font>
          <br >
          <font style="letter-spacing:-0.18pt;">Denmark </font>
          <br >
          <font style="letter-spacing:-0.18pt;">Telephone: +45 31 31 97 53</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:1.2pt; text-align:center; width:541.31pt; line-height:9pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font><font style="font-size:8.5pt;">&#8203;<font style="letter-spacing:0.17pt;"> </font></font>
        </div>
        <div style="margin-top:5.4pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 5.39999999999998pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5.9pt; text-align:center; width:541.31pt; line-height:9.5pt;font-size:8.5pt;">
          <font style="letter-spacing:0.17pt;">Copy of all communications including communications sent to agent for service, should be sent to: </font>
        </div>

          <table style="width:541.31pt;margin-top:4.69999999999999pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; width:172.44pt;">
                <div style="text-align:center; line-height:10.78pt;">
                  <font style="letter-spacing:-0.18pt;">Dwight A. Kinsey</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">Michael D. Baird</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">Duane Morris LLP</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">230 Park Avenue</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">Suite 1130</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">New York, NY 10169</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">Telephone: (212) 818-9200</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; width:172.44pt;">
                <div style="text-align:center; line-height:10.78pt;">
                  <font style="letter-spacing:-0.18pt;">Lars L&#252;thjohan</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">Mazanti-Andersen</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">AdvokatPartnerselskab</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">Amaliegade 10</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">DK-1256 Copenhagen K</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">Denmark</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">Telephone: +45 3314 3536</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; width:172.43pt;">
                <div style="text-align:center; line-height:10.78pt;">
                  <font style="letter-spacing:-0.18pt;">John J. Hart</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">Ellenoff Grossman &amp; Schole LLP</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">1345 Avenue of the Americas</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">New York, NY 10105</font>
                  <br >
                  <font style="letter-spacing:-0.18pt;">Telephone: (212) 370-1300</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:8.52pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:40pt; margin-top:5.9pt; width:541.31pt; line-height:9.5pt;font-size:8.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.17pt;">Approximate date of commencement of proposed sale to the public:</font><font style="letter-spacing:0.17pt;"> As soon as practicable after this registration statement becomes effective. </font>
        </div>
        <div style="text-indent:20pt; margin-top:3.5pt; width:541.31pt; line-height:9pt;font-size:8.5pt;">
          <font style="letter-spacing:0.17pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933 (as amended, the &#8220;Securities Act&#8221;), check the following box. &#9746; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3.5pt; width:541.31pt; line-height:9pt;font-size:8.5pt;">
          <font style="letter-spacing:0.17pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3.5pt; width:541.31pt; line-height:9pt;font-size:8.5pt;">
          <font style="letter-spacing:0.17pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3.5pt; width:541.31pt; line-height:9.5pt;font-size:8.5pt;">
          <font style="letter-spacing:0.17pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="margin-left:20pt; margin-top:3.5pt; width:521.31pt; line-height:9.5pt;font-size:8.5pt;">
          <font style="letter-spacing:0.17pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act. </font>
        </div>
        <div style="margin-left:20pt; margin-top:3.5pt; width:521.31pt; line-height:9.5pt;font-size:8.5pt;">
          <font style="letter-spacing:0.17pt;">Emerging growth company &#9746; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3.5pt; width:541.31pt; line-height:9.5pt;font-size:8.5pt;">
          <font style="letter-spacing:0.17pt;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. &#9744; </font>
        </div>
        <div style="margin-top:9.333pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 9.33333333333337pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">&#8224;</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.18pt;">The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April&#160;5, 2012. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:6.3pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 6.29999999999995pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:541.31pt; line-height:9.5pt;font-weight:bold;font-size:8.5pt;">
          <font style="letter-spacing:-0.17pt;">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act, or until this registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a) may determine.</font><font style="font-weight:normal;letter-spacing:0.17pt;"> </font>
        </div>
        <div style="margin-top:3.833pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 3.83333333333337pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 2pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="position:relative;overflow-x:hidden;min-height:775.71pt;page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:738.83pt;left:24pt;height:30.02pt;width:706pt;transform-origin:0pt -0pt;transform:rotate(-90deg) translate(0%, 0%);">
        <div style="text-align:justify; width:706pt; line-height:9.5pt;font-weight:bold;color:#FC0014;font-family:Helvetica, Arial, sans-serif;font-size:8pt;">
          <font style="letter-spacing:-0.08pt;">The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</font><font style="color:#000000;letter-spacing:-0.08pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:63pt;width:505.31pt;">

          <div style="width:505.31pt; line-height:7.5pt;font-weight:bold;color:#FC0014;">
            <font style="letter-spacing:-0.14pt;">PRELIMINARY PROSPECTUS </font><font style="margin-left:109.46pt;letter-spacing:-0.14pt;">SUBJECT TO COMPLETION</font><font style="float:right;"><font style="letter-spacing:-0.14pt;"> DATED JANUARY 30, 2024</font><font style="font-weight:normal;color:#000000;letter-spacing:0.14pt;"> </font>
            </font>
          </div>


          <div style="margin-top:3pt; text-align:center; width:505.31pt; line-height:10pt;font-weight:bold;font-size:10pt;">
            <font style="letter-spacing:-0.2pt;">UP TO 2,032,520 AMERICAN DEPOSITARY SHARES REPRESENTING </font>
            <br >
            <font style="letter-spacing:-0.2pt;">20,325,200 ORDINARY SHARES</font>
            <br >
            <font style="letter-spacing:-0.2pt;">AND UP TO 2,032,520 PRE-FUNDED WARRANTS TO PURCHASE UP TO </font>
            <br >
            <font style="letter-spacing:-0.2pt;">2,032,520&#160;AMERICAN DEPOSITARY SHARES </font>
            <br >
            <font style="letter-spacing:-0.2pt;">AND UP TO 2,032,520 SERIES A WARRANTS TO PURCHASE UP TO</font> <br ><font style="letter-spacing:-0.2pt;">2,032,520&#160;AMERICAN DEPOSITARY SHARES</font><br ><font style="letter-spacing:-0.2pt;">AND PLACEMENT AGENT WARRANTS TO PURCHASE UP TO 101,626&#160;AMERICAN </font><br ><font style="letter-spacing:-0.2pt;">DEPOSITARY SHARES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font></div>


          <div style="margin-top:3pt; text-align:center; width:505.31pt; line-height:7pt;font-weight:bold;">
            <font style="letter-spacing:-0.14pt;">(and 2,032,520 American Depositary Shares representing 20,325,200 ordinary shares underlying the Pre-Funded Warrants and 2,032,520 American Depositary Shares representing 20,325,200 ordinary shares underlying the Series&#160;A Warrants and 101,626 American Depositary Shares representing 1,016,260 ordinary shares underlying the Placement Agent Warrants)</font><font style="font-weight:normal;letter-spacing:0.14pt;"> </font>
          </div>

        <div style="position:relative;margin-top:2.5pt; text-align:center; width:505.31pt;">
          <img src="lg_evaxionaiimmunology-bwlr.jpg" alt="[MISSING IMAGE: lg_evaxionaiimmunology-bwlr.jpg]" height="32" width="305" >
        </div>
        <div style="margin-top:5.3pt; text-align:center; width:505.31pt; line-height:12.5pt;font-weight:bold;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">Evaxion Biotech A/S</font><font style="font-weight:normal;letter-spacing:0.24pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:7pt;">
            <font style="letter-spacing:0.14pt;">We are offering up to 2,032,520 American Depositary Shares (&#8220;ADSs&#8221;) representing an aggregate of 20,325,200 ordinary shares, DKK 1 nominal value per share, together with Series&#160;A warrants to purchase up to 2,032,520 ADSs representing 20,325,200 ordinary shares (the &#8220;Warrants&#8221;). The ADSs and Warrants will be sold in a fixed combination, with each ADS accompanied by one Warrant to purchase one ADS. The ADSs and Warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. The assumed public offering price for each ADS and accompanying Warrant is $7.38, which is based upon the closing price of our ADSs on The Nasdaq Capital Market on January&#160;26, 2024. The Warrants will have an exercise price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and will be immediately exercisable for a term of five (5)&#160;years from the date of issuance. The recent market price used throughout this prospectus may not be indicative of the final offering price. The final public offering price will be determined through negotiation between us and investors based upon a number of factors, including our history and our prospects, the industry in which we operate, our past and present operating results, the previous experience of our executive officers and the general condition of the securities markets at the time of this offering. </font>
          </div>


          <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:7pt;">
            <font style="letter-spacing:0.14pt;">We are also offering to certain purchasers whose purchase of ADSs in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding ordinary shares, including ordinary shares represented by ADSs immediately, following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, pre-funded warrants, in lieu of ADSs that would otherwise result in such purchaser&#8217;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our ADSs. The public offering price of each pre-funded warrant will be equal to the price at which an ADS is sold to the public in this offering, minus an amount in US dollars equal to DKK 10 at the time of pricing of this offering, which amount is equal to $1.479 as of the date of the prospectus, and the exercise price of each pre-funded warrant will be $1.479 per ADS, provided that such exercise price shall not be less than the USD equivalent to DKK 10 at the time of exercise. The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. For each pre-funded warrant we sell, the number of ADSs we are offering will be decreased on a one-for-one basis. The ADSs and pre-funded warrants can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. This prospectus also relates to the ADSs issuable upon exercise of the Warrants and any pre-funded warrants sold in this offering. </font>
          </div>

        <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:7pt;">
          <font style="letter-spacing:0.14pt;">There is no established public trading market for the Warrants and pre-funded warrants, and we do not expect a market to develop. We do not intend to apply for listing of the Warrants and pre-funded warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the warrants will be limited. </font>
        </div>

          <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:7pt;">
            <font style="letter-spacing:0.14pt;">This offering will terminate on March&#160;1, 2024, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will have one closing for all the securities purchased in this offering. </font>
          </div>


          <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:7pt;">
            <font style="letter-spacing:0.14pt;">Our ADSs are listed on the Nasdaq Capital Market, or Nasdaq, under the symbol &#8220;EVAX&#8221;. On January&#160;26, 2024, the closing trading price for our ADSs, as reported on Nasdaq, was $7.38 per ADS. </font>
          </div>


          <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:7pt;">
            <font style="letter-spacing:0.14pt;">On January&#160;22, 2024, we effected a change to the ratio of our ADSs to our ordinary shares from one ADS representing one (1)&#160;ordinary share to one ADS representing ten (10) ordinary shares, or the ADS Ratio Change. Except as otherwise indicated, all information in this prospectus, including the number of ADSs being offered and the assumed offering price gives retroactive effect to the ADS Ratio Change. The assumed market price and number of securities to be sold used throughout this prospectus may not be indicative of the final offering price and number of securities to be sold in this offering. </font>
          </div>


          <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:7pt;">
            <font style="letter-spacing:0.14pt;">We have engaged H.C. Wainwright &amp; Co., LLC (the &#8220;Placement Agent&#8221;) to act as our exclusive Placement Agent in connection with this offering. The Placement Agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The Placement Agent is not purchasing or selling any of the securities we are offering and the Placement Agent is not required to arrange the purchase or sale of any specific number of securities or dollar amount. We have agreed to pay to the Placement Agent the Placement Agent Fees set forth in the table below, which assumes that we sell all of the securities offered by this prospectus. There is no arrangement for funds to be received in escrow, trust or similar arrangement. There is no minimum offering requirement as a condition of closing of this offering. Because there is no minimum offering amount required as a condition to closing this offering, we may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us. The investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue our business goals described in this prospectus. In addition, because there is no escrow account and no minimum offering amount, investors could be in a position where they have invested in our company, but we are unable to fulfill all of our contemplated objectives due to a lack of interest in this offering. Further, any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. We will bear all costs associated with the offering. See &#8220;Plan of Distribution&#8221; on page <a href="#tPOD">275</a> of this prospectus for more information regarding these arrangements. </font>
          </div>

        <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:7pt;font-weight:bold;">
          <font style="letter-spacing:-0.14pt;">We are a &#8220;foreign private issuer,&#8221; and an &#8220;emerging growth company&#8221; each as defined under the federal securities laws, and, as such, we are subject to reduced public company reporting requirements. See the section entitled &#8220;Prospectus Summary&#8201;&#8212;&#8201;Implications of Being an Emerging Growth Company and a Foreign Private Issuer&#8221; for additional information.</font><font style="font-weight:normal;letter-spacing:0.14pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:7pt;font-weight:bold;">
          <font style="letter-spacing:-0.14pt;">Investing in our securities involves a high degree of risk. Before buying any ADSs, you should carefully read the discussion of material risks of investing in the ADSs and the company. See &#8220;Risk Factor Summary&#8221; beginning on page <a href="#tRIFA">16</a> for a discussion of information that should be considered in connection with an investment in our securities.</font><font style="font-weight:normal;letter-spacing:0.14pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:7pt;font-weight:bold;">
          <font style="letter-spacing:-0.14pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.14pt;"> </font>
        </div>
        <table style="width:465.31pt;height:42.0400000000001pt;margin-left:20pt;margin-top:2.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
          <tr style="line-height:7.87pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.44pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.71pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:7.86pt;">
                <font style="letter-spacing:-0.14pt;">Per ADS and</font>
                <br >
                <font style="letter-spacing:-0.14pt;">Warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.71pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:7.86pt;">
                <font style="letter-spacing:-0.14pt;">Per Pre-Funded Warrant </font>
                <br >
                <font style="letter-spacing:-0.14pt;">and Warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.71pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.14pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.99000000000001pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:1.247pt 0pt 0.5pt 0pt; width:297.44pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.14pt;">Public offering price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.89pt;width:0pt;">&#8203;</td>
            <td style="padding:1.247pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.247pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:8.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.545pt;width:0pt;">&#8203;</td>
            <td style="padding:1.247pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.247pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:25.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.247pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.247pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.99000000000001pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:1.507pt 0pt 0.5pt 0pt; width:297.44pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.14pt;">Placement Agent Fees</font><font style=" position:relative; bottom:2.75pt;font-size:4.5pt;letter-spacing:0.11pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.89pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:8.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.545pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:25.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.99000000000001pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:1.507pt 0pt 0.5pt 0pt; width:297.44pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.14pt;">Proceeds to us (before expenses)</font><font style=" position:relative; bottom:2.75pt;font-size:4.5pt;letter-spacing:0.11pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.89pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:8.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.545pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:25.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6.3pt; width:505.31pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-top:3.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.14pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:3.4pt; margin-bottom:0pt; line-height:7.5pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.14pt;">We have agreed to pay the Placement Agent cash fee equal to 7.5% of the gross proceeds raised in this offering. We have also agreed to reimburse the Placement Agent for its non-accountable expenses in the amount of $35,000, for its legal fees and expenses and other out-of-pocket expenses in an amount up to $100,000 (plus an additional $50,000 for the fees and expenses of local legal counsel), and for its clearing expenses in the amount of $15,950. In addition, we have agreed to issue to the Placement Agent, warrants to purchase up to a number of our ADSs equal to 5.0% of the number of ADSs being offered, including the ADSs issuable upon exercise of any pre-funded warrants, at an exercise price equal to 135% of the public offering price per ADS and accompanying Warrant. See &#8220;Plan of Distribution&#8221; for additional information and a description of the compensation payable to the Placement&#160;Agent. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; line-height:7.5pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.14pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:7.5pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.14pt;">We estimate the total expenses of this offering payable by us, excluding the Placement Agent fee, will be approximately $0.8&#160;million. Because there is no minimum number of securities or amount of proceeds required as a condition to closing in this offering, the actual public offering amount, Placement Agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above. For more information, see &#8220;Plan of Distribution.&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:7.5pt;">
            <font style="letter-spacing:0.14pt;">We anticipate that delivery of the securities against payment will be made on or about &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2024, subject to satisfaction of customary closing conditions. </font>
          </div>


          <div style="margin-top:2pt; text-align:center; width:505.31pt; line-height:12.5pt;font-weight:bold;font-size:12pt;">
            <font style="letter-spacing:-0.24pt;">H.C. Wainwright &amp; Co.</font>
          </div>

        <div style="margin-top:2pt; text-align:center; width:505.31pt; line-height:7.5pt;">
          <font style="letter-spacing:0.14pt;">Prospectus dated, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199; 2024</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:370.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:422.72pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">PAGE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">ii</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF">iii</a></font> <a href="#tSNRF"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU"><font style="letter-spacing:0.2pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRSU">1</a></font> <a href="#tPRSU"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHOF"><font style="letter-spacing:0.2pt;">THE OFFERING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTHOF">12</a></font> <a href="#tTHOF"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSCFD"><font style="letter-spacing:0.2pt;">SUMMARY CONSOLIDATED FINANCIAL DATA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSCFD">14</a></font> <a href="#tSCFD"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">16</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIPO"><font style="letter-spacing:0.2pt;">DIVIDEND POLICY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDIPO">107</a></font> <a href="#tDIPO"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMIAO"><font style="letter-spacing:0.2pt;">MARKET, INDUSTRY AND OTHER DATA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMIAO">107</a></font> <a href="#tMIAO"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">107</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCAP"><font style="letter-spacing:0.2pt;">CAPITALIZATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCAP">109</a></font> <a href="#tCAP"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIL"><font style="letter-spacing:0.2pt;">DILUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDIL">111</a></font> <a href="#tDIL"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSFD"><font style="letter-spacing:0.2pt;">SELECTED FINANCIAL DATA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSFD">112</a></font> <a href="#tSFD"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:422.72pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tMDAA"><font style="letter-spacing:0.2pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMDAA">114</a></font> <a href="#tMDAA"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tBUOV"><font style="letter-spacing:0.2pt;">BUSINESS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tBUOV">137</a></font> <a href="#tBUOV"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMAN"><font style="letter-spacing:0.2pt;">MANAGEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMAN">217</a></font> <a href="#tMAN"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSHOW"><font style="letter-spacing:0.2pt;">SHARE OWNERSHIP </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSHOW">231</a></font> <a href="#tSHOW"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOSC"><font style="letter-spacing:0.2pt;">DESCRIPTION OF SHARE CAPITAL </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOSC">234</a></font> <a href="#tDOSC"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOAD"><font style="letter-spacing:0.2pt;">DESCRIPTION OF AMERICAN DEPOSITARY SHARES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOAD">251</a></font> <a href="#tDOAD"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMITC"><font style="letter-spacing:0.2pt;">MATERIAL INCOME TAX CONSIDERATIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMITC">259</a></font> <a href="#tMITC"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOSW"><font style="letter-spacing:0.2pt;">DESCRIPTION OF SECURITIES WE ARE OFFERING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOSW">270</a></font> <a href="#tDOSW"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">275</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEOTO"><font style="letter-spacing:0.2pt;">EXPENSES OF THE OFFERING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEOTO">277</a></font> <a href="#tEOTO"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">278</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">278</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">278</a></font>
            </td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the Placement Agent have authorized anyone to provide information different from that contained in this prospectus, any amendment or supplement to this prospectus or in any free writing prospectus prepared by us or on our behalf. Neither we nor the Placement Agent take any responsibility for, and can provide no assurance as to the reliability of, any information other than the information in this prospectus, any amendment or supplement to this prospectus, and any free writing prospectus prepared by us or on our behalf. Neither the delivery of this prospectus nor the sale of the ADSs means that information contained in this prospectus is correct after the date of this prospectus. This prospectus is not an offer to sell or the solicitation of an offer to buy the ADSs in any circumstances under which such offer or solicitation is unlawful. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should rely only on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to which we have referred you. We or the Placement Agent have not authorized anyone to provide you with information that is different. We and the Placement Agent are offering to sell the ADSs, and seeking offers to buy the ADSs, only in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of the ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For investors outside of the United States: Neither we nor the Placement Agent have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions relating to this offering and the distribution of this prospectus outside the United States.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless the context requires otherwise, in this prospectus Evaxion Biotech A/S and its subsidiaries (&#8220;Subsidiar(y/ies)&#8221;) shall collectively be referred to as &#8220;EVAX,&#8221;, &#8220;Evaxion&#8221;, &#8220;the Company,&#8221; &#8220;the Group&#8221;, &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; unless otherwise noted. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains our audited consolidated financial statements as of December&#160;31, 2022 and 2021 and for the&#160;years ended December&#160;31, 2022, 2021 and 2020 and the related notes, prepared in accordance with International Financial Reporting Standards or IFRS, as issued by the International Accounting Standards Board, or IASB and our unaudited condensed consolidated interim financial statements as of September&#160;30, 2023, and for the three and nine&#160;months ended September&#160;30, 2023 and 2022 and the related notes. The unaudited condensed consolidated interim financial statements of the Company are prepared in accordance with International Accounting Standard 34, &#8220;Interim Financial Reporting.&#8221; Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with IFRS have been condensed or omitted. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements as of and for the year ended December&#160;31, 2022. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">All references in this Prospectus to &#8220;$&#8221; mean U.S. dollars and all references to &#8220;DKK&#8221; mean Danish Kroner. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our financial information is presented in our presentation currency, U.S. Dollar, or USD. Our functional currency is the Danish Krone, or DKK. Certain Danish Krone amounts in this prospectus have been translated solely for convenience into USD at an assumed exchange rate of DKK 6.9722 per $1.00, which was the rounded official exchange rate of such currencies as of December&#160;31, 2022 for the&#160;years ended December&#160;31, 2020, 2021, and 2022. We used an assumed exchange rate of DKK 7.0390 per $1.00, which was the official rounded exchange rate of such currencies as of September&#160;30, 2023 for the unaudited interim periods ended September&#160;30, 2022 and 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Foreign currency transactions are translated into our functional currency, DKK, using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized as financial income or financial expenses in the consolidated statements of comprehensive loss. Non-monetary items in foreign currency, which are measured at cost at the consolidated statements of financial position date are translated into our functional currency, DKK, using the exchange rates at the date of the transaction. Such DKK translated amounts are not necessarily indicative of the amounts of DKK that could have actually been purchased with the underlying currency being exchanged into DKK at the dates indicated. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Assets and liabilities in our functional currency are translated to our presentation currency, USD, at the exchange rates applicable on December&#160;31, 2022 and September&#160;30, 2023 for the respective period. Income and expenses in our functional currency are translated to USD at the average exchange rate, which corresponds to an approximation of the exchange rates prevailing on each individual transaction date. Translation differences arising in the translation to presentation currency are recognized in other comprehensive income. Such USD amounts are not necessarily indicative of the amounts of USD that could actually have been purchased upon exchange of DKK at the dates indicated. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have made rounding adjustments to some of the figures contained in this prospectus. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On January&#160;22, 2024, we effected a change to the ratio of our ADSs to our ordinary shares from one ADS representing one (1)&#160;ordinary share to one ADS representing ten (10) ordinary shares, or the ADS Ratio Change. Except as otherwise indicated, all information in this prospectus gives retroactive effect to the ADS Ratio Change. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have made rounding adjustments to reach some of the figures included in this prospectus. As a result, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that precede them. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:108pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus includes statistical, market and industry data and forecasts which we obtained from publicly available information and independent industry publications and reports that we believe to be reliable sources. These publicly available industry publications and reports generally state that they obtain their information from sources that they believe to be reliable, but they do not guarantee the accuracy or completeness of the information. Although we believe that these sources are reliable, we have not independently verified the information contained in such publications. In addition, assumptions and estimates of our and our industry&#8217;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the &#8220;Risk Factor Summary&#8221;. These and other factors could cause our future performance to differ materially from our assumptions and estimates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Some of our trademarks and trade names are used in this prospectus, which are intellectual property owned by the Company. This prospectus also includes trademarks, trade names, and service marks that are the property of other organizations. Solely for convenience, our trademarks and trade names referred to in this prospectus appear without the </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">TM</font><font style="letter-spacing:0.2pt;"> symbol, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and trade names. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company discusses in this prospectus its business strategy, market opportunity, capital requirements, product introductions and development plans and the adequacy of the Company&#8217;s funding. Other statements contained in this prospectus, which are not historical facts, are also forward-looking statements. The Company has tried, wherever possible, to identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates&#8221; and other comparable terminology. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company cautions investors that any forward-looking statements presented in this prospectus, or that the Company may make orally or in writing from time to time, are based on the beliefs of, assumptions made by, and information currently available to, the Company. These statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties and factors that are beyond its control or ability to predict. Although the Company believes that its assumptions are reasonable, they are not a guarantee of future performance, and some will inevitably prove to be incorrect. As a result, its actual future results can be expected to differ from its expectations, and those differences may be material. Accordingly, investors should use caution in relying on forward-looking statements, which are based only on known results and trends at the time they are made, to anticipate future results or trends. Certain risks are discussed in this prospectus and also from time to time in the Company&#8217;s other filings with the Securities and Exchange Commission (&#8220;SEC&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and all subsequent written and oral forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. The Company does not undertake any obligation to release publicly any revisions to its forward-looking statements to reflect events or circumstances after the date of this prospectus. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In particular, you should consider the risks provided under &#8220;Risk factors&#8221; in this prospectus.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">iii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">The following summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all the information you should consider before investing in our securities. Before deciding to invest in the ADSs, you should read this entire prospectus carefully, including the sections titled &#8220;Risk Factors,&#8221; &#8220;Business&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes included elsewhere in this prospectus. Unless otherwise indicated, all share amounts and prices assume the consummation of the ADS Ratio Change, to be effected prior to the effectiveness of the registration statement of which this prospectus is a part.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform: AI-Immunology&#8482;. The AI-Immunology&#8482; platform consists of multiple proprietary and scalable AI prediction models harnessing the power of machine learning and artificial intelligence to decode the human immune system. This enables the development of novel vaccines for treatment of various cancers, bacterial and viral infections. We believe we are the first in the world to demonstrate a link between predictive power of Artificial Intelligence, or AI, and clinical response in patients as evidenced by a clear association between AI-Immunology&#8482; predictions and progression free survival in metastatic cancer patients. AI-Immunology&#8482; allows for fast and effective discovery, design and development of novel vaccines and offers a strong value proposition towards existing and potential pharma partners as the AI platform is preclinically and clinically validated, adaptable, scalable to other disease areas and, we believe, reduces development cost and risks significantly. Partnerships are a key element in our approach to realizing value of the opportunities AI-Immunology&#8482; caters for. Further, we have developed a clinical-stage oncology pipeline of novel personalized therapeutic vaccines and a pre-clinical prophylactic vaccine pipeline for bacterial and viral diseases with high unmet medical needs based on AI-Immunology&#8482; identified vaccine targets. Evaxion is committed to transforming patients&#8217; lives by providing innovative and targeted treatment options through AI-Immunology&#8482;. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">During 2023, our strategy was refined with stronger focus on value realization and execution. The core of our strategy is the AI-Immunology&#8482; platform, which has been continuously developed and improved over the past 15&#160;years. This has provided us with a pioneering and differentiated position within AI led target discovery as well as design and development of vaccine candidates. We are now well positioned for value realization via our three-pronged business model focusing on Targets, Pipeline and Responders. This value realization is to be pursued via a multi-partner approach. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The strategy refinement also means that Evaxion is shifting focus from larger scale clinical development towards a stronger and earlier focus on partnerships based upon the AI-Immunology&#8482; platform. The AI-Immunology&#8482; platform holds the potential for generating one new target every 24 hours, is delivery modality agnostic and easily adaptable to partner needs. The platform is currently trained in cancer and infectious diseases and is scalable to other therapeutic areas. The high throughput, combined with a very flexible model, offers a strong value proposition towards existing and future pharma partners. Developing partnerships with pharma is now an integrated part of our value creation strategy. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">AI-Immunology&#8482; contains five interrelated proprietary AI prediction models: (i)&#160;PIONEER&#8482;, our cancer neoantigen prediction model, (ii)&#160;ObsERV&#8482;, our endogenous retrovirus (ERV) tumor antigen prediction model, (iii)&#160;EDEN&#8482;, our B-cell antigen prediction model, (iv)&#160;RAVEN&#8482;, our T-cell antigen prediction model and (v)&#160;AI-DeeP&#8482; our responder prediction model. Common for all is that they build upon the same technology backbone as well as the strong Evaxion immunoinformatic capability base within machine learning, neural networks and artificial intelligence coupled with deep immunological insight. After having developed and matured our AI-Immunology&#8482; platform, we believe we are in a unique position to realize the value of the investments made and further to address significant unmet patient needs in collaboration with current and future partners. The potential of our AI-Immunology&#8482; platform is supported by the participation of MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">arm of Merck &amp; Co., Inc, Rahway NJ USA in our most recent private placement in December&#160;2023 as well as our vaccine target discovery collaboration with a leading pharmaceutical company. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The shift in strategy towards a much stronger focus on partnering based upon AI-Immunology&#8482; and reduced clinical trial activities significantly reduces our cash needs, both for the short- and the longer-term. The ambition for 2024 is to generate business development income equal to full year 2024 cash burn (excluding financing activities). </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The following figure summarizes our refined and focused strategy in a simple overview. </font>
          </div>
          <div style="position:relative;margin-top:9.7pt; text-align:center; width:456pt;">
            <img src="fc_fig06ourstarat-4c.jpg" alt="[MISSING IMAGE: fc_fig06ourstarat-4c.jpg]" height="335" width="608" >
          </div>
          <div style="margin-top:16.41pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Figure 1: The Evaxion strategy.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We have had encouraging progress on the refined strategy in the latter part of 2023. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Within the </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Target</font><font style="letter-spacing:0.2pt;"> part of the strategy, we in September&#160;2023 announced two partnerships. First, a partnership with a leading pharmaceutical company focused on vaccine target discovery for a bacterial pathogen with a high medical need, where no vaccine currently is available. The objective here is to deploy two of the AI-Immunology&#8482; prediction models, EDEN&#8482; and RAVEN&#8482;, for rapid design of a completely novel vaccine candidate capable of eliciting both a humoral (antibody) and cellular (T cell) immune response to the pathogen. Further, we announced a partnership with Afrigen Biologics to develop a novel mRNA vaccine against Gonorrhea. Both partnerships demonstrate the unique opportunities in our partnership focused strategy based upon AI-Immunology&#8482;. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Within the </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Pipeline</font><font style="letter-spacing:0.2pt;"> part of the strategy, the initial Phase&#160;2 data from the EVX-01 trial presented at the SITC annual meeting in November&#160;2023 was encouraging. The initial Phase&#160;2 data confirm the strong Phase&#160;1 findings presented earlier in 2023 at ASCO. It is worth highlighting a specific patient case: a metastatic melanoma patient with initial progressive disease presented with a significant and continuous tumor reduction after being administered with our AI-Immunology&#8482; designed EVX-01 personalized cancer vaccine. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Finally, within the </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Responder</font><font style="letter-spacing:0.2pt;"> part of our strategy we have obtained Proof of Principle for our Immune Checkpoint Inhibitor responder model as presented in November&#160;2023. Building on our core capabilities within immunological data, machine learning and predictions, we have set out on the journey of improving patient care and reducing the health care burden. The goal is to be able to predict which patients will respond to a given therapy. With Proof of Principle for our initial approach towards predicting Immune Checkpoint Inhibitor non-responders, we are now moving towards designing a commercial offering in a partnership-based approach. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Looking into 2024, we are anticipating several important milestones derived from our refined and focused strategy. Of particular importance are the following anticipated 2024 milestones: </font>
          </div>
          <div style="position:relative;margin-top:10.69pt; text-align:center; width:456pt;">
            <img src="tb_fig02milestones-4c.jpg" alt="[MISSING IMAGE: tb_fig02milestones-4c.jpg]" height="230" width="527" >
          </div>
          <div style="margin-top:14pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Figure 2: Anticipated 2024 milestones.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Looking ahead, we remain confident about our ability to generate value from our refocused strategy. We believe that our pioneering AI-Immunology&#8482; platform holds a unique and differentiated position compared to competing platforms. Effective AI-based vaccine discovery, validation and development require a multidisciplinary capability skillset around the AI platform as well as constant learning loops. We have built a very strong capability skillset around the AI-Immunology&#8482; platform focusing on key parts of the drug discovery and development value chain. As a result, we can quickly test vaccine candidates in pre-clinical models and efficiently progress them towards IND filling by using our capabilities within pre-clinical development, regulatory affairs, CMC and early-stage clinical trials. Further, applying continuous learning loops with the AI platform, we iteratively refine the precision of the platform by integrating learnings from experimental and clinical assessments of the predicted targets. This iterative process facilitates ongoing improvement and adjustment of the AI-Immunology&#8482; platform resulting in a new cycle of predictions and experimental assessments. Over the&#160;years, this approach has led to a mature and well-developed platform, where predictions demonstrate a distinctive correlation with both pre-clinical and clinical outcomes. </font>
          </div>
          <div style="position:relative;margin-top:10.79pt; text-align:center; width:456pt;">
            <img src="fc_fig03aiimmunolonew-4clr.jpg" alt="[MISSING IMAGE: fc_fig03aiimmunolonew-4clr.jpg]" height="308" width="547" >
          </div>
          <div style="margin-top:14pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Figure 3: The AI-Immunology&#8482; position</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Financial Update</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>

            <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
              <font style="letter-spacing:0.2pt;">Our cash and cash equivalents were $7.7&#160;million as of January&#160;29, 2024. This amount is unaudited and preliminary and is subject to completion of our financial closing procedures and is not necessarily indicative of any future period and should be read together with &#8220;Risk Factors,&#8221; &#8220;Cautionary Note Regarding Forward-Looking Statements,&#8221; and our financial statements and related notes contained in this prospectus. As a result, this amount may differ from the amount that will be reflected in our financial statements. Our financial statements for 2023 will not be available until after this offering is completed, and consequently will not be available to you prior to investing in this offering. </font>
            </div>

          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our AI-Immunology&#8482; platform</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our AI-Immunology&#8482; platform is the core of Evaxion. The platform has been developed and improved over the past 15&#160;years and consists of several AI prediction models. The AI-Immunology&#8482; platform holds following key features: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Vaccine target discovery, design and development of personalized and precision therapeutic cancer vaccine candidates </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Vaccine target discovery, design and development of prophylactic bacterial and viral vaccine candidates </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">AI prediction models trained in cancer and infectious diseases </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Potential for one new target every 24 hours </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Platform is delivery modality agnostic </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Unique predictive capabilities </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Adaptability to partner needs </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Scalable to other therapeutic areas </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The AI prediction models in AI-Immunology&#8482; each offer unique predictive capabilities in their respective areas and an overview can be seen below. </font>
          </div>
          <div style="position:relative;margin-top:9.51pt; text-align:center; width:456pt;">
            <img src="pc_fig04aiimmunolo-4c.jpg" alt="[MISSING IMAGE: pc_fig04aiimmunolo-4c.jpg]" height="287" width="474" >
          </div>
          <div style="margin-top:16pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Figure 4: The AI-Immunology&#8482; platform</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our PIONEER&#8482; Model</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">PIONEER&#8482; is our proprietary AI prediction model for the rapid discovery and design of patient-specific-neoantigens used to derive cancer vaccines. It has been shown that neoantigens, which arise from </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">patient-specific tumor mutations, play a critical role in T-cell mediated antitumor immune response. Neoantigens, being absent in normal tissues, are, we believe, ideal cancer vaccine targets because they distinguish themselves from germline proteins and can be recognized as non-self by the immune system. We believe our AI modules within PIONEER&#8482; enable us to efficiently identify and select those neoantigens that will generate a </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> T-cell response leading to significant antitumor effect in each patient. By combining these neoantigens with a purposefully selected delivery modality believed to further enhance this antitumor effect, we design and deliver our vaccines to patients, effectively training their immune systems to target and kill cancer cells with no or very limited adverse effects on healthy non-cancer cells. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our proprietary AI modules identifying neoantigens within PIONEER&#8482; have been trained using gradient-boosted decision trees, transformers and a conditional generative adversarial network approach on our internally generated data as well as other data, including, but not limited to, next generation sequencing data from tumor samples, mass spectrometry immunopeptidomics, peptide-MHC-binding affinity data, T-cell immunogenicity data and peptide-MHC-binding stability data. We have demonstrated that development and iterative training of our AI modules improves its predictive power in identifying and selecting therapeutic neoantigens. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The strong predictive capabilities of PIONEER&#8482; have been proven in a clinical trial setting, where we in the EVX-01 Phase&#160;1 trial demonstrated a clear link between quality of the predictions from PIONEER&#8482; and Progression Free Survival in metastatic melanoma patients. We believe that we are the first in the world to establish a link between AI prediction and clinical outcomes. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our ObsERV&#8482; Model</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">ObsERV&#8482; is our proprietary AI model for the discovery of patient-specific virus-derived sequences, so-called ERVs (endogenous retroviruses), expressed in cancer. Targeting this novel class of tumor antigens may allow for developing a completely new type of immunotherapy against immunologically cold tumors with low response rates to immunotherapy. ObsERV&#8482; can rapidly discover ERV tumor antigens and design personalized and precision vaccines containing these antigens. Our proprietary AI modules within ObsERV&#8482;, for the prediction of antigen-specific T-cell responses have been trained using transformers and a conditional generative adversarial network approach. This allows us to efficiently identify and select those ERV-antigens that we believe are most likely to generate a strong, </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> T-cell response leading to significant antitumor effect in each patient. The goal of our ObsERV&#8482; model derived cancer vaccines is to deliver therapeutic ERV-antigens to patients in a way that trains the patients&#8217; own immune system to target and kill tumor cells with no or very limited adverse effects on healthy non-cancer cells. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We have demonstrated that overexpression of ERVs is strongly associated with the overall survival of cancer patients. Hence, we believe such ERV-based therapies will induce a directed T-cell dependent immune response leading to tumor eradication. Our EVX-03 development candidate contains a combination of PIONEER predicted neoantigens and ObsERV&#8482; predicted ERV-antigens. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We believe that ObsERV&#8482; will allow us to develop therapeutic cancer vaccines benefitting a broader range of cancer patients for which no or limited treatment options exist. This includes providing novel treatment solutions for cancer patients that are unlike to respond to immunotherapy and cancer vaccines that targets neoantigens. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">At the ASH conference in December&#160;2023, we showcased a novel usage of ERVs for hematological cancers offering potential for a completely novel treatment paradigm. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our EDEN&#8482; Model</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">EDEN&#8482; is our proprietary AI prediction model that rapidly identifies novel, highly protective B-cell targets for use in pathogen-specific prophylactic vaccines against bacteria and virus, including antimicrobial resistant bacteria. Our proprietary algorithms in EDEN&#8482; allow us to predict and identify antigens that we believe will trigger a robust, protective immune response against almost any pathogen. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The core of our EDEN&#8482; model is a proprietary machine learning ensemble of artificial neural networks trained using a feed-forward backpropagation approach to interpret immunological-relevant information in relation to bacterial antigens that incur protection in a vaccine setting. EDEN&#8482; has been </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">trained on our own curated data set derived by trawling through publicly available patents and publications with reported truly protective and non-protective antigens tested in clinical and pre-clinical settings. The input to the artificial neural network ensemble is a feature transformation of the protein data set, in which several global and sequence-resolved properties are extracted. These structural and functional features have been selected for their relevance in protein chemistry, immunology and protein structure and their ability to guide the network in discriminating protective versus non-protective antigens. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We believe our approach can be used to target almost any pathogenic infection and rapidly enables the discovery and development of vaccine product candidates. We have applied EDEN&#8482; in seven bacteria pathogens to test its predictive power. For each pathogen, EDEN&#8482; identified novel vaccine antigens which were subsequently expressed as proteins and tested in pre-clinical, mouse infection models, demonstrating protection against all seven pathogens. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">EDEN&#8482; forms the basis for several pipeline compounds. EVX-B1, our novel vaccine product candidate for the prevention of </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;">, has now completed pre-clinical development and is ready for partnering. Currently, a study with a potential partner is ongoing under MTA, conclusion is expected in the first quarter of 2024. In continuation of this we are currently developing two pre-clinical bacterial vaccine programs; EVX-B2/EVX-B2-mRNA, targeting Neisseria gonorrhoeae, or N. gonorrhoeae infections, and EVX-B3, an undisclosed bacterial pathogen with a high medical need. The latter is in collaboration with a leading pharmaceutical company. In addition, EDEN&#8482; is applied to a virus vaccine against cytomegalovirus, or CMV, EVX-V1 which is being developed in collaboration with ExpreS2ion Biotechnologies AB. The EDEN&#8482; AI prediction model is already the basis for three existing partnerships, and we see great potential for further partnerships based upon the unique predictive capabilities of EDEN&#8482;. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our RAVEN&#8482; Model</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">RAVEN&#8482; is our AI model that rapidly identifies T-cell epitopes in pathogenic virus and bacteria for the use in prophylactic infectious disease vaccines. The RAVEN&#8482; model synergizes with EDEN&#8482; as RAVEN&#8482; identified T-cell antigens can be used either as a stand-alone or incorporated into known or novel EDEN&#8482; identified B-cell antigens. We believe that a vaccine comprising both RAVEN&#8482; and EDEN&#8482; identified antigens will elicit both an antibody and a T-cell response. This may result in highly efficacious and broadly protective vaccines through robust memory T-cell populations. The RAVEN&#8482; model is a transformer-based neural network, trained using a conditional generative adversarial network approach. The algorithm is adjustable and can be used to ensure the broadest possible response across human tissue types and entire virus species, or alternatively to target specific human populations with common tissue types and/or selected viral strains in outbreaks. In a study using 17 T-cell epitopes identified by RAVEN&#8482; across the SARS-CoV-2 genome, 15 epitopes (88%) induced T-cell activation and provided significant protection against lethal SARS-CoV-2 challenge in a mouse model. Moreover, T-cell epitope enrichment involving engraftment of CD4+ T-cell epitopes from hemagglutinin genetic information across numerous influenza species improved antibody response in pre-clinical studies. Hemagglutinin, a viral fusion protein like the spike protein in coronaviruses, plays a crucial role in cellular entry. Enrichment of hemagglutinin significantly enhanced antibody response, resulting in 5-10 times better neutralization compared to non-enriched hemagglutinin. These identified antigens can be administered by any established vaccine delivery technology such as protein, DNA or mRNA. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We have applied RAVEN in our current pre-clinical vaccine program; EVX-V1, targeting CMV and in our EVX-B3 bacteria vaccine development. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Our AI-DeeP</font><font style="letter-spacing:0.2pt;">&#8482; </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Model</font><font style="letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">AI-DeeP&#8482; is our proprietary AI model designed to predict if patients respond to cancer immunotherapies and is an instrumental part for the Responder part of our strategy. It utilizes immunogenomic expression profiles as well as neoantigen and ERV-antigen burden to differentiate between patients who could benefit from these therapies and those who may not. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Initially, the model&#8217;s effectiveness was highlighted through a clinical trial (EVX-01) where it successfully retrospectively predicted patient outcomes based on immunogenomic profiles from tumor biopsies. This prediction was statistically significant and shows promise in identifying patient response to immunotherapy. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Furthermore, AI-DeeP&#8482; was improved by incorporating additional features, including neoantigen and ERV-antigen burden, resulting AI-DeeP&#8482; outperforming classical biomarkers in identifying non-responding patients. It showcased the ability to pinpoint 10-30% of non-responsive cases with a precision of 95%, compared to 70-80% precision achieved by traditional biomarkers tumor mutational burden, or TMB and PD-L1 tumor expression. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">This AI model shows promise in reducing clinical development risks and enhancing benefits for patients and healthcare payers by stratifying patients based on their predicted likelihood to respond to immunotherapy. Hence, it holds great promise for improving outcomes and addressing the significant healthcare burden. Ongoing efforts aim to further refine and validate AI-DeeP&#8482; by accumulating more data, enhancing its sensitivity, and increasing predictive accuracy. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We presented Proof of Principle for our Responding model in November&#160;2023 at Biomarkers &amp; Precision Oncology Europe conference. We are looking forward to pursuing a potential commercial Responder offering via a partnership-based approach. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The immune system is generally considered nature&#8217;s strongest weapon to fight disease. When the immune system is engaged, people are often able to entirely eliminate a disease or infection from the body. Using our deep understanding of the human immune system and our proprietary AI-Immunology&#8482; technology, we can mimic the human immune system </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> and predict whether certain stimuli induce an immune response. Our predictive power relies on our ability to process and interpret vast amounts of immune-related data, a process known as computational immunology. Using our </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> AI models, we are able to transform such data into advanced algorithms that we believe can accurately predict cellular interactions within the immune system and identify the right vaccine targets that will stimulate a relevant response. To translate the identified targets into product candidates, we test multiple delivery modalities and move the most promising forward. We believe this process allows us to discover new product candidates and move them into the clinic without expending time and resources on clinical development of product candidates that may ultimately fail to produce a therapeutic or prophylactic response. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Based upon the AI-Immunology&#8482; platform we have established a broad pre-clinical and clinical pipeline within cancer and infectious diseases. Our pipeline candidates are a mix of proprietary and partnered programs. Please see the chart below for an overview of the current Evaxion pipeline. </font>
          </div>
          <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
            <img src="fc_fig05stagedevelop-4c.jpg" alt="[MISSING IMAGE: fc_fig05stagedevelop-4c.jpg]" height="234" width="530" >
          </div>
          <div style="margin-top:16.6pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Figure 5: The Evaxion pipeline.</font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Patent Portfolio and Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">To protect and maintain exclusivity to our products and AI-Immunology&#8482; platform, we have developed what we believe is a strong portfolio of patents and trade-secrets. Our strategy for protecting our AI-Immunology&#8482; platform is to pursue patent protection on some essential features while keep other </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">essential features as trade secrets. The strategy allows us to obtain patent protection on essential features and protect our technology against copying. We believe this strategy effectively protects our proprietary position and exclude competitors from utilizing our technology. In addition, we pursue patent protection for our pipeline products focusing on obtaining patent rights covering; composition of matter, methods, and use of same. We own twenty-seven (27) patent families; twenty-six (26) granted patents and seventy (70) patent applications. In generally our strategy is to file a priority document with the European Patent office (EPO) followed by a Patent Co-operation Treaty (PCT) application and subsequently national or regional filings, e.g. Unites States, Europe (EPO), Japan, China, Australia, and Canada. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We believe our AI-Immunology&#8482; platform is uniquely positioned for generating novel immune related products and vaccines by utilizing the existing platform or integrating novel functionality to the platform. We plan to continue to innovate and partner to develop novel groundbreaking products and maintain the position of AI-Immunology&#8482; as state-of-the art. We will continue to capture value of our innovation by patenting and trade-secrets following our strategy on intellectual property. These assets will continue to build and strengthen our position within AI, infectious disease, cancer vaccines and cancer treatment response predictions. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Management Team</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">To deliver on our objectives, we have built an experienced and broadly skilled management team. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our Chief Executive Officer, Christian Kanstrup joined us on September&#160;1, 2023. Christian Kanstrup has more than 25&#160;years of experience in the life science industry, coming from a position of Executive Vice President at Mediq before joining Evaxion. Prior to that, Christian held a broad range of senior management roles at Novo Nordisk A/S, latest as Senior Vice President and global head of Biopharm Operations, and previously held other senior leadership roles within commercial, strategy and corporate development roles. Christian also holds various board and advisory positions in the life science industry, advising on corporate strategy and company growth. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our Chief Science Officer Dr.&#160;Birgitte R&#248;n&#248; joined in 2017 and was appointed CSO in 2021. Dr.&#160;R&#248;n&#248; has more than 20&#160;years&#8217; experience in biopharmaceutical drug discovery from academia and industry and received her PhD in experimental oncology and immunology from National Institutes of Health, Bethesda, USA, and Copenhagen University Hospital, Denmark. Prior to joining Evaxion, Birgitte R&#248;n&#248; served as a specialist, team leader and project manager at Novo Nordisk A/S, where she was leading early drug discovery projects, evaluating in-licensing opportunities, and supporting drug development projects with pre-clinical and biomarker expertise. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Jesper Nyegaard Nissen joined as Chief Operating Officer in 2022 and was also appointed interim Chief Financial Officer in 2023. For over 25&#160;years, Jesper Nyegaard Nissen has worked broadly across the pharma value chain in global operations positions at Novo Nordisk anchored in research, development and finance. He has covered business areas across a variety of focus points, including finance operation, external innovation and collaborations, digitalization of business process optimization, development and shaping of organizational capacities, and implementation of performance and process improvement structures. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Andreas Holm Mattsson serves as Chief AI Officer at Evaxion Biotech, where he&#8217;s been at the forefront in silico-based vaccine target discovery. He has played a key role in developing Evaxion&#8217;s innovative AI-Immunology platform, a proprietary AI technology for identifying novel vaccine targets for cancer and infectious diseases. Andreas brings a strong educational background in bioinformatics from the Technical University of Denmark and has previously worked at Novo Nordisk. Since founding Evaxion in 2008, he has been an essential part of the company&#8217;s growth, serving in various executive roles. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Our Strengths</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Since our inception, we have applied our AI-Immunology&#8482; capabilities to transform complex biological data into tangible AI-Immunology&#8482; powered vaccines. We believe that we were one of the first companies to challenge status quo in drug discovery and development using AI technology. By building our capabilities, gathering data and developing our AI prediction models, we hold a pioneering position with our AI-Immunology&#8482; platform. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="margin-left:20pt; width:436pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our key strengths include:</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our flexible, scalable and adaptable AI-Immunology&#8482; platform offers a strong value proposition toward existing and potential partners </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our five AI models PIONEER&#8482;, ObsERV&#8482;, AI-DEEP&#8482;, EDEN&#8482; and RAVEN&#8482; ingrained in the AI-Immunology&#8482; platform, have allowed us to generate numerous pipeline candidates within both cancer and infectious diseases, all with first-in-class potential and with our first two oncology product candidates currently in clinical development </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our AI-Immunology&#8482; platform offers the potential to expand our partnerships and product candidate portfolio and allows for entering into additional therapy areas </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our AI-Immunology&#8482; platform facilitates the identification of novel effective vaccine targets, enhancing the potential for clinical success </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our in-house capabilities for experimental screening and testing of novel targets allow us to move rapidly from target identification to pre-clinical development </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our model for iterative training allows for continuous improvement of our AI-Immunology&#8482; platform as data are generated throughout the drug development stages </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We have established a direct link between the predictive power of our AI-Immunology&#8482; platform and preclinical and clinical outcome </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our existing collaborations are confirming the strength of our AI-Immunology&#8482; platform </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We have welcomed MSD GHI as a new shareholder substantiating pharma interest in our AI-Immunology&#8482; platform </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Associated with Our Business</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the section of this prospectus titled &#8220;Risk Factors&#8221; immediately following this prospectus summary. These risks include, but are not limited to, the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We are a clinical stage AI-Immunology company with only two product candidates in the early stages of clinical trials </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We have incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We will require substantial additional financing to achieve our goals which may not be available </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We will need to develop our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Pharmaceutical product development is inherently uncertain, and there is no guarantee that any of our product candidates will receive marketing approval </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">No vaccine has been approved using our technology, and none may ever be approved </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our product candidates may not work as intended, may cause undesirable side effects or may have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our business model is based upon partnering and there is no guarantee that we will be able to secure needed partnerships to be able to monetize our assets. Our future partners, if any, may not be able to obtain regulatory approval for products, if any, derived from our product candidates under applicable US, European and other international regulatory requirements </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We face significant competition in an environment of rapid technological and scientific change, and our failure to effectively compete would prevent us from achieving our goals </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Even if products derived from our product candidates receive regulatory approval, such products may not gain market acceptance and our future partners, if any, may not be able to effectively commercialize them </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">If we are not successful in developing our product candidates and our future partners, if any, are not successful in commercializing any products derived from our product candidates, our ability to expand our business and achieve our strategic objectives will be impaired </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We rely on third parties in the conduct of significant aspects of our pre-clinical studies and clinical trials and intend to rely on pharma partners in the conduct of future clinical trials. If these third parties/</font>&#8203;<font style="letter-spacing:0.2pt;">pharma partners do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements and/or fail to meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates </font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our future partners, if any, may encounter difficulties in manufacturing to supply clinical studies and the marked </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Certain of our product candidates may be uniquely manufactured for each patient and we and/or our future partners may encounter difficulties in manufacturing, particularly with respect to the scaling-out of manufacturing capabilities </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">If our efforts to obtain, maintain, protect, defend and/or enforce the intellectual property related to our product candidates and technologies are not adequate, we may not be able to compete effectively in our market </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We may be involved in lawsuits to protect or enforce our intellectual property or the intellectual property of our licensors, or to defend against third-party claims that we infringe, misappropriate or otherwise violate such third party&#8217;s intellectual property </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We were incorporated under the laws of the Kingdom of Denmark on August&#160;11, 2008, as a private limited liability company (in Danish: </font><font style="font-style:italic;letter-spacing:0.2pt;">Anpartsselskab</font><font style="letter-spacing:0.2pt;">, or </font><font style="font-style:italic;letter-spacing:0.2pt;">ApS</font><font style="letter-spacing:0.2pt;">) and are registered with the Danish Business Authority (in Danish: </font><font style="font-style:italic;letter-spacing:0.2pt;">Erhvervsstyrelsen</font><font style="letter-spacing:0.2pt;">) in Copenhagen, Denmark under registration number 31762863. On March&#160;29, 2019, our company was converted into a public limited liability company (in Danish: </font><font style="font-style:italic;letter-spacing:0.2pt;">Aktieselskab</font><font style="letter-spacing:0.2pt;">, or </font><font style="font-style:italic;letter-spacing:0.2pt;">A/S)</font><font style="letter-spacing:0.2pt;">. Our principal executive offices are located at Dr.&#160;Neergaards Vej 5F, 2970 H&#248;rsholm, Denmark and our telephone number is +45 31 31 97 53. Our website address is www.evaxion-biotech.com. The information on, or that can be accessed through, our website is not part of and is not incorporated by reference into this prospectus. We have included our website address as an inactive textual reference only. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being an &#8220;Emerging Growth Company&#8221;</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act of 1933, as amended, or the Securities Act. As such, we are eligible to, and intend to, take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not &#8220;emerging growth companies&#8221; such as not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting of Section&#160;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. We could remain an &#8220;emerging growth company&#8221; for up to five&#160;years, or until the earliest of (a)&#160;the last day of the first fiscal year in which our annual gross revenue exceeds $1.235&#160;billion, (b)&#160;the date that we become a &#8220;large accelerated filer&#8221; as defined in Rule&#160;12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of all our ordinary shares, including those represented by the ADSs, that are held by non- affiliates exceeds $700&#160;million as of the last business day of our most recently completed second fiscal quarter, or (c)&#160;the date on which we have issued more than $1&#160;billion in nonconvertible debt during the preceding three-year period. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Recent Developments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Private Placement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On December&#160;18, 2023, the Company, entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) and an Investment Agreement (the &#8220;Investment Agreement&#8221;; and, together with the Purchase </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">

            <div style="width:456pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Agreement referred to herein as the &#8220;Purchase Agreements&#8221;), with certain Institutional Accredited Investors, Qualified Institution Buyers and other Accredited Investors, including all members of the Company&#8217;s Management and Board of Directors and MSD GHI (&#8220;MSD&#8221;), a subsidiary of Merck Inc. (collectively, the &#8220;Purchasers&#8221;), for the issuance and sale in a private placement (the &#8220;Private Placement&#8221;) of 9,726,898 of the Company&#8217;s ordinary shares, represented by American Depositary Shares, and accompanying warrants to purchase up to 9,726,898 Ordinary Shares represented by ADSs at a purchase price of $0.544 per ordinary share. The warrants are exercisable immediately upon issuance, expire three (3)&#160;years after the closing date of the Private Placement and have an exercise price equal to $0.707 per Ordinary Share. The above number of Ordinary Shares and neither the purchase price thereof nor the exercise price of the warrants reflect the one&#160;(1) ADS for ten (10) ordinary shares Ratio Change effected on January&#160;22, 2024, described below. </font>
            </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">MSD participated in the Private Placement accounting for some 25% of the full offering amount. Further, the Private Placement included significant participation by all members of the Company&#8217;s management and board of directors. </font>
          </div>

            <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">The gross proceeds to the Company from the Private Placement were approximately $5.3&#160;million</font><font style="font-weight:bold;letter-spacing:-0.2pt;">,</font><font style="letter-spacing:0.2pt;"> with up to an additional $6.8&#160;million of gross proceeds upon cash exercise of the warrants, before deducting offering expenses payable by the Company. </font>
            </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The Private Placement was subject to the satisfaction of customary closing conditions and closed on December&#160;21, 2023. </font>
          </div>

            <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">In connection with the Private Placement, the Company entered into a registration rights agreement with the Purchasers dated as of December 18, 2023, pursuant to which the Company agreed to prepare and file an initial registration statement (the &#8220;registration statement&#8221;) with the SEC registering the resale of the ordinary shares represented by ADSs and the ordinary shares represented by ADSs issuable upon the exercise of the warrants. All members of the Company&#8217;s management and board of directors have agreed to a lock-up period of 180 days from the effective date of such registration statement. </font>
            </div>

          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">ADS Ratio Change</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>

            <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Our Board of Directors approved the change in the ratio of ADSs evidencing ordinary shares from one (1)&#160;ADS representing one (1)&#160;ordinary share to one (1)&#160;ADS representing ten (10) ordinary shares, which will result in a one for ten (10) reverse split of the issued and outstanding ADSs (the &#8220;ADS Ratio Change&#8221;). The ADS Ratio Change was effective on January&#160;22, 2024. All ADS and related warrant information presented in this prospectus, including our financial statements and accompanying footnotes, has been retroactively adjusted to reflect the reduced number of ADSs resulting from the ADS Ratio Change, unless otherwise noted. </font>
            </div>

        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTHOF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-bottom:9.78999999999996pt; margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Securities offered by us </font>
            </div>
          </div>

            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:11pt;">
              <font style="letter-spacing:0.2pt;">Up to 2,032,520 ADSs representing 20,325,200 ordinary shares and accompanying Warrants to purchase up to 2,032,520 ADSs representing 20,325,200 ordinary shares, or 2,032,520 pre-funded warrants to purchase 2,032,520 ADSs representing 20,325,200 ordinary shares and 2,032,520 accompanying Warrants to purchase 2,032,520 ADSs representing 20,325,200 ordinary shares. The ADSs or prefunded warrants, respectively and Warrants are immediately separable and will be issued separately in this offering but must initially be purchased together in this offering. Each Warrant has an exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199; per ADS, is immediately exercisable and will expire 5&#160;years from the date of issuance. See &#8220;Description of Securities&#8221;. We are also registering the ADSs issuable upon exercise of the pre-funded warrants and the Warrants. </font>
            </div>

          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">ADSs </font>
            </div>
          </div>

            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:11pt;">
              <font style="letter-spacing:0.2pt;">Each ADS represents 10 ordinary shares. As a holder of ADSs, we will not treat you as one of our shareholders. The depositary, through its custodian, will be the holder of the ordinary shares underlying the ADSs, and you will have the rights of a holder of ADSs or beneficial owner (as applicable) as provided in the deposit agreement among us, the depositary and owners and holders of ADSs from time to time. To better understand the terms of the ADSs you should read the section herein entitled &#8220;Description of Share Capital and Articles of Association&#8221; in this prospectus. We also encourage you to read the deposit agreement, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </font>
            </div>

          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Series&#160;A Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>

            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:11pt;">
              <font style="letter-spacing:0.2pt;">Each Warrant will be immediately exercisable, will expire five (5) years from the date of issuance and have an exercise price of $&#8199;&#8199;&#8199;&#8199;, subject to adjustment as set forth therein. </font>
            </div>

          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Pre-Funded Warrants Offered</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>

            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:11pt;">
              <font style="letter-spacing:0.2pt;">We are also offering to certain purchasers whose purchase of ADSs in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding ADSs immediately following the closing of this offering, the opportunity to purchase, if such purchasers so choose, pre-funded warrants and accompanying Warrants to purchase ADSs, in lieu of ADSs that would otherwise result in any such purchaser&#8217;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding ADSs. Each pre-funded warrant will be exercisable for one ADS. The purchase price of each pre-funded warrant and accompanying Warrant will be equal to the price at which an ADS and accompanying Warrant is being sold to the public in this offering, minus an amount in US dollars equal to DKK 10 at the time of pricing of this offering, which amount is equal to $1.479 as of the date of the prospectus, and the exercise price of each pre-funded warrant will be $1.479, provided that such exercise price shall not be less than the USD equivalent to DKK&#160;10 at the time of exercise. The pre-funded warrants will be exercisable immediately and may be exercised at any time until all of the pre-funded warrants are exercised in full. This prospectus also relates to the ADSs issuable upon exercise of any pre-funded warrants sold in this offering. For each pre-funded warrant we sell, the number of ADSs we are offering will be decreased on a one-for-one basis. </font>
            </div>

          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Term of the offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>

            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">This offering will terminate on March&#160;1, 2024, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. </font>
            </div>

        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-bottom:14pt; margin-left:12pt;width:456pt;">
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Ordinary shares outstanding before this Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>

            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">40,540,546 ordinary shares </font>
            </div>


            <div style="width:144pt;">
              <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">ADSs outstanding before this Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
              </div>
            </div>


            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">2,099,610 ADSs. To date, not all of the holders of outstanding ordinary shares have converted their ordinary shares to ADSs. </font>
            </div>


            <div style="width:144pt;">
              <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Ordinary shares and ADSs to be outstanding after this offering, including ordinary shares represented by ADSs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
              </div>
            </div>


            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">60,865,746 ordinary shares, and 5,194,829 ADSs, assuming no sale of pre-funded warrants, which, if sold, would reduce the number of ADSs that we are offering on a one-for-one basis, and no exercise of the Warrants or the warrants issued to the Placement Agent (the &#8220;Placement Agent Warrants&#8221;). As noted above, to date, not all of the holders of outstanding ordinary shares have converted their ordinary shares to ADSs. </font>
            </div>

          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Use of proceeds</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>

            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">We estimate that our net proceeds from this offering will be approximately $12.9&#160;million. This is based on a public offering price of $7.38 per ADS, which is the last reported trading price of our ADSs on The Nasdaq Capital Market on January&#160;26, 2024, and after deducting the estimated Placement Agent fees and commissions and estimated offering expenses payable by us. We intend to use the net proceeds of this offering to advance our preclinical and clinical pipeline, and for continuing operating expenses and working capital. </font>
            </div>

          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Risk factors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">You should read the &#8220;Risk Factor Summary&#8221; section within this prospectus (&#8220;Risk Factors&#8221;), for a discussion of factors to consider carefully before deciding to invest in our securities. </font>
          </div>
          <div style="width:144pt;">
            <div style="white-space:nowrap; margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Nasdaq Capital market </font>
              <br >
              <font style="letter-spacing:-0.2pt;">symbol</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">ADSs on the Nasdaq Capital Market under the symbol &#8220;EVAX.&#8221;</font>
          </div>

            <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">The number of our ordinary shares (including shares represented by ADSs in proportion to the designated ratio or ten (10) ordinary shares to one (1) ADS, as described in this registration statement) to be outstanding after this offering is based on 40,540,546 ordinary shares outstanding as of January&#160;29, 2024 and excludes: </font>
            </div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">12,828,684 ordinary shares issuable upon the exercise of warrants outstanding as of the date of this prospectus, pursuant to our Warrant Incentive Plans, at a weighted average exercise price of $0.84 per warrant; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">48,728,964 ordinary shares reserved for future issuance under our warrant plans. Includes 1,000,000 ordinary shares reserved for future issuance to employees, officers, directors, advisors and consultants, 728,964 ordinary shares reserved for future issuance under the EIB Warrants, as described below in the section entitled &#8220;Our EIB Warrants&#8221;), and 47,000,000 shares reserved for future issuance under warrants the may be issued to future investors, lenders, consultants and/or advisors, if any. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

            <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">For the description of the Warrant Incentive Plan see &#8220;Warrant Incentive Plan&#8221; herein. </font>
            </div>


            <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Unless otherwise stated, all information in this prospectus assumes no exercise of the outstanding options and warrants described above into ordinary shares, treats all restricted shares issued with outstanding restrictions to be vested as issued and outstanding ordinary shares, no exercise of the Warrants and Placement Agent Warrants issued in this offering and no sale of pre-funded warrants in this offering. </font>
            </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Except as otherwise indicated all references to our articles of association in this prospectus refer to our articles of association, as amended as currently in force for the Company at the date of this prospectus. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSCFD">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-bottom:9.5pt; margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Summary Consolidated Financial Data</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The following tables set forth our summary financial data for the periods indicated. We have derived the summary statements of comprehensive loss data for the&#160;years ended December&#160;31, 2022, 2021 and 2020 from our audited financial statements included elsewhere in this prospectus. We have derived the summary consolidated statements of comprehensive loss for the three and nine&#160;months ended September&#160;30, 2023 and 2022 and the summary consolidated statements of financial position as of September&#160;30, 2023, from the unaudited condensed consolidated interim financial statements included elsewhere in this prospectus. We have prepared the unaudited condensed consolidated interim financial statements on the same basis as the audited financial statements, and the unaudited condensed consolidated financial data include all adjustments, that we consider necessary for a fair presentation of our financial position and results of operations as of and for the periods presented. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our financial statements are prepared and presented in accordance with IFRS, as issued by the IASB. IFRS differ in certain significant respects from U.S. GAAP. Our historical results are not necessarily indicative of results expected for future periods and our consolidated operating results for the three and nine&#160;months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the entire year ended December&#160;31, 2023. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The summary financial data below should be read together with our financial statements and related notes, and our unaudited condensed consolidated interim financial statements and related notes included elsewhere in this prospectus, as well as the sections of this prospectus titled &#8220;Selected Financial Data&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Summary Statements of Comprehensive Loss</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <table style="width:456pt;height:166pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:291.36pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:0pt;text-align:center;" colspan="16">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:291.36pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2022 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2021 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2020 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:291.36pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt; width:0pt;text-align:center;" colspan="16">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">(USD in thousands, except per share amounts) </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.75pt 0pt 0.5pt 0pt; width:291.36pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Research and development </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">17,056</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">19,583</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,902</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:2pt 0pt 1pt 0pt; width:291.36pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">General and administrative </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,208</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,251</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">5,666</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:1.75pt 0pt 1pt 0pt; width:291.36pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Total operating expenses </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">25,264</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">25,834</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">16,568</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.75pt 0pt 0.5pt 0pt; width:291.36pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.2pt;">Operating loss</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,264<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,834<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,568<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2pt 0pt 0.5pt 0pt; width:291.36pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Finance income </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,831</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,039</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">216</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:2pt 0pt 1pt 0pt; width:291.36pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Finance expenses </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,508<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(915<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(223<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.75pt 0pt 0.5pt 0pt; width:291.36pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.2pt;">Net loss before tax</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(23,941<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(24,710<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,575<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:2pt 0pt 1pt 0pt; width:291.36pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Income tax benefit </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">772</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">178</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,557</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:1.75pt 0pt 1pt 0pt; width:291.36pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.2pt;">Net loss for the year</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(23,169<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(24,532<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,018<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.75pt 0pt 1.75pt 0pt; width:291.36pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.2pt;">Net loss attributable to shareholders of Evaxion Biotech A/S</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(23,169<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(24,532<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,018<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.25pt 0pt 1.75pt 0pt; width:291.36pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Loss per share&#8201;&#8211;&#8201;basic and diluted </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(0.98<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1.26<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(0.97<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
          <table style="width:456pt;height:175.5pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Three Months Ended</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2023 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2022 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2023 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2022 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:273.85pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; width:0pt;text-align:center;" colspan="22">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">(USD in thousands, except per share amounts) </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.75pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Research and development </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,830</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,068</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,618</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">12,983</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:2pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">General and administrative </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,932</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,015</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,215</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">5,756</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:1.75pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Total operating expenses </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">5,762</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">6,083</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">17,833</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">18,739</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.75pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.2pt;">Operating loss</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,762<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,083<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,833<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(18,739<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Finance income </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">72</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">703</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">404</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,761</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:2pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Finance expenses </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(182<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(535<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(786<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(918<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:1.75pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.2pt;">Net loss before tax</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,872<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,915<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(18,215<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,896<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:1.75pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Income tax benefit </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">194</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">175</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">613</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">599</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:1.75pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.2pt;">Net loss for the period</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,678<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,740<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,602<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,297<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.75pt 0pt 0.75pt 0pt; width:273.85pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.2pt;">Net loss attributable to shareholders of Evaxion Biotech A/S</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,678<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,740<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,602<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,297<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt 0pt 0.75pt 0pt; width:273.85pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Loss per share&#8201;&#8211;&#8201;basic and diluted </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(0.21<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(0.24<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(0.66<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(0.69<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Summary Consolidated Statement of Financial Position</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>

            <table style="width:456pt;height:145pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
                <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:242.68pt;text-align:left;">&#8203;</td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                  <div style="text-align:center;">
                    <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                    <br >
                    <font style="letter-spacing:-0.16pt;">2023 </font>
                  </div>
                </td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                  <div style="text-align:center;">
                    <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                    <br >
                    <font style="letter-spacing:-0.16pt;">2022 </font>
                  </div>
                </td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                  <div style="text-align:center;">
                    <font style="letter-spacing:-0.16pt;">As </font>
                    <br >
                    <font style="letter-spacing:-0.16pt;">Adjusted</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
                  </div>
                </td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                  <div style="text-align:center;">
                    <font style="letter-spacing:-0.16pt;">Pro Forma</font>
                    <br >
                    <font style="letter-spacing:-0.16pt;">As </font>
                    <br >
                    <font style="letter-spacing:-0.16pt;">Adjusted</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</font>
                  </div>
                </td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
                <td style="padding:0pt 0pt 0.5pt 0pt; width:242.68pt;text-align:left;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
                  <div style="white-space:nowrap; text-align:center;">
                    <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
                  </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
                <td style="padding:3.25pt 0pt 1.5pt 0pt; width:242.68pt;text-align:left;">
                  <div style="white-space:nowrap;">
                    <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
                  </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
                <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,605</td>
                <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
                <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">13,184</td>
                <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,484</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">23,402</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
                <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.68pt;text-align:left;">
                  <div style="white-space:nowrap;">
                    <font style="letter-spacing:0.2pt;">Total assets </font>
                  </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">11,942</td>
                <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">22,025</td>
                <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">19,821</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">32,739</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
                <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.68pt;text-align:left;">
                  <div style="white-space:nowrap;">
                    <font style="letter-spacing:0.2pt;">Total liabilities </font>
                  </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">14,676</td>
                <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">13,722</td>
                <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">14,676</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">14,676</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
                <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.68pt;text-align:left;">
                  <div style="white-space:nowrap;">
                    <font style="letter-spacing:0.2pt;">Share capital </font>
                  </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,415</td>
                <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,886</td>
                <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">46,219</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,202</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
                <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.68pt;text-align:left;">
                  <div style="white-space:nowrap;">
                    <font style="letter-spacing:0.2pt;">Other reserves </font>
                  </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">82,614</td>
                <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">77,076</td>
                <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">88,689</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">98,624</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
                <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.68pt;text-align:left;">
                  <div style="white-space:nowrap;">
                    <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
                  </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(89,763<font style="position:absolute;">)</font></td>
                <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(72,659<font style="position:absolute;">)</font></td>
                <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(89,763<font style="position:absolute;">)</font></td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(89,763<font style="position:absolute;">)</font></td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
                <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.68pt;text-align:left;">
                  <div style="white-space:nowrap;">
                    <font style="letter-spacing:0.2pt;">Total equity </font>
                  </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,734<font style="position:absolute;">)</font></td>
                <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">8,303</td>
                <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">5,145</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">18,063</td>
                <td style="padding:0pt;padding-left:2.56pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
            </table>

          <div style="margin-top:12.5pt; width:456pt;">
            <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
          </div>

            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">(1)</font>
              <br >
            </div>
            <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
              <font style="letter-spacing:0.2pt;">The as adjusted financial position data gives effect to the Private Placement closed December&#160;21, 2023, related to the issuance and sale of 9,726,898 of our ordinary shares, represented by ADSs, and accompanying warrants to purchase up to 9,726,898 ordinary shares represented by ADSs at a purchase price of $0.544 per ordinary share for an aggregate purchase price of $5.3&#160;million. The as adjusted financial position also gives effect to the sale of 263,355 ADSs representing 2,633,550 ordinary shares that occurred on January 25, 2024 at a volume weighted average price (VWAP) of $9.7559 per ADS for an aggregate purchase price of approximately $2.5 million. </font>
            </div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">(2)</font>
              <br >
            </div>
            <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
              <font style="letter-spacing:0.2pt;">The pro forma as adjusted financial position data gives further effect the adjustments set forth in footnote 1 above and to additionally reflect the issuance and sale of 2,032,520 ADSs, representing 20,325,200 ordinary shares, in the offering at an assumed public offering price of $7.38 per ADS (the last reported closing trading price of the ADSs on The Nasdaq Capital Market on January&#160;29, 2024) and after deducting estimated placement agent commission and estimated offering expenses payable by us. The pro&#160;forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed public offering price of $7.38 per ADS, which is the closing trading price for our ADSs on January&#160;29, 2024, as reported on Nasdaq and as set forth on the cover page of this prospectus, would increase (decrease) the amount of cash, cash equivalents and short-term investments, working capital, total assets and total stockholders&#8217; equity (deficit) on a pro&#160;forma as adjusted basis by approximately $2.0 million, assuming the number of securities offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of securities we are offering. Each increase (decrease) of 100,000 ADSs offered by us would increase (decrease) cash, cash equivalents and short-term investments, working capital, total assets and total stockholders&#8217; equity (deficit) on a pro&#160;forma as adjusted basis by approximately $0.7 million, assuming the assumed public offering price of $7.38 per ADS, which is the closing trading price for our ADSs on January&#160;26, 2024, as reported on Nasdaq and as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated placement agent and estimated offering expenses payable by us.</font>
            </div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">We are a clinical-stage TechBio company with an ambition to partner on targets, pipeline and responder models with no pharmaceutical products approved for commercial sale. Also, we have not yet made out-licensing agreements. Our business faces significant risks. You should carefully consider all of the information set forth in this registration statement, including the following risk factors which we face and which are faced by our industry. Our business, financial condition, results of operations or prospects could be materially adversely affected by any of these risks. This registration statement also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described below and elsewhere in this registration statement. See &#8220;Special Note Regarding Forward-Looking Statements&#8221; above.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to our Financial Condition and Capital Requirements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have incurred significant losses since our inception and we anticipate that we will continue to incur significant losses for the foreseeable future, which makes it difficult to assess our future viability. We have not generated significant revenue and may never be profitable.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have incurred net losses in each year since our inception in 2008, including net losses of $23.2&#160;million, $24.5&#160;million, and $15.0&#160;million for the&#160;years ended December&#160;31, 2022, 2021, and 2020, respectively. As of December&#160;31, 2022, we had accumulated deficit of $72.7&#160;million. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We have devoted most of our financial resources to research and development, including our pre-clinical and clinical development activities and the development of our AI-Immunology&#8482; platform. To date, we have financed our operations primarily through the sale of equity securities, issuance of convertible debt instruments and through private and governmental grants. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, sales of assets, collaborations, including our out-licensing arrangements, if any, and grants. We believe that the cost and expense of most clinical testing, regulatory and marketing approval and commercialization of our product candidates are beyond the resources of all but the large biopharmaceutical and pharmaceutical companies. Therefore, we currently intend to develop our immunotherapies through pre-clinical or clinical proof of concept, or PoC, and then enter into partnership arrangements with large biopharmaceutical and pharmaceutical companies to conduct clinical trials, regulatory and marketing approval and commercialization of our product candidates. We have not yet entered into any such partnership arrangements and may be unable to do so on economically viable terms, if at all. As a result, clinical trials, including late stage clinical trials as well as pivotal clinical trials for our product candidates have not been commenced under any such partnership arrangements and even if such trials are commenced in the near future, it will be several&#160;years, if ever, before we, or our partners, if any, have a product candidate ready for commercialization. Even if our future partners, if any, obtain regulatory approval to market a product candidate, our future revenues will depend upon the size of any markets in which our product candidates receive such approval, upfront, milestone and any other payments we receive from our future partners, if any, and our future partners&#8217;, if any, ability to achieve sufficient market acceptance, reimbursement from third-party payors, and adequate market share in those markets. We may never achieve profitability. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our ability to generate revenue and achieve profitability depends on our ability to successfully complete the development of, and our partners&#8217; ability to obtain the regulatory approvals necessary to commercialize, our product candidates. We do not anticipate generating substantial revenues in the near term from any of our commercialization partnerships we may establish. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect to continue to incur significant expenses and operating losses for the foreseeable future. For the current year the primary cost drivers are: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">continue our research or development of our programs in pre-clinical and clinical development; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">continue to invest in our AI-Immunology&#8482; platform to improve its predictive capabilities and identify novel vaccines; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">invest in generated needed pre-clinical evidence to support our partnership strategy </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">change or add more suppliers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">add more infrastructure to our quality control, quality assurance, legal, accounting, compliance and other groups to support our operations including our operation as a public company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">attract and retain skilled personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">make milestone or other payments under any in-license agreements; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintain, protect, defend, enforce and expand our intellectual property portfolio. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our ability to generate future revenues from our potential commercialization partnerships depends heavily on our success in: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">completing research and pre-clinical development, and successfully entering into partnership arrangements with large biopharmaceutical and pharmaceutical companies to conduct clinical trials, regulatory and marketing approval and commercialization of our product candidates for both our immuno-oncology and infectious disease product candidates to validate our AI-Immunology&#8482; platform; and other business efforts </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">seeking, negotiating and obtaining agreements with future partners, if any, on favorable terms for the completion of clinical trials, and United States and non-United States marketing approvals and commercialization of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our relationships with our third-party manufacturers in order to provide adequate (in amount and quality) products and services to support clinical development of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our future partners, if any, obtaining market acceptance of our product candidates as treatment options; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our future partners, if any, launching and commercializing our product candidates for which marketing approval and reimbursement have been obtained; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">addressing any competing technological and market developments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">implementing additional internal systems and infrastructure; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintaining, defending, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and attracting, hiring and retaining qualified personnel. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict. If our operating results fall below expectations, the market price of the ADSs could decline. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our financial condition and operating results have varied in the past and will continue to fluctuate from one financial period to the next due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this prospectus: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays or failures in advancement of existing or future product candidates into pre-clinical studies or clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">failures in further development of our AI-Immunology&#8482; platform; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability of our future partners, if any, to manufacture and successfully commercialize our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to manage our growth; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the outcomes of research programs, pre-clinical studies and clinical trials, and other product development or approval processes conducted by us and/or our future partners, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our relationships, and any associated exclusivity terms, with partners; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our contractual or other obligations to provide resources to fund our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our operations in a net loss position for the foreseeable future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">risks associated with the international aspects of our business outside of Denmark, including the conduct of clinical trials in multiple locations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our and our partners&#8217;, to the extent relevant, consistent ability to have our products and product candidates manufactured by third parties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to develop programs to fit into a clinical work-flow and treatment regimen; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to accurately report our financial results in a timely manner; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our dependence on, and the need to attract and retain, key management and other personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our and our partners&#8217; ability to obtain, protect, maintain, defend and enforce our intellectual property rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our and our partners&#8217; ability to prevent the theft or infringement, misappropriation or other violation of our intellectual property, trade secrets, know-how or technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">potential advantages that our competitors and potential competitors may have in securing funding, obtaining the rights to critical intellectual property or developing competing technologies or products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to obtain additional capital that may be necessary to expand our business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">our future partners, if any, ability to obtain additional capital that may be necessary to develop and commercialize products under any future collaboration or licensing agreements; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.69pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.69pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">business interruptions such as power outages, strikes, acts of terrorism, pandemics or natural disasters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.69pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.69pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effects of climate change on our operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effects of the continuing conflict between Russian and the Ukraine and in the Middle East may have on our business and operations; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.69pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.69pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to use our net operating loss, or NOL, carryforwards to offset future taxable income. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Due to the various factors mentioned above, and others, the projected financial information included in this should not be relied upon as indications of our future operating performance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have a history of losses and will require additional funding to support ongoing operational needs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We have incurred recurring losses since inception. We expect to continue to incur significant expenses related to the research, development and manufacturing of our product candidates and in connection with conducting clinical studies related thereto. Additionally, we may encounter unforeseen difficulties, complications, development delays and other unknown factors that require additional expense. As a result of these expenditures, we expect to continue to incur significant losses for the foreseeable future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We have not yet established a source of revenues sufficient to cover our operating costs, and as such, we have financed our operations through successive capital increases, collaboration agreements and receipt of research grants. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">These facts and conditions raise substantial doubt about our ability to continue as a going concern, and our independent registered public accounting firm has included an explanatory paragraph regarding going concern qualification in its audit report. While we have entered into arrangements for financing with Lincoln Park Capital and Global Growth Holdings, those facilities are not yet operational or effective and may never be. The failure to raise additional funding may have a material adverse effect on our business, results of operations and financial position, and may adversely affect our ability to continue as a going concern. If we do not become consistently profitable, our accumulated deficit will grow larger and our cash balances will decline further, and we will require further financings to continue operations. Any such financings may not be accessible on acceptable terms, if at all. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research and development programs of our product candidates or be required to file for reorganization or liquidation under applicable reorganization or bankruptcy laws. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We will need substantial additional financing to achieve our goals, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We estimate that our cash and cash equivalents were $7.7 million as of January 29, 2024. The net proceeds from our IPO completed in February&#160;2021 was $25.3&#160;million, based on the initial public offering price of $10.00 per ADS, after deducting underwriting discounts and commissions and offering expenses. The net proceeds from our follow-on offering completed in November&#160;2021 was $24.9&#160;million, based on the public offering price of $7.00 per ADS after deducting underwriting discounts and commissions and offering expenses. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2020, we executed a loan agreement, or the EIB Loan Agreement, with the European Investment Bank, or EIB, for a principal amount of &euro;20.0&#160;million, divided into three tranches of tranche 1 in the amount of &euro;7.0&#160;million, tranche 2 in the amount of &euro;6.0&#160;million and tranche 3 in the amount of &euro;7.0&#160;million, or the EIB Loan. Under the EIB Loan Agreement, the EIB Loan tranche balances are due six&#160;years from their respective disbursement dates. In connection with disbursement of each tranche, EIB is entitled to receive certain warrants, or the EIB Warrants. In November&#160;2020, we initiated the process to receive the funds from the disbursement of tranche 1 of the EIB Loan in the aggregate amount of &euro;7.0&#160;million but due to the timing of our IPO we did not finalize a disbursement offer. In connection therewith, EIB received 351,036 EIB Warrants, which vested immediately, pursuant to the terms of a separate warrant agreement, or the EIB Warrant Agreement. We received the proceeds from the drawdown of the first tranche of the EIB loan of &euro;7.0&#160;million on February&#160;17, 2022. As of the date of this registration statement, we have not initiated a drawdown on any additional tranches of the EIB Loan and under the present business plans we do not expect to draw the remaining 2 tranches. The remaining two tranches have become void. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In June&#160;2022, we entered into a purchase agreement, or the LPC Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, pursuant to which we may, from time to time and at our sole discretion, for a period of 36-months, direct Lincoln Park to purchase up to 4,649,250 of our ordinary shares represented by the ADSs, subject to the development in the ADS price. If the ADS price is between $5.00 and $40.00 (as adjusted to take into account the ADS ratio change) the number of purchase shares is limited to 50,000. If the price is not below $40.00 the purchase share limit may be increased to 60,000 purchase shares and if the price is not below $6.00 the purchase shares limit may be increased to 70,000 purchase shares. Under the terms of the LPC Purchase Agreement, we may receive up to $40,000,000 in aggregate gross proceeds from any sales of our ordinary shares represented by ADSs that we make to Lincoln Park thereunder. In connection with the LPC Purchase Agreement, we issued 428,572 ADSs representing ordinary shares to Lincoln Park as consideration for a commitment fee of $1,200,000 for Lincoln Park&#8217;s agreement to purchase ordinary shares represented by ADSs under the LPC Purchase Agreement, or the Commitment Shares. As of the date of this prospectus, Lincoln Park has not purchased any additional ordinary shares represented by the ADSs and we have not received any proceeds therefrom. At current, the closing conditions to make the LPC Purchase Agreement operational have not yet been met. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In October&#160;2022, we initiated an at-the-market, or ATM, program with JonesTrading Institutional Services LLC, or JonesTrading, acting as sales agent, relating to the sale of up to $14,439,000 of the ADSs. As of the date of this prospectus, we have raised gross proceeds of $9,229,131 from the sale of ADSs under this ATM program. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On July&#160;31, 2023, we entered into an agreement with Global Growth Holding Limited, or GGH, for the issuance of, and subscription to, convertible notes, or the Notes, convertible into new ordinary shares, nominal value DKK 1, or the ordinary shares, or the GGH Agreement, with ten shares represented by one (1)&#160;American Depositary Share, or the ADSs. Pursuant to the GGH Agreement, we may elect to sell to GGH up to $20,000,000 in such Notes, subject to certain limitations and conditions set forth in therein. The Notes are subject to conversion into new ordinary shares at any time upon submission of a request for conversion by GGH. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the GGH Agreement, on any business day over the 36-month term of the GGH Agreement, we have the right, but not the obligation, at our sole discretion and subject to certain conditions, to direct GGH to purchase tranches of up to $700,000 in aggregate value of Notes, or a Tranche. The Notes carry a zero coupon and will be issued at a subscription price corresponding to their par value. The conversion price </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">of the Notes will be determined as 83.5% of the second lowest closing volume weighted average share price (VWAP) of the ADSs for the eight (8)&#160;trading days immediately preceding the issuance of each conversion request by GGH, unless the lowest closing VWAP of the ADSs over the such eight (8)&#160;trading days is the most recent trading day in which case the conversion price will be 85% of the lowest closing VWAP of the ADSs over such eight (8)&#160;day period. The closing conditions to the GGH Agreement, which will include filing a registration statement, have not yet been met and the facility is not yet available to us. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">On December&#160;18, 2023, we entered into a securities purchase agreement, or the Securities Purchase Agreement, and an Investment Agreement, or the Investment Agreement, with certain Institutional Accredited Investors, Qualified Institution Buyers and other Accredited Investors, including all members of the Company&#8217;s Management and Board of Directors and MSD GHI, or MSD, a subsidiary of Merck Inc., for the issuance and sale in a private placement of 9,726,898 of the Company&#8217;s ordinary shares, DKK 1 nominal value represented by American Depositary Shares and accompanying warrants to purchase up to 9,726,898 Ordinary Shares represented by ADSs at a purchase price of $0.544 per Ordinary Share. The Warrants are exercisable immediately upon issuance, expire three (3)&#160;years after the closing date and have an exercise price equal to $0.707 per Ordinary Share. The above number of ordinary shares and neither the purchase price thereof nor the exercise price of the warrants reflect the one (1) ADS for ten&#160;(10) ordinary shares Ratio Change effected on January 22, 2024, described herein.</font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We expect that the net proceeds from our IPO, our follow-on offering, our private placement in December&#160;2023 and the net proceeds, we have received and may receive in the future under the ATM program and our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditures until the end of April&#160;2024. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, sales of assets, other collaborations and licensing arrangements, or a combination of these approaches. In any event, we will require additional capital to achieve our goals. We will seek additional capital if market conditions are favorable or if we have specific strategic considerations. Our spending will vary based on new and ongoing development and corporate activities. Due to high uncertainty of the length of time and activities associated with discovery and development of our product candidates, we are unable to estimate the actual funds we will require for our development activities. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our future funding requirements, both near and long term, will depend on many factors, including, without limitation: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the initiation, progress, timing, costs, and results of pre-clinical or nonclinical studies and clinical trials for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the results of research and our other platform activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the clinical development plans we establish for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the terms of any agreements with our future partners, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number and characteristics of any technology that we develop or may in-license; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA, the TGA and other comparable regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of filing, prosecuting, obtaining, maintaining, protecting, defending and enforcing our patent claims and other intellectual property rights, including actions for patent and other intellectual property infringement, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">misappropriation and other violations brought by third parties against us regarding our product candidates or actions by us challenging the patent or intellectual property rights of others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effect of competing technological and market developments, including other products that may compete with one or more of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost and timing of completion and further expansion of clinical scale manufacturing activities by third parties sufficient to support all of our current and future programs. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the impact and duration of the COVID-19 pandemic and its effect on the global economy and our business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effects of climate change on the global economy and our business; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effects of the continued conflict between Russia and the Ukraine and in the Israel-Gaza region on the global economy and our business. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To date, we have financed our operations primarily through the sale of equity securities, the EIB loan and from private and governmental grants and we cannot be certain that additional funding will be available on favorable terms, or at all. Until we can generate sufficient upfront fees, milestone payments and royalty revenues from our agreements with future partners, if any, to finance our operations, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, sales of assets, out-licensing arrangements, and other product development arrangements. Any fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop our product candidates, the AI-Immunology&#8482; platform as well as establishing partnerships. In addition, we cannot guarantee that future financing will be available in sufficient amounts, at the right time, on favorable terms, or at all. Negative clinical trial data or setbacks, or perceived setbacks, in our programs or with respect to our technology could impair our ability to raise additional financing on favorable terms, or at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of the ADSs to decline. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that may adversely affect our securityholders&#8217; rights. </font>
        </div>

          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">We may not be in compliance with the EIB Loan&#8217;s beneficial ownership requirements following this offering</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The EIB Loan contains a requirement that, at all times while the EIB Loan is outstanding, Niels Iverson Moller, one of our co-founders and a director, and Andreas Holm Mattsson, our Chief AI and Culture Officer, and/or their affiliates together must beneficially own at least 20% of our issued and outstanding ordinary shares, or the EIB Ownership Requirement. Currently, it is anticipated that together Messrs. Moller and Mattsson will beneficially own approximately 14.1% of our issued and outstanding ordinary shares following this offering (see the section herein entitled &#8220;Share Ownership&#8221;), which would cause us not to be in compliance with the EIB Ownership Requirement. Currently, we are in discussions with EIB to obtain a waiver of the EIB Ownership Requirement. EIB has initially indicated that, in order to grant such a waiver, it would request a partial repayment of the EIB Loan in an amount which we anticipate may be in the range of $500,000 to $750,000, which, if agreed between EIB and us, we would anticipate paying out of our current cash on hand. While we believe we will be able to obtain such a waiver, we cannot give you any assurance that we will be able to do so. If we are unable to obtain a waiver, EIB may have rights to demand repayment of the EIB Loan.</font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">This offering is being made on a best efforts basis and we may sell fewer than all of the securities offered hereby and may receive significantly less in net proceeds from this offering, which will provide us only limited working capital.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">This offering is being made on a best efforts basis and we may sell fewer than all of the securities offered hereby and may receive significantly less in net proceeds from this offering. Assuming that we receive net proceeds of approximately $12.9 million from this offering (assuming an offering with gross proceeds of $15.0&#160;million), we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will satisfy our capital into the middle of 2025 under our current business plan. Assuming that we receive net proceeds of approximately $9.5&#160;million from this offering (assuming an offering with gross proceeds of $11.25&#160;million), we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will satisfy our capital needs towards the end of the first quarter of 2025 under our current business plan. Assuming that we receive net proceeds of approximately $5.9&#160;million from this offering (assuming an offering with gross proceeds of $7.5&#160;million), we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will satisfy our capital needs into the beginning of the first quarter of 2025 under our current business plan. Without giving effect to the receipt of any proceeds from this offering, we currently estimate that our existing cash and cash </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">equivalents are sufficient to fund business operations until end of April 2024 assuming no income from ongoing business development discussions. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We will need to develop our company, and we may encounter difficulties in managing this development, which could disrupt our operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">As of the date of this prospectus, we have 49 full-time equivalent employees and, in connection with the development and advancement of our pipeline, partnerships and becoming a public company, we expect to keep developing our operations. To manage our anticipated development, we must continue to implement and improve our managerial, operational, legal, compliance and financial systems, and retain as well as recruit and train additional qualified personnel. Also, our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these development activities. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a developing TechBio company, we are actively pursuing technologies, drug classes, platforms and product candidates in more therapeutic areas and across a wide range of diseases. Successfully developing product candidates for and fully understanding the regulatory and manufacturing pathways to all of these therapeutic areas and disease states requires significant human capital resources with a depth of talent, and corporate processes in order to allow simultaneous execution across multiple areas. Due to our limited resources, we may not be able to effectively manage this simultaneous execution and the development of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, legal or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the commitments in being Nasdaq listed and low liquidity in the capital markets may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to compete effectively and develop our product candidates will depend in part on our ability to effectively manage the future development of our company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we experience additional material weaknesses in the future, we may not be able to accurately or timely report our financial condition or results of operations and investors may lose confidence in our financial reports and the market price of the ADSs could be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section&#160;404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on internal control over financial reporting. The Sarbanes-Oxley Act also requires that our management report on internal control over financial reporting be attested to by our independent registered public accounting firm, to the extent we are no longer an &#8220;emerging growth company,&#8221; as defined by the JOBS Act. We do not expect to have our independent registered public accounting firm attest to our management report on internal control over financial reporting for so long as we are an emerging growth company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As defined in the standards established by the U.S. Public Company Accounting Oversight Board, a &#8220;material weakness&#8221; is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our company&#8217;s annual consolidated financial statements will not be prevented or detected on a timely basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the preparation of our financial statements for the year ended December&#160;31, 2022, we continued to be in the process of designing and implementing controls to monitor and provide oversight over the design and operating effectiveness of internal control over financial reporting in order to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act. We determined that management failed to implement certain components of the COSO framework, including elements of the control environment, information and communication, control activities and monitoring of control activities. Therefore, we have </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">assessed that we lacked sufficient internal controls to support effective financial reporting as of December&#160;31, 2022, which constitutes a material weakness. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To remediate this material weakness, we will continue to make further progress on the design and operating effectiveness of our internal controls over financial reporting, including the monitoring, oversight and evaluation of our internal controls. We will allocate more internal resources to internal controls and intend to engage external advisors to provide training and to reassess and redesign processes and develop new controls as appropriate including assisting with the evaluation and documentation of the risk assessment, design and operating effectiveness of our internal controls over financial reporting and assist with the remediation of any deficiencies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, in the&#160;years ended December&#160;31, 2021 and 2020, we had identified a material weakness in our internal control over financial reporting, which remained unremediated as of December&#160;31, 2022. The unremediated material weakness identified relates to the lack of accounting and supervisory personnel that possess an appropriate level of technical accounting experience and training, and their lack of supervision over third party service providers in areas such as books and records, financial controlling, and financial statements preparation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To remediate this previously identified material weakness, we retained an advisory firm to provide additional depth and breadth to our technical accounting and financial reporting capabilities and are taking steps such as the hiring of additional finance staff. Also, during 2021, we hired four additional accounting personnel with financial statement closing experience and technical IFRS knowledge for the purposes of timely and reliable financial reporting in accordance with IFRS and the requirements set forth by the SEC. In 2022 external advisors were engaged and processes and control procedures were documented and implementation of systems for monitoring and documenting control performance were initiated. A new Chief Financial Officer with considerable public company experience was hired, but the loss of key employees delayed the remediation plans for 2022. Substitutions have been hired effective from the second quarter of 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While we have implemented and intend to continue implementing our plans to remediate these material weaknesses, we cannot predict the success of such plans or if they will result in remediation of these material weaknesses or that additional material weaknesses will not be identified in the future. If we are unable to remediate these material weaknesses or if we experience additional material weaknesses in the future or otherwise continue to fail in maintaining an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations. Our investors may lose confidence in the accuracy and completeness of our financial reports, the market price of the ADSs could be adversely affected, and we could become subject to investigations by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities, which could require additional financial and management resources. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We do not carry insurance for all categories of risk that our business may encounter, and insurance coverage is becoming increasingly expensive. We do not know if we will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. If our future partners, if any, obtain marketing approval for any product candidates that we or our future partners, if any, may develop, we intend to acquire insurance coverage to include the sale of commercial products, but we may be unable to obtain such insurance on commercially reasonable terms or in adequate amounts, if at all. If our losses exceed our insurance coverage, our financial condition would be adversely affected. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources. Clinical trials or regulatory approvals for any of our product candidates could be suspended, which could adversely affect our results of operations and business, including by preventing or limiting the development and commercialization of any product candidates that we or our future partners, if any, may develop. We also expect that operating as a public company will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our Board, our board committees or our management team. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, such as actual events or concerns involving liquidity, defaults or non-performance, could adversely affect our operations and liquidity.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to market-wide liquidity problems. For example, on March&#160;10, 2023, Silicon Valley Bank, or SVB, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation, or the FDIC, as receiver. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">While a statement by the U.S. Department of the Treasury, the Federal Reserve and the FDIC stated that all depositors of SVB would have access to all of their money, uncertainty and liquidity concerns in the broader financial services industry remain. Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. The U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25&#160;billion of loans to financial institutions secured by such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments. However, widespread demands for customer withdrawals or other needs of financial institutions for immediate liquidity may exceed the capacity of such program. There is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions in a timely fashion or at all. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">While we maintain our cash and cash equivalents in multiple financial institutions worldwide, our access to our cash and cash equivalents in amounts adequate to finance our operations could be significantly impaired by the financial institutions with which we have arrangements directly facing liquidity constraints or failures. In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any material decline in available funding or our ability to access our cash and cash equivalents could adversely impact our ability to meet our operating expenses, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws, any of which could have material adverse impacts on our operations and liquidity. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Inflation could adversely affect our business and results of operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">While inflation in the United States has been relatively low in recent&#160;years, from 2021 to 2023, the economy in the United States encountered a material level of inflation. The impact of COVID-19, geopolitical developments such as the Russia-Ukraine and Middle East conflicts and global supply chain disruptions continue to increase uncertainty in the outlook of near-term and long-term economic activity, including whether inflation will continue and how long, and at what rate. Increases in inflation raise our costs for commodities, labor, materials and services and other costs required to grow and operate our business, and failure to secure these on reasonable terms may adversely impact our financial condition. Additionally, increases in inflation, along with the uncertainties surrounding COVID-19, geopolitical developments and global supply chain disruptions, have caused, and may in the future cause, global economic uncertainty and uncertainty about the interest rate environment, which may make it more difficult, costly or dilutive for us to secure additional financing. A failure to adequately respond to these risks could have a material adverse impact on our financial condition, results of operations or cash flows. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to our Business and Industry</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our AI approach to the discovery of product candidates is novel and unproven, and we do not know whether we or our future partners, if any, will be able to develop any products of commercial value. If we or our future partners, if any, are unable to advance our product candidates in clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are leveraging our AI-Immunology&#8482; platform to create a pipeline of cancer immunotherapies and bacterial and viral infectious disease product candidates for patients whose diseases have not been adequately addressed to date by other approaches, and, together with our partners, if any, to design and conduct efficient clinical trials with a potentially greater likelihood of success. We will also aim at out-licensing identified targets or product candidates earlier in the development process as well as partner on target discovery. While we believe that applying our AI-Immunology&#8482; platform to create medicines for defined patient populations may potentially enable drug discovery research that is more efficient than conventional drug research, our approach is both novel and unproven and, therefore, the cost and time needed to develop our product candidates either by us or our future partners, if any, is difficult to predict. Our efforts may not result in the discovery and development of commercially viable medicines. We may also be incorrect about the effects of our product candidates on the diseases of our targeted patient populations, which may limit the utility of our approach or the perception of the utility of our approach. Furthermore, our defined patient populations available for study and treatment may be lower than expected, which could adversely affect our, or our partners, ability to conduct clinical trials and may also adversely affect the size of any market for medicines we, or our partners, may successfully commercialize. Our approach may not result in clinical effect, time savings, higher success rates or reduced costs as we expect and, if not, we may not attract future partners, if any, or develop new drug candidates as quickly or cost effectively as expected and therefore our future partners, if any, may not be able to commercialize our approach as originally expected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our AI approach may fail to help us discover and develop additional product candidates, which could materially harm our business, financial condition, results of operations and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any drug discovery that we are conducting using our AI-Immunology&#8482; platform may not be successful in identifying compounds that have commercial value or therapeutic utility. Our AI-Immunology&#8482; platform may initially show promise in identifying potential product candidates, yet fail to yield viable product candidates for clinical development or commercialization for a number of reasons, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may not be successful in our efforts to identify new product candidates as well as in securing partnerships for these. If we are unable to identify suitable additional compounds attractive to partners for pre-clinical and clinical development, our ability to develop product candidates and generate revenue in future periods could be compromised, which could result in significant harm to our financial position and adversely impact the market price of the ADSs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">compounds found through our AI-Immunology&#8482; platform may not demonstrate efficacy, safety or tolerability; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to receive marketing approval and achieve market acceptance; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">competitors may develop alternative therapies that render our potential product candidates non-competitive or less attractive; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a product candidate may not be capable of being manufactured at an acceptable cost and speed; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may not be able to scale up manufacturing of personalized therapies to a commercial scale. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may experience challenges with the acquisition, development, enhancement or deployment of technology necessary for our AI-Immunology&#8482; platform.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our business requires sophisticated computer systems and software. Some of the technologies are changing rapidly and we must continue to adapt to these changes in a timely and effective manner at an </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">acceptable cost. There can be no guarantee that we will be able to develop, acquire, enhance, deploy or integrate new technologies, that these new technologies will meet our needs or achieve our expected goals, or that we will be able to do so as quickly or cost-effectively as our competitors. Significant technological change could render our AI-Immunology&#8482; platform obsolete. Our continued success will depend on our ability to adapt to changing technologies, manage and process ever-increasing amounts of data and information and improve the performance features of our AI-Immunology&#8482; platform in response to an ever-changing patient population. We may experience difficulties that could delay or prevent the successful design, development, testing, and introduction of advanced versions of our AI-Immunology&#8482; platform, limiting our ability to identify new product candidates. Any of these failures could have a material adverse effect on our operating results and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our product candidates may not work as intended, may cause undesirable side effects or may have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, which could materially harm our business, financial condition, results of operations and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As with most biological and vaccine products, use of our product candidates could be associated with side effects or adverse events which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. The potential for adverse events is especially acute in the oncology setting, where patients may have advanced disease, have compromised immune and other systems and be receiving numerous other therapies. Undesirable side effects or unacceptable toxicities caused by our product candidates could cause us, our future partners, if any, or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA, the TGA or comparable regulatory authorities. Results of clinical trials of our product candidates could reveal a high and unacceptable severity and prevalence of side effects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If unacceptable side effects arise in the development of our product candidates, we, our future partners, if any, the FDA, the EMA, the TGA, competent authorities of the European Union member states, ethics committees, the institutional review boards, or IRBs, at the institutions in which clinical trials of our product candidates are conducted, or a Data Safety Monitoring Board, or DSMB, could suspend or terminate our clinical trials. The FDA, the EMA, the TGA or comparable regulatory authorities could also order us or our future partners, if any, to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our or our partners&#8217; clinical trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect that we or our future partners, if any, may have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Monitoring the safety of patients receiving our product candidates is challenging, which could adversely affect our and our partners&#8217; ability to obtain regulatory approval and commercialize our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In our ongoing and planned clinical trials, we have contracted with and are expected to continue to contract with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, these centers and hospitals may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us, our future partners, if any, or the FDA, EMA, TGA or other comparable regulatory authority delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. We also expect the centers using our product candidates, if approved, on a commercial basis could have similar difficulty in managing adverse events. Medicines used at centers to help manage adverse side effects of our product candidates may not adequately control the side effects and may have a detrimental impact on the treatment. Use of these medicines may increase with new physicians and centers administering our product candidates. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, even if our future partners, if any, successfully advance one or more of our product candidates into and through late stage clinical trials, such trials will likely only include a limited number of subjects and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be discovered when a significantly larger number of patients are exposed to the product candidate. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If any of our product candidates were to receive marketing approval and we, our future partners, if any, or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory authorities may withdraw their approval of products derived from one or more of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our future partners, if any, may be required to recall products derived from one or more of our product candidates or change the way such products are administered to patients; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">additional restrictions may be imposed on the marketing of the products derived from one or more of our product candidates or the manufacturing processes for such products or any component thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our future partners, if any, may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a Medication Guide outlining the risks of such side effects for distribution to patients; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we or our future partners, if any, could be sued and held liable for harm caused to patients; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the products derived from one or more of our product candidates may become less competitive; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our reputation may suffer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any of the foregoing events could prevent our future partners, if any, from achieving or maintaining market acceptance of the particular product candidate, even if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business. In addition, if one or more of our product candidates generally prove to be unsafe, our AI-Immunology&#8482; platform and product pipeline could be affected, which would have a material adverse effect on our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pre-clinical development, including the timeline from target identification to clinical development, is uncertain. Our pre-clinical programs may experience delays or may never advance to clinical trials, which would adversely affect our partners&#8217; ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all and would have an adverse effect on our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A portion of our product pipeline is in pre-clinical development and these programs could be delayed or not advanced into the clinic. In addition, due to our current financial position and adverse market conditions for raising additional capital, we intend to out-license certain targets we may identify and certain of our pre-clinical programs to future partners, if any, earlier than we might have otherwise done if we had the funds to mature them into more valuable opportunities for partners. We may not be able to enter into any such out-licensing arrangements for such current or future targets and as a result, we may not be able to further develop such targets or product candidates in a timely fashion or at all. In addition, we may not be able to identify any new targets and even if we do, we may not be able to enter into any such out-licensing arrangements for such new targets and as a result, we may not be able to further develop such new targets or product candidates in a timely fashion or at all. Before we or our future partners, if any, can initiate clinical trials for product candidates, we or our future partners, if any, must complete extensive pre-clinical studies, including IND-enabling Good Laboratory Practice toxicology testing that supports our planned INDs in the United States or similar applications in the EMA, the TGA and other jurisdictions. We, or our future partners, if any, must also complete extensive work on CMC activities (including collecting yield, purity and stability data) to be included in the IND filing or other equivalent regulatory filing. CMC activities for a new category of medicines require extensive manufacturing processes and analytical </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">development, which are uncertain and lengthy. For instance, issues have occurred in the past as we attempted to scale up our manufacturing and these issues may occur in the future. In addition, we, or our future partners, if any, may have difficulty identifying appropriate buffers and storage conditions to enable sufficient shelf life of batches of our pre-clinical or clinical product candidates. If we, or our future partners, if any, are required to produce new batches of our product candidates due to insufficient shelf life, it may delay the commencement or completion of pre-clinical studies or clinical trials of such product candidates. For example, we, and our future partners, if any, cannot be certain of the timely completion or outcome of our pre-clinical testing and studies and cannot predict if the FDA, the EMA, the TGA or other regulatory authorities will accept the results of our, or our future partners, if any, pre-clinical testing or our proposed clinical programs or if the outcome of our pre-clinical testing, studies and CMC activities will ultimately support the further development of our programs. As a result, we cannot be sure that we or our future partners, if any, will be able to submit INDs or similar applications for our or their pre-clinical programs on the expected timelines, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin. Additionally, while we have demonstrated our ability to move from target identification to clinical development within as little as 18&#160;months with our EVX-02 product candidate, which is now in Phase&#160;1/2a trial, no assurance can be given that we or our future partners, if any, will be able to do the same with other product candidates in various phases of clinical development and trials in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">A variety of risks associated with conducting research and clinical trials in the United States and other countries outside of Denmark and marketing our product candidates, if approved, by our future partners, if any, internationally could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We anticipate that commercialization of our product candidates, if approved, will take place globally by future partners. Accordingly, we expect that we and our future partners, if any, will be subject to additional risks related to operating in multiple countries, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">differing regulatory, application of AI and personal data requirements in such countries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in various countries and shipping the product candidate to patients in other countries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">import and export requirements and restrictions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">economic weakness, including inflation, or political instability in particular economies and markets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling in other countries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">taxes, including withholding of payroll taxes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">difficulties staffing and managing operations outside of Denmark; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">workforce uncertainty in countries where labor unrest is more common; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">potential liability under the U.S. Foreign Corrupt Practices Act of 1977 or comparable regulations in Denmark, Australia and other jurisdictions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">challenges enforcing our contractual and intellectual property rights, especially in those countries that do not respect and protect intellectual property rights to the same extent as do Denmark and the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities in other countries; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">business interruptions resulting from geopolitical actions, including war and terrorism, such as the invasion of Ukraine by Russia and the resulting armed conflict, as well the conflict in the Israel-Gaza region, as well as those resulting from climate change, natural disasters, cybersecurity attacks, and pandemics such as COVID-19 and variants such as Delta, Omicron and others. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These and other risks associated with our international operations and our collaborations with our future partners, if any, may materially adversely affect our ability to attain or maintain profitable operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interim top-line and preliminary data from studies or trials that we and/or our future partners, if any, announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data. Adverse differences between preliminary or interim data and final data could materially harm our business, financial condition, results of operations and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we and/or our future partners, if any, may publish interim top-line or preliminary data from pre-clinical studies or clinical trials. Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We and/or our future partners, if any, may also make assumptions, estimations, calculations and conclusions as part of the analyses of data, and we and/or our future partners, if any, may not have received or had the opportunity to fully evaluate all data. As a result, the top-line results that we and/or our future partners, if any, report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we and/or our future partners, if any, may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could materially harm our business prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, others, including the FDA, the EMA, the TGA and other regulatory agencies, may not accept or agree with our and/or our future partners&#8217;, if any, assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we and/or our future partners, if any, choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we and/or our future partners, if any, determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the top-line data that we and/or our future partners, if any, report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Results of pre-clinical studies and clinical trials of our product candidates may not be predictive of future trial results.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after positive results in earlier pre-clinical studies or clinical trials. These setbacks have been caused by, among other things, pre-clinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Notwithstanding any potential promising results in earlier studies and trials, we and/or our future partners, if any, cannot be certain that we and/or our future partners, if any, will not face similar setbacks. Even if our or our partners&#8217; clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, the results of our pre-clinical studies may not be predictive of the results of outcomes in human clinical trials. For example, our current product candidates and any future product candidates may demonstrate different chemical, biological and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">pharmacological properties in patients than they do in pre-clinical studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials. Even if we and/or our future partners, if any, are able to initiate and complete clinical trials, the results may not be sufficient to obtain regulatory approval for our product candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our current and/or planned clinical trials or those of our future partners, if any, may reveal significant adverse events not seen in our pre-clinical or nonclinical studies and may result in a safety profile that could delay or terminate clinical trials, or delay or prevent regulatory approval or market acceptance of any of our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There is typically an extremely high rate of attrition for product candidates across all categories of medicines proceeding through clinical trials. These product candidates may fail to show the desired safety and efficacy profile in later stages of clinical trials despite having progressed through nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in later-stage clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Some of our product candidates may need to be co-administered with other developmental therapies or approved medicines. Such combinations may have additional side effects, which may be difficult to predict in future clinical trials. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If significant adverse events or other side effects are observed in any of our and/or our future partners&#8217;, if any, current or future clinical trials, we and/or our future partners, if any, may have difficulty recruiting trial participants to any of our and/or our partners&#8217; clinical trials, trial participants may withdraw from trials, or we and/or our future partners, if any, may be required to abandon the trials or our development efforts of one or more product candidates altogether. We, and/or our future partners, if any, the FDA, the EMA, the TGA or other applicable regulatory authorities, ethics committees or an IRB may impose a clinical hold on, or suspend or terminate, clinical trials of a product candidate at any time for various reasons, including a belief that participants in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, an unfavorable benefit-risk ratio may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We and/or our future partners, if any, may not be able to develop or obtain approval for companion diagnostics required for commercialization of some of our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Some of our product candidates may require the use of companion diagnostic tools. If safe and effective use of a biologic product depends on an </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> companion diagnostic, then the FDA generally requires approval or clearance of the diagnostic, known as a companion diagnostic, concurrently with approval of the therapeutic product. To date, the FDA has generally required </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> companion diagnostics intended to select the patients who will respond to cancer treatment to obtain a pre-market approval, or PMA, for that diagnostic, which can take up to several&#160;years, simultaneously with approval of the biologic product. Similarly, in the European Union, an </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> companion diagnostic may be placed on the market only if it conforms to certain &#8220;essential requirements&#8221; and bears the Conformit&#233; Europ&#233;enne Mark, or CE Mark, and the conformity assessment process to obtain the CE Mark can be lengthy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For our personalized immunotherapy candidates, the FDA and similar regulatory authorities outside of the United States such as the EMA or the TGA, may require the development and regulatory approval of a companion diagnostic assay as a condition to approval. The FDA may require PMA supplemental approvals for use of that same companion diagnostic as a condition of approval of additional individualized therapeutic candidates. We do not have experience or capabilities in developing or commercializing </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">companion diagnostics and plan to, if required, rely in large part on third parties to perform these functions. Companion diagnostic assays are subject to regulation by the FDA and other comparable regulatory authorities in other jurisdictions as medical devices and require separate regulatory approval prior to the use of such diagnostic assays with our therapeutic candidates. If we, or any third parties that we engage to assist us, are unable to successfully develop companion diagnostic assays for use with our therapeutic candidates, or are unable to obtain regulatory approval or experience delays in either development or obtaining regulatory approval, we and/or our future partners, if any, may be unable to identify patients with the specific profile targeted by our product candidates for enrollment in our clinical trials. Accordingly, further investment may be required to further develop or obtain the required regulatory approval for the relevant companion diagnostic assay, which would delay or substantially impact our ability to conduct additional clinical trials or obtain regulatory approval. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The FDA, EMA, TGA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There may not be pharmacologic therapies approved to treat the underlying causes of many diseases that we and/or our future partners, if any, may address in the future. For instance, we and/or our future partners, if any, may apply our technology to develop therapeutics in indications for which no or few clinical trials have been attempted. As a result, any future design and conduct of clinical trials of product candidates for the treatment of certain diseases may take longer, cost more, or be less effective as part of the novelty of development in these diseases. Even if we decide to conduct clinical trials and the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we and/or our future partners, if any, may conduct for our programs. Further, even if we and/or our future partners, if any, do achieve the pre-specified criteria, our and/or our future partners&#8217;, if any, clinical trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we and/or our future partners, if any, achieve statistically significant results on that endpoint, if we and/or our future partners, if any, do not do so on the secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe, Australia and other countries may make similar findings with respect to these endpoints. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The FDA, EMA, TGA or other comparable regulatory authorities may disagree with our and/or our future partners&#8217;, if any, regulatory plan and we and/or our future partners, if any, may fail to obtain regulatory approval of our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the results of our and/or our future partners&#8217;, if any, clinical trials are sufficiently compelling, we and/or our future partners, if any, intend to discuss with the FDA, the EMA, the TGA or other regulatory authorities, submission of a BLA, EMAA, AMAA or other comparable submissions or to obtain regulatory approval in the United States or elsewhere, an European Union marketing authorization, an Australian marketing authorization or other regulatory authorization for our product candidates. However, we and/or our future partners, if any, do not have any agreement or guidance from the FDA that our and/or our future partners&#8217;, if any, regulatory development plans will be sufficient for submission of a BLA, EMAA, AMAA or other comparable submissions or to obtain regulatory approval in the United States or elsewhere for any of our product candidates. The FDA, EMA, TGA or other regulatory agencies may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA, EMA, TGA or other regulatory agencies may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA, EMA, TGA or other regulatory agencies that are more accelerated than those available for regular approvals. In addition, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA, EMA, TGA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our and/or our future partners&#8217;, if any, clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the FDA, the EMA, the TGA or comparable regulatory authorities may disagree with the design or implementation of our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we and/or our future partners, if any, may be unable to demonstrate to the satisfaction of the FDA, the EMA, the TGA or comparable regulatory authorities that our product candidates are safe and effective for any of their proposed indications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA, the TGA or comparable regulatory authorities for approval, including due to the heterogeneity of patient populations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we and/or our future partners, if any, may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the FDA, the EMA, the TGA or comparable regulatory authorities may disagree with our and/or our future partners&#8217;, if any, interpretation of data from pre-clinical studies or clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA, the EMA, the TGA or comparable regulatory authorities to support the submission of a BLA, EMAA, AMAA or other comparable submissions or to obtain regulatory approval in the United States or elsewhere; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the FDA, the EMA, the TGA or comparable regulatory authorities will inspect our third-party manufacturers&#8217; and/or our future partners&#8217;, if any, manufacturing facilities and may not approve such facilities; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the approval policies or regulations of the FDA, the EMA, the TGA or comparable regulatory authorities may significantly change in a manner rendering our or our future partners&#8217;, if any, clinical data insufficient for approval. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We and/or our future partners, if any, may not be able to file INDs with the FDA, clinical trial applications with the competent authorities of European Union member states, clinical trial applications with the competent authorities in Australia or similar applications with other comparable regulatory authorities to commence additional clinical trials on the timelines we and/or our future partners, if any, expect, and even if we and/or our future partners, if any, are able to, one or more of these regulatory authorities may not permit us or our future partners, if any, to proceed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The timing of filing on our product candidates is dependent on further pre-clinical, clinical and manufacturing success. We and/or our future partners, if any, cannot be sure that filing of an IND or IND amendment with the FDA, a clinical trial application with the competent authorities of European Union member states, a clinical trial application with the competent authorities in Australia or similar application with other comparable regulatory authorities will result in the FDA, the competent authorities of European Union member states, the competent authorities in Australia or any comparable regulatory authority allowing testing and clinical trials to begin, or that, once begun, issues will not arise that result in the suspension or termination of such clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, clinical trial application or similar applications, no assurance can be given that such regulatory authorities will not change their requirements in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We and/or our future partners, if any, may seek orphan drug designation for some or all of our product candidates across various indications, but we and/or our future partners, if any, may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We and/or our future partners, if any, may seek for orphan drug designation in the United States and other jurisdictions, such as the European Union, where a similar designation may be available for our product candidates. In the United States, under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population of 200,000 or greater in the United States where there is no reasonable expectation that the cost of developing the drug or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">biologic will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives, such as opportunities for grant funding toward clinical trial costs, tax advantages, and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full new drug application, or NDA, or a BLA, to market the same drug or biologic for the same indication for seven&#160;years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the original manufacturer is unable to assure sufficient product quantity. Similar rules apply in the European Union and Australia with respect to drugs or biologics designated as orphan medicinal products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective. Further, even if we and/or our future partners, if any, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may receive and be approved for the same condition, and only the first applicant to receive approval will receive the benefits of marketing exclusivity. Even after an orphan-designated product is approved, the FDA can subsequently approve a later drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior if it is shown to be safer, more effective, or makes a major contribution to patient care. Similar considerations apply in the European Union and Australia with respect to drugs or biologics designated as orphan medicinal products. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process. In addition, while we and/or our future partners, if any, may seek orphan drug designation for our product candidates, we may never receive such designations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We and/or our future partners, if any, may seek breakthrough therapy or fast-track designation for one or more of our product candidates, but we and/or our future partners, if any, may not receive such designations. Even if we and/or our future partners, if any, do receive such designations, it may not lead to a faster development or regulatory review or approval process, and it may not increase the likelihood that such product candidates will receive marketing approval.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We and/or our future partners, if any, may seek a breakthrough therapy designation in the United States and other jurisdictions, such as the European Union, where a similar designation may be available, for one or more of our product candidates. In the United States, a breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we and/or our future partners, if any, believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for qualification, or it may decide that the time period for FDA review or approval will not be shortened. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We and/or our future partners, if any, may also seek Fast Track Designation in the United States and/or a Conditional Market Authorization, or CMA, in the European Union for some of our product candidates. If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">demonstrates the potential to address significant unmet medical needs for this condition, the drug sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, and even if we and/or our future partners, if any, believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. In January&#160;2023, we received Fast&#160;Track Designation for our EVX-01 product candidate, to be used in combination with pembrolizumab (KEYTRUDA) for the treatment of patients with unresectable metastatic melanoma to improve progression free survival. Even though we have received this Fast Track Designation and even if we receive Fast Track Designation, for any of our other product candidates, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track Designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We expect some of the product candidates we develop will be regulated as biologics in the United States and elsewhere and therefore they may be subject to competition from biosimilars approved through an abbreviated regulatory pathway sooner than expected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the other company&#8217;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that any of our product candidates approved as a biological product under a BLA should qualify for a 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We and/or our future partners, if any, may be unable to obtain regulatory approval for our product candidates under applicable international regulatory requirements. The denial or delay of such approval would delay commercialization of our product candidates and adversely impact our potential to generate revenue, which could materially harm our business, financial condition, results of operations and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Approval by the FDA in the United States, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. In order to eventually market any of our product candidates in any other jurisdiction, we and/or our future partners, if any, must establish and comply with numerous and varying regulatory requirements on a jurisdiction-by-jurisdiction basis regarding safety and efficacy. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Seeking regulatory approval in other jurisdictions could result in difficulties and costs for us and require additional pre-clinical studies or clinical trials which could be costly and time-consuming. Regulatory </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. The European Union, Australia and other jurisdictions&#8217; regulatory approval processes involve all of the risks associated with FDA approval. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we and/or our future partners, if any, fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if we and/or our future partners, if any, receive regulatory approval of our product candidates, we and/or our future partners, if any, will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. We may be subject to penalties if we and/or our future partners, if any, fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even if we and/or our future partners, if any, obtain regulatory approval in a jurisdiction, the applicable regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we and/or our future partners, if any, fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">issue a warning letter asserting that we are in violation of the law; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">seek an injunction or impose civil or criminal penalties or monetary fines; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">suspend or withdraw regulatory approval or revoke a license; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">suspend any ongoing clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">refuse to approve a pending BLA or supplements to a BLA submitted by us; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">seize product; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">refuse to allow us to enter into supply contracts, including government contracts. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our and/or our partners&#8217; ability to commercialize any approved products and generate revenues. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If any of our product candidates cause undesirable side effects, it could delay or prevent their regulatory approval, limit the commercial potential, or result in significant negative consequences following any potential marketing approval. Product candidates we and/or our future partners, if any, may develop may be associated with an adverse immune response or other serious adverse events, undesirable side effects or unexpected characteristics. In addition to serious adverse events or side effects caused by any of our product candidates, the administration process or related procedures also can cause undesirable side effects. If any such events occur, the clinical trials of any of our product candidates could be suspended or terminated. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If in the future, we and/or our future partners, if any, are unable to demonstrate that such adverse events were caused by factors other than our product candidates, the FDA, the EMA, the TGA or other regulatory authorities could order us to cease further development of, or deny approval of, any of our product candidates for any or all targeted indications. Even if we and/or our future partners, if any, are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled trial participants to complete the trial. Moreover, if we and/or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">our future partners, if any, elect, or are required, to delay, suspend or terminate any clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product sale revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our and/or our partners&#8217; ability to identify and develop product candidates, and may materially harm our business, financial condition, result of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, if we and/or our future partners, if any, successfully obtain regulatory approval for a product candidate, the FDA, the EMA, the TGA or other regulatory authority could require us to adopt a REMS or a risk management plan, or RMP, to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry. Furthermore, if we, our future partners, if any, or others later identify undesirable side effects caused by any product that we and/or our future partners, if any, develop based on one or more of our product candidates, several potentially significant negative consequences could result, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory authorities may suspend or withdraw approvals or revoke licenses of such product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory authorities may require additional warnings on the label; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we and/or our future partners, if any, may be required to change the way a product is administered or conduct additional clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we could be sued and held liable for harm caused to patients and their children; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our reputation may suffer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any of these events could prevent us from achieving or maintaining market acceptance of any products we and/or our future partners, if any, may identify and develop based on one or more of our product candidates and could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we and/or our future partners, if any, are successful in gaining approval for any of our product candidates, we and/or our future partners, if any, will continue to face significant regulatory oversight of the manufacturing and distribution of our products. Product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA, the EMA, the TGA and other regulatory authorities for compliance with Current Good Manufacturing Practices, or cGMP, and adherence to commitments made in the BLA. If we, our future partners, if any, or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we and/or our future partners, if any, as applicable, are not successful in discovering, developing and commercializing additional product candidates beyond our current portfolio, our ability to expand our business and achieve our strategic objectives would be impaired.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A key element of our strategy is to discover and, through our future partners, if any, potentially develop and commercialize additional product candidates beyond our current portfolio to treat various conditions and in a variety of therapeutic areas. We intend to do so by investing in our own AI-Immunology&#8482; platform to engage in drug and target discovery efforts, exploring potential collaborations for the development of new product candidates, and potentially in-licensing delivery technologies. We may also out-license potential new product candidates to future partners, if any, that have their own delivery technology. Furthermore, we may enter into co-development or other partnership arrangements based on our AI-Immunology&#8482; platform without pre-clinical or clinical studies including but not limited to responder models. Identifying new product candidates requires substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Even if we identify product candidates that initially show promise, we and/or our future partners, if any, may fail to successfully develop and commercialize such product candidates for many reasons, including the following: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our AI-Immunology&#8482; platform may not successfully identify potential product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">competitors may develop alternatives that render our product candidates obsolete; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an approved product may not be accepted as safe and effective by trial participants, the medical community or third-party payors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are unsuccessful in identifying, developing and, through our future partners, if any, commercializing additional products, our potential for growth may be impaired. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new or existing product candidates from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could materially harm our business, financial condition, results of operations and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The ability of the FDA and other government agencies to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency has fluctuated in recent&#160;years as a result. In addition, government funding of government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Disruptions at the FDA and other government agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several&#160;years, including beginning on December&#160;22, 2018, the United States government has shut down several times and certain regulatory agencies, such as the FDA, has had to furlough critical FDA and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process its regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The ability of the FDA and other regulatory authorities outside the United States to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s or other regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s or other regulatory authorities&#8217; ability to perform routine functions. For example, average review times at the FDA have fluctuated in recent&#160;years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, such as the EMA following its relocation to Amsterdam and resulting staff changes, may also slow the time necessary for new drugs, medical devices and biologics or modifications to approved drugs, and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several&#160;years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections at domestic and foreign manufacturing facilities from March&#160;2020 until July&#160;2021. Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic, and any resurgence of the virus may lead to further inspectional delays. Regulatory authorities outside the United States have adopted similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the FDA or other regulatory authorities become unable to continue their current level of performance, we and/or our future partners, if any, could experience delays and setbacks for our product candidates and for any approvals we and/or our future partners, if any, may seek which could adversely affect our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business, operations and clinical development plans and timelines have been affected by the COVID-19 pandemic and a future pandemic, epidemic, or outbreak of an infectious disease, such as the COVID-19 pandemic, may materially and adversely affect our business operations, including the manufacturing, clinical trial and other business activities performed by us, our future partners, if any, or by suppliers or third parties with whom we conduct business, including our CDMOs, CROs, shippers and others.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our business has been and could be further adversely affected by health epidemics wherever we have clinical trial sites or other business operations. In addition, health epidemics could cause significant disruption in the operations of third-party CDMOs, CROs and other third parties upon whom we rely. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If there is a future pandemic, other aspects of our ongoing clinical trials and future planned clinical trials may be adversely affected, delayed or interrupted, including, for example, site initiation, patient recruitment and enrollment, availability of clinical trial materials, clinical trial site data monitoring and efficacy, safety and translational data collection, and data analysis. Some patients and clinical investigators may not be able to comply with clinical trial protocols and patients may choose to withdraw from our trials or we may have to pause enrollment or we may choose to or be required to pause enrollment and/or patient dosing in our ongoing or planned clinical trials in order to preserve health resources and protect trial participants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, we depend on a global supply chain, including timely shipment of patient specimens and ingredients, to manufacture product candidates used in our pre-clinical studies and clinical trials. Quarantines, &#8220;shelter-in-place&#8221; and similar government orders, or the expectation that such orders, shutdowns or other restrictions could occur, whether related to COVID-19 or other epidemics, could impact personnel at third-party manufacturing facilities in the United States, Europe and other countries, or the availability or cost of materials, any of which factors, either individually or collectively, could disrupt our supply chain. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, it has been widely reported that there has been a global shortage of microchips that has been affecting almost every industry, which has impacted the production of machinery and final products. This shortage could adversely impact our suppliers&#8217; ability to meet their contractual obligations to provide us with necessary products and materials. If our relationships with our suppliers or other vendors are terminated or scaled back as a result of the COVID-19 pandemic or other epidemics, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Replacing or adding additional suppliers or vendors involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new supplier or vendor commences work. As a result, delays may occur, which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. Although we carefully manage our relationships with our suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not harm our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, our business, including our pre-clinical studies and clinical trials have been and may continue to be affected by the COVID-19 pandemic or other pandemics. Clinical site initiation, patient enrollment and activities that require visits to clinical sites, including data monitoring, have been and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic or concerns among patients about participating in clinical trials during a pandemic. Some patients may have difficulty following certain aspects of clinical trial protocols if quarantines impede patient movement or interrupt </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">healthcare services. For example, some patients, may not be able to attend follow-ups and comply with trial protocols. These challenges have and, in the future, may continue to also increase the costs of completing our clinical trials. Similarly, if we are unable to successfully recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 or experience additional restrictions by their institutions, city or state, our clinical trial operations could be adversely impacted. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event that government authorities were to impose restrictions on employees coming to the workplace, our employees who currently are not working from home may no longer be able to access our facilities, including our laboratories and our operations may be further limited or curtailed. An increase in the number of personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. Further, any such restrictions may also impact the availability or cost of materials, which would disrupt our supply chain and manufacturing efforts and could affect our ability to enter into partnerships and discovery collaborations and to conduct ongoing and planned clinical trials and preparatory activities. We may also face difficulties in obtaining access to manufacturing slots for our product candidates. For example, a number of vaccines for COVID-19 were granted Emergency Use Authorization by the FDA in late 2020 and early 2021, and resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, personnel working from home could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors. Further, we and our third-party service providers, including our CROs, the clinical trial sites, our manufacturers and suppliers, may experience staffing shortages as a result of personnel contracting COVID-19 and its variants such as Delta, Omicron and others. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, we may experience additional disruptions that could severely impact our business and clinical trials, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">limitations on employee resources that would otherwise be focused on the conduct of our pre-clinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">refusal of the FDA or other regulatory authorities to accept data from clinical trials in these affected geographies; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">shipment of patient specimens / biological material across county boarders and nationally. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These and similar, and perhaps more severe, disruptions in our operations could materially harm our business, financial condition, results of operations, and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Russia&#8217;s invasion of Ukraine and ancillary developments may have an adverse effect on our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The invasion of Ukraine by Russia, the resulting conflict and retaliatory measures by the global community have created global security concerns, including the possibility of expanded regional or global conflict, which have had, are likely to continue to have, short-term and likely longer-term adverse impacts on Ukraine and Europe and around the globe. Potential ramifications include disruption of the supply chain </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">including research activities and complications with the conduct of ongoing and future clinical trials of our product candidates, including patient enrollment. We and our collaborators rely on global networks of contract research organizations and clinical trial sites to enroll patients. Delays in research activities or in the conduct of our clinical trials could increase associated costs and, depending upon the duration of any delays, require us to find alternative suppliers at additional expense. In addition, the conflict between Russia and the Ukraine has had significant ramifications on global financial markets, which may adversely impact our ability to raise capital on favorable terms or at all </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unfavorable global and regional economic, political, health, climate and other conditions and events, including recent conflict in the Israel-Gaza region, could adversely affect our business, financial condition or results of operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our results of operations could be adversely affected by global or regional economic, political, health, climate and other conditions and events, including recent conflict in the Israel-Gaza region. A global financial crisis or global or regional political and economic instability, wars, terrorism, civil unrest, outbreaks of disease and pandemics, such as COVID-19, and other unexpected events, such as natural disasters, internet security threats, and damage to global communication networks, could cause extreme volatility, disrupt our business and increase our costs and expenses. Business disruptions could include, among others, disruptions to clinical enrollment, clinical site availability, patient accessibility, conduct of our clinical trials and commercialization activities, as well as temporary closures of our facilities and the facilities of suppliers or manufacturers in our supply chain. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For example, trade policies and geopolitical disputes (including as a result of China-Taiwan geo-political instability) and other international conflicts can result in tariffs, sanctions and other measures that restrict international trade, and can materially adversely affect our business, particularly if these measures occur in regions where our third-party contract manufacturers operate. Countries may also adopt measures, such as controls on imports or exports of goods, technology or data, that could adversely impact our operations and supply chain. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For example, the military conflict between Russia and Ukraine has increased the likelihood of supply interruptions and made it difficult to conduct business operations, including clinical trials, in the region and in nearby countries. Such developments could negatively impact such operations or require us to delay or suspend clinical trial activities, which may increase product development costs and harm our business. In addition, the COVID-19 outbreak, including developments involving subsequent COVID-19 variants, significantly affected the financial markets of many countries and resulted and may in the future result in a variety of regulatory orders, guidance and restrictions. Similarly, global climate change could result in certain types of natural disasters occurring more frequently or with more intense effects. We do not have multiple-site capacity for all of our operations in the event of a business disruption. Furthermore, parties in our supply chain and our partners are similarly vulnerable to these global or regional economic, political, health, climate and other conditions and events. Global or regional economic, political, health, climate and other conditions and events could result in a variety of risks to our business, including our ability to raise capital when needed on acceptable terms, if at all. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which such conditions and events could adversely impact our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to the Manufacturing of our Product Candidates and Future Pipeline</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We and/or our future partners, if any, may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping. If we, and/or our future partners, if any, or any of the third-party manufacturers we and/or our future partners&#8217;, if any, work with encounter such difficulties, our and/or our future partners, if any,&#8217; ability to supply materials for clinical trials or any approved product could be delayed or stopped.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At early-stage development product knowledge is limited. Specifically, due to the nature of our personalized immunotherapies and novel delivery technologies, we and/or our future partners, if any, may encounter difficulties in manufacturing, product release, shelf life, testing, storage and supply chain management, or shipping. These difficulties could be due to any number of reasons including, but not limited to, complexities of producing batches at larger scale, equipment failure, choice and quality of raw </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">materials and excipients, analytical testing technology, and product instability. In an effort to optimize product features, we have in the past and we and/or our future partners, if any, may in the future make changes to our product candidates in their manufacturing and stability formulation and conditions. This may in the future result in our and/or our future partners&#8217;, if any, having to resupply batches for pre-clinical or clinical activities when there is insufficient product stability during storage and insufficient supply. Insufficient stability or shelf life of our product candidates could materially delay our and/or our future partners&#8217;, if any, ability to continue the clinical trial for that product candidate or require us and/or our future partners, if any, to begin a new clinical trial with a newly formulated drug product, due to the need to manufacture additional pre-clinical or clinical supply. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For our personalized therapies, we and/or our future partners, if any, may encounter issues with our and/or our future partners&#8217;, if any, ability to timely and efficiently manufacture product given the on-demand requirements of such therapies, thereby potentially impacting clinical and commercial supply. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As we and/or our future partners, if any, continue developing new manufacturing processes for our drug substances and drug products, the changes we and/or our future partners, if any, implement to manufacturing process may in turn impact specification and stability of our drug products. Changes in our manufacturing processes may lead to failure of lots and this could lead to substantial delays in our clinical trials. Our product candidates may prove to have a stability profile that leads to a lower than desired shelf life of the final approved immunotherapy. This poses risk in supply requirements, wasted stock and higher cost of goods. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We and/or our future partners, if any, may be dependent on a number of equipment providers who are also implementing novel technology. Further, we and/or our future partners, if any, may develop custom manufacturing equipment for certain of our product candidates. If such equipment malfunctions or we and/or our future partners, if any, encounter unexpected performance issues, we and/or our future partners, if any, could encounter delays or interruptions to clinical and commercial supply. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Due to the number of different products being manufactured in the same facility, we and/or our future partners, if any, may have cross contamination of products in the manufacturing facility, or in in the pharmacy during preparation of the final drug for patient administration that affect the integrity of our product candidates. Additionally supplied raw materials and consumables can be contaminated or/or adulterated. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As we and/or our future partners, if any, scale the manufacturing output for particular programs, we plan to continuously improve process robustness, yield, purity, and the stability profile and shelf-life of our product candidates from clinical stage studies through commercial launch. Due to continuous improvement in manufacturing processes, we and/or our future partners, if any, may introduce changes to the manufacturing process, raw materials and/or manufacturing facilities for a particular program during development. However, such changes might require extended pharmaceutical property testing, such as six- or 12-month stability testing that could delay clinical trials. Additionally, there is always the risk of unexpected problems when introducing changes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We and/or our future partners, if any, may utilize a number of raw materials and excipients that are either new to the pharmaceutical industry or are being employed in a novel manner. Some of these raw materials and excipients may not have been scaled to a level to support commercial supply and could experience unexpected manufacturing or testing failures, or supply shortages. Such issues with raw materials and excipients could cause delays or interruptions to clinical and commercial supply of our product candidates. Further, one or more of our programs may have a single source of supply for raw materials and excipients. Additionally, we and our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or supply chain issues, such as those experienced due to the COVID-19 pandemic, or as a result of climate change, or unstable political environments, such as recent events in Ukraine and Russia or in the Israel-Gaza region, or other geopolitical uncertainty. If we and/or our future partners, if any, and manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to manufacture our products, or to make our product candidates available for clinical trials could be jeopardized. Any such delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We and/or our future partners, if any, may learn that any or all of our product candidates are less stable than desired. We and/or our future partners, if any, may also find that transportation conditions negatively impact product quality. This may require changes to the formulation or manufacturing process for one or more of our product candidates and result in delays or interruptions to clinical or commercial supply. In addition, the cost associated with such transportation services and the limited pool of vendors may also add additional risks of supply disruptions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The occurrence of any of these factors could materially harm our business, financial condition, results of operations, and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We expect to rely on external CDMOs or a future partner, if any, for the manufacture of our product candidates. Our or our future partners&#8217;, if any, inability to manufacture or have manufactured sufficient quantities of our product candidates, or our or our future partners&#8217;, if any, failure to comply with applicable regulatory requirements, would materially and adversely affect our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Manufacturing is a vital component of all of our product candidates. All manufacturing for clinical and commercial use must be performed in compliance with cGMP regulations. We expect to rely on external CDMOs for the manufacture of our product candidates. For our personalized immunotherapies, it is not possible to build up product stocks in advance as for standard pharmaceuticals due to the personalized nature of the therapy. If any of the facilities of our CDMOs experiences difficulties, including related to manufacturing, product release, shelf life, testing, storage and supply chain management or shipping, our and/or our future partners, if any,&#8217; clinical development programs may be delayed or suspended until we and/or our future partners, if any, can resume operations. We may also be required to incur significant expenditures to resolve such difficulties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CDMOs facilities and the facilities of our future partners, if any, are subject to various regulatory requirements and may be subject to inspection by the FDA, EMA, TGA or other regulatory authorities. If our CDMOs or our future partners, if any, cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA, TGA or comparable regulatory authorities in other jurisdictions, we and or our future partners, if any, may not be able to rely on our CDMOs&#8217; manufacturing facilities for the manufacture of our product candidates. If the FDA, EMA, TGA or another comparable regulatory authority finds our CDMOs&#8217; facilities or the facilities of our future partners, if any, inadequate for the manufacture of our product candidates or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we and /or our future partners, if any, may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates. Additionally, we and/or our future partners, if any, may experience manufacturing difficulties due to resource constraints, labor disputes, the effects of climate change, cybersecurity breaches or unstable political environments. If we and/or our future partners, if any, were to encounter any of these difficulties, our and/or our future partners&#8217;, if any, ability to provide our product candidate to patients in clinical trials, or to provide product for the treatment of patients once approved, would be jeopardized. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are, and our future partners, if any, shall be subject to regulatory and operational risks associated with the physical and digital infrastructure at both our future partners&#8217;, if any, internal manufacturing facilities and at those of external service providers.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may engage CDMOs that have facilities with a high level of digitization for clinical manufacturing relative to industry standards. While this is meant to improve operational efficiency, this may pose additional risk of process equipment malfunction and even overall manufacturing system failure or shutdown due to internal or external factors including, but not limited to, design issues, system compatibility or potential cybersecurity breaches. This may lead to delay in supply or shutdown of our CDMOs&#8217; or our future partners&#8217;, if any, facilities. Any disruption in our CDMOs or our future partners, if any,&#8217; manufacturing capabilities could cause delays in production capacity for drug substances or drug products, impose additional costs, or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">may require us to identify, qualify and establish relationships with additional CDMOs with alternative manufacturing sites, the occurrence of which could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">As the development and commercial capacity for our or our future partners&#8217;, if any, product candidates and products expand, we and/or our future partners, if any, may need to establish additional manufacturing capabilities and expand to other locations or geographies, which may lead to regulatory delays or prove costly. If we or our future partners, if any, fail to select the correct location, complete the construction in an efficient manner, recruit the required personnel, and generally manage our growth effectively, the development and production of our product candidates could be delayed or curtailed. Additional investments may be needed if changes in our manufacturing process lead to required changes in our infrastructure. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Certain of our product candidates rely on the availability of key raw materials, which may not be available to us on acceptable terms or at all.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Certain of our product candidates require key raw materials, some of which are manufactured by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. These suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also do not have contracts with many of these suppliers, and we may not be able to contract with them on acceptable terms or at all. Accordingly, we may in the future experience delays in receiving key raw materials to support clinical or commercial manufacturing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our product candidates are inherently sensitive to shipping and storage conditions and could be subject to risk of loss or damage.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our product candidates are sensitive to temperature, storage and handling conditions. Loss in product candidates could occur if the product or product intermediates are not stored or handled properly. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are subject to significant regulatory oversight with respect to identification and manufacturing our product candidates. We do not have our own manufacturing facilities and rely on CDMOs or our future partners, if any, to manufacture our product candidates. The manufacturing facilities of our CDMOs or our future partners, if any, may not meet regulatory requirements. Failure to meet cGMP requirements set forth in regulations promulgated by the FDA, the EMA, the TGA and other comparable regulatory authorities could result in significant delays in and costs of any products we or our future partners, if any, develop.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The manufacturing of all of our product candidates, for clinical trials or commercial sale, if approved, is subject to extensive regulation. cGMP requirements govern manufacturing processes and procedures, including record-keeping, and the implementation and operation of quality systems to control and assure the quality of products and materials used in clinical trials. We do not have our own manufacturing facilities and rely on third party CDMOs or future partners, if any, to manufacture our product candidates. The manufacturing facilities of our third-party CDMOs or future partners, if any, may not meet regulatory requirements. Failure to meet cGMP requirements set forth in regulations promulgated by the FDA, the EMA, the TGA and other comparable regulatory authorities could result in significant delays in and costs of our product candidates. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Poor control of the cGMP production processes can lead to product quality failures that can impact our or our future partners&#8217;, if any, ability to supply product, resulting in lost revenue, cost overruns and delays to clinical timelines, which could be extensive. Such production process issues include but are not limited to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">critical deviations in the manufacturing process; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">facility and equipment failures; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">contamination of the product due to an ineffective procedures; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">facility contamination as assessed by the facility and utility environmental monitoring program; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">ineffective process, equipment or analytical change management, resulting in failed lot release criteria; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">raw material failures due to ineffective supplier qualification or regulatory compliance issues at critical suppliers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">ineffective corrective actions or preventative actions taken to correct or avoid critical deviations due to our developing understanding of the manufacturing process as we scale; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">failed or defective components or consumables. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All necessary documentation in support of clinical trials as well as a BLA or other marketing authorization application must be provided on a timely basis and must adhere to the FDA&#8217;s, the EMA&#8217;s, the TGA&#8217;s and other countries&#8217; cGMP or other quality assurance requirements which are enforced, in the case of the FDA, in part through its facility inspection program. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Regulatory authorities typically require representative manufacturing site inspections to assess adequate compliance with cGMPs and manufacturing controls as described in the filing. If one of our third-party or future partners&#8217;, if any, manufacturing sites fails to provide sufficient quality assurance or control, approval to initiate clinical trials or to commercialize our product candidates may not be granted. Inspections by regulatory authorities may occur at any time during the development or commercialization phase of products. The inspections may be product-specific or facility-specific for broader cGMP inspections or as a follow up to development or market issues that the regulatory agency may identify. Deficient inspection outcomes may negatively affect the ability of our third-party CDMOs or future partners, if any, to fulfill their supply obligations, impacting or delaying supply or delaying the development of one or more of our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The manufacturing process for any products that we may develop is subject to the FDA&#8217;s, the EMA&#8217;s, the TGA&#8217;s and other regulatory authorities&#8217; approval processes, and we may need to contract with manufacturers who we believe can meet applicable regulatory authority requirements on an ongoing basis. If our third-party CDMOs or future partners, if any, are not able to reliably produce product candidates to specifications acceptable to the FDA, the EMA, the TGA or other regulatory authorities, we or our future partners, if any, may not be able to obtain or maintain the approvals we or they need for our clinical trials or to commercialize such product candidates. Even if our future partners, if any, obtain regulatory approval for any of our product candidates, there is no assurance that either our CDMOs or our future partners, if any, will be able to manufacture our product candidates to specifications acceptable to the FDA, EMA, TGA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts or increase our cost of goods. The occurrence of any of the foregoing could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we may not have direct control over the ability of our CDMOs or our future partners, if any, to maintain adequate quality control, quality assurance and qualified personnel. Furthermore, our CDMOs may be engaged with other companies to supply or manufacture materials or products for such companies, which exposes our CDMOs to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">may generally affect the regulatory status of our CDMOs&#8217; facilities. Our future partners&#8217;, if any, failure, or the failure of our third-party CDMOs, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our products and product candidates (including those of our future partners, if any,) and our overall business operations. Our future dependence upon others for the manufacture of our product candidates and raw materials may adversely affect our future profit margins and our ability to conduct our clinical trials and the ability of our future partners, if any, to commercialize any products that receive regulatory approval on a timely and competitive basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA, EMA, TGA and other regulatory authorities may require our future partners, if any, to submit product samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA, the TGA or other regulatory authorities may require that our future partners, if any, do not distribute a lot or lots until the relevant agency authorizes such release. Deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Our third-party CDMOs or future partners, if any, may have, in the past, experienced lot failures and some may have experienced product recalls. Lot failures or product recalls with respect to product produced by either our future partners&#8217;, if any, facilities or those of our third-party CDMOs could cause us and our future partners, if any, to delay clinical trials or product launches, which could be costly to us and otherwise materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our future partners, if any, and our third-party CDMOs also may encounter problems hiring and retaining the experienced scientific, quality-control and manufacturing personnel needed to operate our or our future partners&#8217;, if any, manufacturing processes and operations, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. While we will train and qualify all personnel around the appropriate handling of our product candidates and materials, we may not be able to control for or ultimately detect intentional sabotage or negligence by any of our employees, the employees of our future partners, if any, or any contractor. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to the Commercialization of our Pipeline</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We will rely on our future partners, if any, to further develop our product candidates in late-stage clinical trials and to commercialize our product candidates if regulatory approval is obtained. The successful commercialization of our product candidates by our future partners, if any, will depend in part on the extent to which governmental authorities, private health insurers and other third-party payors provide coverage and adequate reimbursement levels and implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our partners&#8217; ability to market those products and thereby decrease our ability to generate revenue, which could materially harm our business, financial condition and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will rely on our future partners, if any, to develop our product candidates in late-stage clinical trials and to commercialize our product candidates if regulatory approval is obtained. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments such as the medicines that we and our future partners, if any, hope to develop and sell. In addition, because several of our product candidates represent new approaches to the treatment of cancer, we and/or our future partners, if any, cannot accurately estimate how these products would be priced, whether reimbursement could be obtained, or any potential revenue. Sales of our product candidates will depend substantially, both domestically and in other countries, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, our future partners, if any, may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow our future partners, if any, to establish or maintain pricing sufficient to realize a sufficient return on our investment in our products, if any. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products, including genetic medicines. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the United States Department of Health and Human Services, or HHS, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel products such as any we may develop. Reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States but have not been approved for reimbursement in certain European countries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Outside the United States, certain countries, including a number of member states of the European Union and Australia, set prices and reimbursement for pharmaceutical products, with limited participation from the marketing authorization holders. We cannot be sure that such prices and reimbursement will be acceptable to us or our future partners, if any. If the regulatory authorities in these jurisdictions set prices or reimbursement levels that are not commercially attractive for our future partners, if any, our revenues from sales by our future partners, if any, and the potential profitability of our drug products, if approved, in those countries would be negatively affected. An increasing number of countries are taking initiatives to attempt to reduce large budget deficits by focusing cost-cutting efforts on pharmaceuticals for their state-run health care systems. These international price control efforts have impacted all regions of the world but have been most drastic in the European Union. In the European Union, changes to pricing and reimbursement are almost exclusively a matter for national, and not European Union, law and policy. Additionally, some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. As a result, our future partners, if any, might obtain marketing approval for a product in a particular country, but then may experience delays in the reimbursement approval of such product or be subject to price regulations that would delay our partners&#8217; commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of the product in that particular country. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, increasing efforts by governmental and third-party payors, in the United States and in other countries, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. For example, the United States government has released a &#8220;blueprint,&#8221; which is a plan to reduce the cost of drugs. The blueprint contains certain measures that the HHS is already working to implement. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect that our future partners, if any, will experience pricing pressures in connection with the sale of any of our product candidates that may be approved, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products in the marketplace. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We face significant competition in an environment of rapid technological and scientific change, and our failure to effectively compete would prevent us from achieving our goals. Most of our competitors have significantly greater resources than we do, and we may not be able to compete successfully.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The pharmaceutical market is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and other public and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to target. Many of our competitors have: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">more extensive experience in pre-clinical testing, conducting clinical trials, obtaining regulatory approvals, and in manufacturing, marketing and selling drug products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">product candidates that are based on previously tested or accepted technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">products that have been approved or are in late stages of development; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborative arrangements in our target markets with leading companies and research institutions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our product candidates may face intense competition from drugs that have already been approved and accepted by the medical community for the treatment of the conditions for which drugs that may be developed from our product candidates are designed to address. We also expect that our product candidates will face competition from new drugs that enter the market. There are a number of drugs currently under development, which may become commercially available in the future, for the treatment of conditions for which we and our future partners, if any, are trying, or may in the future try, to develop drugs. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively, than any products developed using our technologies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We anticipate competing with the largest pharmaceutical companies in the world, many of which are all currently conducting research in the fields of immuno-oncology and infectious diseases. These companies have significantly greater financial and human resources than we currently have. In addition to these large pharmaceutical companies, we may directly compete with fully integrated biopharmaceutical companies and other immunotherapy-focused oncology companies, as well as a number of companies focused on immunotherapies, some of which have entered into collaboration and funding agreements with larger pharmaceutical or biotechnology companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we successfully develop product candidates, and our future partners, if any, obtain approval for them, we and our future partners, if any, will face competition based on many different factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the safety and effectiveness of our products relative to alternative therapies, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing and scope of regulatory approvals for these products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the availability and cost of manufacturing, marketing and sales capabilities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the price of any approved immunotherapy; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reimbursement coverage; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">intellectual property position. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our and our future partners&#8217;, if any, competitors may develop or commercialize products with significant advantages over any products we or our future partners, if any, develop based on any of the factors listed above or on other factors. In addition, our competitors may develop collaborations with or receive funding from larger pharmaceutical or biotechnology companies, providing them with an advantage over us. Our competitors may therefore be more successful in commercializing their products than our future partners, if any, are, which could adversely affect our competitive position and business. Competitive products may make any products our future partners, if any, develop using our technologies obsolete or noncompetitive before we and our future partners, if any, can recover the expenses of developing and commercializing our products, if approved. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The market opportunities for certain of our product candidates may be limited due to the rarity of the disease or limited to those patients who are ineligible for or have failed prior treatments, and may be small. Therefore, we must be able to successfully identify trial participants and achieve a significant market share to maintain profitability and growth.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA often approves new cancer immunotherapies initially only for use by patients with relapsed or refractory advanced cancer, or new bacterial vaccines initially only for use by patients with certain advanced diseases. We expect our future partners, if any, will initially seek approval of certain of our product </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">candidates in this context. Subsequently, for those product candidates that prove to be sufficiently beneficial, if any, we would expect our future partners, if any, to seek approval in earlier lines of treatment and potentially as a first-line therapy but there is no guarantee that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we and/or our future partners, if any, may have to conduct additional clinical trials. In the future, we may also develop product candidates for the treatment of rare diseases. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our projections of the number of people who have or will have the diseases we may be targeting may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of trial participants may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if for our product candidate, if approved, obtain significant market share, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We do not intend to establish a marketing and sales organization and as a company, we have no experience in marketing pharmaceutical products. We will rely on the marketing and sales capabilities of our future partners, if any, and other third parties, which may not be able to market and sell our product candidates effectively in the United States, Europe and other jurisdictions, if approved, or generate product sales revenue.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Given our stage of development, we have no sales, distribution or marketing capabilities, and we have not designed our pre-clinical studies and clinical trials with specific commercialization or marketing considerations in mind. We do not intend to establish marketing and sales organization and as a company, we have no experience in marketing pharmaceutical products. We will rely on the marketing and sales capabilities of our future partners, if any, and other third parties to commercialize any products that may result from our development programs in the United States, Europe and other regions. We intend to enter into collaborations with other entities to utilize their mature marketing and distribution capabilities, but we may be unable to enter into such collaboration agreements on favorable terms, if at all. If our future partners, if any, do not commit sufficient resources to commercialize products developed using our technologies, if any, product sales revenue may not be generated in amounts sufficient to sustain our business. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our future profitability, if any, depends in part on our future partners&#8217;, if any, ability to penetrate global markets, where they may be subject to additional regulatory burdens and other risks and uncertainties associated with international operations that could materially adversely affect our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our future profitability, if any, will depend in part on the ability of our future partners, if any, to commercialize any products that our future partners, if any, may develop in markets throughout the world. Commercialization of products in various markets could subject us to risks and uncertainties, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining, on a country-by-country basis, the applicable marketing authorization from the competent regulatory authority; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the burden of complying with complex and changing regulatory, tax, accounting, labor and other legal requirements in each jurisdiction that we or our future partners, if any, pursue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reduced protection for intellectual property rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">differing medical practices and customs affecting acceptance in the marketplace; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">import or export licensing requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">governmental controls, trade restrictions or changes in tariffs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">economic weakness, including inflation, or political instability in particular non-United States economies and markets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities in other countries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">longer accounts receivable collection times; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">longer lead times for shipping; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">language barriers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">foreign currency exchange rate fluctuations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reimbursement, pricing and insurance regimes; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the interpretation of contractual provisions governed by local laws in the event of a contract dispute. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our future partners, if any, may have limited experience in these areas. Failure to successfully navigate these risks and uncertainties may limit or prevent market penetration for any products that our future partners, if any, may develop using our technologies, which would limit their commercial potential and our revenues. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if our future partners, if any, obtain regulatory approval for our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community necessary for commercial success.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even with the requisite approvals, the commercial success of products using our technologies will depend in part on the medical community, patients, and third-party or governmental payors accepting immunotherapies in general, including more traditional prophylactic vaccines against viruses and bacteria that we may also develop, and such products in particular, as medically useful, cost-effective and safe. Any product developed using our technologies that our future partners, if any, bring to the market may not gain market acceptance by physicians, trial participants, third-party payors, and others in the medical community. Additionally, ethical, social and legal concerns about genetic research could result in additional regulations restricting or prohibiting the products and processes we may use. If these products do not achieve an adequate level of acceptance, our future partners, if any, may not generate significant product sales revenue and may not become profitable, which could materially harm our business, financial condition, results of operations and prospects. The degree of market acceptance of products derived from our product candidates, if approved for commercial sale, will depend on a number of factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the potential efficacy and potential advantages over alternative treatments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability to offer such products, if approved, at competitive prices; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the prevalence and severity of any side effects resulting from checkpoint inhibitors or other drugs or therapies with which our products are administered; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">relative co nvenience and ease of administration; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any restrictions on the use of our products, if approved, together with other medications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the strength of marketing and distribution support and timing of market introduction of competitive products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">publicity concerning our products or competing products and treatments; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">sufficient third-party insurance coverage or reimbursement, and patients&#8217; willingness to pay out-of-pocket in the absence of third-party coverage or adequate reimbursement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even if a potential product displays a favorable efficacy and safety profile in pre-clinical studies and clinical trials, market acceptance of the product will not be known until after it is launched. Our and our future partners&#8217;, if any, efforts to educate the medical community and third-party payors on the benefits of the products may require significant resources and may never be successful. Our and our future partners&#8217;, if any, efforts to educate the marketplace may require more resources than are required by the conventional technologies marketed by our competitors due to the complexity and uniqueness of our programs. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Commercial success of any approved products will also depend in large part on the availability of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs and entry into managed care organizations, which may be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. If government and other healthcare payors do not provide adequate coverage and reimbursement levels for any products derived from our product candidates once approved, whether due to healthcare reform legislation or otherwise, market acceptance and commercial success would be reduced. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, if any products derived from our product candidates are approved for marketing, we and/or our future partners, if any, will be subject to significant regulatory obligations regarding the submission of safety and other post-marketing information and reports for such product, and will need to continue to comply (or ensure that our third-party providers comply) with cGMP and current good clinical practices, or GCP, for any clinical trials that we or our future partners, if any, conduct post-approval. In addition, there is always the risk that we or a partner or regulatory authority might identify previously unknown problems with a product post-approval, such as adverse events of unanticipated severity or frequency. Compliance with these requirements is costly, and any such failure to comply or other issues with products derived from our product candidates identified post-approval could materially harm our business, financial condition and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for our future partners, if any, to sell products derived from our product candidates, if approved, profitably.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Successful sales of our product candidates, if approved, will depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which regulatory approval is obtained. In addition, because our product candidates generally represent new approaches to the treatment of cancer and prevention of infectious diseases, we cannot accurately estimate the potential revenue from any of our product candidates that might be approved. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a covered benefit under its health plan; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">safe, effective and medically necessary; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">appropriate for the specific patient; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">cost-effective; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">neither experimental nor investigational. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of products derived from our product candidates. Even if coverage for a given product is obtained, if the resulting reimbursement rates are insufficient, hospitals may not approve the product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use products, if any, derived from our product candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of such products. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payors rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payors and reduce the willingness of physicians to use our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect that our future partners, if any, will seek approval to market products derived from our product candidates in the United States, the European Union, Australia and other selected jurisdictions. If approval for a product in any particular jurisdiction, our future partners, if any, will be subject to rules and regulations in that jurisdiction. In some countries, particularly those in Europe and Australia, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the marketplace. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The marketability of any product derived from our product candidates which receives regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products which receives regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Enacted and future legislation may increase the difficulty and cost for us or our future partners, if any, to obtain marketing approval of and commercialize any products derived from our product candidates and affect the prices we may charge for such products.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2010, the ACA was enacted, which substantially changes the way health care is financed by both governmental and private insurers, and significantly impacts the United States pharmaceutical industry. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and promoted a new Medicare Part&#160;D coverage gap discount program. Considerable uncertainty remains regarding the implementation and impact of the ACA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since its enactment, there have been and there remain executive, judicial and congressional challenges to certain aspects of the ACA. As a result, there have been delays in the implementation of, and action taken to repeal or replace, certain aspects of the ACA. Since January&#160;2017, former President Trump has signed two Executive Orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. On January&#160;20, 2017, former President Trump signed the first Executive Order, directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">provision of the ACA that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On October&#160;13, 2017, former President Trump signed the second Executive Order terminating the cost-sharing subsidies (CSRs), that reimburse insurers under the ACA. On August&#160;14, 2020, the United States Court of Appeals for the Federal Circuit ruled in two separate cases that the federal government is liable for the full amount of unpaid CSRs for the&#160;years preceding and including 2017. For CSR claims made by health insurance companies for&#160;years 2018 and later, further litigation will be required to determine the amounts due, if any. Payments are expected to increase premiums on certain policies issued by qualified health plans under the ACA. Further, on June&#160;14, 2018, the United States Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay to third-party payors more than $12&#160;billion in ACA risk corridor payments that they argued were owed to them. This decision was appealed to the United States Supreme Court, which on April&#160;27, 2020, reversed the decision, concluding the government has an obligation to pay these risk corridor payments under the relevant formula. It is not clear what effect this result will have on our business, but we will continue to monitor any developments. While Congress has not passed comprehensive repeal legislation to date, it has enacted laws that modify certain provisions of the ACA such as the Tax Cuts and Jobs Act of 2017 (TCJA), which decreased the &#8220;individual mandate&#8221; to $0. On December&#160;14, 2018, a Texas United States District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed. On June&#160;17, 2021, the United States Supreme Court dismissed this case. It is unclear how the Supreme Court&#8217;s decision will impact the ACA and our business. There is significant uncertainty regarding the future of the ACA and its impact on our business and operations. We continue to evaluate the effect that the ACA and its possible repeal and replacement has on our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, in August&#160;2011, the Budget Control Act of 2011 was signed into law, which, among other things, included aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year through 2030, with the exception of a temporary suspension from May&#160;1, 2020 through March&#160;31, 2021, unless Congress takes additional action. Proposed legislation, if passed, would extend this suspension until the end of the COVID-19 pandemic. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent United States congressional inquiries and legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, the United States Presidential administration&#8217;s budget proposal for the fiscal year 2021 includes a $135&#160;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March&#160;10, 2020, the Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part&#160;D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part&#160;D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Further, the Trump administration previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May&#160;2019, CMS issued a final rule that amends the Medicare Advantage and Medicare Part&#160;D prescription drug benefit regulations to reduce out of pocket costs for plan enrollees and allow Medicare plans to negotiate lower rates for certain drugs. Among other things, the final rule now allows Medicare Advantage plans the option to use step therapy, a type of pre-authorization, for Part&#160;B drugs beginning January&#160;1, 2020. This final rule codified CMS&#8217;s policy change that was effective January&#160;1, 2019. In addition, there have been several changes to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain healthcare facilities. Some of these changes are undergoing legal challenges, and their status is currently in question. It is unclear how these developments could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, on July&#160;24, 2020 and September&#160;13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September&#160;24, 2020, effective November&#160;30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November&#160;20, 2020, CMS issued an interim final rule implementing Former President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part&#160;B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January&#160;1, 2021. On December&#160;28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against the implementation of the interim final rule. Although a number of these executive orders and other proposed measures will require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, we expect that Congress will continue to seek new legislative measures to control drug costs. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control costs of pharmaceutical and biological products. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As noted above, since its enactment, there have been judicial, Congressional and executive branch challenges to certain aspects of the ACA. On June&#160;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states on procedural grounds without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on August&#160;16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part&#160;D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how other health reform measures of the Biden administration will impact our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Also, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which have resulted in several Congressional inquiries, presidential executive orders, and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, at the federal level, in July&#160;2021, the Biden administration released an executive order with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September&#160;9, 2021, the HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things, (1)&#160;directs the HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2)&#160;imposes rebates under Medicare Part&#160;B and Medicare Part&#160;D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October&#160;14, 2022, directing HHS to submit a report within 90&#160;days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Medicaid beneficiaries. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. We expect that additional state and federal healthcare reform measures will be adopted in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States and in some other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing approval of our drug or biologic candidates, restrict or regulate post-approval activities, or affect our future partners&#8217;, if any, ability to profitably sell any drug or biologic candidates for which they obtain marketing approval, if any. Further, increased scrutiny by the United States Congress of the FDA&#8217;s approval process for drugs and biological products may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. There also are a number of state and local legislative and regulatory efforts related to drug or biologic pricing, including drug or biologic price transparency laws that apply to pharmaceutical manufacturers, that may have an impact on our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the Drug Supply Chain Security Act enacted in 2013 imposes new obligations on manufacturers of pharmaceutical products related to product tracking and tracing, and that law is expected to be fully implemented over a ten-year period. Most recently, on December&#160;20, 2019, former President Trump signed the Further Consolidated Appropriations Act for 2020 into law (P.L. 116-94) that includes a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the &#8220;CREATES Act.&#8221; The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic and biosimilar product developers access to samples of brand products. The CREATES Act establishes a private cause of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially reasonable, market-based terms.&#8221; Whether and how generic and biosimilar product developments will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on our future commercial products are unknown. Other legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical or biological products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our drug or biologic candidates, may be or whether such changes will have any other impacts on our business. In addition, increased scrutiny by the United States Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us or our future partners, if any, to more stringent product labeling and post-marketing conditions and other requirements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect that the healthcare reform measures that have been adopted, and that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the European Union, similar political, economic and regulatory developments may affect our future partners&#8217;, if any, ability to profitably commercialize products derived from our product candidates. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union member state level may result in significant additional requirements or obstacles that may increase our operating costs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products derived from our product candidates, this could prevent or delay marketing approval of products derived from our product candidates, restrict or regulate post-approval activities, and affect our or our future partners, if any,&#8217; ability to commercialize any products derived from our product candidates for which we or they obtain marketing approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect that additional healthcare reform measures or proposals will be adopted in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for products derived from our product candidates or additional pricing pressures. In the event that the pricing structures for healthcare products, such as the product candidates we are developing, change materially and limit payments for such product candidates, our business will be adversely impacted as any products derived from our product candidates may no longer be commercially viable based on their expected net present value; we may have invested significant resources in product candidates that cannot be commercially developed; or we may determine that assets that have reached an early phase of development cannot or will not be taken into further development, notwithstanding their clinical viability. In addition, development assets or clinical programs that are part of our collaborations including any future collaborations we may enter into may no longer be deemed commercially viable to pursue based on our partners&#8217; assessments of the impact of any proposed, announced, or legislated pricing reforms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot predict what healthcare reform initiatives may be adopted in the future. Our personalized cancer vaccines may be issued with PD-1 or PD-L1 inhibitors and as a result become too expensive for government, or commercial payors coverage and as a result may reduce our potential market. Further legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from products derived from our product candidates that we may successfully develop and for which we or our future partners, if any, may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">European Union drug marketing and reimbursement regulations may materially affect our partners&#8217; ability to market and receive coverage for products derived from our product candidates in the European Union member states.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect that our future partners, if any, will have to seek approval to market products derived from our product candidates in the United States, the European Union and in other selected jurisdictions. If our future partners, if any, obtain approval for products derived from our product candidates in a particular jurisdiction, they will be subject to rules and regulations in that jurisdiction. In some countries, particularly those in the European Union, the pricing of biologics is subject to governmental control and other market regulations that could put pressure on the pricing and usage of products derived from our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of products derived from our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for any such product and may be affected by existing and future healthcare reform measures. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, in most countries outside the United States, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we and/or our future partners, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">if any, may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and, generally, prices tend to be significantly lower in the European Union. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our future partners, if any, and the potential profitability of any of our product candidates in those countries would be negatively affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to our Reliance on Third Parties</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We will rely on third parties in the conduct of significant aspects of our pre-clinical studies and clinical trials and intend to rely on third parties in the conduct of future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or fail to meet expected deadlines, regulatory approval for our product candidates may not be obtained, which would materially harm or business, financial condition, results of operations and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, future partners, if any, medical institutions and clinical investigators, to conduct various and significant elements of our clinical trials. We currently rely and expect to continue to rely on third parties to conduct certain research and pre-clinical testing activities. In some cases, these third parties may terminate their engagements with us. If we need to enter into alternative arrangements, it would delay our discovery or product development activities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our regulatory or contractual responsibilities. We will be responsible for ensuring that each of our pre-clinical studies and clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, the FDA requires us to comply with Good Clinical Practice, or GCP, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions. For any violations of laws and regulations during the conduct of our pre-clinical studies and clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We and our CROs will be required to comply with regulations, including GCP, for conducting, monitoring, recording and reporting the results of pre-clinical studies and clinical trials to ensure that the data and results are scientifically credible and accurate and that the trial participants are adequately informed, among other things, of the potential risks of participating in clinical trials. We also are responsible for ensuring that the rights of our clinical trial participants are protected. These regulations are enforced by the FDA, the competent authorities of the member states, and comparable regulatory authorities of other jurisdictions for any product candidates in clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we or our CROs fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable regulatory authorities of other jurisdictions may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our future clinical trials will comply with GCP. In addition, our clinical trials must be conducted with product candidates produced in accordance with the requirements of cGMP </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">regulations. Our failure or the failure of our CROs or CDMOs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Although we intend to design the clinical trials for certain of our product candidates, our future partners, if any, may design the clinical trials that they are managing (in some cases, with our input) and in the case of clinical trials controlled by us, we expect that CROs will conduct all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future pre-clinical studies and clinical trials will also result in less direct control over the management of data developed through pre-clinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also potentially lead to mistakes as well as difficulties in coordinating activities. Outside parties may: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">have staffing difficulties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">fail to comply with contractual obligations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">experience regulatory compliance issues; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">undergo changes in priorities or become financially distressed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">form relationships with other entities, some of which may be our competitors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">have human errors; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">be subject to cyberattacks. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These factors may materially adversely affect the willingness or ability of third parties to conduct our pre-clinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. If the CROs do not perform pre-clinical studies and clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, our future partners, if any, may not be able to obtain regulatory approval and commercialize products derived from our product candidates, or our development programs may be materially and irreversibly harmed. If we are unable to rely on pre-clinical and clinical data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay the development of our product candidates and/or commercialization of any products derived from our product candidates and could require significantly greater expenditures. In addition, any delays by such third parties related to our expected milestones and/or data readouts or preliminary or full trial reports could adversely affect the development of our product candidates and cause us to incur significant additional expenses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also expect to rely on other third parties to transport, store and distribute the required materials for our clinical trials. In the past certain of our third-party vendors have mishandled our materials, resulting in loss of full or partial lots of material. Any further performance failure on the part of these third parties could result in damaged products and could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, if approved, producing additional losses and depriving us of potential product sales revenue, causing us to default on our contractual commitments, result in losses that are not covered by insurance, and damage our reputation and overall perception of our products in the marketplace. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our existing collaborations, or any future collaboration arrangements or agreements with our future partners, if any, that we may enter into, may not be successful, which could significantly limit the likelihood of receiving the potential economic benefits of the collaboration and adversely affect our ability to develop our product candidates and the commercialization of any products derived from our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have entered into collaborations under which our collaborators may in the future provide funding and other resources for developing our product candidates and potentially commercializing any products derived from our product candidates. We intend to enter into additional collaborations and agreements with future partners, if any, to access additional funding, capabilities and expertise in the future. Our existing </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">collaborations, and any future collaborations or agreements with future partners, if any, we enter into, may pose a number of risks, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">future partners, if any, may not perform or prioritize their obligations as expected; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the clinical trials conducted as part of such collaborations may not be successful; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our future partners, if any, may not pursue development and commercialization of any products derived from our product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization of programs based on clinical trial results, changes in the partners&#8217; focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our future partners, if any, may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our future partners, if any, could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if our future partners, if any, believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">product candidates developed in collaborations with us may be viewed by our future partners, if any, as competitive with their own product candidates or products, which may cause our future partners, if any, to cease to devote resources to the development or commercialization of products derived from our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our future partners, if any, with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of any such product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">disagreements with our future partners, if any, including disagreements over proprietary rights, contract interpretation, or the preferred course of development of any product candidates, may cause delays or termination of the research, development of such product candidates or commercialization of products derived from our product candidates, may lead to additional responsibilities for us with respect to such product candidates, or may result in litigation or arbitration, any of which would be time-consuming and expensive; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our future partners, if any, may not properly maintain, protect, defend or enforce our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our future partners, if any, may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborations may be terminated for the convenience of our future partners, if any, and, if terminated, the development of our product candidates may be delayed, and we could be required to raise additional capital to pursue further development of the applicable product candidates or commercialization of products derived from such product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">future relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing shareholders, or disrupt our management and business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we could face significant competition in seeking appropriate future partners, if any, and the negotiation process is time-consuming and complex; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our international operations through any future collaborations, acquisitions or joint ventures may expose us to certain operating, legal and other risks not encountered in the United States. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If our collaborations do not result in the successful development of our product candidates or commercialization of products derived from such product candidates, or if one or more of our future partners, if any, terminates its agreement with us, we may not receive any future research funding or milestone, earn-out, royalty, or other contingent payments under the collaborations. If we do not receive the funding we expect under these agreements, our development of product candidates could be delayed, and we may need additional resources to develop our product candidates. In addition, in general our future partners, if any, may have the right to terminate their agreements with us for convenience. If one or more of our future partners, if any, terminates its agreement with us, we may find it more difficult to attract new partners, if any, and the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and commercialization described in this registration statement apply to the activities of our future partners, if any. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business is dependent on the successful development, regulatory approval and commercialization of product candidates based on our AI-Immunology&#8482; platform. If our current or future partners, if any, are unable to obtain approval for, and effectively commercialize, our product candidates for the treatment of patients in their intended indications, our business, financial condition, results of operations and prospects would be materially harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that the cost and expense of discovery and development of product candidates, including clinical testing, regulatory approval and commercialization of products for disease indications targeted by our product candidates are very high. Therefore, we intend to enter into partnership arrangements with large biopharmaceutical and pharmaceutical companies to conduct such drug development activities as well as clinical trials, regulatory and marketing approval and commercialization of our product candidates. We have entered into few early collaborations and target more but may be unable to do so on economically viable terms, if at all. As a result, late-stage clinical trials as well as pivotal clinical trials for our product candidates have not been commenced and even if such processes are commenced in the near future, it will be several&#160;years, if ever, before we or our future partners, if any, have a product candidate ready for commercialization. Even if we complete the necessary pre-clinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain, and our future partners, if any, may not be able to obtain approvals for the commercialization of any product candidates we may develop. Any product candidates that we or our future partners, if any, may develop, and the activities associated with its development and commercialization, including design, testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA, the EMA, the TGA and by comparable global health authorities. To obtain the requisite regulatory approvals to commercialize any of our product candidates, we and our future partners, if any, must demonstrate through extensive pre-clinical studies and clinical trials that our products are safe and effective, including in the target populations. Successful completion of clinical trials is a prerequisite to submitting a biologics license application, or BLA, or a NDA to the FDA, a Marketing Authorization Application, or EMAA, to the EMA, a Marketing Authorization Application to the TGA, or AMAA and similar marketing applications to comparable global regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Failure to obtain marketing approval for a product candidate will prevent our future partners, if any, from commercializing the product candidate in a given jurisdiction. Neither we nor our future partners, if any, have received approval to market any of our product candidates from regulatory authorities in any jurisdiction, and it is possible that none of our product candidates, or any product candidates we may seek to develop in the future, will ever obtain regulatory approval. We have limited experience in filing and supporting the applications necessary to gain marketing approvals and intend to rely on our future partners, if any, to conduct this process. To our knowledge, there is no current precedent for a personalized cancer immunotherapy such as the type we are developing being approved for sale by the FDA, the EMA, the TGA or any other regulatory agency elsewhere in the world. Securing regulatory approval requires the submission of extensive pre-clinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we or our future partners, if any, develop may not be effective, may be only moderately effective, or may prove to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The process of obtaining marketing approvals in the United States, the European Union, Australia and elsewhere, is expensive, may take many&#160;years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. The FDA, the EMA, the TGA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that the data are insufficient for approval and require additional pre-clinical, clinical or other trials. In addition, varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or our future partners, if any, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. Additional delays, or non-approval if an FDA panel of experts, referred to as an Advisory Committee, or the EMA, the TGA or other regulatory authority recommends non-approval or restrictions on approval. In addition, we and our future partners, if any, may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials, and the review process. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Regulatory agencies also may approve an immunotherapy/vaccine for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA, the EMA, the TGA and other regulatory agencies review the Chemistry, Manufacturing and Controls, or CMC, section of regulatory filings. Any aspects found unsatisfactory by regulatory agencies may result in delays in clinical trials and commercialization. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the regulatory agencies typically conduct pre-approval inspections at the time of a BLA, NDA, EMAA, AMAA or comparable filing. Any findings by regulatory agencies and failure to comply with requirements may lead to delay in approval and failure to commercialize the potential product candidate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If our future partners, if any, experience delays in obtaining, or if they fail to obtain, approval of any product candidates we may develop, the commercial prospects for those product candidates will be harmed, and our ability to generate revenues from our collaboration agreements will be materially impaired. Additionally, even if our future partners, if any, are successful in obtaining marketing approval for product candidates, because our pre-clinical studies and clinical trials have not been designed with specific commercialization considerations, the commercial prospects for those product candidates could be harmed, and our ability to generate revenues could be materially impaired. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our research and development plans.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our research and product development programs and the potential commercialization of any product candidates we develop alone or with future partners, if any, will require substantial additional cash to fund expenses, and we expect that we will continue to seek collaborative arrangements with others in connection with the development and commercialization of current and future product candidates or the development of ancillary technologies. We face significant competition in establishing relationships with appropriate partners. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future partners, if any. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the partner&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed partner&#8217;s evaluation of a number of factors. Those factors may include, among other things and as applicable for the type of potential product or technology, an assessment of the opportunities and risks of our technology, the design or results of studies or trials, the likelihood of approval, if necessary, of the FDA, the EMA, the TGA or similar regulatory authorities outside the United States, Europe and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Australia, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products and technologies and industry and market conditions generally. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our future partners, if any, may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us. Additionally, we may be restricted under existing collaboration agreements from entering into future agreements on certain terms or for certain development activities with potential partners. Similarly, our collaboration agreements may contain non-competition provisions that could limit our ability to enter into collaborations with future partners, if any. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we do enter into additional collaboration agreements, the negotiated terms may force us to relinquish rights that diminish our potential profitability from development and commercialization of the subject product candidates or others. If we are unable to enter into additional collaboration agreements, we may have to curtail the research and development of the product candidate or technology for which we are seeking to collaborate, reduce or delay research and development programs, delay potential commercialization timelines, reduce the scope of any sales or marketing activities or undertake research, development or commercialization activities at our own expense. If we elect to increase our expenditures to fund research, development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have entered into in-licensing arrangements and may form or seek to enter into additional licensing arrangements in the future, and we may not realize the benefits of such licensing arrangements.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may obtain licenses that give us rights to third-party intellectual property, including patents and patent applications that are necessary or useful for our business. In particular, we have entered into license agreements with Statens Serum Institut, or SSI, and PharmaJet, Inc. or PharmaJet to obtain licenses for intellectual property useful in pharmaceutical formulations and delivery devices. We may enter into additional licenses to third-party intellectual property in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The success of products developed based on in-licensed technology will depend in part on the ability of our current and future licensors to prosecute, obtain, maintain, protect, enforce and defend patent protection for our in-licensed intellectual property. Our current and future licensors may not successfully prosecute any patent applications we may license. Even if patents were issued in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we may sublicense our rights under various third-party licenses to our partners. Any impairment of these sublicensed rights could result in reduced revenues under our collaboration agreements or result in termination of an agreement by one or more of our partners. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope of rights granted under the license agreement and other interpretation-related issues; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate the intellectual property of the licensor that is not subject to the licensing agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our right to sublicense patent and other intellectual property rights to third parties under collaborative relationships; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our diligence obligations with respect to the use of the licensed intellectual property and technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ownership of inventions, trade secrets, know-how and other intellectual property resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the priority of invention of patented technology. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For instance, in April&#160;2022, SSI initiated a legal proceeding against us in The Danish Maritime and Commercial High Court (S&#248; og Handelsretten), claiming sole ownership of a patent application we filed related to a method for treating malignant neoplasm by administering a composition comprising a high dose of neopeptides, a solvent and SSI&#8217;s liposomal adjuvant, CAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">09b, or the Invention, for which we have an exclusive, royalty-bearing sub-licensable license to use in formulation with PIONEER identified neopeptides, from SSI. We believe that we and our employees are the sole inventors of the Invention and that we have strong defenses against SSI&#8217;s claim and that SSI&#8217;s claim is without merit. Since May&#160;2023 the court proceedings has been paused while non-court mediated nogotiations between us and SSI is ongoing. We have reached terms with SSI which do not include compensation from Evaxion to SSI, however formal agreement needs to be signed. If disputes over intellectual property that we have in-licensed or other related contractual rights prevent or impair our ability to maintain our current licensing arrangements on favorable terms, we may be unable to successfully develop our product candidates and the commercialization of any products derived from such product candidates may be adversely affected. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described herein. If we, our co-owners or our licensors fail to adequately protect, defend, maintain or enforce this intellectual property, our ability to commercialize products could suffer and our business, financial condition, results of operations and prospects would be materially harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We rely on third parties to manufacture certain of our clinical product supplies, and we will rely on third parties to produce and process our product candidates, if approved.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We rely on outside vendors to manufacture supplies and process our product candidates. None of our product candidates have been manufactured or processed on a late-stage clinical trial or commercial scale and our third party CDMOs and our future partners, if any, may not be able to achieve late-stage clinical trial or commercial-scale manufacturing and processing and may be unable to create an inventory of mass-produced product to satisfy demands for our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost and rights to manufacture and process our product candidates could materially and adversely affect the availability of our product candidates in sufficient quantities to conduct our clinical trials or the commercial viability of any products derived from our product candidates. As a result, we and/or our future partners, if any, may never be able to develop a commercially viable product. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, our reliance on a limited number of third-party manufacturers exposes us to the following risks: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA, the EMA, the TGA or other regulatory authorities may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our product candidates or any products derived from our product candidates after receipt of regulatory authority questions, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our third-party CDMOs might not be able to timely formulate and manufacture our product candidates or any products derived from our product candidates or produce the quantity and quality required to meet our and our partners&#8217; clinical and commercial needs, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">CDMOs may not be able to execute our manufacturing procedures appropriately; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our future CDMOs may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our product candidates or any products derived from our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the United States Drug Enforcement Administration, or the DEA, and corresponding state agencies and by regulatory authorities in other jurisdictions to ensure strict compliance with GMP and other government regulations and corresponding standards in other jurisdictions. We do not have control over third-party CDMOs or our future partners, if any, compliance with these regulations and standards; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party CDMOs in the manufacturing process for our products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our third-party CDMOs could breach or terminate their agreement with us; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our third-party CDMOs would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each of these risks could delay our clinical trials, the approval, if any, of our product candidates or any products derived from our product candidates by the FDA, the EMA, the TGA or regulatory authorities in other jurisdictions or the commercialization of our product candidates, or result in higher costs or deprive us of potential product sales revenue. In addition, we will rely on third parties to perform release tests on our product candidates or any products derived from our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We and/or our future partners, if any, may, in the future, be dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We and/or our future partners, if any, may, in the future, be dependent on single-source suppliers for some of the components and materials used in, and manufacturing processes required to develop, our product candidates. We cannot ensure that these suppliers or service providers will remain in business, or have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our or our future partners, if any, use of single-source suppliers of raw materials, components, key processes and finished goods exposes us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or our future partners, if any, commercial sale of any products derived from our product candidates. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we intend to maintain adequate inventory of the single source components and materials used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, as part of the FDA&#8217;s approval of our product candidates, FDA review of the individual components of our process, which include the manufacturing processes and facilities of our single-source suppliers will also be required. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our reliance on these suppliers, service providers and manufacturers may subject us to a number of risks that could materially harm our reputation, business, and financial condition, results of operations and prospects, including, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays to the development timelines for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">63</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a lack of long-term supply arrangements for key components with our suppliers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delay in delivery due to our suppliers&#8217; prioritizing other customer orders over ours; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">damage to our reputation caused by defective components produced by our suppliers; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If any of these risks materialize, costs could significantly increase and our and/or our partners&#8217; ability to meet demand for our product candidates or any products derived from our product candidates could be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Intellectual Property</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our efforts to obtain, maintain, protect, defend and/or enforce the intellectual property related to our product candidates and technologies are not adequate, we may not be able to compete effectively in our market.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our commercial success depends in part on our ability to obtain, maintain, protect, defend and enforce patent and other intellectual property, including trade secret and know-how, protection for our product candidates, proprietary technologies and their uses, as well as our and our future partners, if any, ability to&#160;operate, develop, manufacture and commercialize our product candidates without infringing, misappropriating or otherwise violating the intellectual property or other proprietary rights of our competitors or any other third parties, including any non-practicing entities or patent assertion entities. We generally seek to protect our intellectual property position by filing and/or licensing patent applications in the United States, and Europe as well as in other countries related to our product candidates, proprietary technologies (including methods of manufacture) and their uses that are important to our business. While in some jurisdictions patent applications can be enforced through the issuance of a preliminary injunction, in general, our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent that the issued claims cover third parties&#8217; activities in the countries in which they are performed. We cannot be certain that the claims in any of our patent applications will be considered patentable by the United States Patent and Trademark Office, or the USPTO, courts in the United States or the patent offices and courts in Europe and in other jurisdictions, nor can we be certain that the claims in our issued patents will not be found invalid or unenforceable if challenged. Accordingly, there can be no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued patents will adequately cover our product candidates or otherwise afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated or held unenforceable. Furthermore, we may not be able to obtain patents on certain aspects of our current or future product candidates, proprietary technologies and their uses in a timely fashion, at a reasonable cost, in all jurisdictions, or at all, and any potential patent protection we obtain may not be sufficient to prevent substantial competition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings before various patent offices or in courts in the United States, Europe or other jurisdictions. The degree of future protection for our intellectual property and other proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our technologies or permit us to gain or keep any competitive advantage. If we do not adequately obtain, maintain, protect, defend and enforce our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">64</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">intellectual property and proprietary technology, competitors may be able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our current or future licensors or future partners, if any, will be successful in prosecuting, obtaining, protecting, maintaining, enforcing or defending patents and patent applications necessary or useful to protect our product candidates, proprietary technologies (including methods of manufacture) and their uses. These risks and uncertainties include, from time to time, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the USPTO and various other governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application or a finding that a patent is unenforceable, and partial or complete loss of patent rights in the relevant jurisdiction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">patent applications may not result in any patents being issued; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">issued patents that we own (solely or jointly) or have in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use, sell, import or otherwise exploit our product candidates or other technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">other parties may have designed around our patent claims or developed technologies that may be related or competitive to our product candidates or other technologies, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent filings, either by claiming the same or overlapping methods, products, reagents or devices or by claiming subject matter that could dominate one or more of our patent claims; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any successful opposition to any patents owned by or in-licensed to us could deprive us of rights necessary for the economically feasible development and exploitation of our product candidates and other technologies or the economically successful commercialization of any product candidates and other technologies that we may develop; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">because patent applications in the United States, Europe and most other jurisdictions are confidential for a period of time after filing, we cannot be certain that we, our co-owners or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a court or patent office proceeding, such as a derivative action or interference, can be provoked or instituted by a third party or a patent office, and might determine that one or more of the inventions described in our patent filings, or in those we licensed, was first invented by someone else, so that we may lose rights to such invention(s); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a court or other patent proceeding, such as an inter parties review, post grant review or opposition, can be instituted by a third party to challenge the inventorship, scope, validity and/or enforceability of our patent claims and might result in invalidation or revision of one or more of our patent claims, or in a determination that such claims are unenforceable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">there may be significant pressure on the United States government, European government and other international governmental bodies to limit the scope of patent protection both inside and outside the United States and Europe for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">United States government, European government and other international governments, may receive compulsory licensing wherein patents are required to be made available to third parties at reduce rates; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">65</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">countries other than the United States may have patent laws less favorable to patentees than those upheld by United States courts, allowing competitors a better opportunity to create, develop and market competing product candidates. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent&#160;years. The standards that the USPTO and its counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the United States and other countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts and lawmakers. Moreover, there are periodic changes in patent law, as well as discussions in the Congress of the United States and in international jurisdictions about modifying various aspects of patent law. There is no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. In certain countries, for example, methods for the medical treatment of humans are not patentable. More generally, the laws of some countries do not protect intellectual property rights to the same extent as United States laws, and those countries may lack adequate rules and procedures for granting, maintaining, protecting, defending and enforcing our intellectual property rights. However, while certain incentives such as natural occurring products are currently not patentable in the United States, such inventions may be patentable in the United States in the future and in other jurisdictions, including Europe. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, the patent prosecution process is also expensive and time-consuming, and we may not be able to file, prosecute, maintain, protect, defend, enforce or license all necessary or desirable patents or patent applications, as applicable, at a reasonable cost or in a timely manner. It is possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate future partners, if any, outside scientific future partners, if any, CROs, CDMOs, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. We also rely to a certain extent on trade secrets, know-how, and technology, which are not protected by patents, to maintain our competitive position. If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business, financial position, results of operations and prospects could be materially harmed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The issuance of a patent is not conclusive as to its inventorship, priority date, scope, term, validity or enforceability so that any patents that may issue or that we may license may be challenged in the courts or patent offices in the United States, Europe and other jurisdictions. Once granted, patents may remain open to a variety of challenges, including opposition, interference, re-examination, post-grant review, inter parties review, nullification or derivation action in court or before patent offices or similar proceedings, and furthermore, may be challenged as a defense in any enforcement action that we might bring. Such challenges may result in loss of exclusivity or in patent claims being narrowed, terminated, disclaimed, invalidated, assigned to others or held unenforceable, any or all of which could limit our ability to stop others from using or commercializing similar or identical products, or limit the scope and/or term of patent protection of our products and product candidates and/or eliminate it altogether, thus hindering or removing our ability to limit third parties from making, using or selling products or technologies that are similar or identical to ours, and/or reduce or eliminate royalty payments to us from our licensees. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our ability to enforce our owned and in-licensed patent and other intellectual property rights depends on our ability to detect infringement, misappropriation and other violation of such patents and other intellectual property. It may be difficult to detect infringers, misappropriators and other violators who do not advertise the components or methods that are used in connection with their products and services. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">66</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, it may be difficult or impossible to obtain evidence of infringement, misappropriation or other violation in a competitor&#8217;s or potential competitor&#8217;s product or service, and in some cases, we may not be able to introduce obtained evidence into a proceeding or otherwise utilize it to successfully demonstrate infringement. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, proceedings to enforce or defend our owned or in-licensed patents could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. If any of our owned or in-licensed patents covering our product candidates or other technologies are narrowed, invalidated or found unenforceable, or if a court found that valid, enforceable patents held by third parties covered one or more of our product candidates or other technologies, our competitive position could be harmed or we could be required to incur significant expenses to protect, enforce or defend our rights. If we initiate lawsuits to protect, defend or enforce our patents, or litigate against third-party claims, such proceedings would be expensive and would divert the attention of our management and technical personnel, even if the eventual outcome is favorable to us. Furthermore, because of the potentially substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during the course of litigation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The degree of future protection for our intellectual property and other proprietary rights is uncertain, and we cannot ensure that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates and other technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any of our pending patent applications or those of our licensors may issue as patents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">others will not or may not be able to make, use, offer to sell or sell products that are the same as or similar to our own product candidates or any products derived from our product candidates, but that are not covered by the claims of the patents that we own or license; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our future partners, if any, will be able to successfully commercialize products derived from our product candidates on a substantial scale, if approved, before the relevant patents that we own, or license expire; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we were the first to make the inventions covered by each of the patents and pending patent applications that we own or license; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we, our co-owners or our licensors were the first to file patent applications for these inventions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">others will not develop similar or alternative products or technologies that do not infringe the patents we own or license; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any of the patents we own, or license will be found to ultimately be valid and enforceable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates and other technologies or will provide us with any competitive advantages; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a third party may not challenge the patents we own, or license and, if challenged, a court would hold that such patents are valid, enforceable and infringed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may develop or in-license additional proprietary technologies that are patentable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the patents of others will not have an adverse effect on our business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">67</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we will develop additional proprietary technologies or product candidates that are separately patentable; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our development and commercialization activities of our future partners, if any, including manufacturing processes, or products derived from our product candidates will not infringe upon the patents of our competitors or any other third parties, including any non-practicing entities or patent assertion entities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other companies or organizations may challenge our intellectual property rights or may assert intellectual property rights that prevent us from developing our product candidates and other technologies, and may prevent our future partners, if any, from commercializing any products derived from our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our business involves new and evolving scientific fields, the continued development and potential use of which has resulted in many different patents and patent applications from organizations and individuals seeking to obtain intellectual property protection in the fields. We own and in-license patent applications and issued patents that describe and/or claim certain technologies, including products, reagents, formulations and methods including uses and manufacturing methods, or features or aspects of any of these. These issued patents and pending patent applications claim certain compositions of matter and methods relating to the discovery, development, manufacture and commercialization of therapeutic modalities and our delivery technologies, including LNPs. If we, our co-owners, our licensors, including our future partners, if any, are unable to obtain, maintain, protect, defend or enforce patent protection with respect to our product candidates and other technology and any product candidates and technology we develop, our business, financial condition, results of operations and prospects could be materially harmed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As the scientific fields mature, our known competitors and other third parties have filed, and will continue to file, patent applications claiming inventions in the field in the United States and in other countries. There is uncertainty about which patents will issue, and, if they do, as to when, to whom and with what claims. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We, our co-owners or our licensors, including our future partners, if any, may in the future become a party to patent proceedings or priority disputes in the United States, Europe or other jurisdictions. For instance, in April&#160;2022, SSI initiated a legal proceeding against us in The Danish Maritime and Commercial High Court (S&#248; og Handelsretten), claiming sole ownership of a patent application we filed related to a method for treating malignant neoplasm by administering a composition comprising a high dose of neopeptides, a solvent and SSI&#8217;s liposomal adjuvant, CAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">09b, or the Invention, for which we have an exclusive, royalty-bearing sub-licensable license to use in formulation with PIONEER identified neopeptides, from SSI. We believe that we and our employees are the sole inventors of the Invention and that we have strong defenses against SSI&#8217;s claim and that SSI&#8217;s claim is without merit. Since May&#160;2023 the court proceedings has been paused while non-court mediated negotiations between us and SSI is ongoing. We have reached terms with SSI which do not include compensation from Evaxion to SSI, however formal agreement needs to be signed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If disputes such as the SSI dispute, over intellectual property that we have in-licensed or other related contractual rights prevent or impair our ability to maintain our current licensing arrangements on favorable terms, we may be unable to successfully develop our product candidates and the commercialization of any products derived from such product candidates may be adversely affected. In any event, if it is determined that that SSI are co-owners of part of the subject matter of the patent application, such a determination would not, in and of itself, prevent us from carrying on with EVX-01. However, if co-ownership of part of the patented subject matter is the end result of the court proceedings, our practical use of such part of the patented subject matter in any enforcement proceeding or as an object of licensing could be problematic. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Leahy-Smith America Invents Act, or the America Invents Act, enacted in September&#160;2011, included a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent through USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">68</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">proceedings. We expect that our competitors and other third parties may institute litigation and other proceedings, such as interference, reexamination and opposition proceedings, as well as inter partes and post-grant review proceedings against us and the patents and patent applications that we own and in-license. We expect that we may be subject to similar proceedings or priority disputes, including oppositions, in Europe or other foreign jurisdictions relating to patents and patent applications in our portfolio. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we, our co-owners or our licensors, including our future partners, if any, are unsuccessful in any interference proceedings or other priority or validity disputes, including any derivations, post-grant review, inter partes review or oppositions, to which we or they are subject, we may lose valuable intellectual property rights through the narrowing or loss of one or more patents owned or in-licensed, or our owned or in-licensed patent claims may be narrowed, invalidated or held unenforceable. In many cases, the possibility of appeal exists for either us or our opponents, and it may be&#160;years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material adverse impact on our business and our ability to successfully compete against our current and future competitors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are many issued and pending patent filings that claim aspects of technologies that we or our future partners, if any, may need for our product candidates or any products derived from our product candidates, including patent filings that relate to relevant delivery technologies. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for vaccines we wish to develop. In addition, there may be issued and pending patent applications that may be asserted against us in a court proceeding or otherwise based upon the asserting party&#8217;s belief that we or our future partners, if any, may need such patents for the development, manufacturing and commercialization of our product candidates or any products derived from our product candidates. Thus, it is possible that one or more organizations, ranging from our competitors to non-practicing entities or patent assertion entities, has or will hold patent rights to which we may need a license, or hold patent rights which could be asserted against us. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If those organizations refuse to grant us a license to such patent rights on reasonable terms or a court rules that we need such patent rights that have been asserted against us and we are not able to obtain a license on reasonable terms or at all, we may be unable to perform research and development or other activities or market products covered by such patents, and we or our future partners, if any, may need to cease the development, manufacture and commercialization of one or more of the product candidates or any products derived from our product candidates we or our future partners, if any, may develop. Any of the foregoing could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not be successful in obtaining, maintaining, protecting or defending the necessary intellectual property rights to allow us to identify and develop product candidates, product components and manufacturing processes for our development pipeline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently have rights to certain intellectual property, through our owned and in-licensed patents and other intellectual property rights, relating to identification and development of our product candidates or other technologies. As our pipeline may involve additional product candidates that could require the use of intellectual property and other proprietary rights held by third parties, the growth of our business could depend in part on our ability to acquire, in-license or use such intellectual property and proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these intellectual property and other proprietary rights may be held by others. We may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary, on reasonable terms, or at all, for product candidates and other technologies that we may develop. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">69</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For example, we have in the past and may continue to collaborate with academic institutions in certain aspects of our pre-clinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. However, these institutions may not honor our option and right of first negotiation for intellectual property rights or we may otherwise be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer intellectual property rights to other parties, potentially blocking our ability to pursue our program or otherwise continue to develop certain product candidates or other technologies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, some of our owned patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain, or continue to maintain, exclusive rights to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technologies. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could materially harm our competitive position, business, financial conditions, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, third parties that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain, protect, defend or enforce the existing intellectual property rights we have, we may have to abandon the development of the relevant program or product candidate and our future partners, if any, may have to abandon the commercialization of any products derived from our product candidates, which could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The lifespans of our patents may not be sufficient to effectively protect our product candidates, technologies and business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20&#160;years after its first effective non-provisional filing date, assuming maintenance fees are timely paid after the patent has issued. Most foreign jurisdictions also provide a 20-year nominal patent term, though many require payment of regular, often annual, annuities to maintain pendency of an application or viability of an issued patent. In some jurisdictions, one or more options for extension of a patent term may be available, but even with such extensions, the lifespan of a patent, and the protection it affords, is limited. Even if patents covering our product candidates, proprietary technologies and their uses are obtained, once the patent term has expired, we may be subject to competition from third parties that can then use the inventions included in such patents to create competing products and technologies. In addition, although upon issuance in the United States a patient&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such candidates are commercialized. If any patents that we own or in-license expire, we would not be able to stop others from using or commercializing similar or identical technology and products, and our competitors could market competing products and technology. Any of the foregoing could materially harm our competitive position, business, financial conditions, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business, financial condition, results of operations and prospects may be materially harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five&#160;years </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">70</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may be reliant upon licenses to certain intellectual property and other proprietary rights from third parties that are important or necessary to the development and commercialization of our technology and product candidates, and we expect to enter into similar license agreements in the future. Licensing of intellectual property is important to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Our licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in any or all of our licenses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Where we obtain licenses from, or collaborate with, third parties, in some circumstances we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from third parties, or such activities, if controlled by us, may require the input of such third parties. In some cases, patent prosecution of our in-licensed intellectual property is controlled solely by the licensor. We may also require the cooperation of our licensors and future partners, if any, to enforce or defend any in-licensed patent rights, and such cooperation may not be provided. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, protected, enforced or defended in a manner consistent with the best interests of our business. Any patents or patent applications that we in-license may be challenged, narrowed, circumvented, invalidated or held unenforceable, or our licensors may not properly maintain such patents or patent applications and they may expire. If our licensors fail to obtain, maintain, defend, protect or enforce the intellectual property we license from them, we could lose our rights to the intellectual property and our competitors could market competing products using the inventions in such intellectual property. In certain cases, we control the prosecution of patents included from in-licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our partners. Any of the foregoing could materially harm our competitive position, business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, any failure to satisfy obligations or any material breach under any of our licenses to third-party intellectual property could give the licensor the right to terminate the license. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone and royalty payment, exclusivity and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license agreement, in which event we would not be able to develop, market and commercialize product candidates covered by the license agreement. In spite of our best efforts and even if we disagree, our licensors might still conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize the product candidates covered by these license agreements. In the event that any of our license agreements were to be terminated by the licensor, we may need to negotiate new or reinstated agreements, which may not be available to us on equally favorable terms, or at all. If these license agreements are terminated, or if the underlying patents or other intellectual property fail to provide the intended exclusivity, competitors would have the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">71</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">freedom to seek regulatory approval of, and to market and commercialize, products similar or identical to ours. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing license agreements in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described in this section. If we, our co-owners or our licensors, including our future partners, if any, fail to adequately protect this intellectual property, our and our future partners, if any, ability to develop our product candidates, as well as the economic feasibility and our partners&#8217; ability to develop, market and commercialize any products derived from our product candidates, could suffer. Moreover, if disputes over intellectual property that we have in-licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop our product candidates, and our future partners, if any, may not be able to successfully market and commercialize any products derived from our product candidates, which could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our current proprietary position for certain product candidates depends upon our owned or in-licensed patent filings covering components of such product candidates, manufacturing-related methods, formulations and/or methods of use, which may not adequately prevent a competitor or other third party from using the same product candidate for the same or a different use.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Composition of matter patent protection is generally considered to be desirable because it provides protection without regard to any particular method of use or manufacture or formulation. While we have obtained patent protection covering components of certain product candidates, manufacturing-related methods, formulations and/or methods of use and claims issued that are directed to a vaccine formulation containing a broadly defined protein antigen, we do not currently have any claims in our owned or in-licensed issued United States or European patents that cover the overall construct used in our product candidates, and we cannot be certain that claims in any future patents issuing from our pending owned or in-licensed patent applications or our future owned or in-licensed patent applications will cover the composition of matter of our current or future product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Method of use patents protect the use of a product for the specified method and formulation patents cover formulations to deliver therapeutics. These types of patents do not prevent a competitor or other third party from developing, marketing or commercializing a similar or identical product for an indication that is outside the scope of the patented method or from developing a different formulation that is outside the scope of the patented formulation. Moreover, with respect to method of use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method of use patents, the practice is common and this type of infringement is difficult to prevent or enforce. Consequently, we may not be able to prevent third parties from practicing our inventions in the United States or other countries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, competitors or other third parties may in their commercial activities rely on secret know-how, including reliance on secret technologies. Such secret technologies may include manufacturing processes, intermediary products, manufacturing tools etc., the existence and utility of which is by nature not known to the public and for which we at a later stage may therefore seek patent protection and obtain valid patents. Such competitors and third parties could, if they can document their prior secret use of the patented technologies, have acquired prior user rights under applicable national laws, including in the United States the defense to patent infringement defined in 35 U.S.C. &#167;273, that protect such competitors and third parties from claims of patent infringement raised by us. Under such circumstances, we might not be able to adequately prevent such a competitor or third party from commercially exploiting our patented technology in the United States or in other countries. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">72</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual property rights of third parties could adversely affect our partners&#8217; ability to commercialize any products derive from our product candidates, and we and/or our future partners, if any, might be required to litigate or obtain licenses from third parties in order to develop or market our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because some of our product candidates are still in early developmental stages, and one or more features of the product candidates or related technologies such as their manufacture, formulation or use, may still change, we cannot be confident that we are aware of all third-party intellectual property that might be relevant to products that we eventually hope to commercialize. Various third-party competitors practice in relevant spaces, and may have issued patents, or patent applications that will issue as patents in the future, that will impede or preclude our ability to commercialize products. Furthermore, while United States patent laws provide a &#8220;safe harbor&#8221; to our clinical product candidates under 35 U.S.C. &#167;&#160;271(e)(1), which exempts from patent infringement activities related to pursuing FDA approval for a drug product, that exemption expires when a BLA or NDA is submitted. Given the uncertainty of clinical trials, we cannot be certain of the timing of their completion and it is possible that we might want to submit a BLA or NDA at a time when one or more relevant third-party patents is in force. Thus, it is possible that at the time that we commercialize our product candidates, one or more third parties may have issued patent claims that cover our products or critical features of their production or use. We may not be able to commercialize our products if patents issued to third parties or other third-party intellectual property rights cover, or may be alleged to cover, our products or elements thereof, or their methods of manufacture or use at the time that we seek to commercialize them. In such cases, we may not be in a position to develop or commercialize product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, successfully design around their claims, or enter into a license agreement with the intellectual property right holder(s). Such litigation or licenses could be costly or not available on commercially reasonable terms or at all, and design-around could be prohibitively expensive or impossible. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">It is also possible that we have failed to identify relevant third-party patents that cover, or applications that will mature into patents that cover, one or more aspects of our platforms or product candidates. Given that, in most jurisdictions, a patent application is confidential when initially filed, and typically remains so until it is published about 18&#160;months after the initial filing, it may not be possible for us to identify certain relevant filings in time to avoid using the technology that they claim. Additionally, the claims of pending patent applications and divisional continuation applications filed at a late stage can, subject to certain limitations, be amended over time, so that even patent applications whose claims did not cover our products or activities when published could be amended to cover one or more aspects of our platforms or product candidates over time, and we might not be aware that such amendment had been made. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be involved in lawsuits to protect or enforce our intellectual property or the intellectual property of our licensors, or to defend against third-party claims that we infringe, misappropriate or otherwise violate such third party&#8217;s intellectual property, each of which could be expensive, time consuming and unsuccessful.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, ex parte reexaminations, post-grant review, and inter partes review proceedings before the USPTO and corresponding European and other non-United States patent offices. Competitors and other third parties may infringe, misappropriate or otherwise violate our intellectual property rights or those of our licensors. To prevent infringement, misappropriation or other unauthorized use, we may be required to file claims, which can be expensive and time-consuming. In certain instances, we may institute inter partes review proceedings against issued United States patents and opposition proceedings against European patents owned by third parties in the field of immunotherapy. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, in a patent infringement proceeding, our owned, or in-licensed patents may be challenged and a court may decide that a patent we own, or in-license is not valid, is unenforceable and/or is not infringed. If we or our future partners, if any, were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">73</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms for challenging the validity and enforceability of a patent exist in ex-United States patent offices and may result in the revocation, cancellation or amendment of any ex-United States patents we hold in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would materially harm our competitive position, business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Third parties, ranging from our competitors to non-practicing entities or patent assertion entities, may assert that we are employing their intellectual property and other proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use, development, manufacture or commercialization of our product candidates. As patent applications can take many&#160;years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that our technologies infringe upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may obtain injunctive or other equitable relief, which could effectively block our ability to develop and commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms, or at all, or may be non-exclusive. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same intellectual property and technology. Our defense of litigation, interference, derivation or similar proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing collaborations that would help us bring our product candidates to market. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may not be made available on commercially favorable terms, if at all, or may require substantial time and expense. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">74</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same intellectual property and technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and product candidates, which could limit our ability to generate revenues or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. Moreover, certain of our collaborations provide, and we expect additional collaborations to provide, that royalties payable to us for licenses to our intellectual property may be offset by amounts paid by our future partners, if any, to third parties for licenses to such third parties&#8217; intellectual property in the relevant fields, which could result in significant reductions in our revenues from products developed through collaborations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, in connection with certain license and collaboration agreements, we have agreed, and may in the future agree, to indemnify certain third parties for certain costs incurred in connection with litigation relating to intellectual property rights or the subject matter of the agreements. The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation in the United States, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments in any litigation or other intellectual property proceedings. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of the ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents or applications. We have systems in place to remind us to pay these fees and we may employ outside firms and rely on our outside counsel to pay these fees due to non-United States patent agencies; however, we cannot guarantee that we will successfully pay these fees. The USPTO and various non-United States governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our in-licensed intellectual property, and we cannot guarantee that they will do so. In such an event, our competitors might be able to enter the market with similar or identical products or technology, and this would materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in patent law in the United States or in other countries could diminish the value of patents in general, thereby impairing our ability to protect our products.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As is the case with other biotechnology companies, our success is dependent on our intellectual property rights, particularly patents that we own and in-license. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and therefore obtaining and enforcing biotechnology patents is costly, time-consuming and inherently uncertain. Moreover, there are periodic changes in patent law. For example, after March&#160;2013, under the America Invents Act, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. The America Invents Act and its implementation could increase the uncertainties </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">75</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, recent United States Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the United States Congress, the federal courts and the USPTO, and their equivalents in other jurisdictions, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to obtain, maintain, protect, defend or enforce our intellectual property in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to seeking patent protection for some of our technology and product candidates, we also seek to rely on trade secret protection and confidentiality agreements to maintain our competitive position and protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets and know-how may be difficult to protect. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We seek to protect these trade secrets, know-how and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate future partners, if any, outside scientific future partners, if any, CROs, CDMOs, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants and require all of our employees and key consultants who have access to our trade secrets, proprietary know-how, information or technology to enter into confidentiality agreements. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our best efforts, any of these parties may breach the agreements and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. We may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret or know-how is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets and know-how. If any of our trade secrets or know-how were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially harm our business, operating results, financial condition and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be subject to claims that we have wrongfully hired an employee from a competitor, or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have received confidential and proprietary information from third parties in the course of our research and other collaborations with others in the industry, academic institutions and other third parties. In addition, many of our employees, consultants and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, independent contractors and advisors do not use the confidential or proprietary information, trade secrets or know-how of others in their work for us, we may be subject to claims that we have inadvertently or otherwise used or disclosed confidential or proprietary information, trade secrets or know-how of these third parties, or that our employees, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">76</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">consultants, independent contractors or advisors have inadvertently or otherwise used or disclosed confidential information, trade secrets or know-how of such individual&#8217;s current or former employer. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. Claims that we, our employees, consultants or advisors have misappropriated the confidential or proprietary information, trade secrets or know-how of third parties could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have been and may, in the future, be, subject to claims that current or former employees, consultants, independent contractors, collaborators, future partners, if any, or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. While it is our policy to require our employees, consultants, independent contractors, future partners, if any, and other third parties who may be involved in the conception, development or reduction to practice of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives, develops or reduces to practice such intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants, independent contractors, future partners, if any, or other third parties who are involved in developing and commercializing our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For instance, in April&#160;2022, SSI initiated a legal proceeding against us in The Danish Maritime and Commercial High Court (S&#248; og Handelsretten), claiming sole ownership of a patent application we filed related to a method for treating malignant neoplasm by administering a composition comprising a high dose of neopeptides, a solvent and SSI&#8217;s liposomal adjuvant, CAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">09b, or the Invention, for which we have an exclusive, royalty-bearing sub-licensable license to use in formulation with PIONEER identified neopeptides, from SSI. We believe that we and our employees are the sole inventors of the Invention and that we have strong defenses against SSI&#8217;s claim and that SSI&#8217;s claim is without merit. Since May&#160;2023 the court proceedings has been paused while non-court mediated negotiations between us and SSI is ongoing. We have reached terms with SSI which do not include compensation from Evaxion to SSI, however formal agreement needs to be signed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If disputes such as the SSI dispute, over intellectual property that we have in-licensed or other related contractual rights prevent or impair our ability to maintain our current licensing arrangements on favorable terms, we may be unable to successfully develop our product candidates and the commercialization of any products derived from such product candidates may be adversely affected. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could materially harm our business, financial condition, results of operations and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, the laws of some countries do not protect intellectual property and other proprietary rights or establish ownership of inventions to the same extent or in the same manner as the laws of the United States. A majority of our employees work in Denmark and are subject to Danish employment law. Employees&#8217; inventions that are either patentable or registrable as Danish utility models are subject to the provisions of the Danish Act on Employee Inventions, which regulates the ownership of, and compensation for, inventions made by employees. We face the risk that disputes can occur between us and our employees or former employees pertaining to alleged non-adherence to the provisions of this act. Such disputes may be costly to defend and may take up our management&#8217;s time and efforts regardless of whether we prevail or fail in any such dispute. There is a risk that the compensation we provided to employees who have assigned the rights to inventions to us may be deemed to be insufficient and we may under Danish law be required to increase the compensation due to such employees for the assignment of rights to such inventions. In those </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">77</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">cases where rights to employees&#8217; inventions have not been assigned to us, we may need to agree with the respective employees on the assignment of such inventions, including i.e. by paying suitable compensation for the use of those patents. If we are required to pay additional compensation or face other disputes under the Danish Act on Employee Inventions, our business, financial condition, results of operations and prospects could be materially harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws in Denmark and the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and to the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own product candidates and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement, misappropriation or other violation of our patents and other intellectual property or development, marketing and commercialization of competing products in violation of our intellectual property and other proprietary rights generally. Proceedings to enforce our intellectual property rights in such jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or in-license. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects could be materially harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our unregistered trademarks or trade names, as well as any trademarks or service marks that we may register or have registered, may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential future partners, if any, or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">78</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, know-how, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual property rights do not necessarily address all potential threats to our business or permit us to maintain any competitive advantage we may have.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain any competitive advantage we may have. For example: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">others may be able to make personalized cancer immunotherapies and infectious disease products or product candidates that are similar to any product candidates we may develop and commercialize or utilize similar technologies that are not covered by the claims of the patents that we now or may in the future own or have exclusively in-licensed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we, our co-owners or our licensors or future partners, if any, might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or have exclusively in-licensed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we, our co-owners or our licensors or future partners, if any, might not have been the first to file patent applications covering certain of our or their inventions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">it is possible that our pending patent applications or those that we may own or in-license in the future will not lead to issued patents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">issued patents that we own or have exclusively in-licensed may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may not develop additional proprietary technologies that are patentable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the patents of others may have an adverse effect on our business; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Should any of these events occur, they could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Cybersecurity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We and our future partners, if any, or other contractors or consultants depend on information technology systems, and any failure of these systems could materially harm our business, financial condition, results of operations and prospects. Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could also materially harm our business, financial condition, results of operations and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our internal computer systems and those of our future partners, if any, vendors, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, pandemics, terrorism, cybersecurity threats, war, and telecommunication and electrical failures. If any such </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">79</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">material system failure, accident or security breach were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of pre-clinical data and/or clinical trial data from one or more ongoing or completed pre-clinical projects or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, because of our approach to running multiple projects in parallel, any breach of our computer systems may result in a loss of data or compromised data integrity across many of our programs in many stages of development. Any such breach, loss or compromise of clinical trial participant personal data may also subject us to civil fines and penalties, including under the GDPR and relevant member state law in the European Union, and the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, and other relevant state and federal privacy laws in the United States. To the extent that any disruption or security breach were to result in a loss of, or damage to, data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While we have not experienced any material system failures, accidents or security breaches to date, we cannot guarantee that third parties will not be able to gain unauthorized access to or otherwise breach our systems in the future. Any such unauthorized access or breach could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Government Regulation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if our future partners, if any, obtain regulatory approval for a product derived from one of our product candidates, such products will remain subject to regulatory scrutiny. Failure to obtain and/or maintain regulatory approval of our product candidates or to comply with ongoing regulatory requirements if regulatory approval is obtained, would materially harm our business, financial condition, results of operations and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a product derived from one of our product candidates is approved, it will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post- market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">BLA and NDA holders, as well as manufacturers of drug and biologics facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any approved marketing application. Accordingly, we, our partner and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our future partners, if any, will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, our future partners, if any, may not promote our products &#8220;off-label&#8221; for indications or uses for which they do not have approval. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. Our future partners, if any, could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">80</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">our future partners, if any, fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">issue warning letters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">impose civil or criminal penalties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">suspend or withdraw regulatory approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">suspend any of our clinical studies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">refuse to approve pending applications or supplements to approved applications submitted by us; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">seize or detain products, or require a product recall. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any government investigation of alleged violations of law could require us and/or our future partners, if any, to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our partners&#8217; ability to commercialize and generate revenue from any products derived from our product candidates. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, the policies of the FDA, the EMA, the TGA and other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of any products derived from our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States, Europe or other countries. For example, certain policies of the current United States administration may impact our business and industry. Namely, the current United States administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these orders will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose restrictions on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We and our future partners, if any, may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws. If we and/or our future partners, if any, are unable to comply, or have not fully complied, with such laws, we and/or our future partners, if any, could face substantial penalties, which could materially harm our business, financial condition, results of operations and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We and/or our future partners, if any, may be subject to additional healthcare regulation and enforcement by the United States federal government and by authorities in the United States, the European Union and other jurisdictions in which we conduct our business. If our future partners, if any, obtain FDA approval for any products derived from our product candidates and begin commercializing those products in the United States, our operations may be indirectly through our future partners, if any, and their prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without limitation, the federal Health Care Program Anti-Kickback Statute, the federal civil and criminal False Claims Act, and the Physician Payments Sunshine Act and regulations. Many states and other jurisdictions have similar laws and regulations, some of which may be broader in scope. These laws will impact, among other things, our proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws enacted by both the federal government and the states in which we conduct our business. The laws that will affect our operations include, but are not limited to the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">81</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers, and formulary managers on the other. The ACA amends the intent requirement of the federal Anti-Kickback Statute to provide that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment or approval from Medicare, Medicaid or other government payors. The ACA provides, and recent government cases against pharmaceutical and medical device manufacturers support, the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the False Claims Act; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care providers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The United States Federal Food, Drug, and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The United States Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Federal transparency laws, including the federal Physician Payment Sunshine Act, which require disclosure of payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">State law equivalents of each of the above federal laws, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare professionals or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances which are also applicable to us, and many of them differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts in certain circumstances; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, United States companies and their employees and agents, as well as non-United States companies registered with the SEC from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Similar healthcare laws and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Due to the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">82</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of European Union member states, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Payments made to physicians in certain European Union member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization or the regulatory authorities of the individual European Union member states. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the European Union member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are subject to certain anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Among other matters, anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as &#8220;trade laws&#8221;, prohibit companies and their employees, agents, CROs, CDMOs, legal counsel, accountants, consultants, contractors and other future partners, if any, from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, intellectual property (including patents) and other regulatory approvals, and we can be held liable for the corrupt or other illegal activities of our personnel, agents or future partners, if any, even if we do not explicitly authorize or have prior knowledge of such activities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are subject to stringent privacy laws, information security policies and contractual obligations governing the use, processing, and cross-border transfer of personal information and our data privacy and security practices. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We receive, generate and store significant and increasing volumes of sensitive information, such as employee, personal and patient data. We are subject to a variety of local, state, national and international laws, directives and regulations that apply to the collection, use, storage, retention, protection, disclosure, transfer and other processing of personal data, collectively referred to as &#8220;data processing&#8221;, in the different jurisdictions in which we operate, including comprehensive regulatory systems in the United States and Europe. Legal requirements relating to data processing continue to evolve and may result in ever-increasing public scrutiny and escalating levels of enforcement, sanctions and increased costs of compliance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Compliance with United States and international data protection laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Moreover, complying with these various laws could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with United States, European and other international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Various states in the United States, such as California and Massachusetts, have implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of patient health information and other personal information. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. California&#8217;s patient privacy laws, for example, provide for penalties of up to $250,000 and permit injured </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">83</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">parties to sue for damages. In addition to the California Confidentiality of Medical Information Act, California also recently enacted the California Consumer Privacy Act of 2018, or CCPA, which became effective on January&#160;1, 2020. The CCPA has been characterized as the first &#8220;GDPR-like&#8221; privacy statute to be enacted in the United States because it mirrors a number of the key provisions of the European Union General Data Protection Regulation (described below). The CCPA establishes a new privacy framework for covered businesses in the State of California, by creating an expanded definition of personal information, establishing new data privacy rights for consumers imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. An initiative called the California Privacy Rights Act, or CCPA 2.0, passed in November&#160;2020 and builds upon and amends the original CCPA aligning it more closely with the GDPR. CCPA 2.0 expands the privacy rights of California residents and could impact our operations or that of our future partners, if any. Other states have been considering legislation similar to the CCPA, and several federal privacy proposals are under consideration in the current session of Congress. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The collection and use of personal health data in the European Union had previously been governed by the provisions of the Data Protection Directive, which has been replaced by the European Union General Data Protection Regulation, or GDPR. While the Data Protection Directive did not apply to organizations based outside the European Union, the GDPR has expanded its reach to include any business, regardless of its location, that provides goods or services to residents in the European Union. The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for &#8220;sensitive information&#8221; which includes health and genetic information of data subjects. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. The GDPR is a complex law and the regulatory guidance is still evolving, including with respect to how the GDPR should be applied in the context of clinical studies. Furthermore, some of the countries within the European Union are still in the process of drafting supplementary data protection legislation in key fields where the GDPR allows for national variation, including the fields of clinical study and other health-related information. These variations in the law may raise our costs of compliance and result in greater legal risks. Additionally, on July&#160;16, 2020, the Court of Justice of the European Union, or the CJEU, issued a landmark opinion in the case Maximilian Schrems vs. Facebook (Case C-311/18), called Schrems II. This decision calls into question certain data transfer mechanisms as between the European Union member states and the United States. The CJEU is the highest court in Europe and the Schrems II decision heightens the burden on the data exporters (transferring the data out of the European Union) as well as the data importers (the recipient of the data in the United States) to assess United States national security laws on their business and future actions of European Union data protection authorities are difficult to predict at the early date. Consequently, there is some risk of any such data transfers from the European Union being halted. Any contractual arrangements requiring the transfer of personal data from the European Union to us in the United States will require greater scrutiny and assessments as required under Schrems II and may have an adverse impact on cross-border transfers of personal data, or increase costs of compliance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since we are located in the European Union, we are subject to the GDPR. GDPR regulations have imposed additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous and may interrupt or delay our development activities, and materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other jurisdictions outside the European Union are similarly introducing or enhancing privacy and data security laws, rules and regulations, which could increase our compliance costs and the risks associated with non-compliance. For instance, Australia, where we are currently conducting clinical trials for EVX-01, regulates data privacy and protection through a mix of federal, state and territory laws. The federal Privacy Act 1988 (Cth) (Privacy Act) or the Privacy Act, and the Australian Privacy Principles, or the APPs, contained in the Privacy Act apply to private sector entities (including body corporates, partnerships, trusts and unincorporated associations) with an annual turnover of at least AU$3&#160;million, and all Commonwealth Government and Australian Capital Territory Government agencies. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">84</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Privacy Act regulates the handling of personal information by relevant entities and under the Privacy Act, the Privacy Commissioner has authority to conduct investigations, including own motion investigations, to enforce the Privacy Act and seek civil penalties for serious and egregious breaches or for repeated breaches of the APPs where an entity has failed to implement remedial efforts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2022, the Australian Government increased fines for violations of the Privacy Act. The maximum fine for a serious invasion or repeated invasions of privacy (i.e. breaches of the privacy law) was increased to up to the greater of AUD $50m, three times the benefit of a contravention, or (where the benefit can&#8217;t be determined) 30% of domestic turnover. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, most States and Territories in Australia (except Western Australia and South Australia) have their own data protection legislation applicable to relevant State or Territory government agencies, and private businesses that interact with State and Territory government agencies. These Acts include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Information Privacy Act 2014 (Australian Capital Territory) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Information Act 2002 (Northern Territory) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Privacy and Personal Information Protection Act 1998 (New South Wales) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Information Privacy Act 2009 (Queensland) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Personal Information Protection Act 2004 (Tasmania), and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Privacy and Data Protection Act 2014 (Victoria) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, there are other parts of Australian State, Territory and federal legislation that relate to data protection. For example, the following all impact privacy and data protection for specific types of data or activities: the Telecommunications Act 1997 (Cth), the Criminal Code Act 1995 (Cth), the National Health Act 1953 (Cth), the Health Records and Information Privacy Act 2002 (NSW), the Health Records Act 2001 (Vic) and the Workplace Surveillance Act 2005 (NSW). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Specific regulators have also expressed an expectation that regulated entities should have specified data protection practices in place. For example, the Australian Prudential and Regulatory Authority, or the APRA, which regulates financial services institutions requires regulated entities to comply with Prudential Standards, including Prudential Standard CPS 234 Information Security (CPS 234), and the Australian Securities and Investment Commission regulates corporations more generally. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot guarantee that we are, or will be, in compliance with all applicable international regulations as they are enforced now or as they evolve. For example, depending on the jurisdiction, our privacy policies may be insufficient to protect any personal information we collect, or may not comply with applicable laws, in which case we may be subject to regulatory enforcement actions, lawsuits or reputational damage, all of which may adversely affect our business. There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with the GDPR, especially with regard to clinical trial conduct. For example, it is not clear if the authorities will conduct random audits of companies doing business in the European Union, or if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated. Enforcement uncertainty and the costs associated with ensuring GDPR compliance may be onerous and materially harm our business, financial condition, results of operations and prospects. If we fail to comply with the GDPR and the applicable national data protection laws of the European Union member states, or if regulators assert we have failed to comply with these laws, it may lead to regulatory enforcement actions, which in a worst-case scenario can result in monetary penalties of up to $20,000,000 or up to 4% of the total worldwide annual revenue of the preceding financial year, whichever is higher, and other administrative penalties. If any of these events were to occur, our business and financial results could be significantly disrupted and adversely affected. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, and liability under federal or state laws that protect </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">85</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the privacy of personal information, as well as regulatory penalties. In the United States, notice of breaches must be made to affected individuals and the United States Secretary of HHS, and for extensive breaches, notice may need to be made to the media or state Attorneys General. Such a notice could harm our reputation and our ability to compete. HHS has the discretion to impose penalties without attempting to resolve violations through informal means. In addition, state Attorneys General are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. Although we have implemented security measures to prevent unauthorized access to patient data, such data is currently accessible through multiple channels, and there is no guarantee we can protect our data from breach. Unauthorized access, loss or dissemination could also damage our reputation or disrupt our operations, including our ability to conduct our analyses, deliver test results, process claims and appeals, provide customer assistance, conduct research and development activities, collect, process and prepare company financial information, provide information about our tests and other patient and physician education and outreach efforts through our website, and manage the administrative aspects of our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we, our future partners, if any, or our third-party suppliers fail to comply with environmental, health and safety and regulations, we could become subject to fines or penalties or incur costs that could materially harm our business, financial condition, results of operations and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We and our future partners, if any, will become subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations and the operations of our future partners, if any, will involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations and the operations of our future partners, if any, also may produce hazardous waste products. We generally anticipate contracting with third parties for the disposal of these materials and wastes. We will not be able to eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our business operations and the operations of our future partners, if any, and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If any of the physicians or other providers or entities with whom we expect to do business were found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">86</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">our ability to operate our business. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General Risks Related to our Business</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified executive management and scientific personnel.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel with capabilities and expertise in immuno-oncology and infectious diseases as well as in artificial intelligence. We are highly dependent upon members of our management and scientific teams. We may not be able to retain these persons due to the competitive environment in the biotechnology industry. The loss of any of these persons&#8217; services may adversely impact the achievement of our research, development, financing and commercialization objectives. We currently do not have &#8220;key person&#8221; insurance on any of our employees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we rely on consultants, contractors and advisors, including scientific and clinical advisors, to assist us in formulating our research and development, regulatory approval and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The loss of the services of one or more of our current employees or advisors might impede the achievement of our research, development, regulatory approval and commercialization objectives. In addition, we have flexibly grown our workforce through the use of contractors and part-time workers. We may not be able to retain the services of such personnel, which might result in delays in the operation of our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, also will be critical to our success. Competition for skilled personnel, clinical operations, regulatory affairs, therapeutic area management and manufacturing, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on favorable terms, or at all, given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. In addition, adverse publicity, failure to succeed in pre-clinical studies or clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of our current or future product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We face an inherent risk of product liability exposure related to the testing of any of our current or future product candidates in clinical trials, and we may face an even greater risk if any products derived from our product candidates are commercialized. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">decreased demand for any product candidate that we may develop; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">loss of revenue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">substantial monetary awards to patients, healthy volunteers or their children; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">significant time and costs to defend the related litigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">withdrawal of clinical trial participants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the inability to commercialize any product candidates that we may develop; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">injury to our reputation and significant negative media attention. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">87</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We carry clinical trial insurance, including product liability insurance, which we believe to be sufficient in light of the status of our current clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when any products derived from our product candidates obtain regulatory approval, we intend to expand our insurance coverage; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause the price of the ADSs to decline and, if judgments exceed our insurance coverage, could materially harm our business, financial condition, result of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our products become subject to a product recall it could harm our reputation, business financial condition, results of operations and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA, the EMA, the TGA and similar governmental authorities in other jurisdictions have the authority to require the recall of certain commercialized products. In the case of the FDA, the authority to require a recall of a biologic product must be based on an FDA finding that a batch, or a lot of other quantity of the biologic product presents an imminent or substantial hazard to the public health. For products developed using our AI-Immunology&#8482; platform, a product recall may prevent other products derived from one or more of our product candidates using our AI-Immunology&#8482; platform that target the same disease indication until we can demonstrate that the reason for any such product recall did not involve our technology. In addition, some governmental bodies outside the United States have the authority to require the recall of any product derived from one or more of our product candidates in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if any material deficiency in a product is found. A government-mandated or voluntary recall by us could occur as a result of manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our product candidates would divert managerial and financial resources and could materially harm our business, financial condition, results of operations and prospects. Also, a recall announcement could harm our reputation with customers and negatively affect our sales, if any. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we engage in future acquisitions, joint ventures, partnerships or collaborations, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. We may not realize the benefits of these acquisitions, joint ventures or collaborations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may evaluate various acquisitions and collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition, joint venture, partnerships or collaboration may entail numerous risks, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">increased operating expenses and cash requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the assumption of additional indebtedness or contingent liabilities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the diversion of our management&#8217;s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, if we undertake acquisitions, we may utilize our cash, issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">88</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, we may not be able to locate suitable acquisition or collaboration opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be adversely affected by global climate change or by legal, regulatory or market responses to such change.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Increasing stakeholder environmental, social and governance, or ESG, expectations, physical and transition risks associated with climate change, and emerging ESG regulation and policy requirements may pose risk to our market outlook, brand and reputation, financial outlook, cost of capital, global supply chain and production continuity, which may impact our ability to achieve our business objectives. Changes in environmental and climate change laws or regulations could lead to additional operational restrictions and compliance requirements upon us, our future partners, if any, or other third parties upon whom we depend or otherwise could negatively impact our business. Physical impacts of climate change may drive increased costs to us and our suppliers and impact our continuity and facilities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We, our future partners, if any, or other third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and our, our future partners, if any, and such other third parties business continuity and disaster recovery plans may not adequately protect us or them from a serious disaster.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevented us, our future partners, if any, or other third parties upon whom we depend from using all or a significant portion of our or their facilities, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which could materially harm our business, financial condition, results of operations and prospects. Furthermore, integral parties in our supply chain are operating from single locations, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our ability to conduct our clinical trials, our development plans and business, which could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to this Offering and Ownership of ADSs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The price of the ADSs has been and may continue to be highly volatile and fluctuate substantially, which could result in substantial losses for purchasers of the ADSs who may not be able to resell the ADSs at or above the price they paid. Since the closing of our IPO in February&#160;2021 and our follow-on offering in November&#160;2021, the market price of the ADSs has decreased significantly and has been and may continue to be highly volatile. The stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, ADS holders may not be able to resell the ADSs at or above the price they paid for our ADSs. The market price for the ADSs may be influenced by many factors, including, but not limited to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">results of our pre-clinical development and clinical trials of our product candidates or those of our competitors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the success of existing competitive products or technologies or new competitive products or technologies that may emerge; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">announcements by us or our competitors of commencement or termination of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory or legal developments in the United States and other countries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">developments or disputes concerning patent applications, issued patents, or other intellectual property or proprietary rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the recruitment or departure of key personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">89</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">issuances or sales of our ordinary shares or ADSs by us, our insiders or our other shareholders or holders of the ADSs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the level of expenses related to any of our product candidates or clinical development programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the results of our efforts to discover, develop, acquire or in-license additional product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">actual or anticipated changes in estimates as to our financial condition, results of operations, development timelines or issuance of new or updated research, reports or recommendations by securities analysts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">variations in our financial results or those of companies that are perceived to be similar to us; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">announcement or expectation of additional debt or equity financing efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">currency fluctuations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">changes in the structure of healthcare payment systems; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">market conditions in the pharmaceutical and biotechnology sectors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">general economic, industry and market conditions, including the disruption in the financial markets caused by the COVID-19 pandemic and the ongoing military conflict between Russia and Ukraine and the conflict in the Israel-Gaza region; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the numerous programs in our pipeline, the development of which could each generate news or significant adverse events that could impact financial results or recommendations by securities analysts. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If our quarterly or annual results fall below the expectations of investors or securities analysts, the price of the ADSs could decline substantially. Furthermore, any such fluctuations in our results may, in turn, cause the price of the ADSs to fluctuate substantially. We believe that period-to-period comparisons of our results are not necessarily meaningful and should not be relied upon as an indication of our future performance. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation often has been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management&#8217;s attention and resources, which could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">An active and liquid market for the ADSs and our ordinary shares may not be sustained, which could harm the market price of the ADSs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although the ADSs are listed on the Nasdaq Capital Market, an active trading market for the ADSs may not be sustained. In the absence of an active trading market for the ADSs, investors may not be able to sell their ADSs at the desired price or at the time that they would like to sell. In addition, the market price of the ADSs in our follow-on offering was based on the closing price of the ADSs at the time of such follow-on offering, there is no guarantee that such price will be free from challenge by our existing shareholders based on allegations that it does not reflect the &#8220;market price&#8221; at which we are required by our articles of association and Danish law to sell our ordinary shares. Any such shareholder challenge could be time consuming and costly and, if decided in a manner unfavorable to us, could result in liability to us and our directors, and could prevent any such offering from closing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has been and will continue to be required to devote substantial time to compliance initiatives. We are subject to financial reporting and other requirements for which our accounting and other management systems and resources may not be adequately prepared. We may fail to comply with the rules that apply to public companies, including Section&#160;404 of the Sarbanes-Oxley Act, which could result in sanctions or other penalties that would materially harm our business, financial condition, results of operations and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a public company, and particularly if we are no longer an &#8220;emerging growth company&#8221; as defined in the JOBS Act, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, since becoming a public company as a result of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">90</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">our IPO in February&#160;2021, the federal securities laws, including the Sarbanes-Oxley Act, and rules subsequently implemented by the SEC and The Nasdaq Stock Market LLC, or Nasdaq, have imposed various requirements on our company, including requirements to file annual and event-driven reports with respect to our business and financial condition, and to establish and maintain effective disclosure and financial controls and corporate governance practices. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, these rules and regulations have made it more difficult and more expensive for us to obtain director and officer liability insurance. We may not be able to produce reliable financial statements or file these financial statements as part of a periodic report in a timely manner with the SEC or comply with Nasdaq listing requirements. In addition, we could make errors in our financial statements that could require us to restate our financial statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to Section&#160;404 of the Sarbanes-Oxley Act, or Section&#160;404, we are required to furnish a report in connection with issuing our annual financial statements by our management on our internal control over financial reporting, and may be required to provide the attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm in our annual filings with the SEC. To achieve compliance with Section&#160;404 within the prescribed period, we have been and will continue to be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&#160;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In July&#160;2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act. Additional legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five&#160;years from the last day of the fiscal year following the fifth anniversary of the closing of our IPO in February&#160;2021 (December&#160;31, 2026). We intend to take advantage of this additional legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Shareholder activism, the current political environment, and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance initiatives. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are an &#8220;emerging growth company&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make our ordinary shares and the ADSs less attractive to investors.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company&#8221; under the JOBS Act, and we will remain an emerging growth company until the earlier of: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the last day of the first fiscal year in which our annual gross revenues exceed $1.235&#160;billion; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the date on which we have issued more than $1&#160;billion in nonconvertible debt securities during the previous three&#160;years; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the first day of the year following the first year in which, as of the last business day of our most recently completed second fiscal quarter, the market value of our common equity held by non-affiliates exceeds $700&#160;million; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">91</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the last day of the fiscal year following the fifth anniversary of the closing of our IPO (December&#160;31, 2026). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to public companies that are not emerging growth companies. These exemptions include: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reduced disclosure obligations regarding executive compensation; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of reduced reporting burdens in this Form F-1. In particular, we have not included all of the executive compensation information that would be required if we were not an emerging growth company. We cannot predict whether investors will find the ADSs less attractive if we rely on certain or all of these exemptions. If some investors find the ADSs less attractive as a result, there may be a less active trading market for the ADSs and the price per ADS may be more volatile. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the JOBS Act provides that an emerging growth company may take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Such provisions are only applicable under U.S. GAAP, whereas our financial statements are prepared under the IFRS/IAS standards. As a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required or permitted by the IASB. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">As a &#8220;foreign private issuer,&#8221; we are exempt from a number of rules under the United States securities laws, as well as Nasdaq rules, and we are permitted to file less information with the SEC than are domestic United States issuers. This may limit the information available to holders of the ADSs and may make our ordinary shares and the ADSs less attractive to investors.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We qualify as a foreign private issuer. As a result, in accordance with the listing requirements of The Nasdaq Capital Market, we rely on home country governance requirements and certain exemptions thereunder rather than relying on the corporate governance requirements of The Nasdaq Capital Market. For instance, the Listing Rules for The Nasdaq Stock Market, or The Nasdaq Listing Rules, for domestic United States issuers require listed companies to have, among other things, a majority of their board members be independent, and to have independent director oversight of executive compensation, nomination of board members and corporate governance matters. As a foreign private issuer, however, while we intend to comply with these requirements, we are permitted to follow home country practice in lieu of the above requirements. Danish law does not require that a majority of our board consist of independent directors or the implementation of a remuneration committee or nominating and corporate governance committee, and our board may thus in the future not include, or include fewer, independent directors than would be required if we were subject to The Nasdaq Listing Rules, or they may decide that it is in our interest not to have a remuneration committee or nominating and corporate governance committee, or have such committees governed by practices that would not comply with Nasdaq Listing Rules. Since a majority of our board of directors may not consist of independent directors if we decide to rely on the foreign private issuer exemption to The Nasdaq Listing Rules, our board&#8217;s approach may, therefore, be different from that of a board with a majority of independent directors, and as a result, the management oversight of our company could, in the future, be more limited than if we were subject to the Nasdaq Listing Rules. We intend to follow home country practice with regard to, among other things, quorum requirements generally applicable to general meetings of shareholders. In addition, we have opted to follow home country law </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">92</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">instead of the Nasdaq Listing Rules that require that a listed company obtain shareholder approval for certain dilutive events, such as certain transactions other than a public offering involving issuances of a 20% or greater interest in the company. Following our home country governance practices as opposed to the requirements that would otherwise apply to a United States company may provide our shareholders with less protection than they would have as shareholders of a domestic U.S. company.</font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, Danish law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in Denmark, thus our practice varies from the requirement of Nasdaq Listing Rule&#160;5620(b). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Due to the above exemptions for foreign private issuers, our ADS holders will not be afforded the same protections or information generally available to investors holding shares in public companies organized in the United States, some investors may find the ADSs less attractive as a result, and there may be a less active trading market for the ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our failure to meet Nasdaq&#8217;s continued listing requirements could result in a delisting of our ADSs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we fail to satisfy the applicable continued listing requirements of Nasdaq, such as certain corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our ADSs. Such a delisting would likely have a negative effect on the price of our ADSs and would impair your ability to sell or purchase our ADSs when you wish to do so. In the event of a delisting, any action taken by us to restore compliance with listing requirements may not i) allow our ADSs to become listed again, ii)&#160;stabilize the market price or iii) improve the liquidity of our ADSs, iv) prevent our ADSs from dropping below the Nasdaq minimum bid price requirement or v) prevent future non-compliance with the listing requirements of Nasdaq. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We qualify as a foreign private issuer and, as a result, we will not be subject to United States proxy rules and will be subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a United States domestic public company.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We report under the Exchange Act, as a non-United States company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act and although we are subject to Danish laws and regulations with regard to such matters, we are exempt from certain provisions of the Exchange Act that are applicable to United States domestic public companies, including (i)&#160;the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; (ii)&#160;the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and (iii)&#160;the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form 20-F until four&#160;months after the end of each fiscal year, while United States domestic issuers depending on their size are required to file their annual report on Form 10-K within 60 or 90&#160;days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation&#160;Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information. As a result of the above, our shareholders and the holders of the ADSs may not have the same protections afforded to shareholders of companies that are not foreign private issuers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our status as a &#8220;foreign private issuer&#8221; allows us to adopt IFRS accounting principles, which are different than accounting principles under U.S. GAAP.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have adopted and presented our financial statements in accordance with IFRS as issued by the IASB. IFRS is an internationally recognized body of accounting principles that are used by many companies outside of the United States to prepare their financial statements; and the SEC permits foreign private issuers such as our company to prepare and file their financial statements in accordance with IFRS rather than U.S. GAAP. IFRS accounting principles are different from those of U.S. GAAP, and SEC rules do not require us to provide a reconciliation of IFRS accounting principles to those of U.S. GAAP. Persons who are not familiar with IFRS may misunderstand certain information presented in our financial statements. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">93</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accordingly, we suggest that readers of our financial statements familiarize themselves with the provisions of IFRS accounting principles in order to better understand the differences between these two sets of principles. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may lose our foreign private issuer status, which would then require us to comply with the Exchange Act&#8217;s domestic reporting regime and cause us to incur significant legal, accounting and other expenses.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We qualify as a foreign private issuer and therefore we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to United States domestic issuers. If we cease to be a foreign private issuer, which is measured as of the end of our second fiscal quarter in each fiscal year after the completion of our IPO, we will be required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to United States domestic issuers as of January&#160;1 of the following year. In order to maintain our current status as a foreign private issuer, either (a)&#160;a majority of our ordinary shares or ADSs must be either directly or indirectly owned of record by non-residents of the United States or (b)(i) a majority of our executive management or directors may not be United States citizens or residents, (ii)&#160;more than 50% of our assets cannot be located in the United States and (iii)&#160;our business must not be administered principally inside the United States. If we lost this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to United States domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under United States securities laws if we are required to comply with the reporting requirements applicable to a United States domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to United States domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Holders of the ADSs may be subject to certain limitations on the transfer of the ADSs and the withdrawal of the underlying ordinary shares.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our ADSs, which may be evidenced by American Depositary Receipts, or ADRs, are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of the ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason subject to a holder&#8217;s right to cancel the ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of the ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders&#8217; meeting or we are paying a dividend on our ordinary shares. In addition, holders of ADSs may not be able to cancel the ADSs and withdraw the underlying ordinary shares when such holder owes money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities. See &#8220;Description of Securities.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">A significant portion of our total outstanding ordinary shares may be sold in the near future. The large number of shares eligible for sale or subject to rights requiring us to register them for sale could cause the market price of the ADSs to drop significantly, even if our business is performing well.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Sales of a substantial number of ordinary shares or the ADSs could occur at any time. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of the ADSs. We had 40,540,546 ordinary shares outstanding and 2,099,610 ADSs </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">94</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">outstanding as of January&#160;29, 2024. To date, not all of the holders of outstanding ordinary shares have converted their ordinary shares to ADSs. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;6, 2021, we filed a registration statement on Form S-8 under the Securities Act of 1933, as amended, or the Securities Act, to register a total of 4,808,076 ordinary shares, representing all ordinary shares issued or issuable under our equity incentive scheme pursuant to the Appendices to our Articles of Association. Such Form S-8 registration statement automatically became effective upon filing. Accordingly, shares registered under such registration statement are available for sale in the open market following the expiration of the applicable lock-up period. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">You will experience immediate dilution. As of January&#160;29, 2024, there were 12,477,648 warrants outstanding. If these warrants are exercised then an additional 12,477,648 ordinary shares, which are convertible into 1,247,764 ADSs, will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule&#160;144 and Rule&#160;701 under the Securities Act. If these additional ordinary shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of the ADSs could decline. Any sales of securities by these security holders could have a negative effect on the trading price of our ordinary shares and ADSs. In addition, as of January&#160;29, 2024, there were 351,036 warrants issued to EIB under the loan agreement with EIB, which are expected to be cash settled. For a more detailed description of the EIB warrants see the section herein entitled &#8220;Our EIB warrants.&#8221; </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, on November&#160;28, 2021, we entered into a Share Sale and Restriction Agreement with, Dr.&#160;Lars Staal Wegner, our former Chief Executive Officer, Dr.&#160;Niels Iversen M&#248;ller our Co-Founder, and current member of our Board of Directors, and Andreas Mattsson, our Co-Founder and Chief AI and Culture Officer, pursuant to which Dr.&#160;Wegner agreed to exercise 211,849 warrants in each of the two week exercise windows established under our Articles of Association that are expected to open two trading days following publication of our annual report and interim quarterly financial reports in March&#160;2022, May&#160;2022, August&#160;2022 and November&#160;2022, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of this agreement, Dr.&#160;Wegner, Dr.&#160;M&#248;ller and Mr.&#160;Mattsson further agreed with us that in the corresponding open trading window related to each such exercise consisting of the four-week period commencing on the third full trading day after the date of publication of our annual report or interim financial reports in March&#160;2022, May&#160;2022, August&#160;2022 and November&#160;2022, each a Trading Window, Dr.&#160;Wegner would sell such Ordinary Shares and Dr.&#160;M&#248;ller and Mr.&#160;Mattsson will purchase such ordinary shares, with each of Dr.&#160;M&#248;ller and Mr.&#160;Mattsson purchasing fifty per cent (50%) of such shares, at a purchase price per share equal to the Volume Weighted Average Price, or VWAP, of our ADSs at the close of the market on the date of exercise as reported on Nasdaq. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Under the terms of the agreement, Dr.&#160;M&#248;ller and Mr.&#160;Mattsson agreed that during each Trading Window each of them will sell 328,731 ADSs representing ordinary shares at a price equal to the prevailing market price thereof on the date of such sale as reported on Nasdaq. Furthermore, pursuant the terms of the agreement, Dr.&#160;M&#248;ller and Mr.&#160;Mattsson are required to sell such shares and are prohibited from exercising any subsequent influence over how, when, or whether to affect the trade(s). As of December&#160;31, 2022, due to market conditions, Dr.&#160;M&#248;ller and Mr.&#160;Mattsson had only sold 43,196 of such ADSs representing ordinary shares, thereby, leaving a total of 285,535 ADSs subject to future sale under this arrangement. The number of ADSs referred to in this section do not reflect the one to ten ratio change effective January 22, 2024.</font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In addition, on June&#160;7, 2022, we entered into the LPC Purchase Agreement pursuant to which we issued 428,572 ordinary shares represented by ADS&#8217; (&#8220;Commitment Shares&#8221;) to Lincoln Park as consideration for a commitment fee of $1,200,000 for Lincoln Park&#8217;s agreement to purchase ordinary shares represented by ADSs under the LPC Purchase Agreement. As of the date of this prospectus we have not issued any additional ordinary shares represented by ADSs to Lincoln Park. In accordance with the terms of the LPC Purchase Agreement, we filed a selling shareholder Form F-1 Registration Statement with the SEC on July&#160;7, 2002, which was declared effective by the SEC on August&#160;26, 2022 registering the potential future sale by Lincoln Park of up to 4,649,250 ADSs represented ordinary shares inclusive of the 428,572 Commitment Shares. As of the date of this prospectus, Lincoln Park has only sold an aggregate of 102,000 of such Commitment Shares thereby leaving 326,572 of such Commitment Shares available for sale. The number of ADSs referred to in this section do not reflect the one to ten ratio change effective January&#160;22, 2024.</font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">95</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Additionally, on October&#160;3, 2022, we entered into a Capital on DemandTM Sales Agreement, or the Sales Agreement, with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which we may sell from time to time, at our option, ADSs representing ordinary shares through or to JonesTrading, as sales agent or principal. The ADSs are offered pursuant to a prospectus supplement, dated October&#160;3, 2022, or the Prospectus Supplement, which was filed with the SEC on such date and our Form F-3 (Registration No.&#160;333-265132) shelf registration statement filed with the SEC on May&#160;20, 2022 and declared effective by the SEC on June&#160;3, 2022. Pursuant to the Prospectus Supplement, we may offer and sell up to an aggregate of $14,439,000 of ADSs. Sales of the ADSs made pursuant to the Sales Agreement, are made by any method deemed to be an &#8220;at the market offering&#8221;, or ATM, as defined in Rule&#160;415(a)(4) promulgated under the Securities Act. JonesTrading is not required to sell any specific number or dollar amount of ADSs, but has agreed to use its commercially reasonable efforts to sell the ADSs from time to time, based upon our instructions, including any price, time or size limits or other customary parameters or conditions we may impose. As of the date of this prospectus, we have sold a total of 4,062,161 ADSs under this ATM program (not taking into account the ADS Ratio Change that became effective on January 22, 2024) for an aggregate purchase price of $9,229,131, thereby leaving up to an aggregate $5.2&#160;million of ADSs available for future sale under this ATM program, depending in the development in the share price. The number of ADSs referred to in this section do not reflect the one to ten ratio change effective January&#160;22, 2024.</font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, on July&#160;31, 2023 we entered into a financing agreement with Global Growth Holding Limited (&#8220;GGH&#8221;), for the issuance of convertible notes into our ordinary shares represented by ADSs, DKK 1 nominal value, with each ordinary share represented by one ADSs. Pursuant to the agreement, we may elect to sell to GGH up to $20.0&#160;million in such notes on any business day over the 36 month term of the agreement. We have under certain circumstances the right, but not the obligation to direct GGH to purchase traches of up to $0.7&#160;million, subject to certain limitations and conditions set forth in the agreement. In connection with the agreement, we are obligated to pay GGH a commitment fee totaling $1.1&#160;million. At any time, GGH may, in its sole discretion, convert the notes into ordinary shares at specified conversion prices upon submission of a request for conversion by GGH to us. The financing agreement between us and GGH is subject to approval by the SEC through the date of this prospectus. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Additionally, on December&#160;18, 2023, we entered into a Securities Purchase Agreement, and an Investment Agreement, with certain Institutional Accredited Investors, Qualified Institution Buyers and other Accredited Investors (the &#8220;Purchasers&#8221;), including all members of the Company&#8217;s Management and Board of Directors and MSD GHI, or MSD, a subsidiary of Merck Inc., for the issuance and sale in a private placement (the &#8220;Private Placement&#8221;) of 9,726,898 of the Company&#8217;s ordinary shares, DKK 1 nominal value represented by American Depositary Shares and accompanying warrants to purchase up to 9,726,898 Ordinary Shares represented by ADSs at a purchase price of $0.544 per Ordinary Share. The Warrants are exercisable immediately upon issuance, expire three (3)&#160;years after the closing date and have an exercise price equal to $0.707 per Ordinary Share. The number of ADSs referred to in this section do not reflect the one to ten ratio change effective January 22, 2024.</font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In connection with the Private Placement, the Company entered into a registration rights agreement with the Purchasers dated as of December 18, 2023, pursuant to which the Company agreed to prepare and file an initial registration statement with the SEC registering the resale of the ordinary shares represented by ADSs and the ordinary shares represented by ADSs issuable upon the exercise of the warrants. All members of the Company&#8217;s management and board of directors have agreed to a lock-up period of 180 days from the effective date of such registration statement.</font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sales of ADSs or our ordinary shares as restrictions end or pursuant to the above described agreements or pursuant to registration rights may make it more difficult for us to finance our operations through the sale of equity securities in the future at a time and at a price that we deem appropriate. These sales also could cause the trading price of the ADSs to fall and make it more difficult for holders of ADSs to sell the ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">FINRA sales practice requirements may limit a stockholder&#8217;s ability to buy and sell our securities.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Effective June&#160;30, 2020, the SEC implemented Regulation&#160;Best Interest requiring that &#8220;A broker, dealer, or a natural person who is an associated person of a broker or dealer, when making a recommendation of any securities transaction or investment strategy involving securities (including account recommendations) to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">96</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">a retail customer, shall act in the best interest of the retail customer at the time the recommendation is made, without placing the financial or other interest of the broker, dealer, or natural person who is an associated person of a broker or dealer making the recommendation ahead of the interest of the retail customer.&#8221; This is a significantly higher standard for broker-dealers to recommend securities to retail customers than before under FINRA &#8220;suitability rules. FINRA suitability rules do still apply to institutional investors and require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending securities to their customers, broker-dealers must make reasonable efforts to obtain information about the customer&#8217;s financial status, tax status, investment objectives and other information, and for retail customers determine the investment is in the customer&#8217;s &#8220;best interest&#8221; and meet other SEC requirements. Both SEC Regulation&#160;Best Interest and FINRA&#8217;s suitability requirements may make it more difficult for broker-dealers to recommend that their customers buy speculative, low-priced securities. They may affect investing in our ADSs, which may have the effect of reducing the level of trading activity in our securities. As a result, fewer broker-dealers may be willing to make a market in our ADSs, reducing a shareholder&#8217;s ability to resell ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Holders of the ADSs are not treated as shareholders of our company and will not have the same voting rights as our shareholders, which may affect the value of the ADSs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Holders of ADSs are not treated as our shareholders unless they withdraw the ordinary shares underlying the ADSs from the depositary, which is the holder of the ordinary shares underlying the ADSs. Holders of ADSs, therefore, do not have any rights as shareholders of our company, other than the rights that they have pursuant to the deposit agreement. As such, holders of ADSs will not be able to directly vote underlying ordinary shares. Holders of ADSs may instruct the depositary how to vote the ordinary shares underlying their ADSs. If we ask it to, the depositary will send out information about shareholder meetings and solicit voting instructions and will try to carry out voting instructions it receives. However, we are not required to instruct the depositary to take action with respect to shareholder meetings. If we do not do so, holders of the ADSs can still send voting instructions to the depositary and the depositary may try to carry out those instructions, but it is not required to do so. Holders of the ADSs may not become aware of shareholder meetings if the depositary does not send out information. Even if the depositary does solicit voting instructions, holders of ADSs may not receive the information in time. As a result of these factors, holders of ADSs may not be able to effectively exercise voting rights that they would have if they held our ordinary shares directly. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we issue new ordinary shares or sell ADSs in future financings, shareholders or holders of ADSs may experience immediate dilution and, as a result, the price of the ADSs may decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may from time-to-time issue additional ordinary shares or sell ADSs at a discount from the current trading price of our ordinary shares or ADSs. As a result, our shareholders and holders of ADSs could experience further immediate dilution upon the issuance of any ordinary shares or ADSs sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, ordinary shares or ADSs. If we issue ordinary shares or securities convertible or exchangeable into ordinary shares, such as ADSs, shareholders and holders of the ADSs could experience additional dilution and, as a result, the price of the ADSs may decline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Raising additional capital may cause dilution to our existing shareholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may seek additional capital through a combination of public and private equity offerings, debt financings, collaborations and licensing arrangements. To the extent that we raise additional capital through the sale of equity or debt securities, our existing shareholders&#8217; ownership interest will be diluted and the terms may include liquidation preferences or other preferences that adversely affect our holders of ADS. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as imitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through collaborations and licensing arrangements </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">97</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with third parties or through asset sales, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investors should be aware that the rights provided to our shareholders under Danish corporate law and our articles of association differ in certain respects from the rights that you would typically enjoy as a shareholder of a United States company under applicable United States federal and state laws.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under Danish corporate law, except in certain limited circumstances (which require as a minimum that a proposal for inspection has been supported by a minimum of 25% of the shareholders voting and being present at a general meeting), our shareholders may not ask for an inspection of our corporate records, while under Delaware corporate law any shareholder, irrespective of the size of such shareholder&#8217;s shareholdings, may do so. Shareholders of a Danish limited liability company are also unable to initiate a derivative action, a remedy typically available to shareholders of United States companies, in order to enforce a right of our company, in case we fail to enforce such right ourselves, other than in certain cases of director/management liability under limited circumstances. In addition, a majority of our shareholders may release a director or manager from any claim of liability we may have, including if such director or manager has acted in bad faith, negligently or fraudulently. However, a shareholder may bring a derivative action on behalf of our company against, among other persons, a director or manager, provided that the circumstances of the act or omission giving rise to the claim of liability was not known to the shareholder at the time of such shareholder resolution, or if shareholders representing at least 10% of the share capital represented at the relevant general meeting have opposed such shareholder resolution. In contrast, most United States federal and state laws prohibit a company or its shareholders from releasing a director from liability altogether if such director has acted in bad faith or has breached such director&#8217;s duty of loyalty to our company. Additionally, distribution of dividends from Danish companies to foreign companies and individuals can be eligible for non-refundable withholding tax, and not all receiving countries allow for deduction. Also, the rights as a creditor may not be as strong under Danish insolvency law, as under United States law or other insolvency law, and consequently creditors may recover less in the event our company is subject to insolvency compared to a similar case including a United States debtor. In addition, the use of the tax asset consisting of the accumulated tax deficit requires that we are able to generate positive taxable income and can be restricted by future amendments to Danish tax law. Finally, Danish corporate law may not provide appraisal rights in the case of a business combination equivalent to those generally afforded a shareholder of a United States company under applicable United States laws. As a result of these differences between Danish corporate law and our articles of association, on the one hand, and United States federal and state laws, on the other hand, in certain instances, holders of the ADSs could receive less protection as a shareholder of our company than such holders would as a shareholder of a United States company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Holders of our ordinary shares or ADSs may not be able to exercise their pre-emptive subscription rights and may suffer dilution of their shareholding in the event of future issuances of our ordinary shares.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Danish Companies Act, our shareholders benefit from a pre-emptive subscription right on the issuance of ordinary shares for cash consideration only and not in the event of issuance of shares against non-cash contribution or debt conversion. Even the shareholders&#8217; pre-emptive subscription rights in the event of issuances of shares against cash payment may be disapplied by a resolution of the shareholders at a general meeting of our shareholders and/or the shares or ADSs may be issued on the basis of an authorization granted to the board of directors pursuant to which the board may disapply the shareholders&#8217; pre-emptive subscription rights. Such shares or ADSs may be issued above or at market value. In addition, a shareholder may not be able to exercise the shareholder&#8217;s pre-emptive right on a timely basis or at all, unless the shareholder complies with the Danish Companies Act and applicable laws in the jurisdiction in which the shareholder is resident. Furthermore, the use of pre-emptive subscription rights in relation to future capital increases in our company can be restricted for United States residents according to United States securities law. As a result, the ownership interest of shareholders or ADS holders may be materially diluted in the event shares or ADSs are issued in the future. Shares or ADSs may be issued at a discount to market price in rights offerings provided that the resolution is approved by two-thirds of the votes cast and the share capital represented at the general meeting and in these cases a restriction on the ability to exercise pre-emptive rights may materially dilute the value of the ordinary shares or ADSs held by the shareholder or ADS holder in question. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">98</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Our shareholders have authorized our board of directors to issue securities, including in connection with (i)&#160;issues of new ordinary shares with preemptive rights for our existing shareholders at market price or at a discount price against cash payment, (ii)&#160;issues of new ordinary shares without preemptive rights for our existing shareholders at market price or at a discount price against cash payment, (iii)&#160;issues of warrants without preemptive rights for our existing shareholders at market price or at a discount price against cash payment, and (iv)&#160;issues of convertible loan notes without preemptive rights for our existing shareholders at market price against cash payment. The absence of pre-emptive rights for existing shareholders may cause dilution to such holders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">However, holders of the ADSs in the United States will not be entitled to exercise or sell pre-emptive subscription rights related to their ordinary shares, unless we register the pre-emptive subscription rights and the securities to which the pre-emptive subscription rights relate under the Securities Act or an exemption from the registration requirements is available. In addition, the deposit agreement provides that the depositary will not make rights available to ADS holders unless both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Holders of ADSs may not receive distributions on our ordinary shares represented by the ADSs or any value for them.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">If we offer holders of our ordinary shares the option to receive dividends in either cash or shares, under the deposit agreement the depositary may require satisfactory assurances from us that extending the offer to holders of ADSs does not require registration of any securities under the Securities Act before making the option available to holders of ADSs. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to participate in our rights offerings or to elect to receive dividends in shares and may experience dilution in their holdings. In addition, if the depositary is unable to sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case ADS holders will receive no value for these rights. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">United States holders of ADSs may suffer adverse tax consequences if we are characterized as a passive foreign investment company.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A non-United States corporation will be classified as a passive foreign investment company, or PFIC, for United States federal income tax purposes for any taxable year, if either (i)&#160;75% or more of its gross income for such year consists of certain types of &#8220;passive&#8221; income or (ii)&#160;50% or more of the value of its assets (determined on the basis of a quarterly average) during such year produce or are held for the production of passive income. Passive income generally includes dividends, interest, royalties, rents, annuities, net gains from the sale or exchange of property producing such income and net foreign currency gains. In addition, a non-United States corporation will be treated as owning its proportionate share of the assets and earning its proportionate share of the income of any other corporation in which it owns, directly or indirectly, more than 25% (by value) of the stock. We have not made a determination as to whether we will or will not be treated as a PFIC in the 2022 taxable year and subsequent taxable&#160;years. The determination of PFIC status is inherently factual, is subject to a number of uncertainties, and can be determined only annually after the close of the tax year in question. Additionally, the analysis depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. There can be no assurance that we will or will not be determined to be a PFIC for the 2024 tax year or any prior or future tax year, and no opinion of legal counsel or ruling from the IRS concerning our status as a PFIC has been obtained or will be requested. U.S. Holders should consult their own U.S. tax advisors regarding our PFIC status. If we were to be or become a PFIC for any taxable year during which a United States holder (defined below in &#8220;Taxation&#8201;&#8212;&#8201;Certain Material United States Federal Income Tax Considerations&#8221;) holds ADSs, certain adverse United States federal income tax consequences could apply to such United States holder. See: &#8220;Taxation&#8201;&#8212;&#8201;Certain Material U.S. Federal Income Tax Considerations&#8201;&#8212;&#8201;Passive Foreign Investment Company Considerations.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Danish tax treatment of ADSs by the Danish tax authorities is uncertain.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The specific treatment of ADSs under Danish tax law is highly uncertain and not codified in law. The interpretation by the Danish tax authorities may have adverse effects on the taxation of investors. In the tax </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">99</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">description contained herein we are assuming that the ADSs are to be treated as listed shares for Danish tax purposes. This is based on recent communications and tax rulings relating to similar structures from the Danish tax authorities which indicate that a holder of ADSs will be treated as holding listed shares in the company for Danish tax purposes. In the event that the holders of ADSs are not treated as holding listed shares in the company, it is likely that they will be treated as either holding unlisted shares or financial instruments for Danish tax purposes, which will impact the Danish tax treatment of the ADS holders, including in respect of the taxation of dividends paid to ADS holders. Furthermore, the communications and tax rulings from the Danish tax authorities indicate that the voting and economic rights attached to the underlying shares have been effectively transferred to the ADS holders and that they will therefore be considered as holding listed shares. In the event that the Danish tax authorities should rule differently with respect to the Company and the depositary agreement with Bank of New York Mellon and not treat the ADS holders as holders of shares in the Danish company, then the depository bank may be considered the holder of the ordinary shares in the company for Danish tax purposes. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Claims of United States civil liabilities may not be enforceable against us.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are incorporated under the laws of Denmark. Substantially all of our assets are located outside the United States. A number of our directors and the majority of our officers and employees reside outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce against them or us in United States courts, including judgments predicated upon the civil liability provisions of the securities laws of the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The United States and Denmark currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon United States securities laws, would not automatically be recognized or enforceable in Denmark. In order to obtain a judgment which is enforceable in Denmark, the party in whose favor a final and conclusive judgment of the United States court has been rendered will be required to file its claim with a court of competent jurisdiction in Denmark. Such party may submit to the Danish court the final judgment rendered by the United States court. If and to the extent that the Danish court finds that the jurisdiction of the United States court has been based on grounds which are internationally acceptable and that proper legal procedures have been observed, the Danish court should, in principle, give binding effect to the judgment of the United States court, unless such judgment contravenes principles of public policy of Denmark. Danish courts are likely to deny the recognition and enforcement of punitive damages or other awards. Moreover, a Danish court may reduce the amount of damages granted by a United States court and recognize damages only to the extent that they are necessary to compensate actual losses or damages. Enforcement and recognition of judgments of United States courts in Denmark are solely governed by the provisions of the Danish Administration of Justice Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Based on the lack of a treaty as described above, United States investors may not be able to enforce against us or members of our board of directors, our executive board, our executive management or certain experts named herein who are residents of Denmark or countries other than the United States any judgments obtained in United States courts in civil and commercial matters, including judgments under the United States federal securities laws. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may fail to meet our publicly announced guidance or other expectations about our business, which could cause the market value of our ADSs to decline significantly.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may provide from time-to-time guidance regarding our expected financial and business performance. Correctly identifying key factors affecting business conditions and predicting future events is inherently an uncertain process, and our guidance may not ultimately be accurate in all respects. If our guidance varies from actual results, the market value of the ADSs could decline significantly. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If securities or industry analysts do not publish research or reports about our business or if they publish negative evaluations of the ADSs, the market price of the ADSs and their trading volume could decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The trading market for the ADSs will rely, in part, on the research and reports that securities or industry analysts publish about us or our business. If no or only limited securities or industry analysts cover our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">100</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">company, the trading price for the ADSs would be negatively impacted. If any of the analysts who cover us downgrades our equity securities or issues an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, the market price of the ADSs would likely decline. If one or more of these analysts cease to cover the ADSs, or downgrades our securities, we could lose visibility in the market for the ADSs, which in turn could cause the market price of the ADSs to decline or their trading volume to decline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our principal shareholders and executive management own a significant&#160;percentage of our ordinary shares and will be able to exert significant control over matters subject to shareholder approval.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">As of January&#160;29, 2024, our executive management, directors, holders of 5% or more of our ordinary shares and their respective affiliates beneficially own 33.5% of our outstanding voting securities. As a result, these security holders will have the ability either alone or voting together as a group to determine and/or significantly influence the outcome of matters submitted to our shareholders for approval, including the election and removal of directors, payment of dividends, amendments to our articles of association, including changes to our share capital or any mergers, demergers, liquidations and similar transactions. This may prevent or discourage unsolicited acquisition proposals or offers for our ordinary shares or ADSs that holders of ADSs may feel are in their best interest as a holder of ADSs. In addition, this group of shareholders may have the ability to control our management and affairs. Such control and concentration of ownership may affect the market price of the ADSs and may discourage certain types of transactions, including those involving actual or potential change of control of us (whether through merger, consolidation, take-over or other business combination), which might otherwise have a positive effect on the market price of the ADSs. </font>
          </div>


          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">We have broad discretion in the use of our cash, cash equivalents and investments, including the funds raised from our follow-on offering, our sales of ADSs we made pursuant to the Sales Agreement through or to JonesTrading under the ATM program and any sales to Lincoln Park of ADSs representing ordinary shares under the LPC Purchase Agreement and we may not use them effectively.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our management will have broad discretion in the application of our cash, cash equivalents and investments, including the funds raised from our follow-on offering, our sales of ADSs we made pursuant to the Sales Agreement through or to JonesTrading under the ATM program and any sales to Lincoln Park of ADSs representing ordinary shares under the LPC Purchase Agreement, and could spend these funds in ways that do not improve our results of operations or enhance the value of our ordinary shares or ADSs. The failure by our management to apply these funds effectively could result in financial losses that could materially harm our business, financial condition, results of operations and prospects and could cause the market price of the ADSs to decline, and delay the development of our product candidates. Pending their use, we may invest our cash, cash equivalents and investments, in a manner that does not produce income or that loses value. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not have sufficient funds available to pay amounts due and owing European Investment Bank upon the exercise of certain warrants and may be required to use our cash, cash equivalents and investments to make such payments.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2020, we executed a loan agreement, or the EIB Loan Agreement, with the European Investment Bank, or EIB, for a principal amount of &euro;20.0&#160;million, divided into three tranches of tranche 1 in the amount of &euro;7.0&#160;million, tranche 2 in the amount of &euro;6.0&#160;million and tranche 3 in the amount of &euro;7.0&#160;million, or the EIB Loan. Under the EIB Loan Agreement, the EIB Loan tranche balances are due six&#160;years from their respective disbursement dates. In connection with disbursement of each tranche, EIB is entitled to receive certain warrants, or the EIB Warrants. In November&#160;2020, we initiated the process to receive the funds from the disbursement of tranche 1 of the EIB Loan in the aggregate amount of &euro;7.0&#160;million but due to the timing of the IPO we did not finalize a disbursement offer. In connection therewith, EIB received 351,036 EIB Warrants, which vested immediately, pursuant to the terms of a separate warrant agreement, or the EIB Warrant Agreement. As of December&#160;31, 2021, we initiated the drawdown of the first tranche of the EIB Loan Agreement amounting to &euro;7.0&#160;million. We received the first tranche of &euro;7.0&#160;million on February&#160;17, 2022. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">101</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under Article&#160;18, Paragraph 2 of the Statute of the European Investment Bank, or the EIB Statute, establishing EIB, a direct equity investment by EIB requires a separate authorization from the EIB Board of Governors pursuant to which the EIB Board of Directors, acting by qualified majority, has to establish the terms and conditions of such direct equity investment. Under the EIB Statute, in the absence of a separate authorization from the EIB Board of Governors, commercial shareholdings financed from EIB&#8217;s own resources are not allowed. Since the EIB Loan is being made from EIB&#8217;s own resources, the EIB Statute does not allow EIB to acquire any of our ordinary shares, therefore, we fully expect that if and when EIB exercises the EIB Warrants, it will do so on either a net cash settlement basis at a price equal to the market price on the date of exercise thereof, or by means of exercising its right to cause us to purchase the EIB Warrants at a purchase price equal to the volume weighted average price per ordinary share, or VWAP, for a period of six&#160;months following the exercise of such Put Right. Since we fully expect the EIB Warrants to be cash settled, we do not expect them to affect our share capital at any time. However, since the amount of cash that we will need in order to meet our obligations to pay the amounts due and payable to EIB upon the exercise of the EIB Warrants is based on valuations to be determined in the future and, therefore, cannot be determined as of the date of this prospectus, we may not have sufficient funds on hand to pay such amounts in which case we may be required to use a portion of our investments for such payments. For a more detailed discussion of the terms of the EIB Warrants see &#8220;Description of Share Capital&#8201;&#8212;&#8201;Our EIB Warrants.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Because we do not currently pay cash dividends on our ordinary shares and do not anticipate doing so in the foreseeable future, capital appreciation, if any, will be the sole source of gain on investments in the ADSs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Currently, we do not have any plans to declare or pay cash dividends on our ordinary shares. Our intention is to retain all future earnings, if any, to finance the growth and development of the business. Additionally, the terms of any future debt agreements may preclude dividend payments. As a result, capital appreciation, if any, on the ADSs will be the sole source of gain for the foreseeable future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">You may be subject to limitations on surrenders of the ADSs and the withdrawal of the underlying shares.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Temporary delays in the cancellation of the ADSs and withdrawal of the underlying shares may arise because the depositary has closed its books or we have closed our transfer books, the transfer of shares is blocked to permit voting at a shareholders&#8217; meeting or we are paying a dividend on our shares. In addition, you may not be able to cancel the ADSs and withdraw the underlying shares when you owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of shares or other deposited securities. See &#8220;Description of American Depositary Shares.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We could be subject to securities class action litigation.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant price volatility in recent&#160;years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement or relating to our ordinary shares or the ADSs, which could result in less favorable outcomes to the plaintiffs in an action of that kind.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The deposit agreement governing the ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement, including any claim under United States federal securities laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">102</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs. It is advisable that holders of ADSs consult legal counsel regarding the jury waiver provision before entering into the deposit agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you or any other ADS holders bring a claim against us or the depositary in connection with matters arising under the deposit agreement or relating to the ADSs, including claims under federal securities laws, you may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us or the depositary. If a lawsuit is brought against us or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiffs in that action. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Nevertheless, if this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No condition, stipulation or provision of the deposit agreement or the ADSs serves as a waiver by any ADS holder or by us or the depositary of compliance with any substantive provision of the United States federal securities laws and the rules and regulations promulgated thereunder </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have broad discretion in the use of the net proceeds from this offering and any exercise of the Warrants and consequently may not use them effectively.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our management will have broad discretion in the application of the net proceeds from this offering and any exercise of any Warrant and could spend any such proceeds in ways that do not improve our results of operations or enhance the value of our ADSs. The failure by our management to apply these funds effectively could result in financial losses that could cause the price of our ADSs to decline and delay the development of our product candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we fail to meet the requirements for continued listing on the Nasdaq Capital Market or Nasdaq, our ADSs could be delisted from trading, which would decrease the liquidity of our ADSs and our ability to raise additional capital.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our ADSs are currently listed for quotation on The Nasdaq Capital Market. We are required to meet specified financial requirements in order to maintain our listing on the Nasdaq Capital Market. These requirements include maintaining a minimum bid price of at least $1.00 per share for our ADSs, which is referred to as the Bid Price Rule. On September&#160;29, 2023, we received a deficiency letter from the Listings Qualifications Department of the Nasdaq Stock Market notifying that we were not in compliance with the Bid Price Rule. In accordance with Nasdaq Listing Rule&#160;5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until March&#160;27, 2024, to regain compliance. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The Company continues to execute its business plan and is looking into various options available to regain compliance with Nasdaq&#8217;s continued listing standards and maintain its continued listing on the Nasdaq Capital Market. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule requirement or will otherwise be in compliance with other Nasdaq listing rules. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">On January 22, 2024, we effected a change to the ratio of our ADSs to our ordinary shares from one ADS representing one (1) ordinary share to one ADS representing ten (10) ordinary shares, or the ADS Ratio Change. As a result of the ADS Ratio Change, the ADS trading price has traded above the minimum bid price of $1.00, although the Company can give no assurance that the ADS trading price after the ADS Ratio Change will continue to be greater than $1.00 prior or will have any effect on the liquidity in the Company.</font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">103</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">There is no public market for Warrants or pre-funded warrants being offered by us in this offering.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There is no established public trading market for the Warrants or pre-funded warrants, and we do not expect a market to develop. In addition, we do not intend to apply to list the Warrants or pre-funded warrants on any national securities exchange or other nationally recognized trading system. Without an active market, the liquidity of the Warrants or pre-funded warrants will be limited. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Warrants and pre-funded warrants are speculative in nature.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The Warrants and pre-funded warrants offered hereby do not confer any rights of ADS ownership on their holders, such as voting rights, but rather merely represent the right to acquire ADSs represented by ordinary shares at a fixed price. Specifically, holders of the pre-funded warrants may acquire the ADSs issuable upon exercise of such warrants at an exercise price of $1.479 per ADS or the USD equivalent to DKK 10 at the time of exercise, and holders of the Warrants may acquire the ADSs issuable upon exercise of such warrants at an exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per ADS. Moreover, following this offering, the market value of the Warrants and pre-funded warrants is uncertain and there can be no assurance that the market value of the Warrants and pre-funded warrants will equal or exceed their public offering prices. There can be no assurance that the market price of the ADSs will ever equal or exceed the exercise price of the Warrants and pre-funded warrants, and consequently, whether it will ever be profitable to exercise the Warrants and pre-funded warrants. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Holders of the Warrants and pre-funded warrants offered hereby will have no rights as ADS holders with respect to the ADSs underlying the Warrants or pre-funded warrants until such holders exercise their Warrants or pre-funded warrants and acquire our ADSs, except as otherwise provided in the Warrants or pre-funded warrants.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Until holders of the Warrants and pre-funded warrants acquire ADSs upon exercise thereof, such holders will have no rights with respect to the ADSs underlying such Warrants or pre-funded warrants, except as otherwise provided in the Warrants or pre-funded warrants. Upon exercise of the Warrants or pre-funded warrants, the holders will be entitled to exercise the rights of an ADS holder only as to matters for which the record date occurs after the exercise date. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">This is a best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term business plans.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Placement Agent has agreed to use its reasonable best efforts to solicit offers to purchase the securities in this offering. The Placement Agent has no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There is no required minimum number of securities that must be sold as a condition to completion of this offering. Because there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, Placement Agent fees and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth above. We may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our continued operations, including our near-term continued operations. Thus, we may not raise the amount of capital we believe is required for our operations in the short-term and may need to raise additional funds, which may not be available or available on terms acceptable to us. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">You will experience immediate dilution in the book value per ADS purchased in the offering.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Because the price per share of our ADSs being offered may be higher than the net tangible book value per ADS, you will experience dilution to the extent of the difference between the offering price per ADS you pay in this offering and the net tangible book value per ADS immediately after this offering. Our net tangible book value as of September&#160;30, 2023, was approximately $(2.7) million, or $(0.98) per ADS. Net tangible book value per ADS is equal to our total tangible assets minus total liabilities, all divided by the number of ADSs outstanding. See the section titled &#8220;Dilution&#8221; for a more detailed discussion of the dilution you will incur if you purchase shares in this offering. </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">104</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">You may suffer immediate and substantial dilution in the net tangible book value of the common stock you purchase in this offering. After giving further effect to (i) 2,032,520 ADSs in this offering (assuming no sale of pre-funded warrants) at an assumed offering price of $7.38 per ADS and after deducting the Placement Agent commission and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value at September 30, 2023 would have been $10.2 million, $2.12 per ADS. This represents an immediate increase in pro forma as adjusted net tangible book value of $3.1 per ADS to existing investors and immediate dilution of $5.27 per ADS to new investors in this offering. See the section of this prospectus titled &#8220;Dilution&#8221; for a more detailed description of these factors.</font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If you purchase our securities in this offering you may experience future dilution as a result of future equity offerings or other equity issuances.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In order to raise additional capital, we believe that we will offer and issue additional ADSs or other securities convertible into or exchangeable for our ADSs in the future. We cannot assure you that we will be able to sell ADSs or other securities in any other offering at a price per ADS that is equal to or greater than the price per ADS paid by investors in this offering, and investors purchasing other securities in the future could have rights superior to existing stockholders. The price per ADS at which we sell additional ADSs or other securities convertible into or exchangeable for our ADSs in future transactions may be higher or lower than the price per ADS in this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, we have a significant number of share options and warrants outstanding. To the extent that outstanding share options or warrants have been or may be exercised or other shares issued, you may experience further dilution. Further, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We face risks and uncertainties related to litigation, regulatory actions and government investigations and inquiries.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to, and may become a party to, litigation, claims, suits, regulatory actions and government investigations and inquiries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The outcome of any litigation, regardless of its merits, is inherently uncertain. Any claims and lawsuits, and the disposition of such claims and lawsuits, could be time- consuming and expensive to resolve, divert management attention and resources, and lead to attempts on the part of other parties to pursue similar claims. Negative perceptions of our business may result in additional regulation, enforcement actions by the government and increased litigation, or harm to our ability to attract or retain customers or strategic partners, any of which may affect our business. Any damage to our reputation, including from publicity from legal proceedings against us or companies that work within our industry, governmental proceedings, unfavorable media coverage or class action could adversely affect our business, financial condition and results of operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">An unfavorable outcome or settlement or any other legal, administrative and regulatory proceeding may result in a material adverse impact on our business, results of operations, financial position and overall trends. In addition, regardless of the outcome, litigation can be costly, time-consuming, and disruptive to our operations. Any claims or litigation, even if fully indemnified or insured, could damage our reputation and make it more difficult to compete effectively or to obtain adequate insurance in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Purchasers who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the purchasers that enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract provides those investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement including: (i)&#160;timely delivery of shares; (ii)&#160;agreement to not enter into variable rate financings for six months from closing, subject to certain exceptions; (iii)&#160;agreement to not issue any ordinary shares or ADSs or securities convertible into ordinary shares or ADSs for sixty (60) days from closing, subject to certain exceptions; and (iv)&#160;indemnification for breach of contract. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">105</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:404pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unstable market and economic factors could adversely affect our business, financial condition or results of operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Uncertain or unfavorable global economic or market conditions, such as a recession, an economic slowdown, inflation or reduced growth rates, could significantly impact our operating results or lead to significant reductions in funding sources available to the Company, which could adversely affect our business, results of operations or financial condition. Our operations have required substantial amounts of cash since inception. We expect to continue to spend substantial amounts to continue the development of our GD-T cell-based therapeutic candidates, including for future clinical trials. In the event of unstable markets and unfavorable market conditions, we cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our GD-T cell-based therapeutic candidates or other research and development initiatives. Furthermore, uncertain or unfavorable global economic or market conditions may cause our manufacturers, suppliers, distributors, contractors, logistics providers and other external business partners to suffer financial or operational difficulties, which could impact their ability to provide us with or distribute finished product, raw and packaging materials or services in a timely manner or at all. We could also face difficulty collecting or recovering accounts receivables from third parties facing financial or operational difficulties. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">106</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIPO">&#8203;</a><a name="tMIAO">&#8203;</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DIVIDEND POLICY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have never declared or paid any cash dividends on our ordinary shares. We do not anticipate paying cash dividends on our equity securities in the foreseeable future and intend to retain all available funds and any future earnings for use in the operation and expansion of our business. If we pay any dividends on our ordinary shares, we will pay those dividends, which shall be payable in respect of the ordinary shares underlying the ADSs, to the depositary, as the registered holder of such ordinary shares, and the depositary then will pay such amounts to the ADS holders in proportion to the ordinary shares underlying the ADSs held by such ADS holders, subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. See the section entitled &#8220;Description of American Depositary Shares&#8221; in this prospectus. Cash dividends on our ordinary shares, if any, will be paid in USD. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MARKET, INDUSTRY AND OTHER DATA</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains statistics, estimates, projections and other information concerning our industry, our business, and the markets for our product candidates, including data regarding the total sales of product in those markets, the estimated patient population in those markets, their projected growth rates, the perceptions and preferences of patients and physicians regarding the disease indications that we are pursuing or may pursue, as well as data regarding market research, statistics, estimates and forecasts prepared by our management. Information that is based on statistics, estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. For example, certain information contained in this prospectus regarding industry and market data was obtained from Medtrack, a database of private and public biotechnology companies. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. In addition, assumptions and estimates of our and our industry&#8217;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#8220;Risk Factors.&#8221; These and other factors could cause our future performance to differ materially from our assumptions and estimates. See &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We estimate that our net proceeds from this offering will be approximately $12.9&#160;million, after deducting placement agent fees and estimated offering expenses of approximately $2.1&#160;million (based on an assumed public offering price per ADS of $7.38 per ADS and accompanying warrant, which was the last reported sales price of our ADSs on The Nasdaq Capital Market on January&#160;26, 2024), based on an assumed offering with aggregate gross proceeds of $15,000,000. However, because this is a best efforts offering and there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, the placement agent&#8217;s fees and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page of this prospectus. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If all of the Warrants to purchase ADSs issued in connection with this offering are fully exercised for cash, we would receive additional aggregate proceeds of approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We intend to use the net proceeds of this offering for continuing operating expenses and working capital. More specifically the net proceeds will be used to drive forward the key milestones in 2024 as laid out in figure 2. This includes both progressing our AI-Immunology&#8482; platform as well as our clinical (EVX-01) and pre-clinical (EVX-B1, EVX-B2 and EVX-B3) pipeline. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table presents our use of proceeds if 100%, 75%, or 50% of the securities in this offering are sold. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">107</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <table style="width:456pt;height:134.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:274.69pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">$m </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">100% </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">% of</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Total </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">75% </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">% of</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Total </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">50% </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">% of</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Total </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.25pt 0pt 0.5pt 0pt; width:274.69pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.2pt;">Gross Proceeds from Offering</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">15.0</td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">11.25</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">7.5</td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:274.69pt;text-align:left;">
                <font style="letter-spacing:-0.2pt;">Use of Proceeds</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:274.69pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Placement Agent Fees and Expenses </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">1.3 </td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">9<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1.0 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">9<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">0.8 </td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">10<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:274.69pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Offering Expenses </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">0.8</td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">5<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">0.8</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">7<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">0.8</td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">10<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:274.69pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Artificial Intelligence </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">2.5 </td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">16<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1.8 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">16<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">1.2 </td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">16<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:274.69pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Infectious Diseases </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">2.1 </td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">14<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1.5 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">13<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">1.0 </td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">13<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:274.69pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Immuno-Oncology </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">2.6 </td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">18<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">2.0 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">17<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">1.3 </td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">17<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:274.69pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">General &amp; Administrative </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">5.7 </td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">38<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">4.3 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">38<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">2.5 </td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">33<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:274.69pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.2pt;">Total Use of Proceeds</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">15.0</td>
              <td style="padding:0pt;padding-left:0.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">11.25</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">7.5</td>
              <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">If Gross Proceeds of this offering amounts to $15.0&#160;million we expect to be able to fund current operations into the middle of&#160;2025 based on the offering net proceeds. If Gross Proceeds of this offering amounts to $11.25 million we expect to be able to fund current operations towards the end of the first quarter of 2025 based on the offering net proceeds. If Gross Proceeds of this offering amounts to $7.5 million we expect to be able to fund current operations into the beginning of the first quarter of 2025 based on the offering net proceeds. This is excluding any income from ongoing business development activities which would extend the runway. For our expected 2024 cash spend excluding financing activities, 21% is consumed by AI related activities, 18% by our Infectious Diseases programs, 23% by our Immuno-Oncology programs and 38% for General &amp; Administrative expenses. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we expect to use the At-The-Market facility in place with JonesTrading as well as other financial tools signed by the company as shared in SEC filings and furnished on Form 6-Ks. These tools require to a different extent liquidity in the EVAX share. Also, the ambition for 2024 is to generate business development income equal to the annual 2024 cash burn excluding financing costs. Obviously, this is an ambition with quite some uncertainty as it requires on-going discussions to turn out positively. However, the recently announced investment from MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck &amp; Co. Inc., Rahway, NJ, USA talks to the external interest of the company focus and efforts. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In common with many clinical development stage biotechnology companies our future liquidity needs, and ability to address them, will largely be determined by the availability of capital, both generally and in particular to fund our product candidates and key development and regulatory projects. As a pre-revenue biotechnology company, we have financed our operations though continuously raising capital; and we expect to continue having to raise capital routinely on the capital markets, taking advantage of our public listing. We are constantly formulating and implementing potential funding initiatives to ensure we have adequate working capital. These initiatives could be in the form of further equity raises, as noted earlier and/or non-dilutive financings arising from collaborations or licensing arrangements. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our clinical trials, the potential for achieving accelerated regulatory approval and the amount of cash used in our operations. We therefore cannot estimate with certainty the amount of net proceeds to be used for the purposes described above. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. Our shareholders may not agree with the manner in which our management chooses to allocate and spend the net proceeds. Moreover, our management may use the net proceeds for corporate purposes that may not result in our being profitable or increase our market value. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pending these uses, we plan to invest these net proceeds in short-term, interest-bearing obligations; investment-grade instruments; certificates of deposit; or direct or guaranteed obligations of the United States and Denmark. The goal with respect to the investment of these net proceeds is capital preservation and liquidity so that such funds are readily available to fund our operations. Our investment positions will also take into consideration the law and rules under the U.S. Investment Company Act of 1940, so as to avoid being characterized as an investment company thereunder.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">108</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCAP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAPITALIZATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The table below sets forth our cash and cash equivalents and our total capitalization as of September&#160;30, 2023 on: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">an actual basis and; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(2)</font>
            <br >
          </div>
          <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">an as adjusted basis to give effect to the Private Placement closed on December&#160;21, 2023, related to the issuance and sale of 9,726,898 of our ordinary shares represented by ADSs and accompanying warrants to purchase up to 9,726,898 ordinary shares represented by ADSs at a purchase price of $0.544 per ordinary share for an aggregate purchase price of $5.3&#160;million. The as adjusted financial position also gives effect to the sale of 263,355 ADSs representing 2,633,550 ordinary shares that occurred on January 25, 2024 at a volume weighted average price (VWAP) of $9.7559 per ADS for an aggregate purchase price of approximately $2.5 million.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(3)</font>
            <br >
          </div>
          <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">a pro&#160;forma basis as adjusted to give effect to the sale of 2,032,520 ADSs and Warrants (assuming no sale of pre-funded warrants) pursuant to this prospectus at an assumed public offering price of $7.38 per ADS, which was the last reported sales price of our ADSs on The Nasdaq Capital Market on January&#160;26, 2024, and after giving effect to the ADS ratio change as further described above, in this offering and after deducting the Placement Agent commission and estimated offering expenses payable by us. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our capitalization following the closing of this offering will be adjusted based on the actual public offering price and other terms of the offering determined at pricing. You should read this information together with our unaudited interim financial statements and related notes appearing at the end of this prospectus and the information set forth under the &#8220;Prospectus Summary&#8201;&#8212;&#8201;Summary Financial Data,&#8221; &#8220;Use of Proceeds&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections. </font>
        </div>

          <table style="width:456pt;height:122.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:285.61pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">2023 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">As Adjusted</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Pro Forma</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">As Adjusted</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:285.61pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,605</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">10,484</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">23,402</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:285.61pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Total assets </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">11,942</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">19,821 </td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">32,739</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:285.61pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Total liabilities </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">14,676</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">14,676</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">14,676</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:285.61pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Share capital </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,415</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">6,219 </td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,202</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:285.61pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Other reserves </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">82,614</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">88,689</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">98,624</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:285.61pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(89,763<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(89,763<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(89,763<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:285.61pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Total equity </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,734<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">5,145</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">18,063</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.6pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">The pro&#160;forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed public offering price of $7.38 per ADS, which is the closing trading price for our ADSs on January&#160;26, 2024, as reported on Nasdaq and as set forth on the cover page of this prospectus, would increase (decrease) the amount of cash, cash equivalents and short-term investments, working capital, total assets and total stockholders&#8217; equity (deficit) on a pro&#160;forma as adjusted basis by approximately $2.0 million, assuming the number of securities offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated placement agent fees, commissions and estimated offering expenses payable by us. We may also increase or decrease the number of securities we are offering. Each increase (decrease) of 100,000 ADSs offered by us would increase (decrease) cash, cash equivalents and short-term investments, working capital, total assets and total stockholders&#8217; equity (deficit) on a pro&#160;forma as adjusted basis by approximately $0.7 million, assuming the assumed public offering price of $7.38 per ADS, which is the closing trading price for our ADSs on January&#160;26, 2024, as reported on Nasdaq and as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated placement agent fees, commissions and estimated offering expenses payable by us. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">109</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:280pt;margin-left:69.66pt;width:456pt;">

          <div style="text-indent:20pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The number of our ordinary shares (including shares represented by ADSs in proportion to the designated ratio, as described in this registration statement) to be outstanding after this offering is based on 40,540,546 ordinary shares outstanding as of January&#160;29, 2024 and excludes: </font>
          </div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">[1]</font>
            <br >
          </div>
          <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">12,828,684 ordinary shares issuable upon the exercise of warrants outstanding as of January&#160;29, 2024, pursuant to our Warrant Incentive Plan, at a weighted average exercise price of $0.84 per warrant;</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">[2]</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">48,728,964 ordinary shares reserved for future issuance under our warrant plans, including 1,000,000 ordinary shares reserved for future issuance to employees, officers, directors, advisors and consultants, 728,964&#160;ordinary shares reserved for future issuance under the EIB Warrants, as described below in the section entitled &#8220;Our EIB Warrants&#8221;), and 47,000,000&#160;shares reserved for future issuance under warrants the may be issued to future investors, lenders, consultants and/or advisors, if any. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the description of the Warrant Incentive Plan see &#8220;Warrant Incentive Plan&#8221; below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise stated, all information in this prospectus assumes no exercise of the outstanding options and warrants described above into ordinary shares or ADSs, treats all restricted shares issued with outstanding restrictions to be vested as issued and outstanding shares, no exercise of the Warrants or Placement Agent Warrants issued in this offering and no sale of pre-funded warrants in this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise indicated all references to our articles of association in this prospectus refer to our articles of association, as amended as currently in force for Evaxion Biotech A/S at the date of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent these outstanding options or any newly issued options are exercised, or we issue additional ordinary shares in the future, there will be further dilution to the new investors purchasing ordinary shares represented by ADSs in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our shareholders. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">110</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DILUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">If you invest in our ADSs in this offering, your ownership interest of our ordinary shares will be immediately diluted to the extent of the difference between the public offering price per ADS in this offering and the pro&#160;forma as adjusted net tangible book value per ADS after this offering. For the purposes of calculating the potential impact of dilution, the full value of an assumed offering price of $7.38 per ADS and Warrant has been ascribed to the ADSs. Dilution results from the fact that the public offering price per ADS is substantially in excess of the net tangible book value per ADS after this offering. </font>
          </div>


          <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">As of September&#160;30, 2023, we had a historical net tangible book value deficit of $2.70 million, or $0.98 per ADS. Our net tangible book value per ADS represents total tangible assets less total liabilities, divided by the number of ordinary shares outstanding on September&#160;30, 2023. </font>
          </div>


          <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">After giving further effect to (i)&#160;2,032,520 ADSs in this offering (assuming no sale of pre-funded warrants) at an assumed offering price of $7.38 per ADS and after deducting the Placement Agent commission and estimated offering expenses payable by us, our pro&#160;forma as adjusted net tangible book value at September&#160;30, 2023 would have been $10.2&#160;million, $2.12 per ADS. This represents an immediate increase in pro&#160;forma as adjusted net tangible book value of $3.10 per ADS to existing investors and immediate dilution of $5.27 per ADS to new investors in this offering. The following table illustrates this dilution to new investors purchasing ADSs in this offering: </font>
          </div>


          <table style="width:456pt;height:81.5pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; width:383.26pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Assumed public offering price per ADS </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 1pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">7.38 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:383.26pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Historical net tangible book value per ADS as at September&#160;30, 2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">(0.98<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:383.26pt;white-space:normal;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Increase in net tangible book value per ADS attributable to transactions in the period through the present offering, as described above </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">3.10 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:383.26pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Pro&#160;forma net tangible book value per ADS as of September&#160;30, 2023 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:16.5pt; text-align:right; white-space:nowrap;">2.12 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">2.12 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.25pt 0pt; width:383.26pt;text-align:left;">
                <div style="white-space:nowrap;font-weight:normal;">
                  <font style="letter-spacing:0.2pt;">Dilution per ADS to new investors purchasing ADSs in this offering </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">5.27</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <div style="text-indent:20pt; margin-top:9.7pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The dilution information discussed above is illustrative only and will change based on the actual offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed offering price of $7.38 per ADS, which is the price set forth on the cover page of this prospectus, would increase (decrease) our pro&#160;forma as adjusted net tangible book value as of September&#160;30, 2023, after this offering by $0.42 per ADS, and would increase (decrease) dilution to new investors by $0.58 per ADS, assuming that the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same. An increase of 100,000 in the number of ADSs we are offering would increase our pro&#160;forma as adjusted net tangible book value as of September&#160;30, 2023, after this offering by $0.11 per ADS, and would decrease dilution to new investors by $0.11 per ADS, assuming the assumed offering price per ADS remains the same. A decrease of 100,000 in the number of ADSs we are offering would decrease our pro&#160;forma as adjusted net tangible book value as of September&#160;30, 2023, after this offering by $0.11 per ADS, and would increase dilution to new investors by $0.11 per ADS, assuming the assumed offering price per ADS remains the same. </font>
          </div>


          <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The number of our ordinary shares (including shares represented by ADSs in proportion to the designated ratio, as described in this registration statement) to be outstanding after this offering is based on 40,540,546 ordinary shares outstanding as of January&#160;29, 2024 and excludes: </font>
          </div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">12,828,684 ordinary shares issuable upon the exercise of warrants outstanding as of January&#160;29, 2024, pursuant to our Warrant Incentive Plan, at a weighted average exercise price of $0.84 per warrant </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">48,728,964 ordinary shares reserved for future issuance under our warrant plans. Includes 1,000,000 ordinary shares reserved for future issuance to employees, officers, directors, advisors and consultants, 728,964 ordinary shares reserved for future issuance under the EIB Warrants, as described below in the section entitled &#8220;Our EIB Warrants&#8221;), and 47,000,000 shares reserved for future issuance under warrants the may be issued to future investors, lenders, consultants and/or advisors, if any. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise stated, all information in this prospectus assumes no exercise of the outstanding options and warrants described above into ordinary shares or ADSs, treats all restricted shares issued with outstanding restrictions to be vested as issued and outstanding shares, no exercise of the Warrants and Placement Agent Warrants issued in this offering and no sale of pre-funded warrants in this offering. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">111</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSFD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:107.16pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SELETED FINANCIAL DATA</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following tables present selected financial data as of and for the&#160;years ended December&#160;31, 2022, 2021 and 2020 and the selected consolidated financial data for the three and nine&#160;months ended September&#160;30, 2023 and 2022. We derived the selected statements of comprehensive loss for the&#160;years ended December&#160;31, 2022, 2021 and 2020 and the selected statements of financial position data as of December&#160;31, 2022, 2021 and 2020 from our audited financial statements included elsewhere in this prospectus. The selected statements of comprehensive loss data for the three and nine&#160;months ended September&#160;30, 2023 and 2022 and the selected consolidated statement of financial position data as of September&#160;30, 2023 have been derived from our unaudited condensed consolidated interim financial statements included elsewhere in this prospectus and have been prepared on the same basis as the audited financial statements. In the opinion of management, the unaudited interim condensed consolidated data reflects all adjustments necessary for a fair presentation of the financial information in those statements. We present our financial statements in USD and in accordance with IFRS as issued by the IASB. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The selected financial data below should be read together with our financial statements and related notes, and our unaudited condensed consolidated interim financial statements and related notes, included elsewhere in this prospectus, as well as the sections of this prospectus titled &#8220;Capitalization&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Our historical results for any prior period are not necessarily indicative of results to be expected in any future period, and the results for the three and nine&#160;months ended September&#160;30, 2023 are not necessarily indicative of the results to be expected for the full year ended December&#160;31, 2023. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Summary Statements of Comprehensive Loss</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:220pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:291.36pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:291.36pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:291.36pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands, except per share amounts) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:291.36pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">17,056</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">19,583</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,902</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:291.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,208</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,251</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">5,666</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:291.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">25,264</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">25,834</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">16,568</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:291.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Operating loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,264<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,834<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,568<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,831</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,039</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">216</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:291.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,508<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(915<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(223<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:291.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss before tax</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(23,941<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(24,710<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,575<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:291.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax benefit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">772</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">178</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,557</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:291.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss for the year</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(23,169<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(24,532<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,018<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:291.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss attributable to shareholders of Evaxion Biotech A/S</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(23,169<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(24,532<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,018<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:291.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss per share&#8201;&#8211;&#8201;basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(0.98<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1.26<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(0.97<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">112</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:69.5pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:214.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:273.85pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands, except per share amounts) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,830</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,068</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">12,983</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,932</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,015</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,215</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">5,756</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">5,762</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">6,083</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">17,833</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">18,739</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Operating loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,762<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,083<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,833<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(18,739<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">72</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">703</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">404</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,761</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(182<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(535<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(786<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(918<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss before tax</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,872<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,915<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(18,215<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,896<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax benefit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">194</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">175</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">613</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">599</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss for the period</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,678<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,740<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,602<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,297<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss attributable to shareholders of Evaxion Biotech A/S</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,678<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,740<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,602<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,297<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss per share&#8201;&#8211;&#8201;basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(0.21<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(0.24<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(0.66<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(0.69<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Summary Consolidated Statement of Financial Position</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <table style="width:456pt;height:136pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:221.02pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">2023 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">2022 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">As Adjusted</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">As Adjusted</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:221.02pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:221.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,605</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">13,184</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,484</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">23,402</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:221.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Total assets </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">11,942</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">22,025</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">19,821</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">32,739</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:221.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Total liabilities </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">14,676</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">13,722</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">14,676</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">14,676</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:221.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Share capital </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,415</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,886</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,219</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,202</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:221.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Other reserves </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">82,614</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">77,076</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">88,689</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">98,624</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:221.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(89,763<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(72,659<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(89,763<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(89,763<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:221.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Total equity </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,734<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">8,303</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">5,145</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">18,063</td>
              <td style="padding:0pt;padding-left:7.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">The as adjusted financial position data gives further effect to the Private Placement closed December&#160;21, 2023, related to the issuance and sale of 9,726,898 of the Company&#8217;s Ordinary Shares, represented by ADSs, and accompanying Warrants to purchase up to 9,726,898 Ordinary Shares represented by ADSs at a purchase price of $0.544 per Ordinary Share for an aggregate purchase price of $5.3&#160;million. The as adjusted financial position also gives effect to the sale of 263,355 ADSs representing 2,633,550 ordinary shares that occurred on January 25, 2024 at a volume weighted average price (VWAP) of $9.7559 per ADS for an aggregate purchase price of approximately $2.5 million.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(2)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">The as adjusted financial position data gives effect the pro&#160;forma adjustments set forth in footnote 1 above and to additionally reflect the issuance and sale of 2,032,520 ADSs, representing 20,325,200 ordinary shares, in the offering at an assumed public offering price of $7.38 per ADS (the last reported closing trading price of the ADSs on The Nasdaq Capital Market on January&#160;26, 2024) and after deducting estimated placement agent commission and estimated offering expenses payable by us. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">113</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMDAA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND </font>
          <br >
          <font style="letter-spacing:-0.2pt;">RESULTS OF OPERATIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our audited financial statements as of and for the&#160;years ended December&#160;31, 2022, 2021 and 2020 and our unaudited interim condensed consolidated financial statements as of September&#160;30, 2023 and for the nine&#160;months ended September&#160;30, 2023 and 2022, including the notes thereto, included with this report. The following discussion is based on our financial information prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) have been condensed or omitted. IFRS as issued by the International Accounting Standards Board, and as adopted by the European Union, might differ in material respects from generally accepted accounting principles in other jurisdictions.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our financial information is presented in our presentation currency, United States Dollar, or USD. Our functional currency is the Danish Krone, or DKK. Some Danish Krone amounts in this discussion and analysis have been translated solely for convenience into USD at an assumed exchange rate of DKK 7.0390 per $1.00, which was the official exchange rate of such currencies as of September&#160;30, 2023 rounded to four decimal places.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Special Note Regarding Forward-Looking Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This interim report contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this interim report can be identified by the use of forward-looking words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, statements about: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the initiation, timing, progress, results, and cost of our research and development programs and our current and future pre-clinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing of and our ability to obtain and maintain regulatory approval for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to identify research opportunities and discover and develop investigational medicines including our ability to establish partnerships around these; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability and willingness of our third-party collaborators to continue research and development activities relating to our development candidates and investigational medicines; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations regarding the size of the patient populations for our product candidates, if approved for commercial use; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our estimates of our expenses, ongoing losses, future revenue and capital requirements and our needs for or ability to obtain additional financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to identify, recruit and retain key personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our and our collaborators&#8217; ability to protect and enforce our intellectual property protection for our proprietary and collaborative product candidates, and the scope of such protection; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the development of and projections relating to our competitors or our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our or our collaborators&#8217; ability to commercialize our product candidates, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the pricing and reimbursement of our investigational medicines, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the rate and degree of market acceptance of our investigational medicines; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">114</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the amount of and our ability to use our net operating losses, or NOLs, and research and development credits to offset future taxable income; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to manage our business and organizational development; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory developments in the United States, Europe, Australia and other foreign countries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">adverse effects on our business condition and results for operation from the global COVID-19 pandemic, including the pace of global economic recovery from the pandemic; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to manufacture our product candidates with advantages in turnaround times or manufacturing cost; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to have our product candidates manufactured by third parties/collaborators or partners with advantages in turnaround times or manufacturing cost; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to implement, maintain and improve effective internal controls; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act and a foreign private issuer; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">adverse effects on our business condition and results for operation from general economic and market conditions and overall fluctuations in the United States and international equity markets, including deteriorating market conditions due to investor concerns regarding inflation and hostilities between Russia and Ukraine; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">other risk factors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These forward-looking statements are based on senior management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this report may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section herein entitled &#8220;Risk Factors.&#8221; You are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this report. Except as required by law, we are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise. Given these risks and uncertainties, you are cautioned not to rely on such forward-looking statements as predictions of future events. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to this prospectus completely and with the understanding that our actual future results may be materially different from what we expect. You should also review the factors and risks we describe in the reports we will file or submit from time to time with the U.S. Securities and Exchange Commission, or the SEC, after the date of this prospectus. We qualify all of our forward-looking statements by these cautionary statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Significant Risks and Uncertainties</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a TechBio company, we face a number of risks and uncertainties. These are common for the biopharmaceutical industry and relate to operations, research and development, commercial and financial activities. For further information about risks and uncertainties the Company faces, refer to the section herein entitled &#8220;Risk Factors&#8221;. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a pioneering TechBio company based upon its AI platform: AI-Immunology&#8482;. Our proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel vaccines for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology&#8482;, we have developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. we are </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">115</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">committed to transforming patients&#8217; lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology&#8482; platform and vaccine pipeline, please visit our website. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have during the past three&#160;months revisited our strategy. Key focus has been to refine the Evaxion strategy with a strong focus on execution and value realization to secure the continuous development of our world-class organization and business with strong potential for addressing significant unmet needs within cancer and infectious diseases. The AI-Immunology&#8482; platform provides in this context lower risks than traditional drug development. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are pleased to share the refined strategy in a simple, straightforward overview below. The core of our strategy lies in our pioneering AI-Immunology&#8482; platform, which has been continuously refined and validated over the past many&#160;years. This platform holds the potential for generating one new target every 24 hours, is delivery modality agnostic, and is easily adaptable to partner needs. Based on the unique multi-disciplinary capabilities built around our different AI prediction models, we focus on value realization via Targets, Pipeline and Responders. We have already seen substantial progress within each of these three areas: Two partnerships announced within Targets and encouraging initial EVX-01 Phase&#160;2 data showcase significant progress in our Pipeline. Within Responders, we have obtained Proof of Principle for our checkpoint inhibitor responder model. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The refined strategy also means reduced focus on Evaxion-driven clinical trials, significantly reducing the cash burn. Combined with a stronger focus on value realization based upon our AI-Immunology&#8482; platform, we have the ambition of being able to generate full-year 2024 business development income equal to our cash burn in 2024 excluding financing expenses. We believe we are set for strong business execution based on our refined strategy. </font>
        </div>
        <div style="position:relative;margin-top:10.1pt; text-align:center; width:456pt;">
          <img src="fc_fig06ourstarat-4c.jpg" alt="[MISSING IMAGE: fc_fig06ourstarat-4c.jpg]" height="335" width="608" >
        </div>
        <div style="margin-top:9.2pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 6: The Evaxion Strategy.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are also excited to see that the validation of the AI-Immunology&#8482; platform has continued. The EDEN&#8482; AI prediction model has been validated for B-cell antigen discovery across seven different pathogens and formed a central component of the two important partnerships Evaxion entered into during the third quarter. One of these partnerships brings together AI-discovered antigens and mRNA technology&#8201;&#8212;&#8201;a first in the Evaxion pipeline. EDEN&#8482; and the T-cell epitope discovery model, RAVEN&#8482;, are pivotal components of the other partnership forged with a leading pharmaceutical company to discover and develop vaccines against a pathogen with high unmet medical need for which no vaccines are available. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">116</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Evaxion plans to build on this momentum and leverage our AI-Immunology&#8482; platform to pursue new partnerships for novel vaccine targets within infectious diseases. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have also seen significant developments in our cancer portfolio and capabilities. A comprehensive clinical update on the EVX-01 Phase&#160;2 trial shared at the SITC conference confirms the encouraging Phase&#160;1 immune profile seen for our lead personalized cancer vaccine asset. This achievement solidifies our confidence in the potential AI-Immunology&#8482; holds at becoming a new treatment paradigm for metastatic melanoma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Another truly exciting element in the AI-Immunology&#8482; platform is the ObsERV&#8482; model, which is unique to Evaxion and allows us to harness a new source of tumor-specific antigens in oncology patients. With ObsERV&#8482;, we hope to expand the therapeutic reach of personalized cancer vaccines to patients with high mutational burden tumors but low numbers of high-quality neoantigens and patients with low tumor mutational burden who would otherwise not qualify for many of the treatment options available today. One exciting possibility we are currently looking into is whether we could use ObsERV&#8482; to identify shared cancer antigens in particular cancer subtypes. This would hold the promise to develop the first precision cancer vaccines targeting indications with no equivalent treatment option to date. Details on this principle have been shared at ASH in December&#160;2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">With the recent development within cancer and infectious diseases, we have been seeing a further confirmation of our approach and are looking forward to discussing partnering opportunities across all parts of our strategy and associated with our three-pronged business model: Targets, Pipeline, and Responders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Looking into 2024 we are anticipating several important milestones derived from our refined and focused strategy. Of particular importance are the following 2024 milestones: </font>
        </div>
        <div style="position:relative;margin-top:9.1pt; text-align:center; width:456pt;">
          <img src="tb_fig02milestones-4c.jpg" alt="[MISSING IMAGE: tb_fig02milestones-4c.jpg]" height="256" width="585" >
        </div>
        <div style="margin-top:8.31pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 7: Anticipated 2024 Milestones.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recent events (July-December&#160;2023)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Christian Kanstrup Leads Evaxion&#8217;s AI Strategy as CEO</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We appointed Christian Kanstrup as CEO, emphasizing his unique leadership and strategic development skills. Kanstrup&#8217;s vision aims to harness the full potential of Evaxion&#8217;s AI platform for therapeutic innovation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Evaxion&#8217;s EDEN&#8482; Model Validated: Revolutionizing Vaccine Development</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We shared data at the Vaccines Europe conference validating the EDEN&#8482; model for bacterial vaccine discovery. This groundbreaking achievement emphasizes the models&#8217; ability to swiftly generate novel vaccine targets, offering a faster, cheaper, and lower-risk approach to vaccine development. CEO Christian Kanstrup and Founder Andreas Holm Mattsson highlight its potential impact on high unmet medical needs, signaling a paradigm shift in vaccine discovery. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">117</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Evaxion Initiates AI-Designed Vaccine Program EVX-B3 in Collaboration with Leading Pharmaceutical Partner</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We launched EVX-B3, an AI-guided vaccine program, in collaboration with a leading pharmaceutical company. Leveraging Evaxion&#8217;s EDEN&#8482; and RAVEN&#8482; AI models, the project aims to efficiently identify protective antigens against an undisclosed bacterial pathogen, addressing a critical global health concern. The collaborative effort highlights Evaxion&#8217;s dedication to harnessing AI for innovative vaccine design. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Evaxion and Afrigen Join Forces for Gonorrhea mRNA Vaccine</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We partnered with Afrigen Biologics to develop an mRNA vaccine against gonorrhea, utilizing EDEN&#8482; discovered targets. The collaboration, leveraging mRNA technology from the WHO and Medicines Patent Pool, aims to address the global medical need for a gonorrhea vaccine. Evaxion CEO Christian Kanstrup sees this collaboration as a strategic step to bring AI-designed vaccines to market, emphasizing the importance of identifying the right partners. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Evaxion&#8217;s EVX-01 Phase&#160;2 Trial Shows Promise in Personalized Cancer Treatment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We reported encouraging Phase&#160;2 data for its personalized cancer vaccine, EVX-01, confirming earlier Phase&#160;1 findings. Notably, a metastatic melanoma patient with initial progressive disease showed significant and continuous tumor reduction after EVX-01 treatment. CEO Christian Kanstrup highlights the potential of their AI-Immunology&#8482; platform to revolutionize oncology. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Webinar: Evaxion Shares Insights on EVX-01 Phase&#160;2 Clinical Data</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We hosted an online webinar on November&#160;8 featuring KOL Professor Adnan Khattak, Principal Investigator of the EVX-01 Phase&#160;2 clinical trial. The 30-minute event explores malignant melanoma, summarizes Phase&#160;1 results, and details the Phase&#160;2 update. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Evaxion Introduces AI Model for Predicting Cancer Immunotherapy Responses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We unveiled its AI model at the Biomarkers &amp; Precision Oncology Europe conference, aiming to predict patient responses to cancer immunotherapy. The model shows promise in enhancing outcomes and reducing healthcare costs, aligning with Evaxion&#8217;s commitment to advancing AI-Immunology&#8482; powered vaccines. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Evaxion Unveils Innovative Precision Vaccine Concept for Hematological Malignancies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We announced a groundbreaking precision vaccine concept for hematological malignancies at the 65th American Society of Hematology (ASH) Annual Meeting. The use of AI-Immunology&#8482; to target endogenous retroviruses represents a significant advancement, offering tailored vaccines for hematological malignancies. The oral presentation on December&#160;9 signifies a major milestone in Evaxion&#8217;s pursuit of innovative cancer solutions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Results of Operations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Impact from COVID-19 Pandemic</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The COVID-19 pandemic has affected countries where we are operating, where we have planned or have ongoing clinical trials, and where we rely on third-parties to manufacture preclinical, clinical and commercial supply. While COVID-19 had an impact on how we work and conduct our activities, we have managed to avoid significant disruptions to our clinical and manufacturing operations. We monitor the risks from the pandemic closely, and work with relevant stakeholders to avoid and limit disruptions, and to develop and establish working measures. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Russia&#8217;s Invasion of Ukraine</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;24, 2022, Russia invaded Ukraine creating a global conflict. The resulting conflict and retaliatory measures by the global community have created global security concerns, which have had, and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">118</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">are likely to continue to have, short-term and more likely longer-term adverse impacts on Ukraine and Europe, and around the globe. Potential ramifications affecting the Company from the conflict include delays in research activities or in the conduct of clinical trials could increase associated costs and, depending upon the duration of any delays, require the Company to find alternative suppliers at additional expense. In addition, the conflict between Russia and the Ukraine has had significant ramifications on global financial markets, which may adversely impact the Company&#8217;s ability to raise capital on favorable terms or at all. As of September&#160;30, 2023, the Company has not directly experienced a materially negative impact from Russia&#8217;s invasion of Ukraine on the consolidated financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Silicon Valley Bank Failure</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Recent bank failures could impair our ability to access our existing cash, cash equivalents, and marketable securities and to timely pay key vendors and others. For example, on March&#160;10, 2023, the Federal Deposit Insurance Corporation (the &#8220;FDIC&#8221;) announced that Silicon Valley Bank (&#8220;SVB&#8221;) had been closed by the California Department of Financial Protection and Innovation, and the FDIC was appointed as receiver, which resulted in all funds held at SVB being temporarily inaccessible by SVB&#8217;s customers. We did not have any funds in SVB or other financial institutions that have been closed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While we maintain our cash and cash equivalents in multiple financial institutions worldwide, our access to our cash and cash equivalents in amounts adequate to finance our operations could be significantly impaired by the financial institutions with which we have arrangements directly facing liquidity constraints or failures. In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any material decline in available funding or our ability to access our cash and cash equivalents could adversely impact our ability to meet our operating expenses, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws, any of which could have material adverse impacts on our operations and liquidity. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of the three&#160;months ended September&#160;30, 2023 and 2022</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our statements of profit or loss for the periods indicated (unaudited): </font>
        </div>
        <table style="width:456pt;height:188pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324.84pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:324.84pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:324.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,830</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,068</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,238<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:324.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,932</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,015</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">917</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:324.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">5,762</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">6,083</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(321<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:324.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Operating loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,762<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,083<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">321</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">72</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">703</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(631<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:324.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(182<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(535<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">353</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:324.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss before tax</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,872<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,915<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:324.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax benefit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">194</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">175</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">19</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:324.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss for the period</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,678<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,740<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">62</td>
            <td style="padding:0pt;padding-left:0.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses were $2.8&#160;million for the three&#160;months ended September&#160;30, 2023 as compared to $4.1&#160;million for the three&#160;months ended September&#160;30, 2022. The decrease in research and development expenses was primarily due to a decrease of $0.7&#160;million in employee-related costs due to reduced headcount and different employee mix and a decrease in external costs of $0.5&#160;million due to projects running less expensive. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">119</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General and Administrative</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses were $2.9&#160;million for the three&#160;months ended September&#160;30, 2023 as compared to $2.0&#160;million for the three&#160;months ended September&#160;30, 2022. The increase in general and administrative expenses was primarily due to an increase of $0.4&#160;million in external costs related to capital raises and an increase in employee-related costs of $0.5&#160;million due to a changed employee mix and termination accrual. These increases are due to the timing of funding projects and business initiatives compared to 2022 and the full year effect of the expansion of the organization throughout 2022 to meet the requirements as a listed company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Finance Income</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Finance income consisting primarily of interest from bank deposits was nominal for the three&#160;months ended September&#160;30, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Finance income was related to foreign exchange gains of $0.5&#160;million, primarily due to the strengthening of USD compared to DKK for the three&#160;months ended September&#160;30, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Finance Expenses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Finance expenses primarily related to interest expense and related loan costs of $0.2&#160;million on the EIB Loan Agreement, for the three&#160;months ended September&#160;30, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Finance expenses primarily related to interest expense on the EIB Loan Agreement and our loan from our lessor were $0.4&#160;million for the three&#160;months ended September&#160;30, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Income Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The income tax benefit was $0.2&#160;million for the three&#160;months ended September&#160;30, 2023, and $0.2&#160;million for the three&#160;months ended September&#160;30, 2022. Our effective tax rates for the three&#160;months ended September&#160;30, 2023 and 2022 were different from the Danish Corporate tax rate of 22%, as only expected tax receivable from R&amp;D Tax Schemes in Denmark and Australia are recognized. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of the nine&#160;months ended September&#160;30, 2023 and 2022</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our statements of profit or loss for the periods indicated (unaudited): </font>
        </div>
        <table style="width:456pt;height:188pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:316.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:316.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:316.89pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:316.89pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">12,983</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(3,365<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,215</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">5,756</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,459</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">17,833</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">18,739</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">906</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Operating loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,833<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(18,739<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(906<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">404</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,761</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,357<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(786<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(918<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">132</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss before tax</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(18,215<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,896<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,319<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax benefit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">613</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">599</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:316.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss for the period</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,602<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,297<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,305<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.1pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses were $9.6&#160;million for the nine&#160;months ended September&#160;30, 2023 as compared to $13.0&#160;million for the nine&#160;months ended September&#160;30, 2022. The decrease in research and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">120</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">development expenses was primarily due to a decrease of $2.5&#160;million in external costs related to finalized clinical trials, and a decrease in employee-related costs of $0.5&#160;million due to reduced headcount and different employee mix. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General and Administrative</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses were $8.2&#160;million for the nine&#160;months ended September&#160;30, 2023 as compared to $5.8&#160;million for the nine&#160;months ended September&#160;30, 2022. The increase in general and administrative expenses was primarily due to a $1.7&#160;million increase in external costs related to legal cost, professional fees and capital raise costs, and an increase in employee-related costs of $0.8&#160;million due to a changed employee mix. These increases are due to the timing of funding projects and business initiatives compared to 2022 and the full year effect of the expansion of the organization throughout 2022 to meet the requirements as a listed company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Finance Income</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finance income consists primarily of foreign currency gains recognized and interest income from bank deposits of $0.1&#160;million, and a gain from changes in fair value of liability-classified warrants of $0.3&#160;million for the nine&#160;months ended September&#160;30, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finance income was related to foreign exchange gains of $2.2&#160;million, primarily due to the strengthening of USD compared to DKK, and a gain from the change in warrant liability of $0.4&#160;million for the nine&#160;months ended September&#160;30, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Finance Expenses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finance expenses primarily related to interest expense and related loan costs of $0.5&#160;million on the EIB Loan Agreement, interest expense of $0.1&#160;million for leasing liabilities, and foreign exchange losses of $0.2&#160;million for the nine&#160;months ended September&#160;30, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finance expenses was related to remeasurement of warrant obligation of $0.3&#160;million, interest expense and related loan costs on the EIB Loan Agreement and our loan from our lessor and were $0.6&#160;million for the nine&#160;months ended September&#160;30, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Income Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The income tax benefit was $0.6&#160;million for the nine&#160;months ended September&#160;30, 2023, and $0.6&#160;million for the nine&#160;months ended September&#160;30, 2022. Our effective tax rates for the six&#160;months ended September&#160;30, 2023 and 2022 were different from the Danish Corporate tax rate of 22%, as only expected tax receivable from R&amp;D Tax Schemes in Denmark and Australia are recognized. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Liquidity and Capital Resources</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a pioneering TechBio company using artificial intelligence to decode the human immune system and develop novel vaccines for cancer, bacterial diseases, and viral infections we are exposed to a variety of financial risks including liquidity risks. We have incurred significant losses and negative cash flows from operations since our inception. As of September&#160;30, 2023, we had an accumulated deficit of $89.8&#160;million and expect to continue to incur significant losses for the foreseeable future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of September&#160;30, 2023, and December&#160;31, 2022, our available liquidity, comprised of cash and cash equivalents, was $2.6&#160;million and $13.2&#160;million, respectively and our total equity was $(2.7) million and $8.3&#160;million, respectively. We have not generated any revenues during the nine&#160;months ended September&#160;30, 2023, and prior periods. We will not start generating significant revenue before we have obtained an out-licensing partnership. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We monitor the funding situation closely to ensure that we have access to sufficient liquidity to meet our forecasted cash requirements. Analyses are run to reflect different scenarios including, but not limited </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">121</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">to, cash runway, human capital resources and pipeline priorities to identify liquidity risk. This enables Management and the Board of Directors to prepare for new financing transactions and/or adjust the cost base accordingly. In March&#160;2023 the Company adjusted the organization and reprioritized development programs to focus the operations and to save costs. Further, in the third quarter of 2023 we refined our strategi and adjusted the organization to reflect this focus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The funding strategy is to finance cash needs through equity offerings, or other capital sources, including potential collaborations or licenses and adjust spending on new and ongoing development and corporate activities, as needed. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On December&#160;21, 2023 we closed a Private Placement related to the issuance and sale of 9,726,898 of our ordinary shares, DKK 1 nominal value (&#8220;Ordinary Shares&#8221;), represented by American Depositary Shares (&#8220;ADSs&#8221;), and accompanying warrants (the &#8220;Private Placement Warrants&#8221;) to purchase up to 9,726,898 Ordinary Shares represented by ADSs at a purchase price of $0.544 per Ordinary Share for an aggregate purchase price of $5.3&#160;million. The Private Placement Warrants are exercisable immediately upon issuance, have a term of three&#160;years, and an exercise price equal to $0.707 per Ordinary Share. Each Ordinary Share is represented by one (1)&#160;ADS. The Private Placement was priced at-the-market under Nasdaq rules. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The net proceeds to the Company from the Private Placement were approximately $4.9&#160;million, and if Private Placement Warrants are exercised we could receive up to an additional $6.5&#160;million of net proceeds before deducting offering expenses payable by the Company. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This is an important step in our long-term funding strategy and will fund operations towards the end of March&#160;2024. Cash burn in the first quarter of 2024 is expected to be significantly higher than for the remaining quarters of 2024. The ambition for 2024 is on a full year basis to generate income from collaboration or license agreements equal to $14&#160;million to balance expected cash burn in 2024 excluding financing activities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Based on the current cash position and the forecasted cash requirements, it will require additional financing to fund operations by the end of March&#160;2024. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to the Private Placement in December&#160;2023, financing has been obtained from various sources but primarily from the initial public offering in February&#160;2021 and the follow-on public offering in November&#160;2021 securing proceeds of $25.3&#160;million and $24.9&#160;million respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2020, we executed a loan agreement, or the EIB Loan Agreement, with the European Investment Bank, or EIB, for a principal amount of &euro;20.0&#160;million. We have drawn the first tranche of &euro;7.0&#160;million but will not draw the remaining part of the loan as we have changed our business plans. The EIB Loan tranche balances are due six&#160;years from disbursement dates. EIB has received 351,036 warrants attributable to the first tranche of &euro;7.0&#160;million. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The EIB Loan contains a requirement that, at all times while the EIB Loan is outstanding, Niels Iverson Moller, one of our co-founders and a director, and Andreas Holm Mattsson, our Chief AI and Culture Officer, and/or their affiliates together must beneficially own at least 20% of our issued and outstanding ordinary shares, or the EIB Ownership Requirement. Currently, it is anticipated that together Messrs. Moller and Mattsson will beneficially own approximately 14.1% of our issued and outstanding ordinary shares following this offering (see the section herein entitled &#8220;Share Ownership&#8221;), which would cause us not to be in compliance with the EIB Ownership Requirement. Currently, we are in discussions with EIB to obtain a waiver of the EIB Ownership Requirement. EIB has initially indicated that, in order to grant such a waiver, it would request a partial repayment of the EIB Loan in an amount which we anticipate may be in the range of $500,000 to $750,000, which, if agreed between EIB and us, we would anticipate paying out of our current cash on hand. While we believe we will be able to obtain such a waiver, we cannot give you any assurance that we will be able to do so. If we are unable to obtain a waiver, EIB may have rights to demand repayment of the EIB Loan.</font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;5, 2021, we completed our initial public offering (&#8220;IPO&#8221;) through which we issued and sold 3,000,000 ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. We received aggregate net proceeds of $25.3&#160;million from the IPO, after deducting the underwriting </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">122</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">discounts and commissions and offering expenses. Upon the completion of the IPO, our registered, issued, and outstanding share capital was nominal DKK 19,198,668. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On November&#160;9, 2021, we completed a follow-on public offering through which we issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November&#160;5, 2021. We received aggregate net proceeds of $24.9&#160;million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and offering expenses. Upon the completion of the follow-on public offering, our registered, issued, and outstanding share capital was nominal DKK 23,141,524 </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;7, 2022, we entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, pursuant to which we have the right, but not the obligation, to sell to Lincoln Park up to $40.0&#160;million of our ordinary shares, DKK 1 nominal value, represented by American Depositary Shares, or the ADSs, subject to certain limitations, from time to time over the 36-month period commencing on the date that a registration statement covering the resale of the ADSs is declared effective by the SEC. If the adjusted market price of the ADS decreases to below $0.50 we cannot sell ordinary shares to Lincoln Park under the purchase agreement. In connection with the execution and delivery of the Purchase Agreement, we issued 428,572 ordinary shares represented by ADSs to Lincoln Park as consideration for a commitment fee of $1.2&#160;million for Lincoln Park&#8217;s commitment to purchase ordinary shares represented by ADSs under the Purchase Agreement, or the Commitment Shares. Registration statement covering the resale by Lincoln Park to the public as the selling shareholder of up to 4,649,250 ADSs with each ADS representing one ordinary share, comprised of: (i)&#160;the 428,572 Commitment Shares, and (ii)&#160;up to an additional 4,220,678 ordinary shares represented by ADSs that we have reserved for sale to Lincoln Park under the Purchase Agreement from time to time, if and when we determine to sell additional ordinary shares represented by ADSs to Lincoln Park under the Purchase Agreement. We cannot sell ordinary shares under this agreement if the beneficial ownership by Lincoln Park and its affiliates exceeds 9.99% of our issued and outstanding ADS. We have not yet sold shares under the purchase agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;3, 2022 we entered into an At-The-Market Issuance Sales Agreement with JonesTrading Institutional Services LLC (&#8220;JonesTrading&#8221;) under which we could sell up to an aggregate of $14.4&#160;million of our ordinary shares represented by ADSs. We agreed to pay JonesTrading commission equal to 3% of the gross proceeds of the sales price of all our ordinary shares represented by ADSs sold through them as sales agent under the Sales Agreement. The offering of our ordinary shares represented ADSs pursuant to the Sales Agreement will terminate on the earliest of (1)&#160;the sale of all the ordinary shares represented by ADSs subject to the Sales Agreement, or (2)&#160;termination of the Sales Agreement by us or JonesTrading. We or JonesTrading may terminate the sales agreement at any time upon ten days prior notice. JonesTrading may terminate the Sales Agreement at any time in certain circumstances, including the occurrence of a material adverse change that, in their judgment, may make it impracticable or inadvisable to market or sell our ordinary shares represented by ADSs or a suspension or limitation of trading our ordinary shares represented by ADSs on The NASDAQ Capital Market. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have sold 3,442,064 ordinary shares represented by ADSs under this agreement until September&#160;30, 2023 of which 118,852 were sold in 2022. Each ADSs at DKK 1 nominal value with each ordinary share represented by one ADSs, at a VWAP of $1.84 per ADS Gross proceeds from the sale of ordinary shares represented by ADSs were approximately $6.3&#160;million. In connection with the sale, we registered aggregate share capital increase of nominal DKK 3,442,064 with the Danish Business Authority. The value of the remaining number of shares under this agreement amount to approximately $7.8&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After the sale of the ordinary shares represented by ADSs and warrant exercises, our outstanding share capital as of September&#160;30, 2023 was nominal DKK 27,814,140. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;31, 2023 we entered into a financing agreement with Global Growth Holding Limited (&#8220;GGH&#8221;), for the issuance of convertible notes into our ordinary shares represented by ADSs, DKK 1 nominal value, with each ordinary share represented by one ADSs. Pursuant to the agreement, we may elect to sell to GGH up to $20.0&#160;million in such notes on any business day over the 36 month term of the agreement. We have under certain circumstances the right, but not the obligation to direct GGH to purchase traches of up to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">123</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">$0.7&#160;million, subject to certain limitations and conditions set forth in the agreement. In connection with the agreement, we are obligated to pay GGH a commitment fee totaling $1.1&#160;million. At any time, GGH may, in its sole discretion, convert the notes into ordinary shares at specified conversion prices upon submission of a request for conversion by GGH to us. The financing agreement between us and GGH is subject to approval by the SEC through the date of this prospectus. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">On January&#160;22, 2024, we effected a change to the ratio of our ADSs to our ordinary shares from one ADS representing one (1)&#160;ordinary share to one ADS representing ten (10) ordinary shares, or the ADS Ratio Change. Except as otherwise indicated, all information in this prospectus, including the number of ADSs being offered and the assumed offering price gives retroactive effect to the ADS Ratio Change. The assumed market price and number of securities to be sold used throughout this prospectus may not be indicative of the final offering price and number of securities to be sold in this offering. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Financing Requirements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We anticipate incurring additional losses until such time, if ever, we can complete our research and development activities and obtain out-licensing partnerships for our product candidates and generate revenues from such product candidates. Substantial additional financing will be needed by us to fund our operations and to continue development of our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We monitor our funding situation closely to ensure that it has access to sufficient liquidity to meet its forecasted cash requirements. Analyses are run to reflect different scenarios including, but not limited to, cash runway, human capital resources and pipeline priorities to identify liquidity risk. This enables Management and the Board of Directors to prepare for new financing transactions and/ or adjust the cost base accordingly. In March&#160;2023, we adjusted our organization and reprioritized development programs to focus the operations and to save costs. With our current strategic plans, we anticipate that with the current cash position and the forecasted cash requirements from our forecast from December&#160;2023, we will require additional financing to fund our operations and to continue development of its product candidates by March&#160;2024. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We plan to finance our cash needs through equity offerings, or other capital sources, including potential collaborations or licenses and adjust spending on new and ongoing development and corporate activities, as needed. Due to the continuing operating losses, expected negative cash flows and the need for additional funding to finance future operations, we have concluded that there is significant doubt about our ability to continue as a going concern through one year from the balance sheet date of September&#160;30, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying unaudited condensed consolidated interim financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the unaudited condensed consolidated interim financial statements have been prepared on a basis that assumes we will continue as a going concern and which contemplates the realization of assets and discharge of its liabilities and commitments in the normal course of business. We will seek additional capital if market conditions are favorable or if we have specific strategic considerations as well as operational requirements. Our spending will vary based on new and ongoing development and corporate activities. Due to high uncertainty of the length of time and activities associated with discovery and development of our product candidates, we are unable to estimate the actual amount of funds we will require for our developmental activities. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our future financing requirements will depend on many factors, including, but not limited to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope, progress, results and costs of researching and developing our AI platforms; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing of, and the costs involved in providing support to our future partners, if any, in connection with their efforts in seeking regulatory approvals in the United States and elsewhere for any future products derived from our product candidates if clinical trials are successful; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of providing support to our future partners, if any, in connection with their commercialization activities for products derived from our product candidates, if approved for sale, including marketing, sales and distribution costs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">124</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:46pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of manufacturing any future product candidates for clinical trials and scaling up manufacturing in preparation for late stage clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number and characteristics of additional product candidates that we pursue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to establish and maintain collaborations, partnerships, licensing or other arrangements with third parties, including the timing of receipt of any potential milestone payments, licensing fees or royalty payments under these agreements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the impact of the COVID-19 pandemic on the initiation or completion of pre-clinical studies or clinical trials and the supply of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the impact of climate change on our business operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effects of the continuing hostilities between Ukraine and Russia and other global conflicts, along with the retaliatory measures by the global community have created global security concerns, including the possibility of expanded regional or global conflict, which have had, are likely to continue to have, short-term and likely longer-term adverse impacts on Ukraine and Europe and around the globe; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense, and enforcement of any patents or other intellectual property rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing, receipt, and amount of sales of, or royalties on, any products developed by our future partners, if any, derived from our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our need and ability to retain and hire additional management, scientific, technical and business personnel; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the extent to which we acquire or invest in businesses, products, or technologies (although we currently have no commitments or agreements relating to any of these types of transactions). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect to finance cash needs through equity offerings, debt financings or other capital sources but as part of the refined strategy we have the ambition to obtain income from business deals such as collaborations, licenses and other similar arrangements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of current shareholders could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of the current shareholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable and/or may reduce the value of our ordinary shares. Failure to raise capital or enter into such other arrangements when needed could have a negative impact on financial conditions and our ability to pursue our business plans and strategies. If we are unable to raise additional capital when needed, we could be forced to delay, limit, reduce or terminate our product candidate development or grant rights to develop and market our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we are unable to obtain additional financing on a timely basis we may be required to file for reorganization or liquidation under applicable reorganization or bankruptcy laws. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">125</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of the Fiscal Year Ended December&#160;31, 2022, to Fiscal Year Ended December&#160;31, 2021 and Comparison of Fiscal Year Ended December&#160;31, 2021, to Fiscal Year Ended December&#160;31, 2020:</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:187.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:202.72pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:202.72pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 vs 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 vs 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202.72pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:202.72pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:202.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">17,056</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">19,583</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,902</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">(2,527<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">8,681</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:202.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,208</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,251</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">5,666</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">1,957</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">585</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:202.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">25,264</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">25,834</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">16,568</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">(570<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">9,266</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:202.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Operating loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,264<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,834<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,568<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">570</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(9,266<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:202.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,039</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">216</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">792</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,823</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:202.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,508<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(915<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(223<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">(593<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(692<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:202.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss before tax</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(23,941<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(24,710<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,575<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">769</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(8,135<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:202.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">772</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">178</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,557</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">594</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,379<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:202.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss for the year</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(23,169<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(24,532<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,018<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">1,363</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(9,514<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.63pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses were $17.1&#160;million for the year ended December&#160;31, 2022 compared to $19.6&#160;million for the year ended December&#160;31, 2021. The decrease in research and development expenses was primarily due to a decrease in third-party vendor costs of $3.1&#160;million, after recognizing grant income of $0.5&#160;million in 2022, for ongoing development on our platform, pre-clinical product candidates, and clinical trials. The decrease is partially offset by increased employee-related costs of $0.3&#160;million due to higher headcount and an increase in depreciation expense related to the property, plant, and equipment in our lab space of $0.3&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses were $19.6&#160;million for the year ended December&#160;31, 2021 compared to $10.9&#160;million for the year ended December&#160;31, 2020. The increase in research and development expenses was primarily due to increased spending of $5.7&#160;million, net of grant income of $0.3&#160;million in 2021, for ongoing development on our platform, pre-clinical product candidates, and clinical trials. In addition, employee-related costs increased by $3.0&#160;million due to higher headcount. </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General and Administrative</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses were $8.2&#160;million for the year ended December&#160;31, 2022, as compared to $6.3&#160;million for the year ended December&#160;31, 2021. The increase in general and administrative expenses was primarily due to a $1.8&#160;million increase in professional fees related to the expansion of our corporate function as a listed company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses were $6.3&#160;million for the year ended December&#160;31, 2021, as compared to $5.7&#160;million for the year ended December&#160;31, 2020. The increase in general and administrative expenses was primarily due to a $1.4&#160;million increase in professional fees related to the expansion of our corporate function for our IPO, partially offset by a decrease of $0.9&#160;million in employee-related costs. </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Finance Income</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finance income consists primarily of foreign currency gains recognized of $2.4&#160;million, and a gain from changes in fair value of liability-classified warrants of $0.4&#160;million for the year ended December&#160;31, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finance income primarily related to foreign exchange gains recognized were $2.0&#160;million and $0.2&#160;million for the&#160;years ended December&#160;31, 2021 and 2020, respectively. </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Finance Expenses</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finance expenses for the year ended December&#160;31, 2022 were $1.5&#160;million, compared to $0.9&#160;million for the year ended December&#160;31, 2021. The increase in finance expense was primarily due to increased </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">126</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">interest expense and related loan costs of $0.6&#160;million on the EIB Loan Agreement and interest expense of $0.2&#160;million for leasing liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finance expenses for the year ended December&#160;31, 2021 were $0.9&#160;million, compared to $0.2&#160;million for the year ended December&#160;31, 2020. The increase in finance expenses were primarily related to an increase of $0.6&#160;million in foreign exchange losses recognized. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Income Taxes</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The benefits from income tax were $0.8&#160;million for the year ended December&#160;31, 2022, compared to $0.2&#160;million for the year ended December&#160;31, 2021. Our effective tax rates for the year ended December&#160;31, 2022 and 2021 were different from the Danish effective statutory tax rate of 22% since we only recognize deferred tax assets on temporary differences to the extent the requirements for capitalization are met. Taxable income is mainly related to expected tax receivable from R&amp;D Tax Schemes in Denmark and Australia based on tax losses incurred in the current financial year. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The benefits from income tax were $0.2&#160;million for the year ended December&#160;31, 2021, compared to $1.6&#160;million for the year ended December&#160;31, 2020. Our effective tax rates for the year ended December&#160;31, 2021 and 2020 were different from the Danish effective statutory tax rate of 22% since we only recognize deferred tax assets on temporary differences to the extent the requirements for capitalization are met. Taxable income is mainly related to expected tax receivable from R&amp;D Tax Schemes in Denmark and Australia based on tax losses incurred in the current financial year. In connection with our IPO, we incurred non-deductible expenses which resulted in differences in our effective tax rates. In December&#160;2021, as a result of a tax ruling from the Australian tax authorities, we were forced to reevaluate our Australian tax benefit and reverse approximately $1.0&#160;million of tax benefit previously reported in prior&#160;years. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Tax losses carried forward for which deferred tax assets have not been recognized in the statement of financial position were $13.6&#160;million for the year ended December&#160;31, 2022 as compared to $9.5&#160;million for the year ended December&#160;31, 2021 and $3.8&#160;million for the year ended December&#160;31, 2020. Deferred tax assets will be recognized for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Currently no deferred tax assets from tax losses carried forward are recognized. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidity and Capital Resources</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are a clinical development stage AI-Immunology company that has not generated revenues for the&#160;years ended December&#160;31, 2022, 2021 or 2020. We are exposed to a variety of financial risks including liquidity risks. We have incurred significant losses and negative cash flows from operations since our inception. As of December&#160;31, 2022, we had an accumulated deficit of $72.7&#160;million and expect to continue to incur significant losses for the foreseeable future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2022 and December&#160;31, 2021, our available liquidity, comprised of cash and cash equivalents, was $13.2&#160;million and $32.2&#160;million, respectively and our total equity was $8.3&#160;million and $32.4&#160;million, respectively. We have not generated any revenues during the periods ended December&#160;31, 2022 and December&#160;31, 2021. We will not start generating significant revenue before we have obtained an out-licensing partnership. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2020, we executed a loan agreement, or the EIB Loan Agreement, with the European Investment Bank, or EIB, for a principal amount of &euro;20.0&#160;million, divided into three tranches of &euro;7.0&#160;million, &euro;6.0&#160;million and &euro;7.0&#160;million on the EIB Loan. Under the EIB Loan Agreement, the EIB Loan tranche balances are due six&#160;years from their respective disbursement dates. For all tranches, EIB is entitled to an aggregate of 1,003,032 cash settled warrants with an exercise price of 1 DKK per warrant. The 351,036 warrants attributable to the first tranche of &euro;7.0&#160;million were incorporated in the articles of association on December&#160;17, 2020. As of December&#160;31, 2021, we initiated the draw down of the first tranche of the EIB Loan Agreement amounting to &euro;7.0&#160;million. The Company received the first tranche of &euro;7.0&#160;million on February&#160;17, 2022. Under the current business plans we cannot draw the remaining two tranches of the loan. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">127</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The EIB Loan contains a requirement that, at all times while the EIB Loan is outstanding, Niels Iverson Moller, one of our co-founders and a director, and Andreas Holm Mattsson, our Chief AI and Culture Officer, and/or their affiliates together must beneficially own at least 20% of our issued and outstanding ordinary shares, or the EIB Ownership Requirement. Currently, it is anticipated that together Messrs. Moller and Mattsson will beneficially own approximately 14.1% of our issued and outstanding ordinary shares following this offering (see the section herein entitled &#8220;Share Ownership&#8221;), which would cause us not to be in compliance with the EIB Ownership Requirement. Currently, we are in discussions with EIB to obtain a waiver of the EIB Ownership Requirement. EIB has initially indicated that, in order to grant such a waiver, it would request a partial repayment of the EIB Loan in an amount which we anticipate may be in the range of $500,000 to $750,000, which, if agreed between EIB and us, we would anticipate paying out of our current cash on hand. While we believe we will be able to obtain such a waiver, we cannot give you any assurance that we will be able to do so. If we are unable to obtain a waiver, EIB may have rights to demand repayment of the EIB Loan.</font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2020, we received $6.6&#160;million of additional funding from the issuance of 745,380 of our ordinary shares as part 1 of our &#8220;bridging round&#8221; with outside investors. On October&#160;15, 2020, we successfully completed part 2 of our &#8220;bridging round&#8221; of capital with outside investors in the amount of $2.4&#160;million from the issuance of 269,136 of our ordinary shares and received the proceeds in November&#160;2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2020, we entered into a lease for approximately 1,356 square meters, which is allocated on 839 square meters of office space, and 518 square meters of laboratory space in H&#248;rsholm, Denmark. The commencement date for the lease of the 839 square meters of office space was February&#160;1, 2021 and the lease continues for a term of 10&#160;years from that date. In October&#160;2020, we entered into a lease for approximately 518 square meters, which was allocated for additional laboratory space, in H&#248;rsholm, Denmark. The commencement date for the lease was August&#160;13, 2021 and the lease continues for a term of 10&#160;years with a subsequent 12-month cancellation notice period. The lease agreement contains an early termination provision which would trigger a termination fee of $2.7&#160;million. As of December&#160;31, 2022, the monthly payment is approximately $26,000, which consists of $11,000 for the office space and approximately $15,000 for the laboratory space. Throughout the term, the lease is subject to annual increases ranging from two to four&#160;percent on the annual lease payment amount. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the ordinary lease payments, we obtained financing from DTU Science Park A/S (&#8220;DTU&#8221;) in 2021 for rebuilding the laboratory facility and engineering building to match ours needs. We will repay the $1.3&#160;million financing at a fixed interest rate of 6% over 8&#160;years. If the lease is terminated due to default by us before the outstanding balance, including interest accrued, has been repaid, the remaining balance is due immediately. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;5, 2021, we completed our IPO through which we issued and sold 3,000,000 ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. We received aggregate net proceeds of $25.3&#160;million from the IPO, after deducting the underwriting discounts and commissions and offering expenses. Upon the completion of the IPO, our registered, issued, and outstanding share capital was nominal DKK 19,198,668. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On November&#160;9, 2021, we completed a follow-on public offering through which we issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November&#160;5, 2021. We received aggregate net proceeds of $24.9&#160;million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and offering expenses. Upon the completion of the follow-on public offering, our registered, issued, and outstanding share capital was nominal DKK 23,141,524. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;7, 2022, we entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, pursuant to which we have the right, but not the obligation, to sell to Lincoln Park up to $40.0&#160;million of our ordinary shares, DKK 1 nominal value, represented by American Depositary Shares, or the ADSs, subject to certain limitations, from time to time over the 36-month period commencing on the date that a registration statement covering the resale of the ADSs is declared effective by the SEC. In connection with the execution and delivery of the Purchase Agreement, we issued </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">128</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">428,572 ordinary shares represented by ADSs to Lincoln Park as consideration for a commitment fee of $1.2&#160;million for Lincoln Park&#8217;s commitment to purchase ordinary shares represented by ADSs under the Purchase Agreement, or the Commitment Shares. In the Purchase Agreement, Lincoln Park represented to the Company, among other things, that it was an &#8220;accredited investor&#8221; &#8203;(as such term is defined in Rule&#160;501(a) of Regulation&#160;D under the Securities Act of 1933, or the Securities Act). The securities were sold by the Company under the Purchase Agreement in reliance upon an exemption from the registration requirements under the Securities Act afforded by Section&#160;4(a)(2) of the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;7, 2022, we filed a &#8220;selling shareholder&#8221; registration statement covering the resale by Lincoln Park to the public as the selling shareholder of up to 4,649,250 ADSs with each ADS representing one ordinary share, comprised of: (i)&#160;the 428,572 Commitment Shares, and (ii)&#160;up to an additional 4,220,678 ordinary shares represented by ADSs that we have reserved for sale to Lincoln Park under the Purchase Agreement from time to time, if and when we determine to sell additional ordinary shares represented by ADSs to Lincoln Park under the Purchase Agreement. Lincoln Park is deemed to be an &#8220;underwriter&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act of 1933, as amended, or the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;3, 2022 we entered into an At-The-Market Issuance Sales Agreement with JonesTrading Institutional Services LLC (&#8220;JonesTrading&#8221;) under which we could sell up to an aggregate of $14.4&#160;million of our ordinary shares represented by ADSs. We agreed to pay JonesTrading commission equal to 3% of the gross proceeds of the sales price of all our ordinary shares represented by ADSs sold through them as sales agent under the Sales Agreement. The offering of our ordinary shares represented ADSs pursuant to the Sales Agreement will terminate on the earliest of (1)&#160;the sale of all the ordinary shares represented by ADSs subject to the Sales Agreement, or (2)&#160;termination of the Sales Agreement by us or JonesTrading. We or JonesTrading may terminate the sales agreement at any time upon ten days prior notice. JonesTrading may terminate the Sales Agreement at any time in certain circumstances, including the occurrence of a material adverse change that, in their judgment, may make it impracticable or inadvisable to market or sell our ordinary shares represented by ADSs or a suspension or limitation of trading our ordinary shares represented by ADSs on The NASDAQ Capital Market. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the period between October&#160;13, 2022 and October&#160;20, 2022 we sold 114,402 ordinary shares represented by ADSs, DKK 1 nominal value, with each ordinary share represented by one ADSs, at a volume weighted average price (VWAP) of $2.76 per ADS. The ordinary shares represented by ADSs were sold pursuant to the Sales Agreement with JonesTrading dated October&#160;3, 2022. After deducting fees and expenses, total proceeds from the sales of the ordinary shares represented by ADSs were approximately $0.3&#160;million. In connection with such sales, we registered aggregate share capital increases of nominal DKK 114,402 with the Danish Business Authority. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;29, 2022 we sold 4,450 ordinary shares represented by ADSs, DKK 1 nominal value, with each ordinary share represented by one ADSs, at a VWAP of $2.24 per ADS. The ordinary shares represented by ADSs were sold pursuant to the Sales Agreement with JonesTrading dated October&#160;3, 2022. Gross proceeds from the sale of ordinary shares represented by ADSs were approximately $9,956. In connection with the sale, we registered aggregate share capital increases of nominal DKK 4,450 with the Danish Business Authority. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2022, due to warrant exercise, our outstanding share capital was nominal DKK 24,139,413. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Financing Requirements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We anticipate incurring additional losses until such time, if ever, we can complete our research and development activities and obtain an out-licensing partnership for our product candidates and generate revenues from such product candidates. Substantial additional financing will be needed by us to fund our operations and to continue development of our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company monitors its funding situation closely to ensure that it has access to sufficient liquidity to meet its forecasted cash requirements. Analyses are run to reflect different scenarios including, but not limited to, cash runway, human capital resources and pipeline priorities to identify liquidity risk. This enables Management and the Board of Directors to prepare for new financing transaction and/ or adjust the cost </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">129</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">base accordingly. In March&#160;2023 the Company adjusted the organization and reprioritized development programs to focus the operations and to save costs. The Company, with its current strategic plans, anticipates that with the current cash position and the forecast cash requirements per the 2023 updated Annual Budget, it will require additional financing to fund its operations and to continue development of its product candidates by December&#160;2023.The Company plans to finance cash needs through equity offerings, debt financings or other capital sources, including potential collaborations or licenses and adjust spending on new and ongoing development and corporate activities, as needed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Due to the continuing operating losses, expected negative cash flows and the need for additional funding to finance future operations, the Company concluded that there is significant doubt about its ability to continue as a going concern through one year from the balance sheet date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and discharge of its liabilities and commitments in the normal course of business. The matters that raise significant doubt about the Company&#8217;s ability to continue as a going concern also raise substantial doubt as contemplated by the Public Company Accounting Oversight Board (PCAOB) standards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will seek additional capital if market conditions are favorable or if we have specific strategic considerations. Our spending will vary based on new and ongoing development and corporate activities. Due to high uncertainty of the length of time and activities associated with discovery and development of our product candidates, we are unable to estimate the actual amount of funds we will require for our developmental activities. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Future financing requirements will depend on many factors, including, but not limited to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope, progress, results and costs of researching and developing our AI platforms; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing of, and the costs involved in providing support to our future partners, if any, in connection with their efforts in seeking regulatory approvals in the United States and elsewhere for any future products derived from our product candidates if clinical trials are successful; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of providing support to our future partners, if any, in connection with their commercialization activities for products derived from our product candidates, if approved for sale, including marketing, sales and distribution costs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of manufacturing any future product candidates for clinical trials and scaling up manufacturing in preparation for late stage clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number and characteristics of additional product candidates that we pursue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to establish and maintain collaboration, partnerships, licensing or other arrangements with third parties, including the timing of receipt of any potential milestone payments, licensing fees or royalty payments under these agreements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the impact of the COVID-19 pandemic on the initiation or completion of pre-clinical studies or clinical trials and the supply of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the impact of climate change on our business operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effects of the recent invasion of Ukraine by Russia, the resulting conflict and retaliatory measures by the global community have created global security concerns, including the possibility of expanded regional or global conflict, which have had, are likely to continue to have, short-term and likely longer-term adverse impacts on Ukraine and Europe and around the globe; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense, and enforcement of any patents or other intellectual property rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing, receipt, and amount of sales of, or royalties on, any products developed by our future partners, if any, derived from our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">130</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our need and ability to hire additional management, scientific, technical and business personnel; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the extent to which we acquire or invest in businesses, products, or technologies (although we currently have no commitments or agreements relating to any of these types of transactions). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect to finance cash needs through equity offerings, or other capital sources, including potential collaborations or licenses and further adjust spending on new and ongoing development and corporate activities, as needed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of current shareholders could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of the current shareholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable and/or may reduce the value of our ordinary shares. Failure to raise capital or enter into such other arrangements when needed could have a negative impact on financial conditions and our ability to pursue our business plans and strategies. If we are unable to raise additional capital when needed, we could be forced to delay, limit, reduce or terminate product candidate development or grant rights to develop and market product candidates and ultimately wind-up activities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash Flows</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash Flows for the Nine Months Ended September&#160;30, 2023 and 2022</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our cash flows for the periods indicated (unaudited): </font>
        </div>
        <table style="width:456pt;height:111pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:328.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:328.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:328.25pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:328.25pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash Flow Data:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:328.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,684<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(19,943<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:328.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash used in investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(94<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(324<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:328.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">5,433</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">7,307</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:328.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net decrease in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,345<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,960<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Operating Activities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities was $15.7&#160;million for the nine&#160;months ended September&#160;30, 2023. The largest components of our cash used in operating activities during this period was a net loss for the period of $17.6&#160;million, offset by non-cash adjustments of $0.9&#160;million, tax credits received $0.8&#160;million and $0.1&#160;million of interest received. The non-cash charges primarily consisted of non-cash interest expense of $0.7&#160;million, share-based compensation expense of $0.5&#160;million, depreciation and amortization of $0.5&#160;million, and various other immaterial changes of $0.2&#160;million. These non-cash charges were offset by a change in income tax benefit of $0.6&#160;million, and a gain from changes in fair value of liability-classified warrants of $0.3&#160;million. The negative net cash attributable to changes in our current operating assets (excluding cash) and our current operating liabilities during the period was primarily comprised of decrease of $0.6&#160;million in other liabilities, due to the timing, a decrease of $0.4&#160;million in receivables and prepayments due to the timing of prepayments in our research and development activities, offset by an increase of $1.0&#160;million in other payables related to employees due to the timing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities was $19.9&#160;million for the six&#160;months ended September&#160;30, 2022. The largest components of our cash used in operating activities during this period was a net loss for the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">131</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">period of $16.3&#160;million, non-cash adjustments of $1.2&#160;million, and a net cash change in our working capital during the period of $2.2&#160;million. The non-cash adjustments primarily consisted of a change in income tax benefit of $0.6&#160;million, a change in tax credit schemes accounted for as grants of $0.2&#160;million, and foreign exchange rate adjustments and various other immaterial changes of $2.4&#160;million. The non-cash adjustments were offset by share-based compensation expense of $1.0&#160;million and interest expenses $0.6&#160;million. The negative net cash attributable to changes in our current operating assets (excluding cash) and our current operating liabilities during the period was primarily comprised of increase in prepayments $2.2&#160;million due to prepayments in research and developments activities and decreases of $0.5&#160;million in trade payables, due to the timing and payment of invoices received, and a decrease in the value of the warrant liability of $0.2&#160;million due to a decrease in the Company&#8217;s stock price from issuance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing Activities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in investing activities for the nine&#160;months ended September&#160;30, 2023 was nominal and primarily driven by the purchase of property and equipment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in investing activities for the nine&#160;months ended </font><font style="font-style:italic;letter-spacing:0.2pt;">September</font><font style="letter-spacing:0.2pt;"> 30, 2022 was primarily driven by the purchase of property and equipment in the amounts of $0.3&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Financing Activities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities was $5.4&#160;million for the nine&#160;months ended September&#160;30, 2023, which was primarily due to proceeds from the issuance of shares of $6.1&#160;million. This is partially offset by repayments of borrowings of $0.3&#160;million, transaction costs related to the issuance of shares of $0.2&#160;million, and repayments of lease liabilities of $0.2&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities was $7.3&#160;million for the nine&#160;months ended September&#160;30, 2022, which was primarily due to our draw down on the EIB Loan totaling $7.8&#160;million. This is partially offset by transaction costs related to issuance of shares of $0.4&#160;million, repayments of lease liabilities of $0.2&#160;million and repayments of borrowings of $0.1&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Off-balance Sheet Arrangements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">As of September&#160;30, 2023, we did not have any material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources. We did not have any other off-balance sheet arrangements, as defined in the rules and regulations of the SEC, as of or during the periods presented. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Market risk is the risk that the fair value of, or future cash flows from, a financial instrument will vary due to changes in market prices. The type of market risk that primarily impacts us is foreign currency risk. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Foreign Currency Risk</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The primary exposure derives from our expenditures in foreign currencies, mainly the USD, the Australian Dollar and the British Pound. This exposure is known as transaction exposure. We are exposed to foreign currency risk as a result of operating transactions and the translation of foreign currency bank accounts and short-term deposits. We seek to minimize our exchange rate risk by maintaining cash positions in the currencies in which we expect to incur the majority of our future expenses and we make payments from those positions. For the nine&#160;months ended September&#160;30, 2023 we experienced a net foreign exchange gain of $0.3&#160;million whereas the same period in 2022 showed a gain of $2.7&#160;million. We believe a 10% change in foreign exchange rate would not have a material impact on our operating results. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interest Rate Risk</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We manage interest rate risk by monitoring short- and medium-term interest rates and placing cash on deposit for periods that optimize the amount of interest earned while maintaining access to sufficient funds </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">132</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">to meet day-to-day cash requirements. We do not currently have any loans or holdings that have variable interest rate. Accordingly, we are not exposed to material interest rate risk. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Recently Adopted Accounting Pronouncements and Accounting Pronouncements Not Yet Adopted</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A description of recently adopted accounting pronouncements and accounting pronouncements not yet adopted that may potentially impact our financial position and results of operations is disclosed in Note&#160;3 to our audited consolidated financial statements in our Annual Report on Form 20-F for the year ended December&#160;31, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash Flows for the Fiscal Year Ended December&#160;31, 2022, 2021 and 2020</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our cash flows for the periods indicated (in thousands): </font>
        </div>
        <table style="width:456pt;height:111pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:311.89pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash Flow Data:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,774<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(21,933<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,438<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash used in investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(268<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,330<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(393<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">7,853</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">49,805</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,817</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net (decrease)/increase in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(18,189<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">26,542</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(4,014<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.9pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Operating Activities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities was $25.8&#160;million for the year ended December&#160;31, 2022. The largest components of our cash used in operating activities during this period was a net loss for the year of $23.2&#160;million, offset by non-cash adjustments of $0.3&#160;million, net cash change in our working capital during the period of $2.9&#160;million, and $0.8&#160;million of income taxes received. The non-cash charges primarily consisted of share-based compensation expense of $0.9&#160;million, non-cash interest expense of $0.8&#160;million, depreciation and amortization of $0.6&#160;million, and various other immaterial changes of $0.1&#160;million. These non-cash charges were offset by exchange rate adjustments in foreign currencies of $1.3&#160;million, a change in income tax benefit of $0.8&#160;million, a gain from changes in fair value of liability-classified warrants of $0.4&#160;million, and a change in tax credit schemes accounted for as grants of $0.2&#160;million. The negative net cash attributable to changes in our current operating assets (excluding cash) and our current operating liabilities during the period was primarily comprised of a $1.3&#160;million increase of receivables due to timing of prepayments in our research and development activities, a decrease of $0.8&#160;million in trade payables and a decrease of $0.4&#160;million in other payables, both due to the timing of invoices received and other immaterial changes of $0.4&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities was $21.9&#160;million for the year ended December&#160;31, 2021. The largest components of our cash used in operating activities during this period was a net loss for the year of $24.5&#160;million offset by non-cash adjustments of $0.5&#160;million, $0.8&#160;million of income taxes received, and net cash change in our working capital during the period of $1.2&#160;million. The non-cash charges primarily consisted of share-based compensation expense of $1.4&#160;million. This non-cash charge was offset by a change in income tax benefit of $0.2&#160;million and various other immaterial changes of $0.7&#160;million. The positive net cash attributable to changes in our current operating assets (excluding cash) and our current operating liabilities during the period was primarily comprised of an increase of $1.9&#160;million of receivables due to timing of prepayments in our research and development activities, offset by a decrease of $0.6&#160;million in trade payables and a decrease of $0.1&#160;million in other payables, both due to the timing of invoices received. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities was $12.4&#160;million for the year ended December&#160;31, 2020. The largest component of our cash used in operating activities during this period was a net loss for the year of $15.0&#160;million offset by non-cash charges of $1.6&#160;million, $0.8&#160;million of income taxes received, and net cash change in our working capital during the period of $0.2&#160;million. The non-cash charges primarily consisted of share-based compensation expense of $3.4&#160;million and various other immaterial changes of $0.3&#160;million. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">133</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These increases in non-cash charges were offset by a change in income tax benefit of $1.6&#160;million and a change in tax credit schemes accounted for as grants of $0.5&#160;million. The positive net cash attributable to changes in our current operating assets (excluding cash) and our current operating liabilities during the period was primarily comprised of an increase of $2.0&#160;million in trade payables and an increase of $1.1&#160;million in other payables, both due to the timing of invoices received, offset by a $2.7&#160;million increase of receivables due to timing of prepayments in our research and development activities and other immaterial changes of $0.2&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing Activities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in investing activities was primarily driven by the purchase of property and equipment in the amounts of $0.4&#160;million, $1.3&#160;million, and $0.1&#160;million, and changes in leasehold deposits which were nominal, nominal, and $0.2&#160;million, for the&#160;years ended December&#160;31, 2022, 2021 and 2020, respectively. Net cash used in investing activities for the purchase of intangible assets was nominal, $0.1&#160;million, and nominal, for the&#160;years ended December&#160;31, 2022, 2021, and 2020, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Financing Activities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities was $8.0&#160;million for the year ended December&#160;31, 2022, which was primarily due to proceeds from borrowings under the EIB Loan Agreement of $7.9&#160;million, and net proceeds from the issuance of shares of $0.4&#160;million, partially offset by $0.3&#160;million related to repayment of lease liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities was $49.8&#160;million for the year ended December&#160;31, 2021, which was primarily due to net proceeds from the issuance of shares of $53.9&#160;million, partially offset by transaction costs of $3.8&#160;million related to the issuance of shares and $0.3&#160;million related to repayment of lease liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities was $8.8&#160;million for the year ended December&#160;31, 2020, which was primarily due to net proceeds from the issuance of shares of $9.0&#160;million, partially offset by transaction costs of $0.1&#160;million related to the issuance of shares and $0.1&#160;million related to repayment of lease liabilities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Off-balance Sheet Arrangements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2022, we did not have any material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources. We did not have any other off-balance sheet arrangements, as defined in the rules and regulations of the SEC, as of or during the periods presented. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following summarizes our contractual obligations, which include research and development and other service contract commitments, as of December&#160;31, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Tabular Disclosure of Contractual Obligations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:111pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:199.64pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Payments Due by Period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:199.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Within 1 Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">1&#8201;&#8211;&#8201;2 Years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2&#8201;&#8211;&#8201;5 Years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Over 5 Years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:199.64pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:199.64pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Leases</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">147</td>
            <td style="padding:0pt;padding-left:9.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">165</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">623</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.2pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,320</td>
            <td style="padding:0pt;padding-left:5.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,255</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:199.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loan from lessor</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">136</td>
            <td style="padding:0pt;padding-left:9.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">145</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">490</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.2pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">297</td>
            <td style="padding:0pt;padding-left:5.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,068</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:199.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">EIB Loan</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">224</td>
            <td style="padding:0pt;padding-left:9.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">224</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">672</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.2pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">9,671</td>
            <td style="padding:0pt;padding-left:5.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,791</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:199.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Purchase obligations</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">598</td>
            <td style="padding:0pt;padding-left:9.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">56</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">904</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.2pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.2pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,558</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:199.64pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Total</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)(4)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,105</td>
            <td style="padding:0pt;padding-left:9.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">590</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,689</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.2pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">11,288</td>
            <td style="padding:0pt;padding-left:5.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">15,672</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">134</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2020, we entered into a 10-year lease for office and laboratory space. The office space commenced in February&#160;2021 and the laboratory space commenced in August&#160;2021. The initial monthly payment was $28,800 and the lease is subject to two to four&#160;percent increases in annual lease payment throughout the term. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">We enter into contracts in the normal course of business with Clinical Research Organizations, or CROs, and other third parties for clinical trials and pre-clinical research studies and testing. Purchase obligations in the preceding table include agreements that are enforceable and legally binding on us and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum or variable price provisions, and the approximate timing of the transaction. For obligations with cancellation provisions, the amounts included in the preceding table are limited to the non-cancelable portion of the agreement terms or the minimum cancellation fee. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2020, we entered into a license agreement for the rights to certain intellectual properties which triggered a milestone payment of $35,000 upon execution. Throughout the term, the agreement may require additional future milestone payments between $70,000 to $250,000. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2020, we entered into a license agreement with SSI for the rights to three issued United States patents and other patents which triggered an upfront payment of $60,000. In addition, in the event we commercialize any PIONEER derived immunotherapies administered together or in combination with licensed adjuvant on our own, we are required to pay SSI a royalty on net sales in the low teens. However, if any PIONEER derived immunotherapies administered together or in combination with licensed adjuvant are commercialized by one of our partners, if any, we are required to pay SSI a&#160;percentage of any out-licensing revenue (milestones and royalties) earned by us and our affiliates. The size of the income share depends on the stage of the development of any such immunotherapy when the out-licensing arrangement is entered into and ranges from the lower to mid double digits. For more information on the terms of the SSI license agreement see the section herein entitled &#8220;Business Overview&#8201;&#8212;&#8201;In-Licensing.&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:4.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The loan amount as of December&#160;31, 2022 is still subject to possible minor adjustment. Further information is provided in Note 18 to our financial statements appearing at the end of this prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:4.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Further information is provided in Note 18 to our financial statements appearing at the end of this prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Market risk is the risk that the fair value of, or future cash flows from, a financial instrument will vary due to changes in market prices. The type of market risk that primarily impacts us is foreign currency risk. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Foreign Currency Risk</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The primary exposure derives from our expenditures in foreign currencies, mainly USD, AUD and GBP. This exposure is known as transaction exposure. We are exposed to foreign currency risk as a result of operating transactions and the translation of foreign currency bank accounts and short-term deposits. For the&#160;years ended December&#160;31, 2022 and 2021, our net foreign exchange gain was $2.4&#160;million and $1.3&#160;million, respectively. For the year ended December&#160;31, 2020 our foreign exchange loss was immaterial. We believe a 10% change in foreign exchange rate would not have a material impact on our operating results. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interest Rate Risk</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We manage interest rate risk by monitoring short- and medium-term interest rates and placing cash on deposit for periods that optimize the amount of interest earned while maintaining access to sufficient funds to meet day-to-day cash requirements. We do not currently have any loans or holdings that have variable interest rate. Accordingly, we are not exposed to material interest rate risk. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">135</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:572pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Recently Adopted Accounting Pronouncements and Accounting Pronouncements Not Yet Adopted</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">A description of recently adopted accounting pronouncements and accounting pronouncements not yet adopted that may potentially impact our financial position and results of operations is disclosed in Note&#160;3 to our financial statements appearing at the end of this prospectus.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">136</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tBUOV">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Business Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are a clinical-stage TechBio company that aspires to lead the exploration of artificial intelligence, or AI, to develop vaccines with improved efficacy when compared to currently marketed products for patients with unmet medical needs. We were founded in 2008 as an AI company and over the&#160;years have developed into an AI-TechBio company with a robust clinical pipeline of personalized cancer vaccines and a broad pre-clinical pipeline of vaccines for various infectious diseases. Our pipeline programs are derived from our proprietary AI-Immunology&#8482; platform, consisting of several models: PIONEER&#8482;, ObsERV&#8482;, AI-DeeP&#8482;, EDEN&#8482;, and RAVEN&#8482; and we are utilizing these unique AI models to build a strong drug development pipeline. Drug development is a long and costly process with high attrition rates. We believe our unique AI-Immunology&#8482; platform, trained to translate vast amounts of data to identify novel targets for the development of unique vaccines, have the potential to significantly reduce drug development timelines, costs and attrition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We aim to capture the value from the predictive power of our proprietary AI-Immunology&#8482; platform and its ability to identify novel targets for drug development by building a solid pipeline of AI-powered vaccines within the areas of cancer and infectious diseases, both attractive markets with high unmet medical needs. The associated business model is to partner our vaccines after pre-clinical or clinical Proof of Concept, or PoC, with large biopharmaceutical and pharmaceutical companies to conduct clinical trials, regulatory and marketing approval and commercialization of our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are currently advancing our first two product vaccine candidates, EVX-01 and EVX-02, for the treatment of various solid cancers. Our third cancer vaccine candidate, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is a clinically ready asset. We are actively seeking partnership opportunities to further advance the development of the EVX-03 vaccine candidate. In addition, we are currently developing three pre-clinical bacterial vaccine product candidates, EVX-B1, EVX-B2 and EVX-B3, targeting </font><font style="font-style:italic;letter-spacing:0.2pt;">Staphylococcus aureus</font><font style="letter-spacing:0.2pt;">, or </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;">, and </font><font style="font-style:italic;letter-spacing:0.2pt;">Neisseria gonorrhoeae</font><font style="letter-spacing:0.2pt;">, or </font><font style="font-style:italic;letter-spacing:0.2pt;">N.&#160;gonorrhoeae</font><font style="letter-spacing:0.2pt;"> infections, and an undisclosed bacteria target respectively, and one viral vaccine product candidate, EVX-V1, targeting cytomegalovirus, or CMV. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our AI-Immunology&#8482; Platform and Product Development Pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The immune system is widely regarded as a highly important defense system. We use the power of AI to decode the immune system and to direct it towards internal or external threats such as cancer and infectious diseases. Our AI technologies include the immuno-oncology AI models PIONEER&#8482; &amp; ObsERV&#8482;, the bacterial and viral disease AI models EDEN&#8482; &amp; RAVEN&#8482;, and our Immune Checkpoint Inhibitor responder AI model AI-DeeP&#8482;. These AI technologies are based on the current understanding of the human immune system and can transform large amounts of biological data into algorithms that may accurately predict cellular interactions within the immune system and potentially more accurately identify targets that will stimulate a relevant immune response. We believe that the predictive power of our AI models will reduce both the development time and risk of failure during the various stages of drug development. We have demonstrated that our AI models are able to identify novel targets in just days, rather than&#160;years as is common for standard drug discovery methods. We believe that this predictive accuracy can significantly decrease the risk of failure by reducing the risk of low efficacy or unacceptable toxicity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">PIONEER&#8482; is our AI model for the discovery of patient-specific cancer targets which we use to develop truly personalized cancer vaccines. PIONEER&#8482; identifies patient-specific tumor mutations, so called neoantigens, that can induce strong T-cell dependent immune responses leading to tumor eradication. We believe such neoantigen-based therapies will induce a directed immune response to each patient&#8217;s tumor that can eradicate the cancer cells from the body. We are currently developing three programs for personalized cancer vaccines; EVX-01, EVX-02, and EVX-03, of which the first two are currently in clinical development. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">ObsERV&#8482; is our AI model for the discovery of patient- or indication-specific virus-derived targets, so-called ERVs (endogenous retroviruses), selectively expressed in cancer. We have demonstrated that overexpression of such ERVs antigens is strongly associated with the overall survival of cancer patients. In </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">137</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">addition, we have preclinically demonstrated complete tumor eradication in animal models when targeting ObsERV&#8482; identified ERVs. We believe that ERV-based therapies will induce a directed T-cell dependent immune response leading to tumor eradication. Our EVX-03 vaccine candidate contains a combination of PIONEER&#8482; predicted neoantigens and ObsERV&#8482; predicted ERV antigens. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">AI-DeeP&#8482; is our AI model for predicting patient responses to cancer checkpoint inhibitor immunotherapy. The AI model can predict patient immunotherapy treatment outcomes with high precision and may inform decision on treatment. AI-DeeP&#8482; is part of the &#8216;Responder&#8217; leg of our corporate strategy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EDEN&#8482; is our AI model for the discovery of B-cell antigen vaccine targets. EDEN&#8482; has been designed to identify novel infectious disease B-cell antigen targets that, we believe, have the potential to be more effective than what have previously been identified using standard drug discovery methods. We apply EDEN in our current development of three pre-clinical bacterial vaccine programs; EVX-B1, targeting Staphylococcus aureus, or S. aureus infections, EVX-B2/EVX-B2-mRNA targeting Neisseria gonorrhoeae, or N. gonorrhoeae infections, and EVX-B3, targeting an undisclosed bacterial pathogen with a high medical need where no vaccine is currently available. We believe EDEN is applicable for virus vaccine development, hence it is applied in the development of our EVX-V1 virus vaccine against cytomegalovirus (CMV). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">RAVEN&#8482; is our AI model for the discovery of vaccine antigen targets, that can induce strong T-cell immune responses for infectious diseases. We apply RAVEN in our current development of the pre-clinical viral vaccine program; EVX-V1, targeting cytomegalovirus (CMV). We believe RAVEN is also applicable for bacterial vaccine development, hence it is applied in the development of EVX-B3. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">1) Product Development Pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that our AI-identified targets can be delivered using any delivery modality, such as peptides, recombinant proteins, mRNA and our proprietary DNA-targeting technology, and we are building a diverse vaccine pipeline utilizing such different delivery modalities. </font>
        </div>
        <div style="position:relative;margin-top:9.01pt; text-align:center; width:456pt;">
          <img src="fc_fig05stagedevelop-4c.jpg" alt="[MISSING IMAGE: fc_fig05stagedevelop-4c.jpg]" height="234" width="530" >
        </div>
        <div style="margin-top:11.81pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 8: Our AI models and vaccine pipeline. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">EVX-01</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EVX-01 is a novel liposomal, peptide-based cancer vaccine designed to engage a patient&#8217;s own immune system to fight their cancer by mounting a targeted response towards the tumor. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2023 we reported complete clinical data from the Phase&#160;1/2a trial of EVX-01 in metastatic unresectable melanoma demonstrated an overall response rate of 67% across all 12 patients compared with a historical overall response rate of 40% with anti-PD-1 treatment alone. In addition, the data showed induction of neoantigen-specific T cells in 100% of patients and a favorable safety profile. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EVX-01 is currently in a Phase&#160;2 global multi-center clinical trial for the treatment of metastatic melanoma and is administered in combination with KEYTRUDA</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (pembrolizumab), a humanized anti-human PD-1 monoclonal antibody developed by Merck &amp; Co., Inc., or Merck. A Clinical Trial Collaboration </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">138</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and Supply Agreement, or CTCSA, is in place with MSD International GmbH and MSD International Business GmbH (known collectively as MSD outside the United States and Canada), both of which are subsidiaries of Merck, to evaluate the combination of EVX-01 with MSD&#8217;s KEYTRUDA</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The first patient in the EVX-01 Phase&#160;2 trial was dosed in Australia in September&#160;2022. In November&#160;2022, we submitted an Investigational New Drug Application, or IND, along with a Fast Track designation request to the U.S. Food and Drug Administration, or FDA, for the Phase&#160;2 clinical trial of EVX-01 in combination with KEYTRUDA</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> for the treatment of patients with metastatic melanoma. On December&#160;22, 2022, the FDA notified us that it had reviewed our IND and determined that we could proceed with our Phase&#160;2 trial. In January&#160;2023, we received Fast Track designation from the FDA for the study. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, we have received approval of our Clinical Trial Applications, or CTAs, for the Phase&#160;2 trial from regulatory authorities in Australia and Italy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The initial data from five patients from the Phase&#160;2 clinical study were presented at the annual meeting of the Society of Cancer Immunotherapy, or SITC, in San Diego, California November&#160;2023. We believe the data confirmed the previously reported Phase&#160;1/2a findings and further indicated a promising clinical outcome. Full Phase&#160;2 study readout is expected in 2025. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">EVX-02</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EVX-02 is a DNA-based cancer vaccine designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma, when administered in combination with a PD-1 inhibitor. In March&#160;2022, we reported completion of recruitment of the EVX-02 Phase&#160;1/2a clinical trial and in November&#160;2022, we announced an interim study readout from eight patients. The data demonstrates activation of neoantigen-specific T cells with tumor killing potential and that T-cell responses were robust and long lasting indicating potential for a clinically relevant anti-tumor immune attack. The treatment appeared to be well tolerated in all patients, with only very mild AEs, observed in relation to EVX-02 treatment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;18, 2023, we presented final clinical data from the Phase&#160;1/2a study. Data were presented in the Late Breaking Research: Clinical Research 2 session at the 2023 AACR (American Association for Cancer Research) meeting in Orlando, Florida. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The study showed that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">All 10 patients who received the full dosing schedule of eight immunizations with EVX-02 were relapse-free at their last assessment </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Of these 10 patients, nine completed the full study and were relapse-free at the 12-month end of study visit. One patient was prematurely terminated due to non-EVX-02 related adverse events, or AEs, and was relapse-free at the last visit at nine&#160;months </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The combination of EVX-02 and nivolumab was well tolerated and only mild EVX-02-associated AEs were observed </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Robust and long-lasting neoantigen-specific T-cell immune responses were confirmed in all EVX-02 completers </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The induced T-cell immune responses involved both CD4+ and CD8+ T cells </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe the data serve as a validation of our PIONEER platform and provide proof of mechanism for our DNA-based approach to personalized cancer therapies. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">EVX-03</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EVX-03 is an improved, next generation DNA-based cancer vaccine with a proprietary antigen-presenting cell, or APC, targeting unit, for the treatment of various cancers. We believe our DNA technology has the potential to improve antigen presentation, anti-tumor immunity and hence clinical response. The goal of our EVX-03 cancer vaccine is to promote T-cell priming and expansion of effector T cells for direct and specific tumor killing, and we intend to develop EVX-03 for the treatment of multiple cancers, including non-small cell lung cancer. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">139</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our EVX-03 product candidate is clinically ready asset with pre-clinical data demonstrating that adding our APC-targeting unit leads to high levels of neoantigen-reactive T cells, significant tumor reduction even at very low doses and a favorable toxicology profile. We believe the promising clinical, immune and safety data from the EVX-02 Phase&#160;1/2a clinical trial together with the superior EVX-03 pre-clinical data, support moving EVX-03 into clinical development. We are actively seeking partnership opportunities to further advance the development of EVX-03. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">EVX-B1</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EVX-B1 is a prophylactic multi-component vaccine initially in development for the prevention of </font><font style="font-style:italic;letter-spacing:0.2pt;">S.&#160;aureus</font><font style="letter-spacing:0.2pt;">-induced skin and soft tissue infections, or SSTI, in patients undergoing elective abdominal hernia surgery. EVX-B1 includes two proprietary and highly protective antigens identified by EDEN&#8482; as well as a chimeric toxoid, formulated with a potent adjuvant. We believe that the predictive power of EDEN&#8482; and our unique approach to vaccine design will result in a highly protective vaccine. EVX-B1 has now completed pre-clinical development. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">EVX-B2</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EVX-B2 is a prophylactic vaccine being developed to target diseases caused by </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae</font><font style="letter-spacing:0.2pt;">. EVX-B2 is composed of a fusion protein with two antigen subunits, identified by EDEN&#8482; and formulated with a potent adjuvant. We believe that our EVX-B2 vaccine candidate will induce a protective immune response against </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae</font><font style="letter-spacing:0.2pt;"> and thereby minimize the risk of infection for the general population and groups at risk. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2022, together with UMass Chan Medical School, we received a grant from the U.S. National Institutes of Health, or NIH, to support the evaluation of our EVX-B2 candidate using DNA and mRNA vaccine delivery platforms and to progress the development of our EVX-B2 vaccine candidate. In September&#160;2023, we initiated a collaboration with Afrigen Biologics with the goal of developing an mRNA-based gonorrhea vaccine for low- and middle-income countries (LMICs). The mRNA vaccine will be based on the same two EDEN&#8482; discovered antigens having demonstrated high levels of protection in preclinical studies. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">EVX-B3</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2023, we initiated a new collaboration with a leading pharmaceutical company to address a serious global medical issue by targeting a pathogen associated with repeated infections, increasing incidence, and often serious medical complications for which no vaccines are currently available. Our proprietary AI-Immunology&#8482; platform, with the EDEN&#8482; and the RAVEN&#8482; models, will be utilized for the rapid design of a completely novel vaccine candidate, EVX-B3, with the goal to be capable of eliciting both a strong humoral (antibody) and cellular immune response to the bacterial pathogen. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">EVX-V1</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2022, we announced the development of our first viral vaccine product candidate, targeting Cytomegalovirus, or CMV. We are utilizing our AI models RAVEN&#8482; and EDEN&#8482; to design a next-generation vaccine candidate that elicits both cellular and humoral responses. Ten EDEN&#8482; predicted novel B-cell antigens have been selected and are now being produced as recombinant proteins for further evaluation in preclinical models. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">EVX-V1 is being developed in collaboration with ExpreS</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">2</font><font style="letter-spacing:0.2pt;">ion Biotechnologies AB, or ExpreS2ion. We believe this partnership has the potential to deliver a truly differentiated, highly immunogenic vaccine for protection against CMV infections. EVX-V1 is currently in a pre-clinical discovery phase. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Strengths</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Our flexible, scalable and adaptable AI-Immunology&#8482; platform offers a strong value proposition toward existing and potential partners </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Our five AI models PIONEER&#8482;, ObsERV&#8482;, AI-DeeP&#8482;, EDEN&#8482; and RAVEN&#8482; ingrained in the AI-Immunology&#8482; platform, have allowed us to generate numerous pipeline candidates within </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">140</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">both cancer and infectious diseases, all with first-in-class potential and with our first two oncology product candidates currently in clinical development </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Our AI-Immunology&#8482; platform offers the potential to expand our partnerships and product candidate portfolio and allows for entering into additional therapy areas </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Our AI immunology&#8482; platform facilitates the identification of novel effective vaccine targets, enhancing the potential for clinical success </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Our in-house capabilities for experimental screening and testing of novel targets allow us to move rapidly from target identification to pre-clinical development </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Our model for iterative training allows for continuous improvement of our AI-Immunology&#8482; platform as data are generated throughout the drug development stages </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">We have established a direct link between the predictive power of our AI-Immunology&#8482; platform and preclinical and clinical outcome </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Our existing collaborations are confirming the strength of our AI-Immunology&#8482; platform </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">During 2023, the Evaxion strategy was refined with stronger focus on value realization and execution. The core of the Evaxion strategy is the AI-Immunology&#8482; platform, which has been continuously developed and improved over the past 15&#160;years. This has provided Evaxion with a pioneering and differentiated position within AI led target discovery as well as design and development of vaccine candidates. Evaxion is now well positioned for value realization via its three-pronged business model focusing on Targets, Pipeline and Responders. This value realization is to be pursued via a multi-partner approach. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The strategy refinement also means that Evaxion is shifting focus from larger scale clinical development towards a stronger and earlier focus on partnerships based upon the AI-Immunology&#8482; platform. The AI-Immunology&#8482; platform holds the potential for generating one new target every 24 hours, is delivery modality agnostic and easily adaptable to partner needs. The platform is currently trained in cancer and infectious diseases and is scalable to other therapeutic areas. The high throughput, combined with a very flexible model, offers a strong value proposition towards existing and future pharma partners. Developing partnerships with pharma is now an integrated part of the Evaxion value creation strategy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">AI-Immunology&#8482; contains five interrelated proprietary AI prediction models: (i)&#160;PIONEER&#8482;, our cancer neoantigen prediction model, (ii)&#160;ObsERV&#8482;, our endogenous retrovirus (ERV) tumor antigen prediction model, (iii)&#160;EDEN&#8482;, our B-cell antigen prediction model, (iv)&#160;RAVEN</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">TM</font><font style="letter-spacing:0.2pt;">, our T-cell antigen prediction model and (v)&#160;AI-DeeP&#8482; our responder prediction model. Common for all is that they build upon the same technology backbone as well as the strong Evaxion immunoinformatic capability base within machine learning, neural networks and artificial intelligence coupled with deep immunological insight. After having developed and matured our AI-Immunology&#8482; platform, we believe we are in a unique position to realize the value of the investments made and further to address significant unmet patient needs in collaboration with current and future partners. The potential of our AI-Immunology&#8482; platform is supported by the participation of MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck &amp; Co., Inc, Rahway NJ USA in our most recent private placement in December&#160;2023 as well as our vaccine target discovery collaboration with a leading pharmaceutical company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The shift in strategy towards a much stronger focus on partnering based upon AI-Immunology&#8482; and reduced clinical trial activities significantly reduces the company&#8217;s cash needs, both for the short- and the longer-term. The ambition for 2024 is to generate business development income equal to full year 2024 cash burn. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The below figure 9 summarizes the refined and focused Evaxion strategy in a simple overview. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">141</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:44.5pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="fc_fig06ourstarat-4c.jpg" alt="[MISSING IMAGE: fc_fig06ourstarat-4c.jpg]" height="301" width="547" >
        </div>
        <div style="margin-top:14.69pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 9: The Evaxion strategy.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have had encouraging progress on the refined strategy in the latter part of 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Within the </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Target</font><font style="letter-spacing:0.2pt;"> part of the strategy, we in September&#160;2023 announced two partnerships. First, a partnership with a leading pharmaceutical company focused on vaccine target discovery for a bacterial pathogen with a high medical need, where no vaccine currently is available. The objective here is to deploy two of the AI-Immunology&#8482; prediction models, EDEN&#8482; and RAVEN&#8482;, for rapid design of a completely novel vaccine candidate capable of eliciting both a humoral (antibody) and cellular (T cell) immune response to the pathogen. Further, we announced a partnership with Afrigen Biologics to develop a novel mRNA vaccine against Gonorrhea. Both partnerships demonstrate the unique opportunities in our partnership focused strategy based upon AI-Immunology&#8482;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Within the </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Pipeline</font><font style="letter-spacing:0.2pt;"> part of the strategy, the initial Phase&#160;2 data from the EVX-01 trial presented at the SITC annual meeting in November&#160;2023 was encouraging. The initial Phase&#160;2 data confirm the strong Phase&#160;1 findings presented earlier in 2023 at ASCO. It is worth highlighting a specific patient case: a metastatic melanoma patient with initial progressive disease presented with a significant and continuous tumor reduction after being administered with our AI-Immunology&#8482; designed EVX-01 personalized cancer vaccine. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Finally, within the </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Responder</font><font style="letter-spacing:0.2pt;"> part of our strategy we have obtained Proof of Principle for our Immune Checkpoint Inhibitor responder model as presented in November&#160;2023. Building on our core capabilities within immunological data, machine learning and predictions, we have set out on the journey of improving patient care and reducing the health care burden. The goal is to be able to predict which patients will respond to a given therapy. With Proof of Principle for our initial approach towards predicting Immune Checkpoint Inhibitor non-responders, we are now moving towards designing a commercial offering in a partnership-based approach. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Looking into 2024, we are anticipating several important milestones derived from our refined and focused strategy. Of particular importance are the following anticipated 2024 milestones: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">142</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tb_fig02milestones-4c.jpg" alt="[MISSING IMAGE: tb_fig02milestones-4c.jpg]" height="218" width="498" >
        </div>
        <div style="margin-top:14.69pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 10: Anticipated 2024 Milestones.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Looking ahead, we remain confident about our ability to generate value from our refocused strategy. We believe that our pioneering AI-Immunology&#8482; platform holds a unique and differentiated position compared to competing platforms. Effective AI-based vaccine discovery, validation and development require a multidisciplinary capability skillset around the AI platform as well as constant learning loops. We have built a very strong capability skillset around the AI-Immunology&#8482; platform focusing on key parts of the drug discovery and development value chain. As a result we can quickly test vaccine candidates in pre-clinical models and efficiently progress them towards IND filling by using our capabilities within pre-clinical development, regulatory affairs, CMC and early-stage clinical trials. Further, applying continuous learning loops with the AI platform, we iteratively refine the precision of the platform by integrating learnings from experimental and clinical assessments of the predicted targets. This iterative process facilitates ongoing improvement and adjustment of the AI-Immunology&#8482; resulting in a new cycle of predictions and experimental assessments. Over the&#160;years, this approach has led to a mature and well-developed platform, where predictions demonstrate a distinctive correlation with both pre-clinical and clinical outcomes. </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="fc_fig03aiimmunolonew-4clr.jpg" alt="[MISSING IMAGE: fc_fig03aiimmunolonew-4clr.jpg]" height="291" width="517" >
        </div>
        <div style="margin-top:14.69pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 11: The AI-Immunology&#8482; position.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See &#8220;Our Strategy&#8221; in this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">143</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Management Team</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that our fully AI-driven approach and our AI-Immunology&#8482; platform places us at the forefront of effectively translating the immune system into novel vaccine candidates that trigger the immune system to treat a variety of diseases. To deliver on our objectives, we have built an experienced and broadly skilled management team. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Chief Executive Officer, Christian Kanstrup joined us on September&#160;1, 2023. Christian Kanstrup has more than 25&#160;years of experience in the life science industry, coming from a position of Executive Vice President at Mediq before joining Evaxion. Prior to that, Christian held a broad range of senior management roles at Novo Nordisk A/S, latest as Senior Vice President and global head of Biopharm Operations. Prior to that Christian among others held senior leadership roles within the commercial part of the business as well as within strategy and corporate development. Christian also holds various board and advisory positions in the life science industry, advising on corporate strategy and company growth. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Chief Science Officer Birgitte R&#248;n&#248; joined in 2017 and was appointed CSO in 2021. Dr.&#160;R&#248;n&#248; has more than 20&#160;years&#8217; experience in biopharmaceutical drug discovery from academia and industry and received her PhD in experimental oncology and immunology from National Institutes of Health, Bethesda, USA, and Copenhagen University Hospital, Denmark. Prior to joining Evaxion, Birgitte R&#248;n&#248; served as a specialist, team leader and project manager at Novo Nordisk A/S, where she was leading early drug discovery projects, evaluating in-licensing opportunities, and supporting drug development projects with pre-clinical and biomarker expertise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Jesper Nyegaard Nissen joined as Chief Operating Officer in 2022 and was also appointed interim Chief Financial Officer in 2023. For over 25&#160;years, Jesper Nyegaard Nissen has worked broadly across the pharma value chain in global operations positions in Novo Nordisk anchored in research, development and finance. He has covered business areas across a variety of focus points, including finance operation, external innovation and collaborations, digitalization of business process optimization, development and shaping of organizational capacities, and implementation of performance and process improvement structures. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Andreas Holm Mattsson serves as Chief AI Officer at Evaxion Biotech, where he&#8217;s been at the forefront </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;">-based vaccine target discovery. He has played a key role in developing Evaxion&#8217;s innovative AI-Immunology&#8482; platform, a proprietary AI technology for identifying novel vaccine targets for cancer and infectious diseases. Andreas brings a strong educational background in bioinformatics from the Technical University of Denmark and has previously worked at Novo Nordisk. Since founding Evaxion in 2008, he has been an essential part of the company&#8217;s growth, serving in various executive roles. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Background on Cancer Vaccines and the Role of Neoantigens and ERVs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The immune system is our body&#8217;s natural defense system that protects us against infection and diseases. It keeps track of all of the substances normally found in the body and raises an alarm if an unfamiliar substance is found, launching an attack against it. However, cancer cells can present a more challenging target for the immune system. Cancer cells are altered normal cells and therefore the immune system doesn&#8217;t always recognize them as foreign. In fact, cancer cells possess several mechanisms through which they escape immune surveillance as they: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Harbor genetic changes that make them less visible to the immune system </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Express proteins on their cell surface that inhibit immune cell effector functions </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Induce changes in the normal cells around the tumor thus interfering with how the immune system responds to the cancer cells </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To overcome this, vaccines use different ways to seek the power of the patient&#8217;s own immune system to fight cancerous cells. The regulatory approval of immune checkpoint inhibitors, or CPIs, has been a major breakthrough in treatment of patients suffering from advanced solid cancers by demonstrating beneficial clinical responses, durable disease control and improved survival in subsets of patients. Detailed mapping of the underlying mechanisms has revealed that the CPI-induced antitumor effect is associated with the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">144</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">patient&#8217;s ability to mount a tumor-specific T-cell response. To further improve clinical efficacy, different co-targeting strategies are currently being explored, including the combination of CPI and T-cell vaccines capable of directing and improving the patients&#8217; immune response specifically towards essential functions in the cancer cells. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The Role of T Cells in Cancer Vaccines</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">T cells are a type of white blood cells that play a central role in the immune system. T cells are involved in both detecting and killing infected or abnormal cells, such as cancer cells, as well as coordinating immune responses. T cells can be classified into two major subsets, CD4+ T cells and CD8+ T cells, each possessing different functionalities. CD8+ T cells are considered the main effectors in T-cell mediated tumor killing, however, several reports have highlighted the importance of inducing both CD4+ and CD8+ T cells as T helper 1, or Th1, CD4+ T cells support CD8+ T-cell priming as well as promote the desired effects via secretion of effector cytokines. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">T cells recognize cancer cells using T-cell receptors, or TCRs, that interact with specific immune targets, or epitopes, presented by a molecular structure on the surface of cells known as the major histocompatibility complex, or MHC. The MHC molecules bind to peptides from protein degradation inside the cell before being transported to the cell surface to present the peptide to TCRs. If a peptide bound to the MHC molecule is recognized by T cells, it is called an epitope. There are two classes of MHC molecules, class I and class II, that activate CD8+ and CD4+ T cells, respectively. In humans, MHC is encoded by the genes of the HLA locus. HLA genes show high allelic variation, resulting in MHC molecules that have different peptide binding preferences. Each person expresses a unique combination of molecularly distinct class I and class II MHC molecules that bind a specific set of peptides and epitopes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Mutated genes in cancer cells lead to expression of altered proteins which are, like all proteins, processed by the cellular machinery into protein fragments known as peptides. When these mutated peptides are presented on MHC molecules, by either tumor cells or antigen presenting cells, and recognized by T cells, they are known as neoantigens. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Another class of tumor antigens are derived from endogenous viral elements, hereunder endogenous retroviruses (ERVs). ERVs are found in the genome of all cells but their expression is tightly regulated in healthy cells. Due to the way cancer cells evolve, this tight transcriptional regulation of ERVs is often compromised, leading to expression and production of cancer-specific, ERV-derived antigens. As a limited number of somatic mutations and ERVs are shared among two different tumors, no general cancer vaccine can be produced, making it necessary to design and produce a new personalized or precision product specific for each patient or for groups of patients. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The immune system refrains from targeting the body&#8217;s own healthy cells principally through processes known as central and peripheral tolerance, by which T cells are educated not to respond to MHCs displaying peptides from normal proteins and, therefore, T cells avoid targeting normal cells for destruction. The TCR-peptide-MHC interaction is a vital immune mechanism that allows the body both to respond against threats, including cancer, as well as to avoid targeting the body&#8217;s own healthy cells. Understanding the interactions between TCRs, peptides and specific MHC alleles is critical to directing and activating an immune response to cancer. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Neoantigen- and Endogenous Retrovirus-based Cancer Vaccines</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The common feature of cancer is accumulation of mutations in the genes, which manifests as tumors with uncontrolled growth. Cancer is a complex, extremely heterogeneous condition. Despite this complexity and variability, patients with the same type and stage of cancer have historically been administered the same treatment. This approach has been altered in recent&#160;years with the introduction of precision medicine cancer vaccines, a tailored approach for selecting therapy at the individual patient or groups of patients&#8217; level based on the genetic makeup of the patient&#8217;s cancer. Discovery of molecular cancer biomarkers (i.e., cancer oncogenes) has paved the way for the first generation of personalized and precision therapies. Genomic screening approaches have been commonly employed to identify tumor-specific, overexpressed proteins or genetic mutations that may confer targets for an effective cancer vaccine. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">145</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:48pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe a truly personalized or precision approach, incorporating the entirety of the tumor ecosystem, while taking a more unbiased approach to drug design, is required to advert the inherent complexities of the tumor microenvironment and heterogeneous cellular landscape, and to improve the clinical outcome of cancer vaccines. We believe such approach can be achieved by directing vaccines towards cancer-exclusive peptide sequences, so called neoantigens and endogenous retroviruses, or ERVs, displayed on the surface of tumor cell originating from patient-specific mutations and highly expressed ERV sequences, respectively. Neoantigen-targeting vaccines have shown great promise in pre-clinical animal models as well as in early clinical trials. Of note, Moderna and Merck recently announced their personalized neoantigen targeting therapy met the primary endpoint in a Phase&#160;2b trial in melanoma patients. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neoantigens and ERVs provide an avenue for tumor-specific immune cell recognition, a prerequisite for a beneficial clinical response of a neoantigen/ERV based vaccine. Antigen presenting cells, or APCs, educate the immune system by presenting neoantigens and the ERVs to T cells. Tumor cells often present neoantigens and ERV-derived sequences on their cell surface, providing accessible targets for T cells. T cells recognize and kill neoantigen and/or ERV-presenting cancer cells and effect a positive feedback loop to heighten and broaden the cancer specific immune response as more epitopes will be available for APC uptake upon T-cell mediated tumor cell lysis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Once patient-specific neoantigens and/or ERVs are administered to the patient, APCs will process the neoantigens and ERVs by the MHC epitope presentation machinery, migrate to the lymph node and present neoantigens and ERVs to T cells. TCRs on circulating CD4+ and CD8+ T cells bind to the presented neoantigens and ERVs triggering initial T-cell activation. Once activated, the T cells will enter the circulation to reach distant organs, including the tumor. In the tumor, reactive T cells will encounter tumor cell surface displayed neoantigens and/or ERVs, resulting in T cell mediated tumor cell killing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Cancer patients normally do not have a meaningful numbers of T cells that recognize their tumor. We believe a neoantigen and ERV-targeting approach will generate a strong, </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> tumor-specific T-cell response which will lead to killing of tumor cells and thereby an improved clinical response. Further, we believe such approach has encouraging therapeutic potential because neoantigens and ERVs represent foreign elements to the immune system and are unique to each person&#8217;s tumor cells which means neither self-tolerance nor adverse side effects are likely to limit the clinical application of a neoantigen and/or ERV-based vaccine. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe our truly personalized or precision approaches targeting neoantigens and ERVs will allow us to harness the natural power of a patient&#8217;s own immune system to elicit a strong, cancer-specific immune response, potentially holding the key to long-lasting tumor control or even a possible cure for many cancer patients. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PIONEER&#8482;&#8201;&#8211;&#8201;Our AI model for the Discovery of Novel, Personalized Neoantigen-targeting Cancer Vaccines</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Overview</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">PIONEER&#8482; is our proprietary AI model for the rapid discovery and design of personalized neoantigen-targeting therapies. Our proprietary PIONEER&#8482; model allow us to efficiently identify and select those neoantigens that we believe are most likely to generate a strong, </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> T-cell response leading to significant antitumor effect in each patient. The goal of our PIONEER&#8482; derived cancer vaccines is to deliver therapeutic neoantigens to patients in a way that trains the patients&#8217; own immune system to target and kill tumor cells with no or very limited adverse effects on healthy non-cancer cells. As shown in Figure 12 below, PIONEER&#8482; simulates the key biological steps in presenting each neoantigen to the patient&#8217;s immune system with our high-performance, AI-based </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> modules. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">146</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="fc_fig12cancer-4c.jpg" alt="[MISSING IMAGE: fc_fig12cancer-4c.jpg]" height="142" width="521" >
        </div>
        <div style="margin-top:13.2pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 12: Illustration of mechanisms within the tumor cell that are required for a neoantigen to have a clinical effect in patients.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Key biological steps simulated by PIONEER&#8482; include: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Step 1&#8201;&#8212;&#8201;Mutation:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;PIONEER&#8482; identifies cancer-specific mutations by comparing DNA sequencing data from the tumor sample(s) and normal tissue sample using our proprietary AI-based somatic variant caller. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Step 2&#8201;&#8212;&#8201;Expression:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Only a subset of the cancer-specific mutations is found in genes that are expressed in the tumor cells. The expression levels of each gene are determined by analyzing tumor RNA sequencing data. In addition, PIONEER&#8482; calculates the mutation-specific expression levels using an in-house developed computational module. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Step 3&#8201;&#8212;&#8201;Translation:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Not all cancer-specific mutations result in altered protein sequences. Some mutations may be found in regions that do not code for protein sequences or they may simply be synonymous mutations (where the DNA sequence is altered, but the encoded amino acid is the same). PIONEER&#8482; determines the effects of each cancer-specific mutation. The coding regions around non-synonymous mutations are then translated into amino acid sequences, generating cancer-specific neoantigen sequences. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Step 4&#8201;&#8212;&#8201;Presentation on MHC Class&#160;I and Class&#160;II Molecules:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To induce an immune response, neoantigens must contain subsequences that are bound by MHC molecules and presented on the cell surface. The identified neoantigens are given as input to our proprietary AI-based tool suite, EvaxMHC, along with the patient&#8217;s HLA type to identify neoantigens containing MHC ligands bound by the patient&#8217;s MHC molecules specifically. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Step 5&#8201;&#8212;&#8201;T-cell Response:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Neoantigens presented by MHC class I and class II molecules are recognized by T cells, triggering an immune response and T cell mediated tumor cell death. However, while being presented as MHC ligands is a prerequisite for generating an immune response, not all MHC ligands are recognized by T cells. PIONEER&#8482; includes an </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> module that predicts the likelihood of a given mutated MHC ligand eliciting a T-cells response. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Step 6&#8201;&#8212;&#8201;Clonal Neoantigens:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Tumors are extremely heterogeneous, meaning that not all tumor cells necessarily encode and express the same neoantigens. Targeting clonal neoantigens, defined as neoantigens arising from clonal mutations that are present in all cancer cells, allows for systemic eradication of the whole tumor, as well as potential metastases in the patient. Multiple reports suggest that targeting clonal neoantigens result in a more effective treatment. PIONEER&#8482; determines the clonal status of a neoantigen by analyzing the DNA sequencing data using </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> AI modules. For patients where DNA sequencing data from multiple tumor biopsies is available, PIONEER&#8482; seamlessly integrates the information from each biopsy to improve the clonality estimate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Identifying those neoantigens that will induce a strong antitumor immune response capable of eradicating all tumor cells in the patient requires sophisticated AI-based </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> tools. Such tools must be capable of accurately identifying tumor specific mutations along with all steps involved in neoantigen processing, presentation and TCR recognition. State-of-the-art, publicly available </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> tools for neoantigen prediction return a vast number of candidates, of which only a handful are ever found to trigger bona fide antitumor responses in patients. We have benchmarked our proprietary </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> tools from PIONEER&#8482; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">147</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">against state-of-the-art public tools (Mutect2, MixMHCpred-v2.1/MixMHC2pred-v1.2, RSEM-v1.2.0 quantified expression) and we believe our platform produces superior results: </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="bc_fig13pioneer-4c.jpg" alt="[MISSING IMAGE: bc_fig13pioneer-4c.jpg]" height="263" width="421" >
        </div>
        <div style="margin-top:14.69pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 13: Benchmark study of PIONEER&#8482; against state-of-the-art, public tools for number of hits identified in the top 10 best-ranked neoantigens.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To compare PIONEER&#8482; to a pipeline of state-of-the-art public tools, we designed a simulation study with 3,000 patients. Each patient was assigned 500 potential neoantigens in a 1:5 positive to negative ratio. Both pipelines were tasked with selecting a set of 10 neoantigens for each patient and the average number of positive neoantigens was assessed. Results are depicted in Figure 13 above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our benchmark study demonstrates that the publicly available tools are only capable of identifying 2.6 correct neoantigens in the top 10, which, we believe, in a neoantigen-based cancer vaccine is not sufficient to reach a strong antitumor effect. In comparison, PIONEER&#8482; was able to identify 8.7 correct neoantigens in the top 10, which we anticipate is optimal to drive an enhanced antitumor immune response. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">PIONEER&#8482; include several </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> modules, some of which are AI-based, corresponding to each biological step in neoantigen presentation to the immune system. We believe that our multi-parameter improvements incorporated across our </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> AI modules will translate into better antitumor effect. In pre-clinical studies, we have already demonstrated that enhanced neoantigen prediction directly links to improved antitumor effect in mice (see Figure 14 below). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Improved Neoantigen Prediction Directly Translate into Better Antitumor Effect</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our proprietary </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> AI modules identifying neoantigens within PIONEER&#8482; have been trained using gradient-boosted decision trees, transformers and a conditional generative adversarial network approach on our internally generated data as well as other data, including, but not limited to, next generation sequencing data from tumor samples, mass spectrometry immunopeptidomics, peptide-MHC-binding affinity data, T-cell immunogenicity data, peptide-MHC-binding stability data. We have demonstrated that development and iterative training of our AI model directly translates into improved antitumor effect in pre-clinical studies. In a pre-clinical tumor study, the efficacy of three versions of PIONEER&#8482; version 0.1, 1.0 and 2.0), each with increasing number of new features were directly compared (see Figure 14 below). Mice treated with neoantigens predicted by PIONEER&#8482; 2.0 developed statistically significant smaller tumors compared to mice treated with neoantigens predicted by earlier versions of PIONEER&#8482;, thereby demonstrating that improved neoantigen prediction directly translates into improved antitumor effect. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">148</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="lc_fig14tumorvolum-4c.jpg" alt="[MISSING IMAGE: lc_fig14tumorvolum-4c.jpg]" height="307" width="426" >
        </div>
        <div style="margin-top:10.91pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 14: To explore the biological impact of different improvements, three versions of PIONEER&#8482; were evaluated in the CT26 mouse tumor model. For each version, the top 10 ranked neoantigens were encoded in separate DNA constructs, designated PIONEER&#8482; 0.1, PIONEER&#8482; 1.0, and PIONEER&#8482; 2.0. Mice were intramuscularly treated twice with the various DNA constructs prior to CT26 cells inoculation. A &#8220;mock&#8221; DNA plasmid without neoantigens was included as control.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will continue to train and incorporate more data into PIONEER&#8482; model to ensure that our nested AI modules remain state-of-the-art. In addition, we continue to include new features in the model to further increase its predictive power. </font>
        </div>
        <div style="margin-top:11.71pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Key Advantages of Our PIONEER&#8482; model</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Identification of Therapeutic Neoantigens:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;PIONEER&#8482; can identify therapeutic neoantigens that drive a T-cell response with higher accuracy compared to predictions done by state-of-the-art public tools. Clinical data from the Phase&#160;1/2a trial of EVX-01 demonstrated induction of neoantigen-specific T cells in 100% of patients with an overall response rate of 67% compared with a historical overall response rate of 40% with anti-PD-1 treatment alone. Further, clinical data from the Phase&#160;1/2a trial of EVX-02 demonstrated activation of neoantigen-specific T cells with tumor killing potential in patients, and that T-cell responses were robust and long lasting. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Identification of Multiple Neoantigens:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;PIONEER&#8482; identifies multiple neoantigens that can be incorporated in the cancer vaccine to increase therapeutic effect and overcome issues related to cancer clonal heterogenicity and tumor immune escape. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">World Wide Clinical Applicability:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;PIONEER&#8482; is clinically applicable, automated and deployable anywhere in the world and has been through a process of validation according to the International Society for Pharmacoepidemiology, ISPE&#8217;s, latest revised guide for Good Manufacturing Practice, or GAMP5, to ensure compliance with legislature and good practice regulations to maintain a high standard of quality in the system. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe we are uniquely positioned to develop a neoantigen-based cancer vaccine and address the shortcomings from competing approaches through our proprietary algorithms and AI modules contained in the PIONEER&#8482; model. </font>
        </div>
        <div style="margin-top:11.72pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ObsERV</font><font style="font-weight:normal;letter-spacing:0.2pt;">&#8482;</font><font style="letter-spacing:-0.2pt;">&#8201;&#8212;&#8201;Our AI model for the Design of Personalized or Precision ERV-based Cancer Targets</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Overview</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">ObsERV&#8482; is our proprietary AI model for the discovery of patient-specific virus-derived sequences, so-called ERVs (endogenous retroviruses), expressed in cancer. Targeting this novel class of tumor antigens may </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">149</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">allow for developing a completely new type of immunotherapy against immunologically cold tumors with low response rates to immunotherapy. ObsERV&#8482; can rapidly discover ERV tumor antigens and design of personalized or precision vaccine containing these antigens. Our proprietary AI modules within ObsERV&#8482;, for the prediction of antigen-specific T-cell responses, have been trained using transformers and a conditional generative adversarial network approach. This allows us to efficiently identify and select those ERV-antigens that we believe are most likely to generate a strong, de novo T-cell response leading to significant antitumor effect in each patient. The goal of our ObsERV&#8482; model derived cancer vaccines is to deliver therapeutic ERV-antigens to patients in a way that trains the patients&#8217; own immune system to target and kill tumor cells with no or very limited adverse effects on healthy non-cancer cells. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have demonstrated that overexpression of ERVs is strongly associated with the overall survival of cancer patients. Hence, we believe such ERV-based therapies will induce a directed T-cell dependent immune response leading to tumor eradication. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that ObsERV&#8482; will allow us to develop therapeutic cancer vaccines benefitting a broader range of cancer patients for which no or limited treatment options exist. This includes providing novel treatment solutions for cancer patients that are unlike to respond to immunotherapy and cancer vaccines that targets neoantigens. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Key Advantages of Our ObsERV&#8482; Model</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Identification of Therapeutic ERV-antigens</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;We believe ObsERV&#8482; can identify therapeutically relevant ERV-antigens that drive a T-cell response with a state-of-the-art high accuracy and effect. We have preclinically demonstrated complete tumor eradication in animal models when targeting ERVs. While previous published reports highlight some success with retroviral therapy against specific antigens, our in silico-designed cancer vaccine using ERV-antigens is the first to show lasting tumor protection and a robust, diverse T-cell response. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Identification of Multiple ERV-antigens</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;ObsERV&#8482; identifies multiple ERV-antigens that can be incorporated in the cancer vaccine to increase therapeutic effect and overcome issues related to cancer clonal heterogenicity and tumor immune escape. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Worldwide Clinical Applicability:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As with PIONEER&#8482;, ObsERV&#8482; is designed to be clinically applicable, automated and deployable anywhere in the world and has been through a process of validation according to the International Society for Pharmacoepidemiology, ISPE&#8217;s, latest revised guide for Good Manufacturing Practice, or GAMP5, to ensure compliance with legislature and good practice regulations to maintain a high standard of quality in the system. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe we are uniquely positioned to develop ERV-antigen based cancer vaccines and address the shortcomings from competing approaches through our proprietary algorithms and AI modules contained in ObsERV&#8482;. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Using PIONEER&#8482; and ObsERV&#8482; to Design Our Cancer Vaccine Candidates</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="fc_fig15pioneer-4c.jpg" alt="[MISSING IMAGE: fc_fig15pioneer-4c.jpg]" height="194" width="547" >
        </div>
        <div style="margin-top:13pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 15: Our process for manufacturing a personalized cancer vaccine.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">150</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As shown in Figure 15 above, the following steps describe our process for designing a personalized cancer vaccine: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Step 1&#8201;&#8212;&#8201;Tissue Biopsy:</font><font style="font-weight:normal;letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Tumor tissue sample(s) and a blood sample are collected from the patient. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Step 2&#8201;&#8212;&#8201;DNA and RNA sequencing:</font><font style="font-weight:normal;letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We then apply deep-sequencing to the patient&#8217;s tumor biopsy specimen and blood to derive high-quality DNA and RNA sequence information. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Step 3A&#8201;&#8212;&#8201;Identify Critical Neoantigens:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;PIONEER&#8482; uses this sequence information to identify tumor mutations. Next, PIONEER&#8482; identifies potential neoantigens from the tumor mutations and selects the top 10-20 neoantigen candidates and designs the final cancer vaccine. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Step 3B&#8201;&#8212;&#8201;Identify Critical ERV antigens:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;ObsERV&#8482; uses tumor RNA sequence data from tumor biopsies to identify and rank the most vaccine-relevant ERV antigens. The top 10-20 ERV antigen candidate are selected for the final cancer vaccine design. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Step 4&#8201;&#8212;&#8201;Manufacturing:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The PIONEER&#8482; and ObsERV&#8482; antigen cancer vaccines are manufactured. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Step 5&#8201;&#8212;&#8201;Administer cancer vaccine to Patient:</font><font style="font-weight:normal;letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The manufactured cancer vaccines are administered to the patient. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Initially, our personalized vaccines are intended for the use as a combination therapy with CPIs. Evidence suggests that in patients responding well to CPI treatment, the response is partly mediated by tumor antigen-reactive T cells. Induction of </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> tumor antigen-specific T cells in combination with CPIs may increase the number of patients responding to treatment as well as improve the long-term clinical outcome. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our PIONEER&#8482; and ObsERV&#8482; Derived Cancer Vaccine Programs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are currently advancing a clinical pipeline of personalized cancer vaccines derived from our PIONEER&#8482; and ObsERV&#8482; models (see Figure 16). </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="bc_fig16stage-4c.jpg" alt="[MISSING IMAGE: bc_fig16stage-4c.jpg]" height="121" width="546" >
        </div>
        <div style="margin-top:12.6pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 16: Our immuno-oncology product candidates derived from PIONEER&#8482; and ObsERV&#8482;. </font>
          <br >
          <font style="letter-spacing:-0.2pt;">Note: The role of MERCK in the EVX-01 clinical trial is to supply</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font><font style="font-style:normal;letter-spacing:-0.2pt;">KEYTRUDA</font><font style=" position:relative; bottom:4.25pt;font-style:normal;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="font-style:normal;letter-spacing:-0.2pt;"> (pembrolizumab).</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Our EVX-01 Product Candidate</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Overview</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our EVX-01 product candidate is a liposomal, peptide-based therapeutic cancer vaccine designed to engage a patient&#8217;s own immune system to fight their cancer by mounting a targeted response towards the tumor. EVX-01, in combination with anti-PD-1 or other CPIs, is intended for the first-line treatment of a variety of metastatic and unresectable cancers amenable to PD-1 inhibition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EVX-01 consists of five to 10 PIONEER identified neoantigens formulated as peptides (neopeptides) together with a strong CD8+ and CD4+ T-cell inducing adjuvant, CAF09, in-licensed from Statens Serum Institute, or SSI. When administered to the patient, we believe EVX-01 will induce neoantigen-specific T cells that will migrate to the tumor site and induce tumor killing or target circulating tumor cells to eliminate these before becoming metastatic. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">151</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The development and Phase&#160;1/2a clinical trial of EVX-01 was partly funded through a $3&#160;million grant from the Innovation Fund&#160;Denmark and conducted in collaboration with a consortium consisting of Center for Cancer Immune Therapy at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen and the Center for Vaccine Research at SSI. Evaxion retains all of the commercial development rights to EVX-01. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A clinical Phase&#160;1/2a trial was conducted from 2019 to 2022. Results from this trial was presented at American Society of Clinical Oncology, or ASCO, Annual Meeting in June&#160;2023 and showed that EVX-01 in combination with anti-PD-1 treatment induced strong anti-tumor response in 67% of patients. 8 patients had a clinical response to treatment i.e. tumor shrinkage with 2 patients having a complete response i.e. no sign of disease. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">EVX-01 is currently in clinical Phase&#160;2 development in a global multi-center trial in metastatic melanoma, administered in combination with KEYTRUDA</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (NCT05309421). The trial is currently conducted globally at clinical sites across in Europe and Australia in collaboration with Merck. Patients enrolled in the Phase&#160;2 clinical trial receive standard of care treatment along with KEYTRUDA</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> in combination with EVX-01, or in the event of progression, another standard of care treatment in combination with EVX-01. We are responsible for the conduct of the trial. We will continue to collaborate with Merck as the data mature. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The first patient in the Phase&#160;2 trial was dosed in Australia in September&#160;2022. Initial readout from the first five patients was presented at the 38</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> annual meeting of SITC in November&#160;2023 in San Diego, California. The initial data demonstrated that the EVX-01 therapy was well tolerated, induced an EVX-01-specific immune response in all five patients and further promising signs were observed as three out of the five patients experienced improved clinical outcome upon EVX-01 and pembrolizumab treatment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Addressable Market for EVX-01</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are currently developing EVX-01 for the treatment of advanced or metastatic unresectable melanoma with the potential to expand into other solid tumor types such as non-small cell lung cancer, or NSCLC, and bladder cancer. According to the American Cancer Society, in 2023 there will be in the U.S.: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">97,610 new melanoma cases and 7,990 deaths from melanoma; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">238,340 new lung cancer cases and 127,070 deaths from lung cancer. NSCLC makes up on average 84% of all lung cancer cases; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">82,290 new cases of bladder cancer and 16,710 deaths from bladder cancer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The treatment paradigm for metastatic and unresectable melanoma, NSCLC and bladder cancer has been revolutionized over the last few&#160;years with the approval of PD-1/PD-L1 CPIs across treatment lines, including first line for metastatic and unresectable melanoma and in NSCLC as monotherapy or in combination with chemotherapy/other CPIs depending on a patient&#8217;s status. In bladder cancer, PD-1/</font>&#8203;<font style="letter-spacing:0.2pt;">PD-L1 CPIs are approved in the first line setting for cisplatin ineligible patients as well as later line treatments. Only a minority of patients in these three indications have durable responses to PD-1/PD-L1 CPIs with a majority of patients ultimately showing progressive disease. We believe that our therapeutic neoantigens and ERV-antigens could change the treatment paradigm in combination with PD-1/PD-L1 CPIs across these three indications by expanding the patient population responding to PD-1/PD-L1 inhibitor treatment (CPI-resistant patients) and potentially increasing the effect in patients already responding to PD-1/PD-L1inhibitor treatment. </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Data Readout from our EVX-01 Phase&#160;1/2a Clinical Trial</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our EVX-01 Phase&#160;1/2a clinical trial was a first-in-human clinical trial of EVX-01 in combination with anti-PD-1 or anti-PD-L1 (NCT03715985). The trial commenced in January&#160;2019 and was an open-label, single-arm trial. The objectives of the trial were to evaluate the safety/tolerability (primary endpoint) and immunogenicity and feasibility of manufacturing (secondary endpoint) and establish a recommended Phase&#160;2b dose, or RP2D. The trial was initially intended as a basket trial for three indications: metastatic melanoma, NSCLC and bladder cancer. The indications were subsequently changed to advanced or metastatic unresectable melanoma. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">152</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="fc_fig17vaccine-4clr.jpg" alt="[MISSING IMAGE: fc_fig17vaccine-4clr.jpg]" height="295" width="481" >
        </div>
        <div style="margin-top:12.1pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 17: Clinical design of the first-in-human Phase&#160;1/2a clinical trial in the EVX-01 program. (a)&#160;biopsy, Positron emission tomography/computed tomography scan, or PET/CT scan, and blood samples were collected at baseline (T1). Treatment with anti-PD-1 was either initiated at time of first biopsy (group A) or had already been initiated &gt;4&#160;months before biopsy (group B). EVX-01 vaccine was administered at week 6-8 and every 2nd week for 6 total vaccinations: 3 x IP followed by 3 x IM. (b)&#160;Dose escalation of administered peptide pool and number of patients at each dose level. CPI: checkpoint inhibitor, IP: intraperitoneal, IM: intramuscular, ORR: overall response rate, PFS: progression free survival, T: timepoint, FU: follow-up.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2023, we announced data readout from the Phase&#160;1/2a clinical trial showing that EVX-01 in combination with anti-PD-1 compares favorably to anti-PD-1 treatment alone. The data demonstrated an overall response rate, or ORR, of 67% across all 12 patients compared with a historical ORR of 40% with anti-PD-1 treatment alone. The study also demonstrated a complete response, or CR, of 17%, compared with a historical CR of 7% with anti-PD-1 treatment alone. Among the four patients on the highest doses, all had a clinical response (ORR of 100%). Two patients with stable disease, or SD, for 10 and eight&#160;months on anti-PD-1 treatment alone, achieved CR and a partial response, or PR, respectively, following EVX-01 administration. In addition, the data showed induction of neoantigen-specific T cells in 100% of patients. 58% of the administered neoantigens induced reactive T cells in patients, of which 85% were </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> responses. Data from the trial also showed that EVX-01 appeared to be well-tolerated with only Grade 1 and 2 adverse events such as fatigue and fever (see figure 18). </font>
        </div>
        <div style="position:relative;margin-top:9.2pt; text-align:center; width:456pt;">
          <img src="tb_fig18tumor-4c.jpg" alt="[MISSING IMAGE: tb_fig18tumor-4c.jpg]" height="224" width="546" >
        </div>
        <div style="margin-top:12.01pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 18: Patient disease status, treatment outcome and immune response from the EVX-01 Phase&#160;1/2a clinical trial.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">153</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As shown in Figure 19 below, a benefit of the combination therapy was observed for nine patients. Of these, two patients had a CR, six patients had a PR, one patient had SD, and three patients had progressive disease, or PD, as best outcome. Furthermore, a complete remission of target tumor lesions was observed in 4 patients (33%). </font>
        </div>
        <div style="position:relative;margin-top:9.5pt; text-align:center; width:456pt;">
          <img src="bc_fig19lesions-4c.jpg" alt="[MISSING IMAGE: bc_fig19lesions-4c.jpg]" height="270" width="363" >
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 19: % change in target lesion size for patients treated with EVX-01. Disease development determined according to RECIST criteria. PD: Progressive disease, SD: Stable disease, PR: Partial response, CR: Complete response. % change for lymph-node target lesions was set to <font style="white-space:nowrap;">-100%</font> when lymph-node was normal size (10 mm or below).</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Data from our clinical trial, as depicted in Figure 20, prove that patients treated with higher dose levels of EVX-01 neopeptides (dose level three, 200 ug/peptide) have an increased T-cell response compared to lower doses. When investigating the effect of peptide dose on T-cell response in general, we found that higher dose levels increase ORR in patients i.e. all patients at dose level 3 has an objective clinical response. The data supported the selection of the Phase&#160;2 dose as dose level 3 i.e. 200 ug/peptide. </font>
        </div>
        <div style="position:relative;margin-top:9.5pt; text-align:center; width:456pt;">
          <img src="lc_fig20prepost-bw.jpg" alt="[MISSING IMAGE: lc_fig20prepost-bw.jpg]" height="322" width="395" >
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 20: Dose-responsiveness of immunogenic neoantigens. Pre, immune responses to EVX-01 neopeptides before vaccination, Post; Immune responses to EVX-01 neopeptides after vaccination.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">154</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">When investigating the safety profile, we found that increasing the dose level of EVX-01 does not affect the safety profile. Only grade 1 and 2 treatment related adverse events, or TRAEs, were observed across the three dose levels. Most frequently observed TRAEs include fatigue, stomach pain and fever&#8201;&#8212;&#8201;see table below of the TRAE: </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tb_fig20trae-4clr.jpg" alt="[MISSING IMAGE: tb_fig20trae-4clr.jpg]" height="125" width="442" >
        </div>
        <div style="margin-top:18.7pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Neoantigen and Clinical Response Correlations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">As shown in Figure 21 below, we observed a correlation between broadness of immune response and clinical benefit when investigated if responding patients had a higher frequency of neoantigens resulting in a tumor-specific immune response as measured in blood by ELISpot. As seen in Figure 21, responding patients in general had a higher frequency of immunogenic neoantigens after treatment with EVX-01&#8201;&#8212;&#8201;a trend not observed pre EVX-01 treatment (see &#8220;Pre&#8221; boxplot to the left in Figure 21). Furthermore, the prevalence for immunogenic neoantigens in patients with clinical response increases in the follow-up samples. We interpret the increased profile of more immunogenic neoantigens in responders post EVX-01 treatment as indirect evidence of effect for EVX-01. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Clinical outcome correlates with neoantigen immunogenicity</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="lc_fig21prepostfollow-bw.jpg" alt="[MISSING IMAGE: lc_fig21prepostfollow-bw.jpg]" height="218" width="395" >
        </div>
        <div style="margin-top:14.69pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 21: Frequency of immunogenic neoantigens in patients. Pre-; before EVX-01 treatment but after initiation of PD-1 CPI treatment, Post: After 3 and 6 rounds of EVX-01 treatment and Follow up: After end EVX-01 treatment until progression. Clinical response as defined by RECIST, immunogenic neoantigens are defined as neoantigens where the T-cell response (SFU) is at least 3 times the standard deviation of the response induced by irrelevant peptides at the same timepoint, frequency of immunogenic neoantigens is calculated per patient.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We also observed a significant correlation between PIONEER quality score (prediction scores), immunogenicity, clinical response and Progression Free Survival, or PSF, as seen in Figure 22 and 23. PIONEER (v4.2) assigns significantly higher quality scores to immunogenic compared to non-immunogenic neoantigens and significantly higher quality scores to neoantigens administered to patients responding to treatment compared non-responding patients. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">155</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="lc_fig22mannwhitney-bw.jpg" alt="[MISSING IMAGE: lc_fig22mannwhitney-bw.jpg]" height="220" width="426" >
        </div>
        <div style="margin-top:13.4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 22: left: PIONEER quality scores for EVX-01 peptides inducing functional responses detected by ELISpot (immunogenic) compared to non-immunogenic EVX-01 peptides. Right: PIONEER quality scores for EVX-01 administered neopeptides in responders (CR/PR) and non-responders (SD/PD). P-value by t-test.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We further investigated if PIONEER quality score impacted PFS, i.e. time from treatment start to disease progression or death, of patients treated with EVX-01 by dividing patients in high and low PIONEER quality groups (n=6 in each). As seen from Figure 23, the high-quality group have significant longer time to progression compared to the low-quality group. To investigate if the longer PSF in the high score group was driven by a higher mutational load, the same analysis using TMB was conducted. As depicted in Figure 23, TMB did not seem to be the determining factor for PSF in this patient cohort, indicating that the quality of administered EVX-01 neopeptides is important for clinical benefit. </font>
        </div>
        <div style="position:relative;margin-top:10.1pt; text-align:center; width:456pt;">
          <img src="lc_fig23neoantigen-4c.jpg" alt="[MISSING IMAGE: lc_fig23neoantigen-4c.jpg]" height="233" width="456" >
        </div>
        <div style="margin-top:13.2pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 23: Kaplan-Meier plots displaying PFS of patients based on TMB high/low calculated FDA guidelines (left) Median PIONEER score (right).</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our Phase&#160;2 Clinical Trial</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based on our Phase&#160;1/2a clinical trial interim data readout on October&#160;21, 2021, we entered into the Merck CTCSA to evaluate in a new Phase&#160;2 clinical trial, the combination of our personalized cancer vaccine, EVX- 01, with MSD&#8217;s anti-PD-1 therapy KEYTRUDA</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (pembrolizumab), a humanized anti-human PD-1 monoclonal antibody. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Phase&#160;2 clinical trial is an open-label, multi-center, single arm trial evaluating the efficacy (best objective response, overall response rate, progression free survival and overall survival) and safety of EVX-01 in adults with advanced or metastatic unresectable melanoma on pembrolizumab. The trial is designed to show an improvement in the best overall response of patients with SD or PR after 12 weeks on pembrolizumab </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">156</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">treatment. The trial design is guided by recently published KEYNOTE-001 and 006 data from MSD which demonstrates that advanced melanoma patients with SD at week 12 and subsequent progression had poor survival outcomes. We believe EVX-01 in combination with pembrolizumab has the potential to significantly improve patient outcomes. The trial design is developed in collaboration with world leading KOLs; Georgina Long (Melanoma Institute Australia, AU), Patrick Ott (Dana-Faber Cancer Institute, USA) and Inge-Marie Svane (Center for Cancer Immune Therapy, Denmark), and is conducted in partnership with MSD. </font>
        </div>
        <div style="position:relative;margin-top:8.41pt; text-align:center; width:456pt;">
          <img src="fc_fig24pembrolizumab-4c.jpg" alt="[MISSING IMAGE: fc_fig24pembrolizumab-4c.jpg]" height="103" width="516" >
        </div>
        <div style="margin-top:10.91pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 24: Schematic presentation of the EVX-01 Phase&#160;2 clinical trial design. Each patient receives 18 cycles with pembrolizumab (approximately two&#160;years).</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2022, we received regulatory clearance from the Australia Therapeutic Goods Administration, or the TGA, to initiate the Phase&#160;2 clinical trial of EVX-01, and in September&#160;2022, we announced enrollment of the first patient in our Phase&#160;2 trial in Australia. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2022, we submitted a CTA to the Italian Medicines Agency, which was approved on September&#160;16, 2022. Further, on November&#160;23, 2022, we submitted an IND to the FDA, which was granted approval on December&#160;22, 2022. Further, we received Fast Track designation from the FDA on January&#160;17, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of November&#160;2023, 16 patients were enrolled the Phase&#160;2 study and commenced the combination treatment with EVX-01 and pembrolizumab. Initial readout from the first five patients was presented at the 38</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> annual meeting of SITC in November&#160;2023 in San Diego, California. The initial data demonstrated that the EVX-01 treatment appeared safe and well tolerated. Few AEs related to EVX-01 have been reported and these were either grade 1 or 2. No SAEs have been reported in this patient cohort. Safety data cut-off: 30-Sep-2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For all five patients EVX-01 induced a specific immune response over time as evidenced by an increase in magnitude of vaccine neoantigen-specific T cells. Further, a clinical benefit was observed in 3 out 5 patients. One patient (patient 10004) presented with progressive disease after 12 weeks of pembrolizumab treatment, indicating unresponsiveness to pembrolizumab. Following EVX-01 administration commencing at week 12, a profound tumor size reduction was observed from week 24 with further reduction at subsequent visits (see figure 25a). At study week 52 a fluorodeoxyglucose positron emission tomography, or FDG PET, scan demonstrated a completed metabolic response with resolution of the FDG avidity (Figure 25b), indicating tumor cell inactivity. </font>
        </div>
        <div style="position:relative;margin-top:8.41pt; text-align:center; width:456pt;">
          <img src="ph_fig25week-4c.jpg" alt="[MISSING IMAGE: ph_fig25week-4c.jpg]" height="223" width="547" >
        </div>
        <div style="margin-top:10.81pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 25: Longitudinal reduction in tumor volume for patient 100004. a) the tumor size was 28 mm at baseline (Oct 2022). Prior to EVX-01 administration and following 12 weeks of pembrolizumab, the patient </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">157</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">presented with Progressive Disease (RECIST1.1 criteria), tumor size 44 mm (Jan 2023). Following EVX-01 administration, the patient started to respond to treatment showing a reduction in tumor size at week 24 (38&#160;mm). This was further confirmed at the assessments week 36 (Jun 2023) and 48 (Sep 2023) where the target lesion was 30 mm and 27 mm, respectively. b) Patient 100004 FDG PET scan demonstrating complete metabolic response at week 52 with resolution of FDG avidity in the right adrenal target lesion.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that the initial data from the EVX-01 Phase&#160;2 study confirm the findings of the EVX-01 Phase&#160;1 study. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">One year data readout is expected in Q3 2024 and full study readout is expected in 2025. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Manufacturing of Our EVX-01 Drug Product</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The peptide-based format used to deliver PIONEER-identified neoantigens in EVX-01 is able to specifically stimulate neoantigen-specific T cells and has a turnaround time of approximately seven weeks from collection of patient-specific biopsies to administration of the therapy. We believe that this seven-week turnaround time is significantly shorter as compared to other current patient-specific, peptide-based, cancer vaccines, which have been shown to have turnaround times of 20 or more weeks. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Our EVX-02 and EVX-03 DNA Product Candidates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Overview</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our additional two personalized cancer vaccines, EVX-02 and EVX-03, developed based on our PIONEER AI model, are in early clinical and late pre-clinical development, respectively. EVX-02 comprise PIONEER top-ranked neoantigens contained in a plasmid DNA and EVX-03 contains a combination of PIONEER predicted neoantigens and ERV antigens. EVX-02 is our product candidate for adjuvant treatment of resectable melanoma, whereas EVX-03 is an improved, next generation vaccine with a proprietary APC targeting unit, intended for treatment of patients with locally advanced or metastatic solid tumors, including non-small cell lung cancer. The goal of the two cancer vaccines is to promote T-cell priming and expansion of cancer-specific effector T cells for direct and specific tumor killing. Both personalized vaccine candidates will be administered to patients in combination with CPI. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Summary</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our pre-clinical studies demonstrated that both EVX-02 and EVX-03 inhibited tumor growth in mice and induced functional therapy-specific T cells. Direct comparison of the potency of EVX-02 and EVX-03 in mice clearly indicated a beneficial effect of the APC targeting unit, as evidenced by a lower tumor protective dose of EVX-03 compared to EVX-02 and higher levels of neoantigen-specific T cells induced by EVX-03 compared to EVX-02. Further, the combination of our EVX-02 DNA therapy and CPI treatment of mice enhanced the antitumor effect, which we believe indicates a positive interplay of the two therapies. Furthermore, a favorable safety profile of EVX-03 in mice was observed in a Good Laboratory Practices, or GLP, toxicology study investigating repeated high doses of EVX-03. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Final data from a first-in-human Phase&#160;1/2a clinical trial investigating the safety, tolerability and pharmacodynamic response of EVX-02, substantiated a promising safety profile and ability to activate neoantigen-specific T cells as well as indicated encouraging clinical outcome data of our first-generation neoantigen DNA therapy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that the data from the EVX-02 Phase&#160;1/2a trial substantiates the clinical relevance of DNA-mediated delivery of neoantigens. We believe that the clinical data from our EVX-02 DNA therapy in combination with the improved EVX-03 anti-tumor effect in pre-clinical models, support moving into a first-in-human Phase&#160;1 clinical trial, investigating the safety and pharmacodynamic effect of EVX-03. To expedite the development of EVX-03, we are actively exploring partnership opportunities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Background</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have chosen to use a DNA-based vaccine format for several reasons: It is well-established that DNA vaccines harbor self-adjuvating capacities as they can activate the innate DNA sensing machinery in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">158</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">mammalian cells. This directs the immune response towards Th1-like immunity which is generally considered to be preferable in cancer therapies. Further, the DNA plasmid allows for full inclusion of highest ranking immunogenic neoantigens. Moreover, with the recent approval of a plasmid DNA vaccine for prevention of severe COVID-19 disease, it is now established that DNA vaccines can induce a clinically relevant immune response. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">When administered to the patient, we expect that the EVX-02 and EVX-03 DNA therapies (see figure&#160;26) will be taken up by APCs and will be expressed as peptides, processed into smaller components, and loaded onto the MHC molecules on the cell surface eliciting an antigen-specific immune response. The APC unit is believed to mediate effective recruitment and activation of APCs to the local site of injection, thus further enhancing the antigen-specific immune response. </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="ph_fig26evx2evx3-4clr.jpg" alt="[MISSING IMAGE: ph_fig26evx2evx3-4clr.jpg]" height="259" width="486" >
        </div>
        <div style="margin-top:12.6pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 26: Illustration of our two neoantigen targeting DNA therapies, EVX-02 and EVX-03. EVX-03 also includes ERV antigen in the antigen unit. Both candidates comprise PIONEER-identified neoantigens inserted as a neoantigen unit into a backbone plasmid with immune stimulating elements. Furthermore, EVX-03 comprises an APC-targeting unit linked to the antigen unit via a dimerization unit, illustrated in dark blue.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our EVX-02 Phase&#160;1/2a Clinical Trial</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The EVX-02 clinical trial is a first-in-human, open label, safety and pharmacodynamic multi-center trial in resectable Stage III/IV melanoma patients (NCT04455503), initiated in the third quarter of 2020. Each patient received, upon tumor resection, a unique EVX-02 vaccine designed based on their tumor genomic fingerprint in combination with PD-1 CPI. Each patient was treated with eight doses of EVX-02 at a two-week interval. Anti-PD-1 therapy was administered before, during and after administration of EVX-02 to unleash the potential of the EVX-02-specific T cells to mediate tumor killing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Data Readout from Our EVX-02 Phase&#160;1/2a Clinical Trial</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;18, 2023, we presented clinical data from our Phase&#160;1/2a first-in-human study of its DNA-based personalized cancer vaccine, EVX-02 in combination with the checkpoint inhibitor nivolumab. Data were presented in the Late Breaking Research: Clinical Research 2 session at the 2023 AACR (American Association for Cancer Research) annual meeting in Orlando, Florida. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The information shared during the 2023 AACR meeting was initially deemed preliminary since, at the time of presentation, the clinical database had not been locked. Final data cleaning and subsequent database lock on 14</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> of July&#160;2023 did not result in any modifications to the data presented at the AACR meeting. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The study, in patients with resected melanoma, showed that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">All 10 patients who received the full dosing schedule of 8 immunizations with EVX-02 were relapse-free at their last assessment </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">159</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Of these 10 patients, 9 completed the full study and were relapse-free at the 12-month end of study visit. One patient was prematurely terminated due to non-EVX-02 related adverse events (AEs), and was relapse-free at the last visit at 9&#160;months </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The combination of EVX-02 and nivolumab was well tolerated and only mild EVX-02-associated AEs were observed </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Robust and long-lasting neoantigen-specific T-cell immune responses were confirmed in all EVX-02 completers </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The induced T-cell immune responses involved both CD4+ and CD8+ T cells </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe the data serve as a validation of our PIONEER platform and provide proof of mechanism for our DNA-based approach to personalized cancer therapies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our EVX-02 and EVX-03 Pre-Clinical Data</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The pharmacological effect of EVX-02 and EVX-03 was addressed in the well-established CT26 syngeneic mouse model of colorectal cancer. As both vaccines are truly personalized and the therapy design is based on each patient&#8217;s individual tumor mutational profile, pre-clinical efficacy testing of personalized EVX-02 and EVX-03 therapies is not feasible. Instead, mouse surrogate compounds were designed by PIONEER through identification of CT26 tumor-specific neoantigens. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In several </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> pharmacology studies, treatment with mouse specific EVX-02 and EVX-03 vaccines, or mEVX-02 and mEVX-03, induced robust, antitumor immunity in the CT26 tumor model (see figure 27A and 29A). Further, detailed complementary </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> analyses, unravelling the mEVX-02 and mEVX-03 induced T-cell responses, demonstrated neoantigen-reactive T cells in immunized mice as evidenced by cytokine positive CD4+ and CD8+ T cells (See figure 27B-C and figure 29B-C, respectively). </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="lc_fig27tumor-4c.jpg" alt="[MISSING IMAGE: lc_fig27tumor-4c.jpg]" height="202" width="473" >
        </div>
        <div style="margin-top:12.61pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 27: In vivo pharmacology study testing the antitumor effect of a mouse EVX-02 surrogate compound, mEVX-02. P-values were calculated using unpaired t-test with Welch&#8217;s correction. A: P&lt;0.001 (tumor volume AUC of Empty plasmid vs mEVX-02); B: P&lt;0.05 Empty plasmid vs mEVX-02, C: P&lt;0.05 Empty plasmid vs mEVX-02.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As shown in Figure 27 above, groups of BALB/c mice were intramuscular, or IM, administered with 100 &#956;g empty plasmid or mEVX-02 plasmids encoding 13 top ranked PIONEER identified CT26 neoantigens. (n=13-14 in both groups). The mice were prophylactically immunized once a week starting two weeks prior to CT26 tumor cell inoculation and the diameters of the tumors were recorded three times a week. Splenocytes from immunized mice were collected at endpoint and restimulated with vaccine relevant peptides for 10 hours. Subsequently the splenocytes were stained with antibodies for detection of intracellular cytokines (IFN</font><font style="font-family:Arial, Helvetica, sans-serif;letter-spacing:-0.067pt;">&#611;</font><font style="letter-spacing:0.2pt;"> and TNF</font><font style="font-family:Times New Roman, Times, serif;letter-spacing:0.35pt;">&#593;</font><font style="letter-spacing:0.2pt;">).</font><font style="font-family:Times New Roman, Times, serif;letter-spacing:0.35pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In an additional </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> pharmacology study, co-treatment with a suboptimal mEVX-02 dose and an anti-mouse PD-1, or mPD-1, antibody led to a combinatorial antitumor effect in a syngeneic tumor model illustrated by an increase in time to reach humane endpoints in mEVX-02 + anti-mPD-1 administered mice compared to single compound treatment groups (see figure 28 below). </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">160</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:108.03pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="lc_fig28isotype-4c.jpg" alt="[MISSING IMAGE: lc_fig28isotype-4c.jpg]" height="273" width="456" >
        </div>
        <div style="margin-top:14.69pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 28: In vivo tumor study investigating the combinatorial effect of mEVX-02 and anti-mPD-1 antibody. P-values were calculated using log-rank (Mantel-Cox) test P&lt;0.01.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In Figure 28, the time to reach either tumor ulceration or a tumor diameter of more than 12 mm, was increased in CT26 tumor bearing BALB/c mice receiving IM injections of a sub-optimal mEVX-02 dose and intraperitoneal, or IP, injections of 200 &#956;g anti-mPD-1 antibody compared to mEVX-02 and anti-PD-1 monotherapy. The anti-PD-1 antibody treatment was initiated when the tumors reached a mean volume 80-100 mm</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">3</font><font style="letter-spacing:0.2pt;"> in the groups receiving mEVX-02 treatment. As control for unspecific antibody mediated antitumor effect, parallel isotype control antibody groups were included (n=12-13 in all groups). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our next-generation DNA vaccine, EVX-03, is, we believe, further optimized by including an APC targeting unit to enhance the antitumor effect. APC-targeting is accomplished by introducing a Chemokine (C-C motif) ligand 19, or CCL19, that selectively engage cell surface receptors on APC populations and additionally directs the neoantigens to the APCs. We believe that this dual mechanism induces an effective and specific immune response. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To address if APC targeting of the neoantigens potentiated the effect of our EVX-03 product candidate, we immunized mice with neoantigen vaccines with and without a targeting unit. Figure 29A below shows that tumor establishment in the majority of mice treated with mouse mEVX-03 was completely prevented compared to mice immunized with a non-APC targeted neoantigen vaccine. Figure 29B below shows that higher levels of neoantigen-reactive T cells were obtained in the mEVX-03 APC targeted group compared to mEVX-03 without an APC targeted unit. Figure 29B and C demonstrate that mEVX-03 induces both a CD4+ and CD8+ neoantigen-specific T-cell response detected by intracellular cytokine staining. We believe that the data clearly demonstrate that the inclusion of the APC targeting unit potentiated the effect of the neoantigen DNA therapy. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">161</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="lc_fig29control-4c.jpg" alt="[MISSING IMAGE: lc_fig29control-4c.jpg]" height="271" width="451" >
        </div>
        <div style="margin-top:10.91pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 29. In vivo pre-clinical data for EVX-03. A: Antitumor effect of mEVX-03 containing 13 PIONEER predicted neoantigens, P&lt;0.0001 (tumor volume AUC of Untreated vs mEVX-03) and P&lt;0.05 tumor volume AUC of mEVX-03 without targeting unit vs mEVX-03. B-C: mEVX-03 induces neoantigen-reactive CD4+ and CD8+ T cells detected by intracellular cytokine staining.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As shown in Figure 29 above, groups of BALB/c mice were intramuscularly, or IM, administered with 5 &#956;g empty plasmid or mEVX-03 plasmids with and without targeting unit (n=13-14 in all groups). The mice were prophylactically immunized once a week starting two weeks prior to CT26 tumor cell inoculation and the diameters of the tumors were recorded three times a week. Splenocytes from immunized mice were collected at endpoint and restimulated with vaccine relevant peptides for 10 hours. Subsequently the splenocytes were stained with antibodies for detection of intracellular cytokines (IFN</font><font style="font-family:Arial, Helvetica, sans-serif;letter-spacing:-0.067pt;">&#611;</font><font style="letter-spacing:0.2pt;"> and TNF</font><font style="font-family:Times New Roman, Times, serif;letter-spacing:0.35pt;">&#593;</font><font style="letter-spacing:0.2pt;">).</font><font style="font-family:Times New Roman, Times, serif;letter-spacing:0.35pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To directly compare the efficacy of mEVX-02 and mEVX-03, we conducted a dose titration study in which mice were immunized with 0.25-5 &#956;g mEVX-02 or mEVX-03. Both DNA therapies reduced the tumor growth dose dependently. With a mEVX-03 dose as low as 0.25 &#956;g, a significant antitumor response was obtained, whereas a dose of 5 &#956;g was required to mediate a similar effect with mEVX-02. The 20-fold difference in pharmacological effective dose of the two DNA therapies and the superior levels of neoantigen-specific T cells induced by EVX-03, clearly substantiate that the addition of the APC targeting unit significantly increases the potency of the DNA therapy. </font>
        </div>
        <div style="position:relative;margin-top:8.41pt; text-align:center; width:456pt;">
          <img src="lc_fig30inoculation-4c.jpg" alt="[MISSING IMAGE: lc_fig30inoculation-4c.jpg]" height="227" width="486" >
        </div>
        <div style="margin-top:10.91pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 30: mEVX-02 A)&#160;and mEVX-03 B)&#160;dose-dependently inhibited the growth of subcutaneous CT26 tumors. Antitumor of EVX-02 and EVX-03 was obtained at doses as low as 5 and 0.25 &#956;g, respectively.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As shown in Figure 30 above, in BALB/c mice IM administered with either 0.25, 2 or 5 &#956;g mEVX-02 or mEVX-03 encoding 13 PIONEER identified CT26 neoantigens, a clear dose-response effect was obtained </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">162</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(n=13-14 in all groups). BALB/c mice were prophylactically treated once a week starting two weeks&#160;prior&#160;to CT26 tumor cell inoculation and the diameters of the tumors were subsequently recorded three times a week. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To assess if ObsERV identified mouse ERV antigens can induce antitumor effects in preclinical models, mice were prophylactically immunized with a mEVX-03 vaccine containing 13 ERV antigens (mEVX-03_ERV13_CT26) derived from the CT26 mouse tumor cell line. The immunized mice developed smaller tumor over time compared to mice administered with a plasmid without ERV antigens (mEVX-03 backbone) (see figure 31A and B). Complementary immune analyses demonstrated induction of ERV-reactive CD4+ and CD8+ T cells detected by intracellular cytokine staining (see figure 31C and D). Collectively, these data qualify ERV-derived sequences as relevant tumor vaccine targets. </font>
        </div>
        <div style="position:relative;margin-top:8.41pt; text-align:center; width:456pt;">
          <img src="lc_fig31backbone-4c.jpg" alt="[MISSING IMAGE: lc_fig31backbone-4c.jpg]" height="188" width="486" >
        </div>
        <div style="margin-top:10.91pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 31: Pre-clinical data for mEVX-03 containing ObsERV&#8482; identified ERV antigens (mEVX-03_ERV_CT26). A-B: Antitumor effect of mEVX-03 with ERV antigens, ** p&lt;0.005, Kruskal-Wallis analysis (tumor volume AUC of mEVX-03 backbone vs mEVX-03_ERV13_CT26). C-D: mEVX-03 induces ERV-reactive CD8+ and CD4+ T cells detected by intracellular cytokine staining.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As shown in Figure 31 above, in BALB/c mice immunized IM with 25 &#956;g mEVX-03 containing 13 ERV antigens (mEVX-03_ERV13_CT26) a clear tumor growth delay was observed compared to mice administered with a plasmid without ERV antigens (mEVX-03 backbone) (n=12 in both groups). BALB/c mice were prophylactically treated once a week starting two weeks prior to CT26 tumor inoculation, and the tumor diameters were subsequently measured three times a week. Splenocytes from immunized mice were collected at endpoint and restimulated with vaccine relevant peptides for 10 hours. Subsequently the splenocytes were stained with antibodies for detection of intracellular cytokines (IFN</font><font style="font-family:Arial, Helvetica, sans-serif;letter-spacing:-0.067pt;">&#611;</font><font style="letter-spacing:0.2pt;"> and TNF</font><font style="font-family:Times New Roman, Times, serif;letter-spacing:0.35pt;">&#593;</font><font style="letter-spacing:0.2pt;">). (n = 2 technical replicates from a pool of splenocytes from 5 mice per group). Group mean was &#177; SD.</font><font style="font-family:Times New Roman, Times, serif;letter-spacing:0.35pt;"> </font>
        </div>
        <div style="margin-top:11.91pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">EVX-03 GLP toxicology study</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In a toxicology study, performed under GLP standards, no organ weight, no macroscopic nor microscopic changes were observed in a repeated dose study in mice, potentially demonstrating a favorable safety profile of the EVX-03 DNA technology. </font>
        </div>
        <div style="position:relative;margin-top:8.4pt; text-align:center; width:456pt;">
          <img src="tb_fig32inoculatnew-4clr.jpg" alt="[MISSING IMAGE: tb_fig32inoculatnew-4clr.jpg]" height="193" width="486" >
        </div>
        <div style="margin-top:10.82pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 32: Results obtained in GLP toxicology study of EVX-03.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">163</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The final report from the GLP toxicology study concluded that EVX-03 administered intramuscularly to BABL/c mice on eight dosing occasions with 2-week intervals was well tolerated and did not cause any adverse changes at local or systemic level. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that the comprehensive </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> pharmacology data package provides clear evidence of complete mEVX-02 and mEVX-03 induced antitumor responses accompanied by induction of reactive CD4+ and CD8+ T cells. Moreover, a beneficial effect was obtained in mice by combining our DNA therapy with CPI treatment, holding great promise for a combination therapy approach in humans. We further believe that our EVX-03 pre-clinical data demonstrates that adding an APC-targeting unit leads to high levels of neoantigen-reactive T cells and significant tumor reduction even at very low doses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Manufacturing</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The production process of a personalized drug consists of multiple steps. For our EVX-02 drug product, DNA plasmids are designed to encode 13 PIONEER identified neoantigens. We have established a manufacturing process with a number of different contract development and manufacturing organizations, or CDMOs, and the entire process from the time of patient biopsy to the time of treatment takes approximately 10 to 12 weeks. With the release of our final batch for EVX-02, we have confirmed our manufacturing process, which we believe will allow us to progress our DNA-based cancer vaccine programs into larger global trials to explore the clinical benefits of the compounds further. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our EVX-03 Clinical Development Plans</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Based on the readout from our Phase&#160;1/2a EVX-02 study demonstrating a favorable safety profile, induction of a robust and long-lasting CD4+ and CD8+ specific T-cell responses as well as a favorable clinical outcome in all patients, we believe we have validated our PIONEER&#8482; AI model, DNA technology and manufacturing process of the DNA therapy. Our next-generation DNA vaccine, EVX-03, is further optimized by including an APC targeting unit thereby leading to improved anti-tumor effect in pre-clinical models. Collectively, we believe these data constitute an attractive out-licensing package for potential partners, supporting progression into a first-in human Phase&#160;1 clinical trial to assess the safety, tolerability and pharmacodynamic effect of EVX-03. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">AI-DeeP&#8482;, Our Proprietary Immuno-Oncology AI Model for Prediction of Drug Response</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have developed AI-DeeP&#8482;, an AI drug response prediction model, that is based on genomic signatures in the tumor microenvironment, neoantigen and ERV burden and seeks to identify patients who may or may not benefit from cancer immunotherapies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As shown in Figure 33 below, we believe AI-DeeP&#8482; identifies patients responding to therapy with high precision from the immunogenomic signatures alone. </font>
        </div>
        <div style="position:relative;margin-top:9.6pt; text-align:center; width:456pt;">
          <img src="lc_fig33clinical-bw.jpg" alt="[MISSING IMAGE: lc_fig33clinical-bw.jpg]" height="233" width="236" >
        </div>
        <div style="margin-top:12.2pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 33: Prediction of patient response to immunotherapy from immunogenomic profiles in baseline tumor biopsy. At enrollment to the Phase&#160;1/2a EVX-01 clinical trial, tumor biopsies were collected from malignant </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">164</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">melanoma patients. Immunogenetic profiling was performed on the tumor biopsies using RNA sequencing. Leave-one-patient-out analysis demonstrated that patient outcomes can be successfully predicted on the 18 patients in the EVX-01 clinical trial. The prediction of patient outcome was found statistically significant (p=0.01) using the permutation test.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We further developed AI-DeeP by including additional genomic signatures as well as neoantigen and ERV burden. We developed a training dataset of 937 patients treated with CPI and used this dataset for model training. When applied to genomic data from CPI treated cancer patients not included in the training dataset, AI-DeeP&#8482; outperforms stratification of patients by classical biomarkers; &#8216;TMB &amp; PD-L1&#8217; (see figure 34). For the three CPI treated cohorts, we can identify 10-30% of the non-responding patients with (progressive disease) with 95% precision versus 70-80% precision with classical biomarkers. Hence, AI-DeeP&#8482; predicts progressive disease patients with high precision thus effectively identifying patients that will not benefit from CPI treatment. We believe this AI model can decrease clinical development risk and increase patient and payer benefit through patient stratification based on predicted likelihood of response to immunotherapy. We continue to generate and acquire data to further develop, validate and increase sensitivity and precision of AI-DeeP&#8482;. </font>
        </div>
        <div style="position:relative;margin-top:9.9pt; text-align:center; width:456pt;">
          <img src="lc_fig34liuhugovan-4c.jpg" alt="[MISSING IMAGE: lc_fig34liuhugovan-4c.jpg]" height="172" width="548" >
        </div>
        <div style="margin-top:12.8pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 34: Prediction of patient response to immunotherapy from genomic profiles, neoantigen and ERV antigen signatures in baseline tumor biopsy. Genomic data of baseline biopsies from 937 CPI treated cancer patients were curated from 14 studies and divided in 3 cohorts. AI-DeeP&#8482; (blue line) predicts a subset of progressive disease patients with high precision. In the anti-PD1 &amp; anti-CTLA4 treated cohort, AI-DeeP&#8482; can identify 10% of the non-responding patients with 95% precision, versus with classical biomarkers (&#8216;TMB &amp; PD-L1&#8217;, red line) with 70% precision. In the anti-PD1 treated cohort, AI-DeeP&#8482; can identify 25% of the non-responding patients with 95% precision, versus with classical biomarkers with 80% precision. In the anti-CTLA4 treated cohort, AI-DeeP&#8482; can identify 30% of the non-responding patients with 95% precision, versus with classical biomarkers with 70% precision.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Bacterial Diseases</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Drug-resistant bacteria pose a major medical and societal issue as bacteria are rapidly becoming resistant to many of the antibiotics that are currently used as standard of care. According to the World Health Organization, or the WHO, antibiotic resistance is one of the biggest threats to global health and it is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common bacterial diseases. A misuse of antibiotics is accelerating this process. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe the development of prophylactic vaccines is the sustainable solution to address and counteract drug-resistant bacterial infections for several reasons, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Vaccines can be used for decades without generating significant resistance </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Vaccines reduce antimicrobial use to further diminish pressure toward resistance </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Vaccines are cost-effective </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The market for combatting drug-resistant bacteria is projected to increase significantly. According to The World Bank, drug-resistant infections could by 2050 cause global economic damage on par with the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">165</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2008 financial crisis. In a recent report by Data Bridges Market Research Group, the Global Bacterial Vaccines Market was valued at $19.68&#160;billion in 2021 and is projected to reach $36.97&#160;billion by 2029, growing at a CAGR of 8.2% from 2022 to 2029. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Bacterial Vaccinology</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Vaccines work by training the immune system to recognize and combat pathogens, such as bacteria, viruses or parasites. To do this, certain molecules, called antigens, from the pathogen must be introduced into the body to trigger a protective immune response. By injecting vaccines containing antigens, the immune system will safely recognize them and trigger an immune response that leads to protective immunity. If the antigen-harboring bacteria or virus appears in the body during an early infection, the immune system will recognize the antigens displayed and immediately attack the pathogen before it can invade and establish a persistent infection and cause disease. The antigens can be surface exposed molecules, secreted toxins or specific virulence factors and by targeting them, the pathogen can more easily be neutralized. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The adaptive immune response following vaccination protects the body from infections by mounting a specific antibody-mediated immune response (B-cell response) and/or a cellular immune response (T-cell response). Antibodies can have different functions, but in general they either lead to neutralization of the pathogen (blocking function of important surface molecules or toxins), opsonization (antibodies bind to pathogen surface and flag them for phagocytosis and killing by immune cells) or complement activation (bound antibodies trigger a cascade of proteins that bind to the pathogen and form a pore that eventually lyses the bacteria or enhances opsonization further). On the other hand, the cellular immune response involves cell-mediated cytotoxicity (killing of infected cells), release of cytokines and chemokines as well as phagocytosis (pathogens are taken up and neutralized by macrophages). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to provoke the correct type of immunity as well as receive long-lasting and high protection, many vaccines include adjuvants as part of the formulation. Different adjuvants systems trigger different parts of the immune system. Even though adjuvants are critical components of the vaccines, they typically do not have protective properties by themselves in the absence of the specific antigens. The use of correct adjuvants in combination with the selected vaccine antigen(s) is important for the vaccine design. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A typical bacterial pathogen consists of thousands of unique proteins, where only a few elicit a protective immune response in a vaccine setting. Modern sequencing technology has enabled detailed insight into the entire genome of several clinical isolates of the same pathogen. This in turn has paved the way for computational antigen selection tools that can select a limited number of vaccine antigen candidates from whole bacterial genomes as a starting point for vaccine development. A challenge in computational, or bioinformatic, predictions, however, is to correctly identify posttranslational modifications and other molecular mechanisms that can change the structure and potential antigenic properties of bacterial antigens and optimize antigens in terms of stability, epitope presentation, ease of production and safety. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EDEN&#8482;&#8201;&#8212;&#8201;Our AI model for the Discovery and Design of Novel Prophylactic B-cell antigen Vaccines for Infectious Diseases</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Overview</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that our AI model EDEN&#8482;, can rapidly identify novel, highly protective antigens for the use in pathogen-specific prophylactic vaccines against drug-resistant bacteria. Within EDEN&#8482;, our proprietary algorithms allow us to predict and identify those antigens that we believe will trigger a robust, protective immune response against almost any pathogen. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The core of our EDEN&#8482; technology is a proprietary machine learning ensemble of artificial neural networks trained using a feed-forward backpropagation approach to interpret immunological-relevant information in relation to infectious disease antigens that incur protection in a vaccine setting. EDEN&#8482; has been trained on our own curated data set derived by trawling through publicly available patents and publications reported to identify truly protective and non-protective antigens tested in clinical and pre-clinical settings. The input to the artificial neural network ensemble is a feature transformation of the protein data set, in which several global and sequence-resolved properties are extracted. These structural and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">166</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:115.89pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">functional features have been selected for their relevance in protein chemistry, immunology and protein structure and ability to guide the network in discriminating protective versus non-protective antigens. </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="ph_fig35bacterial-4c.jpg" alt="[MISSING IMAGE: ph_fig35bacterial-4c.jpg]" height="191" width="547" >
        </div>
        <div style="margin-top:14.69pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 35: EDEN</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8482; </font><font style="letter-spacing:-0.2pt;">is a self-taught AI model that provides important insight into what makes antigens elicit a protective immune response. EDEN</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8482;</font><font style="letter-spacing:-0.2pt;"> identifies novel protective proteins by recognizing abstract features shared with known highly protective proteins.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We believe our approach can be used to target almost any bacterial infection and rapidly enable the discovery and development of vaccine product candidates. We have applied EDEN&#8482; to seven bacterial pathogens to test its predictive power. For each pathogen, EDEN&#8482; identified novel vaccine antigens which were subsequently expressed as proteins and tested in pre-clinical, mouse infection models, demonstrating protection against all seven pathogens. Within these studies, where vaccine formulations were distinguished by variations in EDEN&#8482; scores, we demonstrated the precision of EDEN&#8482;. This precision is evident through the correlation observed between EDEN&#8482; prediction scores and the level of protection in pre-clinical infection models. Notably, EDEN&#8482; outperforms reverse vaccinology (RV) by not only identifying the same bacterial vaccine antigens as RV but also uncovering numerous additional potential vaccine antigens that RV has overlooked, all through computation. By employing proteome-wide AI predictions, this tool not only identifies protective proteins but also predicts the level of protection each protein offers. We intend to develop a broad pipeline of vaccine product candidates using this AI model. EVX-B1, our vaccine candidate for the prevention of </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;">, has completed pre-clinical development and is ready for out-licensing. We are currently focused on the development of EVX-B2/EVX-B2-mRNA, our vaccine candidate for the prevention of </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae</font><font style="letter-spacing:0.2pt;"> infections, and EVX-B3, a vaccine against an undisclosed bacterial pathogen with a high medical need where no vaccine is currently available. Furthermore, we believe EDEN&#8482; is applicable in virus vaccine development, hence is applied in the development of a virus vaccine EVX-V1 against cytomegalovirus (CMV). We develop our vaccine candidates through pre-clinical development with the ambition to enter co-development or out-licensing partnerships prior to clinical development. EVX-B2-mRNA, EVX-B3 and EVX-V1 are being co-developed with the pharmaceutical company Afrigen Biologics, with an undisclosed leading pharmaceutical partner and the company Expres2ion Biotechnologies, respectively. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">167</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="fc_fig36discovery-4c.jpg" alt="[MISSING IMAGE: fc_fig36discovery-4c.jpg]" height="353" width="396" >
        </div>
        <div style="margin-top:13.2pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 36: Our approach to bacterial vaccine discovery and design. To identify novel, broadly protective antigens for bacterial vaccines, EDEN&#8482; utilizes proteomes from clinically relevant bacterial strains as input. EDEN&#8482; then identifies unique feature combinations and ranks all proteins according to their predicted probability of eliciting a protective immune response. The EDEN&#8482; output is a ranked list of protective antigens, of which the highest ranking are selected, and constructs are designed and produced. Verification of protection and immunogenicity is conducted with pre-clinical models and assays, and if needed, further optimization steps follow, to finally derive at a CMC ready, potent product candidate.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Key Advantages of our EDEN</font><font style="letter-spacing:0.2pt;">&#8482; </font><font style="font-style:italic;letter-spacing:0.2pt;">Model</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that our AI-based vaccine discovery and design approach for bacterial diseases has several advantages over more traditional approaches, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Ability to Predict Protective Vaccine Antigens:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The ability of EDEN&#8482; to predict protective vaccine antigens has been shown in pre-clinical models. Once clinically validated, we believe our approach may have the ability to improve on the attrition rates for new vaccine product candidates. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Identification of Novel and Unbiased Targets</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;EDEN&#8482; has been trained to identify the underlying feature patterns (e.g. structural or immunological elements) that we believe are important for protection to enable discovery of novel and unbiased targets that are not necessarily homologous to existing products. Traditional reverse vaccinology, or RV, relies heavily on sequence homology (proteins identical to previously tested antigens) in antigen identification. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Data Driven Precision</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;With carefully curated data, we believe EDEN&#8482; has learned to filter away irrelevant proteins, narrowing the field of candidates substantially from thousands to a few dozen proteins, reducing the burden on pre-clinical development. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Ability to Provide Broad Protection</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;The rapid &#8220;evolution&#8221; of the genome that can occur in some bacterial pathogens makes it difficult to capture all pathogen strains by a single vaccine. EDEN&#8482; is capable of leveraging genomic sequencing data to find important targets or domains that are present in the majority of clinical strains. By combining the correct antigens, we believe that most, if not all, relevant strains can be covered. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Speed</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;Traditionally, developing and verifying the safety and efficacy of a novel vaccine takes between 10 to 15&#160;years, often resulting in a new vaccine arriving too late on the market to influence </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">168</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:94.48pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">the spread of infections to the general population. We believe that EDEN&#8482; is capable of identifying vaccine antigens in a matter of weeks instead of&#160;years thus potentially lowering the overall development time significantly. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We are continuously improving our EDEN&#8482; model to ensure it remains state-of-the-art and incorporates multiple aspects of vaccine development from discovery to clinical testing. We explore among other improvements, incorporation of new translational features and data into EDEN&#8482;, novel machine learning architectures such as deep learning and probabilistic programming to enhance protein structure and function prediction, generation of novel high-throughput data to be incorporated into our AI technology for assessment of solubility and CMC-readiness and methods for determining broadness of protection across strains. By continuous improvement in all aspects of vaccine development, we believe the EDEN&#8482; model will continue to produce potent vaccine product candidates with minimal testing required before entering clinical development. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">EDEN</font><font style="letter-spacing:0.2pt;">&#8482; </font><font style="font-style:italic;letter-spacing:0.2pt;">Prospective In Vivo PoC Showing Remarkable Predictive Precision</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To obtain initial </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> PoC, EDEN&#8482; was applied to seven bacterial pathogens reported to exhibit resistance to standard antibiotics, identifying both novel and known antigens. For each pathogen, EDEN&#8482; identified vaccine antigens were expressed as proteins and their protective ability tested in pre-clinical infection models. IP rights have been filed for all identified targets conferring significant protection. See table below for overview: </font>
        </div>
        <table style="width:456pt;height:158.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:191.77pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Bacterial species </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:22.13pt;text-align:center;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:-0.16pt;">In vivo</font>
                <br >
                <font style="font-style:normal;letter-spacing:-0.16pt;">PoC </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:191.77pt;">
              <div style="white-space:nowrap;font-style:italic;">
                <font style="letter-spacing:-0.16pt;">In vivo</font><font style="font-style:normal;letter-spacing:-0.16pt;"> model (mouse challenge models) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:14.33pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">IP</font>
                <br >
                <font style="letter-spacing:-0.16pt;">filed </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:191.77pt;">
              <div style="font-style:italic;">
                <font style="letter-spacing:0.2pt;">Staphylococcus aureus</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:22.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#10003; </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:191.77pt;">
              <font style="letter-spacing:0.2pt;">Lethal peritonitis and skin abscess model </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:14.33pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#10003; </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:191.77pt;">
              <div style="font-style:italic;">
                <font style="letter-spacing:0.2pt;">Pseudomonas aeruginosa</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:22.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#10003; </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:191.77pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Lethal peritonitis and lethal acute pneumonia model </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:14.33pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#10003; </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:191.77pt;">
              <div style="font-style:italic;">
                <font style="letter-spacing:0.2pt;">Non-typeable Haemophilus influenzae</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:22.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#10003; </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:191.77pt;">
              <font style="letter-spacing:0.2pt;">Lung colonization model </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:14.33pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#10003; </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:191.77pt;">
              <div style="font-style:italic;">
                <font style="letter-spacing:0.2pt;">Moraxella catarrhalis</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:22.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#10003; </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:191.77pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Lethal peritonitis and lung colonization model </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:14.33pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#10003; </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:191.77pt;">
              <div style="font-style:italic;">
                <font style="letter-spacing:0.2pt;">Neisseria gonorrhoeae</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:22.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#10003; </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:191.77pt;">
              <font style="letter-spacing:0.2pt;">Vaginal colonization model </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:14.33pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#10003; </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:191.77pt;">
              <div style="font-style:italic;">
                <font style="letter-spacing:0.2pt;">Acinetobacter baumannii</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:22.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#10003; </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:191.77pt;">
              <font style="letter-spacing:0.2pt;">Lethal acute pneumonia model </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:14.33pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#10003; </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:191.77pt;">
              <div style="font-style:italic;">
                <font style="letter-spacing:0.2pt;">Klebsiella pneumoniae</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:22.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#10003; </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:191.77pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Lethal peritonitis and lethal acute pneumonia model </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:14.33pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:9.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In the protective PoC studies, where vaccine formulations could be distinguished by variations in EDEN&#8482; scores, the results are depicted in Figure 37 below. This illustration demonstrates the precision of EDEN&#8482;, showing that the EDEN&#8482; prediction score correlates with the level of protection in pre-clinical infection models. There exists a significant correlation between the protein-specific EDEN&#8482; prediction score and the actual in vivo and in vitro protection in mice across four bacteria, encompassing gram-positive and gram-negative strains. This correlation strongly supports the notion that the top EDEN&#8482; antigens are indeed the most optimal B-cell antigens for use in a given bacterial vaccine. This discovery holds promise for reducing risk and cost in the development of infectious disease vaccines. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">169</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:51.55pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="lc_fig37neisseria-bw.jpg" alt="[MISSING IMAGE: lc_fig37neisseria-bw.jpg]" height="473" width="547" >
        </div>
        <div style="margin-top:14.69pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 37: Correlation between EDEN prediction and protection. The EDEN&#8482; score shows a strong correlation with both the in vivo and in vitro efficacy of vaccine targets. This correlation is evident in various instances, such as the EDEN&#8482; score&#8217;s association with increased in vivo bacterial clearance across multiple N. gonorrhea strains in a vaginal colonization model, as well as its correlation with in vitro bacteria killing. Furthermore, the EDEN&#8482; score demonstrates a correlation with a reduced p-value for in vivo survival in challenge models involving S. aureus, A. baumannii, and K. pneumoniae, signifying increased survival.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">EDEN&#8482; Retrospective Proof of Concept</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our retrospective Proof of Concept of EDEN&#8482; utilized a published reverse vaccinology (RV) study. Figure 38 below demonstrates EDEN&#8482; model&#8217;s superior computational approach, not only identifying the same bacterial vaccine antigens as RV but also uncovering numerous additional potential antigens overlooked by RV. Specifically, EDEN swiftly analyzed the S. pyogenes proteome, identifying all six highly protective antigens within days, a process that took&#160;years using RV. Additionally, EDEN uncovered the &#8216;M protein&#8217; and 15 novel potential vaccine antigens among its top-ranked proteins, overlooked by RV. We believe this discovery approach promises cost-effective infectious disease vaccine development, surpassing RV by revealing known and overlooked antigens solely through computational methods. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">170</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="fc_fig38eden-4clr.jpg" alt="[MISSING IMAGE: fc_fig38eden-4clr.jpg]" height="320" width="457" >
        </div>
        <div style="margin-top:13.99pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 38: EDEN&#8482; outperform Reverse Vaccinology. The Group A Streptococcus (GAS) proteome, consisting of approximately 1700 proteins, underwent EDEN&#8482; processing. Within days of computational processing, EDEN&#8482; ranked the proteome proteins based on the probability of being optimal vaccine antigens. Among the top 30 EDEN&#8482; ranked proteins were the same six best-performing antigens identified by reverse vaccinology, along with the well-known highly protective M protein and 15 novel antigens.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Our EVX-B1 Product Candidate</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Overview</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our EVX-B1 product candidate is a multi-component subunit prophylactic vaccine, initially being developed for the prevention of SSTI in patients undergoing elective hernia surgery. EVX-B1 includes two proprietary and protective antigens identified by EDEN&#8482; in combination with two known toxins that play a key role in </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> pathogenesis formulated together with an adjuvant, CAF01. EVX-B1 is intended to be administered prior to surgery. Upon administration to the patient, we believe that EVX-B1 will significantly reduce </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> related SSTI. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">EVX-B1 has completed pre-clinical development. We intend to partner EVX-B1 prior to start of manufacturing and clinical assessment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Previous attempts to design vaccines to combat </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> have not been successful. We believe EVX-B1 is a highly competitive vaccine capable of out-performing other programs in clinical development as it has been designed to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Include Novel Antigens with High Protection Abilities</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Our proprietary AI model EDEN&#8482; has identified several novel vaccine antigens and of these, two have been selected based on protection levels observed in different pre-clinical animal models such as sepsis and skin abscess, and when using multiple challenge strains. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Induce Broad and Effective Protection</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;By including antigens widely present and highly conserved among multiple clinically relevant strains, the vaccine will have a broad coverage and effectively address the medical need. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Include Multiple Antigens</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;By including multiple antigens with conserved B- and T-cell epitopes, the infecting bacteria is attacked from several angles and critical functions needed for bacterial pathogenicity, persistence and growth are targeted. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">171</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Target Critical Toxins</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;To increase protection even further, EVX-B1 includes a proprietary designed toxoid fusion protein targeting two critical toxins released by the bacteria during infection. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Include a Potent Adjuvant</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;By including the liposomal adjuvant CAF01, driving a balanced Th1 and Th17 type of immune response, we believe the vaccine induces the most optimal response needed to combat the pathogen. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Addressable Market for EVX-B1</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> is responsible for significant morbidity and mortality worldwide and antibiotic-resistant </font><font style="font-style:italic;letter-spacing:0.2pt;">S.&#160;aureus</font><font style="letter-spacing:0.2pt;">, and in particular MRSA infections, are, according to the CDC, of critical concern and remain a prevention priority. In the United States, </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> is estimated to cause 20,000 deaths and amount to a total bill of $15&#160;billion on the health service annually. According to an IMARC Group Research Report, the global MRSA drugs market size reached US$ 3.6&#160;billion in 2022. Looking forward, it is expected that the global market will reach US$ 4.5&#160;billion by 2028, exhibiting a CAGR of 3.6% during 2023-2028. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are initially developing EVX-B1 for the prevention of </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> induced SSTI in patients undergoing hernia surgery. To date, no prophylactic vaccine for the prevention of </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> infections has received marketing authorization. With the development of EVX-B1, we are addressing this unmet medical need and believe our candidate has the potential to be the first vaccine to receive approval for the prevention of </font><font style="font-style:italic;letter-spacing:0.2pt;">S.&#160;aureus</font><font style="letter-spacing:0.2pt;"> infections. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our EVX-B1 Pre-Clinical Data</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EVX-B1 is a multicomponent vaccine, consisting of three components to derive a strong vaccine candidate: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Novel, EDEN&#8482;-identified vaccine antigens evaluated in pre-clinical protection and challenge studies and with critical functions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Uniquely designed toxoids selected from a long list of relevant toxins and pre-clinically evaluated as single proteins and fusion protein constructs. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Adjuvant selected based on pre-clinical tests and optimal profile for clinical indication. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each component has been carefully tested and evaluated pre-clinically as outlined in Figure 39 below. </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="fc_fig39vaccine-4c.jpg" alt="[MISSING IMAGE: fc_fig39vaccine-4c.jpg]" height="222" width="456" >
        </div>
        <div style="margin-top:12.6pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 39: Multicomponent approach to the development of EVX-B1.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Evaluation and Selection of Vaccine Antigens</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We applied EDEN&#8482; to the proteome of </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> to predict the antigens most likely to induce protective immunity. Forty-four (44) novel vaccine antigens were identified, expressed as recombinant proteins and assessed for protection in a </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> mouse sepsis model. Of these, 13 antigens demonstrated consistent high and significant protection in this model. The protection data is summarized in the table below: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">172</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:221.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:103.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;"># </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:43.12pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Protein</font>
                <br >
                <font style="letter-spacing:-0.16pt;">ID </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">No. of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Experiments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">No. of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Test</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Mice </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">No. of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Control</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Mice </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">%</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Survival of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Test Mice </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">%</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Survival of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Control Mice </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Difference in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">% Survival</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Test vs. Control) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:103.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:43.12pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">EDEN-1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">59</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">60</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">76<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">28<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">48<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.12pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">EDEN-2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">58<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">13<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">46<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">3 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.12pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">EDEN-3 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">44</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">77<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">32<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">45<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">4 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.12pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">EDEN-4 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">68<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">25<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">43<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">5 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.12pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">EDEN-5 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">68<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">25<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">43<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">6 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.12pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">EDEN-6 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">85<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">43<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">42<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">7 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.12pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">EDEN-7 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">61<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">19<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">42<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">8 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.12pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">EDEN-8 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">61</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">64</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">51<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">41<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">9 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.12pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">EDEN-9 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">44</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">63<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">30<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">33<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">10 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.12pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">EDEN-10 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">69<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">36<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">33<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">11 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.12pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">EDEN-11 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">32</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">35</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">53<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">20<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">33<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">12 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.12pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">EDEN-12 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">62<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">31<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">31<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">13 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.12pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">EDEN-13 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:18.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:5.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:7.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">47<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">28<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.26pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">19<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:23.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.01pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 13 antigens were further subject to extensive bioinformatic analyses to determine their function. Also, early production and formulation characteristics were addressed. Two antigens were selected based on the following parameters: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Level of protection in different challenge models and against different </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> challenge strains as single antigens and as part of a fusion protein construct. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Virulence functions critical for </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> pathogenicity and infection, including evasion of innate and adaptive immunity, secretion of virulence factors and toxins and replication, verified by functional assays. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Attractive CMC profile of the individual constructs </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:7.12pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The two lead antigens were designed and expressed as one fusion protein, EDEN-Fusion-1. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Evaluation and Selection of Toxins</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have evaluated multiple </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> toxins and selected the two most promising candidates for our proprietary toxoid fusion protein, which has demonstrated protection in sepsis models and skin abscess models of infection using two different challenge strains. Our toxoid fusion protein, Hla-LukE, includes inactivated forms of &alpha;-hemolysin (Hla) and Leukotoxin E (LukE), two toxoids having demonstrated high levels of protection when assessed in animal models amongst publicly described </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> toxins. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Evaluation and Selection of Adjuvant</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The vaccine antigens will be formulated with CAF01, a potent cationic liposomal adjuvant. The hallmark for CAF01 is its ability to induce CD4+ T-cell responses, especially Th1 cells and Th17 cells after parenteral vaccination with strong antibody response. CAF01 has been used in other vaccine programs undergoing clinical testing (in Tuberculosis and Chlamydia) and has an attractive safety and immunogenicity profile. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our EVX-B1 Product Candidate</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EVX-B1 will include two EDEN&#8482; predicted antigens as one fusion protein (EDEN-Fusion-1), two toxins as one toxoid fusion protein (Hla-LukE). EVX-B1 will therefore comprise a total of four antigens expressed as two fusion protein constructs and formulated with CAF01. All protein constructs are engineered to be proprietary to Evaxion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pre-clinical data testing our EVX-B1 product demonstrated highly significant levels of protection in two different challenge models (Figure 40 and 41) and high IgG titers (Figure 42), suggesting good overall immunogenicity. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">173</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:33.66pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="lc_fig40evxb1-4c.jpg" alt="[MISSING IMAGE: lc_fig40evxb1-4c.jpg]" height="205" width="382" >
        </div>
        <div style="margin-top:14.69pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 40: Assessing protection of EVX-B1 in a mouse sepsis model. Survival proportions of mice having received EVX-B1 product or PBS was followed for 7&#160;days post infection (p.i.). Statistical analysis was performed using Log-rank Mantel-Cox test (p-value &lt;0.0001****).</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Figure 40 above shows that EVX-B1 is inducing 79% protection compared to control (PBS) in a mouse sepsis model using </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> USA300 for challenge. </font>
        </div>
        <div style="position:relative;margin-top:11.2pt; text-align:center; width:456pt;">
          <img src="lc_fig41abcess-4c.jpg" alt="[MISSING IMAGE: lc_fig41abcess-4c.jpg]" height="348" width="268" >
        </div>
        <div style="margin-top:14.69pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 41: Assessing protection of EVX-B1 in a mouse skin infection model. Abscess sizes are presented as area under the curve (AUC) for individual mice and mean with standard deviation. Statistical significance was calculated with Mann-Whitney test (p-value &lt;0.0001****).</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Figure 41 above shows that EVX-B1 is inducing highly significant protection compared to control (PBS) in an abscess mouse model of infection using </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> USA300 for challenge. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">174</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="lc_fig42halfmax-4c.jpg" alt="[MISSING IMAGE: lc_fig42halfmax-4c.jpg]" height="257" width="271" >
        </div>
        <div style="margin-top:14.69pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 42: IgG titers. Mice were immunized with EVX-B1. IgG titers are shown as half-max titers for individual mice, groups median values and 95% confidence interwall are shown.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to study the immune response following immunization, IgG titers were investigated. Figure 42 above shows that the EVX-B1 product induce high IgG titers specific for both of the two fusion protein constructs, EDEN-Fusion-1 and Hla-LukE, and holds promise for continued development. </font>
        </div>
        <div style="position:relative;margin-top:11.2pt; text-align:center; width:456pt;">
          <img src="bc_fig43kidneys-4c.jpg" alt="[MISSING IMAGE: bc_fig43kidneys-4c.jpg]" height="241" width="271" >
        </div>
        <div style="margin-top:14.69pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 43: EVX-B1 prevents both disease and infection. EVX-B1 immunized mice having survived a lethal challenge with S. aureus USA300 have also cleared the infection from internal organs (kidneys) 30&#160;days after infection. This is not observed for mice having received only the adjuvant CAF01. This demonstrates that EVX-B1 not only prevents disease but also prevents infection. Bacterial numbers as colony forming&#160;units (CFU) in individual kidneys from mice are shown.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To study if EVX-B1 can not only prevent disease but also prevent infection, we challenged CAF01 and EVX-B1 immunized mice with </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> USA300 in a sepsis model. Surviving mice were left for 30&#160;days before they were sacrificed, and several organs tested for presence of </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> bacteria. None of the organs collected (kidneys, heart and spleens) from EVX-B1 immunized mice (5 mice) showed any presence of bacteria, suggesting that EVX-B1 not only prevents disease but also prevents infection (See figure 43). In contrast three of five mice having received only the adjuvant CAF01 showed high numbers of bacteria in organs. We believe this important data holds much promise for the future EVX-B1 product. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">175</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our EVX-B1 Development Plan</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe the pre-clinical data package demonstrates that our EDEN&#8482; platform is capable of identifying highly protective antigens based on the bacterium proteome. A finding we believe holds true for multiple bacteria with diverse pathogenicity, emphasizing the broad usability of the AI model. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EVX-B1 is currently in pre-clinical development, and we plan to assess the final formulation of EVX-B1 in a non-clinical, repeat dose toxicity study and to partner the candidate prior to start of manufacturing and clinical assessment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Our EVX-B2 Product Candidate</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Overview</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our EVX-B2 prophylactic vaccine candidate is being developed to target all diseases caused by </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae</font><font style="letter-spacing:0.2pt;">. Gonorrhea is a sexually transmitted bacterial infection which has developed resistance to many commonly used antibiotics and represents a large unmet medical need. EVX-B2 is currently in pre-clinical development. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EVX-B2 is a gonorrhea vaccine candidate composed of one fusion protein with two antigen subunits and formulated with the adjuvant GLA-SE. We believe that our EVX-B2 vaccine candidate will induce a protective immune response against </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae</font><font style="letter-spacing:0.2pt;"> and thereby minimize the risk of infection for the general population and groups at risk. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, the EVX-B2 vaccine candidate is currently being evaluated for suitability in DNA and mRNA vaccine delivery platforms. In September&#160;2022, together with UMass Chan Medical School, we received a grant from the NIH to support this strategy and the further development of our EVX-B2 vaccine candidate. Furthermore, in September&#160;2023, we initiated a collaboration with Afrigen Biologics with the goal of developing an mRNA-based gonorrhea vaccine for low- and middle-income countries, or LMICs. The mRNA vaccine will be based on the same EDEN&#8482; discovered antigens having demonstrated high levels of protection in preclinical studies. This partnership will explore the expression and biological activity of the antigens in mRNA format. Following the validation phase, Evaxion and Afrigen Biologics will negotiate a subsequent agreement for clinical development and commercialization, with the opportunity to bring in additional partners. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Addressable Market for EVX-B2</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Identified by the CDC as one of the five most urgent antibiotic resistance threats, gonorrhea can result in ectopic pregnancy, infertility, newborn blindness and life-threatening sepsis. Each year, more than 80&#160;million global cases of gonorrhea infections show resistance to at least one of the commonly used antibiotics. As one of the world&#8217;s most urgent antibiotic-resistance threats with no vaccine available, we believe that the development of a safe and efficacious gonorrhea vaccine is critical, fills a major unmet medical need and addresses a global public health concern. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Evaluation and Selection of Vaccine Antigens</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EVX-B2 was developed using our, proprietary AI model EDEN&#8482; for B-cell antigen discovery, to identify novel and, we believe, highly efficacious B-cell antigen vaccine targets. Ten proteomes of </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae</font><font style="letter-spacing:0.2pt;"> were processed through EDEN&#8482;. The strains were selected to represent the </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae</font><font style="letter-spacing:0.2pt;"> phylogenetic landscape and include several different antibiotic resistance profiles. EDEN&#8482; identified several </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae</font><font style="letter-spacing:0.2pt;"> vaccine antigens. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Out of the 30 top-ranking antigens identified by EDEN&#8482;, 26 were successfully expressed and purified as recombinant proteins and tested for their protection and immunogenicity in mice in collaboration with UMass Chan Medical School. The proteins were tested in 11 combinations each comprising two to three antigens formulated together with the adjuvant Glucopyranosyl Lipid A Stable oil-in-water Emulsion, or GLA-SE. Further, the ability of immune sera to neutralize different </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae</font><font style="letter-spacing:0.2pt;"> strains in a bactericidal assay was studied. The data demonstrated a total of 11 antigens that showed significant protection in a mouse vaginal colonization model and induced immune sera with demonstrated bactericidal activity against at </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">176</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:19.68pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">least two </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae</font><font style="letter-spacing:0.2pt;"> strains. One combination with two EDEN&#8482; identified antigens (NGO0265 and NGO1549) induced immune sera capable of killing all four tested </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae</font><font style="letter-spacing:0.2pt;"> strains and showed protection against a highly antibiotic resistant challenge strain in mice. Based on these promising results, NGO0265 and NGO1549 were selected for further evaluation as vaccine antigens. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Evaluation and Selection of Adjuvant</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We have evaluated different adjuvants together with the antigens and their combined effect to induce antigen-specific antibody responses, bactericidal activity and protection </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;">. GLA-SE was identified to have the highest adjuvanting capacity on the antigens, resulting in a formulation with high immunogenicity and protective efficacy </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">GLA-SE is a synthetic analog of Monophosphoryl Lipid A (MPL). GLA-SE has been included in multiple vaccine formulations and the adjuvant has been confirmed to have a favorable immunogenicity and safety profile. The adjuvant induces a Th1 skewed immune response. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Fusion Protein Generation and Pre-Clinical Development</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To reduce the number of proteins required for vaccine production and thereby the associated costs, a fusion protein construct combining the two lead antigen candidates, NGO0265 and NGO1549, was produced. The EVX-B2 formulation (see figure 44), consisting of the fusion protein together with the adjuvant GLA-SE was tested for protection in the vaginal colonization model. </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="fc_fig44glase-4c.jpg" alt="[MISSING IMAGE: fc_fig44glase-4c.jpg]" height="337" width="324" >
        </div>
        <div style="margin-top:14.69pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 44. EVX-B2 is composed of a fusion protein of NGO0265 and NGO1549 formulated with adjuvant GLA-SE.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Immunization with EVX-B2 enhanced the bacterial clearance rate with a strong reduction of bacterial burden from three days and complete bacterial clearance seven days after challenge compared to adjuvant controls where infection was still detectable 10&#160;days after challenge (Figure 45). </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">177</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="lc_fig45evxb2-4c.jpg" alt="[MISSING IMAGE: lc_fig45evxb2-4c.jpg]" height="260" width="249" >
        </div>
        <div style="margin-top:12.01pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 45. EVX-B2 induce significant protection against challenge in a N. gonorrhoeae vaginal colonization model. Mice received three immunizations and were challenged intravaginally two weeks after the last booster. Vaginal bacterial burden was measured daily to determine bacterial clearance rate. Statistical significance was calculated with Kruskal-Wallis test (Dunn&#8217;s multiple comparison test) (p-value = 0.0029**).</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have also tested the antigen&#8217;s protective capacity when given individually to mice in a vaginal colonization model. In Figure 46 below, mice were immunized with NGO0265, NGO1549, the combination of both proteins or the EVX-B2 product candidate, including the fusion protein. Mice were challenged with </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae,</font><font style="letter-spacing:0.2pt;"> and the number of bacteria was followed over time. Both proteins individually induced protection compared to the control group, having received only adjuvant GLA-SE. The protection was even enhanced for the fusion protein, which is included in the EVX-B2 product candidate. </font>
        </div>
        <div style="position:relative;margin-top:9.2pt; text-align:center; width:456pt;">
          <img src="lc_fig46auclog-4c.jpg" alt="[MISSING IMAGE: lc_fig46auclog-4c.jpg]" height="354" width="296" >
        </div>
        <div style="margin-top:12.01pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 46. Both antigens used in the product candidate induce protection, which was enhanced when the antigens were fused together, as was the case in EVX-B2. Female BALB/c mice were immunized with three intramuscular injections of NGO0265, NGO1549, both proteins combined, or EVX-B2 including the fusion protein, using a 3-week schedule. Mice were challenged intravaginally with N. gonorrhoeae and the bacterial </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">178</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">burden in vaginal swabs was monitored for 8&#160;days. Bacterial clearance was determined as log</font><font style=" position:relative; bottom:-2.25pt;font-size:7.5pt;letter-spacing:-0.15pt;">10</font><font style="letter-spacing:-0.2pt;"> colony forming&#160;units (CFU) detected over time and the resulting area under the curve (AUC) was calculated. Statistical significance was calculated with Kruskal-Wallis test (p-value &lt;0.01**, p-value &lt;0.001***)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">EVX-B2 was also shown to be highly immunogenic in mice, inducing fusion-protein specific antibody responses already after one dose (Figure 47). This antibody response is further increased with subsequent second and third immunization doses (see figure 47). </font>
        </div>
        <div style="position:relative;margin-top:10.3pt; text-align:center; width:456pt;">
          <img src="bc_fig47immunization-4c.jpg" alt="[MISSING IMAGE: bc_fig47immunization-4c.jpg]" height="249" width="295" >
        </div>
        <div style="margin-top:13.59pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 47. EVX-B2 demonstrates high level of immunogenicity as specific antibodies can be detected already after one immunization. Furthermore, a significant booster effect after the second and the third immunization can be detected. The bars represent median values of OD</font><font style=" position:relative; bottom:-2.25pt;font-size:7.5pt;letter-spacing:-0.15pt;">405</font><font style="letter-spacing:-0.2pt;"> nm measured with a 1/100 sera dilution.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The EVX-B2 formulation has also been shown to induce a strong cellular immune response. Antigen-specific IFN</font><font style="font-family:Arial, Helvetica, sans-serif;letter-spacing:-0.067pt;">&#611;</font><font style="letter-spacing:0.2pt;"> T-cell responses against both antigen candidates (NGO0265 and NGO1549) were induced in mice immunized with EVX-B2 (see figure 48). Also, three immunizations with the vaccine candidate EVX-B2 (CHIM_0265_1549 formulated in GLA-SE) raised a higher IFN</font><font style="font-family:Arial, Helvetica, sans-serif;letter-spacing:-0.067pt;">&#611;</font><font style="letter-spacing:0.2pt;"> T-cell response than immunization with a combination of individual NGO0265 and NGO1549 formulated with GLA-SE. We believe these data are very promising as they suggest that a strong Th1 type of immune response is induced following immunization with EVX-B2.</font><font style="font-family:Arial, Helvetica, sans-serif;letter-spacing:-0.067pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.3pt; text-align:center; width:456pt;">
          <img src="bc_fig48splenocytes-4c.jpg" alt="[MISSING IMAGE: bc_fig48splenocytes-4c.jpg]" height="122" width="426" >
        </div>
        <div style="margin-top:13.59pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 48. Female BALB/c mice were administered three intramuscular immunizations with either a combination of NGO0265 and NGO1549 or EVX-B2 (CHIM_0265_1549) using a 3-week schedule. Both formulations included adjuvant GLA-SE. Spleens were collected two weeks after the last immunization, and splenocytes were restimulated with full-length protein as indicated on the x-axis (NGO0265, NGO1549, or CHIM_0265_1549). Antigen-specific IFN</font><font style="font-family:Arial, Helvetica, sans-serif;">&#611;</font><font style="letter-spacing:-0.2pt;"> T-cell responses against both antigen candidates (NGO0265 and NGO1549) were induced by EVX-B2 (CHIM_0265_1549). Furthermore, three immunizations with EVX-B2 raised a higher IFN</font><font style="font-family:Arial, Helvetica, sans-serif;">&#611;</font><font style="letter-spacing:-0.2pt;"> T-cell response than immunization with a combination of NGO0265 and NGO1549.</font><font style="font-style:normal;font-weight:normal;font-family:Arial, Helvetica, sans-serif;letter-spacing:-0.067pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, the EVX-B2 induced antibody response demonstrated a high level of bacterial killing activity against a large number of clinically relevant </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae</font><font style="letter-spacing:0.2pt;"> isolates. As shown in Figure 49, all 50 (100%) different </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae</font><font style="letter-spacing:0.2pt;"> strains tested were efficiently killed by EVX-B2 immune sera, using either </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">179</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">20% or 40% immune serum. We therefore believe the vaccine has the potential to present protection against a majority of global </font><font style="font-style:italic;letter-spacing:0.2pt;">N. gonorrhoeae</font><font style="letter-spacing:0.2pt;"> strains. </font>
        </div>
        <table style="width:456pt;height:131pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;min-height:11pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:328pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">20% serum </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:116pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">40% serum </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:125pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 16pt 0pt; width:328pt;">
              <div style="position:relative;">
                <img src="bc_fig49akilling-4c.jpg" alt="[MISSING IMAGE: bc_fig49akilling-4c.jpg]" height="140" width="426" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0.5pt 20pt 0pt; width:116pt;text-align:right;">
              <div style="position:relative;text-align:right;">
                <img src="bc_fig49killing-4c.jpg" alt="[MISSING IMAGE: bc_fig49killing-4c.jpg]" height="135" width="155" >
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.62pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 49. EVX-B2 demonstrates broad protection in a bactericidal assay using a panel of 50 different relevant clinical isolates with &gt;50% bactericidal killing recognized as efficacy. Two different immune serum concentrations were used, 20% and 40%, together with 20% normal human serum as a source of complement and bacterial survival was assessed after 30 min.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.61pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe the pre-clinical and bactericidal data generated to date holds great promise for future vaccine development and the population at risk. </font>
        </div>
        <div style="margin-top:10.72pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Our EVX-B3 Product Candidate</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have expanded Evaxion&#8217;s preclinical bacterial vaccine pipeline through a new collaboration with a leading pharmaceutical company. The EVX-B3 project is a collaboration with a company that has strong scientific alignment and complementary skill sets and capabilities. EVX-B3 is a vaccine discovery project addressing a serious global medical issue by targeting a pathogen associated with repeated infections, increasing incidence, and often serious medical complications for which no vaccines are currently available. Evaxion&#8217;s proprietary AI-Immunology&#8482; platform, with the EDEN&#8482; and the RAVEN&#8482; models, will be utilized for the rapid design of a completely novel vaccine candidate capable of eliciting both a strong humoral (antibody) and cellular (T cell) immune response to the bacterial pathogen. </font>
        </div>
        <div style="margin-top:10.62pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Viral disease Background</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Newly emerging and reemerging infectious viral diseases have threatened humanity throughout history and the advent of globalization have accelerated both the emergence and spread of human and animal viruses as existential human threats. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the coronavirus disease 2019 (COVID-19) pandemic engulfed the entire world in less than six&#160;months with high mortality in the elderly and those with associated comorbidities, and severely disrupted the world economy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.62pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">While the challenges posed by the COVID-19 pandemic have highlighted the need for effective vaccines to prevent viral diseases and control future pandemics, the number of new and improved human viral vaccines licensed in recent&#160;years remain few despite the high need. Over the past 20&#160;years, great concerns have been expressed by the World Health Organization, or WHO, and other bodies following disease outbreaks by avian influenza A subtypes H5N1, H7N9, H9N2, and H3N2v and the SARS and MERS coronaviruses, Ebola filoviruses and the Zika flaviviruses. Further, according to the WHO, various disease vaccines are being added to pipelines round the globe with a number of these currently undergoing clinical trials. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.62pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe our AI-approach to the design of viral vaccine candidates holds great promise for the development of novel, effective vaccines against hard-to-treat viral infections and emerging viral diseases. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.61pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The global viral vaccines market was valued at $35.5&#160;billion in 2020 and is projected to reach $74.4&#160;billion by 2029, growing by at a CAGR of 8.49% from 2020 to 2026. </font>
        </div>
        <div style="margin-top:10.52pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Viral Vaccinology</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Vaccines work by training the immune system to recognize and combat pathogens, such as bacteria, viruses or parasites. To do this, certain molecules, called antigens, from the pathogen must be introduced </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">180</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12.14pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">into the body to trigger a protective immune response. By injecting vaccines containing antigens, the immune system will safely recognize them and trigger an immune response that leads to protective immunity. If the antigen-harboring pathogen appears in the body during an early infection, the immune system will recognize the antigens displayed and immediately attack the pathogen before it can invade and establish an infection and cause disease. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The adaptive immune response following vaccination protects the body from infections by mounting a specific antibody-mediated immune response (B-cell response) and/or a cellular immune response (T-cell response). Antibodies can have different functions, but key to protect against a viral disease is their ability to bind to surface molecules and thereby prevent function or virus uptake by the target cell, while the key cellular immune response involves cell-mediated cytotoxicity (killing of infected cells). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">A virus is fully dependent on the host cell machinery to successfully establish an infection. With the many ways of the host immune system to recognize and prevent infection, viruses have established various strategies to manipulate the cellular environment to prevent recognition or limit any immune responses against it. In addition, when a virus replicates, &#8220;copying errors&#8221; of its genome, i.e., mutations, can cause the virus to further evade the immune system by gaining new traits preventing them from being recognized by an otherwise trained immune system. Viral evasion strategies pose a great challenge for the vaccine development and calls for new strategies to target the virus from multiple angles, i.e., by combining B-cell and T-cell antigens for activation of both humoral and cellular pathways and targeting selected viral strains and/or human populations for specific or broad coverage. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our approach to viral vaccine design is an unbiased and fully AI-based target discovery approach, which traditionally, to a large extent, has been a manual process. In addition, while many licensed viral vaccines in the past have been focused on generation of a neutralizing antibody (B-cell) response, our AI model RAVEN&#8482; allows integration of a T-cell component in the vaccine design. We believe our approach will help combat some of the historic challenges with viral vaccines, most recently observed in relation to vaccines developed to protect against the SARS-CoV-2 pandemic, including durability and breadth of response. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RAVEN</font><font style="font-weight:normal;letter-spacing:0.2pt;">&#8482;</font><font style="letter-spacing:-0.2pt;">&#8201;&#8212;&#8201;Our AI Model for the Discovery and Design of Novel Prophylactic Vaccines for Infectious Diseases</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Overview</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">RAVEN&#8482; is our AI-Immunology&#8482; model that rapidly identifies T-cell antigens in infectious virus and bacteria for the use in pathogen-specific prophylactic vaccines. RAVEN&#8482; combines essential AI modules from our PIONEER&#8482; model to discover novel T-cell antigens. The RAVEN&#8482; model synergizes with EDEN&#8482; as RAVEN&#8482; identified T-cell antigens can be used either as a stand-alone or incorporated into known or novel EDEN&#8482; identified B-cell antigens. To construct a combined T- and B-cell antigen vaccine, we have generated a range of novel structural design tools, which graft T-cell epitopes into the B-cell antigens while maintaining the overall structural integrity of the B-cell antigen essential for eliciting the humoral response. We believe that a vaccine comprising both RAVEN&#8482; and EDEN&#8482; identified antigens, separately or in one integrated antigen, will elicit both a humoral/antibody response and cytotoxic T-cell responses, which may result in highly efficacious and broadly protective vaccines through robust memory T-cell populations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The ability of RAVEN&#8482; to include T-cell epitopes in the vaccine design serves multiple purposes, both in the cellular response as cytotoxic T cells clearing pathogen-infected cells from the body and helper T-cells boosting both the cellular and humoral responses. The high-throughput nature of the RAVEN&#8482; model enables rapid identification of vaccine antigens for any viral or bacterial pathogen. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">181</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="fc_fig50panproteome-4c.jpg" alt="[MISSING IMAGE: fc_fig50panproteome-4c.jpg]" height="194" width="486" >
        </div>
        <div style="margin-top:13.99pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 50: RAVEN</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8482; </font><font style="letter-spacing:-0.2pt;">workflow with EDEN&#8482; integration.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The input to RAVEN&#8482; is genomic and proteomic data from any pathogen target as well as MHC data on the indented human population. The cross-protective B-cell antigens are identified either from literature, if known, or by our EDEN&#8482; model. In order to predict the protective B-cell antigenicity of a given full length protein sequence, the models receive the proteome of a given pathogen as input and generate an output list ranking the proteins based on prediction scores (see above). The models leverage genomic sequencing data to find important targets or domains that are present in the majority of clinical strains for a given pathogen in order to capture a majority of pathogen strains by a single vaccine. Proteins are ranked by predicting B-cell antigen protection level by calculating an antigen prediction score ranging from 1 to 0, where 1 is highest predicted level of protection and 0 is the lowest. Adaptation of the EDEN&#8482; approach have been successfully applied to several viral targets where verified antigens rank high. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The protective T-cell epitopes are identified using a proprietary model composed of several computational features which identifies peptides presented on MHC class I and II molecules on the surface of cells, a model adapted from our PIONEER&#8482; model. The model is a transformer-based neural network with seven million parameters, trained using a conditional generative adversarial network approach. A second model is subsequently applied to down select the full pool of T-cell epitopes to a set of peptides containing epitopes covering a target human population defined by MHC allele distribution, anywhere from a single individual to a world-wide population and a virus population defined by the genomes of the desired virus population. The algorithm is adjustable and can be used to ensure the broadest possible response across human tissue types (MHC-I and -II alleles) and entire virus species, or alternatively to target specific human populations and/or selected viral strains in outbreaks. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The identified B- and T-cell antigens can be administered as individual components or combined. A third ensemble of RAVEN&#8482; is further capable of examining the B-cell antigen structure and identify sites where the T-cell epitopes can be grafted into the protein thus preserving the B-cell mediated antibody generation whilst also eliciting a T-cell response. We expect that such T-cell epitope enrichment of the B-cell antigen will increase B-cell activation, resulting in increased breadth, avidity, magnitude and duration of the generated antibody response or can be designed to elicit a broadly protective cytotoxic T-cell response alongside the antibody response. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These identified antigens can be administered by any established vaccine delivery technology such as protein, DNA or mRNA </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Key Advantages of our RAVEN&#8482; Model</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe, the combination of EDEN&#8482; and RAVEN&#8482; models results in several unique features of a vaccine design: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Promiscuous T-cell Epitopes</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;The AI modules of our RAVEN&#8482; model enable the identification and combination of T-cell epitopes that cover the immunological diversity of the human populations (HLA type). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">182</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Multiple Hits on Target</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;By combining multiple potent epitopes in one vaccine, we believe different T cells will be able to target the infected cells, avoiding antigenic drift and curtail spread of the infection more effectively. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Potential Coverage of Entire Viral Cycle</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;By selecting epitopes from multiple proteins in the viral genome, vaccine generated T cells may be able to kill infected cells at selected stages of the viral replication cycle. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Mutation Proof</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;Combining multiple epitopes ensures covering of several variants of a strain, hence new mutations are likely to have little effect on the vaccine efficacy. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Neutralizing Focused</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;Design of minimal constructs from viral fusogens for the generation of neutralizing antibodies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Cross-reactive Antibodies</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;The RAVEN&#8482; and EDEN&#8482; viral fusion protein antigen is designed using information from all available variants of the target strain to ensure that the generated antibodies offer cross-reactive neutralization. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Broadly Applicable</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;The RAVEN&#8482; model can be applied to any known pathogen and is delivery platform agnostic. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Early Pre-clinical PoC for RAVEN&#8482;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have already demonstrated the predictive capabilities of our AI model PIONEER&#8482; and EDEN&#8482; to identify T- and B-cell antigens, respectively. We have further demonstrated that when integrated into RAVEN, T-cell epitope prediction capabilities are maintained. In an </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> study with 17 T-cell epitopes identified by RAVEN&#8482; across the entire SARS-CoV-2 genome, we found that 15 of the 17 (88%) epitopes induced T-cell activation and provided significant protection against lethal SARS-CoV-2 challenge in a K18-hACE2 mouse model (Figure 51). </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="bc_fig51tcellresponse-4c.jpg" alt="[MISSING IMAGE: bc_fig51tcellresponse-4c.jpg]" height="224" width="486" >
        </div>
        <div style="margin-top:13pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 51. 17 RAVEN&#8482; predicted T-cell epitopes from SARS-CoV-2 ORF1a/b, ORF3a, ORF6, ORF8, S, M, and N was incorporated into a plasmid DNA delivery platform containing an antigen-presenting cell targeting unit (APCt), a dimerization domain and the 17 T-cell epitopes. To evaluate immunogenicity and protection, mice were immunized intramuscularly five times with one-week intervals with 25 ug plasmid DNA expressing the RAVEN&#8482; predicted SARS-CoV-2 T-cell epitopes as &#8216;beads-on-a-string&#8217;. Figure 51A: Splenocytes from female C57BL/6 mice (n=2) immunized with the plasmid showed IFN-</font><font style="font-family:Arial, Helvetica, sans-serif;">&#611;</font><font style="letter-spacing:-0.2pt;"> response against 15 of the 17 included epitopes upon restimulation. Figure 51B: K18-hACE2 transgenic mice, carrying the human ACE2 receptor immunized with our RAVEN&#8482; predicted SARS-CoV-2 T-cell vaccine, were protected against lethal infection of SARS-CoV-2 (WA1/USA 2020) compared to APCt-Mock DNA immunized mice (n=8).</font><font style="font-style:normal;font-weight:normal;font-family:Arial, Helvetica, sans-serif;letter-spacing:-0.067pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have further demonstrated that our approach to T-cell epitope enrichment using CD4</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">+</font><font style="letter-spacing:0.2pt;"> T-cell epitope engraftment of hemagglutinin using hemagglutinin genetic information from &gt;26.000 influenza species results in an improved antibody response in a pre-clinical study. Hemagglutinin is a viral fusion protein located on the surface of the influenza virus where it facilitates cellular entry, serving the same purpose as </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">183</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the spike protein in coronaviruses and its neutralization is therefore key in the development of an effective vaccine. As seen in Figure 52 below, the antibody response towards the enriched hemagglutinin was significantly enhanced, evidenced by a 5-10-fold better neutralization compared to non-enriched hemagglutinin. </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="bc_fig52antibody-4c.jpg" alt="[MISSING IMAGE: bc_fig52antibody-4c.jpg]" height="257" width="159" >
        </div>
        <div style="margin-top:12.61pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Figure 52. Six Influenza CD4+ T-cell epitopes were integrated into a hemagglutinin antigen. Subsequent immunization with the supercharged hemagglutinin antigen induced higher antigen-specific antibody titers compared to the standard antigen.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our first viral candidate, EVX-V1, entered our pipeline in 2022. Once we achieve PoC on our RAVEN&#8482; model, we plan to target other viruses that display seasonal recurrence and/or pandemic potential or general medical need, either through co-development or other partnership arrangements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Our EVX-V1 Product Candidate</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2022, we announced our first viral target, Cytomegalovirus (CMV), against which we will use our RAVEN&#8482; and EDEN&#8482; AI models to identify promising vaccine targets. Our EVX-V1 vaccine candidate will be developed in collaboration with ExpreS</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">2</font><font style="letter-spacing:0.2pt;">ion Biotechnologies, or ExpreS2ion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">CMV is a member of the herpesvirus family and is a widespread infection with approximately half of the US population estimated to be infected by age 40. The virus is transmitted in body fluids, and once infected, the virus stays for life. People with weakened immune systems, including organ transplant patients, can develop severe symptoms affecting for example, eyes, lungs and liver. CMV can also be passed from a pregnant woman to her unborn child, and congenitally infected babies may suffer from intellectual disability and loss of vision and hearing. As there are currently no commercially available vaccines or other effective treatment options against CMV, it represents a critical unmet medical need. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the discovery phase of the collaboration, we utilized both EDEN&#8482; and RAVEN&#8482; models to find the most optimal vaccine candidate eliciting both a potent antibody and cellular response. By using EDEN&#8482;, we were able to identify novel B-cell antigens not pursued by other competing programs. We believe that including novel EDEN&#8482; antigens and RAVEN&#8482; T-cell epitopes in the final vaccine is a differentiator for us and a critical competitive edge. The CMV vaccine field has long focused on the same few antigens, yet without being able to develop a successful vaccine. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The antigen constructs derived from our AI platform will be produced by ExpreS2ion using their proprietary ExpreS2 platform, a protein expression system utilizing fruit fly cells, and subsequently process through our pre-clinical models. We believe this partnership has the potential to deliver a truly differentiated, highly immunogenic vaccine for protection against CMV infections. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The project has completed the vaccine discovery activities using the EDEN&#8482; model. Fifteen (15) potential targets were identified, and a detailed assessment resulted in a final selection of 10 new targets to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">184</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">investigate further. The antigens are present and well-conserved across multiple globally collected clinical isolates. The 10 new vaccine targets have been the basis for vaccine antigen design activities and are now being expressed using the ExpreS2 platform. We believe the new EDEN&#8482; antigens, together with RAVEN-identified T-cell epitopes, constitute a new and promising strategy to pursue in the development of a much-needed CMV vaccine. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Third-Party Collaborations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are collaborating with MSD on the Phase&#160;2 clinical trial which will combine our patient-specific neoantigen cancer vaccine compound, EVX-01, with MSD&#8217;s anti-PD-1 therapy KEYTRUDA</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> compound, a humanized anti-human PD-1 monoclonal antibody. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The planned multi-center Phase&#160;2 clinical trial will enroll patients with Stage III and IV advanced or metastatic unresectable melanoma and will investigate EVX-01 in combination with KEYTRUDA</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">. We will act as the sponsor of the clinical trial and MSD will supply all the necessary KEYTRUDA</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">. We will continue to collaborate with MSD as the data mature. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are also collaborating with the National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen and the Center for Vaccine Research at SSI on the development and Phase&#160;1/2a clinical trial of our EVX-01 product candidate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We retain the commercial rights to EVX-01 and our other clinical stage programs. We plan to continue to identify potential collaborators who can contribute meaningful resources and insights to our programs and allow us to more rapidly expand our impact to broader patient populations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are also collaborating with ExpreS</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">2</font><font style="letter-spacing:0.2pt;">ion Biotechnologies, or ExpreS2ion, on the joint development of a novel CMV vaccine candidate, EVX-V1. Under the terms of the agreement, ExpreS2ion will have the exclusive right to license the CMV vaccine candidate under a potential Development and Commercialization Agreement. The research and intellectual property licensing costs for the collaboration project will be divided 50:50 between us and ExpreS2ion until 2025. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the EVX-B2 we are collaborating with Afrigen Biologics to develop an mRNA-based gonorrhea vaccine for LMICs. Following the validation phase, the partners will negotiate a subsequent agreement for clinical development and commercialization, with the opportunity to bring in additional partners. Afrigen will be responsible for the development and commercialization of the resulting mRNA vaccine in LMICs and African territories. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our latest vaccine project, EVX-B3, targets a bacterial pathogen for which no vaccine is yet available. The new vaccine project is a co-funded effort between us and an undisclosed leading pharmaceutical company. The collaboration is leveraging unique assets and know-how from both organizations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Government Regulation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Government authorities in the United States, at the federal, state and local levels, and in the European Union and other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, record-keeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting and import and export of pharmaceutical products, including biological products. In addition, some jurisdictions regulate the pricing of pharmaceutical products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other requirements of regulatory authorities, require the expenditure of substantial time and financial resources. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Regulation and Procedures Governing Approval of Drug and Biological Products in the United States</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and the FDCA&#8217;s implementing regulations and regulates biologics under both the FDCA, the Public Health Service Act, or the PHSA, and their implementing regulations. Both drugs and biologics also are </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">185</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the product development process, approval process or following approval may subject a sponsor to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, clinical hold, untitled or warning letters, voluntary or mandatory product recalls, market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A sponsor seeking approval to market and distribute a new drug or biological product in the United States generally must satisfactorily complete each of the following steps: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">pre-clinical laboratory tests, animal studies and formulation studies all performed in accordance with applicable regulations, including the FDA&#8217;s good laboratory practice, or GLP, regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">approval by the institutional review board, or IRB, or ethics committee representing each clinical site before each clinical trial may be initiated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">performance of adequate and well-controlled human clinical trials to establish the safety, potency and purity of the product candidate for each proposed indication, in accordance applicable regulations, including with good clinical practice, or GCP, regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">preparation and submission to the FDA of a NDA for a drug product, or a biologics license application, or BLA, for a biological product requesting marketing approval for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product in clinical development, evidence of safety, efficacy, purity and potency from pre-clinical testing and clinical trials, and proposed labeling; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">review of the product by an FDA advisory committee, if applicable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with current good manufacturing practice, or cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">satisfactory completion of any FDA audits of the clinical trial sites to assure compliance with GCPs, and the integrity of clinical data in support of the NDA or BLA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">payment of user fees and securing FDA approval of the NDA or BLA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">compliance with any post-approval requirements, including the potential requirement to implement a REMS and to conduct any post-approval studies required by the FDA. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The pre-clinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our investigational medicines and any future investigational medicines will be granted on a timely basis, or at all. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pre-Clinical Studies and IND Application</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Before testing any drug or biological product candidate in humans, the product candidate must undergo pre-clinical testing. Pre-clinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as animal studies to evaluate the potential for activity and toxicity. The conduct of the pre-clinical tests and formulation of the compounds for testing must comply with federal regulations and requirements. The results of the pre-clinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, are submitted to the FDA as part of an IND. The IND automatically becomes effective 30&#160;days after receipt by the FDA, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">186</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and places the trial on a clinical hold. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trial can begin. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a result, submission of the IND may result in the FDA not allowing the trial to commence or not be conducted on the terms originally specified by the sponsor in the IND. If the FDA raises concerns or questions either during this initial 30-day period, or at any time during the IND process, it may choose to impose a partial or complete clinical hold. If the FDA imposes a clinical hold, trials being conducted under the IND may not recommence without FDA authorization and then only under terms authorized by the FDA. A clinical hold issued by the FDA may therefore delay either a proposed clinical trial or cause suspension of an ongoing trial, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigation may proceed. This could cause significant difficulties in completing planned clinical trials in a timely manner. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA may impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Human Clinical Trials in Support of an NDA or a BLA</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease to be treated under the supervision of qualified principal investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation. Clinical trials are conducted under trial protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, dosing procedures and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of an IND. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of the NDA or BLA so long as the clinical trial is well-designed and well-conducted in accordance with GCP, including review and approval by an independent ethics committee, and the FDA is able to validate the trial data through an onsite inspection, if necessary. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors and the safety of human subjects. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group may recommend continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check points based on access to certain data from the trial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Phase&#160;1 clinical trials (or Phase&#160;1) are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or, on occasion, in patients, such as in the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">187</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Phase&#160;2 clinical trials (or Phase&#160;2) are generally conducted in a limited patient population to identify possible adverse effects and safety risks, preliminarily evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase&#160;2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger Phase&#160;3 clinical trials. When a drug is intended to treat life-threatening or severely debilitating illnesses, the FDA may accept well-controlled Phase&#160;2 clinical trials as adequate to provide sufficient data on the drug&#8217;s safety and effectiveness to support a decision on its approvability for marketing, in which case Phase&#160;3 clinical trials would not be required. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Phase&#160;3 clinical trials (or Phase&#160;3) proceed if the Phase&#160;2 clinical trials demonstrate that a certain dose or dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase&#160;3 clinical trials are undertaken within an expanded patient population, often at geographically dispersed clinical trial sites, to gather additional information about safety and effectiveness necessary to evaluate the overall benefit-risk relationship of the product and to provide an adequate basis for product labeling. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In some cases, the FDA may approve an NDA or a BLA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase&#160;4 clinical trials (or Phase&#160;4). These studies may be used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase&#160;4 clinical trial requirement or to request a change in the product labeling. Failure to exhibit due diligence with regard to conducting required Phase&#160;4 clinical trials could result in withdrawal of approval for products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other trials, tests in laboratory animals or </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. The FDA or the sponsor or its DSMB may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the new drug candidate or biological product candidate has been associated with unexpected serious harm to patients. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Compliance with cGMP Requirements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Before approving an NDA or a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and adequate to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">188</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">assure consistent production of the product within required specifications. Among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final drug or biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug or biological product does not undergo unacceptable deterioration over its shelf life. In particular, the PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sponsors of BLAs and NDAs must report changes in CMC including manufacturing sites to FDA. Such changes may result in delays in approval of pending BLAs and NDAs or delays in manufacturing approved producers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Manufacturers and others involved in the manufacture and distribution of approved drugs and biological products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The manufacturing facilities may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Manufacturers may have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting or refusing inspection by the FDA may lead to a product being deemed to be adulterated. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Review and Approval of an NDA or a BLA</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The results of product candidate development, pre-clinical testing and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of an NDA or a BLA requesting a license to market the product. These applications must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling. The FDA charges drug and biologic product manufacturers user fees, which are adjusted on an annual basis in accordance with the Prescription Drug User Fee Act, or PDUFA. The fee for the submission of an NDA or BLA for which clinical data is substantial (for example, for the fiscal year 2021 this application fee exceeds $2.8&#160;million), and the sponsor of an approved NDA or BLA is also subject to an annual program fee, currently more than $300,000 per program. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA has 60&#160;days after submission of the application to conduct an initial review to determine whether the NDA or BLA is sufficient to accept for filing based on the agency&#8217;s threshold determination that it is substantially complete so as to permit substantive review. Once the submission has been accepted for filing, the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under PDUFA, the FDA aims to complete its initial review of a standard application and respond to the sponsor within ten&#160;months of the 60-day filing date, and for a priority review application within six&#160;months. The FDA does not always meet its PDUFA goal dates for standard and priority NDA or BLA applications, and its review goals are subject to change from time to time. The review process may often be significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may also be extended by three&#160;months if the FDA requests or if the sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three&#160;months before the PDUFA goal date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Pediatric Research Equity Act, or PREA, as amended, a BLA or supplement to a BLA must contain data that are adequate to assess the safety and efficacy of the product candidate for the claimed indications in all relevant pediatric populations and to support dosing and administration for each pediatric population for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The Food and Drug Administration Safety and Innovation Act, or the FDASIA, enacted in 2012, made permanent PREA to require a sponsor who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration to submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-Phase&#160;2 meeting or, if there is no such meeting, as early as practicable before the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">189</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">initiation of the Phase&#160;3 or Phase&#160;2/3 clinical trial. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from pre-clinical studies, early phase clinical trials or other clinical development programs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA reviews NDA and BLA applications to determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with GMP requirements to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of clinical trial sites to assure compliance with GCPs, the FDA may issue an approval letter, denial letter or complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. Under the FDCA, the FDA may approve an NDA if it determines that the product is safe and effective for its intended use, the benefits of the drug outweigh any risks, and the methods used in manufacturing the drug and the controls used to maintain the drug&#8217;s quality are adequate to preserve the drug&#8217;s identity, strength, quality and purity. Under the PHSA, the FDA may approve a BLA if it determines that the product is safe, pure and potent and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure and potent. If the application is not approved, the FDA will issue a complete response letter, or CRL, which describes the conditions that must be met in order to secure final approval of the application, and when possible, will outline recommended actions the sponsor might take to obtain approval of the application. If a CRL is issued, the sponsor may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sponsors that receive a CRL who elect to address the deficiencies may submit to the FDA information that represents a complete response to the issues identified by the FDA in the response letter. Such resubmissions are classified under PDUFA as either Class&#160;1 or Class&#160;2, based on the information submitted by a sponsor in response to an action letter. Under the goals and policies agreed to by the FDA under PDUFA, the FDA aims to review and act on a Class&#160;1 resubmission with two&#160;months of receipt and, with respect to a Class&#160;2 resubmission, within six&#160;months of receipt. The FDA will not approve an application until issues identified in the CRL have been addressed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA may also refer the application to an Advisory Committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. In particular, the FDA may refer applications for novel drug or biological products or drug or biological products that present difficult questions of safety or efficacy to an advisory committee. Typically, an Advisory Committee is a panel of independent experts, including clinicians and other scientific experts. The FDA is not bound by the recommendations of an Advisory Committee, but it considers such recommendations carefully when making decisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the FDA approves a new product, it may limit the approved indications for use of the product or limit the approval to specific dosages. It may also require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may call for post-approval studies, including Phase&#160;4 clinical trials, to further assess the product&#8217;s safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including risk evaluation and mitigation strategies, or REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if required. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">190</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Fast Track, Breakthrough Therapy and Priority Review Designations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA may designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough therapy designation and priority review designation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA may designate a product for fast-track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request that the FDA designate the drug or biologic as a fast-track product at any time during the clinical development of the product. For fast-track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast-track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast-track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a fast-track application does not begin until the last section of the application is submitted. Fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2012, Congress enacted the FDASIA. This law established a new regulatory scheme allowing for expedited review of products designated as &#8220;breakthrough therapies.&#8221; A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to facilitate the design of clinical trials in an efficient manner. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application to six&#160;months (compared to 10&#160;months under standard review). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Fast track designation, priority review and breakthrough therapy designation may expedite the development or approval process, but do not change the standards for approval. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Accelerated Approval Pathway and Regenerative Medicine Advanced Therapy Designation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">191</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has stated that although it has limited experience with accelerated approvals based on intermediate clinical endpoints, such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a product. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&#160;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, may lead the FDA to withdraw the product from the market. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accelerated approval pathways are available for regenerative medicine therapies that meet certain conditions. Regenerative medicine therapies include cell therapies (both allogenic and autologous), therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products, except those regulated under section 361 of the PHSA. Human gene therapies, including genetically modified cells, that lead to a sustained effect on cells or tissues, may also meet the definition of a regenerative medicine therapy, as may xenogeneic cell products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Regenerative medicine therapies designed to treat, modify, reverse or cure serious conditions are eligible for FDA&#8217;s expedited programs, including fast track designation, breakthrough therapy designation, priority review and accelerated approval, if they meet the criteria for such programs. They may also be eligible for Regenerative Medicine Advanced Therapy Designation, or RMAT designation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">An investigational drug is eligible for RMAT designation if it meets the definition of regenerative medicine therapy, it is intended to treat, modify, reverse or cure a serious condition, and preliminary clinical evidence indicates that the regenerative medicine therapy has the potential to address unmet medical needs for such condition. An unmet medical need is a condition whose treatment or diagnosis is not addressed adequately by available therapy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">RMAT designation confers all the benefits of the fast track and breakthrough therapy designation programs, including early actions with the FDA. The FDA reviews each application on a case-by-case basis to determine whether the clinical evidence is sufficient to support RMAT designation, considering factors such as the rigor of data collection, the consistency and persuasiveness of the outcomes, the number of patients or subjects, and the severity, rarity or prevalence of the condition, among other factors. The FDA may decline to grant RMAT designation if it finds the clinical evidence insufficient. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">RMAT designation may expedite the development or approval process, but it does not change the standards for approval. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">192</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Patent Term Restoration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Depending upon the timing, duration and specifics of FDA approval of our drugs, some of our US patents may be eligible for limited patent term extension. These patent term extensions permit a patent restoration term of up to five&#160;years as compensation for any patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND, and the submission date of an NDA or BLA, plus the time between the submission date of an NDA or BLA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension, and the extension must be applied for prior to expiration of the patent. The United States Patent and Trademark Office, or the USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pediatric Exclusivity</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pediatric exclusivity is a type of non-patent marketing exclusivity available in the United States and, if granted, it provides for the attachment of an additional six&#160;months of marketing protection to the term of any existing regulatory exclusivity or listed patents. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six&#160;months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA, subject to certain limited exceptions, cannot approve another application. The issuance of a Written Request does not require the sponsor to undertake the described studies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Post-Approval Regulation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If regulatory approval for marketing of a new drug or biologic product or for a new indication for an existing product is obtained, the sponsor will be required to comply with rigorous and extensive post-approval regulatory requirements as well as any post-approval requirements that the FDA has imposed on the particular product as part of the approval process. The sponsor will be required, among other things, to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the BLA holder and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented, and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market study requirements or clinical trial requirements to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">fines, untitled letters or warning letters or holds on post-approval clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">193</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">adverse publicity; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">product seizure or detention, or refusal to permit the import or export of products; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">injunctions, fines, debarment, disgorgement of profits or the imposition of civil or criminal penalties. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Pharmaceutical products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. Most recently, the Drug Supply Chain Security Act, or DSCSA, was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States, including most biological products. The DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers over a 10-year period, starting in 2013 and is expected to culminate soon. From time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. It is impossible to predict whether further legislative or regulatory changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Biosimilars and Reference Product Exclusivity</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. A federal district court ruling in Texas struck down the Affordable Care Act in its entirety based on constitutionality, and in December&#160;2019 the Fifth Circuit Court of Appeals upheld lower court&#8217;s finding that the individual mandate in the law is unconstitutional. On June&#160;17, 2021, the Supreme Court reversed the District Court decision on the basis that the Plaintiffs lacked standing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A reference biological product is granted 12&#160;years of data exclusivity from the time of first licensure of the product, and the first approved interchangeable biologic product will be granted an exclusivity period of up to one year after it is first commercially marketed. If pediatric studies are performed and accepted by the FDA as responsive to a Written Request, the 12-year exclusivity period will be extended for an additional six&#160;months. In addition, the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four&#160;years after the date of first licensure of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">194</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a supplement for the reference product for a subsequent application filed by the same sponsor or manufacturer of the reference product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate implementation and impact of the BPCIA is subject to significant uncertainty. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Regulation of Combination Products in the United States</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain products may be comprised of components that would normally be regulated under different types of regulatory authorities and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">A product comprised of two or more regulated components that are physically, chemically or otherwise combined or mixed and produced as a single entity; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">A drug, or device or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device or biological product where both are required to achieve the intended use, indication or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration or significant change in dose; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Any investigational drug, device or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device or biological product where both are required to achieve the intended use, indication or effect. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. That determination is based on the &#8220;primary mode of action&#8221; of the combination product. Thus, if the primary mode of action of a device-biologic combination product is attributable to the biological product, the FDA center responsible for premarket review of the biological product would have primary jurisdiction for the combination product. The FDA has also established an Office of Combination Products to address issues surrounding combination products and provide more certainty to the regulatory review process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to clarify the regulation of combination products, and for assignment of the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can initiate clinical trials or market and sell the product in those countries or jurisdictions. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">195</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Regulation&#160;Outside of the United States</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products outside of the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the 27-member European Union and Australia, before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly between countries and jurisdictions and can involve additional testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Regulation and Procedures Governing Approval of Medicinal Products in the European Union</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The process governing approval of medicinal products, including biological medicinal products and advanced therapy medicinal products, or ATMPs, which comprise gene therapy products, somatic cell therapy products and tissue-engineered products, in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of pharmaceutical development, nonclinical and clinical studies to establish the safety and efficacy of the medicinal product for each proposed indication. Moreover, an applicant must also demonstrate the ability to manufacture the product to a suitable quality. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Clinical Trial Approval</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the currently applicable Clinical Trials Directive 2001/20/EC and the Directive 2005/28/EC on GCP, a system for the approval of clinical trials in the European Union has been implemented through national legislation of the member states. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Clinical trials must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization, or ICH, guidelines on GCP. Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the European Union, it must appoint an entity within the European Union to act as its legal representative. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under this system, a sponsor must obtain approval from the competent national authority of a European Union member state in which the clinical trial is to be conducted or in multiple member states if the clinical trial is to be conducted in a number of member states. Furthermore, the sponsor may only start a clinical trial at a specific trial site after the independent ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by a copy of the trial protocol and an investigational medicinal product dossier with supporting information prescribed by Directive 2001/20/EC and Directive&#160;2005/28/EC and corresponding national laws of the member states and further detailed in applicable guidance documents. Moreover, the sponsor must take out a clinical trial insurance policy, and in most European Union countries the sponsor is liable to provide &#8216;no fault&#8217; compensation to any trial subject injured in the clinical trial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In April&#160;2014, the new Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation) was adopted, and implemented in January&#160;2023. The Clinical Trials Regulation is directly applicable in all the European Union Member States, repealing the current Clinical Trials Directive 2001/20/EC. Conduct of all clinical trials performed in the European Union initiated before January&#160;2023 will continue to be bound by the Clinical Trials Directive 2001/20/EC. The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on the duration of the clinical trial. If a clinical trial continues for more than three&#160;years from the day on which the Clinical Trials Regulation became applicable (January&#160;2023) the Clinical Trials Regulation will at that time begin to apply to the clinical trial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">196</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">via a single-entry point, the &#8220;EU portal&#8221;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part&#160;I is assessed by the competent authorities of all European Union Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part&#160;II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned European Union Member State. However, overall related timelines will be defined by the Clinical Trials Regulation. The sponsor of a clinical trial must register the clinical trial in advance, and information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial will be made public as part of the registration. The results of the clinical trial must be submitted to the competent authorities and, with the exception of non-pediatric Phase&#160;1 trials, will be made public at the latest within 12&#160;months after the end of the trial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the development of a medicinal product, the EMA and national medicines regulators within the European Union provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Scientific Advice Working Party of the Committee for Medicinal Products for Human Use, or CHMP. A fee is incurred with each scientific advice procedure. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future marketing authorization application of the product concerned. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Marketing Authorization</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To obtain a marketing authorization for a product under the European Union regulatory system, a sponsor must submit a marketing authorization application, or MAA, either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in EU member states (decentralized procedure, national procedure or mutual recognition procedure). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All application procedures require an application in the common technical document, or CTD, format, which includes the submission of detailed information about the manufacturing and quality of the product, and nonclinical and clinical trial information. There is an increasing trend in the European Union toward greater transparency and, while the manufacturing or quality information is currently generally protected as confidential information, the EMA and national regulatory authorities are now liable to disclose much of the nonclinical and clinical information in marketing authorization dossiers, including the full clinical trial reports, in response to freedom of information requests after the marketing authorization has been granted. In October&#160;2014, the EMA adopted a policy under which clinical trial reports would be posted on the agency&#8217;s website following the grant, denial or withdrawal of a MAA, subject to procedures for limited redactions and protection against unfair commercial use. A similar requirement is contained in the new Clinical Trials Regulation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A marketing authorization may be granted only to a sponsor established in the European Union. Regulation (EC) No. 1901/2006 on medicinal products for pediatric use provides that prior to obtaining a marketing authorization in the European Union in the centralized procedure, a sponsor must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver or deferral for one or more of the measures included in the Pediatric Investigation Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union member states. Pursuant to Regulation (EC) No. 726/</font>&#8203;<font style="letter-spacing:0.2pt;">2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. </font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">197</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the centralized procedure, the CHMP established at the EMA is responsible for conducting the assessment of a product to define its risk/benefit profile. Under the centralized procedure, the maximum timeframe for the evaluation of an MAA is 210&#160;days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions from the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health determined by three cumulative criteria: (i)&#160;the seriousness of the disease (e.g., heavy disabling or life-threatening diseases) to be treated, (ii)&#160;the absence or insufficiency of an appropriate alternative therapeutic approach, and (iii)&#160;anticipation of high therapeutic benefit. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the CHMP accepts such a request, the time limit of 210&#160;days will be reduced to 150&#160;days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Committee for Advanced Therapies, or CAT, is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CAT is primarily responsible for the scientific evaluation of ATMPs and prepares a draft opinion on the quality, safety and efficacy of each ATMP for which a MAA is submitted. The CAT&#8217;s opinion is then taken into account by the CHMP when giving its final recommendation regarding the authorization of a product in view of the balance of benefits and risks identified. Although the CAT&#8217;s draft opinion is submitted to the CHMP for final approval, the CHMP may depart from the draft opinion if it provides detailed scientific justification. The CHMP and CAT are also responsible for providing guidelines on ATMPs and have published numerous guidelines, including specific guidelines on gene therapies and cell therapies. These guidelines, which are not legally binding, provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, inter alia, the pre-clinical studies required to characterize ATMPs, the manufacturing and control information that should be submitted in a MAA; and post-approval measures required to monitor patients and evaluate the long-term efficacy and potential adverse reactions of ATMPs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The European Commission may grant a so-called &#8220;marketing authorization under exceptional circumstances.&#8221; Such authorization is intended for products for which the applicant can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because the indications for which the product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence, or in the present state of scientific knowledge, comprehensive information cannot be provided, or it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, marketing authorization under exceptional circumstances may be granted subject to certain specific obligations, which may include the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the applicant must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the benefit/risk profile; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital, and in the case of a radio-pharmaceutical, by an authorized person; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A marketing authorization under exceptional circumstances is subject to annual review to reassess the risk-benefit balance in an annual re-assessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of the marketing authorization of a medicinal product under exceptional circumstances follows the same rules as a &#8220;normal&#8221; marketing authorization. After five&#160;years, the marketing authorization will then be renewed under exceptional circumstances for an unlimited period, unless the EMA decides on justified grounds, to proceed with one additional five-year renewal. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The European Commission may also grant a so-called &#8220;conditional marketing authorization&#8221; prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">198</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Such conditional marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products) if the CHMP finds that all the following requirements are met: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the benefit-risk balance of the product is positive; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">it is likely that the applicant will be able to provide comprehensive data; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">unmet medical needs will be fulfilled; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the benefit to public health of the medicinal product&#8217;s immediate availability on the market outweighs the risks due to need for further data. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization. Once comprehensive data on the medicinal product have been obtained, the marketing authorization may be converted into a standard marketing authorization which is no longer subject to specific obligations. Initially, this is valid for five&#160;years, but can be renewed for unlimited validity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The European Union medicines rules expressly permit the member states to adopt national legislation prohibiting or restricting the sale, supply or use of any medicinal products containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Conditional Approval</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In specific circumstances, European Union legislation (Article&#160;14(7) Regulation (EC) No 726/2004 and Regulation (EC) No 507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1)&#160;the risk-benefit balance of the product candidate is positive, (2)&#160;it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3)&#160;the product fulfills unmet medical needs and (4)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pediatric Studies</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to obtaining a marketing authorization in the European Union, applicants have to demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine in children is not needed or is not appropriate, such as for diseases that only affect the elderly population. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">199</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Before a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">European Union Regulatory Exclusivity</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the European Union, new products authorized for marketing (i.e., reference products) qualify for eight&#160;years of data exclusivity and an additional two&#160;years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the European Union during a period of eight&#160;years from the date on which the reference product was first authorized in the European Union. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the European Union until ten&#160;years have elapsed from the initial authorization of the reference product in the European Union. The ten-year market exclusivity period can be extended to a maximum of eleven&#160;years if, during the first eight&#160;years of those ten&#160;years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">European Union Orphan Designation and Exclusivity</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The criteria for designating an orphan medicinal product in the European Union, are similar in principle to those in the United States. Under Article&#160;3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1)&#160;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2)&#160;either (a)&#160;such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b)&#160;the product, without the benefits derived from orphan status, would not generate sufficient return in the European Union to justify investment; and (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten&#160;years of market exclusivity for the approved therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the marketing authorization application if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The ten-year market exclusivity in the European Union may be reduced to six&#160;years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the applicant consents to a second orphan medicinal product application; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the applicant cannot supply enough orphan medicinal product. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">PRIME Designation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The EMA grants access to the Priority Medicines, or PRIME, program to investigational medicines for which it determines there to be pre-liminary data available showing the potential to address an unmet medical need and bring a major therapeutic advantage to patients. As part of the program, EMA provides early and enhanced dialogue and support to optimize the development of eligible medicines and speed up their evaluation, aiming to bring promising treatments to patients sooner. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">200</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Periods of Authorization and Renewals</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A marketing authorization is valid for five&#160;years, in principle, and it may be renewed after five&#160;years on the basis of a reevaluation of the risk benefit balance by the EMA or by the competent authority of the authorizing Member State. To that end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six&#160;months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is not followed by the placement of the product on the European Union market (in the case of the centralized procedure) or on the market of the authorizing Member State within three&#160;years after authorization ceases to be valid. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Regulatory Requirements after Marketing Authorization</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include compliance with the European Union&#8217;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. The holder of a marketing authorization must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs. All new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the marketing authorization. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. RMPs and PSURs are routinely available to third parties requesting access, subject to limited redactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the manufacturing of authorized products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the EMA&#8217;s GMP requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities and controls used in the manufacturing, processing and packing of products to assure their safety and identity. Specifically, medicinal products may only be manufactured in the European Union, or imported into the European Union from another country, by the holder of a manufacturing/import authorization from the competent national authority. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with European Union standards of good manufacturing practice, or GMP, before releasing the product for commercial distribution in the European Union or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finally, the marketing and promotion of authorized products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of products and/or the general public, are strictly regulated in the European Union. In principle, all advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the European Union. Although general requirements for advertising and promotion of medicinal products are established under Directive 2001/83/EC, as amended, the details are governed by regulations in each member state and can differ from one country to another. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Human Cells and Tissues</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Human cells and tissues that are intended for human applications but that do not fall within the scope of rules governing medicinal products or medical devices are not subject to premarket review and approval, nor do they require extensive pre-clinical and clinical testing. However, there are European Union rules governing the donation, procurement, testing and storage of human cells and tissues intended for human </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">201</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">application, whether or not they are ATMPs. These rules also cover the processing, preservation and distribution of human cell and tissues that are not ATMPs. Establishments that conduct such activities must be licensed and are subject to inspection by regulatory authorities. Such establishments must implement appropriate quality systems and maintain appropriate records to ensure that cells and tissues can be traced from the donor to the recipient and vice versa. There are also requirements to report serious adverse events and reactions linked to the quality and safety of cells and tissues. More detailed rules may exist at the national level. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Named Patient Supplies</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The European Union medicines rules allow individual member states to permit the supply of a medicinal product without a marketing authorization to fulfill special needs, where the product is supplied in response to a bona fide unsolicited order, formulated in accordance with the specifications of a healthcare professional and for use by an individual patient under his direct personal responsibility. This may in certain countries also apply to products manufactured in a country outside the European Union and imported to treat specific patients or small groups of patients. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Australian Regulatory Requirements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are currently conducting a Phase&#160;2 clinical trial of our EVX-01 product candidate in Australia, which has laws and regulations related to the conduct of clinical trials with which we and the entities and persons conducting the clinical investigations must comply. A failure to do so, may affect our ability to use the data from such trial when seeking marketing authorization and/or may result in regulatory action by the TGA, including, but not limited to, civil and criminal penalties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Therapeutic Goods Act 1989, or the 1989 Act, sets out the legal requirements for the import, export, manufacture and supply of pharmaceutical products in Australia. The 1989 Act requires that all pharmaceutical products to be imported into, supplied in, manufactured in or exported from Australia be included in the Australian Register of Therapeutic Goods, or the ARTG, unless specifically exempted under the Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Medicines with a higher level of risk (prescription medicines, some non-prescription medicines) are evaluated for quality, safety and efficacy and are registered on the ARTG. Medicines with a lower risk (many over the counter medicines including vitamins) are assessed only for quality and safety. Medicines included in the ARTG can be identified by the AUST R number (for registered medicines) or an AUST L number (for listed medicines) which appears on the packaging of the medicine. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In order to ensure that a product can be included in the ARTG, a sponsoring company must make an application to the TGA. The application usually consists of a form accompanied by data (based on the EU requirements) to support the quality, safety and efficacy of the product for its intended use and payment of a fee. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The first phase of evaluation, known as the Application Entry Process, is usually a short period during which an application is assessed at an administrative level to ensure that it complies with the basic guidelines. The TGA may request further details from the applicant and may agree with sponsors that additional data (which while not actually required by the application, could enhance the assessment outcome) may be submitted later at an agreed time. The TGA must decide within at least 40 working days whether it will accept the application for evaluation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Once an application is accepted for evaluation, aspects of the data provided are allocated to evaluators within the different relevant sections, who prepare clinical evaluation reports. Following evaluation, the chemistry, quality control bioavailability and pharmacokinetics aspects of a product may be referred to a Pharmaceutical Sub-Committee, or the PSC, which is a sub-committee of the TGA prescription medicine expert advisory committee, the Advisory Committee on Prescriptive Medicines, or the ACPM, to review the relevant clinical evaluation reports. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The clinical evaluation reports (along with any resolutions of the ACPM sub-committee) are sent to the sponsoring company who then has the opportunity to comment on the views expressed within the evaluation report, provide corrections and to submit supplementary data to address any issues raised in the evaluation reports. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">202</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Once the evaluations are complete, the TGA prepares a summary document on the key issues on which advice will be sought from either the ACPM (for new medicines) or from the Peer Review Committee, or the PRC, for extensions to products which are already registered. This summary is sent to the sponsoring company, which is able to submit a response to the ACPM or PRC dealing with issues raised in the summary and those not previously addressed in the evaluation report. The ACPM/PRC provide independent advice on the quality, risk/benefit, effectiveness and access of the product and conduct medical and scientific evaluations of the application. The ACPM meets every two&#160;months to examine the applications referred by the TGA and its resolutions are provided to the sponsoring company within five working days after the ACPM meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The TGA takes into account the advice of the ACPM or PRC in reaching a decision to approve or reject a product. Any approval for registration on the ARTG may have conditions associated with it. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From the time that the TGA accepts the initial application for evaluation, the TGA must complete the evaluation and make a decision on the registration of the product within at least 255 working days. If not completed within 255 working days, the TGA forfeits 25% of the evaluation fee otherwise payable by the sponsor, but any time spent waiting for a response from the sponsor is not included in the 255 working days. The TGA also has a system of priority evaluation for products that meet certain criteria, including where the product is a new chemical entity that it is not otherwise available on the market as an approved product, and is for the treatment of a serious, life-threatening illness for which other therapies are either ineffective or not available. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Rest of the World Regulation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For other countries outside of the European Union, Australia and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from jurisdiction to jurisdiction. Additionally, the clinical trials must be conducted in accordance with cGCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">European Data Collection and Data Protection Laws</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are required to comply with strict data protection and privacy legislation in the jurisdictions in which we operate, including the General Data Protection Regulation (EU) 2016/679, or GDPR. The GDPR governs our collection and use of personal data in the European Union relating to individuals (e.g., patients). The GDPR imposes several requirements on organizations that process such data, including: to observe core data processing principles; to comply with various accountability measures; to provide more detailed information to individuals about data processing activities; to establish a legal basis to process personal data (including enhanced consent requirements); to maintain the integrity, security and confidentiality of personal data; and to report personal data breaches. The GDPR also restricts the transfer of personal data outside of the European Economic Area (e.g., to the United States and other countries that are not deemed to provide adequate protection under their domestic laws). The GDPR may impose additional responsibility and liability in relation to personal data that we process and require us to put in place additional mechanisms ensuring compliance with the new data protection rules. This may be onerous and adversely affect our business, financial condition, results of operations and prospects. Failure to comply with the requirements of the GDPR and related national data protection laws of European Union member states may result in a variety of enforcement measures, including significant fines and other administrative measures. The GDPR has introduced substantial fines for breaches of the data protection rules, increased powers for regulators, enhanced rights for individuals, and new rules on judicial remedies and collective redress. We may be subject to claims by third parties, such as patients or regulatory bodies, that we or our employees or independent contractors inadvertently or otherwise breached GDPR and related data protection rules. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we do not prevail, we could be required to pay substantial fines and/or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">203</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">damages and could suffer significant reputational harm. Even if we are successful, litigation could result in substantial cost and be a distraction to management and other employees. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Australian Privacy Laws</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Australia, where we are currently conducting clinical trials for EVX-01, regulates data privacy and protection through a mix of federal, state and territory laws. The federal Privacy Act 1988 (</font><font style="font-style:italic;letter-spacing:0.2pt;">Cth</font><font style="letter-spacing:0.2pt;">) (Privacy Act) or the Privacy Act, and the Australian Privacy Principles, or the APPs, contained in the Privacy Act apply to private sector entities (including body corporates, partnerships, trusts and unincorporated associations) with an annual turnover of at least AU$3&#160;million, and all Commonwealth Government and Australian Capital Territory Government agencies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Privacy Act regulates the handling of personal information by relevant entities and under the Privacy Act, the Privacy Commissioner has authority to conduct investigations, including own motion investigations, to enforce the Privacy Act and seek civil penalties for serious and egregious breaches or for repeated breaches of the APPs where an entity has failed to implement remedial efforts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2022, the Australian Government increased fines for violations of the Privacy Act. The maximum fine for a serious invasion or repeated invasions of privacy (i.e. breaches of the privacy law) was increased to up to the greater of AUD $50&#160;million, three times the benefit of a contravention, or (where the benefit can&#8217;t be determined) 30% of domestic turnover. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, most States and Territories in Australia (except Western Australia and South Australia) have their own data protection legislation applicable to relevant State or Territory government agencies, and private businesses that interact with State and Territory government agencies. These Acts include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Information Privacy Act 2014</font><font style="letter-spacing:0.2pt;"> (Australian Capital Territory) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Information Act 2002</font><font style="letter-spacing:0.2pt;"> (Northern Territory) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Privacy and Personal Information Protection Act 1998</font><font style="letter-spacing:0.2pt;"> (New South Wales) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Information Privacy Act 2009</font><font style="letter-spacing:0.2pt;"> (Queensland) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Personal Information Protection Act 2004</font><font style="letter-spacing:0.2pt;"> (Tasmania), and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Privacy and Data Protection Act 2014</font><font style="letter-spacing:0.2pt;"> (Victoria) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, there are other parts of Australian State, Territory and federal legislation that relate to data protection. For example, the following all impact privacy and data protection for specific types of data or activities: the </font><font style="font-style:italic;letter-spacing:0.2pt;">Telecommunications Act 1997</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Cth</font><font style="letter-spacing:0.2pt;">), the </font><font style="font-style:italic;letter-spacing:0.2pt;">Criminal Code Act 1995</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Cth</font><font style="letter-spacing:0.2pt;">), the </font><font style="font-style:italic;letter-spacing:0.2pt;">National Health Act 1953</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Cth</font><font style="letter-spacing:0.2pt;">), the </font><font style="font-style:italic;letter-spacing:0.2pt;">Health Records and Information Privacy Act 2002</font><font style="letter-spacing:0.2pt;"> (NSW), the </font><font style="font-style:italic;letter-spacing:0.2pt;">Health Records Act 2001</font><font style="letter-spacing:0.2pt;"> (Vic) and the </font><font style="font-style:italic;letter-spacing:0.2pt;">Workplace Surveillance Act 2005</font><font style="letter-spacing:0.2pt;"> (NSW). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Specific regulators have also expressed an expectation that regulated entities should have specified data protection practices in place. For example, the Australian Prudential and Regulatory Authority, or the APRA, which regulates financial services institutions requires regulated entities to comply with Prudential Standards, including Prudential Standard CPS 234 Information Security (CPS 234), and the Australian Securities and Investment Commission regulates corporations more generally. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Coverage, Pricing and Reimbursement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sales of pharmaceutical products approved by the FDA will depend in significant part on the availability of third-party coverage and reimbursement for the products. Third-party payors include government healthcare programs in the United States such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">204</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">approved products for a particular indication. We may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Moreover, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development. Our product candidates may not be considered cost-effective. It is time consuming and expensive to seek reimbursement from third-party payors. Reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of our product candidate to currently available therapies (so called health technology assessment, or HTA) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally tend to by significantly lower. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution (arbitrage between low-priced and high-priced member states) can further reduce prices. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other United States Healthcare Laws and Regulations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Our current and future arrangements with providers, researchers, consultants, third-party payors and customers are subject to broadly applicable federal and state fraud and abuse, anti-kickback, false claims, transparency and patient privacy laws and regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations include, without limitation, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the United States federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in-cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or a specific intent to violate it in order to have committed a violation. Moreover, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">205</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious, or fraudulent or knowingly making, using, or causing to be made or used a false record or statement to avoid, decrease, or conceal an obligation to pay money to the federal government; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or a specific intent to violate it in order to have committed a violation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations, including the Final Omnibus Rule published in January&#160;2013, which impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without the appropriate authorization by entities subject to the law, such as healthcare providers, health plans and healthcare clearinghouses and their respective business associates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">federal government price reporting laws, which require us to calculate and report complex pricing metrics to government programs and which may be used in the calculation of reimbursement and/or discounts on marketed products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Foreign Corrupt Practices Act, a United States law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the national anti-bribery laws and laws governing interactions with healthcare professionals of European Union Member States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the U.K. Bribery Act 2010; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring pharmaceutical manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures and pricing information. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Violations of these laws can subject us to criminal, civil and administrative sanctions including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">206</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we may be required to curtail or restructure our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to similar actions, penalties, and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could impact our future operations and business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Current and Future Healthcare Reform Legislation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, in December&#160;2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and devices and to spur innovation, but its ultimate implementation is uncertain. In addition, in August&#160;2017, the FDA Reauthorization Act was signed into law, which reauthorized the FDA&#8217;s user fee programs and included additional drug and device provisions that build on the Cures Act. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As previously mentioned, a primary trend in the United States health care industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other health care funding and applying new payment methodologies. For example, in March&#160;2010, the Affordable Care Act was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; imposed mandatory discounts for certain Medicare Part&#160;D beneficiaries as a condition for manufacturers&#8217; outpatient drugs coverage under Medicare Part&#160;D; and established a Center for Medicare Innovation at the United States Centers for Medicare and Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. As noted above, a 2018 federal district court ruling struck down the Affordable Care Act in its entirety although the Fifth Circuit Court of Appeals recently limited it to the individual mandate and remanded the case to the district court to determine if other reforms not specifically related to the individual mandate or health insurance could be severed from the rest of the Affordable Care Act. On June&#160;17, 2021, the Supreme Court reversed the district court decision on the basis that the plaintiffs lacked standing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act that affect health care expenditures. There has been heightened governmental scrutiny in recent&#160;years over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical and biologic products. Notably, on December&#160;20, 2019, President Trump signed the Further Consolidated Appropriations Act for 2020 into law (P.L. 116-94) that includes a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">207</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">CREATES Act. The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic and biosimilar product developers access to samples of brand products. Because generic and biosimilar product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic and biosimilar products. To remedy this concern, the CREATES Act establishes a private cause of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially reasonable, market-based terms.&#8221; Whether and how generic and biosimilar product developments will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on our future commercial products are unknown. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Packaging and Distribution in the United States</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The failure to comply with any of these laws or regulatory requirements subjects&#8217; firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Changes in regulations, statutes, or the interpretation of existing regulations could impact our business in the future by requiring, for example, (i)&#160;changes to our manufacturing arrangements, (ii)&#160;additions or modifications to product labeling, (iii)&#160;the recall or discontinuation of our products or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other United States Environmental, Health and Safety Laws and Regulations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">208</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We maintain workers&#8217; compensation employers&#8217; liability insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Introduction</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We actively seek to protect the intellectual property (IP) and proprietary technology that we believe is important to our business. Further, we seek to protect our proprietary position by, amongst other methods, filing patent applications in Europe, the United States and potentially other relevant jurisdictions relating to our inventions, improvements and product candidates. We also pursue IP protection for assets that may be used in future development programs and/or that may be of interest to our collaborators, or otherwise may prove valuable in the field. We pursue a patent strategy which seeks to protect marketed products and methods of their production, as well as therapy methods enabled by our proprietary AI-Immunology&#8482; platform without disclosure to the public the core elements in our technology. Furthermore, we have filed patent protection of aspects of our PIONEER&#8482;, EDEN&#8482;, AI-DeeP&#8482; and RAVEN&#8482; models, however, we do not believe that the value of obtaining patent protection for all component of our platform technologies outweighs the risks of disclosing such information. We rely on trade secrets and know-how relating to our proprietary technologies to develop, maintain and strengthen our proprietary position in AI-based drug discovery and development. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Patent applications that relate to the PIONEER&#8482; technology cannot meaningfully be directed to single antigens and their various uses; neoantigens identified by PIONEER&#8482; are by nature unique for each patient, therefore, the precise nature of each neoantigen has no relevance as an object for intellectual property rights. We are therefore establishing patent portfolio around the PIONEER&#8482; model which protects generally applicable aspects of the model, enabling personalized cancer vaccine, i.e. protection of additional features and elements which characterize the PIONEER-enabled therapy compositions, and which could be applied to other anti-cancer therapies that are based on immunization against neoantigens. The focus on the patent protection in the PIONEER&#8482; setting is therefore aiming at securing patent protection for 1) specific essential elements/ features needed to identify neoantigens not specific to the PIONEER&#8482; system, 2) specific features characterizing the composition of the designed therapy, and 3) specific features related to patient safety of the administered composition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the AI-Immunology&#8482; model; EDEN&#8482;, we file patents to protect vaccine antigens identified, vaccine compositions, antibodies, and antibody compositions as well as methods for prophylactic treatment of infectious diseases where the vaccine antigens and antibodies constitute the active ingredient. We file applications relating to several vaccine targets for each infectious agent causing the diseases and prosecute those antigens that have shown greatest promise as protective antigens in animal models. Our patent strategy for the EDEN technology also entails identification of optimal combinations of vaccine antigens as well as identification of specific vaccine formulations and modes of immunization that can be made the subject of second- and later generation patent applications that protect the final marketed product. Furthermore, we have one patent family pending covering the EDEN&#8482; method itself. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the AI-Immunology&#8482; model; RAVEN&#8482;, we have filed patent applications related to some aspects of the method for viral vaccine design as well as product claims related to viral vaccines designed by RAVEN thus harboring unique features of the RAVEN&#8482; design. However, the core functionality of RAVEN&#8482; is protected by trade-secret and not patents as we have assessed that disclosure of methods do not outweigh the benefit of obtaining patent protection. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Most of our IP assets were developed and are owned solely by us. In the few cases where our IP assets are jointly owned or in-licensed from third parties, we retain full rights to the commercial exploitation of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">209</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">such assets. We expect that we will continue to make additional patent application filings and will continue to pursue opportunities to acquire and license additional IP assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Regardless, given the early stage of prosecution for some of our patent application, we cannot be certain that any of the patent filings or other IP rights that we have pursued or obtained will provide protection for any product candidates that may ultimately be commercialized. Our most advanced product candidates are currently in clinical testing, with no certainty that they will be successful, or that significant modification or adjustment may not be required for successful commercialization. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our success will depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technologies, inventions, and know-how related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable patents and proprietary rights of third parties. For more information, please see &#8220;Risk Factors&#8201;&#8212;&#8201;Risk Related to Our Intellectual Property&#8221;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">An issued patent provides its owner (or possibly its licensee) with a right to exclude others from making, using or selling that which is claimed in the patent, for a specified period of time (the &#8220;term&#8221; of the patent), in the jurisdiction in which the patent is issued. In the United States, and in many other countries, patents have a presumptive term of 20&#160;years from their accorded filing date (which is the earliest filing date to which the patent claims lineage, excluding filing dates claimed as priorities under the Paris Convention Priorities and/or priorities claimed from provisional patent applications). We believe that due to the patient-specific nature of our PIONEER&#8482; based cancer vaccines, in which our PIONEER&#8482; model is an inherent part of the product, and the platform predicted neoantigens cannot, we believe, be copied, such therapies will not be subject to competition from generic products even when the patent protection expires. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Patent Portfolio</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;1st, 2023, we owned a total of 27 patent families, of which 9 are currently in their priority year or international phase and we own several granted patents in the United States (11), Germany&#160;(4), France (4), Spain (1), Great Britain (5)&#160;and 1 European unitary patent (in force 17 EU-member states) and have 59 pending national/regional applications. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">So far none of our granted patents has been subject to opposition, administrative reexamination, inter partes review, invalidity actions, or similar actions aiming at revoking or restricting the scope of a granted patent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The patent portfolio related to our most advanced product candidates and technologies as of December&#160;1st, 2023 are summarized below. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">EVX-01</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">EVX-01 is protected by trade secrets, patent applications related to, and the proprietary nature of the AI-Immunology model; PIONEER. In addition to IP protection of the PIONEER&#8482; model, our patent portfolio related to EVX-01 currently includes one patent family directed to a method of treating cancer in a patient using neopeptides (EVX-01). The patent application has entered national phase in CA, CN, US, EP, JP and AU. We expect the patent family to lapse in January&#160;2040. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">EVX-02</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">EVX-02 is protected by trade secrets, patent applications related to, and the proprietary nature of the PIONEER&#8482; models. In addition to IP protection of the PIONEER&#8482; model, our patent portfolio related to EVX-02 currently includes two patent families. The first patent family is claiming a method directed at inducing an anti-cancer immune response in patients by administrating the EVX-02 vaccine concept comprising DNA plasmid and polaxomer 188, a novel adjuvant. The second patent family is directed at a method of inducing and anti-cancer immune response in patients by administrating the EVX-02 plasmid alone. As of December&#160;1st, 2023, both patent families are in national phase in EP, CA, CN, US, JP and AU. The first patent family is expected to lapse in March&#160;2040 and the second in December&#160;2040. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">210</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">EVX-03</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">EVX-03 is protected by trade secrets, patent applications related to, and the proprietary nature of the PIONEER model. Furthermore, due to the similarities between our two DNA-based cancer vaccines, EVX-03 and EVX-02, our patent families covering EVX-02 also applies to EVX-03. In addition, one patent family has been filed that specifically relates to the targeting unit, unique to EVX-03. The patent family is a composition of matter application directed to the EVX-03 product concept. As of December&#160;1st, 2023, the patent family is in international stage. We expect that the patent rights will lapse in April&#160;2041. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">EVX-B1</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our patent portfolio related to EVX-B1 as of December&#160;1st, 2023 includes five patent families. The patent families are composition of matter patents, or methods for inducing anti </font><font style="font-style:italic;letter-spacing:0.2pt;">s. aureus</font><font style="letter-spacing:0.2pt;"> immunity, directed against compositions comprising one or more </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> antigens. As of December&#160;1st, 2023, the first patent family comprise five issued patents in the US, one in DE, one in FR and one in GB as well as one pending application in US and one pending application in EP. The patent family is expected to expire in April&#160;2032. The second patent family comprises one US patent, one US and one EP pending application. We expect the patent family to lapse in December&#160;2034. The third patent family comprises one US, one GB, one DE and one FR registered patents. We expect the family to lapse in February&#160;2037. Our fourth EVX-B1 related patent family comprises one issued US patent as well as pending applications in EP and US. We expect this patent family to lapse in July&#160;2037. The fifth family claims a composition used for vaccination against </font><font style="font-style:italic;letter-spacing:0.2pt;">S. aureus</font><font style="letter-spacing:0.2pt;"> comprising our EVX-B1 vaccine. The application is in international phase and upon entry into national stage, we expect this patent family to lapse in 2042. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">EVX-B2</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Patent portfolio related to EVX-B2 comprise two patent families. Both families are directed against antigens useful in vaccines against N. gonorrhoeae. The first patent family is at national stage and contains pending applications in EP and the US. Subject to grant, we expect these patents to expire in 2041. The second family is in international phase, and we expect, upon entry into national applications, that patent arising from the international application will expire in 2042. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">PIONEER</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The AI-Immunology&#8482; model: PIONEER&#8482; is mainly protected as a trade secret as computational methods are complicated to patent and protect from infringement. However, our current patent portfolio comprises one patent family related to PIONEER&#8482; covering some aspects that are important for neoantigen selection and detectable for infringement. The patent family is directed against a method for selecting and de-selection of neoantigens for treatment of cancer comprising the SLICE model used in PIONEER for epitope prioritization. As of December&#160;1st, 2023, the patent family comprise one AU, one CA, one CN, one EP, one JP and one US application. We expect the family to lapse in July&#160;2041. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">ObsERV</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The AI-Immunology&#8482; model: ObsERV&#8482; is, like the PIONEER&#8482; model, protected by trade-secrets and one patent family. The family supplements the identification of neoantigens with a system for identifying highly immunogenic epitopes from human endogenous retroviral sequences, or hERVs, and other normally non-expressed tumor specific epitopes found in the human genome and use these to treat cancer. The patent discloses a method for deselecting potentially harmful and non-immunogenic hERV epitopes. This patent application is in international stage as of December&#160;1st, 2023. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">RAVEN</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our AI-Immunology&#8482; model; RAVEN&#8482;, is in addition to trade secrets and the proprietary nature of the model, protected by two patent families. The first patent family is a composition of matter family directed to the vaccine delivery concept that can be utilized together with the RAVEN&#8482; model. As of December&#160;1</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">st</font><font style="letter-spacing:0.2pt;"> the family comprise one AU, one CA, one CN, one, EP, one JP and one US patent application. We expect the patent family to lapse in July&#160;2041. The second patent family also a matter of composition patent aimed </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">211</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">at a vaccine product designed from analyzing genomes of pathogens by the RAVEN model. As of December&#160;1st, 2023, this patent family comprise one EP and one US patent application. We expect the patent family to lapse in 2042. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">AI-DeeP</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our AI-Immunology&#8482; model; AI-DeeP&#8482;, is in addition to trade-secret and the proprietary nature of the model, protected by one patent family. The patent family discloses a method for identifying patients&#8217; response to immunotherapy comprising measuring and relating HLA expression in patient&#8217;s tumor sample. The method disclosed is comprised in the AI-DeeP model&#8482;. As of December&#160;1</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">st</font><font style="letter-spacing:0.2pt;"> 2023 the patent family is in national phase. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">EDEN</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our AI-Immunology&#8482; model EDEN&#8482;, has provided input for multiple patent applications within our bacterial vaccine portfolio. The model itself is been kept as trade-secret, however one patent application has been filed to cover the EDEN&#8482; method. As of December&#160;1</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">st</font><font style="letter-spacing:0.2pt;">, 2023, the application is in priority year and is expected to lapse in 2043. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">In-Licensing</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have pursued a strategy of identifying and in-licensing third-party patents that we believe are complementary to or otherwise interact synergistically with our own intellectual property portfolio. On November&#160;30, 2020 we entered into a CAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">09b Supply, Patent Know How Trademark License Agreement with Statens Serum Institut, or SSI, which will grant us an exclusive, royalty-bearing sub-licensable license to a product comprising SSI&#8217;s adjuvant technology CAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">09b and PIONEER identified neopeptides. Pursuant to the terms of the agreement, we or our affiliates may import, have imported, export, have exported, formulate or have formulated, commercialize, market, use, offer for sale, sell, have sold, supply, or have supplied PIONEER derived cancer vaccines administered together or in combination with licensed adjuvant, but not, on a stand-alone basis, the licensed adjuvant. The license specifically excludes any manufacturing rights to the licensed adjuvant, unless the license is extended and the license further excludes any research and development in relation to the licensed adjuvant other than where such research and development is in connection with and for the purpose of research and development in respect of PIONEER derived cancer vaccines administered together or in combination with licensed adjuvant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the SSI agreement, we have rights to three issued United States patents and other patents and patent applications in jurisdictions outside the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SSI license requires us to pay to SSI an upfront licensing fee equal to &euro;50,000. In addition, in the event we commercialize any PIONEER derived cancer vaccines administered together or in combination with licensed adjuvant on our own, we are required to pay SSI a royalty on net sales in the low teens. The royalty term extends for a fixed period of 10&#160;years commencing on the first calendar day of the calendar month following the first commercial sale of a PIONEER&#8482; derived cancer vaccine administered together or in combination with the licensed adjuvant. Upon expiration thereof, the SSI license shall be deemed to be fully paid up, royalty-free, irrevocable and perpetual with respect to such vaccine. However, if any PIONEER&#8482; derived cancer vaccine administered together or in combination with licensed adjuvant are commercialized by one of our partners, if any, we are required to pay SSI a&#160;percentage of any out-licensing revenue (milestones and royalties) earned by us and our affiliates. The size of the income share due to SSI shall be determined and reflect the extent to which we have invested in carrying out the Phase&#160;2 and Phase&#160;3 clinical trials in respect of the PIONEER&#8482; derived cancer vaccines administered together or in combination with licensed adjuvant prior to entering into a sub-license agreement. If we enter into a sublicense agreement with a partner on our EVX-01 product candidate subsequent to the initiation of a Phase&#160;2 clinical trial, we are required to pay to SSI a&#160;percentage of any sublicensing income in an amount in the lower double-digit range. If we enter into a sublicense agreement with a partner on our EVX-01 product candidate subsequent to the initiation of a Phase&#160;3 trial, we are required to pay to SSI a&#160;percentage of any sublicensing income in the lower double-digit range. The agreements states that if we enter into a sublicense agreement with a partner on our EVX-01 product candidate without initiating Phase&#160;2 trial, we are required to pay to SSI a&#160;percentage of any sublicensing income in the mid double-digit range. We have initiated a Phase&#160;2 trial, hence this term </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">212</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">is no longer relevant. Prior to any out-licensing or commercialization of EVX-01, we are not required to make any additional payments to SSI outside of the &euro;50.000 upfront fee mentioned above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The SSI license will terminate on the earlier of (i)&#160;a fixed period of 10&#160;years commencing on the first calendar day of the calendar month following the first commercial sale of a PIONEER&#8482; derived cancer vaccine administered together or in combination with licensed adjuvant and (ii)&#160;the effective date of termination. In this connection, we or SSI may terminate the license upon prior written notice in the event of (a)&#160;a material breach which is not capable of remedy, or if capable of being remedied, such remedy does not occur within a specified time after notification or (b)&#160;an order is made or a resolution passed for the winding up of either SSI or us. In addition, we may terminate the SSI License upon prior written notice if we are not able to reach a supply agreement with SSI&#8217;s designated commercial supplier of the licensed adjuvant. Apart from such causes, SSI may not terminate the license agreement and we may only terminate the SSI license on (c)&#160;the grounds of lack of efficacy of a PIONEER&#8482; derived cancer vaccine administered together or in combination with licensed adjuvant, as a result of which we determine not to progress with the development and commercialization of such product or (d)&#160;due to safety concerns, market and/or competitive situation that would prevent commercialization of a PIONEER&#8482; derived cancer vaccine administered together or in combination with licensed adjuvant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On April 28, 2022, we received formal notice that on April 21, 2022, SSI, had initiated a legal proceeding against us in The Danish Maritime and Commercial High Court (S. og Handelsretten), claiming sole ownership of a patent application (PCT/EP2020/050058 and subsequently national filings, EP3906045), we had filed related to a method for treating malignant neoplasm by administering a composition comprising a high dose of neopeptides, a solvent and an liposomal adjuvant, e.g. CAF.09b, for which we have a license agreement.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The patent application for the Invention relates solely to the use of the adjuvant CAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">09b in conjunction with a high dose of neopeptides in our EVX-01 product candidate. SSI&#8217;s claim to the patent application does not relate to any other aspect of our patent portfolio covering EVX-01 or the PIONEER&#8482; model. The patent application stems from work we performed under a collaboration agreement we entered into with SSI, DTU, Center for Cancer Immune Therapy (Herlev Hospital) and the Center for Genomic Medicine (Rigshospitalet). The patent application names us and certain of our employees as the sole invertors of the Invention. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In its filing, SSI&#8217;s primary claim is that the Invention disclosed in the patent application was not made by us and our employees, but rather, that SSI and members of its staff made the Invention and, therefore, SSI and certain of its staff members should be listed as the sole inventors of the Invention. Subsidiary claims are that SSI should have co-ownership with us of the patent application and the Invention. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">It is our position that we and our employees are the sole inventors of the Invention. We believe that we have strong defenses against SSI&#8217;s claim and that SSI&#8217;s claim is without merit. We intend to vigorously defend the action. In any event, even if SSI&#8217;s claim were to be upheld by the court, while no assurance can be given, we do not expect that the claim would have a material impact on our rights to use the Invention in the development and commercialization of EVX-01, as we believe that such rights are covered by our current license agreement with SSI and SSI would be excluded from enforcing its rights in the Invention to prevent us from developing and commercializing our EVX-01 product candidate. The opinion of our legal counsel is that the ongoing legal proceedings will not have a material impact on our future financial results or business operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;1st, 2023, we and SSI have completed several rounds of written statements to the courts after which the court will announce official dates for court meetings to take place. The court proceedings have been paused since May&#160;2023 on the basis that non-court mediated negotiations are ongoing between us and SSI to resolve the situation without further court proceedings. In December&#160;2023 terms were agreed between us and SSI which results in a situation where we retain all commercial rights to EVX-01 and the patent application, the law-suit will be lifted on a walk-away basis and no compensation by Evaxion to SSI. Final contracts remain to be signed. We expect the case to be finally closed in the first quarter of 2024. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;29, 2020, we entered into a license agreement with PharmaJet or the PharmaJet License Agreement, which grants us non-exclusive, sub-licensable license to certain intellectual property of PharmaJet </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">213</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">and supply of the Stratis</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> device and disposable needle-free syringes and filling adapter items for use with any products derived from one or more of our product candidates in the field of prophylaxis, diagnosis prediction, and/or treatment of cancer in humans and/or animals. Subject to meeting certain development milestones, additional consideration of up to $320,000 is to be transferred to the seller. Further, $250,000 is to be transferred to the seller upon each regulatory approval of an Evaxion product utilizing the in-licensed technology. Also, we will owe PharmaJet customary royalties in the low single digits based on net commercial sales of any products derived from our product candidates for so long as we continue to use in our product candidates the intellectual property and products licensed from PharmaJet pursuant to the PharmaJet License Agreement. The PharmaJet License Agreement will remain in effect for an initial period until successful completion of the first Phase&#160;1/2a clinical study of our product candidate in combination with the PharmaJet product with the option to extend the term for additional 10&#160;years, after which the term will automatically extend for successive periods of 24&#160;months if not terminated prior to the beginning of each such subsequent extension. Either party may terminate the agreement upon six&#160;months prior notice with effect immediately prior to a subsequent extension term. Either party may terminate the agreement with immediate effect upon written notice to the other party due to a material breach by the other party. Moreover, we may terminate the agreement in the event of i) change of control or divestment, ii) regulatory action taken by the FDA or EMA, iii) termination of development of our product in combination with PharmaJet product or iv) if PharmaJet undergoes a change of control to a third party who does not agree to continue to supply us PharmaJet product. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Trade secret protection</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain of our technologies, including in particular certain proprietary manufacturing processes or technologies and/or AI-based prediction technologies, are protected as trade secrets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to patent protection, we rely upon unpatented trade secrets and confidential know-how and continuing technological innovation to develop and maintain our competitive position. We protect certain of our technologies, including but not limited to algorithms and software, from becoming public knowledge. However, trade secrets and confidential know-how are difficult to protect. We seek to protect our proprietary information, in part, by using confidentiality agreements with any future collaborators, scientific advisors, employees and consultants, invention assignment agreements with our employees and internal processes for handling trade-secrets. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. See &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to our Intellectual Property&#8221; for a more comprehensive description of risks related to our intellectual property. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Competition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We compete in an industry characterized by rapidly advancing technologies, intense competition and a complex intellectual property landscape. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">AI-Immunology&#8482; platform</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We face competition from several companies developing AI platforms and software including Schrodinger, BenevolentAI, Atomwise, AI Therapeutics, Insilico Medicine, Recursion Pharmaceuticals, Lantern Pharma, Adaptive Biotechnologies, Immatics, BIOVIA, and Citrine, among others. However, because most of these companies are not focused on developing therapeutic drug candidates centered around neoantigens, ERV antigens or bacteria or viral antigens, we do not consider the majority of them to be our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">214</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">direct competitors. Below is a description of the companies we consider to be our main competitors for each of our three AI models and their respective indications. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">PIONEER&#8482;&#8201;&#8212;&#8201;Neoantigen vaccines</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The immuno-oncology therapeutics landscape in general is highly competitive and includes large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions. It includes both competition from marketed therapies as well as potential new therapeutics in development. We may compete with products with different mechanisms of action as well as against established standards of care. Well-established companies such as AstraZeneca, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Merck &amp; Co., Novartis, Pfizer, Roche and Sanofi are developing diversified immuno-oncology programs and have substantial resources. Smaller companies are also developing immuno-oncology drugs, such as Jounce Therapeutics, Arcus Biosciences, ALX Oncology, iTeos Therapeutics and Five Prime Therapeutics, among others. We expect our vaccine candidates for the treatment of solid tumors to face direct competition from companies such as Moderna in collaboration with Merck &amp; Co., BioNTech SE in collaboration with Roche and Nykode in collaboration with Roche. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also expect to face competition from smaller specialized oncology companies active in the neoantigen/</font>&#8203;<font style="letter-spacing:0.2pt;">personalized cancer therapy space including Agenus, Gritstone Bio, Achilles Therapeutics, NousCom, Immunetune, ISA Pharmaceuticals, PACT Pharma, PersImmune, and Geneos Therapeutics. </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">EDEN&#8482;&#8201;&#8212;&#8201;B-cell antigen vaccines</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our main competitors taking a prophylactic approach to bacterial diseases are BioNTech SE, GlaxoSmithKline, Pfizer and Sanofi Pasteur. Additional competitors within the bacterial disease space include well-established pharmaceutical companies including AbbVie, Bayer, Gilead, Janssen Pharmaceuticals, Merck &amp; Co. and Novartis. In addition, Seqirus UK, Biomedical Corp. of Quebec and AstraZeneca produce vaccines. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">RAVEN&#8482;&#8201;&#8212;&#8201;T-cell antigen vaccines</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our plans to leverage our RAVEN platform to develop vaccines against viral diseases will put us in competition with several other companies focused on viral vaccines including Moderna, BioNTech, CureVac, Novavax, Johnson &amp; Johnson, GSK, Merck &amp; Co. and AstraZeneca. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Many of our competitors and potential competitors, either alone or with their collaborators, have greater scientific, research and product development capabilities as well as greater financial, marketing, sales and human resources and experience than we do. In addition, smaller or early-stage companies, including immunotherapy-focused therapeutics companies, may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Some of our collaborators may also be competitors within the same market or other markets. Accordingly, our competitors may be more successful than us in developing and potentially commercializing technologies and achieving widespread market acceptance. In addition, our competitors may design technologies that are more efficacious, safer or more effectively marketed than ours or have fewer side effects or may obtain regulatory approvals more quickly than we are able to, which could eliminate or reduce our commercial potential. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We anticipate that the key competitive factors affecting our technologies will be efficacy, safety, cost, speed and convenience. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. The timing of market introduction of our products and competitive products will also affect competition among products. We expect the relative speed with which we can develop our products, complete the clinical trials and approval processes, and supply commercial quantities of the products to the market to be important competitive factors. Our competitors also may obtain FDA or other regulatory approval for their products more </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">215</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:75.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employees</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2023, we had 49 full-time equivalent employees, of which 20 hold a doctoral degree or higher. The following tables provide breakdowns of our full-time equivalent employees as of September&#160;30, 2023 by function: </font>
        </div>
        <table style="width:416pt;height:83.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:377.08pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Function </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:377.08pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Clinical Research &amp; Development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:4.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:377.08pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Scientific Research &amp; Development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:4.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:377.08pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Supporting Functions </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">13.5</td>
            <td style="padding:0pt;padding-left:4.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:377.08pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Commercial &amp; Business Development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.5</td>
            <td style="padding:0pt;padding-left:4.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:377.08pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">TOTAL</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">49</td>
            <td style="padding:0pt;padding-left:4.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since 2022, our workforce has decreased by 17%. The workforce will in the future be adjusted according to the business plans. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">None of our employees have engaged in any labor strikes. We have no collective bargaining agreements with our employees. We consider our relationship with our employees to be positive and have not experienced any major labor disputes. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Organizational Structure</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Evaxion was formed as a private limited liability company organized under Danish law on August&#160;11, 2008 and re-registered as a public limited liability company on March&#160;29, 2019. Certain of our operations are conducted through our wholly owned subsidiaries, Evaxion Biotech Australia PTY LTD (Australia) and Evaxion Biotech, Inc., in Australia and the United States, respectively, both of which are listed in Exhibit&#160;8.1 to this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Property and Equipment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2020, the Company entered into a lease for approximately 1,356 square meters, which is allocated on 839 square meters of office space, and 518 square meters of laboratory space in H&#248;rsholm, Denmark. The commencement date for the lease of the 839 square meters of office space was February&#160;1, 2021 and the lease continues for a term of 10&#160;years from that date. The commencement date for the lease of the laboratory space is August&#160;13, 2021 and the lease continues for a term of 10&#160;years. Both leases have a subsequent 12-month cancellation notice period. The lease agreement contains an early termination provision which would trigger a termination fee of $2.7&#160;million. Through-out the term, the lease is subject to annual increases ranging from two to four&#160;percent on the annual lease payment amount. As of December&#160;31, 2022, the monthly payment is approximately $26,000, which consists of $11,000 for the office space and approximately $15,000 for the laboratory space. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unresolved Staff Comments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">None.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">216</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMAN">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MANAGEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Directors, Senior Management and Employees</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Directors and Senior Management</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have a two-tier governance structure consisting of a board of directors and an executive management team. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Executive Management</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth certain information relating to our executive management as of the date of December&#160;31, 2023. </font>
        </div>
        <table style="width:416pt;height:83.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:155.61pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:24pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Age </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:212.39pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Position(s) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:155.61pt;">
              <font style="letter-spacing:-0.2pt;">Executive Management:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:212.39pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:155.61pt;">
              <font style="letter-spacing:0.2pt;">Christian Kanstrup, MSc</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">51 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:212.39pt;">
              <font style="letter-spacing:0.2pt;">Chief Executive Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:155.61pt;">
              <font style="letter-spacing:0.2pt;">Jesper Nyegaard Nissen, MSc</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">54 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:212.39pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Chief Operating Officer &amp; Chief Financial Officer </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:155.61pt;">
              <font style="letter-spacing:0.2pt;">Birgitte R&#248;n&#248;, Ph.D. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">47 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:212.39pt;">
              <font style="letter-spacing:0.2pt;">Chief Scientific Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:155.61pt;">
              <font style="letter-spacing:0.2pt;">Andreas Holm Mattsson </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">48 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:212.39pt;">
              <font style="letter-spacing:0.2pt;">Chief AI and Culture Officer</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Kanstrup entered into an agreement to join us on August&#160;24, 2023, and joined us on September&#160;1, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Nissen entered into an agreement to join us on January&#160;16, 2022, and joined us on March&#160;14, 2022. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following is a brief summary of the prior business experience of the members of our executive management: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Chief Executive Officer, Christian Kanstrup joined us on September&#160;1, 2023. Christian Kanstrup has more than 25&#160;years of experience in the life science industry, coming from a position of Executive Vice President at Mediq before joining Evaxion. Prior to that, Christian held a broad range of senior management roles at Novo Nordisk A/S, latest as Senior Vice President and global head of Biopharm Operations. Prior to that Christian among others held senior leadership roles within the commercial part of the business as well as within strategy and corporate development. Christian also holds various board and advisory positions in the life science industry, advising on corporate strategy and company growth. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Jesper Nyegaard Nissen joined as Chief Operating Officer in 2022 and was also appointed interim Chief Financial Officer in 2023. For over 25&#160;years, Jesper Nyegaard Nissen has worked broadly across the pharma value chain in global operations positions at Novo Nordisk anchored in research and finance. He has covered business areas across a variety of focus points, including finance operation, external innovation and collaborations, digitalization of business process optimization, development and shaping of organizational capacities, and implementation of performance and process improvement structures. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Chief Science Officer, Birgitte R&#248;n&#248;, joined in 2017 and was appointed CSO in 2021. Dr.&#160;R&#248;n&#248; has more than 20&#160;years&#8217; experience in biopharmaceutical drug discovery from academia and industry and received her PhD in experimental oncology and immunology from National Institutes of Health, Bethesda, USA, and Copenhagen University Hospital, Denmark. Prior to joining Evaxion, Birgitte R&#248;n&#248; served as a specialist, team leader and project manager at Novo Nordisk A/S, where she was leading early drug discovery projects, evaluating in-licensing opportunities, and supporting drug development projects with pre-clinical and biomarker expertise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Andreas Holm Mattsson serves as Chief AI Officer at Evaxion Biotech, where he&#8217;s been at the forefront in silico-based vaccine target discovery. He has played a key role in developing Evaxion&#8217;s innovative AI-Immunology platform, a proprietary AI technology for identifying novel vaccine targets for cancer and infectious diseases. Andreas brings a strong educational background in bioinformatics from the Technical University of Denmark and has previously worked at Novo Nordisk. Since founding Evaxion in 2008, he has been an essential part of the company&#8217;s growth, serving in various executive roles. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">217</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2023, Per Norl&#233;n, our Chief Executive Officer, or CEO, stepped down and Christian Kanstrup assumed Per Norl&#233;n duties as CEO. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In July&#160;2023 Bo Karmark, our Chief Financial Officer, or CFO, stepped down and Jesper Nyegaard Nissen assumed Bo Karmarks duties as CFO. In March&#160;2023, Dr.&#160;Erik Deichmann Heegaard, our Chief Medical Officer, or CMO, at the time stepped down and Dr.&#160;Norl&#233;n along with our Vice President of Clinical Development assumed Dr.&#160;Heegaard&#8217;s duties as CMO. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Family Relationships</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are no family relationships among any of our directors and/or executive management. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation of Executive Management and Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of the date of this Form F1, our executive management consists of our Chief Executive Officer, Chief Operating Officer, Chief AI and Culture Officer, Chief Scientific Officer and Chief Financial Officer. The members of our executive management are eligible to receive an annual performance-based cash bonus subject to certain predefined corporate and individual goals as determined by our board of directors on an annual basis. The members of our executive management are also eligible to receive an extraordinary bonus at the discretion of our board of directors. This financial information has been prepared by and is the responsibility of our management. Our independent registered public accounting firm, EY Godkendt Revisionspartnerselskab, has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, EY Godkendt Revisionspartnerselskab does not express an opinion or any other form of assurance with respect thereto. These results could change as a result of further review. Complete financial results for the year ended December&#160;31, 2023 will be included in our Annual Report on Form 20-F. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table presents compensation received by our executive management, for the&#160;years ended December&#160;31, 2023, 2022, and 2021. </font>
        </div>
        <table style="width:416pt;height:286pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:332pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:332pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Per Norl&#233;n (CEO)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(7)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Salary </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">346</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">85</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bonus </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other employee benefits </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">21</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">346</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">114</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Bo Karmark (CFO)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(9)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Salary </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">332</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">160</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bonus </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">74</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other employee benefits </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">35</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">332</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">269</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Jesper Nygaard Nissen (COO and CFO)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(10)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Salary </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">267</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">209</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Bonus</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">44</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other employee benefits</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">39</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">300</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">292</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Lars Staal Wegner</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(6)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">218</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:558pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:332pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:332pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:332pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Salary </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">352</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">378</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bonus </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">71</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">105</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other employee benefits </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(16<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">127</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">407</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">610</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Niels Iversen M&#248;ller (CBO)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(3)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Salary </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">67</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">245</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bonus </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">23</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other employee benefits </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">75</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">268</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Andreas Holm Mattsson (CAICO)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Salary </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">232</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">229</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">245</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Bonus</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">68</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">45</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other employee benefits</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">22</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">247</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">319</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">290</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Erik Deichmann Heegaard, Ph.D., DMSc (CMO)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(4)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Salary </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">267</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">265</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">214</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bonus </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">52</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">52</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other employee benefits </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">162</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">266</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">267</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">479</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">532</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Birgitte R&#248;n&#248;, Ph.D. (CSO)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(5)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Salary </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">232</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">235</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">110</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Bonus</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">23</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">45</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">33</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other employee benefits</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">7</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">56</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">56</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">262</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">336</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Christian Kanstrup (CEO)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(8)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Salary </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">115</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Bonus</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other employee benefits</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">97</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">224</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Glenn S. Vraniak</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(1)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Salary </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">310</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bonus </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">73</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other employee benefits </font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;font-weight:bold;letter-spacing:-0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">65</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:332pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">448</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Vraniak resigned as the Chief Financial Officer of the Company effective November&#160;1, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">In 2019, Mr.&#160;Vraniak our CFO at the time, was issued 150,660 warrants. The terms of the warrants issued to Mr.&#160;Vraniak were amended, resulting in an acceleration of stock-based compensation expense in 2020. Mr.&#160;Vraniak resigned as our CFO effective November&#160;1, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Effective November&#160;1, 2021, Mr.&#160;M&#248;ller became our Interim Chief Business Officer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">219</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Heegaard joined our company in April&#160;2021 as CMO and did not receive any compensation from us in 2019 and 2020. Dr.&#160;Heegaard has been terminated as CMO on March&#160;31, 2023 and his last day of employment is March&#160;31, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:3.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;R&#248;n&#248; was appointed Chief Scientific Officer in September&#160;2021. Prior to September&#160;2021, Dr.&#160;R&#248;n&#248; was a non-executive employee. The salary above is for the period July&#160;1, 2021 to December&#160;31, 2021, as Dr.&#160;R&#248;n&#248; took the responsibility on July&#160;1, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Wegner stepped down as CEO in September&#160;2022 and Dr.&#160;Wegner&#8217;s employment terminated on December&#160;31, 2022. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Norl&#233;n stepped down as CEO in August&#160;2023 and Dr.&#160;Norl&#233;n&#8217;s employment is terminated on August&#160;31, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Kanstrup was appointed Chief Executive Officer in September&#160;2023. The salary above is for the period September&#160;1, 2023 to December&#160;31, 2023, as Mr.&#160;Kanstrup took on the responsibility on September&#160;1, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(9)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Bo Karmark stepped down as CFO in July&#160;2023 and Mr.&#160;Karmarks employment ends without further notice on Februry 29, 2024 </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(10)</font>
          <br >
        </div>
        <div style=" margin-top:3.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Following the termination of the CFO Mr.&#160;Karmark, the COO Jesper Nyegaard Nissen, on August&#160;1, 2023, took on the duties of the Chief Financial Officer acting as Interim CFO. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Bonus and other employee benefits regarding 2023 will be paid out in January&#160;2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table lists compensation to our board of directors for the&#160;years ended December&#160;31, 2023, 2022, and 2021: </font>
        </div>
        <table style="width:456pt;height:376.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:372pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:372pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Marianne S&#248;gaard (Chairman of the Board of Directors)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(1)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Board and committee fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">146</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">132</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">121</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other Fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">23</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">75</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">45</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">166</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">165</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">166</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Roberto Prego</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Board and committee fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">63</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">57</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">55</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other Fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">68</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">62</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">69</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Steven Projan</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(6)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Board and committee fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">63</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">59</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other Fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">68</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">73</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Lars Holtug</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(4)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Board and committee fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">59</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">59</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other Fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">64</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">64</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">50</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Helen M. Boudreau</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(2)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Board and committee fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">220</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:241pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:372pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:372pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:372pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other Fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:372pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Jo Ann Suzich</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(3)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Board and committee fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other Fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:372pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Niels Iversen M&#248;ller</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:-0.15pt;">(5)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Board and committee fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">52</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">45</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other Fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">22</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:372pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">79</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">49</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Ms.&#160;S&#248;gaard was appointed as Chairman of the Board on November&#160;25, 2020. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Ms.&#160;Boudreau elected not to stand for re-election to the Board in 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Ms.&#160;Suzich elected not to stand for re-election to the Board in 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Holtug was elected as a member of the Board at the 2021 Annual General Meeting held on May&#160;25, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;M&#248;ller was appointed as a member of the Board in 2022. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Projan stepped down from his position as member of the Board effective from May&#160;24, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Share-based compensation regarding 2023 was granted by the Board on December&#160;11, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No member of the board of directors is entitled to any kind of compensation upon retirement from his or her position as a member of the board of directors. We have not allocated funds for any pension benefits, severance schemes or similar measures, or undertaken any other obligations to do so on behalf of the board of directors, and we have no obligation to do so. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table lists aggregate compensation to our employees, excluding executive management and board of directors, and subsequently aggregate executive management compensation and Board of Directors compensation for the&#160;years ended December&#160;31, 2023, 2022 and 2021: </font>
        </div>
        <table style="width:456pt;height:165pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:352.88pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:352.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:352.88pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:352.88pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Employee costs, excluding Executive Management and Board of Directors</font>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Salaries </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,521</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,201</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,743</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash bonus </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">269</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">421</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">337</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">111</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">592</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">778</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other social security contributions </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">19</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other staff costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">196</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">389</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">364</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total employee costs, excluding Executive Management and Board of Directors </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,115</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7,622</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:352.88pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Executive Management compensation</font>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">221</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:316pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:352.88pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:352.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:352.88pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Salaries </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,792</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,602</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,502</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash bonus </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">138</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">368</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">331</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">321</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">514</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other social security contributions </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other staff costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total Executive Management compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,130</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,291</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,347</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Board of Directors compensation</font>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Board and committee fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">383</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">379</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">313</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Travel allowance </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">90</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">87</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total board of directors compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">473</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">408</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total employee costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8,718</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,321</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">9,997</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Recognized as follows in the Statement of Comprehensive Loss:</font>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,451</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,156</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7,845</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,267</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">2,165</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,152</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total employee costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8,718</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,321</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">9,997</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Average number of full-time employees </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">54</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">60</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">53</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Number of full-time employees </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">49</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">63</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">61</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:19.7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Management Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Christian Kanstrup, M.Sc.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2023, we entered into an executive service contract with Mr.&#160;Kanstrup, who started in September&#160;2023. Mr.&#160;Kanstrup&#8217;s executive service contract also confirms his title, base salary, his eligibility for an annual bonus, and his eligibility for benefits and provides for certain benefits upon termination of his employment under specified conditions. Mr.&#160;Kanstrup&#8217;s employment under the executive service contract continues until terminated by us or Mr.&#160;Kanstrup. We may terminate Mr.&#160;Kanstrup&#8217;s employment for any reason with 9&#160;months&#8217; notice and Mr.&#160;Kanstrup may terminate his employment with three&#160;months&#8217; notice. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Jesper Nyegaard Nissen, M.Sc.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2022, we entered into an executive service contract with Mr.&#160;Nissen, who started in March&#160;2022. Mr.&#160;Nissen&#8217;s executive service contract also confirms his title, base salary, his eligibility for an annual bonus, and his eligibility for benefits and provides for certain benefits upon termination of his employment under specified conditions. Mr.&#160;Nissen&#8217;s employment under the executive service contract continues until terminated by us or Mr.&#160;Nissen. We may terminate Mr.&#160;Nissen&#8217;s employment for any reason with 9&#160;months&#8217; notice and Mr.&#160;Nissen may terminate his employment with three&#160;months&#8217; notice. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Birgitte R&#248;n&#248;, Ph.D.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2021, we entered into an executive service contract with Dr.&#160;R&#248;n&#248;. The contract confirms Dr.&#160;R&#248;n&#248;&#8217;s employment by the Company since September&#160;2017. Dr.&#160;R&#248;n&#248;&#8217;s executive service contract also confirms her title, base salary, her eligibility for an annual bonus, and her eligibility for benefits and provides for certain benefits upon termination of her employment under specified conditions. Dr.&#160;R&#248;n&#248;&#8217;s employment under the executive service contract continues until terminated by us or Dr.&#160;R&#248;n&#248;. We may terminate Dr.&#160;R&#248;n&#248;&#8217;s employment for any reason with 12&#160;months&#8217; notice and Dr.&#160;R&#248;n&#248; may terminate her employment with three&#160;months&#8217; notice. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">222</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Andreas Holm Mattsson</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2020, we entered into an executive service contract with Mr.&#160;Mattsson. The executive service contract confirms Mr.&#160;Mattsson&#8217;s title, his base salary, his eligibility for an annual bonus, and his eligibility for benefits and also provides for certain benefits upon termination of his employment under specified conditions. Mr.&#160;Mattsson&#8217;s employment under the executive service contract continues until terminated by us or Mr.&#160;Mattsson. We may terminate Mr.&#160;Mattsson&#8217;s employment for any reason with 12&#160;months&#8217; notice and Mr.&#160;Mattsson may terminate his employment with three&#160;months&#8217; notice. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Board of Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Descriptions and summaries of the prior business experience of the members of our board of directors are described in &#8220;Board practices&#8221; below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Warrant Incentive Plan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our directors, executive management, employees, consultants, and advisors are eligible to participate in our warrant incentive program. Warrants have been issued by the board of directors pursuant to valid authorizations in our articles of association or by the shareholders acting in general meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The terms and conditions of the warrants have, in accordance with applicable Danish laws and regulations, been incorporated into our articles of association as appendices 1-3 and 5. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Warrants granted to our directors, executive management and employees during 2023</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During 2023, the Company granted 416,074 warrants, of which 169,167 were granted to its Chief Executive Officer (&#8220;CEO&#8221;), 6,250 were granted to its Chief AI and Culture Office, 12,500 were granted to its Chief Scientific Officer and 12,500 were granted to its Chief Operating Officer. All granted employee and management warrants vest with 1/36 part per month. Board warrants vest with 1/12 part per month. The weighted average exercise price of the warrants granted during 2023 was USD 1.30 per warrant. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Warrants granted during 2022</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During 2022, the Company granted 491,612 warrants, of which 35,000 were granted to its Chief AI and Culture Officer (&#8220;CAICO&#8221;), 25,000 were granted to its Chief Scientific Officer (&#8220;CSO&#8221;), 61,667 were granted to its Chief Financial Officer (&#8220;CFO&#8221;), 25,000 were granted to its Chief Medical Officer (&#8220;CMO&#8221;), 45,833 were granted to its Chief Operating Officer (&#8220;COO&#8221;), 3,125 were granted to its Chief Business Officer (&#8220;CBO&#8221;) and 53,125 were granted to its Chief Executive Officer (&#8220;CEO&#8221;). All granted warrants will vest over 36&#160;months. The weighted average exercise price of the warrants granted during 2022 was USD 2.24 per warrant. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Warrants granted during 2021</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2021 62,147 warrants were granted to the Chief Medical Officer with an exercise price of DKK&#160;1 per warrant. The warrants vest over 36&#160;months. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2021 523,599 warrants were granted to employees, members of the board of directors and members of executive management with an exercise price of USD 5.38 per warrant. The warrants vest over 36&#160;months for employees and executive management. For the board of directors, warrants vest immediately. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General matters related to warrants granted under Warrant Incentive Plan</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2023, our board of directors is authorized to issue an additional 6,568 warrants to members of the company&#8217;s board of directors and executive management as well as key-employees, advisors and consultants during the period ending January&#160;3, 2026. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The grant of warrants to any participant is at the discretion of our board of director and based on the recommendation of our Compensation Committee. The board of directors may determine the terms and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">223</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">conditions of the warrants issued, including exercise periods, subscription price and adjustments caused by changes to our company&#8217;s share capital. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Warrants granted for the&#160;years 2016&#8201;&#8211;&#8201;2018 vest upon certain exit or liquidation events, which include an event such as the closing of our IPO in February&#160;2021. Warrants granted for the&#160;years 2019&#8201;&#8211;&#8201;2021 generally vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month. However, in relation to all warrants granted and issued prior to the closing of our IPO, our board of directors established four annual exercise windows in which warrants may be exercised following the completion of our IPO. The first such exercise window began in November&#160;2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Warrants granted before or during the second quarter of 2021 have an exercise price of DKK 1 per warrant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Warrants granted before or during 2019 expire December&#160;31, 2036. Warrants granted thereafter expire December&#160;31, 2031. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The table below provides an overview of the warrants granted to our board of directors and executive management as of December&#160;31, 2023. </font>
        </div>
        <table style="width:416pt;height:146.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:215.74pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:106.04pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Grant Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Ordinary Shares</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Underlying Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:215.74pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Marianne S&#248;gaard (Chairman)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:106.04pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">2018&#8201;&#8211;&#8201;2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">188,487</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:215.74pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Niels Iversen M&#248;ller (Director)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:106.04pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">2022&#8201;&#8211;&#8201;2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">8,750</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:215.74pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Lars Holtug (Director)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:106.04pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">2021&#8201;&#8211;&#8201;2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">14,583</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:215.74pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Roberto Prego (Director)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:106.04pt;text-align:right;">
              <div style="white-space:nowrap; text-align:right;">
                <font style="letter-spacing:0.2pt;">2017&#8201;&#8211;&#8201;2018, 2021&#8201;&#8211;&#8201;2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">48,747</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:215.74pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Jesper Nyegaard Nissen (COO)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:106.04pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">2022&#8201;&#8211;&#8201;2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">58,333</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:215.74pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Andreas Holm Mattsson (CAICO)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:106.04pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">2022&#8201;&#8211;&#8201;2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">41,250</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:215.74pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Birgitte R&#248;n&#248; (CSO)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:106.04pt;text-align:right;">
              <div style="white-space:nowrap; text-align:right;">
                <font style="letter-spacing:0.2pt;">2017&#8201;&#8211;&#8201;2019, 2021&#8201;&#8211;&#8201;2022</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">111,876</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:215.74pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Christian Kanstrup (CEO)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:106.04pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">169,167</td>
            <td style="padding:0pt;padding-left:18.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Warrants granted to investors and consultants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Warrants granted during 2023</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August the company granted 150,000 warrants to a consultant. 37,500 of such warrants vested on 20 November&#160;2023, 37,500 warrants vest on 20 February&#160;2024, 37,500 warrants vest on 20 May&#160;2024 and 37,500 warrants vest on 20 August&#160;2024. The warrants granted and vested may be exercised until and including 19 September&#160;2026. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, In December the company granted 9,726,898 warrants to investors. Such warrants vested immediately and may be exercised until 21 December&#160;2026. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2023, our board of directors is authorized to issue 728,964 warrants to the company&#8217;s investors during the period ending November&#160;23, 2025. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2023, our board of directors is authorized to issue 20,123,102 warrants to investors, lenders, consultants and/or advisors in the company or its subsidiaries during the period ending May&#160;1, 2027. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Insurance and Indemnification</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under Danish law, members of the board of directors or senior management may be held liable for damages in the event that loss is caused due to their negligence. They may be held jointly and severally liable for damages to the company and to third-parties for acting in violation of the articles of association and Danish law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The general meeting is permitted to discharge our directors and members of our executive management from liability for any particular financial year based on a resolution relating to the period covered by the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">224</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">financial statements for the previous financial year. This discharge means that the general meeting will relieve such directors and members of our executive management from liability to us. However, the general meeting cannot discharge any claims by individual shareholders or other third parties. In addition, the discharge can be set aside in case the general meeting prior to its decision to discharge was not presented with all reasonable information necessary for the general meeting to assess the matter at hand. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, we have agreed to indemnify our directors and members of our executive management and employees in relation to certain claims. We will not, however, indemnify our directors, executive management and employees, in respect of: (i)&#160;claims against a person pursuant to Danish law raised before the Danish Courts, except claims arising from the offer, sale and listing of our securities in the United States and/or our subsequent status as a listed company in the United States, including in respect of our reports filed with or furnished to the SEC; (ii)&#160;claims against a person for damages and legal costs related to criminal and/or grossly negligent or willful acts or omissions committed by the indemnified person; (iii)&#160;claims against an indemnified person, which is attributable to the gaining or purported gaining of any profit or advantage to which the indemnified person or any related natural or legal person was not legally entitled; (iv)&#160;claims covered by insurance; (v)&#160;claims brought against the indemnified person by the Company or any subsidiary of the Company; and (vi)&#160;any sum payable to a regulatory authority by way of a penalty in respect of the indemnified person&#8217;s personal non-compliance with any requirement of a regulatory nature howsoever arising. The indemnification will be limited to a maximum amount per claim per person equivalent to the gross proceeds obtained by us in connection with the offering of ADSs in the United States. The indemnification shall remain in force for a period of five&#160;years after the resignation of the indemnified person from the company or its subsidiaries, if the claims made within such period are related to such person&#8217;s services to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There is a risk that such indemnification will be deemed void under Danish law, either because the indemnification is deemed contrary to the rules on discharge of liability in the Danish Companies Act (</font><font style="font-style:italic;letter-spacing:0.2pt;">Selskabsloven</font><font style="letter-spacing:0.2pt;">) as set forth above, because the indemnification is deemed contrary to sections 19 and 23 of the Danish Liability for Damages Act (</font><font style="font-style:italic;letter-spacing:0.2pt;">Erstatningansvarsloven</font><font style="letter-spacing:0.2pt;">), which contain mandatory provisions on recourse claims between an employee (including members of our executive management) and the company, or because the indemnification is deemed contrary to the general provisions of the Danish Contracts Act (</font><font style="font-style:italic;letter-spacing:0.2pt;">Aftaleloven</font><font style="letter-spacing:0.2pt;">). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, we provide our directors and executive management with directors&#8217; and officers&#8217; liability insurance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Board practices</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Members of Our Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our Board of Directors</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth certain information relating to our board of directors as of the date of this F1. The terms of office of all of our directors expire at the next annual general meeting to be held in 2024. All directors are eligible for re-election. </font>
        </div>
        <table style="width:416pt;height:77.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:154.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:43.22pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Age </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:53.43pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Independent </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year of first</font>
                <br >
                <font style="letter-spacing:-0.16pt;">appointment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Expiration</font>
                <br >
                <font style="letter-spacing:-0.16pt;">of current term </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:154.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Marianne S&#248;gaard</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)(2)(3)(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:43.22pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Chairman </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">55</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:53.43pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Independent </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.58pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2020</td>
            <td style="padding:0pt;padding-left:10.58pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2024</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:154.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Roberto Prego</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)(2)(3)(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.22pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">53</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:53.43pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Independent </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.58pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:10.58pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2024</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:154.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lars Holtug</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.22pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">65</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:53.43pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Independent </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.58pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2021</td>
            <td style="padding:0pt;padding-left:10.58pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2024</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:154.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Niels Iversen M&#248;ller</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.22pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">45</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:53.43pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">No </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.58pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2022</td>
            <td style="padding:0pt;padding-left:10.58pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2024</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.2pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Member of Nominating and Corporate Governance Committee </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Member of Audit Committee </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Member of Compensation Committee </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Member of Capital market, communication and BD Committee </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">225</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:60pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following is a brief summary of the prior business experience of the members of our board of directors: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Marianne S&#248;gaard</font><font style="letter-spacing:0.2pt;"> joined us in 2018 as an executive and legal advisor and in November&#160;2020 she was elected and became the Chairman of our board of directors. In 1996, Ms.&#160;S&#248;gaard joined Kammeradvokaten/</font>&#8203;<font style="letter-spacing:0.2pt;">Law Firm Poul Schmith where she worked for more than 20&#160;years as a lawyer, primarily working with technology and processes to acquire technology solutions. For more than 17&#160;years, Ms.&#160;S&#248;gaard was a partner at Kammeradvokaten/Law Firm Poul Schmith and from January&#160;2014 to March&#160;2017 she served on the board of directors of the law firm. Ms.&#160;S&#248;gaard serves as a member of the board of directors at various privately held companies e.g. Altapay A/S a payment solution company, PiiGuard a software solution for personal data, and including being the chairperson of the board at Garbanzo ApS, a small startup food company. Ms.&#160;S&#248;gaard received her Master of Law degree from Aarhus Universitet in 1993. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In preparation of becoming a publicly traded company in the United States and in order to ensure compliance with the requirements of a company listed on the Nasdaq Capital Market, we underwent a restructuring of our Board. In connection therewith, on November&#160;4, 2020, we asked our Chairman, Kim Bjoernstrup, to step down from the Board, and Mr.&#160;Bjoernstrup submitted his resignation. In his place, the Board nominated Marianne S&#248;gaard for the position of Chairman of the Board, subject to the approval of our shareholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Roberto Prego</font><font style="letter-spacing:0.2pt;"> joined us in 2018. Mr.&#160;Prego has over 20&#160;years of pharmaceutical experience and was one of our first outside investors. Mr.&#160;Prego was with Teva Venezuela as its General Manager from 1998 to 2012 and with Teva Latin American Region as its Head of Region from 2011 to 2015. Since 2015, he has served as the General Manager of Viax Dental Technologies, a research and development venture firm in the dental field. Mr.&#160;Prego has a B.S. in Economics from Universidad Cat&#243;lica Andr&#233;s Bello in Caracas, Venezuela and an M.B.A. from Fuqua School of Business at Duke University. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Lars Holtug</font><font style="letter-spacing:0.2pt;"> joined us in 2021. Mr.&#160;Holtug was a partner at PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab, or PwC from 1993 to 2015. Mr.&#160;Holtug also currently serves as a board member of Ascendis Pharma and as chairman of Erhvervsinvest Management A/S, a private equity firm, of Gaming Investment A/S, a gaming solutions provider, and its 11 subsidiaries, and of Caretag ApS, a healthcare technology comopany. Previously, he was Chairman of PwC in Denmark from 2005 to 2009. From 2004 to 2015, Mr.&#160;Holtug was a member of the Danish Commercial Appeals Board (Erhvervsankenaevnet) and a board member of the Danish Company law association (Dansk Forening for Selskabsret). He was also a member of the Accounting Standards Board of the Federation of State Authorized Accountants in Denmark (Foreningen af Statsautoriserede Revisorer) from 1998 to 2002, and a member of the Auditing Standards Board from 1993 to 1998. Mr.&#160;Holtug holds an M.Sc. from Copenhagen Business School and is educated as a state authorized public accountant in Denmark </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Niels Iversen M&#248;ller, M.D.</font><font style="letter-spacing:0.2pt;"> is one of our co-founders. Dr.&#160;M&#248;ller joined our Board in 2022. From our inception in 2008 until August&#160;2017, Dr.&#160;M&#248;ller was our Chief Executive Officer and in 2016, he was awarded &#8220;CEO of the Year&#8221; in the vaccine industry by European CEO. From August&#160;2017 to November&#160;2021, Dr.&#160;M&#248;ller served as our Chief Business Officer. Beginning on November&#160;1, 2021, Dr.&#160;M&#248;ller replaced Mr.&#160;Vraniak as our Interim Chief Financial Officer and served in that position until August&#160;2022, when he stepped down to join our Board and was replaced by Bo Karmark. From 2009 to 2011 he was a Medical Director within the area of Companion Diagnostics for Medical Prognosis A/S and from 2008 to 2009 he was a Medical Advisor within the area of cancer and biopharmaceuticals for AstraZeneca. Dr.&#160;M&#248;ller began this career at Servier Pharmaceuticals as Marketing Manager. Dr.&#160;M&#248;ller received his M.D. from the University of Copenhagen and his BA in Economics from Copenhagen Business School. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">226</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Director Compensation Policy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors and shareholders have approved and adopted a policy with respect to the compensation payable to our directors, which became effective as of January&#160;1, 2022. Under this policy, each director will be eligible to receive compensation for his or her service on the board of directors and for service on each committee on which the director is a member, which will consist of annual cash retainers. Our directors have received the following annual cash payments for their service in 2023: </font>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:111.07pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Board Member </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:43.22pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:228pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Committees </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Retainer </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:111.07pt;vertical-align:top;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Marianne S&#248;gaard </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:43.22pt;vertical-align:top;">
              <font style="letter-spacing:0.2pt;">Chairman </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:228pt;">
              <font style="letter-spacing:0.2pt;">Audit, Nominating and Corporate Governance, </font>
              <br >
              <font style="letter-spacing:0.2pt;">Compensation, Capital market Communication and </font>
              <br >
              <font style="letter-spacing:0.2pt;">BD Committee </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:center;">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; white-space:nowrap;text-align:center;">156,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:111.07pt;vertical-align:top;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Roberto Prego </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:43.22pt;vertical-align:top;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:228pt;">
              <font style="letter-spacing:0.2pt;">Audit, Nominating and Corporate Governance, </font>
              <br >
              <font style="letter-spacing:0.2pt;">Compensation Committee, Capital Market, </font>
              <br >
              <font style="letter-spacing:0.2pt;">Communication and BD Committee </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:center;">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; white-space:nowrap;text-align:center;">63,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:111.07pt;vertical-align:top;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Niels Iversen M&#248;ller </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:43.22pt;vertical-align:top;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:228pt;">
              <font style="letter-spacing:0.2pt;">Capital Market, Communication and BD Committee, </font>
              <br >
              <font style="letter-spacing:0.2pt;">Nominating and Corporate Governance Committee </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:center;">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; white-space:nowrap;text-align:center;">74,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:111.07pt;vertical-align:top;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lars Holtug </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:43.22pt;vertical-align:top;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:228pt;">
              <font style="letter-spacing:0.2pt;">Audit, Compensation </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:center;">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:24.75pt; white-space:nowrap;text-align:center;">59,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:7.81pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Directors may also receive equity awards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Directors will be reimbursed for travel, food, lodging and other expenses directly related to their service as directors. Directors are also entitled to the protection provided by their indemnification agreements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Committees of our Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Board of Directors has four standing committees: an Audit Committee, a Compensation Committee, a Capital Market, Communication and BD Committee, and a Nominating and Corporate Governance Committee. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Audit Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The audit committee consists of Lars Holtug, Roberto Prego and Marianne S&#248;gaard, and assists the board of directors in overseeing our accounting and financial reporting processes. Mr.&#160;Holtug serves as chairperson of the audit committee. The audit committee consists exclusively of members of our board of directors who are financially literate, and Mr.&#160;Holtug is considered an &#8220;audit committee financial expert&#8221; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq rules and regulations. Our board of directors has determined that all of the members of the audit committee satisfy the &#8220;independence&#8221; requirements set forth in Rule&#160;10A-3 under the Exchange Act and the Nasdaq rules. The audit committee will be governed by a charter that complies with Nasdaq rules. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The audit committee&#8217;s responsibilities include, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">recommending and supervising our external auditors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">pre-approve all non-audit services to be provided by any external auditors exceeding a cap determined by our board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">providing our board of directors with advice regarding the proposed external auditors from time to time as well as evaluate the quality of work being performed by the external auditors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">ensuring that appropriate policies with regard to hiring employees from our external auditors are in place; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and monitoring the independence and quality of work being performed by our external auditors, especially the appropriateness of the provision of non-audit services; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">evaluating the information contained in our external financial reporting; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing our annual and quarterly financial statements prior to publication and/or filing (or submission, as the case may be) with the SEC; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">227</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">informing our board of directors of the result of the statutory audit, including the financial reporting process; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">monitoring the financial reporting process and submit recommendations or proposals to ensure its integrity and monitoring of remediation of the material weakness in internal controls over financial reporting; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">evaluating the &#8220;going-concern&#8221; principle, including any special assumptions, qualifications and/or uncertainties related thereto; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">evaluating the main accounting policies and principles applied including to make recommendations to our board of directors regarding whether these should be amended; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">evaluating significant accounting estimates and judgments made and changes hereto; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and evaluating transactions with related parties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">evaluating relevant risks and uncertainties for the relevant year, e.g. in relation to the outlook in the financial reporting; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">evaluating the overall presentation of our financial reporting in order to ensure that it provides a true and fair view of the financial position as well as our development and performance; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">evaluating our compliance with relevant audit and accounting related laws and regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">supervising our internal audit program; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">such other matters that are specifically delegated to our audit committee by our board of directors from time to time; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">meeting separately, periodically, with management, internal auditors and the independent auditor. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The compensation committee consists of Roberto Prego, Lars Holtug and Marianne S&#248;gaard. Mr.&#160;Prego serves as chairperson of the compensation committee. Under SEC and Nasdaq rules, there are heightened independence standards for members of the compensation committee, including a prohibition against the receipt of any compensation from us other than standard director fees. Although foreign private issuers are not required to meet this heightened standard, all of our compensation committee members are expected to meet this heightened standard. The compensation committee&#8217;s responsibilities include, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">At least annually, review the compensation philosophy of the Company </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Obtain information on market trends in executive compensation and shall review the competitiveness of the Company&#8217;s executive compensation programs to ensure (i)&#160;the attraction and retention of officers </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">At least annually, review and recommend to the Board for approval the corporate goals and objectives relevant to CEO and other officer compensation, evaluate CEO and officer performance in light of those goals and objectives, and review and recommend to the Board all compensation of the Company&#8217;s officers based on such evaluation </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Periodically and as and when appropriate, review and recommend to the Board the following as they affect the Company&#8217;s officers: (i)&#160;any employment agreements and severance arrangements, including any amendments, supplements or changes thereto; (ii)&#160;any change-in-control agreements and change-in-control provisions affecting any elements of compensation and benefits and (iii)&#160;any special or supplemental compensation and benefits for the officers and individuals who formerly served as officers, including supplemental retirement benefits and the perquisites provided to them during and after employment </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Oversee the Company&#8217;s compliance with the requirement under NASDAQ rules that, with limited exceptions, shareholders approve equity compensation plans. Subject to such shareholder approval, or otherwise required by the Exchange Act, the Code or other applicable law, the Committee shall have </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">228</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">the power to periodically review and make recommendations to the Board regarding annual bonus, long-term incentive compensation, equity awards, employee pension and welfare benefit plans including 401(k) plans, employee share purchase plans, long-term incentive plans, management incentive plans and others and with respect to each plan shall have responsibility for making recommendations to the Board </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Be responsible for recommending that the Board certify that any and all performance targets used for any performance-based compensation plans have been met before payment of any officer bonus or compensation or exercise of any officer award granted under any such plan(s) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Periodically review and make recommendations to the Board regarding policies concerning perquisite benefits </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Determine the Company&#8217;s policy with respect to change of control or &#8220;parachute&#8221; payments </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Monitor the Company&#8217;s compliance with applicable legal requirements of the Sarbanes Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act and other applicable local laws and regulations relating to employee compensation and benefits </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Review and make recommendations regarding the compensation policies applicable to all employees of the Company, including periodic reviews of the adequacy of the Company&#8217;s compensation structure, performance review procedures, employee turn-over and retention, successorship plans and other human resource issues </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Review and discuss with the Executive Management of the Company the compensation disclosures to be included in the Company&#8217;s filings and submissions with the SEC </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Periodically review and make recommendations to the Board with respect to the compensation of the Board&#8217;s non-management board members </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Annually and with input from the Nominating and Corporate Governance Committee of the Board if deemed appropriate, perform an evaluation of the performance of the Committee and its members, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Annually and with input from the Nominating and Corporate Governance Committee if deemed appropriate, review and reassess this Charter and submit any recommended changes to the Board for its consideration </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nominating and Corporate Governance Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Nominating and Corporate Governance Committee consists of Marianne S&#248;gaard, Roberto Prego and Niels Iversen M&#248;ller. Ms.&#160;S&#248;gaard serves as chairperson of the nominating and corporate governance committee. The Nominating and Corporate Governance Committee&#8217;s responsibilities include, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Prior to each annual meeting of stockholders at which board members are to be elected or reelected, the Committee shall recommend to the Board for nomination by the Board such candidates as the Committee, in the exercise of its judgment, has found to be well qualified and willing and available to serve. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">After a vacancy arises on the Board or a member of the Board advises the Board of his or her intention to resign, the Committee shall recommend to the Board for appointment by the Board to fill such vacancy, such prospective member of the Board as the Committee, in the exercise of its judgment, has found to be well qualified and willing and available to serve. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Annually, review the performance of each current board member and shall consider the results of such evaluation when determining whether or not to recommend the nomination of such board member for an additional term </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">In appropriate circumstances, the Committee, in its discretion, shall consider and may recommend the removal of a board member for cause, in accordance with the applicable provisions of the Rules of Procedure and applicable law </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">229</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Oversee the Board in the Board&#8217;s review of its performance (including its composition and organization), which will occur once per fiscal year, and will make appropriate recommendations to improve performance </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Make recommendations to the Board regarding governance matters, including, but not limited to, the Rules of Procedure, this Charter and the charters of the Board&#8217;s other committees </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Review and assess the composition of the various committees of the Board and recommend, for approval by the Board, the assignment and rotation of Board members to such committees. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Develop, review and recommend to the Board the Rules of Procedure and, on a regular basis, review and recommend revisions to the Rules of Procedure </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Develop and recommend to the Board a policy regarding the consideration of candidates to the Board recommended by the Company&#8217;s security holders and procedures for submission by security holders of nominee recommendations to the Board </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Consider, develop and recommend to the Board such policies and procedures with respect to the nomination of members to the Board or other corporate governance matters as may be required or required to be disclosed pursuant to any rules promulgated by the Securities and Exchange Commission, NASDAQ, or otherwise considered to be desirable and appropriate in the discretion of the Committee </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Review the leadership structure of the Board and provide the Board with any recommendations for changes in such leadership structure </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Recommend to the Board the employment and appointment of future executive officers, as well as promotion and changes in position of incumbent executive officers upon review of their performance </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Periodically report to the Board on its findings and actions </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">At least annually, perform an evaluation of the performance of the Committee and its members, including a review of the Committee&#8217;s compliance with this Charter, and provide any written material with respect to such evaluation to the Board, as appropriate, including any recommendations for changes in procedures or policies governing the Committee. The Committee shall conduct such evaluation and review in such manner as it deems appropriate </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Review and reassess this Charter at least annually and submit any recommended changes to the Board for its consideration </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Capital Market, Communication and BD Committee</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Capital Market, Communication and BD Committee consists of Marianne S&#248;gaard, Roberto Prego and Niels Iversen M&#248;ller. Marianne S&#248;gaard serves as chairperson of the Capital Market, Communication and BD Committee. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Capital Market, Communication and BD Committee&#8217;s responsibilities include, among other things: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The committee will review and comment on the Company&#8217;s business development, capial market strategy and/or plan and whether the Company is being properly valued and positioned with shareholders whose investment objectives are consistent with the Company&#8217;s strategy of creating and attaining long-term shareholder value. Specifically, the Committee will: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Review and assess the overall capital markets activities, business development and communication strategy and/or plan periodically to determine its status and progress. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Periodically review issues that affect capital markets activities, business development and communication including trends in corporate governance, shareholder activism, and regulatory actions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Monitor the results of the capital market activities, business development and communication strategy and/or plan and offer suggestions for improvement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">230</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSHOW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:10.45pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Ensure that Executive Management has allocated adequate resources to support the implementation and achievement of the objectives of the capital market activities, business development and communication strategy and/or plan. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Based on information provided by the Executive Management, make recommendations&#8201;&#8212;&#8201;as necessary&#8201;&#8212;&#8201;to the Board on possible actions with regard to shareholder engagement and value. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Receive and review information from various sources as necessary. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Participate to the extent necessary or desirable in meetings with investors or potential investors </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employees</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2023, 2022 and 2021, we had 49, 63 and 61 employees, respectively. All of our employees are engaged in either general and administrative or research and development functions. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Share Ownership</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Major Shareholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">The following table presents information, as of January&#160;29, 2024, regarding the beneficial ownership of our ordinary shares: (i)&#160;prior to the consummation of the offering and (ii)&#160;as adjusted to reflect the sale of the ADSs representing ordinary shares in the offering (assuming none of the persons or entities listed below purchases any ADSs in this offering), for: </font>
          </div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding ordinary shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each of our directors and members of our executive management individually; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each of our directors and members of our executive management as a group. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">The number of ordinary shares beneficially owned by each entity, person, and member of our board of directors or members of our executive management is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any ordinary shares over which the individual has sole or shared voting power or investment power as well as any ordinary shares that the individual has the right to acquire within 60&#160;days of January&#160;29, 2024 through the exercise of any option, warrant or other right. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all ordinary shares held by that person. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">The&#160;percentage of outstanding ordinary shares is computed on the basis of 40,540,546 ordinary shares, DKK 1 nominal value per share, each outstanding as of January&#160;29, 2024. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">The&#160;percentage of shares beneficially owned on an as adjusted basis after the offering is based on 60,865,746 shares to be outstanding after the offering after giving effect to the completion of this offering, Ordinary shares that a person has the right to acquire within 60&#160;days of January&#160;29, 2024 are deemed outstanding for purposes of computing the&#160;percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the&#160;percentage ownership of any other person, except with respect to the&#160;percentage ownership of all members of our board of directors or executive management as a group. None of our shareholders has different voting rights from other shareholders. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company. Unless otherwise indicated, the business address for each beneficial owner is Dr.&#160;Neergaards Vej 5F, 2970 H&#248;rsholm, Denmark. </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">231</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <table style="width:456pt;height:259pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:267.02pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Before Offering </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">After Offering </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:267.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Name of Beneficial Owner </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Number </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Percent </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Number </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Percent </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:267.02pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">5</font><font style="font-style:italic;letter-spacing:0.2pt;">% or Greater Shareholders</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">NIMedical Holding ApS</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,232,893</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">10.4 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,232,893</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.0 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Mattsson Holding af 2008 ApS</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,142,521</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">10.2 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,142,521</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.8 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Merck Global Innovation Fund&#160;LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,595,588</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">10.7 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,595,588</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.3 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.02pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Executive Management</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Christian Kanstrup</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,493,014</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">3.6 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,493,014</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.4 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Andreas Holm Mattsonb</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,267,931</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">10.5 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,267,931</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.0 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Jesper Nyegaard Nissen</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">99,913</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">99,913</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Birgitte R&#248;n&#248;</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">148,123</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">148,123</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.02pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Directors</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Roberto Prego</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">539,069</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">1.3 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">539,069</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.9 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Niels Iverson M&#248;ller</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,292,678</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">10.6 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,292,678</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.1 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Lars Holtug</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(8)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">157,891</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">157,891</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.02pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Marianne S&#248;gaard</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(9)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,684,547</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">4.1 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,684,547</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.7 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 1.5pt 0pt; width:267.02pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">All current directors and executive management, as a group (8&#160;persons) </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12,683,165</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">29.7 </td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12,683,165</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">20.1</td>
              <td style="padding:0pt;padding-left:3.68pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Represents beneficial ownership of less than 1% </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:3.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 4,232,893 ordinary shares held by NIMedical Holding ApS, which is a personal investment company wholly-owned by Dr.&#160;M&#248;ller. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 4,142,521 ordinary shares held by Mattsson Holding af 2008 ApS, which is a personal investment company wholly-owned by Mr.&#160;Mattsson. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(3)</font>
            <br >
          </div>
          <div style=" margin-top:3.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Includes 2,297,704 shares subject to Warrants that are exercisable within 60&#160;days of January&#160;29, 2024. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(4)</font>
            <br >
          </div>
          <div style=" margin-top:3.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Include 757,720 shares subject to Warrants that are exercisable within 60&#160;days of January&#160;29, 2024. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(5)</font>
            <br >
          </div>
          <div style=" margin-top:3.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Include 70,263 shares subject to Warrants that are exercisable within 60&#160;days of January&#160;29, 2024. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(6)</font>
            <br >
          </div>
          <div style=" margin-top:3.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Include 63,148 shares subject to Warrants that are exercisable within 60&#160;days of January&#160;29, 2024. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(7)</font>
            <br >
          </div>
          <div style=" margin-top:3.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Include 111,358 shares subject to Warrants that are exercisable within 60&#160;days of January&#160;29, 2024. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(8)</font>
            <br >
          </div>
          <div style=" margin-top:3.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Include 136,909 shares subject to Warrants that are exercisable within 60&#160;days of January&#160;29, 2024. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(9)</font>
            <br >
          </div>
          <div style=" margin-top:3.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Include 24,687 shares subject to Warrants that are exercisable within 60&#160;days of January&#160;29, 2024. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(10)</font>
            <br >
          </div>
          <div style=" margin-top:3.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Include 84,362 shares subject to Warrants that are exercisable within 60&#160;days of January&#160;29, 2024. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(11)</font>
            <br >
          </div>
          <div style=" margin-top:3.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Include 867,532 shares subject to Warrants that are exercisable within 60&#160;days of January&#160;29, 2024. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Holdings by United States Shareholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">As of January&#160;29, 2024, approximately six&#160;percent (6%) of our issued and outstanding ordinary shares were held by ten&#160;(10) United States record holders. The number of individual holders of record is based exclusively upon our share register and does not address whether a share or shares may be held by the holder of record on behalf of more than one person or institution who may be deemed to be the beneficial owner of a share or shares in our company. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Significant Changes in Percentage Ownership</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company. To Evaxion&#8217;s knowledge, and other than changes in&#160;percentage ownership as a result of the shares issued in connection with Evaxion&#8217;s initial public offering in the United States, there has been no significant change in the&#160;percentage ownership held by the major shareholders listed above in the last three&#160;years, except as discussed below in &#8220;Related Party Transactions.&#8221; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">232</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:180pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Related Party Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Below is a summary of our grants, agreements, and transactions since January&#160;1, 2017 in which the amount involved exceeded or will exceed $120,000, and in which any of our then directors, executive management or holders of more than 10% of any class of our voting securities at the time of such transaction, or any members of their immediate family, had or will have a direct or indirect material interest. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Share-based Awards to Directors and Executive Management </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have granted share-based awards to certain of our directors and executive management. For more information regarding the warrants granted to our executive management and directors see the section herein entitled &#8220;Warrant Incentive Plan&#8221;. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Employment Agreements and Indemnification Agreements </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have entered employment agreements with each member of our executive management and intend to enter into indemnification agreements with each member of our executive management and each of our directors. For more information see the sections herein entitled &#8220;Compensation of Executive Officers and Directors&#8221; and &#8220;Insurance and indemnification.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Policies and Procedures for Related Person Transactions </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to our IPO, we have not had a formal policy regarding approval of transactions with related parties. We have adopted a related person transaction policy setting forth the policies and procedures for the identification, review and approval or ratification of related person transactions. This policy covers, with certain exceptions set forth in Item&#160;404 of Regulation&#160;S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and a related person were or will be participants and the amount involved exceeds $120,000, including purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness and guarantees of indebtedness. In reviewing and approving any such transactions, our audit committee will consider all relevant facts and circumstances as appropriate, such as the purpose of the transaction, the availability of other sources of comparable products or services, whether the transaction is on terms comparable to those that could be obtained in an arm&#8217;s length transaction, management&#8217;s recommendation with respect to the proposed related person transaction, and the extent of the related person&#8217;s interest in the transaction. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interests of Experts and Counsel</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Not applicable.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">233</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOSC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following describes our issued share capital, summarizes the material provisions of our articles of association and highlights certain differences in corporate law in the Kingdom of Denmark and Delaware corporate law, the law under which many publicly listed companies in the United States are incorporated. Please note that this summary is not intended to be exhaustive. For further information, please refer to the full version of our articles of association, which are included as an exhibit to the registration statement of which this prospectus is a part.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Introduction</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of association and relevant provisions of the Danish Companies Act. The summary includes certain references to and descriptions of material provisions of our articles of association to be effective in connection with the consummation of the offering and Danish law in force as of the date of this prospectus. The summary below contains only material information concerning our share capital and corporate status and does not purport to be complete and is qualified in its entirety by reference to our articles of association. Further, please note that as an ADS holder you will not be treated as one of our shareholders and will not have any shareholder rights. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We were incorporated under the laws of Denmark on August&#160;11, 2008, as a private limited liability company (in Danish: </font><font style="font-style:italic;letter-spacing:0.2pt;">Anpartsselskab</font><font style="letter-spacing:0.2pt;">, or </font><font style="font-style:italic;letter-spacing:0.2pt;">ApS</font><font style="letter-spacing:0.2pt;">) and are registered with the Danish Business Authority (in Danish: </font><font style="font-style:italic;letter-spacing:0.2pt;">Erhvervsstyrelsen</font><font style="letter-spacing:0.2pt;">) in Copenhagen, Denmark under registration number 31762863. On March&#160;29, 2019, our company was converted into a public limited liability company (in Danish: </font><font style="font-style:italic;letter-spacing:0.2pt;">Aktieselskab</font><font style="letter-spacing:0.2pt;">, or </font><font style="font-style:italic;letter-spacing:0.2pt;">A/S</font><font style="letter-spacing:0.2pt;">). The ADSs were publicly listed for trading on The Nasdaq Capital Market under the symbol &#8220;EVAX&#8221; on February&#160;5, 2021. Our principal executive offices are located at Dr.&#160;Neergaards Vej 5f, DK-2970 H&#248;rsholm, Denmark and our telephone number is + 45 53 53 18 50. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our website address is www.evaxion-biotech.com. The information on, or that can be accessed through, our website is not part of and is not incorporated by reference into this prospectus. We have included our website address as an inactive textual reference only. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Development of the Share Capital</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">As January&#160;29, 2024, our registered, issued and outstanding share capital was nominal DKK 40,540,546 divided into 40,540,546 ordinary shares of DKK 1. The development of our share capital since December&#160;31, 2016 to January&#160;26, 2024 is set forth in the table below. The below Price Per Share (DKK) is based on the registrations with the Danish Business Authority. </font>
          </div>


          <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:86.59pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Date </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:252pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Transaction </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Share</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Capital</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">After </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Transaction </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Price Per</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Share</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">(DKK)</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">(Rounded) </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">August&#160;2008 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Formation (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">250,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">March&#160;2014 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">268,148</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">120.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;2014 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">316,751</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">178.22</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;2015 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">336,549</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">435.76</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">March&#160;2016 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">342,880</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">432.12</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">September&#160;2017 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">358,806</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1,034.75</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">March&#160;2019 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Transfer of reserves (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">717,612</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">July&#160;2019 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Cash contribution and debt conversion (Nominal DKK 2) </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">836,994</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">914.71(avg<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;2019 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">843,564</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1,037.50</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">September&#160;2020 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">884,974</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1,002.90</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">234</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:86.59pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Date </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:252pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Transaction </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Share</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Capital</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">After </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Transaction </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Price Per</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Share</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">(DKK)</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">(Rounded) </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">October&#160;2020 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">899,926</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,008.45</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;2021 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Share split 2-for-1 (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">899,926</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;2021 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Bonus share issuance 17-for-1(Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">16,198,668</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">February&#160;2021 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Initial public offering (3,000,000 ADSs / 3,000,000 new </font>
                <br >
                <font style="letter-spacing:0.2pt;">share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">19,198,668</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">61.99</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">November&#160;2021 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Follow-on public offering (3,942,856 ADSs / 3,942,856 new </font>
                <br >
                <font style="letter-spacing:0.2pt;">share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">23,141,524</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">45.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">November&#160;2021 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">23,184,656</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:252pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">November&#160;2021 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">23,203,808</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">April&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">23,257,880</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">June&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">23,350,193</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">June&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash Contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">23,387,858</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">June&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Conversion of Debt (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">23,816,430</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">19.54</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">June&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash Contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">23,833,694</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">August&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash Contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">23,926,007</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">August&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash Contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">23,967,092</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">September&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash Contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">23,977,928</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">October&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (23,405 ADSs / 23,405 new </font>
                <br >
                <font style="letter-spacing:0.2pt;">share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">24,001,333</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">21.67</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">October&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (26,396 ADSs / 26,396 new </font>
                <br >
                <font style="letter-spacing:0.2pt;">share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">24,027,729</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">21.83</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">October&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (64,601 ADSs / 64,601 new </font>
                <br >
                <font style="letter-spacing:0.2pt;">share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">24,092,330</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">22.60</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">24,134,963</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (4,450 ADSs / 4,450 new </font>
                <br >
                <font style="letter-spacing:0.2pt;">share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">24,139,413</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">15.62</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (186,584 ADSs / 186,584 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">24,325,997,</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">13.82</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (447,829 ADSs / 447,829 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">24,773,826,</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">13.40</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (94,278 ADSs / 94,278 new </font>
                <br >
                <font style="letter-spacing:0.2pt;">share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">24,868,104</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">12.59</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (259,407 ADSs / 259,407 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">25,127,511</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">12.24</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (79,657 ADSs / 79,657 new </font>
                <br >
                <font style="letter-spacing:0.2pt;">share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">25,207,168</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11.47</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (71,678 ADSs / 61,678 new </font>
                <br >
                <font style="letter-spacing:0.2pt;">share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">25,278,846</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11.19</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">February&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (96,271 ADSs / 96,271 new </font>
                <br >
                <font style="letter-spacing:0.2pt;">share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">25,375,117</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">12.42</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">February&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (1,003,802 ADSs / 1,003,802 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">26,378,919</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">13.86</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">235</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:8.11000000000001pt;margin-left:69.66pt;width:456pt;">

          <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:86.59pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Date </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:252pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Transaction </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Share</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Capital</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">After </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Transaction </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Price Per</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Share</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">(DKK)</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">(Rounded) </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.917pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">February&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.917pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (42,808 ADSs / 42,808 new </font>
                <br >
                <font style="letter-spacing:0.2pt;">share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">26,421,727</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">11.79</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">March&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (16,280 ADSs 16,280 new </font>
                <br >
                <font style="letter-spacing:0.2pt;">share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">26,438,007</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8.94</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">May&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash Contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">26,572,737</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">May&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash Contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">26,623,862</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">June&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash Contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">26,773,862</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">June&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement (861,614 ADSs* / 861,614 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">27,635,476</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">12.03</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">June&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash Contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">27,640,300</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">July&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Jones Trading Sales Agreement (11,348 ADSs* / 11,348 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">27,651,648</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8,43</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">September&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash Contribution (Nominal DKK 1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">27,662,484</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">September&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Jones Trading Sales Agreement (54,099 ADSs* / 54,099 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">27,716,583</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.50</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">September&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Jones Trading Sales Agreement (51,750 ADSs* / 51,750 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">27,768,333</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.33</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">September&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Jones Trading Sales Agreement (45,807 ADSs* / 45,807 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">27,814,140</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.29</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">October&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Jones Trading Sales Agreement (54,829 ADSs* / 54,829 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">27,868,969</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6.04</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">November&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Jones Trading Sales Agreement (50,281 ADSs* / 50,281 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">27,919,250</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7.92</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">November&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Jones Trading Sales Agreement (19,387 ADSs* / 19,387 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">27,938,637</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4.95</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">November&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Jones Trading Sales Agreement (77,119 ADSs* / 77,119 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">27,015,756</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,08</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">November&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Jones Trading Sales Agreement (43,950 ADSs* / 43,950 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">28,059,706</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.19</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">November&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Jones Trading Sales Agreement (21,136 ADSs* / 21,136 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">28,080,842</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.40</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">November&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Jones Trading Sales Agreement (24,316 ADSs* / 24,316 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">28,105,158</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.61</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Jones Trading Sales Agreement (65,724 ADSs* / 65,724 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">28,170,882</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.63</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Capital Increase (PIPE) (9,726,898 ADSs* / 9,726,898 new </font>
                <br >
                <font style="letter-spacing:0.2pt;">share issue) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">37,897,780</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3.71</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;2024 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Cash Contribution (Nominal DKK1) </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">37,906,996 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.00 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 1.5pt 0pt; width:86.59pt;text-align:left;vertical-align:top;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January 2024 </font> </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; width:252pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Jones Trading Sales Agreement (263,355 ADSs / 2,633,550 </font>
                <br >
                <font style="letter-spacing:0.2pt;">new share issue)</font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">40,540,546 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6.73</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:13.69pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">*</font>
            <br >
          </div>
          <div style=" margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Does not take into account ADS Ratio Change of January 22, 2024.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">236</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Authorizations to the Board of Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">As of Janury 26, 2024, our board of directors is authorized to increase the share capital as follows: </font>
          </div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The board of directors is until November&#160;23, 2025, authorized, on or more occasions, to issue warrants to the company&#8217;s investors entitling the holder to subscribe shares for a total of up to nominal value of DKK 728,964 without pre-emptive rights for the company&#8217;s shareholders. The exercise price for the warrants shall be equal to the nominal value of the company&#8217;s shares, currently DKK 1. The board of directors shall determine the terms for the warrants issued and distribution hereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The board of directors is until January&#160;3, 2026, authorized at one or more times to increase the company&#8217;s share capital by the issuance of new shares with up to nominal DKK 11,000,000 with pre-emptive subscription rights for the company&#8217;s shareholders. Capital increases according to this authorization shall be carried out by the board of directors by way of cash contributions. The shares may be issued at market price or at a discount price as determined by the board of directors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The board of directors is until January&#160;3, 2026, authorized at one or more times to obtain loans against issuance of convertible loan notes which give the right to subscribe for shares for a total of up to nominal value of DKK 14,700,000 without pre-emptive subscription rights for the company&#8217;s shareholders. The conversion shall be carried out at a price that corresponds in aggregate to at least the market price at the time of the decision of the board of directors. Shares shall be considered issued at market price if the shares are issued at +/-10 of the listed price for the company&#8217;s shares on a relevant stock exchange in Europe or the USA. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The board of directors is until January&#160;3, 2026, authorized at one or more times to issue warrants to members of our board of directors and executive management, as well as to key employees, advisors and consultants, and to increase our share capital by up to nominal DKK 1,000,000 without pre-emptive subscription rights for existing shareholders in connection with the exercise, if any, of said warrants and to determine the terms and conditions thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The board of directors is until 1 May&#160;2027 authorized at one or more times to issue warrants to investors, lenders, consultants and/or advisors in the company or its subsidiaries entitling the holder to subscribe for shares for a total of up to nominal value of DKK 47,000,000 without pre-emptive subscription rights for the company&#8217;s shareholders. The exercise price for the warrants issued according to this authorization shall at the time of issuance be determined by the board of directors at minimum market price. The board of directors shall determine the terms for the warrants issued and the distribution hereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">The board of directors is until May&#160;1, 2027, authorized at one or more times to increase the company&#8217;s share capital by up to nominal DKK 44,366,450 without pre-emptive subscription rights for the company&#8217;s shareholders. Capital increases according to this authorization must be carried out by the board of directors by way of cash contributions. The shares may be issued at market price or at a discount to the listed price of the ADSs as determined by the board of directors. The board of directors is authorized to make the required amendments to the articles of association if the authorization to increase the share capital is used and to cause such shares to be deposited with a depositary bank and the simultaneous issuance of ADSs representing such shares. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The ADSs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Trades in ADSs are settled through The Depository Trust Company, or DTC, in accordance with its customary settlement procedures for equity securities. Each person owning ADSs held through DTC must rely on the procedures thereof and on institutions that have accounts therewith to exercise any rights of a holder of the ADSs. The ADSs are listed for trading on The Nasdaq Capital Market under the symbol &#8220;EVAX.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Warrants</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have established warrant programs for members of our board of directors, our executive management, other employees, consultants and advisors. Under the terms of our warrant plans, warrants are issued to our directors, executive management and employees, on a discretionary basis following </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">237</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">consultation with and recommendation from our Compensation Committee. All warrants have been issued by the general meeting or by our board of directors pursuant to valid authorizations in our articles of association and the terms and conditions have, in accordance with the Danish Companies Act, been incorporated in our articles of association. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The description below merely contains a summary of the applicable terms and conditions and does not purport to be complete. As of January&#160;29, 2024, we have issued and outstanding 2,750,750&#160;warrants (excluding the 351,036 warrants issued to the European Investment Bank, or EIB, as described below and in the section herein entitled &#8220;EIB Warrants&#8221; and 9,726,898 warrants to investors as part of a direct offering in December&#160;2023 described below in the section entitled &#8220;Investor warrants, December&#160;21, 2023&#8221;. Each such warrant confers upon the holder thereof the right to subscribe to nominal DKK 1 share. Our warrants have previously been granted, on the dates, and with exercise prices as set forth below: </font>
          </div>


          <table style="width:456pt;height:322pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:119.61pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Grant Date </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:117.45pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Vesting Period </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Expiration Date </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:47.72pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Exercise Price </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Number of </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Warrants </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;19, 2016 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:117.45pt;">
                <font style="letter-spacing:0.2pt;">Upon IPO Event </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;31, 2036 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:47.72pt;">
                <font style="letter-spacing:0.2pt;">DKK 1.0 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">758,448</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;10, 2017 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:117.45pt;">
                <font style="letter-spacing:0.2pt;">Upon IPO Event </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;31, 2036 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47.72pt;">
                <font style="letter-spacing:0.2pt;">DKK 1.0 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">632,700</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;19, 2017 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:117.45pt;">
                <font style="letter-spacing:0.2pt;">Upon IPO Event </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;31, 2036 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47.72pt;">
                <font style="letter-spacing:0.2pt;">DKK 1.0 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">141,804</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;17, 2020 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:117.45pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">See vesting principles below </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;31, 2031 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47.72pt;">
                <font style="letter-spacing:0.2pt;">DKK 1.0 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">757,620</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">June&#160;2021 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:117.45pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">See vesting principles below </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;31, 2031 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47.72pt;">
                <font style="letter-spacing:0.2pt;">DKK 1.0 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">62,147</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.99999999999997pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;7, 2021 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:117.45pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">See vesting principles below </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;31, 2031 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47.72pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">USD 5.38 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">523,599</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">March&#160;11 2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:117.45pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">See vesting principles below </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;31, 2031 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47.72pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">USD 2.96 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">35,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">June&#160;14, 2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:117.45pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">See vesting principles below </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;31, 2031 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47.72pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">USD 1.83 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">65,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">September&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:117.45pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">See vesting principles below </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;31, 2031 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47.72pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">USD 2.42 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">11.000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;2022 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:117.45pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">See vesting principles below </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;31, 2031 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47.72pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">USD 2.23 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">380,612</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">March&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:117.45pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">See vesting principles below </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;31, 2031 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47.72pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">USD 1.90 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">10,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">September&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:117.45pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">See vesting principles below </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;31, 2031 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47.72pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">USD 1.02 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">100,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">September&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:117.45pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">See vesting principles below </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">September&#160;19, 2026 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47.72pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">USD 1.50 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">150,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:117.45pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">See vesting principles below </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;31, 2031 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47.72pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">USD 0.75 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">216,074</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:117.45pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">See vesting principles below </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:82.81pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">December&#160;31, 2031 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47.72pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">USD 0.75 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">90,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:119.61pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Exercised </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:117.45pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:82.81pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:47.72pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">(811,196<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:119.61pt;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Lapsed or annulled without </font>
                  <br >
                  <font style="letter-spacing:0.2pt;">exercise </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:117.45pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:82.81pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:47.72pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; white-space:nowrap;text-align:center;">(372,058<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 1.833pt 0pt; width:119.61pt;white-space:normal;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Total issued and outstanding as of January&#160;29, 2024 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:117.45pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:82.81pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:47.72pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:center;">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; white-space:nowrap;text-align:center;">
                <div style="font-weight:bold;">2,750,750</div>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-left:20pt; margin-top:14pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;17, 2020, we issued 757,620 warrants related to 2018&#8201;&#8211;&#8201;2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Vesting Principles Generally</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Warrants granted for the&#160;years 2016&#8201;&#8211;&#8201;2018 vested upon the closing of our initial public offering. Warrants granted for the&#160;years 2019 and 2020 generally vest at a rate of 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month. Vested warrants may be exercised in four annual exercise windows of two weeks each that each commence two trading days following publication of our annual report, the six-month report and the interim quarterly reports. However, our board of directors determined that the first such exercise window began November&#160;2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the 331,632 warrants granted in 2019 (issued in 2020), 117,612 warrants were fully vested on the date of grant and 214,020 warrants vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month from date of grant. For the 236,196 warrants granted and issued in 2020, 120,888 warrants were fully vested on the date of issuance, 6,084 vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month starting on January&#160;1, 2020, 19,008 warrants vest three&#160;years from the date of joining us, 90,216 warrants vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month starting on January&#160;1, 2021. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">238</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">62,147 warrants granted on June&#160;17, 2021 and on October&#160;21, 2021 formally issued shall vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month and vesting shall be calculated from April&#160;1, 2021. For warrants granted on December&#160;7, 2021, 500,683 warrants vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month from January&#160;1, 2022 and 22,916 warrants shall be deemed fully vested at the time of issuance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">35,000 warrants granted on March&#160;11, 2022, vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month from April&#160;1, 2022. 65,000 warrants were granted on June&#160;14, 2022. 10,000 warrants vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month from February&#160;1, 2022, 10,000 warrants vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month from April&#160;1, 2022, and 45,000 warrants vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month from June&#160;1, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">11,000 warrants were granted on September&#160;15, 2022. 5,000 warrants vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month from August&#160;1, 2022 and 6,000 warrants vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month from August&#160;8, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For 380,612 warrants granted on December&#160;12, 2022, 2,500 warrants were fully vested per December&#160;7, 2022, 50,000 warrants vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month from December&#160;7, 2022, 299,362 warrants vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month from January&#160;1, 2023 and 28,750 warrants vest with 1/12 per month from January&#160;1, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">10,000 warrants were granted on March&#160;15, 2023. The warrants vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month from January&#160;1, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">100,000 warrants were granted on September&#160;1, 2023. The warrants vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month from September&#160;1, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">150,000 Warrants were granted on September&#160;30, 2023. The warrants vest with &#188;</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per quarter from November&#160;2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">90,000 warrants granted on December&#160;11, 2023. The warrants vest with 1/12</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month from January&#160;1, 2024. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">216,074 warrants granted on December&#160;11, 2023. The warrants vest with 1/36</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> per month from January&#160;1, 2024. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There are certain restrictions on exercise in the event that warrant holders terminate their employment or are dismissed for prior to exercise. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Adjustments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Warrant holders are entitled to an adjustment of the number of warrants issued and/or the exercise price applicable in the event of certain changes to our share capital at a price other than the market price. Events giving rise to an adjustment include, among other things, increases or decreases to our share capital at a price below or above market value, respectively, and issuance of bonus shares. For the purpose of implementing the capital increases necessary in connection with the exercise of warrants, our board of directors has been authorized to increase our share capital by one or more issuances of shares with a total nominal value corresponding to the number of warrants issued upon cash payment of the exercise price without any preemptive subscription rights to existing shareholders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investor warrants December&#160;21, 2023</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In connection with Private Placement, on December&#160;21, 2023 we issued 9,726,898 warrants to purchase 9,726,898 ordinary shares to a group of investors. The warrants vested immediately upon issue with an exercise price of $0.707 and an expiration date on December&#160;21, 2026 </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EIB Warrants</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the EIB Loan Agreement, we agreed to issue the EIB Warrants to EIB in the event we make draws on the EIB Loan. Under the terms of the EIB Warrant Agreement, we are obligated to issue up to an aggregate of 1,047,744 EIB Warrants in three separate tranches with each tranche of EIB Warrants to be issued upon a drawdown of a tranche of the EIB Loan in accordance with the following schedule: (i)&#160;351,036 EIB Warrants upon a drawdown of the first tranche of the EIB Loan in the amount of &euro;7.0&#160;million; (ii)&#160;345,672 EIB Warrants upon a drawdown of the second tranche of the EIB Loan in the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">239</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">amount of &euro;6.0&#160;million, upon shareholders&#8217; approval and (iii)&#160;351,036 EIB Warrants upon a drawdown of the third and final tranche of the EIB Loan in the amount of &euro;7.0&#160;million, upon shareholders&#8217; approval. In November&#160;2020, we initiated the process of making a draw down on the first tranche of the EIB Loan in the amount of &euro;7.0&#160;million and, in connection therewith, on December&#160;17, 2020 and through the date of the annual report, our board of directors approved the issuance of 351,036 EIB Warrants to EIB. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the EIB Warrant Agreement, each EIB Warrant entitles EIB to subscribe for one ordinary share, nominal DKK 1, at an exercise price of DKK 1 per ordinary share. In addition, EIB has the right to cause us to net settle the exercise of the EIB Warrants in cash based on the value of our ordinary shares on the date of exercise thereof. Finally, upon the occurrence of certain events, including the completion of our initial public offering, the prepayment of the EIB Loan, the sale of all or substantially all of our issued share capital or assets, a change in control transaction, or Messrs. Mattsson and Moller cease to own and control directly or indirectly 25% or more of the voting rights or economic interest of our company, EIB has the right, but not the obligation, to cause us to purchase any EIB Warrant, or the Put Right. If EIB exercise its Put Right, we are required to pay EIB an amount equal to the volume weighted average price per ordinary share, or VWAP, for a period of six&#160;months following the exercise of such Put Right. In the first six&#160;months following the completion of our initial public offering, the VWAP price to be paid by us is calculated for the entire period from the completion of our initial public offering until the exercise of the Put Right. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under Article&#160;18, Paragraph 2 of the Statute of the European Investment Bank, or the EIB Statute, establishing EIB, a direct equity investment by EIB requires a separate authorization from the EIB Board of Governors pursuant to which the EIB Board of Directors, acting by qualified majority, has to establish the terms and conditions of such direct equity investment. As of the date of this prospectus, the EIB Board of Governors has not granted any such special authorization to the EIB Board of Directors. Under the EIB Statute, in the absence of a separate authorization from the EIB Board of Governors, commercial shareholdings financed from EIB&#8217;s own resources are not allowed. Since the EIB Loan is being made from EIB&#8217;s own resources, the EIB Statute does not allow EIB to acquire any of our ordinary shares, therefore, we fully expect that if and when EIB exercises the EIB Warrants it will do so on either a net cash settlement basis or by means of exercising its Put Right. In either case, we may not have sufficient funds on hand to pay such amounts in which case we may be required to use a portion of the proceeds from our initial public offering in order to meet our obligations to pay the amounts due and payable to EIB upon the exercise of the EIB Warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the EIB Warrant Agreement, EIB may not exercise the EIB Warrants and cause us to settle the exercise of the EIB Warrants on a net cash basis or pursuant to its Put Right, for a period of 180&#160;days from the date of the completion of our initial public offering, provided that such lock-up arrangement shall cease to be effective in the event there is a material adverse event relating to our company as determined in accordance with ordinary principles of Danish law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The number of our ordinary shares that may be subject to either net cash settlement or EIB&#8217;s Put Right upon the exercise of the EIB Warrants are subject to adjustment in the event of changes to our capital structure which are not carried out at the then current market price, provided that there shall be no such adjustment as a result of the issuance of additional shares or warrants to employees as well as for any future exercise of such warrants. In addition, the EIB Warrants are not subject to any adjustment in the event of any capital increases in directed issuances or our ordinary shares following the completion of our initial public offering with customary discounts of up to 10% of the market price. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Shareholders&#8217; Register</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are obligated to maintain an owners&#8217; register (DK: </font><font style="font-style:italic;letter-spacing:0.2pt;">ejerbog</font><font style="letter-spacing:0.2pt;">). The owners&#8217; register is maintained by Computershare A/S (company registration number (CVR) no.&#160;27088899), Lottenborgvej 26 D, 1., DK-2800 Kgs. Lyngby, Denmark, our Danish share registrar and transfer agent. It is mandatory that the owners&#8217; register is maintained within the European Union and that it is available to public authorities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Danish Companies Act public and private limited liability companies are required to register with the Danish Business Authority information regarding shareholders who own at least 5% of the share capital or the voting rights. Pursuant to the Danish Companies Act, we will file registrations with </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">240</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the Public Owners&#8217; Register of the Danish Business Authority. Shareholders that exceed or fall below the ownership threshold must notify us and we will subsequently file the information with the Danish Business Authority. Reporting is further required upon passing or falling below thresholds of 5, 10, 15, 20, 25, 50, 90, and 100% or 1/3 or 2/3. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Articles of Association and Danish Corporate Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Objects Clause</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our corporate object, as set out in article 1.2 of our articles of association, is to create advanced software that enables the development of novel immune therapies and vaccines. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Summary of Provisions Regarding the Board of Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to our articles of association, our board of directors shall be elected by our shareholders at the general meeting and shall be composed of not less than three and no more than seven members. With respect to the duration of the term which our directors severally hold office, the board of directors is elected to serve for a term of one year subject to re-election at the next annual general meeting of shareholders or until their successors have been duly elected and qualified, subject to their earlier removal, retirement or death. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Currently, the board of directors consists of four members who are elected by the shareholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The board of directors shall appoint and employ an executive management consisting of one to seven members to attend to our day-to-day management, and the board of directors shall determine the terms and conditions of their employment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each shareholder is entitled to one vote for each share owned at the time of any general meeting. As compared with Danish citizens, there are no limitations under the articles of association or under Danish law on the rights of foreigners or non-Danish citizens to hold or vote our ordinary shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividend Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our shareholders may at general meetings authorize the distribution of ordinary and extraordinary dividends. Our shareholders may not distribute dividends in excess of the recommendation from our board of directors and may only pay out dividends from our distributable reserves, which are defined as results from operations carried forward and reserves that are not bound by law or our company&#8217;s articles of association after deduction of loss carried forward. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our shareholders are eligible to receive any dividends declared and paid out. However, we have not to date declared or paid any dividends and we currently intend to retain all available financial resources and any earnings generated by our operations for use in the business and we do not anticipate paying any dividends in the foreseeable future. The payment of any dividends in the future will depend on a number of factors, including our future earnings, capital requirements, financial condition and future prospects, applicable restrictions on the payment of dividends under Danish law and other factors that our board of directors may consider relevant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">See &#8220;Certain Material Tax Considerations&#8221; for a summary of certain tax consequences in respect of dividends or distributions to holders of our ordinary shares or ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pre-emptive Subscription Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under Danish law, all shareholders have pre-emptive subscription rights in connection with capital increases that are carried out as cash contributions. An increase in share capital can be resolved by the shareholders at a general meeting or by the board of directors pursuant to an authorization given by the shareholders. In connection with an increase of a company&#8217;s share capital, the shareholders may, by resolution at a general meeting, approve deviations from the general Danish pre-emptive rights of the shareholders. Under the Danish Companies Act, such resolution must be adopted by the affirmative vote of shareholders </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">241</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">holding at least a two-thirds majority of the votes cast and the share capital represented at the general meeting, and requires that such capital increases will be carried out as a cash contribution at market price. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The board of directors may resolve to increase our share capital without pre-emptive subscription rights for existing shareholders pursuant to the authorizations set forth above under the caption &#8220;Authorizations to the Board of Directors&#8221;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless future issuances of new shares and/or pre-emptive rights are registered under the Securities Act or with any authority outside Denmark, United States shareholders and shareholders in jurisdictions outside Denmark may be unable to exercise their pre-emptive subscription rights. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rights on Liquidation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon a liquidation or winding-up of the Company, shareholders will be entitled to participate, in proportion to their respective shareholdings, in any surplus assets remaining after payment of our creditors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Limitations on Holding of Shares</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are no limitations on the right to hold shares under the articles of association or Danish law. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Disclosure Requirements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to Section&#160;55 of the Danish Companies Act, a shareholder is required to notify us when such shareholder&#8217;s stake represents 5% or more of the voting rights in our company or the nominal value accounts for 5% or more of the share capital, and when a change of a holding already notified entails that the limits of 5, 10, 15, 20, 25, 50, 90 or 100% and the limits of one-third and two-thirds of the share capital&#8217;s voting rights or nominal value are reached or are no longer reached. The notification shall be given within two weeks following the date when the limits are reached or are no longer reached. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The notification shall provide information on the date of the acquisition or disposal of the shares, the full name, civil registration (CPR) number, and address of the shareholder or, in the case of an enterprise, registered office and business registration (CVR) number, the number of shares and their nominal value and share classes (if applicable) as well as information about the basis on which the calculation of the holdings has been made. In the event that the shareholder is a non-resident company or citizen of Denmark, the notification shall include documentation, which clearly identifies the owner. The company shall cause the notification to be entered in the owners&#8217; register. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to The Danish Companies Act, section 58a, we are obligated to collect and store for a period of at least five&#160;years certain information regarding the beneficial owners of shares in the Company. A beneficial owner is a physical person who ultimately holds or controls, directly or indirectly, a sufficient part of the ownership interests or voting rights or exercises control by other means, except for owners of companies whose ownership interests are traded on a regulated market or a similar market which is subject to a duty of disclosure in accordance with EU law or similar international standards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The legal status of the notification obligations is not fully clarified in relation to ADS holders and an ADS holder may be subject to such obligations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General Meetings</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The general meeting of shareholders is the highest authority in all matters, subject to the limitations provided by Danish law and the articles of association. The annual general meeting shall be held at our home address or in the Greater Copenhagen area not later than the end of May in each year. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the annual general meeting, the audited annual report is submitted for approval, together with the proposed appropriations of profit/treatment of loss, the election of the board of directors and election of our auditors. In addition, the board of directors reports on our activities during the past year. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">General meetings are convened by the board of directors with a minimum of two weeks&#8217; notice and a maximum of four weeks&#8217; notice. A convening notice will also be forwarded to shareholders recorded in our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">242</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">owners&#8217; register, who have requested such notification and by publication in the Danish Business Authority&#8217;s computerized information system and on the company&#8217;s website. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the latest, two weeks before a general meeting (inclusive of the day of the general meeting), we shall make the following information and documents available at our website. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the convening notice, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the documents that shall be presented at the general meeting, and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the agenda and the complete proposals. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Shareholders are entitled to attend general meetings, either in person or by proxy and they or their proxy may be accompanied by one advisor. A shareholder&#8217;s right to attend general meetings and to vote at general meetings is determined on the basis of the shares that the shareholder holds on the registration date. The registration date shall be one week before the general meeting is held. The shares which the individual shareholder holds are calculated on the registration date on the basis of the registration of ownership in the owners&#8217; register as well as notifications concerning ownership which the Company has received with a view to update the ownership in the owners&#8217; register. In addition, any shareholder who is entitled to attend a general meeting and who wishes to attend must have requested an admission card from us no later than three days in advance of the general meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any shareholder is entitled to submit proposals to be discussed at the general meetings. However, proposals by the shareholders to be considered at the annual general meeting must be submitted in writing to the board of directors not later than six weeks prior the general meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Extraordinary general meetings must be held upon resolution of a general meeting to hold such a meeting or upon request of, the board of directors, our auditors or shareholders representing at least 1/20 of the registered share capital or such lower&#160;percentage as our articles of association may provide. Our articles of association do not state such lower&#160;percentage. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Holders of ADSs are not entitled to directly receive notices or other materials and may not attend or vote at general meetings. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Resolutions in General Meetings</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Resolutions made by the general meeting generally may be adopted by a simple majority of the votes cast, subject only to the mandatory provisions of the Danish Companies Act and our articles of association. Resolutions concerning all amendments to the articles of association must be passed by two-thirds of the votes cast as well as two-thirds of the share capital represented at the general meeting. Certain resolutions, which limit a shareholder&#8217;s ownership or voting rights, are subject to approval by a nine-tenth majority of the votes cast and the share capital represented at the general meeting. Decisions to impose or increase any obligations of the shareholders towards the company require unanimity. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Quorum Requirements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There are no quorum requirements generally applicable to general meetings of shareholders. To this extent, our practice varies from the requirement of Nasdaq Listing Rule&#160;5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Squeeze out</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">According to Section&#160;73 of the Danish Companies Act, a minority shareholder may require a majority shareholder that holds more than 90% of the company&#8217;s registered share capital and the corresponding voting rights to redeem his or her shares. Similarly, a majority shareholder holding more than 90% of the company&#8217;s share capital and the corresponding voting rights may, according to Section&#160;70 of the same act, redeem the minority shareholder&#8217;s shares. In the event that the parties cannot agree to the terms of redemption and the valuation basis of the redemption price, this shall be determined by an independent evaluator appointed by the court for the district in which the registered office of the company is situated. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">243</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of Danish Corporate Law and our Articles of Association and Delaware Corporate Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following comparison between Danish corporate law, which applies to us, and Delaware corporate law, the law under which many publicly listed companies in the United States are incorporated, discusses additional matters not otherwise described in this prospectus. This summary is subject to Danish law, including the Danish Companies Act, and Delaware corporation law, including the Delaware General Corporation Law. Further, please note that as an ADS holder you will not be treated as one of our shareholders and will not have any shareholder rights. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Duties of Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Public limited liability companies in Denmark are usually subject to a two-tier governance structure with the board of directors having the ultimate responsibility for the overall supervision and strategic management of the company in question and with an executive board/management being responsible for the day-to-day operations. Each Director and member of the executive board/management is under a fiduciary duty to act in the interest of the company, but shall also take into account the interests of the creditors and the shareholders. Under Danish law, the members of the board of directors and executive management of a limited liability company are liable for losses caused by negligence whether shareholders, creditors or the company itself suffers such losses. They may also be liable for wrongful information given in the annual financial statements or any other public announcements from the company. An investor suing for damages is required to prove its claim with regard to the incurred loss, negligence and causation. Danish courts, when assessing negligence, have been reluctant to impose liability unless the directors and officers neglected clear and specific duties. This is also the case when it comes to liability with regard to public offerings or liability with regard to any other public information issued by the company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The board of directors bears the ultimate responsibility for managing the business and affairs of a corporation. In discharging this function, directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its stockholders. Delaware courts have decided that the directors of a Delaware corporation are required to exercise informed business judgment in the performance of their duties. Informed business judgment means that the directors have informed themselves of all material information reasonably available to them. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation. In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the shareholders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Terms of the Members of our Board of Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under Danish law, the members of the board of directors of a limited liability company are generally appointed for an individual term of one year (terms may have a maximum period of four&#160;years). There is no limit in the number of consecutive terms the directors may serve. Pursuant to our articles of association, our directors are appointed by the general meeting of shareholders for a term of one year. Election of directors is, according to our articles of association, an item that shall be included on the agenda for the annual general meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the general meeting, shareholders are entitled at all times to dismiss a director elected by the general meeting by a simple majority vote. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Danish Companies Act, in a limited liability company that employed an average of at least 35 employees in the preceding three&#160;years, the employees are entitled to elect a minimum of two representatives and alternate members to the company&#8217;s board of directors and up to one half the number of the shareholder elected directors. If the number of representatives to be elected by the employees is not a whole number, such number must be rounded up. However, as of September&#160;30, 2023 our company had 52 full time employees. As of the date of this prospectus, our employees have not demanded representation on our board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law generally provides for a one-year term for directors, but permits directorships to be divided into up to three classes, of relatively equal size, with up to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">244</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">three-year terms, with the&#160;years for each class expiring in different&#160;years, if permitted by the certificate of incorporation, an initial bylaw or a bylaw adopted by the stockholders. A director elected to serve a term on a &#8220;classified&#8221; board may not be removed by stockholders without cause. There is no limit in the number of terms a director may serve. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Director Vacancies</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under Danish law, new directors are elected by the shareholders in a general meeting also in the event of vacancies. A general meeting will thus have to be convened in order to fill a vacancy on the board of directors. However, the board of directors may choose to wait to fill vacancies until the next annual general meeting of the company, provided that the number of remaining directors is more than two, and provided that the remaining directors can still constitute a quorum. It is only a statutory requirement to convene a general meeting to fill vacancies if the number of remaining members on the board is less than three. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law provides that vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) unless (1)&#160;otherwise provided in the certificate of incorporation or bylaws of the corporation or (2)&#160;the certificate of incorporation directs that a particular class of stock is to elect such director, in which case any other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Conflict-of-interest Transactions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under Danish law, directors may not take part in any matter or decision-making that involves a subject or transaction in relation to which the director has a conflict of interest with us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law generally permits transactions involving a Delaware corporation and an interested director of that corporation if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the material facts as to the director&#8217;s relationship or interest are disclosed and a majority of disinterested directors consent; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the material facts are disclosed as to the director&#8217;s relationship or interest and a majority of shares entitled to vote thereon consent; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the transaction is fair to the corporation at the time it is authorized by the board of directors, a committee of the board of directors or the stockholders. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proxy Voting by Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In the event that a director in a Danish limited liability company is unable to participate in a board meeting, the elected alternate, if any, shall be given access to participate in the board meeting. Unless the board of directors has decided otherwise, or as otherwise is set out in the articles of association, the director in question may in special cases grant a power of attorney to another director, provided that this is considered safe considering the agenda in question. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;A director of a Delaware corporation may not issue a proxy representing the director&#8217;s voting rights as a director. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stockholder Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Notice of Meeting</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;According to the Danish Companies Act, general meetings in limited liability companies shall be convened by the board of directors with a minimum of two weeks&#8217; notice and a maximum of four weeks&#8217; notice as set forth in the articles of association. A convening notice shall also be forwarded to shareholders recorded in our owners&#8217; register, who have requested such notification. There are specific requirements as to the information and documentation required to be disclosed in connection with the convening notice. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">245</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60&#160;days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Voting Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Each ordinary share confers the right to cast one vote at the general meeting of shareholders, unless the articles of association provide otherwise. Each holder of ordinary shares may cast as many votes as it holds shares. Shares that are held by us or our subsidiaries do not confer the right to vote. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, each stockholder is entitled to one vote per share of stock, unless the certificate of incorporation provides otherwise. In addition, the certificate of incorporation may provide for cumulative voting at all elections of directors of the corporation, or at elections held under specified circumstances. Either the certificate of incorporation or the bylaws may specify the number of shares and/or the amount of other securities that must be represented at a meeting in order to constitute a quorum, but in no event can a quorum consist of less than one third of the shares entitled to vote at a meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Stockholders as of the record date for the meeting are entitled to vote at the meeting, and the board of directors may fix a record date that is no more than 60 nor less than ten days before the date of the meeting, and if no record date is set then the record date is the close of business on the day next preceding the day on which notice is given, or if notice is waived then the record date is the close of business on the day next preceding the day on which the meeting is held. The determination of the stockholders of record entitled to notice or to vote at a meeting of stockholders shall apply to any adjournment of the meeting, but the board of directors may fix a new record date for the adjourned meeting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Shareholder Proposals</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;According to the Danish Companies Act, extraordinary general meetings of shareholders will be held whenever our board of directors or our appointed auditor requires. In addition, one or more shareholders representing at least 1/20</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> of the registered share capital of the company may, in writing, require that a general meeting be convened. If such a demand is forwarded, the board of directors shall convene the general meeting within two weeks thereafter. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All shareholders have the right to present proposals for adoption at the annual general meeting, provided that the proposals are made in writing and forwarded at the latest six weeks prior thereto. In the event that the proposal is received at a later date, the board of directors will decide whether the proposal has been forwarded in due time to be included on the agenda. Any business not included on the agenda may be transacted by the general meeting only if all shareholders&#8217; consent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Delaware law does not specifically grant stockholders the right to bring business before an annual or special meeting of stockholders. However, if a Delaware corporation is subject to the SEC&#8217;s proxy rules, a stockholder who owns at least $2,000 in market value, or 1% of the corporation&#8217;s securities entitled to vote, may propose a matter for a vote at an annual or special meeting in accordance with those rules. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Action by Written Consent</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under Danish law, it is permissible for shareholders to take action and pass resolutions by written consent in the event of unanimity; however, this will normally not be the case in listed companies and for a listed company, this method of adopting resolutions is generally not feasible. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Although permitted by Delaware law, publicly listed companies do not typically permit stockholders of a corporation to take action by written consent. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Appraisal Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The concept of appraisal rights does not exist under Danish law, except in connection with statutory redemptions rights according to the Danish Companies Act. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">246</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">According to Section&#160;73 of the Danish Companies Act, a minority shareholder may require a majority shareholder that holds more than 90% of the company&#8217;s registered share capital to redeem his or her shares. Similarly, a majority shareholder holding more than 90% of the company&#8217;s share capital may, according to Section&#160;70 of the same act, squeeze out the minority shareholders. In the event that the parties cannot agree to the redemption squeeze out price, this shall be determined by an independent evaluator appointed by the court. Additionally, there are specific regulations in Sections&#160;249, 267, 285 and 305 of the Danish Companies Act that require compensation in the event of national or cross-border mergers and demergers. Moreover, shareholders who vote against a cross-border merger or demerger or cross-border conversion are, according to Sections&#160;286, 306 and 318 m of the Danish Companies Act, entitled to have their shares redeemed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law provides for stockholder appraisal rights, or the right to demand payment in cash of the judicially determined fair value of the stockholder&#8217;s shares, in connection with certain mergers and consolidations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Shareholder Suits</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under Danish law, only a company itself can bring a civil action against a third party; an individual shareholder does not have the right to bring an action on behalf of a company. An individual shareholder may, in its own name, have an individual right to take action against such third party in the event that the cause for the liability of that third party also constitutes a negligent act directly against such individual shareholder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a stockholder may bring a derivative action on behalf of the corporation to enforce the rights of the corporation. An individual also may commence a class action suit on behalf of himself and other similarly situated stockholders where the requirements for maintaining a class action under Delaware law have been met. A person may institute and maintain such a suit only if that person was a stockholder at the time of the transaction which is the subject of the suit. In addition, under Delaware case law, the plaintiff normally must be a stockholder at the time of the transaction that is the subject of the suit and throughout the duration of the derivative suit. Delaware law also requires that the derivative plaintiff make a demand on the directors of the corporation to assert the corporate claim before the suit may be prosecuted by the derivative plaintiff in court, unless such a demand would be futile. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Repurchase of Shares</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Danish limited liability companies may not subscribe for newly issued shares in their own capital. Such company may, however, according to the Danish Companies Act Sections&#160;196-201, acquire fully paid shares of its own capital provided that the board of directors has been authorized thereto by the shareholders acting in a general meeting. Such authorization can only be given for a maximum period of five&#160;years and the authorization shall fix (i)&#160;the maximum value of the shares and (ii)&#160;the minimum and the highest amount that the company may pay for the shares. Shares may generally only be acquired using distributable reserves. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a corporation may purchase or redeem its own shares unless the capital of the corporation is impaired or the purchase or redemption would cause an impairment of the capital of the corporation. A Delaware corporation may, however, purchase or redeem out of capital any of its preferred shares or, if no preferred shares are outstanding, any of its own shares if such shares will be retired upon acquisition and the capital of the corporation will be reduced in accordance with specified limitations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anti-takeover Provisions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under Danish law, it is possible to implement limited protective anti-takeover measures. Such provisions may include, among other things, (i)&#160;different share classes with different voting rights, (ii)&#160;specific requirements to register the shares on name in the company&#8217;s owners register and (iii)&#160;notification requirements concerning participation in general meetings. We have currently not adopted any such provisions. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">247</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In addition to other aspects of Delaware law governing fiduciary duties of directors during a potential takeover, the Delaware General Corporation Law also contains a business combination statute that protects Delaware companies from hostile takeovers and from actions following the takeover by prohibiting some transactions once an acquirer has gained a significant holding in the corporation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;203 of the Delaware General Corporation Law prohibits &#8220;business combinations,&#8221; including mergers, sales and leases of assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested stockholder that beneficially owns 15% or more of a corporation&#8217;s voting stock, within three&#160;years after the person becomes an interested stockholder, unless: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the transaction that will cause the person to become an interested stockholder is approved by the board of directors of the target prior to the transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">after the completion of the transaction in which the person becomes an interested stockholder, the interested stockholder holds at least 85% of the voting stock of the corporation not including shares owned by persons who are directors and officers of interested stockholders and shares owned by specified employee benefit plans; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">after the person becomes an interested stockholder, the business combination is approved by the board of directors of the corporation and holders of at least 66.67% of the outstanding voting stock, excluding shares held by the interested stockholder. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A Delaware corporation may elect not to be governed by Section&#160;203 by a provision contained in the original certificate of incorporation of the corporation or an amendment to the original certificate of incorporation or to the bylaws of the company, which amendment must be approved by a majority of the shares entitled to vote and may not be further amended by the board of directors of the corporation. Such an amendment is not effective until 12&#160;months following its adoption. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Inspection of Books and Records</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;According to Section&#160;150 of the Danish Companies Act, a shareholder may request an inspection of the company&#8217;s books regarding specific issues concerning the management of the company or specific annual reports. If approved by shareholders with simple majority, one or more investigators are elected. If the proposal is not approved by simple majority but 25% of the share capital votes in favor, then a shareholder can request the court to appoint an investigator. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, any stockholder may inspect certain of the corporation&#8217;s books and records, for any proper purpose, during the corporation&#8217;s usual hours of business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pre-emptive Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under Danish law, all shareholders have pre-emptive subscription rights in connection with capital increases that are carried out as cash contributions. In connection with an increase of a company&#8217;s share capital, the shareholders may, by resolution at a general meeting, approve deviations from the general Danish pre-emptive rights of the shareholders. Under the Danish Companies Act, such resolution must be adopted by the affirmative vote of shareholders holding at least a two-thirds majority of the votes cast and the share capital represented at the general meeting and requires that such capital increases will be carried out as a cash contribution at market price. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The board of directors may resolve to increase our share capital without pre-emptive subscription rights for existing shareholders pursuant to the authorizations described above under the caption &#8220;Development of the Share Capital.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless future issuances of new shares are registered under the Securities Act or with any authority outside Denmark, United States shareholders and shareholders in jurisdictions outside Denmark may be unable to exercise their pre-emptive subscription rights under United States securities law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, stockholders have no pre-emptive rights to subscribe for additional issues of stock or to any security convertible into such stock unless, and to the extent that, such rights are expressly provided for in the certificate of incorporation. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">248</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under Danish law, the distribution of ordinary and extraordinary dividends requires the approval of a company&#8217;s shareholders at a company&#8217;s general meeting. Under the Danish Companies Act the general meeting may authorize the board of directors to resolve to distribute extraordinary dividends after presentation of a company&#8217;s first financial statements. The authorization may be subject to financial and time restrictions. The shareholders may not distribute dividends in excess of the recommendation from the board of directors and may only pay out dividends from our distributable reserves, which are defined as amounts stated as retained earnings in the Company&#8217;s latest approved financial statements, and reserves not being non-distributable under a statute or the Company&#8217;s articles of association, less retained earnings. The decision to pay out extraordinary dividends shall be accompanied by a balance sheet, and the board of directors determine whether it will be sufficient to use the balance sheet from the annual report or if an interim balance sheet for the period from the annual report period until the extraordinary dividend payment shall be prepared. If extraordinary dividends are paid out later than six&#160;months following the financial year for the latest annual report, an interim balance sheet showing that there are sufficient funds shall always be prepared. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, it is possible under Danish law to distribute assets other than cash as dividends. If assets other than cash are distributed as dividends, a valuation report must be prepared. The valuation report must be prepared by one or more impartial valuation experts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a Delaware corporation may pay dividends out of its surplus (the excess of net assets over capital), or in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year (provided that the amount of the capital of the corporation is not less than the aggregate amount of the capital represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets). In determining the amount of surplus of a Delaware corporation, the assets of the corporation, including stock of subsidiaries owned by the corporation, must be valued at their fair market value as determined by the board of directors, without regard to their historical book value. Dividends may be paid in the form of shares, property or cash. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Shareholder Vote on Certain Reorganizations</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under Danish law, all amendments to the articles of association shall be approved by the general meeting of shareholders with a minimum of two-thirds of the votes cast and two-thirds of the represented share capital. The same applies to solvent liquidations, mergers with the company as the discontinuing entity, mergers with the company as the continuing entity if shares are issued in connection therewith and demergers with the company as the transferor company and demergers with the company as the existing transferee if amendment of the articles of association for any purpose other than the adoption of the transferor company&#8217;s name or secondary name as the transferee company&#8217;s secondary name is required to be made. Under Danish law, it is debatable whether the shareholders must approve a decision to sell all or virtually all of the company&#8217;s business/assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, the vote of a majority of the outstanding shares of capital stock entitled to vote thereon generally is necessary to approve a merger or consolidation or the sale of all or substantially all of the assets of a corporation. The Delaware General Corporation Law permits a corporation to include in its certificate of incorporation a provision requiring for any corporate action the vote of a larger portion of the stock or of any class or series of stock than would otherwise be required. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Delaware General Corporation Law, no vote of the stockholders of a surviving corporation to a merger is needed, however, unless required by the certificate of incorporation, if (1)&#160;the agreement of merger does not amend in any respect the certificate of incorporation of the surviving corporation, (2)&#160;the shares of stock of the surviving corporation are not changed in the merger and (3)&#160;the number of shares of common stock of the surviving corporation into which any other shares, securities or obligations to be issued in the merger may be converted does not exceed 20% of the surviving corporation&#8217;s common stock outstanding immediately prior to the effective date of the merger. In addition, stockholders may not be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">249</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:352pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">entitled to vote in certain mergers with other corporations that own 90% or more of the outstanding shares of each class of stock of such corporation, but the stockholders will be entitled to appraisal rights. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amendments to Governing Documents</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Denmark</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;All resolutions made by the general meeting may be adopted by a simple majority of the votes, subject only to the mandatory provisions of the Danish Companies Act and the articles of association. Resolutions concerning all amendments to the articles of association must be passed by two-thirds of the votes cast as well as two-thirds of the share capital represented at the general meeting. Certain resolutions, which limit a shareholder&#8217;s ownership or voting rights, are subject to approval by a nine-tenth majority of the votes cast and the share capital represented at the general meeting. Decisions to impose any or increase any obligations of the shareholders towards the company require unanimity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a corporation&#8217;s certificate of incorporation may be amended only if adopted and declared advisable by the board of directors and approved by a majority of the outstanding shares entitled to vote, and the bylaws may be amended with the approval of a majority of the outstanding shares entitled to vote and may, if so provided in the certificate of incorporation, also be amended by the board of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent and registrar for our shares is Computershare A/S, Lottenborgvej 26 D, 1., DK-2800&#160;Kgs. Lyngby, Denmark. The Bank of New York Mellon serves as the depositary, registrar and transfer agent for the ADSs. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">250</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOAD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">American Depositary Shares</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Under the terms of that certain Deposit Agreement, dated as of February&#160;4, 2021, as amended and supplemented from time to time, or the Deposit Agreement, by and among us, The Bank of New York Mellon as the depositary, and all holders and beneficial owners of the ADSs, the depositary will register and deliver the ADSs. As of the effectiveness of the Ratio Change on January&#160;22, 2024, each ADS represents ten ordinary shares (or a right to receive ten ordinary shares) deposited with the depositary, acting through an office located in the United Kingdom, as custodian&#160;for&#160;the depositary. Each ADS will also represent any other securities, cash or other property which may be held by the depositary. The deposited shares together with any other securities, cash or other property held by the depositary are referred to as the deposited securities. The depositary&#8217;s office at which the ADSs will be administered and its principal executive office are located at 240 Greenwich Street, New York, New York&#160;10286. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may hold ADSs either (i)&#160;directly (a)&#160;by having an American Depositary Receipt, or an ADR, which is a certificate evidencing a specific number of ADSs registered in your name, or (b)&#160;by having uncertificated ADSs registered in your name, or (ii)&#160;indirectly by holding a security entitlement in ADSs through your broker or other financial institution that is a direct or indirect participant in The Depository Trust Company, or DTC. If you hold ADSs directly, you are a registered ADS holder, or an ADS holder. This description assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures are. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Registered holders of uncertificated ADSs will receive statements from the depositary confirming their holdings. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. European and Danish law governs shareholder rights. The depositary will be the holder of the shares underlying the ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADR. Those documents are filed as exhibits to the registration statement of which this prospectus forms a part. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends and Other Distributions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How will ADS holders receive dividends and other distributions on the ordinary shares?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary has agreed to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on shares or other deposited securities, upon payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary will convert any cash dividend or other cash distribution we pay on the shares into United States dollars, if it can do so on a reasonable basis. If that is not possible or if any government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Before making a distribution, any withholding taxes, or other governmental charges that must be paid will be deducted. See &#8220;Taxation&#8221; included elsewhere in this prospectus. The depositary will distribute only </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">251</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">whole United States dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some of the value of the distribution. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Shares</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary may distribute additional ADSs representing any shares we distribute as a dividend or free distribution. The depositary will only distribute whole ADSs. It will sell shares which would require it to deliver a fraction of an ADS (or ADSs representing those shares) and distribute the net proceeds in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed shares (or ADSs representing those shares) sufficient to pay its fees and expenses in connection with that distribution. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rights to purchase additional shares</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we offer holders of our securities any rights to subscribe for additional shares or any other rights, the depositary may (i)&#160;exercise those rights on behalf of ADS holders, (ii)&#160;distribute those rights to ADS holders or (iii)&#160;sell those rights and distribute the net proceeds to ADS holders, in each case after deduction or upon payment of its fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse. </font><font style="font-style:italic;letter-spacing:0.2pt;">In that case, you will receive no value for them.</font><font style="letter-spacing:0.2pt;"> The depositary will exercise or distribute rights only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase the securities to which the rights relate and distribute those securities or, in the case of shares, new ADSs representing the new shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. United States securities laws may restrict the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Distributions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary will send to ADS holders anything else we distribute on deposited securities by any means it thinks is legal, fair and practical. If it cannot make the distribution in that way, the depositary has a choice. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. The depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. United States securities laws may restrict the ability of the depositary to distribute securities to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. </font><font style="font-style:italic;letter-spacing:0.2pt;">This means that you may not receive the distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to you.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Deposit, Withdrawal and Cancellation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How are ADSs issued?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary will deliver ADSs if you or your broker deposits shares or evidence of rights to receive shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made the deposit. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">252</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:64pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How can ADS holders withdraw the deposited securities?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may surrender the ADSs to the depositary for the purpose of withdrawal. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer will deliver the shares and any other deposited securities underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and expense, the depositary will deliver the deposited securities at its office, if feasible. However, the depositary is not required to accept surrender of ADSs to the extent it would require delivery of a fraction of a deposited share or other security. The depositary may charge you a fee and its expenses for instructing the custodian regarding delivery of deposited securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How do ADS holders interchange between certificated ADSs and uncertificated ADSs?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR and will send to the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How do ADS holders vote?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ADS holders may instruct the depositary how to vote the number of deposited shares their ADSs represent. If we request the depositary to solicit your voting instructions (and we are not required to do so), the depositary will notify you of a shareholders&#8217; meeting and send or make voting materials available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of the Denmark and the provisions of our articles of association or similar documents, to vote or to have its agents vote the shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions, you can still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except by instructing the depositary as described above, you won&#8217;t be able to exercise voting rights unless you surrender the ADSs and withdraw the shares. However, you may not know about the meeting enough in advance to withdraw the shares. In any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to vote as instructed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your ordinary shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. </font><font style="font-style:italic;letter-spacing:0.2pt;">This means that you may not be able to exercise voting rights and there may be nothing you can do if your ordinary shares are not voted as you requested.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to deposited securities, if we request the depositary to act, we agree to give the depositary notice of any such meeting and details concerning the matters to be voted upon at least 45&#160;days in advance of the meeting date. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">253</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fees and Expenses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:180pt;">
              <font style="letter-spacing:-0.16pt;">Persons depositing or withdrawing</font>
              <br >
              <font style="letter-spacing:-0.16pt;">shares or ADS holders must pay: </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:264pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">For: </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 1.5pt 0pt; width:180pt;">
              <font style="letter-spacing:0.2pt;">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.5pt 0pt; width:264pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">Any cash distribution to ADS holders </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 7.583pt 0pt; width:180pt;">
              <font style="letter-spacing:0.2pt;">$0.05 (or less) per ADS </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;margin-bottom:5pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:180pt;">
              <font style="letter-spacing:-0.16pt;">Persons depositing or withdrawing</font>
              <br >
              <font style="letter-spacing:-0.16pt;">shares or ADS holders must pay: </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:264pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">For: </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:180pt;">
              <font style="letter-spacing:0.2pt;">A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:264pt;">
              <font style="letter-spacing:0.2pt;">Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:180pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">$0.05 (or less) per ADS per calendar year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264pt;">
              <font style="letter-spacing:0.2pt;">Depositary services </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:180pt;">
              <font style="letter-spacing:0.2pt;">Registration or transfer fees </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:264pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 2.833pt 0pt; width:180pt;">
              <font style="letter-spacing:0.2pt;">Expenses of the depositary </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 2.833pt 0pt; width:264pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">Cable and facsimile transmissions (when expressly provided in the deposit agreement)</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">Converting foreign currency to United States dollars </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:180pt;">
              <font style="letter-spacing:0.2pt;">Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:264pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">As necessary </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:180pt;">
              <font style="letter-spacing:0.2pt;">Any charges incurred by the depositary or its agents for servicing the deposited securities </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:264pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">As necessary</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary may convert currency itself or through any of its affiliates and, the custodian or we may convert currency and pay U.S. dollars to the depositary. Where the depositary converts currency itself or through any of its affiliates, the depositary acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">254</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary&#8217;s obligations under the deposit agreement. The methodology used to determine exchange rates used in currency conversions made by the depositary is available upon request. Where the custodian converts currency, the custodian has no obligation to obtain the most favorable rate that could be obtained at the time or to ensure that the method by which that rate will be determined will be the most favorable to ADS holders, and the depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate. In certain instances, the depositary may receive dividends or other distributions from us in U.S. dollars that represent the proceeds of a conversion of foreign currency or translation from foreign currency at a rate that was obtained or determined by us and, in such cases, the depositary will not engage in, or be responsible for, any foreign currency transactions and neither it nor we make any representation that the rate obtained or determined by us is the most favorable rate and neither it nor we will be liable for any direct or indirect losses associated with the rate. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Payment of Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">You will be responsible for any taxes or other governmental charges payable on or with respect to the ADSs or the deposited securities represented by any of the ADSs. The depositary may refuse to register any transfer of the ADSs or allow you to withdraw the deposited securities represented by the ADSs until those taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by the ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary will not tender deposited securities in any voluntary tender or exchange offer unless instructed to do by an ADS holder surrendering ADSs and subject to any conditions or procedures the depositary may establish. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">If deposited securities are redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call for surrender of a corresponding number of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of those ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">If there is any change in the deposited securities such as a sub-division, combination or other reclassification, or any merger, consolidation, recapitalization or reorganization affecting the issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu of the old deposited securities, the depositary will hold those replacement securities as deposited securities under the deposit agreement. However, if the depositary decides it would not be lawful and practical to hold the replacement securities because those securities could not be distributed to ADS holders or for any other reason, the depositary may instead sell the replacement securities and distribute the net proceeds upon surrender of the ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">If there is a replacement of the deposited securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs representing the new deposited securities or ask you to surrender your outstanding ADRs, if any, in exchange for new ADRs identifying the new deposited securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">If there are no deposited securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become apparently worthless, the depositary may call for surrender or of those ADSs or cancel those ADSs upon notice to the ADS holders. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">255</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:20pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amendment and Termination</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How may the deposit agreement be amended?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30&#160;days after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold the ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How may the deposit agreement be terminated?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary will initiate termination of the deposit agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">60&#160;days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we delist the ADSs from an exchange in the United States on which they were listed and do not list the ADSs on another exchange in the United States or make arrangements for trading of ADSs on the United States over-the-counter market; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we delist our ordinary shares from an exchange outside the United States on which they were listed and do not list the shares on another exchange outside the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the depositary has reason to believe the ADSs have become, or will become, ineligible for registration on Form F-6 under the Securities Act; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we appear to be insolvent or enter insolvency proceedings </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">there are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">there has been a replacement of deposited securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the deposit agreement will terminate, the depositary will notify ADS holders at least 90&#160;days before the termination date. At any time after the termination date, the depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro&#160;rata benefit of the ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">After the termination date and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the depositary may refuse to accept a surrender for the purpose of withdrawing deposited securities or reverse previously accepted surrenders of that kind that have not settled if it would interfere with the selling process. The depositary may refuse to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date, the depositary is not required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit agreement except as described in this paragraph. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">256</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:38pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Limitations on Obligations and Liability</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Limits on our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of ADSs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the depositary: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith, and the depositary will not be a fiduciary or have any fiduciary duty to holders of ADSs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">are not liable if we are or it is prevented or delayed by law or by events or circumstances beyond our or its control from performing our or its obligations under the deposit agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">are not liable if we or it exercises discretion permitted under the deposit agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the depositary has no duty to make any determination or provide any information as to our tax status, or any liability for any tax consequences that may be incurred by ADS holders as a result of owning or holding ADSs or be liable for the inability or failure of an ADS holder to obtain the benefit of a foreign tax credit, reduced rate of withholding or refund of amounts withheld in respect of tax or any other tax benefit. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Requirements for Depositary Actions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Before the depositary will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary may require: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any shares or other deposited securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">257</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:2pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Your Right to Receive the Shares Underlying the ADSs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ADS holders have the right to cancel their ADSs and withdraw the underlying shares at any time except: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">when temporary delays arise because (i)&#160;the depositary has closed its transfer books or we have closed our transfer books, (ii)&#160;the transfer of shares is blocked to permit voting at a shareholders&#8217; meeting or (iii)&#160;we are paying a dividend on our ordinary shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">when you owe money to pay fees, taxes and similar charges; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of shares or other deposited securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This right of withdrawal may not be limited by any other provision of the deposit agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Direct Registration System</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the deposit agreement, all parties to the deposit agreement acknowledge that the Direct Registration System, or DRS, and Profile Modification System, or Profile, will apply to the ADSs. DRS is a system administered by DTC that facilitates interchange between registered holding of uncertificated ADSs and holding of security entitlements in ADSs through DTC and a DTC participant. Profile is a feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of uncertificated ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS holder to register that transfer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery as described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary&#8217;s reliance on and compliance with instructions received by the depositary through the DRS/Profile system and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Shareholder Communications; Inspection of Register of Holders of ADSs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Jury Trial Waiver</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement, including any claim under the United States federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You will not, by agreeing to the terms of the deposit agreement, be deemed to have waived our or the depositary&#8217;s compliance with United States federal securities laws and the rules and regulations promulgated thereunder.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">258</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMITC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MATERIAL INCOME TAX CONSIDERATIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following summary contains a description of material Danish and U.S. federal income tax consequences of the acquisition, ownership and disposition of our ordinary shares. This summary should not be considered a comprehensive description of all the tax considerations that may be relevant to the decision to acquire our ordinary shares.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Danish Tax Considerations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following discussion describes the material Danish tax consequences under present law of an investment in the ADSs. The summary is for general information only and does not purport to constitute tax or legal advice. It is specifically noted that the summary does not address all possible tax consequences relating to an investment in the ADSs. The summary is based solely on the tax laws of Denmark in effect on the date of this prospectus. Danish tax laws may be subject to change, possibly with retroactive effect. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The summary does not cover investors to whom special tax rules apply, and, therefore, may not be relevant, for example, to investors subject to the Danish Tax on Pension Yields Act (</font><font style="font-style:italic;letter-spacing:0.2pt;">i.e.</font><font style="letter-spacing:0.2pt;">, pension savings), professional investors, certain institutional investors, insurance companies, pension companies, banks, stockbrokers and investors with tax liability on return on pension investments. The summary does not cover taxation of individuals and companies who carry on a business of purchasing and selling shares. The summary only sets out the tax position of the direct owners of the ADSs and further assumes that the direct investors are the beneficial owners of the ADSs and any dividends thereon. Sales are assumed to be sales to a third party. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Potential investors in the ADSs are advised to consult their tax advisors regarding the applicable tax consequences of acquiring, holding and disposing of the ADSs based on their particular circumstances. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Investors who may be affected by the tax laws of other jurisdictions should consult their tax advisors with respect to the tax consequences applicable to their particular circumstances as such consequences may differ significantly from those described herein. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Taxation of Danish Tax Resident Holders of the ADSs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">It is currently not clear under the current Danish tax legislation or case law how the listed ADSs are to be treated for tax purposes, and therefore no level of assurance can be given on this matter. For the purpose of the below comments, it is assumed that Danish tax resident holders of the ADSs should be treated as holders of listed shares in the company for both Danish corporate law purpose and Danish tax purposes, even though the company&#8217;s ordinary shares are not admitted to trading on a regulated market. Recent communications and binding rulings from the Danish Tax Assessment Council indicate that the holders of ADSs for Danish tax purposes are treated as holders of listed ordinary shares. The same communications and rulings indicate that the actual distribution of dividends on ADSs to Danish investors are considered dividends for Danish tax purposes. However, it should be emphasized that these communications and binding rulings are based on the actual facts and circumstances and terms and conditions of the depositary agreement implying that a holder of ADSs might not be able to rely on said rulings, the position cannot therefore be said to be clear. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event that the holders of ADSs are not treated as holding listed shares, it is likely that they will be treated as either holding unlisted shares or financial instruments for tax purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As described above, the below summary assumes that the holders of ADSs listed in the U.S. should be treated as holding listed ordinary shares in the company for Danish tax purposes, but if this is not the case, then this will impact the Danish tax treatment of the holders of ADSs, including in respect of the taxation of dividends paid to holders of ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Sale of the ADSs (Individuals) assuming treatment as listed shares under Danish tax law</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For individual investor in 2024, gains from the sale of shares are include in the computation of the annual share income subject to 27% tax on the first DKK 61,000 or cohabiting spouses, a total of DKK 122,000) and at a rate of 42% on share income exceeding DKK 61,000 (for cohabiting spouses over DKK </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">259</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">122,000). Such amounts are subject to annual adjustments and include all share income (</font><font style="font-style:italic;letter-spacing:0.2pt;">i.e.</font><font style="letter-spacing:0.2pt;">, all capital gains and dividends derived by the individual or cohabiting spouses, respectively). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Gains and losses on the sale of shares are calculated as the difference between the purchase price and the sales price. The purchase price is generally determined using the average method (in Danish &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">gennemsnitsmetoden</font><font style="letter-spacing:0.2pt;">&#8221;) as a proportionate part of the aggregate purchase price for all the shareholder&#8217;s shares in a company (</font><font style="font-style:italic;letter-spacing:0.2pt;">i.e.</font><font style="letter-spacing:0.2pt;"> not the purchase price paid for each share). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Losses on the sale of listed shares can only be offset against other share income deriving from listed shares (</font><font style="font-style:italic;letter-spacing:0.2pt;">i.e.</font><font style="letter-spacing:0.2pt;">, dividends and capital gains on the sale of listed shares) and subject to the Danish tax authorities having received certain information concerning the ownership of the shares in due time. Unused losses will automatically be offset against a cohabiting spouse&#8217;s share income deriving from listed shares and any additional losses can be carried forward and offset against future share income deriving from listed shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Sale of the ADSs (Companies) assuming treatment as unlisted shares under Danish tax law</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the purpose of taxation of sales of shares made by shareholders (companies), a distinction is made between Subsidiary Shares, Group Shares, Tax-Exempt Portfolio Shares and Taxable Portfolio Shares (note that the ownership threshold described below is applied on the basis of the number of all shares issued by a company, and not on the basis of the number of the ADSs issued): </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Subsidiary Shares</font><font style="letter-spacing:0.2pt;">&#8221; are generally defined as shares owned by a shareholder holding at least 10% of the nominal share capital of the issuing company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Group Shares</font><font style="letter-spacing:0.2pt;">&#8221; are generally defined as shares in a company in which the shareholder of the company and the issuing company are subject to Danish joint taxation or fulfill the requirements for international joint taxation under Danish law (</font><font style="font-style:italic;letter-spacing:0.2pt;">i.e.</font><font style="letter-spacing:0.2pt;">, the company is controlled by the shareholder). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Tax-Exempt Portfolio Shares</font><font style="letter-spacing:0.2pt;">&#8221; are defined as shares not admitted to trading on a regulated market or multilateral trading facility owned by a shareholder holding less than 10% of the nominal share capital of the issuing company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Taxable Portfolio Shares,</font><font style="letter-spacing:0.2pt;">&#8221; which are defined as shares that do not qualify as Subsidiary Shares, Group Shares or Tax-Exempt Portfolio Shares, e.g. shares admitted to trading on a regulated market (such as the ordinary shares and the ADSs) owned by a shareholder holding less than 10% of the nominal share capital of the issuing company </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Gains or losses on disposal of Subsidiary Shares and Group Shares and Tax-Exempt Portfolio Shares are generally not included in the taxable income of the shareholder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Special rules apply with respect to Subsidiary Shares and Group Shares to prevent certain holding company structures just as other anti-avoidance rules may apply. These rules will not be described in further detail. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Capital gains on listed Taxable Portfolio Shares are taxable at the general corporate tax rate of 22% and losses on such shares are generally deductible. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Gains and losses on listed Taxable Portfolio Shares are taxed under the mark-to-market principle irrespective of realization. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">According to the mark to market principle, each year&#8217;s taxable gain or loss on Taxable Portfolio Shares is calculated as the difference between the market value of the shares at the beginning of the tax year and the market value of the shares at the end of the tax year. Hence, taxation will take place on an accrual basis even if no shares have been disposed of and no gains or losses have been realized. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A change of status from respectively Subsidiary Shares/Group Shares/Tax-Exempt Portfolio Shares to Taxable Portfolio Shares is for tax purposes considered a disposal of the shares and a reacquisition of the shares at market value at the time of change of status. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">260</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Dividends (Individuals)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">As described above, the recent communications and binding rulings from the Danish Tax Assessment Council indicate that the holders of ADSs for Danish tax purposes are treated as holders of listed ordinary shares. The same communications and rulings indicate that the actual distribution of dividends on ADSs to Danish investors are considered dividends for Danish tax purposes. Provided that such distributions to Danish tax resident individual investors are treated as dividends, taxation as share income, as described above, will take place. All share income must be included when calculating whether the amounts described above are exceeded. Dividends paid to individuals are generally subject to 27% withholding tax. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Dividends (Companies)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">For corporate investors, dividends paid (subject to the same uncertainty as described immediately above) on Subsidiary Shares and Group Shares generally are tax-exempt irrespective of ownership period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Dividends paid on Tax-Exempt Portfolio Shares are partly taxable as 70% of the dividends received are included in the taxable income, which corresponds to an effective taxation of 15.4% irrespective of ownership period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Dividends paid on Taxable Portfolio Shares are taxable at the general corporate rate of 22% and tax is generally withheld with 22%. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The actual withholding tax rate is as a starting point 27% but may be reduced (0%, 15.4%, 22%) if certain requirements are met. A claim for repayment may be made within two&#160;months or the excess tax will be offset the corporation income tax for the year in question. The statute of limitation is three&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Taxation of Shareholders Residing Outside Denmark</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">It is currently not clear under current Danish tax legislation or case law how the listed ADSs are to be treated for tax purposes, and therefore no level of assurance can be given on this matter. For the purpose of the below comments, it is assumed that non-Danish tax resident holders of the ADSs should be treated as holders of listed shares in our company for both Danish corporate law purposes and Danish tax purposes, even though our company&#8217;s ordinary shares are not admitted to trading on a regulated market. Recent communications and binding rulings from the Danish Tax Assessment Council indicates that the holders of ADSs for Danish tax purposes are treated as holders of listed ordinary shares. The same communications and rulings indicate that the actual distribution of dividends on ADSs to Danish investors are considered dividends for Danish tax purposes. However, it should be emphasized that these communications and binding rulings are based on an individual analysis based on the actual facts and circumstances and terms and conditions of the depositary agreement implying that a holder of ADSs might not be able to rely on said rulings. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event that the holders of ADSs are not treated as holding listed shares in our company, it is likely that they will be treated as either holding unlisted shares or financial instruments for Danish tax purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As described above, the below summary assumes that the holders of ADSs listed in the U.S. should be treated as holding listed ordinary shares in our company for Danish tax purposes, but if this is not the case, then this will impact the Danish tax treatment of the holders of ADSs, including in respect of the taxation of dividends paid to holders of ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Sale of the ADSs (Individuals and Companies)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Holders of the ADSs not resident in Denmark are normally not subject to Danish taxation on any gains realized on the sale of ADSs, irrespective of the ownership period, subject to certain anti-avoidance rules seeking to prevent that taxable dividend payments are converted to tax exempt capital gains. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No Danish share transfer tax or stamp duties should be payable on transfer of ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If an investor holds the ADSs in connection with a trade or business conducted from a permanent establishment in Denmark, gains on shares may be included in the taxable income of such activities pursuant to the rules applying to Danish tax residents as described above. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">261</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Dividends (Individuals)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As described above, the recent communications and binding rulings from the Danish Tax Assessment Council indicate that the holders of ADSs for Danish tax purposes are treated as holders of listed ordinary shares in the company. The same communications and rulings indicate that the actual distribution of dividends on ADSs to investors are considered dividends for Danish tax purposes. In principle the holders of the ADSs should therefore be entitled to apply for a refund of Danish withholding tax on dividends paid by the company. However, it remains uncertain how the Danish tax authorities will accept/handle this in practice and whether. the holders of ADSs will in fact be entitled to apply for a refund of Danish withholding tax on dividends paid by the company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the holders of ADS for Danish purposes are treated as holders of the ordinary shares in the company and are entitled to apply for a refund of Danish withholding tax on dividends paid by the company, then the below should apply: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Dividends paid to individuals are generally subject to 27% withholding tax. The withholding tax is 44% for dividends paid to beneficial owners in &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Blacklisted Jurisdictions</font><font style="letter-spacing:0.2pt;">&#8221;. The 44% rate only applies to &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Main Shareholders</font><font style="letter-spacing:0.2pt;">&#8221; which generally encompass individual shareholders holding more than 25% of the shares or 50% of the votes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Non-residents of Denmark are not subject to additional Danish income tax in respect to dividends received on shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the holders of the ADSs are considered beneficial owners of the dividends according to the applicable double tax treaty between Denmark and the tax residence country of the ADS holder, the withholding tax rate under such double tax treaty may apply to the extent the tax residency of the ADS holder can be documented and to the extent it can be documented that the dividends are in fact paid onwards to the holder of the ADSs as the beneficial owner. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For holders of ADSs (as the beneficial owners of the dividends on the ordinary shares), if the withholding tax rate applied is higher than the applicable final tax rate (as reduced according to domestic law or an applicable double tax treaty) for the holder of ADSs, a request for a refund of Danish tax in excess hereof can be made in the following situations: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Reduction According to Tax Treaty</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event that the ADS holder is a resident of a state with which Denmark has entered into a tax treaty, the holder may generally, through certain certification procedures, seek a refund from the Danish tax authorities of the tax withheld in excess of the applicable treaty rate, which is typically 15%. Denmark has entered into tax treaties with approximately 80 countries, including the United States, Switzerland and almost all members of the European Union. The tax treaty between Denmark and the United States generally provides for a 15% tax rate. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Reduction According to Danish Tax Law</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the ADS holder holds less than 10% of the nominal share capital (in the form of ordinary shares in the company and not on the basis of the number of the ADSs issued) of the company and the ADS holder is tax resident in a state which has a double tax treaty or an international agreement, convention or other administrative agreement on assistance in tax matters according to which the competent authority in the state of the ADS holder is obligated to exchange information with Denmark, dividends are subject to tax at a rate of 15%. If the ADS holder is tax resident outside the European Union, it is an additional requirement for eligibility for the 15% tax rate that the ADS holder together with related ADS holders holds less than 10% of the nominal share capital of the company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Note that the reduced tax rate does not affect the withholding rate, which is why the holder must claim a refund as described above in order to benefit from the reduced rate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Where a non-resident of Denmark holds shares which can be attributed to a permanent establishment in Denmark, dividends are taxable pursuant to the rules applying to Danish tax residents described above. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">262</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The recent communications and binding rulings from the Danish Tax Assessment Council indicates that a holder of ADSs selling such ADSs back to the company should be exempt from withholding tax on the basis of a specific exception applying to shares in listed companies. It should be emphasized that these rulings are based on an individual analysis based on the actual facts and circumstances and terms and conditions of the depositary agreement implying that a holder of ADSs might not be able to rely on said rulings. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends (Companies)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As described above, the recent communications and binding rulings from the Danish Tax Assessment Council indicates that holders of ADSs for Danish tax purposes are treated as holders of listed ordinary shares. The same communications and rulings indicate that the actual distribution of dividends on ADSs to investors are considered dividends for Danish tax purposes. In principle the holders of the ADSs should therefore be entitled to apply for a refund of Danish withholding tax on dividends paid by the company. However, it remains uncertain how the Danish tax authorities will accept/handle this in practice and whether the holders of ADSs will in fact be entitled to apply for a refund of Danish withholding tax on dividends paid by the company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the holders of ADS for Danish purposes are treated as holders of the ordinary shares in the company and are entitled to apply for a refund of Danish withholding tax on dividends paid by the company, then the below should apply: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Dividends paid to companies are generally subject to 27% withholding tax. The withholding tax is 44% for dividends paid on Group Shares and Subsidiary Shares held by beneficial owners in Blacklisted Jurisdictions as mentioned above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Non-residents of Denmark are not subject to additional Danish income tax in respect to dividends received on shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the investors of the ADSs are considered beneficial owners of the dividends according to the applicable double tax treaty between Denmark and the tax residence country of the ADS holder, the withholding tax rate under such double tax treaty may apply to the extent the tax residency of the ADS holder can be documented and to the extent it can be documented that the dividends are in fact paid onwards to the holder of the ADSs as the beneficial owner. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For investors (as beneficial owners of the dividends on the ordinary shares), if the withholding tax rate applied is higher than the applicable final tax rate (as reduced according to domestic law or an applicable double tax treaty) for the investor, a request for a refund of Danish tax in excess hereof can be made. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Dividends from Subsidiary Shares are tax exempt provided the taxation of the dividends is to be waived or reduced in accordance with the Parent-Subsidiary Directive (2011/96/EEC) or in accordance with a tax treaty with the jurisdiction in which the company investor is resident. If Denmark is to reduce taxation of dividends to a foreign company under a tax treaty, Denmark will not&#8201;&#8212;&#8201;as a matter of domestic law&#8201;&#8212;&#8201;exercise such right and will in general exempt from imposing any withholding tax. Further, dividends from Group Shares&#8201;&#8212;&#8201;not also being Subsidiary Shares&#8201;&#8212;&#8201;are exempt from Danish tax provided the company investor is a resident of the European Union or the EEA and provided the taxation of dividends should have been waived or reduced in accordance with the Parent-Subsidiary Directive (2011/96/EEC) or in accordance with a tax treaty with the country in which the company investor is resident had the shares been Subsidiary Shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Dividend payments on both Tax-Exempt and Taxable Portfolio Shares will generally be subject to a tax rate of 22% irrespective of ownership period. While the actual withholding tax rate is as a starting point 27%, it can be reduced if certain requirements are met as described below. If the withholding tax rate applied is higher than the applicable final tax rate for the shareholder, a request for a refund of Danish tax in excess hereof can be made by the shareholder in the following situations: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Reduction According to Tax Treaty</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event that the shareholder is a resident of a state with which Denmark has entered into a double taxation treaty, the shareholder may generally, through certain certification procedures, seek a refund from </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">263</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the Danish tax authorities of the tax withheld in excess of the applicable treaty rate, which is typically 15%. Denmark has entered into tax treaties with a large number of countries, including the United States and almost all members of the European Union. The tax treaty between Denmark and the United States generally provides for a 15% rate. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Reduction According to Danish Tax law</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the shareholder holds less than 10% of the nominal share capital (in the form of ordinary shares in the company and not on the basis of the number of the ADSs issued) in the company and the shareholder is resident in a jurisdiction which has a tax treaty or an international agreement, convention or other administrative agreement on assistance in tax according to which the competent authority in the state of the shareholder is obligated to exchange information with Denmark, dividends are generally subject to a tax rate of 15%. If the shareholder is tax resident outside the European Union, it is an additional requirement for eligibility for the 15% tax rate that the shareholder together with related shareholders holds less than 10% of the nominal share capital of the company. Note that the reduced tax rate does not affect the withholding rate, hence, in this situation the shareholder must also in this situation claim a refund as described above in order to benefit from the reduced rate. Where a non-resident company of Denmark holds shares which can be attributed to a permanent establishment in Denmark, dividends are taxable pursuant to the rules applying to Danish tax residents described above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The recent communications and binding rulings from the Danish Tax Assessment Council indicate that a holder of ADSs selling such ADSs back to the company should be exempt from withholding tax on the basis of a specific exception applying to shares in listed companies. It should be emphasized that these rulings are based on an individual analysis based on the actual facts and circumstances and terms and conditions of the depositary agreement implying that a holder of ADSs might not be able to rely on said rulings. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Share Transfer Tax and Stamp Duties</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No Danish share transfer tax or stamp duties should be payable on transfer of the shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Certain Material U.S. Federal Income Tax Considerations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following discussion describes certain material United States federal income tax considerations relating to the acquisition, ownership and disposition of ADSs by a United States Holder (as defined below) that acquires the ADSs and holds them as a capital asset (generally property held for investment) under the Internal Revenue Code of 1986, as amended from time to time, or the &#8220;Code&#8221;. This discussion is based upon existing U.S. tax law (including the Code, its legislative history, existing, temporary and proposed United States Department of the Treasury Regulations promulgated thereunder, or the &#8220;Treasury Regulations&#8221;, administrative and judicial interpretations thereof, and other published rulings, guidance, and court decisions) in effect on the date hereof. These tax laws are subject to change, possibly with retroactive effect, and subject to differing interpretations that could affect the tax consequences described herein. No ruling has been sought from the Internal Revenue Service, or the &#8220;IRS&#8221;, or any other taxing authority, with respect to any United States federal income tax consequences described below. In addition, because the authorities upon which this summary is based are subject to various interpretations, the IRS, other taxing authorities, and the U.S. courts could disagree with one or more of the positions taken in this summary. This summary is not binding on the IRS or any other taxing authority or court, none of which are precluded from taking a position that is different from or contrary to, any position taken in this summary and there can be no assurance that the IRS, other taxing authority, or a court will not take a contrary position. No opinion from U.S. legal counsel has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership and disposition of the ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This discussion does not address all aspects of United States federal income taxation that may be applicable to U.S. Holders in light of their particular circumstances or status including investors subject to special tax rules (such as, bank thrifts, and other financial institutions, insurance companies, broker-dealers in stocks, securities, currencies, or notional principal contracts, traders that have elected to mark securities to market, regulated investment companies, real estate investment trusts, partnerships or other pass-through entities, tax-exempt organizations including private foundations and charitable remainder trusts, pension plans, persons that hold the ADSs or ordinary shares as part of a straddle, hedge, conversion, constructive </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">264</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">sale, or other integrated investment or transaction as determined for U.S. federal income tax purposes, persons subject to alternative minimum tax or whose &#8220;functional currency&#8221; is not the USD, U.S. expatriates or former long-term residents of the United States, persons that directly, indirectly or constructively own 10% or more (by vote or value) of the Company, persons who acquired interests in the Company pursuant to the exercise of any employee share option or otherwise as compensation, or persons holding interests in the Company through partnerships or other pass-through entities). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This section does not address the treatment of a non-U.S. holder, nor does it address the tax treatment under the laws of any U.S. state or local state or non-U.S. taxing jurisdiction or any U.S. estate or alternative minimum tax consequences. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder as a result of the acquisition, ownership and disposition of the ADSs. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any particular U.S. Holder. Except as specifically set forth below, this summary does not discuss applicable tax reporting requirements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is a beneficial owner of the ADSs that, for United States federal income tax purposes, is: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an individual who is a citizen or resident of the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States or of any State thereof or the District of Columbia; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an estate the income of which is subject to United States federal income taxation regardless of its source; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a trust if (i)&#160;a court within the United States is able to exercise primary supervision over the trust&#8217;s administration and one or more United States persons have the authority to control all substantial decisions of the trust or (ii)&#160;a valid election under the Treasury regulations is in effect for the trust to be treated as a United States person. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a partnership or other pass-through entity (including any entity or arrangement treated as a partnership or other pass-through entity for U.S. federal income tax purposes) holds the ADSs, the tax treatment of a person treated as a partner or other owner in the partnership or other pass-through entity for U.S. federal income tax purposes generally will depend on the status of the partner or other owner and the activities of the partnership or other pass-through entity. Partnerships (and other entities or arrangements so treated for U.S. federal income tax purposes) and their future partners should consult their own tax advisors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In general, and taking into account the earlier assumptions, for U.S. federal income tax purposes, a holder of ADSs will be treated as the owner of the shares represented by those ADSs. Exchanges of shares for ADSs, and ADSs for shares, generally will not be subject to United States federal income tax. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">This discussion addresses only U.S. Holders and does not discuss any tax considerations other than United States federal income tax considerations. Prospective investors are urged to consult their own tax advisors regarding the United States federal, state and local, and non-U.S. income and other tax consequences of the purchase, ownership, and disposition of ADSs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the United States federal income tax laws, and subject to the PFIC rules discussed below under &#8220;&#8212; Passive Foreign Investment Company Considerations&#8221;, any distributions of cash or other property with respect to the ADSs (including any amounts withheld in respect thereof), generally will, to the extent made out of our current and accumulated earnings and profits as determined for U.S. federal income tax purposes, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">265</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">constitute dividends for U.S. federal income tax purposes. Generally, the gross amount of any dividend we pay out of our current or accumulated earnings and profits (as determined for United States federal income tax purposes) is includible in income for a U.S. Holder and subject to U.S. federal income taxation. Dividends paid to a non-corporate U.S. Holder that constitute dividend income from a &#8220;qualified foreign corporation&#8221; will be taxable at a preferential tax rate applicable to long-term capital gains, provided that the U.S. Holder holds the ADSs for more than 60&#160;days during the 121-day period beginning 60&#160;days before the ex-dividend date and meets other holding period requirements. A non-United States corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation (i)&#160;if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of information program, or (ii)&#160;with respect to any dividend it pays on stock (or ADSs in respect of such stock) which is readily tradable on an established securities market in the United States. The ADSs are listed on The Nasdaq Capital Market, which is an established securities market in the United States. We therefore expect that dividends we pay with respect to the ADSs generally will constitute qualified dividend income. There can be no assurance, however, that the ADSs will be considered readily tradeable on an established securities market in later&#160;years. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A U.S. Holder must include any Danish tax withheld from the dividend payment, as described above under &#8220;&#8212; Danish Tax Considerations&#8201;&#8212;&#8201;Taxation of Shareholders Residing Outside Denmark,&#8221; in the gross amount of dividend paid even though the holder does not in fact receive it. The dividend is taxable to the holder when the depositary receives the dividend, actually or constructively. Because we are not a United States corporation and do not expect to meet the dividends-received deduction eligibility criteria for non-U.S. corporations, the dividend is not expected to be eligible for the dividends-received deduction generally allowed to U.S. corporations in respect of dividends received from other United States corporations. The amount of the dividend distribution includible in a U.S. Holder&#8217;s income will be the USD value of the Danish Krone payments made, determined at the spot Danish Krone/USD rate on the date the dividend distribution is includible in income, regardless of whether the payment is in fact converted into USD. Generally, any gain or loss resulting from currency exchange fluctuations during the period from the date the dividend payment is included in income to the date the payment is converted into USD will be treated as ordinary income or loss to the U.S. Holder and will not be eligible for the special tax rate applicable to qualified dividend income. The currency gain or loss generally will be income or loss from sources within the United States for foreign tax credit limitation purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To the extent a distribution with respect to ADSs exceeds our current or accumulated earnings and profits, as determined under U.S. federal income tax principles, the distribution will be treated, first, as a tax-free return of the U.S. Holder&#8217;s capital invested in the Company, up to the holder&#8217;s adjusted tax basis in its ADSs, and, thereafter, as capital gain, which is subject to the tax treatment described below in &#8220;&#8212;&#160;Gain on Sale, Exchange or Other Taxable Disposition.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because we do not intend to determine our earnings and profits on the basis of United States federal income tax principles, all distributions paid will generally be treated as &#8220;dividends&#8221; for United States federal income tax purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Dividends paid by the Company generally will be treated as income from foreign sources for United States foreign tax credit purposes and generally will constitute passive category income. A U.S. Holder may be eligible, subject to a number of complex limitations, to claim a foreign tax credit in respect of any foreign withholding taxes imposed on dividends received on the ADSs, including the Danish tax withheld in accordance with the Treaty and paid over to the Danish taxing authority, which may, subject to such limitations, be creditable against a U.S. Holder&#8217;s United States federal income tax liability. A U.S. Holder who does not elect to claim a foreign tax credit for foreign tax withheld, may instead claim a deduction, for United States federal income tax purposes, in respect of such withholdings, but only for a year in which such U.S. Holder elects to do so for all creditable foreign income taxes. To the extent a refund of the tax withheld is available to a U.S. Holder under Danish law or under the Treaty, the amount of tax withheld that is refundable will not be eligible for credit against a U.S. Holder&#8217;s U.S. federal income tax liability. See &#8220;&#8212;&#160;Danish Taxation&#8201;&#8212;&#8201;Withholding Tax Refund for United States Treaty Beneficiaries&#8221; above for the procedures for obtaining a tax refund. Investors are urged to consult their own tax advisors about the availability of any foreign tax credits or deductions in respect to their specific tax situations. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">266</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Gain on Sale, Exchange or Other Taxable Disposition</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the PFIC rules described below under &#8220;&#8212; Passive Foreign Investment Company Considerations&#8221;, a U.S. Holder that sells, exchanges or otherwise disposes of ADSs in a taxable disposition generally will recognize capital gain or loss for United States federal income tax purposes equal to the difference between the United States dollar value of the amount realized and the holder&#8217;s adjusted tax basis, determined in United States dollars, in the ADSs. Gain or loss recognized on such a sale, exchange or other disposition of ADSs generally will be long-term capital gain if the U.S. Holder&#8217;s holding period in the ADSs exceeds one year. Long-term capital gains of non-corporate U.S. Holders are generally taxed at preferential rates. The gain or loss generally will be income or loss from sources within the United States for foreign tax credit limitation purposes. A U.S. Holder&#8217;s ability to deduct capital losses is subject to limitations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Passive Foreign Investment Company Considerations</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have not made a determination as to whether the Company will or will not be treated as a PFIC in the current taxable year and subsequent taxable&#160;years. The determination of PFIC status is inherently factual, is subject to a number of uncertainties, and can be determined only annually after the close of the tax year in question. Additionally, the analysis depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. There can be no assurance that the Company will or will not be determined to be a PFIC for the current tax year or any prior or future tax year, and no opinion of legal counsel or ruling from the IRS concerning the status of the Company as a PFIC has been obtained or will be requested. U.S. Holders should consult their own U.S. tax advisors regarding our PFIC status. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we were classified as a &#8220;passive foreign investment company&#8221;, or a &#8220;PFIC&#8221;, for U.S. federal income tax purposes in any taxable year, a U.S. Holder would be subject to special rules with respect to distributions on and sales, exchanges and other dispositions of the ADSs. A non-U.S. corporation, such as the Company, will be classified as a PFIC for United States federal income tax purposes for any taxable year, if either (i)&#160;75% or more of its gross income for such year consists of certain types of &#8220;passive&#8221; income (the &#8220;income test&#8221;) or (ii)&#160;50% or more of the value of its assets (generally determined on the basis of a quarterly average) during such year is attributable to assets that produce or are held for the production of passive income (the &#8220;asset test&#8221;). For this purpose, cash and assets readily convertible into cash are categorized as passive assets and the company&#8217;s goodwill and other unbooked intangibles are taken into account. Passive income generally includes, among other things, dividends, interest, rents, royalties, and gains from the disposition of passive assets. However, certain rents and royalties received from unrelated parties in connection with the active conduct of a trade or business are not considered passive income for purposes of the PFIC test. For purposes of the PFIC test, we will be treated as owning a proportionate share of the assets and earning a proportionate share of the income of any other corporation in which we own, directly or indirectly, at least 25% (by value) of the stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we were a PFIC with respect to a U.S. Holder, then unless such U.S. Holder makes one of the elections described below, a special tax regime would apply to the U.S. Holder with respect to (i)&#160;any &#8220;excess distribution&#8221; &#8203;(generally, aggregate distributions in any year that are greater than 125% of the average annual distribution received by the holder in the shorter of the three preceding&#160;years or the holder&#8217;s holding period for the ADSs) and (ii)&#160;any gain realized on the sale or other disposition of the ADSs. Under this regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to tax as if (a)&#160;the excess distribution or gain had been realized ratably over the U.S. Holder&#8217;s holding period, (b)&#160;the amount deemed realized in each year had been subject to tax in each year of that holding period at the highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. Holder&#8217;s regular ordinary income rate for the current year and would not be subject to the interest charge discussed below), and (c)&#160;the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those&#160;years. If we were determined to be a PFIC, this tax treatment for U.S. Holders would apply also to indirect distributions and gains deemed realized by U.S. Holders in respect of stock of any of our subsidiaries determined to be PFICs. In addition, dividend distributions would not qualify for the lower rates of taxation applicable to long-term capital gains discussed above under &#8220;&#8212; Taxation of Dividends.&#8221; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">267</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A U.S. Holder that holds the ADSs at any time during a taxable year in which we are classified as a PFIC generally will continue to treat such ADSs as ADSs in a PFIC, even if we no longer satisfy the PFIC income and asset tests described above, unless the U.S. Holder elects to recognize gain, which will be taxed under the excess distribution rules as if such ADSs had been sold on the last day of the last taxable year for which we were a PFIC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain elections by a U.S. Holder would alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment of the ADSs, as described below. These elections include a &#8220;qualified electing fund&#8221; or &#8220;QEF&#8221; election and a &#8220;mark-to-market&#8221; election, which is described in more detail below. We do not expect that a U.S. Holder would be able to make a QEF election with respect to the ADSs because we do not intend to provide to U.S. Holders the required information to make a valid QEF election. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event we are determined to be a PFIC, the rules applicable to PFICs described above would not apply to a U.S. Holder that makes a &#8220;mark-to-market&#8221; election with respect to the ADSs, but this election will be available with respect to the ADSs only if they meet certain minimum trading requirements to be considered &#8220;marketable stock&#8221; for purposes of the PFIC rules. Generally, shares of ADSs will be treated as marketable stock if they are &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221; within the meaning of applicable Treasury Regulations. ADSs generally will be considered regularly traded during any calendar year during which they are traded, other than in </font><font style="font-style:italic;letter-spacing:0.2pt;">de minimis</font><font style="letter-spacing:0.2pt;"> quantities, on at least 15&#160;days during each calendar quarter. Any trades that have as their principal purpose meeting this requirement will be disregarded. The ADSs will be considered marketable stock as long as they remain listed on The Nasdaq Capital Market and are regularly traded. We anticipate that the ADSs should qualify as being regularly traded, but no assurances may be given in this regard. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A U.S. Holder that makes a valid mark-to-market election for the first tax year in which the holder holds (or is deemed to hold) ADSs and for which we are a PFIC will be required to include each year an amount equal to the excess, if any, of the fair market value of such ADSs the holder owns as of the close of the taxable year over the holder&#8217;s adjusted tax basis in such ADSs. The U.S. Holder will be entitled to a deduction for the excess, if any, of the holder&#8217;s adjusted tax basis in the ADSs over the fair market value of such ADSs as of the close of the taxable year, but only to the extent of any net mark-to-market gains with respect to such ADSs included by the U.S. Holder under the election for prior taxable&#160;years and may be subject to certain other limitations. The U.S. Holder&#8217;s adjusted tax basis in such ADSs will be adjusted to reflect the amounts included or deducted pursuant to the election. Amounts included in income pursuant to a mark-to-market election, as well as gain on the sale, exchange or other taxable disposition of such ADSs, will be treated as ordinary income. The deductible portion of any mark-to-market loss, as well as loss on a sale, exchange or other disposition of ADSs to the extent that the amount of such loss does not exceed net mark-to-market gains previously included in income, will be treated as ordinary loss. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because a mark-to-market election cannot be made for any lower-tier PFICs that we may own, a U.S. Holder may continue to be subject to the PFIC rules with respect to such U.S. Holder&#8217;s indirect interest in any investments held by us that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The mark-to-market election applies to the taxable year for which the election is made and all subsequent taxable&#160;years, unless the ADSs cease to be treated as marketable stock for purposes of the PFIC rules or the IRS consents to its revocation. The excess distribution rules described above generally will not apply to a U.S. Holder for tax&#160;years for which a mark-to-market election is in effect. However, if we were a PFIC for any year in which the U.S. Holder owns the ADSs but before a mark-to-market election is made, the interest charge rules described above would apply to any mark-to-market gain recognized in the year the election is made. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A U.S. Holder of PFIC shares must generally file an annual information return on IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations with respect to U.S. federal income tax. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">268</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:116pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">U.S. Holders are urged to consult their tax advisors as to our status as a PFIC, and the tax consequences to them if we were a PFIC, including the reporting requirements and the desirability of making, and the availability of, a mark-to-market election with respect to the ADSs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Net Investment Income Tax</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Non-corporate U.S. Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion of their net investment income, which may include their gross dividend income and net gains from the disposition of ADSs. A U.S. person that is an individual, estate or trust is encouraged to consult its tax advisors regarding the applicability of this net investment income tax to its income and gains in respect of any investment in ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Information Reporting with Respect to Foreign Financial Assets</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Individual U.S. Holders may be subject to certain reporting obligations on IRS Form 8938 (Statement of Specified Foreign Financial Assets) with respect to the ADSs for any taxable year during which the U.S. Holder&#8217;s aggregate value of these and certain other &#8220;specified foreign financial assets&#8221; exceed a threshold amount that varies with the filing status of the individual. This reporting obligation also applies to domestic entities formed or availed of to hold, directly or indirectly, specified foreign financial assets, including the ADSs. Significant penalties can apply if U.S. Holders are required to make this disclosure and fail to do&#160;so. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">U.S. Holders who acquire ADSs for cash may be required to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) with the IRS and to supply certain additional information to the IRS if (i)&#160;immediately after the transfer, the U.S. Holder owns directly or indirectly (or by attribution) at least 10% of our total voting power or value or (ii)&#160;the amount of cash transferred to us in exchange for ADSs, when aggregated with all related transfers under applicable regulations, exceeds $100,000. Substantial penalties may be imposed on a U.S. Holder that fails to comply with this reporting requirement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Information Reporting and Backup Withholding</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dividend payments with respect to the ADSs and proceeds from the sale, exchange or redemption of the ADSs may be subject to information reporting to the IRS and possible United States backup withholding tax. In general, information reporting, including IRS Form 1099 reporting, will apply to dividends in respect of ADSs and the proceeds from the sale, exchange or redemption of ADSs that are paid to a holder of ADSs within the United States (and in certain cases, outside the United States), unless such holder is an exempt recipient such as a corporation. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct taxpayer identification number and makes other required certifications, or who is otherwise exempt from backup withholding. U.S. Holders that are required to establish their exempt status generally must provide such certification on IRS Form W-9. Backup withholding is not an additional tax. A U.S. Holder generally may obtain a refund of any amounts withheld under the backup withholding rules that exceed the U.S. Holder&#8217;s income tax liability by filing a refund claim with the IRS. U.S. Holders are urged to consult their tax advisors regarding the application of the United States information reporting and backup withholding rules. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">269</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOSW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF SECURITIES WE ARE OFFERING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are offering up to 2,032,520 ADSs, pre-funded warrants to purchase up to 2,032,520 ADSs, and Warrants to purchase up to 2,032,520 ADSs. For each pre-funded warrant we sell, the number of ADSs we are offering will be decreased on a one-for-one basis. We are also registering the ADSs issuable from time to time upon exercise of the Warrants and pre-funded warrants offered hereby. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">American Depositary Shares (&#8216;ADSs&#8217;)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For a description of our ADSs see the section &#8220;Description of American Depositary Shares&#8221;. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On January&#160;22, 2024, we effected a change to the ratio of our ADSs to our ordinary shares from one ADS representing one (1)&#160;ordinary share to one ADS representing ten (10) ordinary shares, or the ADS Ratio Change. Except as otherwise indicated, all information in this prospectus, including the number of ADSs being offered and the assumed offering price gives retroactive effect to the ADS Ratio Change. </font>
          </div>


          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Duration and Exercise Price</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Each Warrant will have an exercise price equal to $ per ADS. The Warrants will be immediately exercisable from the date of issuance until the five (5)&#160;year anniversary of the initial exercise date. The exercise price and number of ADSs issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, subsequent rights offerings, pro rate distributions, reorganizations, or similar events affecting the Company&#8217;s ordinary shares and ADSs and the exercise price. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Exercisability</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to the Company a duly executed exercise notice accompanied by payment in full for the number of ADSs purchased upon such exercise. A holder (together with its affiliates) may not exercise any portion of such holder&#8217;s Warrants to the extent that the holder would own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding ordinary shares represented by ADSs immediately after exercise, except that upon prior notice from the holder to the Company, the holder may increase or decrease the amount of ownership of outstanding ADSs after exercising the holder&#8217;s Warrants up to 9.99% of the number of the Company&#8217;s ordinary shares outstanding immediately after giving effect to the exercise, as such&#160;percentage ownership is determined in accordance with the terms of the Warrants, provided that any increase will not be effective until 61&#160;days following notice to us. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">At the time a holder exercises its Warrants, if a registration statement registering the issuance or resale of the ordinary shares represented by ADSs issuable upon exercise of the Warrants under the Securities Act is not then effective or available for the issuance of such ordinary shares represented by ADSs, we shall be obligated to pay certain liquidated damages of up to $20 per day per $1,000 of Warrant ADSs subject to exercise as further described in Section 2(c) of the Warrants.</font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Trading Market</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">There is no established trading market for the Warrants, and the Company does not expect an active trading market to develop. The Company does not intend to apply to list the Warrants on any securities exchange or other trading market. Without a trading market, the liquidity of the Warrants will be extremely limited. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Rights as a Stockholder</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Except as otherwise provided in the Warrants or by virtue of the holder&#8217;s ownership of the Company&#8217;s ADSs, such holder of Warrants does not have the rights or privileges of a holder of the Company&#8217;s ADSs, including any voting rights, until such holder exercises such holder&#8217;s Warrants. The Warrants will provide that the holders of the Warrants have the right to participate in distributions or dividends paid on the Company&#8217;s ADSs. </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">270</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Fundamental Transactions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">If at any time the Warrants are outstanding, the Company, either directly or indirectly, in one or more related transactions effects a Fundamental Transaction (as defined in the Warrant), a Holder of Warrants will be entitled to receive, upon exercise of the Warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Warrants immediately prior to the Fundamental Transaction. Notwithstanding the foregoing, in the event of a fundamental transaction, the holders of the Warrants have the right to require us or a successor entity to redeem the Warrants for cash in the amount of the Black-Scholes Value (as defined in each Warrant) of the unexercised portion of the Warrants concurrently with or within 30&#160;days following the consummation of a fundamental transaction. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">However, in the event of a fundamental transaction which is not in our control, including a fundamental transaction not approved by our board of directors, the holders of the Warrants will only be entitled to receive from us or our successor entity, as of the date of consummation of such fundamental transaction the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the Warrants that is being offered and paid to the holders of our ADSs in connection with the fundamental transaction, whether that consideration is in the form of cash, stock or any combination of cash and stock, or whether the holders of our ADSs are given the choice to receive alternative forms of consideration in connection with the fundamental transaction. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Waivers and Amendments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The Warrants may be modified or amended or the provisions of the Warrants waived with the Company&#8217;s and the holder&#8217;s written consent. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pre-Funded Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The term &#8220;pre-funded&#8221; refers to the fact that the purchase price of the pre-funded warrants in this offering includes almost the entire exercise price that will be paid under the pre-funded warrants, except for an amount in US dollars equal to DKK 10 at the time of pricing of this offering, which amount is equal to $1.479 as of the date of the prospectus, provided that such exercise price shall not be less than the USD equivalent to DKK 10 at the time of exercise. The purpose of the pre-funded warrants is to enable investors that may have restrictions on their ability to beneficially own more than 4.99% (or, at the election of such purchaser, 9.99%) of our outstanding ordinary shares represented by ADSs following the consummation of this offering the opportunity to invest capital into the Company without triggering their ownership restrictions, by receiving pre-funded warrants in lieu of ADSs which would result in such ownership of more than 4.99% or 9.99%, as applicable, and receiving the ability to exercise their option to purchase the ADSs underlying the pre-funded warrants at a price at a later date. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following is a brief summary of certain terms and conditions of the pre-funded warrants being offered by us. The following description is subject in all respects to the provisions contained in the form of pre-funded warrant, the form of which will be filed as an exhibit to the registration statement of which this prospectus forms a part. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exercise Price</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Pre-funded warrants will have an exercise price of $1.479, provided that such exercise price shall not be less than the USD equivalent to DKK 10 at the time of exercise. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our ADSs and also upon any distributions of assets, including cash, stock or other property to our stockholders. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exercisability</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The pre-funded warrants are exercisable at any time after their original issuance and until exercised in full. The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and by payment in full of the exercise price in immediately available </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">271</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">funds for the number of ADSs purchased upon such exercise. No fractional ADSs will be issued in connection with the exercise of a pre-funded warrant. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
            <font style="letter-spacing:0.2pt;">At the time a holder exercises its Warrants, if a registration statement registering the issuance or resale of the ordinary shares represented by ADSs issuable upon exercise of the pre-funded warrants under the Securities Act is not then effective or available for the issuance of such ordinary shares represented by ADSs, we shall be obligated to pay certain liquidated damages of up to $20 per day per $1,000 of pre-funded warrants ADSs subject to exercise as further described in Section 2(c) of the pre-funded warrants.</font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
            <font style="letter-spacing:0.2pt;">As set forth in the pre-funded warrant that is an exhibit to this registration statement, investors who purchase pre-funded warrants may, at the option of the investor, deliver the aggregate exercise price at closing of the offering to our Danish counsel , which shall be held in trust by our Danish counsel until the time of exercise of the pre-funded warrants by the investors.</font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exercise Limitations</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The pre-funded warrants may not be exercised by the holder to the extent that the holder, together with its affiliates, would beneficially own, after such exercise more than 4.99% of the ADSs then outstanding (including for such purpose the ADSs issuable upon such exercise). However, any holder may increase or decrease such beneficial ownership limitation upon notice to us, provided that such limitation cannot exceed 9.99%, and provided that any increase in the beneficial ownership limitation shall not be effective until 61&#160;days after such notice is delivered. Purchasers of pre-funded warrants in this offering may also elect prior to the issuance of the pre-funded warrants to have the initial exercise limitation set at 9.99% of our outstanding ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transferability</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Subject to applicable laws, the pre-funded warrants may be offered for sale, sold, transferred or assigned without our consent. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Trading Market</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">There is no established trading market for the pre-funded warrants and we do not expect a market to develop. In addition, we do not intend to apply for the listing of the pre-funded warrants on any national securities exchange or other trading market. Without an active trading market, the liquidity of the pre-funded warrants will be limited. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fundamental Transactions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">In the event of a fundamental transaction, as described in the pre-funded warrants and generally including any reorganization, recapitalization or reclassification of our ADSs, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding ADSs, or any person or group becoming the beneficial owner of more than 50% of the voting power represented by our outstanding ADSs, upon consummation of such a fundamental transaction, the holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the pre-funded warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rights as a Shareholder</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise provided in the pre-funded warrant or by virtue of such holder&#8217;s ownership of shares of our ADSs, the holder of a pre-funded warrant does not have the rights or privileges of a holder of our ADSs, including any voting rights, until the holder exercises the pre-funded warrant. The pre-funded warrants will provide that holders have the right to participate in distributions or dividends paid on our ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Placement Agent Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following summary of certain terms and provisions of the Placement Agent Warrants that are being issued hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">272</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Placement Agent Warrants, the form of which will be filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of Placement Agent Warrant for a complete description of the terms and conditions of the Placement Agent Warrant. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Duration and Exercise Price</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each Placement Agent Warrant offered hereby will have an initial exercise price equal to $ per ADS (135% of the public offering price per ADS). The Placement Agent Warrants will be immediately exercisable and will expire five&#160;years from the commencement of sales in this offering. The exercise price and number of ADSs issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our ADSs and the exercise price. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exercisability</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Placement Agent Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of ADSs purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the Placement Agent Warrant to the extent that the holder would own more than 4.99% of the outstanding ADSs immediately after exercise, except that upon notice from the holder to us, the holder may increase or decrease the amount of beneficial ownership of outstanding stock after exercising the holder&#8217;s Placement Agent Warrant up to 4.99% of the number of ADSs outstanding immediately after giving effect to the exercise, as such&#160;percentage ownership is determined in accordance with the terms of the Placement Agent Warrants and in accordance with the rules and regulations of the SEC, provided that any increase in the beneficial ownership limitation shall not be effective until 61&#160;days following notice to us. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fractional ADSs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">No fractional ADSs will be issued upon the exercise of the Placement Agent Warrants. Rather, the number of ADSs to be issued will be rounded up to the next whole share or we will pay a cash adjustment equal to such fraction multiplied by the exercise price to the holder. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transferability</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to applicable laws, a Placement Agent Warrant may be transferred at the option of the holder upon surrender of the Placement Agent Warrant to us together with the appropriate instruments of transfer. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Trading Market</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There is no trading market available for the Placement Agent Warrants on any securities exchange or nationally recognized trading system, and we do not expect a trading market to develop. We do not intend to list the Placement Agent Warrants on any securities exchange or other trading market. Without a trading market, the liquidity of the Placement Agent Warrants will be extremely limited. The ADSs issuable upon exercise of the Placement Agent Warrants is currently listed on the Nasdaq Capital Market. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Right as a Shareholder</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise provided in the Placement Agent Warrants or by virtue of such holder&#8217;s ownership of ADSs, the holders of the Placement Agent Warrants do not have the rights or privileges of holders of our ADSs, including any voting rights, until they exercise their Placement Agent Warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fundamental Transaction</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">If at any time the Warrants are outstanding, the Company, either directly or indirectly, in one or more related transactions effects a Fundamental Transaction (as defined in the Placement Agent Warrant), a Holder of Placement Agent Warrants will be entitled to receive, upon exercise of the Placement Agent Warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Placement Agent Warrants immediately prior to the Fundamental Transaction. </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">273</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:468.81pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the foregoing, in the event of a fundamental transaction, the holders of the Placement Agent Warrants have the right to require us or a successor entity to redeem the Placement Agent Warrants for cash in the amount of the Black-Scholes Value (as defined in each Placement Agent Warrant) of the unexercised portion of the Placement Agent Warrants concurrently with or within 30&#160;days following the consummation of a fundamental transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">However, in the event of a fundamental transaction which is not in our control, including a fundamental transaction not approved by our board of directors, the holders of the Placement Agent Warrants will only be entitled to receive from us or our successor entity, as of the date of consummation of such fundamental transaction the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the Placement Agent Warrants that is being offered and paid to the holders of our ADSs in connection with the fundamental transaction, whether that consideration is in the form of cash, stock or any combination of cash and stock, or whether the holders of our ADSs are given the choice to receive alternative forms of consideration in connection with the fundamental transaction. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">274</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We have engaged H.C. Wainwright &amp; Co., LLC, or the Placement Agent, to act as our exclusive Placement Agent to solicit offers to purchase the securities offered pursuant to this prospectus on a reasonable best efforts basis. The engagement agreement does not give rise to any commitment by the Placement Agent to purchase any of our securities, and the Placement Agent will have no authority to bind us by virtue of the engagement agreement. The Placement Agent is not purchasing or selling any of the securities offered by us under this prospectus, nor is it required to arrange for the purchase or sale of any specific number or dollar amount of securities, other than to use its &#8220;reasonable best efforts&#8221; to arrange for the sale of such securities by us. Therefore, we may not sell all of the securities being offered. The terms of this offering were subject to market conditions and negotiations between us, the Placement Agent and prospective investors. This is a best efforts offering and there is no minimum offering amount required as a condition to the closing of this offering. Because there is no minimum offering amount required as a condition to closing this offering, we may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us. The Placement Agent does not guarantee that it will be able to raise new capital in any prospective offering. The Placement Agent may engage sub-agents or selected dealers to assist with the offering. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Investors purchasing securities offered hereby will have the option to execute a securities purchase agreement with us. In addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the purchasers which enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract is material to larger purchasers in this offering as a means to enforce the following covenants uniquely available to them under the securities purchase agreement: (i)&#160;a covenant to not enter into variable rate financings for a period of six (6)&#160;months following the closing of the offering, subject to certain exceptions; and (ii)&#160;a covenant to not issue any ordinary shares or ADSs or securities convertible into ordinary shares or ADSs for sixty (60) days from closing of the offering, subject to certain exceptions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The nature of the representations, warranties and covenants in the securities purchase agreements shall include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">standard issuer representations and warranties on matters such as organization, qualification, authorization, no conflict, no governmental filings required, current in SEC filings, no litigation, labor or other compliance issues, environmental, intellectual property and title matters and compliance with various laws such as the Foreign Corrupt Practices Act; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">covenants regarding matters such as registration of warrant shares, no integration with other offerings, filing of a 6-K to disclose entering into these securities purchase agreements, no shareholder rights plans, no material nonpublic information, use of proceeds, indemnification of purchasers, reservation and listing of ADSs, and no issuance of any ordinary shares or ADSs or securities convertible into ordinary shares or ADSs for sixty (60&#160;) days from closing of the offering, subject to certain exceptions. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect to deliver the securities being offered pursuant to this prospectus on or about [&#8226;], 2024, subject to satisfaction of certain customary closing conditions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fees and Expenses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table shows the per ADS and Warrant and per pre-funded warrant and Warrant and total Placement Agent fees we will pay in connection with the sale of the securities in this offering. </font>
        </div>
        <table style="width:416pt;height:62.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:233.56pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per ADS and</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per Pre-Funded</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Warrant and Warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:233.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Public offering price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:7.16pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:21.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:233.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Placement Agent Fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:7.16pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:21.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:233.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds to us (before expenses) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:7.16pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:21.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have agreed to pay the Placement Agent cash fee equal to 7.5% of the gross proceeds raised in this offering. We have also agreed to reimburse the Placement Agent for certain of its offering-related expenses, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">275</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">to reimburse the Placement Agent for its non-accountable expenses in the amount of $35,000, for its legal fees and expenses and other out-of-pocket expenses in an amount up to $100,000 (plus an additional $50,000 for the fees and expenses of local legal counsel), and for its clearing expenses in the amount of $15,950. We estimate the total expenses of this offering payable by us, excluding the Placement Agent fee, will be approximately $0.8&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Placement Agent Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we have agreed to issue to the Placement Agent or its designees warrants to purchase up to ADSs (which represents 5.0% of the aggregate number of ADSs issued in this offering and issuable upon the exercise of the pre-funded warrants issued in this offering) with an exercise price of $[&#8226;] per ADS (representing 135% of the public offering price per ADS) and exercisable for five&#160;years from the date of the commencement of sales in this offering. The Placement Agent warrants and underlying ADSs are registered on the registration statement of which this prospectus is a part. The form of the Placement Agent warrant is included as an exhibit to this registration statement of which this prospectus forms a part. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lock-up Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We and each of our officers and directors have agreed with the Placement Agent to be subject to a lock-up period of 60 days following the date of closing of the offering pursuant to this prospectus. This means that, during the applicable lock-up period, we and such persons may not offer for sale, contract to sell, sell, distribute, grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly, any of our ADSs or any securities convertible into, or exercisable or exchangeable for, ADSs, subject to customary exceptions. The Placement Agent may waive the terms of these lock-up agreements in its sole discretion and without notice. In addition, we have agreed to not issue any securities that are subject to a price reset based on the trading prices of our ADS or upon a specified or contingent event in the future, or enter into any agreement to issue securities at a future determined price for a period of six (6)&#160;months following the closing date of this offering, subject to certain exceptions. The Placement Agent may waive this prohibition in its sole discretion and without notice. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Right of First Refusal</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have granted the Placement Agent a right of first refusal for a period of nine&#160;(9)&#160;months following the closing of this offering, to act as exclusive financial advisor, sole book-running manager, sole underwriter, sole Placement Agent or sole agent for each and every future debt financing or refinancing and public or private equity offering or acquisition or disposition by us or any of our successors or subsidiaries. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Tail</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have also agreed to pay the Placement Agent a tail fee equal to the cash compensation in this offering, if any investor, who was brought over-the-wall by the Placement Agent during the term of its engagement, provides us with capital in any public or private offering or other financing or capital raising transaction during the 12-month period following expiration or termination of our engagement of the Placement Agent. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Regulation&#160;M</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Placement Agent may be deemed to be an underwriter within the meaning of Section&#160;2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the securities sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the Placement Agent would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule&#160;10b-5 and Regulation&#160;M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of our securities by the Placement Agent acting as principal. Under these rules and regulations, the Placement Agent (i)&#160;may not engage in any stabilization activity in connection with our securities and (ii)&#160;may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">276</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tEOTO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have agreed to indemnify the Placement Agent against certain liabilities, including certain liabilities arising under the Securities Act and to contribute to payments that the Placement Agent may be required to make for these liabilities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Determination of Offering Price</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The actual offering price of the securities we are offering has been negotiated between us and the investors in the offering based on the trading of our ADSs prior to the offering, among other things. Other factors considered in determining the public offering price of the securities we are offering include our history and prospects, the stage of development of our business, our business plans for the future and the extent to which they have been implemented, an assessment of our management, the general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Electronic Offer, Sale and Distribution of Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A prospectus in electronic format may be made available on the websites maintained by the Placement Agent, if any, participating in this offering and the Placement Agent may distribute prospectuses electronically. Other than the prospectus in electronic format, the information on these websites is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or the Placement Agent, and should not be relied upon by investors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Relationships</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From time to time, the Placement Agent or its affiliates have in the past or may in the future provide in the future, various advisory, investment and commercial banking and other services to us in the ordinary course of business, for which they have received and may continue to receive customary fees and commissions. However, except as disclosed in this prospectus, we have no present arrangements with the Placement Agent for any further services. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Listing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our ADSs are listed on The Nasdaq Capital Market under the symbol &#8220;EVAX.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Depositary</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary for our ADSs is The Bank of New York Mellon. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPENSES OF THE OFFERING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Set forth below is an itemization of the total anticipated expenses, excluding Placement Agent commissions, expected to be incurred in connection with the offer and sale of the ADSs by us. With the exception of the SEC registration fee and the FINRA filing fee, all amounts are estimates, in United States dollars: </font>
        </div>
        <table style="width:456pt;height:100pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:406.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SEC registration fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">3,052</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:406.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">FINRA filing fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">3,601</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:406.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Printing and engraving expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">100,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:406.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legal fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">610,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:406.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accounting fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">44,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:406.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Miscellaneous expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:406.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">800,653</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>

          <div style="text-indent:20pt; margin-top:13.2pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In addition to the expenses noted in the table above, the estimated fair value of Placement Agent Warrants to be issued as part of this offering is $750,000. </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">277</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are being represented by Duane Morris LLP, New York, New York with respect to certain legal matters of United States federal securities and New York state law. We are being represented by Mazanti-Andersen AdvokatPartnerselskab, Denmark with respect to certain legal matters of the law of Denmark. Ellenoff Grossman &amp; Schole LLP, New York, New York is acting as counsel for the placement agent with respect to this offering.</font>
          </div>

        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements of Evaxion Biotech A/S at December&#160;31, 2022 and 2021, and for each of the three&#160;years in the period ended December&#160;31, 2022, appearing in this Prospectus and Registration Statement have been audited by EY Godkendt Revisionspartnerselskab, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern as described in Note 2 to the consolidated financial statements) appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The registered business address of EY Godkendt Revisionspartnerselskab is Dirch Passers All&#233; 36, 2000 Frederiksberg, Denmark. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have filed with the SEC a registration statement on Form F-1 under the Securities Act relating to this offering. This prospectus does not contain all of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus that is included in the registration statement. Statements made in this prospectus concerning the contents of any contract, agreement or other document are summaries of all material information about the documents summarized, but are not complete descriptions of all terms of these documents. If we filed any of these documents as an exhibit to the registration statement, you may read the document itself for a complete description of its terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">You may read and copy the registration statement, including the related exhibits and schedules, and any document we file with the SEC without charge at the SEC&#8217;s public reference room at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington, DC 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also maintains an Internet website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public through the SEC&#8217;s website at </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements are filing reports with the SEC. Those other reports or other information may be inspected without charge at the locations described above. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&#160;16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. registrants whose securities are registered under the Exchange Act. However, we are required to file with the SEC, within 120&#160;days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and will furnish to the SEC, on Form 6-K, unaudited interim financial information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We maintain a corporate website at www.evaxion-biotech.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. We will post on our website any materials required to be so posted on such website under applicable corporate or securities laws and regulations, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">278</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:524pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">including, posting any XBRL interactive financial data required to be filed with the SEC and any notices of general meetings of our shareholders. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION</font>
          <br >
          <font style="letter-spacing:-0.2pt;">FOR SECURITIES ACT LIABILITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been informed that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">279</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a><a name="TOC3">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:259.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INDEX TO THE AUDITED</font>
          <br >
          <font style="letter-spacing:-0.2pt;">CONSOLIDATED FINANCIAL STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:152.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Audited Consolidated Financial Statements:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tROIR"><font style="letter-spacing:0.2pt;">Report of Independent Registered Public Accounting Firm </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tROIR">F-2</a></font> <a href="#tROIR"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Financial Statements: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.33pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <a href="#tCSOC"><font style="letter-spacing:0.2pt;">Consolidated Statements of Comprehensive Loss for the Years Ended December&#160;31, 2022, 2021 and 2020 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSOC">F-3</a></font> <a href="#tCSOC"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:10pt;font-size:9.9pt;">
                <a href="#tCSOF"><font style="font-size:10pt;letter-spacing:0.198pt;">Consolidated Statements of Financial Position as of December 31, 2022 and December&#160;31, 2021</font><font style="font-size:10pt;">&#8203;</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSOF">F-4</a></font> <a href="#tCSOF"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <a href="#tCSOC1"><font style="letter-spacing:0.2pt;">Consolidated Statements of Changes in Equity for the Years Ended December&#160;31, 2022, 2021 and </font>
                  <br >
                  <font style="letter-spacing:0.2pt;">2020 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSOC1">F-5</a></font> <a href="#tCSOC1"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:10pt;font-size:9.9pt;">
                <a href="#tCSOC2"><font style="font-size:10pt;letter-spacing:0.198pt;">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2022, 2021 and 2020</font><font style="font-size:10pt;">&#8203;</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSOC2">F-6</a></font> <a href="#tCSOC2"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tNTTC"><font style="letter-spacing:0.2pt;">Notes to Consolidated Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tNTTC">F-7</a></font>
            </td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INDEX TO THE INTERIM CONDENSED</font>
          <br >
          <font style="letter-spacing:-0.2pt;">CONSOLIDATED FINANCIAL STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:118pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:424pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#fUCC1"><font style="letter-spacing:0.2pt;">Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss for the Three and Nine Months Ended September&#160;30, 2023 and 2022 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fUCC1">F-49</a></font> <a href="#fUCC1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#fUCC2"><font style="letter-spacing:0.2pt;">Unaudited Condensed Consolidated Interim Statements of Financial Position as of September&#160;30, 2023 and December&#160;31, 2022 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fUCC2">F-50</a></font> <a href="#fUCC2"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#fUCC3"><font style="letter-spacing:0.2pt;">Unaudited Condensed Consolidated Interim Statements of Changes in Equity for the Three and Nine Months Ended September&#160;30, 2023 and 2022 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fUCC3">F-51</a></font> <a href="#fUCC3"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#fUCC4"><font style="letter-spacing:0.2pt;">Unaudited Condensed Consolidated Interim Statements of Cash Flows for the Nine Months Ended </font>
                  <br >
                  <font style="letter-spacing:0.2pt;">September&#160;30, 2023 and 2022 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fUCC4">F-52</a></font> <a href="#fUCC4"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#fNTTU"><font style="letter-spacing:0.2pt;">Notes to the Unaudited condensed consolidated interim financial statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fNTTU">F-53</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tROIR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:18pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Report of Independent Registered Public Accounting Firm</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the Shareholders and the Board of Directors of Evaxion Biotech A/S </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Opinion on the Financial Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have audited the accompanying consolidated statements of financial position of Evaxion Biotech A/S (the &#8220;Company&#8221;) as of December&#160;31, 2022 and 2021, the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the three&#160;years in the period ended December&#160;31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the three&#160;years in the period ended December&#160;31, 2022, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Company&#8217;s Ability to Continue as a Going Concern</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has had no revenues, continued net losses and requires additional funding, which raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Basis for Opinion</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">/s/ EY Godkendt Revisionspartnerselskab </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have served as the Company&#8217;s auditor since 2019. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Copenhagen, Denmark</font> <br ><font style="letter-spacing:0.2pt;">April&#160;27, 2023</font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:163pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Consolidated Statements of Comprehensive Loss</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:408pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:283.56pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:283.56pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:16.33pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Note </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:283.56pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="19">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands, except per share amounts) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:283.56pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="white-space:nowrap; text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">6, 7</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">17,056</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">19,583</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,902</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:16.33pt;">
              <div style="white-space:nowrap; text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">6, 7</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,208</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,251</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">5,666</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">25,264</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">25,834</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">16,568</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Operating loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,264<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,834<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,568<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">9</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,039</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">216</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">9</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,508<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(915<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(223<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss before tax</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(23,941<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(24,710<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,575<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax benefit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">10</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">772</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">178</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,557</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss for the year</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(23,169<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(24,532<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,018<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss attributable to shareholders of Evaxion Biotech A/S</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(23,169<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(24,532<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,018<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 0.833pt 0pt; width:283.56pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Other comprehensive income that may be reclassified to profit or loss </font>
                <br >
                <font style="letter-spacing:0.2pt;">in subsequent periods (net of tax):</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange differences on translation of foreign operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(25<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(83<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(18<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange rate adjustments of investments in subsidiaries </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(3<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">93</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Tax on other comprehensive income/(expense) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:283.56pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Other comprehensive income that will not be reclassified to profit or loss in subsequent periods (net of tax):</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:283.56pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Exchange differences on currency translation to presentation currency </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,324<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,547<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">412</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Other comprehensive income/(loss) for the year, net of tax</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,352<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,542<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">394</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total comprehensive loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,521<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(26,074<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(14,624<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:283.56pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.2pt;">Total comprehensive loss attributable to shareholders of Evaxion Biotech A/S</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,521<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(26,074<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(14,624<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss per share&#8201;&#8211;&#8201;basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">11</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(0.98<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1.26<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(0.97<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSOF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:18.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Consolidated Statements of Financial Position</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:552.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:331.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:331.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:16.33pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Note </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:331.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">ASSETS</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Non-current assets </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Intangible assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">12</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">93</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">13</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4,675</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">5,174</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Government grants receivables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">209</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Tax receivables, non-current </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Leasehold deposits, non-current </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">17</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">156</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">191</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total non-current assets</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">5,040</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">5,458</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current assets </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Prepayments and other receivables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">14</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,791</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,138</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Government grants receivable, current </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">221</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">563</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Tax receivables, current </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">789</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">838</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">16</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">13,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">32,166</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total current assets</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">16,985</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">34,705</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">TOTAL ASSETS</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">22,025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">40,163</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">EQUITY AND LIABILITIES</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">20</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,886</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,755</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other reserves </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">20</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">77,076</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">79,114</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">20</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(72,659<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(50,432<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total equity</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">8,303</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">32,437</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Non-current liabilities </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Lease liabilities, non-current </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">17</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,952</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,206</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Borrowings, non-current </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">18</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">7,864</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,044</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Provisions </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">23</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">153</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total non-current liabilities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">9,960</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">3,403</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current liabilities </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Lease liabilities, current </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">17</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">303</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">314</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">19</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">573</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Borrowings, current </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">18</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">136</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">126</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Trade payables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,085</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,848</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other payables </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">15</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">665</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">1,035</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total current liabilities</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,762</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4,323</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total liabilities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">13,722</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">7,726</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">TOTAL EQUITY AND LIABILITIES</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">22,025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">40,163</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:10pt; margin-top:5pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of consolidated financial statements.</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSOC1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:207pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Consolidated Statements of Changes in Equity</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:364pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:172.44pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Other reserves </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:172.44pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:16.33pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Note </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Share capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Share</font>
                <br >
                <font style="letter-spacing:-0.16pt;">premium </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Foreign</font>
                <br >
                <font style="letter-spacing:-0.16pt;">currency</font>
                <br >
                <font style="letter-spacing:-0.16pt;">translation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">reserve </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Equity at December&#160;31, 2019</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">2,481</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">22,862</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(169<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,812<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">9,362</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss for the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,018<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(15,018<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other comprehensive income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">395</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">395</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">8</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,551</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,551</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of shares for cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">20</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">167</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">8,853</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">9,020</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Transaction costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">20</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(272<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(272<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Equity at December&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">2,648</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">31,443</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">226</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(27,279<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">7,038</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss for the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(24,532<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(24,532<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other comprehensive income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,537<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(1,537<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Tax effects on OCI </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">8</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,379</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,379</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of shares for cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">20</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1,107</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">56,502</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">57,609</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Transaction costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">20</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(7,515<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(7,515<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Equity at December&#160;31, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">3,755</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">80,430</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,316<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(50,432<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">32,437</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss for the period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(23,169<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(23,169<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other comprehensive income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,335<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(2,335<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">8</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">942</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">942</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of shares for cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">20</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">70</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">358</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">428</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:172.44pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Transaction costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">20</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">61</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(61<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:172.44pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Equity at December&#160;31, 2022</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">3,886</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">80,727</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(3,651<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(72,659<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">8,303</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:10pt; margin-top:5pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSOC2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:19pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Consolidated Statements of Cash Flows</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:554pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:289.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:289.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:22.71pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Note </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:289.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Operating activities:</font>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss for the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(23,169<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(24,532<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,018<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Adjustments for non-cash items </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:22.71pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">16</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(323<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">541</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,583</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest received </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest paid </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(172<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(25<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(30<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income taxes received </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">754</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">846</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">812</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.265pt 0pt 0.985pt 0pt; width:289.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Cash flow from operating activities before changes in working capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.265pt 0pt 0.985pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.265pt 0pt 0.985pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(22,897<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.265pt 0pt 0.985pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.265pt 0pt 0.985pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(23,170<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.265pt 0pt 0.985pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.265pt 0pt 0.985pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,653<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Cash flow from changes in working capital:</font>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in net working capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:22.71pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">16</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(2,877<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">1,237</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">215</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Net cash used in operating activities</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(25,774<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(21,933<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,438<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Investing activities:</font>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Investment in intangible assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:22.71pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">12</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(60<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(35<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Purchase of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:22.71pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">13</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(292<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(1,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(149<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payment of non-current financial assets&#8201;&#8211;&#8201;leasehold deposits </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(209<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Net cash (used in)/provided by investing activities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(268<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(1,330<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(393<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Financing activities:</font>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:289.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from issuance of shares and exercise of warrants, less underwriter discounts </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:22.71pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">20</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">428</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">53,854</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,019</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Transaction costs related to issuance of shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(3,760<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(128<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds from borrowings </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:22.71pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">18</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">7,849</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Repayment of borrowings </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:22.71pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">18</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(119<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(63<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leasing installments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:22.71pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">16,17</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(305<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(226<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(74<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Net cash provided by/ (used in) financing activities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">7,853</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">49,805</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,817</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net increase/ (decrease) in cash and cash equivalents</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(18,189<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">26,542</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(4,014<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents at January&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:22.71pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">16</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">32,166</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">5,834</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,559</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange rate adjustments on cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(793<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(210<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">288</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:289.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Cash and cash equivalents at December&#160;31</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:22.71pt;">
              <div style="text-align:center;font-style:italic;font-weight:normal;">
                <font style="letter-spacing:0.2pt;">16</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">13,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">32,166</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(5,834<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Supplemental disclosure of cash flow information</font>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Non-cash investing and financing activities</font>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:289.18pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Acquisition of property and equipment through loan from </font>
                <br >
                <font style="letter-spacing:0.2pt;">lessor </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:22.71pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">16</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">84</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.18pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Capitalized intangible assets included in trade payables </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:22.71pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">12</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">60</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:289.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Acquisition of property and equipment included in trade payables </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.71pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">90</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements.</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tNTTC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 1. General Company Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Evaxion Biotech A/S (the &#8220;Company&#8221; or &#8220;Evaxion&#8221;) is a clinical-stage biotech company developing AI-powered immunotherapies. Evaxion uses its proprietary and scalable artificial intelligence, or AI, technology to decode the human immune system to identify and develop immunotherapies for patients in the global market. Unless the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;Evaxion,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;, refer to Evaxion Biotech A/S and its subsidiaries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Evaxion is a public limited liability company incorporated and domiciled in Denmark with its registered office located at Dr.&#160;Neergaards Vej 5f, DK-2970 H&#248;rsholm, Denmark. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;5, 2021, the Company completed an initial public offering (&#8220;IPO&#8221;), which resulted in the listing of American Depository Shares (&#8220;ADS&#8221;) representing the company&#8217;s ordinary shares, under the symbol &#8220;EVAX&#8221; in the United States on the NASDAQ Capital Market. Through the IPO, the Company sold 3,000,000 ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. The Company received net proceeds of $25.3&#160;million from the IPO, after deducting the underwriting discounts and commissions and offering expenses. Upon the completion of the IPO, authorized share capital consists of 3,000,000 shares of ordinary shares, par value DKK 1 per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On November&#160;9, 2021, the Company completed a follow-on public offering through which we issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November&#160;5, 2021. The Company received aggregate net proceeds of $24.9&#160;million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Upon the completion of the follow-on public offering, the Company&#8217;s registered, issued, and outstanding share capital was nominal DKK 23,141,524. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2022, we entered into a purchase agreement, or the LPC Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park. In connection with the LPC Purchase Agreement, we issued 428,572 ADSs representing ordinary shares to Lincoln Park as consideration for a commitment fee of $1.2&#160;million for Lincoln Park&#8217;s agreement to purchase ordinary shares. After issue of shares following the At the Market program with JonesTrading Institutional Services LLC we entered into in October&#160;2022 and due to warrant exercise, the outstanding share capital amounted to nominal DKK 24,139,413 at year end. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements of Evaxion Biotech A/S and its subsidiaries (collectively, the &#8220;Group&#8221;) for the year ended December&#160;31, 2022, were approved, and authorized for issuance, by the Audit Committee of the board of directors on April&#160;27, 2023. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Emerging Growth Company Status</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Evaxion is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the International Accounting Standards Board (&#8220;IASB&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has elected to take advantage of specified reduced reporting and regulatory requirements in contrast to those otherwise applicable generally to public companies. This provision includes the exemption from the auditor attestation requirement in the assessment of the Company&#8217;s internal control over financial reporting pursuant to Section&#160;404 the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Evaxion will remain an emerging growth company until the earliest of (i)&#160;the last day of the first fiscal year (a)&#160;following the fifth anniversary of the completion of the global offering, (b)&#160;in which its annual gross revenue totals at least $1.235&#160;billion or (c)&#160;when the Company is deemed to be a large accelerated filer, which means the market value of the Company&#8217;s ordinary shares that is held by non-affiliates exceeds </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">$700.0&#160;million as of the prior June&#160;30th and (ii)&#160;the date on which the Company has issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Impact from COVID-19</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company continues to closely monitor the potential impact of COVID-19 on the 2022 financial results and cash flows and beyond. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has worked closely with laboratories and investigators to ensure safe continuation and working requirements of its ongoing research activities and human clinical trials. The Company has resumed business travel and has remained active and effective in the process of raising capital with institutional investors by conducting key meetings in person and on a virtual basis when appropriate. As of December&#160;31, 2022, the Company has not experienced a materially negative impact from COVID-19 on the audited consolidated financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Russia&#8217;s Invasion of Ukraine</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;24, 2022, Russia invaded Ukraine creating a global conflict. The resulting conflict and retaliatory measures by the global community have created global security concerns, including the possibility of expanded regional or global conflict, which have had, and are likely to continue to have, short-term and more likely longer-term adverse impacts on Ukraine and Europe and around the globe. Potential ramifications include disruption of the supply chain including research activities and complications with the conduct of ongoing and future clinical trials of our product candidates, including patient enrollment. The Company relies on global networks of contract research organizations and clinical trial sites to enroll patients. Delays in research activities or in the conduct of our clinical trials could increase associated costs and, depending upon the duration of any delays, require us to find alternative suppliers at additional expense. In addition, the conflict between Russia and the Ukraine has had significant ramifications on global financial markets, which may adversely impact our ability to raise capital on favorable terms or at all. As of December&#160;31, 2022, the Company has not directly experienced a materially negative impact from Russia&#8217;s invasion of Ukraine on the consolidated financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 2. Liquidity and Going Concern Assessment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has considered whether conditions and events exist that, when considered in aggregate, raise significant doubt about the Company&#8217;s ability to continue as a going concern for at least a year from the date of the financial statements. The Company has a history of incurring operating losses and negative cash flows from operations. The Company anticipates incurring additional losses until such time, if ever, it can complete its research and development (&#8220;R&amp;D&#8221;) activities and obtain an out-licensing partnership for its product candidates and generate revenues from such product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company monitors its funding situation closely to ensure that it has access to sufficient liquidity to meet its forecasted cash requirements. Analyses are run to reflect different scenarios including, but not limited to, cash runway, human capital resources and pipeline priorities to identify liquidity risk. This enables Management and the Board of Directors to prepare for new financing transaction and/ or adjust the cost base accordingly. In March&#160;2023 the Company adjusted the organization and reprioritized development programs to focus the operations and to save costs. The Company, with its current strategic plans, anticipates that with the current cash position and the forecast cash requirements per the 2023 updated Annual Budget, it will require additional financing to fund its operations and to continue development of its product candidates by December&#160;2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company plans to finance cash needs through equity offerings, or other capital sources, including potential collaborations or licenses and adjust spending on new and ongoing development and corporate activities, as needed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Due to the continuing operating losses, expected negative cash flows and the need for additional funding to finance future operations, the Company concluded that there is significant doubt about its </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">ability to continue as a going concern through one year from the balance sheet date. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and discharge of its liabilities and commitments in the normal course of business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The matters that raise significant doubt about the Company&#8217;s ability to continue as a going concern also raise substantial doubt as contemplated by the Public Company Accounting Oversight Board (PCAOB) standards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interest of current shareholders could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of the current shareholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises funds through collaborations, licenses and other similar arrangements with third parties, it may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable and/or may reduce the value of our ordinary shares. Failure to raise capital or enter into such other arrangements when needed could have a negative impact on the Company&#8217;s financial condition and its ability to pursue its business plans and strategies. If the Company is unable to raise additional capital when needed, it could be forced to delay, limit, reduce or terminate its product candidate development or grant rights to develop and market its product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;7, 2022 the Company entered into a Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with an unrelated third party, Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), to sell up to $40.0&#160;million of its ordinary shares represented by American Depository Shares (&#8220;ADSs&#8221;) over a 36 month period. the Company is not obligated to sell any ordinary shares represented by ADSs pursuant to the Purchase Agreement and will control the timing and amount of any such sales, but in no event will Lincoln Park be required to purchase more than $1.5&#160;million in ordinary shares represented by ADSs in any single regular purchase. Upon execution and delivery of the Purchase Agreement, the Company issued 428,572 ordinary shares represented by ADSs as consideration for a commitment fee of $1.2&#160;million for Lincoln Park&#8217;s commitment to purchase its ordinary shares represented by ADSs under the Purchase Agreement. As of December&#160;31, 2022, the Company had not issued and sold any additional ordinary shares represented by ADSs to Lincoln Park under the Purchase Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;3, 2022 the Company entered into an At-The-Market Issuance Sales Agreement with JonesTrading Institutional Services LLC (&#8220;JonesTrading&#8221;) to sell up to $14.4&#160;million of its ordinary shares represented by ADSs. The Company agreed to pay JonesTrading commission equal to 3% of the gross proceeds of the sales price of all ADSs sold through them as sales agent under the Sales Agreement. The offering of the Company&#8217;s ADSs pursuant to the Sales Agreement will terminate on the earliest of (1)&#160;the sale of all of the ordinary shares subject to the Sales Agreement, or (2)&#160;termination of the Sales Agreement by the Company or JonesTrading. The Company and JonesTrading may terminate the sales agreement at any time upon ten days prior notice. JonesTrading may terminate the Sales Agreement at any time in certain circumstances, including the occurrence of a material adverse change that, in their judgment, may make it impracticable or inadvisable to market or sell the Company&#8217;s ADSs or a suspension or limitation of trading the Company&#8217;s ADSs on The NASDAQ Capital Market. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 3. Summary of Significant Accounting Policies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Basis of Preparation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The financial statements have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the International Accounting Standards Board (&#8220;IASB&#8221;). </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates and requires management to exercise its judgment in the process of applying the Company&#8217;s accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note&#160;4. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The financial statements are presented in the Company&#8217;s presentation currency, U.S. dollar (&#8220;USD&#8221;) which is not the functional currency of the parent company. The Group&#8217;s financial statements are presented in USD as the result of the Company&#8217;s publicly listing the ADSs in the United States. The company&#8217;s functional currency is DKK for Denmark, AUD for Australia, and USD for the United States. The financial statements have been prepared on a going concern basis using a historical cost basis. All financial assets and liabilities are measured at amortized cost unless otherwise stated. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Reclassifications of prior period presentation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain items included in the notes to prior year consolidated financial statements have been reclassified to conform to the current period&#8217;s presentation. The reclassifications are immaterial to the consolidated financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Basis of Consolidation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The audited consolidated financial statements of the Company comprise the Statement of Financial Position as of December&#160;31, 2022 and 2021, and the Statement of Comprehensive Loss for the twelve&#160;months ended December&#160;31, 2022, 2021 and 2020. Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and can affect those returns through its power over the entity. The financial statements of subsidiaries are included in the audited consolidated financial statements from the date that control commences until the date that control ceases. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Company. Control is reassessed whenever facts and circumstances indicate that there are changes of the control. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All intra-Group assets and liabilities, equity, income, expenses, and cash flows relating to transactions between members of the Group are eliminated in full in consolidation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Retrospective effect of share split and bonus share issuance</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All share and per share data, including that related to warrants, in the consolidated financial statements give retroactive effect to a 2:1 share split and a bonus issue of shares in the ratio of 17:1 of the Company&#8217;s authorized, issued and outstanding ordinary shares, which was effective on January&#160;4, 2021, with the corresponding impacts on both share capital and share premium also retroactively recognized. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Currency translation of transactions and balances</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized as financial income or financial expenses in the statements of comprehensive loss. Non-monetary items in foreign currency which are measured at cost at the statements of financial position date are translated using the exchange rates at the date of the transaction. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Translation of foreign operations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Assets and liabilities in the Company&#8217;s functional currency, DKK and AUD, for Denmark and Australia, respectively, are translated to the Company&#8217;s presentation currency at the exchange rate applicable on December&#160;31 for the respective year. Income and expenses in the Company&#8217;s functional currency are </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">translated to USD at the average exchange rate which corresponds to an approximation of the exchange rates prevailing on each individual transaction date. Translation differences arising in the translation to presentation currency are recognized in other comprehensive income. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and development expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses are primarily internal and external costs incurred in the development of the Company&#8217;s product candidates, including personnel costs, share-based compensation, external research and development expenses, maintenance of the Company&#8217;s patents, overhead allocation and enhancements and maintenance of the Company&#8217;s technology platforms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The research activities are comprised of activities performed before filing an IND or equivalent and necessary pre-clinical activities for such product candidates. All research expenses are recognized in the period in which they are incurred and payments made prior to the receipt of goods or services to be used in research and development are deferred until the goods or services are received. The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors and others. Payments for these activities are based on the terms of the individual agreements, which may differ from the timing of the expense recognition of these costs, in which case, they are reflected in the financial statements as either prepaid- or accrued expenses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The development activities are comprised of the activities performed following the filing of an IND or equivalent clinical-enabling activities for such product candidates, including but not limited to, research and clinical development activities. In line with industry practice, internal and subcontracted development costs are expensed as incurred. Due to regulatory uncertainties and other uncertainties inherent in the development of new products, development expenses do not qualify for capitalization as intangible assets until marketing approval by a regulatory authority is obtained or considered highly probable. To date, the Company has not incurred any development costs which qualified for capitalization. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Contract Research Organizations expenses and related prepayments and accruals</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Substantial portions of the Company&#8217;s clinical studies are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively, the &#8220;CROs&#8221;). The CROs generally bill monthly or quarterly for services performed. For studies, the Company accrues expenses based upon estimated&#160;percentage of work completed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CROs invoice the Company upon the occurrence of predetermined contractual or activity-based milestones; however, the timing of these invoices and the Company&#8217;s related payments often do not correspond directly to the level of performance of contracted activities. To the extent payments are made by the Company in advance of the related activities performed by the CROs, they are included in prepayments to clinical research organizations and expensed when the activities performed by the CROs. To the extent the payments are made by the Company following the performance of the related activities, the expense is accrued for as a payable to clinical research organizations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Intellectual property</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company actively seeks to create, maintain and protect intellectual property and proprietary information and technology that is considered important to the Company&#8217;s business, which includes seeking and maintaining patents covering proprietary technology, product candidates, proprietary processes and any other inventions that are commercially and / or strategically important to the Company&#8217;s business development. These expenses are expensed as incurred and not capitalized as intangible assets until marketing </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">approval by a regulatory authority is obtained or considered highly probable. The Company has not incurred any costs that qualify for capitalization. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Income from government grants</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company receives grants for certain research and development activities. The grant income is recognized as a reduction of research and development expenses in the period in which the underlying expenditures were incurred and when there is reasonable assurance that the Company will comply with all conditions to receive the grant income. Government grants comprise direct grants and tax credits related to qualifying research and development costs in excess of the corporate tax rate. Tax credits in an amount up to the corporate tax rate are classified as income tax benefits. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses consist primarily of fees paid to external consultants and personnel costs, including share-based compensation for the Company&#8217;s executive, finance, corporate and business development functions. In addition, general and administrative expenses also include depreciation and other expenses for the Company&#8217;s corporate headquarters as well as other allocated overhead. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Share-based payments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company issues warrants as an incentive to employees and non-employees. The fair value of the warrants granted is recognized as an expense with a corresponding credit to accumulated deficit. The fair value is expensed over the requisite service period of the awards. The expense recognition is based on an estimate of the number of warrants expected to vest. The estimate is reassessed regularly, and on a cumulative basis, the expense is equal to the fair value of the number of warrants which actually vest. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For employees and consultants providing services similar to employees of the Company, the fair value of the equity instruments is determined at the date of grant resulting in a fixed fair value at grant date that is not adjusted for future changes in the fair value of the equity awards that may occur over the service period. The grant date is defined as the date at which the parties agree to the contractual terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For consultants providing other services that are not similar to employees of the Company, the transactions are measured at the fair value of the services received unless this is not reliably measurable. In such cases, the transactions are measured at fair value of the equity instruments granted at the dates when the services are provided. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Modification of warrants which are beneficial are accounted for with their incremental value or over the shorter vesting period. Non-beneficial modifications such as an extension of the vesting period are not accounted for. Consequently, the original terms are deemed to continue to exist. The Company estimates the fair value of warrants using the underlying value of the Company&#8217;s ordinary shares. Since the warrants granted before December&#160;2020 are exercisable for nominal consideration, the warrants are valued using the fair value of the Company&#8217;s ordinary shares on grant date less the exercise consideration. Warrants granted during 2022 and 2021 are valued using a black-scholes share option pricing model. The assumptions used in calculating the fair value of share-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. The key assumption in this estimate is the fair value of the Company&#8217;s ordinary share on the warrant grant date. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Accounting for joint operations&#8201;&#8212;&#8201;Southern Denmark University</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company enters into agreements from time to time that may be subject to the requirements of IFRS 11, </font><font style="font-style:italic;letter-spacing:0.2pt;">Joint Arrangements</font><font style="letter-spacing:0.2pt;">. The Company evaluates these agreements on execution and applies the requirements of the guidance. The collaboration agreement with </font><font style="font-style:italic;letter-spacing:0.2pt;">Southern Denmark University</font><font style="letter-spacing:0.2pt;"> (&#8220;SDU&#8221;) is considered a joint operation as defined in IFRS 11, with the principal place of business being Denmark. In September&#160;2020, the Company terminated its existing agreement with SDU. For the year ended </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">December&#160;31, 2020, the Company recorded $0.3&#160;million in compensation cost for SDU employees which was reported in research and development costs in the statement of comprehensive loss. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Accounting for joint operations&#8201;&#8212;&#8201;MSD International GmbH and MSD International Business GmbH</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has entered into a collaboration agreement with MSD International GmbH and MSD International Business GmbH (jointly &#8216;MSD&#8217;). Under the arrangement, the Company will share its clinical trial in which the Company&#8217;s compound and MSD&#8217;s compound is dosed in combination. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In determining the accounting treatment for these types of arrangements, the Company carefully evaluates the relationship between the two parties in order to determine whether the arrangement is, in substance, a collaboration arrangement between the two parties (to be accounted for in accordance with IFRS 11, Joint Arrangements), or rather, a vendor-customer contract (to be accounted for in accordance with IFRS 15, Revenue from Contracts with Customers). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Management has determined that MSD does not meet the definition of a customer under IFRS 15. Consequently, the arrangement is classified as a collaboration arrangement and is accounted for as a joint operation in accordance with IFRS 11 resulting in the recognition of the Company&#8217;s own income and expense and assets and liabilities, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Finance Income</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finance income consists primarily of foreign currency gains, and a gain from changes in fair value of liability-classified warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Finance Expense</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finance expenses consists primarily of foreign currency losses, interest expense and related loan costs on the EIB Loan Agreement (as defined herein), and interest expense on leasing liabilities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Income tax</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The income tax for the period comprises current and deferred tax, including prior-year adjustments and changes in provisions for uncertain tax positions. Tax is recognized in the statement of comprehensive loss, except to the extent that it relates to items recognized in equity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development tax credits are available to the Group under the tax laws of Denmark and Australia respectively, based on qualifying research and development spend as defined under those tax laws. Tax credits not exceeding the corporate tax rate are recognized as an income tax benefit. Tax credits in excess of the corporate tax rate are classified as government grants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Accruals for uncertain tax positions and/or valuation of government grant receivables require management to make judgments of potential exposures. Accruals for uncertain tax positions and/or valuation of government grant receivables are measured using either the most likely amount or the expected value amount, depending on taxable amounts. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Deferred taxes</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. Where the tax value can be determined according to alternative tax rules, deferred tax is measured on the basis of the planned use of the asset or the settlement of the obligation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Deferred tax assets are measured at the value at which they are expected to be utilized, either through elimination against tax on future earnings or through a set-off against deferred tax liabilities. Deferred tax assets are set off within the same legal tax entity and jurisdiction. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Given the complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions could necessitate future adjustments to tax income and expenses already recorded. As at December&#160;31, 2022 and 2021, the Company has not recognized any provisions for uncertain tax positions resulting in a risk that the deferred tax asset related to warrants is lower than disclosed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes deferred income tax assets if it is probable that sufficient taxable income will be available in the future against which the temporary differences and unused tax losses can be utilized. Management has considered future taxable income in assessing whether deferred income tax assets should be recognized and has concluded that the deferred income tax assets do not meet the criteria for recognition as assets in the statements of financial position. </font>
        </div>
        <div style="margin-top:9.83pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Tax receivables</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Current tax assets for the current and prior periods are measured at the amount expected to be recovered from the taxation authorities, using the tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. </font>
        </div>
        <div style="margin-top:9.83pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">EIB Loan</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All loans and borrowings are classified as financial liabilities and are initially recorded at fair value less the value attributable to any separately accounted for embedded derivative. Further, considerations from the lender for other elements in the transaction are accounted for separately. After initial recognition, any such loans and borrowings are measured at amortized cost using the effective interest method, with the amortization recognized in finance costs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2020, we executed the EIB Loan Agreement, with European Investment Bank (&#8220;EIB&#8221;) for a principal amount of &euro;20.0&#160;million, divided into three tranches of &euro;7.0&#160;million, &euro;6.0&#160;million, and &euro;7.0&#160;million (the &#8220;EIB Loan&#8221;). During the year ended December&#160;31, 2021, the Company initiated the draw of the first tranche of the EIB Loan Agreement. The Company received the proceeds from the draw of the first tranche of &euro;7.0&#160;million (approximately $7.8&#160;million) on February&#160;17, 2022. Under the EIB Loan Agreement, the EIB Loan tranche balances are due six&#160;years from their respective disbursement dates. We received the first tranche of &euro;7.0&#160;million (approximately $7.8&#160;million) on February&#160;17, 2022. The loan is initially recorded at fair value less the value attributable to any separately accounted for embedded derivative. The loan is subsequently measured at amortized cost, with the unwinding of the discount recorded in finance costs over the life of the loan. </font>
        </div>
        <div style="margin-top:9.82pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">EIB Warrants</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the EIB Loan Agreement, EIB is entitled to an aggregate of 1,003,032 cash settled EIB Warrants with an exercise price of 1 DKK per warrant for all tranches (the &#8220;EIB Warrants&#8221;). On February&#160;17, 2022, 351,036 EIB Warrants were issued to EIB as part of the drawdown of the first tranche of the EIB Loan. The EIB Warrants are part of the overall return to EIB on the financing arrangement and are thus accounted for in accordance with the Financial Instruments Standards (IAS) 32 and IFRS 9. The cost upon initial recognition is accounted for as transaction costs as it is directly linked to the draw down on each individual tranche of the EIB loan. EIB is entitled to elect net in cash settlement of its warrants at any time, and consequently a financial liability for the redemption amount is recognized. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The liability is measured initially at its fair value and is subsequently remeasured at the redemption amount. The redemption amount is equal to the current share price. The remeasurements are presented as finance expense or finance income. </font>
        </div>
        <div style="margin-top:9.73pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Leases</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities for future remaining lease payments and right-of-use assets representing the right to use the underlying assets. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Leasehold improvements and Loan from lessor</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s lease contract comprises funding for the customization of the premises to the Company&#8217;s specific needs. The payment is determined based on the actual costs incurred for the customization, a repayment period of 8&#160;years and an interest rate of 6% per annum. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has assessed whether this is a lease component, or a leasehold improvement funded by the lessor. We have considered the following factors: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:7.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Which party designed the customization </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:7.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Which party had the right to direct changes to the work </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Who is taking on the economic risk of the cost price of the work </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A third party has designed the project according to the Company&#8217;s instructions, and the Company had the right to direct changes to the work during the construction period. Further, the Company has the full economic risk of the work due to 1:1 linkage between construction costs and payments to the lessor. Consequently, the Company has assessed that the customization is a leasehold improvement funded by the lessor and accordingly presented a leasehold improvement and a corresponding liability for the loan from the lessor. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Right-of-use assets</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes a right-of-use asset at the lease commencement date (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, lease payments made at or before the commencement date less any lease incentives received, initial direct costs incurred, and restoration costs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Right-of-use assets are depreciated over the shorter of the lease term and the useful life of the right-of-use asset using the straight-line method. In addition, right-of-use assets are reduced by impairment losses, if any, and adjusted for certain remeasurements. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s right-of-use assets are presented within property and equipment, net. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Lease liabilities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of the following payments, when applicable: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">fixed payments (including in-substance fixed payments), less any lease incentives receivable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">variable lease payments (linked to an index or interest rate); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expected payments under residual value guarantees; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the exercise price of purchase options, where exercise is reasonably certain; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">lease payments in optional renewal periods, where exercise of extension options is reasonably certain; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">and penalty payments for the termination of a lease, if the lease term reflects the exercise of the respective termination option. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The lease payments are discounted using the interest rate implicit in the lease if this rate can be readily determined. Otherwise, the Company&#8217;s incremental borrowing rate is used, being the rate that the Company </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions. Generally, the Company uses its incremental borrowing rate as the discount rate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Lease liabilities are subsequently measured at amortized cost using the effective interest method. In addition, the carrying amount of the lease liabilities are remeasured if there is a modification, a change in the lease term, or a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Intangible assets</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company recognized intangible assets for licenses. Licenses are measured at cost less cumulative amortization and impairment. Cost is measured at fair value of the consideration transferred with addition of transactions costs. If additional consideration is transferred to the seller due to meeting certain milestones, these payments are added to the cost price once the conditions for making the payments are met. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The capitalized assets are amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the license or similar development agreement. Amortization commences only once the necessary regulatory and marketing approval has been received for the product candidates to which they relate. To date, the Company has not received any regulatory and marketing approval for any of its product candidates. Consequently, the Company did not recognize any amortization expense for its intangible assets. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Property and equipment</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Property and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, as follows: </font>
        </div>
        <table style="width:416pt;height:53.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:164pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:240pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Useful life </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:164pt;">
              <font style="letter-spacing:0.2pt;">Properties </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:240pt;">
              <font style="letter-spacing:0.2pt;">Shorter of lease term and useful life of the asset </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:164pt;">
              <font style="letter-spacing:0.2pt;">Leasehold improvements </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:240pt;">
              <font style="letter-spacing:0.2pt;">11&#160;years </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:164pt;">
              <font style="letter-spacing:0.2pt;">Other equipment </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:240pt;">
              <font style="letter-spacing:0.2pt;">5&#8201;&#8211;&#8201;10&#160;years</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Impairment of non-financial assets</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Assets are tested for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating&#160;units). Non-financial assets other than goodwill that suffered impairment are reviewed for possible reversal of the impairment at the end of each reporting period. The Company has not recognized any impairment losses to date. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Provisions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Provisions are recognized when we have an existing legal or constructive obligation as a result of events occurring prior to or on the balance sheet date, and it is probable that the utilization of economic resources will be required to settle the obligation. Provisions are measured as the best estimate of the expense necessary to settle the obligation at the balance sheet date. Provisions that are estimated to mature after more than one year after the balance sheet date are measured at their present values, using a discount rate based on the Company&#8217;s risk adjusted incremental borrowing rate. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Financial instruments</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial instruments are classified at initial recognition, including on the basis of the purpose for which the instrument was acquired and managed. This classification determines the valuation of the instruments. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">(i) Non-derivative financial assets</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Non-derivative financial assets are recognized initially on the date they are originated. The Company derecognizes non-derivative financial assets when the contractual rights to cash flows expire or it transfers the right to receive cash flows in a transaction which transfers substantially all the risks and rewards of ownership of the asset. The Company&#8217;s financial assets are initially recognized at fair value and subsequently measured at amortized cost less accumulated impairment losses. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company holds the following categories of non-derivative financial assets: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Receivables</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Receivables (including lease deposits, receivables and receivables from unpaid capital) represent the Company&#8217;s right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). They are measured at amortized cost less impairment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prepayments include expenditures related to future financial periods and are measured at amortized cost. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cash and cash equivalents</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cash is comprised of cash on hand and in bank deposit accounts. Cash equivalents are instruments with original maturities of 90&#160;days or less. The Company does not have any cash equivalents for the&#160;years ended December&#160;31, 2022 and 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">(ii) Non-derivative financial liabilities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Non-derivative financial liabilities comprise other payables which are measured initially at fair value and subsequently at amortized cost. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Trade Payables</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Trade payables and accruals relate to the Group&#8217;s purchase of products and services from various vendors in the normal course of business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Payables</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Other payables are comprised of payables to clinical research organizations, employee liabilities and other liabilities. The contract liabilities consist of CROs and vendor accruals. Employee cost liabilities are comprised of provision for holiday allowance, provision for salaries and other employee related provisions. Other liabilities consist of commitments and liabilities related to government grants received in advance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Segment Information</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">An operating segment is a part of the Company that conducts business activities from which it can generate revenue and incur costs, and for which independent financial information is available. Identification of segments is based on internal reporting to the chief operating decision maker (&#8220;CODM&#8221;). The CODM for the Company is the Chief Executive Officer. The Company does not divide its operations into different segments and the CODM operates and manages the Company&#8217;s entire operations as one segment, which </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">is consistent with the Company&#8217;s internal organization and reporting system. The Company does not have any revenue and there are no material non-current assets attributable to countries other than Denmark. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Shareholders&#8217; Equity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The share capital comprises the nominal amount of the company&#8217;s ordinary shares, each at a nominal value of DKK 1. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Other reserves includes the share premium comprising the amount received, attributable to shareholders&#8217; equity, in excess of the nominal amount of the shares issued at the company&#8217;s capital increases, reduced by any expenses directly attributable to the capital increases as well as translation reserves. Translation reserves include exchange rate adjustments of equity and intragroup receivables forming part of the net investments in our group enterprises. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Accumulated deficit includes the accumulated profit or loss as well as well as the reserve for share-based payment representing the corresponding entries to the share-based payment recognized in the profit or loss, arising from our warrant programs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Loss Per Share</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The calculation of basic loss per share is based on the Company&#8217;s net loss for the year attributable to shareholders of Evaxion Biotech A/S and on the weighted average number of ordinary shares outstanding during the year. The number of shares outstanding take in effect the 2 for 1 stock split and the 17 for 1 bonus share issuance on January&#160;4, 2021. In calculating diluted loss per share, earnings and the average number of shares are adjusted for the dilutive effects of potential ordinary shares. Loss per share is not adjusted for any dilution that results in a loss per share that is lower than loss per ordinary share before dilution. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Standards issued but not yet effective</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There were a number of standards and interpretations which were issued but were not yet effective at December&#160;31, 2022 and have not been adopted for these financial statements, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current (January&#160;1, 2024) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Amendment to IAS 1 Presentation of Financial Statements: Disclosure of Accounting Policies (January&#160;1, 2023) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Amendment to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates (January&#160;1, 2023) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Amendment to IAS 12 Accounting Policies, Deferred tax related to Assets and Liabilities arising from a Single Transaction (January&#160;1, 2023) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Amendments to IFRS 16 Accounting Policies, Lease Liability in a Sales and Leaseback (January&#160;1, 2024) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company expects to adopt these standards, updates and interpretations when they become mandatory. These standards are not expected to have a significant impact on disclosures or amounts reported in the Company&#8217;s financial statements in the period of initial application and future reporting periods. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 4. Significant Accounting Judgements, Estimates, and Assumptions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The preparation of the consolidated financial statements in conformity with IFRS as issued by the IASB requires management to make judgements, estimates and assumptions that affect the application of policies and amounts reported in the financial statements and accompanying notes. The estimates and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The critical accounting policies which involve significant estimates, assumptions or judgements, the actual outcome of which could have a material impact on the Company&#8217;s results and financial position outlined below, are as follows: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Share-based compensation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Management determines costs for share-based payments using market-based valuation techniques. The fair value of the share awards is determined at the date of grant using generally accepted valuation techniques or valuation based on the Company&#8217;s fundraising events. Assumptions are made and judgments are used in applying valuation techniques. Prior to the Company&#8217;s IPO completed in February&#160;2021, these assumptions and judgments include estimating the fair value for the underlying Ordinary share on the warrant grant date, as well as the likelihood of liquidity events such as IPOs. Such judgments and assumptions are inherently uncertain. Changes in these assumptions affect the fair value estimates as well as the term applied to the expense recognition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subsequent to the Company&#8217;s IPO completed in February&#160;2021, determining the initial fair value and subsequent accounting for equity awards require significant judgment regarding expected life and volatility of an equity award; however, as a public listed company there is objective evidence of the fair value of an ordinary share on the date an equity award is granted. Refer to Note 8 for further detail surrounding share-based compensation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">European Investment Bank Loan and warrant liability</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2022, the first tranche related to the Company&#8217;s loan agreement with the European Investment Bank (EIB) was drawn down. As part of the loan arrangement warrants were granted to EIB. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The liability is initially recognized at fair value, net of transaction costs incurred (this includes the amount attributable to the warrants (see below). The loan is subsequently measured at amortized cost using the effective interest method. The effective interest rate is determined based on the outstanding amount and the fixed interest payments during the period outstanding and the accumulated payment-in-kind interest payment to be paid upon repayment. The warrants are considered a liability as they can be settled in cash and form part of the overall return to EIB on the financing arrangement and are thus accounted for in accordance with the Financial instruments standards IAS 32 and IFRS 9. The liability is measured initially at its fair value. The cost upon initial recognition is accounted for as transaction costs as it is directly linked to the draw down on each individual tranche of the EIB loan. The warrant liability is subsequently remeasured at the redemption amount. Significant judgment is made in respect of valuation of the warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Leasehold Improvements and Loan from Lessor</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A significant judgment was made in respect of determining whether customization of leased premises forms part of the lease or is a leasehold improvement funded by the lessor. See the section &#8220;Leasehold improvements and Loan from lessor&#8221; in Note 3. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There have been no other changes to the application of critical accounting judgments, or estimation uncertainties regarding accounting estimates. Refer to Note 2 &#8220;Liquidity and Going Concern&#8221; and Note 3 for a summary of significant accounting policies for further discussion. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 5. Financial Instruments and Risk Management</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Financial risk management and risk management framework</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In terms of financial risks, the Company has exposure to liquidity risk and market risk comprising foreign exchange risk. This note presents information about the Company&#8217;s exposure to each of the above risks together with the Company&#8217;s objectives, policies and processes for measuring and managing risks. The Company&#8217;s Board of Directors monitors each of these risks on a regular basis and implements policies as and when they are required. Details of the current risk management policies are provided below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Liquidity risk</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The exposure to liquidity risk primarily relates to the risk of failure to meet the Company&#8217;s obligations when they become due, which could happen if current assets are not enough to cover the amount of short-term liabilities. The Company has considered whether conditions and events exist that, when considered in aggregate, raise significant doubt about the Company&#8217;s ability to continue as a going concern for at least a year from the date of the financial statements. The Company has a history of incurring operating losses and negative cash flows from operations. The Company anticipates incurring additional losses until such time, if ever, it can complete its research and development (&#8220;R&amp;D&#8221;) activities and obtain an out-licensing partnership for its product candidates and generate revenues from such product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company monitors its funding situation closely to ensure that it has access to sufficient liquidity to meet its forecasted cash requirements. Analyses are run to reflect different scenarios including, but not limited to, cash runway, human capital resources and pipeline priorities to identify liquidity risk. This enables Management and the Board of Directors to prepare for new financing transaction and/ or adjust the cost base accordingly. In March&#160;2023 the Company adjusted the organization and optimized the strategy around EVX-01 to focus the operation and save costs. As of the date of these consolidated financial statements the Company, with its current strategic plans, anticipates that the current cash position and the cash requirements per the 2023 Annual Budget will provide sufficient cash until the beginning of December&#160;2023. Substantial additional financing will be needed by the Company to fund its operations and to continue development of its product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company plans to finance cash needs through equity offerings, or other capital sources, including potential collaborations or licenses and adjust spending on new and ongoing development and corporate activities, as needed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Due to the continuing operating losses, expected negative cash flows and the need for additional funding to finance future operations, the Company concluded that there is significant doubt about its ability to continue as a going concern through one year from the balance sheet date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and discharge of its liabilities and commitments in the normal course of business. The matters that raise significant doubt about the Company&#8217;s ability to continue as a going concern also raise substantial doubt as contemplated by the Public Accounting Oversight Board (PCAOB) standards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2022 and December&#160;31, 2021, our available liquidity, comprised of cash and cash equivalents, was $13.2&#160;million and $32.2&#160;million, respectively and our total equity was $8.3&#160;million and $32.4&#160;million, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;5, 2021, the Company completed our initial public offering through which we issued and sold 3,000,000 ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. We received aggregate net proceeds of $25.3&#160;million from the initial public offering, after deducting the underwriting discounts and commissions and offering expenses payable by us. Upon the completion of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">initial public offering, our registered, issued, and outstanding share capital was nominal DKK 19,198,668 divided into 19,198,668 ordinary shares of DKK 1 each. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On November&#160;9, 2021, we completed a follow-on public offering through which we issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November&#160;5, 2021. We received aggregate net proceeds of $24.9&#160;million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and offering expenses payable by us. Upon the completion of the follow-on public offering, the Company&#8217;s registered, issued, and outstanding share capital was nominal DKK 23,141,524. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;7, 2022 the Company entered into a Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with an unrelated third party, Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), to sell up to $40.0&#160;million of its ordinary shares represented by American Depository Shares (&#8220;ADSs&#8221;) over a 36 month period. the Company is not obligated to sell any ordinary shares represented by ADSs pursuant to the Purchase Agreement and will control the timing and amount of any such sales, but in no event will Lincoln Park be required to purchase more than $1.5&#160;million in ordinary shares represented by ADSs in any single regular purchase. Upon execution and delivery of the Purchase Agreement, the Company issued 428,572 ordinary shares represented by ADSs as consideration for a commitment fee of $1.2&#160;million for Lincoln Park&#8217;s commitment to purchase its ordinary shares represented by ADSs under the Purchase Agreement. Upon completion of the Purchase Agreement, the Company&#8217;s registered, issued, and outstanding share capital was nominal DKK 23,686,452. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;3, 2022 the Company entered into an At-The-Market Issuance Sales Agreement with JonesTrading Institutional Services LLC (&#8220;JonesTrading&#8221;) to sell up to $14.4&#160;million of its ordinary shares represented by ADSs. The Company agreed to pay JonesTrading commission equal to 3% of the gross proceeds of the sales price of all ADSs sold through them as sales agent under the Sales Agreement. The offering of the Company&#8217;s ADSs pursuant to the Sales Agreement will terminate on the earliest of (1)&#160;the sale of all of the ordinary shares subject to the Sales Agreement, or (2)&#160;termination of the Sales Agreement by the Company or JonesTrading. The Company and JonesTrading may terminate the sales agreement at any time upon ten days prior notice. JonesTrading may terminate the Sales Agreement at any time in certain circumstances, including the occurrence of a material adverse change that, in their judgment, may make it impracticable or inadvisable to market or sell the Company&#8217;s ADSs or a suspension or limitation of trading the Company&#8217;s ADSs on The NASDAQ Capital Market. During the period between October&#160;13, 2022 and October&#160;20, 2022, the Company sold 114,402 ordinary shares represented by ADSs, at a volume weighted average price of $2.76 per ADS. The ADSs were sold in an at-the-market offering pursuant to the terms and subject to the conditions contained in a Capital Demand Sales Agreement between the Company and JonesTrading Institutional Services LLC, dated October&#160;3, 2022. After deducting fees and expenses, total proceeds to the Company from the sales of the ADSs were approximately $0.3&#160;million. In connection with such sales, the Company registered aggregate share capital increases of nominal DKK 114,402 with the Danish Business Authority. Upon completion of the Sales Agreement and related capital increases during the period between October&#160;13, 2022 and October&#160;20, 2022, the Company&#8217;s registered, issued, and outstanding share capital was nominal DKK 24,092,330. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;29, 2022 the Company sold 4,450 ordinary shares represented by ADSs, DKK 1 nominal value with each ordinary share represented by one ADSs, at a VWAP of $2.24 per ADS. The ordinary shares represented by ADSs were sold pursuant to the Sales Agreement with JonesTrading dated October&#160;3, 2022. Gross proceeds from the sale of ordinary shares represented by ADSs were approximately $9,968. In connection with the sale, the Company registered aggregate share capital increase of nominal DKK 4,450 with the Danish Business Authority. Upon completion of the sale, the Company&#8217;s registered, issued, and outstanding share capital was nominal DKK 24,139,413. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At year end, due to warrant exercise, the outstanding share capital was nominal DKK 24,139,413. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">As of the date of these consolidated financial statements the Company, with its current strategic plans, anticipates that the current cash position and the cash requirements per the 2023 Annual Budget will provide a positive cash runway until beginning of December&#160;2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to their reputation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following are the contractual undiscounted outflows associated with the Company&#8217;s financial liabilities in the current and prior year: </font>
        </div>
        <table style="width:456pt;height:135pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:182.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="34">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:182.75pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="34">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:182.75pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carrying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Contractual</font>
                <br >
                <font style="letter-spacing:-0.16pt;">cash flows </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">&lt;1 year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">1&#8201;&#8211;&#8201;5&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">&gt;5&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:182.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Borrowings </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.475pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11,859</td>
            <td style="padding:0pt;padding-left:3.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">360</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,531</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">9,968</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11,859</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:182.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lease payables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,255</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.475pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,255</td>
            <td style="padding:0pt;padding-left:3.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">147</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">788</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,320</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,255</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:182.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Trade payables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,085</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.475pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,085</td>
            <td style="padding:0pt;padding-left:3.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,085</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,085</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:182.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Provisions </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.475pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:3.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:182.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other payables </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">312</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.475pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">312</td>
            <td style="padding:0pt;padding-left:3.475pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">312</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">312</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:182.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">12,796</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.475pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">16,655</td>
            <td style="padding:0pt;padding-left:3.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,904</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,319</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">11,432</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">16,655</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:135pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:192.15pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="34">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:192.15pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="34">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:192.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carrying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Contractual</font>
                <br >
                <font style="letter-spacing:-0.16pt;">cash flows </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">&lt;1 year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">1&#8201;&#8211;&#8201;&#8201;5&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">&gt;5&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:192.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Borrowings </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,170</td>
            <td style="padding:0pt;padding-left:1.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,458</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">192</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">769</td>
            <td style="padding:0pt;padding-left:5.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.529999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">497</td>
            <td style="padding:0pt;padding-left:0.529999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,458</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lease payables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,520</td>
            <td style="padding:0pt;padding-left:1.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,698</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">326</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,223</td>
            <td style="padding:0pt;padding-left:5.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.529999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,149</td>
            <td style="padding:0pt;padding-left:0.529999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,698</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Trade payables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,848</td>
            <td style="padding:0pt;padding-left:1.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,848</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,848</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.529999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.529999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,848</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Provisions </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">153</td>
            <td style="padding:0pt;padding-left:1.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">153</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.529999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">153</td>
            <td style="padding:0pt;padding-left:0.529999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">153</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:192.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other payables </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">46</td>
            <td style="padding:0pt;padding-left:1.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">46</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">46</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.529999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.529999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">46</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:192.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">6,737</td>
            <td style="padding:0pt;padding-left:1.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">8,203</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,412</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,992</td>
            <td style="padding:0pt;padding-left:5.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.529999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,799</td>
            <td style="padding:0pt;padding-left:0.529999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">8,203</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13.5pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The financial liabilities include estimated or contractual interest rate payments. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Market risk</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. The type of market risk that impacts the Company is currency risk. The Company does not currently have any loans or holdings that have variable interest rate. Accordingly, the Company is not exposed to material interest rate risk. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Foreign currency risk</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The primary exposure derives from the Company&#8217;s operating expenses paid in foreign currencies, mainly USD and Australian dollars. This exposure is known as transaction exposure. Any reasonable or likely movements in foreign exchange rates would not have a material impact on the Company&#8217;s operating results. The Company&#8217;s policy for managing foreign currency risks is to convert cash received from financing activities to currencies consistent with the Company&#8217;s expected cash outflows. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Credit risk</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument, leading to a financial loss for the Company. The Company&#8217;s exposure to credit risk is limited to deposits with banks with high credit ratings. Accordingly, the Company does not have material credit risk and no provision for credit risk is recognized. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Capital management</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s objectives when managing capital are to safeguard the Company&#8217;s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company raises capital from the issue of equity, grants or convertible loan notes. On a regular basis, management receives financial and operational performance reports that enable management to assess the adequacy of resources on hand and the Company&#8217;s liquidity position to determine future financing needs. For further information on financing needs refer to Note 2. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fair values</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Financial instruments measured at fair value in the statements of financial position are grouped into three levels of fair value hierarchy. This grouping is determined based on the lowest level of significant inputs used in fair value measurement, as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Level I&#8201;&#8212;&#8201;quoted prices in active markets for identical assets or liabilities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Level II&#8201;&#8212;&#8201;inputs other than quoted prices included within Level I that are observable for the instrument, either directly (i.e. as prices) or indirectly (i.e. derived from prices). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Level III&#8201;&#8212;&#8201;inputs for instrument that are not based on observable market data (unobservable inputs). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company issued warrants in connection with the EIB Loan Agreement. The EIB Warrants liability is measured in full upon issuance. The liability is measured initially at its fair value and is subsequently remeasured at the redemption amount. The liability is classified in level 1 of the fair value hierarchy. Due to the fact that the exercise price is insignificant compared to the share price, there is virtually no time value. Refer to Note 18 for further information regarding the EIB Warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There were no financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of December&#160;31, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 6. Operating Activities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:109pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:321.88pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:321.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:321.88pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:321.88pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Employee salary and benefit expenses, excluding share-based </font>
                <br >
                <font style="letter-spacing:0.2pt;">compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,396</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,794</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,337</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:321.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">760</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,051</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,496</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:321.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">512</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">92</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 0.5pt 0pt; width:321.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">External expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">8,388</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">11,465</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">5,977</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:321.88pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total research and development expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">17,056</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">19,583</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,902</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">During the&#160;years ended December&#160;31, 2022, 2021 and 2020, the Company recognized $0.5&#160;million, $0.3&#160;million and $0.8&#160;million, respectively, related to government grants as a reduction of research and development expenses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:111pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.88pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:336.88pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Employee salary and benefit expenses, excluding share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,983</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,824</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,098</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">182</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">328</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,912</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Professional and other fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,901</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,644</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">142</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">71</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:336.88pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total general and administrative expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">8,208</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">6,251</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,666</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.99pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 7. Employees and Employee-Related Costs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The number of employees, including executive and non-executive directors, during the year was as follows: </font>
        </div>
        <table style="width:456pt;height:82.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Average number of full-time employees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">60</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">53</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">33</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354.89pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Number of employees at end of period: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Denmark and United States </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">63</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">61</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">35</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:354.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total employees, at end of period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">63</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">61</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">35</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.99pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Employee Costs:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:126pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:331.88pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:331.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:32.71pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:27.71pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:27.71pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:331.88pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:331.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Wages and salaries </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,182</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7,558</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,222</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash bonus </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">789</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">668</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">942</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,379</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,408</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other social security expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">19</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:331.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other staff expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">389</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">364</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">196</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:331.88pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,321</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,997</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7,843</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:96pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:331.88pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:331.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:32.71pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:27.71pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:27.71pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:331.88pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:331.88pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Total Employee costs classified as:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:331.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,156</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7,845</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,833</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:331.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">2,165</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,152</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,010</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:331.88pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,321</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,997</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7,843</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <table style="width:456pt;height:96pt;margin-top:12pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.88pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:336.88pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.88pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Non-management employee benefit expenses classified as:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,639</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,414</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,009</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">983</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">836</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">611</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:336.88pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7,622</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,620</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.82pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Remuneration to the Board of Directors and Executive Management</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:217pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.88pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:336.88pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.88pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Remuneration to the Executive Management:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Wages and salaries </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,970</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,833</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,298</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">321</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">514</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,566</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,291</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,347</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,864</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.88pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Remuneration to the Board of Directors:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Wages and salaries </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">379</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">313</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">87</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">359</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">408</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">359</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Remuneration to the Board of Directors and Executive Management classified as:</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,517</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,431</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">824</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,182</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,316</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,399</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:336.88pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,699</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,747</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,223</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:10.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Executive Management was comprised of four members in January&#160;2019 and expanded again to five members in October&#160;2019, of which one member resigned in 2020 and one other member resigned in 2021. It was expanded to 5 members again in 2021, and was expanded to 6 members in 2022. </font>
        </div>
        <div style="margin-top:9.72pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 8. Share-Based Payments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Warrant Program and Amendments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s Articles of Association allow for the granting of equity compensation, in the form of equity settled warrants, to employees, consultants and Scientific Advisory Board members who provide services similar to employees, members of executive management, and the board of directors. The warrants granted in 2018 or prior vested upon the closing of our initial public offering in February&#160;2021 (&#8220;IPO&#8221;). The warrants granted in 2020 vest either gradually over 36&#160;months or vest immediately. Vested warrants granted in 2020 are exercisable in certain exercise windows beginning in the second half of the year of 2021. Warrants granted up until 2019 expire on December&#160;31, 2036. Warrants granted in 2022, 2021 and 2020 expire on December&#160;31, 2031. For the&#160;years ended December&#160;31, 2022, 2021 and 2020, the number of warrants outstanding as a&#160;percentage of outstanding ordinary shares was 11.4%, 11.8% and 13.8%, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During 2022, the Company granted 491,612 warrants, of which 35,000 were granted to its Chief AI and Culture Officer (&#8220;CAICO&#8221;), 25,000 were granted to its Chief Scientific Officer (&#8220;CSO&#8221;), 16,667 were granted to its Chief Financial Officer (&#8220;CFO&#8221;), 25,000 were granted to its Chief Medical Officer (&#8220;CMO&#8221;), 20,833 were granted to its Chief Operating Officer (&#8220;COO&#8221;), 3,125 were granted to its Chief Business Officer (&#8220;CBO&#8221;) and 3,125 were granted to its Chief Executive Officer (&#8220;CEO&#8221;). All granted warrants will vest over 36&#160;months. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the appointment of a new Chief Executive Officer (&#8220;CEO&#8221;) in September&#160;2022, the new Chief Financial Officer (&#8220;CFO&#8221;) in May&#160;2022 and the new Chief Operating Officer (&#8220;COO&#8221;) in March&#160;2022 they were all granted warrants, the CEO was granted 50,000 warrants to purchase, the CFO 45,000 warrants to Purchase and the COO 25,000 warrants to purchase of the Company&#8217;s ordinary shares with DKK 1 nominal value. The granted warrants have an exercise price equal to the fair market value of the Company&#8217;s ordinary shares represented by ADSs on the date of grant thereof and they vest over a period of 36&#160;months. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the second quarter of 2021, the Company granted 62,147 warrants to its Chief Medical Officer (&#8220;CMO&#8221;) which vest over 36&#160;months. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2019, the Company granted 150,660 warrants to its Chief Financial Officer (&#8220;CFO&#8221;) which were exercisable upon an exit event. In December&#160;2020, the terms of the warrants issued to the Company&#8217;s CFO were amended to no longer comprise exercisability upon an exit event. Consequently, these warrants did not vest upon the IPO in February&#160;2021 and will vest in accordance with the vesting schedule for warrants granted in 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;4, 2021, the Company effected its Stock Split which also resulted in a reduction of the nominal value of the Company&#8217;s ordinary shares from DKK 2 to DKK 1. In accordance with the anti-dilution provisions of the warrant agreements, the number of warrants was increased by a ratio of 36 to 1 and the exercise price was decreased from DKK 2 to 1 DKK. Accordingly, information related to the Company&#8217;s warrants, have been retroactively adjusted to reflect the stock split and the bonus shares for all periods presented. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following schedule specifies the granted warrants: </font>
        </div>
        <table style="width:456pt;height:297.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:280pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price/Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Contractual</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Life (years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:280pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants granted as at December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,932,156</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">DKK1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:280pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">363,168</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">DKK1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:280pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants forfeited </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(45,216<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">DKK1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:280pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants cancelled </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(22,032<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">DKK1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:280pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants granted as at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,228,076</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">DKK1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:280pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants granted during 2021</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">63,802</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">DKK1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:280pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants granted December&#160;2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">523,599</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 5.38 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:280pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(62,284<font style="position:absolute;">)<font style=" position:relative; bottom:4.25pt;font-size:6.5pt;">(2)</font> </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">DKK1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:280pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants forfeited </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(10,178<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">DKK1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:280pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants cancelled </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(10,397<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">DKK1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:280pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants granted as at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,732,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">DKK 7.53 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:280pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">491,612</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 2.24 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:280pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(388,181<font style="position:absolute;">)<font style=" position:relative; bottom:4.25pt;font-size:6.5pt;">(2)</font> </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 2.42 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:280pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants forfeited </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(92,956<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 1.28 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:280pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants cancelled </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:7.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:50.93pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:280pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants granted as at December&#160;31, 2022</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,743,093</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:50.93pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 1.50</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:7.5pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:1.75pt 0pt 1.5pt 0pt; width:280pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants exercisable as at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:7.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:50.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:280pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants exercisable as at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,072,122</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:50.93pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 2.25pt 0pt; width:280pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants exercisable as at December&#160;31, 2022</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,988,106</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:50.93pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt; width:7.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Of which 62,147 warrants were legally granted in June&#160;2021 and the remaining 1,655 warrants were legally granted in December&#160;2020. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:10pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:10pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The weighted average share price at the date of exercise were USD 2.42 and USD 5.59 for the&#160;years ended December&#160;31, 2022 and 2021, respectively. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Number of warrants exclude EIB Warrants referred to in Note 19. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">December&#160;31, 2022 USD-end rate used. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During 2019 employees, external consultants, executive management and board members became contractually entitled to warrants that was rectified on December&#160;17, 2020: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2019, 45,216 warrants were granted to a member of executive management. They vest from December&#160;2020&#8201;&#8211;&#8201;December&#160;2022. Fair value at grant date amounted to $0.3&#160;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2019, 7,956 warrants were granted to an employee. They vest from December 2020&#8201;&#8211;&#8201;December&#160;2022. Fair value at grant date amounted to $0.1&#160;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2019, 54,000 warrants were granted to an employee. The warrants vested immediately. Fair value at grant date amount to $0.5&#160;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2019, 150,660 warrants were granted to a member of executive management. The warrants vest annually over 3&#160;years. Fair value at grant date amounted to $1.3&#160;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2020, an aggregate of 126,972 warrants attributable to 2019 entitlements were granted to employees, members of our board of directors and consultants who provide similar services as employees. 63,612 warrants vested immediately and 63,360 warrants vest monthly over three&#160;years from January&#160;2020&#8201;&#8211;&#8201;December&#160;2022. Fair value at grant date amounted to $1.2&#160;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2020, an aggregate of 236,196 warrants attributable to 2020 entitlements were granted to employees, members of our board of directors and consultants who provide similar services as employees. Of the warrants granted, 120,888 warrants vested immediately and 115,308 warrants vest monthly over three&#160;years from January&#160;2020&#8201;&#8211;&#8201;December&#160;2022. Fair value at grant date amounted to $2.3&#160;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2021, 62,147 were granted to a member of Executive Management. Fair value at grant date amounted to $0.4&#160;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">During 2021, an aggregate of 523,599 warrants attributable to 2021 entitlements were granted to employees, members of our board of directors and executive management. Of the warrants 22,916 were granted to our board of directors vested immediately. The warrants granted to employees and executive management vest over 36&#160;months. Fair value at grant date amounted to $1.5&#160;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">For the year ended December&#160;31, 2019 the Company had 22,032 outstanding warrants to SDU employees and recognized an immaterial amount of expense for these warrants as research and development expenses in the statement of comprehensive loss. In September&#160;2020, the Company terminated its existing agreement with SDU for business reasons. Under the terms of the SDU agreement, the Company did not incur a termination penalty and has no further obligations under this agreement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">A member of the executive board terminated his employment contract as of April&#160;30, 2020 and forfeited his right to 45,216 unvested warrants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">A member of the executive board terminated his employment contract as of October, 2021 but no granted warrants remained unvested as of that date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">During 2022, an aggregate of 491,612 warrants attributable to 2022 entitlements were granted to employees, members of our board of directors and executive management. Of the warrants 2,500 were granted to our employees vested immediately. The warrants granted to employees and executive management vest over 36&#160;months. Fair value at grant date amounted to $0.8&#160;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">During 2022 the former Chief Executive Officer of the Company forfeited his right to 45,327 unvested warrants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2022 employees received a number of warrants based on the individual employee&#8217;s grade and performance in 2022. The warrants were granted at the share price equal to the fair market value thereof on the date of grant and will vest 1/36 per month over 36&#160;months beginning January&#160;1, 2023. For the&#160;years ended December&#160;31, 2022, 2021 and 2020, a service cost of $1.0&#160;million, $1.4&#160;million and $3.4&#160;million has been recognized, respectively, based on the estimated fair value of the warrants granted in prior periods and warrants expected to be granted. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Share-based compensation expenses included in the statements of comprehensive loss: </font>
        </div>
        <table style="width:416pt;height:81pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:304.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:304.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:304.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:304.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">760</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,051</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,496</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:304.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">182</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">328</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,912</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:304.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">942</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,379</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,408</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2020 an amount of $0.1&#160;million related to warrants issued as compensation for arranging investors to subscribe for shares has been recognized in equity as a share-based compensation expense related to the capital increase. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Determination of Fair Value of Warrants</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The warrants issued under the share-based payment arrangement until December&#160;2021 are exercisable for nominal consideration compared to the fair value of the shares resulting in virtually no time value. The Company values these warrants based on the intrinsic value of the shares measured as the difference between the fair value of the Company&#8217;s Ordinary shares and the warrant exercise price. Due to the highly specialized nature of services provided by consultants who provide services similar to those provided by employees of the Company, transactions with those consultants are measured at fair value of the equity instruments granted. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the share-based payment arrangement, there is no protection against capital increases at a discount and dividend distribution. However, dividends are not likely to be distributed and there is generally no reason to raise new capital at below the current share price. On this basis, the Company has assessed that it is generally appropriate to assume that no such transactions will take place during the holding period. When issuing warrants in 2018, convertible bonds with a potential dilutive effect were outstanding, and fair value was adjusted to reflect this potential dilution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The stock split and bonus share issuance executed on January&#160;4, 2021 resulted in a dilution of the warrant holders due to the increase of the exercise price compared to the pre stock split and bonus share issue. For warrants granted on December&#160;17, 2020, the fair value was adjusted to reflect this dilution. For other grants, no such adjustment has been made. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The fair values of the warrants are measured with reference to the share price of the underlying share. Up until December&#160;2020, this share value was determined using the value established in different financing transactions with unrelated parties. In each of these transactions, the relative ownership of the Company was changed, and a share value was established using these fund-raising transactions. The fair values of warrants are estimated using a linear interpolation in USD of the share value on grant date based on the value established on capital event dates before and after the grant date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For warrants granted in December&#160;2020, the Probability-Weighted Expected Return Method (&#8220;PWERM&#8221;) was applied, based on the weighted value of the share in a stay private scenario and an IPO scenario. 40% weight was put to the stay private scenario applying a share price equal to the share price of USD 8.89 at the November&#160;2020 capital increase and 60% weight was put to the IPO scenario applying the mid-price of the indicative IPO price range of USD 11.00 available on the balance sheet. A 10% lack of marketability discount (DLOM) was applied to the IPO price. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:24pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Warrants granted prior to December&#160;2020 are exercisable only upon an exit event or upon the Board of Director&#8217;s decisions, which is a post vesting restriction. Since the warrants granted prior to 2020 do not expire until December&#160;31, 2036, Management considers it highly unlikely that the warrants will not become exercisable and no downward adjustment to reflect the risk of the warrant not becoming exercisable is made to the fair value of the warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During 2020, the Company revised the estimated date of an IPO exit event to occur in February&#160;2021. As of December&#160;31, 2019, the estimated IPO exit event was December&#160;2021. As a result of this change in estimate, the Company recognized an acceleration of expense of $0.8&#160;million for the year ended December&#160;31, 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subsequent to the Company&#8217;s IPO, determining the initial fair value and subsequent accounting for equity awards require significant judgment regarding expected life and volatility of an equity award; however, as a public listed company there is objective evidence of the fair value of an ordinary share on the date an equity award is granted. On the other hand, due to the fact that as of 2021, warrants will be granted at the share price on the date of grant, fair value comprises a time value which is significantly affected by the expected life and expected volatility. The expected life of a warrant is based on the assumption that the holder will not exercise until after the equity award is fully vested. Actual exercise patterns may differ from the assumption used herein. The expected volatility is based on peer group data and reflects the assumption that the historical volatility over a period similar to the life of the warrant is indicative of future trends, which may not necessarily be the actual outcome. The peer group consists of listed companies that management believes are similar to the Company in respect to industry and stage of development. Even with objective evidence of the fair value of an ordinary share, small changes in any other individual assumption or in combination with other assumptions could have resulted in significantly different valuations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following assumptions have been applied for the warrants issued during the year ended December&#160;31, 2022: </font>
        </div>
        <table style="width:416pt;height:55pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:381.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term (in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.5</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:381.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.66<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:381.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">85<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:381.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.10</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Amendments to Warrants</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As discussed above, the terms of the warrant granted to the company&#8217;s CFO were amended to no longer comprise an accelerated vesting upon an exit clause. This is considered a non-beneficial change, and consequently the accelerated vesting upon an exit event clause is deemed to continue to exist. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For warrants to which the employees became entitled in 2019 but were not granted until December&#160;2020, the Company recognized stock-based compensation expenses during the year ended December&#160;31, 2019 and the interim period ended September&#160;30, 2020, based on the terms expected to apply for these awards. Management expected the terms to be similar to the terms applicable to warrants granted up until 2018, including the accelerated vesting upon an exit clause. However, these warrants were granted subjected to a vesting schedule up to three&#160;years and did not allow for immediate vesting upon an exit event. Because the warrants were not granted until December&#160;2020, the Company recognized the difference in expenses as a change in accounting estimate and not a modification of existing awards. As a result of this change in the accounting estimate, the share-based payment expense for 2020 was reduced by $0.4&#160;million. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following schedule specifies the outstanding warrants as at December&#160;31, 2022: </font>
        </div>
        <table style="width:456pt;height:317.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Outstanding program </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per warrant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">grant date </font>
                <br >
                <font style="letter-spacing:-0.16pt;">fair value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(DKK) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">warrants</font>
                <br >
                <font style="letter-spacing:-0.16pt;">outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">exercise price</font>
                <br >
                <font style="letter-spacing:-0.16pt;">per warrant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(DKK) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">term to</font>
                <br >
                <font style="letter-spacing:-0.16pt;">maturity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (December&#160;2016) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">20.91</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">437,114</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (September&#160;2017) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">28.71</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">617,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (December&#160;2017) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">28.71</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">122,040</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (during 2018) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">37.05</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">170,496</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (February&#160;2019) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">42.57</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">7,956</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (September&#160;2019) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">56.35</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">54,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (October&#160;2019) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">56.97</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">150,660</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (December&#160;2020) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">56.75</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">193,064</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (April&#160;2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">45.31</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,655</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (June&#160;2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">40.86</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">62,147</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (December&#160;2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">19.22</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">435,165</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 5.38 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (March&#160;2022) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">13.46</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">35,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 2.96 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (June&#160;2022) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8.85</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">10,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 1.83 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (June&#160;2022) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8.85</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">10,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 1.83 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (June&#160;2022) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8.85</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">45,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 1.83 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (September&#160;2022) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10.46</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">11,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 2.42 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (December&#160;2022) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10.95</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 2.23 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (December&#160;2022) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10.95</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">330,612</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:44.26pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 2.23 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 2.75pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted at December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,743,093</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:44.26pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.75pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants exercisable at December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,988,106</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:44.26pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:14.19pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following schedule specifies the outstanding warrants as at December&#160;31, 2021: </font>
        </div>
        <table style="width:456pt;height:234.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Outstanding program </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per warrant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">grant date </font>
                <br >
                <font style="letter-spacing:-0.16pt;">fair value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(DKK) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">warrants</font>
                <br >
                <font style="letter-spacing:-0.16pt;">outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">exercise price</font>
                <br >
                <font style="letter-spacing:-0.16pt;">per warrant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(DKK) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">term to</font>
                <br >
                <font style="letter-spacing:-0.16pt;">maturity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (December&#160;2016) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">20.91</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">701,356</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (September&#160;2017) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">28.71</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">617,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (December&#160;2017) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">28.71</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">122,040</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (during 2018) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">37.05</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">174,564</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (February&#160;2019) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">42.57</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">7,956</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (September&#160;2019) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">56.35</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">54,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (October&#160;2019) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">56.97</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">150,660</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (December&#160;2020) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">56.75</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">317,457</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (April&#160;2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">45.31</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,655</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (June&#160;2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">40.86</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">62,147</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:44.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (December&#160;2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">19.22</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">523,599</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:44.26pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 5.38 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:7.5pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,732,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:44.26pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants exercisable at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,732,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.26pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The following schedule specifies the outstanding warrants as at December&#160;31, 2020: </font>
        </div>
        <table style="width:456pt;height:202.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Outstanding program </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per warrant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">grant date </font>
                <br >
                <font style="letter-spacing:-0.16pt;">fair value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(DKK) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">warrants</font>
                <br >
                <font style="letter-spacing:-0.16pt;">outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">exercise price</font>
                <br >
                <font style="letter-spacing:-0.16pt;">per warrant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(DKK) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">term to</font>
                <br >
                <font style="letter-spacing:-0.16pt;">maturity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (December&#160;2016) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">20.91</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">712,332</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (April&#160;2017) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">24.05</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">13,896</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (September&#160;2017) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">28.71</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">617,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (December&#160;2017) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">28.71</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">127,044</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (during 2018) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">37.05</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">181,836</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (February&#160;2019) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">42.57</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">7,956</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (September&#160;2019) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">56.35</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">54,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (October&#160;2019) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">56.97</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">150,660</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant (December&#160;2020) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">56.75</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">363,168</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,228,076</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:7.5pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:248.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants exercisable at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.34pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The Board of Directors and Executive Management holding of share awards for the&#160;years ended December&#160;31, 2020, 2021 and 2022 is shown below: </font>
        </div>
      </div>
      <div style="margin-top:12pt;margin-bottom:12pt;margin-left:27.16pt;width:541pt;">
        <table style="width:541pt;height:298.53pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
          <tr style="line-height:6.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:113.65pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.85pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.12pt;">January&#160;1,</font>
                <br >
                <font style="letter-spacing:-0.12pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.85pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.12pt;">Warrants </font>
                <br >
                <font style="letter-spacing:-0.12pt;">held when </font>
                <br >
                <font style="letter-spacing:-0.12pt;">becoming </font>
                <br >
                <font style="letter-spacing:-0.12pt;">or leaving as </font>
                <br >
                <font style="letter-spacing:-0.12pt;">a member of </font>
                <br >
                <font style="letter-spacing:-0.12pt;">management </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.85pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.12pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.85pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.12pt;">Forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.85pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.12pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.12pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.85pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.12pt;">Warrants </font>
                <br >
                <font style="letter-spacing:-0.12pt;">held when </font>
                <br >
                <font style="letter-spacing:-0.12pt;">becoming </font>
                <br >
                <font style="letter-spacing:-0.12pt;">or leaving as </font>
                <br >
                <font style="letter-spacing:-0.12pt;">a member of </font>
                <br >
                <font style="letter-spacing:-0.12pt;">management </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.85pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.12pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.85pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.12pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.85pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.12pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.12pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.85pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.12pt;">Warrants </font>
                <br >
                <font style="letter-spacing:-0.12pt;">held when</font>
                <br >
                <font style="letter-spacing:-0.12pt;">becoming </font>
                <br >
                <font style="letter-spacing:-0.12pt;">or leaving as </font>
                <br >
                <font style="letter-spacing:-0.12pt;">a member of </font>
                <br >
                <font style="letter-spacing:-0.12pt;">management </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.85pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.12pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.85pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.12pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.85pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.12pt;">Forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.85pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.12pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.12pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.24pt 0pt 2.71pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Thomas William Wylonis (former)</font><font style=" position:relative; bottom:2.5pt;font-size:4.5pt;letter-spacing:0.09pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">342,612</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">(369,252<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">26,640</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">369,252</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">369,252</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">(184,626<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">184,626</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.49pt 0pt 2.71pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Steven Projan </font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">24,436</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">18,612</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">42,048</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,583</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">46,631</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">51,631</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.49pt 0pt 2.71pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Roberto Prego </font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">19,800</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">14,364</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">34,164</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,583</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">38,747</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.71pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">43,747</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.48pt 0pt 2.72pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Jo Ann Suzich (former) </font><font style=" position:relative; bottom:2.5pt;font-size:4.5pt;letter-spacing:0.09pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10,260</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,260</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,260</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10,260</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.48pt 0pt 2.72pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Marianne S&#248;gaard </font><font style=" position:relative; bottom:2.5pt;font-size:4.5pt;letter-spacing:0.09pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">65,952</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">28,368</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">94,320</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">9,167</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">103,487</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10,000</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.48pt 0pt 2.72pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">113,487</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.47pt 0pt 2.73pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Helen Boudreau (former) </font><font style=" position:relative; bottom:2.5pt;font-size:4.5pt;letter-spacing:0.09pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,436</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,436</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">(5,436<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.47pt 0pt 2.73pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Kim Bj&#248;rnstrup (former) </font><font style=" position:relative; bottom:2.5pt;font-size:4.5pt;letter-spacing:0.09pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">5,868</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,868</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,868</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,868</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,868</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.47pt 0pt 2.73pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Lars Holtug </font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,583</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,583</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.47pt 0pt 2.73pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">9,583</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.46pt 0pt 2.74pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Niels Iversen M&#248;ller </font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,750</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 2.74pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,750</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.46pt 0pt 3.1pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.12pt;">Board of Directors in Total</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">385,848</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">(309,168<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">109,548</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">561,348</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">22,916</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">(5,436<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">578,828</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">28,750</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">(184,626<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.46pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">422,952</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.2pt 0pt 2.75pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Lars Aage Staal Wegner </font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">844,416</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7,668</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">852,084</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">64,167</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">916,251</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">(62,736<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">(45,327<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.2pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">808,188</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.45pt 0pt 2.75pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Birgitte R&#248;n&#248; </font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">29,376</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">45,000</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">74,376</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">99,376</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.45pt 0pt 2.75pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Thomas Bogenrieder (former) </font><font style=" position:relative; bottom:2.5pt;font-size:4.5pt;letter-spacing:0.09pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">49,572</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">(4,356<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">(45,216<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,356</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,356</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.45pt 0pt 2.75pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,356</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.44pt 0pt 2.76pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Erik Heegaard </font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">97,564</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">97,564</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">122,564</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.44pt 0pt 2.76pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Glenn S. Vraniak (former) </font><font style=" position:relative; bottom:2.5pt;font-size:4.5pt;letter-spacing:0.09pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">150,660</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">150,660</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">150,660</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">(112,995<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.44pt 0pt 2.76pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">37,665</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.43pt 0pt 2.77pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Andreas Holm Mattsson </font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">35,000</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">35,000</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.43pt 0pt 2.77pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Bo Karmark </font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">45,000</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">16,667</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">61,667</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.43pt 0pt 2.77pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Jesper Nyegaard Nissen </font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">20,833</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.43pt 0pt 2.77pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">45,883</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.42pt 0pt 2.78pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Niels Iversen M&#248;ller </font><font style=" position:relative; bottom:2.5pt;font-size:4.5pt;letter-spacing:0.09pt;">(8)</font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,125</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 2.78pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,125</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.42pt 0pt 3.1pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.12pt;">Per Norl&#233;n </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,125</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.42pt 0pt 3.1pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">53,125</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6pt;">
            <td style="padding:3.16pt 0pt 3.85pt 0pt; width:113.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.12pt;">Executive Management in total</font>
              </div>
            </td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,044,648</td>
            <td style="padding:0pt;padding-left:1.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">(4,356<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">(45,216<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,007,100</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">29,376</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">206,731</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,243,207</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">120,000</td>
            <td style="padding:0pt;padding-left:5.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">128,750</td>
            <td style="padding:0pt;padding-left:0.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">(175,731<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">(45,327<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt; width:1.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.16pt 0pt 3.1pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,270,899</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Former board member until June&#160;30, 2020, 252 warrants were granted for services provided after retirement from the Board of Director position. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F-31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:10pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:10pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">As of November&#160;25, 2020, 26,964 warrants were granted for services provided before taking on the Board of Directors position. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:5.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:5.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Former board member from June&#160;30, 2020 to May&#160;25, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:5.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:5.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Former board member from June&#160;30, 2020 to November&#160;4, 2020. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:5.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:5.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Part of Executive Management until March&#160;31, 2020. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:5.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:5.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Vraniak resigned as the Chief Financial Officer of the Company effective November&#160;1, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:5.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:5.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Board member until May&#160;25, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:5.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:5.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Became a Board member in 2022. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 9. Financial Income and Expenses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:217pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.3pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:297.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.99999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:297.3pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Financial income: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.3pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income, bank </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.3pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">395</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:297.3pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Foreign exchange gains </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,423</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,039</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">216</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:297.3pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total financial income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,831</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,039</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">216</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.3pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Financial expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.3pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;<br >&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(34<font style="position:absolute;">)</font><br >(<font style="position:absolute;">5)</font></td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(29<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.3pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expenses, lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(176<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(123<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.3pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expenses, loan from lessor </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(588<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(31<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:297.3pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Foreign exchange losses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(710<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(756<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(194<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:297.3pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total financial expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,508<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(915<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(223<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:297.3pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net financial items </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,323</td>
            <td style="padding:0pt;padding-left:0.310000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,124</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(7<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.49pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 10. Income Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">(a) Analysis of charge/(credit) for the year:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:66pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302.3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302.3pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:302.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:302.3pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax expense/(benefit) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(772<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(178<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,557<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:302.3pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total income taxes for the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(772<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(178<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,557<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.5pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;31, 2022, the Company had tax loss carry-forwards in Denmark of $13.6&#160;million (2021: $9.5&#160;million in Denmark; 2020: $3.8&#160;million in Denmark) for income tax purposes, all of which can be carried forward infinitely according to Danish Corporate Income Tax Act. As of December&#160;31, 2022, the Company did not have any tax loss carry-forwards in any other tax jurisdictions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The benefit from income taxes for each year includes a tax credit for research and development expenditures at the applicable tax rate under the Danish Tax Assessment Act and Australian tax legislation, respectively. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:46.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">(b) Reconciliation of effective tax rate to Danish statutory tax rate</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:142.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:314.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:314.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Statutory corporate income tax rate in Denmark </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">22<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">22<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">22<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Difference in corporate income tax rate in subsidiaries </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Non-deductible income / (expenses) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Non-taxable income / (expenses) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additional tax deduction R&amp;D expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Tax credit research and development expenditures </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Change in deferred tax asset not capitalized </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(16<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(23<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(25<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total effective tax rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">(c) Deferred tax in the statements of financial position</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:141pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:276.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:276.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:276.89pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:276.89pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Deferred Tax Positions: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">739</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,118</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,289</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss carry forward </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">13,581</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,530</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3,759</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expenditures </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">262</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other items </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(214<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;<br >&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(98<font style="position:absolute;">)</font><br >(<font style="position:absolute;">6)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:276.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Deferred tax assets not recognized </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(14,106<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,550<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(8,042<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:276.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total Deferred Tax </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">262</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Deferred tax attributable to research and development expenditures relates to development costs recognized as an expense in the consolidated financial statements in 2020 and are tax deductible in 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under Danish tax legislation, the value of warrants to employees is income tax exempt subject to meeting certain conditions. The value of income tax exempt warrants is not tax deductible for the issuer. There is currently uncertainty in respect of the extent to which the conditions for being tax exempt are met and consequently the extent to which a tax deduction will be available for the company. Consequently, the deferred tax asset disclosed above is subject to uncertainty and there is a risk that the amount disclosed above is not tax deductible in full. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 11. Basic and Diluted Loss Per Share</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Basic loss per share is calculated by dividing the net loss attributable for the year to shareholders of Evaxion Biotech A/S by the weighted average number of ordinary shares outstanding during the year. As net losses from continuing operations were recorded in the&#160;years 2022, 2021 and 2020, the dilutive potential shares are anti-dilutive for the earnings per share calculation. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <table style="width:456pt;height:120pt;margin-top:12pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:227.96pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:227.96pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:227.96pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands, except share amounts and per share amounts) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:227.96pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Loss per share before and after dilution</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:227.96pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Net loss attributable to shareholders of Evaxion Biotech A/S </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(23,169<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(24,532<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(15,018<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:227.96pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted-average number of ordinary shares outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">23,638,685</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">19,493,143</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">15,434,758</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:227.96pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Loss per share before and after dilution</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(0.98<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(1.26<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(0.97<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following potential shares are anti-dilutive and are therefore excluded from the weighted average number of shares for the purpose of diluted loss per share: </font>
        </div>
        <table style="width:416pt;height:37pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:258.76pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:258.76pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:258.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,743,093</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,732,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,228,076</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 12. Intangible Assets</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2020, the Company entered into a license agreement for the rights to certain intellectual properties. Upon execution of the license agreement, the Company was obligated to make a milestone payment of $35,000. The agreement remains in effect until the Company completes a Phase&#160;I/IIa clinical study, after that the Company has an option to extend the agreement for an additional 10-year term. Over the initial term of the agreement, the Company is obligated to make various additional milestone payments based on the progress of developed drug candidates. The Company determined that the milestone payments meet the definition of intangible assets and will be capitalized. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the twelve&#160;months ended December&#160;31, 2020, the Company capitalized $35,000 as intangible assets for the acquisition of a non-exclusive technology license. Subject to meeting certain development milestones, additional consideration of up to $320,000 is to be transferred to the seller. Further, $250,000 is to be transferred to the seller upon each regulatory approval of an Evaxion product utilizing the in-licensed technology. As of December&#160;31, 2020, the Company accrued for an additional $60,000 related to the license. The Company did not recognize any amortization expense for the&#160;years ended December&#160;31, 2021 and 2020 as the asset has not been put in use. No intangible assets were recognized in earlier periods as the Company&#8217;s expenditures did not qualify for capitalization. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the twelve&#160;months ended December&#160;31, 2020, the Company capitalized $60,000 as intangible assets for the acquisition of a non-exclusive technology license from SSI. Subject to successful commercialization of any Evaxion product utilizing the in-licensed technology, Evaxion is required to pay to the seller a royalty on net sales in the low teens. In the event any Evaxion product utilizing the in-licensed technology are commercialized by one of the Company&#8217;s partners, Evaxion is required to pay to the seller a&#160;percentage of any out-licensing revenue earned by the Company or its affiliates. If Evaxion enters into a sublicense agreement with a partner subsequent to the initiation of a Phase&#160;2 clinical trial, Evaxion is required to pay to the seller a&#160;percentage of any sublicensing income in an amount in the lower double-digit range. If Evaxion enters into a sublicense agreement with a partner subsequent to the initiation of a Phase&#160;3 trial, Evaxion is required to pay to the seller a&#160;percentage of any sublicensing income in the lower double-digit range. If Evaxion enters into a sublicense agreement with a partner without initiating a Phase&#160;2 trial, Evaxion is required to pay to SSI a&#160;percentage of any sublicensing income in the mid double-digit range. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company did not recognize any amortization expense for the year ended December&#160;31, 2021 as the asset has not been put in use. During the year ended December&#160;31, 2022 the Company wrote-off $87k of its intangible assets balance as the Company does not expect the non-exclusive technology licenses to be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">available for use in the foreseeable future. As of December&#160;31, 2022 the carrying amounts of the Company&#8217;s intangible assets were wrote-off to zero. </font>
        </div>
        <table style="width:416pt;height:157.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.52pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Intangible</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:338.52pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">93</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">93</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additions during the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange rate adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(6<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(6<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost at December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">87</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">87</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Amortization at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Impairment for the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(87<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(87<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange rate adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 2pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Amortization at December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(87<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(87<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying amount at December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.390000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:416pt;height:157.5pt;margin-left:20pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.42pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Intangible</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.42pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:338.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:338.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additions during the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:338.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange rate adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(7<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(7<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:338.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">93</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">93</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:338.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Amortization at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:338.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Amortization for the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:338.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange rate adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 2pt 0pt; width:338.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Amortization at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:338.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying amount at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">93</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">93</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 13. Property and Equipment, Net</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:200.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:268.91pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Property </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Leasehold</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Improvements </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:268.91pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,756</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,225</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,567</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,548</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additions during the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">220</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">156</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">376</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Disposals during the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 0.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange rate adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(163<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(77<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(91<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(331<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost at December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,593</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,368</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,632</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,593</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(155<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(161<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(58<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(374<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation for the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(234<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(196<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(141<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(571<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation revaluation during the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 0.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange rate adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 0.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation at December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(369<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(352<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(197<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(918<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying amount at December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,224</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,016</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,435</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,675</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.75pt 0pt; width:268.91pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Carrying amount of right-of-use assets at December&#160;31, </font>
                <br >
                <font style="letter-spacing:0.2pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,224</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,224</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:68.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <table style="width:456pt;height:226.5pt;margin-top:12pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:268.91pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Property </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Leasehold</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Improvements </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:268.91pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">257</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">263</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">520</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additions during the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,891</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,025</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,634</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,550</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Disposals during the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(244<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(244<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange rate adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(148<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(63<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(67<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(278<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,756</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,225</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,567</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,548</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(237<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(62<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(299<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation for the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(179<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(105<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(59<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(343<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation reversed on disposals during the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">244</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">244</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange rate adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(155<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(161<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(58<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(374<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:268.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying amount at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,601</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,064</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,509</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,174</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:268.91pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Carrying amount of right-of-use assets at December&#160;31, </font>
                <br >
                <font style="letter-spacing:0.2pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,601</td>
            <td style="padding:0pt;padding-left:0.859999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,601</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Depreciation included in the statement of comprehensive loss: </font>
        </div>
        <table style="width:416pt;height:96pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:314.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:314.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:314.89pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">446</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">270</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">90</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">125</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">73</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total depreciation included in the statement of comprehensive loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">571</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">343</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">105</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:314.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total accumulated depreciation of right-of-use assets at December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">369</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">155</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">236</td>
            <td style="padding:0pt;padding-left:0.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 14. Prepayments and other receivables</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:96pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:336.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">VAT receivables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">287</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">387</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Prepayments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,494</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">638</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other receivables </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">113</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total prepayments and other receivables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,791</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,138</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The increase in prepayments derives from upfront payments made in relation to planned clinical trials. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 15. Other Payables</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:81pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.53pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.53pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:338.53pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:338.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Employee cost liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">353</td>
            <td style="padding:0pt;padding-left:1.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">989</td>
            <td style="padding:0pt;padding-left:1.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.44pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">312</td>
            <td style="padding:0pt;padding-left:1.44pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.44pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">46</td>
            <td style="padding:0pt;padding-left:1.44pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:338.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total other payables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">665</td>
            <td style="padding:0pt;padding-left:1.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,035</td>
            <td style="padding:0pt;padding-left:1.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:15.51pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 16. Cash and Cash Equivalents</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:66pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:326.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:326.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:326.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:326.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">13,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">32,166</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:326.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">13,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">32,166</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Cash and cash equivalents consist mainly of cash on deposit with banks. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Changes in Net Working Capital</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:96pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290.22pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:290.22pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Changes in receivables and tax receivables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,486<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,863</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,501<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Changes in trade payables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(599<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(647<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,798</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:290.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Changes in other payables </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(792<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">21</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">918</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:290.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Changes in net working capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,877<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,237</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">215</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.01pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Working capital is defined as current assets (excluding cash) less current liabilities and measures the net liquid assets the Company has available for the business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Adjustments for non-cash items</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Adjustments of non-cash items in the statements of comprehensive loss: </font>
        </div>
        <table style="width:456pt;height:170.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:314.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:314.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:314.89pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(772<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(178<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,557<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Tax credit schemes accounted for as grants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(226<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(12<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(510<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">571</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">344</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">105</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Impairment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">87</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(13<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">798</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">159</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share-based compensation expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">942</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,379</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3,408</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Acquisition of property, plant and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(90<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Gain in change from fair value of warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(395<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <table style="width:444pt;height:78pt;margin-left:6pt;margin-top:12pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:314.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:314.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:314.89pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:1.917pt 0pt 1.833pt 0pt; width:314.89pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Other adjustments: Other adjustments, primarily exchange rate adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,315<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,061<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">107</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.833pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total adjustments for non-cash items </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(323<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">541</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,583</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="20">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Reconciliation of Liabilities from Financing Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:90pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:110.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Cash </font>
                <br >
                <font style="letter-spacing:-0.16pt;">flows </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">interest </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transaction</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Additions </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exchange rate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">adjustment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:110.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,520</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(305<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">176</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.225pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.225pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.415pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:8.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(151<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,255</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:110.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Borrowings </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,170</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7,730</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">524</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.225pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,117<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.225pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.415pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">84</td>
            <td style="padding:0pt;padding-left:8.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(391<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,000</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:110.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Provisions </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">153</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.225pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.225pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.415pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.415pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(9<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.583pt 0pt; width:110.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Total liabilities from financing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,843</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7,425</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">700</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.225pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,117<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.225pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.415pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">99</td>
            <td style="padding:0pt;padding-left:8.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(551<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,399</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:90pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:115.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Cash </font>
                <br >
                <font style="letter-spacing:-0.16pt;">flows </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">interest </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transaction</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Additions </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exchange rate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">adjustment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:115.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(226<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">123</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.745pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:9.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,731</td>
            <td style="padding:0pt;padding-left:2.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(128<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,520</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:115.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Borrowings </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">31</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.745pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,269</td>
            <td style="padding:0pt;padding-left:2.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(130<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,170</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:115.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Provisions </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.745pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.745pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.06pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">161</td>
            <td style="padding:0pt;padding-left:2.06pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(8<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">153</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.583pt 0pt; width:115.36pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Total liabilities from financing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(226<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">154</td>
            <td style="padding:0pt;padding-left:11.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.745pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.06pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,161</td>
            <td style="padding:0pt;padding-left:2.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(266<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,843</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 17. Leases</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Leases</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a result of the lease accounting of IFRS 16, the Company has capitalized the only right-of-use asset being the domicile lease. Upon implementation on January&#160;1, 2018, the Company has recognized a liability to make lease payments (i.e. the lease liabilities) of $0.2&#160;million and an asset representing the right to use the underlying asset during the lease term (i.e. the right-to-use asset) of $0.2&#160;million. The liability was measured at the present value of the remaining lease payments, discounted using the lessee&#8217;s incremental borrowing rate as of the standard adoption date of January&#160;1, 2018. The Company applied an incremental borrowing rate of 3.8%. For the&#160;years ended December&#160;31, 2020, 2021 and 2022, the expense related to variable lease payments not included in the lease liabilities was immaterial and was recognized in operating expense. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2020, the Company entered into a lease for approximately 1,356 square meters, which is allocated on 839 square meters of office space, and 518 square meters of laboratory space in H&#248;rsholm, Denmark. The commencement date for the lease of the 839 square meters of office space was February&#160;1, 2021 and the lease continues for a term of 10&#160;years from that date. The commencement date for the additional laboratory space was August&#160;13, 2021 and the lease continues for a term of 10&#160;years with a subsequent 12-month cancellation notice period. The lease agreement contains an early termination provision which would trigger a termination fee of $2.7&#160;million. As of December&#160;31, 2022 the monthly payment is approximately $26,000 which consists of approximately $11,000 for the office space and approximately $15,000 for the laboratory space. Throughout the term, the lease is subject to annual increases ranging from two to four&#160;percent on the annual lease payment amount. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company had one operating lease in Copenhagen, Denmark as of December&#160;31, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We also occupied an office space in New York, New York, United States. The terms of the lease agreement included a 13 month occupancy period from January&#160;2, 2020 through January&#160;31, 2021. A termination notice was provided in November&#160;2020 and the lease and occupancy terminated on January&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For the&#160;years ended December&#160;31, 2022, 2021 and 2020, the expense related to variable lease payments not included in the lease liabilities was immaterial and was recognized in operating expense. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Set out below are the carrying amounts of the Company&#8217;s right-of-use assets and lease liabilities and the movements during the period: </font>
        </div>
        <table style="width:416pt;height:136.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:325.76pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:32.82pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Right-of-</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Use Asset </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:33.42pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Lease </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:325.76pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:325.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">At December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,601</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,520</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:325.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additions </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:325.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(214<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:325.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest Expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">176</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:325.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(305<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:325.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Translation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(163<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(151<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:325.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">At December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,224</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,255</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:416pt;height:136.5pt;margin-left:20pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:325.76pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:32.82pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Right-of-</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Use Asset </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:33.42pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Lease </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:325.76pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:325.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">At December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:325.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additions </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,891</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,731</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:325.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(179<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:325.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest Expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">123</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:325.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(226<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:325.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Translation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(131<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(128<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:325.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">At December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,601</td>
            <td style="padding:0pt;padding-left:2.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,520</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The total cash outflow for leases was $0.3&#160;million in 2022, $0.2&#160;million in 2021, and $0.2&#160;million in 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 18. Borrowings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Loan from Lessor</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2020, the Company entered into a lease for approximately 1,356 square meters, which is allocated on 839 square meters of office space, and 518 square meters of laboratory space in H&#248;rsholm, Denmark. In addition to the ordinary lease payments, the Company obtained financing from DTU Science Park A/S (&#8220;DTU&#8221;) for rebuilding the laboratory facility and engineering building to match the Company&#8217;s needs. The Company will repay the $1.3&#160;million financing at a fixed interest rate of 6% over 8&#160;years. If the lease is terminated due to default by the Company before the outstanding balance, including interest accrued, has been repaid, the remaining balance is due immediately. The finance liability is recorded at amortized cost, which approximates fair value at the time of issuance. As of December&#160;31, 2022, the Company is still in discussions with DTU on the actual costs incurred. For the&#160;years ended December&#160;31, 2022 and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:19pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2021 interest expense related to the loan from lessor was $0.2&#160;million and $nil, respectively. During the year ended December&#160;31, 2022 the Company had additions for borrowings related to the loan from lessor of $0.1&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a result of the structure of the DTU financing this amount is not included as </font><font style="font-style:italic;letter-spacing:0.2pt;">Purchase of property, plant and equipment</font><font style="letter-spacing:0.2pt;"> within the consolidated statements of cash flows. The leasehold improvements recognized will be subject for adjustment when the actual costs incurred are made available from DTU. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">EIB Loan</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2020, the Company executed the EIB Loan, for a principal amount of &euro;20.0&#160;million, divided into three tranches of tranche 1 in the amount of &euro;7.0&#160;million, tranche 2 in the amount of &euro;6.0&#160;million and tranche 3 in the amount of &euro;7.0&#160;million. Under the EIB Loan Agreement, the tranche balances are due six&#160;years from their respective disbursement dates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2021, the Company initiated the draw of the first tranche of the EIB Loan Agreement. The Company received the proceeds from the draw of the first tranche of &euro;7.0&#160;million (approximately $7.8&#160;million) on February&#160;17, 2022. The Company will repay the first tranche of the EIB Loan at a fixed interest rate of 3% per annum and a payment-in-kind interest rate of 4% per annum. The loan is amortized to maturity using an effective monthly interest rate of 0.78%.For the&#160;years ended December&#160;31, 2022 and 2021 interest expense related to the EIB Loan was $0.6&#160;million and $nil, respectively. The loan is repayable in full six&#160;years after drawing down. Under the present business plans the Company cannot draw the remaining two tranches of the loan. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Borrowings are summarized as follows (in thousands): </font>
        </div>
        <table style="width:416pt;height:98pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loan from lessor </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,068</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,170</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">EIB Loan </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">6,932</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total Borrowings </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,170</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Less: Borrowings, current portion </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(136<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(126<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:336.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total Borrowings, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7,864</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,044</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 19. Warrant Liability</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company received the proceeds from the draw of the first tranche of the EIB Loan on February&#160;17, 2022. In connection therewith, EIB received 351,036 EIB Warrants, at an exercise price of DKK 1 per warrant, which vested immediately, pursuant to the terms of a separate warrant agreement, the EIB Warrant Agreement.The EIB Warrants are exercisable at any time after issuance either net in cash or through payment of the exercise price and receipt of shares. Therefore, the warrant liability is recognized in full upon issuance. The liability is measured initially at its fair value and is subsequently remeasured at the redemption amount. The liability is classified in level 1 of the fair value hierarchy. Due to the fact that the exercise price is insignificant compared to the share price, there is virtually no time value. Consequently, the present value of the redemption amount is equal to the current share price. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As the warrant liability is a non-cash financing cost the amount related to the initial recognition of the warrant liability is not included within the consolidated statements of cash flows. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the changes to the warrant liability: </font>
        </div>
        <table style="width:416pt;height:97.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.52pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Warrant Liability </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:338.52pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying amount at January&#160;1, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.52pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Initial recognition of warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,007</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.52pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Remeasurement of warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(395<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.52pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Foreign currency translation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(39<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying amount at December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">573</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.7pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 20. Capital Structure and Financial Matters</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Share Capital&#8201;&#8212;&#8201;Ordinary Shares</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Capital transactions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2020, the Company issued 745,380 shares of ordinary shares to existing investors in the Company. The purchase price was $8.89 per share for aggregate proceeds of $6.6&#160;million. The Company incurred immaterial issuance costs. The proceeds were received by the Company on September&#160;17, 2020. On August&#160;10, 2020, the Company&#8217;s articles of association were amended in connection with the execution of this transaction. The revised articles increased the authorized number of shares the Company can issue by: (i)&#160;the 745,380 shares issued in this transaction, as well as (ii)&#160;an additional 1,800,000 shares of Common ordinary share at a nominal price of DKK 1, to be issued any time prior to June&#160;1, 2025. The amended articles also allow the Company to issue an additional 1,298,196 of compensatory ordinary share warrants to employees and consultants any time prior to June&#160;1, 2025. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2020, the Company successfully completed part 2 of its &#8220;bridging round&#8221; of capital with outside investors in the amount of $2.4&#160;million with a purchase price of $8.89 per share from the issuance of 269,136 of the Company&#8217;s ordinary shares and received the proceeds in November&#160;2020. Transaction costs directly attributable to the third quarter of 2020 &#8220;bridging round&#8221; of capital with outside investors have a total amount of $144,022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2021, the Company completed its IPO through which the Company issued and sold 3,000,000 American Depositary Shares, or ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. The Company received aggregate net proceeds of $25.3&#160;million from the IPO, after deducting the underwriting discounts and commissions and offering expenses. Upon the completion of the IPO, our registered, issued, and outstanding share capital was nominal DKK 19,198,668. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2021, the Company completed a follow-on public offering through which the Company issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November&#160;5, 2021. The Company received aggregate net proceeds of $24.9&#160;million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Upon the completion of the follow-on public offering, the Company&#8217;s registered, issued, and outstanding share capital was nominal DKK 23,141,524. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Lincoln Park Purchase Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;7, 2022, the Company entered into the Purchase Agreement, with Lincoln Park, pursuant to which the Company may elect to sell up to $40.0&#160;million in the Company&#8217;s ordinary shares, DKK 1 nominal value, represented by ADSs, with each ADS representing one (1)&#160;ordinary share of the Company, subject to certain limitations and conditions set forth in the Purchase Agreement. In addition, upon execution of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Purchase Agreement, the Company paid a commitment fee in the form of 428,572 ordinary shares at a price of $2.80 per share, for a total commitment fee of $1.2&#160;million (the &#8220;Commitment Fee&#8221;). Under the Purchase Agreement, the Company may from time to time, at its discretion, direct Lincoln Park to purchase on any single business day, or a regular purchase, up to 50,000 ordinary shares represented by ADSs which may be increased to 70,000 ordinary shares represented by ADSs under certain circumstances set forth in the Purchase Agreement over the 36 month term of the Purchase Agreement. The purchase price of the ordinary shares represented by ADSs will be based upon the prevailing market price of the ADSs at the time of the purchase without any fixed discount. In addition, the Company may direct Lincoln Park to purchase additional amounts as accelerated purchases and additional accelerated purchases under certain circumstances. The Company is not obligated to sell any ordinary shares represented by ADSs pursuant to the Purchase Agreement and will control the timing and amount of any such sales, but in no event will Lincoln Park be required to purchase more than $1.5&#160;million in ordinary shares represented by ADSs in any single regular purchase. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;7, 2022, the Company filed a &#8220;selling shareholder&#8221; registration statement with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to the Purchase Agreement with Lincoln Park as the selling shareholder, through which the Company registered 4,649,250 ordinary shares represented by ADSs for resale to the public by Lincoln Park. Each ADS represents one ordinary share. The Company will not receive any proceeds from the resale of ADSs by Lincoln Park, however, assuming that the Company sells the full amount of its ordinary shares represented by ADSs to Lincoln Park, under the Purchase Agreement the Company may receive up to $40.0&#160;million in aggregate proceeds. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2022, the Company had issued and sold 428,572 ordinary shares represented by ADSs to Lincoln Park. Such shares were issued to Lincoln Park as payment of the Commitment Fee in consideration for Lincoln Park&#8217;s&#8217; commitment to purchase our ordinary shares represented by ADSs under the Purchase Agreement. As of such date, the Company had not issued or sold any additional ordinary shares represented by ADSs to Lincoln Park under the Purchase Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;3, 2022 the Company entered into an At-The-Market Issuance Sales Agreement with JonesTrading Institutional Services LLC (&#8220;JonesTrading&#8221;) under which the Company could sell up to an aggregate of $14.4&#160;million of its ordinary shares represented by ADSs. The Company agreed to pay JonesTrading commission equal to 3% of the gross proceeds of the sales price of all ADSs sold through them as sales agent under the Sales Agreement. The offering of the Company&#8217;s ADSs pursuant to the Sales Agreement will terminate on the earliest of (1)&#160;the sale of all of the ordinary shares subject to the Sales Agreement, or (2)&#160;termination of the Sales Agreement by the Company or JonesTrading. The Company and JonesTrading may terminate the sales agreement at any time upon ten days prior notice. JonesTrading may terminate the Sales Agreement at any time in certain circumstances, including the occurrence of a material adverse change that, in their judgment, may make it impracticable or inadvisable to market or sell the Company&#8217;s ADSs or a suspension or limitation of trading the Company&#8217;s ADSs on The NASDAQ Capital Market. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the period between October&#160;13, 2022 and October&#160;20, 2022 the Company sold 114,403 ADSs representing the Company&#8217;s ordinary shares, DKK 1 nominal value, with each ADS representing one ordinary share, at a volume weighted average price (VWAP) of $2.76 per ADS. The ADSs were sold pursuant to the Sales Agreement with JonesTrading dated October&#160;3, 2022. After deducting fees and expenses, total proceeds to the Company from the sales of the ADSs were approximately $0.3&#160;million. In connection with such sales, the Company registered aggregate share capital increases of nominal DKK 114,403 with the Danish Business Authority. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;29, 2022 the Company sold 4,450 ordinary shares represented by ADSs, DKK 1 nominal value with each ordinary share represented by one ADSs, at a VWAP of $2.24 per ADS. The ordinary shares represented by ADSs were sold pursuant to the Sales Agreement with JonesTrading dated </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">October&#160;3, 2022. Gross proceeds from the sale of ordinary shares represented by ADSs were approximately $9,968. In connection with the sale, the Company registered aggregate share capital increase of nominal DKK&#160;4,450 with the Danish Business Authority. Upon completion of the sale, the Company&#8217;s registered, issued, and outstanding share capital was nominal DKK 24,139,413. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At year end, due to warrant exercise, the outstanding share capital was nominal DKK 24,139,413. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following are changes in the Company&#8217;s share capital for the&#160;years ended December&#160;31, 2020, 2021 and 2022: </font>
        </div>
        <table style="width:456pt;height:349pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Ordinary Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Share Capital</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(DKK in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share capital, December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">15,184,152</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">15,184</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at September&#160;17, 2020 (issuance of shares for cash) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">745,380</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">745</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at October&#160;15, 2020 (issuance of shares for cash) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">269,136</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">269</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share capital, December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">16,198,668</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,198</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at February&#160;9, 2021 (for initial public offering) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,000,000</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,000</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at November&#160;9, 2021 (for follow-on offering) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,942,856</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,943</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase November&#160;2021 (exercised warrants) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">62,284</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">63</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share capital, December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">23,203,808</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">23,204</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase April&#160;2022 (exercised warrants) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">54,072</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">54</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase June&#160;2022 (exercised warrants) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">92,313</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">92</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase June&#160;2022 (exercised warrants) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">37,665</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">38</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at June&#160;7, 2022 (LPC purchase agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">428,572</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">429</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase June&#160;2022 (exercised warrants) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">17,264</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase August&#160;2022 (exercised warrants) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">92,313</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">92</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase August&#160;2022 (exercised warrants) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">41,085</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">41</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase September&#160;2022 (exercised warrants) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10,836</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at October&#160;13, 2022 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">23,405</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">23</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at October&#160;17, 2022 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">26,396</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">26</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at October&#160;20, 2022 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">64,601</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">65</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at December&#160;5, 2022 (exercised warrants) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">42,633</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at December&#160;29, 2022 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">4,450</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share capital, December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">24,139,413</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">24,139</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13.1pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s share capital consists of the following ordinary shares: </font>
        </div>
        <table style="width:416pt;height:93pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:336.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Authorized, issued and fully paid</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 1.833pt 0pt; width:336.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">24,139,413 (2021: 23,203,808) ordinary shares of DKK 1 each (2021: ordinary shares of DKK 1 each) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,886</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,755</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total share capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,886</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,755</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.09pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s ordinary shares shall confer on the holders thereof the right to receive notice of, attend and vote at general meetings of the Company. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Management&#8217;s and Board of Director&#8217;s holding of shares</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At December&#160;31, the board of directors and executive management held the following shareholdings in the Company: </font>
        </div>
        <table style="width:416pt;height:144pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:258.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Number of ordinary shares owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:258.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Per Norl&#233;n </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:258.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bo Karmark </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:258.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jesper Nyegaard Nissen </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:258.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Birgitte R&#248;n&#248; </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:258.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Erik Deichmann Heegaard </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:258.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Andreas Holm Mattsson </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">4,071,961</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">4,163,832</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">4,163,832</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:258.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Niels Iversen M&#248;ller </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">4,292,604</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">4,292,604</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:258.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lars Aage Staal Wegner (former) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">82,124</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">182,124</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">182,124</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:258.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Executive Management in total</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">4,156,085</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">8,638,560</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">8,638,560</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:416pt;height:114pt;margin-left:20pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:274.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Number of ordinary shares owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:274.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Niels Iversen M&#248;ller </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">4,196,840</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Roberto Prego </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">310,248</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">310,248</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">310,248</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Thomas William Wylonis (former) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">485,676</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lars Holtug </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Marianne S&#248;gaard </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">41,652</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">41,652</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">41,652</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:274.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Steven Projan </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">27,288</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">27,288</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">27,288</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:274.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Board of Directors in total</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">4,576,028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">379,188</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">864,864</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.21pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 21. Related Party Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:80.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:324pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">The Company&#8217;s transactions with other related parties:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Balances with related parties at year-end (asset): </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Prepaid rent and deposit for a leased property from a related party </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8199;7</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s related parties are comprised of significant shareholders of the Company, the executive management group, the board of directors and the close members of the family of these persons. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has not granted any loans, guarantees, or other commitments to or on behalf of any of the members in the board of directors or executive management. Other than the remuneration and other transactions relating to the board of directors or executive management and capital increases on the same terms as other investors, no other significant transactions have taken place with the board of directors or executive management for the&#160;years ended December&#160;31, 2022, 2021 and 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 22. Commitments and Contingencies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Legal Proceedings</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;28, 2022, the Company received formal notice that on April&#160;21, 2022, Statens Serum Institut (&#8220;SSI&#8221;), had initiated a legal proceeding against the Company in The Danish Maritime and Commercial </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">High Court (S&#248; og Handelsretten), claiming sole ownership of a patent application (PCT/EP2020/050058 and subsequently national filings, EP3906045), the Company filed related to a method for treating malignant neoplasm by administering a composition comprising a high dose of neopeptides, a solvent and SSI&#8217;s liposomal adjuvant, CAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">09b, for which the Company has a non-exclusive, royalty-bearing sub-licensable license to use from SSI (the &#8220;Invention&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The patent application for the Invention relates solely to the use of the adjuvant CAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">09b in conjunction with a high dose of neopeptides in the Company&#8217;s EVX-01 product candidate. SSI&#8217;s claim to the patent application does not relate to any other aspect of the Company&#8217;s patent portfolio covering EVX-01 or the PIONEER platform technology. The patent application stems from work the Company performed under a collaboration agreement the Company entered into with SSI, DTU, Center for Cancer Immune Therapy (Herlev Hospital) and the Center for Genomic Medicine (Rigshospitalet). The patent application names the Company and certain of the Company&#8217;s employees as the sole invertors of the Invention. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In its filing, SSI&#8217;s primary claim is that the Invention disclosed in the patent application was not made by the Company and its employees, but rather, that SSI and members of its staff made the Invention and, therefore, SSI and certain of its staff members should be listed as the sole inventors of the Invention. In the alternative, SSI claims that it should have co-ownership with the Company of the patent application and the Invention. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">It is the Company&#8217;s position that the Company and its employees are the sole inventors of the Invention. The Company believes that it has strong defenses against SSI&#8217;s claim and that SSI&#8217;s claim is without merit. The Company intends to vigorously defend the action. In any event, even if SSI&#8217;s claim were to be upheld by the court, while no assurance can be given, the Company does not expect that it would have a material impact on its rights to use the Invention in the development and commercialization of EVX-01, as the Company believes that such rights are covered by its current license agreement with SSI and SSI would be excluded from enforcing its rights in the Invention to prevent the Company from developing and commercializing its EVX-01 product candidate. As of December&#160;31, 2022 the opinion of the Company&#8217;s legal counsel is that the ongoing legal proceedings will not have a material impact on the Company&#8217;s future financial results. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2022 the Company and SSI have begun to make written statements to the courts, and this process has been ongoing through the date of issuance of this Form 20-F; whereafter the court will announce official dates for court meetings to take place. The Company and SSI are presently in communication on the Board and Executive Management levels to the resolve the legal dispute through an out of court settlement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Contractual obligations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The contractual obligations are similar individually and, in the aggregate, not material to the future financial position, operating profit or cash flow. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At December&#160;31, 2022, the Company had the following contractual commitments which fall due as follows: </font>
        </div>
        <table style="width:456pt;height:88pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:190.65pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="34">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:190.65pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="34">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:190.65pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Contractual</font>
                <br >
                <font style="letter-spacing:-0.16pt;">cash flows </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">&lt;1 year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">1&#8201;&#8211;&#8201;2&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2&#8201;&#8211;&#8201;5&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">&gt;5&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:190.65pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="34">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:190.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Purchase obligations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.845pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">598</td>
            <td style="padding:0pt;padding-left:2.845pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.385pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">56</td>
            <td style="padding:0pt;padding-left:10.385pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">904</td>
            <td style="padding:0pt;padding-left:7.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.385pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:4.385pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,558</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:190.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.845pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">598</td>
            <td style="padding:0pt;padding-left:2.845pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.385pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">56</td>
            <td style="padding:0pt;padding-left:10.385pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">904</td>
            <td style="padding:0pt;padding-left:7.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.385pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.385pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,558</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The majority of the purchase obligations of $0.8&#160;million relate to CRO&#8217;s as of December&#160;31, 2022. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">At December&#160;31, 2021, the Company had the following contractual commitments which fall due as follows: </font>
        </div>
        <table style="width:456pt;height:88.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:200.82pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="34">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:200.82pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="34">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:200.82pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Contractual</font>
                <br >
                <font style="letter-spacing:-0.16pt;">cash flows </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">&lt;1 year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">1&#8201;&#8211;&#8201;2&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2&#8201;&#8211;&#8201;5&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">&gt;5&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:200.82pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="34">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:200.82pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Purchase obligations </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.33pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:12.33pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">72</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.385pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">72</td>
            <td style="padding:0pt;padding-left:10.385pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.885pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:7.885pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.385pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:4.385pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.265pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">72</td>
            <td style="padding:0pt;padding-left:1.265pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:200.82pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">72</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.385pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">72</td>
            <td style="padding:0pt;padding-left:10.385pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.385pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.385pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">72</td>
            <td style="padding:0pt;padding-left:1.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has purchase obligations of $72&#160;thousand due to CRO&#8217;s and a nominal amount due system provider as of December&#160;31, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 23. Provisions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is required to restore the lease premises of its office and laboratory space in H&#248;rsholm, Denmark to its original condition at the end of the lease term. A provision is recognized for the present value using a discount rate based on the Company&#8217;s risk adjusted incremental borrowing rate of the estimated expenditure required to remove any leasehold improvements. These costs have been capitalized as part of the cost of leasehold improvements and are amortized over the lease term. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Changes in the provision balance during the year ended December&#160;31, 2022 are as follows: </font>
        </div>
        <table style="width:416pt;height:136.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:368.52pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Provisions </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:368.52pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:368.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying amount at January&#160;1, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">153</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:368.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Provisions recognized </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:368.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additions </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:368.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Utilization of provision </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:368.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Change in the provision </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:368.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Currency adjustment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(9<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:368.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying amount at December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:14.2pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Changes in the provision balance during the year ended December&#160;31, 2021 are as follows: </font>
        </div>
        <table style="width:416pt;height:136.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:368.52pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Provisions </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:368.52pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:368.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying amount at January&#160;1, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:368.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Provisions recognized </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">161</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:368.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additions </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:368.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Utilization of provision </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:368.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Change in the provision </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:368.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Currency adjustment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(8<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:368.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying amount at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">153</td>
            <td style="padding:0pt;padding-left:7.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 24. Fees to auditors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table presents the fees to our independent registered public accounting firm, EY Godkendt Revisionspartnerselskab, recognized in general and administrative expenses in the Statement of Profit or Loss for the&#160;years ended December&#160;31, 2022 and 2021. This note was prepared in accordance with the requirements of the Danish Financial Statements Act: </font>
        </div>
        <table style="width:416pt;height:96pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.52pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.52pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:338.52pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Audit fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">172</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">177</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Audit related fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">50</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">108</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other fees </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">156</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">328</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">378</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">613</td>
            <td style="padding:0pt;padding-left:3.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.99pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Audit fees</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Audit fees consist of fees billed for professional services rendered by EY for the audit of our annual consolidated financial statements or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Audit-Related fees</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Audit-related fees consist of assurance and related services performed by EY that are reasonably related to the performance of the audit or review of our consolidated financial statements and are not reported under &#8220;Audit-Related fees.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other fees</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other fees consist of services provided by EY for other permitted services, including fees for work performed by EY in connection with the initial public offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 25. Events After the Reporting Period</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Vaccine Discovery Collaboration Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Effective January&#160;1, 2023 the Company entered into a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech Holding AB&#8217;s affiliate ExpreS2ion Biotechnologies ApS (&#8220;ExpreS2ion&#8221;) for the joint development of a novel cytomegalovirus (CMV) vaccine candidate. During the discovery phase of the collaboration, Evaxion will use its proprietary AI platform, RAVEN, to design a next-generation vaccine candidate that elicits both cellular and humoral/antibody responses. The antigen constructs derived from Evaxion&#8217;s AI platform will be produced by ExpreS2ion in the company&#8217;s ExpreS2 platform, followed by assessments in Evaxion&#8217;s state-of-the-art pre-clinical models. The joint discovery project will be included in Evaxion&#8217;s development pipeline under EVX-V1. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the collaboration, ExpreS2ion will have the exclusive right to license the CMV vaccine candidate under a potential Development and Commercialization Agreement. The research and intellectual property licensing costs for the collaboration project will be divided 50/50 between the parties until 2025, with all costs expected to be contained in each party&#8217;s existing operating expenses. A potential future Development and Commercialization Agreement for the jointly discovered CMV vaccine candidate is expected to include an upfront payment and future milestone payments to Evaxion from ExpreS2ion not exceeding a six-digit USD amount, as well as sub-licensing royalty to Evaxion from ExpreS2ion based on mid </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:448pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">to lower two-digit&#160;percentage range of third-party licensee income depending on the clinical development stage of the CMV asset at the time of sublicensing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Share Issuances After the Reporting Period</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the period between January&#160;1, 2023 and March&#160;3, 2023 the Company sold 2,298,594 ADSs representing the Company&#8217;s ordinary shares, DKK 1 nominal value, with each ADS representing one ordinary shares, at a volume weighted average price (VWAP) of $1.90 per ADS. The ADSs were sold pursuant to the Sales Agreement with JonesTrading dated October&#160;3, 2022. After deducting fees, and expenses, total proceeds to the Company from the sales of the ADSs were approximately $4.2&#160;million. In connection with such sales, the Company registered aggregate share capital increases of nominal DKK 2,298,594 with the Danish Business Authority.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fUCC1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:156.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Unaudited Condensed Consolidated Interim Statements of </font>
          <br >
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Comprehensive Loss</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:402.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:273.85pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands, except per share amounts) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:273.85pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,830</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,068</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">12,983</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,932</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,015</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,215</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">5,756</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">5,762</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">6,083</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">17,833</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">18,739</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Operating loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,762<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,083<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,833<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(18,739<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">72</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">703</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">404</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,761</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(182<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(535<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(786<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(918<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss before tax</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,872<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,915<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(18,215<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,896<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax benefit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">194</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">175</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">613</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">599</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss for the period</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,678<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,740<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,602<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,297<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss attributable to shareholders of Evaxion Biotech A/S</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,678<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,740<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,602<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,297<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 0.833pt 0pt; width:273.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Other comprehensive income that may be reclassified to profit or loss in subsequent periods:</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange differences on translation of foreign operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">7</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(46<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">19</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Tax on other comprehensive income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:273.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 1.833pt 0pt; width:273.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Exchange differences on currency translation to presentation currency </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">84</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,063<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">171</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(3,278<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Other comprehensive income/(loss) for the period, net of tax</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">91</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,051<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">125</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(3,259<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total comprehensive loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,587<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,791<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,477<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(19,556<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:273.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.2pt;">Total comprehensive loss attributable to shareholders of Evaxion Biotech A/S</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,587<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,791<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,477<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(19,556<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:273.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss per share&#8201;&#8211;&#8201;basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(0.21<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(0.24<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(0.66<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(0.69<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:10pt; margin-top:5pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4.8pt; text-align:center; width:456pt; line-height:11pt;font-style:italic;font-size:9.2pt;">
          <font style="letter-spacing:0.184pt;">The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.</font><font style="font-style:normal;font-size:10pt;">&#8203;<font style="letter-spacing:0.2pt;"> </font></font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fUCC2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:26.51pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Unaudited Condensed Consolidated Interim Statements of </font>
          <br >
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Financial Position</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:548.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:310.66pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:16.33pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Note</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:310.66pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">ASSETS</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Non-current assets </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4,312</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4,675</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Government grants receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">22</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">209</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Tax receivables, non-current </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">594</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Leasehold deposits, non-current </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">160</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">156</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total non-current assets</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">5,089</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">5,040</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current assets </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Prepayments and other receivables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,350</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,791</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Unpaid capital contributions </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">117</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">0</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Government grants receivable, current </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">221</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Tax receivables, current </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">781</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">789</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">2,605</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">13,184</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total current assets</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">6,853</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">16,985</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:310.66pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">TOTAL ASSETS</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="font-weight:bold;">11,942</font> </td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="font-weight:bold;">22,025</font> </td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">EQUITY AND LIABILITIES</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">8</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4,415</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,886</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other reserves </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">82,614</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">77,076</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(89,763<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(72,659<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total equity</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(2,734<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">8,303</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Non-current liabilities </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Lease liabilities, non-current </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,856</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,952</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Borrowings, non-current </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">5</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">7,989</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">7,864</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Provisions </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">143</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total non-current liabilities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">9,988</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">9,960</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current liabilities </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Lease liabilities, current </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">311</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">303</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">6</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">252</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">573</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Borrowings, current </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.33pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="letter-spacing:0.2pt;">5</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">150</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">136</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Trade payables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,608</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,085</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other payables </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">1,367</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">665</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total current liabilities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">4,688</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">3,762</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:310.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total liabilities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">14,676</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">13,722</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:310.66pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">TOTAL EQUITY AND LIABILITIES</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:16.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="font-weight:bold;">11,942</font> </td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="font-weight:bold;">22,025</font>
            </td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4.8pt; text-align:center; width:456pt; line-height:11pt;font-style:italic;font-size:9.2pt;">
          <font style="letter-spacing:0.184pt;">The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.</font><font style="font-style:normal;font-size:10pt;">&#8203;<font style="letter-spacing:0.2pt;"> </font></font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fUCC3">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:31.01pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Unaudited Condensed Consolidated Interim Statements of </font>
          <br >
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Changes in Equity</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:249.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:168.45pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:55.68pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Other reserves </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:168.45pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:16.33pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Note </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:27.71pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Share </font>
                <br >
                <font style="letter-spacing:-0.16pt;">capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:32.71pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Share</font>
                <br >
                <font style="letter-spacing:-0.16pt;">premium </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:55.68pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Foreign currency</font>
                <br >
                <font style="letter-spacing:-0.16pt;">translation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">reserve </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:43.26pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:39.87pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:168.45pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Equity at December&#160;31, 2022</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">3,886</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">80,727</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(3,651<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(72,659<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">8,303</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss for the period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,924<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,924<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other comprehensive income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">34</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">34</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share</font><font style="font-style:italic;letter-spacing:0.2pt;">-</font><font style="letter-spacing:0.2pt;">based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-style:italic;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">
              <div style="font-style:italic;">7</div>
            </td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">326</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">326</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of shares for cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-style:italic;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">
              <div style="font-style:italic;">8</div>
            </td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">504</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">5,469</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">5,973</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Transaction costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(176<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(176<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Equity at June&#160;30, 2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">4,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">86,020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(3,618<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(84,257<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,535</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss for the period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(5,678<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(5,678<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other comprehensive income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">87</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">87</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share</font><font style="font-style:italic;letter-spacing:0.2pt;">-</font><font style="letter-spacing:0.2pt;">based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-style:italic;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">
              <div style="font-style:italic;">7</div>
            </td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">172</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">172</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of shares for cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-style:italic;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">
              <div style="font-style:italic;">8</div>
            </td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">129</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">154</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Transaction costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:168.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Equity at September&#160;30, 2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">4,415</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">86,145</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(3,531<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(89,763<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,734<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:279.5pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:168.45pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:55.68pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Other reserves </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:168.45pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:16.33pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Note </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:27.71pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Share </font>
                <br >
                <font style="letter-spacing:-0.16pt;">capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:32.71pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Share</font>
                <br >
                <font style="letter-spacing:-0.16pt;">premium </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:55.68pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Foreign currency</font>
                <br >
                <font style="letter-spacing:-0.16pt;">translation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">reserve </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:43.26pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:39.87pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:168.45pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Equity at December&#160;31, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">3,755</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">80,430</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,316<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(50,432<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">32,437</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss for the period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,559<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(10,559<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other comprehensive income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,205<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(2,205<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share</font><font style="font-style:italic;letter-spacing:0.2pt;">-</font><font style="letter-spacing:0.2pt;">based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-style:italic;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">
              <div style="font-style:italic;">7</div>
            </td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">665</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">665</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of shares for cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-style:italic;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">
              <div style="font-style:italic;">8</div>
            </td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Transaction costs paid in shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">61</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(61<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">0</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Transaction costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(216<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(216<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Equity at June&#160;30, 2022</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">3,844</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">80,153</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(3,521<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(60,326<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(20,150<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss for the period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(5,740<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(5,740<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other comprehensive income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,058<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(1,058<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share</font><font style="font-style:italic;letter-spacing:0.2pt;">-</font><font style="letter-spacing:0.2pt;">based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-style:italic;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">
              <div style="font-style:italic;">7</div>
            </td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">306</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">306</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of shares for cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-style:italic;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">
              <div style="font-style:italic;">8</div>
            </td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Transaction costs paid in shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:168.45pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Transaction costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(130<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(130<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:168.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Equity at September&#160;30, 2022</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">3,864</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">80,023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,579<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(65,760<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.61pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">13,548</td>
            <td style="padding:0pt;padding-left:1.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4.8pt; text-align:center; width:456pt; line-height:11pt;font-style:italic;font-size:9.2pt;">
          <font style="letter-spacing:0.184pt;">The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.</font><font style="font-style:normal;font-size:10pt;">&#8203;<font style="letter-spacing:0.2pt;"> </font></font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fUCC4">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:102.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Unaudited Condensed Consolidated Interim Statements of Cash Flows</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:470.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:359.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:359.93pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Operating activities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss for the period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,602<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(16,297<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Adjustments for non-cash items </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">880</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(1,247<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest received </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">128</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest paid </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(50<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(156<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income taxes paid/received, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">804</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash flow from operating activities before changes in working capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,840<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(17,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Cash flow from changes in working capital:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in net working capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">156</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(2,243<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Net cash used in operating activities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,684<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(19,943<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Investing activities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Purchase of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(88<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(353<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Receipt (payment) of non-current financial assets&#8201;&#8211;&#8201;leasehold deposits </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(6<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Net cash used in investing activities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(94<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(324<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Financing activities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds from issuance of shares and exercise warrants, less underwriter discounts </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,127</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">48</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Transaction costs related to issuance of shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(180<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(355<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds from borrowings </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">65</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">7,933</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Repayment of borrowings </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(334<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(88<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leasing installments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(245<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(231<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Net cash provided by financing activities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">5,433</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">7,307</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net increase/(decrease) in cash and cash equivalents</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,345<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(12,960<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents at January&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">13,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">32,166</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange rate adjustments on cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(234<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(1,353<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Cash and cash equivalents at September&#160;30</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:normal;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">
                <font style="font-weight:bold;">2,605</font> </div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">17,853</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Supplemental disclosure of cash flow information</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Non-cash investing and financing activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Acquisition of property and equipment through loan from lessor </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">65</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4.8pt; text-align:center; width:456pt; line-height:11pt;font-style:italic;font-size:9.2pt;">
          <font style="letter-spacing:0.184pt;">The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.</font><font style="font-style:normal;font-size:10pt;">&#8203;<font style="letter-spacing:0.2pt;"> </font></font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fNTTU">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 1. General Company Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform: AI-Immunology&#8482;. Evaxion&#8217;s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel vaccines for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology&#8482;, Evaxion has developed a clinical stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Evaxion is a public limited liability company incorporated and domiciled in Denmark with its registered office located at Dr.&#160;Neergaards Vej 5f, DK-2970 H&#248;rsholm, Denmark. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The unaudited condensed consolidated interim financial statements of Evaxion Biotech A/S and its subsidiaries (collectively, the &#8220;Group&#8221;) for the three and nine&#160;months ended September&#160;30, 2023 and 2022, were approved, and authorized for issuance, by the Audit Committee of the board of directors on November&#160;13, 2023. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 2. Liquidity and Going Concern Assessment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On December&#160;21, 2023 the company closed a Private Placement related to the issuance and sale of 9,726,898 of the Company&#8217;s ordinary shares, DKK 1 nominal value (&#8220;Ordinary Shares&#8221;), represented by American Depositary Shares (&#8220;ADSs&#8221;), and accompanying warrants (the &#8220;Private Placement Warrants&#8221;) to purchase up to 9,726,898 Ordinary Shares represented by ADSs at a purchase price of $0.544 per Ordinary Share for an aggregate purchase price of $5.3&#160;million. The Private Placement Warrants are exercisable immediately upon issuance, have a term of three&#160;years, and an exercise price equal to $0.707 per Ordinary Share. Each Ordinary Share is represented by one (1)&#160;ADS. The Private Placement was priced at-the-market under Nasdaq rules. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The gross proceeds to the Company from the Private Placement are expected to be $5.3&#160;million, and up to an additional $6.9&#160;million of gross proceeds upon cash exercise of the Private Placement Warrants before deducting offering expenses payable by the Company. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This is an important step in Evaxion&#8217;s long-term funding strategy and will fund operations to the end of March&#160;2024. Cash burn in Q1, 2024 is significantly higher than for the remaining quarters of 2024. The ambition for 2024 is on a full year basis to generate income from collaboration or license agreements equal to 14&#160;million USD to balance expected cash burn in 2024 excluding financing activities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company expects to incur additional losses until such income from business deals, including potential collaborations or licenses is obtained. The losses are planned to be financed through equity offerings, or other capital sources and adjust spending on new and ongoing development and corporate activities, as needed. Based on the current cash position and the forecasted cash requirements, it will require additional financing to fund operations by end of March 2024. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Due to uncertainty of related to the result of future funding activities, the continuing operating losses, expected cash flows, the Company concluded that there is significant doubt about its ability to continue as a going concern through one year from September&#160;30, 2023. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and discharge of its liabilities and commitments in the normal course of business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The matters that raise significant doubt about the Company&#8217;s ability to continue as a going concern also raise substantial doubt as contemplated by the Public Company Accounting Oversight Board (PCAOB) standards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interest of current shareholders could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">rights of the current shareholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises funds through collaborations, licenses and other similar arrangements with third parties, it may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable and/or may reduce the value of our ordinary shares. Failure to raise capital or enter into such other arrangements when needed could have a negative impact on the Company&#8217;s financial condition and its ability to pursue its business plans and strategies. If the Company is unable to raise additional capital when needed, it could be forced to delay, limit, reduce or terminate its product candidate development or grant rights to develop and market its product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;7, 2022 the Company entered into a Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with an unrelated third party, Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), to sell up to $40.0&#160;million of its ordinary shares represented by American Depository Shares (&#8220;ADSs&#8221;) over a 36 month period. The Company is not obligated to sell any ordinary shares represented by ADSs pursuant to the Purchase Agreement and will control the timing and amount of any such sales, but in no event will Lincoln Park be required to purchase more than $1.5&#160;million in ordinary shares represented by ADSs in any single regular purchase. The purchase agreement is dependent on a market price of the ADSs being above $0.50. Upon execution and delivery of the Purchase Agreement, the Company issued 428,572 ordinary shares represented by ADSs as consideration for a commitment fee of $1.2&#160;million for Lincoln Park&#8217;s commitment to purchase its ordinary shares represented by ADSs under the Purchase Agreement. As of June&#160;30, 2023, the Company had not issued and sold any additional ordinary shares represented by ADSs to Lincoln Park under the Purchase Agreement. See Note 8 for detailed information on the purchase agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;3, 2022 the Company entered into an At-The-Market Issuance Sales Agreement with JonesTrading Institutional Services LLC (&#8220;JonesTrading&#8221;) to sell up to $14.4&#160;million of its ordinary shares represented by ADSs. The Company agreed to pay JonesTrading commission equal to 3% of the gross proceeds of the sales price of all ADSs sold through them as sales agent under the Sales Agreement. The offering of the Company&#8217;s ADSs pursuant to the Sales Agreement will terminate on the earliest of (1)&#160;the sale of all of the ordinary shares subject to the Sales Agreement, or (2)&#160;termination of the Sales Agreement by the Company or JonesTrading. The Company and JonesTrading may terminate the sales agreement at any time upon ten days prior notice. JonesTrading may terminate the Sales Agreement at any time in certain circumstances, including the occurrence of a material adverse change that, in their judgment, may make it impracticable or inadvisable to market or sell the Company&#8217;s ADSs or a suspension or limitation of trading the Company&#8217;s ADSs on The NASDAQ Capital Market. The value of the remaining number of shares under this agreement amounts to approximately $7.8&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;31, 2023 the Company entered into a financing agreement with Global Growth Holding Limited (&#8220;GGH&#8221;), for the issuance of convertible notes into the Company&#8217;s ordinary shares represented by ADSs, DKK 1 nominal value, with each ordinary share represented by one ADSs. Pursuant to the agreement, the Company may elect to sell to GGH up to $20.0&#160;million in such notes on any business day over the 36 month term of the agreement. The Company has the right, but not the obligation to direct GGH to purchase traches of up to $0.7&#160;million, subject to certain limitations and conditions set forth in the agreement. In connection with the agreement, the Company is obligated to pay GGH a commitment fee totaling $1.1&#160;million. At any time, GGH may, in its sole discretion, convert the notes into ordinary shares at specified conversion prices upon submission of a request for conversion by GGH to the Company. The financing agreement between the Company and GGH is subject to approval by the SEC through the date of issuance of this report. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 3. Summary of Significant Accounting Policies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Basis of Preparation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unaudited condensed consolidated interim financial statements of the Company are prepared in accordance with International Accounting Standard 34, &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Interim Financial Reporting</font><font style="letter-spacing:0.2pt;">.&#8221; Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) have been condensed or omitted. Accordingly, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements for the year ended December&#160;31, 2022 and accompanying notes, which have been prepared in accordance with IFRS as issued by the International Accounting Standards Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates and requires management to exercise its judgment in the process of applying the Company&#8217;s accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the unaudited condensed consolidated interim financial statements are disclosed in Note 4. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accounting policies applied are consistent with the accounting policies as outlined in the basis of presentation section included in Note 3 of the audited financial statements as of and for the year ended December&#160;31, 2022, except for amendments to standards mentioned below.</font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The implementation of the amendments did not give rise to changes to reported financial figures. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Implemented standards</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Amendment to IAS 1 Presentation of Financial Statements: Disclosure of Accounting Policies (January&#160;1, 2023) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Amendment to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates (January&#160;1, 2023) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Amendment to IAS 12 Accounting Policies, Deferred tax related to Assets and Liabilities arising from a Single Transaction (January&#160;1, 2023) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Standards issued but not yet effective</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There were a number of standards and interpretations which were issued but were not yet effective at September&#160;30, 2023 and have not been adopted for these financial statements, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current (January&#160;1, 2024) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Amendments to IFRS 16 Accounting Policies, Lease Liability in a Sales and Leaseback (January&#160;1, 2024) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company expects to adopt these standards, updates and interpretations when they become mandatory. These standards are not expected to have a significant impact on disclosures or amounts reported in the Company&#8217;s financial statements in the period of initial application and future reporting periods. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 4. Significant Accounting Judgements, Estimates, and Assumptions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the application of its accounting policies, the Company is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unaudited condensed consolidated interim financial statements do not include all the information and disclosures required in the annual consolidated financial statements, and should be read in conjunction with the Company&#8217;s annual report on Form 20-F. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Significant accounting estimates made in the process of applying our accounting policies and that have the most significant effect on the amounts recognized in our unaudited condensed consolidated interim </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">financial statements relate to share-based compensation. See Note 7 below for additional information regarding share-based compensation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have as mentioned in note 2 evaluated the cash position and future funding requirements and have concluded that there is a significant doubt about the Company&#8217;s ability to continue as a going concern. Besides this there have been no other changes to the application of critical accounting judgments, or estimation uncertainties regarding accounting estimates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 5. Borrowings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Loan from Lessor</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2020, the Company entered into a lease for approximately 1,356 square meters, which is allocated on 839 square meters of office space, and 518 square meters of laboratory space in H&#248;rsholm, Denmark. In addition to the ordinary lease payments, the Company obtained financing from DTU Science Park A/S (&#8220;DTU&#8221;) for rebuilding the laboratory facility and engineering building to match the Company&#8217;s needs. The Company will repay the $1.3&#160;million financing at a fixed interest rate of 6% over 8&#160;years. If the lease is terminated due to default by the Company before the outstanding balance, including interest accrued, has been repaid, the remaining balance is due immediately. The finance liability is recorded at amortized cost, which approximates fair value at the time of issuance. For the three&#160;months ended September&#160;30, 2023 and 2022, interest expense related to the loan from lessor was nominal. For the nine&#160;months ended September&#160;30, 2023 and 2022, interest expense related to the loan from lessor was $0.1&#160;million and $0.1&#160;million, respectively. During the three&#160;months ended September&#160;30, 2023 and 2022 the Company had additions for borrowings related to the loan from lessor of $nil and $nil, respectively. During the nine&#160;months ended September&#160;30, 2023 and 2022 the Company had additions for borrowings related to the loan from lessor of $0.1&#160;million and $nil, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a result of the structure of the DTU financing this amount is not included as </font><font style="font-style:italic;letter-spacing:0.2pt;">Purchase of property, plant and equipment</font><font style="letter-spacing:0.2pt;"> within the unaudited condensed consolidated interim statements of cash flows as it is netted against the loan balance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">EIB Loan</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2020, the Company executed the EIB Loan, for a principal amount of &euro;20.0&#160;million, divided into three tranches of tranche 1 in the amount of &euro;7.0&#160;million, tranche 2 in the amount of &euro;6.0&#160;million and tranche 3 in the amount of &euro;7.0&#160;million. Under the EIB Loan Agreement, the tranche balances are due six&#160;years from their respective disbursement dates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2021, the Company initiated the draw of the first tranche of the EIB Loan Agreement. The Company received the proceeds from the draw of the first tranche of &euro;7.0&#160;million (approximately $7.8&#160;million) on February&#160;17, 2022. The Company will repay the first tranche of the EIB Loan at a fixed interest rate of 3% per annum and a payment-in-kind interest rate of 4% per annum. The loan is amortized to maturity using an effective monthly interest rate of 0.78%. For the three&#160;months ended September&#160;30, 2023 and 2022, interest expense related to the EIB Loan was $0.2&#160;million and $0.1&#160;million, respectively. For the nine&#160;months ended September&#160;30, 2023 and 2022, interest expense related to the EIB Loan was $0.5&#160;million and $0.3&#160;million, respectively. The loan is repayable in full six&#160;years after drawing down. Under the current business plans the Company cannot draw the remaining two tranches of the EIB loan. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Borrowings are summarized as follows (in thousands): </font>
        </div>
        <table style="width:416pt;height:93.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:298.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loan from lessor </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,016</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,068</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">EIB Loan </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7,123</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">6,932</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total Borrowings </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8,139</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8,000</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Less: Borrowings, current portion </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(150<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(136<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:298.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total Borrowings, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7,989</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7,864</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:62pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 6. Warrant Liability</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company received the proceeds from the draw of the first tranche of the EIB Loan on February&#160;17, 2022. In connection therewith, EIB received 351,036 EIB Warrants, at an exercise price of DKK 1 per warrant, which vested immediately, pursuant to the terms of a separate warrant agreement, the EIB Warrant Agreement. The EIB Warrants are exercisable at any time after issuance either net in cash or through payment of the exercise price and receipt of shares. Therefore, the warrant liability is recognized in full upon issuance. The liability is measured initially at its fair value and is subsequently remeasured at the present value of the redemption amount. The liability is classified in level 1 of the fair value hierarchy. Due to the fact that the exercise price is insignificant compared to the share price, there is virtually no time value. Consequently, the present value of the redemption amount is equal to the current share price. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As the warrant liability is a non-cash financing cost the amount related to the initial recognition of the warrant liability during the nine&#160;months ended September&#160;30, 2023 and 2022 is not included within the unaudited condensed consolidated interim statements of cash flows. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the changes to the warrant liability (in thousands): </font>
        </div>
        <table style="width:416pt;height:82.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.52pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:65.48pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Warrant Liability </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:338.52pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:65.48pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying amount at January&#160;1, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.075pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">573</td>
            <td style="padding:0pt;padding-left:21.075pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.52pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Remeasurement of warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.075pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(323<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:21.075pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.52pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Foreign currency translation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.075pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:21.075pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying amount at September&#160;30, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.075pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">252</td>
            <td style="padding:0pt;padding-left:21.075pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:416pt;height:97.5pt;margin-left:20pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.52pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:65.48pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Warrant Liability </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:338.52pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:65.48pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(USD in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying amount at January&#160;1, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.52pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Initial recognition of warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,007</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.52pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Remeasurement of warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.52pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Foreign currency translation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(126<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:338.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying amount at September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">881</td>
            <td style="padding:0pt;padding-left:18.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 7. Share-Based Payments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Warrant Program and Amendments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s Articles of Association allow for the granting of equity compensation, in the form of equity settled warrants, to employees, consultants and Scientific Advisory Board members who provide services similar to employees, members of executive management, and the board of directors. The warrants granted in 2018 or prior vested upon the closing of our initial public offering in February&#160;2021 (&#8220;IPO&#8221;). The warrants granted in 2020 vest either gradually over 36&#160;months or vest immediately. Vested warrants granted in 2020 are exercisable in certain exercise windows beginning in the second half of the year of 2021. Warrants granted up until 2019 expire on December&#160;31, 2036. Warrants granted in 2022, 2021, and 2020 expire on December&#160;31, 2031. As of September&#160;30, 2023 and 2022, the number of warrants as a&#160;percentage of outstanding ordinary shares was 9.2% and 10.6%, respectively. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following schedule specifies the granted warrants: </font>
        </div>
        <table style="width:416pt;height:134pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:291.92pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:40.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price/Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:291.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants granted as at December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,743,093</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 1.50</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.92pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants exercised</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(351,515<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 0.14 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.92pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">260,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 1.33 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.92pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants forfeited </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(82,381<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 2.72 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:291.92pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants cancelled </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:291.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants granted as at September&#160;30, 2023</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,569,197</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 1.47</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:291.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants exercisable as at September&#160;30, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,894,591</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 1.11</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:416pt;height:134pt;margin-left:20pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:291.92pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:40.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price/Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:291.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants granted as at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,732,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">DKK 7.53</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.92pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants exercised</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(345,548<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 0.13 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.92pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">161,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 2.72 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.92pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants forfeited </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(16,623<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 5.37 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:291.92pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants cancelled </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:291.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants granted as at September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,531,447</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 1.32</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:291.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants exercisable as at September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,962,252</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:59.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">USD 0.57</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">December&#160;31, 2022 and 2021 USD and DKK end-rates used. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">September&#160;30, 2023 USD-end rate used. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Number of warrants exclude EIB Warrants referred to in Note 6. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The weighted average share price at the date of exercise was $1.40 and $2.31 for the nine&#160;months ended September&#160;30, 2023 and 2022, respectively. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the nine&#160;months ended September&#160;30, 2023, the Company&#8217;s Board of Directors granted 100,000 onboarding warrants to a member of executive management and 150,000&#160;warrants to an external consultant. On March&#160;15, 2023, the Company&#8217;s board of directors granted 10,000 warrants to an employee of the Company. In connection with the grant of the warrants, the Company amended its Articles of Association to provide for the grant thereof. The warrants were issued on the terms and conditions set out in the Company&#8217;s Articles of Association and vest with 1/36 per month over 36&#160;months beginning January&#160;1 and October&#160;1, 2023 except for the warrants granted to external consultants which vest quarterly with 1/4 in the period until September&#160;2024. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the nine&#160;months ended September&#160;30, 2022, the Company granted 161,000 warrants. All granted warrants will vest 1/36 per month over 36&#160;months. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Employees will be entitled to receive a number of warrants based on the individual employee&#8217;s grade and performance for 2023. The warrants will be granted in February&#160;2024 at the share price equal to the fair market value thereof on the date of grant and vests 1/36 per month over 36&#160;months beginning March&#160;1, 2024. For the three and nine&#160;months ended September&#160;30, 2023, a service cost of $0.1&#160;million and $0.4&#160;million has been recognized respectively, based on the estimated fair value of the warrants granted in prior periods and warrants expected to be granted. For the three and nine&#160;months ended September&#160;30, 2022, a service cost of $0.2&#160;million and $0.7&#160;million has been recognized respectively, based on the estimated fair value of the warrants granted in prior periods and warrants expected to be granted. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subsequent to the Company&#8217;s IPO, determining the initial fair value and subsequent accounting for equity awards require significant judgment regarding expected life and volatility of an equity award; however, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">as a public listed company there is objective evidence of the fair value of an ordinary share on the date an equity award is granted. On the other hand, due to the fact that as of 2021, warrants will be granted at the share price on the date of grant, fair value comprises a time value which is significantly affected by the expected life and expected volatility. The expected life of a warrant is based on the assumption that the holder will not exercise until after the equity award is fully vested. Actual exercise patterns may differ from the assumption used herein. The expected volatility is based on peer group data and reflects the assumption that the historical volatility over a period similar to the life of the warrant is indicative of future trends, which may not necessarily be the actual outcome. The peer group consists of listed companies that management believes are similar to the Company in respect to industry and stage of development. Even with objective evidence of the fair value of an ordinary share, small changes in any other individual assumption or in combination with other assumptions could have resulted in significantly different valuations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following assumptions have been applied for the warrants issued during the nine&#160;months ended September&#160;30, 2023 and 2022, respectively: </font>
        </div>
        <table style="width:416pt;height:77.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:283.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:54.06pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:54.06pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:283.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term (in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:54.06pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">5.0&#8201;&#8211;&#8201;7.0 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:54.06pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">6.5 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:283.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:54.06pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">4.60&#8201;&#8211;&#8201;4.61% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:54.06pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.97&#8201;&#8211;&#8201;4.06% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:283.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:54.06pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">85% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:54.06pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">85% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:283.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:54.06pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">$0.60&#8201;&#8211;&#8201;1.78 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:54.06pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">$1.71&#8201;&#8211;&#8201;3.03</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 8. Capital Structure and Financial Matters</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Share Capital&#8201;&#8212;&#8201;Ordinary Shares</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following are changes in the Company&#8217;s share capital for the period ended September&#160;30, 2023: </font>
        </div>
        <table style="width:456pt;height:318pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Ordinary Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Share Capital</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(DKK in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share capital, December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">24,139,413</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">24,139</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at January&#160;4, 2023 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">634,413</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">634</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at January&#160;5, 2023 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">94,278</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">94</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at January&#160;20, 2023 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">259,407</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">259</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at January&#160;24, 2023 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">151,335</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">151</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at February&#160;7, 2023 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">96,271</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">96</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at February&#160;9, 2023 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,003,802</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,004</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at February&#160;13, 2023 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">42,808</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at March&#160;3, 2023 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">16,280</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercised warrants, May&#160;17, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">134,730</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">135</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercised warrants, May&#160;24, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">51,125</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">51</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercised warrants, June&#160;1, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">150,000</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">150</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at June&#160;5, 2023 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">861,614</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">862</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercised warrants, June&#160;30, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,824</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at July&#160;18, 2023 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,348</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercised warrants, September&#160;13, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10,836</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at September&#160;22, 2023 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">54,099</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">54</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at September&#160;26, 2023 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">51,750</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">52</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital increase at September&#160;27, 2023 (JonesTrading sales agreement) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">45,807</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">46</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:310.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Share capital, September&#160;30, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">27,814,140</td>
            <td style="padding:0pt;padding-left:4.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">27,814</td>
            <td style="padding:0pt;padding-left:19.135pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Lincoln Park Purchase Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;7, 2022, the Company entered into the Purchase Agreement, with Lincoln Park, pursuant to which the Company may elect to sell up to $40.0&#160;million in the Company&#8217;s ordinary shares, DKK 1 nominal value, represented by ADSs, with each ADS representing one (1)&#160;ordinary share of the Company, subject to certain limitations and conditions set forth in the Purchase Agreement. In addition, upon execution of the Purchase Agreement, the Company paid a commitment fee in the form of 428,572 ordinary shares at a price of $2.80 per share, for a total commitment fee of $1.2&#160;million (the &#8220;Commitment Fee&#8221;). Under the Purchase Agreement, the Company may from time to time, at its discretion, direct Lincoln Park to purchase on any single business day, or a regular purchase, up to 50,000 ordinary shares represented by ADSs which may be increased to 70,000 ordinary shares represented by ADSs under certain circumstances set forth in the Purchase Agreement over the 36 month term of the Purchase Agreement. The purchase price of the ordinary shares represented by ADSs will be based upon the prevailing market price of the ADSs at the time of the purchase without any fixed discount. If the adjusted market price of the ADSs decreases to below $0.50 the Company cannot sell ordinary shares under the purchase agreement with Lincoln Park. In addition, the Company may direct Lincoln Park to purchase additional amounts as accelerated purchases and additional accelerated purchases under certain circumstances. The Company is not obligated to sell any ordinary shares represented by ADSs pursuant to the Purchase Agreement and will control the timing and amount of any such sales, but in no event will Lincoln Park be required to purchase more than $1.5&#160;million in ordinary shares represented by ADSs in any single regular purchase. The Company cannot sell ordinary shares under this agreement if beneficial ownership by Lincoln Park and its affiliates exceeds 9.99% of the Company&#8217;s issued and outstanding ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;7, 2022, the Company filed a &#8220;selling shareholder&#8221; registration statement with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to the Purchase Agreement with Lincoln Park as the selling shareholder, through which the Company registered 4,649,250 ordinary shares represented by ADSs for resale to the public by Lincoln Park. Each ADS represents one ordinary share. The Company will not receive any proceeds from the resale of ADSs by Lincoln Park, however, assuming that the Company sells the full amount of its ordinary shares represented by ADSs to Lincoln Park, under the Purchase Agreement the Company may receive up to $40.0&#160;million in aggregate proceeds. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of September&#160;30, 2023, the Company had issued 428,572 ordinary shares represented by ADSs to Lincoln Park. Such shares were issued to Lincoln Park as payment of the Commitment Fee in consideration for Lincoln Park&#8217;s commitment to purchase our ordinary shares represented by ADSs under the Purchase Agreement. No shares have been sold under sold under the Purchase Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">JonesTrading Sales Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;3, 2022 the Company entered into an At-The-Market Issuance Sales Agreement with JonesTrading Institutional Services LLC (&#8220;JonesTrading&#8221;) under which the Company could sell up to an aggregate of $14.4&#160;million of its ordinary shares represented by ADSs. The Company agreed to pay JonesTrading commission equal to 3% of the gross proceeds of the sales price of all ADSs sold through them as sales agent under the Sales Agreement. The offering of the Company&#8217;s ADSs pursuant to the Sales Agreement will terminate on the earliest of (1)&#160;the sale of all of the ordinary shares subject to the Sales Agreement, or (2)&#160;termination of the Sales Agreement by the Company or JonesTrading. The Company and JonesTrading may terminate the sales agreement at any time upon ten days prior notice. JonesTrading may terminate the Sales Agreement at any time in certain circumstances, including the occurrence of a material adverse change that, in their judgment, may make it impracticable or inadvisable to market or sell the Company&#8217;s ADSs or a suspension or limitation of trading the Company&#8217;s ADSs on The NASDAQ Capital Market. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the period between January&#160;1, 2023 and September&#160;30, 2023 the Company sold 3,323,212&#160;ordinary shares represented by ADSs, DKK 1 nominal value with each ordinary share represented by one ADSs, at a VWAP of $1.79 per ADS. The ordinary shares represented by ADSs were sold pursuant to the Sales Agreement with JonesTrading dated October&#160;3, 2022. Gross proceeds from the sale of ordinary shares represented by ADSs were approximately $6.0&#160;million. In connection with the sale, the Company registered aggregate share capital increase of nominal DKK 3,323,212. The value of the remaining number of shares under the agreement with JonesTrading amounts to approximately $7.8&#160;million. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Financing Agreement Global Growth Holding</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;31, 2023 the Company entered into a financing agreement with Global Growth Holding Limited (&#8220;GGH&#8221;), for the issuance of convertible notes into the Company&#8217;s ordinary shares represented by ADSs, DKK 1 nominal value, with each ordinary share represented by one ADSs. Pursuant to the agreement, the Company may elect to sell to GGH up to $20.0&#160;million in such notes on any business day over the 36 month term of the agreement. The Company has the right, but not the obligation to direct GGH to purchase traches of up to $0.7&#160;million, subject to certain limitations and conditions set forth in the agreement. In connection with the agreement, the Company is obligated to pay GGH a commitment fee totaling $1.1&#160;million. At any time, GGH may, in its sole discretion, convert the notes into ordinary shares at specified conversion prices upon submission of a request for conversion by GGH to the Company. The financing agreement between the Company and GGH is subject to approval by the SEC through the date of issuance of this report. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 9. Commitments and Contingencies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Legal Proceedings</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;28, 2022, we received formal notice that on April&#160;21, 2022, SSI, had initiated a legal proceeding against us in The Danish Maritime and Commercial High Court (S&#248; og Handelsretten), claiming sole ownership of a patent application (PCT/EP2020/050058 and subsequently national filings, EP3906045), we had filed related to a method for treating malignant neoplasm by administering a composition comprising a high dose of neopeptides, a solvent and SSI&#8217;s liposomal adjuvant, CAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">09b, for which we have an exclusive, royalty bearing sub-licensable license to use from SSI, or the Invention. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The patent application for the Invention relates solely to the use of the adjuvant CAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">09b in conjunction with a high dose of neopeptides in our EVX-01 product candidate. SSI&#8217;s claim to the patent application does not relate to any other aspect of our patent portfolio covering EVX-01 or the PIONEER platform technology. The patent application stems from work we performed under a collaboration agreement we entered into with SSI, DTU, Center for Cancer Immune Therapy (Herlev Hospital) and the Center for Genomic Medicine (Rigshospitalet). The patent application names us and certain of our employees as the sole invertors of the Invention. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In its filing, SSI&#8217;s primary claim is that the Invention disclosed in the patent application was not made by us and our employees, but rather, that SSI and members of its staff made the Invention and, therefore, SSI and certain of its staff members should be listed as the sole inventors of the Invention. Subsidiary claims is that SSI should have co-ownership with us of the patent application and the Invention. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">It is our position that we and our employees are the sole inventors of the Invention. We believe that we have strong defenses against SSI&#8217;s claim and that SSI&#8217;s claim is without merit. We intend to vigorously defend the action. In any event, even if SSI&#8217;s claim were to be upheld by the court, while no assurance can be given, we do not expect that the claim would have a material impact on our rights to use the Invention in the development and commercialization of EVX-01, as we believe that such rights are covered by our current license agreement with SSI and SSI would be excluded from enforcing its rights in the Invention to prevent us from developing and commercializing our EVX-01 product candidate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">After several rounds of written statements to the courts the court proceedings has been paused since May&#160;2023 on the basis that non-court mediated negotiations are ongoing between us and SSI to resolve the situation without further court proceedings. We expect these negotiations to be completed during the first quarter of 2024. It is the opinion of the executive management team that the legal proceedings will not have material impact on the company&#8217;s future financial results. Further, the expectation is a settlement will be reached with a good outcome for the company. Our legal counsel has confirmed that they support our evaluation that the ongoing legal proceedings will not have a material impact on our future financial results or business operations. As of the date of this filing, we cannot reasonably estimate any range of potential future charges, and therefore, we have not recorded any accrual for liabilities associated with these legal proceedings. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:388pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 10. Events After the Reporting Period</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Through the date of adoption of these interim financial statements 356,742&#160;ADSs were sold. After deducting fees, and expenses, total proceeds to the Company from the sales of the ADSs were $0.3&#160;million. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">On December&#160;21, 2023 the company closed a Private Placement related to the issuance and sale of 9,726,898 of the Company&#8217;s ordinary shares, DKK 1 nominal value (&#8220;Ordinary Shares&#8221;), represented by American Depositary Shares (&#8220;ADSs&#8221;), and accompanying warrants (the &#8220;Private Placement Warrants&#8221;) to purchase up to 9,726,898 Ordinary Shares represented by ADSs at a purchase price of $0.544 per Ordinary Share for an aggregate purchase price of $5.3&#160;million. The Private Placement Warrants are exercisable immediately upon issuance, have a term of three&#160;years, and an exercise price equal to $0.707 per Ordinary Share. Each Ordinary Share is represented by one (1)&#160;ADS. The Private Placement was priced at-the-market under Nasdaq rules. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The gross proceeds to the Company from the Private Placement are $5.3&#160;million, and if warrants are exercised up to an additional $6.9&#160;million of gross proceeds upon exercise of the Private Placement Warrants before deducting offering expenses payable by the Company. The Company intends to use the proceeds from the Private Placement for working capital and general corporate purposes. No brokerage, finder&#8217;s fees, or commissions were payable by the Company in connection with the Private Placement. In connection with such sales, the Company registered aggregate share capital increases of nominal DKK 9,726,898 with the Danish Business Authority.</font>
          </div>

      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:14pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="margin-top:11.52pt; text-align:center; width:456pt; line-height:13.5pt;">
            <font style="letter-spacing:-0.28pt;">UP TO 2,032,520&#160;AMERICAN DEPOSITARY SHARES REPRESENTING </font>
            <br >
            <font style="letter-spacing:-0.28pt;">20,325,200 ORDINARY SHARES</font>
            <br >
            <font style="letter-spacing:-0.28pt;">AND UP TO 2,032,520 PRE-FUNDED WARRANTS TO PURCHASE UP TO </font>
            <br >
            <font style="letter-spacing:-0.28pt;">2,032,520&#160;AMERICAN DEPOSITARY SHARES </font>
            <br >
            <font style="letter-spacing:-0.28pt;">AND UP TO 2,032,520 SERIES A WARRANTS TO PURCHASE UP TO 2,032,520&#160;AMERICAN DEPOSITARY SHARES </font>
            <br >
            <font style="letter-spacing:-0.28pt;">AND PLACEMENT AGENT WARRANTS TO PURCHASE UP TO 101,626&#160;AMERICAN DEPOSITARY SHARES</font>
          </div>


          <div style="margin-top:-0.5pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:normal;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">(and </font><font style="font-weight:bold;letter-spacing:-0.2pt;">2,032,520 </font><font style="letter-spacing:0.2pt;">American Depositary Shares representing </font><font style="font-weight:bold;letter-spacing:-0.2pt;">20,325,200</font><font style="letter-spacing:0.2pt;"> ordinary shares underlying the Pre-Funded Warrants and </font><font style="font-weight:bold;letter-spacing:-0.2pt;">2,032,520 </font><font style="letter-spacing:0.2pt;">American Depositary Shares representing </font><font style="font-weight:bold;letter-spacing:-0.2pt;">20,325,200</font><font style="letter-spacing:0.2pt;"> ordinary shares underlying the Series&#160;A Warrants and </font><font style="font-weight:bold;letter-spacing:-0.2pt;">101,626</font><font style="letter-spacing:0.2pt;"> American Depositary Shares representing </font><font style="font-weight:bold;letter-spacing:-0.2pt;">1,016,260</font><font style="letter-spacing:0.2pt;"> ordinary shares underlying the Placement Agent Warrants) </font>
          </div>

        <div style="position:relative;margin-top:50pt; text-align:center; width:456pt;">
          <img src="lg_evaxionaiimmunology-bwlr.jpg" alt="[MISSING IMAGE: lg_evaxionaiimmunology-bwlr.jpg]" height="32" width="305" >
        </div>
        <div style="margin-top:53.96pt; text-align:center; width:456pt; line-height:18pt;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">EVAXION BIOTECH A/S</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:60pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">PRELIMINARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:60pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="margin-top:24pt; text-align:center; width:456pt; line-height:18pt;font-size:16pt;">
            <font style="letter-spacing:-0.32pt;">H.C. Wainwright &amp; Co.</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
          </div>

        <div style="margin-top:108pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2024</font>
        </div>
        <div style="margin-top:62.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 62.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.51pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.50999999999999pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PART II</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INFORMATION NOT REQUIRED IN PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;6.</font>
          <br >
        </div>
        <div style=" margin-top:12pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification of Directors and Officers</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The general meeting is allowed to discharge our board members and members of our executive management from liability for any particular financial year based on a resolution relating to the financial statements. This discharge means that the general meeting will discharge such board members and members of our executive management from liability to our company. However, the general meeting cannot discharge any claims by individual shareholders or other third parties. In addition, the discharge can be set aside in case the general meeting prior to its decision to discharge was not presented with all reasonable information necessary for the general meeting to assess the matter at hand. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, we have agreed to indemnify our board members and members of our executive management and employees, in relation to certain claims. We will not, however, indemnify our board members, executive management and employees, in respect of: (i)&#160;claims against a person pursuant to Danish law raised before the Danish Courts, except claims arising from the offer, sale and listing of the our securities in the United States and/or its subsequent status as a listed company in the United States, including in respect of our reports filed with or furnished to the U.S. Securities and Exchange Commission; (ii)&#160;claims against a person for damages and legal costs related to criminal and/or grossly negligent or willful acts or omissions committed by the indemnified person; (iii)&#160;claims against an indemnified person, which is attributable to the gaining or purported gaining of any profit or advantage to which the indemnified person or any related natural or legal person was not legally entitled; (iv)&#160;claims covered by insurance; (v)&#160;claims brought against the indemnified person by us or any subsidiary of ours; and (vi)&#160;any sum payable to a regulatory authority by way of a penalty in respect of the indemnified person&#8217;s personal non-compliance with any requirement of a regulatory nature howsoever arising. The indemnification is limited to a maximum amount of DKK 534.5&#160;million per claim per person. The indemnification shall remain in force for a period of five&#160;years after the resignation of the indemnified person from us or our subsidiaries, if the claims made within such period are related to such person&#8217;s services to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There is a risk that such indemnification will be deemed void under Danish law, either because the indemnification is deemed contrary to the rules on discharge of liability in the Danish Company Act, as set forth above, because the indemnification is deemed contrary to sections 19 and 23 of the Danish Liability and Compensation Act, which contain mandatory provisions on recourse claims between an employee (including members of our executive management) and the company, or because the indemnification is deemed contrary to the general provisions of the Danish Contracts Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, we provide our board members and executive management with directors&#8217; and officers&#8217; liability insurance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:11.8pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;7.</font>
          <br >
        </div>
        <div style=" margin-top:11.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recent Sales of Unregistered Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">2022 Sales of Unregistered Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lincoln Park Purchase Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;7, 2022, we completed a private placement to Lincoln Park Capital Fund, LLC pursuant to which we have the right to sell to Lincoln Park up to $40,000,000 of our ordinary shares represented by American Depositary Shares (the &#8220;ADSs&#8221;), subject to certain limitations, from time to time over the 36-month period commencing on the date that a registration statement covering the resale of the ADSs is declared effective by the SEC. We issued 428,572 ordinary shares to Lincoln Park as consideration for its commitment to purchase our shares under the Purchase Agreement. In the Purchase Agreement, Lincoln </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Park represented to the Company, among other things, that it was an &#8220;accredited investor&#8221; &#8203;(as such term is defined in Rule&#160;501(a) of Regulation&#160;D under the Securities Act of 1933, or the Securities Act). The securities were sold by the Company under the Purchase Agreement in reliance upon an exemption from the registration requirements under the Securities Act afforded by Section&#160;4(a)(2) of the Securities Act. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">2023 Securities Purchase Agreement and Investment Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On December&#160;18, 2023, the Company, entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) and an Investment Agreement (the &#8220;Investment Agreement&#8221;; and, together with the Purchase Agreement referred to herein as the &#8220;Purchase Agreements&#8221;), with certain Institutional Accredited Investors, Qualified Institution Buyers and other Accredited Investors, including all members of the Company&#8217;s Management and Board of Directors and MSD GHI (&#8220;MSD&#8221;), a subsidiary of Merck Inc. (collectively, the &#8220;Purchasers&#8221;), for the issuance and sale in a private placement (the &#8220;Private Placement&#8221;) of 9,726,898 of the Company&#8217;s ordinary shares, represented by American Depositary Shares, and accompanying warrants to purchase up to 9,726,898 Ordinary Shares represented by ADSs at a purchase price of $0.544 per ordinary share. The Warrants are exercisable immediately upon issuance, expire three (3)&#160;years after the closing date of the Private Placement and have an exercise price equal to $0.707 per Ordinary Share. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">MSD participated in the Private Placement accounting for some 25% of the full offering amount. Further, the Private Placement included significant participation by all members of the Company&#8217;s management and board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The gross proceeds to the Company from the Private Placement were approximately $5.3&#160;million</font><font style="font-weight:bold;letter-spacing:-0.2pt;">,</font><font style="letter-spacing:0.2pt;"> with up to an additional $6.8&#160;million of gross proceeds upon cash exercise of the Warrants, before deducting offering expenses payable by the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Private Placement was subject to the satisfaction of customary closing conditions and closed on December&#160;21, 2023. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:11.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;8.</font>
          <br >
        </div>
        <div style=" margin-top:11.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exhibits and Financial Statement Schedules</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <table style="width:456pt;height:284.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:27.83pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Exhibits </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Number </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:416.17pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Description </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:1.917pt 0pt 0.5pt 0pt; width:27.83pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">4.1* </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:1.917pt 0pt 0.5pt 0pt; width:416.17pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1828253/000110465924007286/tm244277d1_ex1-1.htm">Articles of Association of Evaxion Biotech A/S, as amended (incorporated by reference to Exhibit&#160;1.1 to the Form 6-K (File No. 001-39950) filed with the Commission on January&#160;26, 2024).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:1.667pt 0pt 0.5pt 0pt; width:27.83pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">4.2* </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:1.667pt 0pt 0.5pt 0pt; width:416.17pt;white-space:normal;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1201935/000101915521000011/evaxionda.htm">Form of American Depositary Receipt evidencing American Depositary Shares (included in Exhibit&#160;4.3).</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:1.667pt 0pt 0.5pt 0pt; width:27.83pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">4.3* </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:1.667pt 0pt 0.5pt 0pt; width:416.17pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1201935/000101915521000011/evaxionda.htm">Form of Deposit Agreement among Evaxion Biotech A/S, The Bank of New York Mellon, as depositary, and all owners and holders of American Depositary Shares issued thereunder (incorporated by reference to Exhibit&#160;1 to the Form F-6 (File No. 333-252038) filed with the Commission on January&#160;12, 2021).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:27.83pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">4.4**</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:416.17pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="tm2334005d4_ex4-4.htm">Form of Pre-Funded Warrant for this Offering</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:27.83pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">4.5**</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:416.17pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="tm2334005d4_ex4-5.htm">Form of Series&#160;A Ordinary Warrant for this Offering</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:27.83pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">4.6**</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:416.17pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="tm2334005d4_ex4-6.htm">Form of Placement Agent Warrant for this Offering</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:1.667pt 0pt 0.5pt 0pt; width:27.83pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">5.1**</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:1.667pt 0pt 0.5pt 0pt; width:416.17pt;white-space:normal;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="tm2334005d4_ex5-1.htm">Form of Opinion of Mazanti-Andersen regarding the validity of the Ordinary Shares being registered.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:27.83pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">8.2</font><font style="letter-spacing:0.2pt;">** </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:416.17pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="tm2334005d4_ex8-2.htm">Form of Tax Opinion of Mazanti-Andersen</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:27.83pt;">
                <font style="letter-spacing:0.2pt;">10.1**</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:416.17pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="tm2334005d4_ex10-1.htm">Form of Securities Purchase Agreement for this Offering</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:27.83pt;">
                <font style="letter-spacing:0.2pt;">23.1** </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:416.17pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="tm2334005d4_ex23-1.htm">Consent of, independent registered public accounting firm</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:27.83pt;">
                <font style="letter-spacing:0.2pt;">23.2**</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:416.17pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="tm2334005d4_ex5-1.htm">Consent of Mazanti-Andersen (included in Exhibit&#160;5.1).</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:27.83pt;">
                <font style="letter-spacing:0.2pt;">24.1*</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:416.17pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1828253/000110465924003760/evax-20230930xf1.htm#POWEROFATTORNEY_131435">Power of Attorney (included on signature page to this registration statement). </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:27.83pt;">
                <font style="letter-spacing:0.2pt;">107** </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:416.17pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="tm2334005d4_ex-filingfees.htm">Filing Fee Table.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.41pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Previously Filed </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">**</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Filed herewith </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; line-height:12pt; margin-top:13.19pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;9.</font>
          <br >
        </div>
        <div style=" margin-top:13.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Undertakings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(A)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933, as amended, or the Securities Act; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or any decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the registration statement is on Form F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the SEC by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended, or Exchange Act, that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&#160;424(b) that is part of the registration statement. </font>
        </div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">To file a post-effective amendment to the registration statement to include any financial statements required by Item&#160;8.A of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section&#160;10(a)(3) of the Exchange Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph&#160;(a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information required by Section&#160;10(a)(3) of the Exchange Act or Rule&#160;3-19 of Regulation&#160;S-K if such financial statements and information are contained in periodic reports filed with or furnished to the SEC by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act that are incorporated by reference in this Form&#160;F-1. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:40pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">That, for the purpose of determining liability under the Securities Act to any purchaser: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">Each prospectus filed by the registrant pursuant to Rule&#160;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">Each prospectus required to be filed pursuant to Rule&#160;424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&#160;430B relating to an offering made pursuant to Rule&#160;415(a)(1)(i), (vii), or (x)&#160;for the purpose of providing the information required by section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&#160;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </font>
        </div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iv)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(B)</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:524pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(C)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or Section&#160;15(d) of the Exchange Act that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSIG">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:95.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SIGNATURES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies it has reasonable grounds to believe that it meets all of the requirements for filing this amended registration statement on Form F-1 with the Securities and Exchange Commission and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Copenhagen, Denmark, on January&#160;30, 2024. </font>
          </div>

        <div style="margin-left:220pt; margin-top:8pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH A/S</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:220pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">By:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:240pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">/s/ Christian Kanstrup</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:240pt; margin-top:2.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-left:240pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Name:</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:276pt;">
          <font style="letter-spacing:0.2pt;">Christian Kanstrup </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:240pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">Title:</font>
            <br >
          </div>
          <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:276pt;">
            <font style="letter-spacing:0.2pt;">Chief Executive Officer </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </font>
        </div>

          <table style="width:456pt;height:260.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;min-height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:168pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Signature </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:168pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Title </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:96pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Date </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;height:52.25pt; white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:19.917pt 0pt 0.5pt 0pt; width:168pt;">
                <div>
                  <font style="letter-spacing:0.2pt;">/s/ Christian Kanstrup</font>
                </div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt;">
                  <font style="letter-spacing:0.2pt;">Christian Kanstrup </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:19.917pt 0pt 0.5pt 0pt; width:168pt;vertical-align:middle;">
                <font style="letter-spacing:0.2pt;">Chief Executive Officer (</font><font style="font-style:italic;letter-spacing:0.2pt;">Principal Executive Officer</font><font style="letter-spacing:0.2pt;">) </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:19.917pt 0pt 0.5pt 0pt; width:96pt;white-space:nowrap;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">January&#160;30, 2024 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;height:49pt; white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 5.833pt 0pt; width:168pt;">
                <div>
                  <font style="letter-spacing:0.2pt;">/s/ *</font>
                </div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt;">
                  <font style="letter-spacing:0.2pt;">Jesper Nyegaard Nissen </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:1px 0pt; width:168pt;vertical-align:middle;">
                <font style="letter-spacing:0.2pt;">Interim Chief Financial Officer (</font><font style="font-style:italic;letter-spacing:0.2pt;">Principal Financial Officer and Principal Accounting Officer</font><font style="letter-spacing:0.2pt;">) </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 5.833pt 0pt; width:96pt;white-space:nowrap;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">January&#160;30, 2024 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;height:39pt; white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:168pt;white-space:normal;">
                <div>
                  <font style="letter-spacing:0.2pt;">/s/ *</font>
                </div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt;">
                  <font style="letter-spacing:0.2pt;">Marianne S&#248;gaard </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:1px 0pt; width:168pt;vertical-align:middle;">
                <font style="letter-spacing:0.2pt;">Chairman of the Board of Directors </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">January&#160;30, 2024 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;height:39pt; white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:168pt;white-space:normal;">
                <div>
                  <font style="letter-spacing:0.2pt;">/s/ *</font>
                </div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt;">
                  <font style="letter-spacing:0.2pt;">Roberto Prego </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:1px 0pt; width:168pt;vertical-align:middle;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">January&#160;30, 2024 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;height:39pt; white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:168pt;white-space:normal;">
                <div>
                  <font style="letter-spacing:0.2pt;">/s/ *</font>
                </div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt;">
                  <font style="letter-spacing:0.2pt;">Lars Holtug </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:1px 0pt; width:168pt;vertical-align:middle;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">January&#160;30, 2024 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:168pt;white-space:normal;">
                <div>
                  <font style="letter-spacing:0.2pt;">/s/ *</font>
                </div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt;">
                  <font style="letter-spacing:0.2pt;">Niels Iversen M&#248;ller </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:1px 0pt; width:168pt;vertical-align:middle;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">January&#160;30, 2024</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <table style="width:456pt;margin-bottom:5pt;margin-top:19pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
                <div style=" float:left; line-height:10pt; text-align:left; width:24pt;white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">*By:</font>
                  <br >
                </div>
                <div style=" line-height:10pt; text-align:left; margin-left:24pt;">
                  <font style="letter-spacing:0.2pt;">/s/ Christian Kanstrup</font>
                </div>
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
                <div style="margin-left:24pt; margin-top:2.5pt; line-height:0pt;">
                  <div style="margin-left: 0pt; width: 156pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-left:24pt; margin-top:4pt;">
                  <font style="letter-spacing:0.2pt;">Christian Kanstrup</font>
                  <br >
                  <font style="font-style:italic;letter-spacing:0.2pt;">Attorney-In-Fact</font>
                  <br >
                  <font style="letter-spacing:0.2pt;">January 30, 2024</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:15pt;white-space:nowrap;text-align:left;vertical-align:top;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;" colspan="4">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:506pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Evaxion Biotech A/S, has signed this Amendment No. 1 to this Form F-1 Registration Statement in New York, New York on January&#160;30, 2024. </font>
          </div>

        <div style="margin-left:220pt; margin-top:8pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EVAXION BIOTECH, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:220pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">By:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:240pt;">
          <font style="letter-spacing:0.2pt;">/s/ Roberto Prego</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:240pt; margin-top:2.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Roberto Prego </font>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Director</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>tm2334005d4_ex4-4.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 4.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PREFUNDED
WARRANT TO</B></FONT><B> SUBSCRIBE FOR ORDINARY SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPRESENTED BY AMERICAN DEPOSITARY SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>EVAXION
BIOTECH A/S</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>ADSs: ______</FONT></TD>
  <TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt"><FONT STYLE="font-size: 10pt">Initial Exercise Date: ________, 2024</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">THIS
PREFUNDED </FONT>WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the &ldquo;<U>Warrant</U>&rdquo;)
certifies that, for value received, ______ or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to
the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise
Date</U>&rdquo;) until this Warrant is exercised in full (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe
for and purchase from Evaxion Biotech A/S, a public limited liability company incorporated under the laws of the Kingdom of Denmark (the
 &ldquo;<U>Company</U>&rdquo;), up to ______ Ordinary Shares (the &ldquo;<U>Warrant Shares</U>&rdquo;) represented by _______ ADSs (the
 &ldquo;<U>Warrant ADSs</U>&rdquo;), as subject to adjustment hereunder. The subscription price of one Warrant ADS under this Warrant shall
be equal to the Exercise Price, as defined in Section&nbsp;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;1</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section&nbsp;1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>ADS(s)</U>&rdquo;
means American Depositary Shares issued pursuant to the Deposit Agreement, each representing ten (10)&nbsp;Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal or national holiday in the United States
or Denmark or any day on which banking institutions in the State of New York or Denmark are authorized or required by law to remain closed;
provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to
 &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp; or any other similar orders or
restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic
funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally open for use by customers
on such day or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Danish Counsel</U>&rdquo; means Mazanti-Andersen, Amaliegade 10 1256 Copenhagen K, Denmark, or any successor Danish counsel to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Deposit
Agreement</U>&rdquo; means the Deposit Agreement, dated as of February&nbsp;4, 2021, among the Company, The Bank of New York Mellon as
Depositary and the owners and holders of ADSs from time to time, as such agreement may be amended or supplemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Depositary</U>&rdquo;
means The Bank of New York Mellon and any successor depositary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary
Share(s)</U>&rdquo; means the ordinary shares of the Company, DKK 1 nominal value per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the securities purchase agreement, dated as of _____, 2024, by and between the Company and each of the purchasers
signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form&nbsp;F-1 (File No.&nbsp;333-276505).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Ordinary Shares and/or ADSs are listed or quoted for trading
on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the
New York Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Computershare A/S, the current transfer agent of the Company, with a mailing address of Lottenborgvej 26 D, 1.,
DK-2800 Kgs. Lyngby, Denmark and company registration number (CVR) no. 27088899, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the ADSs are then listed or
quoted on a Trading Market, the daily volume weighted average price of the ADSs for such date (or the nearest preceding date) on the Trading
Market on which the ADSs are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.&nbsp;(New York
City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB Venture Market (&ldquo;<U>OTCQB</U>&rdquo;) or OTCQX Best Market
(&ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the ADSs for such date (or the nearest preceding
date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the ADSs are not then listed or quoted for trading on OTCQB or OTCQX and if prices
for the ADSs are then reported in the &ldquo;Pink&rdquo; Open Market (&ldquo;<U>Pink Market</U>&rdquo;) operated by OTC Markets,&nbsp;Inc.
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per ADS so reported,
or (d)&nbsp;in all other cases, the fair market value of an ADS as determined by an independent appraiser selected in good faith by the
Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of
which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;2</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
of Warrant</U>. This Warrant may be exercised, in whole or in part, at any time or times on or after the Initial Exercise Date and on
or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the
Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). On the Trading Day (based on New York City
time) on which the delivery of the Notice of Exercise occurs, the Holder shall deliver to the Company Danish Counsel the aggregate Exercise
Price for the Warrant ADSs specified in the applicable Notice of Exercise by wire transfer to the Company Danish Counsel pursuant to the
bank wire transfer instructions set forth on the Notice of Exercise attached hereto. No ink-original Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder
has subscribed for all of the Warrant ADSs available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the final Notice
of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in the subscription of a portion of the total number
of Warrant ADSs available hereunder shall have the effect of reducing the outstanding number of Warrant ADSs purchasable hereunder in
an amount equal to the applicable number of Warrant ADSs subscribed. The Company shall record the number of Warrants issued to the Holder
and the number of Warrant ADSs subscribed through exercise and the date of such subscription of the Warrant ADSs. The Company shall deliver
any objection to any Notice of Exercise within one (1)&nbsp;Trading Day of receipt of such notice. The Holder and any assignee, by acceptance
of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the subscription for a portion of
the Warrant ADSs hereunder, the number of Warrant ADSs available for subscription hereunder at any given time may be less than the amount
stated on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: White">b)</FONT><FONT STYLE="color: Black; background-color: White">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $___<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1
</SUP></FONT>per Warrant ADS, was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional
consideration (other than the nominal exercise price of $___<SUP>1</SUP> per Warrant ADS) shall be required to be paid by the Holder
to any Person to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion,
of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever. The remaining unpaid exercise price per
Warrant ADS under this Warrant shall be $____<SUP>1</SUP>, subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;),
<U>provided</U>, <U>however</U>, that in no event shall the Exercise Price paid by the Holder be less than the amount in US dollars (rounded
to four decimal places) equal to 10 Danish Krone, at the exchange rate published by the Danish
National Bank, on the date of the Holder&rsquo;s delivery of the Notice of Exercise.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Unavailability
of Registration Statement</U>. Notwithstanding anything to the contrary contained herein, if there is no effective registration statement
registering, or the prospectus contained therein is not available for, the sale of all of the Warrant Shares underlying the Warrant ADSs
issuable under this Warrant at any time following the Initial Exercise Date and ending on the Termination Date, the Holder shall be permitted
to exercise this Warrant by delivery of a Notice of Exercise to the Company, and, within one (1)&nbsp;Trading Day (based on New York City
time) following the delivery of such Notice of Exercise, deliver to the Company Danish Counsel the aggregate Exercise Price with respect
to such exercise of this Warrant.&nbsp; Upon delivery of a Notice of Exercise during a Registration Failure Period (as defined below)
and the timely payment of the aggregate Exercise Price, the Company shall be required to (1)&nbsp;pay in cash to the Holder on each Trading
Day during the Registration Failure Period an amount equal to 1.0% of the product of (A)&nbsp;the number of Warrant ADSs subject to the
exercise by the Holder pursuant to the immediately preceding sentence and (B)&nbsp;the VWAP of the ADSs on the date of delivery of the
Notice of Exercise to the Company, and (2)&nbsp;on the Trading Day immediately following the date on which the Registration Failure Period
ends, deliver all of the Warrant ADSs required to be delivered pursuant to such Notice of Exercise by crediting the account of the Holder&rsquo;s
prime broker with The Depository Trust Company through DWAC (as defined below).&nbsp; The Company shall pay any cash amounts owed pursuant
to clause (1)&nbsp;of the immediately preceding sentence no later than two (2)&nbsp;Business Days after a written request by the Holder
(which request may be delivered by email). As used herein, &ldquo;<U>Registration Failure Period</U>&rdquo; means the period (x)&nbsp;beginning
on the date of delivery of a Notice of Exercise at a time when there is no registration statement registering, or the prospectus contained
therein is not available for, the sale of all of the Warrant Shares underlying the Warrant ADSs issuable under this Warrant, and (y)&nbsp;ending
on the later of (A)&nbsp;the date that there is an effective registration statement registering, and the prospectus contained therein
is available for, the sale of all of the Warrant Shares underlying the Warrant ADSs issuable hereunder and (B)&nbsp;the date of delivery
of all of the Warrant ADSs required to be delivered pursuant to the Notice of Exercise by crediting the account of the Holder&rsquo;s
prime broker with The Depository Trust Company through DWAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-right: auto; margin-bottom: 3pt; text-align: left; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP></FONT>amount in US dollars equal to 10 Danish Krone, at the exchange rate published by the Danish National Bank on the date of
the Purchase Agreement, or $____ on the date of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of Warrant ADSs Upon Exercise</U>. Upon the exercise of this Warrant, the Company shall enter the Warrant Shares in the name of the Holder
in the Company&rsquo;s share register, deposit the Warrant Shares in connection with such exercise with the Depositary for the ADSs, and
instruct the Depositary to transmit the Warrant ADSs purchased hereunder to the Holder by crediting the account of the Holder&rsquo;s
or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit/Withdrawal At Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
if the Depositary is then a participant in such system and there is an effective registration statement permitting the issuance of the
Warrant Shares represented by the Warrant ADSs to the Holder, by the date that is the earlier of (i)&nbsp;two (2)&nbsp;Trading Days after
the delivery to the Company of the Notice of Exercise and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period
after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant ADS Delivery Date</U>&rdquo;), provided
that the Company shall not be obligated to deliver the Warrant ADSs hereunder unless the Company Danish Counsel has received the aggregate
Exercise Price on or before the Trading Day (based on New York City time) immediately prior to the Warrant ADS Delivery Date. Upon delivery
of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant ADSs
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant ADSs, provided that payment
of the aggregate Exercise Price is received by the Warrant ADS Delivery Date. If the Company fails for any reason (other than solely as
a result of actions or omissions by the Holder) to cause the Depositary to deliver to the Holder the Warrant ADSs subject to a Notice
of Exercise by the Warrant ADS Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty,
for each $1,000 of Warrant ADSs subject to such exercise (based on the VWAP of the ADSs on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant ADS Delivery Date) for each Trading
Day after such Warrant ADS Delivery Date until such Warrant ADSs are delivered or Holder rescinds such exercise. The Company agrees to
maintain a depositary and a transfer agent that each are a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a
number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the ADSs as in effect on the date of delivery of
the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s)&nbsp;of Exercise delivered on or prior to 12:00 p.m.&nbsp;(New
York City time) on the Trading Day prior to the Initial Exercise Date, which may be delivered at any time after the time of execution
of the Purchase Agreement, the Company agrees to deliver the Warrant ADSs subject to such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New York City
time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant ADS Delivery Date for purposes hereunder, provided
that payment of the aggregate Exercise Price is delivered to Company Danish Counsel by 12:00 p.m.&nbsp;(New York City time) on the Trading
Day prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant ADSs, deliver to the Holder a new Warrant certificate
evidencing the rights of the Holder to subscribe for the unsubscribed Warrant ADSs called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rescission
Rights</U>. If the Company fails to cause the Depositary to transmit to the Holder the Warrant ADSs pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant ADS Delivery Date, then the Holder will have the right to rescind such exercise prior to the delivery of such Warrant ADSs
hereunder (with the effect that the Holder&rsquo;s right to acquire such Warrant ADSs pursuant to this Warrant shall be restored) and
the Company shall return to the Holder the aggregate Exercise Price paid to the Company Danish Counsel for such Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant ADSs Upon Exercise</U>. In addition to any other rights available to the Holder, if the
Company fails to cause the Depositary to deliver to the Holder the Warrant ADSs in accordance with the provisions of Section&nbsp;2(d)(i)&nbsp;above
pursuant to an exercise on or before the Warrant ADS Delivery Date, and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, ADSs to deliver in satisfaction
of a sale by the Holder of the Warrant ADSs which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase price
(including brokerage commissions, if any) for the ADSs so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number
of Warrant ADSs that the Company failed to deliver to the Holder in connection with the exercise at issue by (2)&nbsp;the price at which
the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the Holder, either reinstate the portion
of the Warrant in respect of the equivalent number of Warrant ADSs for which such exercise was not honored and return any amount received
by the Company Danish Counsel in respect of the Exercise Price for those Warrant ADSs (in which case such exercise shall be deemed rescinded)
or deliver to the Holder the number of Warrant ADSs that would have been issued had the Company timely complied with its exercise and
delivery obligations hereunder. For example, if the Holder purchases ADSs having a total purchase price of $11,000 to cover a Buy-In with
respect to an attempted exercise of Warrants for ADSs with an aggregate sale price giving rise to such purchase obligation of $10,000,
under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide
the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence
of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder,
at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s
failure to timely deliver Warrant ADSs upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Fractional Ordinary Shares or Warrant ADSs</U>. No fractional Warrant Shares or Warrant ADSs shall be issued upon the exercise of this
Warrant. As to any fraction of a Warrant ADS which the Holder would otherwise be entitled to subscribe upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole ADS, provided that the fraction of an ADS shall not be rounded up to the next whole
ADS if such rounding would result in the issue price being lower than the nominal value of the Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant ADSs shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant ADSs, all of which taxes and expenses shall be paid by the Company, and such Warrant
ADSs shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant ADSs are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise
shall be accompanied by the Assignment Form&nbsp;attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Depositary
and Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for same-day electronic issuance and delivery of the Warrant ADSs.
The Company shall pay all applicable fees and expenses of the Depositary and Transfer Agent in connection with the issuance of the Warrants
ADSs hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing
of Books</U>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of Ordinary Shares beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of
Ordinary Shares underlying such Warrant ADSs issuable upon exercise of this Warrant with respect to which such determination is being
made, but shall exclude the number of Ordinary Shares underlying Warrant ADSs which would be issuable upon (i)&nbsp;exercise of the remaining,
nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise
or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other
Ordinary Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes
of this Section&nbsp;2(e), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and
the rules&nbsp;and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the
Holder that such calculation is in compliance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the Holder is solely responsible for
any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section&nbsp;2(e)&nbsp;applies,
the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e),
in determining the number of outstanding Ordinary Shares, a Holder may rely on the number of outstanding Ordinary Shares as reflected
in (A)&nbsp;the Company&rsquo;s most recent annual report on Form&nbsp;20-F, Report on Form&nbsp;6-K or other public filings filed with
the Commission, as the case may be, (B)&nbsp;a more recent public announcement by the Company or (C)&nbsp;a more recent written notice
by the Company or the Depositary or the Transfer Agent setting forth the number of Ordinary Shares outstanding.&nbsp; Upon the written
or oral request of a Holder, the Company shall within one (1)&nbsp;Trading Day confirm orally and in writing to the Holder the number
of Ordinary Shares then outstanding.&nbsp; In any case, the number of outstanding Ordinary Shares shall be determined after giving effect
to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties
since the date as of which such number of outstanding Ordinary Shares was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be [4.99%] [9.99%] of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of the Ordinary
Shares issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number
of Ordinary Shares outstanding immediately after giving effect to the issuance of Ordinary Shares upon exercise of this Warrant held by
the Holder and the provisions of this Section&nbsp;2(e)&nbsp;shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e)&nbsp;to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;3</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Share
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a share dividend or otherwise makes
a distribution or distributions on its ADSs or Ordinary Shares or any other equity or equity equivalent securities payable in ADSs or
Ordinary Shares (which, for avoidance of doubt, shall not include any Warrant Shares or Warrant ADSs issued by the Company upon exercise
of this Warrant), (ii)&nbsp;subdivides outstanding Ordinary Shares or ADSs into a larger number of Ordinary Shares or ADSs, as applicable,
(iii)&nbsp;combines (including by way of reverse share split) outstanding ADSs or Ordinary Shares into a smaller number of Ordinary Shares
or ADSs, as applicable, or (iv)&nbsp;issues by reclassification of ADSs, Ordinary Shares or any shares of capital stock of the Company,
then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Ordinary Shares or
ADSs as applicable (excluding treasury Ordinary Shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of Ordinary Shares or ADSs, as applicable, outstanding immediately after such event, and the number of ADSs issuable
upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged,
provided that any reduction in the nominal value of the Ordinary Shares without any dividend or distribution shall not lead to any such
adjustment and provided, further, that the Exercise Price cannot be adjusted to a price that is lesser than the nominal value of the Ordinary
Shares. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall become effective immediately after the record date for the determination
of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the
case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, exclusive license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares (including Ordinary Shares
underlying the ADSs) are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted
by the holders of 50% or more of the outstanding Ordinary Shares (including Ordinary Shares underlying the ADSs) or 50% or more of the
voting power of the common equity of the Company, (iv)&nbsp;the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the
Ordinary Shares effectively converted into or exchanged for other securities, cash or property, or (v)&nbsp;the Company, directly or indirectly,
in one or more related transactions consummates a share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other
Person or group acquires 50% or more of the outstanding Ordinary Shares (including Ordinary Shares underlying the ADSs) or 50% or more
of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share represented by the Warrant ADSs that would
have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder
(without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the number of shares of capital stock of
the successor or acquiring corporation or of the Company, if the Company is the surviving corporation, and any additional consideration
(the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of
Warrant Shares represented by the Warrant ADSs for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one Ordinary Share (including any Warrant Shares underlying the ADSs), in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Ordinary Shares are given any choice as to the securities, cash or
property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all
of the obligations of the Company under this Warrant in accordance with the provisions of this Section&nbsp;3(b)&nbsp;pursuant to written
agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to
such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant, a security of
the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Warrant Shares
underlying the Warrant ADSs acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such
shares of capital stock (but taking into account the relative value of the Ordinary Shares underlying the Warrant ADSs pursuant to such
Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price
being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction),
and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the
Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation
of such Fundamental Transaction, each and every provision of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to
each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities,
jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor
Entities shall assume all of the obligations of the Company prior thereto under this Warrant with the same effect as if the Company and
such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt,
the Holder shall be entitled to the benefits of the provisions of this Section&nbsp;3(b)&nbsp;regardless of (i)&nbsp;whether the Company
has sufficient authorized Ordinary Shares for the issuance of Warrant Shares represented by Warrant ADSs and/or (ii)&nbsp;whether a Fundamental
Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be. For
purposes of this Section&nbsp;3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum
of the number of Ordinary Shares (including Ordinary Shares underlying ADSs, but excluding treasury ordinary shares, if any) issued and
outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant ADSs and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Ordinary Shares or ADSs, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares
or ADSs, (C)&nbsp;the Company shall authorize the granting to all holders of the Ordinary Shares or ADSs rights or warrants to subscribe
for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any shareholders of the Company shall
be required in connection with any reclassification of the Ordinary Shares or ADSs, any consolidation or merger to which the Company is
a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Ordinary
Shares are converted into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder
at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of
such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the
Ordinary Shares or ADSs of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Ordinary Shares (including Warrant Shares underlying Warrant ADSs)
of record shall be entitled to exchange their Ordinary Shares for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in
the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that
any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Report on Form&nbsp;6-K. The Holder shall remain entitled
to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice
except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">e)</TD><TD STYLE="text-align: justify">The Company shall take no action that would result in the Exercise Price per ADS being adjusted
                                                            hereunder to less than ten (10)&nbsp;Danish Krone, the nominal amount per share of the Ordinary Shares for ten (10) Ordinary Shares,
                                                            as expressed in United States dollars at the applicable exchange rate published by the Danish National Bank.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;4</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transfer
of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: White">a)</FONT><FONT STYLE="color: Black; background-color: White">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transferability</U>.
This Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of
the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall
issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three
(3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The
Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the subscription for Warrant ADSs without
having a new Warrant issued.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical with this
Warrant except as to the number of Warrant ADSs issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;5</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Rights as Shareholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive cash payments pursuant to Section&nbsp;2(d)(i)&nbsp;and
Section&nbsp;2(d)(iv)&nbsp;herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant ADSs, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period that the Warrant is outstanding, its directors will have authority to allot a sufficient number of shares to provide
for the issuance of the Warrant ADSs and the underlying Ordinary Shares upon the exercise of any subscription rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the
duty of issuing the Warrant Shares needed for the Depositary to issue the necessary Warrant ADSs upon the exercise of the subscription
rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares and
Warrant ADSs may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the applicable
Trading Market upon which the ADSs and/or Ordinary Shares may be listed. The Company covenants that all Warrant Shares represented by
Warrant ADSs which may be issued upon the exercise of the subscription rights represented by this Warrant will, upon exercise of the subscription
rights represented by this Warrant and payment for such Warrant ADSs in accordance herewith, be duly authorized, validly issued, fully
paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than any
taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles
of association or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any
other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times
in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to
protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company
will (i)&nbsp;not increase the nominal value of any Warrant Shares represented by Warrant ADSs above the amount payable therefor upon
such exercise immediately prior to such increase in nominal value, (ii)&nbsp;take all such action as may be necessary or appropriate in
order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares represented by Warrant ADSs upon the
exercise of this Warrant and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant ADSs for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the Kingdom of Denmark, without regard to the principles of conflict of
laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of this Warrant shall
be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &ldquo;<U>New York Courts</U>&rdquo;).
Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York
Courts, or such New York Courts are improper or inconvenient venue for such proceeding. Each party hereto hereby irrevocably waives, to
the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating
to this Warrant. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If any party shall commence an action or proceeding to enforce any provisions of this Warrant, then the
prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys&rsquo; fees and other costs and
expenses incurred in the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares represented by Warrant ADSs acquired upon the exercise of this Warrant, if not registered,
will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by email, or sent by a nationally recognized overnight courier service, addressed
to the Company, at Dr.&nbsp;Neergaards Vej 5f, DK-2970 Hoersholm, Denmark, Attention: <B>Anne-Sofie Wiemann </B>and <B>Susanne Bech</B>,
email addresses <B>awi@evaxion-biotech.com</B> and <B>sbe@evaxion-biotech.com</B> and <B>investor@evaxion-biotech.com</B> or such other
email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications
or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by email, or sent by a nationally
recognized overnight courier service addressed to each Holder at the email number or address of such Holder appearing on the books of
the Company, or if no such email number or address appears on the books of the Company. Any notice or other communication or deliveries
hereunder shall be deemed given and effective on the earliest of (i)&nbsp;the time of transmission, if such notice or communication is
delivered via email at the email address set forth in this Section&nbsp;prior to 5:30 p.m.&nbsp;(New York City time) on any date, (ii)&nbsp;the
next Trading Day after the time of transmission, if such notice or communication is delivered via email at the email address set forth
in this Section&nbsp;on a day that is not a Trading Day or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (iii)&nbsp;the
second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv)&nbsp;upon actual
receipt by the party to whom such notice is required to be given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to subscribe for
Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for
the subscription price of any Warrant Shares or Warrant ADSs or as a shareholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Company
Acknowledgement; Notice of Successor Danish Counsel; Payment of Aggregate Exercise Price</U>. The Company acknowledges and agrees that
the Holder&rsquo;s payment of the aggregate Exercise Price to Company Danish Counsel in connection with any exercise hereunder shall be
deemed to be the delivery by the Holder of the aggregate Exercise Price to the Company and shall satisfy the Holder&rsquo;s obligations
under this Warrant for the payment of the aggregate Exercise Price in connection with any exercise hereunder and shall require the Company
to deliver the Warrant ADSs upon such exercise to the Holder pursuant to the terms hereunder. If the Company changes its Company Danish
Counsel after the Initial Exercise Date, the Company shall promptly deliver notice of the successor Company Danish Counsel (including
the bank wire transfer instructions of such successor Company Danish Counsel) to the Holder (including, without limitation, any successor
holder of this Warrant) on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer of the Company, with
instructions in writing to pay the aggregate Exercise Price of this Warrant to such successor Company Danish Counsel. The Company acknowledges
that, if the Company Danish Counsel has received from the Holder the aggregate Exercise Price of the Warrant ADSs issuable upon exercise
of this Warrant pursuant to Section&nbsp;2.2(b)(ii)&nbsp;of the Purchase Agreement, the Company Danish Counsel shall convert such aggregate
Exercise Price of this Warrant into Danish Krone on the Initial Exercise Date and shall hold such amount in trust for the Holder and shall
release the applicable portion of such amount to the Company to apply it in connection with exercises of this Warrant pursuant to Section&nbsp;2
herein by the Holder or any subsequent assignee of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Reimbursement</U>.
The Company shall reimburse the Holder for any fees charged to the Holder by the Depositary in connection with the issuance or holding
or sale of the Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -0.01pt; width: 50%"></TD>
  <TD STYLE="padding-left: 0in; text-indent: -0.01pt"><B>EVAXION <FONT STYLE="text-transform: uppercase">BIOTECH A/S</FONT></B></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -0.01pt; width: 15pc">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -0.01pt">&nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -0.01pt; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">By:&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -0.01pt; width: 47%">&nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -0.01pt; width: 50%"></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
  <TD STYLE="padding-left: 0in; text-indent: -0.01pt; width: 47%">Name:</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -0.01pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="padding-left: 0in; text-indent: -0.01pt">Title:</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT><FONT STYLE="text-transform: uppercase">&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>EVAXION
BIOTECH A/S</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
undersigned hereby elects to subscribe for ________ Warrant ADSs of the Company pursuant to the terms of the attached Warrant (only if
exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Payment
shall take the form of lawful money of the United States to be delivered to Company Danish Counsel pursuant to the following bank wire
transfer instructions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Bank
Name</U></FONT>: Danske Bank&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Bank
Address</U></FONT>: Holmens Kanal 2, 1092 Copenhagen K, Denmark&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Bank
Account Name</U></FONT>: Mazanti-Andersen main client account&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Bank
Account Number</U></FONT>: 4777175572&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>IBAN</U></FONT>:
DK7130004777175572&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>SWIFT-BIC</U></FONT>:
DABADKKK&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Reference</U></FONT>:
Evaxion Biotech A/S&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Contact
Person and Telephone Number</U></FONT>: Lars L&uuml;thjohan. Ph. no.: +4540283536 E-mail: LLJ@mazanti.dk</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT> <FONT STYLE="font-size: 10pt">Please
issue said Warrant ADSs in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">DTC Participant name and number: ________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Contact of DTC Participant: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Telephone Number of DTC Participant
Contact: _____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="white-space: nowrap; text-align: justify; padding-left: 0in; text-indent: -0.01pt; width: 18%">Name of Investing Entity:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 0in; text-indent: -0.01pt"> &nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="white-space: nowrap; text-align: justify; padding-left: 0in; text-indent: -0.01pt; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signature</I></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>of Authorized Signatory of Investing Entity</I></FONT>:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 0in; text-indent: -0.01pt">&nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="white-space: nowrap; text-align: justify; padding-left: 0in; text-indent: -0.01pt; width: 20%">Name of Authorized Signatory:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 0in; text-indent: -0.01pt"> &nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="white-space: nowrap; text-align: justify; padding-left: 0in; text-indent: -0.01pt; width: 20%">Title of Authorized Signatory:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 0in; text-indent: -0.01pt"> &nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0in; text-indent: -0.01pt; width: 5%">Date:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 0in; text-indent: -0.01pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to subscribe for Warrant ADSs.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: White">Name:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; background-color: White; text-align: justify; width: 50%"> </TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-top: 1pt; text-align: justify">&nbsp;</TD>
  <TD STYLE="padding-top: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: White">(Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0in; text-indent: -0.01pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -0.01pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0in; text-indent: -0.01pt">Address:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-top: 1pt; text-align: justify">&nbsp;</TD>
  <TD STYLE="padding-top: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: White">(Please
  Print)</FONT>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0in; text-indent: -0.01pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -0.01pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0in; text-indent: -0.01pt">Phone Number:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -0.01pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0in; text-indent: -0.01pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -0.01pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0in; text-indent: -0.01pt">Email Address:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -0.01pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0in; text-indent: -0.01pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -0.01pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="background-color: White; text-align: justify; padding-left: 0in; text-indent: -0.01pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: _______________ __, ______</FONT> <FONT STYLE="background-color: White">&nbsp;</FONT></TD>
  <TD STYLE="background-color: White; text-align: justify; padding-left: 10pt; text-indent: -0.01pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="white-space: nowrap; text-align: justify; padding-left: 0in; text-indent: -0.01pt; width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: White">Holder&rsquo;s
Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 37%">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -0.01pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0in; text-indent: -0.01pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -0.01pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="white-space: nowrap; text-align: justify; padding-left: 0in; text-indent: -0.01pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: White">Holder&rsquo;s
Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -0.01pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>3
<FILENAME>tm2334005d4_ex4-5.htm
<DESCRIPTION>EXHIBIT 4.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;<FONT STYLE="font-size: 10pt"><B>EXHIBIT&#8239;4.5</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERIES A WARRANT TO SUBSCRIBE FOR ORDINARY
SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPRESENTED BY AMERICAN DEPOSITARY SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>EVAXION
BIOTECH A/S</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Warrant ADSs: ______</FONT></TD>
  <TD STYLE="text-align: right; padding-left: 10pt; width: 50%">Initial Exercise Date: ________, 2024</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS SERIES A WARRANT TO SUBSCRIBE
FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received,
______ or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or
prior to 5:00 p.m.&#8239;(New York City time) on ______<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT>
(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Evaxion Biotech A/S, a public limited
liability company incorporated under the laws of the Kingdom of Denmark (the &ldquo;<U>Company</U>&rdquo;), up to ______ Ordinary Shares
(the &ldquo;<U>Warrant Shares</U>&rdquo;) represented by _______ ADSs (the &ldquo;<U>Warrant ADSs</U>&rdquo;), as subject to adjustment
hereunder. The subscription price of one Warrant ADS under this Warrant shall be equal to the Exercise Price, as defined in Section&#8239;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&#8239;1</U>.</FONT>
 &#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Definitions</U>. In addition to the terms defined elsewhere in
this Warrant, the following terms have the meanings indicated in this Section&#8239;1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>ADS(s)</U>&rdquo;
means American Depositary Shares issued pursuant to the Deposit Agreement, each representing ten (10)&#8239;Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule&#8239;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal or national holiday in the United States
or Denmark or any day on which banking institutions in the State of New York or Denmark are authorized or required by law to remain closed;
provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to
 &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&#8239; or any other similar orders or
restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic
funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally open for use by customers
on such day or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1 </SUP> Insert the date that is the five (5) year anniversary
of the Initial Exercise Date, provided that, if such date is not a Trading Day, insert the immediately following Trading Day</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Danish Counsel</U>&rdquo; means Mazanti-Andersen, Amaliegade 10 1256 Copenhagen K, Denmark, or any successor Danish counsel to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Deposit
Agreement</U>&rdquo; means the Deposit Agreement, dated as of February&#8239;4, 2021, among the Company, The Bank of New York Mellon as
Depositary and the owners and holders of ADSs from time to time, as such agreement may be amended or supplemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Depositary</U>&rdquo;
means The Bank of New York Mellon and any successor depositary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&#8239;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary
Share(s)</U>&rdquo; means the ordinary shares of the Company, DKK 1 nominal value per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the securities purchase agreement, dated as of _____, 2024, by and between the Company and each of the purchasers
signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form&#8239;F-1 (File No.&#8239;333-276505).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&#8239;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Ordinary Shares and/or ADSs are listed or quoted for trading
on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or
the New York Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Computershare A/S, the current transfer agent of the Company, with a mailing address of Lottenborgvej 26 D, 1.,
DK-2800 Kgs. Lyngby, Denmark and company registration number (CVR) no. 27088899, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&#8239;if the ADSs are then listed or
quoted on a Trading Market, the daily volume weighted average price of the ADSs for such date (or the nearest preceding date) on the
Trading Market on which the ADSs are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.&#8239;(New
York City time) to 4:02 p.m.&#8239;(New York City time)), (b)&#8239; if OTCQB Venture Market (&ldquo;<U>OTCQB</U>&rdquo;) or OTCQX Best
Market (&ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the ADSs for such date (or the nearest
preceding date) on OTCQB or OTCQX as applicable, (c)&#8239;if the ADSs are not then listed or quoted for trading on OTCQB or OTCQX and
if prices for the ADSs are then reported in the &ldquo;Pink&rdquo; Open Market (&ldquo;<U>Pink Market</U>&rdquo;) operated by OTC Markets,&#8239;Inc.
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per ADS so reported,
or (d)&#8239;in all other cases, the fair market value of an ADS as determined by an independent appraiser selected in good faith by the
Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of
which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&#8239;2</U>.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
of Warrant</U>. This Warrant may be exercised, in whole or in part, at any time or times on or after the Initial Exercise Date and on
or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the
Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). On the Trading Day (based on New York City
time) on which the delivery of the Notice of Exercise occurs, the Holder shall deliver to the Company Danish Counsel the aggregate Exercise
Price for the Warrant ADSs specified in the applicable Notice of Exercise by wire transfer to the Company Danish Counsel pursuant to
the bank wire transfer instructions set forth on the Notice of Exercise attached hereto. No ink-original Notice of Exercise shall be
required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder
has subscribed for all of the Warrant ADSs available hereunder and the Warrant has been exercised in full, in which case, the Holder
shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the final
Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in the subscription of a portion of the total
number of Warrant ADSs available hereunder shall have the effect of reducing the outstanding number of Warrant ADSs purchasable hereunder
in an amount equal to the applicable number of Warrant ADSs subscribed. The Company shall record the number of Warrants issued to the
Holder and the number of Warrant ADSs subscribed through exercise and the date of such subscription of the Warrant ADSs. The Company
shall deliver any objection to any Notice of Exercise within one (1)&#8239;Trading Day of receipt of such notice. The Holder and any assignee,
by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the subscription
for a portion of the Warrant ADSs hereunder, the number of Warrant ADSs available for subscription hereunder at any given time may be
less than the amount stated on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. The exercise price per ADS under this Warrant shall be <B>$</B>_____, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Unavailability
of Registration Statement</U>. Notwithstanding anything to the contrary contained herein, if there is no effective registration statement
registering, or the prospectus contained therein is not available for, the sale of all of the Warrant Shares underlying the Warrant ADSs
issuable under this Warrant at any time following the Initial Exercise Date and ending on the Termination Date, the Holder shall be permitted
to exercise this Warrant by delivery of a Notice of Exercise to the Company, and, within one (1)&#8239;Trading Day (based on New York
City time) following the delivery of such Notice of Exercise, deliver to the Company Danish Counsel the aggregate Exercise Price with
respect to such exercise of this Warrant.&#8239; Upon delivery of a Notice of Exercise during a Registration Failure Period (as defined
below) and the timely payment of the aggregate Exercise Price, the Company shall be required to (1)&#8239;pay in cash to the Holder on
each Trading Day during the Registration Failure Period an amount equal to 1.0% of the product of (A)&#8239;the number of Warrant ADSs
subject to the exercise by the Holder pursuant to the immediately preceding sentence and (B)&#8239;the VWAP of the ADSs on the date of
delivery of the Notice of Exercise to the Company, and (2)&#8239;on the Trading Day immediately following the date on which the Registration
Failure Period ends, deliver all of the Warrant ADSs required to be delivered pursuant to such Notice of Exercise by crediting the account
of the Holder&rsquo;s prime broker with The Depository Trust Company through DWAC (as defined below).&#8239; The Company shall pay any
cash amounts owed pursuant to clause (1)&#8239;of the immediately preceding sentence no later than two (2)&#8239;Business Days after a
written request by the Holder (which request may be delivered by email). As used herein, &ldquo;<U>Registration Failure Period</U>&rdquo;
means the period (x)&#8239;beginning on the date of delivery of a Notice of Exercise at a time when there is no registration statement
registering, or the prospectus contained therein is not available for, the sale of all of the Warrant Shares underlying the Warrant ADSs
issuable under this Warrant, and (y)&#8239;ending on the later of (A)&#8239;the date that there is an effective registration statement
registering, and the prospectus contained therein is available for, the sale of all of the Warrant Shares underlying the Warrant ADSs
issuable hereunder and (B)&#8239;the date of delivery of all of the Warrant ADSs required to be delivered pursuant to the Notice of Exercise
by crediting the account of the Holder&rsquo;s prime broker with The Depository Trust Company through DWAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Delivery
of Warrant ADSs Upon Exercise</U>. Upon the exercise of this Warrant, the Company shall enter the Warrant Shares in the name of the Holder
in the Company&rsquo;s share register, deposit the Warrant Shares in connection with such exercise with the Depositary for the ADSs,
and instruct the Depositary to transmit the Warrant ADSs purchased hereunder to the Holder by crediting the account of the Holder&rsquo;s
or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit/Withdrawal At Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
if the Depositary is then a participant in such system and there is an effective registration statement permitting the issuance of the
Warrant Shares represented by the Warrant ADSs to the Holder, by the date that is the earlier of (i)&#8239;two (2)&#8239;Trading Days after
the delivery to the Company of the Notice of Exercise and (ii)&#8239;the number of Trading Days comprising the Standard Settlement Period
after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant ADS Delivery Date</U>&rdquo;), provided
that the Company shall not be obligated to deliver the Warrant ADSs hereunder unless the Company Danish Counsel has received the aggregate
Exercise Price on or before the Trading Day (based on New York City time) immediately prior to the Warrant ADS Delivery Date. Upon delivery
of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant ADSs
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant ADSs, provided that payment
of the aggregate Exercise Price is received by the Warrant ADS Delivery Date. If the Company fails for any reason (other than solely
as a result of actions or omissions by the Holder) to cause the Depositary to deliver to the Holder the Warrant ADSs subject to a Notice
of Exercise by the Warrant ADS Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty,
for each $1,000 of Warrant ADSs subject to such exercise (based on the VWAP of the ADSs on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant ADS Delivery Date) for each Trading
Day after such Warrant ADS Delivery Date until such Warrant ADSs are delivered or Holder rescinds such exercise. The Company agrees to
maintain a depositary and a transfer agent that each are a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a
number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the ADSs as in effect on the date of delivery of
the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s)&#8239;of Exercise delivered on or prior to 12:00
p.m.&#8239;(New York City time) on the Trading Day prior to the Initial Exercise Date, which may be delivered at any time after the time
of execution of the Purchase Agreement, the Company agrees to deliver the Warrant ADSs subject to such notice(s)&#8239;by 4:00 p.m.&#8239;(New
York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant ADS Delivery Date for purposes hereunder,
provided that payment of the aggregate Exercise Price is delivered to Company Danish Counsel by 12:00 p.m.&#8239;(New York City time)
on the Trading Day prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">ii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant ADSs, deliver to the Holder a new Warrant certificate
evidencing the rights of the Holder to subscribe for the unsubscribed Warrant ADSs called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">iii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rescission
Rights</U>. If the Company fails to cause the Depositary to transmit to the Holder the Warrant ADSs pursuant to Section&#8239;2(d)(i)&#8239;by
the Warrant ADS Delivery Date, then the Holder will have the right to rescind such exercise prior to the delivery of such Warrant ADSs
hereunder (with the effect that the Holder&rsquo;s right to acquire such Warrant ADSs pursuant to this Warrant shall be restored) and
the Company shall return to the Holder the aggregate Exercise Price paid to the Company Danish Counsel for such Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">iv.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; <FONT STYLE="font-size: 10pt"><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant ADSs Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Depositary to deliver to the Holder the Warrant ADSs in accordance with the provisions of
Section&#8239;2(d)(i)&#8239;above pursuant to an exercise on or before the Warrant ADS Delivery Date, and if after such date the
Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm
otherwise purchases, ADSs to deliver in satisfaction of a sale by the Holder of the Warrant ADSs which the Holder anticipated
receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A)&#8239;pay in cash to the Holder the amount,
if any, by which (x)&#8239;the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the ADSs so
purchased exceeds (y)&#8239;the amount obtained by multiplying (1)&#8239;the number of Warrant ADSs that the Company failed to
deliver to the Holder in connection with the exercise at issue by (2)&#8239;the price at which the sell order giving rise to such
purchase obligation was executed, and (B)&#8239;at the option of the Holder, either reinstate the portion of the Warrant in respect
of the equivalent number of Warrant ADSs for which such exercise was not honored and return any amount received by the Company
Danish Counsel in respect of the Exercise Price for those Warrant ADSs (in which case such exercise shall be deemed rescinded) or
deliver to the Holder the number of Warrant ADSs that would have been issued had the Company timely complied with its exercise and
delivery obligations hereunder. For example, if the Holder purchases ADSs having a total purchase price of $11,000 to cover a Buy-In
with respect to an attempted exercise of Warrants for ADSs with an aggregate sale price giving rise to such purchase obligation of
$10,000, under clause (A)&#8239;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The
Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon
request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other
remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Company&rsquo;s failure to timely deliver Warrant ADSs upon exercise of the Warrant as
required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">v.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Fractional Ordinary Shares or Warrant ADSs</U>. No fractional Warrant Shares or Warrant ADSs shall be issued upon the exercise of this
Warrant. As to any fraction of a Warrant ADS which the Holder would otherwise be entitled to subscribe upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole ADS, provided that the fraction of an ADS shall not be rounded up to the next whole
ADS if such rounding would result in the issue price being lower than the nominal value of the Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">vi.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant ADSs shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant ADSs, all of which taxes and expenses shall be paid by the Company, and such Warrant
ADSs shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant ADSs are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form&#8239;attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all
Depositary and Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic issuance and delivery of
the Warrant ADSs. The Company shall pay all applicable fees and expenses of the Depositary and Transfer Agent in connection with the
issuance of the Warrants ADSs hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">vii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing
of Books</U>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&#8239;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&#8239; For purposes of the foregoing sentence,
the number of Ordinary Shares beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of
Ordinary Shares underlying such Warrant ADSs issuable upon exercise of this Warrant with respect to which such determination is being
made, but shall exclude the number of Ordinary Shares underlying Warrant ADSs which would be issuable upon (i)&#8239;exercise of the remaining,
nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&#8239;exercise
or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other
Ordinary Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Affiliates or Attribution Parties.&#8239; Except as set forth in the preceding sentence, for purposes
of this Section&#8239;2(e), beneficial ownership shall be calculated in accordance with Section&#8239;13(d)&#8239;of the Exchange Act and
the rules&#8239;and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the
Holder that such calculation is in compliance with Section&#8239;13(d)&#8239;of the Exchange Act and the Holder is solely responsible for
any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section&#8239;2(e)&#8239;applies,
the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section&#8239;13(d)&#8239;of the Exchange Act and the rules&#8239;and regulations promulgated thereunder. For purposes of this Section&#8239;2(e),
in determining the number of outstanding Ordinary Shares, a Holder may rely on the number of outstanding Ordinary Shares as reflected
in (A)&#8239;the Company&rsquo;s most recent annual report on Form&#8239;20-F, Report on Form&#8239;6-K or other public filings filed with
the Commission, as the case may be, (B)&#8239;a more recent public announcement by the Company or (C)&#8239;a more recent written notice
by the Company or the Depositary or the Transfer Agent setting forth the number of Ordinary Shares outstanding.&#8239; Upon the written
or oral request of a Holder, the Company shall within one (1)&#8239;Trading Day confirm orally and in writing to the Holder the number
of Ordinary Shares then outstanding.&#8239; In any case, the number of outstanding Ordinary Shares shall be determined after giving effect
to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties
since the date as of which such number of outstanding Ordinary Shares was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of Ordinary Shares outstanding
immediately after giving effect to the issuance of the Ordinary Shares issuable upon exercise of this Warrant. The Holder, upon notice
to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section&#8239;2(e), provided that the
Beneficial Ownership Limitation in no event exceeds 9.99% of the number of Ordinary Shares outstanding immediately after giving effect
to the issuance of Ordinary Shares upon exercise of this Warrant held by the Holder and the provisions of this Section&#8239;2(e)&#8239;shall
continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such
notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section&#8239;2(e)&#8239;to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;<FONT STYLE="font-size: 10pt"><U>Section&#8239;3</U>.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Share
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&#8239;pays a share dividend or otherwise
makes a distribution or distributions on its ADSs or Ordinary Shares or any other equity or equity equivalent securities payable in ADSs
or Ordinary Shares (which, for avoidance of doubt, shall not include any Warrant Shares or Warrant ADSs issued by the Company upon exercise
of this Warrant), (ii)&#8239;subdivides outstanding Ordinary Shares or ADSs into a larger number of Ordinary Shares or ADSs, as applicable,
(iii)&#8239;combines (including by way of reverse share split) outstanding ADSs or Ordinary Shares into a smaller number of Ordinary Shares
or ADSs, as applicable, or (iv)&#8239;issues by reclassification of ADSs, Ordinary Shares or any shares of capital stock of the Company,
then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Ordinary Shares
or ADSs as applicable (excluding treasury Ordinary Shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of Ordinary Shares or ADSs, as applicable, outstanding immediately after such event, and the number of ADSs issuable
upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged,
provided that any reduction in the nominal value of the Ordinary Shares without any dividend or distribution shall not lead to any such
adjustment and provided, further, that the Exercise Price cannot be adjusted to a price that is lesser than the nominal value of the
Ordinary Shares. Any adjustment made pursuant to this Section&#8239;3(a)&#8239;shall become effective immediately after the record date
for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&#8239;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&#8239;the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, exclusive license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii)&#8239;any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares (including Ordinary Shares
underlying the ADSs) are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted
by the holders of 50% or more of the outstanding Ordinary Shares (including Ordinary Shares underlying the ADSs) or 50% or more of the
voting power of the common equity of the Company, (iv)&#8239;the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to
which the Ordinary Shares effectively converted into or exchanged for other securities, cash or property, or (v)&#8239;the Company, directly
or indirectly, in one or more related transactions consummates a share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires 50% or more of the outstanding Ordinary Shares (including Ordinary Shares underlying the ADSs) or
50% or more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon
any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share represented by the Warrant
ADSs that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option
of the Holder (without regard to any limitation in Section&#8239;2(e)&#8239;on the exercise of this Warrant), the number of shares of capital
stock of the successor or acquiring corporation or of the Company, if the Company is the surviving corporation, and any additional consideration
(the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of
Warrant Shares represented by the Warrant ADSs for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section&#8239;2(e)&#8239;on the exercise of this Warrant). For purposes of any such exercise, the
determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one Ordinary Share (including any Warrant Shares underlying the ADSs), in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Ordinary Shares are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the
event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable
at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the
public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount
of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation
of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within the Company's control,
including not approved by the Company's Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor
Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of
this Warrant, that is being offered and paid to the holders of Ordinary Shares (including Ordinary Shares underlying ADSs) of the Company
in connection with the Fundamental Transaction, whether that consideration be in the form of cash, shares or any combination thereof,
or whether the holders of Ordinary Shares (including Ordinary Shares underlying ADSs) are given the choice to receive from among alternative
forms of consideration in connection with the Fundamental Transaction; <U>provided</U>, <U>further</U>, that, if holders of Ordinary
Shares (including any Ordinary Shares underlying ADSs) of the Company are not offered or paid any consideration in such Fundamental Transaction,
such holders of Ordinary Shares (including any Ordinary Shares underlying ADSs) will be deemed to have received common equity of the
Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black
Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo;
function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting
(A)&#8239;a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public
announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B)&#8239;an expected volatility equal to
the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization
factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C)&#8239;the
underlying price per share used in such calculation shall be the greater of (i)&#8239;the sum of the price per Ordinary Share being offered
in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii)&#8239;the
highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable contemplated
Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of
the Holder&rsquo;s request pursuant to this Section&#8239;3(b), (D)&#8239;a remaining option time equal to the time between the date of
the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E)&#8239;a zero cost of borrow.
The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within
the later of (i)&#8239;five Business Days of the Holder&rsquo;s election and (ii)&#8239;the date of consummation of the Fundamental Transaction.
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of
this Section&#8239;3(b)&#8239;pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by
the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the
Holder in exchange for this Warrant, a security of the Successor Entity evidenced by a written instrument substantially similar in form
and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or
its parent entity) equivalent to the Warrant Shares underlying the Warrant ADSs acquirable and receivable upon exercise of this Warrant
(without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price
which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the Ordinary
Shares underlying the Warrant ADSs pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under
this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this
Warrant referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor Entities,
jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right
and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company
prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and
severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions
of this Section&#8239;3(b)&#8239;regardless of (i)&#8239;whether the Company has sufficient authorized Ordinary Shares for the issuance
of Warrant Shares represented by Warrant ADSs and/or (ii)&#8239;whether a Fundamental Transaction occurs prior to the Initial Exercise
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Calculations</U>.
All calculations under this Section&#8239;3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be. For
purposes of this Section&#8239;3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum
of the number of Ordinary Shares (including Ordinary Shares underlying ADSs, but excluding treasury ordinary shares, if any) issued and
outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&#8239;3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant ADSs and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">ii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice
to Allow Exercise by Holder</U>. If (A)&#8239;the Company shall declare a dividend (or any other distribution in whatever form) on the
Ordinary Shares or ADSs, (B)&#8239;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares
or ADSs, (C)&#8239;the Company shall authorize the granting to all holders of the Ordinary Shares or ADSs rights or warrants to subscribe
for or purchase any shares of capital stock of any class or of any rights, (D)&#8239;the approval of any shareholders of the Company shall
be required in connection with any reclassification of the Ordinary Shares or ADSs, any consolidation or merger to which the Company
is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the
Ordinary Shares are converted into other securities, cash or property, or (E)&#8239;the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by
email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days
prior to the applicable record or effective date hereinafter specified, a notice stating (x)&#8239;the date on which a record is to be
taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Ordinary Shares or ADSs of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y)&#8239;the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is
expected to become effective or close, and the date as of which it is expected that holders of the Ordinary Shares (including Warrant
Shares underlying Warrant ADSs) of record shall be entitled to exchange their Ordinary Shares for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver
such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified
in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding
the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Report on
Form&#8239;6-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the
effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">e)</TD><TD STYLE="text-align: justify"><U>Voluntary Adjustment By Company</U>. Subject
                                            to the rules&#8239;and regulations of the Trading Market, the Company may at any time during
                                            the term of this Warrant reduce the then current Exercise Price to any amount and for any
                                            period of time deemed appropriate by the board of directors of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">f)</TD><TD STYLE="text-align: justify">The Company shall take no action that would
                                            result in the Exercise Price per ADS being adjusted hereunder to less than  ten (10)&#8239;Danish
                                            Krone, the nominal amount per share of the Ordinary Shares for ten (10) Ordinary Shares, as expressed in United States
                                            dollars at the applicable exchange rate published by the Danish National Bank.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&#8239;4</U>.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transferability</U>.
This Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of
the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall
issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three
(3)&#8239;Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The
Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the subscription for Warrant ADSs without
having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&#8239;4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical
with this Warrant except as to the number of Warrant ADSs issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;<FONT STYLE="font-size: 10pt"><U>Section&#8239;5</U>.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Rights as Shareholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section&#8239;2(d)(i), except as expressly
set forth in Section&#8239;3. Without limiting any rights of a Holder to receive cash payments pursuant to Section&#8239;2(d)(i)&#8239;and
Section&#8239;2(d)(iv)&#8239;herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant ADSs, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&#8239;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period that the Warrant is outstanding, its directors will have authority to allot a sufficient number of shares to
provide for the issuance of the Warrant ADSs and the underlying Ordinary Shares upon the exercise of any subscription rights under this
Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of issuing the Warrant Shares needed for the Depositary to issue the necessary Warrant ADSs upon the exercise of the subscription
rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares and
Warrant ADSs may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the applicable
Trading Market upon which the ADSs and/or Ordinary Shares may be listed. The Company covenants that all Warrant Shares represented by
Warrant ADSs which may be issued upon the exercise of the subscription rights represented by this Warrant will, upon exercise of the
subscription rights represented by this Warrant and payment for such Warrant ADSs in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than any taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles
of association or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&#8239;not increase the nominal value of any Warrant Shares represented by Warrant ADSs above the amount payable therefor
upon such exercise immediately prior to such increase in nominal value, (ii)&#8239;take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares represented by Warrant ADSs upon
the exercise of this Warrant and (iii)&#8239;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant ADSs for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the Kingdom of Denmark, without regard to the principles of conflict of
laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of this Warrant shall
be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &ldquo;<U>New York Courts</U>&rdquo;).
Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York
Courts, or such New York Courts are improper or inconvenient venue for such proceeding. Each party hereto hereby irrevocably waives,
to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating
to this Warrant. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to
such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If any party shall commence an action or proceeding to enforce any provisions of this Warrant, then the
prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys&rsquo; fees and other costs and
expenses incurred in the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares represented by Warrant ADSs acquired upon the exercise of this Warrant, if not registered,
will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of
this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any
Notice of Exercise, shall be in writing and delivered personally, by email, or sent by a nationally recognized overnight courier service,
addressed to the Company, at Dr.&#8239;Neergaards Vej 5f, DK-2970 Hoersholm, Denmark, Attention: <B>Anne-Sofie Wiemann </B>and <B>Susanne
Bech</B>, email addresses <B>awi@evaxion-biotech.com</B> and <B>sbe@evaxion-biotech.com</B> and <B>investor@evaxion-biotech.com</B> or
such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other
communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by email, or sent
by a nationally recognized overnight courier service addressed to each Holder at the email number or address of such Holder appearing
on the books of the Company, or if no such email number or address appears on the books of the Company. Any notice or other communication
or deliveries hereunder shall be deemed given and effective on the earliest of (i)&#8239;the time of transmission, if such notice or communication
is delivered via email at the email address set forth in this Section&#8239;prior to 5:30 p.m.&#8239;(New York City time) on any date,
(ii)&#8239;the next Trading Day after the time of transmission, if such notice or communication is delivered via email at the email address
set forth in this Section&#8239;on a day that is not a Trading Day or later than 5:30 p.m.&#8239;(New York City time) on any Trading Day,
(iii)&#8239;the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or
(iv)&#8239;upon actual receipt by the party to whom such notice is required to be given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to subscribe for
Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for
the subscription price of any Warrant Shares or Warrant ADSs or as a shareholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Company
Acknowledgement; Notice of Successor Danish Counsel</U>. The Company acknowledges and agrees that the Holder&rsquo;s payment of the aggregate
Exercise Price to Company Danish Counsel in connection with any exercise hereunder shall be deemed to be the delivery by the Holder of
the aggregate Exercise Price to the Company and shall satisfy the Holder&rsquo;s obligations under this Warrant for the payment of the
aggregate Exercise Price in connection with any exercise hereunder and shall require the Company to deliver the Warrant ADSs upon such
exercise to the Holder pursuant to the terms hereunder. If the Company changes its Company Danish Counsel after the Initial Exercise
Date, the Company shall promptly deliver notice of the successor Company Danish Counsel ((including the bank wire transfer instructions
of such successor Company Danish Counsel) to the Holder (including, without limitation, any successor holder of this Warrant) on Company
letterhead and executed by the Chief Executive Officer or Chief Financial Officer of the Company, with instructions in writing to pay
the aggregate Exercise Price of this Warrant to such successor Company Danish Counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Reimbursement</U>.
The Company shall reimburse the Holder for any fees charged to the Holder by the Depositary in connection with the issuance or holding
or sale of the Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">p)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&#8239;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVAXION
    BIOTECH A/S</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    &#8239;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; text-transform: uppercase">To:</FONT><FONT STYLE="text-transform: uppercase">&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B>EVAXION
BIOTECH A/S</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(1)</FONT> <FONT STYLE="font-size: 10pt">The
undersigned hereby elects to subscribe for ________ Warrant ADSs of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if
any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(2)</FONT> <FONT STYLE="font-size: 10pt">Payment
shall take the form of lawful money of the United States to be delivered to Company Danish Counsel (as defined in the Warrant)
pursuant to the following bank wire transfer instructions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><U>Bank Name</U>: Danske Bank</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><U>Bank Address</U>: Holmens Kanal 2,
1092 Copenhagen K, Denmark</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><U>Bank Account Name</U>: Mazanti-Andersen
main client account</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><U>Bank Account Number</U>: 4777175572</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><U>IBAN</U>: DK7130004777175572</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><U>SWIFT-BIC</U>: DABADKKK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><U>Reference</U>: Evaxion Biotech A/S</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><U>Contact Person and Telephone Number</U>:
Lars L&uuml;thjohan. Ph. no.: +4540283536 E-mail: LLJ@mazanti.dk</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(3)</FONT>&#8239;<FONT STYLE="font-size: 10pt">Please
issue said Warrant ADSs in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">DTC Participant name and number: ________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Contact of DTC Participant: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Telephone Number of DTC Participant
Contact: _____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 405.75pt"><B>EXHIBIT&#8239;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left"><I>(To assign the foregoing Warrant, execute
this form and supply required information. Do not use this form to subscribe for Warrant ADSs.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%"></TD>
  <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Phone Number:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%"></TD></TR>
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
  <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-size: 10pt">Email Address:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
</TABLE>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Dated: _______________ __, ______</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Signature: ___________________________________</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Address:&#8239; ___________________________________</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>4
<FILENAME>tm2334005d4_ex4-6.htm
<DESCRIPTION>EXHIBIT 4.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 4.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PLACEMENT
AGENT WARRANT TO</B></FONT><B> SUBSCRIBE FOR ORDINARY SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPRESENTED BY AMERICAN DEPOSITARY SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>EVAXION
BIOTECH A/S</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 65%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant ADSs: ______</FONT></TD>
  <TD STYLE="padding-left: 0in; text-indent: -0.01pt; width: 35%"><FONT STYLE="font-size: 10pt">Initial
Exercise Date: ________, 2024</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">THIS
PLACEMENT AGENT </FONT>WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the &ldquo;<U>Warrant</U>&rdquo;)
certifies that, for value received, ______ or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to
the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise
Date</U>&rdquo;) and on or prior to 5:00 p.m.&nbsp;(New York City time) on ______<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT>
(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Evaxion Biotech A/S, a public limited
liability company incorporated under the laws of the Kingdom of Denmark (the &ldquo;<U>Company</U>&rdquo;), up to ______ Ordinary Shares
(the &ldquo;<U>Warrant Shares</U>&rdquo;) represented by _______ ADSs (the &ldquo;<U>Warrant ADSs</U>&rdquo;), as subject to adjustment
hereunder. The subscription price of one Warrant ADS under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b).
This Warant is being issued pursuant to that certain Engagement Agreement, dated as of September&nbsp;27, 2023, by and between the Company
and H.C. Wainwright&nbsp;&amp; Co., LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;1</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section&nbsp;1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>ADS(s)</U>&rdquo;
means American Depositary Shares issued pursuant to the Deposit Agreement, each representing ten (10)&nbsp;Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal or national holiday in the United States
or Denmark or any day on which banking institutions in the State of New York or Denmark are authorized or required by law to remain closed;
provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to
 &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp; or any other similar orders or
restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic
funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally open for use by customers
on such day or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> Insert the date that is the five (5) year anniversary
of the commencement of sales pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Danish Counsel</U>&rdquo; means Mazanti-Andersen, Amaliegade 10 1256 Copenhagen K, Denmark, or any successor Danish counsel to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Deposit
Agreement</U>&rdquo; means the Deposit Agreement, dated as of February&nbsp;4, 2021, among the Company, The Bank of New York Mellon as
Depositary and the owners and holders of ADSs from time to time, as such agreement may be amended or supplemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Depositary</U>&rdquo;
means The Bank of New York Mellon and any successor depositary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary
Share(s)</U>&rdquo; means the ordinary shares of the Company, DKK 1 nominal value per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the securities purchase agreement, dated as of _____, 2024, by and between the Company and each of the purchasers
signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form&nbsp;F-1 (File No.&nbsp;333-276505).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Ordinary Shares and/or ADSs are listed or quoted for trading
on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the
New York Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Computershare A/S, the current transfer agent of the Company, with a mailing address of Lottenborgvej 26 D, 1.,
DK-2800 Kgs. Lyngby, Denmark and company registration number (CVR) no. 27088899, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the ADSs are then listed or
quoted on a Trading Market, the daily volume weighted average price of the ADSs for such date (or the nearest preceding date) on the Trading
Market on which the ADSs are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.&nbsp;(New York
City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB Venture Market (&ldquo;<U>OTCQB</U>&rdquo;) or OTCQX Best Market
(&ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the ADSs for such date (or the nearest preceding
date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the ADSs are not then listed or quoted for trading on OTCQB or OTCQX and if prices
for the ADSs are then reported in the &ldquo;Pink&rdquo; Open Market (&ldquo;<U>Pink Market</U>&rdquo;) operated by OTC Markets,&nbsp;Inc.
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per ADS so reported,
or (d)&nbsp;in all other cases, the fair market value of an ADS as determined by an independent appraiser selected in good faith by the
Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of
which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;2</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
of Warrant</U>. This Warrant may be exercised, in whole or in part, at any time or times on or after the Initial Exercise Date and on
or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the
Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). On the Trading Day (based on New York City
time) on which the delivery of the Notice of Exercise occurs, the Holder shall deliver to the Company Danish Counsel the aggregate Exercise
Price for the Warrant ADSs specified in the applicable Notice of Exercise by wire transfer to the Company Danish Counsel pursuant to the
bank wire transfer instructions set forth on the Notice of Exercise attached hereto. No ink-original Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder
has subscribed for all of the Warrant ADSs available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the final Notice
of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in the subscription of a portion of the total number
of Warrant ADSs available hereunder shall have the effect of reducing the outstanding number of Warrant ADSs purchasable hereunder in
an amount equal to the applicable number of Warrant ADSs subscribed. The Company shall record the number of Warrants issued to the Holder
and the number of Warrant ADSs subscribed through exercise and the date of such subscription of the Warrant ADSs. The Company shall deliver
any objection to any Notice of Exercise within one (1)&nbsp;Trading Day of receipt of such notice. The Holder and any assignee, by acceptance
of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the subscription for a portion of
the Warrant ADSs hereunder, the number of Warrant ADSs available for subscription hereunder at any given time may be less than the amount
stated on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. The exercise price per ADS under this Warrant shall be <B>$</B>_____, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Unavailability
of Registration Statement</U>. Notwithstanding anything to the contrary contained herein, if there is no effective registration statement
registering, or the prospectus contained therein is not available for, the sale of all of the Warrant Shares underlying the Warrant ADSs
issuable under this Warrant at any time following the Initial Exercise Date and ending on the Termination Date, the Holder shall be permitted
to exercise this Warrant by delivery of a Notice of Exercise to the Company, and, within one (1)&nbsp;Trading Day (based on New York City
time) following the delivery of such Notice of Exercise, deliver to the Company Danish Counsel the aggregate Exercise Price with respect
to such exercise of this Warrant.&nbsp; Upon delivery of a Notice of Exercise during a Registration Failure Period (as defined below)
and the timely payment of the aggregate Exercise Price, the Company shall be required to (1)&nbsp;pay in cash to the Holder on each Trading
Day during the Registration Failure Period an amount equal to 1.0% of the product of (A)&nbsp;the number of Warrant ADSs subject to the
exercise by the Holder pursuant to the immediately preceding sentence and (B)&nbsp;the VWAP of the ADSs on the date of delivery of the
Notice of Exercise to the Company, and (2)&nbsp;on the Trading Day immediately following the date on which the Registration Failure Period
ends, deliver all of the Warrant ADSs required to be delivered pursuant to such Notice of Exercise by crediting the account of the Holder&rsquo;s
prime broker with The Depository Trust Company through DWAC (as defined below).&nbsp; The Company shall pay any cash amounts owed pursuant
to clause (1)&nbsp;of the immediately preceding sentence no later than two (2)&nbsp;Business Days after a written request by the Holder
(which request may be delivered by email). As used herein, &ldquo;<U>Registration Failure Period</U>&rdquo; means the period (x)&nbsp;beginning
on the date of delivery of a Notice of Exercise at a time when there is no registration statement registering, or the prospectus contained
therein is not available for, the sale of all of the Warrant Shares underlying the Warrant ADSs issuable under this Warrant, and (y)&nbsp;ending
on the later of (A)&nbsp;the date that there is an effective registration statement registering, and the prospectus contained therein
is available for, the sale of all of the Warrant Shares underlying the Warrant ADSs issuable hereunder and (B)&nbsp;the date of delivery
of all of the Warrant ADSs required to be delivered pursuant to the Notice of Exercise by crediting the account of the Holder&rsquo;s
prime broker with The Depository Trust Company through DWAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of Warrant ADSs Upon Exercise</U>. Upon the exercise of this Warrant, the Company shall enter the Warrant Shares in the name of the Holder
in the Company&rsquo;s share register, deposit the Warrant Shares in connection with such exercise with the Depositary for the ADSs, and
instruct the Depositary to transmit the Warrant ADSs purchased hereunder to the Holder by crediting the account of the Holder&rsquo;s
or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit/Withdrawal At Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
if the Depositary is then a participant in such system and there is an effective registration statement permitting the issuance of the
Warrant Shares represented by the Warrant ADSs to the Holder, by the date that is the earlier of (i)&nbsp;two (2)&nbsp;Trading Days after
the delivery to the Company of the Notice of Exercise and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period
after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant ADS Delivery Date</U>&rdquo;), provided
that the Company shall not be obligated to deliver the Warrant ADSs hereunder unless the Company Danish Counsel has received the aggregate
Exercise Price on or before the Trading Day (based on New York City time) immediately prior to the Warrant ADS Delivery Date. Upon delivery
of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant ADSs
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant ADSs, provided that payment
of the aggregate Exercise Price is received by the Warrant ADS Delivery Date. If the Company fails for any reason (other than solely as
a result of actions or omissions by the Holder) to cause the Depositary to deliver to the Holder the Warrant ADSs subject to a Notice
of Exercise by the Warrant ADS Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty,
for each $1,000 of Warrant ADSs subject to such exercise (based on the VWAP of the ADSs on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant ADS Delivery Date) for each Trading
Day after such Warrant ADS Delivery Date until such Warrant ADSs are delivered or Holder rescinds such exercise. The Company agrees to
maintain a depositary and a transfer agent that each are a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a
number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the ADSs as in effect on the date of delivery of
the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s)&nbsp;of Exercise delivered on or prior to 12:00 p.m.&nbsp;(New
York City time) on the Trading Day prior to the Initial Exercise Date, which may be delivered at any time after the time of execution
of the Purchase Agreement, the Company agrees to deliver the Warrant ADSs subject to such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New York City
time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant ADS Delivery Date for purposes hereunder, provided
that payment of the aggregate Exercise Price is delivered to Company Danish Counsel by 12:00 p.m.&nbsp;(New York City time) on the Trading
Day prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant ADSs, deliver to the Holder a new Warrant certificate
evidencing the rights of the Holder to subscribe for the unsubscribed Warrant ADSs called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rescission
Rights</U>. If the Company fails to cause the Depositary to transmit to the Holder the Warrant ADSs pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant ADS Delivery Date, then the Holder will have the right to rescind such exercise prior to the delivery of such Warrant ADSs
hereunder (with the effect that the Holder&rsquo;s right to acquire such Warrant ADSs pursuant to this Warrant shall be restored) and
the Company shall return to the Holder the aggregate Exercise Price paid to the Company Danish Counsel for such Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant ADSs Upon Exercise</U>. In addition to any other rights available to the Holder, if the
Company fails to cause the Depositary to deliver to the Holder the Warrant ADSs in accordance with the provisions of Section&nbsp;2(d)(i)&nbsp;above
pursuant to an exercise on or before the Warrant ADS Delivery Date, and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, ADSs to deliver in satisfaction
of a sale by the Holder of the Warrant ADSs which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase price
(including brokerage commissions, if any) for the ADSs so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number
of Warrant ADSs that the Company failed to deliver to the Holder in connection with the exercise at issue by (2)&nbsp;the price at which
the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the Holder, either reinstate the portion
of the Warrant in respect of the equivalent number of Warrant ADSs for which such exercise was not honored and return any amount received
by the Company Danish Counsel in respect of the Exercise Price for those Warrant ADSs (in which case such exercise shall be deemed rescinded)
or deliver to the Holder the number of Warrant ADSs that would have been issued had the Company timely complied with its exercise and
delivery obligations hereunder. For example, if the Holder purchases ADSs having a total purchase price of $11,000 to cover a Buy-In with
respect to an attempted exercise of Warrants for ADSs with an aggregate sale price giving rise to such purchase obligation of $10,000,
under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide
the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence
of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder,
at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s
failure to timely deliver Warrant ADSs upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Fractional Ordinary Shares or Warrant ADSs</U>. No fractional Warrant Shares or Warrant ADSs shall be issued upon the exercise of this
Warrant. As to any fraction of a Warrant ADS which the Holder would otherwise be entitled to subscribe upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole ADS, provided that the fraction of an ADS shall not be rounded up to the next whole
ADS if such rounding would result in the issue price being lower than the nominal value of the Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant ADSs shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant ADSs, all of which taxes and expenses shall be paid by the Company, and such Warrant
ADSs shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant ADSs are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise
shall be accompanied by the Assignment Form&nbsp;attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Depositary
and Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for same-day electronic issuance and delivery of the Warrant ADSs.
The Company shall pay all applicable fees and expenses of the Depositary and Transfer Agent in connection with the issuance of the Warrants
ADSs hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing
of Books</U>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of Ordinary Shares beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of
Ordinary Shares underlying such Warrant ADSs issuable upon exercise of this Warrant with respect to which such determination is being
made, but shall exclude the number of Ordinary Shares underlying Warrant ADSs which would be issuable upon (i)&nbsp;exercise of the remaining,
nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise
or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other
Ordinary Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes
of this Section&nbsp;2(e), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and
the rules&nbsp;and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the
Holder that such calculation is in compliance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the Holder is solely responsible for
any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section&nbsp;2(e)&nbsp;applies,
the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e),
in determining the number of outstanding Ordinary Shares, a Holder may rely on the number of outstanding Ordinary Shares as reflected
in (A)&nbsp;the Company&rsquo;s most recent annual report on Form&nbsp;20-F, Report on Form&nbsp;6-K or other public filings filed with
the Commission, as the case may be, (B)&nbsp;a more recent public announcement by the Company or (C)&nbsp;a more recent written notice
by the Company or the Depositary or the Transfer Agent setting forth the number of Ordinary Shares outstanding.&nbsp; Upon the written
or oral request of a Holder, the Company shall within one (1)&nbsp;Trading Day confirm orally and in writing to the Holder the number
of Ordinary Shares then outstanding.&nbsp; In any case, the number of outstanding Ordinary Shares shall be determined after giving effect
to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties
since the date as of which such number of outstanding Ordinary Shares was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of Ordinary Shares outstanding
immediately after giving effect to the issuance of the Ordinary Shares issuable upon exercise of this Warrant. The Holder, upon notice
to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;2(e), provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance
of Ordinary Shares upon exercise of this Warrant held by the Holder and the provisions of this Section&nbsp;2(e)&nbsp;shall continue to
apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered
to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with
the terms of this Section&nbsp;2(e)&nbsp;to correct this paragraph (or any portion hereof) which may be defective or inconsistent with
the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give
effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;3</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Share
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a share dividend or otherwise makes
a distribution or distributions on its ADSs or Ordinary Shares or any other equity or equity equivalent securities payable in ADSs or
Ordinary Shares (which, for avoidance of doubt, shall not include any Warrant Shares or Warrant ADSs issued by the Company upon exercise
of this Warrant), (ii)&nbsp;subdivides outstanding Ordinary Shares or ADSs into a larger number of Ordinary Shares or ADSs, as applicable,
(iii)&nbsp;combines (including by way of reverse share split) outstanding ADSs or Ordinary Shares into a smaller number of Ordinary Shares
or ADSs, as applicable, or (iv)&nbsp;issues by reclassification of ADSs, Ordinary Shares or any shares of capital stock of the Company,
then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Ordinary Shares or
ADSs as applicable (excluding treasury Ordinary Shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of Ordinary Shares or ADSs, as applicable, outstanding immediately after such event, and the number of ADSs issuable
upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged,
provided that any reduction in the nominal value of the Ordinary Shares without any dividend or distribution shall not lead to any such
adjustment and provided, further, that the Exercise Price cannot be adjusted to a price that is lesser than the nominal value of the Ordinary
Shares. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall become effective immediately after the record date for the determination
of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the
case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, exclusive license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares (including Ordinary Shares
underlying the ADSs) are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted
by the holders of 50% or more of the outstanding Ordinary Shares (including Ordinary Shares underlying the ADSs) or 50% or more of the
voting power of the common equity of the Company, (iv)&nbsp;the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the
Ordinary Shares effectively converted into or exchanged for other securities, cash or property, or (v)&nbsp;the Company, directly or indirectly,
in one or more related transactions consummates a share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other
Person or group acquires 50% or more of the outstanding Ordinary Shares (including Ordinary Shares underlying the ADSs) or 50% or more
of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share represented by the Warrant ADSs that would
have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder
(without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the number of shares of capital stock of
the successor or acquiring corporation or of the Company, if the Company is the surviving corporation, and any additional consideration
(the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of
Warrant Shares represented by the Warrant ADSs for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one Ordinary Share (including any Warrant Shares underlying the ADSs), in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Ordinary Shares are given any choice as to the securities, cash or
property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the
event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable
at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the
public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount
of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation
of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within the Company's control,
including not approved by the Company's Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor
Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this
Warrant, that is being offered and paid to the holders of Ordinary Shares (including Ordinary Shares underlying ADSs) of the Company in
connection with the Fundamental Transaction, whether that consideration be in the form of cash, shares or any combination thereof, or
whether the holders of Ordinary Shares (including Ordinary Shares underlying ADSs) are given the choice to receive from among alternative
forms of consideration in connection with the Fundamental Transaction; <U>provided</U>, <U>further</U>, that, if holders of Ordinary Shares
(including any Ordinary Shares underlying ADSs) of the Company are not offered or paid any consideration in such Fundamental Transaction,
such holders of Ordinary Shares (including any Ordinary Shares underlying ADSs) will be deemed to have received common equity of the Successor
Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes
Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function
on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A)&nbsp;a
risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement
of the applicable contemplated Fundamental Transaction and the Termination Date, (B)&nbsp;an expected volatility equal to the greater
of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as
of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C)&nbsp;the
underlying price per share used in such calculation shall be the greater of (i)&nbsp;the sum of the price per Ordinary Share being offered
in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii)&nbsp;the
highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable contemplated
Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the
Holder&rsquo;s request pursuant to this Section&nbsp;3(b), (D)&nbsp;a remaining option time equal to the time between the date of the
public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E)&nbsp;a zero cost of borrow.
The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within
the later of (i)&nbsp;five Business Days of the Holder&rsquo;s election and (ii)&nbsp;the date of consummation of the Fundamental Transaction.
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of
this Section&nbsp;3(b)&nbsp;pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by
the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder
in exchange for this Warrant, a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance
to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity)
equivalent to the Warrant Shares underlying the Warrant ADSs acquirable and receivable upon exercise of this Warrant (without regard to
any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise
price hereunder to such shares of capital stock (but taking into account the relative value of the Ordinary Shares underlying the Warrant
ADSs pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and
such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such
Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental
Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence
or consummation of such Fundamental Transaction, each and every provision of this Warrant referring to the &ldquo;Company&rdquo; shall
refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity
or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the
Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant with the same
effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein.
For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section&nbsp;3(b)&nbsp;regardless of
(i)&nbsp;whether the Company has sufficient authorized Ordinary Shares for the issuance of Warrant Shares represented by Warrant ADSs
and/or (ii)&nbsp;whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be. For
purposes of this Section&nbsp;3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum
of the number of Ordinary Shares (including Ordinary Shares underlying ADSs, but excluding treasury ordinary shares, if any) issued and
outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant ADSs and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Ordinary Shares or ADSs, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares
or ADSs, (C)&nbsp;the Company shall authorize the granting to all holders of the Ordinary Shares or ADSs rights or warrants to subscribe
for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any shareholders of the Company shall
be required in connection with any reclassification of the Ordinary Shares or ADSs, any consolidation or merger to which the Company is
a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Ordinary
Shares are converted into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder
at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of
such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the
Ordinary Shares or ADSs of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Ordinary Shares (including Warrant Shares underlying Warrant ADSs)
of record shall be entitled to exchange their Ordinary Shares for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in
the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that
any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Report on Form&nbsp;6-K. The Holder shall remain entitled
to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice
except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">e)</TD><TD STYLE="text-align: justify"><U>Voluntary Adjustment By Company</U>. Subject to the rules&nbsp;and regulations of the Trading Market,
the Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of
time deemed appropriate by the board of directors of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">f)</TD><TD STYLE="text-align: justify">The Company shall take no action that would result in the Exercise Price per ADS being adjusted hereunder
to less than one (1)&nbsp;Danish Krone, the nominal amount per share of the Ordinary Shares, as expressed in United States dollars at
the applicable exchange rate published by the Danish National Bank.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;4</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transfer
of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transferability</U>.
This Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of
the Co<FONT STYLE="background-color: White">mpany or its designated agent, together with a written assignment of this Warrant substantially
in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable
upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant
or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant
to the Company within three (3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form to the Company assigning
this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the subscription
for Warrant ADSs without having</FONT> a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical with this
Warrant except as to the number of Warrant ADSs issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;5</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Rights as Shareholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive cash payments pursuant to Section&nbsp;2(d)(i)&nbsp;and
Section&nbsp;2(d)(iv)&nbsp;herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant ADSs, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period that the Warrant is outstanding, its directors will have authority to allot a sufficient number of shares to provide
for the issuance of the Warrant ADSs and the underlying Ordinary Shares upon the exercise of any subscription rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the
duty of issuing the Warrant Shares needed for the Depositary to issue the necessary Warrant ADSs upon the exercise of the subscription
rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares and
Warrant ADSs may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the applicable
Trading Market upon which the ADSs and/or Ordinary Shares may be listed. The Company covenants that all Warrant Shares represented by
Warrant ADSs which may be issued upon the exercise of the subscription rights represented by this Warrant will, upon exercise of the subscription
rights represented by this Warrant and payment for such Warrant ADSs in accordance herewith, be duly authorized, validly issued, fully
paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than any
taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles
of association or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any
other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times
in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to
protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company
will (i)&nbsp;not increase the nominal value of any Warrant Shares represented by Warrant ADSs above the amount payable therefor upon
such exercise immediately prior to such increase in nominal value, (ii)&nbsp;take all such action as may be necessary or appropriate in
order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares represented by Warrant ADSs upon the
exercise of this Warrant and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant ADSs for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the Kingdom of Denmark, without regard to the principles of conflict of
laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of this Warrant shall
be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &ldquo;<U>New York Courts</U>&rdquo;).
Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York
Courts, or such New York Courts are improper or inconvenient venue for such proceeding. Each party hereto hereby irrevocably waives, to
the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating
to this Warrant. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If any party shall commence an action or proceeding to enforce any provisions of this Warrant, then the
prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys&rsquo; fees and other costs and
expenses incurred in the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares represented by Warrant ADSs acquired upon the exercise of this Warrant, if not registered,
will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by email, or sent by a nationally recognized overnight courier service, addressed
to the Company, at Dr.&nbsp;Neergaards Vej 5f, DK-2970 Hoersholm, Denmark, Attention: <B>Anne-Sofie Wiemann </B>and <B>Susanne Bech</B>,
email addresses <B>awi@evaxion-biotech.com</B> and <B>sbe@evaxion-biotech.com</B> and <B>investor@evaxion-biotech.com</B> or such other
email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications
or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by email, or sent by a nationally
recognized overnight courier service addressed to each Holder at the email number or address of such Holder appearing on the books of
the Company, or if no such email number or address appears on the books of the Company. Any notice or other communication or deliveries
hereunder shall be deemed given and effective on the earliest of (i)&nbsp;the time of transmission, if such notice or communication is
delivered via email at the email address set forth in this Section&nbsp;prior to 5:30 p.m.&nbsp;(New York City time) on any date, (ii)&nbsp;the
next Trading Day after the time of transmission, if such notice or communication is delivered via email at the email address set forth
in this Section&nbsp;on a day that is not a Trading Day or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (iii)&nbsp;the
second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv)&nbsp;upon actual
receipt by the party to whom such notice is required to be given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to subscribe for
Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for
the subscription price of any Warrant Shares or Warrant ADSs or as a shareholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Company
Acknowledgement; Notice of Successor Danish Counsel</U>. The Company acknowledges and agrees that the Holder&rsquo;s payment of the aggregate
Exercise Price to Company Danish Counsel in connection with any exercise hereunder shall be deemed to be the delivery by the Holder of
the aggregate Exercise Price to the Company and shall satisfy the Holder&rsquo;s obligations under this Warrant for the payment of the
aggregate Exercise Price in connection with any exercise hereunder and shall require the Company to deliver the Warrant ADSs upon such
exercise to the Holder pursuant to the terms hereunder. If the Company changes its Company Danish Counsel after the Initial Exercise Date,
the Company shall promptly deliver notice of the successor Company Danish Counsel ((including the bank wire transfer instructions of such
successor Company Danish Counsel) to the Holder (including, without limitation, any successor holder of this Warrant) on Company letterhead
and executed by the Chief Executive Officer or Chief Financial Officer of the Company, with instructions in writing to pay the aggregate
Exercise Price of this Warrant to such successor Company Danish Counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Reimbursement</U>.
The Company shall reimburse the Holder for any fees charged to the Holder by the Depositary in connection with the issuance or holding
or sale of the Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>EVAXION BIOTECH A/S</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT><FONT STYLE="text-transform: uppercase">&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>EVAXION
BIOTECH A/S</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&nbsp;<FONT STYLE="font-size: 10pt">The
undersigned hereby elects to subscribe for ________ Warrant ADSs of the Company pursuant to the terms of the attached Warrant (only if
exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&nbsp;<FONT STYLE="font-size: 10pt">Payment
shall take the form of lawful money of the United States to be delivered to Company Danish Counsel (as defined in the Warrant) pursuant
to the following bank wire transfer instructions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Bank
Name</U></FONT>: Danske Bank</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Bank
Address</U></FONT>: Holmens Kanal 2, 1092 Copenhagen K, Denmark</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Bank
Account Name</U></FONT>: Mazanti-Andersen main client account</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Bank
Account Number</U></FONT>: 4777175572</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>IBAN</U></FONT>:
DK7130004777175572</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>SWIFT-BIC</U></FONT>:
DABADKKK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Reference</U></FONT>:
Evaxion Biotech A/S</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Contact
Person and Telephone Number</U></FONT>: Lars L&uuml;thjohan. Ph. no.: +4540283536 E-mail: LLJ@mazanti.dk</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT>&nbsp;<FONT STYLE="font-size: 10pt">Please
issue said Warrant ADSs in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">DTC Participant name and number: ________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Contact of DTC Participant: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Telephone Number of DTC Participant
Contact: _____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 16%">Name of Investing Entity:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 84%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; width: 35%">Signature of Authorized Signatory of Investing Entity:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; width: 65%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">Name of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">Title of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 96%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: right; text-indent: 0"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to subscribe for Warrant ADSs.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Name:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Address:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(Please Print) </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Phone Number: </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Email Address:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dated: _______________ __, ______</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 13%">Holder&rsquo;s Signature:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 36%">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Holder&rsquo;s Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>tm2334005d4_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 40%"><IMG SRC="tm2334005d4_ex5-1img001.jpg" ALT=""></TD>
  <TD STYLE="width: 30%"><P STYLE="margin-top: 0; margin-bottom: 0">Mazanti-Andersen</P>

<P STYLE="margin-top: 0; margin-bottom: 0">Advokatpartnerselskab</P>

<P STYLE="margin-top: 0; margin-bottom: 0">VAT: DK35892052</P>

<P STYLE="margin-top: 0; margin-bottom: 0">www.mazanti.dk</P>

</TD>
  <TD STYLE="text-align: left; width: 30%"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Amaliegade 10</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">DK-1256 K&oslash;benhavn K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">+45 3314 3536</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Klosterbakken 12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">DK-5000 Odense C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">+45 6314 1414</P>

</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left; width: 30%"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Evaxion Biotech A/S</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Dr Neergaards Vej 5F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">DK-2970 H&oslash;rsholm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Denmark</P>

</TD>
  <TD STYLE="width: 70%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">30.01.2024</P>
                               <P STYLE="margin-top: 0; margin-bottom: 0">Ref. 70451/LLJ</P>
                               <P STYLE="margin-top: 0; margin-bottom: 0">ID 3159</P></TD>
  <TD></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-size: 5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left"><IMG SRC="tm2334005d4_ex5-1img002.jpg" ALT=""></TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left"><B>Lars L&uuml;thjohan</B> <BR>
  Attorney-at-law<BR>
  D: +45 3319 3749<BR>
  M: +45 4028 3536 <BR>
  llj@mazanti.dk</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Re. Evaxion Biotech A/S &ndash; Form F-1 Registration Statement (File No. 333-276505)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.05pt">1.</TD><TD>Introduction</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50pt; text-align: justify">I act as Danish legal adviser to Evaxion
Biotech A/S (the &ldquo;Company&rdquo;), in connection with the Registration Statement on Form F-1/A (File No. 333-276505) (the &ldquo;Registration
Statement&rdquo;) filed by the Company with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) on January 30, 2024
for purposes of registering under the Securities Act of 1933 (the &ldquo;Securities Act&rdquo;) the offer and sale of the Company&rsquo;s
ordinary shares, DKK 1 nominal value (the &ldquo;Ordinary Shares&rdquo;), represented by American Depositary Shares (&ldquo;ADSs&rdquo;),
with each ADS representing ten (10) ordinary shares (&ldquo;Placement Shares&rdquo;) as well as Series A Warrants (the &ldquo;Series A
Warrants&rdquo;), Pre-Funded Warrants (the &rdquo;Pre=Funded Warrants&rdquo;) and Placement Agent Warrants (the &ldquo;Placement Agent
Warrants&rdquo;; and along with the Pre-Funded Warrants and the Series A Warrants sometimes hereinafter collectively referred to as the
 &ldquo;Warrants&rdquo;) each such Warrant conferring the right to purchase ADSs with each ADS representing ten (10) Ordinary Shares.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.05pt">1.1</TD><TD STYLE="text-align: justify">This opinion is being rendered in connection with the filing of the Registration Statement with the Commission.
Certain terms used in this opinion are defined in Annex 1 (Definitions).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.05pt">2.</TD><TD>Danish Law</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.05pt">2.1</TD><TD STYLE="text-align: justify">This opinion is limited to Danish law in effect on the date of this opinion and we express no
                                                             opinion with regard to the laws of any other jurisdiction. The opinion (including all terms used in it) is in all respects to be
                                                             construed in accordance with Danish law. This opinion does not include an assessment or opinion as to whether the Shares and the Warrants have been subscribed at market
price in accordance with the Danish Companies Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm2334005d4_ex5-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.05pt">3.</TD><TD>Scope of Inquiry</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.05pt">3.1</TD><TD STYLE="text-align: justify">For the purpose of this opinion, I have examined, and relied upon the accuracy of the factual statements
and compliance with the undertakings in, the following documents:</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 51.05pt">3.1.1</TD><TD STYLE="text-align: justify">A copy of the Registration Statement, in the form filed and to be filed with the Commission, and the exhibits filed or to be filed
in connection therewith.</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 51.05pt">3.1.2</TD><TD STYLE="text-align: justify">A copy of:</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 51.05pt"></TD><TD STYLE="text-align: justify; width: 25.5pt">(a)</TD><TD STYLE="text-align: justify">the Company&rsquo;s deed of incorporation and articles of association as in effect on today&rsquo;s date;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 51.05pt"></TD><TD STYLE="text-align: justify; width: 25.5pt">(b)</TD><TD STYLE="text-align: justify">a compiled summary from the Danish Business Authority dated as of today&rsquo;s date; and</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 51.05pt"></TD><TD STYLE="text-align: justify; width: 25.5pt">(c)</TD><TD STYLE="text-align: justify">the Owners&rsquo; Register.</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 51.05pt">3.2</TD><TD STYLE="text-align: justify">A copy of:</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 51.05pt"></TD><TD STYLE="text-align: justify; width: 25.5pt">(a)</TD><TD STYLE="text-align: justify">the form of Securities Purchase Agreement dated [&#9679;] between the Company and the purchasers signatory thereto (the &rdquo;SPA&rdquo;)
filed as Exhibit 10.1 to the Registration Statement;</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 51.05pt"></TD><TD STYLE="text-align: justify; width: 25.5pt">(b)</TD><TD STYLE="text-align: justify">the form of Pre-Funded Warrants between the Company and the purchasers thereof to purchase ADSs representing Ordinary Shares filed
as Exhibit 4.4 to the Registration Statement; and</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 51.05pt"></TD><TD STYLE="text-align: justify; width: 25.5pt">(c)</TD><TD STYLE="text-align: justify">the form of Series A Warrants between the Company and the purchasers thereof to purchase ADSs representing Ordinary Shares filed as
Exhibit 4.5 to the Registration Statement</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 51.05pt">3.3</TD><TD STYLE="text-align: justify">In addition, I have examined such documents, and performed such other investigations, as I consider necessary
for the purpose of this opinion. My examination has been limited to the text of the documents. With your consent I have relied upon certificates
and other assurances of officers of the Company and others
as to factual matters without having independently verified such factual matters.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm2334005d4_ex5-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify; width: 48px"><FONT STYLE="font-size: 10pt"><B>4.&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Assumptions</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><B></B>In giving this opinion
we have assumed, without further verification, the completeness and accuracy of all documentation that we have reviewed. We have also
relied upon the following assumptions, which we have not independently verified:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: justify">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Copies of documents, conformed copies or drafts of documents
    provided to us are true and complete copies of, or in the final forms of, the originals.</P></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="text-align: justify">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">That the final forms of the SPA, the Series A Warrant instrument,
the Pre-Funded Warrant instrument and the Placement Agent Warrant instrument as signed by the parties thereto will conform in all material
respects to the drafts thereof as filed with the Registration Statement.</P></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">All signatures, initials and seals are genuine.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="text-align: justify">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accuracy and completeness of all factual
representations expressed in or implied by the documents we have examined.</P></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.5</FONT></TD>
    <TD STYLE="text-align: justify">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">That all public records of the Company which we have examined
are accurate, true and complete and that such information has not since then been altered and did not fail to disclose any information
which had been delivered for registration but did not appear on the public records.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.6</FONT></TD>
<TD>The Board Resolutions remain in full force and effect and have not been revoked.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.7</FONT></TD>
<TD>There is nothing under any law (other than the law of the Kingdom of Denmark) which would or might affect the opinions hereinafter appearing.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Specifically, we have made no independent investigation of
the laws of the USA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;<IMG SRC="tm2334005d4_ex5-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in">5. Opinion</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.05pt">5.1</TD><TD STYLE="text-align: justify">Based on the documents and investigations referred to in paragraph 3 above, I am of the following opinion:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.05pt"></TD><TD STYLE="width: 25.5pt">1.</TD><TD STYLE="text-align: justify">upon issuance of the Placement Shares and Warrants against full payment therefor in the circumstances
contemplated by the SPA and the Warrant agreements,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.05pt"></TD><TD STYLE="width: 25.5pt">2.</TD><TD STYLE="text-align: justify">registration of the Board of Directors&rsquo; resolutions to increase the share capital and issue the
Warrants with the Danish Business Authority, and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.05pt"></TD><TD STYLE="width: 25.5pt">3.</TD><TD STYLE="text-align: justify">the due entry into the Owners&rsquo; Register of the Placement Shares by the Company&rsquo;s share registrar
and the entry of the Warrants in the Company&rsquo;s warrant register</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.05pt; text-align: justify">the Company is authorised to issue
the Placement Shares to be issued by the Company for issuance in connection with the ADSs and when issued, the Placement Shares will have
been validly issued and will be fully paid and nonassessable. Nonassessable shall in this context mean, in relation to a share, that the
issuer of the share has no right to require the holder of the share to pay to the issuer any amount (in addition to the amount required
for the share to be fully paid) solely as a result of his shareholding. The Warrants will have been validly issued and will be exercisable
pursuant to the terms and conditions set out in the Warrant Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in">6. Reliance</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.05pt">6.1</TD><TD STYLE="text-align: justify">This opinion is for your benefit in connection with the Registration Statement and may be relied upon
by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Securities Act. It may not be supplied, and
its contents or existence may not be disclosed, to any person other than as an exhibit to the Registration Statement and may not be relied
upon for any purpose other than the Registration.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.05pt">6.2</TD><TD STYLE="text-align: justify">Any and all liability and other matters relating to this opinion shall be governed exclusively by Danish
law and the Danish courts shall have exclusive jurisdiction to settle any dispute relating to this opinion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 51.05pt">6.3</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">The Company may:</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.05pt"></TD><TD STYLE="width: 25.5pt">(a)</TD><TD STYLE="text-align: justify">file this opinion as an exhibit to the Registration Statement; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm2334005d4_ex5-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.05pt"></TD><TD STYLE="width: 25.5pt">(b)</TD><TD STYLE="text-align: justify">refer to Mazanti-Andersen Law Firm giving this opinion under the heading &ldquo;Legal Matters&rdquo; in
the Registration Statement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.05pt">6.4</TD><TD STYLE="text-align: justify">The previous sentence is no admittance from me (or Mazanti-Andersen Law Firm) that I am (or Mazanti-Andersen
Law Firm is) in the category of persons whose consent for the filing and reference in that paragraph is required under Section&nbsp;7
of the Securities Act or any rules or regulations of the SEC promulgated under it.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yours
sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2334005d4_ex5-1img003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lars L&uuml;thjohan</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<IMG SRC="tm2334005d4_ex5-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Annex 1 &ndash; Definitions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this opinion:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Danish law</B>&rdquo; means the law
directly applicable in Denmark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Company</B>&rdquo; means Evaxion Biotech
A/S, with corporate seat in H&oslash;rsholm, Denmark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Owners&rsquo; Register</B>&rdquo; means
the Issuer&rsquo;s owners&rsquo; register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Registration</B>&rdquo; means the registration
of the ADSs, Placement Shares and Warrants with the SEC under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Registration Statement</B>&rdquo; means
the registration statement on Form F--1 (Registration No. 333-276505) filed with the SEC on January 12, 2024, as amended by Amendment
No. 1 to Form F-1 Registration Statement filed with the SEC on January 30, 2024, in relation to the Registration, as amended and supplemented
to the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>SEC</B>&rdquo; means the U.S. Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Securities Act</B>&rdquo; means the
U.S. Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.2
<SEQUENCE>6
<FILENAME>tm2334005d4_ex8-2.htm
<DESCRIPTION>EXHIBIT 8.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 8.2</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%"><IMG SRC="tm233400d4_ex8-2img001.jpg" ALT=""></TD><TD STYLE="width: 25%; text-align: left">Mazanti-Andersen<BR>
 Advokatpartnerselskab<BR>
VAT: DK35892052<BR>
 <BR>
www.mazanti.dk</TD><TD STYLE="text-align: justify; width: 25%">Amaliegade 10<BR>
 DK-1256 K&oslash;benhavn K<BR>
 +45 3314 3536 <BR>
<BR>
Klosterbakken 12<BR>
 DK-5000 Odense C <BR>
+45 6314 1414</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EVAXION BIOTECH A/S<BR>
 Dr Neergaards Vej 5F <BR>
2970 H&oslash;rsholm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 1.5in"><FONT STYLE="font-size: 10pt">January 30, 2024<BR>
    Ref. 61047LLJ ID 3158</FONT></TD>
    <TD STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    regarding the registration with the US Securities and exchange Commission of American Depositary Shares representing ordinary shares
    in the share capital of Evaxion Biotech A/S</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"><B>Lars L&uuml;thjohan</B> Attorney-at-law <BR>
D: +45 3319 3749<BR>
 M: +45 4028 3536<BR>
 llj@mazanti.dk</TD><TD STYLE="text-align: left; width: 0.5in; vertical-align: middle"><FONT STYLE="text-transform: uppercase"><B>1.</B></FONT></TD><TD STYLE="text-align: left; vertical-align: middle"><FONT STYLE="text-transform: uppercase"><B>Introduction</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify">I act as a Danish tax adviser to Evaxion Biotech A/S (the &ldquo;Issuer&rdquo;) with the Registration
Statement on Form&nbsp;F-1 (Registration No.&nbsp;333-276505) (the &ldquo;Registration Statement&rdquo;) filed on January&nbsp;12, 2024,
as amended and supplemented to the date hereof. This opinion is being furnished in accordance with the requirements of Item 601(b)(8)&nbsp;of
Regulation S-K under the Securities Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration
Statement or related prospectus (the &ldquo;Prospectus&rdquo;) other than expressly stated herein with respect to the statements in the
Registration Statement under the heading &ldquo;Danish Tax Considerations&rdquo; on pages&nbsp;257-262. Certain terms used in this opinion
are defined in Annex 1 (Definitions).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>2.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>Danish Law</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">2.1</TD><TD>This opinion is limited to Danish law in effect on the date of this opinion and we express no opinion with regard to the laws of any
other jurisdiction. The opinion (including all terms used in it) is in all respects to be construed in accordance with Danish law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>3.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>Scope of Inquiry</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">3.1</TD><TD STYLE="text-align: justify">For the purpose of this opinion,&nbsp;I have examined, and relied upon the accuracy of the factual statements
and compliance with the undertakings in, the following documents:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">3.1.1</TD><TD>A copy of the Registration Statement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">3.1.2</TD><TD>A copy of the Issuer&rsquo;s deed of incorporation and articles of association as in effect on today&rsquo;s date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm233400d4_ex8-2img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">3.2</TD><TD>In addition I have examined such documents, and performed such other investigations, as I consider for the purpose of this opinion.
My examination has been limited to the text of the documents. With your consent I have relied upon certificates and other assurances of
officers of the Issuer and others as to factual matters without having independently verified such factual matters.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>4.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>Opinion</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">Based on the documents and investigations referred to in paragraph 3,&nbsp;I am of the following opinion:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">The statements in the Registration
Statement under the heading &ldquo;Danish Tax considerations&rdquo; on pages&nbsp;257-262, insofar they purport to constitute summaries
of certain provisions of Danish tax law include accurate summaries thereof in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>5.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>Reliance</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">5.1</TD><TD STYLE="text-align: justify">This opinion is an exhibit to the Registration Statement and may be relied upon for the purpose of the
Registration. It may not be supplied, and its contents or existence may not be disclosed, to any person other than as an exhibit to (and
therefore together with) the Registration Statement and may not be relied upon for any purpose other than the Registration.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">5.2</TD><TD STYLE="text-align: justify">Any and all liability and other matters relating to this opinion shall be governed exclusively by Danish
law and the Danish courts shall have exclusive jurisdiction to settle any dispute relating to this opinion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">5.3</TD><TD STYLE="text-align: justify">The Issuer may:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">file this opinion as an exhibit to the Registration Statement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">refer to Mazanti-Andersen Law Firm giving this opinion under the heading &ldquo;Danish Tax Considerations&rdquo;
in the Registration Statement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm233400d4_ex8-2img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">5.4</TD><TD STYLE="text-align: justify">The previous sentence is no admittance from me (or Mazanti-Andersen Law Firm) that I am (or Mazanti-Andersen
Law Firm is) in the category of persons whose consent for the filing and reference in that paragraph is required under Section&nbsp;7
of the Securities Act or any rules&nbsp;or regulations of the SEC promulgated under it.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Yours sincerely</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;<IMG SRC="tm233400d4_ex8-2img002.jpg" ALT=""></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Lars L&uuml;thjohan</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm233400d4_ex8-2img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><B>Annex 1 &ndash; Definitions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">In this opinion:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;<B>Danish law</B>&rdquo; means the law
directly applicable in Denmark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;<B>Issuer</B>&rdquo; means Evaxion Biotech
A/S, with corporate seat in H&oslash;rsholm, Denmark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;<B>Registration</B>&rdquo; means the registration
of the Shares with the SEC under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;<B>Registration Statements</B>&rdquo; means
the registration statement on Form&nbsp;F-1 (Registration No.&nbsp;Registration No.&nbsp;333-276505) in relation to the Registration filed
with the SEC on January&nbsp;12, 2024, as amended and supplemented to the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;<B>SEC</B>&rdquo; means the U.S. Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;<B>Securities Act</B>&rdquo; means the
U.S. Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;<B>Shares</B>&rdquo; means up to 20,325,200
ordinary shares, which may be represented by 2,032,520 American Depositary Shares and that may be issued from time to time by the Company
as set out in the Registration Statement, together with Series&nbsp;A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">warrants to purchase up to 2,032,520 ADSs representing
20,325,200 ordinary shares, and pre-funded warrants to purchase up to 2,032,520 ADSs representing 20,325,200 ordinary shares and placement
agent warrants to purchase up to 101,626 American Depositary Shares representing 1,016,260 ordinary shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>7
<FILENAME>tm2334005d4_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase
Agreement (this &ldquo;<U>Agreement</U>&rdquo;), dated as of _____, 2024, is between Evaxion Biotech A/S, a public limited liability
company incorporated under the laws of the Kingdom of Denmark (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the
signature pages&nbsp;hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below),
the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the
Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,&nbsp;IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which
are hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;I.<BR>
DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings
set forth in this Section&nbsp;1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>ADS(s)</U>&rdquo;
means American Depositary Shares issued pursuant to the Deposit Agreement (as defined below), each representing ten (10)&nbsp;Ordinary
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal or national holiday in the United States
and Denmark or any day on which banking institutions in the State of New York or Denmark are authorized or required by law to remain
closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized or required by law
to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp; or any
other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so
long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York and Copenhagen,
Denmark are generally open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section&nbsp;2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i)&nbsp;the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii)&nbsp;the
Company&rsquo;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second
(2<SUP>nd</SUP>) Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Danish Counsel</U>&rdquo; means Mazanti-Andersen, Amaliegade 10 1256 Copenhagen K, Denmark, or any successor Danish counsel to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
US Counsel</U>&rdquo; means Duane Morris LLP, 230 Park Avenue, Suite&nbsp;1130, New York, New York 10169-0079.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Deposit
Agreement</U>&rdquo; means the Deposit Agreement, dated as of February&nbsp;4, 2021, among the Company, The Bank of New York Mellon as
Depositary and the owners and holders of ADSs from time to time, as such agreement may be amended or supplemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Depositary</U>&rdquo;
means The Bank of New York Mellon and any successor depositary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i)&nbsp;if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m.&nbsp;(New York City
time) and before midnight (New York City time) on any Trading Day, 9:01 a.m.&nbsp;(New York City time) on the Trading Day immediately
following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii)&nbsp;if this Agreement
is signed between midnight (New York City time) and 9:00 a.m.&nbsp;(New York City time) on any Trading Day, no later than 9:01 a.m.&nbsp;(New
York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman&nbsp;&amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a)&nbsp;Ordinary Shares, ADSs or options to employees, officers, directors or consultants
of the Company pursuant to any stock or option plan duly adopted for such purpose, which issuance was approved by a majority of the non-employee
members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose
for services rendered to the Company, provided that any issuance to consultants under this clause (a)&nbsp;shall be subject to a customary
written lock-up agreement with the Company pursuant to which the consultant agrees to not sell or transfer any of the securities issued
under this clause (a)&nbsp;during the prohibition period in Section&nbsp;4.12(a)&nbsp;herein, (b)&nbsp;ADSs or Ordinary Shares upon the
exercise or exchange of or conversion of any Securities issued hereunder, warrants to the Placement Agent in connection with the transactions
pursuant to this Agreement and any securities upon exercise of warrants to the Placement Agent and/or other securities exercisable or
exchangeable for or convertible into ADSs or Ordinary Shares issued and outstanding on the date of this Agreement, provided that such
securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise
price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend
the term of such securities, (c)&nbsp;securities issued pursuant to acquisitions or strategic transactions approved by a majority of
the disinterested directors of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined
in Rule&nbsp;144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith
during the prohibition period in Section&nbsp;4.12(a)&nbsp;herein, and provided that any such issuance shall only be to a Person (or
to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business
synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds,
but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an
entity whose primary business is investing in securities, and (d)&nbsp;up to $____ of ADSs and Warrants issued to other purchasers pursuant
to the Prospectus concurrently with the Closing at the Per Share Purchase Price, less the aggregate Subscription Amount pursuant to this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Existing
ATM</U>&rdquo; means the Company&rsquo;s at-the-market offering pursuant to the Capital on Demand<SUP>TM</SUP> Sales Agreement, dated
as of October&nbsp;3, 2022, between the Company and JonesTrading Institutional Services LLC as sales agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Existing Note Equity Line</U>&rdquo; means the Company&rsquo;s
facility for the issuance of convertible notes pursuant to that certain Agreement for the Issuance of and Subscription to Notes Convertible
into Ordinary Shares, dated as of July 31, 2023, by and between the Company and Global Growth Holding Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>IFRS</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Lock-Up
Agreement</U>&rdquo; means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors and officers
of the Company, in the form of <U>Exhibit&nbsp;B</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section&nbsp;3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary
Share(s)</U>&rdquo; means the ordinary shares of the Company, DKK 1 nominal value per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary
Share Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Ordinary Shares or ADSs, including, without limitation, any debt, preferred share, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Ordinary
Shares or ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary
Warrant ADSs</U>&rdquo; means the ADSs issuable upon exercise of the Ordinary Warrants and the Company&rsquo;s deposit of the Ordinary
Warrant Shares with the Depositary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary
Warrant Shares</U>&rdquo; means the Ordinary Shares issuable upon exercise of the Ordinary Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary
Warrants</U>&rdquo; means, collectively, the ADS purchase warrants delivered to the Purchasers at the Closing in accordance with Section&nbsp;2.2(a)&nbsp;hereof,
which Ordinary Warrants shall be exercisable immediately, have a term of exercise equal to five (5)&nbsp;years and be in the form of
<U>Exhibit&nbsp;A-2</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per ADS
Purchase Price</U>&rdquo; equals $_____ (inclusive of any Depositary ADS issuance fee), subject to adjustment for reverse and forward
stock splits, stock dividends, stock combinations and other similar transactions of the ADSs and/or the Ordinary Shares, as applicable,
that occur after the date of this Agreement, provided that the purchase price per Prefunded Warrant shall be the Per ADS Purchase Price
minus $___<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright&nbsp;&amp; Co., LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Prefunded Warrant Aggregate Exercise Price Amount&rdquo; means, as to each Purchaser, an amount equal to the aggregate Exercise
Price of the Prefunded Warrants purchased by such Purchaser, which aggregate Exercise Price shall be paid in United States dollars and
in immediately available funds by the Purchaser at Closing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prefunded
Warrants</U>&rdquo; means, collectively, the Prefunded ADS purchase warrants delivered to the Purchasers at the Closing in accordance
with Section&nbsp;2.2(a)&nbsp;hereof, which Prefunded Warrants shall be exercisable immediately and will expire when exercised in full,
in the form of <U>Exhibit&nbsp;A-1</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prefunded
Warrant ADSs</U>&rdquo; means the ADSs issuable upon the exercise of the Prefunded Warrants and the Company&rsquo;s deposit of the Prefunded
Warrant Shares with the Depositary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prefunded
Warrant Shares</U>&rdquo; means the Ordinary Shares issuable upon the exercise of the Prefunded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Preliminary
Prospectus</U>&rdquo; means any preliminary prospectus included in the Registration Statement, as originally filed or as part of any
amendment thereto, or filed with the Commission pursuant to Rule&nbsp;424(a)&nbsp;of the rules&nbsp;and regulations of the Commission
under the Securities Act, including all information, documents and exhibits filed with or incorporated by reference into such preliminary
prospectus, including all information, documents and exhibits filed with or incorporated by reference into such preliminary prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pricing
Prospectus</U>&rdquo; means (i)&nbsp;the Preliminary Prospectus relating to the Securities that was included in the Registration Statement
immediately prior to ___ a.m./p.m.&nbsp;(New York City time) on the date hereof and (ii)&nbsp;any free writing prospectus (as defined
in the Securities Act) identified on <U>Schedule I</U> hereto, taken together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif">amount in US dollars equal to 10 Danish Krone, at the exchange rate
published by the Danish National Bank on the date hereof, or $___ on the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement on Form&nbsp;F-1 (File No.&nbsp;333-276505) which registers the sale
of the Securities to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;144</U>&rdquo;
means Rule&nbsp;144 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted from
time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;424</U>&rdquo;
means Rule&nbsp;424 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted from
time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the ADSs, the Warrants, the Warrant Shares and the Warrant ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the Ordinary Shares, as represented by ADSs issued pursuant to the Deposit Agreement, each ADS representing ten (10)&nbsp;Ordinary
Shares, issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule&nbsp;200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing Ordinary Shares and/or ADSs).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for ADSs and Warrants purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page&nbsp;of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s aggregate exercise price of the
Prefunded Warrants, which amounts shall be paid as and when such Prefunded Warrants are exercised).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Ordinary Shares and/or ADSs are listed or quoted for trading
on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or
the New York Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, the Lock-Up Agreement, all exhibits and schedules thereto and hereto and any
other documents or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Computershare A/S, the current transfer agent of the Company, with a mailing address of Lottenborgvej 26 D, 1.,
DK-2800 Kgs. Lyngby, Denmark and company registration number (CVR) no. 27088899, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.12(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
ADSs</U>&rdquo; means, collectively, the Ordinary Warrant ADSs and the Prefunded Warrant ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means, collectively, the Ordinary Warrant Shares and the Prefunded Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Ordinary Warrants and the Prefunded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;II.<BR>
PURCHASE AND SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell and issue, and the Purchasers,
severally and not jointly, agree to purchase and subscribe for, up to an aggregate of $____ of ADSs and Ordinary Warrants. Notwithstanding
anything herein to the contrary, to the extent that the Purchaser determines, in its sole discretion, that the Purchaser&rsquo;s Subscription
Amount would cause the Purchaser&rsquo;s beneficial ownership of Ordinary Shares (including any Ordinary Shares underlying any ADSs)
to exceed the Beneficial Ownership Limitation, or, as the Purchaser may otherwise choose in its sole discretion, the Purchaser may elect
to purchase Prefunded Warrants in lieu of the ADSs as determined pursuant to Section&nbsp;2.2(a). The &ldquo;<U>Beneficial Ownership
Limitation</U>&rdquo; shall be 4.99% (or, at the election of the Purchaser at Closing, 9.99%) of the number of Ordinary Shares (including
any Ordinary Shares underlying any ADSs) outstanding immediately after giving effect to the issuance of the Securities on the Closing
Date. Each Purchaser&rsquo;s Subscription Amount as set forth on the signature page&nbsp;hereto executed by such Purchaser shall be made
available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designee, except as otherwise directed by the
Placement Agent. The Company shall deliver to each Purchaser its respective ADSs and/or a Prefunded Warrant and an Ordinary Share Warrant
(as applicable to the Purchaser), as determined pursuant to Section&nbsp;2.2(a), and the Company and each Purchaser shall deliver the
other items set forth in Section&nbsp;2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in
Sections 2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the Closing documentation. Unless otherwise directed
by the Placement Agent, settlement of the ADSs shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e.,
on the Closing Date, the Company shall issue the ADSs registered in the Purchasers&rsquo; names and addresses and released by the Transfer
Agent directly to the account(s)&nbsp;at the Placement Agent identified by each Purchaser; upon receipt of such ADSs, the Placement Agent
shall promptly electronically deliver such ADSs to the applicable Purchaser, and payment therefor shall be made by the Placement Agent
(or its clearing firm) by wire transfer to the Company). For purposes of clarity, the issuance of the Securities at the Closing hereunder
shall occur upon the receipt by the Company Danish Counsel (on behalf of the Company) of the aggregate net proceeds to the Company from
the sale of the Securities from the Placement Agent (or its clearing firm) and/or the Purchasers, as directed by the Placement Agent.
Each Purchaser acknowledges that, concurrently with the Closing and pursuant to the Prospectus, the Company may sell up to $____ of additional
ADSs and Warrants to purchasers not party to this Agreement, less the aggregate Subscription Amount pursuant to this Agreement, and will
issue to such purchasers such ADSs and Ordinary Warrants or Prefunded Warrants and Ordinary Warrants in the same form and at the same
Per ADS Purchase Price. Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement
by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing (the &ldquo;<U>Pre-Settlement
Period</U>&rdquo;), such Purchaser sells to any Person all, or any portion, of the ADSs to be issued hereunder to such Purchaser at the
Closing (collectively, the &ldquo;<U>Pre-Settlement ADSs</U>&rdquo;), such Purchaser shall, automatically hereunder (without any additional
required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, such Pre-Settlement ADSs at the
Closing; provided, that the Company shall not be required to deliver any Pre-Settlement ADSs to such Purchaser prior to the Company&rsquo;s
receipt of the purchase price of such Pre-Settlement ADSs hereunder; and provided further that the Company hereby acknowledges and agrees
that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement
Period such Purchaser shall sell any Ordinary Shares to any Person and that any such decision to sell any Ordinary Shares by such Purchaser
shall solely be made at the time such Purchaser elects to effect any such sale, if any. Notwithstanding the foregoing, with respect to
any Notice(s)&nbsp;of Exercise (as defined in the Warrants) delivered on or prior to 12:00 p.m.&nbsp;(New York City time) on the Trading
Day prior to the Closing Date, which may be delivered at any time after the time of execution of this Agreement, the Company agrees to
deliver the Warrant ADSs subject to such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New York City time) on the Closing Date and the Closing Date
shall be the Warrant ADS Delivery Date (as defined in the Warrants) for purposes thereunder, provided that payment of the aggregate Exercise
Price is delivered to Company Danish Counsel by 12:00 p.m.&nbsp;(New York City time) on the Trading Day prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">this
Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">legal
opinions of Company US Counsel and Company Danish Counsel, respectively, addressed to the Placement Agent and the Purchasers, each in
the form reasonably acceptable to the Placement Agent and the Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">subject
to Section&nbsp;2.1, a copy of the irrevocable instructions to the Depositary instructing the Depositary to deliver on an expedited basis
via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) ADSs equal to such Purchaser&rsquo;s
Subscription Amount (minus the portion of such Subscription Amount applicable to Prefunded Warrants) divided by the Per ADS Purchase
Price, registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
applicable, a Prefunded Warrant certificate registered in the name of such Purchaser to purchase up to a number of ADSs equal to the
portion of such Purchaser&rsquo;s Subscription Amount applicable to the Prefunded Warrants divided by the Per ADS Purchase Price minus
$___,<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>2</SUP></FONT> with an exercise price equal to $___,<SUP>2</SUP> subject
to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">an Ordinary Share Warrant certificate registered in the
name of such Purchaser to purchase up to a number of ADSs equal to 100% of the sum of such Purchaser&rsquo;s ADSs and Prefunded Warrants
on the date hereof, with an exercise price equal to $_____, subject to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">subject
to Section&nbsp;2.1, the Company shall have provided each Purchaser with the Company Danish Counsel&rsquo;s wire instructions, on Company
letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">on
the date hereof, the Lock-Up Agreements; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the Preliminary Prospectus and the Prospectus (which may be delivered in accordance
with Rule&nbsp;172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">this
Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">such Purchaser&rsquo;s Subscription Amount (less the aggregate exercise
price of the Prefunded Warrants issuable to such Purchaser hereunder, if applicable), which shall be made available for &ldquo;Delivery
Versus Payment&rdquo; settlement with the Company or its designee, and, at such Purchaser&rsquo;s election, such Purchaser&rsquo;s Prefunded
Warrant Aggregate Exercise Price Amount, which shall be included in such Purchaser&rsquo;s Subscription Amount to be made available for
 &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or shall be separately delivered to the Company Danish Counsel pursuant
to the Company Danish Counsel&rsquo;s wire instructions as provided pursuant to Section 2.2(a)(vi) herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif">amount in US dollars equal to 10 Danish Krone, at the exchange rate
published by the Danish National Bank on the date hereof, or $___ on the date hereof</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing
Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) on
the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which
case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in
all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
delivery by each Purchaser of the items set forth in Section&nbsp;2.2(b)&nbsp;of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of
a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
delivery by the Company of the items set forth in Section&nbsp;2.2(a)&nbsp;of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">there
shall have been no Material Adverse Effect with respect to the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">from
the date hereof to the Closing Date, trading in the ADSs and/or Ordinary Shares shall not have been suspended by the Commission or any
Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have
been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service,
or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;III.<BR>
REPRESENTATIONS AND WARRANTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part
hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding section
of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company that are wholly owned (directly or indirectly) by the Company or that constitute
significant subsidiaries within the meaning of Item 601(b)(21)(ii)&nbsp;of Regulation S-K are set forth on <U>Schedule 3.1(a)</U>. The
Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens,
and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable
and free of preemptive and similar rights to subscribe for or purchase securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Organization
and Qualification</U>. The Company is a public limited liability company duly organized under the laws of the Kingdom of Denmark. Each
of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and, if the concept of good standing is applicable
under the laws of the applicable jurisdiction, in good standing under the laws of the jurisdiction of its incorporation or organization.
Each of the Company and its Subsidiaries have the requisite power and authority to own and use its properties and assets and to carry
on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of
its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and
the Subsidiaries is duly qualified to conduct business and, if the concept of good standing is applicable under the laws of the applicable
jurisdiction, is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case
may be, would not have or reasonably be expected to result in: (i)&nbsp;a material adverse effect on the legality, validity or enforceability
of any Transaction Document, (ii)&nbsp;a material adverse effect on the results of operations, assets, business, or condition (financial
or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii)&nbsp;a material adverse effect on the Company&rsquo;s ability
to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii)&nbsp;or (iii),
a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or
curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary corporate action on the part of the Company and
no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith
other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof and
assuming the due authorization, execution and delivery by the Purchaser, will constitute the valid and binding obligation of the Company
enforceable against the Company in accordance with its terms, except (i)&nbsp;as limited by general equitable principles and applicable
bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights
generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies
and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which
it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i)&nbsp;conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of association, bylaws or other organizational or charter documents, or (ii)&nbsp;conflict with, or constitute a default (or an event
that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii)&nbsp;subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)&nbsp;and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in
connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)&nbsp;the filings
required pursuant to Section&nbsp;4.4 of this Agreement, (ii)&nbsp;the filing with the Commission of the Prospectus, (iii)&nbsp;the notice
and/or application(s)&nbsp;to each applicable Trading Market for the issuance and sale of the Securities and the listing of the ADSs
and Warrant ADSs for trading thereon in the time and manner required thereby, and (iv)&nbsp;such filings as are required to be made under
applicable state securities laws and the laws of the Kingdom of Denmark (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Issuance
of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company.
The Warrant Shares and the Warrant ADSs, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid
and nonassessable, free and clear of all Liens imposed by the Company. The Company has received the necessary authorization to issue
the Warrants and the Ordinary Shares and ADSs issuable upon the exercise of the Warrants and the Ordinary Shares and ADSs issuable pursuant
to this Agreement. The Company and the Depositary have prepared and filed with the Commission a registration statement relating to ADSs
on Form&nbsp;F-6 (File No.&nbsp;333-252038) for registration under the Securities Act (the &ldquo;<U>ADS Registration Statement</U>&rdquo;)
which became effective on February&nbsp;4, 2021, and the ADS Registration Statement is effective as of the date hereof. The Company has
prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on&nbsp;__
, 2024, including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement.
The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the
Registration Statement or suspending or preventing the use of any Preliminary Prospectus or the Prospectus has been issued by the Commission
and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company,
if required by the rules&nbsp;and regulations of the Commission, shall file the Prospectus with the Commission pursuant to Rule&nbsp;424(b).
At the time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing
Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of
the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein not misleading; and the Pricing Prospectus and the Prospectus and any
amendments or supplements thereto, at the time the Pricing Prospectus and the Prospectus or any amendment or supplement thereto was issued
and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and
will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The Company was at the time of the filing of the Registration
Statement eligible to use Form&nbsp;F-1 and is eligible to use Form&nbsp;F-1 on the date hereof and on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Capitalization</U>.
The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>. The Company has not issued any capital
stock since its most recently filed Form&nbsp;6-K under the Exchange Act, other than pursuant to the exercise of employee warrants under
the Company&rsquo;s warrant plans, the issuance of Ordinary Shares to employees pursuant to the Company&rsquo;s employee stock purchase
plans and pursuant to the conversion and/or exercise of Ordinary Share Equivalents outstanding as of the date of the most recently filed
Form&nbsp;6-K under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar
right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the
Securities or as set forth on <U>Schedule 3.1(g)</U>, there are no outstanding options, warrants, scrip rights to subscribe to, calls
or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable
for, or giving any Person any right to subscribe for or acquire, any ADSs, Ordinary Shares, Ordinary Share Equivalents or the capital
stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become
bound to issue additional ADSs, Ordinary Shares or Ordinary Share Equivalents or capital stock of any Subsidiary. The issuance and sale
of the Securities will not obligate the Company or any Subsidiary to issue ADSs, Ordinary Shares, Ordinary Share Equivalents or other
securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary
with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of
securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that
contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company
or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock
appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding shares
of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with
all applicable federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights
or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors
or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar
agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between
or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;thereof,
for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material)
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Pricing Prospectus
and the Prospectus, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Company has never been an issuer subject to Rule&nbsp;144(i)&nbsp;under the Securities Act. The financial
statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the
rules&nbsp;and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have
been prepared in accordance with International Financial Reporting Standards applied on a consistent basis during the periods involved
(&ldquo;<U>IFRS</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited
financial statements may not contain all footnotes required by IFRS, and fairly present in all material respects the financial position
of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the
periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included within
the SEC Reports, except as set forth on <U>Schedule 3.1(i)</U>, (i)&nbsp;there has been no event, occurrence or development that has
had or that could reasonably be expected to result in a Material Adverse Effect, (ii)&nbsp;the Company has not incurred any liabilities
(contingent or otherwise) other than (A)&nbsp;trade payables and accrued expenses incurred in the ordinary course of business consistent
with past practice and (B)&nbsp;liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to IFRS
or disclosed in filings made with the Commission, (iii)&nbsp;the Company has not altered its method of accounting, (iv)&nbsp;the Company
has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any
agreements to purchase or redeem any shares of its capital stock and (v)&nbsp;the Company has not issued any equity securities to any
officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before the
Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement,
no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist
with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial
condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made
or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Litigation</U>.
Except as set forth on <U>Schedule 3.1(j)</U>, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending
or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth on <U>Schedule 3.1(j)</U>, (i)&nbsp;adversely affects or
challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii)&nbsp;could, if there
were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary,
nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal
or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not
pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the
Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed
by the Company or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. Except as set forth on <U>Schedule 3.1(k)</U>, none of the
Company&rsquo;s or its Subsidiaries&rsquo; employees is a member of a union that relates to such employee&rsquo;s relationship with the
Company or such Subsidiary. Neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the
Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive
officer of the Company or any Subsidiary is, or is now expected to be, in violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or
any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the
Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are
in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms
and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239; &#8239;<FONT STYLE="font-size: 10pt"><U>Compliance</U>. Neither the Company nor any Subsidiary: (i)&nbsp;is in default
under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result
in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in
default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it
is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii)&nbsp;is
in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii)&nbsp;is or has been in
violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal,
state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment
and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Environmental
Laws</U>.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company and its Subsidiaries (i)&nbsp;are in compliance with all applicable federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating to
the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as
all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii)&nbsp;have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii)&nbsp;and
(iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any written notice of proceedings relating to the revocation
or modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good
and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in
each case free and clear of all Liens, except for (i)&nbsp;Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii)&nbsp;Liens for the
payment of federal, state, foreign or other taxes, for which appropriate reserves have been made therefor in accordance with IFRS and,
the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company
and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are
in compliance in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intellectual
Property</U>. The Company and the Subsidiaries own, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither
the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired,
terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2)&nbsp;years from the date of this
Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within
the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights are invalid or unenforceable
or violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse
Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement
by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures
to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not
limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. After giving effect to the
receipt by the Company of the proceeds from the sale of the Securities hereunder, neither the Company nor any Subsidiary has any reason
to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage
from similar insurers as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transactions with Affiliates and Employees</U>. Except as set forth on <U>Schedule
3.1(r)</U>, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees
of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services
as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services
to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money
to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity
in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member
or partner, in each case in excess of $120,000 other than for (i)&nbsp;payment of salary or consulting fees for services rendered, (ii)&nbsp;reimbursement
for expenses incurred on behalf of the Company and (iii)&nbsp;other employee benefits, including stock option agreements under any stock
option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Sarbanes-Oxley;
Internal Accounting Controls</U>. Except as set forth on <U>Schedule 3.1(s)</U>, the Company and the Subsidiaries are in compliance in
all material respects with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of
the date hereof, and any and all applicable rules&nbsp;and regulations promulgated by the Commission thereunder that are effective as
of the date hereof and as of the Closing Date and apply to the Company given its status as a foreign private issuer (as such term is
defined under the Securities Act). The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide
reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorizations,
(ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with IFRS and to maintain
asset accountability, (iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific authorization,
and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action
is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined
in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and
procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act
is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules&nbsp;and forms. The
Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the
Subsidiaries as of the end of the period covered by the most recently filed Form&nbsp;20-F under the Exchange Act (such date, the &ldquo;<U>Evaluation
Date</U>&rdquo;). The Company presented in its most recently filed Form&nbsp;20-F under the Exchange Act the conclusions of the certifying
officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since
the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange
Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control
over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(t)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Fees</U>. Except as set forth in the Pricing Prospectus and the Prospectus, no brokerage or finder&rsquo;s fees or commissions are or
will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section&nbsp;that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(u)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Registration
Rights</U>. Except as set forth on <U>Schedule 3.1(w)</U>, no Person has any right to cause the Company or any Subsidiary to effect the
registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(w)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Listing
and Maintenance Requirements</U>. The Ordinary Shares and ADSs are registered pursuant to Section&nbsp;12(b)&nbsp;or 12(g)&nbsp;of the
Exchange Act, and the Company has taken no action designed to, or which to its knowledge is reasonably likely to have the effect of,
terminating the registration of the Ordinary Shares and/or ADSs under the Exchange Act nor has the Company received any written notification
that the Commission is contemplating terminating such registration. Except as set forth on <U>Schedule 3.1(x)</U>, the Company has not,
in the 12 months preceding the date hereof, received written notice from any Trading Market on which the ADSs and/or Ordinary Shares
are or have been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of
such Trading Market. Except as set forth on <U>Schedule 3.1(x)</U>, the Company is, and has no reason to believe that it will not in
the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The ADSs are currently eligible
for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in
payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic
transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its jurisdiction
of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their
obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s
issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(y)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information
that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Pricing Prospectus
and the Prospectus. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions
in securities of the Company. All of the written disclosure furnished by or on behalf of the Company to the Purchasers regarding the
Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules
to this Agreement, taken as a whole, is true and correct and does not contain any untrue statement of a material fact or omit to state
any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made,
not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as
a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading.
The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Section&nbsp;3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(z)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section&nbsp;3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(aa)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Solvency</U>.
Except as set forth on <U>Schedule 3.1(aa)</U>, based on the consolidated financial condition of the Company as of the Closing Date,
after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i)&nbsp;the fair saleable
value of the Company&rsquo;s assets exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing
debts and other liabilities (including known contingent liabilities) as they mature, (ii)&nbsp;the Company&rsquo;s assets do not constitute
unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking
into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements
and capital availability thereof, and (iii)&nbsp;the current cash position of the Company, together with the proceeds the Company would
receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay
all amounts on or in respect of its liabilities when such amounts are required to be paid. <U>Schedule 3.1(aa)</U> sets forth as of the
date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary
has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x)&nbsp;any liabilities for borrowed money
or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y)&nbsp;all guaranties,
endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected
in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments
for deposit or collection or similar transactions in the ordinary course of business; and (z)&nbsp;the present value of any lease payments
in excess of $50,000 due under leases required to be capitalized in accordance with IFRS. As of the date hereof and as of the Closing
Date, neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(bb)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Tax
Status</U>. Except for tax matters that are being challenged on a good faith basis by the Company and tax matters that would not, individually
or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i)&nbsp;has
made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations
required by any jurisdiction to which it is subject, (ii)&nbsp;has paid all taxes and other governmental assessments and charges that
are material in amount, shown or determined to be due on such returns, reports and declarations and (iii)&nbsp;has set aside on its books
provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports
or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction,
and the officers of the Company or of any Subsidiary know of no basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(cc)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Foreign
Corrupt Practices.</U> Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i)&nbsp;directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)&nbsp;made any unlawful payment
to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii)&nbsp;failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its
behalf of which the Company is aware) which is in violation of law, or (iv)&nbsp;violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(dd)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Accountants</U>.
The Company&rsquo;s accounting firm is set forth in the Pricing Prospectus and the Prospectus. To the knowledge and belief of the Company,
such accounting firm (i)&nbsp;is a registered public accounting firm as required by the Exchange Act and (ii)&nbsp;shall express its
opinion with respect to the financial statements to be included in the Company&rsquo;s Annual Report on Form&nbsp;20-F for the fiscal
year ending December&nbsp;31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ee)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby.
The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ff)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity.</U> Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except
for Sections 3.2(f)&nbsp;and 4.14 hereof), it is understood and acknowledged by the Company that: (i)&nbsp;none of the Purchasers has
been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities
of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified
term; (ii)&nbsp;past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short
Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly-traded securities; (iii)&nbsp;any Purchaser, and counter-parties in &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
ADSs and/or Ordinary Shares, and (iv)&nbsp;each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s
length counter-party in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y)&nbsp;one
or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, including,
without limitation, during the periods that the value of the Warrant ADSs deliverable with respect to Securities are being determined,
and (z)&nbsp;such hedging activities (if any) could reduce the value of the existing stockholders' equity interests in the Company at
and after the time that the hedging activities are being conducted.&nbsp; The Company acknowledges that such aforementioned hedging activities
do not constitute a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(gg)</FONT>&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Regulation M Compliance.</U>&nbsp; The Company has not, and to its knowledge
no one acting on its behalf has, (i)&nbsp;taken, directly or indirectly, any action designed to cause or to result in the stabilization
or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the ADSs or Ordinary Shares, (ii)&nbsp;sold,
bid for, purchased, or, paid any compensation for soliciting purchases of, any of the ADSs or Ordinary Shares, or (iii)&nbsp;paid or
agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the
case of clauses (ii)&nbsp;and (iii), compensation paid to the Placement Agent in connection with the placement of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(hh)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged, labeled,
tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical Product</U>&rdquo;),
such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance
with all applicable requirements under FDCA and similar laws, rules&nbsp;and regulations relating to registration, investigational use,
premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices,
product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would
not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any
lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or
any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication
from the FDA or any other governmental entity, which (i)&nbsp;contests the premarket clearance, licensure, registration, or approval
of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of
any Pharmaceutical Product, (ii)&nbsp;withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders
the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii)&nbsp;imposes a clinical hold
on any clinical investigation by the Company or any of its Subsidiaries, (iv)&nbsp;enjoins production at any facility of the Company
or any of its Subsidiaries, (v)&nbsp;enters or proposes to enter into a consent decree of permanent injunction with the Company or any
of its Subsidiaries, or (vi)&nbsp;otherwise alleges any violation of any laws, rules&nbsp;or regulations by the Company or any of its
Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and
operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules&nbsp;and
regulations of the FDA.&nbsp; The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or
use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern
as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Warrant
Plans</U>. Each warrant granted by the Company under the Company&rsquo;s warrant plans was granted (i)&nbsp;in accordance with the terms
of the Company&rsquo;s warrant plans adopted as an integral part of the Articles of Association and (ii)&nbsp;with an exercise price
at least equal to the fair market value of the Ordinary Shares on the date such warrants would be considered granted under IFRS and applicable
law. No warrant granted under the Company&rsquo;s warrant plans has been backdated. The Company has not knowingly granted, and there
is no and has been no Company policy or practice to knowingly grant, warrants prior to, or otherwise knowingly coordinate the grant of
warrants with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial
results or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(jj)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Cybersecurity</U>.&nbsp;
(i)(x)&nbsp;There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s
information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees,
suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;<U>IT Systems
and Data</U>&rdquo;) and (y)&nbsp;the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition
that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii)&nbsp;the Company
and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules&nbsp;and regulations
of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy
and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)&nbsp;the Company and the
Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information
and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv)&nbsp;the Company and the Subsidiaries
have implemented backup and disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(kk)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Data Privacy Laws</U>. (i)&nbsp;To the Company&rsquo;s knowledge, the Company and the Subsidiaries are, and at all times during
the last three (3)&nbsp;years were, in compliance with all applicable state, federal and foreign data privacy and security laws and regulations,
including, without limitation, the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively,
 &ldquo;<U>Privacy Laws</U>&rdquo;); (ii)&nbsp;the Company and the Subsidiaries have in place, comply with, and take appropriate steps
reasonably designed to ensure compliance with their policies and procedures relating to data privacy and security and the collection,
storage, use, disclosure, handling and analysis of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii)&nbsp;the
Company provides accurate notice of its applicable Policies to its customers, employees, third party vendors and representatives as required
by the Privacy Laws; and (iv)&nbsp;applicable Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy
practices relating to its subject matter, and do not contain any material omissions of the Company&rsquo;s then-current privacy practices,
as required by Privacy Laws.&nbsp;&ldquo;<U>Personal Data</U>&rdquo; means (i)&nbsp;a natural person&rsquo;s name, street address, telephone
number, email address, photograph, social security number, bank information, or customer or account number; (ii)&nbsp;any information
which would qualify as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission Act, as amended; (iii)&nbsp;&ldquo;personal
data&rdquo; as defined by GDPR; and (iv)&nbsp;any other piece of information that allows the identification of such natural person, or
his or her family, or permits the collection or analysis of any identifiable data related to an identified person&rsquo;s health or sexual
orientation. (i)&nbsp;None of such disclosures made or contained in any of the Policies have been inaccurate, misleading, or deceptive
in violation of any Privacy Laws and (ii)&nbsp;the execution, delivery and performance of the Transaction Documents will not result in
a breach of any Privacy Laws or Policies.&nbsp; Neither the Company nor the Subsidiaries (i)&nbsp;to the knowledge of the Company, has
received written notice of any actual or potential liability of the Company or the Subsidiaries under, or actual or potential violation
by the Company or the Subsidiaries of, any of the Privacy Laws; (ii)&nbsp;is currently conducting or paying for, in whole or in part,
any investigation, remediation or other corrective action pursuant to any regulatory request or demand pursuant to any Privacy Law; or
(iii)&nbsp;is a party to any order, decree, or agreement by or with any court or arbitrator or governmental or regulatory authority that
imposed any obligation or liability under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ll)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(mm)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section&nbsp;897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(nn)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of
1956, as amended (the &ldquo;BHCA&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;Federal
Reserve&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(oo)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules&nbsp;and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i)&nbsp;as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by
applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with
applicable federal and state securities laws). Such Purchaser is acquiring such Securities hereunder in the ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which
it exercises any Warrants, it will be, an &ldquo;accredited investor&rdquo; as defined in Rule&nbsp;501(a)(1), (a)(2), (a)(3), (a)(7),
(a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and the SEC Reports and has been afforded, (i)&nbsp;the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii)&nbsp;access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii)&nbsp;the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment.&nbsp; Such Purchaser acknowledges and agrees that
neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with
respect to the Securities nor is such information or advice necessary or desired.&nbsp; Neither the Placement Agent nor any Affiliate
has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may
have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided to it.&nbsp; In connection
with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial
advisor or fiduciary to such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that such Purchaser first
received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material pricing
terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other
than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acknowledges and agrees that the
representations contained in this Section&nbsp;3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on the Company&rsquo;s
representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document
or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions
contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;IV.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OTHER AGREEMENTS OF THE PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Warrant
ADSs</U>. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the issuance
or resale of the Warrant Shares represented by the Warrant ADSs, the Warrant ADSs issued pursuant to any such exercise shall be issued
free of all legends. If at any time following the date hereof the Registration Statement (or any subsequent registration statement registering
the sale or resale of the Warrant ADSs) is not effective or is not otherwise available for the sale or resale of the Warrant ADSs, the
Company shall immediately notify the holders of the Warrants in writing that such registration statement is not then effective and thereafter
shall promptly notify such holders when the registration statement is effective again and available for the sale or resale of the Warrant
Shares represented by the Warrant ADSs (it being understood and agreed that the foregoing shall not limit the ability of the Company
to issue, or any Purchaser to sell, any of the Warrant ADSs in compliance with applicable federal and state securities laws). The Company
shall use best efforts to keep a registration statement (including the Registration Statement) registering the issuance or resale of
the Warrant Shares represented by the Warrant ADSs effective during the term of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Furnishing
of Information</U>. Until the earlier of the time that (i)&nbsp;no Purchaser owns Securities or (ii)&nbsp;the Warrants have expired,
the Company covenants to maintain the registration of the Ordinary Shares and ADSs under Section&nbsp;12(b)&nbsp;or 12(g)&nbsp;of the
Exchange Act and to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required
to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting
requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section&nbsp;2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules&nbsp;and
regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless
shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a)&nbsp;by the Disclosure Time, issue a press release disclosing the material terms
of the transactions contemplated hereby, and (b)&nbsp;file a Report on Form&nbsp;6-K, including the Transaction Documents as exhibits
thereto, with the Commission within the time required by the Exchange Act, provided that the Company shall not be required to file such
a Current Report on Form&nbsp;6-K if the Transaction Documents have been previously filed with the Commission as exhibits to a pre-effective
or post-effective amendment to the Registration Statement. From and after the issuance of such press release, the Company represents
to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the
Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without
limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition, effective
upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations
under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors,
agents, employees, Affiliates or agents, including , without limitation, the Placement Agent, on the one hand, and any of the Purchasers
or any of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms
that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and
each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby,
and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the
prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with
respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is
required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement
or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name
of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such
Purchaser, except (a)&nbsp;as required by federal securities law in connection with the filing of final Transaction Documents with the
Commission and (b)&nbsp;to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall
provide the Purchasers with prior notice of such disclosure permitted under this clause (b)&nbsp;and reasonably cooperate with such Purchaser
regarding such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser
is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Non-Public
Information</U>. Except with respect to the material pricing terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section&nbsp;4.4, the Company covenants and agrees that neither the Company, nor any
other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company
reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing
to the receipt of such information and agreed in writing with the Company to keep such information confidential. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To
the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates
delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and
agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective
officers, directors, employees, Affiliates or agents , including, without limitation, the Placement Agent, or a duty to the Company,
any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation,
the Placement Agent, not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject
to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public
information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice
with the Commission pursuant to a Report on Form&nbsp;6-K. The Company understands and confirms that each Purchaser shall be relying
on the foregoing covenant in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Use
of Proceeds</U>. Except as set forth in the Pricing Prospectus and the Prospectus, the Company shall use the net proceeds from the sale
of the Securities hereunder for working capital purposes and shall not use such proceeds: (a)&nbsp; for the satisfaction of any portion
of the Company&rsquo;s debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices),
(b)&nbsp;for the redemption of any ADSs, Ordinary Shares or Ordinary Share Equivalents, (c)&nbsp;for the settlement of any outstanding
litigation or (d)&nbsp;in violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section&nbsp;4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning
of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors, officers, shareholders, agents,
members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or
incur as a result of or relating to (a)&nbsp;any breach of any of the representations, warranties, covenants or agreements made by the
Company in this Agreement or in the other Transaction Documents or (b)&nbsp;any action instituted against the Purchaser Parties in any
capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser
Party, with respect to any of the transactions contemplated by the Transaction Documents unless such action is solely based upon a material
breach of such Purchaser Party&rsquo;s representations, warranties or covenants under the Transaction Documents or any agreements or
understandings such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal
securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or
willful misconduct. If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to
this Agreement, such Purchaser Party shall promptly notify the Company in writing, and, the Company shall have the right to assume the
defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right
to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall
be at the expense of such Purchaser Party except to the extent that (i)&nbsp;the employment thereof has been specifically authorized
by the Company in writing, (ii)&nbsp;the Company has failed after a reasonable period of time to assume such defense and to employ counsel
or (iii)&nbsp;in such action there is, in the reasonable opinion of counsel a material conflict on any material issue between the position
of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses
of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y)&nbsp;for any
settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld
or delayed; or (z)&nbsp;to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser
Party&rsquo;s breach of any of the representations, other Transaction Documents. The indemnification required by this Section&nbsp;4.8
shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received
or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser
Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Reservation
of Ordinary Shares</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available
at all times, free of preemptive rights, a sufficient number of Ordinary Shares and ADSs for the purpose of enabling the Company to issue
ADSs pursuant to this Agreement and Warrant ADSs pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Listing
of ADSs and Warrant ADSs</U>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation of
the ADSs and Warrant ADSs on the Trading Market on which the ADSs are currently listed, and concurrently with the Closing, the Company
shall apply to list or quote, as applicable, all of the ADSs and Warrant ADSs, on such Trading Market and promptly secure the listing
of all of the ADSs and Warrant ADSs on such Trading Market. The Company further agrees, if the Company applies to have the Ordinary Shares
and/or ADSs traded on any other Trading Market, it will then include in such application all of the ADSs and Warrant ADSs (and/or, if
applicable, the Ordinary Shares represented by such ADSs or Warrant ADSs), and will take such other action as is necessary to cause all
of the ADSs and Warrant ADSs to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take
all action reasonably necessary to continue the listing and trading of ADSs and/or Ordinary Shares on a Trading Market and will comply
in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules&nbsp;of the Trading Market.
The Company agrees to maintain the eligibility of the ADSs for electronic transfer through the Depository Trust Company or another established
clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established
clearing corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">[RESERVED]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Subsequent
Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
the date hereof until sixty (60) days after the Closing Date, neither the Company nor any Subsidiary shall (i)&nbsp;issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any ADSs, Ordinary Shares or Ordinary Share Equivalents or (ii)&nbsp;file
any registration statement or any amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form&nbsp;S-8
in connection with any employee benefit plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
the date hereof until six (6)&nbsp;months after the Closing Date, the Company shall be prohibited from effecting or entering into an
agreement to effect any issuance by the Company or any of its Subsidiaries of ADSs, Ordinary Shares or Ordinary Share Equivalents (or
a combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction
in which the Company (i)&nbsp;issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for,
or include the right to receive additional ADSs and/or Ordinary Shares either (A)&nbsp;at a conversion price, exercise price or exchange
rate or other price that is based upon and/or varies with the trading prices of or quotations for ADSs and/or Ordinary Shares at any
time after the initial issuance of such debt or equity securities, or (B)&nbsp;with a conversion, exercise or exchange price that is
subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified
or contingent events directly or indirectly related to the business of the Company or the market for the ADSs and/or Ordinary Shares
or (ii)&nbsp;enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an
 &ldquo;at-the-market offering&rdquo;, whereby the Company may issue securities at a future determined price regardless of whether ADSs
or Ordinary Shares pursuant to such agreement have actually been issued and regardless of whether such agreement is subsequently canceled;
<U>provided</U>, <U>however</U>, that, after sixty (60) days after the Closing Date, the following shall not be deemed a Variable Rate
Transaction: (y)&nbsp;the Company&rsquo;s issuance of ADSs in the Existing ATM or in an &ldquo;at the market&rdquo; offering with the
Placement Agent as sales agent; or (z)&nbsp;the Company&rsquo;s issuance of convertible notes in the Existing Note Equity Line. Any Purchaser
shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to
any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing, this Section&nbsp;4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall
be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid to any Person to
amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered to all
of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by
the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall
not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of
Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it
nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short
Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such time
that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section&nbsp;4.4.&nbsp; Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
pricing terms of the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press
release as described in Section&nbsp;4.4, such Purchaser will maintain the confidentiality of the pricing terms of this transaction (other
than as disclosed to its legal and other representatives).&nbsp; Notwithstanding the foregoing and notwithstanding anything contained
in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i)&nbsp;no Purchaser makes any representation,
warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the
transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.4,
(ii)&nbsp;no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance
with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced
pursuant to the initial press release as described in Section&nbsp;4.4 and (iii)&nbsp;no Purchaser shall have any duty of confidentiality
or duty not to trade in the securities of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors,
employees, Affiliates or agent, including, without limitation, the Placement Agent, after the issuance of the initial press release as
described in Section&nbsp;4.4.&nbsp; Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle
whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct
knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant
set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision
to purchase the Securities covered by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers
in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers
to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required in order to exercise the Warrants.
The Company shall honor exercises of the Warrants and shall deliver Warrant ADSs in accordance with the terms, conditions and time periods
set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Lock-Up
Agreements</U>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except to extend
the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party
to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to seek specific
performance of the terms of such Lock-Up Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;V.<BR>
MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Termination</U>.&nbsp; This Agreement may be terminated by any Purchaser, as to
such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other
Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading
Day following the date hereof; <U>provided</U>, <U>however</U>, that no such termination will affect the right of any party to sue for
any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company shall pay all Depositary fees and Transfer Agent fees
(including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company to issue
ADSs or Warrant ADSs (including in connection with any exercise notice delivered by a Purchaser to the Company)), stamp taxes and other
taxes and duties levied in connection with the delivery of any Securities to the Purchasers and shall reimburse the Purchasers for any
fees charged to the Purchasers by the Depositary in connection with the issuance or holding or sale of the ADSs, Warrant ADSs and/or
Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Pricing Prospectus and the Prospectus,
contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a)&nbsp;the time of transmission, if such notice or communication is delivered via
email attachment at the email address as set forth on the signature pages&nbsp;attached hereto at or prior to 5:30 p.m.&nbsp;(New York
City time) on a Trading Day, (b)&nbsp;the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages&nbsp;attached hereto on a day that is not a Trading Day
or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (c)&nbsp;the second (2<SUP>nd</SUP>) Trading Day following the
date of mailing, if sent by U.S. nationally recognized overnight courier service or (d)&nbsp;upon actual receipt by the party to whom
such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages&nbsp;attached
hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified,
supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and Purchasers which purchased
at least 50.1% in interest of the ADSs and Prefunded Warrants purchased hereunder based on the initial Subscription Amounts hereunder
(or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against whom enforcement of any
such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser
(or group of Purchasers), the consent of at least 50.1% in interest of such disproportionately impacted Purchaser (or group of Purchasers)
shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed
to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement
hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser
relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected
Purchaser. Any amendment effected in accordance with this Section&nbsp;5.5 shall be binding upon each Purchaser and holder of Securities
and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser
(other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns
or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities,
by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations, warranties, and covenants
of the Company in this Agreement and the representations, warranties, and covenants of the Purchasers in this Agreement. This Agreement
is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of,
nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section&nbsp;4.8 and this Section&nbsp;5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents (other than
the Warrants) shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without
regard to the principles of conflicts of law thereof, and the Warrants shall be governed by and construed and enforced in accordance
with the internal laws of the Kingdom of Denmark. Each party agrees that all legal Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under Section&nbsp;4.8, the prevailing party in such Action or Proceeding
shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo;
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page&nbsp;were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any
of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that, in the case of a rescission
of an exercise of a Warrant, the applicable Purchaser shall be required to return any Warrant ADSs subject to any such rescinded exercise
notice and such Purchaser shall be entitled to the return to such Purchaser by the Company of the aggregate exercise price paid to the
Company for such Warrant ADSs and the restoration of such Purchaser&rsquo;s right to acquire such Warrant ADSs pursuant to such Purchaser&rsquo;s
Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and
hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law
would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a
Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or
any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or
are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For
reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through
EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers
with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so
by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction
Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between
and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.18</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Liquidated
Damages</U>.&nbsp; The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts
have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.19 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Company Acknowledgement;
Notice of Successor Danish Counsel; Aggregate Exercise Price of Prefunded Warrants</U>. The Company acknowledges and agrees that the
Purchaser&rsquo;s payment of any amounts of funds to the Company Danish Counsel under the Transaction Documents pursuant to the bank
wire transfer instructions for Company Danish Counsel provided to the Purchasers and/or the Placement Agent in writing by the Company
(and such bank wire transfer instructions for Company Danish Counsel included on the form of Notice of Exercise in the Warrants) shall
be deemed to be the delivery by the Purchaser of such amount of funds to the Company and shall satisfy the Purchaser&rsquo;s obligations
for the payment of such amount of funds under the Transaction Documents. If the Company changes its Company Danish Counsel, the Company
shall promptly deliver notice of the successor Company Danish Counsel (including the bank wire transfer instructions of such successor
Company Danish Counsel) to the Purchasers (including, without limitation, any successor holder of the Prefunded Warrants or Ordinary
Warrants) on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer of the Company, with instructions
in writing to pay the exercise price of the Prefunded Warrants and Ordinary Warrants to such successor Company Danish Counsel. The Company
acknowledges and agrees that, with respect to each Purchaser that has paid its applicable Prefunded Warrant Aggregate Exercise Price
Amount for the Prefunded Warrant ADSs issuable upon exercise of such Purchaser&rsquo;s Prefunded Warrants to Company Danish Counsel,
Company Danish Counsel shall convert such Prefunded Warrant Aggregate Exercise Price Amount into Danish Krone on the date of Closing
and shall hold such amount in trust for such Purchaser and shall release the applicable portion of such amount to the Company to apply
it in connection with exercises of the Prefunded Warrants pursuant to Section 2 therein by such Purchaser or any assignee of the Prefunded
Warrants. Notwithstanding the foregoing, each Purchaser shall have the right, upon three (3) Trading Days&rsquo; notice to the Company,
to require the Company Danish Counsel to return to such Purchaser all or any portion of the remaining amount of the Prefunded Warrant
Aggregate Exercise Price Amount in United States dollars that was paid by such Purchaser, provided that, following such return of such
funds, any future exercise of such Prefunded Warrants pursuant to Section 2 therein by such Purchaser shall require delivery of such
aggregate nominal amount of the Ordinary Shares before the Warrant ADSs are issued thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.20</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.21</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule&nbsp;of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference
to share prices, Ordinary Shares and ADSs in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the ADSs or Ordinary Shares that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.22</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,&nbsp;IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages&nbsp;Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>evaxion biotech
    a/S</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address for Notice:</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">With a copy to (which shall not constitute notice)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">evax
</FONT>SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Purchaser: ________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Purchaser</I>:
_________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: _______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address of Authorized Signatory: _________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Securities to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ADSs: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Prefunded Warrant ADSs: ____________</FONT>&#8239;<FONT STYLE="font-size: 10pt">Beneficial
Ownership Blocker <FONT STYLE="font-family: Wingdings">&#168;</FONT> 4.99% or <FONT STYLE="font-family: Wingdings">&#168;</FONT> 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ordinary Warrant ADSs: __________ Beneficial Ownership Blocker <FONT STYLE="font-family: Wingdings">&#168;
</FONT>4.99% or <FONT STYLE="font-family: Wingdings">&#168;</FONT> 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;
</FONT>Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i)&nbsp;the obligations of the above-signed
to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the
Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii)&nbsp;the
Closing shall occur on the second (2<SUP>nd</SUP>) Trading Day following the date of this Agreement and (iii)&nbsp;any condition to Closing
contemplated by this Agreement (but prior to being disregarded by clause (i)&nbsp;above) that required delivery by the Company or the
above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and
shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument,
certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE I</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>tm2334005d4_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<p style="font: 10pt Times New Roman,Times,serif; margin: 0pt; text-align: right"><font style="font-size: 10pt"><B>Exhibit
                                            23.1</B></FONT></P><P STYLE="font: 10pt Times New Roman,Times,serif; margin: 0pt"></P><P STYLE="font: 10pt Times New Roman,Times,serif; margin: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Consent
                                            of Independent Registered Public Accounting Firm</B></FONT></P><P STYLE="font: 10pt Times New Roman,Times,serif; margin: 0pt">&nbsp;</P><P STYLE="font: 10pt Times New Roman,Times,serif; margin: 0pt"><FONT STYLE="font-size: 10pt">We
                                            consent to the reference to our firm under the caption &quot;Experts&quot; and to the use
                                            of our report dated April 27, 2023 (which contains an explanatory paragraph describing conditions
                                            that raise substantial doubt about the Company&#8217;s ability to continue as a going concern
                                            as described in Note 2 to the consolidated financial statements), in Amendment No. 1 to the Registration Statement
                                            (Form F-1 No. 333-276505) and related Prospectus of Evaxion Biotech A/S for the registration of ordinary
                                            shares and warrants.</FONT></P><P STYLE="font: 10pt Times New Roman,Times,serif; margin: 0pt"><FONT STYLE="font-size: 10pt">&#8203;</FONT></P><P STYLE="font: 10pt Times New Roman,Times,serif; margin: 0pt"><FONT STYLE="font-size: 10pt">/s/
                                            EY Godkendt Revisionspartnerselskab</FONT></P><P STYLE="font: 10pt Times New Roman,Times,serif; margin: 0pt"><FONT STYLE="font-size: 10pt">Copenhagen,
                                            Denmark</FONT></P><P STYLE="font: 10pt Times New Roman,Times,serif; margin: 0pt"><FONT STYLE="font-size: 10pt">January
                                            30, 2024</font></p>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>9
<FILENAME>tm2334005d4_ex-filingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation of Filing Fee Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM F-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Evaxion Biotech A/S </B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Table 1: Newly Registered Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 19%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 7%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 8%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 7%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 7%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 7%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 10%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 8%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 7%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Security</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Type</B></P></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Security</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Class</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Title</B></P></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fee</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rate</B></P></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registered</B></P></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proposed</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Maximum</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Price Per</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Unit</B></P></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Maximum</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aggregate</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Price </B></P></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee Rate</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registration</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fee</B></P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be paid</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares DKK 1 nominal value (1)(2)(3)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,000,000.00</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0001476</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,214.00</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series A Warrants to purchase American Depositary Shares (4)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(g)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares issuable upon exercise of Series A Warrants (1)(2)(5)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,500,000</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0001476</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,321</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded Warrants to purchase American Depositary Shares (4)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(g)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares issuable upon exercise of Pre-Funded Warrants (1)(2)(3)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agent Warrants to purchase American Depositary Shares (4)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(g)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be
    Paid</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares issuable upon exercise of Placement Agent Warrants (2)(6)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,012,500</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.00014760</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">149.45</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees Previously&nbsp;&nbsp;paid</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares DKK 1 nominal value (1)(2)(3)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000,000.00</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0001476</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,476.00</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees Previously&nbsp;&nbsp;Paid</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series A Warrants to purchase American Depositary Shares (4)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(g)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees Previously&nbsp;&nbsp;Paid</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares issuable upon exercise of Series A Warrants (1)(2)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000,000.00</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0001476</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,476.00</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees Previously&nbsp;&nbsp;Paid</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded Warrants to purchase American Depositary Shares (4)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(g)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees Previously&nbsp;&nbsp;Paid</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares issuable upon exercise of Pre-Funded Warrants (1)(2)(3)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees Previously&nbsp;&nbsp;Paid</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agent Warrants to purchase American Depositary Shares (4)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(g)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees Previously&nbsp;&nbsp;Paid</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares issuable upon exercise of Placement Agent Warrants (2)(6)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$675,000</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">00014760</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.63</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Offering Amount</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,512,500</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,684.45</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Fees Previously Paid</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,675,000.00</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,051.63</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Fee Offsets</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-bottom: 1pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net Fee Due</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; vertical-align: bottom">$</TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,632.82</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents
the maximum number of ordinary shares, represented by American Depositary Shares (&ldquo;ADSs&rdquo;), each representing one ordinary
share, offered in this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Registration Statement includes an indeterminate number of additional ordinary shares issuable for no additional consideration pursuant
to any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration, which
results in an increase in the number of outstanding ordinary shares. In the event of a stock split, stock dividend or similar transaction
involving our common stock, in order to prevent dilution, the number of shares registered shall be automatically increased to cover the
additional shares in accordance with Rule 416(a) under the Securities Act of 1933, as amended (the &ldquo;:Securities Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
proposed maximum aggregate offering price of the ADSs will be reduced on a dollar-for-dollar basis based on the offering price of any
pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued
in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any ADS issued in the offering. Accordingly,
the proposed maximum aggregate offering price of the ADSs and pre-funded warrants (including the ordinary shares issuable upon exercise
of the pre-funded warrants), if any, is $15,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
separate registration fee required pursuant to Rule 457(g) under the Securities Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estimated
solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estimated solely for the purpose of
calculating the registration fee pursuant to Rule 457(g) under the Securities Act. The placement agent warrants are exercisable for
up to the number of ADSs or pre-funded warrants equal to 5% of the aggregate number of securities sold in this offering at a per ADS
exercise price equal to 135% of the public offering price of the ADSs. As estimated solely for the purpose of calculating the
registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the
representative&rsquo;s warrants is $1,012,500, which is equal to 135% of $750,000 (5% of the proposed maximum aggregate offering
price of $15,000,000).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>bc_fig13pioneer-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_fig13pioneer-4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$$ &AT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-RXR+6,P,# @-SDN9&5E,V$W-S S+" R,#(R+S X+S$X+3$V.C4P
M.C,P(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.GAM
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240](G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q
M-3 X0S@B('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z-4,W13(V,#-!.#4S
M,3%%14(U,41",S$U,D%!13!$.#$B('AM<$U-.DEN<W1A;F-E240](GAM<"YI
M:60Z-4,W13(V,#)!.#4S,3%%14(U,41",S$U,D%!13!$.#$B('AM<#I#<F5A
M=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@,C8N-2 H36%C:6YT;W-H*2(^
M(#QX;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED
M.C<V961C9#<V+30T,3@M-&8V,BTY9&$Y+64U-V5A.#(X9&4Q."(@<W12968Z
M9&]C=6UE;G1)1#TB>&UP+F1I9#HW-F5D8V0W-BTT-#$X+31F-C(M.61A.2UE
M-3=E83@R.&1E,3@B+SX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY0<FEN=#PO<F1F.FQI/B \+W)D9CI!;'0^
M(#PO9&,Z=&ET;&4^(#PO<F1F.D1E<V-R:7!T:6]N/B \+W)D9CI21$8^(#PO
M>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T 2%!H;W1O<VAO<" S
M+C  .$))300$       /' %:  ,;)4<< @   @ " #A"24T$)0      $/SA
M'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L A  $ P,# P,$ P,$
M!@0#! 8'!00$!0<(!@8'!@8("@@)"0D)" H*# P,# P*# P-#0P,$1$1$1$4
M%!04%!04%!04 00%!0@'" \*"@\4#@X.%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ), ZL# 1$  A$!
M Q$!_\0 L  ! 0 # 0$! 0$           <$!08( P(!"0$! 0$! 0$
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M<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'!
M?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T\
M:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?
MP\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/+
M!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP='
MP<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'!
M ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T
M\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A
M?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/
M+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP=
M'P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'
M! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'
MT\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&
MA?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\
M/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP
M='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\
M'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0
M'T\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/
M&A?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7
M\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#R
MP='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1
M\'! ?3QH7\/+!T?!P0'T\:%_#RP='P<$!]/&A?P\L'1\'! ?3QH7\/+!T?!P
M0'T\:%_#RP='P<$#CKWIGI[@FK6DM9AF,VZPU=7=+O!4SVZG93/DB_ ZQVX]
M8T3>;M1%V+^U +X                   $JI_[E;C^AJ'TO6 54
M
M                                               ENH_O1T=_.+OZ
M!K0*D                   $JI_[E;C^AJ'TO6 54
M
M                                     ENH_O1T=_.+OZ!K0*D
M              $JI_[E;C^AJ'TO6 54
M
M                           ENH_O1T=_.+OZ!K0*D
M    $JI_[E;C^AJ'TO6 54
M
M                 ENH_O1T=_.+OZ!K0*D                   $JI_[E
M;C^AJ'TO6 54
M
M       ENH_O1T=_.+OZ!K0*D                   $JI_[E;C^AJ'TO6
M54
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MO]GH*6FNKJB..HHJV6I>U]/ Z;NL?!$FQ=W9]IYS].L>UZP]2D^Q0#S>@
M        );J/[T='?SB[^@:T"I                   !'KM[_*S]&4OI:<
MH]#J3:CI=27L\
M                                                     :N;^ML,
M_P!^X_R+R34?19INVJF$:T           $MU']Z.COYQ=_0-:!4@
M           CUV]_E9^C*7TM.4>AU)M1TNI+V>
M
M                  -7-_6V&?[]Q_D7DFH^BS3=M5,(UH           );J
M/[T='?SB[^@:T"I                   !'KM[_ "L_1E+Z6G*/0ZDVHZ74
ME[/
M                                           &KF_K;#/]^X_R+R34
M?19INVJF$:T           $MU']Z.COYQ=_0-:!4@
MCUV]_E9^C*7TM.4>AU)M1TNI+V>
M
M       -7-_6V&?[]Q_D7DFH^BS3=M5,(UH           );J/[T='?SB[^@
M:T"I                   !'KM[_*S]&4OI:<H]#J3:CI=27L\
M
M                               :N;^ML,_W[C_(O)-1]%FF[:J81K0
M          2W4?WHZ._G%W] UH%2                   "/7;W^5GZ,I?2
MTY1Z'4FU'2ZDO9X
M                                                       U<W];
M89_OW'^1>2:CZ+--VU4PC6@           ENH_O1T=_.+OZ!K0*D  @MVUCU
M.I]:WZ*V?&['57%]H7(J6[55RJJ:!:+C5A1CXV4DSDEWTV=Q539W?\ -II[K
MG5Y7FN0Z2Y5CZ8IJK8*?EC:!U2E?;:VE<C=RHIJEC(G.:O&,<YCHVN1'?M5K
MT:'STFU=S;43.<WQ*ZV&VVFEP.O;:[C605DU4^KEEXW<? QT,:,;LCWEWW*O
MWMG[% S)=6[[F&;7K ](K727.7%GM@RC*;M-)%::2L<J_P#DH60-=+4U"(UW
M&(U6,CV;'.WE1H'Y=JUD6#9=9,0UAMM!04V4S+1XWEEFFEDMDM=W-VBJHJAK
M9*>9_P#]-V^]DFW9M16J!IM7?F!NNA^88W3YQ9:.33C)*J2E;D=%52K64/%[
MOWIZ1T7WFIOM<YT<B_=WNYM1$<%DN5=7SV)]RQ5]%65$L*5%!)42.Y',QS=]
MKN-A1Z[KD[J.:B_O[H$LIM5\YJ-!WZS_ (':VU#;3)DB6+E<ZI^'14ZU"Q\H
MXG_K*UO_ -O=V]S_ ! _>!YYK)J'A=ESBT6/&:6WWVD974M)57&O6:-DB;4:
M]S*)6[?WJ@'ZR75;.<=T7K-4*K%Z2FOMC9627_&JFLDV-Y!5/IW\14LB5'(Y
M&<:Q5CV.:J ?7%,OUKS'$++F-KL>+Q4E^MU-=J.CGN5P25D=9 V=D<CFT2MW
MD1R-<J;4V@8.:ZRYEB>A[=8'8M31UM!3LFOV,UM5)#-#(M2VED9%.V)[7;CU
M5R*YB;S?L T^3ZZZEZ?81:M4,PPBWU^!5L5'4W26P726:X6V"OW.+D?#54L+
M)D19&L7<D;L<O_A[H%UL=ZMN266W9#9ITJK1=::&NH*ENU$DIZEB21N1%[J;
M6N1>Z!G@1Z[>_P K/T92^EIRCT.I-J.EU)>SP
M
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M2;4=+J2]G@
M                                                 #5S?UMAG^_<
M?Y%Y)J/HLTW;53"-:\Y?,CB]!G65X1C>(5E1:M=J9U1=<6OU')Q3+9;J=6I5
M35^QKE=3R+LA9'NJKY';/\G&(H?#Y9\IDDRK-L-U$L\MKU_A?%7Y9<)Y$F9=
MZ)B\335%(Y$:UE-$US6,A8FXW>14VN<_8'I0",:G*F8ZN::Z:1JDE%:YYL^R
M)C7JUS8+-L@MS7)]CFR5LS7[%_\ LK^X"S@      ENH_O1T=_.+OZ!K0*D
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M "@;75_2?&=9L'KL*R9F['-_K6ZX,:CIZ*M8BI%41;=G=;M5'-VIO-56KW%
MY:KTXS>F^7>ET>M*VVHR"3'.J];<:JHGBHXT=2+2/J&;D#Y']Q5<UJM;W?M
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M#/!'NRJB;7N:]4<O=V(!0 (]=O?Y6?HRE]+3E'H=2;4=+J2]G@
M
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M=O?Y6?HRE]+3E'H=2;4=+J2]G@
M
M     #5S?UMAG^_<?Y%Y)J/HLTW;53"-:           "6ZC^]'1W\XN_H&M
M J0                   1Z[>_RL_1E+Z6G*/0ZDVHZ74E[/
M
M                             &KF_K;#/]^X_P B\DU'T6:;MJIA&M
M         !+=1_>CH[^<7?T#6@5(                   (]=O?Y6?HRE]+
M3E'H=2;4=+J2]G@
M                                                      #5S?UM
MAG^_<?Y%Y)J/HLTW;53"-:           "6ZC^]'1W\XN_H&M J0
M           1Z[>_RL_1E+Z6G*/0ZDVHZ74E[/
M
M                  &KF_K;#/\ ?N/\B\DU'T6:;MJIA&M           !+
M=1_>CH[^<7?T#6@5(                   (]=O?Y6?HRE]+3E'H=2;4=+J
M2]G@
M                                           #5S?UMAG^_<?Y%Y)J
M/HLTW;53"-:           "6ZC^]'1W\XN_H&M J0
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M ;W@'(J/Q>+P&]X!R*C\7B\!O> _3*:FB=OQPL8Y/L<UJ(O_ ,$ ^H
M      2W4?WHZ._G%W] UH%2                   "54_]RMQ_0U#Z7K *
MJ
M                                                        2W4?
MWHZ._G%W] UH%2                   "54_P#<K<?T-0^EZP"J@
M
M                                               $MU']Z.COYQ=_
M0-:!4@                   E5/_<K<?T-0^EZP"J@
M
M                                     $MU']Z.COYQ=_0-:!4@
M               E5/\ W*W']#4/I>L JH
M
M                            !+=1_>CH[^<7?T#6@5(
M      )53_W*W']#4/I>L JH
M
M                  !+=1_>CH[^<7?T#6@5(                   )53_
M -RMQ_0U#Z7K *J
M
M          2W4?WHZ._G%W] UH%2                   "54_]RMQ_0U#Z
M7K *J
M
M2W4?WHZ._G%W] UH%2                   "54_P#<K<?T-0^EZP"J@
M
M                                                   $MU']Z.CO
MYQ=_0-:!4@                   E5/_<K<?T-0^EZP"J@
M
M                                         $MU']Z.COYQ=_0-:!4@
M                   E5/\ W*W']#4/I>L JH
M
M                                !+=1_>CH[^<7?T#6@5(
M          )53_W*W']#4/I>L JH
M
M                      !+=1_>CH[^<7?T#6@5(
M)53_ -RMQ_0U#Z7K *J
M
M              2W4?WHZ._G%W] UH%2                   "54_]RMQ_
M0U#Z7K *J
M
M    2W4?WHZ._G%W] UH%2                   "54_P#<K<?T-0^EZP"J
M@
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MN'K1G7_*)]1H?5]"/BG_ )_GW4\]D
M                                                   );J/[T='?
MSB[^@:T"I                   !YUU.]][OTC3>E*@BU?91T'LO7+[=[!,
MYU(                              R+'_6V(?F;OY.H*]+U_AB>\?QI^
MW=5Z0--R(
M                              );J/[T='?SB[^@:T"I
M       !YUU.]][OTC3>E*@BU?91T'LO7+[=[!,YU(
M            R+'_ %MB'YF[^3J"O2]?X8GO'\:?MW5>D#3<B
M
M          "6ZC^]'1W\XN_H&M J0                   >==3O?>[](TW
MI2H(M7V4=![+UR^W>P3.=2                              ,BQ_UMB'
MYF[^3J"O2]?X8GO'\:?MW5>D#3<B
M                                                 "6ZC^]'1W\X
MN_H&M J0                   >==3O?>[](TWI2H(M7V4=![+UR^W>P3.=
M2                              ,BQ_UMB'YF[^3J"O2]?X8GO'\:?MW
M5>D#3<B
M                            "6ZC^]'1W\XN_H&M J0
M      >==3O?>[](TWI2H(M7V4=![+UR^W>P3.=2
M          ,BQ_UMB'YF[^3J"O2]?X8GO'\:?MW5>D#3<B
M
M       "6ZC^]'1W\XN_H&M J0                   >==3O?>[](TWI2H
M(M7V4=![+UR^W>P3.=2                              ,BQ_P!;8A^9
MN_DZ@KTO7^&)[Q_&G[=U7I TW(@
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M1B_8YKV*J*G^**!]P  #SKJ=[[W?I&F]*5!%J^RCH/9>N7V[V"9SJ0
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M:%@
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MJ=[[W?I&F]*5!%J^RCH/9>N7V[V"9SJ0
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MR;4V[%3]B@?H
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M&H!U0  !YUU.]][OTC3>E*@BU?91T'LO7+[=[!,YU(
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M_5<W_A3:U0L0
M                            );J/[T='?SB[^@:T"I
M     !YUU.]][OTC3>E*@BU?91T'LO7+[=[!,YU(
M          R+'_6V(?F;OY.H*]+U_AB>\?QI^W=5Z0--R(
M
M       );J/[T='?SB[^@:T"I                   !YUU.]][OTC3>E*@
MBU?91T'LO7+[=[!,YU(                              R+'_6V(?F;O
MY.H*]+U_AB>\?QI^W=5Z0--R(
M                                              );J/[T='?SB[^@
M:T"I                   !YUU.]][OTC3>E*@BU?91T'LO7+[=[!,YU(
M                            R+'_ %MB'YF[^3J"O2]?X8GO'\:?MW5>
MD#3<B
M                          "6ZC^]'1W\XN_H&M J0
M    >==3O?>[](TWI2H(M7V4=![+UR^W>P3.=2
M        ,BQ_UMB'YF[^3J"O2]?X8GO'\:?MW5>D#3<B
M
M     "6ZC^]'1W\XN_H&M J0                   >==3O?>[](TWI2H(M
M7V4=![+UR^W>P3.=2                              ,BQ_UMB'YF[^3
MJ"O2]?X8GO'\:?MW5>D#3<B
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MG&OHT_RM*_\ J_!Z6-)R8
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M8K=Y)!P '5'$_,5N\D@X #JCB?F*W>20< !U1Q/S%;O)(.  ZHXGYBMWDD'
M =4<3\Q6[R2#@ .J.)^8K=Y)!P '5'$_,5N\D@X #JCB?F*W>20< !U1Q/S%
M;O)(.  ZHXGYBMWDD'  =4<3\Q6[R2#@ .J.)^8K=Y)!P '5'$_,5N\D@X '
MVI<;QVBG9545HHJ>IC[L<T--%'(U539W'-:BIW -F
M
M   $MU']Z.COYQ=_0-:!4@                   E5/_<K<?T-0^EZP"J@
M
M                                                     $MU']Z.
MCOYQ=_0-:!4@                   E5/\ W*W']#4/I>L JH
M
M                                            !+=1_>CH[^<7?T#6
M@5(                   )53_W*W']#4/I>L JH
M
M                                  !+=1_>CH[^<7?T#6@5(
M            )53_ -RMQ_0U#Z7K *J
M
M                          2W4?WHZ._G%W] UH%2
M   "54_]RMQ_0U#Z7K *J
M
M                2W4?WHZ._G%W] UH%2                   "54_P#<
MK<?T-0^EZP"J@
M
M       $MU']Z.COYQ=_0-:!4@                   E5/_<K<5_\ ^&H/
M2]8!50
M
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M![!L9[29AZTWGG(#V#8SVDS#UIO/.0'L&QGM)F'K3>><@/8-C/:3,/6F\\Y
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M\II:6LI+E S??'NU=NJ&55._:Q6JNY)&UVQ>XOV+W -L
M     !J;_C5FRB"CIKW3\IAM]=276D;OOCW*RWS-G@DVL5-NZ]J+L7N+^U -
ML                     !J,@QBRY1';XKW3<ICM=?2W>A3??'N5M!)QL$G
MW%3;NN3;NKW%_:@&W                      TN18I8<J_"OQVEY5^"7&G
MO5M^^^/BJ^CWN*D^XYN]N[Z_==M:O[4 W0                     &OKK%
M:+E<+9=:^CBJ+C9I)9[54R-VR4\L\+J>1T:_L5T;W,7_  4#8
M       #A-9-3:#2#3B]Y[7P+5NMT364- B[JU-;4/2*"+;L541SW)OJB*K6
M[5V+L G619IJ9HW08AF6HU]I[[8KW<*:TYG;X:**DAM$UTV\544,C-DCH*>1
M$BD;.LCWM7>16N[@'H                      " 97%\T>317/*\$N]IQ2
M@HI)TL&&W"WI5UEQIZ97-9)6U,JIQ$E0K=Z.*)NQC'-1[M[>4#N-!]47:QZ6
MV//IZ)+=75[9H:^C;O+&RJI)7P2K&KMJ[CG,WF[5541=BJJHH%'
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M,CFHI;;+>*"EN$ENJ/\ K4SJN%DJPR=Q/O,5VZ[N?:@&W
M    ":Z\Y3FV$Z89#EV#+;FW*RT4]=,ZZ,EE:D4+-Y>*9$YJ+)LV[N^N[M^U
M% Z'"<@FK].,=RK(*EG'U5DHKG=*M6I%'OR4C)YI-UO<:W:KG;$^P"+674/5
MG.M,;UKSC%R@H+/!RZX8KA,]'')'66BT22L>E;.NV9M35)"_B^)>UD?W.X]%
M<H&Y^J[ N1_B'(ZOD?47VB\=MCW>3\KY#R'_ #?^HX__ $O_  ;?V@7D
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M5SE#W/A.74^<8]!D5+:[G9H:A\C$H+Y2/M]<Q8GJQ5?#(JJB.V;6K^U .A
M                 #09S6W&VX3DMQM&W\6H[575%!NIM=RB*G>^/8G[]Y$
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MJ[*[Y<*I];<;[=%3E$SU:V.-B,:JM8R-C&M:QO<^U?M50.S
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MCITI+-:*:&AM],U5<D=/3L2.-NURJJ[&M3NJNU?V@;$
M  .,U2P>NU'PRYX537G\$HKS!)1W*I;2LJY74LS=U[(T>]J,<J=S>V+_ (=W
MN@9NG^,5^%XC:<4K[K^,I9J:"@I*Y:=M*]U-2Q,AC21K7O17[&_><FS;^X"=
M/^7Y]-9+U@%@RJHM&E&05,]37XU!2QK4P0USE?5T5%6;Z)!2SJYV\Q87N:CG
M(UR;W<"@^S7 NSU%_P"R=4_^DG_L/B/^S_R =4
M
M
M
M
M                                                     !P^FVJF
M,:I,R23&GN<W&;U5X_6*]6+QDM'N_P"M'N.=MBD1VV-W[=B@=P
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M-157[VW]R*O< U^E^<LU+T_L&>1T*VV.^TR5;*%TB3NB:KG-1JO1K$7[-O\
ME0#K@ '#ZMZC+I5@USS=UCJ[]3VN-9JBEHWPQ*R--B*][YGMV,153;N->[]S
M5 Z3&[QUAQVT7_B>3?BM%35W)U=OK'RF)LNYO;$V[N]LV[ -H     &$VZ4U
M32UE1:W-N,E&Z:%\-.]BJM3!M1T.\J[J/1R;JHY>XOV@:? ,COF6XG07_(\<
MJ<2O%7QO*+#6R-FGI^+E?&W>>Q&HN^UJ/3[J=Q0.8U=U>32A<:X['JN[4^27
M>CL4==#+##2TU172*UG&JY72*NZU[D1L2IW-BN;M0"F
M
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M/-*JNUR[)^*HV5]->6SQ*ULCJ6.%=QT2R_Z;XFN8J=W[4 K@
M
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M2;SWRINL5=B,1=KU ](
M                                             -'F6)63/,6NN'9'
M$^:R7FG=2UL<4CHI-Q_=VM>U45%1414_^.U .&MVC%WMEG@L$.J^;26F"-L#
M8Y:BS.J%B:B)NK5I:DJD[B;-YLR._<H%%L=DM6-VBCL5CIFT=JH(TAI:=BJY
M&L3][G*KG.5>ZYSE5SEVJJJJ@;
M ' T^E%KIM5:G5YEYN;LAJ[6VQ2T+EHN0<A9,V=&(U*5)=[?;MWN.V_L^S8!
MWP #@'Z36E^K#-85O%S3)([3U?2B1:+D'X<M0M3N;BTO&[W&+MW^.WOV;=@'
M?@
M
M
&     /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>bc_fig16stage-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_fig16stage-4c.jpg
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M *0  0$  @,! 0             &! 4" P<( 0$! 0$! 0
M  $" P00   & 0(!!0H*!P4%!P4! 0 ! @,$!081$@<A$].4%S$BTI,45+05
M5AA!T3*24W,TE38(44*R(W15=6%Q4C,6@8.SU#61H6)#)"6UL<%R8S=$A!$!
M  ,! 0 " P$! 0        $1$@(3(3%!<0,R46'_V@ , P$  A$#$0 _ /OX
M        !*9'^+<,_BIWH#PHJQ                  2F0_C'#OK;#T10HJ
MQ              8UA]@E?4N?LF U>%?@W'?Z9"]'0 WH              E
M,\^RT?\ 7:ON?Q*18%6(                     ";QK_K.6?U-OT"* I
M                                           $IQ)_!5G\'^1W.3__
M $-BP*L0                                2F1_BW#/XJ=Z \**L0
M               $ID/XQP_ZVP]$4**L0             &-8?8)7U+G[)@-
M7A7X-QW^F0O1T -Z              )3//LM'_7:OTE(L"K$
M         !-8R9*M\L47*GUHA.OP:I@1=2_V *4            !X%Q"XVW&
M(\4',%LI4+$H4J)#<PZXNHK[]1<S7U+*2P_+:4@HIM;4I07Z3W*Y#0D]1 HJ
MWCM62LCS6FFTMA&B8I;P<=C24,F\N=8SDHVH0E!Z((U.)VJ69(V=^M22/0I0
M_5_F,X<E05V1,JGR(MA M[<X[,12I$>!CKBF;!Y])J(DI9<2:.11[S^1N(*&
M?&X\<.I605F-HFO(GVBZ^,TIQDT--S;B&JPAQ73,]4NNQT&X6A&DN1)J)2DD
M:AE99QGP;#+Q^BNY#Z'8#4&1<S&F3<B5S5M*\CAJE.ZD2.==[TB(E&1=\K:G
MO@H:/AIQ!S+/\]SAAYEFLQ'$+5_'TP'HB_*WWFV8[S<A,HGS3J>]S>US6A(-
MHR/4U!,#R[WD<^H\/R;B5D#%7-Q;#\YDX;<UT6._&E+K&'FF"G,N*?>(Y!*=
M3N94G8I.NBDF+0];M/S"<-JNYM:%<J3*L:D[)MQN(P;QORJ2,W,GQF"(]RW6
M&72<4G30]%$DU*2HBE#+<XX82BFJKTBFK@7R*HZ%11]OES]ZRY)C1VC6I*2=
M)IM3CI+4DFR^4?*%"-9_,A2(R2TM94IESA.UB-9EE;:,1GU3UNV=@[7HC["4
MK<I3K9-I1S:5$X>ABT*9WC_A*%0HK$2VE7$VUL,=*HCPC7+:MZIDI#T5TMQ(
M)1M*)Q"B6:%)Y=V@E#!E_F8X:L4E5D$4K.QJ[BGGY%%=A0EN;8-.O9/YW<:=
MBXRB,G4J[GP:GIJH9\'\PG#F?&N)33TUM%1ZFT3(B.,+EIR;_IBHI.;=Y2#Y
M"W;=G*:]I%J%#"LOS)\.ZV!&L29M9C$BNL[<RAP5.FU&H9"HMCSG?$23CK2K
M?R[3+E2:B-.JAML:XOP<LXFV6!4U;)>K*ZFKKK_4!I(HSQ6R5.LD@C,E$@VR
M+11EJ:MQ:%MU-0]*$           2G$G\%6?^X](;%@58@
M                  E,C_%N&?Q4[T!X458@                 )3(?QCA
M_P!;8>B*%%6(             #&L/L$KZES]DP&KPK\&X[_3(7HZ &]
M         $IGGV6C_KM7Z2D6!5B                      FL3^W95_65>
MA1!12B            #S;.>$,?/F,@J+N\E/8KDQQO6%(\U'?;C^3(0V:H3B
MT;F%N$C52N_T5WR=JN46QK[#@7!E2\NDPLEM*U&7VU9>RV8WD^UN15I;0IKO
MVE<XP^EI"7&7=R>3]!F06/.<JX"9)2,XWC>$.,S\:JT9"Z[(NZV);[WK^6W(
M\C<CH=@&3)ZN[E;U-FD]%MGWNEL>A85PCLZK*D\1[:R1!R6^@UJLSH*]EE^K
M<MJZ*F,EV&[(;4^PV22V&A"N^(BU$L=V=<!,8SR[M;2?,DQH.2,U4;*ZQDFS
M;L&J&84V&7.*2:VCWEL<-!]\WR%M5WP6*/".'K.$6&76,:R>F.9=;.7LE#[;
M:4L276D,FEO81&:"0TC0E:GR'R\H6(&M_+-C[,6;3W5]/M\7L\F>S6SHW$1V
M&)5L\I*]CRFT;E1DJ0E9,:EJHBW*,BT%L56(\((&&9GDF2U-J^=/DTY^ZEX^
M\Q%<;;M)J4IDO-R3;\H)#I((S9YS82N4N34A+&AD_EOQ%OA]1X'03YE1_IBY
M5D>/6I<U*=CSN=><2E;3R#;=92AY3/-*3H:"+X2U"QSR;\O5+ETNYE7-Y-UN
MJ2NH7DQFXT<FU4\XK*-*;)#>A+3(U4:--AI[W:%B4R+@?DU5E6$6&(3)$N0O
M++?+,NR!Q,7]Q*M*[R-+C<5Q22-LB)MLFT;E$DC49Z\HMC<M?E?QB+C]7C4*
M\L&ZZLQR]Q;<LF777F\H6;LZ2M2D?YIN*WH(N]3W-- L?CWY8,=DUUQ >O[#
MG+.#CD2/+2W&)V))P]&V!);)3:DJ4>JN=2M)I5N/0DA8V^2<!H>5FP];9!)\
MM3C-KB,IZ/%B1T.Q[PB*2\EIMLD(66A<V22T+X=PEC<87P@KL(RM655UM+?>
MD459CLZ&\EDV7DTR#;COZD@EH7L4HE)2K:9GKH%CT<0          !*<2?P5
M9_[CTAL6!5B                                "4R/\6X9_%3O0'A15
MB    #5JR.C3D2,25/:+)7(2[5%9K^_."VZEA3VG^ G%I1K^DP&NI\]Q>^RF
M^PNJEK?R3&/)SOH9L/ME%\L1SD?<XM"6U<ZCOT;%'R"CJJN)&&769W'#ROLR
M7F="TB3:5#C3S3K<=W9M=2IQ"4.(/G$=\VI6FXM=-0H?N%<1<.XBLV<G#++U
MI$IYKE782$,O--(FLD1N-$IU""6:24DS-&I<I<H4-OD-]5XM16.27;JH]-4Q
MW9MA(2VMTVHS"36ZX:&TJ49(21J/:DST(0=M7;U]U40KZJ>\KJK&,U.@R&TJ
M_>QWVR=;6E*B)7?)41D1EJ P,/S#',^QR%EN)3BL<?L.=\DF)0XT2S8=6PX6
MQU*%D:7&U)/5/P -X   "4R'\8X?];8>B*%%6( #Y:QSC5DF(QN+&07QRLI8
MH<^1BM+6N2&HW,0Y3S++24+YLR,T+>Y37RF7ZPU0JHOYB?\ 4$B%B$''G(V<
M6V09'BJ(9SB3&:7BK!O3)*)9,F9EM4V32>9+5:N70BW!0\_X<\=;B!BF%Y?G
M5G:6AHP*\R>W2RJ*F/,76STM=^SS25<\1*;;:4EQ*.^/<7=,68'JN2\;,EQ/
M&%W]QA"VU&Y+5%<;L6'(+T6+7%9-N)>2CG34^6Z.VDHYZ.),U:-]\,T(S(^/
M636\F]33PCKL/3PM_P!?M26GT-W32IZ%+0I!J;>92XRA"DI09&G=WQJ,M"%H
M;JL_,7!ARJZB<JYLZ' 5B5/>W4MYE,M-AF$9+L9?--H2AQ*"-"I*DFCE<[Q)
M[3(*&?A_YAU9+G--AD[%W*U-Y89+40;!,U$DO*L26A,@UM$T@TH<)?>*W:Z\
MFW3O@H7GK.QM.*)4\.4INEQZI\JM66E)VO3[5W9&0X1D9_NFH[R]",O\Q)G\
M @M!!C6'V"5]2Y^R8#5X5^#<=_ID+T= #>@ #S7\PJN;X&<0WB5S;C-!8NLN
M$HT*0ZW'6IM25$9&2B41&G3X18^QX!#=SG@OP>MN/-3-AIBSL>Q%NKQAV1(F
M07I#CD./(GRE+4V2'WT/&7[GD_66:U#7W\"RXF<9^)O#BRL:*<NJ>G46*6&<
MR+%,1YJ%.2S:-PX]8TEQ\U(-+3FKKF]2C4IO0B+4E2($EQ-XD7N6YGB[4J0W
M2P,<XM8SC\:BT-FR4TY#\J<D2'2=U-MY3VPFN;V&E!:F9BQ VT+\RN;HRZMI
M)$:OL6CN.(-;-KHK:VY[S&'1?*()-%SJ]CKQD:%[DF2OU2(2A@WO%[B5>\+\
M4RV-E])$A99D.(LE)HT;I=>Q;'NL(4PG'30@F'D<VE>\E+02D.;3U,6A]<M;
MN:1N63BMI;G$EH2CT[I%J>FHP.8  CN)!S"J:HZY+2IY757Y,F0I2&37Y4CD
M6I!*41:?H(^46!W<[Q+\THNM3/\ EP#G>)?FE%UJ9_RX!SO$OS2BZU,_Y< Y
MWB7YI1=:F?\ +@'.\2_-*+K4S_EP#G>)?FE%UJ9_RX!SO$OS2BZU,_Y< YWB
M7YI1=:F?\N <[Q+\THNM3/\ EP#G>)?FE%UJ9_RX!SO$OS2BZU,_Y<!^FOB0
M9),F*-)Z=\1O2U<NOP'S1?!_8 _-_$KZ&C\;,Z, W\2OH:/QLSHP#?Q*^AH_
M&S.C -_$KZ&C\;,Z, W\2OH:/QLSHP$_C2N(?EN2\PU2&?K97.ZN3--_D<7N
M?N_T: *#?Q*^AH_&S.C -_$KZ&C\;,Z, W\2OH:/QLSHP#?Q*^AH_&S.C -_
M$KZ&C\;,Z, W\2OH:/QLSHP#?Q*^AH_&S.C -_$KZ&C\;,Z, W\2OH:/QLSH
MP#?Q*^AH_&S.C -_$KZ&C\;,Z, W\2OH:/QLSHP#?Q*^AH_&S.C -_$KZ&C\
M;,Z, W\2OH:/QLSHP#?Q*^AH_&S.C :V_N^(N/U$FX?B4CS,4DJ6VEZ6DS)2
MTHUUYH^YKKW &RW\2OH:/QLSHP#?Q*^AH_&S.C -_$KZ&C\;,Z, W\2OH:/Q
MLSHP#?Q*^AH_&S.C -_$KZ&C\;,Z, W\2OH:/QLSHP#?Q*^AH_&S.C -_$KZ
M&C\;,Z, W\2OH:/QLSHP#?Q*^AH_&S.C -_$KZ&C\;,Z, W\2OH:/QLSHP#?
MQ*^AH_&S.C -_$KZ&C\;,Z, W\2OH:/QLSHP#?Q*^AH_&S.C 37$!7$+_2%C
MY4U2$Q^XW&ER89_Y[>G_ )8"F-?$G4]&:/3X/WLOHP'YOXE?0T?C9G1@&_B5
M]#1^-F=& ;^)7T-'XV9T8!OXE?0T?C9G1@&_B5]#1^-F=& ;^)7T-'XV9T8!
MOXE?0T?C9G1@&_B5]#1^-F=& ;^)7T-'XV9T8!OXE?0T?C9G1@&_B5]#1^-F
M=& ;^)7T-'XV9T8!OXE?0T?C9G1@&_B5]#1^-F=& ;^)7T-'XV9T8!OXE?0T
M?C9G1@&_B7]#1=WZ69W-/J_T@*L0        2F1_BW#/XJ=Z \**L0  !^&>
MTC/E/0M="Y3 ?+F:8_Q$7F>&_F!QZ@FR<AA6SU9:8VF.IFS/$Y.]I3+Q*?-E
M2F=OE#22,B-QWN\@U_X+'A?CF15GY@N-&4653+B8_E)8XJBL'FR2U(]65ZV)
M!%RF:32M1$6XBU[I!/T-+E7#;,,AXE4N<8K'=K)]7D,VFR%Z4VE@IN(VL1HY
M"T+W:N<TXT?,?"EQ>[30@L0N/</N)%5CV35\"ALJ^DE\859-:5C/[EV?A#QH
M3L:2E6JTZMMJ<8(R6:$F6AZ[3MC7W'#_ (RS,-B5674US>U\G#LOK:&J:D>4
M/P+RPEN*J53])!$K;!-+*%+4LF^5!D1ZZK@5&&83Q0C<0<:1DR<@K:&OJ,4?
MQ]ZJ2P[$BE4UJV;:KGFITB:*0\K5S8VOG2)&U9*0DA!ZA^5_'[[%>"6.X_DU
M8_3W<-ZT.37RB)+K92;.5(;UVJ41ZMNI/D,2?L>OB   )3(?QCA_UMAZ(H45
M8@ /.5<"^&JX=W =K'W(F16K60W#:ITP^?M6'">1(UY[5*MZ4F:4:)/:6I<@
MMC][#>&R5&\Q6OQYOKB;DB9[$V6W+19VK9M37$/)=WI3(09H=:29-J+]7N!8
MXU_ CA;5QH$&'2&4"MJ9F.18;DJ4ZQZILUFY*C+0XZHEI<4>XS7JKD+0RT"Q
MT>[[PJ<IZ:CF5,B=7X^B4S4%+LK!]QB/.C'#>8)Q4C>;*F/W7-&>PD\A$%C*
M7P-X9*C)B>IUI8+'2PM2439B=^/IUVQ%F3Q&HDD9D2S[\B/3<%CDUP1X:LVD
M"W;I])E>58:-7WS;>=H4*;K79"369/.Q4J433CFJNYKKM3HL<ZC@MP[H[JKR
M&MK'6[>FEV=C72%3);G-RK[3R]S:MU25<_M+<2B,B_5T"Q75]'65DZTLH;.R
M=<O(DV+YF:E..-,HCH[IGHE*&TD22Y.Z?=,Q!L0&-8?8)7U+G[)@-7A7X-QW
M^F0O1T -Z  )NWR+ I#TG&;ZTJ77R)"9M3-?CJ,N<,MB767%'\HS+:2BY?@
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MHC%H7(@ -9*R&FAWE?C<J6EJ[M69$FOAJ)6YYJ'LYY23TV]YSB-=3^$!LP
M     2G$G\%6?^X](;%@58@      #\49)(U'W"+4_A[@"4A\3N'U@VR[ R2
M!)1(?BQ&#9?2LUO3W#9C$1)U/1UQ*D(5\DU$9:ZD8M"L$ !I9>7XO R"'BLV
MVC1\BL$FN%7..$EYW:1JT01]U6U*E$GY1DDS(M",!N@
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M.J<)*R7.;80T2$:'NY6U;CU+3^T068@      "4XD_@JS_W'I#8L"K$
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M]%%J6I"#L      $KG9&<6C(N[Z\J_\ NDI,6!5"
M  F\52I,_*=Q::W"C+^XX40!2                     )W/6E/83D"$?*\
M@D*^8V:O_L H4F9I(S+0S+4R/X 'Z                     E>(Z37AT]!
M<N]<5)D7=T5*:(_^X6!5"                            #RKC&3+$C';
M.TKUS,<@R5/SCC1Y$V0J4R@W8"4L,.(0K;*2TZGGTK1O2GD2??%8%K@I2?\
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MHTDGO>X:UGWPDBY$    &-8?8)7U+G[)@-5AJMF%8^K::MM7#/:GNGI'1R$
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M5/DA[6VI)GLA2EGR$234?[M9_P"%1Z'\!_JCT\_TO[<YY>\#JP
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M#QNP                     PX'^=8_Q:O^$V-=?C])#,&5
M        8MF6M9.+N_\ IW?V#&N?N$GZ9#?^4W^G8G]DA)5R$
M         &#<_P#2I/\ NO\ C-C?'VD_38.?+5_>?_U&%<0    '8PP_*>;C
M1FEO2'E$AIEM)K6M:CT)*4EJ9F9]PB ?3O";\K[CW,7_ !*0;;7(Y'Q]"M%J
M+ND<E:3[WZM)Z_XC+E2._/\ /_K$]/J=AAF,RW&CH)MAE*6VFTEHE*$%H1$7
MZ"(AZ'-V                  #R?C"]&ASJ:>Y=1<4>9C6!?ZLL4P'8\5I2
M&]["&YZ5$IU\B_\ +Y22D]R5)Y!8%GP\*$G L936HG-UY5<,HJ+;7U@37,(V
M^4[B(^=T^7R%R_ 02*402F1_BW#/XJ=Z \**L0 '@&;1K6FO<PNZ#R^ZQ*TD
MQJO,\;CJ?><AO/1XY,VL!!<I;#629K+)Z+;+G"T6A1*T.^5Q:RYBYN6&6XZ*
M^JM6Z6VK3A2RG4\5RP\G:M%K6E+3L=R+H_WNXBW)5KM2X04/QGBUF#-K3UEK
MS4=;LTH<IPJ^3S4BND2;&/&LVU$:^1U,9AS81DEO>>\S);>BAK\8XE<0;R=B
M35S/*,S+F4$JT<BUCK#?-WE%/D+AN<YSAI2W+8:(E[B41K)"_P"U0Z<;XK94
MB+AU3#:K*Q<RN@3U5AQG8B)"77IK<F.T3ZTDR\I3+"(K:EGJ;BMWP!0ZG>,/
M$6910K>MGP"*S*S=)I%1.7(@.UU,J<Y"DH=-K]ZW*1S/<Y4GM_S- H>B\/\
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M\8X?];8>B*%%6(             #&L/L$KZES]DP&KPK\&X[_3(7HZ &]
M           $IGGV6C_KM7Z2D6!5B                      FL3^W95_6
M5>A1!12B                    #19K^#<B_IDWT=8#/I?^C5W\,S_PT@,X
M                    !*<2/P=.^MA^ELBP*L0
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MH7"#/GN*/#7'<^D5;E,]>1C?77.JWFV:'%M;DJ,D[FU[.<;5IRH41B3 MA
M    0_%2V@4&.0KZU<-FKK;>J?ENI2:S2@YC;9:)21F>JEI+D"9J+$S[S7"'
M^:R.IR/ '/TY:S)[S7"'^:R.IR/ #TY,R>\UPA_FLCJ<CP ].3,GO-<(?YK(
MZG(\ /3DS)[S7"'^:R.IR/ #TY,R>\UPA_FLCJ<CP ].3,GO-<(?YK(ZG(\
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M9DL+):%%^C4NX9?"1\I?"-Q-LLX4    2G$C\'3OK8?I;(L"K$
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M@                    !AU_P NQ/X?+G2U_L)MK0:Z_'Z2&8,J
M            Z)WV"9_#O?\ #4+'W"3].47[)&^I:_8()^UAVB
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M_24BP*L0                     $IA?VK+/ZZ_Z-&%%6(
M       -9DB=^.VZ#/0E0I):_P![2@'5BBC7BU&L^0U5\0S+^]E #<
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MG[)@-7A7X-QW^F0O1T -Z              )3//LM'_7:OTE(L"K$
M              !*87]JRS^NO^C1A15B                    #6Y#_P!
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M"JF"<":MDHRGHYQT&VOF4D1-D:=-$%R)+D$D5(@E,C_%N&?Q4[T!X458@
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MT= #>@                    )3B1^#IWUL/TMD6!5B
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M:$HR[GKXB8CY<I>@6R#=JIS9'H:X[J2,^YRH,AMEKL*_!N._TR%Z.@!O0
M                 $IQ(_!T[ZV'Z6R+ JQ
M   !XKQ49MJ&R*= M\@DG9D_*=BLW,2HKX,:*A!+4A3L5P]B==Z^4S26Y1GH
M7)8'I6#2E3<+Q^:MQUU<FNBO+<D.&\\I3C*5&:W#0T:U&9\J]B=W=T+7004
M"4R/\6X9_%3O0'A15B                  E,A_&.'_ %MAZ(H458@
M        ,:P^P2OJ7/V3 0=K6W-QP*DU./*--[-Q8X]<:#VJ.0[ VH)*O@,S
M/0C^#NB_D=$NKE7%_P +[S'ZU7^G*KRU<_53;1Q&I%:N*RA32S)1J)9DVI*2
M,TZ'KW $=)Q?BM/L)C3T2S@5,V=7*?3%NT][&C7;ZI9MK0ZAPDO5ZT:)03>A
M))LDD:",Z-&S:9G;7=]&Q258V%A!D6$6MCIG,JCS8+%G'6XQ)2M]1Q9#<9EZ
M+$<D,()?.;EKU/< VTO!^(M7(?MZ"!8RSD5M-&E>7645VV=@QK*>_.K]YN)9
M)[F93/-+UVFEO8;V[OS#M_T5Q)<R+&6;&'/M:RCN:BQ@6\^TCNN-5;->]'E-
M2VTF@G9:)#AN*<0VHG$J3M5J@!M,LQ/+YMUQ3;K\=;LXF:TE935+LN0PW"-Q
MMF8Q(5)(U&XEMORE"N];4I?*22U :Z;PGRVNA,V6)K)S,Z:)6X_.E6*DMQ\F
MI6(D=A\I)H4M2'VUI=?BOJ+>AS5/*VXH+&VR;%,YEYA7<3*N&2[BCN$0HU.K
MF$O/XT^GR6812.>2G:O?Y<AM9:\XTA/(8@JN'T.<U=9W9F1HHK2])^F;,MI&
MEF!$CR74%_A<D-.F1_K<JOU@D78@ ('C#1Q\HQ!G&9;JV(MO:U49U]K0W$$F
M<RZ1I)7)RFV1'K\!B3%Q1#S#W0,3]H;'YC'@CEY0WH]T#$_:&Q^8QX(>4&CW
M0,3]H;'YC'@AY0:/= Q/VAL?F,>"'E!H]T#$_:&Q^8QX(>4&CW0,3]H;'YC'
M@AY0:/= Q/VAL?F,>"'E!H]T#$_:&Q^8QX(>4&CW0,3]H;'YC'@AY0:/= Q/
MVAL?F,>"'E!H]T#$_:&Q^8QX(>4&G0Y^3W'S69M9-,2W\"51VE'_ -I*3_\
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M\*_!N._TR%Z.@!O0                    $IQ(_!T[ZV'Z6R+ JQ
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M6(                     "4PO[5EG]=?\ 1HPHJQ
M  !U2$DJ.ZE1:I-"B,C^$C(P&DP4S/"\>UY?_;HI?["921 *
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MRHES'D1XC-Y4J>D/*)#:"5+;0G<H]"+52B26OPF KP
M   !*87]JRS^NO\ HT8458@                    X.I-32TI^4:3(O[S(
M!H,"4E>$X^:>YZOC%_M)I)'_ -Y *(                    !*<2/P=.^M
MA^ELBP*L0                            >+<8RQVZR.AK)D"/E,RH;DR
MYN+041YM]S$QKF6G4,.2XRFF>=)O>]M47(23VI-1BP/2\)ASJ_#J"#:5\>IL
MHU?%:EU<)Q3T:*\AE)+9:6HS-2$'JE)F9ZD0@WP"4R/\6X9_%3O0'A15B
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MT6_H))2ZN61FR\25(/5)FE232HB,C29&1D?PCTQ-N3:B@
M   )3"_M66?UU_T:,**L0                     $UP\_ ]!_!,_LBR*40
M                    2G$C\'3OK8?I;(L"K$
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MG0B(B^ AW8=@                   )3"_M66?UU_T:,**L0
M          $MPV6I>"4)J[I1$)Y.3D3J1?\ <0LBI$
M  $IQ(_!T[ZV'Z6R+ JQ                                !*9(9%EV
M%E\)RIVG4'A15B                  E,A,O]8X<7PF[8:=34**L0
M       &-8?8)7U+G[)@-7A)ZX9CIEW#K(7HZ &]              $KG9F4
M6C,CT/UY5E_VR4D8L"J$                     !*87]JRS^NO^C1A15B
M                     E.&GX#HO[(Q$?\ >2C%D58@
M    E.)'X.G?6P_3&18%6(                                .EW_.8
M_P ONJ^7\OY)_(_M_3_8 [@                 !TN?Y['^7W5?+^7\G]3_
M ._]@#N              'XKY)]SN'W>Y_M <&/\AKY'R$_Y?R.Y^K_9^@!V
M              "4SS[+1_)_Z[5?*_B4]S^T458@
M )O$_M.2_9?^L/?9?E?9X_\ G?\ [?T_V;112"
MF\"_"%7]F_RU_8/LW^8KY']G_P!P%(                     G\V_#4K[+
G_F1O^H?9OM+?RO[?\/\ XM %                        #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>bc_fig19lesions-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_fig19lesions-4c.jpg
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M Q$!_\0 S@ !  ,! 0$! 0            4&!P@$ P(! 0$  @,! 0
M        ! 4! P8' A   0,# 0(&"0L0" 0% @<   $" P0%!@<1$B&R$W.S
M-3%R,Q0T=!4V"$&Q(C*3U196=A<W46%QD=%2@I+"TU2TU%57&$+2(U/#E'5W
M@:*5EN*C)*0EH6+!8T6E9B<H$0$  0(#! 8(!00" @,      0($,@,S$3%Q
M@5&Q<A0T!?!!89$2$Q4&P=%2LA8AH=)3X6(BHD*"PO_:  P# 0 "$0,1 #\
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M1FW=B=*DC(]J[7(W>[#D#"T@
M
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M]SU&PNOQVHR#(J"\6N[WFCLTM)1V=:.7;7*YJ/Y5]=*B(U4VK[!5#+50P
M
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M-]KPJ#:WT,,UUC[E@ORRLG2/#+2@P
M
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ML?<L%^65DZ1X9:4&
M                                                # /1T@AN^7:Q
MYK7,27()\PK;(M4Y-Y[:"U-8R")KEX4:B.V*B=G=;]1 S+3<AU.QC&;I):+F
MM0E7$UCG<G%OMV2-1R;%VIZBD3,NZ,NKX9WKNT\EN+G+C,HV;)]J+^>["/OJ
MOW#_ ,1J[_E>U,_C5Y_U]Y\]V$??5?N'_B'?\KVG\:O/^OO/GNPC[ZK]P_\
M$._Y7M/XU>?]?>?/=A'WU7[A_P"(=_RO:?QJ\_Z^]8L5SFQYBZJ;9UF5:-&+
M-RT>YW7>W=G"NWVJDC)N*<W;\/J5=]Y9G6?P_,V?^6W9LGH60D*M7\TS?&-/
M;%)DN75WD^S121POJ$BEJ%Y29VZQJ,@9(]55?J- KN*ZWZ:YA>X\:M5VD@R&
M9BRT]KN5'5VRHF8U%55A;611<IP-5VQBJNSA#.QY;]K[IACM_N&,5UQJYKW:
M7,9=*:AM=QKDIED:CV\H^GIWL3:U=O Y0;%EPK43"M1*&6X89>8+M! Y&5+(
MMZ.>%SNPV:&5K)(U78NQ'L0,(+7BP6O)-'<UH+K V>&&SUM=!O)M6.IHH'U$
M,C?J*U[$7_Z>J&8>K1:ZUU\TDPFZW.59[A566A?4SN55=)(D#45[E7LN=LVK
M]<$KT&                !FNL?<L%^65DZ1X9:4&
M
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M>!J;=B :;JU]%6<_)^[?J4H8A$Z ?0G@7^B471(&9:.&
M!FNL?<L%^65DZ1X9:4&
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MP7Y963I'AEI08
M                                             ,$]&'V^KG^X5\_P
M0S+>PP           "G:M?15G/R?NWZE*"$3H!]">!?Z)1=$@9EHX8
M          &:ZQ]RP7Y963I'AEI08
M
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M!?Z)1=$@9EHX8                &:ZQ]RP7Y963I'AEI08
M
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M1/>FQ5D<G9;]0WV]Y777%,[/ZJWS/R&WM[:K,HFK;3LWS'3$=#:RX<&
M
M               &">C#[?5S_<*^?X(9E<\OT9Q[,[Y-?KA75L%5,R.-T<#H
MDC1(FHU-F_&Y>PGU355EQ,[7U%6Q!?RWXA^]+E^-!^9,?)AGXY/Y;\0_>ER_
M&@_,CY,'QR?RWXA^]+E^-!^9'R8/CD_EOQ#]Z7+\:#\R/DP?'*XX'II9]/GU
M[[555-2MP2))4JEC7=Y'?V;NXQG9WUV[3[IHBE\S5M70^WRJ^=8-;L^M<%LN
M%PN=K=25#:RDK[+6RV^KBG:Q\:.;)'V?8O=P.14^L!!X7HUC6'7Q^537&[9/
MEBP+217W)*UUPJX*9R[71P^Q8R-JKV=QB+]?A7:9VH%/1SQN"NNM5:LKRRST
M=ZK:BZ7&U6N\R4=')5U;]^5^[&Q')O<"<#^PB(#:OV%8#B6GEJ=9L0MD=NHY
M9%GJ5:KY9IYG)L62::1722/7[Y[E##Q:M?15G/R?NWZE*"$3H!]">!?Z)1=$
M@9EHX8        *+J!BFH>234#\'S]^%PT[9&UL3+3277OESU:K';:E45FXB
M+P-[.WZP997A-5K!!KPN"U^H[\OQO';:ERR[?L]!;F1SUK'LHZ-'0-<])';6
MU&W>1-QNSZH'IC?K#J5J)G]-BFHZX?BV,7&FM%!1QV>@N:R3-HXI*E5DJ-UZ
M;)'?57L^IL G\YO.?X/B&&X;'DJ77.\KO<%@ES"6A@IU@AJ%FGEJ64C-L*R1
M1,Y.-B\#E]DOJ@?+&<VNV Y?FN%9_D,E[L&.6:FRF@R"MBBCK8Z"198ZB&H6
MF9&R1S7Q[T2MC1RHNSAX-@7;2^3+;ACCLDS-\D5TR&=]SIK-(UK4M=!-L2EH
M^!K561D2-=,KDV\JYR=A$#"Z@9KK&B\E@J^HF8V3;[J] RTH,  "*R?S;O'B
M-3T+C5FX)X2F67B,OM4];CPY-[:    "Y:4?2!9NVF_5Y"99ZM/IZE'Y[X+,
MY?NAU,=*\B
M                              #!/1A]OJY_N%?/\$,RWL,
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M.3>V@    N6E'T@6;MIOU>0F6>K3Z>I1^>^"S.7[H=3'2O(@
M
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M-VTWZO(3+/5I]/4H_/?!9G+]T.ICI7D0
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MICI7D0
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MO(@
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MI2@A$Z ?0G@7^B471(&9:.&                !FNL?<L%^65DZ1X9:4&
M!%9/YMWCQ&IZ%QJS<$\)3++Q&7VJ>MQX<F]M    !<M*/I LW;3?J\A,L]6G
MT]2C\]\%F<OW0ZF.E>1
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M\%F<OW0ZF.E>1
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MWZO(3+/5I]/4H_/?!9G+]T.ICI7D0
M                                                 <]Z"U]+BNH^
MK&F=XD2FR*JR6KRFV0R^P6KMMT:Q[7P[?;\FC4W]G8V_6789ET(&
M    9=Z0V8V;#](LH?=)FI5WBWU5GM-&B[9JFMKX701LC9V7;%?ONV=AJ*H9
MA/Z26"OQ;2_#\=NK.3N=MM%%3UL7]W.V%N^S\%VUO_ ,+D
M   9KK'W+!?EE9.D>&6E!@  163^;=X\1J>A<:LW!/"4RR\1E]JGK<>')O;0
M    7+2CZ0+-VTWZO(3+/5I]/4H_/?!9G+]T.ICI7D0
M
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M>MQX<F]M    !<M*/I LW;3?J\A,L]6GT]2C\]\%F<OW0ZF.E>1
M
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MLO$9?:IZW'AR;VT    %RTH^D"S=M-^KR$RSU:?3U*/SWP69R_=#J8Z5Y$
M
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MO$9?:IZW'AR;VT    %RTH^D"S=M-^KR$RSU:?3U*/SWP69R_=#J8Z5Y$
M
M                                                1$1-B)L1.PB
M  &:ZQ]RP7Y963I'AEI08  $5D_FW>/$:GH7&K-P3PE,LO$9?:IZW'AR;VT
M   %RTH^D"S=M-^KR$RSU:?3U*/SWP69R_=#J8Z5Y$
M
M                     1$F5XQ%9*G)7WBB^#U'RO?5T2HC=2Q][O6.1'2H
MY6HK7(K7)MX'<'9 ^.*9IBF<VU;QB%XI;S;62+#)/22)(C)6HBJQZ=EKMBHN
MQR)P*B]@"=            #-=8^Y8+\LK)TCPRTH,  "*R?S;O'B-3T+C5FX
M)X2F67B,OM4];CPY-[:    "Y:4?2!9NVF_5Y"99ZM/IZE'Y[X+,Y?NAU,=*
M\B
M                                         .6[/HCJ7/0X_HSD5-;D
MT:QJ[27>KO,50KZN]TK:F6J@I)Z;8FZJOD3EU=P+N[6NVI[(SM:MA6$5N.ZK
M9W?J6TP6;$[K1V:GM[:5T*1UM521SK/4+#$NV)6)(R'V34WMFT#3@P
M     #-=8^Y8+\LK)TCPRTH,  "*R?S;O'B-3T+C5FX)X2F67B,OM4];CPY-
M[:    "Y:4?2!9NVF_5Y"99ZM/IZE'Y[X+,Y?NAU,=*\B
M
M                        .6M.]+*[6>T5F;:E9IDM/EDMQKZ2MQNV7%;?
M369:6JDB;2<BUKE1VXUK]J[-K7(O#[9QEM.G&E%FTR6Y+:;Q>;JMTY'EO+=<
MZOY/O??W>2WFMW=O*+O?5V)]0"^!@           &:ZQ]RP7Y963I'AEI08
M $5D_FW>/$:GH7&K-P3PE,LO$9?:IZW'AR;VT    %RTH^D"S=M-^KR$RSU:
M?3U*/SWP69R_=#J8Z5Y$
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M
M                                       <QZ.:GZ?Z.X[5Z:ZEU[,:
MSVS5U=->9ZZ&1B75:FJEECKHIFL<DS98W-1-J[W!LV;$0,RLVB%?1YAJ%J)J
M7BE%+18!??)M+;ZF6%],VZ5U"R7OFM9$]&N1O]HV/>V>S5%5?9(J();L&
M         9KK'W+!?EE9.D>&6E!@  163^;=X\1J>A<:LW!/"4RR\1E]JGK<
M>')O;0    7+2CZ0+-VTWZO(3+/5I]/4H_/?!9G+]T.ICI7D0
M
M                          "KY#4Y]#DN-0XS16^HQ2:6H3*JFLDD95P1
M-C18%IFM7=55=MWMY%]3L>V0,EO;?26O-0Y*_!,$N5-!(_O-U=-/.YK-[V*^
MSV[%5$3;LV!G^C0],ZS5FI97QZFVBR6J"%L#;,VPS2S-<GLTE21)%5&HU$CW
M-WZX%_#            ,UUC[E@ORRLG2/#+2@P  (K)_-N\>(U/0N-6;@GA*
M99>(R^U3UN/#DWMH    +EI1](%F[:;]7D)EGJT^GJ4?GO@LSE^Z'4QTKR(
M
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MSH/@D_F2Q?\ =-?_ .3^<'SH/@ELD$J3P13M14;*QKT1>RB.3:;VM]
M
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M*13N5,^60    =[6[J^DYF/BH3X1GI,@
M
M*/F6L.F>GMSALV9Y'36BZ3P-K(::=)%<ZG>]\;7^P8Y-BNC<G_ #FK+Y_1XO
M=X2[8IK/48E%Y3;?_)-&CZFW1W9$>BU<$,L7]E*Y)'[VZ[=7;[4/IM6@3M)F
M45\BTYR:3+KY//#6Y7?JV22>X5-1,U[8G3/>QGL41CTC8U-C>'U555,2V,,
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M?7(->*4BG<J9\L@    [VMW5])S,?%0GPC/29
M
M      1UPQ^PW:9M1=+725T[&I&V6IIXIGHQ%54:CGM5=FU578!Y$PW#53:F
M/VQ4^JE'3_U /=;K+9K1RGDFWTU!RV[RW>L,<&_N[=W>W&IMV;5V;0/<
M        &:ZQ]RP7Y963I'AEI08  $5D_FW>/$:GH7&K-P3PE,LO$9?:IZW'
MAR;VT    %RTH^D"S=M-^KR$RSU:?3U*/SWP69R_=#J8Z5Y$XLU.^D#(O'9?
M7(->*4BG<J9\L@    [VMW5])S,?%0GPC/29
M
M     5C/$U"6Q;=,W6AN2I.Q=F0I4K1.I]CD>FVE5'H_;NJU>QV0.>M([-Z6
MF/X%;[5::+#K=0Q5%>^.DR%MU9<FNFKIY7K(D/L=USG.=%_^6K=H9_HU;2O!
M=0K1DN39YJ;=+;59)D45%2-MUA;.VW4U/;TD1JHM1L>Y[N4]5.#ZJ[> -6#
M           ,UUC[E@ORRLG2/#+2@P  (K)_-N\>(U/0N-6;@GA*99>(R^U3
MUN/#DWMH    +EI1](%F[:;]7D)EGJT^GJ4?GO@LSE^Z'4QTKR)Q9J=](&1>
M.R^N0:\4I%.Y4SY9    !WM;NKZ3F8^*A/A&>DR
M
M         <6VF@3(5TUU;OMUK*_4JZ:A16J^44M5(M/:(VNKFNMT=(CD;$C$
M@C7V3=YWMMNQP?3=L&O]1=M<=3:&@N,MPQVWTECBEC69TU+2W3DZA)8H$558
MU58C%F1G]-/9<(8:X&            9KK'W+!?EE9.D>&6E!@  163^;=X\1
MJ>A<:LW!/"4RR\1E]JGK<>')O;0    7+2CZ0+-VTWZO(3+/5I]/4H_/?!9G
M+]T.ICI7D3BS4[Z0,B\=E]<@UXI2*=RIGRR    #O:W=7TG,Q\5"?",])D
M
M                            XMSC(-"\^RNZ5U?I'G-1E=LK%IKU78_1
MK&[OJ#@3E^]:Q&*_8OMG-W]B]D/I<],=?]$,-LD5DL.'Y!A.'15CJ2:\7"VN
M2WMN"N;&]M55,FG?RJ+NM>LO"U-FW8B(&-CIUCV2,;)&Y'QO1',>U=J*B\**
MBIV44,/T           ,UUC[E@ORRLG2/#+2@P  (K)_-N\>(U/0N-6;@GA*
M99>(R^U3UN/#DWMH    +EI1](%F[:;]7D)EGJT^GJ4?GO@LSE^Z'4QTKR)Q
M9J=](&1>.R^N0:\4I%.Y4SY9    !WM;NKZ3F8^*A/A&>DR
M
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M+]T.ICI7D3BS4[Z0,B\=E]<@UXI2*=RIGRR    #O:W=7TG,Q\5"?",])D
M
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MC/29
M                                  .2WY_KMFB8=EEGS&WX;B.?WFJL
M]EH6VN"OEHXH65+J=U1)4;=^:9:96[C5:FUWJ>U0^FHZ/W'4:DS'-,+U/RAF
M0WBTLMU7:G045-14[K=5MFV3MY!&OY1TC'1R1R)L9N-5JJC@Q+8PP
M    #-=8^Y8+\LK)TCPRTH,  "*R?S;O'B-3T+C5FX)X2F67B,OM4];CPY-[
M:    "Y:4?2!9NVF_5Y"99ZM/IZE'Y[X+,Y?NAU,=*\B<6:G?2!D7CLOKD&O
M%*13N5,^60    =[6[J^DYF/BH3X1GI,@
M
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M.E>1.+-3OI R+QV7UR#7BE(IW*F?+(    .]K=U?2<S'Q4)\(STF0
M
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M]7O<O)14;WK%"Y^\[;NMX-OL=@9VM'##-=8^Y8+\LK)TCPRTH,
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MIO>VWMK-WZFQ0+Z&            9KK'W+!?EE9.D>&6E!@
M      #!M?NMK/XM)QT*3S'%'!Z)]JZ69QCJ9 5+M0    =+:+>8M/XQ/QSH
MK'2AY7]Q^,GA"V9)U3)VS.,A<VVI#C[O3E2"W4@    +#B7A51S:<8@WF&%A
M98IX+5)[1WV%]8K8WK6=S-#H'-     ]MGZTI><0U9V"6_(U(XM *-?J+D/6
MU1^#Q4+FWTX4=UJ2C"0B@    T:A\"IN:9Q4*',Q3Q=%EX8X,@](#P6P\Y4\
M6(I?,=U/-WWVIBS.%/XL-*5WX    .B="?-"J\?EZ*(O_+].>+S+[H\5'8CK
ME?[YU35=JG&0N<C'#B[C3E0BZ4(    )O%>LG\T[C-(EW@YIUGCY+D5*X<<W
MCK:O\8FXZGFV;CGC*1#QFID   )+'/.&T^.T_2M-]OJ4\8ZV)=@'HZ.I63=:
M.[1A;VN!2W>HAR4A@    O\ 9^JZ7FT*3.QRO\C3A&Y9X)!SGY*DBSQ2C7N&
M.*I%FJ0    6K$NX5/;M]92MO-\+6RW2^F<^9M]\1J.C4I+W0K[,K*G>Y,//
M4@    %\T=\^Z+FJCHG%MY3XB.?4^*MSI8[AI    !6;_@&,9-DN.9;>*5\U
M\Q22>6RS-FDC;&ZJ8UDF\QCD:_:C6^V3U/L@9E5>B#H'6U4]94XW,^HJ)'S2
MO\HUZ;7R.5SEV)/L[*AG:NVF^C6GNDJW)<$MC[<MWY%*_?J:BIW^]N4Y/9R\
MC]W9RKO:]D&U?0P           #-=8^Y8+\LK)TCPRTH,
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MBS5(    +5B7<*GMV^LI6WF^%K9;I?3.?,V^^(U'1J4E[H5]F5E3O<F'GJ0
M   "^:.^?=%S51T3BV\I\1'/J?%6YTL=PT@     <M4NI&K&156GVIL>04]L
MT_S'*X;%;\.IJ.)\RVV1U4U)JNKDWG\J[O;ACCV-3>[**FP,MDQ[,;Q7:N9K
M@]:Z&6T6B@M%PM2PQJV6):UL[9XYG[RHY5=&U[.!-C5]4#00P
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M6[U$.2D,    %_L_5=+S:%)G8Y7^1IPC<L\$@YS\E219XI1KW#'%4BS5(
M +5B7<*GMV^LI6WF^%K9;I?3.?,V^^(U'1J4E[H5]F5E3O<F'GJ0    "^:.
M^?=%S51T3BV\I\1'/J?%6YTL=PT@     <;YA:=,IKI#)@&O-MQ2TT5[^$E/
MCM4VDN='17AJR(Z:E261CHF*LLCE@]E'O.5=B<&P^FL:+7#2.QU5QI[5J-0Y
MEJ%D]1'47N[U%93]_5\L+.3ACBA:[@CB:JI'&S>W=J^IV#$MP#
M  ,UUC[E@ORRLG2/#+2@P                            B<DZID[9G&0
ME6VI")=Z<J06ZD    !8<2\*J.;3C$&\PPL++%/!:I/:.^POK%;&]:SN9H=
MYH    'ML_6E+SB&K.P2WY&I'%H!1K]1<AZVJ/P>*A<V^G"CNM2482$4
M&C4/@5-S3.*A0YF*>+HLO#'!D'I >"V'G*GBQ%+YCNIYN^^U,69PI_%AI2N_
M    !T3H3YH57C\O11%_Y?ISQ>9?='BH[$=<K_?.J:KM4XR%SD8X<7<:<J$7
M2A    !-XKUD_FG<9I$N\'-.L\?)<BI7#CF\=;5_C$W'4\VS<<\92(>,U,@
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M]:F:EC?*KD]15<J[4#Y6@           9KK'W+!?EE9.D>&6E!@
M                  !$Y)U3)VS.,A*MM2$2[TY4@MU(    "PXEX54<VG&(
M-YAA866*>"U2>T=]A?6*V-ZUG<S0Z!S0    /;9^M*7G$-6=@EOR-2.+0"C7
MZBY#UM4?@\5"YM].%'=:DHPD(H    -&H? J;FF<5"AS,4\719>&.#(/2 \%
ML/.5/%B*7S'=3S=]]J8LSA3^+#2E=^    #HG0GS0JO'Y>BB+_R_3GB\R^Z/
M%1V(ZY7^^=4U7:IQD+G(QPXNXTY4(NE"    ";Q7K)_-.XS2)=X.:=9X^2Y%
M2N''-XZVK_&)N.IYMFXYXRD0\9J9   "2QSSAM/CM/TK3?;ZE/&.MB78!Z.C
MJ5DW6CNT86]K@4MWJ(<E(8    +_ &?JNEYM"DSL<K_(TX1N6>"0<Y^2I(L\
M4HU[ACBJ19JD    %JQ+N%3V[?64K;S?"ULMTOIG/F;??$:CHU*2]T*^S*RI
MWN3#SU(    !?-'?/NBYJHZ)Q;>4^(CGU/BK<Z6.X:0     .4\KRW']6KQ5
M7;&M!G:C6NWSR4#,LJ9J6VMJ7TKMQR0OD8Y\T3514:JNV?63L!EK^DUUOUUM
M5=8+]IBW3RQVUD,5MM_?-+5TU0R;E.5:V.GC8UB,W6[VU/9;_P!D#3&M1J(U
MJ(C438B)P(B(&']           &:ZQ]RP7Y963I'AEI08
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M&2(U55KE:YKMCN'8J+ZH'H S76/N6"_+*R=(\,M*#
M         ")R3JF3MF<9"5;:D(EWIRI!;J0    %AQ+PJHYM.,0;S#"PLL4\
M%JD]H[["^L5L;UK.YFAT#F@    >VS]:4O.(:L[!+?D:D<6@%&OU%R'K:H_!
MXJ%S;Z<*.ZU)1A(10    :-0^!4W-,XJ%#F8IXNBR\,<&0>D!X+8><J>+$4O
MF.ZGF[[[4Q9G"G\6&E*[\    '1.A/FA5>/R]%$7_E^G/%YE]T>*CL1URO\
M?.J:KM4XR%SD8X<7<:<J$72A    !-XKUD_FG<9I$N\'-.L\?)<BI7#CF\=;
M5_C$W'4\VS<<\92(>,U,@  !)8YYPVGQVGZ5IOM]2GC'6Q+L ]'1U*R;K1W:
M,+>UP*6[U$.2D,    %_L_5=+S:%)G8Y7^1IPC<L\$@YS\E219XI1KW#'%4B
MS5(    +5B7<*GMV^LI6WF^%K9;I?3.?,V^^(U'1J4E[H5]F5E3O<F'GJ0
M  "^:.^?=%S51T3BV\I\1'/J?%6YTL=PT@     <;K=-2\UH<'U#O.I-SQJP
MY]D%59DM=H;#!3VJ'_U<='"KUX7RNFIFQO>_U7;.RG"?36]&J;(,:S_/<%R?
M+[EE];;H[574%77RM?'%0UC)]V-8FI_9SH]KN47?V2,Y-R(WA#$MM#    5/
M,=-<)U JK359E:8[PEE?-)04M4Y[J5'U#6M>Z2!')'*NQJ;O*-=N\.SL@8SB
MV.63#_2IJ[%II3,MN//QA*K,[51(K+?#6NG_ /2KR;?81S.8K%1J(GL%54]L
MX,^I3:ZHTDH]3=2<BUPQ&NG@KKW%2VR^5UFK*FV0T5!314K7I4,8K41[FK[5
M%X$10ROFK%%AE%@FF5JQUE)3Z-U^4VSRLRB5/)DENJ735#$F5-K.]I:E6.E5
MZ[NW9M#"+;DMJTUU.U,JL!H:::UR6ZQT5-8*!8X::IS*O?+#24\4;58QKY(]
MQU0L?"C$5[NP!<M'\RTTL+:;3FBR)ETS:NJ*NKO%V6FFBI[Q?57E+C)!5.A9
M!,YK^!&1O<K8VM;V&\ ;-/404L+ZBJE9!3QIO22R.1C&HGJJY=B(@897JO>K
M-<%P6"@N-+53_#"RNY*">.1^ZDC]J[K7*O &6L!@
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MD    %JQ+N%3V[?64K;S?"ULMTOIG/F;??$:CHU*2]T*^S*RIWN3#SU(
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MY9!J7A6&X]-@MPL&.VRU5_POLT:55#14]--N/D>CF[\3&KL5.!4VAELX8
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M/8V^KL _H'\:UK41K41&IV$3@0#^@ ,UUC[E@ORRLG2/#+2@P
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MJ^ZXE::>S0L1'I)2TMS='/WQ#3N:FQ=K48LJ;5W7\"[.P!K08
M!FNL?<L%^65DZ1X9:4&                            $3DG5,G;,XR$J
MVU(1+O3E2"W4@    +#B7A51S:<8@WF&%A98IX+5)[1WV%]8K8WK6=S-#H'-
M     ]MGZTI><0U9V"6_(U(XM *-?J+D/6U1^#Q4+FWTX4=UJ2C"0B@    T
M:A\"IN:9Q4*',Q3Q=%EX8X,@](#P6P\Y4\6(I?,=U/-WWVIBS.%/XL-*5WX
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MB(KGN5=B(G80,+"            &:ZQ]RP7Y963I'AEI08
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MS!@           &:ZQ]RP7Y963I'AEI08
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MI")=Z<J06ZD    !8<2\*J.;3C$&\PPL++%/!:I/:.^POK%;&]:SN9H= YH
M   'ML_6E+SB&K.P2WY&I'%H!1K]1<AZVJ/P>*A<V^G"CNM2482$4    &C4
M/@5-S3.*A0YF*>+HLO#'!D'I >"V'G*GBQ%+YCNIYN^^U,69PI_%AI2N_
M !T3H3YH57C\O11%_P"7Z<\7F7W1XJ.Q'7*_WSJFJ[5.,A<Y&.'%W&G*A%TH
M0    3>*]9/YIW&:1+O!S3K/'R7(J5PXYO'6U?XQ-QU/-LW'/&4B'C-3(
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MW=:BKZJAE?@P            !FNL?<L%^65DZ1X9:4&
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M7V965.]R8>>I     +YH[Y]T7-5'1.+;RGQ$<^I\5;G2QW#2
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M[U$.2D,    %_L_5=+S:%)G8Y7^1IPC<L\$@YS\E219XI1KW#'%4BS5(
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MI2_V<CO8+)RCO9.V^Q39PJ&6]A@
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MD6:I    !:L2[A4]NWUE*V\WPM;+=+Z9SYFWWQ&HZ-2DO="OLRLJ=[DP\]2
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M,                                    'YD]H[["^L9C>Q.YFAT#F@
M   >VS]:4O.(:L[!+?D:D<6@%&OU%R'K:H_!XJ%S;Z<*.ZU)1A(10    :-0
M^!4W-,XJ%#F8IXNBR\,<&0>D!X+8><J>+$4OF.ZGF[[[4Q9G"G\6&E*[\
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M?%6YTL=PT@                    ,UUC[E@ORRLG2/#+2@P
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M1T:E)>Z%?9E94[W)AYZD     OFCOGW1<U4=$XMO*?$1SZGQ5N=+'<-(
M                #-=8^Y8+\LK)TCPRTH,
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M]R8>>I     +YH[Y]T7-5'1.+;RGQ$<^I\5;G2QW#2
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M<"EN]1#DI#    !?[/U72\VA29V.5_D:<(W+/!(.<_)4D6>*4:]PQQ5(LU2
M   "U8EW"I[=OK*5MYOA:V6Z7TSGS-OOB-1T:E)>Z%?9E94[W)AYZD     O
MFCOGW1<U4=$XMO*?$1SZGQ5N=+'<-(                    #-=8^Y8+\L
MK)TCPRTH,                                     #\<E%]XW[2&=LL
M;(.2B^\;]I!MDV0<E%]XW[2#;)L@Y*+[QOVD&V39!R47WC?M(-LFR']2.-%V
MHQJ*G878@VR;(?HPRHN0];5'X/%0N;?3A1W6I*,)"*    #1J'P*FYIG%0H<
MS%/%T67AC@R#T@/!;#SE3Q8BE\QW4\W??:F+,X4_BPTI7?@    Z)T)\T*KQ
M^7HHB_\ +].>+S+[H\5'8CKE?[YU35=JG&0N<C'#B[C3E0BZ4(    )O%>LG
M\T[C-(EW@YIUGCY+D5*X<<WCK:O\8FXZGFV;CGC*1#QFID   )+'/.&T^.T_
M2M-]OJ4\8ZV)=@'HZ.I63=:.[1A;VN!2W>HAR4A@    O]GZKI>;0I,['*_R
M-.$;EG@D'.?DJ2+/%*->X8XJD6:I    !:L2[A4]NWUE*V\WPM;+=+Z9SYFW
MWQ&HZ-2DO="OLRLJ=[DP\]2     7S1WS[HN:J.B<6WE/B(Y]3XJW.ECN&D
M                   !FNL?<L%^65DZ1X9:4&
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M-(                    #-=8^Y8+\LK)TCPRTH,
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MDZ1X9:4&
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M]SV4]1*W=1?;>Q[ 9;J&
M                      (^^=4U7:IQD-^1CA'N-.5"+I0@    F\5ZR?S3
MN,TB7>#FG6>/DN14KAQS>.MJ_P 8FXZGFV;CGC*1#QFID   )+'/.&T^.T_2
MM-]OJ4\8ZV)=@'HZ.I63=:.[1A;VN!2W>HAR4A@    O]GZKI>;0I,['*_R-
M.$;EG@D'.?DJ2+/%*->X8XJD6:I    !:L2[A4]NWUE*V\WPM;+=+Z9SYFWW
MQ&HZ-2DO="OLRLJ=[DP\]2     7S1WS[HN:J.B<6WE/B(Y]3XJW.ECN&D
M          "L9Q@&.:B4%#:LHCEJ;70UL-R[RCE=%#/+3;58R=K>Z1[5VJQW
M J[/J 6<#&ZGT9=-JR>5E3/?);#/,ZHGQIUYK5M+Y'NWUWH%DV[%<NW9OAG:
MUNWT%#:J&FMELIXZ2W4<3(*2E@:D<444;4:QC&MV(C41-B(@816,8C:,2BN3
M+;RTL]XKZBZW.KJI%FGGJJE4VJYR[/8L8UD<;41$:QK40"K8[H;I]B]_@O\
M:J:K1M!+/4V:SS5D\UIML]7O<O)14;WK%"Y^\[;NMX-OL=@9VM'##-=8^Y8+
M\LK)TCPRTH,
M             1]\ZIJNU3C(;\C'"/<:<J$72A    !-XKUD_FG<9I$N\'-.
ML\?)<BI7#CF\=;5_C$W'4\VS<<\92(>,U,@  !)8YYPVGQVGZ5IOM]2GC'6Q
M+L ]'1U*R;K1W:,+>UP*6[U$.2D,    %_L_5=+S:%)G8Y7^1IPC<L\$@YS\
ME219XI1KW#'%4BS5(    +5B7<*GMV^LI6WF^%K9;I?3.?,V^^(U'1J4E[H5
M]F5E3O<F'GJ0    "^:.^?=%S51T3BV\I\1'/J?%6YTL=PT@
M        ,UUC[E@ORRLG2/#+2@P
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M6.X:0                    &:ZQ]RP7Y963I'AEI08
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ME9.D>&6E!@
M                     XYO'6U?XQ-QU/-LW'/&4B'C-3(   26.><-I\=I
M^E:;[?4IXQUL2[ /1T=2LFZT=VC"WM<"EN]1#DI#    !?[/U72\VA29V.5_
MD:<(W+/!(.<_)4D6>*4:]PQQ5(LU2    "U8EW"I[=OK*5MYOA:V6Z7TSGS-
MOOB-1T:E)>Z%?9E94[W)AYZD     OFCOGW1<U4=$XMO*?$1SZGQ5N=+'<-(
M                    #-=8^Y8+\LK)TCPRTH,
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M963I'AEI08
M                     ..;QUM7^,3<=3S;-QSQE(AXS4R   $ECGG#:?':
M?I6F^WU*>,=;$NP#T='4K)NM'=HPM[7 I;O40Y*0P    7^S]5TO-H4F=CE?
MY&G"-RSP2#G/R5)%GBE&O<,<52+-4@    M6)=PJ>W;ZRE;>;X6MENE],Y\S
M;[XC4=&I27NA7V965.]R8>>I     +YH[Y]T7-5'1.+;RGQ$<^I\5;G2QW#2
M                     S76/N6"_+*R=(\,M*#
M                                                  !QS>.MJ_QB
M;CJ>;9N.>,I$/&:F0   DL<\X;3X[3]*TWV^I3QCK8EV >CHZE9-UH[M&%O:
MX%+=ZB')2&    "_V?JNEYM"DSL<K_(TX1N6>"0<Y^2I(L\4HU[ACBJ19JD
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M*R=(\,M*#
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M9:4&
M               #CF[];5_C$W'4\VS<<\92(>,U,@  !)8YYPVGQRGZ5IOM
M]2GC'6Q+L ]'1U*R;K1W:,+>UP*6[U$.2D,    %_L_5=+S:%)G8Y7^1IPC<
ML\$@YS\E219XI1KW#'%4BS5(    +5B7<*GMV^LI6WF^%K9;I?O.?,V^^(U'
M1J4E[H5]F5E3O<FGGJ0    "^:.^?=%S51T3BV\I\1'/J?%6YTL=PT@
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M:^>V5,==0LN-ZNE=!'50[5CDY&HJ7QJYNW@VM4,KX&
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MM2!N8
M
0                  ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>bc_fig43kidneys-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_fig43kidneys-4c.jpg
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M +T  0 " P$! 0$            '" 0%!@,) @$! 0$! 0$!
M   !!00# A    8! P(!!0D+!@D(!0T   $" P0%!A$2!R$($S$B%'8X05$R
MM!5U%A@)8;'"([,TU)4V%U=Q@4*2,].14F*"TE,D-3=R0W-TE%6U5J&C1)89
MP=&R8X/#A"4F1B='=Q$!  (#   % @8" P        $"$0,$,=$24A0A,T%Q
ML2(3!?#!0G(T_]H # ,!  (1 Q$ /P"_P               *G]X?<ER!P-:
M8I#PJ-6/LW<>8],.S8>?42HRV4HV>$\UH6BSUUU 0?-[R^[BGI6<JM\ AQ<7
M<2T\FVDT=HS!6U(T-M1/JDDC:LE%M42NNI: +:=L_<'#[@L/F6ZZXJC(J9],
M2XKT+-UG5U.]IYE9D1['")7FJZI-)EU+11AW%OR]Q50798W=YK25]\:MBJZ5
M81FGT+]Q*TJ61H,_<)6FH#+?Y+XZC9 C$Y.6T[.4..M,(I7+",F<IZ025-()
M@W/$-2R6DTEMZZEIY0&VOLCQ_%JY=ODUK#IJILR2N;82&XK!*/4R(UNJ2G4]
M.A:@-+BG*/&^=/.1L-RRIO);1&IR- FLOO)27](VT*-1%]W30!7WNT[JKO@^
MSQ^EP!=%;W$KTOZ0U\\W),F%X:(SD;>U'D-*;\5+RU%XGPB+H F?A?EBCY4P
MFCM6KFJF98_5PYV0U55(0ZJ%)DM$I:%L^(XXT1+W)T</7IIJ VF2<O<68=8%
M595F=+3VAF1'"F3X[+Z=?(:FU+)22^ZHB(!U%5;U5[ 9M*2='LJR06Z/-ANH
MD,.)]]+C9J2?\Q@-!4<H<:W\Y^LHLPI;.QC-N/R8D.QBR'FF6/[1:T-N&:4H
MU\Y1]"]T!5[O*Q^/S/BV)6F%<EXW"H(DN>R[&LKIB#7SWTFTDULO;S:=<CFE
M25)/X)+/0_<,+"\'5,G$N&\5J[O)HN3.5U?J_DD:04B$ZR2EN)-J0H_/::09
M-I</35*->GD ;.CY>XKR:T=I,=S2EM+=DEJ7"AV$=][:T1J6I*4+,U$DB,U&
MG73W0'M5<DX%EK<^-AN5U-Y8Q(SDEQFKG1IKK:"+0EJ2RM9DG<9%J9::@*9=
MD7.W+?)_*UM19YE$BZIX]#(F,Q'FH[:4R$2XC:5ZM-(5J27%EY=.H"Q_=IF>
M3\?\%9%E6'6*ZK((;M>F-.:2A:T)?G,M+(B<2I/5*C+R (Z[2>=YEQPU;9KS
M;F<9#C602:^)9W#L:"GPFX<1TF4:$T2S)3BE:$1JZ@++XSF&*9I7_*N(W<&]
MKB/:J372&I3:5?XJC;4K:K[A]0&#'Y)X\F9$>(Q,LIW\J2ZY&51M3XRYY/L$
MHW&SCDX;FY!)5N3MU+0]0&5DV;8;A;<=W,,AK:!J8:DQ%VDMB$EU39$:B0;R
MT;C3J6NGO@,:QY(X]IZBOR"VRNH@T5J6M79R9\9F+*+3=^)=6LD.=.OFF8#]
MIY!P194QMY-5K^D2B10;)K"CGJ,S27HVBS\7J1EYFH#\9;R-@.!DS]-,FK*!
M4GK';L9;,9QPM=-4(<42E$1^4R+0@%0^];GW-\+=P*RXAS H]!?1;!UR;6'%
MF1I*H[C"4FETT.I/;O,O-/W0%M..+N38\78CD>03"7,ET%;/M+!\T-)4Z[#;
M=>=69;4IU,S4?D(@&'7<V</6]L5#5YY02[A2B;;ALV45;BUGTVHT<\]7W$ZF
M Z>_R7'<4KE6^46T.EJDK2VJ=8R&XD<EKZ)2;CJDIU/W"U :*3RUQ;$HVLFD
MYI1M8](=7'CVBK&+Z*Z\UIO;;<\3:I2=2W)29F0#>T&28]E=:BXQBVAW52X9
MI1.KWVY3!J3IJG>TI2=2UZEJ XKN H;#)N',MHZO(X^)S)D,DIOIS_HD1E"7
M4+6E]_\ YMMU"5,K7[A+\A^0!!793A[_ !3A^9V63\@T%O0&['?7&J+=FQKZ
MLF$.FZ^^^E7AM*>(TZE_BH(S/W$A8^/ROQ?,J9E]$S2C?HZY2&Y]DU91%Q6%
MND9H2XZ3AI2I1)/:1GJ?N ,_%LZPO.([LK#<AKK^.P9)?762V99-J/R$OPE*
MVF>G3< V5T\[&I["0PK8^S&><:66AFE:&U&1]?>,@%&NQWG+ECE#DJ^IL]R9
M^ZJHE$Y+CQ7FH[:4R"F1FR61M-H/4DK47E]T!<"=R[Q366CM'8YO0Q;IA[T5
MZM>LXB)2)&[;X1M&YO)>IZ;=-=>@"FU=Q!E$?O$5E[G+./+3\O.350BNFSO5
MQ5.&OY).!NWD?A_B#1\ F^I?XH"[^4YKB&#P4V68WL"A@N&:6G[*2U%2M1>5
M*/$4G<?7R)U,!6'O YVMJ#BS&\RX4S%@V)MWZ!*M:AR-.:4GT1YWPE*-+J4J
MU22MO10"1> ^68SW;[A><\LY7#BV-N4MIZXN)$: E]]$R2E""-7A(-1-M>1)
M:Z)U 2'8<N<5U53!OK+-:.+2V>_Y-GNV,5+$GPEFVLV5^)HLDJ2:5;==#+0P
M'24UY2Y%7,V^/V,:UJI!:L3H+S<EA9?Y+C9J2?\ ,8#4Y9R)@>!MMN9IDM;0
MD\6K";&6S&6X6NFJ$.*)2O\ -(!E8WF&)YE .TQ*\@7E<D]%R:V2U+;2KWE&
MTI6T^GD/J UM#RGQGE-DW38UF5)<6[J5*:KX%C%DR5);+<HTM-N*4>TBU/IT
M(!L\DR_$\-B-3\NO*^A@ON> Q)M)3,-I;NTU;$J>4DC5HDST+W" >,7.\)FX
M\O+HF1UC^*M&I+EXW,857I-M6U6L@E^'YJO-/SO+T :S&N7>+<RL#J<4S*FN
M+0M=(4*?'>?42>IFEM*S4HB]])&0#LP                'SN^TN_W]QY_U
M.S_*Q@'&9CSAW-3>!6<-L>.U5/'*J:%7.9,FJG_C*QMEM#;AONN+923J$IU<
MV:=?-TZ .CXGRO&^(^SS/,QXVR!V;R':2H<"Y6;2HKM7)EFEEI+:34HS)MI;
MRVGR/12_>VF1!R/:_P!H\/G[&;G.,IR*565[4YRNA-0T(=DO2D-H>=>=6]N+
M:7BI(B(MRCW=4Z%J'&XG@UGQOW=XM@ES-*SFT665,4IW71YA+S"HZ]JC4:?Q
M1H\S<>WX.O0!V',4S).Y/NV<XQE6BX-)"N7\<K&NJV8<:M-92GD-:I)3KALN
M+U/JKS4Z[2+0)-R'[/O.L5RNLR#A'-&8Q0-DAJ7=.NQ9\>8VKX3:X<9Q"D&7
MOI3[I'N(!P'?AQJO&,DQCD.WE>)F><QC^DT.,9*K6)E/"@15'#-2$.&VLS4K
M\9U\GD\@"0\;PZ'VS]KMIS?A=O-=S'.L?IF4)DDSX,*39*0:G&-B"5JT3RU(
MWF?5):@*R\6U7;[=UMM;<WYA>P<EE/NE"BU44Y!^<E*SE2'W&WO$4M:E>86T
M_-U-1[N@2GV.\AV.(\\?NYJ;5VRP7)U3XZ$N(4RVX["9=D1IJ65&9M.+0SL4
M6OD7HK7:6@1%Q;QIEG+?+%C@6(V2:EZR.?\ *<QQ;B&4U[3F]U+B6O.<2HR0
M1-^0U::Z%U()F[K.)9/"G"W%V!2[-NX?AVE[(.<TR<=*BE>CN;=BE+/IK[X#
MPY^Y&NZKMKX2XVJI#D6KNJ,K.[)M1H](1'4EMAE1EIJ@E&M:DGT-1(/W '44
M?86\]PU%Y"BY:_&Y#>JDWT*$TA*(*"6QZ2B.;A&3A+-!DDW25HE7]$R+4PTG
MV=Y%]/\ .3]WZ,N]?_Q3(#P^SE_XV7OJS*^/00%M>^7V:<K_ .GJ_P#Q*. I
MSVM]IS//N*6>3Y/D4NJQNMFNUU7"A$AQQ4SPFG7G3\7<E"");1:)3JOWRVEJ
M&!Q;])^V7NVAX W9G+AN7$3'K8VM4,38%L;?@..-ZGHI!/MO$6I[5EIJ9:ZA
MT''1%_\ $,F$1?\ [KR,_P#U$XP$H_:7$7R#QV>G7TNSZ_\ V48!&O<61?5'
MX#Z?\T?_ *8P#:]M';9F$R)A_<7DV2-M46/D=G64JTN2I*ZVL-PTMDM2DH9)
M1I4:$IW=#UZ&>@"+>), R/O$YKNIN87CD-+C3MQ<SD%XSC;!.H::BQDK/1)%
MXB4(U\U"$GT,]",,+NEX"D< 9'44D*Z?N,1MV7IM.<K1#S#S:D-R$+0CS#5_
M9GO2E.XM",O- 2+W<<E9!&XZX=XJ@2G(M"_AE->6K32C04M;K!1V$.Z?"0UX
M"U$GR&I1&?5*= BC-,;[9X?'K;^#YK>6/)<9#*I$>;7FS6S%K6E+J6_Q:5,;
M$FI:36XO7;H?EU()1F<EWW('8W:UN2R5SK'%,DKZR-->4:W7(*DDZP2U*,S-
M2-RVR/\ Q"2 ]NV?M!JN=>-I>7Y-D\ZM;;ER*^BA0DMN-LJ:2A3CKI.ZZDI2
M_P"S1L\FN[KT#^=D%GD>"=R%EQJ<PW*V6BSK;>,A1^CN2*G>M#Z4G_22II24
MJ\NU9@+O=U'7MYY"U_[J7^40 I/VRD7U6>X0].OH/WH;P#DNTWMNA]P)9)](
M[Z;58M0JC'Z)7FCQ'YTI+I(7^-):$DVAL]3V&H]VA&74 P.JN^W3O%JL'IK5
M<QEF]A4<M])&TF76W/@^:\WJ9&:4/I5IU(G$D9>0@'U4R#_<-K_U.1^24 ^-
M'"/,\[A-S+[JC:4K)[ND72TTC1)MQ7GY#+BI*B5Y3;2V9MIT,C7IN\W4!;'L
MB[:CE*C<]\BME-F2U*E8G"DJ)]6]2C-5B_J:M7#5KX.[J1ZN?"V&01?$(O\
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M>9W"<*Y1V_9U0HQV%04=>QBEN_!EPG%RH+I'')]3IJ2HB\%"7#;01[34>AF
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MQ'X[$QYW87B.H4VTS'0@R,]RS,_./<L!-OU'>X/^(D?_ +7-_P!$!]$
M
M            %*^_RVS_ ""IHN+L'QNYMX$A17&02ZR!*E,&31J;BQS<9;4D
MSW$MU:#\FULP$X=KG%9\1<,T./3&/ R&>CY7R!*BVN%/FI2HVUE_C,MDVR?_
M " $R
M
M
M
M
M
M
M
M
M
M       #2Y/E^+836IN,ON8=%5*=3'3-L7VXS)O+(U)02W#(MQDE1D7W &15
M9#17E*SD=/91IU!(:4^Q9QW4.15LHUW+)TCV[2T/4]?< <M0<U<1Y5>?1O',
MVIK.],S2W!C367'75)\I-:*T<,O_ *O4!H^5.+>,;9-IR)G3UK'9J8"Y%@_!
MN+. RB)!;6ZHR9B2&T&9)U\B=3 8/:_C5G0<2P)]NN6F7E$F1D;==.EOSUU\
M.Q-*HD1+LDS<,FXZ6MQ+Z^(:M>H"90
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M;;=4I6A$9GH7D =4
M         YGD9*U\>Y8AM*EN*IK$DH01J4HSBN:$1%J9F?O$ JW$X]RK,.R?
M!8^,P%O9IBRX>1U56^A3;CTBLFO*4UM5H>Y3:E["_I'H7NZ@/?E'G*9SKQ](
MXCX\PC(V,[RWT>NLF[:N=B0ZADW4*E.27U%MVI)*D$>A>77RZ),+9T%0QC]%
M64,51JBU<1B"RHRT,VXS:6DF9?R) ;   0SC9F?<_GOW,4Q[3_M5@ F8
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MR)'D-FI)I/8XVTE2=2,R/0_( ZD
M                           !#&->T_GWJICWQJ> F<
M $-8VM9]SN>H-1F@L4Q[1.O3I*L/<_G,!,H
M                                       "&,:]I_/O53'OC4\!,X
M             (8QKVG\^]5,>^-3P$S@
M                                (2S#E'D.;F=[B'&$;'HL?$DPV\@O
MLPD2F(;MC9,^DL08A1B(S631H6XXI1[=Y%L,RZA)6!WU[DV)UMSDU _B^0/H
M6FRHY2T.KCR&7%-+)+C9FE;:C3O;67PD&1]/( Z,!#&->T_GWJICWQJ> F<
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M^[ P_<7O\I7+2MK)W'-]7'9RF8;#TI;32=[RTH+3>E.NF[70@1<,
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M5PZG7H>3$9E[FI*8!5Q00
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MPC0E[P]?>26O7J LF     ISWX?G?#OK-^%'!5Q@0
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MF1$E.I[4D1:GIJ9'>@    *<]^'YWP[ZS?A1P5<8$
M                                     0QC7M/Y]ZJ8]\:G@)G
M &CS3]CLA^;)OQ=8"NOV?OL_-_/5A]YH%E:8$     $%8M[6'(7JK1?EY BI
MU%0     4Y[\/SOAWUF_"C@JXP(
M                   B_+^XKAK!,AEXIE63H@Y# )HYL%,2;)6T4AM+S>\X
M[#B2W(6E1=0'<XME%%FE!"RC&9?IU%8H4Y#E>&XSO2E:D&>QY*%EYR3+SDD
MVX"&,:]I_/O53'OC4\!,X      T>:?L=D/S9-^+K 5U^S]]GYOYZL/O- LK
M3 @     @K%O:PY"]5:+\O($5.HJ     "G/?A^=\.^LWX4<%7&!
M                                        $3<Y<W_N/J8^03<1M<@H
M%)4JQLZWPBCP3\5IEHGU.*+3Q5NDE #9<F\S8[Q?B=7DEI#F6-A?/,0L?QZN
M;)^PG392-Z&6T$>G0OA*\A>0M5&E)ARF)=Q;D_-JK >1<%N./;S(4N'C;MHI
MJ1#G.,)W+92^ST2Z1::(/[A:D:DDH-(?'G+4CFCE"]P/-J;%ZB\52.ON>AMW
MMF<B!6(CH9>CK=91&;/SEZJW+66TTZ%J D7A'/+S/L.DR<H9CM930VMCCEVY
M W>A/S*F0IA;\??U\-PB)1:^0]2 20 AC&O:?S[U4Q[XU/ 3.      -'FG[
M'9#\V3?BZP%=?L_?9^;^>K#[S0+*TP(     (*Q;VL.0O56B_+R!%3J*@
M  ISWX?G?#OK-^%'!5Q@0
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M:PY"]5:+\O($5.HJ     "G/?A^=\.^LWX4<%7&!
M                    #4B\H       (I[DN.\@Y6X9R/ \6..F\M3@G%.8
MX;+'^S3F)*]RTI69>8VK3S?* UW+O#^19K2X9=89:QZ7D_ 'T3<?GRDJ<A.&
MME+4F*_L(U$T\2$DI24F?333J Y>!Q?SAR7GF*9-SI)Q^NQC")16U5CF-'*>
M],MVRT9D2%R?@I:/ST$DS_Q=.IJ 6/   !#&->T_GWJICWQJ> F<      :/
M-/V.R'YLF_%U@*Z_9^^S\W\]6'WF@65I@0     05BWM8<A>JM%^7D"*G45
M    !3GOP_.^'?6;\*."KC @
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ME)G59J:2:RU<(BC$>J?* MT              (8QKVG\^]5,>^-3P$S@
M #1YI^QV0_-DWXNL!77[/WV?F_GJP^\T"RM,"     ""L6]K#D+U5HOR\@14
MZBH     *<]^'YWP[ZS?A1P5<8$
M     !46WY,P_M<YVSAW.9"7J#D[T.]@RZ_;)GP7X;:F'69D8C)TFG%*4MAQ
M)&70TZ'YVT.OB=\7;K.EL0HU_+7(DN(993\F3"U6XHDIZFU[Y@+%@     #5
M6^3XUCRVF[^Y@U3D@E*83.E,QC<)&FXTDZI.NFI:Z ,V3.A0XB["7):8@-(\
M5R4ZM*&4MZ:[C6HR21?=U :V@S'$<K)X\7OZV[*.>CYUDQB9X9ZZ:+\%:]/Y
MP$:<TYO?NRH_$O',WT'.KN&]86MVE)N%0T#!*)Z:I*>IO.J+P(J>FJS-6I;
M&Y[>+FVR'A'!KN]F/6-O.JF'IDZ2LW'G7%:ZJ6M74S/WS 28 AC&O:?S[U4Q
M[XU/ 3.      -'FG['9#\V3?BZP%=?L_?9^;^>K#[S0+*TP(     (*Q;VL
M.0O56B_+R!%3J*@     ISWX?G?#OK-^%'!5Q@0
M                 %4\'^@V,]T?*KW)DBO9S.Y.NEX986CC.QRH*.;3C45;
MAZ(<;4VE#B#,EF22,B-.I@+%)NL$-:4HL*DW#41((GHVIJ,^A%YWEU =$
M   *R=].)8U9<#9#EEA5QY&24A06JBT<1K(C(E6<1#Q-J]S>DS28##YJA-<@
MYUP3PG:J6>&WR9=WDL)MQ329;5+!0]'86:#2HVU+)9*+7WC+JDC(,+FGCS"^
M#<KXKY4XTIX^,S2RF#C5['K4^C1YE3;(6AU+S2?-4I)-^:K374]QZFE.@2%D
M7;;"GW^69A1YYF%)?96?CV3%991F(SRV&E-1VC\2(XLFFTJ-"$[_ #4F VO
M.!VW#W#];3Y?9SIEE!B^E64>2\F>U \)HB5'ADPV1^"DD;DH+>K<9Z&?0@&+
M]:KA7_O2U_\ =V^_0 '.\2YQC?(7<+GV08J^_(JRQJAC*<E1)5>YXK<F<:B\
M*8TRYIHHO.VZ +$@     #1YI^QV0_-DWXNL!77[/WV?F_GJP^\T"RM,"
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M))'[A>E6!Z%_.8"9@     !H\T_8[(?FR;\76 KK]G[[/S?SU8?>:!96F!
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M/W"Z CHP    %.>_#\[X=]9OPHX*N,"
M        #EN1L(8Y&PZQPZ3:V%(S8^#NLZ=XHTYKP'T/EX;AI41;C1M5TZI,
MR 0-]2>F_BKGWZV;_N '.9=AF;=J2Z+D7&.0;W*<$.TAUF6XQDT@IQ*B3G":
M\>,O1)(<09EIM01ZZ:F:=4F%Q0             !#&->T_GWJICWQJ> F<
M    :/-/V.R'YLF_%U@*Z_9^^S\W\]6'WF@65I@0     05BWM8<A>JM%^7D
M"*G45     !3GOP_.^'?6;\*."KC @
M       YGD"QS2IQ*PG\>TS&09<UX/R?42Y"8;+VYY"7=SJU)).ULUK+4^IE
MH A#]XG>;_!RC_7T;]( :N=A/<7SQ<4-3S!2U&#<9TM@Q<6=;7RTV$ZU>AJW
MM,FMMQQ*6C/X6IIT\OG&2= M2          (IS'D7D=O,9&%<9X,F]?K(C,Z
MWO+B8JIJT'(,_"BQW"8>4^\I*34HTEL;Z;CU/0@Z+BKD-CE##(N5MUSU/*4]
M*@V-3(6EUR+.@/KCOM>(WYJR):#VK3Y2TZ$?0@[0!#&->T_GWJICWQJ> F<
M     :/-/V.R'YLF_%U@*Z_9^^S\W\]6'WF@65I@0     05BWM8<A>JM%^7
MD"*G45     !3GOP_.^'?6;\*."KC @
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MH2+.KB2EMQ[ V>FBY)$;CA_TUZJ_I )H 0SC9&7<_GNI>7%,>,O^U6 "9@
M   !H\T_8[(?FR;\76 KK]G[[/S?SU8?>:!96F!     !!6+>UAR%ZJT7Y>0
M(J=14     %.>_#\[X=]9OPHX*N,"
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M_P 38=7X+W"Y]1ULZRL(YXU0R%2+J<_9RMZY,XMI/2#4LD$22T3KH74!8@
M    :/-/V.R'YLF_%U@*Z_9^^S\W\]6'WF@65I@0     05BWM8<A>JM%^7D
M"*G45     !3GOP_.^'?6;\*."KC @
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M>0(J=14     %.>_#\[X=]9OPHX*N,"
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M?6;\*."KC @
M  #E,UY,X_XY:BNYSDD"A*:HTQ$37TMN.FG3<:$?",DZEN41:%KU ;^JM:R\
MKHMQ2S&+&IFMI>ASHCB7V'FEEJE:'$&:5$?OD8#, 0QC7M/Y]ZJ8]\:G@)G
M     &CS3]CLA^;)OQ=8"NOV?OL_-_/5A]YH%E:8$     $%8M[6'(7JK1?E
MY BIU%0     4Y[\/SOAWUF_"C@JXP(
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M'WF@65I@0     05BWM8<A>JM%^7D"*G45     !3GOP_.^'?6;\*."KC @
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MR%ZJT7Y>0(J=14     %.>_#\[X=]9OPHX*N,"
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M_+R!%3J*@     ISWX?G?#OK-^%'!5Q@0
M                            !#&->T_GWJICWQJ> F<      :/-/V.R
M'YLF_%U@*Z_9^^S\W\]6'WF@65I@0     05BWM8<A>JM%^7D"*G45     !
M3GOP_.^'?6;\*."KC @
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MVWO7W[1F38R"23KJ8MI*CMFHD$DNB&TI\GN )A 0QC7M/Y]ZJ8]\:G@)G
M   &CS3]CLA^;)OQ=8"NOV?OL_-_/5A]YH%E:8$     $%8M[6'(7JK1?EY
MBIU%0     4Y[\/SOAWUF_"C@JXP(
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MTP(     (*Q;VL.0O56B_+R!%3J*@     ISWX?G?#OK-^%'!5Q@0
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M\O($5.HJ     "G/?A^=\.^LWX4<%7&!
M                     !B+JJQRQ:MW(3"[9ELV&9ZFD'(0TH]30EPRW$DS
M\J2/0!Y6U#1W[2&+VLB6C#2M[;4UAN2A*O?(G4J(C 9<:-'AL-Q8C*(\5E)(
M:9:22&T)+R$E*2(B(ON /4  0QC7M/Y]ZJ8]\:G@)G      &CS3]CLA^;)O
MQ=8"NOV?OL_-_/5A]YH%E:8$     $%8M[6'(7JK1?EY BIU%0     4Y[\/
MSOAWUF_"C@JXP(
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MM/Y]ZJ8]\:G@)G      &CS3]CLA^;)OQ=8"NOV?OL_-_/5A]YH%E:8$
M $%8M[6'(7JK1?EY BIU%0     4Y[\/SOAWUF_"C@JXP(
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MX1FT:?.)1EIM6//HT:HTQLUY^LO3FZ-T[IU[,?2/)*0R6P
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MW^,?)'ZZA_H !]7>;_&/DC]=0_T  ^KO-_C'R1^NH?Z  ?5WF_QCY(_74/\
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M  /J[S?XR<D?KJ'^@ )H8:\%EMDUJ=-M*4>(X>JU;2TW*,B+4S]T!Z
M       .&Y@XS@\P<>6_'EE/>K85N<8W)L=*7'4>B26I):)7T/4VB2?\H#%Y
M(X;Q;E'#X&)Y"[+CN5#D>537=>[Z-8PIL1.QN0RX1&1*T\I&1E_.1&0<GA?;
M?"HLTKL_S;,KWD#):-MQK'UWSR%1H'C)V+<;906ANFGIO,_NZ;B29!-X
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M,C,O.4?ND0\]G1LV1BTYAZZ^;7KG-8Q+?#G=(
M
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M3;C,!#2=Q-MDG3<HU*Z]>N@"=P
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MNA= &=VA?_W-_P#Z/>__ '0"R@
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M1Z3NU\7?T\FWS-H#3]D/A?N&A^#MV?*UMIL\33\Z5_K?._P@+&
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M8]-_$[=/@>B^;NUW== '3]I'A_\ \Q>'L_XB7F[P_$\OXKX7B>[[^WH L>
,            /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>bc_fig47immunization-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_fig47immunization-4c.jpg
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M ,0  0$  P$! 0$!           '!08(! ," 0D! 0 !!0$
M   % 0($!@<#$  ! P,# 0,&"0H$! (&"P   0(#! 4&$1('(3$3"$$B%+05
M=E%A,C1U%A<W=T(C,\/4E;4V5QAQ@5)BD:&QLR0XP9+20V.4\7*"HE-$5#55
M)AD1 0 " 0(#! 8(!0,$ P     ! @,1!#%!!2%181)Q(C)2$P;P@9&AL<%"
M%='A8B,4\7+BDK+"TC-#%O_:  P# 0 "$0,1 #\ [^
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M_<+D7]%,_P#_ )"B_; +D
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M )J'_P!H#+
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MC4;^:>FCF:HB(NU>NG4#2_[5_#S_ $]M7_J2?^V!8
M
M
M
M
M
M                                               $MN_.N)VG,(L9
M<JS4#56&ON\;M88)]41&Z(B[FIV/<B^;\>BD;??XZY/+RYRV[;_+&YR[6<W"
MW&M.<Q^7A'-4(Y(YHV2Q/;)%(U'L>Q4<US7)JBHJ=%14)&)U:E,3$Z3Q?HJH
M  .-^"L.Y)YCPVMS"[<Q9;:ZIMXN-O924,U.D"14DVQBIOB<NNB]>H&^Y/?<
MNXDYMXLI+ID===^/,NMOU/N"U[VO1+_3,:M-6/T1J)-5NVL=MT3Y:@9WQ1YW
MD6(\?4=BP:I=2\A9M=J+&\:FB726*>KE19)4Z+HC8VJW=^2KD4#6^2+[FO F
M:85G-QR"OOW$-;!2XMFT5>])/0:Q6LBI[OT1-O>.;K4+V:ZZ:ND;H'NP/+LH
MYGYJO.38_>JBDX3P)7V6BBHY&I37^^*U?2)7N1%[RGIT<B,T=HY=CFJJ*Y .
MA .>?%A?LKM-!QM:<4R"NQN;)\SMMAN%?;'-;4>B5S96/1NY%151='(B]-4
MTWE*FY0\.M/CN:V?E&[YC'6WJCM-7B&1MIJE;C%6.5KFTKXV,>R5J)JFQ/C\
MFUP;OF/&/('+G+=UHLQN=VQ[A2P4=*VPTEDN#*)UYN-0S?/-4.@>LR-@55C1
MCT;U1KF]KMP8_@JIOV&\S\C<(K?Z_)L,QZDMUVLU1=YEK*VW/KV(YU&^=>KF
MJCD=&UW8UO3M=J'2(
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MS:>'?MC3:B><JZ-W;4"U
M                                       ->K<(Q>XY)2995V^.2^43
M=L50O8JIIL<]O8YS/R'+U3_)-/"V"EKQ>8[826/J6XQX+8*VF*6Y?3E//_5L
M)[HT   (]-X5O#U4325$V 6UTLKE?([\\FKG+JJZ)(B=H%3LMFM>.VBAL-DI
MF45GML$=)04D6NR*"%J,8QNJJNC6HB 8?"^.\(XZI*N@P>QTMCHZ^=:NKAHV
M;&R3JU&[EU5>Q$1$1.B>0#[4^#8E39?59]#:86YE6TK:"IO"[G5#J1FU4B17
M*J-;JQJJC4354Z@?FY8'A]XRJTYO<;1!/EMB9)%:;PJ*VI@BF:YKV(YJIJU4
M>_S7:IYR_"H&Q :OG''.$<E6ZGM&=66GOEMI9DJJ>GJMVUDZ,='O38YJZ[7.
M3_,#7<6\/G"F%W>"_P",X1:Z&\TR[J6M2)9I87I^5&LJOV._W-T4#U9'P;P_
MEUZJLBR?"K3=;Y6[%J[A5TS))I5B8V)FYR]5T8UK4^) /3B7#W%N!W1][PW$
MK98[L^%U,^LH:=L,JPO<USF;D\BJUJK_ ( ;N
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                               2_DSG''^.KS;L2I[1=<LSJZPNK*/&
M,>IDJZQ*-CMCJB;<YC8XM45$<Y>JHO3HN@??B[FG'N4*J[V2*W7+&\QQ]S$O
M6+WZG]$N$#)M>[E1J.<U\3].CVN^#73<W4*2
M                                      #Y>E4RU*T231^F)&DRT^Y.
M]2)5VH_;KKMU334IK&NG-?Y+>7S:3IKIKRU[GU*K
M         #CJEN?*EP\4_,=KXUMUK]OMI[!2R9-D"ROH[3:XZ%LBPQ00:222
MU4LG>-3<C$[O50-YXVRO*K9SI5X%S'8+$O)%985J\?SNP0.B2XVB*H_.4DO?
M:R-<QZ;]FNWS>SY+G!1\TYIQ'!+TMAO5%?)ZU(F3]Y;;+<;C3[)-=$[ZFAD9
MNZ=4UU0#77>*'C"*2G;609!0Q5$\-(RIK<?NM+3MEJ9&Q1H^66G:QNY[D3JH
M%G
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M8\4ZJG$%0B+HCKWCB*GPI[<HE LX
M                          !@;]78I5S18=D$U/)/>HWMBMDZ^=,QO:J?
M NJ>:NJ+JGF]4/#);'/J6_5R2.UQ;FD3N,43$8Y]J.7TY_?Q<YT_#UG^V:3C
MR6Y.?00VQF2=WM<D[K?)4NI6Q*_3;N[QCFJY/R>NB*NA#QTR?B<?4^_T-]M\
MXU_Q.RO]_A_3_N_EW^#H^Q7+%TEJ,8Q^>G26QHR">WTZHG<(J=$T_P"2Z:Z+
MT7J3..U/8K^GDT#=8=QI&?+$_P!SMBT\_I^'#L9L]F
M              $7\4_W03_3>.?QNC M
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M)Q3UQP%N B4:)_=]4KY5XW@U_?LP%M D7 7S;D;W^R3UAH%=
M                   (OXI_N@G^F\<_C=&!:
M                    )MXA?N)Y(]V[KZI(!MF$_P F8[]%T7J[ ,Z
M       $1\2GS+B[\2<4]<<!;@(E'_YO:G\-X/X[,!;0)%P%\VY&]_LD]8:!
M70                              "+^*?[H)_IO'/XW1@6@
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MI_#>#^.S 6T"1<!?-N1O?[)/6&@5T
MB_BG^Z"?Z;QS^-T8%H
M XWYJK,SJ,QF@RUG<QPZ^RH(E5:5*95Z/B5?E*[3SW+UUZ+IHB)J>^MDG)Z_
MU=SM_P N8]I7:Q.W[=?:F?:\WC^3)<!UV90Y6E'CK._LTNUU[CF54IF0ZZ))
MJFNDG^C3J[L[-53TZ?;)&32O#FQ?FG%M9VWFS=EX]C3C,]WH[^[TNMC:'&@
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M_;/NZ\]._P#-A. OFW(WO]DGK#3+0*N@
M  $7\4_W03_3>.?QNC M
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M"-^ZBH9KO23UDU/3-3HUL>YL2[>B[.@'3($7\4_W03_3>.?QNC M
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MQ          "(^)3YEQ=^).*>N. MP  !(N OFW(WO\ 9)ZPT"N@
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M4[SDULAO6/I-9*VBMD%//OO-(UN]]-3QR)M54>FUW:U->@'6(
M                              (GX7_Y'R'WLR#UQP&=\1OW"\C^[]Q_
M[#@,SC%@LN2\8XK;+]0Q7"@6U6N;N)V[F]Y%3QN:Y/@5%_Y=.Q3SR8ZWC2T:
MPRMMNLNVOY\5II;MC6/%H_B,:UE-Q@QC4:QN>6)&M1-$1$[[1$0OTT8TSKVR
MMQ50          (CXE/F7%WXDXIZXX"W   $BX"^;<C>_P!DGK#0*Z
M                 U/E"YW.R\;9?=[-0LN=VH;-<*FBMTT??Q3S14TCFQOB
M_P#>-<J:*S\I.GE @?&/A[M-?QWCE=0<TYNE)56^"H:RPWYE#:HUFC218Z:G
M2%Z11L5VUL>[S4Z =04%,E%0TU&D\M2E/%'#Z34/[R:7NVHW?(_1-SG::N7R
MJ!Z  &O67!\5QW(,@RJS6YM+?\J?3RW^M:^1SJI]$QT<*JU[E:W8USD\Q$[>
MH&P@1?Q3_=!/]-XY_&Z,"T
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M7-;IM1RIU0#W@   "+^*?[H)_IO'/XW1@6@
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MM7/$SNHY)D:B/>UFKMJ*[54;JN@'H    $7\4_W03_3>.?QNC M
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MF0>N. SOB-^X7D?W?N/_ &' ;7QY_(&*?0]O]5C F_B/_0\8^_MC_7 6P
M        1'Q*?,N+OQ)Q3UQP%N   )%P%\VY&]_LD]8:!70
M         '/_ (@KPY^;\=8/D&5UF%<<Y&ZZ/O=YH*GV9)4UM%'"ZCH75_3N
M&R[Y%5-R+)MVHNH&C\HX1Q5Q5@]WS7 N1KICV:VZFDK+#W>25%R2XU\;5=#2
MOHZF:=M0V=^D;FHSIKN[$4#J?'ZJX5UAM=;=Z?T2ZU-'3S5U+HJ=U421-=(S
M1>J;7*J 9$    1?Q3_=!/\ 3>.?QNC M
M               (GX7_ .1\A][,@]<<!G?$;]PO(_N_<?\ L. VOCS^0,4^
MA[?ZK&!-_$?^AXQ]_;'^N M@           B/B4^9<7?B3BGKC@+<   2+@+
MYMR-[_9)ZPT"N@                      (AXE<_7!\=M,5QX\I<[Q.\5#
MJ:\RW2:*"U6YR+&E/)5NEIZEK&/<]R=ZYJ-9MZJFJ 0-LF68AR1QV_$/#SB%
MIJK\ESJ:"&ENEKK9+DE)1MGCDIK@E-I2=RCN]W-1>]1=NJ =R4,M5-14TU=
ME+6R1,?4TR/25(I7-17L1Z(B.VKJF[3J!]P   !%_%/]T$_TWCG\;HP+0
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M;P     B_BG^Z"?Z;QS^-T8%H
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M#T@    !%_%/]T$_TWCG\;HP+0
M       "(^&-C),$R..1J/C?E>0->QR:HJ+6.145%[44#%<Q\(MF9+E>#4:-
MJHV[KC9*9J-;,UJ?I*=C=$21$3JQ/E>3SNV#WNQU]>GUPZ/\N?,?DTV^YGU>
M%;S^GPM_3X\O0R/#W"<%FACR?-:5E1?)V:T=KF:DD5'&Y.U[5U1TRIV_Z.Q.
MNJGILMEY/7OQ_!C?,7S%_D:[?;S_ &_U6]__ (_CQ?7Q'_H>,??VQ_KB8:"M
MH           B/B4^9<7?B3BGKC@+<   2+@+YMR-[_9)ZPT"N@
M            <&<@<;>&[B*[183'E_(5PR5R.J&XEB=P],J(&2KWJN?%'"QD
M>[=NVN=N5%W::+J!Y\'X_P##;RM>'X!69?R/9LDJV:LQC+*_T*:KC1-_YMDD
M,D<FB-W;-V[IJB=% [THZ6.AHZ>BA55AIHV0QJY=7;8VHU-5^'1 /N     $
M7\4_W03_ $WCG\;HP+0
M")^%_P#D?(?>S(/7' 6P !$_$?\ H>,??VQ_K@+8           (CXE/F7%W
MXDXIZXX"W   $BX"^;<C>_V2>L- KH                     '.?@QMENK
M.*5Y'JF-J,\S2Y7.ORRY2-3TIU4RNFB; Y5\YK&,8US8^Q%<JHG4#V>,>R66
M;A.[YC4*RBR?#Y:.[XQ>VHC:JDKXZN%L:1O[?SBNV;>S54735J:!<[/4U-;:
M:"LK(^YK*BFAFJ(=%39)(Q'.;HOP*N@'M     "+^*?[H)_IO'/XW1@6@
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M4DCMT]5311M\UJZ;G=5Z)U ZR
M      !$_"__ "/D/O9D'KC@+8  B?B/_0\8^_MC_7 6P           1'Q*
M?,N+OQ)Q3UQP%N   )%P%\VY&]_LD]8:!70
M  <V^)>R^(C-*NDP_C>S1R\;31QOR6HI[K!;+C<&N>Y):)LLNYT$2L1-SFL5
M7[M.S5JAG^(9^5\>GLV#U'#UKP?CJCCEC6JH;_!<'4S6QO>S\RV)'RODEVH]
M[G;EW*]RJO:%S C'BG54X@J41=$=>\<1R?"GMRB7K_P LX
M                           (GX7_ .1\A][,@]<<!;  $3\1_P"AXQ]_
M;'^N M@           B/B4^9<7?B3BGKC@+<   2+@+YMR-[_9)ZPT"N@
M                           $7\4_W03_ $WCG\;HP+0
M                            ")^%_P#D?(?>S(/7' 6P !$_$?\ H>,?
M?VQ_K@+8           (CXE/F7%WXDXIZXX"W   $BX"^;<C>_V2>L- KH
M                            !%_%/]T$_P!-XY_&Z,"T
M                              B?A?\ Y'R'WLR#UQP%L  1/Q'_ *'C
M'W]L?ZX"V           "(^)3YEQ=^).*>N. MP  !(N OFW(WO]DGK#0*Z
M                              1?Q3_=!/\ 3>.?QNC M
M                               (GX7_ .1\A][,@]<<!;  $3\1_P"A
MXQ]_;'^N M@           B/B4^9<7?B3BGKC@+<   2+@+YMR-[_9)ZPT"N
M@                              $7\4_W03_ $WCG\;HP+0
M                /G//#30R5-3(V&GA:LDLLBHUC&-357.5>B(B=JE)F(C6
M5U:S:8B(UF4JLG/>+W?+YL><U::U/<V&VW:1=K)ID714>U438UR_(5?\]->D
M;3J%+9/+RY2V_<_*VXP[6,W&W&U>Z/SF.?W*R2;3@            (GX7_Y'
MR'WLR#UQP%L  1/Q'_H>,??VQ_K@+8           (CXE/F7%WXDXIZXX"W
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M;           !$?$I\RXN_$G%/7' 6X   D7 7S;D;W^R3UAH%=
M                      (OXI_N@G^F\<_C=&!:
M       YW^N-GP;G?EN]W:1%TLF*QTM&UR)-43*EQ5&L1?(FGG.[&F/GSUQ5
M\UDITWIN7?9?AXX],\JQWS].U^,!\0=74Y!44>:K'%:KA+K1U,;4:RB5>C8W
M_#'_ +UZHO5>B^;$[?J,S?2_"?N;SU7Y3K7!%MMK-Z1VQ[WC'CX<_3QZ*:YK
MVH]BHYCD16N1=45%[%12><SF-']"@          1/PO_ ,CY#[V9!ZXX"V
M(GXC_P!#QC[^V/\ 7 6P           1'Q*?,N+OQ)Q3UQP%N   )%P%\VY&
M]_LD]8:!70                              "+^*?[H)_IO'/XW1@6@
M                        ?E[V1L=)(Y&,8BN<YRZ(B)U5550K$3,Z0Y%S
M"DLO)7)^3U%GO+?2ZFGH*?&Z>2-D=-5U-&V1E3'WZKKNEUC2GW>:JM5/RT4U
M[<WQ[F^E?:CAW3X?P[W5.CX-UTG!\3+$3CO.MXB/7Q]UI[.V/>C]/'O8/!.,
MK_FM_DM/<R4-+0R;+O53,5OH^U=%9M=IK(NBHC/^/0P=OM;Y;Z<-.+8^J=:P
M[+#&36+3:/4B/U>/H\79%CLU%CUHH[);D>E#0Q-AA21ZR/VM^%R__1\'0VS'
M2*5BL<(<0W.XON,MLE_:M.LL@7L8          (GX7_Y'R'WLR#UQP%L  1/
MQ'_H>,??VQ_K@+8           (CXE/F7%WXDXIZXX"W   $BX"^;<C>_P!D
MGK#0*Z                               1?Q3_=!/]-XY_&Z,"T
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M(^)3YEQ=^).*>N. MP  !(N OFW(WO\ 9)ZPT"N@
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MO8]ZKVN[N1B.=Y537RG/.J8*X=Q,5X<?M62KA%*(GX7_ .1\A][,@]<<!;
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MW(ZJK)%EFD\^F=IN<JKHG1/(@&6^R'E;^N.0?NRR?L@#[(>5OZXY!^[+)^R
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MPWNPP<BMO=OGM[KCGF0W*WI4-V=_0U4S'0SQ]5U8]$\U0*R
M !(N?<?OF04O'++';Y[@ZW9]C=SN"4[-_<4-)4N?-/)\#&)\I?(!70
M
M
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MSZ)]=0*W=)3JY7+L=NTT5RJBHO730"L
M              <Y<GJE%XM>#ZVL79155OR.CI)'?(]*2C5RM15[%<CFHGP]
M@'\\6^VI9P]:J=N^[57(MBDHV-71Z-A2;O'HG;HW<W<OD Z.
M   YK\8/Z#A[\1K%^N Z4               \];/0T=/)<+C)%3TE&QT\M54
M.:R.&-C55[W/?HC41$U5RKV <Q4=;5>*/EBPY!:H'Q<#\:5[KA0W29CF>W\A
M@\V-].UZ)K3TRHOGZ=5U3\KS ZE               D>:T-WYKQV*?ASE1V,
MP4<U71U]?:*>"XLGJ&HQO=2.<YCXG1*G_NW(OG?X :QX2YZ6UXME''4MK@H<
MHPB_5-MR6OI9I:F.[5TC6O6XNDG59%?.B><UZKMVHG1-&M#H,
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M
M
M
M
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MO151$5K)I&N5%5>W0#9(I8IXF3P/;+#*U'QR,5'-<UR:HJ*G145.Q0/V
M                                                           !
M+><LDP*T8[2VCD3$[GE]AN\R[K?;+7+=F-?2;94?,V/38B*J*U5[=%^ #B#C
M*^^'^APW.,PRGBJOO+KC=[O<\=J&6&6>T45K8B-I*?TA'[&,8YKDDZ^;Y5Z
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MAT3ZAM!)>'(ZNIE[YRR4LB)'%M[EZJU&JWHG8JMT4"K@
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MMC;[1]L]ZOIG?[/-UW_)V_D;=>NH%M
(       ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>bc_fig48splenocytes-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_fig48splenocytes-4c.jpg
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M<(C/T'M,] 'H
M                             :RYR&EQ],9=S-;AIENICQS</3<XK[G8
M1?.4?0O28RX\5\FO;&NC#DS4QZ=TZ:MGV]2[!B9@
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M *ZX)QJ@P_F'G'&\7KF*FAA3,;.)71$$TPT;U,AUS:DNA;EJ4H_C,!T
M
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M_;"2#6;0
M      .1N5Y>>\L9+RU75V7V6'X'Q-5:HAT3WJDVVMW*]<\U2'T]Y+"-I-^&
M711=2T/70/3A^6\@X;,X(R>;D+]UA')='28]<4DXS>>BVYU27F9S#JC-1F\H
ME>/KV]3/<9I-(=8            I/BWW^<]?3,7_ #$T NP
M
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M4N@JO4<]>WRHXS'.?!<>F;>\V\V?EB>4>/O=&BA="
M                                       #ESD;C6YS+/>09O ^;5];
MEMC71Z'E#%K5EYR ^4F(I$1\UH0HVWR8,TI4A*BT])=XE!Y>/N*KS"LHXR=Y
M\S6OF6&.QBQ_C#%*AEY$ I3$,F5ONNK;2IU_P$=JTI21]2/7H ZM
M   !2?%OO\YZ^F8O^8F@%V
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M*\S,4^6JRP>EXZUB<GS6Y^YZK1*4<]XLA!$E"<7N"2DNA$13('80J%TLX
M                                                       :O)*R
M?<X_9U-79NTME-C.QXEO'2EQZ*ZX@TI>0E?0U(,]Q$8#BO$..\DC\R<AXPOS
M$O5.7R)5:A39-QTVUF;4!O13S#^Q/X)+B6VO 4O5/4].P!=^+^7.[B9Q0YOR
M#R7=9T]BZGWZ*NFM,Q8K,J0V;2G5):-6\R2?=[.NG734C"^0           4
MGQ;[_.>OIF+_ )B: 78
M                                 (GRC[LLT^PK3V-T!EXW]W>(_8M=
M[(V"92<$*2\N'^+?^9.1_P!6 7: K*V]_N,?LQ<>VP %F@
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MWB(N[J74P%H          "D^+??YSU],Q?\ ,30"[
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M36S,R+Q%$OP5)(O07>[QH"WP           4GQ;[_.>OIF+_ )B: 78
M
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M4I%U55[Z&;6MLH+'J_B-(61^*TZDB,R+T_R2(MX8:QCE?G?D?#\CRW"WN/\
MC7!)CES'AVKR';:SMB:4TQ^#01>"VUO-1[BZ]2U/7N!TP           "D^+
M??YSU],Q?\Q- +L
M                             $3Y1]V6:?85I[&Z R\;^[O$?L6N]D;!
M,I."%)>7#_%O_,G(_P"K +M 5E;>_P!QC]F+CVV  LT
M                                          '+EWC5KYC>9LWQ#(LB
ML:;B[CDX$%-!32#ANV=A81CD./RG$ZJ\-!=Q"?3VEM/=J&%C$K'RT<JX%7XE
MD5G:<89_.=H;'&+B0J:<*>;)N1Y,1Q6AI(S3HX7P=N[5.P.J0
M4GQ;[_.>OIF+_F)H!=@
M                                 B?*/NRS3["M/8W0&7C?W=XC]BUW
MLC8)E)P0I+RX?XM_YDY'_5@%V@*RMO?[C'[,7'ML !9H
M  \-U+=@4]A.CZ>/&C//-;BU3O;;4HM2Z=-2'O'7NM$3XCE>JS+E>\A%9,Y8
MIA#CBT^$IM.I&@^OR6]-.O0=3?!MZ3IV/6C?X?FW(D+/\?IKJ_\ K.%:+4AY
MDT%LV=4^E*3)1&6I&0U\^WPSAM:M=)A&CI<<VAH,YL)E3A.26E>Z;$^#53I,
M5XB)1H>9CK6A6BB,CT41'U 4CY5>9LJSC'XV)<I&2>0D5D;(:V:?A)*WH)YF
M3,M"6B2G>TO5AXB26ADGTF8"*XISYR$CARG7'6WD?+.99798QB_KR4M16B:E
M.%ZQ()A*-68S2=5;2W'T]&H"967&7F3HJM>28[RZO(LSCH.0YCMI506*2<I)
M:G&;\/8XP1GT0YXGP:FDM3(/5G/*G);R< X[Q2H8QSE_.X[LNT*Q4B?%Q^'!
M01RWU>"HT/JW'LCEKM6?RM.P!J\NQOGSB3'IG(E'R/(SY-&RNPR#%;Z!#CLS
M8<<O$D'$>BH2N.XEM*E-H+>1G\/0C#797EEK/Y0X/SS$LNN48AR2\12,96\A
M-:45%?ZPC\"E.I.&:_PNY9]2]&@"MKW,\<=Y*Y+9Y'YIS/$CJ\A<A45!C,M]
MPDP$1VG%.G'8B2E(;2I1EO[J?1V@.I^*)V*P^-(=O3YQ+S+%D(DS#RV\F(DO
MFRE:UN>.]L:)),Z&DR6E)H).BNP!1F.\L<BYMS[QSD3,]^JX>S1>00L8QTV_
M#7/A4=>MSZSDDM.XO6'G"4PCNZ-H2?IU4&\BU.1\Z<J<D5EOG>08ICN"S8M-
M34&*SOJF0:G8Q/*G2G4)4ITG%&?@DKND2>P].H33R[9C>Y!3Y;BN36Q7]Q@6
M1SL:*^,DD[.B1B0MAY\D:)\8B6;;FGI1J9F>I@)KR1G<'!,.R2]3*AG=4]1.
MM(-;+?2T;[L6.XZV@T[B7M6I&WN_> .-\[@YWAV-WJI4,KJXJ(-I.K8CZ738
M=E1VW7$$G<:]J%+V][[X"K_-9FW)6&4F"_W5RT1\GN\IB5:(SR6E,S$NQWUI
MBN&\1DE+JT(29I-)_P"D0#5<L\ZV%GY8)/+/'$URCOO'KXS[2T-N2J^8=BQ&
MF1'FWD&1+0:EH/<@M2T470R,!N\PRWD;D;E*VX?XMNF\1K<2B0Y>;9>J*W/F
M(D623=C08;+WX,E+:(UK=5KIZ-#3HL,E71>8+CC+Z5IN_7REQS:/E&NT634*
MON*@EZ$4IMU!M)D-%VK;,C7IT26IZ@->O(.2^<,XRJAP')SP7C;"+!5#97D.
M*S,MK6X822I3+*I!*1':CFI*36234H_A)6B0^X&2<E\-<B8QAG(>1?IO@&<2
M%UE#D<B,S"M*ZV0@W&HTKU<DMO-OD1DVO;OW=NA%U".8GCN;^863EV>2N2,D
MP^KA7MA2893XU)1#AM1:I9,IDRT&A1R5.N)4I:%*(BZD2M#+:&?&,EYNYBXB
MQ2KI;)-/D17DK'^1\KA*9:E1X=0\XR\[#0LM">D$EOO(3W%&>B2+L#88NC(N
M*.?*CC.-F=WF.)Y'C\VYL(N3R_K.=5NP'$H;DHDJ2E9,O&:F]BNF[4_@T"FV
M>3\9SBH5G>;\ZW&#Y]D*Y$O$\=J)+Q4U'$2^XU 18L1&7FE&ZE*7'CE+0:T*
MZ:=H"R.<\HO*^BX:9S'D-S$X%T](_3'+,1FJBQGTLUBGTNQW3;5N;=<2DVR\
M,]=VA%V (]0WO#\BDRF7#\P?(LPH4-A-@Q*DR4V<-AV?%V2XL5=:AY6JMC*W
M&VUDEMQ1*TUU(.S '.',>#V.&YP[S!Q[R12\>9+>L,P<@K\I6RBEN"A)VLN*
M-PR4EYI!DG<@C/;V;>]N#0<:PX&8<HT>:<M<Q8MFF8TR7F,,Q/&9<8H$:1);
M-+SZ4;_$?=-&NFJ.[IKJ>B=H=7  "M>9.29V"U$"FQ2,BTY-RU]57AE,L^XY
M+V[G)+Y%U*-%0?C/J[--"U+=J05M2<_Y/"\J$+F2Z9CW&<3">A0HK#?@1I-B
M[:NUL8MA*+N%HE:]%$:B2>FAF Q6]]S_ ,+2<7RSD;,:S,\0NK:%39-51ZIJ
MM54G9J-I#\20TK<\VTX:25XR=RB]!:ZI#=95E/*W(?+=]Q;Q7D<3"ZK"H,&3
MDV1O5[5O+<GVR5/1HS+#ZDM$CP4[U+/KJ W_  AGV7W\[-./>15Q)&=X!8,0
MYUE7MFQ'G0;!CUF%)\(S/PUK1NWH3T+3H M\  4GQ;[_ #GKZ9B_YB: 78
M
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M,D%M26I%UZ@.A0
M                           !$^4?=EFGV%:>QN@,O&_N[Q'[%KO9&P3*
M3@A27EP_Q;_S)R/^K +M 5E;>_W&/V8N/;8 "S0                   :-
M6&8>M2EKQ^M4M1FI2CAL&9F?4S/N#/Y^3]T_?(]$'&L<K)!2ZVHA0Y1$:2?C
MQFFG")7:6Y"2/J/-LM[1I,S/VC:#$
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MA)(8C,(2TTV@NQ*4)(B(B^ B 9P !2?%OO\ .>OIF+_F)H!=@
M
M   B?*/NRS3["M/8W0&7C?W=XC]BUWLC8)E)P0I+RX?XM_YDY'_5@%V@*RMO
M?[C'[,7'ML !9H
M             .+^0LJIN(>0.>:_D!"ZY/*5&A_#<C6TXY&E*C5+L-4!;J$J
M)MQ#A]Q)]-#U/35&H>+C[*Z;EF7Y<\,P!*[*RXX@0+;,[YII:(]6VQ5HC+@J
M=6E)*<?<(D*2C4NZ7;HK:';H           *3XM]_G/7TS%_S$T NP
M                     &@R_+ZG#*E=I:+U,]4QHR3(G'G"+Y*?B_E*["(;
M&#!;-;MJUMQN*X:]UE.UW*F<U5@SD>31_$Q6R7M.&VE)*C-J/N*3T)1'I\G>
M??\ B/07E]ABM7MI]4=?%08_4<M;]U_IGIX+WKK&#;P6+*M?3)A24DMEY!ZD
M9'_Q&789'U(QSUZ32=)X2Z6EZWK%JSK$O4/#V
M                  (GRC[LLT^PK3V-T!EXW]W>(_8M=[(V"92<$*2\N'^+
M?^9.1_U8!=H"LK;W^XQ^S%Q[;  6:
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MU+J.>WNYC-?A'"/Q=)L-K."FEIXST\%CBO60
M                 B?*/NRS3["M/8W0&7C?W=XC]BUWLC8)E)P0I'RWF1_W
MMZ'KIR3D9']W_9@%W *RMO?[C'[,7'ML !9H
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M;>_W&/V8N/;8 \/:S0
M                 <K<E<2Y[9<\(RO%>9X&&95<P_5:+'TP&7)S]=$;)QU#
MB#=3ZTA*TN.$IUM6S70C[I (53\9<CY+RG+LJKS)TUWRE21GH*F"JXDN17L*
M61/I8C&\IMH]2)#JFVR5\U1^@!T?Q1AW+^+2K-WD[D)O-XTEMI-<RW6,5GJR
MT&HW%:LGW]Y&DM#[- %G@         "D^+??YSU],Q?\Q- +L
M                  4GQS_$=SA]#P[V.< NP
M     !#<QY0Q'!I;$"]DN%,D-^,EEALW5);U-)*5V$1&9'I]P;F#:9,T:UC@
M(U^\1QM_\O+_ /PY_P#:&S_Y>?W?>G18M!?5F35$6\IWO'KY:34TLR-)ZI,T
MJ29'U(TJ(R,5V3';'::VYPAS_FV=<BR.0;VBHKLJR%5[$M-$V@TFC1/74T*,
MU&:M3U%_M]OAC#6UJZS*8A';3-^6Z:$JQ?RKQ6VE(2;:&F]3-1Z%\IK30;%-
MOM[3IV)T=24,UZRHJRQD[?6)<1B0]L+1.]UM*U:%UZ:F.8R5BMYB.DO+8#&
M    ")\H^[+-/L*T]C= 9>-_=WB/V+7>R-@F5><FX%:U-J]R)AQ*=D'W[FNT
M-?B())$IQ!=ID9$6]!?ZQ"^V.[K-8Q7^R7.[_9VK:<V/_P"H_G^B&1I5UR?+
M9QS&&51*YQ"';F:YWDMH,]=IF7:G4NZGM6?P$0L<EJ[>.Z_/I"LQ5MN;=M.7
M6?!T'BN+U6'TS-)4(-,=LS6XXH]5NO+TWN+/^4HR'+Y\ULMNZSK,&"F&D4KR
M0RV]_N,?LQ<>VP!@;"S0
M                   <09_F];Q'S5R[?9+43IO*F0P84?AZ8W$=F$ZV[ .,
M;412$F39H?/\,70U:'IJ9]X,M)@&/8=R!P+QCB%02.6<525]R#=Q&-/"@2XC
MGKB)<HB+Q/'>6;;1*4K:6B>FXB,.V@           4GQ;[_.>OIF+_F)H!=@
M                            "D^.?XCN</H>'>QS@%V
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M  LT
M  ?*UH:0IQQ1(;01J6M1Z)))=3,S/L(@&-M428EJ4T;<A"=38?3M61:]TS2H
MM?N= 'TEAE#KCZ&TI?=)).NDDB6LD:[24?:>FIZ:@,@           *3XM]_
MG/7TS%_S$T NP                            !2?'/\ $=SA]#P[V.<
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MP %F@
M  #^?*<BX];JL%QGF&_?8FR,EG2N<Z&[E2&;!^X.*ZB XXT1IWUR'$MZ%&_
M$@VS4711D%Z\"LXDWRKF:^%BTX355P2D'&\8ZA64%(?\8Z\W.X:2C>'XYL=S
M=MU] #I$   %0YOS;94^:/<=<=X7-S[,J^(W8WD6)+C5L2OCR-?!2])E'M\5
MPBW(:TU-/4!EIO,'A4[C+(>3+EF70Q<1?DUV44\U"?7X5E$4E"HNU*MJUK4X
MA+1DK11J+L/70-#2>8NV*\QZ!R)QO<X+1Y=*:K\:O9[\:2RY,DI-3#$IMD]\
M5QW31"5D9Z]O0C,@W7('-TO&LQ;XZP7#;#/<X3"3:V%?!?8A1H4):]B%2)4D
M]B5K,CV-Z:F77TEJ$@XJY4J^4ZFQE1ZZ91WU'-<J<AQ^S2E$R%-:(E&E6TS2
MI"DJ)2'$]%%\9&1!/0 !2?%OO\YZ^F8O^8F@%V
M       *3XY_B.YP^AX=['. 78                               "D_
M,1_OO#G^9%+['/ 78          (GRC[LLT^PK3V-T!EXW]W>(_8M=[(V"92
M<$*2\N'^+?\ F3D?]6 7: K*V]_N,?LQ<>VP %F@
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MC=FXX4VF8EIL6F"13H2V:9*6VB7O025GW"VZZ>C4!T*
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M%M%)XJ*HQ:#$*SS^GKIY-I47C1'X\PUM*[WR5&A)_> 6]^[UPK^I5=_T%?\
M: U>"\X"X9BTME*9PNN)YF*^XV>Q?12&U&78OX2 2[BXS/C/##,S49T57JI1
MFHS/U-KJ9GU,$)8      (GRC[LLT^PK3V-T!EXW]W>(_8M=[(V"92&5*C08
MSLR8ZEB*PDW'GG#)*$(26IF9GV$0FM9F=(YO-K16-9Y*2\N4J*ESDA@Y#9R+
MC,[C(J]DE'XBZRP-DF'MID1EJ:#(R^;Z>TALY]KDPZ3>.;5P;O%GUBDZZ+S&
MJVU96WO]QC]F+CVV  LT
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MQR^ZPQBR36)UAU>TSSFQ1>8TF?;A[FHMO?[C'[,7'ML :S;6:
M                                               *PYNCYQE7%>0U
MG#=F3>>FY&9@28<MN.MIQF:R<E!O&K1"O"2XE1&>OH 08O+=R!H7_P#/6:Z^
MG\*S_P"H!N\1X*S3&LDKKVPYCRJ_A07?%>IK!QI462G:9;'"(M=O74!=H
M        *3XM]_G/7TS%_P Q- +L                          %9M<[X
M'(2IR&S>S(Y+6VF3%Q^X?86;2S;5L<;B&E1$I)EJ1@#W-6$2&7(\BLR%UAU)
MH=:7C-TI*DJ+0R,CAZ&1D)B9B=81,1,:2I/"<QXYC<NYA'=I[I=/CZ*N31,I
MI+60\EZQ;=<=]88*,IQOPS;3X!NI3N(S,MVW46.3U#)>G9^*LQ>FXL>3OC[O
M!>']^&'?_I^1_P#EJ[_$Q6K1ZJCF+#;F\K<>9;MHEE;N.,5Y6--9U[+KK+#D
ME2"=DQVT$KPVEJT-770!/@                   4WYF'"A<<LVC3:#GL7=
M''9>4DC4EF;:Q8[Z",_0XVM2%?=U[2(QFQ9[XIUK.C!FP4RQI>-5P,,,16&X
MT9M+,=E)(::01)0E"2T(B(NA$1#%,S,ZRS1$1&D,@A(  *MC?Q(6?[$5_P"=
MIP);+F[W5Y)_] U_3MC?]/\ \]?;H0I#'B=^H*S0E:>KHTTU^,7F3ZY^+TV7
M'.XN=(V[77ZK=[>W^:2,6Z_Y9^*)=$Y)_9VW^A2?Z)0YEY:?B[W987]A5?L;
M0"6      ")\H^[+-/L*T]C= 9>-_=WB/V+7>R-@F7BY#X[K<[KTZJ*)?1",
MZZQ275)]OAN:=5-F?WTGU+X][:;NV"WC6><*[>;.NXKX6CE/MT5[BW$^3WMN
MU/Y*T.OK")N- 2XAPI*D_.6;?3:>FJM>\OT]!9[CU"E:Z8N<]?!5[;T[):VN
M;E'3Q_3^*]$(0VA+;:20V@B2A"2T(B+H1$1=A$.>=(K2V]_N,?LQ<>VP %F@
M                                                         "BL
MJ\IG%U_>6.5T<BZPS+;5YV7-N<;LY$-UV4^I3BW%(6;B.\I9F9)2D!IU<8>:
M3"R6O!>6866PTEJU59K7]_INZ',BFIU1GJ74]OW@!7-O/V&;BY)X5EV4-LMR
MK?"9;=JE22UU,H:C\4NSYRR 7+Q]G=5R1C$?*J:+.@PY#CK)P[6,J',:<CN&
MVM+C2C/0]2^$P$H          %)\6^_SGKZ9B_YB: 78
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ME:=FHP9,5Z?5&@V8Q
M     #3Y7#R*?CEE"Q.R:I\D?94BMLY#!2FF'C[%J:5H2R+X# 4C_=]YN?\
M^XJ7_P N1P&/'\WYKXRY(QK!N9I]9E6-9NM^'0Y351C@/Q;..T;I,2F"(D;7
M4EH@T]=?3H1Z!T4           "D^+??YSU],Q?\Q- +L
M          8WS>2PXJ.DEODA1M)4>B361=",_@U$QIKQ1.NG!R;QVQ2OV3AR
M'/$M(JG"K(RE;V4(\1:U^$9F>JDK4K1/H[2U'7Z5KCB,?T.+[K7RS.3ZVTL7
MI--G4!_!#6>6R%FB77LEN8<W:&:72U(BW%U<+L3\KH86K6V*8R?3XE;6IFB<
M7UST_-I)6 >96=DF>9%-P[''/T[:IVY,5N]D->K*HFG6VE(44?O[_$U4E9:=
M!RV#-;#>+PZ[<;>N?'-+<I;VKL;/ U%BV<0O4'6V?6HKK!$ZA>\MRD$M)$3G
M>[I+]!]%>@=168S5[Z?;'@Y*T6P6G'?[)\67&$W-OG>'9;81$Q::XM7*VO3J
M:'5IBUTR:EPCT[Z25&)"E'VZGIT(:>^W%<5)Q1QF>?N_5N[#;6RWC+;A6.7O
M_1TV.<=.                 //.G1*R&_83WDQX<9!N//+/1*4I[3'JM9M.
MD<Y>;6BL3,\H<\Y1>7'+4UQF(?U?A\!>Z*;R=?&DM]4+4GTJ(]#Z?S9?Z0Z;
M;[:F"OS1W6ERNYW-]Q;Y9FM837C;DF2])+#<T/P,@8T;B2W#[LDOFD:NPUF7
MR5?/_P!;MK]YL^W^YC^G^"QV.^FT^7D^KI/BMD4Z[  !5L;^)"S_ &(K_P [
M3@2M($*0\QO^]<-_YE4?LTX!=X#5Y)_9VW^A2?Z)0#3\7>[+"_L*K]C: 2P
M     1/E'W99I]A6GL;H#+QO[N\1^Q:[V1L$RDX(  !65M[_ '&/V8N/;8 "
MS0&JR7)*7$**=DN12BA4E:T;\V4:%N;&R,BUV-I4I1ZF1$24F8"KI?F=X:>B
M/M0\FD1I;C:TQY"J2W=2VXI)DE9H]43N))]=NI:C+Y5_"?N%)XS;/7646EK+
MOT9*_(8(UWR8"J9,K:I*244-TS4UH1;=#/KIKZ1T>&)C;TB?;F]0SY^I)TT<
MB4E7^U(Z$HC^:KX#&SM_JGX);,L4QSN__ES?4B^<OX/]88_.OXB:>7=EJ-D^
M91V$^&PT;"&VRUT2DENZ%U&CZI.M*2\RZ$% @
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M-_N<>2*UIQT1+H05"
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M@AJ;S/B\CLK;NG5$NBASR !26$?Q-\L?8F+?]6:"5V@@
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MQ]B8M_U9H)7:"
M $&YEP61R9Q;E6"PWTQIUU <8AO.&9-IDH,G&=YD1F2#6A)+T(^[J Y\>A<Y
M\V2\"XXSGCQ6'8IBME"M<UN793+\2R.G+1J/$0WVM/KZF1&O;T[W=[P6#F%'
MR'R/SSB\%RA^J.+^-YB;U>2/N)4NVL7H>UIF*V7>)#2G5)<,^G=/J7=)07V
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M?6(>VL7C5';9)2X_CDQ&ZU<]75(<4;R6WE&>S=T(]#T] R>;:M+6M')":5_
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M^'CD+[+5_2(!,+0Q_P#\!J_H<?\ HD@AL0   4EA'\3?+'V)BW_5F@E=H(
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M_(]S^)#10?O;>7_]:GOR/<_B0!^]MY?_ -:GOR/<_B0!^]MY?_UJ>_(]S^)
M'[VWE_\ UJ>_(]S^) '[VWE_/_\ =3WY'N/Q(!&.)O,-Q%C_ !_45-O>OQK!
MDY2G6555HHTD]+>=1J:8JBZI41]H":?O0<(?K(]^2;;\3 /WH.$/UD>_)-M^
M)@'[T'"'ZR/?DFV_$P$,S7S%\.S,AP.TCW[ZX-+<R)=DZ55:Z,L.4]A&2LR.
M(1GJZ\VCND?RM>S4!)%^;KR]MIWO9<MIOLWNU5NVG4^PMRH9%J?H >2Y\UW
MTFHL8T?)WUR78SS;3::>XW&M3:B(BUAD6IGV=0%>X/F'E<9PO'6LJ4;F3HK(
M:;I;E;=+<.<3"/'-2D,&DS\3=J:>A^@;T;_/$?5*4LIN3O*?C]BS;U#J8UC'
MU\"053=+4@U%H9I)<91$>GITU'C)O,UZ]MK3H)A^]!PA^LCWY)MOQ,:B#]Z#
MA#]9'OR3;?B8"!Y5YA^('^1\%R-N^?.FIV+INQD_55IHTN:S'0R1I.+N/<:%
M?)(^SJ E_P"]MY?_ -:GOR/<_B0!^]MY?_UJ>_(]S^) '[VWE_\ UJ>_(]S^
M) '[VWE__6I[\CW/XD ?O;>7_P#6I[\CW/XD ?O;>7_]:GOR/<_B0"(R/,=P
MW8<L461Q,@?<IH./V\"5**IM22B3+F5KC*-#B$HS4EAT]2+0MO7M(!._WH.$
M/UD>_)-M^)@'[T'"'ZR/?DFV_$P#]Z#A#]9'OR3;?B8!^]!PA^LCWY)MOQ,!
M!>,?,SPIC.!TE%=9$_%M83*VY4=53;+-"_%6>FJ(BDGT/T& E:?-UY>W-WA9
M<MS8HT+\.JMU[5EVI5MAGM47I2?4!"H/F'XA?YKL<N:O7U8\YBT*J1-^JK0D
MG,:L9;ZV]IQ=^I(<0K7;IU[0$IR[GO@;,,;L<:F93*8CV#7AF^U4VV]"B42T
MJ(CAZ'HI):EZ1FP99Q7B\=!3C<WA]IM+3?+E@A""VI2G'K=*2(O01$CH0N)]
M5C]D??\ HG5)\ S3@O"\E_2B9R%.N9S;"X\=+E';,DDG-"4:C]7<-70M$ETT
M&MN?4/-IV17M@61=>9?A6936,1C(GE/OQ7VFD_5-L6JUMJ21=8A%VF*H:# _
M-'P=28-C%-:9(_'LJZI@1)C!U%NHVWV(S;;B#-,,R/123+H8(2'][;R__K4]
M^1[G\2 /WMO+_P#K4]^1[G\2 /WMO+_^M3WY'N?Q( _>V\O_ .M3WY'N?Q(
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ME$ M8
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MA]R%&>D,Q<Q;?F+9;6XEIHJR<C>X:2,DIU41;E=.H"W@
M
M
M
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MQ?5\.?'??5L+56Q*%F:]I%WMFNGI 3,
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MPFT!VK72_7Z^).V[/666WMG;IXB25I][4!Z0
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MOBOE+!_+N[65-_95G)5A )=969";,J#3S(SKII989V*)MI\C+?NWZ:[M-2T
M1"\QK.N3,==XVK>$6>.<BR9<:)R!G#:*QB(B"T^V]+5%=BF;LDWC;VH0?3O=
M3^<0=B---L-(8922&FTDAM!=A)26A$7W" ?8
M
M                                                   /X_>=7^)K
M.?\ 6K/S3# 2C_W?O\037V-8?_9 /ZL@       YF\^O\.MM]HUOM! /Y- /
M[><"^X_C;]EZ7V!D!80
(       #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>bc_fig49akilling-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_fig49akilling-4c.jpg
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MN#BZ%Y )_;7E>Y"[IHJJB9VQ&WT>MSFZ;VK9$2O>3LAR%@IP*<5"%G9*??\
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M[ZN"XN*KZKY8V<7O55$1ME2ASVW =!Q_>.O1S?\ ][KL_P#.K_=3^,_D\/\
M9N_BL%BY4B[[EY.#0AI:%E(I!!TX;S+=)N84G0G*F8@)K*ZZ\,W=TKGO\K5<
MQ$S,3$_![45Q7&V%\KC?LH% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M%Y0#\-3;O*7MY3\U,>ZV%":HC>A__J-PZ "(SZV@<HCYLD^X'_Z6O7_S[_\
M;_S'YOGST_%T"+N*%F8%O<\<\(I .FX/47QP,DF+82[^(/$ HE#;RCN -*XZ
MKNJFKY9CWOVK?\8\3?YX@OUBV_25[?ZE]^RK\)?-L-V)R9CN>D$8F$NN)D91
MR)@;LVKU!9902E$X[2$.(CH4!'D[U?FK+WM,;9IF(L-L+57.^E H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M.$H8FL9!Z[1$-= <?@KHR<;;BFV7AJ/Z>/1G?.W0QT@ KJ"'DCGD$YO^@/\
MVUT_+"53OA/V-R^S/& /<^Z1N9&J'??=SY=6LC<YU9L3#GLVW%%(MB=0\6R,
M<YVC<QC&% NHB(D$1$?PC6@J[I9F]KJ^>KWSOEM)L(]IDW%YV;)LU.>5DBG,
MW021$P!%JB "*92ZARURYC!KLCF[<A5,U3ME?\S7%=T5+V9"6K.&@?/CA^F]
M=D:-WIQ*U;<8@ 1R42ARAWM*EY&YHO/F^:-NS8IYB]_CH^93_+,K_P S7/ZB
MBO\ [*I?ZMS^S_F4S_T*O@N^$KCNF=0NYE=4N,VZ@IU2,:OC-D&9C($;(*!J
MFW*4OOE#?AJ5GKJB[JI^6-FV-O\ S*K<WGSTQ*LN<I94?7!<K* ;VXE%P<LO
M$H^< ?BY."!2&WFX)MO*!^]I77=Y&ZFBF9FK;,;?1SWV;BZJV3",N3+F9[:M
M^3N)RWM5=M%H"Y511+)<0Q0,4NA=QP#7PN^->M.G7,S$;:O?8\[O/4U5;-DN
M_N)9A'17GB8=H1[ B9%7#IRH5%!,#Z!X1U! H!J.G*-08IF9V1&V5) ?Q3QC
M_G6!_6C/]+7K_K7O[*OPE\VPD8:]+.N-R=E;UPQDL\3(*IV[!ZW=*E3 0*)Q
M*D<P@4!, :_VU^*[FNB-M5,Q;!M3E>3Z4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'&,
M0=JV<>L$7Z$:4%.A?6+(/6I[XE&M9<X='C#/Y_$X(W*?9E=O1QO&IU[W??%K
MGR^)#J>>.PV>^K,>=-ZSF2^XIX\I:6O<KJ_RI_QUH(9*&*R.W./ZGO?2J%<&
M?P?JCE*WI_;+)D/MM;]4A])5\T_!GRZ&H=L6_F]L_IC?YPGQ@KOJW(BP^SAV
M0P_UJ6]*.J@:ACSPY0UEWVPY9B_L[M[YEQSM:M%7W2S>8Q*O;T2D_P#2K0ZW
M0/CSUX7O95XU/?)8B]9\^@6-UOC/%.:D:;WU>,]%?-855BNCW1JXS*3PWVB9
M(^9M[FB]2=2[:/JZ-!D</V^*OONUC)7ST%Z-KLRF#1QYN/4.Z./1CN'U:G>C
M'W-E*ZXWPGW?=%L+B_\ Z7UNH@^B*S\?=_7_ )-5Z*E#?84-T<QYJG5]E;SN
MFU^Q?:]COX$YS,M<N;P*N'-1T_NGAU3>8.U#'?U"Y.;M:Y-.[*[:>KLSV&T2
M>^+^,*JL\L'L_P#V)=_6R6_NJAZEB1XPT^6PZ;'/K3]]=W7"X>=!5FCMI\:>
M2/G<1IY-]0Y;X;+GJ->M.]XY;%CV]'3_ &DNREYTE#>DVU9_3L>+)Y2T5[VR
M@G?TM?YP_P 8:NQN91YQOVU2755OS\]<&H84>71<T_LFW\FK>';K-]5(WTBX
MK]9' CRGE#\:ANAL)^^_(/N#7<C+#A7L"@^C'7C%JS^<^YFV&NIW.98R[-K2
MZ,2^,:M'>=\VLO?XE5K?EO6O''6='FCBN>^PJ_%UY#$FSJN6>/M?&?63_@7-
M2]-WU^/6%/.84HBK+-I3!_K9DWI./]'IU(U/]%D\VCR6%'MZJFT[0<H=.,_1
MJ-4<OA46=4[4.^+&M?WJ%=71+SQ1JZ:.Z+7'<XE-L+_DS^FZ7ZM)\W)6>R_W
M4>34^BNH?16OU='Q1:O,C.]AMSMOM'H.9\:WKCSN!-L*^G?JX)#*7;-:_5V6
M\>WKQT["JMA[:AA\7EO\NE\,ONU1E!E.^SEZ@ONGYKGRE0]2QN$<FKN>R+(<
MTQQZIATG+^D%ZO3Z61R9_-XL\.1D/U>9].0G/TJ?&R>3[D\6.+I?M$>I\)UE
MA>=!4+3<7A*[?X<V3R0"ORI_A#[M7(99EQ1VPWGT'!_&<U,U'#IMGHO:?A\4
M;.]M-[]&0?N.*Z,G@4VR\-1_3QZ,C[[.?_5'7B#UUI5.^+5EL7^F>,ZI&YD:
MH-]]U/EU:R-RBV7ZE6UT4R\06M!5W2RU[WU6RS*=I>+>EI/T4K7+F,&NR.;N
MT_OE:LV>N>-/K<MS :X=,W5V0[\[A3[>J+JLSJ9P)]+R5UK7YDUJ+J7=1X]9
M:7*8<*7"^L60>M3WQ*-5KG#H\82L_B<$;E/LRNWHXWC4Z][OOBUSY?$AU//(
M ;!D\!@ 0%LQU 0U#Z6WK.9'[BGCREI:MRFK0%N@J8 @XP  ?_R#7]'5^+99
M;^2OXR]X^81['.3(&#)NS*I:+TRA6J*:!3&\Z-PU$$RE 1T"N'/X/U1RE9R%
M4S$[99<L(O9?+#.$--S$;%IVV+X&\1(+1X&< ^,GO-PAT-X(Z<H5^,A33-U,
MS$3/S>L;?1Z9R^JNXB80C>RR*KI)&NN[=#G*4?\ S Z[@CI^"NZ::=G;3_\
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MVPWGT'!_&<U,U'#IMGHO:?A\4;.]M-[]&0?N.*Z,G@4VR\-1_3QZ,C[[.?\
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M3(114 %, V&\+WP#07.@Y3[2ET3MEX2NJY;9D#14VR(S\FD2 0QD06?-T5#
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M74KC-FX!!P5>X!.+578H"B0,EP,;AFUW% 3%U'33E"IFF[Z_'K"IFYF+N9A
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M3441\(XB &,Y6'D'7PO[ T"#QU:\+91;NM.W4#-H.(N)VT8('4,L8B2:*(
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M$F[:8 ,B02B(:A^'E&I&F]]7C/17S6%58_1[HU;9E$V]CNU,IS>4;-O1F9]
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M.?\ U1UX@]=:53OBUIIXML;(?LSVB%V1GEA;>A//46!%E4.&](T.?<(I'+N
M3#J8IN0?P5 O_NI\^K61N:UE^I5M=%,O$%K15SMJFUEKWOJMEIW/;\1=MU6%
M:MP-_*X*;>2[&2:B8Z?$05BE=P;B"4Q1Y $!*("%<N8P:[(YN[3^^5AOVTH&
MQ'N(;0MAMY' Q"LJW9-Q.=42D!B8PB)SB8QA$1$PB(]T:X-,W5\'?G<*?;U9
MZK,Z\XGM"W;L;9BAYUD#EE/SJ\5*E YTS+,P9([4]Q# )=O&4$!+H/A5%U+N
MH\>LM+E,*%.QW;$+987=:ENH"U@X>XG31@W,<ZIB))H(  "=01,;\8C5:ZPJ
M/%*S^)P;&4#F3QK=:A!T.6/$Q1_M!5,0KWN^^+7/<8D+%D3%]D8]P_D&5M&,
M"/?78HRDYM0%55>*Y%VD;4 5.8"%W*'-M+H&IAK.9'[BGCREI:]S=7^5/^.M
M!#)0CK4BH^0SY;[QX@"KJ)M:0=QR@B(<)=1\5J8X  @ ZI+*$Y?][\-<&?P?
MJCE*UI^Z4/)8\M*PLY2Z]K,19*7-"KS<QJJJL"KYS(AQ%"@H8VP#"&NTNA?P
M!7S3\&?+H^ZAVQ:M;/Z8W^<)\8*[ZMR(TL XQLF5AK2RL]C 4OJ&),QD?)\5
M4-C923?%$!3 _#$0*JJ4#"770X_V:0=1QYX<H:R[[85K&'9W;WS+CG:U:*ON
MEF\QB3[>CSD.!BKH8VU;DZW!W"RMT1#.0:B8Q 5;K'4(<@F((& ! =.0=:\;
MSLK\9>V2Q>'Y+7G^PK6/=F/\E"R$+Q;S<? D?@HH #'G%PXX1D]=@Z*:F VW
M7E'EJ/IO?5XST6,UA56/8]T:MLRA(+&5EY9N3(=KWY'><X5!6V9!% %54!*X
M19N"@8#(F(;E*8Q!#7N&&I6I=M'U=&@R.'[?%O/0 ,KY**'( *P0 '_^MKKR
MF#1QYN/4.Z/;X,=P^K<[T8^YLI77&^+4ZCNBV'F7Q38COV3&<,M&"+"(@1NR
M/*"RH&3F19JO1<;MVHZJK*")!\'0PAIIIIGZ?N_K_P FK]&:&^PH?HYCS5.K
M_K-LLK>=TVM;S:RF<EV3#2:(.(R1:W"S>MS"(%4078 10@B40$ ,41#D&N7-
MX%7#FHZ?W3PZOVX[#MG&=R8MLFSFAF5O1S&Z3-FYU5%S@9P1NLH(J*F,81,<
MXCRC^+DKDT[LKMIZNO/8:6)[XOXPJJS[Q@BP[5>I9,FG; %I"Y9J1A9E0ZBF
MU:/0#0J.T# !0_/J:B70PZ]WD#2)J6)'C#3Y;#IL4_&<%&VO!S5M0R9D8B'N
M6:CV"1SBH8C=JL1),HG-RF$"E -1Y1JQ1VT^-/)'SN(SY,'2Q)80[H'9<]1K
MUHWO'+8D>WHL&:\9V;9MJ7K>EO,!:7#>4I GGW'%54*L9"40$NTAS"4FIC"8
MVP U&L_IV/%D\I:*][92+OZ6O\X?XPU=C<RB M2S;=N7/S*9FF@N9"V8!*0A
MC\0Y"HN5'2R G$I1 #Z$.;0#:@'=TUTK@U'!CRZ+FG]DVO,K;4+;N>;P5AFW
MDQYN#8RTGX9C@H]6>J)'4 #".W<5(NH!R:ZCWZ_61P(\IY0_&H;H3J?OOR#[
M@UW(S3QAC2SKBQUCW(LJP%:[;1C9#S&]!50@)<<ZX#N3*8"'TUU+N =!J!G/
M?F)MAKJ=R QERXVM(?\ Y8E\8U:*\[YM9>^Q*K6GD2U(2^%[*M*Y$#.8*6N%
M)L_;D4,B8Z1FJXB4#D$#%UT[I1UKPOL*OQZPZ\AB38N>:[5@(VYL2R;%F"+V
M-D_,K)0ISZ)Q_D:A^%M$1 =!2)H(\H<OX:EZ;OK\>L*><PI>JL,VB[1Q[:F4
M397LV]&9GT"[EHI55$BJB!]Z#)%0ABG2,4P" E_#4G4_T63S:/)84>WK+6BF
MR#*]LC,&B8)-&<M'MFR1>X1%"*03(4-=1Y"E *H9?!HLZRG9_OBQCO[U"NKH
MEYXHU=5W.RN+7'<XE-L-^Y\6V-:7LKS,'!Q@H1QX\EPG(9950YI0Q4E^.)S&
M$==Y2^#[W0---*SF6]V:CRZM3/OAOH?1FWS"/BBU?9&=[5@4DU\TVH@J7<DK
M S1%"CW!*95N A7)G<"JV%?3OU(=]CFT,57_ &G:%CL!CH).%G'@(&557,*S
MEPV$YA.L8YAY   Y>X%>.G855L=7MJ&'Q6EO\NE\,ONU0E!EI>S5CFSVJ=PY
M)1CQ^^,Q(2T0_?F54,!F2+\P@F5,3;"@(D*)A NHZ=VH>I8W"GDU5SV18JV+
M&+)A9#9BU;ID:M7TH@@02%.)4DGZQ2EW& 1'0 TY1J]/I9')!S>+/#DV,A%3
M"WV8E23*;SY"<I2%*/T]+O@ 5\CULGD^Y/%CBGLZXRLF'=FR4QBREO"Y)RWF
M,N^.HHH55!NY3*4O".84PU!-,#:%Y=H?VZP]-Q?IE=O\.;)9U6$:"AP\WL_?
M#_\ VJ'X?@5;AE_FGXRKMI8PL:]<Y/I6X8DB[VT&4'+P(HG.V31> =8P'%-$
M2%/H9,AM#@(:A4[4<.BVKHNY"9FAM7+;T [S;?BKZ*:/%%6$(N<SI CC\Z*2
MJ0F+Q -M$2)D*.GX*Z,E,Q<4VR\=0JF/EV3LWOQ[:=I@P?&+;T8!BM7!BF!D
MW 0,5$X@(#L[H#77\T_%,IO:]L>^?Q;[+&=EWQ@.P[CN:.\LF+,M\TI;SD%E
MD1;NO(P/O_-'+N\-),_A?[10K/W_ +\U/EU:B-RB6KC&S'L3$72X0?#<<G&-
M5'\F21=D<*BJB0Q@,<J@&VB(!X.NG(%:*J??/NC\(0+S-WL53$3[MK7<89QT
M>X+/L@L:X):UU2#]"<C2OG145P0CSKIF$"J  '*H0A@-W>0*Y<U[[FOW1NCT
MCXNO)W]=Y5,52^B)K!&+KACK,BI:$X[#'XI#:R/E#@ODP($3(4IA*H J%_,I
MB(*".HE#^W7+*SH] H.09EL*$O\ G[3CKCQNG?$.@A,JJRBK[R,(M8J"*B*?
M# Y!4\L43*EJ'O-NX>36@^=?X4(#RA['9=.M[0/[R@^JL+0Y(''D9%DLLN/@
M1.Y$;4*]3D_)147.?47"8F*85->+IKX.[3O4%_H% H%!'3\]$VO"O[BG7'DD
M-&('=/G(D.IPT4@W&-M3*8PZ!WBE$:#B7L[W1 WK>V9+IMAX$A R,]'&9O 3
M41 X)P[9,_@+%(<-#%$/"*%!"POK%D'K4]\2C6LN<.CQAG\_B<$;E/LRNWHX
MWC4Z][OOBUSY?$AU//'8;/?5F/.F]9S)?<4\>4M+7N5U?Y4_XZT$,E#%9';G
M']3WOI5"N#/X/U1RE;T_MEDR'VVM^J0^DJ^:?@SY=#4.V+?S>V?TQO\ .$^,
M%=]6Y$6'V<.R&'^M2WI1U4#4,>>'*&LN^V'+,7]G=O?,N.=K5HJ^Z6;S&)5[
M>B4G_I5H=;H'QYZ\+WLJ\:GODL1>L^?0+&ZWQGBG-2--[ZO&>BOFL*JQ71[H
MU<9E)X;[1,D?,V]S1>I.I=M'U=&@R.'[?%7WW:QDKYZ"]&UV93!HX\W'J'='
M'HQW#ZM3O1C[FRE=<;X3[ONBV%Q?_P!+ZW40?1%9^/N_K_R:KT5*&^PH;HYC
MS5.K[*WG=-K]B^U['?P)SF9:Y<W@5<.:CI_=/#JF\P=J&._J%R<W:UR:=V5V
MT]79GL-HD]\7\8559Y8/9_\ L2[^MDM_=5#U+$CQAI\MATV.?6G[Z[NN%P\Z
M"K-';3XT\D?.XC3R;ZARWPV7/4:]:=[QRV+'MZ.G^TEV4O.DH;TFVK/Z=CQ9
M/*6BO>V4$[^EK_.'^,-78W,H\XW[:I+JJWY^>N#4,*/+HN:?V3;^35O#MUF^
MJD;Z1<5^LC@1Y3RA^-0W0V$_??D'W!KN1EAPKV!0?1CKQBU9_.?<S;#74[G,
ML9=FUI=&)?&-6CO.^;67O\2JUORWK7CCK.CS1Q7/?85?BZ\AB39U7+/'VOC/
MK)_P+FI>F[Z_'K"GG,*415EFTI@_ULR;TG'^CTZD:G^BR>;1Y+"CV]53:=H.
M4.G&?HU&J.7PJ+.J=J'?%C6O[U"NKHEYXHU=-'=%KCN<2FV%_P F?TW2_5I/
MFY*SV7^ZCR:GT5U#Z*U^KH^*+5YD9WL-N=M]H]!S/C6]<>=P)MA7T[]7!(92
M[9K7ZNRWCV]>.G855L/;4,/B\M_ETOAE]VJ,H,IWV<O4%]T_-<^4J'J6-PCD
MU=SV19#FF./5,.DY?T@O5Z?2R.3/YO%GAR,A^KS/IR$Y^E3XV3R?<GBQQ=+]
MHCU/A.LL+SH*A:;B\)7;_#FR>2 5^5/\(?=JY#+,N*.V&\^@X/XSFIFHX=-L
M]%[3\/BC9WMIO?HR#]QQ71D\"FV7AJ/Z>/1D??9S_P"J.O$'KK2J=\6K+8O]
M,\9U2-S(U0;[[J?+JUD;E%LOU*MKHIEX@M:"KNEEKWOJMEF4[2\6]+2?HI6N
M7,8-=D<W=I_?*U9L]<\:?6Y;F UPZ9NKLAWYW"GV]4759G4S@3Z7DKK6OS)K
M474NZCQZRTN4PX4N%]8L@]:GOB4:K7.'1XPE9_$X(W*?9E=O1QO&IU[W??%K
MGR^)#J>>.PV>^K,>=-ZSF2^XIX\I:6O<KJ_RI_QUH(9*&*R.W./ZGO?2J%<&
M?P?JCE*WI_;+)D/MM;]4A])5\T_!GRZ&H=L6_F]L_IC?YPGQ@KOJW(BP^SAV
M0P_UJ6]*.J@:ACSPY0UEWVPY9B_L[M[YEQSM:M%7W2S>8Q*O;T2%Q_3K)ZX0
M?C3UXWG95XU/;)8O#\E^SY] L;K?&>*<U'TWOJ\9Z+&:PJK%='NC5QF4GAOM
M$R1\S;W-%ZDZEVT?5T:#(X?M\5??=K&2OGH+T;79E,&CCS<>H=T<>C'</JU.
M]&/N;*5UQOA/N^Z+87%__2^MU$'T16?C[OZ_\FJ]%2AOL*&Z.8\U3J^RMYW3
M:_8OM>QW\"<YF6N7-X%7#FHZ?W3PZIO,':ACOZA<G-VM<FG=E=M/5V9[#:)/
M?%_&%56>6#V?_L2[^MDM_=5#U+$CQAI\MATV.?6G[Z[NN%P\Z"K-';3XT\D?
M.XC3R;ZARWPV7/4:]:=[QRV+'MZ.G^TEV4O.DH;TFVK/Z=CQ9/*6BO>V4$[^
MEK_.'^,-78W,H\XW[:I+JJWY^>N#4,*/+HN:?V3;^35O#MUF^JD;Z1<5^LC@
M1Y3RA^-0W0V$_??D'W!KN1EAPKV!0?1CKQBU9_.?<S;#74[G,L9=FUI=&)?&
M-6CO.^;67O\ $JM;\MZUXXZSH\T<5SWV%7XNO(8DV=5RSQ]KXSZR?\"YJ7IN
M^OQZPIYS"E$599M*8/\ 6S)O2<?Z/3J1J?Z+)YM'DL*/;U5-IV@Y0Z<9^C4:
MHY?"HLZIVH=\6-:_O4*ZNB7GBC5TT=T6N.YQ*;87_)G]-TOU:3YN2L]E_NH\
MFI]%=0^BM?JZ/BBU>9&=[#;G;?:/0<SXUO7'G<";85]._5P2&4NV:U^KLMX]
MO7CIV%5;#VU##XO+?Y=+X9?=JC*#*=]G+U!?=/S7/E*AZEC<(Y-7<]D60YIC
MCU3#I.7](+U>GTLCDS^;Q9X<C(?J\SZ<A.?I4^-D\GW)XL<72_:(]3X3K+"\
MZ"H6FXO"5V_PYLGD@%?E3_"'W:N0RS+BCMAO/H.#^,YJ9J.'3;/1>T_#XHV=
M[:;WZ,@_<<5T9/ IMEX:C^GCT9'WV<_^J.O$'KK2J=\6K+8O],\9U2-S(U0;
M[[J?+JUD;E%LOU*MKHIEX@M:"KNEEKWOJMEF4[2\6]+2?HI6N7,8-=D<W=I_
M?+Z3K+KI0*#EV<+=CIJ!C7X7DE8=V0KSRZU;A<.4FZ!7P)'(**Q%C%*LBJF)
MBJI]\O+RZ:"'#W'M0WI=K4N+(=.(M7*Y1%"YKP=2#16VHYEH7218*F5'RDRY
M3@*" \I#<A]0*(T'T5B.V;;M&PXV%M6:-<D:F9=9:?4=%?*OGCA8ZKE=18AC
M 8QU3'$>7D[G>H+O0*!0*!0<8Q"(CE;.(C_\?BP_T0C2@IT+ZQ9!ZU/?$HUK
M+G#H\89_/XG!&Y3[,KMZ.-XU.O>[[XM<^7Q(=3SQV&SWU9CSIO6<R7W%/'E+
M2U[E=7^5/^.M!#)0Q61VYQ_4][Z50K@S^#]4<I6]/[99,A]MK?JD/I*OFGX,
M^70U#MBW\WMG],;_ #A/C!7?5N1%A]G#LAA_K4MZ4=5 U#'GARAK+OMARS%_
M9W;WS+CG:U:*ONEF\QB5>WHE)_Z5:'6Z!\>>O"][*O&I[Y+$7K/GT"QNM\9X
MIS4C3>^KQGHKYK"JL5T>Z-7&92>&^T3)'S-O<T7J3J7;1]71H,CA^WQ5]]VL
M9*^>@O1M=F4P:./-QZAW1QZ,=P^K4[T8^YLI77&^$^[[HMA<7_\ 2^MU$'T1
M6?C[OZ_\FJ]%2AOL*&Z.8\U3J^RMYW3:_8OM>QW\"<YF6N7-X%7#FHZ?W3PZ
MIO,':ACOZA<G-VM<FG=E=M/5V9[#:)/?%_&%56>6#V?_ +$N_K9+?W50]2Q(
M\8:?+8=-CGUI^^N[KA</.@JS1VT^-/)'SN(T\F^H<M\-ESU&O6G>\<MBQ[>C
MI_M)=E+SI*&])MJS^G8\63REHKWME!._I:_SA_C#5V-S*/.-^VJ2ZJM^?GK@
MU#"CRZ+FG]DV_DU;P[=9OJI&^D7%?K(X$>4\H?C4-T-A/WWY!]P:[D98<*]@
M4'T8Z\8M6?SGW,VPUU.YS+&79M:71B7QC5H[SOFUE[_$JM;\MZUXXZSH\T<5
MSWV%7XNO(8DV=5RSQ]KXSZR?\"YJ7IN^OQZPIYS"E$599M*8/];,F])Q_H].
MI&I_HLGFT>2PH]O54VG:#E#IQGZ-1JCE\*BSJG:AWQ8UK^]0KJZ)>>*-731W
M1:X[G$IMA?\ )G]-TOU:3YN2L]E_NH\FI]%=0^BM?JZ/BBU>9&=[#;G;?:/0
M<SXUO7'G<";85]._5P2&4NV:U^KLMX]O7CIV%5;#VU##XO+?Y=+X9?=JC*#*
M=]G+U!?=/S7/E*AZEC<(Y-7<]D60YICCU3#I.7](+U>GTLCDS^;Q9X<C(?J\
MSZ<A.?I4^-D\GW)XL<72_:(]3X3K+"\Z"H6FXO"5V_PYLGD@%?E3_"'W:N0R
MS+BCMAO/H.#^,YJ9J.'3;/1>T_#XHV=[:;WZ,@_<<5T9/ IMEX:C^GCT9'WV
M<_\ JCKQ!ZZTJG?%JRV+_3/&=4C<R-4&^^ZGRZM9&Y1;+]2K:Z*9>(+6@J[I
M9:][ZK99E.TO%O2TGZ*5KES&#79'-W:?WRM6;/7/&GUN6Y@-<.F;J[(=^=PI
M]O5%U69U,X$^EY*ZUK\R:U%U+NH\>LM+E,.%+A?6+(/6I[XE&JUSAT>,)6?Q
M."-RGV97;T<;QJ=>]WWQ:Y\OB0ZGGCL-GOJS'G3>LYDON*>/*6EKW*ZO\J?\
M=:"&2ABLCMSC^I[WTJA7!G\'ZHY2MZ?VRR9#[;6_5(?25?-/P9\NAJ';%OYO
M;/Z8W^<)\8*[ZMR(L/LX=D,/]:EO2CJH&H8\\.4-9=]L.68O[.[>^9<<[6K1
M5]TLWF,2KV]$A<?TZR>N$'XT]>-YV5>-3VR6+P_)?L^?0+&ZWQGBG-1]-[ZO
M&>BQFL*JQ71[HU<9E)X;[1,D?,V]S1>I.I=M'U=&@R.'[?%7WW:QDKYZ"]&U
MV93!HX\W'J'=''HQW#ZM3O1C[FRE=<;X3[ONBV%Q?_TOK=1!]$5GX^[^O_)J
MO14H;["ANCF/-4ZOLK>=TVOV+[7L=_ G.9EKES>!5PYJ.G]T\.J;S!VH8[^H
M7)S=K7)IW97;3U=F>PVB3WQ?QA55GE@]G_[$N_K9+?W50]2Q(\8:?+8=-CGU
MI^^N[KA</.@JS1VT^-/)'SN(T\F^H<M\-ESU&O6G>\<MBQ[>CI_M)=E+SI*&
M])MJS^G8\63REHKWME!._I:_SA_C#5V-S*/.-^VJ2ZJM^?GK@U#"CRZ+FG]D
MV_DU;P[=9OJI&^D7%?K(X$>4\H?C4-T-A/WWY!]P:[D98<*]@4'T8Z\8M6?S
MGW,VPUU.YS+&79M:71B7QC5H[SOFUE[_ !*K6_+>M>..LZ/-'%<]]A5^+KR&
M)-G5<L\?:^,^LG_ N:EZ;OK\>L*><PI1%66;2F#_ %LR;TG'^CTZD:G^BR>;
M1Y+"CV]53:=H.4.G&?HU&J.7PJ+.J=J'?%C6O[U"NKHEYXHU=-'=%KCN<2FV
M%_R9_3=+]6D^;DK/9?[J/)J?174/HK7ZNCXHM7F1G>PVYVWVCT',^-;UQYW
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MS*8-''FX]0[HX]&.X?5J=Z,?<V4KKC?"?=]T6PN+_P#I?6ZB#Z(K/Q]W]?\
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M,IVEXMZ6D_12M<N8P:[(YN[3^^7TG6772@4"@4"@4"@4"@4'&,0<F5LXZ_\
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MBN>^PJ_%UY#$FSJN6>/M?&?63_@7-2]-WU^/6%/.84HBK+-I3!_K9DWI./\
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M;JAUY(]NIHIM$I!J=8RG (&P" H)A-KR::5!R]4?[,3M]WS-+Z(1&\[-!LV
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MAJ8>2I6GU1375MG9_;/16S,3-W,1\$(-Z69J/_F6)_6#7])5C^:C]T?BSO\
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M$[?[HW3Z_P!#*7=47L3,3^#H.>K_ +#E+5AF\;=,.[7)<4.J=)"0:J&!--R
MG,(%4$0*4.4P]X*BZ=5$7OOG9[I6[Z-M$V2AU;TLP5#B%RQ.FX?^8-?P_.58
MB^H_=#,_Q5_MG\'K&5\62QRO=SY[<T2W9+PT,D@X5?M2)J'3,XWE*85-!$NH
M;@#N:A7!GZZ:KNG9,3[YZ+F1IFFCWQL1\Q>MF+Y?O-\C<D4=DM'0Q$7(/VPI
M'.F"^XI3\301+J&H /)J%>^4O*8N*=LQOEX9^BJKY=D3.]E>7G9IF#XI;DB1
M,9JY*4H/VHB)C(G   .)W1&NG^:C]T?BF4W5>V/=/X)ZS+^L1M[.\=$N+IAT
MI0EK&0.R/(-2KE6\C,78)!4W ;7DVZ:ZU$OIB<U,^GS=6HC<IUH7?:*-GVZB
MM<,6DLG&,R*I'?MBG(<J)0$IBBH @(#W0&KM5]1\T_W1^+-7MW7-=7NG?/HR
MJ7C9X9$QJZ^\45Y*TE))1VOY>VX:1#QBI2F.;B:% 3>"&O='DKGO[RB;JO9,
M;HYNW(T54U3MB8?1D9?MBS3U*,A[GB9"27W<%FT?MEUS["B8VU--0QAT !$=
M [E9I:6&@4"@4"@4"@4'R\KB/.$-9,_@BU0@/X9S3B11CKI<N'!9"/A)IPHN
MY;'9 D)5EB@NL1-0%BE'4!'3O!W%[BK&\LPB8^?M6*G4H-HG'1BDNQ;/U46R
M)2D*0IUTS" :%#72@XQBS$N*I')>9&#^QK?=,8V<CD8YLM%,U$FR:D.U4,1$
MADA A3',8X@4  3"(T'7RX8P^0H$)C^VRE#D H0[$ #_ +F@]?P;Q#_D&W/U
M0Q_0T&$N$,+D,!R8ZM@IP[A@A6 #_IX-!F_@WB'_ "#;GZH8_H:#PIA7#BQ=
MJN/;:4* Z@!H=B8-?RHT'XGA7#B("5''MM)@/*(%AV!0U_(C09/X-XA_R#;G
MZH8_H:#"?"&&%#"=3'5LG./=,:%8"/X.Z*-!E_@UB$.3[@6Y^J&/Z&@_#89P
M^<HD/C^VS%$-!*,.Q$!#_L:#PGA+#*1MZ6.[9(;N;BPS !T_(C09?X-XA_R#
M;GZH8_H:#&KA/#2VG&QY;2FG<WPS VFOXT:#T3"^'DB[$\?6V0@=PI8=B <O
M]@(T'K^#>(?\@VY^J&/Z&@P_P0PN!^)_#JV.)KNW^96&NNNNNO!H,W\&\0_Y
M!MS]4,?T-!X4POAY4NQ7'UMG(/=*:'8B'^M&@_$L*8;1UX./+:3U[NR&8%UT
M_$C09/X-XA_R#;GZH8_H:#$IA'#*IMZN.[9.;N;C0S 1_P!:-!D+AG$!2@4N
M/[;*4 T  AV(  !_[&@#AK$(AH-@6YIT0Q_0T&(F$,,)& Z>.K9(<.X8L,P
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M6M.I)A<X<+R)LX3:G$3^0>^WJDT+IW.7O4$_]]O:4_E/"?O4'[/H 7K[2@B
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M\\OQ0L:3&\9=WW+E;8.V7)+-VQGQ(TDF+L3[3*"LJFKY.5$2>3F#13?J-!]
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MN@CMH/F)O$&F"W9,P, LK?1C'3S=AJ6=*O"2Z*^I@=QQUSGT,!>5@JB()G3
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M/*)W<*]@S""+740%%--("JD,8ARJ'UU,'TFO"P=[Q4$^N6%265:JLYQ@U>D
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M%UPY&KP[F58@EY-%HKK$600%0HK*ZB03*<+ADT'6@Y]%6M?R.97JA'D3_&V
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M4VL;)I&4!0Q'>U(5A*;WAP36)O)X(\@CJ%Z(0B9"IIE B9  I"%#0H%#D
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M9.>R6/[9E&SF\K0$9O'2\X5<ZJT*+T'*]MW"S7$%SI,WI=HD7$3@F=)5/N&
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M.(%*4 #41$= H/G_ #/D%ZK<@XLN&RC77BJ];>7=)2,(X(K*J%0, .A:MCZ
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MYC'33\ P$(<FE!])78\G;;M]U(65;:5P2Q%07-"IN4HTRY5%-RYR*J$$@JB
MB8 /M YNZ8.[0?(S8T+=&9+AC[3N9];$AD9NH=Y95S)J';DEV[?;(14Q#+'
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M'0JFNT/IF@4"@P/63*2:+Q\BW2>,'1#(N6K@A5454SAH8AR' 2F*(<@@(4'
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M^\G7 Q&[ X /%6/R%3  , F*<P&*'= *"!8^TQ@62&2!E?L4IYI2,N^$5#$
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MN%333 I2A_84*#<H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
7H% H% H% H% H% H% H% H% H%!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>bc_fig49killing-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_fig49killing-4c.jpg
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M)CM$HB7'QZA&1N8D7-Q:S)2G.H@%M@
M                                          %5/^X/T H\NP.UO@,9
MQF$<6U]&:S(^JX%UTLYAJV((E,YRS'U.:VL!;X!1+0J')K&@W$O-IQ&J)5:C
M<B:<2,<BS* M9D@RVGB3B" 3YP>26)7#=8:XZR6E$64RO#J.-3I"%$?K&0#0
M:Y_;N/\ MDHI9CIEF.JG&7M26J82<</WR.7U0$XWU5M8*?4X[6G=M46M4E3!
M*E2:M5'J>\B1G41H2VW&>(TY22>;-RF98;-H1K?.K'$-IW:55O:XK MHZ)16
M>Z9I1:](<?-O.E',2J"DC/G>J L,VO>-H7AAF22L/7+$!]
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M; 3!'^0:]PGK .P
M                                 53XG=$K0I.DE_WM'GUY=62PY/*.
M_6Z@]!WSTE"C(XJWE,FV1JV-FC*74 6HC_(->X3U@'8
M
M *I\3NMMH5;22_[)CP*\BK*8<@%(?HE09@[YF2A)F<I;*62;,T['#7E/J +4
M1_D&O<)ZP#L
M                             $-\5YF7#MJ#@>'_  WKOM@)@C_(->X3
MU@'8
M                      *J<3E.UT;TEO\ D5>OVR]8NX<4J!'ILQNI=PG(
M1NT$^J4ILG2+*1JW>7'J$ M/'^0:]PGK .P
M                                                     0GQ6SH3
MG#UJ"PB2TI\J=ANR<2:L2?;Q+#''$!-$?Y!KW">L [
M
M!5OB?T/TDI&D%_WQ3;0IT:[4QUU!-7;;,I!2WI"%+=)6;LC-1F M!'^0:]PG
MK .P
M                      54XG-3[@J.DM_VN]IK<T& ;#D3[22$0?%I-M2$
M$4@S1*4[NE$G,7Q6.![2(!:>/\@U[A/6 =@
M                                                     AKBP_Z=
M=0?)I=O: 3#'^0:]PGK .P
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M_P @U[A/6 =@
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M3Q-J=P/=O+5V*#Z@\=3;YHHFKW1/=FV]/KT5SW4REX1;>
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M*O =C-3ILAPF8\QAUY6.5MMU"E'AM/ B/$8FF8^@]0\@
M         PUW7-3K,M:M7=5S45+H<*149>3:LVHK:G%)21\JC)."2]4!2BRT
M\8'$S$=U&IEZLZ=61*>=10*?'S(-QIM9H,TDTWG<2E1&@W'G"S*(\J22 VG\
MN?%S^/CO_N@%H]/Z+<5NV71:)=M7.O7)!C)9J58/,1R7B,\7.=MV_I ;(
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MWI$JKH?7%0:#6E%,6:2/$SY,QCEU=54]&OOGP\TEH>I555/?/>M,*LF
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M/TGK';DB#W*['QA:-/;C*&0XA.AN[.]FO"6AIT%^GM]&ZK!IZN7]1=86)47
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M7\Z?_>*ZYB>C!4XP=0R,='Z5-,N_*SYL4.;56:^'FE-OYI[>*QPK"<
M                   $4TS6#1#5VU;UB0J_%K%JT:))C7@2B?CM(I[K+J7E
MFI26U*94VES!UHS+8>!@( ^SO_;C_KJ'_B-5_P!^ ?9W_MQ_UU#_ ,1JO^_
M6NTZ9LN/8]"8T[4TJR&XJ$T-4=;CK1Q2QRY5NFI9ER[5'B V<   $'<5NJ5W
M:0Z7LW59*HJ:TY5H<#&:UOVMU(2Z:N;F3@>*4[0&FE X]S(C*J6#MV]C,_W
M"<=/%W_3[)8>U>E4Q5VL'(=J<FDYT0$L)<4ILR-Q*3+!O#-B7* K?0=6>*'7
M^35;ET08H-K::09;L*D5"X4.+E5$V#+,O FWL,2,C,B;2E..7.I23 2!H#K?
M>=V75<ND.K])C4;56U$)E.=PF91)T!9I(GVTFI>&&\;,S)6"B61D2<#(@L$
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MO>F,=QW/+H7JK9],I=@:/RY#R;VJ]%?K$..EA:F#BID23YSQ%E2HR9<,B/\
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MEQ\25PT"5;EJHIB+?LF!4D;N4\SF(UR#+U"(EXF7-Q=RI4K(9@+9@(:XL/\
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ME=H6#U3C&:1]#^AZQ_(L+M*16M9?KSE;*<&_#D>@
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M_2>L=N2(/<KL?&%HT]N,H9#B$Z&[L[V:\):&G07Z>WT;JL&GJY?U%UA8E1<
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M:ZYP_-G!L<#SU#ZLJ/>4KM"P>J<8S2/H?T/6/Y%A=I2*UK+]><K93@WX<CT
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M!YZA]65'O*5VA8/5.,9I'T/Z'K'\BPNTI%:UE^O.5LIP;\.1Z
M             56XG=>-(*SI)?\ 85,NZ%(N];#E.124;W?'+8D(2MKL,,Q&
MA1<H"TL?Y!KW">L @2^.G*?Z)0_.;PL.@L_NGRA$[CA#Z'>A0!G- _\ ,/TM
MF>"Q1"[ES4_'UE9=):C)L6N/0]?'D:;VI0Y='?HSAU58(Y@?5M/[SB]H0+(J
M56,YO0#RP5P?6UC>EM(]\X-?5MU?&7?H;G!9H5-85=[BZ;;P\C4;W[XLFBL4
MYRA]Q^WB]8[$.Y1V:?7(!L'#U]U[C])ZQVY(@]RNQ\86C3VXRAD.(3H;NSO9
MKPEH:=!?I[?1NJP:>KE_476%B5%P PM2^^^F?I"OP%X:>O:KR]4GM_/.2RXJ
MJ=5TJ/2WJ/[NA^;A9M)9IX^:$W#FCMX/<.I%.V+\Y9_>)ZY#$X$X,[PW=%[/
ME6L^<I @MQO3E'DM?2Y(??$AT35'OZD><XPQMU^,I\I9ZG++7Y?SI_\ >*ZY
MB>C!4XP=0R,='Z5-,N_*SYL4.;56:^'FE-OYI[>*QPK"<5GIOWWU,](D^ LB
MU]"U1EZH'<.>,F;&U&OIOLC]976,!M_#WT-VGWL[X0Z*[K[]2W4X,?Q"?=FV
MO2FC=N4-VVW9^,M.HMSE+7U]FKUS$XJ[@!Y;>Z;+-\C5KMD<<FML59PF-N^[
M@L.*TF%9K>^M+Y]+JQ[]L6SI6Z?C"O:ZYP_-G!L<#SU#ZLJ/>4KM"P>J<8S2
M/H?T/6/Y%A=I2*UK+]><K93@WX<CT                        ACBO;;+
MAWU!42$YO%O+@6/R[8"8X_R#7N$]8! E\=.4_P!$H?G-X6'06?W3Y0B=QPA]
M#O0H SF@?^8?I;,\%BB%W+FI^/K*RZ2U&38M<>AZ^/(TWM2ARZ._1G#JJP1S
M ^K:?WG%[0@614JL9S>@'E@K@^MK&]+:1[YP:^K;J^,N_0W."S0J:PJ[W%TV
MWAY&HWOWQ9-%8ISE#[C]O%ZQV(=RCLT^N0#8.'K[KW'Z3UCMR1![E=CXPM&G
MMQE#(<0G0W=G>S7A+0TZ"_3V^C=5@T]7+^HNL+$J+@!A:E]]],_2%?@+PT]>
MU7EZI/;^><EEQ54ZKI4>EO4?W=#\W"S:2S3Q\T)N'-';P>X=2*=L7YRS^\3U
MR&)P)P9WANZ+V?*M9\Y2!!;C>G*/):^ER0^^)#HFJ/?U(\YQAC;K\93Y2SU.
M66OR_G3_ .\5US$]&"IQ@ZAD8Z/TJ:9=^5GS8H<VJLU\/-*;?S3V\5CA6$XK
M/3?OOJ9Z1)\!9%KZ%JC+U0.X<\9,V-J-?3?9'ZRNL8#;^'OH;M/O9WPAT5W7
MWZENIP8_B$^[-M>E-&[<H;MMNS\9:=1;G*6OK[-7KF)Q5W #RV]TV6;Y&K7;
M(XY-;8JSA,;=]W!8<5I,*S6]]:7SZ75CW[8MG2MT_&%>UUSA^;.#8X'GJ'U9
M4>\I7:%@]4XQFD?0_H>L?R+"[2D5K67Z\Y6RG!OPY'H
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M\BA3F::3C4E"36<M;9-$T9IV.9L#+# !:B/\@U[A/6 =@
M                                     "LW'!T6T;R\QX'+$WL]V?CZ
MPQ*@HMK  LSP/]*58\@R/"X@A-XLQ\O2687Z%29                  !#?
M%>9EPZZ@X?PW_P ]H!,$?Y!KW">L [
M                       %9N.#HMHWEYCP.6)O9[L_'UAB5!1;6 !9G@?Z
M4JQY!D>%Q!";Q9CY>DLPOT*DR                  "JG$Y1M;VM)=0)M6N
MN@R+)W#BU4IFD/M3CA'(1NVBDG*6DG"+*1KW6!GU"Z@6GC_(->X3U@'8
M                                                 K-QP=%M&\O,
M>!RQ-[/=GX^L,2H*+:P +,\#_2E6/(,CPN((3>+,?+TEF%^A4F0
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M\FBV-1X3\J[[<@R5L14-FY%E5%MMYI1IP,T.(,TJ+JD E7\M>@7X<T'Z$U[
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M?4+U@$8\.&A&C5S:'617:_8U'J-9G4Y+LR=(B(<>=<WBRS+498F>P!*/Y:]
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MHG<KLMA*D-.&2U*Q2E1F9;%=4!O                        !F1<IX?\
MU      '!*2HU$DR,TG@HB/' \"/ _U& Y   !PI24X&HR(C,B+$\-I["(!R
M     X2I*L<ID>!F1X'C@9<I .0   <&I*322C(C4>"2,^4\#/ OU$ Y
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MQ)69J=:UKTVMW)34:I3X1'4J*VX33BY+1J2HT),B3G6E.]-I!F:<>3 @$\@
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MJ;0FSI]J.T]<-ZX]Z9FNKI<DH0HB)+9&33)88&I1$24J 6Y
M         '6^^S%9<DR7$LQV4J<>><42$(0@L5*4H\"(B(L3,P$ 3N*ZDS'9
MK^G5A75?]NTU:VYMR4.!FIJE-*-*TQG'%)-\TX'CD3AU2,R/$!$,O3BU==YO
MVYT!K;5/M6N5JG*UET]JA'#8<*!**6;S\8B4;;IFVK.E',=/$TKQ)>8-VXA-
M9-&=1=*:GIW9\^'?5WW-A3+7M^CX29*:DE>#3^"2P:0R:=YG4:2-);,4F LA
M9M.JE'M"WZ37)'=E;@4V'%J4O$U;Z4PPA#KF)[3S+(SQ 1UJOK;-LVXZ9IU8
M%LO7QJE5V#G,T)E]$./$IZ%9#E3)+A&EM!J(TH(^4^4TXIS!']+O/3[5&X:Q
MI+KSIPW8^IMSPVXKS$W<OMU>+&4I3!PZFTE.=;2L5-D1XI47-4HTG@'ELR\[
MEX:KE@Z/ZPSEU32RJ+[ET^U"E=BPGVE-J2N1)I+8VX>PB_\ \_D@WBR]!ZAI
MCJQ*NG36M-4O2NXD.R+EL=QM3C*:CEP:?I^4R2R2C,C67(22RD1I-&Z"<@%7
M^(B/1JCKAH_2=3DD[I#,<GI*-(Q\6NW&2"*(F:78J29*)+25[#,U$?,S@,_J
MMPZ17GVM1]#VX]EZO4,C>@/4]M$6#4T)(C5#F,H)+:DN$67.9>ZQ3R!BUT*V
M^,/2"DW2XVY:NIE#>=:AU2/F;G4.X(*R)UK,1DLVC6E"\AJQRFD^:X1&03K8
MT*[:=:-'@7W48]7N^/'2W5ZE":-B.^^6.*TH/#J88G@G$\3)*2/*0>B[3K96
MK7#MG#[2%3Y?B?,1&7=VX7N,25L^4R\H"M/#)IGHGJ+H1'15;?AUZOU!R0U?
M4JJ-$[6"K9.*-\G7U_'M++,2F\JDF23)79&HS#UV&NX- -2:?H1=DQVX=(+T
M1(1IY5J@9//PGVDYG*3*-18*0:#P;V8'BDDESE)0&[Z9Z&U72/46LR[)KB8V
MCE<:7,=LI]"W3B5=2B+/#6>QMDT\I8X\B<#(DFD)L 59U4?MMWBJLNGZP[K^
M7AT!YRR6ZCE\4+N<Y1)=-_>?%FZ3.4FR<V$9HPYQD U75RA(9UZMN1PPNP(.
MJD&E5*IW=#II(*F28,1+2HL:H-L8-YY*S4RG,9*+%"C-."%$$A5BU[<XL-,+
M=U,M=UVT]3*:2WK?K:#4B92ZK$<4AZ'(4DB4MDG4J(\4XX<]);32H)ZMIBO1
M;?I<:Z9;$^Y&HK2*K-B-FQ'>E)01.K;;,SRI-6.!?^!<@"+]7=7ZG1*M$TKT
MMC,US66NMFN)$<47<=)AG@2JA4%%CE;01XH1V2SPP(\2)0>6^](;@N73ZU:2
MY=Y2-:;/<;K%LW=*;;8.14XF!NDZPT6V,ZE1-.I(E<W*:L^&"@C3A\U>L;3.
MAW/;&LKT>PM64UBHUN[&:HDX_C%RH2%OMR8KG.)Y&0R;0EM2CP3B6)*(S#;>
M%*FFZK4B^J)3':'IQ>=P'4K-I;[9Q\\9#6[>FH9,BW;<E6!H3@7-3R9<H"Q@
M#X>9:D,N1WT)=8=2;;K:R)25(46!I,CV&1ER@*1:V:,4;1ND6]3XEY7'3]";
MANF+#NNV2D&NET^F3=XX^G>-I)Y#+BT)1M49%F,SS+,L0S_$%#TIN:E6-IAH
MXQ29.IRJM3Y5HN6V3"U4>%&=2Z_-==BXDVPEM./.5SCP41'EQ(+@@(,O#6>_
MJA?%6T\T1M&-=%7MAMIRZ:Q59?<-,B/R$;QJ&VHBQ=?4G:>!Y4<A]7*&&U,M
M:MZL4*V;BMZ?3+8XD[%-55IU'CU%B?N7EI),JGR%(RYFGDD25&I.4CYIGD-1
MF'-N<6^F,FW:A!U>/[#WO2&5L7-:568<-2UI29+[E2:5=T-NECD26*L#VD98
M*4'JX.Z)6J-I/*>G07Z3;M7KM2JUFT:61E(AT&8M*XS:TF9X9E;QPO5)6;VP
M"5-3]0J-I58=;OZOI6Y3J,P3IL-?*//.+2TRRDSV$;CBTHQ/86.)[ $ U/4C
MB<L:'0]2-2*7;[VG]:G0X-:LZ A[QK2HM5>0PRK>KQ2\ZDUI2X@L2-1X$1$>
M9 2?J#9&A=O:0KHMXP(U,TDMM]F>[!C&^B,AUJ3G)*T13-;N=Y?/09*S*5M+
M': A74*NZ;:S7QI=:^@C4:HW5;-9A5J9<E%CG'AT6WXIF;[3KR4(3\:>4D,=
M518'AF(E!<8!X*U7*-;=+DUNX*A'I5'AISRI\UU$>.TDS))&MQPR26)F1%B?
M+L 5IC5CB,UU.J7QI9>%-L:P(4V5"M"*]!:J+E;33WE,+E2G7$N;IIQQ"THW
M:3,B+L3P):@PK<F!Q*QG=/M0F5:=<4NGZ^Z:;/BXMO-O-8+1+A+)6+L5SFJ6
MVE9X$9+2K#*H!+ND]IZ\Q:](N76>[X$[=PDTN!;MOM*;IRS2LEJG2%.MH4<A
M>&&#:221'^H@F(                   'PZZTPTM]]:6V6TFMQQ9DE*4I+$
MS,SV$1%RF KGQ"-S=:M/GZ=HU==-N4J+*1*NFT*9/:<5683*DJ7!7(BN[QG-
ME,LI&6?'#'' !(>A>I%B:C6)#>L6*BC,T=*:;4+5-"6'Z1(9+*<9QDB3E(LI
MY%92)1%U#)1$$9U^BPK3XR+,GV@VEB3?%"JWV[@L8);<8@H)468\@MF=;Q):
MSX;<OJFK$)ZI5D690:B_6*';E+IE7E8]TSX4*/'DNX\N=QM"5*_68#/ *Q:L
MS)NA.M\/7V3#<GZ;7-3F+7O9]E"G7Z2XV\2HTW*G$S9/!*%D1=0^5:D$82!K
M/8]B:V:429[E1C$Q$B+KEKWA%=3_ &!]ALWFY34A![&^86\P5M3ZBB(R#':5
M'!XB.'*VG-5*4W5$5Z#DJK#Y*;-YZ$^MA,E)HRJ0MPVB>)39EAFYNP!,E-IT
M*D4^)2:8PF-3H++<6'&;V(;9922$(3^A*2(B 5AJ%$1Q$:YZ@6'?%=GT^S=/
M6Z<Q2[0IDM<!<YZ>QOG*A)4V9+<2@S)#9%S4DI/)B></#95B(J];U%X2=4IT
MF[+0I\.)7[+J\Y9*JL:GRC-&!/F1GO(SII2VO##LB,MVK(09:F-\7>ED!5B4
M>C4O4^DM$<>W+RGU!%/EQ6,")OQBPZLE/;LOZI1J,BVK,P$J:%:62=)[)<I%
M7J*:O=59GRJ]<]3;3D:?JE042G3:29$9(224I+86.&; L<"#$\25\7-9=B4V
M-9\E%-N&[:[3;6AUMU!.-4TZHXI*I:DGL/(E!DG'D49& BHG[=X?M0BHUIS]
M0M6=1WZ:3M<MIJ>JI0FT.JS]W3$K3E:>7A@TG,?-/DYR34&-H+4F^+DJ^MW"
MW+\17\A],74S2ZY&U0F9D@C4>9]LC^)D&>?*ZDR2I6;G)5O24&[T6S=9M8-1
M+6O76.@P[&M2Q'E5"BVM$FM527-JZDY$R'Y#!FA+3>&9"2YV.PR,CQ(+) *G
M1;5:XE]4M2:??MQU*%;]A5$J#0;/I$Q< V\J,QU.1DVN*=41[DS+ B(RVD ]
MVE%OMW3(U!X:M:T(OJ%84J%(H-4JJ3<E/4FILJ=C&IXC)9/,D64W$J)7.-..
M4@'O<M'4O1RH5*T^'?22W6;7J;311;GD54VWVI63G.SVW\TAY#:E'NVT+5LV
MX\XTD$IZ+:9_RGL&':LBH*JU9<>D5*N512<A2:E.<-Y]:4D18)S'E27[)%CM
M 8'5/7"19EPPM/[$M:5?FIT^.<]- A/(BLQ8)*R=T3)3A*0RE2MB",MO5-.*
M<0T6[-+;PUGMFD:M0J(O2?B&H:EKI#G=3<HWFV%&28TUQI"26R\1'E):#-!'
MM)234E08?AJJ#6HNHEQWEJU,7^8*W%.4P[0D-JB1Z#3#YAJ@,FM9.)?S8NR,
MRNR(MB5$I86;K-K6Q<2X[EP46!5G(IYHJY\5F4II6..*#=2K*?K .RNUVBVI
M0YUP5Z4W3J%2F%R9LMS'=M,-%B9X)(SV%R$18^H KM16-3^)QM5WHNJIZ:Z,
MOFM%LP;>=;CW!566UFGNV3+(E]SI4:3)#*2/_2Y"4H,56)VI_"K6Z76K@NRH
M:A:$566S3:O)KRR?K-"=D+RMR%2"+%UK$^=CL]J24J-)F%HJM2*1<5+DT>MP
MH]3HT]LVI4*4VA^.\TK;E6A9&E1 ->LG2O3C3@Y*[%MBGT)Z81)E/PV$H><2
M1XDE3AXK-)'M).; @&BW#Q7:%VQ<[EJ5.YB.;%?*'49L:-(D4^')4HTDV_*;
M0IM*B,C)7./+@>;# P$'ZW5N\= JAJ!)MYY4>R]9'H4JC7E'YZ*)6)"FH\\W
ME(,C(G(V\?8<2>Q22).."C(-AU9X;='=/='*A?5D.+MJ\+-A*K=#O9F8XJ=)
MFLISMD\Z:\CIRUF398)PS++(6'-,)WLVFTO4:Q[*O*_K9I\FZY%)@5!WNZ$R
M\[%E2(Z'5[HW4*4WSE&9)+:7K@/9JEJA;FDMKJN:X2?D*>?;@TJE0D;Z=4*A
M(Q)J-';V9G%X'ZQ$9@(2J5^%KBY)X>];[!JNG$J](JI=MR.[&)I2TTY:)9DA
MY#1);D-DV3BFE)5@18*P,TDH)$U9T5M_4]-GT:[[BF,631)&,FWM\31UB831
M(B[V5F2]G1@L\$'F7F,]AEB BJS[4MC3CBA:T]T?6?V)JE E2M1K42ZN938#
MS?,B.F3JG,CSQFE"FS/'(>.&"@%H:-;U MQA<6WJ5#I,9Q6\<9@1VHK:EG[8
MTM)21G^D!\7+<M LZA3KFNBH,TN@TYO?39TE65MM&)$7JF9J,R2E*2,U*,B(
MC,P%2KHXHK=N*[';;U%M.1*X9[RB,0J=<U1I,Z"TF4HS-3CCD@B2XV:L%(<9
MRJ;(DK+G$H!ZK1K54X/ZY%LJZ)*ZQPXW'*4Y:%XE\:JC2)9F[W+,4V67=+,S
M63B2P/:XGVZ4!8ZX-,+#N^Z[:OZL4MN3<]L*4[1*HVM;3B4N)/!*S;4G>((U
M9T)7B1'B9<JL0W(                    !6;BZK$-F1IK:]Z39%*T:N.LO
ML7Y48QN-)4B.RER'$?=;,E(9?<-1NF1E@E&;'F@,51]4=&+#JU1HW"_IRJ^K
MHD-M>.'+5:)BFM-,D9-I?J+B5H+'E239*)2L<3S ,&RW5M1Y4WB$X>Z<]:^M
M%ORW*/J#I[5<&6JHMC*;D>2DS;2;N&!MN\W,98'E6G8$U:,:3UFUI=4U'U(G
MIK>K]U(0FLS6_FM/B)/.W38*3QRL-GAF/VZB(SQP(P&6U5UDI6FJJ;0X5-D7
M1J%7U&W;MGTPT]V2LN.9UQ1XDQ'1@>=Y98%@>P\%8!&%=UIXC=-XOVNU+TPI
MTBP&L%U55LU!4NITV.?9.NH<YKI(Y5&@DI+E-22V@)XH-<M/4RSXE<I+D>N6
MA<,7,WO$$XP_'=(TK;=;<(]I'F0XVLL2,C2HL2 0E)X+]-G)3L.#7KFIM@RG
MNZ9U@0ZLZW0GG,V; VC(UDDSY2)>/J&0"PE,IM/HU.B4BDQFX5+@,MQ841A)
M(:98922$(0DMA)2DB(B 5AH\O7'B&^T5YV3?Z=/+2I51F4FSZ7&@LS79CE/7
MNU2:@X[B:4N++ FDD>4O:GABL-XX=;F8U!@UFZ[IH$*F:S4&6[9M[38S24N/
M.TI9*2:5\N[62R5@1X9BV<U*< B?4/46K6CQ87#&LJCN7%J-5+/IU MJD)2?
M<W=3\M4MR1,=Q+=L,-D3B]I8ELQ26*B"Q>D=BW#8=L.1+NN>9==V524Y5*W4
M93BE1T3)))SM0FC(MS'1EP0@B(N56"<<I!K&KFI]Y4N[*!I-I33H<[4>XH[U
M2<G58UE3:528ZMVN6^EK!:S4OF-H3[8MO4(PCM=0O"]JU5>%[B3AP79ESTYV
MHVA=] 2MEB5W&K>&:4.&9MRHZD[TBP(L$X*(TF1K#!::WU4.'"Z[TI_$FMYN
M=<TR-+IVIK4-V13ZJQ!AMPVF7516UJ;=0ALE9%I[):\>HI8;KHFW(U!UIO37
MJC4F11; K%*B4&CN3&E17ZV]%<2M=2-E6"B0E*"9:4HN<GU#)1$%D %=-9]-
M>(&L7:[J3IW>S,<[5:9>M"R4M*;C3EJ3A/:GK4X2'%.D65DSV%R?%'\88;%H
M%J'IYJB5=NZCT1FW=4G%,0M0:0^V3=48EPDFRVEXU$E:VTY5);69%R95$2DF
MD@A>NZB7%1.*'56W--J0=9U.KT"WZ304K1_PZ&VU$WTN?/<(^:U'WK>!8&:U
M&22]0PM#IC9M4L2T(M"KMQSKJKAK=EU.M5)PUK=E25;QTFDGCNV249[MLNQ(
M!N "MMZV;K?8>LM>U3TAHU-O"GWM A0:U2*G*1!>@R:8@FF76W7%)Q:-.U24
MGB9F>S8DP&!O#2O7&39]<U*U&UHF6S=%(AO5.#2;94<&VX/<S9NDT^E1DN2D
MS3E-3FW;[?D,-TT^L:CZRT/2K7J[XC]*U.@P&)KE1I;APE3&UH,MW()!<]AW
M'>DWU"4:<<JE$83G/J$"E0WJC5)3,&GQDFY(ER7$LLMH+E4M:S)*2_29@*[Z
MIZP7):-7A:CTIZFZ@<-DJ/XINV)1BCSWZ<\XK!4Q3C:G">;-*B0MLSRX;#(C
M,E -)CR)'#3(:U/TP=7=?"M=:TS:M282CD.4%R0>!S(>)X[C'8M!X889%X*)
M*@&U:^WK0]:K:I&AVF4QJX*SJ)W#.F3X?QT>E6\Q):DNSY"N1!F;:4-MKP4:
MCPV*RDH+,18[<.,S$9Q)EAM+39&>)Y4$22Q/UB :MJ?&N6I:;W=!L=[)=S]*
MG,4=;:R0M,U3"B;)*L2RKQ/FJ/D5@8"H5#U:TR:X>HG#[:MIS7M5Z[3CMM^R
M9-.>C.>/I#.1^;*D/MI:P0YC*S[S.DB+8@DXI#;HM6U4TKI5AZ5<0=!MJY-(
MKG;I]D-S*3W4Z]%F$R3,5$Q,H\'<^Z)1K;2G*9&M)EE2DPD2D\(VEU,J,!V7
M.N"M6S274R*19E8JSTZWXCJ-J#;B++:2>HEQ:B/JD8">0$8:IZ75&_;HTXN:
MF5-F"[8]<\:R8\EHWVI$5QO(ZE"2,B)[FI)M9]AF-7*1$8:CJ5HWJ1J?JU2K
MB7=A6A9=HPWBMJ51$I<K3LVJ-;F:I:WT&ADB0DD)-)+YI[,#4K -*LVTT:M5
MR_= ==G2OQ.FTN!-H5VMK<A3#:JS"G6T/*C*1@^TE.4SVYN=CC@1F%@=.=*[
M!TGI#M%L*C-4J)(63LQTE+>DR'2QP4\^ZI;BS+$\N96"<3P(@&X*/*1JP,\"
MQP+:8"FVNNIM#U7TGLK4^FTZ;*TXMB^HQZ@4&2T12VH=/?6RHI3"346!DIM9
MMJ/_ %J,W5P"=M2[UTAK.BU=KUR5:GU+3JI4QY)O(=;<1(WC9FVVP6.._P V
M7=I+GI7AR&0#0N%'3:]Z%I)"HVID^-<-H52'3JE;] J,0UR:<3J"DKCO$_F2
M:6W,BFDX8H,L>;L2061                      &/K5"HMR4Q^BW#3HU5I
M$HLLF!.91)CN$1XD2FW"4D\#V[2 1!>%PZA:4U"#:6CFB[%;M!Z*:H\JF3H5
M'BLU%:L,CC&0LJ$I(E+<5AFQV'L,!F-"M-;@L.DUVN7O,8G:A7K4W*[<JX1&
M4-AUQ)(:BQ\=IMLH+ E*VF9GM,L &Q:K:AEI994V]7*'/K\2G+:.;$I:4K>:
MC*46]D*)1ES&D8J5_P".!8J(*UW!4)VG%Y.<7&F3ZM0]*;PC-(O.+LD5.FPV
MS^6@N+P6VTR98.QU8;LTY5X)(E-!:BWKRM&]+18O&B5*-/M&?&5)*>I228)@
MDGO"=SX9,F"B<2O TF1DK# !"O!G".-IM<4NG(4U9-2NRM3+):4E2230U.I;
M9RDK:236AS O9 3U7Z[2K7H=1N.NR4PZ-28SLV?*7B9-L,(-:U8%B9X$6PBV
MGU %<8_$%KQ5*/\ S,HFCYS-)W"[HBL'/2FY7Z;AB4Q$4B41DHN>EHDFHRY#
M-// 2!P\(TFG6Q5[QTAE/.T6[:J_6*G"?=,SA5)XD[Z/W/R,&D]N0L<2,C)1
MHR ()MO5EZR+]UFMVQ(!7'JI==Z.PK9ME"CR-JC14)?GS%;";C-J,S6HU%F-
M.!8$2E)"SU@6*[0&&+BNXX%7U5FP685RW7$B(B+EDRI2TMD22+!",23L).?*
MDS(L")(:?J)Q!QK4NY6GME6I5-0;ZBL(FU:E44DI;I\5S T*DOK(TH6LE$:$
M8;2,L<,4XAK%C5ZP-<M6*+J-1ZC4[3U*L6'+I%S6/4F4QI[L23M2V^VLSQ::
M=4:R6WCM-.;*> #ZU^FTNE:V:#5FHRV*<BGS+CDRJA)6AEEF S2TN236XLR(
MDY2+J@-QTCU-N35^96[B1;S=.T@/*Q:50G$XBIU5;:C)V4;"^:B,K#XK,1*V
M8^J20EL   $!:S:&5VI7-"UDT5F,T#6.F&AN3OC-%/K4'%*5QIR4\IDDN:OE
M,B))X&2%MA+E!M&B4BI3[H1284.\*^W&.XZC#0>:2]%:)M)9U$2C0C:2,<-G
M+M ;"   "!*EPHVA7[JJ%=NJZ[JN"WZC..K2+,J-56Y0U2LY++.PE*34VC B
M0C-L21)VIV )X999CLMQX[:6F&DDVTTV1)0A"2P)*2+ B(B+ B(!4B\ZG'U"
MXD6-+M?&G*)8,8DR-.[=->-(N2=F-._F24FG.XG$B:BF1%F/*9F9X.AZ=,K6
ML^%Q0WC3=(H:&M,V: =/U"I\9)*H7C]3^5N,TV>+>]2UFWB$%E3STG@9F0#*
MTK2V^=#-0V:=IK2SNC06^)9L5ZT'W$?\!>DD9.R6#?/*<8TXYVSQS%S#(U9#
M 3#IIHYIYI$Q5(]A4=NF%692YDYS$W'%&HS-#1+7BHFFB,R;;QP3B?5,S,-(
MXH[CK](M"VK>HE4=MYB]KFIEKUBY8YY7J=3Z@;F^=;7R(6K(2"69EEQ/:1X&
M C"'!M/134BJV[PU:85.][]IT!EF\Y*ZV]%IT9,G!]!/.3%N-.3'B22\J4IP
M3V/MT@/=4[HN7763;FH^EM/\4:S:/5&9'KVG-QJ)A2FJNP4>0T;O-(C6AHR8
M>,DEV6.!D0#:*59>K^LEZ6W=>M-&AV99MFRTU>B63$F(JDF76FB4EF5,D-?%
MDAG',TA&W$SS; $V7K>ML:>6U.NZ\*@W3*#3D9Y$EW$S,SV)0A)8J6M9\U"$
MD9F?( @_^;W$K<D [LL;2**BT%IW]/A5ZJ(B5R=%PS)<2PGF,&LN1#AF?J8X
MD D+1K6NWM8Z5/<A1)%$NJA/]Q7-:U1++.I\G%195E@G,A1H5D7E+' R,B41
MD0=&INEEZWK7(-<M#4^LV.<>,<.53H33,N"\A2S4IPFG,N5XR/+O#-6!$64B
MVXAG-+-*K:TFM]RBT%4B9-G/KG5NN5%PY%1J,YWLWY#I[5*/J%R%ZYF9AM%<
MKM%MFE2J[<50CTJC0D[R7/F.H88:29DDC4M9D18F9$7JGL 0=<G$E6M.[EG(
MU*T]J=-TT6]A1+]I#B*U <BF7,>E)CEBR2\,R2YRL#PRGAF,-+T^N2RJ-KW5
MH5M5*!7M(==(S]0A;E;<B(U<T)O^W176E&>0Y+*S=6EU)&M1I01; $DTSA'X
M>J1<R;LA65&*I-.$^S'=>DO06WB/$EIBN.J9Y>1.3*74(@$V
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M[8N[2WB2T^J#<9I%:MB:;E/K5%J#>ZDQW6U=@^UB:FG",B<;41XEL4D\2V!
M]&O&H\(=Y4_2?4>HKK&A=RF[]B;DE_&2*425))R%,V<YE&\3SB+ DJ)1$2<R
M$!-'Y:=$57S2M2H%KQH-PTQ\IT=5/4J-#<DESFWEQFS)HUH4>=*B27.VGCL
M2X                           #5-1M.;3U5M.;9EYP2FTB86*5%@E^.^
MDCR/L+P/(ZC'FJ]<C(TF9&%2:72:W:.L=H:9\3MP2:U9-%,G=*:J\DFZ15*@
MVO!E54<,S-4MA"D-M(=,R)7*HR61N!>!:$N)4A:24A1&E25%B1D>PR,C 8]*
M*%:M%5NT1*+;U*84XHD$W$AQ8[1&I1X%E0A"2(S/D(@$!IU:USU84_4= +:H
MT*Q&5FW"NZ]52V454VU&E:X46*6])K$L$N.%@K]!XD097337:Y9-\GI!K7;S
M-I:E.,G*HK\-Q3U(K$=!&I:HCBC4:5))*CW:E*/ CQ,E%E ;QJ?HMI[J]%C-
M7E3#<J%///2ZS$<5%J4->8E8LR&\%%M+'*K%..W#$!X]+-"+"TDD3ZI04S*G
M<]423=1N6MR53ZH\RG+E:-Y1))*"RIYJ$EC@6..!8!UZG:VT;3ZIP+2I=+FW
M?J/5T&]2[0HQ)7*4PD\#?D+5S8[!&1_&.>H>!&1*P"/BXG;KLJJP(NO>F,W3
MVA51Y,>)<S$]BMTUIU?8HE.1D$37KXF?5RX$9D$U7M8]G:HVK(MB[H#-8MZH
M)2XE)GM2K#%MYEU!XH66.*5H/_P,P$)L<)*Y:H-OW?J7<=T:64QYM^'9-06@
MFUDPK,TU*E(,EO-(V8(R)PPV8 +(---,-(990EMEM)(;;01)2E*2P(B(MA$1
M /L                !!G$9K'5].F+>M&V]U2[DO>5XL@7?5DY*'2<V!+>?
M=,C2IXB/%II193[)7-3E4&,+@RT<J-,=^V+=3N>\I9$Y/O.?49951R5R[UO*
M[NVR)78(R*(BP(\V&(#S:'5V]M/=3*WPYW_5GKC8@TY-PV)<DL\TN11C=W"X
M\A1F9J6TL\$F>WFJ]KD(@L> P=X7;0;#MBJ7A<TDXE"I#!R9KY(4XHD$9$1)
M2@C-2E&9)21=4P%=J+'X@.(*ANZD42]STRMJ:E3UAT"%'CSG7V$_)R:H^9J^
M5,MK*,2074Q(\P:C0;9O;6JQ:+Q%6"J/;W$5;KDJF5%^+E12KD;IKIL+:?(C
M)"B=2@B0O'+FYF)))"FP],6GM\1C[>J6DM0/2_B9M-::3>-/EMF1958LNM3&
M5-JWJ2)*C8<4V9\W=K(C2DVPLCI7I9;^D]N'1*.MV=4IKJIU?KTU1N3ZG4'=
MKLF0X9F9FH^1.."2_3B9AB];G=7X%L1:]HXN+)K-&E(G5.WY3*7%5: V1[R*
MTXKY-9\I9<%*Y$J(]B@AV1>=P:F672-7^&66B#6;8E2)5X:6J:;CIJ$F2E/=
M34I#24*7)P09LN*[/E3@LL &,I$)W4N<GB)X7)D6AZC*5W'J'857-3,.:\G$
MUMS&T8&B02B,T/$22<[+,E6?,$A69IGJ5?=\MZD\04:CH128CM/M:QX!%.A1
M3E+;6_+D./$HEO*W2"3E,R(B(]AD L
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MNM6FM#M$D/L)<DM/(5G-Q3QEG6I2_C%YS,E*VF6)$ DD
M                    ! FFWB[\Q6INX^QWC+N:+W7XB\8?:+)F3D\8[[^R
M8\N\[GYV;)O.H GL   %5N)[Q=_-K1ONWQ7O/'4?<]R=W_:_#?<[N;N/F=Q\
MF]WNW'L.J M2                                  (DUX[B[GL'NS[-
L8_;"E]S?:WNS=;[(_E[B[D__ #.7<[_XKES=0!+8               /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>bc_fig51tcellresponse-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_fig51tcellresponse-4c.jpg
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M;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4
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M$C(%(<%2$S-!D2)R%#1A@:'1%09"DB-3\.&BLB068M(E_]H # ,!  (1 Q$
M/P#I;>3>"PVVR3$W6#8/#F;*-&SUYPO;(T.X)R-$>2HR,DH:>(G'CUUY>0O[
MX"45&9V);OY%MM8J*1&:IH&35$@D$A;3$I^1">C.&G0E<KD<G&U::Z+,CUY2
M 6
M                         .2=N=XMR;C,,+KLER%YBBOKC+Z1Z4_$KS;F
M/5KRFX#,;R:.3C+[)%SFM\NDX1&1\R@%\;,YK99_M] O[E"$7+<B?66*F4FA
MIR1537H2W4)/L)WH]3E_N\W+X $^
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M:4Z$ V
M                   #\4DE)-*NQ1:'X.!_4 0VNVKP2A>\OQJB@U5TTF3Y
M!9-QT.NQ79O%YUHG-22IP^+AEIS_ -[4!N,0Q.EP?'(&+8^TIFJKT*2T3BC6
MXMQU:G777%'[)QUQ:W%J\*E&8#=@
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MR+Z+/61-MQ9!O&RI"G-.4D^UI/F41AT@
M
M
M   #4S<8QZQF+L)U:P_,=0VT^ZM!&;K;*C6VATNQQ*%*-2"7J23,].T!M@
M
M
M
M
M
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M5<XK:K4U@D)C&9#CKQR"O'I4>2[7D3I)0ZA))><5R*)24^-IV@.GP
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MN<2$]-"G5H+F<2GP)7[,B]0P$Y
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M&P_*,/R>L-6%SXDVKKS3#Z<+1+<?IH+E:Y")/(1)TY2TTT[!*8F)2$$@
M
M                       .+9FA97G&A%_%%KX"^W0*/U>/_)G9'>V8>C\S
M7UB^L0Y%(;37UB^L04@-?6+ZQ!2 U]8OK$%(#7UB^L04@-?6+ZQ!2 U]8OK$
M%(#7UB^L04@-?6+ZQ!2 U]8OK$%(#7UB^L04@-?6+ZQ!2 U]8OK$%(#7UB^L
M04@:Z\T. V1D6GEU=X"_+F!T.G1_Y-FWNEKQ.5I.\.A![WY<:D),]*SB9$9_
MJ]GU1W.J3_J1L;,O[5:=-K_31]R7V!R*R]1TVO\ 31]R7V K(=-K_31]R7V
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MR6<\H^JO@7LC\!>K]0;XT,9TH9@GI&W./0M3FU/86G_]4P-$Z6=JQ@9@
M
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MN[*8Q>T38.PTH7)2EIYKD2X9DD_;4(UUT/L"J8FJ3B4@
M
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M YDM:MSL[YE&>EFP1:GX"KXQ?V$.!U+U8V/JW]5F8RMWSSNA&LD,_F[;\?\
MZ*3^*4.?A\\;863-S/D8GR7?]LNALX4HN[NE6I\WP/5<?#Q.,+E+X=')^2S7
M7G2=61+,B)1Z%KZXWQ$41,S5#,%4I6XFYI&9F13JG0O^U,#1.EE:L4&8
M
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MV^E*^4EI-.NF@PTRRM6:#,
M
M
M
M
M
M
M
M
M
M
M
M
M                                             !I9.8XC#KU6TN_K
M8]6B0<)<YV8PB.4M)F1LFXI9))PC(R-&O-ZP#(DY!00K*'33+6''N+ C5 KW
M9#3<F0E/:;32E$I9%IQY2,!L@
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ME)=FISXQ%Q_]03Y5^J?<52!*DK22T&2D*(C2HN)&1]AC4/T
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M#3CAD6A<RT$9Z%]4QU\.Z;K8F=3"64-B
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MC,Q [9@G*.%&.<MIR:;2#DN1R4EE3O*7.;9*-1DDSUY=3,]!*'N
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M823;+#*2;;0A):$E*4D1$1>H0Y$S72R>H@
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MM)8B1FT,QV4%HA#;:22E*2\!$1:$ ]@
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M=GND^$\EW5_+Z7\%(#ASFNSW2?">2[J_E]+^"D!PYS79[I/A/)=U?R^E_!2
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M38B+Z+DB+V/TG,;7(3&^$$L>3ZFKG66D?J<QEQU!"\0
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MI),JR=T=G2/#[:\9:F6O'E3HDO 1"OXV8OQ9K=+.(HFX\Z0
M                           !67>#]$=][I7?*48$PLT$
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M362"R>3&E6,*L^;I^73O)Y4)E+<]A3[1PXG.^ZT<Q)<$DE6FO$X2M;R#</\
M]L?D?P/8?/SR_F^">I+\MY?G+SZ=3J];DZ'C\W4TZ?'V/ 2.B 0
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M]51BNYC.XF+V:(U-D11<8\*0
M       %0]Y"MD2]MI<]JSDQ&*]^$M^O8Z7D\PG+"*1)?YVU+T3IJ736D^()
MA;P(             %296YA9;_;>MV+%@K-E5EP=,^PMLJY$<FRZQ2$J\=2C
M+7DY>SP^ 1[6N:<4:^U;8EL
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M)(;;01)2E*2T(B(N!$1#DLGV
M          *R[P?HCOO=*[Y2C F%F@@             5'EE!72N\!MYD#M]
M$BV,&LN68] Z2_+):'&R)3C)D7+RM\VJN;3UM>.F/M:YCXHG:MP9-@
M
M                     "H\U[M.T.>7C&0W%)Y/9)<ZLPZ]PXB)GK2$MEH>
MOA4CE6?VP]N%G<7#MI$]B*++HZ"DQFL8IL>KX]951RY68D1M+3:?7T21:F?A
M,^)^$>2Z^;IK,UE+8C$
M       4_P!Y&W5"VXDU95TV45H_#0J=&:2Y%B=*?%5S2EFHC0E6NB3)*O""
M87 "             !3^6XED4_O"[=Y?#@+>QNIJ[B-8V"5(Y&'9#6C25$9\
MWCF?#0A'M:IMGCB?PE< EM
M
M                                    !3.\TS-8%]C<3"[NS^%LA<<@
MQ,=@.UD-HRB-.27Y:WY\22?B()*307;PT+74$I#LM?VU_B#_ ,X7Y3N0U=G.
MJK9$YV+(D,R8CII-M3D)B.RHB(TFDT([#+4]0)6*" !67>#]$=][I7?*48$P
MLT$             "B\W=EEWH=K&DK>*&JGOC6A)K)DU='PD7BF?9V^L,?:T
MW5XXV3W+T&3<
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ME$A6GU &>T\R^@G6'$NM&9D2T&2DZI,TF6I>H9:& ^P
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M71;,S"Y,;M';O':BZ?;2T_8PHTQQI!F:$KD-)<-*3/CH1JX#)LAM 2
M
M   (WN!63;G!\EJZJ,4JWG54^) 9-2&^9^3&6VA/.LR))&I1:F9@()#P_<*O
M[MT#"<=>32;G0,4AT\:0;B%=*?"B(9-*7D&I):FE1-N$?B\W, C,' MR59+A
MS[:+FCPA##\F93)MX\Z=47)V34SVQ]UU:7X;C"5Q4H;ZBD-*4DDIYM2#4[ ;
M2[A8-F5+:Y/4-0:V'BUM3R'&I3#_ "S9N3R+5I"4H49FDX[J3YO KQ3 ?$C:
M[=V/46=G'<L)-O(SB9)E52K@U]?!Y$IYU$:(EQ\F&EI-U#I)4I"M$&CFTT2
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MQ.A=K651ZY==$5$CN*YUMLFP@T(4KPFE.A&80F&Y$I
M                                                          ?+
MC;;J30ZA*T'VI41&7UC ?1$1$1$6A%P(B     ?#;++)K-EM+9N*-;AH22>9
M1]IGIVF?J@/L        !^*2E:30LB4D^!I,M2,@!"$-I)"$DE">!)26A%_L
M(!^@/AMIIHC2TA*",]3))$DC,_#P ?8
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MNM*);2R)2%I,E)4E1:D9&7:1@A]
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MX46//4W"TBJ9CI-3'*:3YTEJLO[PDA=((
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MKQ(K;*;8(AQO",:;>2I#J*J"EQ"R,EDHHR",E$?$C(^W43#.-"0"4@
M                                                KO?3T49'[DQY
MTT"86("
M                          59WAY<5G:JXC//MMR9+L HS*UI2MTT6,8U
M$A)GJHR+U 3"TP0                K7O WUQC&S&97]!,<K[F#7J<AS6="
M<:6:TIYDF9&1'H8QNT,+YI;,I?ALR38XAC]A-=-Z9+K8;\AY6FJW76$*4H].
M'$SU$PRANQ*0
M      5WOIZ*,C]R8\Z:!,+$!
M                                            *G[Q=763-K[*QEPF
M)%A7/0%U\MUI"WHZW+"*E2F5J(U(-1%H9I,@3"V 0                KK?
MFXCX_L]F%Q*JHMY'B5ZUN5-@2E1)!&I*>1TD&2N7CKP,C$3H8WS2)E+,1E(G
M8I136X[<1N371'D1&>#3*7&$*)M'^ZG70O6"$PW(E(
M                                    *[WT]%&1^Y,>=- F%B @
M
M              %9=X/T1WWNE=\I1@3"S00                KS?4L6/:'
M+BS4YR<6\@5\)G5$V<XFN9/^23OB<VNGLN B=#"^G#-4KQ+X/^:M%\$]7X*^
M#XGD/E&G6\GZ".GU-.'-RZ<VGA"&4-P)2
M                           "N]]/11D?N3'G30)A8@(      !^&9)(U
M*/1)<3,^PB 8I6E:9),IC!DH^5)DZCB?J%Q]<!E@
M                                                *A[R";X]MI:J
MYR&FF2_"^&42$.JDK;^$(O3*,I"TH2KFUYNHE1 F%O @               !
M7>_%*SD6S^84K]I$I&9E>M"[6R4I$..1*2KF=4DC,D\-.!&(G0POBMLI7B,1
M,#%**"B0W+1&KHC*93!ZM.DVPA).(/PI5IJGU@AE#<B4@
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M$C%:I,2)25$F*P4-DFVGU2IVKB$\NB5'R)U47'Q2]00E<XE
M                  *NWRQV!*P>^RCKSHUW3UDA5?)A3YD,FUI+G)1ML.H0
MHR/PK28)A,\7Q2FQ6,\S3%*)N6I+KI2YDJ<KF).A<JI3KAI+3P)T($-\
M                              *R[P?HCOO=*[Y2C F%F@@
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MT>B?,/BN3_P F$X:_P I'^$O[ 0^P
M  !4'>1OZ>MVWE4LZ6ABTNWX355&42C4^XS/BK6E.A&7 C+M,@3"WP0
M               IO9#(+N[RC=N+;64B?'JLLD0ZUF0X;B8T9+2#)IHC]B@C
M_ND,8:K)F9G;W+D&3:
M    #EW=B$NAW'GH<R#([Z)EC4;RC"\9MEE=,LLDZEWI04QE(.*I!\5')95[
M/12O!"70^*9!6Y)3MSJQB5$9:4J*[#L(ST.4PZSHE3;C;R25JGU2U2?@,Q*&
M[  %=[Z>BC(_<F/.F@3"Q 0        @%7Z9LD_E^G\ZG@E/P0
M                    "";T>B?,/BN3_P  )A.&O\I'^$O[ 0^P
M   :V^H*?**I^DOHB9M5)Y>O&<-1)5R*):=329'P41'V@*AV7V[PN)9Y1=QZ
MAM%K391;0JR3U'E*8CMDA"6TDI9EH25*+30$RO $                   K
M+O!^B._]TKOE&,"86:"                    %4;/92]D61[GPW:RO@)I,
MG?@-O5\<H[LE*&D>VRE$9]1T_"L_J> 1#79=69_"5KB6P
M                               ',^]>02L=SFVKV[!HW\LJ(,&#8-V4
MJK/&E,25FB=+**RXE3:WU-K0XM25'TS:X-F9B$NE(Z7$L-)=<ZSI(22WB(D\
MZB+BK0N!:]N@E#T  %=[Z>BC(_<F/.F@3"Q 0        @%7Z9LD_E^G\ZG@
ME/P0P;FU:I*R1:/QY,IJ,1*5'@L.2Y*]5$G1#+1*6H^/@+LX@(GCNZ^.Y19G
M55,"Y-]N0N%*>?J9K$>-):02U-/NN-)2VHB-/!1^$O5!-$Z!
M               ()O1Z)\P^*Y/_   F$X:_RD?X2_L!#[             5
MML_V9Y_.-Q_:T"962"                   5EW@_1'?>Z5WRE&!,+-!
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M&L'T,.V<V*A$:,E?#J/'S<$)_O!5$8DS-*2N82V@
M    #F?=B)8W6YE[CN*SV:5J?4U[>=,V-G&K&KF$ZI]MIJ-U(LEY!I;-QMU]
MHTEH?)IS%J(2Z48:;CL-,,I)#32$H;07$DI26A$7U"$H>@  KO?3T49'[DQY
MTT"86("        $ J_3-DG\OT_G4\$I^" !76U'_5;A?S=/\VB F5B@@
M! =S\DSK$*B9DN-PZB92U4)V78-V3\IB2I;7C<K71:<3H:?"H^T$M_BSF:.1
MY"LT9JVI'.GR,J=V0\V;1IXFX<AMLR5KV<O@!#?@                   @
M.]#S/]*<Q3U$<Q5<G4C47@08BJ8A.&76C0VA+B37RD6A*(SX%ZP5*/82@
M        !6VS_9GG\XW']K0)E9((                  !47>/@V$C;:9,C
M6CL.%#?A*G5S;3*VYJ5V$4DH<6XA2T$DRUU:4DSUX@F%N@@
M                                                        <D;]
M6R)NXR3B28$UZ(TF#5JB+H'V(\I+4GJHN2LE=1'+)\EY2/Q$M=7E+JB&4.LX
M_6\G:\HY.OR)ZO2UZ?/IQY=>.FO9J)8O0  5WOIZ*,C]R8\Z:!,+$!
M  " 5?IFR3^7Z?SJ>"4_!  KK:C_ *K<+^;I_FT0$RL4$    ()O1Z)\P^*Y
M/_ "83AK_*1_A+^P$/L       'C*BL38K\.4CJ1I#:F7F]3+F;<2:5%J6A\
M2/P *1Q_:#;A.YV0UB*-)0J>!22ZYGRF8:6I#KLTUK(C>,M5=)O7_"0)JO0$
M       U63J4C&KE:%&E:8,HTJ2>AD9,JT,C(1*8TN=,2PW$Y&(T#TBDA/.O
M5D);RG64.&M2XZ#4:N8CYM3/4]18\+"LFR.R-"LXF+?Q3VSIGVL//L7QRMQ.
M9/KJN/$G1WZ];$EA!-NMJ^$(Y:I4G0R/0]!IS6';&',Q$-V5Q;YQ;8F9TNK!
MPW?            5ML_V9Y_.-Q_:T"962"                   5EW@_1'
M?>Z5WRE&!,+-!
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M*DJ+0R,CX&1EVD _(\>/$CM1(C2&(K"$M,,-))#;;:"Y4I2E.A$1$6A$0#T
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MVSO\=;IV4.S5*<PUVNAKE&IK4V3CG_S:WUFG4G==3YN40R=<B6(
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MJ.6ML:71G=X]$%![K9?*4H6O!Y(V/CV>^XQ/FNWK0&UX@
M                                                  T(M=/#V@
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MTNC.[QZ(*#W6R^4I0M>#R1L?'L]]QB?-=O6@-KQ
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MLB^J.6ML:71G=X]$%![K9?*4H6O!Y(V/CV>^XQ/FNWK0&UX@
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MX3(="X-96=SA6-W%VCIW-A5P9=BWTS9Y93\=#CI=,^*=%J/Q3[.P2AOP
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M1A#"5T*#6ELN4E&4W0C,B[3(=_I5]UUMW%,SVO+CQ$3%'UWR/XOP[XNL/QS
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M8TNC.[QZ(*#W6R^4I0M>#R1L?'L]]QB?-=O6@-KQ
M                -5;XY37LJJF6\4I3U)*^$:PEJ5TVIA-K92]R$9)4I*7%
MDCF(^4SU+CH8#:@-?44E71,R(]4QY.S*E2;!])*6OFDS75/O+\<STYEK4K0N
M!> @&P
M%=[Z>BC(_<F/.F@3"Q 0      #GO?/TBXU\26?G4,<3K'I6_-W-EFE"!5FU
M9'=[_6N>?G=;Y@@6_I7V\;;M[3?I0G//3#FWN5+YHL<WK//9LG?#*QKT>S3]
M4AP9T-BZ.[WZ+:_\^MOE.2+[EO1L^6'GG2M$>A  UN0_J"U_,Y'XI0FW2/YN
M4WZFKOS5G\60H>-ZEVV=[IVZ(;>M_6U3\9UWGK(]&1^XLV]S#%Y9?T>%S<\
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M6ML:71G=X]$%![K9?*4H6O!Y(V/CV>^XQ/FNWK0&UX@
M
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M3[(OJCEK;&ET9W>/1!0>ZV7RE*%KP>2-CX]GON,3YKMZT!M>(
M
M                       %=[Z>BC(_<F/.F@3">39T*LB/3[*2U#@QTFY(
ME2%I:9;07:I:UF1)(O5,P0H?=^QV7NW,<LSEXM8VCN24I64Q3M<_(7"0^25D
MZLS-1MDG@HE'R\OK E:N,9!MHWT,<PRTHDZ]1<:IIY$,M>U;AH8CJ^JI1DGU
MS!"5@   Y[WS](N-?$EGYU#'$ZQZ5OS=S99I0@59M61W>_UKGGYW6^8(%OZ5
M]O&V[>TWZ4)SSTPYM[E2^:+'-ZSSV;)WPRL:]'LT_5(<&=#8NCN]^BVO_/K;
MY3DB^Y;T;/EAYYTIQDDO)XD1I>*UD6TFJ<)+S,V6J"A+6AZJ):&7S,]=/%Y2
M^J/0A&=L<WRK/JN/D5GC\2FH)S"W82VK%4V2;J'3:-"T>3,I(O%4?,2S\' $
MI;D/Z@M?S.1^*4)MTH?S<IOU-7?FK/XLA0\;U+ML[W3MT0V];^MJGXSKO/61
MZ,C]Q9M[F&+RR_H;?7U/C%1+O\@FM5U- 1U9DU\^5MM&I)U4?U3(A<W/<S;L
M9/W?,HM*2]CVT29;RKRL1>R&GYK9JJV]4.\Z4&E)()!))7 :^.W7'O91$K?V
M]S_9DU0L$V^NX:W#)YR#5LN/+6HD\SSII-[4STXJ/QAE%ULZ)A$U0WO;?P)C
MG\R1/,Y@\/4/0N;,+FARJ*>Z"ZNZOZ2[OX@1YZ0L72.6[;&YY,?3#R[Y'\7X
M=\76'XY@7;I7J7?+WO-#G,6-DZQ[F7ZCS+XSC^:I%5ZEZ\[+6,J<[R'IUR?\
MUJO-2'1Z5R7;>Y,*R+M(=F$NZ^ZWZ#\;]TL?E"0*7F/5NVRQ1K%^W(_YEOOE
M!T=C)>E"NYWU99.3_P ,7OQ;.\V<'IQ.67DLYHVK Q[T)57\JQ_DY(JTZ%MC
M2KC#/X-QOXJ@>;-BT87)&Q5,3GG;.]K]R_X(L?=J_P"48PTYOTI;LIZUNU<N
MZ>9R=O< N\QAPT6$JK:;6S#=<-EMQ;KR&2YEI2HR(N?7@0KETTBJTX.'.)?;
M9'9Q3$>]S#E._6<92=)Y1C]3'^!+:+<M\LN0KJ*ADLNF>K1:<W/V^#U!ROY3
M#\,_HNW_ *9F8GU</_J_98FW7>'RO+<^I,0N<?KXD.X\J3Y7$E/..-KC1G)!
M>(MM)&1]/E[?"/3E\Y;C74B)AR>I_P!?QLAA1B7WVW1,T^&O?#7]]WT;4'Q^
MSYI*%CZ3]U;^>Y6IT.&Q?6;I7N1>DG*/B1KSLA4NO<]FR=[!W2*T   X^W*]
M,V<_]I^3T#A]1YXV/H/]9]"_YNYI$^R+ZHY:VQI=&=WCT04'NME\I2A:\'DC
M8^/9[[C$^:[>M ;7B
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MTK[>-MV]IOTH3GGIAS;W*E\T6.;UGGLV3OAE8UZ/9I^J0X,Z&Q='=[]%M?\
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M6R^4I0M>#R1L?'L]]QB?-=O6@-KQ
M
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M+*;2ZT3[3D=WE46I<S;J4K2?K*21C8\C*
M
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MI%U:R[MQ3I)232IG*9MIY>U*>7@9@)$
M
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M+/I\W)V)T$HE/00
M
M
M
3                     #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>bc_fig52antibody-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_fig52antibody-4c.jpg
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M 0 " P$            !,@-Q40(1$A0$_]H # ,!  (1 Q$ /P#OX
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MBXF6;#AU\6,M@R;D.*21I-U1ZZ KHT1
M           &/.@PK.'(KK&.W+KY;:V)45]"7676G"-*T+0HC)25$>AD9:&0
M#R!7P*J%'K:N*S"KHC:68L.,VEEAII!:)0A"")*4D781$ P[[&,;RJ(5?D]/
M!NH!'N*+91F9C)*^4D/)46O\ #(J:>HH8+=91U\:LK6?YJ'"9;C,(U_DMMDE
M)?P$ UU]@^%Y3(8EY/CE7=2HNA1G[*%'F.-:'J6Q3R%&GJ>O0!NV66H[3;##
M:6F&DDAII!$E"4)+0DI(NA$1=A /L!3'(?VB.%/Q3+_!PA1<X@
M                                       *8Y#^T1PI^*9?X.$*+G$
M                  :;),OQ/#8C4_+[ZNQ^"^YW#$FUEL06ENF1JV)6^M!&
MK0C/0CUT(!&?VZ<)?O*Q7_[RN_WX#Z_;CPKL)S]I&+=V9[27]-UVW<7737O^
MT!\_MTX2_>5BO_WE=_OP$JQ_)\;RVO\ I;%;B#>56]3/MU9):F1^\1IN1WC*
MEIW%J6I:@-J                       "F.0_M$<*?BF7^#A"BYQ
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MA3\4R_P<(47.(                     "F(/VL+K^[^L_MF< N<
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M3\4R_P '"%%SB                      IB#]K"Z_N_K/[9G +G
M                   %,<A_:(X4_%,O\'"%%SB
M IB#]K"Z_N_K/[9G +G                          %,<A_:(X4_%,O\
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MS/:K:HTJ(R41*2I*B-*DJ(E)/H9 -V ICD/[1'"GXIE_@X0HN<0
M            %,0?M877]W]9_;,X!<X           *+YFS/D6PSS&N$^)["
M/0Y'?0I-U>Y1*93+.MIXRR9)3#"_56ZZX9H3N[-"[-=R0J&JY&YRP[BV=R&U
MD19= XYRZ]J,TA6;+:)-M3QY4>.AUA:2/N7&")Q:4[M/7/7<2=J@[+A3&+"'
M'GQ5;XLII#[*]--6W4DI)Z?=(P'[@.8_,))S.GYVX;R+"<6D93:PX^1QF8;:
MCCQ4O3HS+"%R9)H4EIM!*4XHS[229$ W%?S'R[A6=8SB?..+T\*GS.5]&462
M8U*??C-62D[FHLEN21+W.?-2HM"U[-2W&D,'A^.SD'F?YTRBS;)ZSHCHZ*G<
M<3JJ-#7%<6\ELS["=6VE9Z?]H#UF.SC/G;?:J6R8C9?@GM]TPTG0GIT.P-IN
M0LBZ&ONVR;(_\OR@/?)3&CSN(IV92&4JOLPOK>TNY:TD;SSQREMD2U'J9D1)
MZ)["-1_*8!Y8F&*'..<L)JVRCX]499[970T$266#LF36XVVDNB4EW:2))="(
M!.K+S+<$T]C,J+/.*^-90'W(LR.OO=S;["S;<0>C9EJE1&0"OY/*7'_)OF'X
MD/ KZ->E4P\I.Q]EW_@2DQ(I-&K>E/SC;5II\@JNEA$
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M"/J>U):$ ^P         !3'(?VB.%/Q3+_!PA1<X@
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M/>1''S,S,W-"5J9F?334S,C,POD!3'(?VB.%/Q3+_!PA1<X@
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M]951&8-;%0346'%;2RPTVGH24-H(DI(O01$ R0%,<A_:(X4_%,O\'"%%SB
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M?TO/924:LP    !"N8OA%GWZO6?AEC':DM<KQU<."?H/C/NJ#X9L<1WT@
M  1_.I%M%PR^D4-*UD=PB#(.'0R%(0S-=-LR)A9K]7:OL,C[>P!S]>U>>0J'
M%[#'?+7B]O:V->4C(X*GJ>$=?--6A,I[Y!&LC3ZW37;\TSU(!'R_;0H]O^$S
M%>ORV5"1?]:0'7K&[N&M[9-+V)W-)T,D'IU21ETZ=@#] %7\R<-L\J,4=G67
M<C%L\Q24J=B^3PVTON1774DEUMQI9I)QIPDIWHW%KM+T:I,(?5\$<B9)FF.9
M?S7G[>41</D%/H,?JZUNLA?2""T1+D*)2E+6D]%)3IHDRZ'H:B4&UY&X-R&X
MSQ'*G%>9.8-GCL--9<.*AM64"RBM'JV3[#II(EHT(B<];U2(B(M-0&QXBX6E
M<?W-_G&89*]FG)63DTU:7[\=N&TW%CE^#CQH[9J2VV1Z;M#ZZ%T+0!$;#R]<
MAXYDF0VO"?)SF$T663';.XQ^55L6L9F?)(N^DQ#>47=J7I\TB^0M=$I)(63P
M_P 4U'$&)JQRNFR+:PFRW[6]O)IZRK"REF1NON:&>AF1)21:GT+J9JU483\!
M3'(?VB.%/Q3+_!PA1<X@                B/*OPOS;W!:^#= 5YQQ\.<-]
MQ5?@VAW,J1QY_2\]E)1JS     $*YB^$6??J]9^&6,=J2URO'5PX)^@^,^ZH
M/AFQQ'?2       <79 ]YLW>>J+(V\&H5VT*ELH=<M$F4JI.&[(09F^_N(DO
M_-V(U+<6IZ=.@;[/L=\WG+^*3N.,DQ_$<=H+U3#5E<Q9DE]^.PR^A]2FV]ZM
MRC[LBTTZ]FI?.(.KX[)1X[4=)FI+2$MDH^TR26FI_P#0 _0          4QR
M']HCA3\4R_P<(47.(                (CRK\+\V]P6O@W0%><<?#G#?<57
MX-H=S*D<>?TO/924:LP    !"N8OA%GWZO6?AEC':DM<KQU<."?H/C/NJ#X9
ML<1WT@      '.G-DG.<[Y>Q3@W&<GF8703ZB7DF0W=4HVK&0S'>*.B-'=(R
M-![CU5H?8K4]=-IACGY.*8SU/E?D<S/J9G?HZG^2@.D&6R9:;9)2E$VDD$I9
MZJ/:6FIGZ3 ?8          ICD/[1'"GXIE_@X0HN<0                1
M'E7X7YM[@M?!N@*\XX^'.&^XJOP;0[F5(X\_I>>RDHU9@    "%<Q?"+/OU>
ML_#+&.U):Y7CJX<$_0?&?=4'PS8XCOI       *-YQX2SCD_)\5R?#,\+"I^
M*ID*AR&JY,J5WTKU'#)\G6E$VM!$A;2M4*TZD K_ #&EYTX^@?26;>:.LHHF
MFJ#FXW4MN.:=-&VS5O</[B$F8#JR(OO(K#G>=]O;0KOM-N_5)'NT]&O;H _8
M!J<ERC'L-I961Y59QZBCA))4F=+63;2-3T(M3[5*,]$I+J9]"Z@(7Q_Y@.'>
M4K-REP7+(MI;M)4X< T/Q)"T(ZJ4VW*;:4X1>DT$>@#9<A\P\9\4,QW>0<DB
MTJI9*5%CN=X])=2@]%*0PPAQQ22,]#42- &PP7D;!^3*E5Y@=Y&O*UM?=/.Q
ME'O:<TW;'6UDE;:M#UT6DC 1K.?,/POQO=%CN9YA#K;S1)N022_*=:)PM4]\
M49MWNM2,C+O-O3KV )Y17U+D]1$O\=GL6E+/1WL.?$<2\RZC4RU2I)F70R,C
M+T'T/J V("F.0_M$<*?BF7^#A"BYQ                !$>5?A?FWN"U\&Z
M KSCCX<X;[BJ_!M#N94CCS^EY[*2C5F     (5S%\(L^_5ZS\,L8[4EKE>.K
MAP3]!\9]U0?#-CB.^D       X)LO,%RIF>6RL.Y-RY'EWKN\V1HRZF2[83&
MBUW&FP?(F6R+I^%0I!?)KZ0D7%G"O%I>8ZTKWWOVCUK&)0+N/>Y!):O3>L'Y
MSC:GR7H;9ZI26TC(].TC =ID1)(DI+0BZ$1=F@#T!7/*7$-7RO88>Y?SEE18
MK:INI%$;2'HMB^TG:TE\EG\U&JNFADHE&1D JCG%NIO>?>$\3Q&.TK/J6T.\
MMI$1))<@XW'07?-OK01;6W]#0A*O3T^_+<'Z\85M?FOFDYGRJ_C-3IN)(I*#
M'?:4$[[''=CN//FT2R,DFMQ&[<77UE>A1@/JHKH."^<^?5X[&;@4^:X2FVMX
M49!-LKLH,]3*']B"))*[M)D?3J:E'VF _'R<T-)DG&=SR+<UT>=DN=7EM-NI
MLII#SKB/:EM)8,W$F?=IVF9([-5'T 9GE;88QK*.:..*I)M8UC>5JD4T,M>[
MBLV;1N&PUKV(0;?JI_A]("VIG,G$-?+D0)^?XW%G17%L2HK]Q :>:>:4:5H6
MA3Q&E23(R4DRU(P%87V;89F?F(X>^I^1U>0^PP\L.=]$S8\_N">B1";[WV=:
M]F_:K;N[=#T[!5="B(                B/*OPOS;W!:^#= 5YQQ\.<-]Q5
M?@VAW,J1QY_2\]E)1JS     $*YB^$6??J]9^&6,=J2URO'5PX)^@^,^ZH/A
MFQQ'?2       :R^QV@RBN<J,EJXEQ5N]'(4]AN2RK4M.J'4J+T@*#M_)WAU
M9:NY1PSD%MQ=E:TFGOZ=];]>X1]=KT1Y7K(U(C[LG$H_S0'1C*74LMI>63CR
M4I)Q9%H2E$74]/1J8#[ 5#YA.2.0^/<49+C##+#+LLMC=8BNPHSDN-7]VE)F
M_(0T1J49[OP:.A*,CU/IH84UP=E47CR2Z_8<6\G77(N6R6?K7G-MCZ&^^>=6
M2>WVI7<1&C/4DD71)=>PB()+D2\QX&YPR_D>OPVXS/CKD6)7N6:,:8*=8U]K
M5-FPG6-N29MN(4:C5J1:J[?5T,-CQ'5YCR+S7><^99C,[$*5JC9Q;$*6X23-
MDY&.1[4_)?9UU:/?JE*3]"O3MU,(C@F49MY8BR'C&WXUR;+<9^EYMCA5[BL,
MK%EV%/7WJ&))$I/<K0HSW&>O4ST3H1*4%E^6S"LOI*S+L[S^"53E_(=X_?2*
M7>3BH$,R)$6.XHNU:4[C/TZ&1&1*(R 63(XWX\F2'9<O$:5^4^M3K[[M=%6X
MXXL]RE*4ILS-1F>IF8"J<IQC&L:\Q'#?U<IH-1[5#RTI/T?&9B]Z3<.&:-_=
M)3NV[CTU[-157Z(@               "(\J_"_-O<%KX-T!7G''PYPWW%5^#
M:'<RI''G]+SV4E&K,     0KF+X19]^KUGX98QVI+7*\=7#@GZ#XS[J@^&;'
M$=](                     %,<A_:(X4_%,O\ !PA1<X@
M   B/*OPOS;W!:^#= 5YQQ\.<-]Q5?@VAW,J1QY_2\]E)1JS     $*YB^$6
M??J]9^&6,=J2URO'5PX)^@^,^ZH/AFQQ'?2                     !3'(
M?VB.%/Q3+_!PA1<X@                B/*OPOS;W!:^#= 5YQQ\.<-]Q5?
M@VAW,J1QY_2\]E)1JS     $*YB^$6??J]9^&6,=J2URO'5PX)^@^,^ZH/AF
MQQ'?2                     !3'(?VB.%/Q3+_  <(47.(
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M924:LP    !"N8OA%GWZO6?AEC':DM<KQU<."?H/C/NJ#X9L<1WT@
M              4QR']HCA3\4R_P<(47.(   HSAYYUN?RJ3;BD%]?;3HDS+
M_P!-$^006;[5*_VSG^D?\8*>U2O]LY_I'_& >U2O]LY_I'_& >U2O]LY_I'_
M !@'M4K_ &SG^D?\8#Z;E23<21O+TU+[X_E_R@(#Y>3-59R I1ZJ/.\C,S/J
M?_F4BHN(  1'E7X7YM[@M?!N@*\XX^'.&^XJOP;0[F5(X\_I>>RDHU9@
M"%<Q?"+/OU>L_#+&.U):Y7CJX<$_0?&?=4'PS8XCOI
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MESA1<8@            IW'/M,9W^JV/^)GBJN(1
M              :RVQVDO)%9+MX+4R332BL*MQTM3CRDH4V3J/\ .)*U%_"
MV8            #6,8[21KZ7D[$%IN_GQV8<RP(OPKL>,I2FFU'\B36HR_R@
M-F
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M]@4=I<U+%G&C.Q[NF*QC?A8TDD;VGB;>22FW$DKL,B4D^WJ D(
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MK&<1QJ7H5@W4-OE*7(G)+YCKKA$:4'ZR2U(^FTU!T
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M.05&HI7?R"6M3RU^O\XR1TT/70DA;H
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MB/!IG)E=RX<!4?.*^*["]MC.K81)9>1W9>U-H,DO&VG5*#7V=.W:C:$X
M                          &-%LJ^<]*CPI;,E^"YW$UIEQ#BV'C22]CA
M),S0K:HE;5==#(P%8^9F'DD_@3/8F)DXJZ<JW"2VQJ;JXQ+2<I"23U,U1R=3
MH74]= 'Z<(7W&F1<*X^O#UP?J;&J6HLZ"KN^[C&A@BDLRT*Z$LCW]Z;GS]37
MJ9*U,*0\J.(Y$C(,WM,0L(<GRTW%U=PJW'9J'']Z&'$MM/P=Q&CV=W<MI6XS
MW);T4DU:*(.MJJIJZ*MBTU+#9KZF"VEB'!BMI989:06B4(0@B))%\A$ S
M   !\.NM,-+??6EIEI)K<<69)2E*2U,S,^A$1=I@/SAS(=C$8GU\AN7!DMI>
MC2F%I=:=:66Y*T+29DI)D>I&1Z& YH\UTB%59IPKD.:-]]Q-69#(5DQ.)WQ6
MISK*$US\A.AD:&U=ZH]2TTW%Z= $P\T;W'5IY?LKF9<_#DU3M:Z_CTG>A9KM
M3:-4%419:ZK4YM(C1VH-6OJ;@'QP7QWFS/&M3CW.:Z[+%U3\.QQAR5'4]-BI
M:90XU[2<A)D4B.M2VTJ3JHB+YQZ@+Q
M'AF1$9F>A%U,S <&9;FR,;Y8M.8/*W2W^3PE2%M\F1:^ Z]BMJ;:C4ZZQ)(S
M5[2@S4HW&6EIU/>1[5+)P.P>+^4,1Y>Q&)F.'2_:($CU),9>B9,22DB-;#Z"
M,]KB=?\ (9:*29I,C,*\R/R?<#9+?R,@E8^[">G+[VS@ULR1!@RU[MQFZPRM
M*2U/M[O;\O;U 7/2TM3CE3#HJ&$S74]>TF/"A1D$VRTT@M"2E)=@#/
M !%N1[W"<<P>\L^1GV&,***XQ<>UD:VG8\@NZ4SL21J6;F[82$D9J,]" <8<
M7\O6GE]O%1GL>RMKRL7<E*J*VR.N<9?I'92M2-M1*<-<1:CW$2]JU$>]*35N
M[P.WK"NQ?/<9<@6+$2_Q.\C)-3:MDF)*C.D2T*29:I41]%H4D_D,CU 5-BOE
M"X)Q#(8N1UU"])DU[OM%5#L9DB;#AO;B62V67EJ3N(RU(U[M#Z]O4!>8
M                          \4HDD:E&1)(M3,^A$1 *AS7D+!N1\3S+CC
MC[-Z:9GUC3V,"MA1+&.J0<MV,XVE*-J^TE'HHT_-[0$0\KG+/&Y\/4>)R;&%
MC.28;%^BLEH;-UNODQID0U)?>6V\:#T=62G5*]"E&2O6(R 0W@O#GLJYUSKF
MWBV^<I>+)ETJ!(JT1B5!ODLPD>TOL[E$2=)IK6AY*3U)2B29:K(!V
M   UUY?4>,UC]UD5E%J:B,6Z1.G/(C,(+T;G'#2DM?\ * Y>\S.9XMG6"8KG
MF%6,/.,/P++*R]S2IJ7VIBCK8^\EJ=;2H^B=W8LMNU1J/U2,P%G9SS3P7;\1
M760VN25=OAME6OMKA)?:7(E=\VHBC)CJ,G">,_5V&DE(/J>FAF01ORA<7YWQ
MIQU%9RC('YE-<0X5C5XQ+C]T]3OR6S=E-&XI2E:*4HC[O1))/4]-QJ =$
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M P.J8O4.^T-/)9,V6WM=Q+;CF9LH41]4FELM#[ %H@
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M+Y%R"3D,/')!G[1"A.$26?:"/YK[G5;B?1T[#U207J
M             #GSD#(N0>2N6Y/"/'F0*PZEQ^M8MLVRB,TAZR-4T]8T*&2^
MC9J1^$6[VZ?]W:L*QY,PO*^-GZ?#N4LEG<G\ Y]/CX_.<NC2=Y1VDE1G$E,R
MD^LHDJ3NW=FA&G9U+<$U3Y5LXGPF\-RKFF^NN*&]K:L9.,U'F/Q6S3MCOV*7
M%.+:T3M-.S33LT =)5M=!IZZ)4U<=$2L@,MQ8<5HMK;3#""0VA!%V)2DB(B
M90       ,&XNJ;'J]VVO["-5U;!:OS9SS<9A!'_ "G'32DOX3 <J>:.#E>4
MP,>Y0P^TC\@<)T<R#899A-?[-+;?8K9/M#DIIYLE]Z1H,VWD:Z(3ZVAIW[0M
M;),6XM\TW%\"95S4NP%D4O&LB@:-SJJ>V1:*1H9*;6A1$EUE6G9Z#)*B"2</
MPN4*[#FJSEZ1!L,IKI#T2/:UZE*]M@LZ)9DO$I*22ZX1&:B3Z-#/11F1!/P
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M+8ED=IR7A#MG14.;PH\U_!9""BP8LQXB=4^<91;F7MID@VB,B0>\NS:2 M\
M                             >*4E*34HR))%J9GT(B(!S;><C9]S?FT
MW"/+UE]928GCT2/*R3/6F6;A;DN:MTF8<1I1FV9$EE2G%F?\*="WAHN%\PR+
M@7*W.#.;5,H5D5C+M<,SEE)-5MH_8/&\_&<Z))I\W5F:4GZ5;.SNS6%K9!P-
M2V'+5'S'C5I)Q;*8:NZR,JY*.YNX)$7X"6A7JZ^JDC<VFK:7\I*%("V@
M    $)Y=H,WR?CN]H^.KQ..Y?+CFBOLU)UT/[YLEEJ;1N)U03R2-3>NY):D
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M.HT)<YPB6X3DIU2=Z#-:NZ3IUW:$V'0@
M  Q;,K(ZV85,;";<V'?H]4LEJC%)V'W1NDV9*-&[3=M/73L <P5/(.:\MT&0
M<!9G</\ &/F*JDD]%GURS8C6;4=7>MR8BR]933A)_#(;5NVZJ3ZN]"0V/E2S
MEC'J5GRZ9I +&N3\)0ZT5:O1+-G"4ZMXID1?8YJ2]SFG4_GET-1)"94'!3N"
M<NO9YQW<E187?H>7F6&=SWD.5-VGW,B*6I)87N/<YH7HT(M%>J%OPH4.MBLP
M*Z.U$@QTDVQ&CH2TTV@NQ*4((B(B^0B ?N
M                   YKH.5,ZX:Y!/CKGVQ39XQDDMUS".1R91%C*<>6:O8
M)R6R)#*DF>C9]A%Z31U0$O\ ,7Q+1<A8<_DARSH,XP]AZWQK+6%]P_!>B(-_
M1;I:'W*C1Z_\GYQ=2 :'%,-H_,EQGQ?R?G4>169W7-QK./=52_8)G>QW#2XD
MEI3J3$@T=YL3IMW>H9>D.@P
M          5USI^R_P#9A>_M@[GZC]S_ ,5WO\]WW_A>S:>M[1N_FMG77[FH
M#A.+^U[ZN0OVJ_7K_"/O9V[_ &'Z6^C-R.X]O[G_ (KV333=IZNW39UV@/Z.
MXW] _5ZI^JW<?5GV./\ 0WL>GLWL/=)[CNMO39W>W;IZ &T
=                                  !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>fc_fig03aiimmunolonew-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_fig03aiimmunolonew-4clr.jpg
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M 0,1 ?_$ +\  0 !!0$! 0             ! @0%!@<#" D! 0$! 0$!
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M%!% H)H% H% H% H(H%!-!% H%!- H(H)H% H%!% H)H%!% H)H% H%!%!-
MH(H%!- H% H% H% H% H% H% H% H% H% H% H% H% H(H%!- H%!% H)H%
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M@F@4"@4"@B@P^W'_ -D=A_\ M7.'_P"[.5$<J^4&_P#W%Z]Y?&S?_E4U-O\
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M9F,[6RIP_P OG9;7\I$S>%TZ##RL!U$B')0A/6V\V;I4#T\P:UXB7:N6Z/\
M_=L;L?\ [VC_ /35RC=>/RC--C8.Z[P2 ZK,E"ECF4I*"!^VM:]ILJ[BLMGY
MS.V[BDA3GZ.OWN1_+)*?V$FU3_H_Y9;YX4)=[!S>L=93F("T\QQ >XU?V&C4
MLLD2/FH[3.2/S5C LN)4KB>L)9LKZ:FW9.FY?.RVEWL--+J0HHRL)Q'L6/4L
M?IXUK?I-.W8,0VAOMU$:0.EM&"6A*1X#X58M5O23M\'8O&2YGR=99V&VI43
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M:6I*[E220 GC>NLVF'.RN!?*7F,)N/>GO9F($8# 9<QG&8KB2$^@XZ^ DI4
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MK^\EI=TW-_JJYK/C67IL^+[5Z-A=?S6JXV"ZS@MA=6]E6#(<6I;CA)/2M7%
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MON;GD=T^]T?9LB[+U/3$?%8V!9"1'::NI00JW,@6]Z]2]1J7_+;\-?T__O\
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MM!*+GRN:M[9TZO\ ->?:#OGJ7;+2HG;7NBF5KFQ:IZL)(<C+<;DLA:G>MLH
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M#G2RWI-=IKQ6(V'N5%[E?,+V[RN&AR(^K0WA#QL^8V65SG4KZUNMI4 >BR@
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M,5CHF/)YF''9CDCVEI*;_73"O1V#"DO-/2HC$B0QQ8?>9;<<0;6]Q2TDI/\
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MPAPXS,>&!;X9EIMIKCP(]-"0DBW#E0R1H<2"R(T&*Q$B^]_EX[2&F;*^U="
M$GJ\>%,(\(^&Q$5Q]V)BX49V2+27&(K+2W1SLLI0"H>Q5Z87*XB1(V/:3'@1
MF8D9%RAF,TAAL$_V$!(X^P4*LQKNO"69XPF.$\G_ )KX*/ZMO/K#=Z8,KR7%
MBSV5QY\=J9&</YC$EM#[2CX%2' H&WA1%:$)0D-MH2VTE/2A"$A*>D?NA-K
M<?*@\XL*#"2L08C$5+JBXXB.TVR%K/,J]-*;GVFF!<&_"_$^= H% H% H%7
M5 H% H% H% H% H% H% H%!36PH%!% H%!- H% H(H%!- H% H% H% H% H%
M H% H% H% H% H(J":H4"@4"@4"@4"@4"@4"@4"@B@4"@F@4"@4"@B@KX5D+
MBH%Q0+BK@.%,!PI@*8"F N*8"_MJ!>K@*8#A3 7I@+T"XI@+BF I@*8"XI@.
M%,!0+B@7% O[:!4"XH%Q5"F I@+BF N*@7% N*!<5<!>@7%,!<4"XJ!<5<!<
M4P%Q3 7H%Q0+BH%Q0+BJ%Q3 7%,!PI@.%,!PI@+BF N*@7% N/.K@+TP%Z8#
MA3 7%,!<4P%Q3 IK04"@B@4"@F@4"@4$4"@F@4"@4"@4"@4"@B@GQJ"KI%3(
MCI%,ATBF0Z13(=(ID.D4R'2*9#I%,ATBF0Z15#I%3(=(ID.D4R(\:H50H% H
M(H%!- H% H%!% H%!- H% H%!%!-!% H% H% H%!-!%0*H4"PH)H(M0*":!0
M1:@4$T"@BU H% H% H)H% H(H)H(H% H)H% H% H% H%!% L*@FJ% H% H%!
M% H% H% H% H%!- H% H(H%!- H% H% H(H%!!5X#B14#JX7MP\#YB@D&XO^
MT4"J(ZN-N'[?'RJ!U<.'G;]E "K^%!55%(4/'A[?"H*DFYH*Z@BH% H% H%
MH% H%4*@4%/C6PH% H(H%!- H(H% H)H% H% H% H% H%!% H)H%!%!- H%
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M]+Y939.XV-Q$?/L0&9+N4PK3R5/J8*L<)C*0KT%O V*[*'NT]?1Y9_!;' V
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M$>VD5-4*"*@51- H% H% H%!% H% H%!- H%!% H)!J">H"I@.H'SI@2%D6
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M?BF/R?$?\![\']=/7XIY_*/B#_ >_#_73U^*8_*?B/\ @/?@_KIZ_%,'KG^
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M]1LJ4D7]Q3B$I7_T%&IZC7FJ,)W,TW8YF+A8;(+ENYI<MO'J0TLMJ7CG'&Y
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MW%B-V (;:2$@FW[Q NH^)J.B\ M]%4*":!0*!0*!010*":!01034"@BJ)H%
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M%2EGF5&MR88MR]JTB:"JLA4"@4$*MP!L0>!!-KW_ )*#YZ@X#6<-WW[@S8N
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MJ2+&YZJS:U)PN,%W]T7(9_8L3FLK!P6/Q;F,3AIV0E-L#(HRT8R4%"5$&Z0
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MG9K5,%.X2PP[.4D<THR#JI:;^1 <L?*N4>MTT<JHF@4$4$\/*J'U4$#VT$U
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M>= ]E!3<CV6'TF]%<J[F?+]H7<E*YCL;]&V3I4&LQC@&U*6H</618A2;\2
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M'XZSS73S'7=4[0]L-'/5JNK0<>Z>*G0A3RE*\SZREB_T"GEO+=+6  X <@
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M=M6\.G@\CYUT9550H% H% H%!%035'C+_P"5?O\ <-8VZK6O;7QR%>1Z2B%
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M4"@4"@4"@4"@L<U_]@\L>/\ R,K_ .076=NEG;5OER4E/83MRI1 'Z#"Y_\
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M+;ZAX=!O6F>$?$H!NN[9/@H?T4R8>H(4+I-QYBJBI'VT^=QQ^NE6."_*[_\
MB-P'_P!'Y_\ _KDVNNG3GO\ [.O5T83010*":!0*!04*MY_6.8^NH.43@K_Q
M/8*P(3_H3)ASA^]^IQ^FWU5S_P"F_AU@'CQXGQ\03YUT8550H% H% H% H%!
MXRO^5>_N&L;]5J=M?KR/240H%%3X40\*"*!12@4 T0H% %!-C010*!0*!0*!
M0*!03RH%!'LH% HJE7T\!_MRH/*3+BP8SLV<^W%AQT];\AU02VA/F2?YJJ5\
M^YO<=J[^Y'(Z%VU6O#:#&5Z>>W$I)^)0DW]-D&UTJMP 5[WC:U=I)IS>WGNU
M_9Q.OMV71M(U[M[KT?6];C^C$:]Y]Y7O//O*^TXXKF5&N6VUMS7;76:S$;'R
MK+2M"UMJ"D*Z5#QJRX,99*/DP?<D"Q_B"NVO[/MRNGTR*5)4GJ00I/F*[=N2
M30*H4"] H% H% H%!%03>J% H%Z!0*!0*">FH'2:9$$$#B:#R>?:CH4](=;8
M938K<>6EI";^!4L@5,J\WIT)AAN6[+93$>4$-OEQ!;4I7()4"02?"F4PMC,1
MEH&1;U^<RO)-)?BMOILXAB>E"DH2XD\/=7;J!J6J^<OE[D=THG<+N-L/>7(1
MHCBG8>'<)CM1$RY[:$)8>:].R>DM-]-D\"57K$XK5Y?3QZA<*%E VZ?;Y?57
M3+"!U'A?CXGV\^%64>0EQ3*7 #[:I[;8>7&ZAZB6E*Z LCG;JX4M5[ &YORY
M_1[*915TTR(L:9$?ST$_R>V@$@7)(3Y=1L/VF@L%Y:,5*;BI7+>!L6V4WM])
M-JSZ:PL<R,O(PV4*U-Q&/@91"$#U5J3Z*^!ZK=)^BLW*S&6#^7)ML]ANW"U
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MO[:@>%!'A0*H5 H%%*!1"@#G03XT$4%;;BVE=3:BE7LY?75EP699&/E$FR9
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MV[=MK$YV3(V^0S*DQ7$)2U'+#2&0E"DGJ5?HN>KSJR8+<MM21R\?+PM6F4U
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M2.#@NI*2#]7&L;;65O3269O_ (Y_LFI8G$]J=0V9EE:-ARF5RN/RCQ6HH6B
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MZ1<=5N'*GD]5GMGU;7-TP[VO[9C6<MAI L]$D=022!8$*0I*DD#Q!JV927#
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MNE;;:P5&P][P/+:.DK<NTFSY'(XR;IN=1U;1H@@XC+SVW4R&ICBX_4F0EQ(
M*UA'4XC]U1M6I?AFSY:SWTAYK'X/&1-3>=P.&GS'GMCR..:]]PI07&FI+HOZ
M;3[G2VI:K@=53:+JK[(;>XZU+U38)KT3**<0[KV#S+H5EA%]+JDBP2CJ82[?
MX95AU- &DO)9\NS ^RNC #<7JB:!0>+S)>CN,AU;!=2H)?9(#J+BQ4@D$=0^
MBLCYMV70'='9RV6>VAS5,7CW).?Q$;'D3,SG'<8$O.RIZ_\ KD)2I(,=I+?2
M!?QKGTZ3EW32-NB[IAW)[#+T:= ?5C<M"D-EIUB>PA"W$%)]BTJ^NNDN6+,-
MB*@.=5$U0H!-K'V\ >52C2>[+NR-=OLVYJ:WVLPEM!]:("J6W&]5'K+9 _>#
M?5U>0O6-NFM>W#L1OQU_+//=I9[KG;.0VAG+;-MB[X]C*I6D],-L!"I#SJ0M
M"VTD'U3?@!:L2UO$=WVS!P>X.FO-3,;.]$MN2T8*2DPI$IYALN-1I">*TH4X
M$\$J''QK=YC$XKCW;O>-?ULKFK<E9KN ZR(N>P+0,;$:G ;4E;C#JB%?#M-A
M/5UK*RXH>'5695L=WU?;,-N6/5F->4\_B/44U&G.M%EJ2E-_S6"2>MLV^U72
M7+-C-5I$T"@4"@4"@4"@B@4"@4"@F@4"@4$4"U H% H%!- H(/$6'/P-!SSN
M=V:U3NRK%.[*[)9D802EXQV*I*0U(E-I0EXI4A74IHI"V^/!58LRN<+7MUN.
M98R*^V/<4-Q=]Q;?5C93?NQ\SBF4]+<I@\O4 2H.MCET]5^-AG7;'#5GRZ;Y
M ?T5T84J]X6Y@_S^%!4"H< 2+\^/ _304\;<;CD+CCR]E!4. '"WL%4*":!0
M*!010*":"*#5-A]P2VQP"GVGE#^_9/\ NKALZZKC/7>BXK'VX2G %I']FUC_
M "U=^I$U^:V,"R0G[H"1]0M75S2>=41030*!0*!0*!010*":"/YZ@@@?0?"U
M! /5Q^GZ0?&@XKW2D8GN]EE]B\7'_4&+ID;IG6T>I'P[35^AE#G%(EN^\$_<
M\E7X<K<UN3#I&B:/@^W6JXS3=;0X,3BF_29=D%!D.W45%;RD(0%*N>?2.%JZ
M289MRV-(MPY>0'*M(F@4"@F@@BXM00>5@D?3]!J"1RJA0*":!0*!0*"A:24+
M1S"TJ21R-E@@B_UU,#Y=S?;=SMOF]6QV->?SV6:D-/:AKF-:$961&(4HLN9A
MZZNEN+\0H./]''K\*Y68=)<NS=I<_M64PLZ'ON3QTW?,7-<;RD;%)2AJ(TNW
MHI("E=0X+][QK6M9L<X[I:A.U1IF)@9;RM>V_8.EC7([@BN9+/94./K;FS;*
MZ(0]-?Y91QX#J'.L[3#6MSTWWMYM:OUO+]LL[%QV*V;766)+<;&K 8D0Y2>K
MU4IM[OI^ZE94HDE5:UJ;1T=)!'#EX6XC]M;835$T"@4$=120H"]CX\1^RH.9
M9J-I';'*R-\RD?(Y_=LZX8>-38Y#).!(!^$AH2$!#2;]2N!4.H\3RKG>&YRP
M>B[]W-=V>5CNXR(#4CU$)8U7 Q_C9T2*\JS4V6^A8#;?4KH6DI)24F]24L3W
M?U.&C,Z[DDX62_I<N3*.]M8%GKF25%#:876A-B6>OK]8H*?=^JKM#6_;PU;<
MVM$R&2[>P4KSS3&67(AAM[U8F!UM;;13\;( 5Z3B%%PI9(-SPO>I+A;'9X4R
M'D8C,_'R$2X,E/J1Y#9NAQ%R.H'QXBNDN7/"YK0B@GCX&Q\#[:@TONTO9&^W
MF<7J:Y#.7#*3ZV/N9J& M)=5'MQZPF_U7K.W36O;A>'WW]%S+[O:2=(';I]M
MMO+[#M3@5#:R*""1CV2$_$R7$]:76TJ3[Y!Y"N<K6'T8\PWNNM+B^IEM<:RJ
M$)6H#]/R\8!25%/O!STRH>XK@>!-=.XQU7SSHVR:SI>4F?JCD^#GL;DI<#7>
MU6%;6MQU >*$Y*2PHE3SKX_-];J 2@FR2.6)6['?M4W;7=P<FL8IX2G,6IMO
M+!"0Y&:DK'6II*SP6IL@@\.8K><L68<'S&NP](U_(:IMT81\_-S S6M;!B/\
M_F\JX9HD_#M1@4%'2U=E?YEN@%73>N>,-YRZOH/<#-[1D<A%V*$W&R2GBMN#
MC!\;%QC922EB=+3T#XE8'J%OH]R_3X5O6L[1T0>7&_MK;*:H4%%N'*Q)!'TW
MXF_A4&E]R.W&+[B8]AJ9+F8V= :E-1IV-6&Y'PTYL-RF+D*!2\A(2H6Y5FZY
M67#GW;O5=SVN?@NY+^3.K:LZZN:='B*5:2L69^*G/J*0Z^KT@?L)M69SRU>.
M'=E$7/(!1X=)N ?8?&NC"JJ%!2KERN/$>8J".D$%*A="KI4@\00001[01PH/
MG[N]JL759<;+8'&YG+;'G9"8,.7#B_J36O8ZRE/_ *?$;])(6[T=/2I5[JZP
M1:N>S<=.[?;;"S<,X9F#,Q+F%;8CQ(.9/I95R.AL .O-'BE0L.KVUJ5FQJ/>
M#2(I:;V/&XPY6476F_T!Q0;PJYJWD].0R#:$A3A:!]U)6 ;6\34VBRM=[8RW
M]>SNP8W YYS=)LI]GULW+:$+ Q'$N)3*@PGNI2"J_4XAI*>'38$\ZDJU]#KL
M%$"]KV%^!MX5T84U1- H% H% H% H%!% J":H4"@4"@4"@4"@4"@4"@4$'EY
M^R@T[N#H,;><8RJ/*.)VS%."5KN?:%W8<M%BDD7'4V2!UHOQK%F5EPQ.C=R)
MD_*K[?[[%&'[D0FNM05;X'*LHX&1$<]T$G[2V[</"_A)M]K8Z,GB+W)OQX\_
MI-;C*JJ% H% H% H% H% H%0:IM7Y:W7+7"T1[?2EQ1/\E<MW71>%/K9_'L?
M::C1B\KV+4#;^:K_ -1/BL_75S*!0*!0*!0*!0*!0*!0*"#?@ .JY M0<IV_
MN!F=@V-_M7VM47-C"/\ VDVI'&%@65\!8BX<DD7Z4 BQMQN3;C=L\1N3YK<=
M&TC7^W>O-:[KK)1'ZB_,E.'KD3)BP/4?>4>)6NP^BMR89MRV6M(FJ% H% H%
M H% H% H% H(H%!-!KVUZC#VZ*B,Y+E8J>@*:8S.-<^'R##3UO50R[972%V'
M5P\*S8N7!,?DL+VR>VO?M'U3'XG3-0G.:_G1ZJCE<HN*XEIYU'5U$64M)18>
M]<^5<LR.F,OH/:M6Q.VX:3@,TR'(DA-TJL0IEPBZ76R/LK1X&NF,N<N'%=?[
M'O0GLDK9IZL'IZ'#^J/IF![+; B,>E#^3FE*+,J%R(X;YD>\;7.?+67;<!.P
M$_$13JS[$C!1T"-%,0E32$-"P0.KWDV X=5:C-91-N*O$V*CXGRO]5:1-430
M*"E7+Z.-2BRRL#]4QTK&B8]CG)+2V6\C"4$2HRG$]/J,K(/0L7N%5+,F7SE_
MIC:.V:&=D_61JR6)\=2M/PK?ZYD\XJ6]\.%3'.MCXEZ0!TM#I0E"S>U^?/IT
M[?0&"S>*W?6(^:QJG?TC+LK00Z T^CB6G$* *@A25)((N:Z3EC#@>6[;;5B]
M@&KZ=BO7CXQQ.6UMM]LP=4Q04JZ),@J4X9LYM22OI44 <.8X#G9AN5V3MWN[
M6VZM'R>31'@9%B5^E3F6' J*K()L>F,L !:5A0(L.=QX5N5BQNE;0H%!! ((
M4+I((4/ @\"*@^;N]6,BZ7DW<] 3*;RN3Q_P^M9]UPJ8Q&0^.81\'CFDHLTI
MZ.7G.I1/O)!X5RV=-72^U^S!]O):?G=A9RVTX>?-0PTN1\1D3AVG>B&J4L)2
ME<CH'YO3^]6M;\,V?*W[LZ?CI>)G[*(\I3S;2!F,?BE?#2<RU=+:(LAX!1#"
M;I]0!/V4D^%+"5S;M^_DM1W-,:-F$YB?*QC3"-&Q'Y.M:ZI7IN,AZ2I1"1Z0
M]/KLI3CA%[$UF7#5F7:=VU56TZZZS:1$SB8]B,=*$1]RWOKAB44.=#+JKMK5
MT&Z2:W9EB5QS"-;5VKV?6,<K-0VU9<J8D=LL4B\&#"*5.KD%XK4/5005N2%6
M*DBUK5B=M_#Z!QF=Q.:D9%C%21*.+?3&E+3]GU%H#B>D\B"D@W%=)6,,C6D*
M!04DD<? ?5_+4'*^\;>2=?U=F2K(-]MB](&XIPGNR2JR/@T+ '_+E17Z_P#9
MK&S6K%:INS>E9"=V_<??V20WEGG,:8[OQC>)UYQ*/07.?  ; LOI0 H\ZD6N
MQ0YL/)0V)^/?1(@R4>HS);OT.(O8D7 -KUN5C"X'(>7E6A-!%!;34/OPY<:(
M^8TQZ.ZU&D@7+3SC:D-N#^Z2%5F\K'R/'UZ1VEV/%Y?-0_@'8LXS)RVUF7E<
MKD0PZA:\6CW?43**B]("B A?"YMQY]-]OHYO9$;_ -N7LUJN+:RBLM&<BG!9
M)9B(#CGY4B/)402DM J"P.9%@?&MYS&.J^>LII\_6968A[U"RF9VJ"PT>U2\
M P6L/C5F.$!$=)79'I/&SRU%74V%+YFN6*Z1W;MYW%9VY,3"LLR,I,QV.CC/
M;,PV?TE>50A")+#3_P"^X'.HGW?HKIK6-HZ$.0_\E;935"@4"@4"@4"@4$4"
M@4"@FH%4*!0*!0*"*!03010*!0/&_C0:MOVAX3N)AF\1F"['DPWDS,1EHJO3
MEP9C7%#S*_!238UBS*RX:GJW</-8#.,]N>[:FXFR.J*->V5*?2@9UM! NDBZ
M6WT@CK;)MQ'O<:DN.UQEU0A058\"? \N'M\:VRJJA0 +U,B>GVTR(Z?;3(GI
MID.FF0Z:9#IID.FF0Z>'T?[Z9&L;H@IC1'!QZG"E?_1 (%<?V.GZUS@@7\CD
M9@-VQT,M'R*4@V'[:NO>4VZD9[I]M=,L'3[:N0Z?;3(=-,B.GVTR)Z?;3(=-
M,ATTR(Z33($6H%4*!04D^-[ >)L$BW$W)X"I5<=S>[YON?FU:-VER"XN&BKZ
M=NWR,"E,1*3TJA0%JZ>J2L<W!_A]25#JY5SMRU.'1M1U#7M%PR<!J\-,/'!Q
M3[_BZ])6 %O/*_>6NPN:W)AG.6=K2%!- H% H% H%!% H)H% H%!% H)H()M
M8GD*@XSW=U#6,0[!WM."3(=7DV?]02DI+C,9LM._^L%LCFXVLI2E5^:N58LP
MW&-[-;E(P<G':9N^R/S<YL6.Q^4P>.R\LSLLU)D-%4Y$ASI ;;2HMAE!-P*D
MN.RS/3<.\^K9+:=8@"#%3E(V&R+>5R>NNK]-O+166UI5$4>)^TI+B>'-(J[3
M*:W#C>O[9'Q^_P"6S&>GN=N-8GKQTR5JD%I1GHZ62TPYDG4V^&0]Z@/I)2YU
M$@FW.L-_P^J[DJN;$*'4DCD0?+V5V<DU1- H(H!H.6]W=-@38C_<!V=*@N:[
M",C)M0VOB'IL''*,I+#8ZD]+G5U%"^-B>5<[/EJ7X8KM?IV_)S6%W&;+3A=*
M<ANF'H6,?/P,5$ELJ:>?)_YEY97U*NE/IJ\^523Y79O_ '"UN5M>J3,/$=DH
MDW2^U%BR_P!/3,4U?_*R'NA=F';V<'3Q%:L9E<!P,_):BYE<Q-PPV#3- EHB
M9[TG?@,5@9>/5ZI3B<< Y\0ZSZP4IY3J.KJ'N^)YY=,/J)IU$AAJ2UU%I]"'
MF[_:Z74A0N/#@>5=I7)Z51-!!Y'G]7.@M,G&=R&+R..:=]!Z;$D16WTB_IK?
M:4VE8_NDUBQ9<5\IXO5,QVIV74H$W%NK_2Y",FC!:\@97*Y-Z&PY&=F-(*FO
M2:E%9>E#K59WI''PYXPZ9R^E]?VR!MFM.;#KK3CPM)8&/F#X=]$V."ER*\GW
MNA87^6KG;VUTSF.>/M\WYK46<9D&H_>"'(P&AY&*_D\7J^J)O";SJI'6E#S_
M !^(F'BZV5)3TJMQM7)T=3[7=R'YD7#Z3G!.R>[?G*GEEKUU8['IZEQ%Y1VX
M2AU;00%]/5[ZN/&NDOVQ9],+WQTF#C863W.'TM0<J[!AYG"1P8J,K-EOMQ$.
MY&4"HKC(04?D= !*;]0O4VGRNM^&W]O96U8/..]NMB7"R,.%B&<KA\MB8J($
M)#!?^&^"2VA;@)04DA75<I\.--:6?+HXO?C^RNC"JJ%!%!Y26$R(SL53BVD/
M)+2G&CTN)"N?2>-C4H^;,KH6X8'91KVC8=4[].?.3PN/X0=:BA1NF;E)'YGQ
M<T@'H04( X\;&U<;PZ1V;MSN+.U:NS-DICP<E!F/87)QV5 QAD8UBMN.K@%I
M(4.DCGQKI*S8W)/*M,E4*!8>5!IF_1Y6'QTS>M4PD?([_ 98B17W$=;WZ:J6
MTN4@<;62WUN?2*Y[-:N1]O.X6-U?9GLANNYOQ\1M'ZD[#Q6?><<F!_\ 5BU
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M,!ECU9!I:[=+R^8 =!2NP)L56K>M9L=!N+V\:TRFJ% H%!% H)H% H(H)H%
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M/N=/UU.5X;'BNYG=&3MS^!V;8(.#?R[\R'CL%*QK);$8('IO8^<QZGQ+J@2
MV^IN_G5^4:OIN2VW =J^UN1R^4A;)%S>Y08$&-D<5&4K'-?#35NN-.DJ47U*
M0CI=X*0.H#[1J1:SD7NCWIC:)E>\F5S./=UK!YAW'2-51C6$*?@IDM1TO"6F
MSB5W=3[EOKI^3\-C=W;NSM4??MUU3/8S!:[H\S)XN+KTN"Q),UW$^HAQZ1*=
M]]@+*>IL)!"N7"K4GTZ9VDV3*;CVPU':LVM"\SF,7%FSEMMAMM;SS25*LA-@
MD7/ "NDZ8O;=*(X]\Q.[;YJVL8_$=K\4_E=]V"4EC&&.V'?ATQR'UK4E1""%
MI0I!"CXU+6IRQF UCN_W7P4*7W;R#NE8EY(1.TK"I2Q-D+95;U'IR2'&DNE/
M464A2"@]/*LR6K;(Z]@<!A-7Q;&$US'L8S$L$^G%C(#2>LDJ4HA/ J422I1Y
MFNDF&:RE:0H% H% H% H% H% H% H% H% H% H% H% H(O;C0<N[B:[/Q+Z]
MIT6-\/L&76F!G9;B@YC8L()+BI[T-8#;SK90$I*SPZCXUSLY:E:'VNR>&P&P
MR8FGY:7-@[?DFR=HSL<WRF390X9+<$'J<](DJ5=Q*$M<$ F_',:L=SVZ=D<5
MJV;R6"9#F6C17'HH* Y9:$'\P@_:],77T^-K5TO3$YKAFD]QV\7M6N18.US-
MX_U% $G;FUMI;C8Q\CJ^)]1]:$1D=7Y182>9O;E7.5JQ]%I(6 IM04A0"D+2
M>"DJ'4"E0YI(Y5T[85#EPY>RM":"*!04J!/#]T?:/LJ#FG>S1I.^:HSCHT%6
M38:EL/9;$LNF-)FPF2HJ2VX >IQ )Z$*X*OQ(K&S6KG7:?:XNA9?/XS:DA'5
M+9Q^1D8F-Z6-A2D@!+L]("4M2W19M89"T (!ZN/#,K5CM._Z/"[B:VYJV2FR
M(4&0\T^ZY%4076T D-+%QU-KZKE)X<!6[,L2X<3QF<SFBS=KWK#HD930=7R#
MF$SDO9,W)E3G515)0^N%%4GTVTIZT>BGKNKC>U<\X;QE]&PYL&<PQ*@R&WH\
MII,B.4GI*V5BX6&S95CYD5URPN/]N?"_LJHFJ(H"5%+@XD CC;B;'V'A4H^?
M^Z.4WW#AS;-DV^-JOZ7(4K4]1Q#9FN957J>FDRR>E:DN)/3T%)0@GJO=(%<K
M;ETF,.NZ1N&+W;78>>Q[K:W5MH;RD,)6!'FA-GHZTN)2JR%]2>(LJUQ<5N7,
M8LPY#M7:'3M1:S&1E9ES3>W,V[F8=Q'5^OY&0\OJ]+XUM/K-M!12$M("DD#C
MP-ZQ9AJ5O'9?8I65TK&XW.SF7-AAI<0W%+K?QWZ>VXI$0O-H4??]$-WYD\U6
M-ZUK>$LY:UWMT[5L1C9.W1\#CY&R9_*P(<[(9>.F=#B*DK0Q\6J.M)2I:$@%
M(5[O#B0*S>%UY5Z)W!@ZULN:[>Y79HFP:]@,>UDD;-&BM0843U%%*H:RRI3:
MR.GK3Z:E*]_IMPI*MCLT62Q-BL3(B_4BR4!V.Y8@+0H7"@% $7%='-[5H*!0
M6>0A1,I E8N>T'H$UI4>6P?WFE_:%ZS5CCV.[(ZAJ\>0]MDR-&[:X5QQW$ZJ
MV$1L4&@JXD9(@#XU]9L?S$W2>";@UCRUEN/;/N;BNY;>8?P.+F0<)B'FXT.9
M,:]!$MM85TNL))N&R$^[U 'S%:ERS9AOE;0H%!2KEY#S\1]%0<V[RZ<[L&IS
M\EA8B/\ 4\9MA"YS9+4U6(9D)D2XK;Z1U)2XV%^X."K])X&L;1K6N,XC9##V
MR-)[:PSVVTG-ML18>">B(?R64GL/=:W&8#:EH:0M(])<AQ:3]HCJ/"L1JOI=
MV/D<ACD3DXZ-$VR.V\<4):>M$24\DM@E5B>E0MU6\*Z?#'R^;(.?RFN9[)(V
M_(Y" K96Y)S67+)3L$]M"%(6<<PR5HA0F.@K;=2L+4M)/3?A7-OE],X";C,G
MAL=.PLPSL4[';$265J6IU#:0CJ6I0!4OW??)XE5ZZSIBLI6D*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*"*":"*!030*"*!030102.=2BOP%1$<.*3R(*2.5P>'"B
ML!I^H8/0<6YB-::<8QZYLG)J3(<+ZOBISI==-S^Z5'@/"LS5J[98O']K-)QN
MHY/1FH*G=:R\B3,G1)3A>4J1+>,A:TK4"4E+AZVS;W2!23@MN6(P/8OMW@X^
M18=8GYTY6)^G/O[%-<RS[<,&Z6F') 46DA0"T]/)7&I-2[+;%?+_ -N,3#RD
M3HRF3_5X#F&>DY;(O3I+$!T%*F8KKH*F4V/#HX4\K=F1D=E^WTR-+AO1)18F
M+Q+D@?%+!*M?#*8=C;ATAA'7][C3RGIDML[9ZAN\E<O88\AZ2[CGL,2Q(4R/
M@I"5H6D "W59:K*JV9)<,!L/87MWLDQB9+3DH3K4-G&2DXS(/06YL2,@(0B:
MEL /^Z E7J7N*GE?2YV7LGH.T2X$M;,_"2\=&1 CNX":YB5N0T$E+#QC@%Q
M)4;*\S2ZI-E>K]D^WFF9/$9;7(4B--P7QPQR52EK:1^JMMM22I%@%72VFWD;
MGQIY6[,MLG;O6]JV#";/DU3(^<P"RJ'+Q\M</K2KINT_Z?\ BM'I%T*X'B*6
M927# -=A^W+6P_Z@;CSPV)7Z@->,UP8(2_X@QUO1X>'"IY7TC&]B.WN)V=K:
M(K>2<D1Y2LC"Q4F>Z]B(DM9OZS$)0]-"Q;W2D<*OGE/7"8O8GM[$6D-HR*HL
M?,,;'#@.Y!U42-D(K;[2#':MTM-E,ASJ;2+*]V_V13ROIDW^TFCR-%R7;9<>
M5_I/,/JES8XDJ$A3RGFWR4O#BD=;2> ^BGE/3B_<_MWG)6V[$N%H66R:\^@-
MP9^O9%R+@G5NMJ1ZN7AW0E:VBKJ)2E?4>)\ZSMVWKT[QVVU9_1^WVKZ9)>1)
MEX+&Q<?*D,W])QYAI*%*;Z@#TDCA<5TDPYVYN6TT0*B 0#8*YCSJP46'.W&J
M%A5$T"@4"@4"@4"@4"@4"@4"@4"@4"@4"@BH)JA0*!0>;\>/*:7&EM)?C.CI
M>8<2%H6F]SU)/"UZR. ]QX>W:/G\UW-G9[&8;$(C,8C578L7]1R,6, "N-&A
MNMI:*G%(#GVQ8)-<[,-RY=([7]P6-UPZ4N-38FQ8MF(<HQE&68TIPR6@XW*]
M.,MUI*'DCU EM:@F]JW+F)9BM*[DZ!H>*,O.;.[).J37E.QM*P<?X161RSMR
M5R76+?$K4I1*/B+)1>X5PK-BZU>]BMRQKVOQM%RN;:?W6 Y*6,02\MV/"4Z5
M1XJGW$!MUUAKI0XEE:[%)(X"FM-H[%8C@>?C75A% H% _P!OV4$'AQY7X$@7
M/&H/G[N%HV?QKN1UMG96\1VK[@9AM.2CI8]3*N93*60(495@ EWT4CU"XDHM
M<"N5G+I*W#LEO,C;<",8_CC"_2H,.1"=0^_,;=Q\M3K3!<D/@*4^"POU!R'"
MKK4VC7>\7;;&MRW]]C--%GJ#^7Q\];PP#*^ 7D9<-A#HENWM[JVE=1YTLP2L
M7VBFA.="W,ZJ!D9LF.XJ;G T)^:BI2OK:C1.I;>/CKN"PA"PNU_=J0KZ((*2
M K@#:P\;>WV&NK":HB@?5?V>=0:_LV&DN [%K.,QDC?8; B8?(Y1)"8[#C@+
MA]5"%K2$@J7TI%E'@>=9L:E<6[?;EE-/Q>2W#-05Y+4\OF?A,[MCQ#$U[(A_
MX%I3<5"E-)C(<(920KJ/,I'(8RU8[QL&'.6QLW&A3;60++[6/GK0%_"2W$%"
M'V[\0I"B% CCPK?<8Z?-^(T[<LEE\3K.D:LWIFS:@_);V'N-(80MN:Y,:(*X
MH *I3B@OK4E_I"238^>,<MYX?1<; MIUK_367DN9:,]&7#R$Q[@Y(#R2ETGB
MKI)N;)!]WE73X<WS5O.G'1Y1QHBLQM5QW1)PRWHB&M7Q@D**$%R*PE9R,\J2
M2VE]FW5TW5;ESL=)7;>VFPZS.P\I..RDER8U);;RT?+K++[4MUIM(0TVZ0EM
MM? MMM$I%[#C<5J,V-^!_DX5ME-4*"+#R]M!J?</4&=SPL2$XRW+>Q<]C+P\
M?*N84N1%2M*&921?J9/62I)!Y#A6-IEJ7#D)S.PZCW"B93/;J=@W&6PXQEM1
MQC#+."Q\0_X9?EO.--MI859/64^L;_9K$X:=YPK^0D8> _DW8K^1>90N0_CE
MEV&M9%R6%V'4D^!M725BLE6D*"*"4GI((M<&XORJ#@W=#4<! W#%93+R\EA=
M6V!U3.Q;+C%OG*N2BGHC1/BXX+[$8K#9"6[I*OM #B.6TPWJV_M?GHD6._I6
M0V*/D\ICWW48E#LGUYKL,%2@'7#<..(',!2E #W@*W+A*]-QQ<G5=GF=Z\=,
M0@XO"*A;)!>1U*>Q4!Q<T^@KC9TDGI!L/,UFSY)?AK?;#8LEI[6J:3G<+"P>
MJ[,W+D:6XW.<E3+K49JFYGKA "U^M[@:ZN) J:W#6TR[.#[RDW2;&QZ3=2;>
M"O(UU<U5[\:HF@4"@4$4"@F@4"@4"@4"@4"@4"@4"@4$4"@F@4$4"@F@4 <Z
ME%59#Z/V'C01;B3^SV4 )L+?M/G0+'SX<O/A0.D^9]GT>1\Z!T^1X>5 Z1P'
M@.-O;5$V_8>8/'G4$$7\3_MRJATCZ.%@1S ]A\*@@(' <.D<A:@D@^?O>?T<
MJ $VX7X>'G0.D?[>('*_G004W\>!'*@FW"U[>5N%J!T^W]G"@F@A7A5@IK0F
M@4"@4"@4"@4"@4"@4$4"@4$T"@4"@4"@B@4"@F@B@5!K>[:DWN.+9AIFKQ>4
M@OB9B<LTVE]4:1T*:*_260EP*;6M!2KA952S*QH4/!X3L-BG)6/,S:-NVB7%
MA0X!N%R'D\%-QF0HHCLMM];G2GI0.@ > K'2]NJY2"G)XS)8D2E,IGQI$%4J
M.H*6R9#:FBM)!^TCJN*U>8DN*X!#[9]SL_\ H6DRDP],U70E%$+:,:@KR64#
M\<QW%LI58-J=;6?7=N%APDB]8Q6LQW_$8V-A\9%Q4-;SD:(V&FW)+JI#Z@GA
M=;B[J43YFNL87E4*":!01;B#08C8]7PVWXE>$SS2W82UH>0ME98?:D-7+;S+
MJ/>;<3?W5IXBLV967#Y7?E[CIVTS<1K\G)?$X:<O#:?K<9*TQ8C#:P8:9' -
MR6YA6YU.N=2T=%^'57)M]>J;#K01(;"FW$I#R%>\@FP*N? @&NKF^4NY&#S.
MK1MRPLK%0FCF<FO8#W6EMJ?7C6I#B2PV@(0M]4IOW@VVTA21U*\+URL=97;.
MS^;QV3UZ5#9S4[.9N%(]?.R<JRJ/)#\P=2"EKBAMI?0HMH;/2D>5;U8KH05?
MZ/'_ &\ZVRFJ)_V% "B@A0\.(^FH/GON=V]PV%S&LL8":]B&-CR[Y4_,>4_A
M<5);95)5*5#>/PZU.*%DI='2%D*^T :Y;3%=)<L[V^[FY^?L^0T%]3V_/XF:
MEF5O,!AF+#$5R.)'JO!HAGJ#A] ".5<KGC>KKM\)=6X=VU;,K1)Z-6<>1.]6
M.F8]&5TR$8M3H^-4RHD%"PSU=*AQ!Y5K9)C+A^M;VG%[.\.TF4D2^VTMJ+$?
MR^UR);J#F1((?:@H?29"WE-!*#TM^D">HJ XUSF6[AVO;<-.WW3X,[&H>Q.Q
M8V4WF<-'EH0M7QL!SJ;:=2#T@.J0/>'%(-QQK=C'3AT>5G#O>:[B=P,=*W+)
M:@4,; O$."/@<.[$/K^@AM?IJDO1PYZQ6ZW[O7[I-8C=CZDA3H^2@1LG!<3)
MA3&TOLO-J2M*DN#J%BDD>P^VNLKGC"X!!Y<O/S^BJB:H4%*CTD$_2#]'E4'$
M>\6$P^O3<?N&6U[]8[<L%US:M<Q[*.J;E7W/\O,E-6Z9"4W4BR[\5WKGM&XP
M_:[?<OKSLC2DZZI^5DLD[.P6K0'S(EX3%2%DJ_47"3':2U="$,,.%2>/NBI+
M@L?1*@ HA)Z@.1\ZZL(JA010>3Z77(LAAA]<53[2VTR6>"V^M)3UI'#WDD]0
MK.%?*67A9[3V86&DXG%:?'TS).3%;ZAKUY64>DK]7T<<TE"G77G4K")!6@)2
MDGC:N73?;NFB[O'[A:V%[1A_TDYIR1!9P.1 ]>7';:N]ZC9NDA:#UE*>'2>-
M;G+-<V=[%Y]C<$LX.8\N)'0'HFX9T_J"L8PHE(AX>(ZIQI#H ]YY00M*;=)'
M2*SCE<NW:MK$+5,*WA<8[*EL,GK>ESGERI#KBC=3BW%DDDGPOPY"ND9K,UI$
MT$4$T"@B@4$T"@4"@4"@B@F@4"@4"@4"@B@4$T"@4"@4"@#G4HJK(4"@4"@4
M"@51-C4"QH(H% H%!-C0+4$4"@4$*\*L%-:$T"@4"@B@4"@4$T"@4"@B@4"@
MF@4"@4"@4"@B@4$T"@4%)O?AR\3X_54',N[&@ZQF6U[]GW<F9.N8Q]F-$QDQ
MV$%A2_5!ZVE H5U6"EIY(O6-HU*U3MYM>5T1_4M=VA6+1A]VC_%82-C)4K)S
MX\AT>JE+A=ZE+:*+];GO>_R-JDJV.YLR8LI!=AR&I33:U-*6PXAY"7$$I6@J
M02 4J!ZAS'C6Y<LWA[#E51-410*!030108W/2,Q#QDN=@(#>3V%MDMP8SJNA
M*U*_=6NX(1YV-8O2QQ"%O><[?=R8,#N#N43/R-H:6G-XV#')@:\J+TAE+3S2
M>"5^HKK5*"5'I'.L9Y:PZOOVJ/;?@XT>#*,;,8B:SFL%* 0ZT,A&2M+16E5T
MJ;(6H$'A6]IEF7#Y_P#UCNS"V_-;3C68^P]TV(T9K9\;&4J+J^(@)!2&R^\6
ME/RK>]=74EOI4.KC6.96^*^CM?V7&;"AYO&RQ.>A(9^+E,I)BN*D)*DK8=MT
M.)LD^\@D5TE8PS@Y5I$T$&]N'.@QN=U[#[7AY6N[%'^)PL\!$MB]B4@@@WY@
M@B]9L(^3)V+SVH[DN'C/C\?,PZVFX& Q:E8[!8F%ZJ F<\HEN(^V\CW7UO*]
M0*4I5N1KGAT^'TQI^]XS>E348F,])QT%*&I69],MX^3*X!UJ-Z@2IQ -R%@=
M!3XUJ5FQRKO)J^/P,^#)Q>.F9#,[6^[CFI;:"]'P>.0VE4A,%E(*6'WPI24/
M)"3U'F.=2Q973M#V^+FV3A7H:\+D\:A##.,R.2@S<D_'9;2$OK1&>=6"H"ZO
M4 /B:LJ6-"[QZ#$CQLKL;$_)1M9S2[;9J^'Z4O9J:\.EK\Y13\/U6"7'$J'#
MG>I9A9<L=VWR&V:?M#VM967"RCTG'(7@>WVN!;C>(],E;S3TI:>E-FRE5GW.
MM2U&U^%27'99GI] ((4E*K$$@$I/#IN.(X>5=8PKJA04G@;CZ?;?PJ"AQKU6
M76%%26WD+:46U%"PE8*3TJ'%)X\".5!A]5U' :5BAAM;AIB1;AR0X3UR)+OB
MY(>(ZW5F_%2^-23"VY9VM(4"@@\OZ*"GI/'S/EROYWYW%0:CO&G3]EDX+.8#
MX1&Y:V\^O 2<D%*BL*GM?#O.J2A*R5H1[S0M8K^UPK&T:UKC6D['F-=8C=S<
MG#;V#3\UE_TY&S960X<\J?+?./4]%C%:HT:/ZB"VI#1"U)'+C6)6['TOZ/2^
M&5J(LJUSPY^/&NN>'-\L;UO$R?*Q>][OFI.OP->ROJX+MU@DR7,KD&6W0E3F
M1#0*DE71[G-D^8/57.UN1]*XO.XG,QH<F!);ZIT5N>Q$6M*)(CNW 4II1"P.
MH*3<IM<&NDK&&0!!Y5I"@4"@4$T"@4"@4"@B@4$T"@4"@4"@4"@4"@4"@4"@
M4$4$T"] N:!010*";FH!/G015"@F@7J!>@BJ)H(H)H%!%0*!5$T"@4"@B@4"
M@4$T"@4"@4"@4"@4"@4"@4"@4"@4"@4"@H=0TXTMI]M+S#J2V\RXD+0MM8LI
M"@;@A0)!%2J^7MW[>0^W>7=_0FW8N.SJGO2=@MKDYN5U N+A1GGPJ-C83:.K
MJ<0XTJR?'E7*S#4N72NR,_&+QQQ&.RN/0N.T5IU#$W>8B(*Q^>F2]=Z4M7 /
M.]2T%:CTJ/"M:I76;$<#P(X$5ME-4*"*!030*"/HXWO:_#@>?'G4'$>\F%=P
M.L92!K6.BX[ ;&LG9\HAI+^8G/N+26XT9*P4+<5[UO6/2D7L1?CSVC>M;EHN
MW2Y$P:9G=?D:OFH4-M_'Q)+Z)1D1 #U$*2I7OM\.OJ/CPJRI8U'OGJ;+&!R&
MW,/N#&1DH>GZRGJ8QLV;ZB6VY4QYA27@AM+B^I"?=62"JIM#6LCV[V*7BME<
M[>O;!C-FPL3&B=&RF*1&BQ,:0I"$PE(BA+*0L*NS^\4IXTUJV.M6MP(L?+E7
M5@H%!%!I'=776=AU94F7%=RS6"*\BC!!YUF--Z$^\U(0TH%Q  *@BQZN5N-<
M]HU*T'LDO:,KE9FR1WG4:<\!%>@2F'(<<=+?4@08ZTH])+2K,E(0E)";\;U-
M5V=OD)DNQ),:'(5$>D,K::DH_P"K6I)"5@>/23?C6[&<OCZ+@Y7:+/PLAE<4
MQBG69KD]\,K$[8,K+O\ :@^EZCYC2DA#"OBO<;(6I-JY=-]OJO7,[CMYUB)G
MHL5YC%Y=E75$F-+:=0.HI4A:7$I-P1S KK.6*^?-BUS5=%V/-X21,S& Q$6$
MU,UAK$L2)3\W(K6M7Q#\EI*G)#@-@&I"BA('"U<[PW.7;^V^W(VK7HR)TV')
MVW'LH1L<6"ZAX1I*E*"4N%LD!12$W'@;UO6L6-QK:% H% H% H% H%!2%%"P
MH'[-B+>8Y5!Q'=NS$09B-EM.1'PR5/NS\CF,I*>7CL4X$]7Q,6"I1C%T$=2?
M5;Z$J][@>-<[&Y66[); _(QN2U>7G1L<;#3WHN$V63TM/Y5OI2^ZM+9/YG0M
MQ7OMW0$VXTUIM&;[B0LEA\?D=PU96-P^>+!&:VV>R9$R)C6N*E1P$KZEIN2A
MI?Y9/.KM$E:+VPRZM0=P3.SZVG$QMO\ 6_3MHR4AI62=D"RD,R>I:DH$@J'H
ML1_<23RXDUF7E;S'>.A:#TK!"N=B+5UC)50H%!- H% H% H%!%!- H,9 S4;
M)9'+8IIM:)6&6PW+"^1^)07&RFWF!4&2!N.//QH)JA0*!0*#QER6H421.D'I
MCQFU/.JYV0@7-0:_KNWL9Z7#8]'T$91+KV-/6%*4RQ]HNI'%*C;EPK.5PUG7
M>\>*RFNQ-BR\1W&-9!G(RH;/0X5%K%#J>!)%BH@CHZ>9X#C2;&'NOO1IK++4
MV0)36&D,.SV,HMI8CN0(]O5D E/V$WL1>]/1A0SWEUWX%<^4T^II3\L-ML,/
M%UJ% #1=>>24GBD/(]U/VK\/&IE<,MA^Y6OYS)S<1#3(1)B?&!EQUM2&Y*L:
ME*I ;)2+!'6CB>=^%7T>6G8#O[B\NPY-RD!6%Q\7X)V3(D!Q8+.10XI'II2+
M]22W8J/NF_"IZ/+,RN\^!@YI&(R&.EPFF8+^0R\F1[GP#;#K;2/504A1#I<3
MT*3PJ^DPNXO=O6)A99B-2Y,]:777X<=I3[C$=AQ+*WE%M)"DA:T@]/G?E3)A
M<Z;W&QFVY"7B5QW8&1BJF+2'4GTGHL!_X=U]*K  )60+7X\QPIDPUT=X$9[6
M=GFZ['^&S. RL3$!I;K;X<3+D);2^DHX64UU+"?"IZ7RV;3=X?VG)Y7%NXI_
M'.8QQ]I"I2T)?>3&>+'J>CP64.$=8<2GH%^DF]65,,-D^\.,A;1L&J,0_6R&
M _3O4>+R/3>_49+#!2A/V@6P]U'^[3T8>C_=K'1M=A9B7$<1D,J_F(N/BH2M
MQN^$]93BW5)!Z4]#76>(OR'&IZ:\K?+=[==Q<=!3'?DR7HSKT9]IIWX5^1%@
MB>\TA72?LM&X)/\ 9^UPIZ3"J)WGPTI]IEK$3?<BN2<H;<8CB(PE>DI)3=94
M@@A2> OQ\:OHPSJ^Y&N-X+"[!^:J%GGA'@A ZU)65=)*R 0$I/VB>5,IAAFN
M]VD/1')K"WW&VRE7N)*A\,MQ3?JJ6$E* %)4.A7OG]E3TN%;W>O1VENI0\])
M_.1'B!A!<,EQ?/H"4DIM<?:YT]&'O-[Q:7!CLNO/K$EY;+!A+'INM2994&67
M2H (4OH5Q58"K=DDJU<[QZ\^_KR,)'D3XN>GX_'_ !P:<0RP<HIU+?5=-^J[
M2N'AX^%3TOE>9#N[IF+R4G$2W7D3X8R!?:#:S_\ 8I3:71?IM=7J M"]UV-K
MVJ^DQ5H_WHU1$>*ZVU,=>R;S+.%9]%Q)F?%M.NL.(/18(4&E=15]GQM>GI<+
M,][,6(^MN?IDETYI^%%G.LH4MB*Y/9=?0V%!)ZE!+1)L>'(\:GHPO5]YM/DL
MSSB98>D8U+CTKU&W?3###B6UK'2+G[5TVYU?286C_?35XL]MJ5'D,09C"7\4
M^^DLF8'4>LV6^M(%E,A3@_#S-3TOEM.5W6% U6)M>-CN9-K)^@,7%00RM\R2
MD)N7  GI"NI0-N5N=7*19O=P?TM\8[8\+(@9Q"#)D06%HEEO'ASTC-46>H);
MZ_W5>]]5)L88U/>W1AC_ -8==?9PS[BH^,R+K:FV9LE#QCEMI2D@ ]8YG@!Q
MIZ7 .]>FJE0XB!)+DM@27%I:4IN.E<LP$!:@FQZGQT>Z?[7V>-/1A1@>\^"S
M$+\Z#*CYHG_+8H-K+DE"I:H2%-$IX7=24F_+[7*GHPJC][--DQ<=/91+./G.
MM1GI!8<"(C\B6N$A+UT7!+J%#V#WN1O4]&$-=[=,DI(AB3,DJ<"8T:.@N+>0
MIPLI6.E)";K2I/2KB.9X&KZ3#.Y;=66-9Q6R8*,<JWG)T3'8]OJ](*<F.J9N
M2JQ 0I)!J79?+!0>].L.SG,-DV'<;L$&48.9QSBT.JAO_NW4@$.)5X%%[4FV
M2S#S9[XZA(Q[&0CL37$S7XL;&L^BM*Y2L@MU#*D71P25,K"K\O&UZ>CS5Q![
MTZADHS4B&U,<7,7':P["F'&USW)96&TM!2!;BVJ_53T>6.F=^]0C.-]#4A,-
MF1%9S$R2VMI$-F8EPH4JZ1=5T6Z1QIZ,-UR^;RD/6V\[CL85ON-!]<::XF.(
MS 0I9<?ZRDD#IZ>E/O$J%7*2-4QW=:;E#CG(^N/_  V2,&,T%NH:>_4,BPY(
M0T4KMTH;#2DK*K7Y@VJ79KRQV0[YP<-A6Y65@M)SZIKD->,1);;'PS#XCN2D
M*6??;2XH)LDW)/#A>GI/+KKB"VXI%[@'@K[P\ZU&2M!0*!0*"*!4"@FJ(H%!
M-!% H% ]@YGSX"H,-M>"7L^L937F)/P;N184PB1Q"02+A"P.);4?=<MS234J
MQ\O9E>RN9K7L;GL2G2SBH+F/1B=490[F,OCHBEMNO!Q*5I8A**"4A:DN=5K
MFN3;ZCUK*8C-:[C,GKZUN85UA+<-3G65A$?\HI47/?*D*3T+*N/4#>ND8K+)
MX_0.5:155"@B@4$T"@P^S:WC-NPLK7\NA2HD@#\Q"BVXTY>Z76UI(*5)MS!K
M-BSAP(0]BUK<=TR<7<X<7(:W$AN2<ULQ2B1/;<2OI8+8NAJ. DCJ82E:R4]1
M/"W)MUCMSOT;NOK\C**UR3"UU]IIH+R;?2U.6M)+Z$1WDI7T-$ =2T]*[@IY
M5N7+-F'+.X?;K5-:$N7E7G%2LH];1]/UIA<-(R" H1WI#L9*%N])/O?$E32.
M*4VN!6;&I7>-41L+>JX-&W+2YM:8,<9QQ'3TJGAL>L1T>[;KO]GA72=,,Q6D
M10*@D$@W!X\[^T4$K4IPW62HCD2;TPJA7+^7SHC5-T2K"1G=XPF%BS]JQ@9#
MDIQH+EIQ3:BJ0EE8'6#TE5DIYWM8UFQ8XOVEW?&:SE?C-JV9U#6RQO67$R*9
M)D+E&2[_ )YUM8M":* AFS@;3[G4!QO696K,N\[1KK6X87]$?G/PH;ZT/*DP
M5]#JV0+J;0X""@.)/VVU!7D:U>68YAV\U!V5O,3;]:U].E:)AHTV"B,/^;SZ
MI" VF7*'V@&2.I!>_,XGJ)X6SAK+JN*V/"YYV4UB)8EF'T^L^TDF.KU"0DM/
M6Z'![IXH)'G6Y<LV896M(5 JB:!0*!0*"*@6'[>=46\_'8[+Q'<9EF$R<;*'
MIRHZ[A+C9X%)MX$'C4H^=M?[4[]DMPC(V:.O$Q]98Q[.,V*,Y';A2FH&2>F%
MN)$C%)9]1IU++O6V.H)XWO7.:UTR^BY3$><P_&FM(D0Y*2W(CNI"D.-J^T%)
M\CY5T<WS3M/:[(:QL;2X<I;N)C.A[6\_GWA*B8-N0KA%QT,*6N1,24DMNR&U
MI3PY<ZY68=)<MN[=[W!QW;'8IN)ART;)AVG,O+BYZ6)STI;Y"$25N1U%*$.]
M!LTT0$]/+C5U9VZRW?(;IE=;C-2MIBQ?2>AKF)5 #R;K;2@] 2_QX]8K<8MP
M\(&_9&9F9>NJ8@MY:-"]9*PZI3:IR1U.,]'45A*1POYU4RML9W2<RN%3LK>.
M0UA5R%0TME2C*#K _.)M[I'44]%ARO>A*KR&[[;A83.1RN-QKS&2:];#LPUO
MAP'@0A\K58\#]IOA>DBVLMIFZC;LCFHB6$,-8EK'*X%1=]:<RIQU"QR!;4GI
M%"7+;ZJE H% H% H(H,="PS$'+9C,-NK6_FU152&E6Z&_@VBR@((X\0;F]3
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:A0*!0*!0*"/IH!]M035"@4"@5 JA0*@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>fc_fig05stagedevelop-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_fig05stagedevelop-4c.jpg
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M Q$!_\0 O0 ! 0 " P$! 0            8$!0(#!P$("0$! 0 # 0$
M          $" P4$!A    4" @,("PT%!0<#! ,   $" P0%!A$2(1,',2(4
M5)34%59!,M*3LU5UE387&%%QL=&2LB,S4W/3-!9A0E*D"(%RPB2TD:)#="4U
M-\%B9/""1":A8X01 0 ! @0$! 4% 0$! 0$    !$0)1$@,3(9%2%3%A!!3P
M08&Q(G&AT3(%(T)BP23_V@ , P$  A$#$0 _ /W\           "4LCMKE\N
M3/@;%%6(               T5[>AMP^39G@%@-M"_)Q_ND?-(!W@
M    ):R_KKG\MR?!,BBI$            $OM&]"*UV/H.QH_?2+ J!
M
M                                      !*61VUR^7)GP-BBK$
M          :*]O0VX?)LSP"P&VA?DX_W2/FD [P            $M9?UUS^6
MY/@F114B            "7VC>A%:^X_QI%@5 @
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MZ S<M")\J9(=DL-'*95'<-4-]<=9Y%Z<,[:LI]DA!OP
M                                  2ED=M<OER9\#8HJQ
M     &BO;T-N'R;,\ L!MH7Y./\ =(^:0#O             2UE_77/Y;D^"
M9%%2(            )?:-Z$5K[C_ !I%@5 @
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M4:TJ4FB4".<6EMO2)#4;.MQ*%RWER'"2;BE&236XHR3C@6.!:!!M@
M                                            2ED=M<OER9\#8HJQ
M               &BO;T-N'R;,\ L!MH7Y./]TCYI .\            !+67
M]=<_EN3X)D45(@  # J-;HU(6PW5:C&@KE&:8R93S;)N*3AB2"699L,2QP 9
MX#HCS8<IR0S&D-O/0W"9EMMK)2FG30EPD+(CQ2HTK2K ^P9'V0'>     F-H
MI&=DUDBTF;&!%^W.D6!3B
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M;TPH*&T+O@WE3G*C C2(K;2VDFU+2A+AIDQ69C2BU:UE@IJ0V>[B1XD>X(*
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MF833IH-Q$=M+9*-IM+2,221=JA"4%[B2(MPA!G    EK+^NN?RW)\$R**D0
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M6ICS6CG !T+?/6ICS6CG !T+?/6ICS6CG !T+?/6ICS6CG !T+?/6ICS6CG
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M2WWUI;9;2:W'%F24I2DL3,S/01$6Z8#DE25I):#)2%$1I41XD9'N&1@/H
M   EK+^NN?RW)\$R**D0            2^T739-:(OL/\:18%0(
M           )RP",K)H)&6!\"9^:02*,                   $K8Y&17%B
M6&-<G?"@450@                  "3H9'^N[M/L&S2L.]OBBL$
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M2(2HJ:7;E HDB3+H]+BT^3-2VB6[%90RIU+!K-LEF@BQRFXO#'^(_=$&S
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M"@                  PZ<6"9G_ #LGYQ#.[Y?HD,P8*
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MCOWC5(<&"Y"2[2'6UE"JK&I)]\W6E)6VZ^TMMUM"5&>5*5$:RP[; TV!ZZ(
M"4LCMKE\N3/@;%%6(,*K5BF4*"NI5>2B)";-*5/.'HS+424I(BQ,S,SP(BT@
M,EA]F4PU)CK)V.\A+C3B3Q2I"RQ29'[AD8#L -W0>X X---,-I990EMI!8(;
M01)21>X1%H(!S       !HKV]#;A\FS/ + ;:%^3C_=(^:0#O
M  2UE_77/Y;D^"9%%2(            )?:-Z$5K[C_&D6!4"
M        ";V?^A-!_P"29^:+(I!                   $M8_U-=\MU'PPL
MBI$                   2=#].[M^YI7@WQ16"
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MB49?L0DO>(O<$&W       !YYMX_\-WMY)D_- ?SX7VZO?,>!O<0
M           85'_[3"^Y2,[_ !E(\&:,%                  !ATWM)G_.
MR?G$,[OE^B0S!@H           "UV;[/KVOFLM%:#3K"HKB3=K.9;#$16Z2C
M>3I)79)*,5?L&=MLSX),T?T MBFU>D4*%3J]555JJL-Y9%26TE@W5?W$:-!:
M,=T]T](]<-,MN*   DZ'Z=W;]S2O!OBBL$
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M)+WBW3/LF>D^R-D11BS10   !)T/T[NW[FE>#?%%8(
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M\<IN$6A2FTI2K=RD9F0@I     &BO;T-N'R;,\ L!MH7Y./]TCYI .\
M       !+67]=<_EN3X)D45(@            E]HWH16ON/\:18%0(
M              )O9_Z$T'_DF?FBR*00                  !+6/\ 4UWR
MW4?#"R*D0                  !)T/T[NW[FE>#?%%8(
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M=6#XHJ_>XWXX;L&4]KJP?%%7[W&_'#=@RGM=6#XHJ_>XWXX;L&4+^KJP,?\
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M(J1                   $G0_3N[?N:5X-\45@@
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MV:RW*E28%0E5.I2ZLN PBM1*@TIE#-0[9[%"VTZMPEFI!MH5E))%H[)I%T(
M      EK+^NN?RW)\$R*-?2]FL&$=:8G/M3Z;7G:JNHL+BMMNN-5AW6.,J>2
M9J-M!&:2+09]DPJ.BH;+(]3LV%8\RLRWZ5%C$AV6X23GOU!@T.19ZWRRGKF'
M6R?3@6EPB,]S *CE7MET.YH<0JW5),BKMQGH4Z>1FE#[4Z)P*7DCFHVV3=09
MJ+5$1)7IP/<"HW= M"+0JM4:REPES*@VQ%7JF]0C@T(W"CDM)*42W4(7JS=/
M2I*4E@6 "C$       >>;>/_  W>WDF3\T!_/A?;J]\QX&]Q
M       !A4?_ +3"^Y2,[_&4CP9HP4               !^Q/Z:+UVE7#"53
MZ]#74+3B(-N)<$A61Y#B-QDC5I?+L8[J.RK<(>G3F9:[HA^B!N8):Q_J:[Y;
MJ/AA9%2(                   DZ'Z=W;]S2O!OBBL$
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M.VN7RY,^!L458@              #17MZ&W#Y-F> 6 VT+\G'^Z1\T@'>
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MYMTBCT^+-K%$C*;3+K<)PJ7'=<=8><=;D:I12'64$C_+)6CML5*W<M@>SB
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MV?\ H30?^29^:+(I!                   $M8_U-=\MU'PPLBI$
M            2=#].[M^YI7@WQ16"
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M]WTN<NI4V+4'(C\!R2TEU4.6E*)#1J+'(XE)J(E%V<#'KAI98
M       F]G_H30?^29^:+(I!                   $M8_U-=\MU'PPLBI$
M                   2=#].[M^YI7@WQ16"
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MC^] CJ+WE()1?" HP                   2UC_ %-=\MU'PPLBI$
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MHO)I7. #5;0^-T7DTKG !JMH?&Z+R:5S@ U6T/C=%Y-*YP :K:'QNB\FE<X
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MT7DTKG !JMH?&Z+R:5S@ U6T/C=%Y-*YP :K:'QNB\FE<X -5M#XW1>32N<
M/AM;0\-$NBX_\M*YP YZJ_\ C='Y-*_' 4@@          "4LCMKE\N3/@;%
M%6(               T5[>AMP^39G@%@-M"_)Q_ND?-(!W@            )
M:R_KKG\MR?!,BBI$            $OM&]"*U]Q_C2+ J!
M    'Q?:*]XP$_87H1;ODV)X%("A                   !+6/]37?+=1\,
M+(J1                   $G0_3N[?N:5X-\45@@
M                   "4LCMKE\N3/@;%%6(               T5[>AMP^3
M9G@%@-M"_)Q_ND?-(!W@            ):R_KKG\MR?!,BBI$
M $QM$(U636226)FQ@1%N]ND6!3B                   /BNU5[Q@-!8B5)
MLJW4J(R45-B8D>@_J4@*                    $M8_U-=\MU'PPLBI$
M                2=#].[M^YI7@WQ16"
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MPJMU+#^Q\TG_ /R0HJ!                   $G0_3N[?N:5X-\45@@
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M:221K6LS4I1X:5&>)F(,@    !HKV]#;A\FS/ + ;:%^3C_=(^:0#O
M       1MN4^%58]WTRHL)DP)=7ELR&'"Q2MM;+)&1_V"C=IMB@E%DQ':>P^
MW-<:D3S>;0M4F0P2"0\\9EOW"U:,%GIWI>X0@Y';-NFX\\JE1%.R'TS'E&R@
MS5(1N.'B7;:3/']I^Z8#&C63:$./'BQ*'!8C1"),5IN.VE#24NF\1((BWI$X
M9K+#</< ?2LZVFSCZBG,QVXSS4A#3"";0;D<\S6))(MZA1$M*=S,1'ND WH
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M)U?RU5/]4L44X@                  "3H?IW=OW-*\&^**P0
M                            !*61VUR^7)GP-BBK$$'M7O\ *P;>*9%4
MVNL2%&J-%669:HL;!V<^A!J3FX-&)R0I..DD8$1G@0L0*2UJXW<E!@UIE33C
M4MLG&WHSB7F'4'VKK:D*5O'$X.(Q/-E,LQ$>)"#<            T5[>AMP^
M39G@%@-M"_)Q_ND?-(!W@            ):R_KKG\MR?!,BBI$
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MY-F> 6 VT+\G'^Z1\T@'>             EK+^NN?RW)\$R**D0
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MZ_*N&LTNI0&$4J(F.]3JG&=6M+A/Y\S#J5I3@ZA*4.&:#4G*XG^V"B
M !%;7O\ QA=?DV1\T;=+^T-6K_24"Y]8O^\?PCZU\0X"@
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MUF:R[>GIVV12V*0[Q@V         "8LC\G5_+54_U2Q13B
M     )2@^FUW^]3/ +%%6(
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M:^X_QI%@5 @                  #XOM%>\8"?L+T(MWR;$\"D!0@
M             F+(_)U?RU5/]4L44X@                  "4H/IM=_O4S
MP"Q15B                                       )2R.VN7RY,^!L45
M8@              #17MZ&W#Y-F> 6 VT+\G'^Z1\T@'>             EK
M+^NN?RW)\$R**D0            2^T;T(K7W'^-(L"H$
M   ?%]HKWC 3]A>A%N^38G@4@-S,F1X+*Y,MUMB,T69UYU1(0DL<,34>@@B)
MF:0DS$1679KD&A"TGB2\,O[<2QT M6+'J\"7-E4Z.^E<Z&2#DQ])+03A8I,R
M,BQ(R[):!A%\3,Q\X;+M.Z+8NF.$^#.&;6              "8LC\G5_+54_
MU2Q13B                   )2@^FUW^]3/ +%%6(
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M@UM+2XDE)W2,TF98E[@DQ,<)6+HGPEWB,@    !,61^3J_EJJ?ZI8HIQ
M               $I0?3:[_>IG@%BBK$
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M**<0                  !*4'TVN_WJ9X!8HJQ
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M1#/U'JIUHBVD6VV^$1Y^+5Z3T4:$W73=-]U]*W7>/#PCA2*0JQY'0
M 3%D?DZOY:JG^J6**<0                  !*4'TVN_P!ZF> 6**L0
M                             '@>R%ZGN;6+OC,P:6U4H;3_  J? J1O
MN.,2YFOC-%"0XXELD)):EK>R.[Y!)03>&.4C;7Y/)C:K;;*66'WUR8#:*A+B
M)>.GI<<<)3<92LI&Y*2:D*7FQ;3I2DS(0>S"  E+([:Y?+DSX&Q15B
M         -%>WH;</DV9X!8#;0OR<?[I'S2 =X            "6LOZZY_+<
MGP3(HJ1            !+[1O0BM?<?XTBP*@0                  !\7VB
MO>,!/V%Z$6[Y-B>!2 H0'S*6..&D ))%N$ ^@               F+(_)U?R
MU5/]4L44X@                  "4H/IM=_O4SP"Q15B
M                 #4W1,33K;J\]4AZ(4:'(=X5$2TN0UD;4>=I+Y&V:RW4
MZS>X]MH >(;!)E2F7A<$BLM'3Y4UM^HL4QB;;M2BGPI]LWG7'**TTZF21DA+
MFO-:5EAD6K*>&4B[IM.OB7=AR&Z:S3;3BSGG'55UXJI.DI2I9(<@(:/&(G%1
MJ1K7E8)/ FD"#TH0 $I9';7+Y<F? V**L0              !HKV]#;A\FS/
M + ;:%^3C_=(^:0#O             2UE_77/Y;D^"9%%2(            )
M+:A(X'L]N*6:264>&X[D/$B/5X*PT>\,[(K-&%]V6VK>4JM0*PV:HCGTB/K6
M5:%I[&DO<_:0V:VA=I3Q:=#U-FM%;>38C0]+RF-<UPT)B]\\*K5"IMUIYVE,
MJB291(I6KBI4Y&+ DN(;Q>6VTVO,M1&E):11B/7YM&C3&X;M&>E0%-QVI=7C
MTJ8TAG6.,DN4AEQ:EJ23;JE:KMTFD]&"58J#4VU<>U.ET*DLNTN4]+;B-*J;
MT^',?E/.1XD$R;49N$25N+<D)4HBW4;AF1XT7.SB]9]X2*PJ6]$5'BK;*(S&
M0ZEPBSNH6LUKWCC2\B396C298YB+0)(OA           'Q?:*]XP$_87H1;O
MDV)X%("A                   !,61^3J_EJJ?ZI8HIQ
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M"R2> 4'93;_I-0:JLTRR4J Y!;A2D&IQ4Q-3C,/Q\C>4E$M:I"6THTF9X>Z
MZWMJ-F1U(;>F.H>=,FVV3C2-:J1]'FCY,F8GTD\VI;1EF22L3+ CP4&,]M?L
M6/$.8_,DMM)Q49'!EY]6AM;CCF4FC/(VEIW6*PP3JU^X%!WR=JEDQ%&AZ<X2
MDN:HR3&D+T$SPDW-ZV>#9-$;F<]&4C,*#=T6YJ1<"G4TMQQQ4<W$2"6TXWJW
M&7W(ZVUYTE@LEM+WIZ<-.X9&(-P  /B^T5[Q@)^PO0BW?)L3P*0%"
M            "8LC\G5_+54_U2Q13B                   )2@^FUW^]3/
M +%%6(                                 #\][&J9"9VNWS/:ITF/)_
MS#.N4U$8)"'I>N-$E$>F0U:Q:BSLJ7)DF;>)FK'$SRD;Z\GXU.VJT<XC,=N;
M4I5,;F5)VFM//,H2MQ*6F'UJ1OWRWCBSS*2@MX1FG>P>S"  E+([:Y?+DSX&
MQ15B               -%>WH;</DV9X!8#;0OR<?[I'S2 =X
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MU?RU5/\ 5+%%.(                   E*#Z;7?[U,\ L458@
M                      Q:G3HM7ILRE3FR=A3F7(TAI1J(E-/)-"DF:#2K
M21]@R,!X!L)CP8=_5QF54Z)(N9R++5)I]*CU1F<VTS4-2;TU$V=*;8)PTI4R
MV2$*6DS5VI8#*11W0Y&MZ^H+!1ZA6%NO-U#"55W(NK6:G7"1#9?D&F6O$LB8
MS3)925V^^P$'L$604J*S*)MQHGVTNDT\DVW49R)65:3TI46.!EV#$'< E+([
M:Y?+DSX&Q15B               -%>WH;</DV9X!8#;0OR<?[I'S2 =X
M        "6LOZZY_+<GP3(HJ1            !,;1"-5DUHDEB>HW"_O)%@4
MX@                  #XOM%>\8"?L+T(MWR;$\"D!0@
M    F+(_)U?RU5/]4L44X@                  "4H/IM=_O4SP"Q15B
M                             #!K4JH0J1/F4J'TA4X\=UV' SDUKWD(
M,T-YS(R3F,L,0'C&QARN/WM<,Z;#KU+IE00_-;@5NFP82E2'Y"34J1(9G2WG
MW6TDEME*FF4(:QWN)C*1C7'"<MW:HF?+=J=29/@]00WJ%U&;*23KJC9AH8AF
M3;44NV3GSFE6Z1X&8>]1WTR8[4E"5)0\A+B4N)-"R)98D2DJP,CTZ2/<&([
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M\Z9_+4Y?RNFFFV&TLLH)MI!$E"$E@1$78(B'%F9F:R^@B(B*1X.8B@
M         .B9^3D?=K^:8#4V5Z&V]Y-A^ 0 WH                   )BR
M/R=7\M53_5+%%.(                   E*#Z;7?[U,\ L458@
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M\ @!O0                   3%D?DZOY:JG^J6**<0
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M3RI+28@2*I3(DR)3Y<QAB?4#<*!%==0AZ0;*<[A-(49*7E3I5E(\"W0&6
M"8LC\I6/+54_U2Q13B                   )2@^FUW^]3/ +%%6(
M                                 E+([:Y?+DSX&Q15B
M    -%>WH;</DV9X!8#;0OR<?[I'S2 3TBUZ1 KE1NJ)+<IU2GMM+J2"D&W#
MD.14$VRZ^WCNI226S4DTYDD258D1"C1T_9?:LBD4^(\X7"H7"I6LI;[D=EN3
M4Y;516XRG.LT)1(8;<CD:CR$@BTEB1JCL7LWLA;4MQ$Q]MI[.<M;<S*G62X[
M\=QP^P2W$R7%F?94K-[@5&NJVR!AV-"B6W57H=.8J#M1*/(<7)2PB0VI!M13
M49DEG%:EFPM*T+-6!X)(B"HV"]C=I2&I351<GSBG*4N9PB6XK6+4TZSB>!D9
M92>4:,#Q29)_A(*C8ELSM0DI5J7CF$Q48[DXGEI?=Z9RG+6X:3(E+6:"41Y=
MZ?:X!48#^QZTGXI13<GH^FD2%/-S'$.GPQIEEYLU%^XHF&SP+LIQ+LA44MN6
MM2;58F,4E*TE/DN3I:EJS9Y#I$2UDDL$IS92-65)8GBH\5&9G!N@ !(6L^<9
MN[I)(-PV:Q,<)LC(C5D89/#$]!8X"C4TW:U GT^WZLJ I%,KTF##7(0^V[P)
MRIQC?CE)(B(TFI>1G1B6=Q.G#'!0=CNT]QBK4:BR*#(9EW+'<>MQ2WV2;F.L
M+-3K&..*%HC?YO?%OFR5ABI)I"@VE;ON)0ZVS1WHJG6Y=.GSX4U#K>J=D4W(
M;D,BQQ)TT+SIQT&1*]P!F4.Z4UBMUF@.P78<^B-P7)6=;;B%'4&5.DE!H,^T
M-*DJQW=TM @H0       >6?U)_\ @>_O)#__ *#.S^T-6K_67\HSW3'1<=\
M                >R?TXJVTE>J"V/9S?WO2Q2<W0^H_^;CO<-W+E^DW<FD:
MM3+3BWZ.>OXOZ?\ ^;Z(_P"H:OA_!O\ -:C-J==J]_DS;[+FQRXZ<!X'6:^R
MO0VWO)L/P" &] ?B#^BRQ+B1$MJ]_P!$6RFVG.F$LWJ2W2N59E+DL8*1B;9%
MF2;.@B^C+_;G<1X,2N4RS7?ZNRL-4Q\ME,ZN0J]6J249/0QW^4%Y;$93W:XO
MH(GG&S,]8[O#3HWKY#,_J9LBM;0OZC%6M;=J1;IKL_9RAJ([-FII[=%6JMO)
M35B69DIQ3!JRI;;WQYMQ2<4G8\$^;7_UDZJW*[LS1<]"3?? +8K<6I(DK<:0
M;QLQ8_2#BVTJ<(FG5$^K+@?_ +D[H0JKVXVE5J7_ $W;(;,?D0;RK3=PVQ :
M6^ZIREU)UQ#J&VU/$:5*C+)1-ZPC(S;TZ!('J%CV54+9V,7#;UW4>@;-W)DB
M0I2;:<<53TH?0RVA]Q3IYLZU%JU%CVI)]X8R2[[>MA528N#9^<:/:%PL<"=J
M\JBI)^'/B9%):-"'<-7F))DZG#%18XF9&8(TEJ-NQ?ZKMHB8Z$O2FK/HI-E@
M3:5K2M9$6C0DC,B]X7Y*\]V+[*]C^T_875=HNUF/%JEY5YVJRKXN>H+U<^F2
MXLAY.1"U*,XG!VDMJ2@LI9<IFDT&1"SXC17?4;HOW^C795(NNH28EPU6X*-#
M56M\J8AHIS\:-+(\4J4YJ4MN$K-F4>G-B>(?,9D:\+PJ7]1FQ#9YM-C*1M)L
M>1<C51JB&\L.KT^;2\(=2CJ(B(M<3"B=1^ZXD]"3Q0E\I1^VA@H  )JR2_Z?
M4OVUFKX\O>%%*(                   E*#Z;7?[U,\ L458@
M                            "4LCMKE\N3/@;%%6(
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M                   )2@^FUW^]3/ +%%6(
M               E;(PS7)@>/_7)G8PPT-_M,450@              #17KZ
M'7#B>!=&S-.&/_ 7V,2 ;:%^3C_=(^:0#O             2UF8:ZYL#Q_ZW
M)[&&'T3/[3%%2(            )?:+@=DUK$\"U&[AC^^GL8D+ J!
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KH)%^MKNTXGA3<2PPP^@7V<=(HJQ                           '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>fc_fig06ourstarat-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_fig06ourstarat-4c.jpg
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M<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"24T$)0
M$/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L A  $ P,# P,$
M P,$!@0#! 8'!00$!0<(!@8'!@8("@@)"0D)" H*# P,# P*# P-#0P,$1$1
M$1$4%!04%!04%!04 00%!0@'" \*"@\4#@X.%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (* [8# 1$
M A$! Q$!_\0 O@ !  (" P$!              4&! <! @,("0$! 0$! 0$
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M,QMM[A# 'VT<1#X54141>O"X&6TZT^T#S)BXRX*&VX"H0D))RBHJ=%14P.^
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M# 8# BMBN'Z&J>LX]3-NC9ZK JQ9.40^JJ O.LB7'W=W*_8BX%!\.?4#X_\
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MG_,I$>*)9P7VSC3H4MM50V)4=U!<:<%45."3KQTY3 MN P& P& P& P& P&
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MB!?<#\WM(D?R%V?Q+YRC@D72-\;GZUO!#S[824L7Q22XJ]$Y$6GN$Z_N'/\
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M\3_ZP&!7O*/DZN\9U5<Z<%ZYV2_GLTVLZ]%,&WY]C)7@ ]QQ4!IL4^)UT_A
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M5,#YB^JJ;(U3S=X&W^X,FM'K;9^#.F$O#$61+)E.]Q?1.6T4_P"JT7W8%_\
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M2CZHBX&?J"-I]=/D'LX[ETR$KG'KW>["3K_LXP/IW 8# 8# 8# 8# 8# 8#
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MIGBKZ!FV4L*;816:XJ?(P:"ZESK,WC7]V$>*V;[Y.*O01[%7GUP-MT?FG6/
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M>K4LPFXA"A@)!\T\KTPD]%0P^Y,#>7E1ZXJ?I9C;9KUY8T5YKVM0)L&16/\
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M[A0T12'\73JB<I@6[Z>O,%-XJ\?L>)/-1GJ.[Z83\-N/-9>(+""CI.,O0B:
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M&Y\#XJ\_;A22?J>\174-94RGU)YT=BL(T.2]'AK(=01[W ;45[>.3[>>U/7
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M!@,!Z]%P& P&!P@B//:B)RO*\)QRJ_;@<X# 8# 8# 8# 8# 8# 8# 8# 8#
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MK"LUKP9X4V2P\74D35K3>["#2W4VI:2*ORQ \X?:+? @A #C? "G]H2_B7G
MW5O?B_3MA\)V7CAFNCAKC=,;%.R #V1G&&%6,\VOV&!H)H7VKZ\\K@?-6E3Z
M;R[]%]5_.?:9=)24MF,9^U;_ 'TBP9K7_P#NT96U$R?(D(6Q%!(E-L2X547
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M[+L]?VN,"*/Z=;?=/IQKO"._%#K;K7FF$I+VJ?<FLI+AH:-2%!YE@D11,FW
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M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'Y!GY%\A"9"FVW7"*J?_I&5]_\
M]4S[NL>9VONZ_P QO(7^K;G_ #&5_B8ZQ.U]S^8WD+_5MS_F,K_$QUAVON?S
M&\A?ZMN?\QE?XF.L.U]S^8WD+_5MS_F,K_$QUAVON?S&\A?ZMN?\QE?XF.L.
MU]S^8WD+_5MS_F,K_$QUAVON?S&\A?ZMN?\ ,97^)CK#M?<_F-Y"_P!6W/\
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M>0O]6W/^8RO\3'6':^Y_,;R%_JVY_P QE?XF.L.U]S^8WD+_ %;<_P"8RO\
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MI%PB)@>F P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M3A>N6V8RDUMN/5,+X:WLM>G;;$"KGZM6F^Q-N(EM"*,#\3E7645QQLC<3CH
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MH)HO:BHA=41<"?.1';>:CN.@,AY"5EHB1#- X[E$5ZKQRG/'I@<!*C.(TH/
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M17GC[\";NO(&]%9_45"V>NJ]BTK2JUOV=>)UV,CD%^J6<0$?M%RKK#A^^O\
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MV;5L,6)!O[N;9P8"FL&+*>)QEA72[C5L%^$5)5^[]'IB21;M;YJ'RH8# 8#
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M53Z\M- )*7V]<#=,1N0U%8:EO)(E V OR$!&T<<040C0$54'N7KQSTPCVP&
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M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?B\[_:'_67^G/0>4Z8# 8#
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M'C->;8Y2]=9?=GDW%?TS??*]-KT>BM1MZ>' @- K\>EK[1DWW9<<7D415\P
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M(S<!NJV\VW-ACI#;X?5EU7VT EZM"#BJX(MJB=V,1.UY\<IB#YGWZ NO/ _
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M 8# 8!41?5.<(84P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P-Q_2I_S :?\ KG_\ _G/[/BZ_3\X_4'/
MC>@8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MMJK6BV$+Z1)8<*W:;BNQ1@RVW5#V4)WE'A(4[Q<'A%3[$S<KG9)XN4)E0P&
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MIT^)[M$W$&,*O,,BZ/!2^Y6T0VNHMH:+W"66<0>FM:MNEIJ+$S6&]>UG69[
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MFNG6S?&MC6%5J\ZSJ9^R/OLUNM5\IN#+N)GN>TLZ2AF##3;(&XXXH@3A" _
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M&R400NO'040-UX0P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M$YYXZI]N!SA3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# _1;Z3/\
MP(U__P!)L?\ B2SE?+Z=/C&ZLC1Z=4Z*GHN!J&?X1BL^>=9\R:R#4<U>DAME
M>BHV+IOQ'66YK2=$[U(A%X4_%T/U[LE^.":_SE?06?,^HP&!J;S-%OZD&/),
M&3#E0=.C.RXU#8,.N,G.=)&_F>]IT/W@-$0-]PKV=Q$G5<UK[+&3Y<.SNY5!
MXU@)$:9V\; 9$^4#SCD4JUD)++K",N-*CHN=IB2KT44Z8U]Q2]VA.5^C^3@F
MVC5O;I)H!LW 8./_ -Y:9KVR(Q5.S][V^YPVJHB%QFIYBQ:_'X7^H[W8Z!;2
M(EJEC!D;7)NVF7(\M^9)G>P2/"KK@<("  (""@B""GIF;S,H:3%O]DWZYWQ9
M,*O@0IMGK,VNBL.^[/CUL@FXKLAPW5#W&E[E$A;_  FH^F+X&V<RA@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@?B\[_:'_67^G/0>4Z8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# _1;Z3/_ C7_\
MTFQ_XDLY7R^G3XQNK(T8# EH$SW4]EU?WJ)\*_[R)_\ +G'?7'+MKMGAG9S=
M# J'E.@L]I\?7^OTS8NVD^,K45MPT;$C[A7A27HG1,LO(\MDUVULO(&CW\1L
M"JZ/\U_,7"-!(/G(HM-=HKU+DDZ\>F)X52]TT?=;:?MM!6US#U%NDNKEE>E)
M!OY (0QP?%R.2=[A<1^6_;Z+W?$J<9J473^';7^;7\6>V'Y'_#OY7[W>G?\
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MI)&YW<P7:J+'<5&G!]>]404+"+86T0SU-K<($298P)$)JQBPXD<G)SK+X"X
M@PO:7>J$GPKPN!H#Q#Y,O)]-KGDO;M@NY,W<8Q16=!2M9-F=8+S*!^H[41T6
M8\83%XE/VR1.\U0N.2MD/?4)XV8J:FV.1.5+:V>UH(00))S(]Y&%5<@261!2
M:?11X$"_'ZCW#\6$69WR/K<301\CVGS57KQ,-R#;GQG(\QM7G$:!HV#3N%PG
M"$$%?M5/LZX$=_-W6FZZ1+F0[.#/8L1I0I940F[%^>XP,D&V6^Y1-":7W$-#
M[.U%7NZ+A<->;IY?39(?C>^\=W<F%"D^0(.I[55., U)$U1WYF%+!T5-IQM0
M'E +JA<\JBHN!?)?FW0X.S0M:E/R0_,+5=<BW'L$M85XG/\ W#WT]'E42%$[
M>U211[NY.,#S7SCH_P"<QJ9I+!]+%Z="I;)F$ZY L9]6)E(BQ'T3M-T?;<$>
M> ,@(1)53 ]/#'E'^;^EAMP4\RD!^1*:89F-]J*VS(=:!0/E4-40$]SCH)\C
M]G.$:Y\4^:QK9MOK'D.SL;*QE;]=ZK47CD/_ +BV;$A&H,1YYAL&FW'D3]T"
M)U7UXPJWU?E'4*21Y'N[39K&97Z_;QH,V#-B*V,&4\TTVU$@@#8N/(\9BHK\
M7)%T7CK@4WS5YQ1_Q?Y%;T*PL];\A:2Q&?LV9,!6WHB/O,^V)F\VXS^^:=[P
M5LU)1ZIZ8&VM,\GZQNMS<ZY5C.BW%"C#DB+:1'H+CT.4A>Q+81Y!5QASL)!/
MUY3JB=,(NF P& P& P& P& P& P/Q>=_M#_K+_3GH/*=,#J1@''>2#W+P/*\
M<K^C"9=L*8%WJM#JIOC^5Y$L-C^0KH-HS22X#<!R5)&3(:]YLQ[70$FU%"Z\
MHO(\<>F9SSAN:RS.6)O6@6.BN5+[LV-<:]L,-++7[Z![@QI<9>$+X'1$VW 5
M41QLTY'$N4VUZJ@+K1(1"8J(_B5%143]>:8S&9/KYM6ZRQ8LE&?D1F)S33G0
MUC2@]QDU%>J(8_$G/V*BY%LPQ!<;-%4#$D3U5%1>,J9$=:(D$3%2).11%3E4
M^],&64_ FQH$&T>95N!9$^->\71'_E"$'E#[T B057TYZ?9A?3+)V%G785M)
M9U>U>N->;]OY2TEQT@O.JH"KG<SWF@]IJ0)\75$YR3/J6STO#+T>@B[CN%!J
MSUA^7L7D^/6I8 U\U[9RG!:%>Q##GJ7^]TQ;B+K)M<,38*L:/8;>B!U7QJYT
MF"+Y(@DXD9TFD-13E$4NWGC$2S%PGZ+4J(Z:EV?<[IZFUR_M)-+!D08XS'VB
M@@T4B4\V1!RRV3P!VMJKB_$J>B=TM](U-9C-N%4GA$B64J!&G,V#,=YQIB:P
MA@W(;;)1%X =03$31.Y$,4)$7KFF,S.'@3K8<]YB/'5>51.$7I@R[85U%QLU
M5 ,25/5$5%5/^C"2RN%>:3U<%.O;U5/Q?=^O!F.3,&T[G"0$^\EX3_RX+<.R
M*BHBIU1?1<#H3K0\]QB/;PA<JB<*OIS@S'8C$![C)!'[U7A,#JKK2()*8H)?
MA7E.%_5@S'*.-J2@A(IIZCRG/_1@RY$A-.0)"3TY1>4P,I^!,BPX$^2RK4.U
M%YRN=+HC[<9SVG#!/M%#11Y]%5%^["XXRQ =;<54 Q)4]4%47C_HPDLHCC:J
M@H8J2\HB(J<KQZ_]&#+A'6E510Q4D]4Y3G!F.2<; D$S$2+\**J(J_JP998U
M\TZQ^Y%DORJ-(:@O2UZ-I*D ;C;2*OJ:BV1<?<F%_+&7IU7HB>N!T1YI14T<
M%03HI(J<)_MPSF.?<;[4/O'L7HA<IPJ_KPN8$XV)(!&B&7X15415_4F#(3C8
M<]YB/"<KRJ)PGI@R"XV?/88EV^O"HO'Z\$L/<!05Q"101%7N3JG3]6#+:>K^
M(JC:W&-:A;Q 9\H3&?F(6K.1GOE#/VO>2&=ERC22U#KV(*@B_#W]R*B8NV/3
MAUFF>,\^S7-;5V-O9L4L!CNLY#JL"RX2-B!AS[A.&OP@#:"1.&O01%57-N<Y
MN/5/>1],7QYNEGII3QM"K1C*4]MM60=63&;D*HBJDO:GN<(O/5.O3GC,ZW,R
MUOKUN%6S3)@,!@,!@,!@,!@,!@,#]%OI,_\  C7_ /TFQ_XDLY7R^G3XQNK(
MT8# Y15%4(5X)%Y14^Q<":ARDDAP71T?Q)_\J9PVUP[Z[99.8;,!@,!@,!@:
MP\O>.;;;I.I[CJ;K#>\:'8K:4[,PB"),8?#V9<-TQ$U;]YOH+J 7:2)TX5<"
M(N-2W;RSL^H2=TI6M5T_3+-K9?D?G&K"=8W$0%&&**PB-M,,*;CAJ1$3B]J(
M(]2PJL[M]/>P7]IY#6IL68=#<DQM>GPVR)IR)O+30-K,,A3H"K%:)>>[JZXJ
M(G&!+[5XTW*12>*(%=&9L+/7-IA[;N$TI ,(Y)1J2LTFD4?C5QZ69@G1$$>W
M[L"Q>&]2VG4Y_D8]CA-Q6-EVR;L=2XW(!]2BS&([ @:"B=AC\OW*G5/B3[EP
MC4FP>(O,<75=P\64=16V^NW&T!MM+L[]E\JX++MM'LG(<J,K)F3H$V?[X242
M%4Z(2<858(/BO?Z+=-BKHVKZS>ZIMET[LC6VV_MOSZ4YI [*C+%-@EDJ#@JL
M51< 1Y137CX4"WO^(YQ><7]Z8>;'2;6)#L;NM(E5QW9:7OCP7Q'H@@D=Y5/A
M>IM-\HOV!4M:\5>0-6VNRUT-:UFWTV9>R=AK-ZL$!ZV@QYDHICD0XKC!$](!
MPR1E_P!Y!$>%7JG:@1:>&_)2%>7\:#$:O*_R4?D?7Z]^:GL6,)R($)V$XX %
M[#Q-B2MN$!")$*+T[E0(3S+J>T5>M[KY,NH;,"YW78='8BZX$@'5CLT<]IMK
MWI0)V*X\XZ:KV(0@"#U5>>()SR?X=\A^0H?D;9(]5&@['M=;3:[24SDUOAJ)
M5SOGGI,MX$(%-POA;$.>T43GJJ\43^R:%Y#N-U\C[#'I6@A;9I#>M5HG/:[Q
ML &0J^XB#\(<R>.Y%7\*KQU3 JM-X?\ )^HR*BP@Z?K>UI<ZW1Z]L5;L$D5&
MIL:&,4(9;#GL.H[%<;7N=9 $<)43A4ZX$O=>*O(SSGF"+#JXCD?=M2K-8I'H
M\IJ%'^9@0I,0W"CH)>RTJRE( %5X$%']I,"PZ9H&^Z_Y/HML>K8B4S^DUFL7
M"E,17H4RJ?<=+M;%M4>%U'. (3'MX7N3TY#"WV?<UWU-Z9(HJI;J8FH7:'!&
M2U#+L69$^)#>^%?B045/NZ_9Q@1.I>%MYT[:/%4\8D6=%U^5L]IM<EB4C33,
MG:RY]N(TX/<;<?HBJO;W)U1.5XP%UX?\BI4^3O%U5$A2]/\ )5Q+O8VU/R4!
MRL_.3;.:P_#[>]PFE;)8Y-DJ%W#WJ/"X&O\ =?:G;GY&KJ2JK]ET'WZ:JVJM
M?VF/0.RY6O,,IVS GLF?=W"#1.,.--O ""O*]Q9!N+5Z'?;+>-_\@5M<%1 W
MW6J<-<ESG6W7(DZ%#?4/FXG:J\(<I.4Y7\!(J?$F44;6O$7EZ+<CM5S3PEM9
M^B6FIWY%;E+FRKAYYIP9G>;2-B$@FT4&AX%D.4^P16"PZMXV\BU5KX*DS:=E
M(_C?7K&DOC&<TX1ORX4:(V3*=J=P<Q>[KQPAHGV+E%9C>$]W+QM0:E>ZDDFW
MJ)U_8P;NHO KKJIG64XYD23!EH*(@J+Q-2&R1?B 31"],#Z'IX>W5/CN%7WS
MP;+NT6K;8L'V2&(W-GBR@F0D0H((9<KW*"??V_9A&C=;\2>3-6U/PY<1JV+*
MW+Q4$^MG:^LT 8L:^V9&.\Y'DJ*B#K?8#@"X(HOQ(JITY*XL/#?D(K&KVEBM
MC.V]AY&C[_=5P31;:A0(<$X#443(>'7U$_<<,405+E$7CA5#>'DVGF;!HMQ3
M0:2#LCTUL&CHK1Q6(DMA70]YLG415;+V^Y6SX^$^U?LPC0/\C?)D"BK["F98
MLUU&_.RT[2-MG?F@I1RH*PYE<],[3#E35789%W^RB()*7*\%678/'OD2XI=%
M>C:K25$VNW6!MUK0T[[3$>'#AM&VK2O>TVDF27?R;B-B/3A.B(JATTOQ=O\
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M7QI,[R>\O/\ Y:MVO82VS9+/8E8:B-3WS<BQ([+<9IF,B]K+8MLB )V@@]W
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M;?CVSNKG1]>M=B;;;N9D"._*]ESW0,G&Q+W.4!M$4T7N44'@57CKQSA%EP&
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M?]IV.#HODVRPZ9@RCC@";G;S]P]HJJ8P7?SQC*GYIDP& P& P& P& P& P&
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M@,!@,!@,!@,!@,!@,!@,!@?B\[_:'_67^G/0>4Z8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M@,!@,!@?B\[_ &A_UE_IST'E.F P& P& P& P& P& P& P& P& P& P& P&
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M"2A(*.\0(T\+9"J$31D/Z<"\X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M!]>/3J&W,(8# 8# 8# 8# 8# 8# 8# 8# 8# _%YW^T/^LO].>@\ITP& P&
MP& P&!P0B2*)(BBOJB]4P@(B"=H(@BGV(G"8'.%,#J3;9JBF DJ>BJB+A+)7
M;"F P& P& P& P& P&!P0B:=I(A"OJB]4P@(B"=H(@C]R)PF!SA3 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# W']*G_ # :?^N?_P  _G/[
M/BZ_3\X_4'/C>@8# K.^ZF>ZZV]21YZU4Y'XLV!8HR,E&)4&0$EHB9-1%P>Y
MM$(%5.4^U,"O_E'F]>J[1KR+]R4\KC_RSL!^4>;_ /5.O?Y/)_\ S[ ?E'F_
M_5.O?Y/)_P#S[ S],TW8*F_N=MVVYCVU];L1(0A!A_(Q(\2"KI (B3KQF9D\
M1D9E]PHB(F!=\"E^6-!/RAH5OH:6A4\>Z;%B7-!@9)HQW(1"(F0HBKPGQ<],
M"N[QXBNMVHM)JG=L6%,TVT@7HS@KFG/FYM7S["FVKJ( ?$O<(KU^],*KEU]-
M\NTM[RQB[Q,A1;?8JW<FXWR,60XS;UA-*G<^[R3L?AK]U'+@&U_WNJ*,IIOP
MC-#7O*6NKM"K&\GR9LJ0[\@TAPBLHXPWT#AS]XBL@(CW<<%\7VX&&?T\1+"R
MA/[!?G95#6EN>/9]:D1MA9$!U0(GA=$R5MWO;;(>!7CMZ8&31^(/(-70RZJ=
MY9MK*Q9C-PM8M#A16CKV6G6W$-X Z3'B%L6B=?7J"ETY(E4/.N\$R*,;J307
ML6NG[):MVNP06JEK\BF--P3A%%.N5WM07N_WGG$<[C<3N7!EYT/T]LZS*\</
M4NQNL1?'?YNY&AE#:-N2[?>Y\Q^VGLMA[BHRV'*"G"<K@8M3].\RJU_2Z -O
M)UK3-DD;9&?6M90Y#\IQ]PFC1'?A%%E/=4^\?]U,&6H-3C[_ /Q;)V+7CL(/
MD.5=29\K4+_3 -8[<M]0,'=@!&@]E6. &2T:JH<"B+Z9!]->2_&S'D&/2R8U
MD[1[1K-@W;Z[=L-B^4>2 JV8N-&J(ZRZ!$#C?</*?;TRHJ5OX 8NJJ[DR]A=
M'R)=W%7L;FV!$:]MF?KZ@E<+<$B)M6&0#M5LS)34B(BY7H5#7GTUV5_"WAB?
MODEV9OLBCFW$HZV+\$C7T95LF@$A1!,F ^%55!%..J_%@;JMZ&'L>M3]8V!/
MG8%M!=K;3M3VO>:DLJR]PB*O;W(2^B],(TO7?3C?-R]1_//(\^TJ]*B6532,
MA7Q(DM*NSAC!]IR4VJJ3K;0 @OH"$JISQSRJE>NH_3<]KDJC<L-RDV<.GUR?
MIA0FX$6&V]3SE @1%;[E!\2!#<?ZDZJ=>/B[AEUK_IQM($?36V]^EK(U*HE:
MNCZ5T/\ >TLI  08 NX8TD&VQ!90]QFG/=T7C!E=]8\5A0^'A\0S+N3/AI4/
MT*7#;;<.2$5]DXX*V+?*";;9)VDO*J2=R]<(H-;]-5K":)9._/R);FFOZ 9!
M50H["5[CA$RX#+:_";:&7=\2]Y<*J\)VX5*-_3PT\[KS-QLCD^FIM/DZ#-@)
M#;8*;6S&@9<-71<56W%%MO\ "G3A?OP.FL^!=EIMCT6\N/(<J[8\>L3:^CBN
MUD1APZZ<RU'5F0\)$KAH##:*[VH1<<]%5>0PO+7YE,\^^(@HY#D*771=C&59
M+ >G1&"LH\5N,V\H]@)[Q-'V_O$7X?NP)6)]/[=9;:?=UFQN-6.MV]ILEJ^]
M"9>.VMKX#;FO.<$ M(0.$#8MC\"=OJH\X&7(\*6L7=K;8=1WFRUK5]GEMV6U
MZO$88<"5. !;-Z-*/]Y$)X6P1Y6T53X]4Z=H5R]^FB;.A;)K5#O,FFT/8[=O
M8SU]:Z-,*+9C+:FN$Q)=)"%HW61+VNW@>O7A511E*W?T\1=GF^1']BV23(C^
M06JE#&,PW$D5\N@1/DY,=\"55,33O)%'A5Z>G3 ];7PAL>TZ#<:MNWD&9>;)
M9G ./L/R$2*U%_*9838_9 ;_ '1<N!R\I%RYZ?"B(B!8J7QG8UGDU[R5.V,K
M&5)H8VNR(10VF>\8KQR/?5QLNA$ZZXO:@<(*H/[*8'CKOA'4:"MWRE+W)E1O
MTN<_80W%[&X\2R D=B1T%?@:[W'G4[>."<7 \_&?BW9=%6/'V#?K+;JFH8^2
MUJ!+88B)%C<("+)-CXI;P@(@+KO':G=P/)*N$;.P& P& P& P& P& P& P&
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M-001J=^;KW*>>,875]NHM8ZH+9RV4)3]T4[N.5/J7"5*^FL(8# 8# 8# 8#
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MQHG?T3A<R\1O'\K<I.!L>O56\_3_ +5:[)4.UM)6K!NWX3H=L20W)E*7N,-
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M>;IISRJ3CT02^ E)412^U$)4^).%^W-SQRXW&;CPA,J& P& P& P& P& P&
MP& P& P& P& P& P&!N/Z5/^8#3_ -<__@'\Y_9\77Z?G'Z@Y\;T# 8# 8#
M8# 8# 8%(W;QPSNUWK%Y(N)E>]J<S\TK&(@QU;*8H$RI/>ZT9$*M.&':)#Z\
M_9A5WPA@,!@,!@,!@,!@,!@,!@,"DSO'+,[R37>35N)C5G607:F/7 ,?Y-84
MDP=> T5M7%(C; D)'$[>..,"[8# 8%)G>.69WDFN\FK<3&K.L@NU,>N 8_R:
MPI)@Z\!HK:N*1&V!(2.)V\<<8%VP& P& P& P& P& P& P& P& P& P& P&
MP& P&!^+SO\ :'_67^G/0>4Z8# 8# X011>Y$1"^_CKA!0!5Y445?O5,#A0
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M&K,(W*A@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@;C^E3_F T_\ 7/\
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M@,!@,!@,!@,!@,!@,!@,!@?B\[_:'_67^G/0>4Z8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8&X_I4_P"8#3_US_\ @'\Y_9\77Z?G'Z@Y\;T# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# _&<OQ+_ .;^J^GI_LS[WE.O]QE#^XP']Q@/[C ?W& _N,!_<8#^
MXP']Q@/[C ?W& _N,!_<8#^XP']Q@/[C ?W& _N,!_<8#^XP']Q@/[C ?W&
M_N,!_<8#^XP']Q@/[C ?W& _N,!_<8#^XP']Q@/[C ?W& _N,!_<8#^XP']Q
M@/[C ?W& _N,!_<8#^XP']Q@/[C ?W& _N,!_<8#^XP']Q@/[C ?W& _N,!_
M<8#^XP']Q@/[C ?W&!N'Z6/_ !]U#^R]9WX?Q?\ F+_IG/[/BZ_5\X_3G/C>
M@8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
6 8# 8# 8# 8# 8# 8# 8# 8# 8'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>fc_fig12cancer-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_fig12cancer-4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$$ &AT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-RXR+6,P,# @-SDN9&5E,V$W-S S+" R,#(R+S X+S$X+3$V.C4P
M.C,P(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.GAM
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240](G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q
M-3 X0S@B('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z-4-!-3%#-#1!.#9$
M,3%%14(U,41",S$U,D%!13!$.#$B('AM<$U-.DEN<W1A;F-E240](GAM<"YI
M:60Z-4-!-3%#-#-!.#9$,3%%14(U,41",S$U,D%!13!$.#$B('AM<#I#<F5A
M=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@,C8N-2 H36%C:6YT;W-H*2(^
M(#QX;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED
M.C8P,F$T-SDS+35E-F4M-#4W9BTX-#DY+3ED9F(X93$U,&$P8R(@<W12968Z
M9&]C=6UE;G1)1#TB>&UP+F1I9#HQ86(U,3 V9BTR9#)F+30W-S M83EC."TU
M,S@R.#4U83,Q96$B+SX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY0<FEN=#PO<F1F.FQI/B \+W)D9CI!;'0^
M(#PO9&,Z=&ET;&4^(#PO<F1F.D1E<V-R:7!T:6]N/B \+W)D9CI21$8^(#PO
M>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T 2%!H;W1O<VAO<" S
M+C  .$))300$       /' %:  ,;)4<< @   @ " #A"24T$)0      $/SA
M'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L A  $ P,# P,$ P,$
M!@0#! 8'!00$!0<(!@8'!@8("@@)"0D)" H*# P,# P*# P-#0P,$1$1$1$4
M%!04%!04%!04 00%!0@'" \*"@\4#@X.%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #T X<# 1$  A$!
M Q$!_\0 R@ !  (# 0$! 0            8'! 4( P(!"0$!  (# 0$!
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MU3+8Z43X^_#':J3M! DAF8'L< 0#U:0>J#*0$! 0$! 0$! 05-DNXN<F[O\
M#.,X=T;.&93[\K7IG,#I+ES%UXI-87$>[%"]SHW.!]Z3</!NI"T;[9WT;+:T
MQK6#$\16&M:\QOVG:X->"TZ'KH4',/;GOGSB6IQ/D6<N.Y5QO(<1R')N=?*8
MYL,F#EQ\39H?1DA#&2_,GU(6UW:R:LWAVFH06?+^(+A5?"29RS3R=:!M-^7B
MK68(J]J?#QQ12F_#%+,USX=)0UK6_:N<UP$9T02&IW4XKD+MJOCWS6J&/9')
ME,K$UAJTF3XX96-]D%XEB8^NYKF2.BV%QV:[M0@CDWXB>WU>&[-*V^X4HL9;
MVP5VV72TLW9%2K8C]"23W3*X,<QVV1NHU9U"!D>^F/B&.BQG'\G/?L\KCX9D
MJ-F..M8I6GUOG?4<UTA#VO@+)(]CM"'=2""$&=D.]G'*1R4+,=D9+U3%Y?-4
M*TD+:[K]? 2B"SZ(E>'L]]S?3=,Q@D:=["YO5!KL-W?Q-ZSA<YG;5_C]&WPJ
M;F%[%6JT+L=%4CDKF6PZVUKI#)$)-&Q,=H6/W.;NTT#)R_?WAG'JV3FY!3RN
M,MXJI1RDN-GI[KDN-R=EM2*U%%&]Y<QLK@R8?'&?B:-1J$NXGS?%\NLYRA3K
MVZ.3X[=&/RE'(1"&=CWPQV(I &N>#'+%*Q[':^!Z@$$()*@(" @(*B[>]RL]
MS#N+R# Y&W5Q-7&122P<.OXF[C^0-KB<01738GG,%BM(6.=NKQ:-WL:YP/Q!
M9'(8N13T&P\8LU:>1?-$)+5Z%]F*.OO!E+8F/C+GEH(9J\#4ZGH-$%<=I^5=
MQN9RY#)9:]BI,-B.09SCMVK#1FK6'Q8BQ)6@L1R&S*T/>Y@=(QS=NA]TC3J$
MOSG<GB/'LLS#9*X\6O7I5+;X8)9X:D^5D]&DRS)$UPB,\A#(]_M&N@(*#59?
MNMQ=TM_CV'RT47*)*62L8)\\3I*UN;%,(LB!VK6S&N_3U6->#IKIT!("-]N.
MY'+>2\EX3CLO)4=0Y#V^K<KO,A@='(W*OFJ,>6/,CM(B)W:,VZC](H)I>[I\
M(QW);7$;5^5N;H-BER48J6G05()X99V36+ B]&.(M@?]H]X;J-NNO1!BT^\7
M [TEVK7O2')T9ZM5^,=!*RY))D6/EJ&&)S09&SLC>^,M\FNUT((08N8[Z=M<
M"UQRF2LQ2Q8V+.V:[<;D))X,7+*Z$V9HV5W.CCC<UWJEP'IZ>]H@V.4[L\"Q
M%D0V\JTU6NI-N9*%CYL?4.5+!2^9LL!CB%@O9Z9>[3WFDZ!P)#RJ=X>WU[.0
M\?JY.1^0FRMGCH<ZI;CKMS%.(SOIOG?$V-LIC#GQ@N]\ [=4'O6[I<.MTI<C
M!;E=1#:SZ5@P2-BO-O/?%6^3>6ALQE?&X-##KYG0$%!M^*<OX_S;%',<<MBU
M4CGFIV6EKHYH+=5YCF@FC> YDD;AHYKA]/@04&\0$! 0:SDF?QW%./9;E&7>
MYF)PM.QD;SV#<X5ZD3II"T=-3M:= @KWM%W&M\R>^#E%SY#F5W'UL^SAQJOK
M-HXF]T@='+-&U]H@CTYYFNV"74!C!MU#9=W^<Y3A>(P5+C[(CR;E^<H\8PUB
MRPRUZL]_>]]F6,.87MAABD>&!PW. ;KU08_+Z_<3C6!S&9Q_*A;I4<!DY9G7
M*546HLE!7$M:S"8HV1E@+'A\4C#KN'7IH@UN)[V8G&\&Q&8Y$VWD\E3XUBN1
M\QM8VL)F8^MD*X>;,[&%I#262R;(FN<(V.=MV@:AL9N^?#HLW-A16R<C:V6Q
MN"M92*IOQ\5K-LB?1>9@_K%/Z\36O:#H7#=HWJ@RK'=#$7\C:XI2%[%YRU3S
M$V&N6:S6LF=A)16LR1QR$NT9(]IC,T;62MU<PN;U08_#^X,U;L/@>Y_,7S7I
MF<9J9W.SU(&F:0_)LGL2,AC#&C\YVUN@"#TI][.'61E!9CO8R;&C%/;#D8!5
M?:CSYD90?7+W[2)7Q2,]]S2TL.\-'5!\8OO=Q'.00LPM>_D,Y+<R..^X8(6&
MZV?#;3<.YT@@,;!)%ME;,6/]1@:XEVB##M_B$[>UL%1Y1$;]KC=NI#?GRD-.
M05ZD,]W[NVS.DV?;,L!S)((]TK-KB6:!!F3][>*5N1.XY8HY6*2+/1<4LY%U
M)WR,.4M0QS5F/DW:[)Q-&(WM:1JX;MH()#34N[[<_'A+%F#*\7;:YG;XM7C9
M7JVVW7X]UN PV'N]3T8Y'5W.<^/1[7-#6N(U)#<1]\^$2Y7$X]GSAIYV;+P8
MO+^B/D)7<=<]N0<9-VK&1&-_O/:-^TENH&J#76OQ&=NZ<%^Q-\\Z.C4Q^3 K
MUQ:,^/RUIM."Q$*[Y/=]5[0]C]LK002SJ@W4/>+C$HF@EK7JF8AS?^&!AKD<
M56W)DW4_O&-C/5E;$1+6^UB/J#?J&CW_ '4$WQMYN3QU3(M@FK-MPLG%:U&8
M;$7J-#MDL9ZM>W71S?(H,I 0$!!!'<*S![Q1]Q1:K?<K.//X^:.V3YHR/N-M
M^KO^#:-NS;IKYZ^2#?5\5DLQQR[A><BE<?D1<J7(L>R6*M)0L/D9&PB5[W[_
M $'-;(=VA?J6Z#0((AV^X?W$X/@\;P:7+XW(\6P38J.)S#H98\J<56:&PP30
MC[ RLC B]9K@' ;O3W:A!"K'8[GU_,3Y?*<BQMZX:O*L8V_+7L?-V*G(V,^4
M]4B39&:AC;%Z<3-AC&OQE!^7>P/*\C1KTW\AIT9Z?$>/\=IWJT$DDD>6XQD6
MY*O:V2G:Z!\L;0^(^]MU]Y!N^4]MNY7*8.-<GNY/C\O<#CMBTX8VQ1GGXW/1
MOQ1PS5W,?(9P\&)D\<^NK7>YM+"=0WW%NWV?P7/W<KMV\?)C9..T\#)5IUG5
M"+-2W9MF6.-I,;(B;+F!G5P#02XDE!9*",<7[?<4X9>RF2X]5GKW,U()LB^:
M[<N->\.>_5K+,TK8^LCND8:/W @YY[I=L,_P[A',>1P6:U23,RX[U\#A(;DN
M,N93[^IV&Y-](EYAF;#&18%;I)J][NK6H)UR/LIR#/Y3)<^I9/&0\YM9/'9.
ME5M577<(^KC*-F@VK:8[;)()8[D[W2C1S';-GPZN#/9VQ[A8CDF+YAQ?-86C
MF+6+^X^4X]V/D9BVP_-R7(K&/BBD:YLL#IY6:3.(F:07[2$&+RKLSRKD#>Z\
M<67HM'<+'XK'4)9HI2^M]VP/ADDG#"&O+]Y<UK T H,CG?9WD7/,KR"_-F:V
M(^]\!B,92GJ1OGFJY3!Y.3*P6")=&R0F9S6NC.A<UOCUZ!8W$:_,XL<Z7G5R
MA9S<KANAP\,L-&%K1MTC,[GRN+OC<7GIKM'AJ0D" @(" @(*YY9P[N-F>4LS
M6#Y1BL?C*D0CQ=.]AI<A+4F>TMFLL>+T#'3.!+&%\1#&:@#WG:A-,96S<%K)
M.RMZ&Y3EF8[%110&"2"NV%C7,E?ZCA*]T@>_<&L #@W3IJ@K?CO;/G/%G\P;
MB>0XP1\QSUCD<UB7'2R34I;45>'9"TVMCRQM=KF/>/C.I:0-$&78[8YL\]QW
M<JOR".'D-.::C?\ ZJ]\-SB[_>CQLC/7Z212_P!999'7U2[W=CRU! >U';OD
M7(N"<<.:G=BHN-9+DUW$XRW1F@MBWDI\E5KR6?5<PNB9!=?(P1M;ZFYI)&WJ
M$GE[+\BJ8;M\<#R2G!RK@F)/'9+5_%_.XW)XU\=>-XFJFPQ\<@-6&9CXI_=<
M'-.K7= SK_:#(9'FF$YA-F8(<I@S!Z&<IU/E,O/69$6ST+4D3Q#-4EE/JB-T
M7V?5K/T@&DJ]@;M3$92CC\K2Q,N7R&!RUNC0J3MPXO8&\V_+:@I.L[:\MUT<
M<<S8G!@:P'1S^J#:Q]EKL=ZUCSG1)PF?E;>>0T7P?UZ+)"TW(.JB</##6-MO
MS&OI^H 3'J1[P#RXIV5R_';_  *[8Y!!<'"YN132M;2=$;8Y+,Z8@'UW>GZ)
M?M!][</8@N- 0$! 0$!!$.9<6Y!RMEO#1YFO5XAEL?-C,QC9* L67ML[F2/B
MG,S6MW1N,>U\+Q^=]"#8X3 W,%:;5J7VCB53'T\?B<(( 'UG5 ]CI#9+RZ0/
M9Z;0PM&W9KJ=W0--RO@-CDO.>$<SCR3:HX5/>LQ470&46G9*H^E('2>HW9LC
MD+FZ-.KO'H@UF3[69&_E^X>4J\FL8N3G>,IXR*:A%Z5K&R8^*>*.>&82:N<[
MUR7#1NFT;2/%!&H.P%R*Y8R!Y' R:UF^.\C?5J8ME6I'8XW&V,PPQMG<6QV
MQNNYSG,Z]7$] ^LEV!?E,)GN/W\Q4O8KD.<RO(;,5K&M=)6L97;Z<E29LS9(
MIZ9:70S,<"[<0X>:#)N]D,O-8SENIS*PRUF(^-QNEM5Q8,HXP7:LO;98S:CN
MM>YMEFL>NOLU!!@^Q,^"RF S%?DQ=<P'(LUR"!HH11POJ\B8YMFEZ;) &[7.
M)BE'PCIM*#UQ79?)X";CV7Q'(F,Y%QV]GYX9I:>ZG:Q_*;;K]JI/")@_[.<L
M?%(R5I'IC4$.*#!K_AZBQU66AB^021TY^+YGBLWKUFRRNFY%<-^W?W![!O\
M6<XMB#=NATUZ(+6XKA7\;XSAN/26!;=B:5:A\T&>EZHJQ-B#]FKMI<&ZD:G1
M!MT! 0$! 0$! 0$%32?AX[<P\^XSSW#8NMB;7'9K]I]2M" RU9O-:&R.=N&P
MQ/#GC:.I<=4$^Q>.Y'5XV,=E\Q%E.1>G,U^7^3%6%[I'N,9^69(X ,:6MT$G
MO::]-4$4P?:V;#=E_P#1\Y<3L9A9N/0YGY?8\5YH70"0P^H07M:[PWZ$A!IK
M?9G.06.)YKC'+ON?E/'<+%QC(9"3&Q7J^0QL)8YCOEI96B&=DC/4CD:]P:7.
M:6N:4&1G>R6.Y/RIO(,]<9/&R"Q0-B"#Y7*6,5=Q[J,^.N6HG@6*[GO=:;OC
MW,DTV$ (,!G9;EL_!7\%S/.SDJ<$V+.*M'%0UWPU\/<AN1^N(Y?MYW_+QQ/F
M+F#;J0P.)*#+N]E[=S(V\LWD(KW9N7T^<5BVF'QQSU<>S&OJO:Z75['Q,U#P
M6N:\Z]0-$&MQW8"[#DF6\OS"?*PBGR/%6)9J43<C:I<F>R3^L6_4<7RUC&QD
M;]@;Z;0T,;UU#U;V 9>QF-PG)<^<GC*O#+? ;HAJ-J2SU+;X'-LL<))&QRQB
MM&&C:YI.I]@ >/).P>2YECIW<EY5Z_*WX>EQR'.PT0P"E2R$.1EE?7,Q:Z>S
M+7B]0A[6- ]QH\PL#BW#+/'N4<PY+/D&VCRVU3N.J,A](5G4J45+:UY>XO#F
MPA_4#0D^2"7(" @(/PZZ'3Q\M4%=T^)\WO7X.6\HGPKN;X7'Y''\>=CX;3:
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MG<*\<+IM6#;J[9N)*#9Y?LT_,.Y8S)6L=E,7S#*PY7*X;)XWYFH^.#&QXYL
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MX^R>XZ-D^$^U!)/'J/! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$!!%LIW%X;ALN,)DLHR"Z+%:C,XLD=!!;OZ
M&K!/,UICBDF!'IMD<"[4?I-U##Q_=KMYE<U%Q_'YMDV4FR%S"LC$,[8QE,<P
MR3U'2NC$;9FL:YPC<X.< 2W71!H>Z_<_+=LL]Q&U+5KV."Y.R^MRNV_<VSCH
M'R05H;K7;PST63V8FS[FDAIU'F@^N5]R\OC^[/"NW&#K5WX_.OOLSV5G#Y'5
MIJM!UZ"O"UKV@R2,87O+M0UFGFX((7D.^^?QO:?G7-9K.$=ROBN5RV.HXEV]
MC+$6'OOI R1FQZN^8-WC:>FHZ%!.8>;<CY#W"RW;GC4M*(\2HTK'+<[9ADE(
MNY1KI:U:K6;(P=8HS+*]\IVM<QH!)):$QXM/RJ:C8;R^M4K92&W8BA=CWO?7
MFJ-?]A,!)[S7.81O82=KM0"1H4&[0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MP:?8P&/]U77G%HB*8X[%)Y-%KS?)/*T^G]'7*\X]&(" @(" @(" @(" @("
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MP=<< YA6YUQ>GR"!HBFD!BNU@=?1LQ=)&:^S7JW^*0K.)U7F._575)EET$!
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M>NY1N.QF9C9'"9G/E='N;7FVL^S;('=6G<=="="I:@9>$XYC,MEI3 )88((
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M@Y9ONW\7@NCF(,O#_P!^8[^D=^P5QS_:MX.^W^]3Q_HL=>>>H$! 0$! 0$!
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MT)T08W:3NYQ7O#QG[_XZ]]>[5?\ *YO"6AZ=['76]'P3QG0@@@[7::.T]H(
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MYI9@,)8FGLY#,U8V,L,9%'2>QA&C3NWN8-6M.O@$82IC&L:&,:&L: &M:-
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M,@@$'>W_ &HV2C@<4MN_G1589_\ L2U%]G[X]25S=C=1TW.T.@1A$JTT(K0
MR,:X1L#FN< 00T @@G4$%&4M[< S\WQKH/M6PQ6GS.9[P8UT8:"XCPU)T",+
MZ1@0$!!3O>C)=X^&6*'</MXYO(^*XANO*N ?+QFW;JZG?8HV&L,OK1M.OI:[
M7::@$^ZXRG7;[N%Q3NAQ6CS+AMYM[#7F_0)H)@ 7P3L!)9*S71S3]8U!!)A*
M$!!YSOEC@ED@C]:9K'.CAW!F]P&H;N/0:GIJL2VK$3,:\(47R//9[D%Z-F=K
M,Q\V-<0W& $F*25H)>]Q/O.+#HPCIH=?-5N2]K3Q['T#R_:8<-9MCMU]7[OZ
M?CS:F5L;H9&RG[(@[SNV]#].HT7):1.C GSV)@>V+YZ$/! ?KN> WS]Y@(U_
M*L=4-XI:>R6>QS7,8^#:Z%VA#FD;=A\VZ="MFC#RK!;C9C #ZEES7EX^%D<+
MVN<X_P  'GJM9X\&U9TXL\N<Y[M6Z-UU:====?'IY:+9J\I9XZD,EBW*V.!F
MKC(?= ;Y#SU/U>*'/A#4P\IQ!>YLDTK07$MEDA+&-;Y D:GI[2%IUP[3AOW-
MI6FIV8?ZH^-\(\6Q%I:TDZ]=OAKXK:'*==>+QR+&,A==DDD8ZK]I$^( N;KH
M'#0]'-/3=N^M)([GK1=:DK-=:<Q\SB[1T1:YNW\WJTEI.GCMZ(Q.G8]]SFN;
M'H3N!+G:CH&^9'CU61\O+(&:D.UD>&L:T%[WRR'1K6-ZDN)^%H1B9[9[$MP7
M;?D&1VNS$IQ--K?= ,<]V4Z="[0&.,>T>\?J7>F"T\^#S^Z\[QTX8HZI_"/U
ME9'&..P<8Q0QD$\EDF22>:>70%TLSMSB&M #1KY!3*4Z8T>6W>ZMN,G7,1']
MFY71#$! 0<M=Y>09GGW/HN!X!KK%?&R_+05&.#6S7RS=*]Y.@ B;JT%W1NCC
MYKE:=9T5^:TWMTPQ:?9ON51A9-'B6U[$/VFZ"Y#ZN]G4.:YK]=WLT*@Y<.2;
M:PAY-MEFVL1^:4\8[U<AXY8^Y.<4YK;8"&2S.9Z60A'\=CM!(/IZ$^TI3<VK
MPM_=OCWEJ3TWC]5Z8+D&'Y+CV9/"6V6ZC^FYA]YKO-KVGJUP]A"L*7BT:PMJ
M7K>-:SK#9+=NU?)7\ACX_DY.)QU9N3MK2G$19$O;3=;#3Z0F,>CPPNTW;>NB
M"BAE/QO:#7!]NM?/[?+?^<0?3,K^-L'[3 ]NW-]C;&5:=?RO*#GODUOOYC/Q
M'\?L<7QG%JO>+(L__P!1C>)SW9JLV*UC/J9UDX]*-NTZLD#A+\)\?2U,OZ%H
MP("#F;OORW)\FY57[=X(.FKU)(VSUX3JZUD)0',C/732)NG0_G$Z^"Y6GL0,
M]YM;IA',5VT[D8T1W*6!N4KT7O\ KPS,;,'LZ[FN:\$:_HA0,N/)-M80<F'+
MU:Q$I[Q7OEE<1/\ <_.JDD_H'TY;C(_3N1$=/MH2!N^MNA^@K;'NICA9UQ;V
M:SI>/U_!>.(S.+SU&/)8>W'<HR_#-$=1J/$$>((\P>JL*VBT:PMJWBT:Q.L,
MY;-A!77<_C7=SD$F,=VOYS5X='7$PR;;6*ARILE^STBTS$;-FC]=/'7Z$$ _
MTW_%C_\ &W&?^Z]/_G(RUV>XM^)?BV&N\AY%WZP^-P>-B=8O7K'&:;8XHF>)
M/O=?8 .I/0=4&L_!7P3G_','R3EG(,MNX9RZX_*<7PS:S*;'0S/<\9%E9GNU
M666.865V= W3V-0=4(P(""&=RNV/&^ZF'JX/D[[3*-2R+L0IRB%QE;&^,;BY
MKP1H]WDI6WW-\%NJO-&W&VIGKTWCAS<T\R_#5S[MED3S+LEE[=D5_>-!KPW)
M,9UW : 1V&?Q"W<?#:Y7N'S''GCHSQ'CV?V4&7RS+MYZ]O:?#T].':G79S\4
M%7DUZ/AO<BNS!<N#Q6@MEIAK69Q[ICD8_K!,3^:?=<>@VG1JA[ORV:1UX_BJ
MF;/S2,D]&2.B[H]4B\$!! .Z%SO'4KXS_1_'8+(6Y)91EO\ $4MB*..(-'IF
M+Y<@DEVN[75!77WM^-7_ /Y_M[_Z7E/]J,M9R*U^+:_@<E3Y7QOMG)QF6M*,
MNW(6\E\G\IL)E,QD.T,#02XGP'5!&?P.6^Y<F/Y-1OQPO[-U;,K.&66/LRPB
M5L[A+'CI+8;/)2 UT=,-0[H/>WH.O48$! 0$! 08>5R5?$8VUD[7\Q5C=(X#
MQ.G@T?23T""L\O;S^;C@RMIT$ IR!S8VL<8XF3#1S'/W:N.T:GIY=$9U3# <
M<N5;<>1R5B.5\+"RI' 7N8UKQU)<_KX>  T1A*$! 0$! 0$! 0$%$9CM_P#B
M@M9C(6L-WBQU##SV9I,?0?QNI,ZO6>\F*(R.=J\L:0TN/CXHRPO]-_Q8_P#Q
MMQG_ +KT_P#G(*-_$EQKO(<-B^WW+>Y-'G7,N168G<3X?CN-U(,D^S%(-;;+
M3)&NILB:'[I]>HW-^'>6AV5VQQ/,,#V_X]A^?Y5N;YC3ILBR^38.DLPUT]X@
M%Y:W:PR$:O(W'J482Q 0$%5,^*;^FE_;*]/W>$/'QSGQGWOM&1!G\?\ \PT?
MU9OV"H^Y^U;V).T^_7V^YON0\CFI3_=V.#?FPT.FF>-6Q!W@ /-Q4';;6+QU
M6Y>]8[O>32>BG/MGN1PY?.$ZG)2ZGV-8!_ K#Z&+_&%7_(S?YS^3]&8SC2",
ME)J/TFL(_<T3Z&+_ !@_D9O\Y_))>.\ADR,CJ%]K6WF-WLD9T9*P="0/(CS"
MKMSMHI'57E[EML]W.2>B_P WO2)5ZS$!!6/<SBG>G/Y6E9[9]P:G$,5%7,=V
ME:Q$&4=-8WDB022D%HVZ-VCZT$)_TW_%C_\ &W&?^Z]/_G(RBO<;$=^."\.R
MG(.X_?3#1<09$Z#(0V.)T; LLG!8:S8'. F=*"6^G^=Y]-2@W'X*>&=S>(=L
M['^/;,D.%REAMSB?'[#-EC'TI-[WE[27>D)BYKVU]Q]/J?B<X(PZ60$!!'.?
M3SUN&YJ:O(Z*9M5X;(PZ.&[H=#Y="@H 5Z[0&MAC#0  -C? ?D1LE/ IYJ5_
M._)O,&N%LSD1^Z/5A<-C]!TW-W'0HPB5:*(UX7.C8YSHVN<YS0YQ<YH)))&I
M))U1E+.W#G5^;XYD!])EB*U'.UGNA[&Q[VAP'CHX:A&)7TC @A_<C"]P,]@(
MJ7;;E$'$L^VU'++D[-&+)L=5:QX?$(I?=!<XL.[Q&W3S057_ *;_ (L?_C;C
M/_=>G_SD9>-O@7XIZ%6>]>[Z8BK2JQOGLV9^-48XHHHVESWO>YP#6M )))T
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M>W+%(R"QIN].1S2&OT\]IZK-9B)XL3R4*WM)^(0::]XG?^@-/\)5O_*VW_\
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M]CZ<#V.#F"-@+@=0-&C77ZD92?MU+%)SG$^G(U^C+>NUP=I]CYZ%&%_(P("
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MZ-3U7;#C^I>*N&?+].DV[D#BQ.(SDL>)R5"LV&QJR&Q2@95L5Y&M):Z-\8U
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MRCBTN)R4IFRF#<R#UW'5\M60$PO<3XD:%A/T#S*EUE.P7ZJ\>Q;2W21 0$!
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M"[-\K8T_9@X]VWRWF![7'\H:U3O+[:VR>,>YIKJLQ7# @(" @(" @(" @("
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M*UPUCE^MP'O?Q@5/V^7KKQYPL]KF^I3CSA8"DI@@(" @(" @(/F2..6-\4K
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M=#,I=M>"T)/6AP=:27Q#K(=:.OM^W+UVILL%.589U2>***"-L,+&QQ,&C(V
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M?+A 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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;$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>fc_fig15pioneer-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_fig15pioneer-4c.jpg
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M Q$!_\0 P0 !  (" P$!              4&! <" P@!"0$!  ,! 0
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M?A7=WZ;VW=W=_6UCM?7_ *"NL_!_5?R=V[UNR$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M?X>O_2';W_?/]LF4^+^L1O\ V6G%;%P&(W3E=YU@EDS^8!HK=B:5Y&:(>70
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M4K!W=> !BB!M780!F$6X\>#,MV;M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M>5N26>",FC-I&=F_:QD[,7E)GU[6)WOXO)GI>ZN^N.L;P6[(0$! 0$! 0$!
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MM->ZB_A@IW*/3NW!=KRUIO6M@N[GC*(G%X(-'9B9M6]M9^'^J_D[MTK=D("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(*5U2VOL[<V
MTKH[SD"GCZ0%/'E7T:6H?9S@^CN^KZ-R?G]FFNBIOK+.JVMLO1Y7Z2]8[G37
M*'BK,LN2V//,3%'R\LD6I:=_"+N_*[MQ./71_=XKC\?DXWZ.C;3+VCBLKCLW
MCJ^6Q-F.YCK8-)7LQ/S 8O\ _%GX.S\6?@_%=TN7-9AF*4" @(" @(" @("
M@(-)]9^M\NS+0;1VC$-W>$[!WI./>C6[[3NQ:-O3E-G9Q'L9G9WUUT6'D\F.
MD[M=-,]:H57I'U]WA&V7W#N<\;-,W.%6S<G&0>;C]%6%XX_<;C[2S^/>]ZMR
MUC$L9SKIT,M06-PS%GMKD;1N4TQVZI:_FC,;=["6GH\S,WM$HSOIW[)QKL]*
M[+WAB-];=J;CPIN]6RSC)">G>0S!P.*1F["%_P"%M';@[+JUVFTS&%F*GU9
M@(" @(" @(" @\L31QY?\60PY?C'5G JL9]G-6QS2PZ:_P"6S&WMKD[^1O\
M]#U.NM@(/+-N*+$?BP@'%:!XJ8#M1AV<UJAK-JS?I:\[^V^JY.WD;_\ 0]3+
MK8" @(" @(" @(" @(" @("".SV%I[BPF0P.0'FI9&O)5FT[6&47'5O;;75O
M;469B9<-%]%-U6MA9J[T6WL;5KE.<SV_;D?EAGCE)S[L'?R2._>1>RY$/I:,
ML=+B\:TVF>L>@Y)(X8SEE-HXHV<C,G81$1;5W=WX,S,MV3S;D+C]?>J]#'XQ
MGEZ=;//O[EO3]G9FYF=]/([2N#1@WZ#&3=NBY[_OM](U_K'I1=#(0$! 0$!
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M?3+;TF(]82Y&S9F*Q8F+4(6+T1:*)R)@\W3FXNY/[6C,TTXPVVS5\6B@@("
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M /Q)RI@]>97[27\ _$G*F#UYE?M)?P#\2<J8/7F5^TE_ /Q)RI@]>97[27\
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MG: -MK\0>\L##YE'<-"',A'Y'L 0\[_E*29UEKTWJ]ZZMVK9F(" @(" @("
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MM;8/6[9&_P"4*%.<\=FS;S<;>80,W;M[HV=Q/W&?F]I:Z^2;,]M+&R%JH("
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M;>PP^RL/)<WC&NDQU;]HTZ^.I5L?4'DJU(@@@#V(XA8!;\C,MV3(0$! 0$!
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MI_ ZA+N05C=OIU/<D_BK/=:*TLUA!R$7,F ?2)]&U[-70:LP76['YK+T,,>
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M"1<_=D)]FND_#<X/EF,NVCU@ES6;V?B,-M^7_P#T-_-8[*>*LPA)2EV]YMD
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M[LVFG*67'3_W9\<69Z_^S/QW1?*T1CP]NQ2R./:C4CI;BFEMAE,1=J49*?\
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M@/"5?J(_F#\28#PE7ZB/Y@_$F \)5^HC^8/Q)@/"5?J(_F#\28'(:]<"8@B
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M @K&[?3J>Y)_%6>ZT5I9K" @(" @(" @(" @(""Q;3^GL_)'X76FBM6I:*B
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(*QNWTZGN2?Q5GNM%:6:P@(" @(" @(" @(" @L6T_I[/R1
M^%UIHK5J6BH@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(""L;M].I[DG\59[K16EFL(" @(" @(" @("
M @(+%M/Z>S\@?A=::*U:EHJ(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @K6Z_3J^X?\59[K17%FL("
M @(" @(" @(" @(+#M7Z:S\D?A=::*U9UHJ(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>fc_fig17vaccine-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_fig17vaccine-4clr.jpg
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M;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4
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M?R)2_P :OB7^9;_97]2_)_\ \KW/J+;YI_\ \L7ZOT%6BS" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M8ZGE;V(/TH1 @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M#7*G8NP=MX1N4=T4;O#'9*>WBLAN"ADILE!=CFA@K^<BB)2=>1@>86,+G:<
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MGA<W7RF]H\*#+R&7QN*?2CR-EE9^1LMHT6O.G>V7L?(V-O\ K%L;C]A!FH"
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MO7\<V.2U#'S#2*8N$<C"X 21N+7 21ES3IVJ(F)3,+ I0C\YG,7MO$6\[F[
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M,R+D#V3M;$"[5SVSM/VJG;G WHLB@@(" @(" @("#PI_SZ6Y_2Q?J]UK391
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M:=\/,3HW37DUTTX(,^%O,._D =-)Y1<[CZP&O@ 0?701/=S%NC@==02.(\*
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M[QIT)U]4$(E+8N4"-U-Y^^USIZ['<6N_T(,] 0:IV+_C=U:_ [9_W.PLEN[
MVLL8(""I=0]]T>GN&JYG(L:*=F[!CY+EA[H:=0V>;EGM3-9)W4(+0TO+=.9S
M0=-=1$SA,0H^:ZW;@Q<L]6IL67(W*>WH=V6XX,I4,?F+I9(Y1%(T.;*YHC+H
M^7A(.PA5YD\K/CZVULI?H-VM@KF<Q%B;&PW+58/-B%N5@BLME;"R-X<R".>)
MUC61KF@G0.Y2G,<KMK]3KVXL1+E\?MFU9V;D<=EK..S5:W'&YWQ=S-:V8$,-
M?SD!Q@D#G::>5RIS&%(NYG,[IN]*]J8VO>K[2W#MR?)O+<Q)%E.>*O4,3W6
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M/"Z,:C]Q!*J!2]P?WZV[^3W/WFK<T?MV8-7?"<\)]=4)%((" @(" 4'DK?\
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M#5FY'S20$UKV7=(1$)AV2,@8.?NSPYB"=5B67ALCV-:R,\C&@!K&Z-: .
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M9E4-C8B_MJSG]KB&1FU<?8AEVO+(2YHJ6HR^6LPG4EL$@Y6Z]@.BJB4GM?\
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M DF&U [EDC>T@%I!\8X^!1$IF$HI0(" @("#X2&M+W'E8T%SG'L :-2?8"#
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MB^+N,G4L.9E"YP>'3.','!W:1I]TCL:6MYM<KX#KV=G@*,KZ@(" @(" @("
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M-NFY\<&4EB$,SJH/WEDNA/-(QO!S_MEDA24\I0(/A( ))  &KG$Z  <223V
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M/;KX#P0BL1N;"C8V-C8V#1C &M'J#@$6<D! 0$! 0$! 0$! 0$! 0$! 0$!
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ML8S&0N8"T2ETK@?NGN)*#&!=')>;(02V1SQIV!CV C7U>!09V*88\=68>)Y
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MA9I]R#H-?5X(. :R/)6V-&G>&*9Q\9(Y/W.5(';A.<T 7]IDDT];G.B"10$
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M&YL@(U#VAS'#BTH("]T9Q-Z*SCY<OD'8*[)YY:Q\CV2&3(=QYOYTZ9S><N(
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M'1X<DNR-:/5LEIH[(B\:%L9/N]/==B@2;&,C8R*)C8HHFAD44;0UC&-&C6M
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MY_-9G: WF,DON22[33P(.RQL7:%G/-W38P]>3<+'QRC(EOW[GA;RL)(/$M'
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M @(/A0:BVKU9M6<UE)-T5[-'#7+-V':[65V31S08JQYI,[6%SYC(7:/<)&-
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M 0$! 0$%)BR6^#U7L8F2IIT[;A&6(;O=CCE38+71]YKK_-\>5!=D! 49! 2
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MC])8^I$6TW,ZJ.B?NKSZYHZ$Q.9YEWSO-OYD!NO=Z:^'QH+T@(" @(" @("
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M27$;]PFTW4>I&2;E=Q^?7)1;:_O!YI),YU=FNC?<LT""](" @(" @(" @("
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M1PDBCL'5A+M-'<-#P/#7BLO43F\PKIQLADY>_*9GU(7&.*,:2EG!SW'CIKX
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M]EQ71_'QBDN;UT[8]RZ=-"78.R7-TTMRM!\;0&Z%:W6]]L]-W5T6BVA 0$!
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M5C>C;YJ5O,[-JO%(]T$YI<HD'>-U:\EVG!I;X./%6KO&N9<'-WCI7RQY><:
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M>;F(.G$ =B"RX*&E6PF-KXR7O\;#5@CIS:Z\\#(VACM?#JT H)! 0$! 0$!
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M" @(" @(""E=7<AL[%=-MQY'J#2?D=F5ZO/F*40+GRP<[1H 'QGW6GVP067
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M" @(" @(" @("#YKQ[/LH-?]9^F%#K!T^R>R[<C:UBSR2X_(.:7FM:C=JV0
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M7AI!#G$'4>HO,]-U6M&K$3:7N.O_ !W2ST]YI2(F(>WPOI+XP(" @(" @("
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M @(" @(" @(" @(" @(/A[$'B7TH/\3+/Y-4_HRN5U?>A[[^W/M6][8_H?\
M]@[F_+HOZ(+8Z/NS[W*_N3[]/_G^;THMUY80$! 0$! 0$! 0$! 0$! 0$! 0
M>?O2S_N7B_RP_P A:?5]QZ7^W_\ L3[FD_1L_P 8L1^37?Z$K5Z3O/1?W!_U
MOB]V'L*ZT/F\OJ)$! 0$! 0$! 0$! 0$! 08]_\ V&U^"D_DE!^9F=_M&]^$
M?_I7G[]Z7V#IOM5]S]!>C_\ A?M3_P NA_>7;T^Y#Y=U_P#V+^]=EE: @("
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M]7NO[:^W?WQ_!/\ H=_VIO#\'3_ZZOT?<EI?W+]VG_S/\7K%;[R0@(" @("
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MG*V05:4MJ.&"HS5KFBQ:<_FT.G+$UQ\(T#T57<Y\$3W<7.8TN/JD(.Q 0$!
M0$! 0$! 0$! 0$!!Y)QF:W!O'>_4J'/=;9]CU\#N.SBL1B&R8N!C:<4;'-<!
M: >>+CQ*#:&SMQ[D;UNR6PKF;DR^W\7M'&7(996Q<UBY).Z.2TYT8 YI&C4@
M>3XD&1TOW;N'/=6>L6W\M==9P^V\AB*^$JEK0VO':QPFE#2 ">9YU\HE!MY
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MC;OQ[<'?W]D*ERMM[O6V9J=7'U15B[^6/R#)(!SN:WW/9KKV!N% 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M]WT_S/\ T?\ ;]?\CY]?^X?^U_\ 43T'^[Z?YG_H_P"WZ_Y'SZ_]P_\ :_\
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M?%F2_J<_P3_:3S:<8^9Y-_#/R/BS)?U.?X)_M)YM.,?,\F_AGY'Q9DOZG/\
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MX5[S>TS+T-*12L5CL=ZHN(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MZ(L3.E '>-:> =QX+#>V9RV=.O+&&QU1D$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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<" @(" @(" @(" @(" @(" @(" @(" @("#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>fc_fig24pembrolizumab-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_fig24pembrolizumab-4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$$ &AT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-RXR+6,P,# @-SDN9&5E,V$W-S S+" R,#(R+S X+S$X+3$V.C4P
M.C,P(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.GAM
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240](G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q
M-3 X0S@B('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z-4,R.$%"1#%!.#9$
M,3%%14(U,41",S$U,D%!13!$.#$B('AM<$U-.DEN<W1A;F-E240](GAM<"YI
M:60Z-4,R.$%"1#!!.#9$,3%%14(U,41",S$U,D%!13!$.#$B('AM<#I#<F5A
M=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@,C8N-2 H36%C:6YT;W-H*2(^
M(#QX;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED
M.C%A.65E96$Q+3=E.34M-#@P-BUA8CDT+34Q.&8S-F(X9#,X-B(@<W12968Z
M9&]C=6UE;G1)1#TB>&UP+F1I9#HT9&)C8S Y-BTW9C)E+31F9&$M.#<U9"UA
M8SDT9C!E,S)A,3@B+SX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY0<FEN=#PO<F1F.FQI/B \+W)D9CI!;'0^
M(#PO9&,Z=&ET;&4^(#PO<F1F.D1E<V-R:7!T:6]N/B \+W)D9CI21$8^(#PO
M>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T 2%!H;W1O<VAO<" S
M+C  .$))300$       /' %:  ,;)4<< @   @ " #A"24T$)0      $/SA
M'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L A  $ P,# P,$ P,$
M!@0#! 8'!00$!0<(!@8'!@8("@@)"0D)" H*# P,# P*# P-#0P,$1$1$1$4
M%!04%!04%!04 00%!0@'" \*"@\4#@X.%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "S WX# 1$  A$!
M Q$!_\0 LP !  (# 0$!              8'! 4( P(! 0$  P$! 0
M         @,$!0$&$   !0," @@#! 4(" ,)     0(#!!$%!A('(1,Q8:$B
M4Y,4%D$5"%$R([1"LG,W.%(S-'0U=787<8&18G)CLS;%ATBQX8+#)%4F)Q@1
M 0 " 0,"!0($!0,%       ! @,1410Q$B%!<3($@1-A(C,%D<'1<D.Q0H+P
MH>%2(__:  P# 0 "$0,1 #\ [^
M
M
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MFM)*T+T&I.I-:'11E7X@/<
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MB
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MAI!'II6E>D!N
M
M        1O/<2+.<5G8NJ<NW(G&SKF---O+2EEY#ID2724GO$C36E4UJ7$B
M5A!^FBSP&H3;.13D+@IL9M/MH;0YZG'4)98E%4U))]QE/(=[O+6C[S9JHH C
M_3-CS$>+'5=GW/3MW.'(=-HB<G0+H2T\B::5ES="31^*DD.:T)6E25:JABRO
MI<L\M2WG\DE29BV6F#FRHD5^09L6^/ 0M2S253(HR72_WS,^GB ]+M],%ENT
M$H;E_DH=1.NL]N:<=IR2KYK_ #?-6LSUN1JF3+U$JTT(^BH"T\&PV-@UHEV:
M')5)C2;G<KLE:VT-K2JZS'9JVS-LBU:%NJ2E1\=-"^ "3
M
M                                                       "H<ND
M[EVG.*V-J?<\;=?AS%)92CDM1IC2[7(CI.E34P\J/<2(_P!!+O'H(!M\-DYI
M[PG0;PJ2Y9V&Y[;JI*2Y:38EMMVY32R26HWHO,<=H9][IH? !8X
M J'*GMS;=FZV[(B?<,>=DQ))&UH)AN+<V56MYDC-)F:HD@F+AU-&[Q/@1 R>
M7>X3>:095XO<2*TFTL6.?"CN.N-RG(ZB4M!LQG34WS$I<D'I5\2^.D!:EL-\
M[=#.2]ZF2;#?.D&V;',7H+4OEGQ1J/CI^'0 R@                    %.
M/N[GPL]?M*2N,S%7Y<B(FYDE!(:8NZ&Y<=Y!D7$H*X\B,LSXZ7FNDZF0:^ZW
MW.6X&1/X2Y>KZP[=XQM-O,HC2H"&GV2?0UZQEKF,2*+IRR7RF^\1EJ+2%Y@
M
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M:(D5-]R&-8I5%N'H:GXY\_;-HZT4XT9^G=KPJ6HB*ND@V]XW_MN*9=DN.9/
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M&.>XPTW.0E)O):I^,T:5*);2J]U?QH D@
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MSKPM3EP<4\XLG5J=<?-1H4K3JU.J[U-5*%6A$0"5@
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ME/M)<-!U(N*350!L0   0G<G*,AQ*#;I]DC1Y3<R4=L=2^VZX:9DYI;5N/\
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M0LR)/'@? OL"8TG0K:+1K"5CQ)'\[_[(R7^ZIWY9P!67T@_PWX#_ %.1^=?
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M%)29:5*IU"45F8U0M>(F(GS2HD()9N$DB<41)4NG$R34R(S^PJF(IOH
M                      'PXRR[_.MI7PT]Y)*X&9'3CUD0".8?F6+YVQ=Y
MN.+-]NVW!^RW-;C"F3]7")/,1WTD:TI)945T"5JS'5"EXMT25*4H22$$24)(
MB2DBH1$701$(IOT                              <UXA_&WN'_A"V_]
M2, Z4                 4E]7W\-^??U./^=8 6-MO^[O$?[EMWY5L!)P
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M;:2'SBY2W":N<1AZB4RXSIK)1L*KWE-FV>M/33B52)5)=LZ:J_N1W=OFK?\
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MV6>XN6A<\B+D2'V&FW'%,'4]39<TDDOH49'2I4,Z[5FO5?3)%]=$L$5@
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MB PKHAPRZ$-H+NF:?O?Z!1>^OA'1MQ8M/S6\;2MP5-(
M         *1W.VPR"U9&6\>SQ)CY_%217RQUT1+_  D4-3+I=!/T+\-S[:?$
MB,KJ7C3MMT9<F.8GOIU_U4/M!;=RMV[=DF!Q(,S#-O;KD=QOF8W9S4B:ZU.4
MBEJC&M">-$?C+IT?>X=Q=UYBND]9T9,47R1->D:^/]'9^,8O8<,L4+&L9@MV
MZRP$<N-%:+@1=)J49U-2E'WE*49FH^)C),S,ZRZ=:Q6-(;<>)
M                 *PWCV<@[GP85TM<U>/;D8ZLY6)99%*DB)(+CRW*?SC#
MGW7&U5(R/_:'(-LRCZBKC]0.46ZUX?\ )]VKY886.7&]+U+LUO3%6V;UW;4;
M9I4VM""4PBJJ*53OGW3#LK9_9_&]GL<5:;0IRX7NX.>LR/(YG?GW.<NIK>>6
M9J.E5*T(U'IK\5&I2@L,
M
M
M    !\.NH8:6\Y]QM)K53B=$E4Q[$:SH\M.D:RT?O*Q^(YY9C9PLK#S\7XGO
M*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLI
MS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>
M68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\
MK'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG
M/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY
M9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[R
ML?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<
M_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGE
MF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*
MQ^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS
M\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>6
M8<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K
M'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/
MQ;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9
MAPLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL
M?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_
M%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF
M'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q
M^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\
M6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68
M<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'
MXCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q
M;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9A
MPLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?
MB.>68<+*<_%N>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%
MN>\K'XCGEF'"RG/Q;GO*Q^(YY9APLIS\6Y[RL?B.>68<+*<_%N>\K'XCGEF'
M"RG/Q;MC;;M#NR''(:E*2V9)5J2:>)E7XBC+AMCG\S1BS5RQK5G"E>
M          QKC_9\O]BY^H8LQ^^/55E]D^DJA'U+Y$
M
M                                                 !.L#_HDO]HG
M]4<;]P]T.[^V^V?5+1RW6                8UQ_L^7^Q<_4,68_?'JJR^R
M?250CZE\B
M
M                 G6!_P!$E_M$_JCC?N'NAW?VWVSZI:.6ZP @EVWCV_LC
M]W1/N+GHL?=]-?[JQ%DR+= D:4KY,F2RVMM#A$M.I)J[E2U::D G#+K<AEM]
MH]33J26A7VI452/_ & /L    !&']PL/C9Y%VS?N249M-MZKQ&M9MNU5"0M3
M9N<S1R_O)5W=>KNF=* ).     QKC_9\O]BY^H8LQ^^/55E]D^DJA'U+Y$
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M'S]WWOR]=':^/V\?\W35=SF-V/,\-N^#7:A7J[6B"UE).55);FR(2$L/2/\
MFI-DE%\>X74-D5K>DUGKIXL$WM2\6CI$SHJ7Z>+MD&26.%MCD<=UF1M=<W6K
MXXX2B0\41:OED=*J][0[S%J29?<91]HS?&FUM*3_ +9;/E16DS>/]\>'\_\
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MTT_!<GT]$9;(8+7_ .V__/=&SXGZ4,7S/U964-C&
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M27!.HR-5"Z &2 QKC_9\O]BY^H8LQ^^/55E]D^DJA'U+Y$
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M55E]D^DJA'U+Y$
M
M                     !.L#_HDO]HG]4<;]P]T.[^V^V?5+1RW6
M         8UQ_L^7^Q<_4,68_?'JJR^R?250CZE\B
M
M                                                 G6!_P!$E_M$
M_JCC?N'NAW?VWVSZI:.6ZP               #&N/]GR_P!BY^H8LQ>^/55E
M]D^DJBX=7:/J'R1PZNT X=7: <.KM .'5V@'#J[0#AU=H!PZNT X=7: <.KM
M .'5V@'#J[0#AU=H!PZNT X=7: <.KM .'5V@'#J[0#AU=H!PZNT X=7: <.
MKM .'5V@'#J[0#AU=H!PZNT X=7: <.KM .'5V@'#J[0#AU=H!PZNT X=7:
M<.KM .'5V@'#J[0#AU=H!PZNT X=7: <.KM .'5V@'#J[0#AU=H!PZNT X=7
M: <.KM .'5V@'#J[0#AU=H!PZNT X=7: <.KM .'5V@'#J[0#AU=H!PZNT X
M=7: <.KM .'5V@'#J[0#AU=H!PZNT X=7: <.KM .'5V@'#J[0#AU=H!PZNT
M X=7: <.KM .'5V@'#J[0#AU=H!PZNT X=7: <.KM .'5V@'#J[0#AU=H!PZ
MNT X=7: <.KM .'5V@'#J[0#AU=H!PZNT X=7: <.KM .'5V@'#J[0#AU=H!
MPZNT X=7: <.KM .'5V@'#J[0#AU=H"<X)_1)?[1/ZHXWS_=#N?MOMGU2T<Q
%U@!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>fc_fig36discovery-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_fig36discovery-4c.jpg
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M;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4
M !#\X1^)R+?)>"\T8C0'6'?K_^X #D%D;V)E &3      ?_; (0 ! ,# P,#
M! ,#! 8$ P0&!P4$! 4'" 8&!P8&" H("0D)"0@*"@P,# P,"@P,#0T,#!$1
M$1$1%!04%!04%!04% $$!04(!P@/"@H/% X.#A04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@#4 .W P$1
M  (1 0,1 ?_$ ,,  0 " P # 0             &!P0%" $" PD! 0$  P$!
M               !! 4& P(0   % @,#!P4(#P4%!P,#!0 ! @,$!081$@<A
M$P@Q(M,4E5<80=*4%A=18=$R4Q4U5G%"DK(C<Y-4M-15=98W6+%2LW<)@9%B
M,R2A<D,T=#8X@F,EP789\(/#)D@1 0 " 0," P8%! ,! 0     ! @,1,P0A
M<3%1$D&!D;$R%&&A(A,5\.%2!=%B(\$T_]H # ,!  (1 Q$ /P#J*J&?SG-V
M_P#CN_?F.HQ?1':')9OKMWEBXG[H]'D8G[H!B?N@&)^Z 8G[H!B?N@&)^Z 8
MG[H!B?N@&)^Z 8G[H!B?N@&)^Z 8G[H!B?N@&)^Z V%",_GF#M_\9']H\.1M
MV[,CC;M>ZUAS3J@!S;QQISZ';HU*2AVN4IM9MJ-"C2MXTF6*<#Y# ?7P/Z"_
MF=7[7E^> \>!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F
M=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7
M[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7
ME^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^
M> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^>
M>!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!
M_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_0
M7\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\
MSJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ
M_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:
M\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\O
MSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP
M#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P
M/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z
M"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_
MF=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=
M7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[
M7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E
M^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^>
M >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >
M!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_
M07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07
M\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\SJ_:\OSP#P/Z"_F=7[7E^> >!_07\S
MJ_:\OSP#P/Z"_F=7[7E^> I_73ACTJL*IZ6Q+=8J;*+JO.F4"KF[4Y+N>GS#
M4EU"<RN:H]F"BVD Z2JGTG-_'N_?F.HQ?1':')9MRW>6(/5X@
M        -A0OIF#^.1_:,?D;=NS(XV[7NM<<TZL <W<<'\DF_P!_TC]( =(@
M
M
M        .<^*?Z>T)_S(HGWR@$PJGTG-_'N_?F.HQ?1':')9MRW>6(/5X@
M                 -A0OIF#^.1_:,?D;=NS(XV[7NM<<TZL <W<<'\DF_W_
M $C]( =(@     #T;>:>S&RXEPD*-"\ADK*M.PTGAR&7E(![@
M
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MUJ,S,U'NL3,SY3,%=2 @
M
M                   #G/BG^GM"?\R*)]\H!,*I])S?Q[OWYCJ,7T1VAR6;
M<MWEB#U>(                   #84+Z9@_CD?VC'Y&W;LR.-NU[K7'-.K
M'-W'!_))O]_TC]( =(@   B[6FVGK% F6M&M:DQ[<J"5MS:6Q"89C/)=QS9T
M-H21F9GCCRX[>4!^'%7C-PJM/AM?\J-)>906)GS6UFDN7;R$ _4K_3^_^/S?
M[ZJ']C0*ZE!       1&^]3;+TS@HJE[SW*52EX$<\XLJ1'0I2B0DG'([3A(
M-1F1%GPQ 8]@:MV!JBB0_8=4768<7%+\UN+*9C$M.7%!.OM-H-9$HCRI,SP
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M,.E0XT9Y]3KLAS=)YZ4[M)$>T\ZR/ MA& L
M                                                   '.?%/]/:$
M_P"9%$^^4 F%4^DYOX]W[\QU&+Z([0Y+-N6[RQ!ZO$
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MEXC6E#T>0V1)<9<-MS*?_"?*6"C(MD
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MJF&*/66X)4URL.-$LW9"&=VVKJZ,R6VE.)Q4K/R$ M($
M                                        <Y\4_P!/:$_YD43[Y0"8
M53Z3F_CW?OS'48OHCM#DLVY;O+$'J\0                   &PH7TS!_'(
M_M&/R-NW9D<;=KW6N.:=6 .;N.#^23?[_I'Z0 Z1     ?@M<G_N*K_^MD_X
MJ@'ZB?Z?W_Q^;_?50_L:!74H(J/6/B2TMT.<BPKRG/O5N:@GF*+36BDS>KF:
MD[Y:5*;0A&*321K61J/XI'@> ;'1_7G3C7"GRYEC3W%RZ>:2J%*FM]7FL$YC
MD4IO%1&A6&Q:%*3Y,<=@"RP   ?)<:.X\B0XRA;[9&3;JDD:TDKE(C,L2Q >
MJX4-Q:G'([2W%))M2U(2:C01XDDS,N0C+' ![JCQUK)U;2%.IPRK-)&HL#Q+
M _L@*CXE;.NF^M(K@LJQZ.W4:Y<75XZUKD,PT,MLOMO&ZXITRS8$WE));=ON
M K&X:+#N.Q]*K=L^_;?8@W#:_6F8LPGH\TG$2Y+L@ULK;Q4WL<)*DGAR +G<
M;;>;6TZ@G&G"-*T*(E)4E18&1D>PR,@1\F(4.+';B18[3,5I)H:8;0E#:4GR
MDE)$1$7O /<V&%,E'-I!L$1))HTED(D\A8<FS !XDQ8LUA<68RW(C.89V7DD
MXA6!D98I41D>!EB ^H#XN0XCN\)UAM9/9=]F0E6?)\7-B6W#R8@/=UEI]!M/
MMI<:/#%"R)23P/$MA^X9 /1V'$?6EQZ.VXXG#*M:$J46!YBP,R]W: \=2A[W
M?]7:W^;>;W(G/GPRYL<,<<-F/N *JU-<U_C5ZFTK1RF6ZBV*C&=15JS5C<*3
M G.+/"0EIM:4N)2G!24[M>9>)*P+E*G-@V;3]/K-HUFTM:WHM(C)85*=_P";
M(?,S6](<VGSWG5+=7Y,RCP!$C 8CU*I<B<Q4Y$*.[4HR31&F.-(4^TE7*2'#
M+,DCQ\A@,AUII]I;+Z$NLN$:7&UD2DJ2>PR,CV&1@!,LDI"B;22FDFALR26*
M4GAB2?<(\" ?*1 @RW6'Y49I]^*HW(KKK:5K:6?*I!J(S2?OD ^ZDI6E2%I)
M2%$9*298D9'RD9 /"T(<0II:24VHC2I"B(TFDRP,C(_( ^#-.I\:&5.CQ&6J
M>DC2F(VVE+)$H\3(D$1)VF>/( ^J8["7">2T@GB3NR<))$K(1XY<>7#W@'JB
M'$;)HFX[:28,S8)*$ED-7+EP+9CCMP "B12)\B8;(I.)R2R)_"&993S[.=LV
M;0'LJ.PMPWEM(4Z:#;-PTD:LAGB:<>7#W@'EIIIAM++*$MM(+!#:")*2+W"(
MMA .<K;L2_W^(>\;ZNFR&56'==.A4@D2)T&7D^;]V:7GHV*B4E1H/*2<33L_
MV%=%=4B=71$W#?5&R2EMC(G=I2WAE(DX8$2<"P]P$>Z664.+>2VE+SA$3CA$
M1*42>3$^4\,=@#&DTFE39<:?,@QY$Z&9G$DNM(<=9,^4VUJ(S3_])@,PR(RP
M/:1\I /"4I0E*$))*$D1)218$1%L(B(@'PAP(-.9ZM3XS42/F->Z8;2TC,K:
M9Y4$18GY0'I,I5+J+D=ZH0H\MV(O>Q''VD.J9<V<YLUD9I/9RD ^ZV&75MN.
M-I6XT9J:4I)&:#,L#-)GR;/< >B(4-M9.-QVD.$:S):4)(R-P\5GB1?;>7W0
M'A$""T1DW%:02D;I1);26+9F9Y3P+DQ,]@#Q)I\"9%ZC,BLR(6"2ZLZVEQK!
M'Q>8HC+9ALV ,A*221)21$DBP(BV$1$ \@
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MUP&W6K6I=,D1*M+P,F'791H-F/CR*7BG>X>0D[>4L0_3T
M
M                                         !SGQ3_3VA/^9%$^^4 F
M%4^DYOX]W[\QU&+Z([0Y+-N6[RQ!ZO$                   !L*%],P?QR
M/[1C\C;MV9'&W:]UKCFG5@#F[C@_DDW^_P"D?I #I$   'H3+)<C:?=Y"Y3
M-TU_<3_N( W37]Q/^X@'LE*4$24D24ER$6P@&NKENV_<\,J=<E)AUBGDLG"B
M5&.U+9):2,B5D>2I.)$9[< 'TI%%H] @HIE"I\:ETUHS-N'!9;C,)-6T\K;2
M4I+'[ #.
M
M     <Y\4_T]H3_F11/OE )A5/I.;^/=^_,=1B^B.T.2S;EN\L0>KQ
M              ;"A?3,'\<C^T8_(V[=F1QMVO=:XYIU8 YNXX/Y)-_O^D?I
M #I$
M
M            !SGQ3_3VA/\ F11/OE )A5/I.;^/=^_,=1B^B.T.2S;EN\L0
M>KQ                    ;"A?3,'\<C^T8_(V[=F1QMVO=:XYIU8 HWBQL
M:\-0=)E4&QJ7\\5YNJT^:B"3S,;,U%<-:SSOK;27W0",>UKB][A8G\10>D /
M:UQ>]PL3^(H/2 'M:XO>X6)_$4'I #VM<7O<+$_B*#T@![6N+WN%B?Q%!Z0
M]K7%[W"Q/XB@]( >UKB][A8G\10>D /:UQ>]PL3^(H/2 'M:XO>X6)_$4'I
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MM:XO>X6)_$4'I #VM<7O<+$_B*#T@![6N+WN%B?Q%!Z0 ]K7%[W"Q/XB@](
M>UKB][A8G\10>D 0'4N1Q8ZE3+*F2M%H]/79EQ0KG8W=>@.]8<@9C)A6+Q94
MKQVJVF0"^ZI])S?Q[OWYCJ,7T1VAR6;<MWEB#U>(      !$9\GV?]@@"@ \
MX'@1^0^00>!0      &PH7TS!_'(_M&/R-NW9D<;=KW6N.:=6
M
M
M  *CJGTG-_'N_?F.HQ?1':')9MRW>6(/5X@      K;7JYZC9.F-0O&DDE52
MH4VF36&G,VZ=RS6DJ;<)!I,T+2I23+$8G*M-::Q[&7Q:Q?)Z9]L2YH\>%T_4
MVE^D2OA&N^_OY0VG\=3SD\>%U?4VE^D2OA#[^_E!_'4\Y7IPW:DU?5FDW9>=
M88;AO.U5B''@1U+4PPS&A-8$G>&H\5&HU*/RF,SB9)R:VE@<S%&.:UCR78-@
MUX      -A0OIF#^.1_:,?D;=NS(XV[7NM<<TZL
M
M                                                    5'5/I.;^
M/=^_,=1B^B.T.2S;EN\L0>KQ      !67$(QO=(:](5%*='IKM.JDR$HLR7H
MD"H,/OH,CV&1MI5RC$Y6W++XF['O^396M'T8ORG-5JT:5;E3@R$DZE+,&%OV
MR5]JZT;9+;47(:5I(3'&*\=(@R3FI.EIGXRRJ[0]);8@N5*Y*1;=)@-)-;DB
M9#@M%E26)Y24C%1^XE)&9^0?5ZXJQK,0^:6RWG2LS/Q0[AZGTFX*=>]XV[#3
M3[8KUS/KH<9ME,9'4X46/&2X322(DYU),S+#E]_$>7$TGU3'AJ]N9$UFM9\8
MA<0SV       #84+Z9@_CD?VC'Y&W;LR.-NU[K7'-.K
M
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M/Y)-_O\ I'Z0 Z,ZM'^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^
M ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5
MHWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^
M11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/
MN2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7
MP '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^
MZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5H
MWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^1
M1]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N
M2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P
M '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  Z
MM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HW
MR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11
M]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2
M^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P
M'5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM
M&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR
M*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]
MR7P '5HWR*/N2^  ZM&^11]R7P '5HWR*/N2^  ZM&^11]R7P .=>*9II%<T
M+2EM!$K4BB9L$D6)9E;.0!,ZI])S?Q[OWYCJ,7T1VAR6;<MWEB#U>(
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MXYIU8 YNXX/Y)-_O^D?I #I$
M
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MZH7)0M5:! A.4=]E-&N.CK6F!5HSZ5JS(8><==:6V24[PE*PS*P+DQ,+'
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M+V[22=XZO LRU88J/#:8(RP
M               '.?%/]/:$_P"9%$^^4 F%4^DYOX]W[\QU&+Z([0Y+-N6[
MRQ!ZO$      &KN6M4*W;>J=<N=YIBW84=QRIK?1O6S8,LBD&W@>?/FR$C \
MQGAY1YY+5K69MX/3'6UK1%?%R"YQJ6];S;5M658)*LN$A46*S4)JDNJC&:N8
M3>1U*493P)"EK(BYO(-1]Y$1I6O1N?L)M^JUOU+RX>[WTHO"VYOLRHK-LOQW
MDNUR@H0A#R'7<20Z:T_\UL\#2A7VOQ<J1F\6]+1^F-)8/+QY*V_7.OE*X!G,
M        !L*%],P?QR/[1C\C;MV9'&W:]UKCFG5@#F[C@_DDW^_Z1^D .D0
M! =;*K>5'TMN65I]3I-4O1V+U.BQH2<SZ)$Q:8Y/IVEAN2<-[''9EV@*8THX
M&=);2H$=5_P"O"[Y#:5U*5*<=3#:>5SE(C-(4C%!&>&=S%2L,W-QRD%5\6?!
MS95OV34-3-*XAT=ZAH*16J$EQQV,]#(R2MYC>&M3:V\<ZDYLIH(^0RYP?GX
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M-DIQ7O$ _<6BTF%0*/3Z%3DFBGTN,S"B(4>)I9C-I;01GY<$I(!G
M                              "*:DV+%U*LRIV9,J<^CL5)*".H4E[J
M\MM33B7$Y58&1I-22):3+G)Q(!C:9Z8V_I;0G*11GIE1FS'>LU>NU9\YE3GR
M2039.2'E8&K*A*4(21$E*2V%RF830
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M0+DHE.N&E+-VEU6,S.@NJ2:#7'DH)QM64]I8I41[0&P
M
M        <Y\4_P!/:$_YD43[Y0"853Z3F_CW?OS'48OHCM#DLVY;O+$'J\0
M     :6[:-5K@H$ND42O2;9J4@B)JLPFVWGVB(]I)2Y@7.+89I,E%Y#(>66D
MVKI$Z/7'>*VUF-7'+G"Y4J+=<FM:P3:S=%KK,G#K=MH5/DJ/::SG-NYI32"+
M::FFW?LD--/&FMM;ZS'X-W',K:NE-(GRET)I1 T&I]:6UI J(=2^:<)_4'77
M?^C3)01=;)XS6E_>%L)PB7EQV88#/P1BBWZ/'1KL\YIK^OPU6X,]@
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MA-I).9Q:MJE'ABI1\I@C(
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MN:GW!2):IEE4*KR:7:$,\#CP)]1;CR:VAE*MJ<CJ68V9/D0I/N@KIL$
M
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M,=V\[YNN^Z?%<0\S1+AJ*7:6IQE1+:4_'8::)\TJ(E8/*4@S+:D%7*"
M   *]U;TBI.K]*IM+JE;K%"^:YB)\>509?4WC6DLII49H61EE,\IX8I/:7N&
M$ELZT*!8=MP+4MF-U2CT]!I9;-1N.+6M1K<<<6K%2W'%J4M:U;5*,S ;T
M
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MC\C;MV9'&W:]UKCFG5@#F[C@_DDW^_Z1^D .D0
M
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MS3JP
M
M                !4=4^DYOX]W[\QU&+Z([0Y+-N6[RQ!ZO$      'JXAM
MYER.^A+L=TC2ZRXDEMK2>PR4E1&1E]DA\S$3XK$Z(&O2:@4V7)JM@RI%BUB6
M>>4Y0R;*#)66.4Y,!U*F'"+$]B20>WE&-/&B)UK^F65')M,:7_5'X_\ +S:[
M&J\:])3%Z3*?4+3;I66F3Z4PN&3TWK*<RI3#CCAH>W?)NU;O+CAM#'&6+_J\
M-#).*:?I\=4]&6Q        &PH7TS!_'(_M&/R-NW9D<;=KW6N.:=6
M
M
M       *CJGTG-_'N_?F.HQ?1':')9MRW>6(/5X@                   -
MA0OIF#^.1_:,?D;=NS(XV[7NM<<TZL
M
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M< ]>>-+NLMGMA/3@'KSQI=UEL]L)Z< ]>>-+NLMGMA/3@'KSQI=UEL]L)Z<
M]>>-+NLMGMA/3@'KSQI=UEL]L)Z< ]>>-+NLMGMA/3@'KSQI=UEL]L)Z< ]>
M>-+NLMGMA/3@'KSQI=UEL]L)Z< ]>>-+NLMGMA/3@'KSQI=UEL]L)Z< ]>>-
M+NLMGMA/3@'KSQI=UEL]L)Z< ]>>-+NLMGMA/3@'KSQI=UEL]L)Z< ]>>-+N
MLMGMA/3@'KSQI=UEL]L)Z<!&;NUXXJK&?M^/<FFUN1W;HJL>@4=**H;INU"9
MFW2#R/'E29IVK5S2\I@BW:I])S?Q[OWYCJ,7T1VAR6;<MWEB#U>(
M           #84+Z9@_CD?VC'Y&W;LR.-NU[K7'-.K '-W'!_))O]_TC]( =
M(@
M
M          .<^*?Z>T)_S(HGWR@$PJGTG-_'N_?F.HQ?1':')9MRW>6(/5X@
M                   -A0OIF#^.1_:,?D;=NS(XV[7NM<<TZL <W<<'\DF_
MW_2/T@!TB
M
M                  YSXI_I[0G_ #(HGWR@$PJGTG-_'N_?F.HQ?1':')9M
MRW>6(/5X@                   -A0OIF#^.1_:,?D;=NS(XV[7NM<<TZL
M<W<<'\DF_P!_TC]( =(@   CUYWU9^GE%<N*]JS&HE':/*<F4O+G6?(AM!8K
M<6?D0A)J]X!SA._U#-"(LSJ\:+7YT<E&2I;$)E#9EY#2EZ0VLR/WTD N?2C7
MC3'6B,\Y8E9*34(J"=FTB2A4:>P@U9<RFE_&3C@6=LU)VD6..P!9(
M
M                                                     #G/BG^G
MM"?\R*)]\H!,*I])S?Q[OWYCJ,7T1VAR6;<MWEB#U>(
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M:8J<1B:VVK:I*)+:7"(_?(E -@
M
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MP/-S4K41)00=Q09L2IPHU2@.I?@S&D2(SZ/BN-.I):%%[QD9&",@
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M$1JRXD2BQ 7E#AQ:?$CP(326(<5M#$=A!8(0TTDDI2DO(1$6! C[
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M.'D 9E-I=,HT)JFT>$Q3Z<R1DS$B-(8901GB>5#9)26WW" 98
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M$)4K89F>W !VB
M
M          YSXI_I[0G_ #(HGWR@'1@      UU4HL&K(PD(RO$7,?1L67PE
M[QCWQ9[8YZ>#'S<>F6.OB@-7MZ;2E&IQ.\C&>"7T%S?]ON&-WAY%<GAXM!GX
MML?CX>;3F1ERC*8@*@ \D1GR"*W5'MR;53)PBW47'G/K+9_])>48F;DUQ_C+
M-P<6V3KX1YI[3*1"I3>2,C\(98+>5M6K[)__ *$-)ES6R3U;[%@KCCHSQXO<
M       !S=QP?R2;_?\ 2/T@!TB
M
M                                    YSXI_I[0G_,BB??* =&
M   \*0E:30M)*0HL%),L2,O?(6)T28U1*LV<AS-(I6"5\IQE'S3_ .Z9\GV#
M&SP<W3I?XM5GX,3UI\$+?CO1W%-/(-#B#P4A18&7^P;:MHF-8:6U9K.DO,>*
M_*=2RPVIQU7Q4)+$S"UXK&LE*3:=(3:C6>RQE?J>#KO*4<MJ"_[Q^4_^S[(T
M^;F3/2GQ;O!P8KUOU_!*B(DD24E@DMA$6PB(AK6U>0         !S;QQ*2C1
M!"UJ)*$UZD&I2CP(B)_:9F8"WO:_I+]?;=[7@], >U_27Z^V[VO!Z8 ]K^DO
MU]MWM>#TP![7])?K[;O:\'I@#VOZ2_7VW>UX/3 'M?TE^OMN]KP>F /:_I+]
M?;=[7@], >U_27Z^V[VO!Z8 ]K^DOU]MWM>#TP![7])?K[;O:\'I@#VOZ2_7
MVW>UX/3 'M?TE^OMN]KP>F /:_I+]?;=[7@], >U_27Z^V[VO!Z8 ]K^DOU]
MMWM>#TP![7])?K[;O:\'I@#VOZ2_7VW>UX/3 'M?TE^OMN]KP>F /:_I+]?;
M=[7@], >U_27Z^V[VO!Z8 ]K^DOU]MWM>#TP![7])?K[;O:\'I@#VOZ2_7VW
M>UX/3 'M?TE^OMN]KP>F /:_I+]?;=[7@], >U_27Z^V[VO!Z8 ]K^DOU]MW
MM>#TP![7])?K[;O:\'I@#VOZ2_7VW>UX/3 'M?TE^OMN]KP>F /:_I+]?;=[
M7@], >U_27Z^V[VO!Z8 ]K^DOU]MWM>#TP![7])?K[;O:\'I@#VOZ2_7VW>U
MX/3 'M?TE^OMN]KP>F /:_I+]?;=[7@], >U_27Z^V[VO!Z8 ]K^DOU]MWM>
M#TP![7])?K[;O:\'I@#VOZ2_7VW>UX/3 'M?TE^OMN]KP>F /:_I+]?;=[7@
M], >U_27Z^V[VO!Z8 ]K^DOU]MWM>#TP![7])?K[;O:\'I@#VOZ2_7VW>UX/
M3 'M?TE^OMN]KP>F /:_I+]?;=[7@], >U_27Z^V[VO!Z8 ]K^DOU]MWM>#T
MP![7])?K[;O:\'I@#VOZ2_7VW>UX/3 'M?TE^OMN]KP>F /:_I+]?;=[7@],
M >U_27Z^V[VO!Z8 ]K^DOU]MWM>#TP![7])?K[;O:\'I@#VOZ2_7VW>UX/3
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M >&C0'NZH?H: #PT: ]W5#]#0 M4
M
M
M
M
M                                             Q( Q( Q( Q( Q(
MQ( Q( Q( Q( Q( Q( Q( Q( Q( Q( Q( Q(
M
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M,/SP#PM7QW^WUZ8?G@'A:OCO]OKTP_/ /"U?'?[?7IA^> >%J^._V^O3#\\
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M3#\\ \+5\=_M]>F'YX!X6KX[_;Z],/SP#PM7QW^WUZ8?G@'A:OCO]OKTP_/
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M?\EECGW2@#F[C@_DDW^_Z1^D .D0
M
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MHJKBL>K-5FBI?=B*EL)<2DGV,,Z<'$H5LQ(\<,#(R,MA@)(
MC5YZ@6=I[$@3[SJS5(AU.:U2X+KR5J)R9()1H;+=I5AB25&:E8)(BVF0"2@
M        "-71?]G67.H5-NBK-4V=<TU-+H3+J7%')F+,B2VG(E1%B:DEF5@G
M$R+': DH                #G/BG^GM"?\ ,BB??* 28^4QUCC7@5
M              &\M'Z>C?8<_P -0PN9M2SN#O1[_DLL<^Z4 <W<<'\DF_W_
M $C]( =(@     #EK4[C@LC3[4=[3FGT.3<4N&^U"J-0C2&V&&9JUDEQE.9*
MC6;6)$L\2P5BGR KJ4$      !RCQ]Q[O5I-2*C0(_7;>I=:CS;GAF@W6EQV
MDJ-DY""^,P3N!.%R8FD_)B14=IVM>B'%S93>FMPLL6CJ,I"/5UF>E"FF*FW@
M;2J?*(B(R,T)2IH\BUI/(25 .@=4]9Z9IB_;=NE!77]0+NE-P+?MZ*ZB/OG3
M4E"W77G,2992:OCFE1^X1X*-)&AM_6B+?9:BZ<UZD';VH=HP9'SK1U/IFQWH
MKT<S1(CODA&=M1+1F2I"33F3CCB"N??]/2N4FV=+M2+BKLI$&C4N<U+GS'<<
MC;#,12UJ/#$SP(N0MI^0!<$;BQCM4JV[\K]GR:/I#=M371Z/=3LQIV2APE.(
M:?E04(Q::<-IS:3JE)))G@>*<0FU]ZW-6_?]*TFLZC>M.H]4C.5!=..6B!$A
MPVD*7O),A2'32I67F-I;,SY3PQ3B%=P.+KUJT7N_4>SK1><NBSE&S6K?G2FD
M,Q,R%J3)4_S-\TG(>+;:2<49&DB+8H!!N&O4*_*_H===5N6RW+GH=45<%6K=
M>=JT:,F<\\?_ %$0H^!NM8MYB29$2"P(BPV )!PC7OHW;^C=Y7=:])F6I:=$
MJ#TBN/U>850D.*;C-.$:5(0@L"2I+;;:4XF?NJ,!O"XNU0K2HVJ=PV++INC]
M?J"J; N%,]B34$$2W6TOOT]""-+:E,KV)=4HLOVV*<2-]KUQ.0-#&;<JDBW7
M+BMNYFE.0*K!FM-EF02%F6[4A1FDVW$K2LCP/D!6NC<5Z8^KMOZ7W78=4MEB
M[$-.VY5I[[*GGFY2E(CJ>AMD:F,ZT*0:5.&M!X9DEY W&L7$Q2]']1;/T^F6
MW.J[MU;I2Y\59)2PV_(ZLG=MFA1ON$HC-2"4G L-IX@+U!%;EH?I]4*O<EP7
M?2(EUUNY7E'(F5B,U)7'@I033,.-G)6Z:;07_AY34HS4K;R!SSHS4)NCFBNN
M=U6R\X_8E%K5:5IT3ZM^V:(F:.EUM2L26R;Q(3CR*-"CY3,%26RK$I54X(GX
M=39)Z=6[?GW1-GKVR7:N\3E0:F..'BI3J5I;P69XX)(N0@%K\.%YU74#0^RK
MKKCIR*Q,@&S.DKVK>>A/.1%.J/\ O.&UG5[Y@B97=9]O7K CTVZ8_7J+&DMS
MGJ:ZK_I)*X^*FTRF^1UI*L'-VOF&I)9B,BP <V4)K22Z.+NCU+3"J4:"_:5#
MFLW!&I:FV"J<J23C+;#3;24H>..DU.O.(-67F)/DYI6ZI527??&G7:=5?^HI
M.F5MM_,4518M,U*J]76]*(C_ /%-ITVLQ?:D0#ULZLKL_C(OBP("=S;UXT2-
M=#D)HB)I%78)MEU\DEL2IY)+4Z9?'5@:L0%I\0+#+^A^HF^:0Z:+<JRVR<0E
M>590G<%%F(\#+R'Y 10FFW$(O2W0S3N;.LBL3]/(-.I\*O7JV;3,6(](437X
M)AP]\^A"SR+<2E*,W-2I1X JXM7=5K7L^M6/1J[:$BXDW)6Z="HE6<8CKID2
M;,<R-ND\\:E)>0G%:2;;QPQYQ -_?6JL:U+GM^P:-2W;AOVYDO/T^D-/(BM-
M0XB34])DR'"433:2(TIP2I2U<U) B-6CKZU=-]5#2JL6-6Z;>5*<2U76DIBS
MZ7%8?0;C$A<I+R#4R\C#*>YQQ/ R(%47H??U9L6I:X-6C9-0O.KE?=6D+I=+
MW4./&AM+7SUONX-D:L%$TRTE2U93YI$ Z+H&O-D5[2.!K"UUENAU DLQZ:EO
M?5%RHK?ZJF"TT@SWCZW_ ,&V23P5B2L23B9$:=O7BI4*^K>LC4ZRI5G'=ZU1
M[8JW7HU4BOS$92ZL^<; V73-:$I^,E1GL5AB9%>]8USJJ?7"HV;9<BY[9L23
M+I]PU)J='B/]>IS*7Y;46*Z1J=W*5IQ,U(S*Q)!*PVA ]8-9=06+NT>I5JVX
M]ZOW;,C59+S-1CL2*D;44I'S>1+,B;;2;J#=6[@2\")/EQ#I6DRITVF1)=3@
MJIE0>:0Y)IRW6WU,.*+%39N-&:%93V8I/ $4/6.*4HEZW18%&T[N&K71;L!-
M09IJ&VVY,TC6@C4VA)NY620LE[Q1YE;$I;-1D"Z-PC7ZI5JMPK/LRQYM4OGY
MCC7'7J'49;%(^:V9A(-N.\X\E9JD&:RYA(P(L#49;2(/I3>(^@532"?JY#MR
MLR8U'<EQJU0XS+3LV'(IR35(WAFXE&Z019C<)7Q3QPQQ(!%9W%NW3[5H&H;V
MGU:]FU01#.M73G93&@.SC2G*VVO*[)2VM6[6ZE"6\VQ)JV /AQ%-0UZQ\/-0
M8;;-U^XY!=9019EM[I@T\XMIE[@"S*3JO4[CORKVE;%J/U:@T&6W JUWM38R
M::V^I*5.LHS<]UYC,9/--D>0]BC(SP :JX-;ZRV5PSK!L>7>5O6D\_%K]79F
MQH".LP4YY;4)M\C7)4P6*5Y<J361H2:E$ S'.(33]S3*C:GTE<FJ0+D?:I]O
M4:,VDZG,JK[AM)@H:-64GB6E1+Q7E(DFK$RP,R*,U:N&Y*OKIH1'NZR%VI5D
MW X]'EHEQZE'E,*0TE2#D,I09.-F19FU)PP,C2HP5V%-D]3AOR]R[(W#:G.K
MQTYWG,A8Y4)Q+%1\A%B".=HO%B[7H%QKLO3*Y*[7+9J4BG5.BDAMA^.U$26=
MV2HMXEM:E[Q#<=)N.*R*/ B!6U=XK+.>T75K10Z)5:Q2F%+C5&FQFVB?@2VL
MA*;EK6LDH3BXC!:<^*5$9)\@#8VIQ"MW!-<E56SJO;]A(M\KE3?$]&%*4RAM
M#CJ"422/!)*/(?QG,N)())D9A@5'B.J=$MN'J16M/*I$TCF&RX5R%)C.SV8<
MI1)8EOTU'X1#*\R3V.*623(S3Y &CUYU?O:D7/I32;$I9SK8NNL0);57BSX[
M*JJV@B?3!:2LRR-NDI"ENN8),L$ERF LJLZJ5.FO42V8=J2)^IU:AN5-5I-R
MXR4P8;"R;<?ES2-32&\ZB;0I)*-:^:DCP/ -79.O46Z'[MMVJVO4Z/J-9.[5
M6K.;-F=+=:?(E-.PW$*0A]"R4DR5S.4C/89&81^R]?+3]B54U7MVPY]/MNFS
M*B3M!I,>-UA)0\SCTIY#9M-MD>!J=/%1I_X@&LG<6[=/M6@:AO:?5KV;5!$,
MZU=.=E,: [.-*<K;:\KLE+:U;M;J4);S;$FK8 M&\M3SH5Q42RK7I'K+>==B
MOU.+3^MM0([=.B&E*WW9#A+Y5+2E"4(4:MI["(S 9FF]^3+[A5IRIT"3;55H
M-4>HL^FRW6WU[YAEEXW$+:YJFUD\6[47QBV@B:@*AOC6^=8^I%N:=R[.ER#N
MY[J]O5PID1F"^XTE*GT+SJSMK;)194&G%>)9<3,%22MZ@5&EZCT+3Z%;KM2.
MM17Z@]5&9<="(42(M#;KK[*SWA)S.H0WE(\ZC,B^*8(K2?Q1EZOU_4"W;*F5
MO2RV9[E-JMR-S8T>2HXZT-O/1X+A9W&DFX6!J<0HRVX$"Z+(NG5FW;<M^WJQ
M%9?K%1O!<=BT:'#2DIE1?F-DZV1;PTI:;0@]X\ZX9(;1M/;@1D:&TM;U5/4N
M1I#>MMO6K?)02J]-9*4W4H4R"9F2E-R&DHRK2:5$:5H+XIX&8*TEP<1[T*W:
MQJ!:UE3;DTOM]YUBHW.U+CQ3?3%=W,EZGQG2-4EEI6*3<-3:5&E67$DX@/&I
M.O%BT^V["N"1:4N[+?O.;3%T"<]%9ZC&DSE&;"W5R,RFWT))2DDELSV?&(!L
M[]XA:38&HM"T[J%KUN5*KJ92HE1C1TN,OG%CFZ3<1"5*<?<4LT-&65!)-1*-
M67$!]M-M<GKTONM::71:,^RKSI4)%88I\]^/+*33''$MD\ER.9I)1*6DE((U
M88X9C,CP(P[CUZJL*EUF[+-L6==M@6ZY(:JUQ1YD:)O/F]2DS7(##N*Y3;!H
M4E3A&A*E)42#5EQ!5F65>-!U M2E7G;$@Y-"K+!28;JDY%X&9I4A:3Y%H42D
M*+R*(P1#;QUA<HU_P]*[0M]RZ+\D4U==D0SE-4V)&IR'-R3CDAU*\5K</*E"
M&U'Y3P+E#56_Q#TJN:>7+>YVQ6$52S9TNDW/:\=#,F=%FT].9\B63B&UMI+:
M;F8O+L!4.?XN5-V%2-3X^G%;E6&\AIVX:VVZPEBG)>?-@B:)S(N4:3+\(;:$
MH29X9\0'TX@-7+WH=<TMI-CTE4RW+NK=-<.K,S&8[E1;)9/II[2'#)3:7DY#
M<><RIRGE\IX!(KTU>I]%N#3>W[WT[E^L%SU:+&I[\HH4J%2YSR\F9$LE.9GF
MTGF_ I+9]L0"67MJJS;=W433J@4ERXK]KK#T]BEH?1#8CT^/B2Y,F0X2B0@U
M%D024*4I6S $:&P=?F+TO6HZ<2[-KE(O"@N[BY,4QI5+@*6VXZPM<M#R5*0^
MA&+2B9VXEB1<H*U=;XC9D*WIFHM"L6?7=)*<ZM,JZX\N*R\[%8=-EZ7$@N'O
M'F$J(\%FM&9)9B++M ?:\.)RU+7F6,B)1:G6*+?BXYTFO16BZD;4E!+P1E-;
MKCY$I);DFB/$\,2,#1EV=KV[7M3#TPNNRZI9E:GP5U:VE5-R.]U^$THR4:DQ
MU+)ETB(U&TI2C+ R,R/#$+E!         !SGQ3_3VA/^9%$^^4 DQ\ICK'&O
M J                    -Y:/T]&^PY_AJ&%S-J6=P=Z/?\EECGW2@#F[C@
M_DDW^_Z1^D .D0    '-?&#Q$MZ,69ZOV[(PU&N5E;=+-!EF@Q<<CDU1;<#+
M:ADCY5XGM)"B ?E;0'''KFI;SJU..N3XZUK69J4I2GDF9F9[3,S ?O,
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M^';0E+[R4$2W33F-)&68\=@"K^%&\;6C\*EP6P[5HQ5]$2XY<B"3A&Y'C[G
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MNDHD4VD/5",E*VT*^+O&OP;7E)KG8F;A@KD6V_\ W%2/_6QO\5((_>D
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M%&1$?DQ ?)^P;%E3DU25;%)?J:#0I$UV#&7((VB(D&3BD&HC21%EV[/( D0
M         YSXI_I[0G_,BB??* 28^4QUCC7@5       ! %           ;R
MT?IZ-]AS_#4,+F;4L[@[T>_Y++'/NE '-W'!_))O]_TC]( =(@ #Y29,:%&>
MF3'D1XD="GI$AY1-MMMMD:E+6I1D24I(L3,^0!Q+28\OC3UH.X:BPXGAWT\D
M+8IL9>9#=8J)8'F6D_C$OFJ67VC.5&Q3BC!5M\;"$-\,]X-MI)*$G3$I2DL"
M(BJ,8B(B($?DU;?_ +BI'_K8W^*D!^](        "'7#JII]:MS4>S:Y78\:
MZJ\^U&I5(+.[)=<?5E1BEM*LB3/[9>5/O@)B   ",VSJ#9UXU:X:';55;J%5
MM265/N",A#J%191YBR*-Q"25M0HL4&HL2,L=@"3         /1YYJ.TX^^M+
M3#236ZXLR2E*$EB:C,]A$1<H"*63J?8>H[U79LBM,UKYB>;C5-V,ES<MO.DI
M24I<4E*5[$GB:#47OX@)<               "(O:H6"Q?,3355<CKOF:AQUF
MBM9G7R;9:4\M3AH2:6^8DS+.HL?( EP      <@"'6QJII_>EQ5:U;4KK%7K
M="0E=69BDM;;!+6:$D;N7=J,S2>Q*C,L-H"8@(C<FJ%@VC<%&M2X*Y'B7+<#
M[42D4KG.27W7UDVC!#:5&E)J/#.O!/O@/%4U1L&C7E3-/I]<81>E8/"!149W
M9"B)"G,5$A*B;+*DU8N&G'R ,F;J#9U.O:FZ<3:JVU>M8B.5"FTDT.FX]%9S
MYUDLD&V6&[7L4LC/*>!; $F
M                        <Y\4_P!/:$_YD43[Y0"3'RF.L<:\"H
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MCZ75JKW!:U3>IDNC/R(T%Q"8R,7%ONN9FVW#42D-L-J=6LR\A KX,<5DBX;
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MFRK(::F-$E9I+>)9=>068BS)P6?-,@1N
M                            <Y\4_P!/:$_YD43[Y0"3'RF.L<:\"H
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M5&*EIH\!-#<:=HR8[*:<ZPLG651DH(FC0LC,E)-.&"L3Q!&<
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M?>E%C>S:P*/9IO-O.0$O+=..E:(R');[DE;3"5FI266U.FAHE'CD(L01,P
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M_P!(_2 '2(
M
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M:(S6&        WEH_3T;[#G^&H87,VI9W!WH]_R66.?=*
M
M                                                          *9
M/E,=8XUX%0       !S+=<F2GC8LF,EYPHRJ+F4R2U$V9G&G<J<<#Y"&JO\
M_IC^O-M:?_DMW_X=-#:M4         -Y:/T]&^PY_AJ&%S-J6=P=Z/?\EECG
MW2@
M
M               "F3Y3'6.->!4      !%-1]0[?TNM.5=UR*6<1E26(T5@
MB-^3*<(S0RWCLQ/ S,SV)21F/#-EC'767OAPSEMZ8<<GQ42JY?+%\Q-*Z=/K
M%.2;$2>AR8]4&8V5:<F^;YA'E<46.Y\HT\\J9OZO3#=QPXBGH]4Z.NM+=4;>
MU8MQ5>H3;T21%=ZK5:5+(BDQ).7-E5AL4E1;4+(BQ]PC(R&WP9XRQK#2Y\%L
M5M)3<9#'        ;RT?IZ-]AS_#4,+F;4L[@[T>_P"2RQS[I0
M
M
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M_/ /$9H-WCV]VE'\\ \1F@W>/;W:4?SP#Q&:#=X]O=I1_/ :<^4QUCC7@5
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MP \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P
M\/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/
MFAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FA
MW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=
MY0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0
M.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.S
MH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_
MF 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F
M'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A
M\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T
M.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[
MO*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*
M!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V
M='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='
M\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P
M \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \
M/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/F
MAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW
M=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y
M0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.
MSH_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F 'A\T.[O*!V='\P \/FAW=Y0.SH
M_F 'A\T.[O*!V='\P \/FAW=Y0.SH_F *)XC](]+K>K&C<>AV=2*<U5[_I%/
MJ:8T-IHI$-XU$XP[E269M?VR3V +9/E,=8XUX%0      %2<0NHE6TJM:AWI
M18K$Z9'K+<54.2DS0ZU)BR$J2E2<%H5L(R4@\?(>)&9#"Y62:1%H\V;Q,49+
M36?+_P"J"\<U^?4B%^6F?",#[Z_E#8_QM/.?R3ZRN)F\:[IWJ+J54*$E;EL?
M-S--H,8W2:0<C.EQYU:L5FDC-*W,.1*=F&TQZTY5IK:TQX/#)PZ1>M8GQU6U
MHKJ-4M5=/X=Y5:E?-$U]YZ.ME)K4PZ3!D1/,FYSLBL<-IG@I)[3&;Q\LY*ZS
M#"Y.&,5_3$ZK &4Q0      ;RT?IZ-]AS_#4,+F;4L[@[T>_Y++'/NE '-W'
M!_))O]_TC]( =(@
M
M                       .<^*?Z>T)_P R*)]\H!)CY3'6.->!4      !
M6.M^H%*TOH5!O.LT9-;@Q:NAC<8D3["WHKY)?8SXHSIPR\\N0SPP/:,/DY(I
M$6F->K,XN*<DS6)TZ*C\=&G_ -4*I]W$&)]]7_%E_P =;_):NBNM$#6A%PSJ
M52%4JDTA<2.TW(4A;[JY*'5.FX2"R92RD22^SC[@RN/G_=UZ,7D\?]G3KK,K
M42E*$);;22&T$24(21)2E);"(B+81%[A#,B-&&\BH      #>6C]/1OL.?X:
MAA<S:EG<'>CW_)98Y]TH YNXX/Y)-_O^D?I #I$   $3U&U(M'2FUW[PO::<
M&B,.M1S<0VM]Q3KZLJ$(;;(U*/E/[!&8"F/'=PX?MZ;V9,Z, \=W#A^WIO9D
MSHP%EZ4:YZ>ZU(JCU@2I,UBCFRB<\_$>BH2N02S0E)NI3F/!!F9%R;/= 60
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M)J;3F<4DCQ/#'R!;H              YSXI_I[0G_,BB??* 28^4QUCC7@5
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M8#]0N$S2M_2?1:C4BJ1%0[FJQKK-=9<3E=1)ED61I98$9*;:2VA23Y%$8"\
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MC3C2>':NCDN@Q=/[DHM4JE(.3%:FSYD%!I>>;;Q,C0I1&:Y,E1+-2L3(RS*
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M:6RXX^I3Z]Z^Z^[AG<<7@1&HR(BV$1$1%L&3BQ1CC2&/ERVR6]5DF'L\0
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MEQ,R,P%L
M                     *.N;0>ZT7[6]1M*M1IEE5NYBC^L,&1 CUNG2G(;
M6Y:634A2#;-*-A8*/WL"V )796F-5H]7;NN_KKDWS>,=IR+3Y\B*Q3H4%A[#
M>E$A1L4-K=RD3CJE+6HB).))Q(PL8        !2]S:$5>\M09=?N:_ZM.TWF
M.1)#NG&5**<MV#D4A"W,YXLFX@G5MDV6<]BE&0*N@$
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M$8$45G>OH1&0DUDI)K;P4M1$>W C!5O@@
M                                                   .<^*?Z>T)
M_P R*)]\H!)CY3'6.->!4      !6FN^H%JZ=Z?29]WT<[@IE7=32440\J6Y
M*WD*<,G%J)1(2E+9JS$1J)1%EV[2Q.3DK2G6-=67Q<5KW_3.FB%TKB'TRNC1
M6X+FETE^13*!'9IM<M*2LI;ZFY2DQXZ3>7\=IP]F^468C2>)9L,<>.32V*=8
M\/8R)XF2N6(U\?:F.@]VZ>798;;NF](3;U+A/FU.H1I)+L>4XA+F9:B,S=)Q
M)DI#IGSB+#9EP+WXMZ6K^F-'ARJ7K?\ 7.OXK.&8PP       &\M'Z>C?8<_
MPU#"YFU+.X.]'O\ DLL<^Z4 <W<<'\DF_P!_TC]( =(@ "*:DZAVYI79=4OJ
MZG%HH]*0E3C;)$M]UQQ9-MM-)4:2-:U*))8F1>4S(B,P'-VG_P#J#Z67564T
MBZZ7,L]I]66/4Y+B)D(C\F^4TE*V\?=R*27E41;0'6T27$J$5F= ?;E0I*$O
M1Y+"TN-.-K+,E:%I,R4DR/$C(P',/'Y6:- T!E4NH.ME5*M4H+=)849;Q3C#
MI/.K2GEP2VE1*5Y,Q%Y2 ;?@NT>GZ3Z2MR+@CG%NJZGBJU0CKV.,1S028K"R
M\BDHQ6I/*E2S2?( ISBSXQKWL2_)6FFE[D>G.49#7SS6G642GUR7VB=W+*72
M4VE"$+3F4:34:]A923S@D?![Q9W3JS<$K3K4<F)%PE&<G4BLQFDQC?0R9;UE
MYILB1G(E9T*0E)92,C+':8=F@   Y^XM+SU&T_LFE7)8==:I*'*M"IL^.<5M
MYY]$Q9ES'W<Y-$67 \&C/:>!E@"HSJ7<NNFE>HM@3?7*'<,._JLJWW;5DT]N
M'2H+THDE'6R\R2I*DM*7SE+5G61>0CP2&PAW%JSIIQ"V78=X7L5ZVYJ)"J2C
M;=IL:G'3YE+94^1QTQ]I-J(DHP6I7*9GBKG -K;ETW-KQ>6H$"A75,M.R;)G
M^K].7141NO3*JPDSD27WI+3Y;E"N8VTA)$LN<H_( CMJ<2E:M.UM6*;JMNJK
M>>D+A-NSX;90VZPQ+6;4%TVDD:65N.&A+F7FI)9&1<H".:[V]J=-X8JW?EQW
MP])K%5IL.=7;:1%C-T)$6:\RYU6*C*;[:X^=.5]3ZU.9.<7.YH3*NZH5:D1-
M*]+;<=G0YE;MMBL5RJ4B JJU*/3(D=EM+<1@D.))QYPS2;RT*)I*3/*:C+ ,
MO1^[M6(^J56LBX(EPU[3%Z'URW;MN*DG39L60C*:XDEQ++"'2/,K(LT$K81<
MG($,T K]9M72_B"N6WH'SI7:3>=T3:=3\JED](8CLK0DTH,E*+$MJ4[3+86T
M!(]'[SJ>HJ[/N:Q=47[J96XES4FU:@B Q(8WD1>+C#1,MNQVVI1MIR-FM+B3
MV+/*>8.F@1KJ]!J52I,F%2*HY1:BZ2=Q4V669#C)I6E1F3<A*VU9B(T\Y/E]
MT!R?PB6Y=4S3BXYD"]9M+@-W%7&3A,0J>X1R4FV92<[S*U8\AFWCD\@*W>F6
MIVI=^\)U9U+GW(J)?-*9K4]BJQX</*LJ2EU;;2V%-&T:%$C!6"2/WP&CO_5O
M6&)PZZ8ZF4:Y&(M8N!^DQ*XWU%DG);D]:C4I+N"D,)P1E,D,X[3,C(!)[HN7
M5_2W633=-Q7FU<5N:B5&12*C;:*<S#B4]65"F3B.IS/*)"G<#4ZLU*).WE+*
M$HC7-<FL6I-ZV=0;AEVG9M@+CTR9*I*6/G.HU>4A3JSWTEMY++$<DDC(EO,X
MHS,U9<$@*QU>CZZGPL7LC52K_-E?H;S\?KM(.*7S]1UNM,MJDDT1DR3F\62T
M-Y#4DB)22Q41A(KWGZG:;\+2KOMJ]C.ITZD4V9&=E4R&M;,1UF.PF,R3:4(+
M+GS;UU#BMF #?WQJS<M'MS2*T+?FM-:@:GG!BE6I;27TPXR8S3LZ83'-2XZ6
M\3NT*P0:E;=A8&&JOF\KVX>;ZLIVLW/,N_2Z]*@5#J;=9;C=?I=1>RFU(8D1
M66<[2BS&II:#RD@\NU6P,"'7]<KBX@;]TIC7S&@4JFTB%.AU%JELFY!;EK;<
M,F&'#6EUXR5NMX^XI))YQ(S; &UT4U#U0GT?5VSJG):O.^--ZC+I]OSWVVX!
MU,]RXJ(W()O*A*C6UE4HC+8K:>S,85[<>K%_Z<EIY4JEJ"NKZE5>L4ZF:A6&
MMJ#*ID1NH*43C2%PF<(KS!I)LB-\U+/G&1ECB%@Z^_S]X=/WM7/T2, Z0!'(
MVI5]:G6W;M]7?>E[+L.\Z;+FO:<V73^H3X\NCP$ENGY3!-2'G"E&AU*G'%-I
M;/G<TN:"M_J#KG6J9IGI!=M8EO6O;5]IAKO:Z*7&*6Y3&Y=/)\D,DXEU+>^>
M5EWII6I"$J-)*5@ D%'N2^Z!9>HUZT*Y&]3;7B4EJH:<R".*^^MUB*^M]B0<
M%#9NJ2X39F9D2U%S=BB 1_1^\ZGJ*NS[FL75%^ZF5N)<U)M6H(@,2&-Y$7BX
MPT3+;L=MJ4;:<C9K2XD]BSRGF# U'N_4BD%J'6[QO9S3^72'Y)Z5T&F=0F?.
M<6&RI:9,J,;,E]Y#ZDI2LE9$M<[DY0'TNR_M;+BX8J!K78%:12[MBTI%5KU*
M:A1I<:;'1BF2MM+[;BFU())O%E/#*1I]PP$MNO4&JU[3W30],+GD-W+?\VGL
M4FJK8ARG^I&V<FHR),=;1MGU>.AS.E"4Y7<J=G( C-UZI.1=;*GI=>=_S-/H
M=/IM-=LJIDU$:CU>8^T9R)$M^2PMI61W*V3!;MM6"MN;8 O+31J]&+&H[6H<
MEN9>:&W"JTMG=$T\YOEY7$$R1((E(RF24ELY 1+
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M-JO>O"_.L=_3V; N2=3J=1*52428S\DUPMR;\F2K.AMAI6[P:2:U+/#G$6)
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MXYO)DG$CNO+6S%-Y/-6;2#2DS3S2/8GFD0(M8
M                                           <Y\4_T]H3_F11/OE
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M&Y%0F.J?=;BH4:T16,VQIA*E&HFT$1&9XJQ/: D
M      KK5K3FZ=0XE(9M:_JI8<BFR5/R7Z2DE];:6DDFVXDUM\F&*<3-)8GB
MD]F 26R;-HM@6U"M:@D\<&&2U+DRW#D2Y,A]:G7Y$AU6UQYYQ2G'%>51["(L
M" 2
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M
M
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M/XV^\6T.S7/U< ]3^-OO%M#LUS]7 /4_C;[Q;0[-<_5P#U/XV^\6T.S7/U<
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M
M
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MI./9X@      WEH_3T;[#G^&H87,VI9W!WH]_P EECGW2@
M
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M/F:S%;6C2TKT&Q:X       !O+1^GHWV'/\ #4,+F;4L[@[T>_Y++'/NE
M
M
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M=Z/?\EECGW2@#F[C@_DDW^_Z1^D .D0
M
M                                       '.?%/]/:%?YD43[Y0"3'R
MF.L<:\"H      "I>(C5&Y-)+%8N.UZ6U4)LF:B$Y)E(6[%AMJ0I>\<0V:3,
MU&G(C%1)Q]_ CP^5FMCKK#-XF&N6VEI2_3:Z*C?>GE#N>N4PJ9-K40W)M+6D
MS:PSJ;Q)#F)FVZDLZ4KQYJO*/3#;]RD3,>+QS4C'DF(GP9%LV':EFSZS/M:F
MM4KY^4P[4(D5)-1-[&2M*5MM)(DH-1+//EV'RX<H^J8:TF9CVI?-:\1%IUT2
M,>SQ        ;RT?IZ-]AS_#4,+F;4L[@[T>_P"2RQS[I0!S=QP?R2;_ '_2
M/T@!TB
M
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MQV24KD+.XI*<3\FT![+K%):I:JVY/C(HJ6NLJJ*GD%%)C#-O#=,\F3#;FQP
M1+2[52W=5Z(_<%O.MG Z[-C02)Y*W7XL*0J,F4;>"5H2Z:34E*DXX&7N@).S
M<=O2:L]08]6A/5V.G._3&Y#2I;:?=4R2C61;?*D!&;CMRL3=1+2N*/>[]&I%
M/1+9DV>E+>XK#CK9X*4I2TJS-%S\"0ODV9=IF$O>J=-C/.1I$QAF0TPJ6ZRX
MZA*T1D'@IU23,C)!'L-9[ 'FGU&GU:&U4*7+9G0'R-3$J,XEYE9$9D9I6@S2
M>TC+88#"BW3;,Z:_3H5:@2:A%=ZO)B,RF7'FGC,RW:T)4:DJQ(^:98[ &V
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M1J=_42#4I;D5E3TF'BHMP\LTYG&C+9D49I]X%?+7^U+7MS5OAX*WJ) I/_\
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M(MNOQ(S2J?6S0PY#6V4E!;>L9B/:IPC<^W)1X'!VX*@
M                YSXI_I[0G_,BB??* 28^4QUCC7@5
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M,Q43K=,J4)9&:X\J/O$+RXF>1:7,R2]TTI-(;.UM+JK2[FK6I5RUEBMZG56
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M7G=TVSF]5+JA5^DV)4H];IC\&FG J-1J$-"B9=FN&^ZAM*%'F4VPDDNG\;#
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MSXXX9M[\7_@^+[P+JGH( /1QEE[)OFTN;M1.-YTDK*M/(HL>0R]T![@
M       (+=NC>F=]UABOW=;[-5K$4D]4EO.ODM@T&1D;61Q)(5BE)YD$1["
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M[[3I]2.C3Z]3HM8)&].GORV&I)-X9LVZ4LE88;<< &Y(R,L2VD?(8
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MK?J'"OJO;T^)UFDTVM7.J(PXMPC)4&(V;)FI*B49I-)'M/;Y0&FNNW:+5?\
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MB,D)R)0M.TX.[X4J/.AQYL1Y$F)):0\Q(;,C0XVXDE)6DRV&2B/$A4?<
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M8(TFC^A=?THN>Z+@5>::['O*>NK5V$[2VXAG,<-U9K96V^K(1J=VIRF6!;,
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MAD @=N: Z+6C6$7!;MC4B#66ED['F)C)<<9<29&2V=YF)I1&6Q3>4P%C@
M
M    YSXI_I[0G_,BB??* =&         ,"J4>#5FLDIO\(18(>3L6G[!_P#Z
M&/?%FMCGHQ\V"F6.J 5BVY])4:\-_$,\$O(+_<2B\AC=X>37)^$M!GXE\7XP
MV-%LY^5ED5/%B.>!I9+8XK[/]TO^T8^?FQ7I7K+)X_!FW6_2$WC18\-E+$5M
M+3*>1"2P+[/OF-/:\VG66[I2*1I$:0^P^7V          #F_C@_DFW^_Z1^D
M .D
M
M            '.?%.1_/NA1^0M2:&7^]2@'1@
M   A^IFF5JZM6PNT+R:>>HRWVI1HC/*CN;U@S-!YT;<"QY %0>!_0OY*M=KR
MOA / _H7\E6NUY7P@'@?T+^2K7:\KX0#P/Z%_)5KM>5\(!X']"_DJUVO*^$
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M0#P/Z%_)5KM>5\(!X']"_DJUVO*^$ \#^A?R5:[7E?" >!_0OY*M=KROA /
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MOA / _H7\E6NUY7P@'@?T+^2K7:\KX0#P/Z%_)5KM>5\(!X']"_DJUVO*^$
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M.C-5I)Y5%Y2Q/88#I$
M
M
M
M
M                                          !KJ]7Z+:U&F7#<4]FF
M42GMF]-G2EDVRTV6S$U'[IF1$7*9["V@* >XZ^'!IU;:;@F.I09I)U%,F9%8
M>4LS9'A]D@'IX[N'']NSNS)?F /'COX<?V[.[,E^8 MG3'6/3G6&FR*EI_6V
MZHB&I*)T8T.1Y4=2\<N\9>2A9$K \JL,JL#P,\# 3L
M
M
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M#V:\9'?32.P(O0@'LUXR.^FD=@1>A /9KQD=]-([ B]" >S7C([Z:1V!%Z$
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MQP?R2;_?](_2 '2(
M
M                        #G/BG^GM"?\ ,BB??* =&        ANJ>I=N
M:1V/5+YN=W+!I[>#$9)D3TJ4O8U':(^5;BMG_"6*CYJ3,!R-P[\2?$7K]J/\
MSQ6:-3;-IZTSKAFMP7%G'A&X>2.VM;^!NO8&V@SVX$I>!Y3(!W6 YMXL=1M<
M=(J+$OS3@J=-L]K+&K\69#4^_#=6O!J02T.HQ:<-1-JQ+F*R\N?FA[<*'$XQ
MKM0Y5'N0H\+4>CD;LV)'(VV9<-2L$26$*4HRRFHD.IQ/*K ^19$0=(
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MS$WOY3J&&\ZN1.9PR+$_(0#6IO6S5R$Q$7%3%2UG@A@IL<W%&?N)SXF WH
M          #%J-3IM(B.5"K3&($!DL794IU##*"_XEK,DE_M,!\J+6Z1<=+C
M5R@3F:E1YJ=Y$G15I=8=1B:<R%IQ)18ERD SP           ?-]]B*RN1)=0
MS':2:W77%$A"4ERFI1X$1$ TU.O2T*O2)MP4NNP)E!IJWFZA569+2X;"XI9G
MB<>)61.[+X^*MGE ;"DU>E5ZFQ:S1)K%1I,ULGH<Z(XEYAUM7(I"T&:5$?O&
M PZ[=MK6PJ*BXJS"I;LUUN/":F2&V7'WGEDVA#2%J)2U*4HB(DD8#<@
M#073>]G6/&9F7C7H%"BR%&AAVHR6XR5J29$>7>*+'#,6;#DQV@-O!GP:I#8J
M-,DM3:?)03L:7&<2\RXVK:2D+09I41^0R,!D
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M%Q/6LU?=!L&[K?J]J5"[6V'[5FU$HCT2:W+/*R1KAR']VM:L$$E1<IEB98D
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M8>H%RT"V;?@UE3EQTU55IU4>@*13<&V]X['5()9IWS1<UTD$I"5\S/FV +A
M                                <Y\4_P!/:$_YD43[Y0#HP      8
MM3FHIE-F5%PLS<-AV0M)<II:0:S+_L ?E3P7TD]0.)J)<%;+K,B"BHW)(S[2
M5*5S$K/'RI=D)67OD0#]8    <5?ZD%JL3=/+4O)+9==I%673E.$7.ZO46%N
M'B?E(EQD8?9 6#P)5^16^'>CQI*C6JB3I],;4?+NTO=807_TD_E+WB =*
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M18YMG*>P%>G$M1OGS5W0&-1D)5=3%RKFYFTDI]%)A[F1,6K_ .V1(+''9CR
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ME*4D@CM^GJP21$6*F$F9[/*9GB8(M
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MD>PSVGB8#-L^Q[5L"E'1+/IC=)I!N*>*&RIPVDK7ACE2M2LI;.1.! )
M                             YSXI_I[0G_,BB??* =&      "/WW_[
M(N7]U3OT9P!^:_\ IW?SVJ/_ .W)OZ5# ?IM7K?H=T4F50KCI\>J4:8@VY4&
M6VEYEQ)^ZE1&6)>0^4O( XSN*S+[X+KD?O[3)$JY- ZDZ2[GM-QQ3KU,-1X;
MYM2L<"26!(>_^AW'FK =8:=:F65JM;C%T6/5&ZE3G"(GFR/+(C.F6)M2&CYS
M:R]P^7E(S+ P% ?ZA/\ (1C]_P #_!D@'^GM_(1_]_S_ /!C .K0
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MAQQ%&1(;7,R,I)2U*:29J21$9;5$0#>@
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M%=@38[#+KTE3CBTR-[&6XU(2M"B23R5J^+E/XN *[#!
M
M!SGQ3_3VA/\ F11/OE .C      !'[[_ /9%R_NJ=^C. /S7_P!.[^>U1_\
MVY-_2H8#]2    <I?ZA/\A&/W_ _P9(!_I[?R$?_ '_/_P &, ZM
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M]+E2B(<CV=+BR$J?;2I$AV2\I#2L5;%J)1*2@]ID>(#J$$
M
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M )OQ_)FPV +"
M                              '.?%/]/:$_YD43[Y0#HP      :FZH
M$JJVQ6J7")*IDZ!*C1TK5E2;KS*D)(U8'@6)\H#\N/ +Q"_F5*[11YH!X!.(
M7\RI7:*/- / )Q"_F5*[11YH!X!.(7\RI7:*/- / )Q"_F5*[11YH#N7A(TJ
MN_1W2MZT;V:CLU=56E34)B/%(;-AYIE*3-1$1$>*%; %\          #F[C@
M_DDW^_Z1^D .D0
M
M                      '.?%/]/:$_YD43[Y0#HP
M        <V<<KJ&-#=^YCNFJY2G'#21J,DH>-1G@7O$ ^Y\<G#F1X>L$P_?^
M:I_0@'CDX<_K!-[*G]" >.3AS^L$WLJ?T(!XY.'/ZP3>RI_0@'CDX<_K!-[*
MG]" >.3AS^L$WLJ?T(!XY.'/ZP3>RI_0@'CDX<_K!-[*G]" >.3AS^L$WLJ?
MT(!XY.'/ZP3>RI_0@'CDX<_K!-[*G]" >.3AS^L$WLJ?T(!XY.'/ZP3>RI_0
M@'CDX<_K!-[*G]" >.3AS^L$WLJ?T(!XY.'/ZP3>RI_0@'CDX<_K!-[*G]"
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M@'CDX<_K!-[*G]" >.3AS^L$WLJ?T(!XY.'/ZP3>RI_0@'CDX<_K!-[*G]"
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8U9)=/EM;JG0S4;KA9VRS&6)8)3B9@/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>fc_fig38eden-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_fig38eden-4clr.jpg
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M;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4
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M-UM1O8)4RH*3^:55;%(FDSZQ/\$>J554DH% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H(IJVPS]CS>R.MEHZUC)2
M<7CE)2?==E1D_P#.UJ5>Q0%J#:;?V35UZ16(^,]?Z(2NJ4E H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M.ROIF]_[:V?/1(S@=;@OB(W$Y"P)##3:6PHCQRXWH+'[AZ:R';V#>T^1M\O
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M]+4_NC"(F)>&P1)D_!Y"% 7[<U^.XVPJ_'YU)( O\+^EZRU6BMXF>V46C,*
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MM\7BUV5\[]<L+WQTAM=7R$3LG7'8^Q0VW7HKOM/%(*4E82"EQ!O=*B#YL?\
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MLIO4/3^N:/E7$NYF*V[)RBFSR;3*F/+?6VD^A#?/V^0_5QO\:#^?<CIDW?\
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M5?T\$B]!L+7]:#^$ VN+V\C^F@%*5&Y )%P"1\#ZT']H/E+;: H)2$A1*E
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MD_GZ5%_J%/'Y8ZIC5.>K$_ZI]G_=A%/M?MON7.0YBWM7O?V_U<K?#\?C6?\
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M0$I)M<JO;Q7=W<C5%>LQ.6M6ELM9AL!GW<]'@1(CT;*LNI+BRDI4P;^7%GX
M?C\:MV;:129F<Q_-$5G+UEZ5M*<F[B?VU]V2MQ24R$I)87R-_<]P_+8WY$D^
M/Z:QKR=?CY9@FDYPZ#CR8N.8AXZ=,93.#3: E;B4K<4E(22D*()N17FYK-IF
M8CHW.RF^P=5V-6T2Y[,)^?%FE*H[K""YQ 2$^V0+D6(\5W.)OU^W$9B)AK7K
M.5DZ3">UC4HD;.OHC.)*ED/+2E+0=45);Y$V\7KE<FT;=LS2,KJ1XQU:[M##
MY+/Z_&7ADF6EAY+[D=FRBZV4D!2;?JXDWM5O"V5UWGRZ(V1,QT:CJ37LSC9&
M0R60CN0XS[:&6VG@4+<4E7+GQ/FP'BYJ[G[J6B*Q.98ZJS"TZY"]7Q5_>OM+
MVO#F%T>.%J!!L<UD4'C^(5[,8_TI4Y6Q_;K^^W\H_P!T>JP:UTE H% H% H%
M H% H% H% H.3_\ $-_] T3_ .V&#_T>50?'VE97&Q?L\D2G9;7M8N/L"\CQ
M6DF/P6^\0X+_ "GVU)78_P )!]#1*C_\-O!9%W?MPV5+2OVF)AT8YU^WR?42
MY3;R$@_$\8ZR?P_K%$([*2%_X@Z01R'][V3;U_2A)O\ U6HE^G&8@G*8F?C4
MN>TJ9'>CAWUXEY!1RM^5Z(?G/]@.*EZGWWNNJ9]GZ//P<++AOQG/E6'HN0C)
M<2 ?7TOX^'F@U4K"9';O\0AUK#(5(_;]GC9"8XG]+4;$MM./E1^ 'M\//J2!
MZFB7I_B$H4SWQK4AWY&%8"$H.$^+(GR[G^JB'3/WLLM;AT/M&.UR4U/R>L/X
MS,9F#&<2ZZS#<4HA3B4D\1P47O/\">7I:B5(_9;KOV_=BZ+*UG></CY.^XB4
M\M;<Y]UI<K'/?S&W$(]U*5A!YH6$I^4!/+]5!<?84+JF%]LG;D;I[%LP=:91
M(8DRH2%)@S)L?V4/.1W%*4'4((]I3B/EY((!-KT$"_PU2/[I[Z/C^XP?'_Q#
ME$*MZ,!'W^Y<'P1GMKN/_BIU [S!/W^X@?CGM4M_^*@T'4WW$];=;][[-%ZE
MS+R\+V;%PZL_JNP!*5(6PJ0MA^,I)4DNI!;2M3?Z@#R2198(<R?;+$[4Z$^Z
M%OI/**+V/RQ>3F8,9PNP7F4Q%R8\]FX'$@(3\Q2E7&Z%"_@$OTLH@H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H*_ZW#N!G;%H$@_)A99FX;DJY5B<FI3S0%[&S3@=9_\ !%;&[YHB
MWQ[_ (PB%@5KI47VY&R2=E3)EH<5C%LH3!6;J:20/YB1\ J_DUZ'@6K[>([^
MK5VYRC60A[&SA\6K)-R!AB%JQJ'.10CDKSX_A)]4A7P]*VJ6US><8SZL)B<+
M.Z<CY1G%SW90<1C'74&"ARX!4 0ZI /H">/Y&N3]1FLVC'?U7ZLX;GL].85J
MSO[1[EPZ@S Q?W?I_/*W'S:]N5OA5'"\/<^;\OQ9;,XZ*EUEC:Y,+,M8+Z@Q
M%15"4D<PE7D?*W?Q[A%_3S:]=G=.N)KY8SEKUSUPR>MXN57MT)<!#J&F"HSE
M<5)0&.)!2N]A<FU@?C6/,M7VIS^2=>?)T ][OLN>Q;W^*O;Y>G.WB_\ 77FX
MQGJVW- 3M(S_  _YY_>4O>?]9[GN<O6_]G_-:O5?_7X>GBT>N?O=+M>Y[2/>
MM[W$>Y;TY6\V_KKRL]^C>49VLC+_ -Z5?4^\K'J:;./".9:'BRN(3X"^7K\?
M2O0<#Q]OIW]6KMSEI]H_O0F-AD; 7@Q]&GZ1+G(  $W]P?\ PEK7OYM:K]'M
MYMX?'[?DQMGIE:G4ZLFK5A^X%PL!]8@%V_+V/'I?SQY<N-<?G^/N=/AU7ZLX
M>';S.4=UYE4$+5";?"LBANY);M\I4!Y*0JUZR^GS6+]>^.B-N<*MP:-E:Q.9
MG87WV\>EE+<Y;7( I4H7X?BI(_44^0FNOMG7-JQ;&?117.)PV/6#V23MD9O%
MJ6J,L*_<4H)+?L@&Q7\+A1'$U7S8K[4^7?T9:\Y7U/$DP9(AFTPM.?3G_P#"
M\3Q]?SKSE,9C/9M2YK@IV3][9$82_P"\'OI!4KG[ON\OFYD_P_VK^+5ZJWM^
M'7'CAI1G/WNFT\N(YVYV'*WI?XUY-O.=M]B99&VY$Y!MU2GWB8:K*4%L'_5A
MLCUL/%A\:]/Q;5]J,?FT[Q.5VZ8WDFM7Q;>7YC()9 =#O^L N> 5?S<)M>]<
M#DS6=D^/9M4SCJK_ +H3/,C%*/(XK@YZ7X"1<?JM\>/I?\ZZ7T[QQ;X_Z*=N
M>B'*;SO]Q4J(=_8OW$FWFW^K'DCUX<__  ;UO9I[W_RPKZ^+%Q2MA;P^9<Q2
MGDXK@TG)J;*@+%?R\;?'^UQ_A]?%9[/#RKY=_1$9Q.$DZD_=!LMH9<_:_969
MX\^SZ?)^7+EZ?&UZU>?X^WU[^C/5G*Z<H)AQLP8ZPGEESZ8G_P"%XGC_ )ZX
M-,>49[-F>SG? HV@;'%$,3$YGWT^^5^YR_5_,]TG^&U[W\5Z?;[?MSG'CC[8
M:=<Y=)UY5NN;MPQ^:&T3TY)AYV:^^HQU!*U^XV39L-$ W %@ /2O4\>]/;CQ
M[8:5XG/5?FM-9%C7\:SEB59%$=M,DJ-U<P/B?B?QKSFZ:S>?'MEMUSCJK3N:
M-DES,=(*'%X=#2DCB"IM,@J-RH#T)3:Q-=7Z=-<3'K_HIVY23J:-E(VLJ^O"
MT1G'E+@MN@A26B!>P/D)*KD5J\^:SLZ?FSU9PGE<Y:U>QYZ!J^!R.PY-13!Q
MK#DE[C^I0;%PE/XJ4;)3^9K.E9M,1'J-+UKA)N&U2.YEE<\]EW'<OF'"GBHR
MYRO=*2/_ ,&DI:_H16>ZT3;IVCHB$NJE)0*!0*!0*!0*!0*!0*!0*#D__$-_
M] T3_P"V&#_T>500C[:/MSZW[;^WW7<OL34['Y22N?$R<K"RUP3D(\>>][2)
MB$\FWO;'RH4M'("PO8"B77>B=;:=UGJK>G:1CDXC"HYJ4&5*+[CSB0E3SCJB
M5K<-A\RCXL +  40K _9[TL=@.W?3YC^]YD?7_W@_>9_U_UO+G[_ +GN_P"L
MY>;VH+UB1Q$BL10XX\&&T-!YY1<=7P2$\EJ/E2C:Y/Q-!66\_;]U_O.TQ][4
M<AKF^1T>TG9];F+QF06WP]OBXM *5_)\EUH*N/RWX^*#8]9]*=>]3?72=3Q[
MBLYEE*<S&?R#SDW*3%K67%%Z0Z2?*CR(3Q!/DB_F@\>V.B>L^ZHL-C?<29<G
M'E7T&0CNKC2V4K(*D!QLCDA5O*5@CX@7\T&ZT;K'1NN=85I^I8=F'@7>9EL.
M%4E<I;J>"U2''BM3I4GY3S)^7Y19( H*<F_8M]N\W/JS?[+,CL+<]YS#1YSS
M< GU4D)'\Q*5?V4.@#T%A06IMG3NC[?IL/KV='D0-)AH2RG"8B2[CHSC#8'%
MIT1R@J0" KC?]7DT&AZ^^V_K7JI^>_H RF$&487&GLLY.4MEVZ5)0X4.K6GW
M&N:BTL>4DT&DPGVA]+:YLT7<\-#RD7;(DGZUO,)RTY4E4A1)<6M2G2%>[R4'
M H64%$'UH&<^T/I;9-FE;GFX>4E[7+D?6N9A66G)DI?206U(4ET!/M!*4MA(
MLD) 'I027=.@.O\ ?\KB\_LO[D[L.$@(QN'S$?(R8DR+[;GNB2VZPM!^HY>K
MBKW_  H/;KWHO1NN<WD-L@G(9O=<HGV9VT[!,<R646Q\MF@ZY8)0."?"$@FP
M!) %@LN@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4%?[LHZWMVL;N@ 1'7/[N9M9-N,7(K!C.'X6;
MD)2+_@LUL:_FK-?SC\O]D2L"M=+Y4A"QQ6D*'X$7%,BJNWLWEX<F!C(KRXT!
M]I3KJFSQ]U:56XD_@D6-OSKL_3]=9B;3UEK[9E'']KVM6BQC]2ZF/]:Y$<R"
M#9Q326PI+94/(%R1?XVM6S&C7[T]/3.&'E/BDO4.9S4]W(09;[DO&,-H6VZZ
M2LMNJ5;@%'R01<V^%JU?J&NE8B8Z2LU3,K4"4I%D@ ?@/%<=>UV==FQ<+D)&
M*;Y9%#+BXZ0 27 GQX^)JW5$3>(MV8V[='/FL97-HV2 [ DOO9!^0A+R%+4L
MN)4H>X'$D^EKDW]*]+OI3VYS'3#4K,Y=*<4\N5ARM:_QM7E6ZYTV';-F<V";
M*<G/Q'XCZVVHZ%%"&DM*LE/#T/I<W]:]/IT:_"(Q$YAIVM.5^823(GX;'S)[
M81+>8:=>1:UEJ2"?!]*\[MB*WF([9;<=85=W!F,HWD8F'2M3.,4S[]@+!USD
M1Y/^C;T_.NM]/UU\9MZJ-LSG"7=89;)Y?6$O9-1=6R\MAF0H6+C2+6)MZVOQ
MO^5:7-UUIL^5GKF9CJF?KX/I6BM?Q*$)3P2D!/\ 9 L/-!H=C6K7]<RF0P<5
MIJ:TR7$!MI-BI/\ $4I OQ!)\ULZ8]S96+3T86Z1T4KJFS;$QL<-UB8_-=EO
M!MYAU:G4O)</S>"; _$$>E=[?IUSKG,1&&M6TY>8W#:!L1R*9CIG*D>T8M_Y
M93[EO9*/P^%3_CZ_;QCIC[2><Y=&))*02+$CR/6QKR[<<\;[F<K+VJ>W*?<:
M1 ?+<-I*B@-(3;BM-CX*A\W*O3<776-<8CO'5IWF<KJTJ9.R&JXN9DB5376;
MN+4+*4 HA*C?XJ2 :X/)K6NR8KV;-)S" ]S3\@A_&XU*U(Q;S:W5I'A+CR%
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M H% H% H% H% H% H%!&]\UQ6U:ID<0Q\N1*!(Q;M^/MSXJ@]&7R^%G4)O\
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M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"O\
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MH[(K3GO;+QUPS$<B.7^LX'T^/MW_ %?#E70GV_=_^6%77Q^YFX.%LLS3\\S
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MZ.P8,%8L4+RV00%25 CU++'!L@^A6:RGY=>/6W\D^JP:UDE H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH%!$.S,++R^IR'\6@JSV%<:S6&XIYK,S'J]U*$I^)<2%-?\ AU=IM$6Z]IZ2
MB6-G>P66-)QVU85"7OWE#*H(<-TH]]',\^)]4 $%-_U>*OX_&\]DUMZ,+VQ&
M6MZ]W?(;/*E8//-M2"65.H=2@)2M%PE:%H\I(^;Q6QR^-75$6HQI>;=)3#%Z
MCK>%=<?QF-98==26W%@%1*#ZI^8FP/Q K1OR-EXQ:5D5B.S%@Z?JNNR'LU"@
M)9?:0M?.ZE^VFQ*N"5$@7'X5G;D;-D>,RB*1'57@[GRGU_O_ $#/[.5?ZFZO
M?]K^USO;E;S;C:NG_P"NKXXSU4^[*?S-&U+.3$YJ5 "WWPEU9"E(0YX!!6@$
M DCUKFUY6VD>,2NFD3U4_P!ARV)>V3FV(J(J(G&*> XEPM #DH>GIX3;X5V^
M)68U1F<YZM;9/5_=@VQC+X?$XIG%1HX@L@+="3R2L?*4M&_A"@+JO<DTU:)I
M>UO*9R6MF(AZ9C/XN7IN)QD?$,QI*7GN3J"JS:FRGDM!]27+_-R)M_DJ->JT
M;;6FV8^W\DS:/&.CXQVUPX.H3, YBH[\A]Y*DNN!12OD"2M?F_-%OEL1_NWF
M^B;;8OY2B+8KAL--VC%X7!YQ$K%,OR V@A7G_G =7[8;<Y<K $W\?#\ZJY&B
MU[UQ;_9E2T1$LK3-NP4(982<#%BJ,1QWE%YJ]U#?ZF5>Z5V!O\#;\16')X][
M>.+3/7U_FFEHZ]&KU/:,%BL^B?)P3$=E15[;K*W7%QKI/Z$K)!OZ?"KM^B]J
M8BW^[&MHB>SRC;=BT[,G.R-?BI:4^'2E"G/<02J_NCSP*QZ_IK*W'M[?C%I[
M(\HSG"WY>A:EDLB<Q(@)<DNJ#KGS+2VXL^>2D @$GX^//QKB5Y6VM?&);,TB
M9RJ3LF5 =VV4W%A(:5&X(E+NH?4+"4GY@"  !9/R^:[/#K:-49GO_!K[)ZKG
MU*='R6MXR9%CB(PXPD(C(_2CA=! _*X\5PN16:[)B9RV:SF'\V/5,/M+#3.5
M;45,$J8>:5P<05>#8^18V^(J=.^^J<U+5BW=!]\CX;3-6CX'&XYIYO(O*45R
M+N%*VT@EV][E?D!/X5O\6;[MDWF>RJ^*QA#,!N2,#@\CC&\7&>ES. 3(<3R2
MM/D*#R2?FXC] 'C\:W]O']R\6S.(^W156^(9^J;A"QF.S,>5AHCBU15.)4TC
MV_>NI*"T[>_R?-?Q5>_CS:U9BT]V5;XB>C5:=LD?7<TK(.XYI\.(6EO@#[C)
M() :N3X/Z3?S:K>1IG93&6-+8EL\7V?M:<NQ(EOHDQ'W4(=A!M*4!#B@FR"!
M<$7\&_GXU5?A:O'$1B?BF-DY6^YJ.M.Y/]X<QC"LCR]SWBGU6/XBF_&_YVKB
M1R-D5\<SAL^,9R^MKV"/JVN9+8)-BB"PIQMM7CW'C\K38M\7%E*!^9JNE?*T
M0R:_KS7I&M:I"AY"RLW*YY#-.^I<R,U1>D$FYO9:BD?D!66V_E;IV]/P1"45
M4DH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H%!5NMX+'NN[1U9E6BW!QLI.5P7MV;XX[)*4\@,^I_D
MO!ULD_D*WO=M2:[*]^TL)B)Z)7JNC8?4U//PU./S7T\%R7B"H(!OQ2$@ #\:
MPW\JVWI/8K2*M[DI\?%P).1E$B/%;4ZY;ULD7\5KTI-K1$>K*9Q"N-=[7<S&
M;9Q>1QS;$.<OV6%H65J2I?A(<!%B#Z>*ZF[@>%/*)ZPIKMS.&T_ZI-8_<_KK
MO?2<_<_;^8]F][VO;EQO\+U3_G[/''K\67M1EK<IV_$@95<*#CC)QL9?M.R.
M?!2N!LHMHMZ#X7(O5M/I\VKF9Q,L9VXE%>Q<OKN4S3,C'PE./J99<E2PX6@\
MA:>24<0#\P2;%7]5;G#U[*TQ,L-DQ,L/;,OJ^1A8AO"XTQY+,9*7G/<(]L G
M^2H?QJ!N>9K/1KV5FWE.8S]I8VF)QAE93/:E(TS'8N+BE(R32W"![I!8<!'-
MPKM=?N?@?^Y6--6V-LVFW3^?_A,VCQPWVA8/5MKUJ=BG(KC$]IU"Y4@.<G.5
MC[:VU$>$_J'&U:W*V[-6R+9Z,Z1%HPV.:U/5=*U#)F0V_-5-]MI3I4 \ISG=
MH)(%D *\GQ5>O?LW;8QB,)FL5J@>DYC 8B1D%9Z(J2F3%<9:4#=-B#R;*?Q<
M\ *^%=#DZ[WB/&<8E528CNR-">UUS;([<S'J2W(4I./0MTNH:<*39*P1\]QX
M!/I6/*C9[4XG\4TQE8C'4NL,9-,[D^N,A8<;@K6"R% W )MR*0?@37,GG[)K
MCI^*[VHRU4_N.-&RBX\3'*D8ME?MKDE?%Q02;*4A%K6'PN?-74^G3-<S/5C.
MWJC_ &!E-/FYY$AJ%(DOEMI<U]AX,(=0M 4D $*^;B1<^*V>)3;6F,Q'P87F
MN6_RW9</7X6*@:S!;<97$:?"7E%*&FUW"6[)\E7@W-_\M:VOA3LFTWGU9SLQ
MC#^3>XFDXJ([CX(7EGN7U+#JC[3/ VO<"ZN7JFW]=*_3I\IS/0G;T:[8MYQ.
MRZ:E62QW++?4^RVRAPI2TXE'+W@L"_$I/Z?C5NGBVU[?EGIC[0QM>)KU1?%Y
M'5VM:RL#)8]:\R[[:HDE"S=:@3QL2#[?#U5_:%;=Z;)V5F)Z,(F,2R-'R6MP
M#E6=BBEY,J(XA+H-P4)^9303\%*('%5_A6/)ILMXS2>TII,1W9FB2=.8SCLF
M9%DI6PTZ_!^I<0\VE+:2I04$I3=?'T^%8<JNV:8B8^]-/'+&P6PZLQLS.0<U
M]+$-QX>Q9];GL%:K)<]M7RFU_3X?"LMNK9.O'EU_FBMHSV= UYMMJ]VWAM.\
MZ_I!2EW&XT#9<Z@^A$=?MP6CX((6_=PI/P;K9U_+2;?'I'^J)6%6LDH% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H(!O8_N_LFL;XW9$:.^<'G5_*E/[?DU)2VXXM7HEF0EM7_A&
MMC5\U9K^<?E_LB4_K72P<U^W?M$T98A.,+*Q**O0-\3?_P!BK-?EY1X]T3C'
M516F/:I%VR.[)5+5$2\$XM;P; #BC9"G^)\6OXM\?6O0\B-LZIQC/K_LU:8R
MZ#KS3;<W;?!P^/V>;#Q[[CD%+Q,FR05-+4J[B$7(Y<;^+_'Q7J>/:]M<3,=6
ME:(B65N+^I2),!6 5(4&XK#4DV0$\4)LF]_/N@>%_"L./&V(GSQWG[?@F^/1
M][,WI9Q&(D8!V0F>IHMNL+"2>+:B"I\^++N?''U%1IG;Y6B^,?;L6\<1A[3(
M^B.ZE!D1I,J/EF75LK24)<?><592^:00D('\"@1_745G=&V8F(F$SXX2#4-E
MU#4=:ESXKC\K)//)0_'=2EMY;@22@) )2&P+_-?^GSXK5Y&G;NV1$XB&=;5K
M#(F[[J^XX#(P,\P]CBRE+S26U)=<4I*AQ+1LD%05_"?A6->+LTWB:]4S>+1U
M0G4X^IR'9R=C?>;*8SJHAX@-@@&ZO!N7!_ GT-;^^=L8\(]?M^2JN/5ZZ"K"
M-;9#<R+SJ6T.'Z!:DI2E3Q!""[Y/'Q^'B]1R_.=4X_/_ &*8RLE?;>M(R9@^
MW(,9+GM&>$CVK@\>5K\N-_C:N5' V>.>F?@O]V,JNV+%Z]C]F?@Q\BXYB?=O
M(<::]Q;(6>2D)-P%VOZ_[M=?3>]M>9CJHM$1+)W1>IKS#(PBY#C#;3+4IQOA
M[:DH0D)+95Y*^-@KEXO6/&]WP^;!?&>CUV]S37X6(7@')'UB(J&E-J2D@,H*
MK>\?%G;W]/\ O5CQXVQ-O/&,_;'W)OX],,;+,::G6L<]BGY)SBE.)>;<2FZB
M".1= -DI'\!3ZUGKG;[DQ;'BB?''3NR [I:M&5'*I"-@1*]Q*2$EQ3Q3:XM8
M>SQ\'X@UCC;[V>GCC[?FGY?'[WC@6M.<UW,*S+C[>90&U,% 22!R^7V 2 HD
M^'.7P]*G;.WW*^.,?;O_ *(KXXG+)T'"Z[GY<O%Y-UY.3?CN)@@) :3X%W ;
MW+B?6Q\6O6/*V;-<1:O;/5-(B>B::OU3^TY%<W+S$3&DMN-,L-H*4J#J2A2E
MW^-CX K0W\_SKBL865U8GJ_N/Z>QL/+-S'I[LC'L+#K4-2 %$I-TI6L'R!X]
M +TO]0M-<8Q/Q3&J,K%DR8\.,],E.)9BQT*=?>6>*$-H!4I2B?0 "YKEQ&5R
M$=7L2Y\#);QDVPB?MLHSHX*>*V\6TGVH#2O-O#0]SQ\5FK]TQ$Q6/^/\_5$)
MY6NDH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H-3L^ A[3KV2UV>!]+DH[D=2B HH*Q\JP#\4*L
MH?F*SI::VB8]!I-$VM.4TF/E<XZ(V0Q8<@9_WE@EJ= 46'^9%@"I2>=O](59
MLUSYXKZ]OS1GH^_[PZOO,#)8*%/^=UAQ+G)*FU!OT]Q/("Z0;5=[.S1:+3'J
MP\HM&%2ZKKV.R.S,8^5EX_LLO)4VIKG_ ,Z+:N02T5  7(^/]5Z[._;:NN9B
ML_T:]:Q,]UO?]8NH_N?[7]>/>Y^U[W%7L<[VX^Y:WKXKB_X>WQ\L-CW*YPJG
M>L=@6-LE(B94)3(>*YX+2W$Q75FZ[E/ZO/S$#TKL<6]YU1FO;M]ZB\1EY;=J
M^*P4B"G'Y=AYF4PTXI#A5[@YCR]\H5_+5^H?'^FLN/OM>)S7M/VA%JQ'JR=D
MU7 8C$X=YG-M*GR6?=<LA;B9"%FX<0$ E*4_I\^O]-8:=][VMFO2/X)M6(B.
MK.B]<,9K68^0US)-3LDEQ?U'(*:;4#;^58^4J1_I#S5=N9--DQ>,0F->8Z#W
M6HQ.M2\CL619@9#F@QC=2VD 7'!5A=2E_P"B/'^6D<SSV1%(S![>(ZM5AM7P
M,[#97(R\\PA^&VE324H< :)4 %.)4 I7+]("15VS?>MZQ%>Z(K$QW8FH8#%Y
M^5+CY'(HA*:CN.1T*!!6M()YW/CBBUU#UK/D;;:XB8C/5%:Q+(TO XS*[(U$
MEY1CV6%E;:6^8,KVP3_*4H"P\7\^;?"L>3MM77F(_P!BE8F6 SA,=*V489G,
M,& X_P"VWD2%!"@I7A(N/U^>/]F_QJR=MHU^4UG..R/&,XRS-GP^NPME=Q\#
M+!N%[G"0M3*W$Q%#PI)4#\]OC;TK#1LV6UYFO7^:;1&>YMNNX?!Y5F'CLLTZ
MPZALN!?)2F>20>:R@$%*K\A;S3C[K7KF:EJQ$FUZQC]?3CE1,JU+5,CMO.-@
M'F>=_P":FP(]M7POYIHWVV9S7&)^WYEJX;QKK9.7UJ!DM<R#,Z==9EDDMMKY
M$60FXNE2/3YO6M>>9X;)B\8AE[>8Z,;*=>M:_K#F3SV0;BYE3J1&91R=;4FQ
M_E>!<J5Z\O05E3E^YL\:QF":8CJ^-*TW%[3C\BDY((S"$I]B.$*_DCE?FJ]N
M85;CX]*GD\FVJT=.B*4BT);J'7CFJ9!>PYV<RI,-ISV@SR"$A2;*6M2P/1-_
M%JTN1R_=KX5CNLIK\9S*6X3=-<V&4Y"Q<P.R6P5!M25(*T#U4CD!<5I[.-LU
MQFT=%D7B>S?UK,T"[0D+R,3%Z!$>4Q/W"08;KC=PI&-CI]Z<J]K>6A[7GU*Z
MV-,8F;?]?Y^B)3EAAF*PU&C-I:CLH2VTT@<4I0@62D >@ %:\SE+TH% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H*ESN$?:V[/ZLTZ&,=NL-.6Q844H:3E\<4(DMA*?)]YOVG
M%D_V2?-=#3MBOC?_ *SB?PEA:,]&'K?6&QMR);N34W!2J*_&9*' XI2WT< ?
ME]$CXW\UN[N;KQ'CUZPIKKEJ,/UKM3V79BS8BH<5E8+\T+24A"3Y+1!N2?AX
MJ[9S-<5S$YGX,8USE[?]4^U?N7TO!GZ#W+?7>ZFWM7_5P_5>WPMZUC_GZ_'/
MK\$^U.6FV359^"S:L6M;;P?7>(^MU">:%GP7;D<#^/+Q6QIWUO3R86K,2V.S
MZ2_AOVY3F3B7?C-)<$F0ELI=3<$(N"2V/@:JT<F+YZ3W^'VZLK4P]LYUSGXD
M;'R,6/WEA<="75Q5!80Y<FR 2+MD'Y36.KF4F9BWR]?7[=RVN?1-]!Q2](P,
MR=LS[<#ZQU+A;=6+-I2GBD$WMR5^ K0Y6SW[Q%(SA;2/&.KTWN%"W+66YN)R
M<8MPG??#JW0EA7@I*5J_A/GQ>L>+:=.S%HGJF\>4=%?870Y>6P^2GM9"&7&4
M)+#34A*D**%<E>\KT0FP^6_Q\UT]G*BEHC$_I_)36F88.KZA+V5V8EB4PPF&
MRM:E%Q)*G+$)%A_ 3^I?I5F_D1KB,QW16F7SJVM/YO8$XI4EJ,62OWW4.H4K
MY00?9L?G\_V?AYIOW12GEC/V]45KF</J-I[ZM@1@7\E :<#P:6XF0DJL#YX)
M_MV]$_C2W(CP\XB?T3X=</'.:MD</G5X5:FW%N.6BOK=0A*T+/RJ<)/R$_Q<
MJRU;ZWIY(FLQ.'ILNHS]<G,19#[#J)24EAXNI3<\1?D";I2#X"CXM6.GD5V1
M,Q$]$VI,-GF^N=CAHA/0&E99AV,US7'4E?!RQ)2+D70+_*H55JYFN<Q/R]4V
MURG&GL,=>:XY(VJ4B&[.?+J8Y/,I/$ ) 3?DH@7/&N?R)GD;,:XSA;3Y8ZOO
M<,8SV+@8LW6);4EV&ZI2$%7%*N2>*D*N+I4/!'*HX]YX]YB\8R7CSCHP="U*
M9I[D_8MF=:A-H8]I*/<"DI1R"E+6H>/@ D"K.5R(W8I3JBE?'K+>Y+*8??\
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M% H% H% H% H% H% H(-VG#E(U]C:<8"<MJ4EO-,!)""Y'8!3+9*CYXN1U.
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M].0UJ>VX]$GI0XV%MM+4VL\'4H6+*0H6*?A05*?O-^V@"_\ ?MK_ .M^3_\
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M&1%N+)4M:F&RI2CY))*?)-!F-QX[3 C--(1&2G@EE*0$!/I8)'BU!@C7L +
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MV6Y#!();=2%I)'D&R@1XH,=C#8B*ZF1%Q\9A]%^#K;+:%BXL;$ $7%!Z2\?
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M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#PFN1&8<A[(*;1
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MT **VPX;)<^8<J#] NJ $]7:0E(LD8#%  >@ A-4$OH% H% H% H% H% H%
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MF*R+N>ELRMA?4??8S>.D/*!?;6M(4E8)7Q/@H6+$%-P0F'^)$B0.SM1<4/\
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M4"@4"@4'.?W=:GEYV"TOL?#0W,FOK;88FP9+&LH+KCF,:6E4A:4#RHM^VE1
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M9)4ZE>%RZ W,9#3BFP5I'H%A/-/Y&@I][[DMW:<=;'1&\+]M2DA28K92KB2
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M2,9H.33(>S4[&LK+?-Q]EY*69+J4EUIE#2TI!2E2E*O0PL97?SVUPNN\3UU
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M"@-NN9[-Y^)]$I^2M'%B'"1[BBM25$N/N?I2$A-[K%!<5$% H% H% H% H%
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M5:B]8CLV==YMW7M5:XH% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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ME=UK@<%B=8PL'7L%%1#Q&-91&AQF_1#;8L//J2?52CY)\GS5,SELQ&&QJ$E
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H('VEV
MGB.KL9BGYL1_*9S8LE'P6MX6*6T.S,G,5Q:;+CJDMM(O^MQ9LD?B; AH=5[L
MD9+>LKUEN&IS-9W?'XK^\$."B0SDF)^,"_:*XSS/"[@<NCVU)'D'SX-$HEA_
MNFD;6_M>-TSK/8\OL.KS1 >PZPQ$?!2A:G5R5N*+;%BVI#: MQQP^B?6P?W9
M_N.F9;[<\AW+UCA%RIC<>0U*C3WF8ZL1)9NTZX\E=_>]E9"DMH%W 1^FYL&+
MB>V<AK7VZP=I[0T7)YC$-8/'F0L.0\P<JR_"2XY+E)*^++2U$%8>N1R_2;6H
M+ R';^IZ7T[@>R\G <Q^(R>/QCF(UZ A#DE3^290J-!CH3P05CEQ%N*0$D^
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M'T_[O':F*2L!(*P7$FRE<1R*;7HA[R]*TZ?B(NO3M?QLG 0>/T6)>AL+A,\
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M^Y.3]6M$7Q6E>U8^/QF?6?Y>GJD&X;SJ^B8].2V>>B&RZ2B.W8N/.J'J&VT
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M#6YG8<#KK+#^?R<7&,RGFXL9<MY# =D/*"4--\R.2U$V2E/DT&RH% H% H%
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M,=Y=$C9-&D:EL7]Y XF6\N'-;EP[LI2D2XBU?S&U#YV5?I"DD$@T2[/H@H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MD>$2C\?R%Z$'<<EF)]V/V_O2'T1VRUL;0<=6EM)6]!]M" I1 Y+4H(2GU42
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M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#G[[L6E,8#KS/H2I2L'O>"G**
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M%V1#3N#R;2H4UA]?MMNM2![9;*@I)^:]O!O0>V&P^-U[$0,#AHZ8F(QD=J%
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MOP<[]Q_3+\S3$Z^MJ3V^,3W_ #4%C]%V[)SQCH^'E(D<N+A>:6RVWY]5K6
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M!0*!0*#2[:K.HUO)N:U+C0<TW'6N)+FLKE,-J0.7)32%ME7@>!RH*P^U3?\
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M8F>G/=BY'(=A;+ZJEYQY:HR3^#<8*("?]!:EIK&=D^G1,:H]>JZ8&/@8J(W
MQ<5F%!9'%F-&;2RT@?@E"  /ZA5:["/YN-HNFR,OVEF8T7'36( 9R^PEHJ?$
M".KF$*4A*EE(-C9(N;#UL*(;K"Y;%9[$0<W@Y#<O#Y%AN7 E,_ZMQAY(6A2?
M ]0;^11+/H.+>U^M]@U?:,C*3#>DX2<^[*ASFD*<;"7E%?MK*0>*DD\?F]?4
M5P=^FU;3\'PSZ[](W\;D6MXS-+3,Q:/O])^^$JZ#Z[SZMG9W'(PGHF*QC;JH
MQ>26U2'W&U-!*$JL2D!1)5Z7L/QM=Q--O+RGM#K_ +6^D[O\B.1>LUK2)QGI
MY3,8Z?U5!L.;R6Q9J;F<NXIR?+=4X[S)^6Y\( /HE(^5(^ K2O:;3F7B^7R=
MG(VVV;)S:T_:/R6A]OVXKUK,YAK)2O9UA,!V=."R2AMQA2$I<2G^TKG[=D^5
M$@>;"MOB;/&9SVP]9^U?J$\;;>+SC5X3:WW8QU_'KC[^BPD_=!K!R/L*PTT8
MSEQ^LY-ESC>W+VK_ /Z=;7^;7/;H])'[TX_GCV[>/QZ9_3_=:&4Q6J]EZNVS
M*"<C@L@A,B+(;)2I*K'BXA7JE:;D&X_%)'J*V[5KMK\8>LWZ.-]2X\1;YZ6Z
MQ/\ K'PG_P 2KS#_ &U:7CLDF;.F3,G%:5R;A/%"&U6-P'"A(*A^0XUJUX5(
MG,]7FN/^SN)KV>5K6O$>DX_CCO\ P9W8W>.%T&=_=_'0?W3+L(3[[25AB/'"
M@"E)4$J)5QL>*1X'QK+=RHUSB(S+8^K_ +EU<"_M4KYWCOZ17[?!D]9]V8?L
M"8K#/Q%8K.A!<:CJ<#K3R4>5>VNR3R \E)3Z>E[&LM/)C9..TK/HW[CU<^WM
MS7PO\,YB?PG_ $6C6V]:4"@4&&O+8IN4(+DZ.F:381E.H#I)_P! F_\ FJV-
M-YKY>,X^.%$\C5%O";1Y?#,9_1H>R7YL?1<X]CRI,D1[<D?J#:E)#A%O2R"J
MMWZ96MN32+=L_P#C^+F?6[7KPMLT[X_AZ_PRY&KZ@^'.A^@'YSFMY%EXJ,%F
M7:*5>0%*0"XE/Y?I-OQ->$_<-:QNK,=YCK_H^I_M"]YX]XG^V+=/TZK W+)R
ML-JN7R<$?\\C1G%LFU^*[6"K?Z-^5<3A:J[=]*6[3+T_U+?;3Q=FRG]U:SC[
M?<X[>>=D.K??6IUYQ16XXLE2E*4;DDGR2:^JQ$1&([/@]K3:9F9S,KWZ2D'8
M]:S>KYYE&1P;/MMICRDAUI3,I*PXR4JN"GY+V_.O#_N#36FRMXZ3;.?RQU?3
MOVER;[--]=NM:3&/SST_A_%S5]POVHY#37)&W];1GLCJBU<YF'0%/2X'(^K8
M\J=9!/YK1_%<757 ILSTEZ[9JQUA=V,^V)_5L7C#I?8^>U',J8::?CID)E8Y
MR9[?)?&,2T#=06KCR/Y55[F>\+HU8[2TNK]9?<9T_F]CV37E8#L"9M,E,W-2
MIRG(>4>6TGBA"5J+;:$)!/!',I3?P!3Y9/GCX2E(^Y/-ZV4M]H=8;#K:1<.Y
M"$V,G!!3ZJ+J0V /C\I5_73PSVD]V8[PF>L?</TSMOMHQFW0F9+G@1L@I6/=
MY?V0)(;!/^])K&:3#.-E9]5E,2&)3*)$5U#S#@Y-NMJ"T*!^((N#6"QZ4"@4
M"@4"@X]UWL;7^FNW>U->[QQJTY3;LG(S.J[,[$^K3E<*IM+<?%-KLHGV4I2V
MTS^GFI23Q/'D2N3[:]/V;2NM$X_9HQQ;D[)Y#*8O75+#G[/C9SY=CP+@D?RP
M2HI'A)41\*"WJ(?+CC;+:WGEI;:;25N.+(2E*4BY))\  4'#,?>MDUKO73/N
M+S<I:.N>VY$W5(T1Q"FDP,.P\EK$NNE=P#)*!--O1*E^;42[)W/;(6CZW/VC
M(PYTZ#CFR](8Q<9<R3[:02I0;1YLD E1/@"B%'_^N-I[FF0.P(6H;-.U)TWS
M66BPFW(F*09!8"9#Q="%._H6I#)7Q"@%*"O%$O[]Q_=FP:GBM%B:/C)DO&[O
ME\0P-FAN--@Q9+Z'Q&B!;B5%^2TA2>2TA"4*\FY%@W':_;&B8?&Z;_UF=?Y.
M7(S66BHPT+(0(TIF#E%/J:9+LCW7&&W>(6ZD-K4OA\/6@GV^]G8G1Y^"UY,.
M1FMSVAYV/KVO0. D2#'1[CSJUNJ0AIEI/S..+5X'H#1"*:]]PN(S&\+ZRR&J
M;#C=\B.MMY6 (:9L6(T^ 6Y3DN,XM'TRPH6=\>MB!1+UV/OJ+BFL]D]=U+-;
M7K.IONQMGSF*3&2PPY&_\H3&1(>:<E*CV(?]E/%%B.5P;!@;C]T77>IZGJ^[
M(CY++:UMRV&\7EH<50@MK?<*"B2^X4I:6C@X5-^5_(KY:#*P_P!Q>N9'L3&]
M>Y/7<]KZ]A$@ZIFLS#$2#EOI!R<]CDOW$W20I'N(22"+A)4D$AM<UW$8N;SV
M)U;5,IMK6H\!M4K%F*GZ9UQGZA,>.W(>;5*?#9"E-M?IND7Y'C1*:ZEL<3<-
M7PVUP&W&8.;A1\C&9> #J&I3:74)< ) 6 H!2?@?%$-#N?96/U7+XS5,?CY6
MQ;SF6W9&.UW&\ \(K'AR5)==4AJ/'2HI1[CJAR6>* HWL&IT'M'4>X/[SZC-
MQ+D+8=:D?MVUZIF6V'RTLE02J[:G67F5E"N"TJ\VN0+BX4Q]HNVZ]U_]K^0V
M[99 @Z]ALIE7Y;P25<4!]*4I0A(N5*44H0D>I(%$K0Q?W!P%[%J>"VG5<MK$
M7?D>YIN5FF(_'E$H2ZAI\17W51WEI6@I;6#ZVY @T&\SO;1B;3E]2U36<CMN
M3UEF-)VD8Y<9GZ)$UM3S#2!*=:]^0MM/N!IO^$BZ@2!1#&'>.!E:EJ.Q8G%S
MY^7WM:V=6UE"66\@^ZTAQUP.E;@:92RAM2GUJ79 _$V!)96N=MIS3FV0,EJN
M:Q&>TQN(YEL2IEN8\^9S;CC?T1B..B0DAL@*3;S<6%C1".=2=F:3G>M,OM_5
M>BS8F%BYB5&.O8^)#ASI4OFU[SX9]UML$^Y=7-P*"4V^ %$J9^W.;C>Q.L=N
MU_L71<IL6'V7/YS+Y_+EEIZ,[):6VM+?\E\2?J!P2AKVF_! "5 "@N?H7>>I
M\SJ&S97KW7!I.J:]DI$++)F1F<8HOP8K+C[[Z$J44\$D)4IU7+Y3RM1#'ROW
M,X3 0\5M6>U/.X[JW-O-Q\?O#S+/TH#YLS(?BAWZIF,Z/F;=6U=0(^7R*)3?
M<^T<3JN1PVN8V%(V7<]B2MW#8#%ELNKC-)NN4\ZXM#3$9-P/=<5Y)LD*-[$.
M?NH\A&R/WF;N\UKCVJS$:<TWE,/(9894F8)D0N.!<92VWDK!"DO)/S@T2Z[H
M@H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H*5^Y'J[>^X
M=3C:=JDG$P((F1LC)F91<GW?=AK4M+:&V&E I4>-U%8/KX^-$K!RL7?LEHTV
M) G0,%V _&<3$GL(7/@1Y5SP5Q?0A2DVM?DCQ^"K>2%9MZ!WEV#AFM/[HRVN
M,ZBHL_O:=61-,[,M1U!1CO.24M(C-/%(+_LI*E"Z$E"5&@O-MMMEM#32 VTV
M E"$@)2E*18  >  *"C-FZL[)RWW":[V] ?P:<%KL%W$-8]]V8)CT:7[ONNJ
M*&2A*T^Y\B?(\>3Y\$OYA>JNQ87W ;%VMD',"]K&Q8YO!2<6ER6J6B%'*"AS
MYV?;4M7"RT'Y?/KX\AJ]#ZF[>Z0.<U/JZ1@,QUWDY;^1P+>P/3(\O#OR .32
MDQFG!)8!2+ +;5?XBY-!9W3_ %A ZDTF/JL68K)SW'W\CFLPXV&5SLE,7S??
M+:24H!-DH0">*$@7)N20B75W0L?KCM'?]Z:E)=Q.RR1)UW&(4OCC_K0EW)6:
M*0V@O/H;L6_^#0D'TH-+VWT?V!-[&B=S](;'%U[?TPQB\U!RJ5KQF3AH\H#O
M!#A"A9*;<+?*E0*5)N0D^KZ'V;"P^?V3<<UC=@[6S<08^.VVAZ'K^/AH*BF,
MP$(4^I)4M3KCJQS6>*?"4@T2\?MLZOV[ISKICK_:).,G-8YY]V!.QBY!4XF4
M\MY8>2^V@ I4JR>'J/7SZD+BH% H%!!NU.K<)VW@(VMY^=/@XYF6W,=.,D&,
MX\EM*DEEPV(+:N7D6^ M65;88VKY0^]#ZAZVZS82UI>N1,:\!9<T(]V8NXL>
M3[G)PW^(Y6_*DVF>Y6L5[)M6+(H%!XRXD7(1'X$YE$F%*;6Q)CNI"VW&G$E*
MT*2;@I4"00:"G^D>O=UZHRVS:*XMN;U&R\)^D3'7^<V*):BM^"IL\B6VU$E*
MR1<^?/,A$RB(PN:H2^5K0VA3CB@AM *EK4;  >223Z 41,Q$9E1N;^YO7H&3
M<AXC$OY2$THH,[WDQTKL;%3:"A9*?PY<:Y]N;6)Z1EX#D_O/1KV3772;UC_E
MG'Z=)_T:)756G]OI=W+1\JO$+E.J.3QDAD.AJ2KYEV"5IXWOR\%23?Q;T%?L
M4W?-6<-"?H?%^K9Y'&O[?E/S5F,XMZ^O3X^L/K>NG6=&ZLR/[&X[D<DJ1'D9
MF8I'%2H;'+Y4-@JXH2M27%>2?%R; 6;>/X:YQUGU3]3_ &_'"^G6]J9O;-9O
M/_QC/:/2(GK/\>SG2N6^9NG>M=_U[K/K_&8W;YBV<E+6[-C8YMM3K[<1]7)M
M2TCP@+\K3R/D*O76T[:ZJ1%N[ZM]'^JZ/IO"I3D6Q:V;17&9BL]L_#/?\UN:
MGN^L[O$7,UR<F2&2!(94"V\T5>G-"@"+V-CZ'X&MW7MK>.DO9<#ZEQ^;7RTV
MSCO'K'XPY [?P>3PG86<_<4+")\IV=#>4#Q<8D+*TE)^/&_ _@17$Y%9K><O
MBWU_C;-/.V>?_*TVB?C$_;#.Z,PF2RW8V*DP4*^FQBE2IT@7XMM!"D@$_BLG
MB!_W :SXM9G9&/1L?MGC;-O.I->U.LS\(_W[.TJ[K[F4"@B'9V<G:]I>1R&-
M46YI]MAIY/JW[RP@K'X$ FQ_&U=3Z7HKNY%:V[=_T<+ZYRK\;AWO3^[I&?AF
M<9^WJY,6M;BU.K45.*)4I:B2HJ)N22?C7TV(B(P^)3,S.9[NG.F\W-V/3%M9
M<F4J&^N#[COSEQGVT* 7?]5@OCY^%?//K6BNGD9IT\HS^$OK_P"V^5?D\/&S
MYO&9KU]8Q'?]<,:;T5ILJ>9;3LN+'4KDN&RXCV_6]DE:%* _KJRGU[D5KB8B
M9^*K;^U.)>_E$VK'PB>G\8RL'#X?'8'',XK%,)CP8XLVVFY]?)))\DD^237#
MW;K[KS>\YF7I^-QM?'UQKUQBL,J0PS*8=BR4!V.^A3;K2A=*D+%E)(_ @U76
MTUF)CO"Z](O6:VC,3TE2V3^WQEV>IS%9CZ?'K5?V7V2ZXV"?0*"T\ORO:O6Z
MOW%,5^>F;?=+Y_O_ &?$WSKV8K\)C,Q_'JL_4=2Q>FXE.*QG)?)7N2)#EO<=
M=( *C;P!86 'I_GKSO,YE^3L\[?E'P>P^G?3M7"U>W3\9GUF6^K2=-SHS@]C
M[O[L5FMFQTS#]6=63RW@,;,0N,YEMA:L3-4CP5,L^"RJ]E?+;PMQ(GLQ[RZ+
MJ&100W9NI>L]QY'9-5QLYY=^4DQT-R?/K_.:"'/_ '591:8832)[PK5[[4]5
MQ3QE]=;/L&D2^14E&-GN.1KG^TVX>:A_2Y6?N3ZL/:CTG#R_NS]UFG6_9-MP
MF]0&C\L;-Q3!E*3^ 6Q:Y_-;U,UE&+QZY/\ K][&U;Y.S.H\S"9;5Q=R> 6C
M+1K?VB$62D?TNG_N4\(GM)[DQWA;6@[Y@.R-=:VC6R^<8ZXXP!*95'=#C*N*
MP4J_ ^+@VJN8PMK:+1F$GJ&10*#E35]'US[D,CV]#[@:5*SN)V"1KF(Q16$/
MX'$QD(7#DPTD'VW)2BIU;UB'N''RA/&B4O\ M)R.U.]?9K7-ER9S\34-AR.N
M8#8R2I.0QN.*$-N(4;E:4J*VTJY*%D\03QHA?E!47W 9:3+U[&=5865]-M'9
MTPZ[%=04EZ/BRV7LK,2A13R#$1+GHH?.M'F@KSM_[<]WVGJ3(ZD=_?RL'"PQ
M*UW!G$8V(V).+:/TK2'8[:7$>![5TGT-$MYU;VLSV[]KD[9'I27M@B8#(8W8
MD\KN(R$2(M"UN7]"ZGB__0N@K+"$?_>YG3<6_8)P^%K_ +F\*#Y[P6VWT_\
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MD@$'\:NT[K:KQ>O>&OR>/3D:[:[QFMH4D[]O>1^M*6,TS^W%7AQ;2_?";_V
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MD!?$<N)\VH*^Q7=VOR.S\IU/L,&3K>R,*"\ K)<4,9F-;R[$<!*2>059%^1
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M?.LK8=:0VY)2HI"%K2$K\H4D\?B/PL2$PH% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H%!QYL^O:O-S7=C6,Q1[3S^3
M3)5GLWE&&(^,UAIB&][<!F:Z'EN/Q[A0:BHNGY>10H7HE7_8T&-G_P##]U/:
M,V')^?Q3,1K'S7WG5*:0K*".04A82O\ E)#8YI58>E!-N\>N]2ZY/2^_:A#7
M#W>7NN%BY#87'7'\A-:GLK,@2GEDEWGP (/R@$I2 DVH-WN^G:C.^]?38<[
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ME-T[-PFEXB;MD#%NZ=/B9Q,J/BEO_59+'<T,$H7+2&VN"OG0"JZORM0>V_\
M1^R[AO\ JG9^"W3^ZNX8/'.8?)/1L<W.8D1)')3@81(=_E*Y.+XJ5SM<'SQ\
M@G=*[3)[DP/;C6U1BO7,><%"Q$F X^I_'N<_<<D2_J4J,A1<4KDEOC<#QZT%
M48C'[?VGV;V5M_3_ &VSK,564CX>;@LOC8.9><=P;(:+S;4D\X\<.+7[-DW6
MKDI5O H)KHC>][AFMVZ6[;V'%=D:H[ATF=GL1&;@N0Y,EU;!@24L?RTO%"??
M;X_.CC<^J:#7:A]KO86N1_[ASNW,C/Z3;7XU=$1IF>_$)NJ"Y.Y*<;CJ_0XE
MGB%H*DA*.5!-\GTQL<SNK"]P1-A@1&M?@JP>.UQ.,663C'"LKY/IDI(=_F*X
M<6^";)%CYH,:-T;LH[1VWLF=L\-YO=,8K Y/"MXU;:6(*&PTRIF1]4I2G4\0
M5E2.*KJL!\M@UDOH7?-HTW#]4]A;=CL[U]B'(+J\BUBU1L],:QJTJ9CK6J0Z
MTSX2$+D-@N+2"#^M1H.@Z(*!0*!0*!0*!0*!0*!0*##RV)Q>=QLG#YJ&SD,5
M-;+,N%*;2\RZVKU2M"P01_300+K'IC ]39'-JU/)Y%&LY52'8FKR)!>QV/=N
M2ZJ,E=U#W"1>ZCZ>I^$Y1$8>6-[_ .LYN[93KV?DEX+:\;)5%1#S;1QZ9G E
M(<B..V0XA1!X>0I7J 18TP96=4)*!0*!0*!0*!0*!0>;[[,9ER1)<2S':25N
MNN*"$)2D7)4HV  _&@C&G=EZ+V!+S,+3,W'S3N =;CY1<0J6RAQ]*E(XNVX.
M \5?,VI0N"+T1E7,;[>$[+NTG=^Y<^[O+D66XYK& =;$?"P(H4?:YQ$DH==X
MVYJ5\I_B"O!J<HPN]MMMIM+320AI "4(2 $I2!8  >@%0R?5 H% H% H% H%
M H% H%!^?^=[+UOM+JOM#)=BYF0>PV#FX6!ZPB^^S'Q8BMK+4E<*-P4^ZB[C
MC\R25(3Y%D\;$E,8V:Z,[%Z/Z8T'L"5PQV0@,8V%MC3YQW[3GL1CF%+;1(?0
M$\E%2FB?F;YCCY5:P3;[;,MO^'WW=>I\QM@[$TC6(T.1AMO)#KS#LKR(#[P4
ML+<"/F(*U%/'U 4$I#?_ 'F9"!"^W+=&)DIF._,9BLPVG7$H6\Z)L=7!M)(*
ME6!-D_"B%7?<CLFNK^VOJXIR\-8<R6M.H*9#:N;<5@A]2;*-PV1\Y_A^-$MW
MGLXQUG]W,#LC89C".M>Q=<1@L?LREWQ\:;'4V\AIQ\'VT!PL@I)/$\[W^55@
MVLMB%V7]WFJ;5ILUK)X+0-?E)V'+P5I>B)E9$/M1X?O-\D*=*7O=* ?"1Y\T
M&A^U';,#KNW=JZ#E97M;ID=\R\B-A$MN+DF*+7D* 39+(XG^83;T_M)N%T_<
M?_Z!>Q__ +7\A_R"J(4N]V+H<W[*8.#:R\7+YR?I\36X."CNI>R3V:<B-PFH
M[<5)+RG$/E)LE'Z4\OT^:)1G>H<'K%'VIZ5L^6B1<WKN3C*S2'9#8^FNVR'"
MLE7RMI6HMI6;)-J"P/NQ&0PV7ZC[CC1W,AIVBYTS-D7#27U-0)YCCZD)1?DA
M*6U"_P"*D_C08WW(3]9[NB];]?=>YF%G\_DMFA9GWL6\W,$'#PF73*FNK9*@
MTA(=0$\R"M1XIN:##<V[7] ^]/;I^V2CCV<UJ6/C85*FW%N3I!?CH#4="$J+
MBRI"@$I\^#^!H(CI6S]4=2]E]E=>_<'A<?&G9#89^S:WM.9QC<QN=C\FL+"/
M>+3I!3;D/X>16DV4FQ#-[DR+:^OM+[NZVTX8_0-*W-K848Z'"&/7DL,EMMM6
M4,9*&RV'%H4EM3B KVBAQ5D^@7?KGW(:)V+E\%@>JGU;1E,DMN1EDH9?8:Q6
M,2.3S\M:VPE"_1IMN]U.*'PN:(5CT_N&OZ9]Q_>6O;'*,//['FL.K!8PMN+D
M3&U,ODK:2E)NA*7$K6KT2GR3:B6;]M^=PDOOO[@F8N2BOO3LOC7H3;3[:U/M
M,M2DN+: 4>:4$@**;V^-!H.R\%M.B=^976=*:6C#_<+C# ==;'\N!EX)"9TR
MU[_+"6ZZ;6)6N_\ #023[L==7J^F==;5AL",UIO6>9AR<QK:6P^A6&:9^G-T
M+"@4MH 1=0('+D? -!L-.[*^WC=<]K,+IW5,1G=IE2&9DA4;#MPW,)":LI^7
M(>5'2&EM^&VTI7=;JDA)MYH.D:(*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"L=Q^W?I/?LNO/[7I>/G9EWR_-
M2'(KKRKWY.F.MOW%?Z2[GX4$VUC5-9TO$,X#4L3$PN&8\MPH+*&&N1 !6H(
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M"@4J%P?!!]"*#6X?7->UY+Z,!B86*1)4')*8,=J,'%B]E+#24\CY/DT&SH%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M_$TZ'59&EXC9L-JL+$[CG_[R[&TET3LZB,W ]\N.K4@AEHE*."%)1\OKQO\
M&H2I]'V@]=Y%0<WK/;1O#G+FL9[,ON-DCTL&/9(M_OJG+'Q7W'B1XL1F"PV$
MQ6&T,M-FZ@$-@)2+JN38#XU#)[4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
4"@4"@4"@4"@4"@4"@4"@4"@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>fc_fig39vaccine-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_fig39vaccine-4c.jpg
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M;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4
M !#\X1^)R+?)>"\T8C0'6'?K_^X #D%D;V)E &3      ?_; (0 ! ,# P,#
M! ,#! 8$ P0&!P4$! 4'" 8&!P8&" H("0D)"0@*"@P,# P,"@P,#0T,#!$1
M$1$1%!04%!04%!04% $$!04(!P@/"@H/% X.#A04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@!S0.V P$1
M  (1 0,1 ?_$ +<  0 !!0$!               $ @,%!@<!" $!  ,! 0$
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M/ G'$)5^C''_ +!V_IQQU'!^]/#2_NYX/>?/
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M      %*UMM%F=6EM.*49G%$@LRSP26*C+:9G@1>T1,\$J@0"0
M    &]6/_MTC^.?["1XO[_YQ\/=_^?\ A/RV<><],     :_>7^S_P#OD?\
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M;./.>F     -?O+_ &?_ -\C_M'=^E_T_L\_]_\ Y_W<^'NOGP
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MC[1W0X7HE               /#Z '6H/\C&_A-_LD/E]3\I^7UFG^$?"0*-
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M*S[CICL1J='J>[/>0:@AU])*C$X1*WQ8[O$\I[=NFMI55?3X_P!L-#6IH_\
M;Z^L?>'<+(IUP4BS:#2[KG>9W-#@L,U:?F-S>R4)^,\ZL#7A]W.>U6&8^D>C
MI15%,15[O/U9IFJ9ICA#/#5D        WJQ_]ND?QS_82/%_?_./A[O_ ,_\
M)^6SCSGI@    #7[R_V?_P!\C_M'=^E_T_L\_P#?_P"?]W/A[KY\
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M.7)O74I(EN92Z,RB-6 ]6F)B/5Y<\./HNBRH              /#Z '6H/\
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M_P )^6SCSGI@    #7[R(_)OT.HQ_M'=^E_T_L\_]_\ Y_W<^'NOGP
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M+H2:MIH/W8>S[!R?K:T5T\/K#M_:T)TZN/TEAAV.(
M                       %;+#TEU##"#<>6>"$)Z3,5JJBF.,K4TS5/"/=
MT^C4XJ73VHAF2G"Q4ZHN@UJVGA]A=!#YW7U-RN9?3?KZ6W1%*>,'0     (E
M3@HJ4%Z&L\-XGX5>Y1'BD_Z#(:Z6IDJBIEK:>Y1-+E\J*_"?7&DH-MY!X&D_
MUE[R,?1T5Q5'&'R]=$T3PGW61=0
M         &3H=(=JTM*,I\HV9'(<]A)_"1^\QS:^M&G3?]'5^OH3JU7?5TXB
M(BP+81=!#YU],      #6[MH[LYA$R*DUR(Y&2VRVFIL]NSWF1^P>A^GK11.
M6?:7F_NZ$UQFCWAH0]IX()
M     9N-17RHDVIO-J(S2A,=&!YC3O$FI>'NP+9]F(XJM>-R*8GYP=U'Z\[5
M5<Q\8^[HCC3;R%-/()QM18*0HB-)E]I&/"B9B>,/H9B)CA+#N6I0W%&KES1C
MTDA:R+^K$=4?MZL?5QS^EI3]%/I&A]ROB+ZQ/F:MJ/!TK.9Z1H?<KXB^L/,U
M;3P=*SF>D:'W*^(OK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB^L/,
MU;3P=*SF>D:'W*^(OK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB^L/
M,U;3P=*SF>D:'W*^(OK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB^L
M/,U;3P=*SF>D:'W*^(OK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB^
ML/,U;3P=*SF>D:'W*^(OK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB
M^L/,U;3P=*SF>D:'W*^(OK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KX
MB^L/,U;3P=*SF>D:'W*^(OK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<K
MXB^L/,U;3P=*SF>D:'W*^(OK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<
MKXB^L/,U;3P=*SF>D:'W*^(OK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?
M<KXB^L/,U;3P=*SF>D:'W*^(OK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H
M?<KXB^L/,U;3P=*SFR,*F0*<1E#82T9[%*+:HR^U1XF,*]6JO\I=.GHT:?XQ
MP2QDU        1IE/A5!!(F,)=(ONFHOB+]!EM(:4:E5'XSP9:FE37^4<6,.
MT:'C_DK+[-XOK'1YFK:YO"TK.9Z1H?<KXB^L/,U;3P=*SF>D:'W*^(OK#S-6
MT\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB^L/,U;3P=*SF>D:'W*^(OK#S-
M6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB^L/,U;3P=*SF>D:'W*^(OK#S
M-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB^L/,U;3P=*SF>D:'W*^(OK#
MS-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB^L/,U;3P=*SF>D:'W*^(OK
M#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB^L/,U;3P=*SF>D:'W*^(O
MK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB^L/,U;3P=*SF>D:'W*^(
MOK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB^L/,U;3P=*SF>D:'W*^
M(OK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB^L/,U;3P=*SF>D:'W*
M^(OK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB^L/,U;3P=*SF>D:'W
M*^(OK#S-6T\'2LYGI&A]ROB+ZP\S5M/!TK.9Z1H?<KXB^L/,U;3P=*SF]1:=
M#0HE<N:L/8IQ9E_5B$_MZL_5,?I:4?1EV6&8[:66&TM-)^ZA!$1%_00Y:JIJ
MGC+KIIBF.$+@JL        QLR@4F<LW9$9.]5M4X@S0HS^W*98_TCHH_8U*/
M2)<VI^MIUSQF/5%](T/N5\1?6-/,U;67@Z5G,](T/N5\1?6'F:MIX.E9S/2-
M#[E?$7UAYFK:>#I6<STC0^Y7Q%]8>9JVG@Z5G,](T/N5\1?6'F:MIX.E9S/2
M-#[E?$7UAYFK:>#I6<STC0^Y7Q%]8>9JVG@Z5G,](T/N5\1?6'F:MIX.E9S/
M2-#[E?$7UAYFK:>#I6<STC0^Y7Q%]8>9JVG@Z5G,](T/N5\1?6'F:MIX.E9S
M/2-#[E?$7UAYFK:>#I6<STC0^Y7Q%]8>9JVG@Z5G,](T/N5\1?6'F:MIX.E9
MS/2-#[E?$7UAYFK:>#I6<STC0^Y7Q%]8>9JVG@Z5G,](T/N5\1?6'F:MIX.E
M9S/2-#[E?$7UAYFK:>#I6<STC0^Y7Q%]8>9JVG@Z5G,](T/N5\1?6'F:MIX.
ME9S/2-#[E?$7UAYFK:>#I6<STC0^Y7Q%]8>9JVG@Z5G,](T/N5\1?6'F:MIX
M.E9S/2-#[E?$7UAYFK:>#I6<STC0^Y7Q%]8>9JVG@Z5G,](T/N5\1?6'F:MI
MX.E9S/2-#[E?$7UAYFK:>#I6<STC0^Y7Q%]8>9JVG@Z5G,](T/N5\1?6'F:M
MIX.E9S/2-#[E?$7UAYFK:>#I6<STC0^Y7Q%]8>9JVG@Z5G,](T/N5\1?6'F:
MMIX.E9S7XUMT:(LG&XI*66TE.&;F']"C,A2K]G4J])EI1^II4SQB&5',Z@
M
M
M
M
M
M
M
M
M
M
M                                69,IB(@EOJRYCRH21&I2E>Y*2Q,S
M_0+TT35[*5UQ3'JCE-EK+,W <R>S>+;0?]68S_K%\E,>]4<V>Y5/M3/)[S4_
MP"N*WUADI[N2<]?;S@YJ?X!7%;ZPR4]W(SU]O.#FI_@%<5OK#)3W<C/7V\X.
M:G^ 5Q6^L,E/=R,]?;S@YJ?X!7%;ZPR4]W(SU]O.#FI_@%<5OK#)3W<C/7V\
MX.:G^ 5Q6^L,E/=R,]?;S@YJ?X!7%;ZPR4]W(SU]O.#FI_@%<5OK#)3W<C/7
MV\X.:G^ 5Q6^L,E/=R,]?;S@YJ?X!7%;ZPR4]W(SU]O.#FI_@%<5OK#)3W<C
M/7V\X.:G^ 5Q6^L,E/=R,]?;S@YJ?X!7%;ZPR4]W(SU]O.#FI_@%<5OK#)3W
M<C/7V\X.:G^ 5Q6^L,E/=R,]?;S@YJ?X!7%;ZPR4]W(SU]O.#FI_@%<5OK#)
M3W<C/7V\X.:G^ 5Q6^L,E/=R,]?;S@YJ?X!7%;ZPR4]W(SU]O.#FI_@%<5OK
M#)3W<C/7V\X.:G^ 5Q6^L,E/=R,]?;S@YJ?X!7%;ZPR4]W(SU]O.#FI_@%<5
MOK#)3W<C/7V\X.:G^ 5Q6^L,E/=R,]?;S@YJ?X!7%;ZPR4]W(SU]O.#FI_@%
M<5OK#)3W<C/7V\X.:G^ 5Q6^L,E/=R,]?;S@YJ?X!7%;ZPR4]W(SU]O.#FI_
M@%<5OK#)3W<C/7V\X.:G^ 5Q6^L,E/=R,]?;S@YJ?X!7%;ZPR4]W(SU]O.'K
M50:4ZF.^A<:0O[C;Q$6;#\*DF:3_ $$>(B=.>'&/6"-6./"?2;TP9-@
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M_$X]B4?'^XP1X)(O<:L,RO\ ]AKJ3E_A'T]_ECI1F_G/U]OAD!@Z
M                                   6I$=F4RIA].9M7]!D9=!D?L,O
M88M35-,\85JIBJ.$K-.==6RII]6:1&6;+B^C-EP-*O\ Q),C,7U(B)XQ[3ZL
M]*9F.$^\>B6,FP     BU!]QB,9L8<PXI+3./1G<,DD9_86.)C33IB9]?9EJ
MU3%/I[KD6*U$9)EK$_[RUJVJ6L^E2C]IF(KKFJ>,K4413'"%X47
M                                 ! J31MH\Q8+_BHI&H\-F=HMJVS]
M^)='N,;:4\?XS[3_ )M8:L<(S1[Q_BQ.2I*TDM)XI41&1^\C&4QP;1/%Z(2
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MHUJ_"/F?LQI_Z3\1]TT9-@
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MZ,T2LVQI19MLW#".GUNB4B'3)T;>MOD3T-E+*E)<:-232K+F+ _;@>T$-Y
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MMF:S;/=YR;41++'*?1B8?3((        6I/\L]_@5^HQ:GWA6KVE1 _D8O\
M";_9(6U/RGY5TOPCX2!FT     $)G_=)?\%C];HUJ_"/F?LQI_Z3\1]TT9-@
M      <WJ6J<RDZNT72R?;KC+5Q1),VC7 J6T4>0F DE26D-9<YNMDI*C1^
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M_'WEC1^57S]H31DV     $*H_>A?\RC]E0VT_K\,=7WI^4T8M@
M &JW/J/9UH5&)1ZY4316)S+DJ/3HS$B;*.*RHDN/J:BMNK2TDU8&XHB3CL(\
M0$.Q8FFM;<DZEV&Q$DNW%BF5<$5*R5-*.LT?$M6!K)"DJ2G'[NTB ;L
M ,+1K1M:W9]5JE!HT*FU*N/G+K,R*PVT]+D'B9K>6DB4L\3,_B/I,SZ3,!F@
M%*W&VR(W%D@E&24FHR+%2CP(BQ]IF J  &&3=-&5=:[*)QWU W3TU=;.X>W/
M)K>..2M_DW1JSI,MWGSX;<,-H#,@             "U)_EGO\"OU&+4^\*U>
MTJ('\C%_A-_LD+:GY3\JZ7X1\) S:     "$S_NDO^"Q^MT:U?A'S/V8T_\
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M'WEC1^57S]H31DV     $*H_>A?\RC]E0VT_K\,=7WI^4T8M@
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ME>:GL(/_ #&4[APO<MKX%%_60G6C^<W^N*-&?X1=Z8)HR;
M TR[-)=-KZK=,N.[K:A5:MTC H,V0@S62"5G)MS*9$ZV2OB)MTE((S/9M,!"
MK^A^DMTU6JURX+2@3ZK7&F6:M)=0K&0F,:5-*425$6\1E21.$6?#9FPV +DW
M1?3"HMUUF;;K#S-S+9<KS2G'\DM4;#=;Q).8&2,"))=!$1%T$">*U7]#]*+I
MFQZE7[8C3I\:"=*1)<6\3BX.7(3+RDN$;R2+[N]S8>P#BG4O2?3NB52G5JE4
M%B+4J3!\HISS:G<&:?M_X=*#6:=WB>.4RPQV]((8FD_E_P!&J%48M4I-GP8L
MR#(?F033O#:CO2BRN[EI2S;;0HNEM"21]@"3;^A^DUK3Z95+?M.# J%&=DOT
MN2TE9N1US2P=)!J4>"#+[J/NI_ND0"T_H/H_)M1^QWK0@*M5^:JJ'322M*&Y
MJS,S=942B6TK:9%NE)(DF:2V&9 )4O1C3"9#I,!RW&&HE#B.TVEMQ5O1=S#D
M&1NLXL.(-27#22G"69YCVGB9F">+=8<.)3XC$"GQVXL&*VEF-%80EIIIILB2
ME"$)(B2E)%@1$6! A>               !!IY[QR;(3_ );CYD@_89-(2V9_
M,DQMJ>D1%W^V.GZS5-_^/1.&+8     0:H>1IB0?W&'VW'#]R3/*9_T9L1MI
M>LS%L,-;TB)LF$X8MP           '/G]#]*9,UV>_;,9;LB5YC,9-;W*R9A
MN;XWY,?>;E]PU_%F=0HP&TTJUK?HE6K-<I4%$:K7"ZU(K,I!J-<EV.T3#:E9
MC,BRH(DEE(@&!K6D&F=Q5VHW+6[:AS:W5X1TNIRW4JQD1#;-K*XDE$DU$@\B
M7,N=*=A*(@'KVD6FLB;!J+UMQ%S*;2O3T)TR5^[I6"B*.1$K TEG5E,RS%B>
M![0&1H6G]F6S*@SJ#1H\&93:6B@0'FB/.S2VG-\F.DS,_@S_ !'[3/I,P$!S
M273AV[7[Z=MR(JZ9614J<9*,G5M)RH<<9S;I;B2Z'%(-1;-NP@%AS1G2YV14
MY3ML0UR*S4FJ[4UJ)9F]4F'"=0^?Q;%9R)1DG E'TD8)XK[^DVG,J[W;]D6[
M%<NR037,U R5^^5'3D:6ZUFW2UH+8E:T&HL"P/80(7K?TQL.UIK%1H5$8B3(
MO,%#<S..\OSJS<D&REQ2B:-U1F:S;(LWMV )EWV-:5^P8M-O"DL5>%"E-5"&
MV^2L6I;&.1U"DFE25$1F6P]I&9'L,!CIFE&G4^Y'+MEV]%<KSRH[LE_XTMON
MPRP8<>82HFG7&BPW:W$*4G L#V%@"I:4:>U>G7%2:I0F9=.NR4W/N*,ZMU2)
MDIG(;:W,5_W=VC*2<"+*6'0 M/:0Z<R)C]0D4-#LZ32_()$A;TA3CE*PPY92
MC=Q-O[/?MZ03Q6T:,Z8H.E?_ "ZPI-#AO4RDH6X\M$>#)0;3K"$J<,MVM"LB
MDF6&7 N@B XLE:>G%E6.HUVO2&X+O+-0$/&MU]U$./\ Y<=M;ZW%(:29XDV@
MR3CMP!#:0           1J@Z3,&0X>W!"B27M-2BP(B^TS/ ::<<:HAGJU<*
M9E<C-&S&99/:;:$H,_M21$*U3QF96HCA3$+HJL     (*3W=6<2K9S#"#;/W
MFRI1*+^C.D;3ZZ<73_G_ ,,8]-2;X_Q_Y3ABV
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M#^,?UQ(HJB)GC_*?ZX)PQ;@
M
M
M                      .#O7)<)?G&C6D54E%:ZM/CJ2J,3R^3.;YLMK?F
MSCEWF0LN?#'#8 [P
M          .%6U<%>D?FOO>VWZI*=MV):U,E1:2MY:HC4AQXB4XAHSRI6HC/
M%1%B8#NH
M"!7''&:+4GF5FVZW%?6VXD\%)4EM1D9'[R,!R?\ *?7JW<WY?;,KEQU*35ZU
M+:FG*J$YU3\AW)4)+:<[BS-2LJ4I26)]! .S@
M                    YI=VJZ[(U0M.S*_2RCVE>+3D2EW3O?@37T+Q;@NM
MY<$;UO#=+SXK6>4D[#,@YZ__ .N>+_\ C,__ (TL!T.V=5SO#5BY["M^E\U;
M-GQ6VZW=!.X-IKKKA?\ E[3>7!9MM$I3JR7\"RR&DMAF'2@
M                                      <UJ.K!T#6*FZ7W'2_+Z9<E
M/5*M2XS>S,S9\8S.3"4C*61Q*#2M'Q'FZ.DR(!H=J_\ K)O_ /\ I"D_ZY -
M\T^U8/4>]+RI%!I6>R[2?;I2+JWV+4VKH(U2F&6\NU#!&DC<S;3Z-AD8#I0
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MS26Q*=9]/<.7*:S2JS5',3>GU.1@J3)<-6*C-:ONYC,R024XG@ WD
M                                            '.M:]+V=5['?H<>1
MY==%/>;JUJ5I!FER!6(9YX[R5)(S(C/X%X%CE4>'Q8 /B6FZQ7U>.L5P4&VZ
M7+I6MMWT"G6343<0EMBDU*"\I-6FXH6:B;::;4ZR:3,TF9=.7:'WOIS85!TP
MLJCV-;;6[I5(82REQ1$3CSI_$Z^YATK=6:EJ]F)[-@#:
M                                    ?->OM)FZ67.C\Q%M1'I5*<AG
M0M4:/$P)R7274[N/.21E@;T19I(U=.[P+%*"48#C'Y6J3-UPMVP+6GQW$Z3:
M3F[4*LAY.#58NB3*>DQF#3B9*9B-.DXHCZ5*P4DTJ(R#[[
M                               :FO3.R%ZA-ZJ*I#1WTU .E(JN*LQ1
MC5C]S')O,#-&]RY\AY,<NP!M@
M                   U.!II8],ORJ:F0:.RS>]9BM0*C5DFK.XPSEP+*9Y2
M,R0@E*).*B0G'H ;8
M          CSH,.IPI--J+")5/F-+CRXSR26VZRZDT+0M)[#2I)F1D8#!V'8
M5J:9VQ$L^RZ>FFT&$;BF8Y*6ZHUO+-:UK<<-2UJ,SZ5*/9@701 -D
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MW"3E5B:,<,# 29E<HM.EQH%0J46).FGEAQ7WVVGGC+I)M"U$:O\ PD G@
MQ\2O42=5:C0H51C2*U2"855:>TZA<B*F6DUL&\VDS4C>)2:D9B+,1; &0
M              0:<6Z7,C)_RVGS-LBZ")U*7#+^M1C;4]8B;O\ 3#2])JBR
M?\^J<,6X     @U0L[+4<_N2'FVW/M1CF47]))P&VEZ3,V0PUO6(BV4X8MP
M                                          $:HM$_!?;,\#R&I"BZ
M4K3\23+[2,B,::<\*H9ZM/&F87([IO1VGC+ W$)69?XB(Q6J.$S"U$\:8E=%
M5@    !!26]JRU*VE&8039>XWE*S'_4@AM[:?S/^/_+"/74^(_S_ .$X8MP
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M['Z=-I]9M"->,%5/CNQE0G%241'(IJ<=<-Y"LQ.$X9)41XEAA@ [2"
M      $*'_-U#^,C_1;&M?XT_'WEC1^57S]H31DV     $*H_>A?\RC]E0VT
M_K\,=7WI^4T8M@                                           %J3
M_+/?X%?J,6I]X5J]I40/Y&+_  F_V2%M3\I^5=+\(^$@9M     !"9_W27_!
M8_6Z-:OPCYG[,:?^D_$?=-&38
M        !%E?Y\'^.K_1=&E'M5\?>&5?O3\_:2F_[=#_ (#?[!!J_G/S)I?A
M'Q"4,VH          -:ORRJ?J%;,NU*M-GP:9.RE+<I4E4*0XTD\5-&Z@C/(
MOH6G^\6SH 82Q=(J)8=3=J\6MU^MS%1B@Q_4%5D5-N-'S$LTQVW3RMYC2G'*
M701%T *+LT?H=WW?3KXEUBLP*_28[L2ENTV:49N.U)(B?)"-VHL7,J<YGCT$
M"6*K'Y?;0N&W*[;5>JU=J<:Y7X[]:F2JBIR6^W"P5'C[S)@AEM19R0VE/Q&9
MGCB!Q92%HS:R*[3+CK\VJW55*(O?T0[@G+FL0I&&7?LL$2&M[[G5(4M/2DR,
M!'EZ)4.1>-8ON+<%P4VXJXAIB>]!GDRVIB-CN6DHW1D2$8GE]NT]H'%=AZ,6
M_ 10BC5BMD_0JA(K292YYN/S*A,2XAUZ8M:#-TS;<4T1'@1(V$18$!Q;+5+&
MMFL790KXFPB.Z+<3):I=00HT+2S.:-IUI>&Q:#(\Q$K[JMI88GB0Q]\:9V_?
MLVWZM4GYU/K=L27)=&JM*E+ARVN81NI#6=..+;R/@<3AM+H,@&M4?\O=C6^[
M;ZZ+*J\-FUJG4*S0XR9ZW&H[]7S%(01.DLS:-*UI))G_ 'U&9FI1F">*ES\O
M-CNT2=1%3:P29MP^LFYZ)RFYL6NJ6I:Y,=U"$Y#7F42BP,OB/# ]H#%:AZ-O
M,4*_ZM8;4NK77>L2# J=+F5-45IZ)!-+1%&>R_N7VXYN)96M67,?[S,6(#7]
M.]*KGDU%Z)<*;HCZ?3:=*I]P6U>E:AUUF<4M.7*PW%SFR;:OB-[>I-1;"3MQ
M(-MI_P"6ZQH%LU>U%U2X)]-J\(Z0;E0JKTM^)25&DS@Q%.D9,L'E(E)2G$R(
MB,]A -EH^DU HMWTV]V)]3?K=+HR;:9YB23C*Z:A1.$AQ!(+,K.1+S=.)>[8
M"&^             (4/^;J'\9'^BV-:_QI^/O+&C\JOG[0FC)L     (51^]
M"_YE'[*AMI_7X8ZOO3\IHQ;             #@_YE:Y,MM_3&?&K%2I$.?>,
M"EUORQ^0WS%,=8D.NM+:CYE+Q-I/W4YL,2+I!+$U.^8]Q_F.TYI%L5NK-V_-
MIM9?K-*450I\1Y^ TTJ,I3,EMHEFG,>.7'H+-]H4Z67[5;4MB\C?C5:[)O\
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M=]28J5??>=D2%0FC8@L)6K!N/%;49J)II!)26=1J4>*CZ< 0V(
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M5;,H$FU;2HEM3*H_6Y5(A,0GJO,_F)2V&R0;KF)J/,K#':HS]YGT@AG
M        $65_GP?XZO\ 1=&E'M5\?>&5?O3\_:2F;:;#P[AO]@@U?SGYDTOP
MI^(2AFU              !\\UZDWE:>JE_R56"YJ#:.I\:EHB$VN(J+$D4R(
M<-R)4D3%D28R_P#.SI2LOB4652CV$M*U<LW5*OO7M2HEER7#7,MR=1SMXX,*
ME5"%37H:GG):E.H>DRT''4TTR\1)::2@T]&)A5J)85]5ZB?F)ATVU)RYU\OT
M0[=(T1RYHH46,P]@O>X$E#C3F!K,L2P47WA REWT74"%4-:HT:S*I7(NKE!3
MZ:J43EL8C[5%7!5 J"'7D&QNUJS-F69"\RL#S8D)%F/IYJ%4:W2(7DTRBNR-
M'I-BKK"U-*9@5R0;*FMXMEQ2L$DR:C4V2L#P+I 1Z52]39]4T.;;TZGTZ7II
M$J]%KA3EQ$4W?*H94Z.XRZAY1NQG%D1YDIV)V$2C( TXM/4I.H6G-P5>T*G2
MFJ?1:U1JWO%T^)2Z9-?)C*W A1'32U"3N32PI&*G"P-6TL1 Q%#L#4>WK%TF
MJ%6L:IU3_INBJT*X[9B36X]2>;GFV2:A35QY*"<2V;67*ITC<0O81%\0#.W#
M8-9BT*AO6?9M=T_KT=BKSJ!-MI]FIKAOU!YE9P*S$?=6S);F*:0\ZG,IMM:"
M+-TJ,/I"RFJXQ9UOLW-&BPKC;IT1%6AT\B3#9EI923K;!$9D3:5XD@B/##H$
MH9T               $*'_-U#^,C_1;&M?XT_'WEC1^57S]H31DV     $*H
M_>A?\RC]E0VT_K\,=7WI^4T8M@
M         %J3_+/?X%?J,6I]X5J]I40/Y&+_  F_V2%M3\I^5=+\(^$@9M
M   !"9_W27_!8_6Z-:OPCYG[,:?^D_$?=-&38
M                    !%E_Y\'^.K_0=&E'M5\?>&5?O3\_:5FG+*/FICNQ
MV/CN<?[[!G\*B_07PJ^TOT"^K''^<?7_ "II3E_A/O'^&0&#H
M                               !;??:C-+??42&D%BI1_\ ZZ1:FF:I
MX0K55%,<91Z<VZEE;[Z30_)6;RVSZ4D9$E*3^TDD1']HOJ3''A'M'HSTHGAQ
MGWGU3!DV     $6H,N/1CW!$<AI2762/81K;/-A_XON_TC33JB)]?9EJTS-/
MI[QZKD62U+92^R?PGL-)[%)472E1>PR/I(5JIFF>$K45Q5'&%X57
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MZ>G>I?E.KE/H/%LW,"0@_>E"2(B/[=I_:(G4].$1P@C2]>,SQE,&38
M !$>IZ%NG(8<7&DJPSN-88+PZ,Z5$:3_ $X8C6-28CA/K#&K2B9XQ/"5/+5+
MQR>"7:$YJ.WF9:^[D<O4O')X)=H,U';S,M?=R.7J7CD\$NT&:CMYF6ONY'+U
M+QR>"7:#-1V\S+7W<CEZEXY/!+M!FH[>9EK[N1R]2\<G@EV@S4=O,RU]W(Y>
MI>.3P2[09J.WF9:^[D<O4O')X)=H,U';S,M?=R.7J7CD\$NT&:CMYF6ONY'+
MU+QR>"7:#-1V\S+7W<CEZEXY/!+M!FH[>9EK[N1R]2\<G@EV@S4=O,RU]W(Y
M>I>.3P2[09J.WF9:^[D<O4O')X)=H,U';S,M?=R.7J7CD\$NT&:CMYF6ONY'
M+U+QR>"7:#-1V\S+7W<CEZEXY/!+M!FH[>9EK[N1R]2\<G@EV@S4=O,RU]W(
MY>I>.3P2[09J.WF9:^[D<O4O')X)=H,U';S,M?=R.7J7CD\$NT&:CMYF6ONY
M'+U+QR>"7:#-1V\S+7W<CEZEXY/!+M!FH[>9EK[N1R]2\<G@EV@S4=O,RU]W
M(Y>I>.3P2[09J.WF9:^[D<O4O')X)=H,U';S,M?=R.7J7CD\$NT&:CMYF6ON
MY'+U+QR>"7:#-1V\S+7W<CEZEXY/!+M!FH[>9EK[N1R]2\<G@EV@S4=O,RU]
MW(Y>I>.3P2[09J.WF9:^[D<O4O')X)=H,U';S,M?=R><K45;%3\$^TT-))7]
M!J-1?V!FH[>9DK[N2]&ALQ<RD8J=<PWCSAYG%8=&)G["]A= I57-2U&G%/RD
M"C0      'BDI6DTJ(E)46"DGM(R/V&")CB@E3G&-D&4MAKV,J(G6R_PDK:7
MZ"5@-MR)_*.+&-*:?QGAS5<O4O')X)=H,U';S3EK[N1R]2\<G@EV@S4=O,RU
M]W(Y>I>.3P2[09J.WF9:^[D<O4O')X)=H,U';S,M?=R.7J7CD\$NT&:CMYF6
MONY'+U+QR>"7:#-1V\S+7W<CEZEXY/!+M!FH[>9EK[N1R]2\<G@EV@S4=O,R
MU]W(Y>I>.3P2[09J.WF9:^[D<O4O')X)=H,U';S,M?=R.7J7CD\$NT&:CMYF
M6ONY'+U+QR>"7:#-1V\S+7W<CEZEXY/!+M!FH[>9EK[N1R]2\<G@EV@S4=O,
MRU]W(Y>I>.3P2[09J.WF9:^[D<O4O')X)=H,U';S,M?=R.7J7CD\$NT&:CMY
MF6ONY'+U+QR>"7:#-1V\S+7W<CEZEXY/!+M!FH[>9EK[N1R]2\<G@EV@S4=O
M,RU]W(Y>I>.3P2[09J.WF9:^[D<O4O')X)=H,U';S,M?=R.7J7CD\$NT&:CM
MYF6ONY'+U+QR>"7:#-1V\S+7W<CEZEXY/!+M!FH[>9EK[N1R]2\<G@EV@S4=
MO,RU]W(Y>I>.3P2[09J.WF9:^[D<O4O')X)=H,U';S,M?=R.7J7CD\$NT&:C
MMYF6ONY'+U+QR>"7:#-1V\S+7W<CEZEXY/!+M!FH[>9EK[N1R]2\<G@EV@S4
M=O,RU]W)X<&2]\,J:M;7M;:23)&7N,RQ5_4H@W(CVC[HVZI]ZL/1(Y6-R_*;
MI/+89=U@67#W8#///'CQ]6F2G+EX>B\*K@                    #35ZF6
M\C5)O2(VI7JARB'<J7B;1R?)%).+E-S/FWF<ONY,,/;[ &Y
M                                         #3:?J50:EJ56-*V&92;
MBHM-CU>4^MM!1%1Y2\B4H62S4:R,RQ(T$7V@-R
M                               69DIN%$D37B,VHS:WG"26*LK:34>!
M;-N! -:TUU!HFJED4F_K<:DLT6L)>5%:G(2U(3R[[D=6=*%N)+XFU88*/8 V
ML                                           %&^9WW+[Q/,9=YNL
M2SY,<,V7IPQV8@/G5_\ ]<\7_P#&9_\ QI8#Z*WS6])C>)WYI-9-8EGR$>!J
MPZ<,3Z0%8
M*"=:4XIE*TFZ@DJ6V1D:DDK'*9ETEC@> #Y\M7_UDW__ /2%)_UR ?09.M&Z
M;)+2;R4DM3>)9B2HS(C,NG S(P%8
M                   ,76W6G[<J;S"TN-+AR#0X@R4DRW2MI&6PP''/R9_^
MFFQ/X4__ .)R@'=&7F9#:7F'$NLJ^ZX@R4D\-FPRV *P
M                         !P3\P=NUVVJC1OS#6*PN3=-C-+8N*E-J,O-
M;6<7O)<<RZ,[&*I#1^P\QX*,DD TGU]:DG\T\35!NH(]$GI =<54]N5,$JLM
M9J4DL5$HONFC#-F^'#'8 W/\OU#K=YUJL_F.O5AV)6KR83!M"D.F>-,M-MPG
M8Z#+'#>25$F0X>TNA2<,RB =^
M                !\\:YT^J:6WC2OS)6NR])ATUI%&U*I#.*SEV\XX666A&
M/^;#6>?9TIZ32A*L0U=O4.UK4_,/J7JA49J7+.C6#1ZHU/9P4B0P^ZDXY,F9
MD2E/FI*&BQ^)2B(!O_Y>;-N)3-9UFU#:4UJ)J(IN6[3U&K+2Z,V7_ P$)/#
MT(/.YB1*S'@HLR3,P[@
M         /%)2M*D++,A1&2B/H,CZ0'S#8QRM#[SKOY?:@;B['N6+4:UI/+7
MF63>*%.SJ/F/'%3*E&ZU[32>*CS+))!SK3B]Z_'_ "OZ6:0:>/;O4W4--3@P
MY*3/_P KI**E*YZHN9=J2;;,R:/$C-6)HQ-& #[!L*RJ+IS9M&LBW4*11Z)&
M3%CFL\7%F6*EN+/HSN+-3BL-F)G@ V,
M             >&1*(TJ+%)[#(]I&1@/AR1^2^M*_, EIEYQ'Y?763GNPDOD
M3:6>;*8JADT2LY,JE%OMB<F[_O;T@'W$VVAI"6FDDAM!$E"$D1)2DBP(B(N@
MB 5                                                    LRXD6
M?$?@3F4284IM;$F.\DEMN-.)-*T+2K$C2HC,C(P'Q19WY.KEIVO<E=PS7YVA
ME%3'F4*+(E;XI:([JGH5->:4LU&U$=6M1[PC2I*4[/C/*'VZ
M                                         YIKKI2UJY84JA1I!TZZ
M8"TU.U:RA2FW8=5C$9M+):=I)7M;<P_NJQ+XB(!R_P#)]H#7=*[:<N;4-M7_
M %"J+/ES$5UU$CRNC,.J6B(VMM2T%O7#-]S(K#:G^\2L0^FP
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M\)Z'FD;\#_T[_8#:JNQCJ;U-^$]#S2-^!_Z=_L!M578QU-ZF_">AYI&_ _\
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M-K-,1D]J#R'@;BB]IF9?#CT%MZ3'15.2.$>_UZ.:F-R<T^WTZ]&2'.Z0
M                                      1I<)N41+(S:E-[69"/OH/_
M +2]Z3V&-**YI^+&5>G%5TVD&0J2QF=(DR&U*;?2703B#P/#[#Z2^P-2G+/I
M[)TZIJCU]_JDC-H     +$R1RL=;Q)SK+!+;?1F6LR2E/])F0O13FG@IJ59:
M>*W#@ICXOO'OISG^:^?3_A3^%)>PA:O4X^D>D*T:>7UGUFW^OHEC)J
M                                    #&RF2IZCJ44LC9'C-93]U;?M
M61>Q2>G'VEL'115G_C/]G-73D_G']^ORR73M(<[I      !!FK=>>;I["S;-
MQ)N/NIV*0T1X8)/V*4>PC]FT;41$1FG^I8:DS,Q3']_C_:4Q'9C-DS'03;9=
M"4E_:?O,9U535/&6M-,4QPA<%5@
M       !2XVV\A33J"6VHL%(46)&7VD8F)F)XPB8B8X2QI,;IPZ4ZM9PGTYX
MYYC)2209&MHU8XF6'1]F)>P=&;C&>/>/?JYLO"<D^T^W1)I:23389%T;EO\
MM20SU?SGY:Z,?PI^(2QDU
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M5A_2PX-:/:KX^\,JX_E3\_:7M-_VZ'_ ;_8(1J_G/S)I?A'Q"4,VH
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MDJ29*21XD"&7 8;U)%]6>D.3F\[Y=YMS_+.>7;K?[C=<SADW^/Q;K'-D^+H
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ME"X      +4G^6>_P*_48M3[PK5[2H@?R,7^$W^R0MJ?E/RKI?A'PD#-H
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M)J5/J*9*E*,E)2F$XLT92(C^/W@AIOY4R7_T9@J61XJK%Q&1G[?_ #R:6/\
M60)EVH$            (4/\ FZA_&1_HMC6O\:?C[RQH_*KY^T)HR;     "
M%4?O0O\ F4?LJ&VG]?ACJ^]/RFC%L          #4]1M/:-J?;#MI7!)F1Z1
M(>CR'_+WDQW5JB/(D-$:S0O8EQM"]GM(!M##1LL-LFXMTVT)0;KAD:U92PS*
M,B(L3Z3V +@  BSJE3J6VV]4YC$)EYU$=IR2XAE*WGCRMMI-9D1J4>Q*2VF?
M0 E -.B:;4&-?<S4)Z549];D))$2-.FO2*?3\6DLNJA1E'NV5.H0DG%)+$_L
MQ/$-F.JTM*W6U38Y.,F:7D&Z@E(-)),R46.PR)2>GWD N*FPD.[A4AI+YFDM
MV:TDK%S[I88X[<-GO 40:E3JFAQVFS&)C;+BF'EQW$.I0ZC#,A1H,\%%B6*3
MV@)0"PJ="0[N%26DOYB1NC6DEYU%B2<,<<3+H(!? 19]3IM+:0]4YC$)EQ:6
MD.274,I4XL\$I(UF1&9F>!$ O.O,L));[B6D&9))2U$DLRCP(L3]IF BM5JC
M/NJCL5&,Z^@E&MI#S:EI)'WC,B5B6'M 2V7F9++<B.XEZ.\E+C3K:B4A:%%B
ME25%B1D9'B1D K          %J3_ "SW^!7ZC%J?>%:O:5$#^1B_PF_V2%M3
M\I^5=+\(^$@9M     !"9_W27_!8_6Z-:OPCYG[,:?\ I/Q'W31DV
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ME.7 @0Q=+THTWHLU-2I=L4^-4$-.QVI2&4FZVU(1NW4MK/$T9T_"K+AB6SH
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M9.1,D3$/SJ9)IWF*VF<B<J)!(Z%++)CLP/I!*]2]<+\NBZY4>W8-#BV7!HM
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MMG6^_-*8Q9+973X%W4"&G'=PE3EN1YS+>)GE;<?03Z&TX)2I2\"P/ @[2"
M       !:D_RSW^!7ZC%J?>%:O:5$#^1B_PF_P!DA;4_*?E72_"/A(&;0
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MQ-![4X8@/:Y9-I7+/@U6OT:)4JE3#STZ5):2X[&61YLS2CVH5]J=N&SH 9X
M                 197^?!_CJ_T71I1[5?'WAE7[T_/VE32E9Z;$/VI:0A1
M>Y2"RF7]!D)U8_G/RC1GC1'PF#)L
M            A03)4B>LONF^22/[4-(2?]HVU/:GX^\L=/\ *KY^T)HQ;
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M_"/F?LQC_I/Q'W31BV
M  0Y:O\ BX#9;5&ZM?\ X4LK(S_K40UHC^-7Q]X8US_*F+_M*TK?4UYQQ#:G
M:>\HW%I;+,MIQ7WC));5)4>T\-I'_9;TKCA[3'-7UTYF?>F>7^E]%2I[B<R)
M36'M(UD1E^DC/$A2=*N/I*\:M$_6%7/P?$M<1/6(VZK)3N4VP<_!\2UQ$]8;
M=5DFY3;!S\'Q+7$3UAMU62;E-L'/P?$M<1/6&W59)N4VP<_!\2UQ$]8;=5DF
MY3;!S\'Q+7$3UAMU62;E-L'/P?$M<1/6&W59)N4VP<_!\2UQ$]8;=5DFY3;!
MS\'Q+7$3UAMU62;E-L'/P?$M<1/6&W59)N4VP<_!\2UQ$]8;=5DFY3;!S\'Q
M+7$3UAMU62;E-L'/P?$M<1/6&W59)N4VP<_!\2UQ$]8;=5DFY3;!S\'Q+7$3
MUAMU62;E-L'/P?$M<1/6&W59)N4VP<_!\2UQ$]8;=5DFY3;!S\'Q+7$3UAMU
M62;E-L'/P?$M<1/6&W59)N4VP<_!\2UQ$]8;=5DFY3;!S\'Q+7$3UAMU62;E
M-L'/P?$M<1/6&W59)N4VP<_!\2UQ$]8;=5DFY3;!S\'Q+7$3UAMU62;E-L'/
MP?$M<1/6&W59)N4VP<_!\2UQ$]8;=5DFY3;!S\'Q+7$3UAMU62;E-L'/P?$M
M<1/6&W59)N4VP<_!\2UQ$]8;=5DFY3;!S\'Q+7$3UAMU62;E-L'/P?$M<1/6
M&W59)N4VP<_!\2UQ$]8;=5DFY3;".Y4>8Q9I>#[Q[#?Z6&_M-70K#\*?[!I&
MGP]:_3_+.=7-Z4>L\H2HL9$2.AA!FK+B:EJ^\I2CQ4H_M,SQ&==6:>+6BC+'
M!>%%P    !;D,-R6'([I8MN)-*L-A[?:1^PR]@M35-,\85JIBJ.$H3<Y<,B8
MJGP&G8F9A^Z<+V&9_P!Q7O(_Z!K.GF]:,/K_ +8QJ9?2O'Z3T2>?@F6)2FL/
MXB>L9[=5DM-RFV#GX/B6N(GK#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)
MZPVZK)-RFV#GX/B6N(GK#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)ZPVZ
MK)-RFV#GX/B6N(GK#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)ZPVZK)-R
MFV#GX/B6N(GK#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)ZPVZK)-RFV#G
MX/B6N(GK#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)ZPVZK)-RFV#GX/B6
MN(GK#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)ZPVZK)-RFV#GX/B6N(GK
M#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)ZPVZK)-RFV#GX/B6N(GK#;JL
MDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)ZPVZK)-RFV#GX/B6N(GK#;JLDW*;
M8.?@^):XB>L-NJR3<IM@Y^#XEKB)ZPVZK)-RFV#GX/B6N(GK#;JLDW*;8.?@
M^):XB>L-NJR3<IM@Y^#XEKB)ZPVZK)-RFV#GX/B6N(GK#;JLDW*;84KJ5/;3
MF7*:(O\ &GK$QI5S]))U:(^L(ZC<JBT))"FZ:A1+6IPC2IXTGBDB2>TD8[3,
M^GHZ!IZ:?_\ 7^/]LIXZG_\ /^?],D.=T@      B38SKAMR8ID4N.9Y"5L2
MM"OO(5[B/ MOL,B&M%41QB?:66I3,\)CWC^N"EJJQ%&2)"N5D?WF7\$*Q^PS
MV*+[4F8F=*KZ>L7(C6I]I])O7>?@^):XB>L4VZK)6W*;8.?@^):XB>L-NJR3
M<IM@Y^#XEKB)ZPVZK)-RFV#GX/B6N(GK#;JLDW*;8.?@^):XB>L-NJR3<IM@
MY^#XEKB)ZPVZK)-RFV#GX/B6N(GK#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#X
MEKB)ZPVZK)-RFV#GX/B6N(GK#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)
MZPVZK)-RFV#GX/B6N(GK#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)ZPVZ
MK)-RFV#GX/B6N(GK#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)ZPVZK)-R
MFV#GX/B6N(GK#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)ZPVZK)-RFV#G
MX/B6N(GK#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)ZPVZK)-RFV#GX/B6
MN(GK#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)ZPVZK)-RFV#GX/B6N(GK
M#;JLDW*;8.?@^):XB>L-NJR3<IM@Y^#XEKB)ZPVZK)-RFV#GX/B6N(GK#;JL
MDW*;8.?@^):XB>L-NJR3<IMA;=JL%OX4O$\Z?W66?WKA_H2G$6C2JGZ</E6=
M:B/KQ^/590B:6\J+C)*EF1(8B9B+(UF(U%FZ,ZND_9L(OM%YFGTIB?2V_HI$
M5>M<QZ_2+NK)#G=*A;++AYG&TJ/WJ21G_:)BJ85FF)]X4\K&[EOY2ZA.>JU&
M2FPY6-W+?REU!GJM,E-ARL;N6_E+J#/5:9*;#E8W<M_*74&>JTR4V'*QNY;^
M4NH,]5IDIL.5C=RW\I=09ZK3)38<K&[EOY2Z@SU6F2FPY6-W+?REU!GJM,E-
MARL;N6_E+J#/5:9*;#E8W<M_*74&>JTR4V'*QNY;^4NH,]5IDIL.5C=RW\I=
M09ZK3)38<K&[EOY2Z@SU6F2FPY6-W+?REU!GJM,E-ARL;N6_E+J#/5:9*;#E
M8W<M_*74&>JTR4V'*QNY;^4NH,]5IDIL.5C=RW\I=09ZK3)38<K&[EOY2Z@S
MU6F2FPY6-W+?REU!GJM,E-ARL;N6_E+J#/5:9*;#E8W<M_*74&>JTR4V'*QN
MY;^4NH,]5IDIL.5C=RW\I=09ZK3)38<K&[EOY2Z@SU6F2FPY6-W+?REU!GJM
M,E-ARL;N6_E+J#/5:9*;#E8W<M_*74&>JTR4V'*QNY;^4NH,]5IDIL.5C=RW
M\I=09ZK3)38<K&[EOY2Z@SU6F2FPY6-W*/E+J#--IDIL72(B+ MA"JX
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M6_E+J#/5:9*;%:&VVRP;22"]R2(OU")F96B(CV5"$@
M    Y4[J?6D?F,9T=*)%]/N6B=S*FF3G.<USZHF[(\^3=Y2QPR9L?: ZJ
M                                                   .6474NN5+
M7VZ-*GXL5- HE"@UB++03G-J?E.9%I69K-!HP/81((_M,!U,
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M4HC)LU9C3\6&&T!LH
M        -:CW]:DF^9FF[<_+>4* U5W::MMQ!J@O+-LG6UJ22%DE1$2LBCRX
MEB X]:O_ *R;_P#_ *0I/^N0#L--OZU*Q>5:L&F3^9NBWF(TJLQ6VW#1'1-(
MS:2MW+DSJ26;)FS8'C@ V4
M            >+42$*6K[J2,SP(SV%]A -+HM^6KJ5IW*NZS9Y5&ARXLQ#;V
M1;2TN,I6VM#C;A)6A25%]U22V8'T&0#FOY09T.F?E;LVI5%]$6GPXE3D2Y+R
MB0TTRU49:UK6H]A)2DC,S,!V&S+PH-_VQ3KPMAYR10:JVIZ"^ZRY'6MM*U-X
M[MU*5$1FD\,2VEM+8 SP
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M"]+W=,+,W-;D%4K]N!]=:O2LJP4N55I?QND2MF+;6.[;(B(L"-6!&HP'3@
M                                                 ?+UU-E^7O5"
MI58G$P]&M6S?:JJEF:8U&NU3*LD@\",DM3229+/\98F:4I21AR'2*9.U:TBT
MR_+9;<A;5+<C2JUJG4XRL%1:*FJ2'&(!.)^Z],,RQ3]Y*,#,E(-1 /O:GT^%
M28$6ETR.B)3H++<:'%922&FF&4DA"$)+824I(B(@$D
M                         'S\_P#E/LA_\P;>N9K2324\\Y;VY+=*KZ5?
M#.SXX88?O#1DQWQ;S-TD ^@0
M                 !\_VM^4ZQK6UWJNM419+;E)5)I=O[DB8A5.3B4F2A68
M\<2-1MHRX(4M6'0C /H
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ML'OZ=$44Q$/G=2N:ZIJGZHXT9
M
M
MD,2W&8TJ,1_NI*4DI/LS(6E1'_41D,ZJ(F8FQK37,4S%O5'&C(
M
M
M
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MI)))(0R9K9VE@L\/[P5:]<:D4\.!3H43I37QXS#MP]!P
M
M
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ME+VC;6G_ />GXZL-&/\ _-5\]'TX/3>6"0
M
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M1>XBV$-&;T2@
M                      $FH0W($UZ(X6!M*,DF?M3TI/\ I(9:=<5TQ,-=
M6B:*IIGZ(PU9
M
M                                               DQX;C\:7*(OW4
M5*3-7LS+6E)%_49F,JJXBJ(M:TT3-,S9U;E=I44VVRG&M,W#]RI@B4X2?^\1
MF1&G'WG^CVCR?T]SC_'VO>Q^[M<(S>]S15D@E&3:C4CV&HLI_P!1&?ZQ[4<?
MJ\.>'T>"4
M
M                                         +L<HIK+FUN(;]NZ0E:C
M^922(4JS</1>G+Q_EQ;XCT_Z;<W>/E>!;W+CO=YB6&;_ +^;#[/Z!XL[N]Z_
/E_7)[L;.Q/#\>?\ Y?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>fc_fig44glase-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_fig44glase-4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$$!&AT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-RXR+6,P,# @-SDN9&5E,V$W-S S+" R,#(R+S X+S$X+3$V.C4P
M.C,P(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.GAM
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240](G5U:60Z-C5%-C,Y,#8X-D-&,3%$0D$V13)$.#@W0T5!
M0T(T,#<B('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z-4%",#5!-C%!.#9$
M,3%%14(U,41",S$U,D%!13!$.#$B('AM<$U-.DEN<W1A;F-E240](GAM<"YI
M:60Z-4%",#5!-C!!.#9$,3%%14(U,41",S$U,D%!13!$.#$B('AM<#I#<F5A
M=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@,C8N-2 H36%C:6YT;W-H*2(^
M(#QX;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED
M.C@Q-C4T,6,P+6,V-&,M-&0Y82TX9C,Y+3@S-6$R,#1D8S5D9B(@<W12968Z
M9&]C=6UE;G1)1#TB>&UP+F1I9#HX,38U-#%C,"UC-C1C+31D.6$M.&8S.2TX
M,S5A,C T9&,U9&8B+SX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY&:6=U<F4@,SD\+W)D9CIL:3X@/"]R9&8Z
M06QT/B \+V1C.G1I=&QE/B \+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&
M/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H
M;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4
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M$0,A,1($05%A$R(R% 5Q@9&AL<'10E(C,P;PX7*"%6+QDJ+"-++20R06_]H
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M=<<5UPH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH%!;EK_\,A?]0U_Z KY?;\\_C+Z[3_CK^$/752TH% H% H% H%!6F7?^/2?H
M;_\ 5IKZ#L_\4/FN^_S3^7[&#K:PE H% H% H% H% H% H% H% H% H% H%
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M8EZB3)M_2^NSMQ'D21(1$;\UY:5-%20E">]1 [NVKO=I,Q&>:B=5XB9F.3.
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M#_='_P#F5%,_*.5_\"N'^Z/_ /,H'Y1RO_@5P_W1_P#YE _*.5_\"N'^Z/\
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M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H.>[ZO\
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M=>69=P\+?,=M*P'K9(0CO4A:%G]!V_Y:JC[I3QB3$I78\TQ[(%!J#*"91_\
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MOJV^,Z_+J5]M.OV=?B'U_3ZG9=W.N>FWR_L5S"\P01J.H-?3HE H% H% H%
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M['5P0+-\ES'G?,KMPUQ=.<LN"V-?RO(V<, EQQ9U2NVP2--5'12%D'Q:'4A
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M,O!E6*8CD7+F#\ <=66):L1P62UF&=.06PD(<C@?*1G7B"XMU7F>+>LD^;_
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M4'G+&W-,^="[.PYJ?PW'D*"8[+6OPAU*4G7O;2D_:5K5KKF)M*W9;&*PZ?2
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M4"HZ9F;)[HB*PV=!(U'<1HH=H(/:".\5L8WAN5GMMWCIC3V M"/[):/ MO\
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MKTV5=ZK./.,X<1SE7(4721D4XQ+$UC-LEF+'R"7NUBLR@E)<VMA&Y9:4%%*
M!HO:JJMU(CBNT7F>"3<-Y[G]KS:1P?RO:;3:+[#LT>\XN+ V6((MP 0N&E&I
M3K'ZI!3^XO4JZ*/=5YB<2YMI$QU0QGJ"ND'">8^%.2\B7\MAUIDW>WW6XEM;
MJ(SDR. VI8;2H]05*3H-?"=*;9Q:)-4=59A3EG]0^+YKS\GE;,K1<SQMBY;L
MN(S4,!R#:7IY6E,ZX=P<=VK6D).J>FF[RQK3UYMF>2[V\4Q'-?GK%FKA^G?*
MDM*!,QVVQ@H'4*2N:TL[3WZA-:-T_"S:(^-=%GBFW6:VP$]!%A1H^G_5,H1_
MFJZL8A3:<R]=21*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#F@JSEC@O&N3G&<
MABR'<9Y*MI2Y9LTMFK<QIQH>!+^PH+S8[.I"TCX5::@T7U1/&.:^FV:\)Y*<
MS7D2\0L0O/#?JMLRX;%VCN1K/R7:HZI5HE2&M%1I#B&D:MNH<"5JV)U[E-I[
M31:TXZ;-%:QGJJS?IF]2N*99C&*\?97/=A\@,QS;8\F:WY<.XF*LML)9D:Z*
M>+7E@I6$E2NS51J>K;'*5>W5/.%N<XXO(S+A[-L:BC6;*M;SL5O0ZJ?AD2D(
MZ==5*:V_75VV,U4ZIQ:%$0L1N>=<8X'ZB.&=D'F.QVMF/<HK&GDWQJVI^4E0
MY+:= IU0:\&O5:2$ZZ[%)S17->J&KJQ::VY+&N%YQSU1^GW(F+ V6[G,A.-/
MV=T!4FWWV"!(;86#H>KC8"%Z#<A7<=0+9M[E?55$3KOZ,UPGD5NY=X*L#^11
MV[BU-MRK'D4&0"I+KT+^ZO!P'KJM*4N>T%6HJ6O%JXE'9FE^"B.1,*Y-XIP3
M*^';98KER%P_DS"DX=*@H5*N=BGJ?0\W&D(0E1+(<2#KM /Q)*5%2:SVK:O#
MP:*VK;XO%M;@D.[6[!<6M]_3Y=]AV>WQ[HWKNVRF8S:'$DCM(4-#6RD8K#%>
M<VE(=Z]NS<=G;MUZ?HJ>$38O;OVG9V;M.FOTTR.6T[UI03H%$ GZ:20U2QCU
M1YFBYC+\^L,.)PA>;U*QVWWN!O5*M$J*H);5.U40M#@.JCH/M%/P[#CKNG/'
MDV6T1CAS;2R9+<6*]-)2MIEI3X4DA25!*=R2".A!Z:&K]NR*4FWE&66*YG"E
M5.N/K7(>.YYY1<<4>TJ6=37YI:TVF9GG+VHC$.*BD4"@4$RXQNB[?E+,;<0Q
M<$*8<3W;@"M!^G4:?77I_;MG3MQYH67M7U"!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!00G-L#@7]*[FPZB#=&T^-]?A9<2.SS/9I^]_EKS>[[.NWXHX
M2[$J2EL*A27(KJVW%MG0K86EUL^]*DD@U\U:G3.$\NG<GVU##N62MUAO-U4G
MY*(ORE?_ %AT>6R![=RNWZJV:.RW;?EK.//E"J^VM><K#Q[&(EA072KYBY.)
MVNR2- E)[4MCN'M/::^P['[=7MXS/&WG_!YVW=-_P4_ZM(DR%@^-\B6YM;DO
MC_)+=?'O*&Y0B%?ENG3V;O*U_P"2MNZ,8EW1.9F/-A<EO]D]0G.V%8OB4MJ\
M\<X"$YAD=RCGS8CTYX P8V[X2H>$*3_$X/LFJYGKM$)Q'169\VR,Z$W=H<NV
M23]U<&7HKQ_ADH4VK]2JU6C@RUG$M9O3_P C1>//2_>;I?G4F5QK,N]L?C+\
M*E2TOER*P1J""XZ^EL?LK+2^*2U;*9OP\4\],&&S<1XBMLN])/YFRQY[)[TM
M8T<+UR(4T%]^H9""0>PJ-6Z:XC*O=;-F#E;\?]9MN>W:1LRPIV/I^](M[RE_
MI"(X_34.6Q+GK_!Y\['^)'J?P;!&QYMBXWAN9??TZ H^?>V?)MJU^TDAA0]R
MU?4M\5\>3M?AUS/FRWJ^MCURX R62P=)5I?M]T:5W@L2VT*/U)<54M\?"AHG
MXD[R[D2/B_$D_E!Q2=(]B;NL4="E<J5'08R.O[SSB$U*;_!E&M/CPCGIAP]_
M">'<<1< K\=OQ5D=Y<7IO7)N9#J=WO#(:!]^M<U5^%+=;-OP1;TMH79G>6L(
M41Y>/YK.5'3V:,3!X/\ U.M1TSQF$MT9B)]'QE2?\2?53BV)*'FX]Q9;5Y+=
M$'38;O-V?+)5[2G5A8^A5<M\5\>3M?AUY\W=RWYEB]1_!V5-D!%S5=<<F$]J
MDOMCRP?ZT@GZJ;.%XES7QI,+&YDRFVX1Q;E.576-&F-6V$IR+$FM-OL.3W"&
MH@4VZE23]\M![*MVS'2KU1,VA3UFXA3:/1Q?L8F,C\Q7^R2<JO"G -Z[FI"9
M[05H.UM#33?N(-413^VNG9_<9:3CERYY](5HLT):/S#<[%;UPUN*V(<GVAQ*
M=JE*Z)\TL*1J>@*M3TJ6.K7P1ST;.*\<<%W&.69.0MMM9 F!$3=FF5;VD34L
MH#R4*^TD+!T/?6BN<<6>V,\&2J2)0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M"!\G\M8_Q'&M5TRNWW-W'KB^J-)O-NCB5&MZP$[52@%!:4KU\.Q*B=#TUZ57
M?9TK::^KDF$"=9<DM$:?#=C7G';FVB0PXG9)B26%>)*@% I4.G>.A]]=X7A'
MC66J?'W%F+9<>8/3QF#?DOX[D3F08K<6D!$R%'NZ 69$<C35*0AK>C7105IT
MZ:9*TB9F&RUYB(M"R.$N3<FCY#,X/Y<6!REC: Y;;HHGRL@M* 2W):4K3>ZE
M U7]I2=2?&ES2W7>?EE5LI&.JK%^GI"L#Y"Y5X262B%:+FC)L:0=#_W;=@DJ
M2DCN1JR/IUKFKA::FWC6+._D+C7-\&SY?./!<=$J\S-!G.#*4&H][82=Q?9'
M0"3W].I5XDZDK0OFS7,3F'=>R)C%GJ]+&.91CV'Y2[D=DE8W#O>33[O8;#<.
MDN+!D! "7!M21U3H-4C73=IH:GIB<2COF)F%Z!2DG5)(/M'2M#,BV4\E<?X1
M<;9:,OR.%9;E>3I;8\QPH+@"@C<H@$-HW';O<*4ZZ]>AJ%MD5G$K*TFT9A*2
M"DE*AH1VBIH-.KQ;>4\RY>Y?RG!<HGQ\ZXUEV].,XSOW6V;:U-.*=B+CZ@*+
MH;W)[E+/70J"DX)ZIF9\F^.F(B/-LGQ'R99^5L+M>:VE/RZG5>1=;<HZKA7!
MC3SXZM>N@)W()^)!!K52W75DO3HLIC@7%;1>\=YJX.RI@2;+ RJ<P\TGHL1+
MAXF'$$CPK0J.'4*TZ*TJC7$3FJ_9,Q,6>OAK)[Y8K?EGIWSN07<TP>*M5@GK
M/2Z8Z=%,.-Z_$64%(T[D$#M0JLG<S/L7KZ2GTQ-HM#.)^$?17PC>YHZ4"@4&
M<PQ*UY79PCM$E"C]">I_4*U]I_EK^*-FQE?8*R@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4&&R;)(.,6Y4Z9XW%'9&CI.BW7-.P>P#O/=6??OKIKF11%_R
M>\9(^7;B^?(UU:B-DI90/<GO/O/6OEM_<WVSQG@LBK#Z"LR3@@'M%'&8LV2W
M.R.)#:S)@:_>0G5$IT_@)^$_1TKT.T[_ &Z)X3FOE_#R4;-,6A:%OGQ;I#:G
MPE[X[HZ:]%)4.U*AW$5]UV^^NZD7KREY=JS6<2[9,:--C/0IK#<J%);4S)C/
MH2ZRZTX-JT+0H$*2H'0@BKYC*,3AAL4PG$,$M[MJPRR0[%;WW2^^Q";#8<=(
MTW+5U4H@=!N/0=!TJ-:17DE:\VYL]V5)!2.1>EOCS)L\DYG<)=R3;+E,:NU\
MQ!I\)LT^Y,!02^\WIKUW**TCM).A )%9YT1,Y:8WS$87<3J?9[AT ]P%:&=4
M7-W&>4Y?)Q/...9<.%R1@TQR7:3<=PB2HTA(2_&=4CJ K;TUZ$%2=1KJ*-M)
MGC"_5>(X3R>GA3BVZX!%OV1YG<&;QR9F<S\2R>Y1P1'04Z^5%8*@D^6WN)^$
M#4Z :)%=U:\<9YN;=G5PCDFF=8LQG&%9#ALE:6V[[;Y,!+RM=K;KS9#3AT[D
M+VJ^JIWKF,*Z6Z9RU2LMIY5Y9L&"^GO+,3N6/X_A3[1Y$OTU)1%G0K4HIA1X
MKA&CGF-Z?"5:JT7\*2:QQ%K8JV3-:YM'BW-T0-$MH#;:0$H;2-$I2!H$@#L
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MMR7,;+:YS$1JWM1K9:I/E^2RI:P5K=D%:U:K/4]@T K+;5:TYEKKNK6,0G_
MO#F?<*P58O*S"!D6$+==E)@*@/1Y<9]U/4QW?.4D(6H!2T+21WIT).L]=+55
M[-E;>'%=E:&='L^Q^7EN"Y-BD!UIB=?+7+ML=^1N\EMR4TIM*E[ 5;03J=!4
M;QF,)TG$Q*E<*].&;<,Q KASD+[V0E"KS8LHA_,V:9*2G0O($9278YZ:#9JK
M;H%+.E9XU6KREHG=6W.&0S#B?FKE^$UC')^5V.PX(76WKG:L.CRURIX95N2A
MQ^<0$)"O$  I.H!*5$#3LTO;FY6]*\HXK7M^+HP[#8F*<<1H-K9M;2&+4Q.2
M\]$2D+W.*=\I27%K7JI2E[M2LZFKNGIC$*9MU3F6KO(7HKS'DW,KKG.2<A6]
M-XN[B7'VHUI>0PVEMM+3;;8,C7:A"$I!/4Z:GK6:=-IG+37?6(Q$++Q/B;U!
MX9C5NQ.S<M6HVBTLB+ $G'6WW6V$:[$>8MW4A Z)W=W2I1KO'BC.RD\X1"_^
ME/DS.LOLV4\C<L#(6K3+9DHMYMRV&$M-NI<6VPTV\&FRL)V[@CZ=:Y[-IGC+
ML;JQ&(AM8XOS%J6>FXDZ?2:UQ&&27S1QS0=<>1'E,MRH;S<B,YU:?86EQM0!
MT)2M!(.A&G0UR)B79C#6_D+YOTY<HN<WVF.Y(XLS!UJ)R/:HVA7$N*E?<W%I
M&H!*E$D^U16D_P!HG3)>)I.8Y2V4F+QB><.WT=W"/=<>Y'N-F*UXG,S2X2K"
MZZGRU*8?0A?5!)*3L\LD>^IZ)Y^2&^.7GADO5G;L&>X_@7+)K1)NF4BXLVS"
M_P +D"#<?Q*?J/+1(*5Z-*2DJ<24*U(&FA\0;XC'J:)G./!GO3?DV-W;CIO%
M;'97L8N.$2'+%?L9EN_,2(<Y"UK6I3I"2L/*WJW;1XMR=-!4M-HF,([JS$Y=
M?J#S;+\>@XAAW'\Q%LS'/[VU8XEW<0ET0HW3SWTH4% J&]'73H-VGBTKFZTQ
MP@TTB<S/@[.!.0LDRF%DN$\@.-N\DX#<56J]R&DI:3-CJ*OEI@0G0#S A0.B
M0#T5]JNZKS/"3;2(XQRE%_4I'1FF7\3<,2I#[=AR^[29F1,Q5EIQZ#;&TJ""
MH=WB<4.[< >X5#=F9B$]&(B9E[/3;=[S8I&9\%Y3,<FW?CJ<$6:7(U+TBP3=
M5Q5$GM".G]%+B4]@%=TSB>F4=T9Q:'GY5B1\J]2_#>(W1IN78[?"O%^E07T)
M=9=6&UH0'$*!"AJPGH??4=GQ7B$M<]-)F'SZ=DN<?YIR1P'(<68&.3DW_$DN
M'<?P:ZZ**$GV(*FB?XE*KNJ<6FKFWC6+/1?G!.]9F%QAXC8<-G3TCM"')3LA
MG7ZPH4M&=CM9QKEXN''6N,.7.6>)#]W92I.<XM'U\"8LM*?F&T!7<E2FT=/W
M#54W]J+3Y1,NWCKB)_)F2XX\I;[QW//*+CBCVE2SJ?\ +7Y]:TVF9GG+T8C$
M%12*!0*"8\97-=ORIF/NT8N"%,.)[MP&]!^G4:?77I_;]G3MQYH67O7U"!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0* 0"-#U![105UE?&EE?2]=(,INSJ
M&JWO-(3$^DZD;/JZ>ZO)[C[?2W&OPS^I.E;6G%8S,J3O=VL%C?\ EW+W G'L
M\RWNF4C^9 KQK]K:L^$_@]W5]B^X;(S&J?S^']N'%GNUBO4E$5B]P(KKGPB8
MZ6">[H% :U+5V=[SC,5]95]Q]F[_ $5ZK:;3'_Q^+]BU[%A]MM2FYKRQ/FZ!
M33R@/)1KU!;3UU]RC7U79_:M>J8M,]5OU?E_%\IMWVMF.22=O4]M>TRHWGF"
M8UR5BL_#<MBF59IX25>60A]EULZMO,K(.QQ![#IIIJ"""14+TBT8E.EYK.81
MSBCAC'.)6KH_;I\^^Y%?%MJN^0WET/SGFXX*66MP'1"!W=23VGHD"--?2G?9
M-EC5:I8"9@N%7')HF:3\>M\G+H*4IB7MV.A<QL(&B"'"-=4CX%'JGN(J$TB9
MRLB\XPD%35@)204G0CL([:.NB;/A0&OFKG,9B,*6&P_+>0R@N*^%(4XI(*CI
MT&NM<F8AV(F7>I)22E0T([0:ZXBG)N8'C[CS)LV0RF2_8[>[*C1W-=CDCHVR
ME>FAVEQ2=VG=4-ENF,IZZ]5L-?;)R1S5Q-%P_.N8;TSE7%^=(C.766S%1'D8
MW+N2 \SKY21N8"2-WV>B@G16W?EB]JXF>4M,TK;,1SAM8E2%I2XVM+C2P%MN
M((4A2%#5*DD=""#J#6V)RQS&% \8+(]57.2U%7S"(E@#"CV!KY5O<!KW:Z5E
MKQO+3;_'#$VY#7IVYU_!4)$7A[EQ\NVY.H3&M63)T"FQW(;>U2E(Z>%2>YHU
MR/[=O24I_N4]89?UG)6WP+=)0&BX-TM4C0G0ZID[/_RJEO\ E0[?YE\J^7N$
M4!]M$F',8 >9<&]IUI]O125 ]J5)40=>ZK^<*.4M;.-+JCT\\C3N#,KD_+\?
M9$^[=^+[U+6 PWYR]7[<XXKHE06=!N(\?7_6IK-2>BV)Y-5X]RN8YMF""#H>
MT5K8W% H% H% H% H% H% H% H% H% H% H% H%!])44*"D]H.HHZUSXM85Q
M!SMDW"K:W!A&4Q#EN$,NJ*TQG@2)D5LDGIX7#I[&P>T]<M/@OAJO\=.IZ?54
MVJ],\6X,=##R;-+>U.;(U"X\;XDD=X^]UTKN[C,0YIX1,^CSXW"B<1>J6[XC
M;FFX.%\JVS\8M,%D):CL7FV[O.;:0  G<E+JM$_OI'<-(U^"^$K3UTSY/9Z@
M4(N')W 5C= 6R_E+L];:AJ"8*6% D>[6N[OFA'3\MG1(2GC?U;1I*-&,?YAL
MZF9 T*6_QVU=4GITW*2E/TET^VN?)=WY]?K#LY=+EP]27 EF3U:C.7JYK'L+
M3"5)/U>37=G&\0YKX4F7SE /'OJNQ/)TZMV3E&U.XY=%="@W6!M,91[-"H)8
M0/KI;X;Y=K\6O'D[\T2)7J[XLCD:_A^.7B;I["ZF0WK^JEO\D.5_Q2\W(RAQ
MYZE^.N0@0S9<YBO87?G-VU'S((5#6O7IJ5*: ]R#2_PWB7:?%28\G=<W/G_6
ME8XR 3^"8+(>>_A5(DNH_P CB?TTGCLARO#7/XNCF5:>.^<^+N8#HS9;JIW"
M<H?T*4):EZJBN.*'L*U*U/<U39\-HEW7\5)AZ+*T)_K.RZ2KQ&Q87#A*_@<E
M/,.Z?3HHTK.=A:,:X_%Y/4/:IN/\@\:<LVO5+:):\-R)0&H,&\[DL%>@Z)"U
MNC4] HIK+]PK/M6F/*4NWG/!F--O3V=*^!>C!1TH% H,YAB%KRRSI1VB2A1^
MA/4_J%:^TC^[7\4;-C*^P5E H% H% H% H% H% H% H% H% H% H% H% H(I
MR!GMIX^L:KM<OOI+A+<""@@./O::Z#MT2.U:N[Z2 :MNR*1F7J_;/MNSOMO1
M3A'C/E'_ #E#3O,^0<GSJ:J3>YBC%"BJ/;VB4161W!*->I_B5JKWUY&S;:\\
M7[%V'VO1V=<:Z\?&WC/Y_NY(M53U7"DI6DI6 I)[01J*$3,<DKPSD+(L(D($
M)Y4RRZ_?V=]9+12>TLDZ^4KV:>'VBM>CNKZIX<O)X'W?[%VWW&L]<=.SPV1'
M'_R_JC]?E+:+'<AM>4VB/>[.[YL*0#T4-KC;B>BFW$_94D]"*^HU;:[*]4/P
MCO\ L=W9;K:=L8M7]$QX3'G$LI5K 4"@Y U_Y3T'UFCJI,3]2O$.:9@,)LMV
M>%T?=<CVN7+CJCP+@\R=JD1'U'1:B?A"@G=]G4D T1NB9PNMIM$96W5ZAK+R
M9BUGY?\ 4]9>-<R8>FX58L0DWI5N;?<80J;+>4QYVK920I.YO:?:D=U9+QU7
MPV4MT4RRG#E\OW%V>R_3CG-P<N45+"KGQGD$HGS9EL&Y2X2U=A<9"5%([MBT
MCP[!7==IK/3+FRL6CJA+_4TR7^ ,_0-=1;4N=/\ 9R65?YJLW_*KT?.S=CQV
MR9YPI8L8O[/S%AOV,VZ-+0""H(<AM%*T'N6VH!:#W* I%>JF')MB\SZH!Z<<
MHO%G_&^ LZD>9FW'JO+MLA9(-QQY1!C/M[NU+25H3[D*0.T&H:K8^&5FZN?B
MAQA/W?JYY80G3:[C]E=7[=R41DC]1KE?\DD_XH6/RQQO:N6<$N>%71?RZY(3
M(M=P U5#N+&I8?&G70$E*P.U"E"KME.J%6N_3.6I?*W*689-Q*YP)G^/7-OF
M&+,BLW:4TSYL2;:K63(7<D/=$G5#8*S\)ZKU )2,=KS,=,ME:1$]4++QSU09
M3;[?8<NY'P+\O\.9*KY>PY3;GES50FT+4RU\^T"HZ*V:Z@(.G5*5=E65W3'/
MDKMIB>4\5ZYE@V#<J8XW9\MM\:_X])")D%Y*ST\Q'@D1I#*@I.Y*NBD*T4GM
MU%:+5K>&:MK4EG[; C6FVPK3""A"M\=J'&#BBXL,QT!M 4M6I40E(U4>IJ<1
MB,(3.9R]-=<*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#7SU2MO8K_A]S;!
M;W2, OS*;H4@[E6BYD-/))3W:IV?_.5FW1B8EJTSG-7;SC(C7'F3T]VZ(X'V
MI%ZFW5I2#JE;##4=Q*QIW%/4&H[)S,.ZN$6?7JM@3[9B^,<MV5M3EYXUOD:[
M+" "I5ND.(:DHZ]Q4&M?=K4M\<I1T3SCS>3/IT/+O4KP,JTO!^THM=VR1AQ/
M8J-*C%;*_K\I-1F>JT)1'3266]5..W.7QW#SW'4DY/QO<X^3P"C7>8["@)*>
MFO0)"7%>Y!J>Z.&4=%N.)\4<A979N4?5'Q[D6+O)F6BV8/)O;ZFU)7\LJZEU
M"67=I.UQ)=0E2#U!JN)ZKQ,)S'328GS3CU(X%=LZXU=>Q=M2\VQ28QDF-AI.
MKRI4 [EMMZ:'<MO4I2.U:4BK=U<QF%6FV)X\E;\/9B>=?4%)Y8A0I$2Q8UB,
M>RO(?:+:6KU-<\R0PDGXMA4\/Z(!Z:U5KGJME=LCHKCS6_SEQHOE?CBXXO">
M3$R!EQJYX[-6=B6;G#)4UJH E*5@J;4K3P[M>ZK]M.J%&J_3*#<&XMRE<>0\
MJY?Y>L[=@R&XVV#CEOMB'&W5+;AI;^9D_=J4$I=<:"DC7KN5IX0":M59SF5N
MVU<1$+2Y,X]L?*F$77!L@*FX-Q0DM2F@"[&E,G>R^@'34H5VC7Q))3WU?>G5
M&%%+],Y1/A?AZZ<;2,BR/+LD5EV>Y0N,BY7M;99 B6]OR8[20HDD[0"M1]B1
MW:F&O7,<9YI[-D6X1R63>K':,EM4FQ7^(B=9YH2F5%<UVJ"%I<00000I*TI6
MD@Z@@&K+UBT8E56TQ.85-<(3]MGR;?)U+K"R-Q^TD]4J^L=:_-M^F=.R:3X?
M\A[-+=49>>J%A0*!06#Q-95R[P[>W$_W: @MM*/87W1H=/H23K](KV?MNG-^
MOPA7:5SU]$B4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@TDY@S%[,<VGOI
M<*K7;UJ@VYO7PAIE1"ECWN*U5KVZ:#NKQ=]^JS]M^Q=A':]K6,?%;XK?C/A^
M4<$"JA[Y0*!065PCD[EERP6)YS2V7X%&P]B9K2=S:A[U)24'^K7I_;]W1LZ?
M"7Q'^X?;H[CL_>B/CT\?_"><?E/']+9>OI7XBJ?FKE')L&DXEB6 VJ)>.0<V
MF.Q+/'N+BFX;+,5"5//.[%()TWI \0 ZD]FAHV[)KPA?JUQ;F^^'^7I6?2KY
MAV86@8SRGBBPC(+ %%;2V5$!$N*I1)4RK5.OB5IN2=Q2I)IKV9X3S-FOIXQR
M33/GGH^ 9;(CDB0U9+FMHI.AWIAND:'N-6;/EE#7\T*$P+B&R<I^DC#,8T;A
M7MJ"]<L<O*1L=@W=4MYP.!:/$$N*&UWW=?B2DC-6G51IM?IOZ+&X!Y,N'(V&
M.QLH;,3D7%)*K'F,%8VN)F1]4I?*>[S@DDZ=-X6!TTJW5?,8E3MIB<QRE%)S
M?RGK6M3W=<L"=1VD^)J4Z3]'1NH3PV)QQU_FDOJ$XWNF=8A&O>(%3/)>%2!?
M<1DM?VRGV"%NQ1[?."!M2>A6E([":GNIF,PCIOB<3RE%LNY1LG+'I0S+,H.Q
MB2NRO1+W;?M0;JDMI<84D]0-Y"FB>U!![=:KM>+465US6ZTN(426^),!;E_^
MTIQVU!WZ?E&_\U:-?RPS[/FE%.9.)KUE=PLW(_&\]JR\O8IJ+3-?Z19\,ZE<
M&5_ K<K83T\2DGHK<FO9KSQCFLU[,<)Y(18Y&0<.?X@>H7G6,RQE&5NV^U6[
M&;"L3"EMA'ELQVE;BG>Z4!7QG:E!).X[:JB9K\5N:R<6Q6O)8W&'.F(\G7";
MCC46=C>=6P%5QQ.^M?+7!"$]JVP>CB0.JM-%)[2G30U=3;%N"J^J:\?!85ZM
MOX]8KI8%KVMW6%*M^X]=!+94U^CQ:U.]<PKK.)4?Z7/P_,/3M#P_)X+4Z-:G
M[EC-[MSXWM.)9D*="%#M&B7DZ'M!&HT-4ZHBU<2OVS-;YA'\7O-P]+^91N,L
MRFNRN#\B>6K!,IEDJ_")2SN5;Y:^Q*-3T5T'^L&B2X$0K,ZYQ/)*T1LC,<VS
MI&G^4$=00>H((K9$LCBCA0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"#8_P H
MVF^<DY3Q8["D6[),::8FM*D$%JX0)"$$R(^@! 0IQ*5 ^T$'M JKLS;"VVO%
M8EG<TQBT9KB-\Q*_D(L]XA/19;RB!Y*5)W![4D %I0#@U/V:E>(F$:3,3P:<
M^F>^3>0^8L>A9%>X-P1Q)8I]LQ>0P'@N\,J>=BIE-><E.J6F5 $]%;4IZ?$1
MCU<;-NWA7ES;KW:TVZ_VJ=8KQ&3,M-TCNPIT1?PNL2$E"T].O4'H1V&MUHS&
M&&LXG+7+@S .,\+Y5NMMA<EG-<TQZW.V.QV*0G8Y:+4EXNO,I7N4V\XVI2DK
M\K38"K5(UZ9-<5BW-JV6M->39=:&W6UM.H2XRXE2'&UI"D+0L:*2I)U!!!T(
M-;)C+)$X5]@/'7$'&-\NUKP.);[3DUW2)EQMR)?G3_E@=R0AEUQ;C; )W!*4
MA/Z!5-:UK/#FMM:]HX\EA]G4=H[*N4B&=J%*;:"$*4IQ90D)!6H^)1T U)[S
M7.$.N*ZXYT/4]P[:#B@4"@C^48TF^LI?C%+=U83HTM71+B.WRUGN_A/=7C_<
M?M\=Q'57YX_7Z-.G;T3QY*R?8?B/JBS&E1Y*.BVG!H1_RCWBOB;Z[4MTVC$O
M4BT3'!\56D4&=QK$[KE$D-PT%N$DCYB:L'RT#OT_>5_"/U5L[?M;[9X<O-"9
M7Y9K1"L5N9MD!&UAD::GXEJ/:I1[R37U6K5776*P@]]6A0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0>*\/N1;1<)3)T=9C/.-GV*0V2/UBHVY+]%8MLK$\I
MF/VOSU)).IZD]IKP']".*.E H%!]-7"X6AYJ[VA =NUO6F5 :4%*#DAD[FT$
M)ZD+(VZ#KUJS7.+1/JR=[KC9VVVL\II?_P#IEM=Q;R+:.5L%M.;V?[M$Y!;G
MPB=5Q)[.B9$=78? KJDD#<@I5WU]C2_5#^:+4Z>"K>4M&_5/P2ZX?NEQ[ZVC
MIK]Y\LL=G]8=:HO\\+Z?XY=GJ+QRZXS+LGJ(PEC?E>"$)R&(WT_$<<<)2^V[
MIV^2%*ZGL0HJ^PFN[:XGJ@U6S'3*T9]\LN:\6W+(K$^)-AON/S9,)[H26GX;
MOA6 >BT'5*T]R@14[6ZJ95UKTWPA?I3>\_T\8*L]J8TMK_Z.=(333\KN[YY1
M7EZ#<^&.2(GJ)QF&[,Q>XMMVCE.T14ZJ5$U2EFXH3WK1HD*/[R4Z]'%FJKQT
M6ZH6:YZZ],NBPY9C_)WJRMN08+<6;UC>.X2XB;=(VI9#TU]>QHE0!"]'4ZH(
MU!W#M!I$]5XF'9KT:YB6R8)!U'0CJ#6MC45FOI5P3,,EN%_CW:[8[!R%QM[,
M,?M#P9M]W6RX'DJ=1]A16-RB 1N\0"5$DY[:<SP::[YB$[SCE7C#B&-:HF9W
MEBPL2TICVF$AIZ0OR(X2V"&V$.*2T@:)WJ&G=VU.;UIP5Q2U^*66:\VC(K5$
MOM@G,7.S3T>;#GQ5AUEU'9JE0[P>B@>H/0C6K*VB8X(368G$J1]84>0GAYG(
M&&U.C&+_ &F\O!(U(:;=4R3I_2=35&_DOT8ZDBYHXHC\L6RWYIA<T6;E&SI;
MN>'90R0TM6Y(>;C2%Z'<RX%>'=KL)[TE25<MKB8S!39,3B7JX2Y?1R9:I5NO
MD7\$Y/QE?RF7XXZ/+<9D-G89#2"=2RXH=VNQ7A[-JE2U[.KA/-';KZ>,<D-X
M11^5.<.;^/ WY4)V?#RNVH2? $7)!4]H.[JZV/JJ&OA>83V<:1*Z<PPRP9SC
MDW%LNMJ;A8+BD)?8=!20H=4.-K'5#B#U0M/45?:L6X*:VFLY03B3C#->+Y,R
MRR\Z>RGCIM@-8[:;E' N%O4%@I3\R"=[:4:HV_#V;4HTJO72:SSX)[+Q:.7%
M:=7J"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4% <F!6-^J'AS*FT ,Y%#N>+
MSG!T*MJ5+9"O;XY T^BLM^%XEJU\:3#->JC*9F,\+WF+:E$7O*7H^-6T)5M4
M5W)9#H&G7JREQ/3VU/=.*HZ(S9!<_P 0MO#V:^G&=: (S5FEG"KB\CPH>;GM
MI2HK]N]UV0YU[U&J9KTS&%U;=46RNGF3-5<<<799F+:PB;;(+B;>HD)TG22(
M\<C7V..)5]5:-EL59M=<VB&L-TX^C<*X%P'R1'CI;R>VWV*YED\>&3(;R5'G
M/H>6>JPVA/DC=V:GVFLO3TQ$M<6ZIF&XN2WN%B=CO.27'3\/L<23<)()"0IN
M(VIPIU/[VW:/IK9:V*Y8JUS.&BS^,W'&N),9]5MP=</)TW+F<DNEQ*EJ/X+/
M=7&3%VZ[0V0D'L^%S;V::8<8CJ;\YMT^C?GS(ZOOTN)$-2?-#Q(VADC?NU]F
MWK7H9X//QQ:'W^7FV7XQE'J]MUXFQI^.9"PUAEI;>*8B<<A/B,\E3>FB@X74
M[^X[7-0=U>?.9^)OC$? WGMD^/>;= NT$?W2YQV)D8?[.4VEU _0JM]9S&6"
MT8G#47D7.>6,ONO)G(O'>42++A_#K[$*V6N-XXEXF1W1^(KD@$!Q"4;CHK<-
MNT #4JK':UIF9CP;:5K$1$^+:W%L@BY9B]DRJ" F)?($:XLH!W! E-)<*-?X
M22GZJV4G,98[1B<-?N7.5^6I.;Y5C'#,B%$A<967\?R^5+81+,V0H!T0$!25
M;=&M3X2E1*5C<-!6:^RV>'@TTUUQFWBO3 <NB9]A&/9K";\F/?8+,PL:Z^4Z
MH;76M>_8X%(U]U:*6ZHRSWKTSASD.6P[(HQ&4?-W/34L@Z(;U[/,4._^$=:\
MGOON=-'PU^*W[/Q6ZM$WX^" 76^72]E/XB\E3:#JVTA"4I3]'37]=?)]QWFW
M?\\O0IJK7DQNT>TUCRLPREBGVZV30_=+:W<XVHU;<4I)3[TZ':?H4#6C3LK6
MV;5ZH<F&P./W>SWBVMR+*I B)\'D)2&RT1]A2!\)_P#D*^KT[*7KFG)!E:O"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'7(8;DL.QG1JT\A3:Q[4K&A_4
M:Y*5;368F.</SZO=JD6*\3[-+!$F!(<C.:C34M**=1[CIJ*\&T8G#^@NWW5W
M:J[*\K1$_I>"HM!0*!023CZUNWG.;#!:!(1*1+>(Z;6HGWJE?I2D?76GMJ=>
MR(]7C?>^ZCMNPW;)_IZ8_&W"$J*T>GKGE:G"(O#_ "\_NWG1$>UY0GMU[D-O
M;O<-%^QJOI/DOZ2_G[YZ>L,KS<@-\]^GUP#^]BYWAHHUT(;4TP%G3W5W;SAS
M5\ME]N-M/-N,2&D/QW4J;>8=2%MN-K!2I"DGH4J!((/=6J8RS1.&J,^U\H^G
MB-E>"8=BMPSOBO*69JL,-M2I^79+C<4%M4>0E*5J\@*7NU(T5H% [BL5AF+4
MS'@VQ-;XF>:\^$<,G\><28EAMV"4W:VPB;@V@A24293JY#C>X=#L+FPD=-16
MK568KQ9MMHM:9A/'&VW6ULNH2XRZE3;K2TA:%H6-%)4DZ@@@Z$&K)C*N)PPV
M-X;B.&M2F,1L,"Q,SG?F)C=NCMQ@Z[UT*]@&NFIVCL3W 5&M8CDE:TSS>Q5[
ML:+LBP+NL)-_=1YK5H5)9$U;>FNY+!5YA&@UUVTZXSASIG&7OJ2+7K-H=M7Z
MO,#1?HD>;;+WB-QMT2/-:0^RJ2PN0\L;' 4DE/3L[#62\9V0UTF8US+"7NS7
M+THY*[F^)1Y$_@"_2$C+<::*G5V*4\H(3-B DGRB2!H?^K5_JU#DQ.N<QR2B
M8VQB>:Z<_M=JY.XCR*W6F0W<;7D=CD.6J9&4%MO*4R7HSB#_ -8A'3ZC5]\6
MKP44S6S ^FO*#E_!6$W1QWS94>#^%RB?B\RV.*BC=[RA"#]=<TSFINC%I>3E
MOAF=E5Y@\E\;75.+<Q65(1$NQ']TN,8#3Y6>E*5;DZ>%*RE7A\*@1MVQV:L\
M8YI:]N.$\F$XYP/EV/E>?\NY\S;+=G5\LJ+/8[-9E_,L)7"8!;>4I2EC53C3
M>U&X]IUTZ576EN-O%9:]>%?!5/#?&&899QC;.7^,N1+M;N7'WIPO\:[R#*M4
M^8Q*5K'DMK2=FJ-AW+"QXNH':(5I,QF)XK+WB)Z9C@O+BCG%O,[K)X_SVUG#
M.8+7TG8W(.UF6D#7SH"U$^8DCQ[-RCMZI*T^*KZ;<\)YL]]6.,<86_6AG<4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@\=WN<2QVBX7NX%2;?:XK\Z6I"=ZPQ&;4
MZLI3WG:DZ#OKEIQ&4HC,X>3%<GLN:XW;,LQR1\U8[NPF3"?*2A1024E*DGJE
M:5 I4GN4#7*VBT9+5FLXE2GJN4NRVWC;D!L@#$LQM[\E1[HTG7S.OL):2/KJ
MC=PF):-'',/KEX)S?U&\3\;,['H..*E9M?$?&$ICG2(%#L&JFM.O_2#ZXWGJ
MM$.T^&DR^_6,RXCB*-DS:"M[%LAM-YWI&JD)2XI@J'UNIJ>_DCH^9Y_5#):S
M9?&/%-N<0ZC/\AC3I8'BUM$%(=<44_ND.[NO[E0V3G$):HQF69]7MI5=> LH
M>B?=O6=V#=(VT?#\M*;0=/9HAQ53W1\*.B?B8?U,9>_</3];(EK4E5XY,79;
M3;T#JI?XB&Y3FT#MZ)V'^E4=ELUCU2U5Q>?1)>>L0CL>FO*\/M[?F1;'8&$1
M4@?8LODN!0']%DFI7K\"&N?[F6%S3D=NT^D7\\,OA,NXXG!@Q5D^+YRXQVX1
MT_B25+5_5J,VQK2K7.QD#QR+1Z49/'2T%,IC#I!>04Z$3UQU3E]/<\3^BN].
M-;G5G9E]\89\BT>EJP\@2W0HV+%G'"M?7<]:T.1FTGVE2VD)^NE;?V\EJ_W,
M,3P'@CS/I@19IB5.W3-;9=KI/WIT4X[>6G$M$CWM!JN4K\'XN[+1[GX,EZ4\
MABS/3OB=PG.>6U96)T6>I?3RT6^2\HZ_0UH:EJGX'-T3UL-Z5+2K*,#R_/;T
MVHR^4;Y<Y;Y6--8&JXS: /8%+> J&JN8F92VSB8B/!C_ $QY-(LWI_8M2W/,
MNMCO-UL48*[4%#WG[B/X \=!]%>=W7>3HT\/FGA'_/1;;5%KI'XB5*6HK<62
MI:U'52E'J23[Z^*F9F<RW1&"N.E H,WBF1R,8N[<YLE41PAN:P.Q;1/;I^\G
MM3_R$UK[7N)U7SX>*,PV*:=;?:0\RH+:<2%MK'84J&H(^D5]?$YC,*WW70H%
M H% H% H% H% H% H% H% H% H% H% H%!KQZA.,9$M:L]L3)=6E"47N,V-5
M;6QM3( '4Z) 2OV  _O&O/[G3GXH?H?^K_=ZUCZ;9./Z)_\ U_?'Z/)K=7G/
MTDH%!PI02-3V= -.I)/0  =23W"A$9;'\-\?R,9@/9!>FO*OMS0$-QE?'%B:
M[@A7L6L^)?LZ#NKZ3L.V]N.JW.7XO_MGWRO>;(T:9SJUSQG^JWG'I'*//C*6
M<@X%CG)N(7'"\I8+MJN"1HZWH'X\AOJT^RI0.UQ![.XC5)Z$UZ-Z1:,/AJ7F
MLY5/Q_P3R!:\^Q[+>3\U8RV%@D*1;L+;:86W)*9*2WYTQ2P-5H;.GQ.*)"=5
M>'K135,3Q77VQ-<0OZM3*Y!([#IKTZ4'%!]*0M&F])3KV:C36F71&F].[LU&
MOT4<:=8-PQB?,60\V?G!4F)R!;,RDBU9/$>6F;;VAO\ E"A(4$J0G9U2>X#:
MI) -8:TBTRWVV36(\EH\/\GY/$R61P;S(I+?)]J;+MFO0Z1\AMB02A]I1 "G
M@E)*N]0!U&]*ZMUWF)Z95;*1,=56.]4N[&W.,.6& GS,-RF.W,4>A^0N8 >&
MOL^YT_K4W<)B31QS#8"?"AS8\JVSF&Y=NEMN1Y45](<9>8=!2I"TGHI*DG0B
MM&,QQ9XG$\&M,"P<H^F.[S&L$L4SD3@^XNN28N.15E=YL<E[52D,@A:EL*/:
M0E0/:K:O52\F+4GAR:\UV1QX2F'IQQJ\<8\)I.=L?@TH/W/(9\)S52X,-W[W
M8X!V*2ALK*>T:Z'KTJ>J.FN95[9ZK8AAK#ZO<"GS(*LGL-[P_&;VM8QW*KQ'
M_P"ZYJ$+4C<7&]?+U*>[>E/VE =:1OCQ=G1/@V!8?;=;9EQ74/,.I0]'?:4'
M&W&U@*0M"DDA22.H(.AK1F)AFQ,2UXXS'^%'J!S/B-P%K%\Y0K,\-'8VB20?
MG8Z!J0/A7H/W6A[16:GPWPU7^*D6\EC\K\,XER];8[5[2[;\BMGWEARBWGR[
MC >2=R"E8(*VPKQ%M1]Z2E7BJV^N+?BJIMFOX(=A%X]2>*7^V85R!C<3-<<<
M>3''(ELEMQGFX@ 'G2X[FA6M/3=X4J5UT*SU-5)O6<2LO%+1F)7G6IE<4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4'5*;:>B2F7TA;#C#R'4+^%2%-J"@=>XCMKEN
M24<U#^C!QU?I[L*7"2VW-N:&->P-_-*5H/=N*JHT?*OW_,QW.<J\<S9DUZ8\
M.>8C15QVKQR#?WF1)%OC-+0[&CMI.@#JU%M70A7B2-0-]0VVZIZ82U1TQU2\
MWH]L;MRL%^Y3R6Y/WK/[M+5CL^=*T^XAV5+;;3+6WM"@$*4>_:/>2T1GB[W$
M\H6=SY<\ @\4Y# Y)NOX1CM[CJMK<A#9D23+<'F,^0PGJXM"T!S;T&B3N('6
MK=LQT\5.J)ZLPJGTT85?\GF6;F?,<E@9(S9K(G%<&3; X$LPXVK3K\E+J4*1
M)*2I"DD;O$2?LU3JKF<KMUL1AL/EV-PLQQ2^8E<3MA7R!)MSKFFNSYALH2X
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M[MTL;Y967]Q2OSVO"EW52%?>)*"X-%*UUJ<:XO&8X2KG9-)Z9XP[/POU>8"
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M>_7.(Y*8QVYV#E_(5>H#F6Z0[-Q+8)+\?C+&[J\VRQ(,=>URXOM+.KJRM/1
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MB5/93&<*DQF9;BU*V)(VI)4 !]DZ:5][VO5NU5MGG#!?9%9GAQ;2=.@2-$@
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M:% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MJ[6I/-;6MXY-;<SMMG].34G/^#.1;:WC[2TO7;B^YW1J?$FH6X H0-KBW$N
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ML1F=R7;K$XAE6V1-4(S:AT(2H:K(_JC3ZZ\C[MOG7HF(YVX?Q7:*=5OP5<
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-*!0*!0*!0*!0*#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>fc_fig50panproteome-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_fig50panproteome-4c.jpg
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M ?_$ -4  0 " @,! 0             &!P0% 0,( @D! 0 " P$!
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MOYP'%5UN>N-2<755-A5AD4 H!0'!( U)  WD[!0R<T,"@% <$A()40$C>3L
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M5QW(0;KD9GJC%NN1W3,E>QW$8%UE+7=+S<DQVX<=7 USIDM(*4 ( "4#74^
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M#DCT5)OMN8>AQ)PU2X(TG0N-*T]TDD<0"O<G:-YJ3@JU(J3I3@;&ID10"@%
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M*,-&Z](@A4;'2#J"N601NTT9JCRS.79\2,2B*[A(4 H!0"@% * 4 H!0"@%
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MFS-1J6P>!Y ^Z;5O'VQXZJN0UQH&5Y/(,Z44ZZ<YS3B&ATXCIJ*WXY(R8U2
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MQWG'N9SU*!!XP--.'LJ$)MLILW?$KA0M:KB\4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H#17^%H1/;&_1#X\?W*OM&KK<N!DT57 4!&\]RA[#<6EY%'BH
MF.Q5LH$=Q9;2KFN!&U203LUJJ[/2JD+D],:FMZ99[)Z@6J?<94!NWKAR1&2V
MTXIT*!;"^(E0&AVZ5"U<<R-JYK5:4)N!J0/#5Y<5'@G6:?F.7MXP_9F(;*TR
ME>=-O+<6/-02.ZH =[2M2W><I4-6W?URTTYEMUN&R51U&ZPS\%R06&-9V)S9
MCLR.>Z\MM6KQ((T2"-FE:=R\XNAK7;[A*E"UP=4I/A /KC6MLV160* 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * ZY#")+*V'/<K&_P'L/J5E.C!$W6ELN+9
M<&CB#PJ%;2=0?-# H!0"@% * 4 H!0"@% * 4 H"-9_9/K_$KE"0GBE-(\[B
M?IH_?'KC5/JUK[B&J#*[L=46CS*E04D*&XC4>K7!.22;IXWS,YL0W\,DK^*V
MLU=8[Z+K/U$3SKI^:L'W\K\5NMW??E[38W62-WTC27.GZFQO7(G)'JG2K-K]
M-EFV^GVLH)(T&AWC4>L:Y!S3*MUO>NUQAVJ/^?G/-QT>+F*T)]0:FI1CJ:1)
M+4Z<SUA&C,0HS,*,GAC1FT,LI\"&TA(^P*]'%45#L4H=M9!R-RO)]L4!Z$.\
MUIGC!63 H!0"@% * 4 H!0"@% * 4 H!0'6^\W'8>DNG1EAM;SA&TA#:2I1T
M\@J+=$92J4^GTINBR@"+O,T.[_07?;K7^XB;'@2/I7I1=&4'A7=9B3OT,%T'
MV:?<1'@2+ PK.,<ZA63]XL5D.2;2'W(G->:4PKG,<)6.%6W0<0VU=":DL"J<
M'%T9(JL*Q0"@% * 4 H!0"@% * 4!B3_ ,VW]\?8JFYP.OY9WY=2]Y@U2=T4
M H#S#U)Z2]0K_P!8).4VBS&187)MN?1+Y[*-6XZ60X>%2PKNE"NRM6474TKE
MJ3N52PP/4+R@MYQ:3JE2E$'Q$UL+(WF4IZ1."97G=MQMC%+>;@];Y,IV6D.-
MM<"'6D)2?E%)UU(.ZJKB;-:_;E-*G,FO2:Q77&>F^/V"^1_-;O!9<1*C\25\
M"E/N+ XD$@[% [#4X*B+;<7&"3-EGEMG7G",BL]L:Y]RGV]^/$8U">-UQ.B4
MZJ( U\=9FJHS-5BTBJ?1TZ>9E@DG(G,LMAMZ)[,5$0EUIWC4TI96/DU*TTU&
M^JK<6F4;>W*%:E[UL&R* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!\.I:
M4TXE_3D%)#FN[ATVT,D)/#J> DHU/"3O([-:W <4!#NJECNN1X-<+/98_G5R
M?<CJ:8XDHU#;J5*[RR!L JB]%RC1%5V+E!I9FEZ*8ID&)6*Z0\AA^9R9,Q+S
M*.-#G$V&@G75!(&T5"Q!Q6)"Q!QBT^99J2 H$[JV39//_2[IOFN.=0&KW>;9
MYM:THG)4_P YI>U\$([J%$[=?!6A:MR4JM&C9M2C.K6&)?U= W2ANL'3O,\I
MS)-UL-L\[MXB1V2]S6F^^VI14-%J!V:UH7K<G*J1I7[4I2JD7RG8A([0E(/E
M TK>1NBL@4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#1WY+(>:4/U@I[X
M'O!N)\=76\@:FK3 H!0"@% * 4 H!0"@% * 4 H -AV[1VBAD\L95:?J+);K
M:@"&F)"RQKVLN_*(^PJO.W8Z9-'(N1TR:-YTH8Y^=P#IJ&&I+Q]1LI'V55=M
M5_419MU\Z)=UT_-6#[^5^*W6SOOR]I=NLD2#HSMPED'<9LH?ABK=GW"W;=Q=
M;*%G,*C3YD90T4S(>;(^]<4*Y$E1G-:HV3OHY:O/LK<N*TZM6J.IQ.HV<Y_Y
M-'J@<1K;VD*SKR-G;1K*O(ORNT= 4!R-RO)]L4!Z$.\UIGC!63 H!0"@% *
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M##,Y+B^:L/H3HH*7JKB.O;K6S#(Z$4U%)F_J9(4 H!0"@% * 4 H!0"@% *
M4 H!0"@,ZSVUV[7%B"ULYBN^K?PH&U2CY!5=R>F-00&;H+C(XE%0#R^\K>0%
M$#73Q5NQR1E'ER_=.NKDJ_765"8FF$_,?=C%-QX$EI;A*-$\X:#3LTK0E;G5
MG.E:N-NE?66!@MARC'NF^61,L0\B<ZW,=8$A_P Y5R?---BN)>@U!V:U=",E
M!U-FU&48-2(3Z-*E)R2\E)*=;6UKH=/\NFJMOWC7VF;ZD>DN:[[]7KFNA1'1
MJ.:[[]7KFE$*CFN^_5ZYI1"HYKOOU>N:40J<\UWWZO7-*(5/+!)/I"DDZDY'
MM)KF?[G:<W_?[?@3SK%B&?Y#DD&9B;4E=O:@AIXQY?FR><'5JVIYB-3PD;=*
MOOPDY8%U^$Y-:?>=?2##^H&/Y/*FY6U)1;5P7&6S(E^<IYQ<01HGF+T.@.W2
MEF$E+$6+<XR^;WEUUNFV* 4 H!0"@% * 4 H!0"@% * 4 H!0"@/O+K%(MN.
MV:YR"I)NKKZVF=-!R6 @)4>WO%9(\6WMK%FXI3DEP,5(56X!0"@% * 4 H!0
M"@% * 4 H!0"@% 5SUHM_G.*,3TIU<M\MM>O@0^"VK[)36AO8UC7D:VY585Y
M,U'0R4URK[ T'/XV).O:4%*F]/4(^S56Q>:(;5X-&YZHXW*R8VMB+(;CJB<Y
MQ:G@I04'>%( X?!PU;NK;G0LO6W.E#:]-[2]8<>-GD.H?>9D.O*=;!""'SQ
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M([,-<M*XG-YA6AQ" #QK4--%4M7G)T9BS?<Y49;];9MB@% * 4 H!0"@% *
M4 H!0"@% * Y2E2E!*05*4= !M))K /1>!XPG&;&VT\D?64K1Z:KM"B.ZCR(
M!T\NOAKS^YO>)+H16V5SZ1/ZOCWW\OV&:Z'EF<NSXF8E#UW"0H!0"@% * 4
MH!0"@% * 4 H!0"@.%-I>0IE>U#J2VH>)8T/LUAJJ,GF/#W56;.;4%'@$:X>
M:N:[.ZI2F3[-<"U\MQ=9R;7RS767QDTB-&EL><O-L!2"$%U:4!1"MH'$1KI7
M6O-)HZ<G0^;=-99LEVN+;B7&&67'.8A04DEIM1(U&S9VUB$J1;">#96F 97?
MLDR"%9KAR%1WFW'7W&V^!Q*6D<6S0Z;]!NK2L7)3DDS3LW92DDR\J[!O"@%
M<C<KR?;% >A#O-:9XP5DP* 4 H!0"@% * 4 H#IERXT")(GS' S"B-+D27E:
M\*&FDE:U'34Z  FHMT53*5<# QW)+#EMI:ON-3V[E9WU+0U,9"@A2FSHH +"
M3L/BK$9*2JB4HN+HS:@$D ;2=@%2('@[TBLQ<RKJ?=6T+*[5CNMG@-C:-6#J
M^L:;RMTJ]85RKLM4CJ68Z8GJSHE@#/3W +?"<:";]=4(N5\>TT69#R>)#1._
MA900@#P\1[:WK,-*-*]/5(L6M@H/IM(6XA!W*4 ?5-89D\Q])L>L_53JCU"S
M3.XR+I/LTY,*VVF7WV&&N8ZA!+9V*#:6@A"5=W4DD:UH6XJ<G4W;DG"*2.ST
MD,/Q["(%AZG8;&9Q_*H%U993Y@D1VY 4A3@);1HGB1P:$I'>2HA796;T%'%&
M+,W+!GHMQB)?+28UUB(=@76(E,Z"L:H4W):!<;(/WVGBK;IJCB:M=+P/SRS7
M';GTMZ@S[-#?6B;8)C<JSS==%J9!#\5W4=I3H%>K7+DM,CJ1>J)^@.*Y#'RW
M&+/E$4 ,WB&S,X$[D+<3\H@?>K"D^I74MRU1J<N<=+H;< J( &I.X5,@:+%\
MSQ;-8\N7BMS;ND:"_P":RW&DN(#;X&O >8E)UT\&RH1FI9$Y0<<S>U80% *
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M"'#A8I?FX49J,VJ!+4I##:&DE7(4-2$  FHS2470C+)E%>C7_B.\_P!UM?\
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MDRMQ6T(CQU\]1.FIT2%J-7V)4CB47X_/AQ-\SZ071?B0X,PBE!T4#R96X_\
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M8J+2>8.7XT:5P^=,-O\  >)'.0ESA5X1Q Z'QBC28.WMJ0/+?_Y"?_<=<O\
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MW(/A4>Z/7[*UMQ=\.->)AL]'MMMLMH::2$--@)0A(T 2D:  > 5YYNI6?58
MH"D?2)_5\>^_E^PS7:\LSEV?$E$H>NX2% * 4 H!0"@% * 4 H!0"@% * 4
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MP4<BN4G)U9NJF0% * 4 H!0"@+!P[_T8?I5_:KA;WZG8>AV/TNTD%:)OB@%
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M0"@% * 4 H!0"@% * 4!8.'?^C#]*O[5<+>_4[#T.Q^EVD@K1-\4 H!0"@%
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MJ(-XLTT"V3K5U(MC,^ZOW=URV2UH?D@)6A.T< T)V:C6HTHR=:Q+ J\I% *
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MN.LJ0$$AX\D $<P;$^.I;?86[[DH3?R_X?<8G><*569-K;D63_O4UC>16*/
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M-:]YC0Z4J6#;X3-MMT&V1QI'@1F(;/9\G&;2TGUPFM63JV^9:E0R:B!0"@%
M* 4 H!0"@% * 4!N<;NGU=-#;JM(LC1#FNY*ON5>W6WMKNB5'DS#18%=PK%
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M\#+;1( 4HZJ\)VUJ7;\904(QTI.N=:O+$MC%IMMU)56J3% * 4 H!0"@% *
M4 H!0'TE2D*"T$I6D@I4-A!&XBLIT!=&+7Q-]M2'UD>>,_)RD_# ]UIX%#;7
MJ]K?\6%>*S*FJ&[K;,"@*:Z^_F+#]_*]AJO->=Y0[?@60*2KRY:0IOI\ZWFJ
ML[%Y4;LO4*C&*CS?@4V&BGW?%[D>ZUUKL/S%/;?;Z/EYZL<Z\N9K^#\^NN).
M.<[IH%JTW::FN+I7(V*D2R'!8%[N\3)84MZS91"X0S=(H2OC2@:!+S2^ZL:'
MA\FRNIMM_*U;=J24[<OROX/@4SM*3U+!F:BRWB66TW^]>>1&U)<,.%&3 ;=4
M@ZIYRTK6M201J4)*0>VJG?MQ^E#2^<I:J=2RKTDM+>;-/E73U65WZ#D$B\N0
MY-LX1!:9C-K2G@<YH*RM7>/%6WM/,5MK3MJ&I2SK)\J<L"NY9UR3KD;&;C=Y
MNLR ]=<C<>@0I+4Q=N8ALQFI"V5<:4NJ2I2BD*VZ;M:U[>YM6XR4+=)236IR
M;I7E@3<&WBS6W_I\Y?\ *8>6N7MR)<;?R_,FFHK:VT!E96GBXUZKVJ.NM;&W
M\Q5FP[*MUC*M?F?'LP(3LZI*5<C8S,:N]SG6R1=<A6_"MLMN=]7LPVH[;[K)
M)0'%)6I1 )U%:\-U;MQDH6Z.47'4Y-T3Y8$W!MJKR-9<.GCUPS%O./KUR/>&
M.6&&T1&EL)2TDH2"%+U5L)U-;%OS*,-N]OX=8NM?F=<<>1!V:SUUQ-JYC5UF
M7>U7.ZW]R7'M+QE,6YN(U&8<?*%("W"E2B2D*[O@K76ZMQMSA"WI<U1RU-NG
M15$]#;3;R)'7/+10"@% * 4 H!0"@% * 4 H#D;E>3[8K(+P.\U]V/#BLF!0
M"@% 1C)<8D3GV[_CCH@99$20R^G1*)*--"T[KL)]ZH^0^*N42<9<S Z;FT"#
M+2V'$Y3S%&_B9^N<[B/AV\O7=IV[^RL0)3)?-A0KE&5#N,9N7%5O:>2%)U\(
M[0?&*FTF5IT(=.Z68H[QO,KDP$)!6O@=#C:4I&I.C@)  \=0<"Q39CVWIAA\
MAIJ<U.DW*&Z.)IQ#B$-+ .FPH3J1J**-0YLF=LM%KLK!C6F&U$:5[OECOK^^
M6=5'U34U%(@VV:C.EXZG'7TY(.*,K9$0WIYR9.G<Y';Q>'LTWU&=#,*UP-5B
M6+7)\P\AS-Q<NZ1VDMVN%(T4(S0&Q;@W%T^/=V[:Q&)*4N")S5A4*R!0"@/M
MIIQ]U##2>)UP\*$[M2:C*2BJO(E&+DTEFS.^H+Q^RGXR?;K6^[M<S:^SO?I'
MU!>/V4_&3[=/N[7,?9WOTG5)M5QAM%^2P6V@0"HD':=VXU.&XMS=$\2N>WN0
M59*B,.M@UQ0"@% * 4 H!0&QLES5:IZ)&TLJ[CZ1VH._U1O%:]^UXD:<39V]
M[PYUX<2SD+2XA+B"%(6 I*AN(.T&O.M4/3)U54?58,D8S3]5B_I%>Q7.WO=1
M*)4/47-G.GF,R\M=M#EVM-N"5W$,2&X[S2%K2VE24N)/'WE;0-U:-BUXLM-:
M-B<]*J:5SJTU9I5A:SG'9F+V_)5-M6B\N2(T^ 7GD)6VT^N.0IE2DJ!'$G3[
M-3^VU)Z)*3CFLF1\2E*JE3LN?4F]6_/D=.6<.>F7QZ&NZ1G4W.*RPY";64*6
M2XCNJ!'N#MI&Q%V_$U85ID\P[GS::&RQ#J+:\KO5XQ5^#+L686#A5=;'< VI
MQ++A 2\RZTI2'6U<2>\D]HJ%VPX14JIQEDT9C--M<4:I_J9>4YW*Z=P\/<F7
M^+!3=N,72*S'7"6H(2L*<1L5J1J@[:FMO'P_$<L*TR>9CQ/FTTQ-U:\HR*9>
M9%@N>*.VJX)@&XP'%W"/*BRN%Y+"F>:RG1M:2L*/&-U5RMQ4=2E55ID34G6E
M"/8SU3R#+5WA-EP.2X+#.=M5RYEV@-$3&/=H;"P.,>!6H%77-O&%*SS5<F0C
M<<JT61OL2ZBV/+Y]SL3+$NT9;90#=<<NS0CS64JTX7$\*E(<:)(T<0HC:-FT
M53<LR@D\'%Y-9$HS3ZS7X_U'N%^SJ]8&K&7(4['4LN7B:N>P\PAJ4 6E-!"
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M=G.%73Z]/*^HIKAU^KIB]JHKJCN;4?<D^7PUT+J^_M.Y%?UH+YU^N/ZET_\
MCD4Q_I2H^Z\NCH)3A((P^R@[Q&__ *BZT/,/_IN=?P1=;[J-]6B6"@% * 4
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M<&ATTUW5K*BDGC2M?\7_ ))D4QS#[SC>,2<6:N[$N(M#[<)YV.M*HR)((6D
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M^D7^,:\C/O,M.BH 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0$VZ?7[S26;/)5I'E'6.3N2]X/YP^SY:ZWE^XTRT/)^\C)&IZ^_F+#]_
M*]AJJ_.\H=OP$"DJ\N6B@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH#D;E>3[8K(+P.\U]V/#BLF!0"@% * 4 H!0"@% * ;0=0="-H(V$&L&3OE3
M94Y:%RW"XIM/ C7L'MGM-5V[48*D50LN797'63K0XBRGX4A$F.KA<3ZRD]J2
M.T&LW+:G'2S%NY*W+5',R6FIU^GK5J"ZOO.N$:(;1N'K=@JF4H6(>F)=&,]Q
M<Z>/02^WVV+;6^",G5Q6Q;RMJUG[0\0KB7;TKCK+U'?LV(VE2.?/B=$Z^V^
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M[D"4VVH^HX4FJY[:]'.$O494XO)HD7">%*]Z%C5"QM2H>$$;#6M4F<5D"@%
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MH+ Y:=-=>(;Z]'L/.GM;*M:-5&W6M,WU&E>VOB2U5H:S^&#?]K*^@'Y=;_\
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MZCS_ .A@XVY.S/EK2K2- UX2#_E'/!75\TRCULU-H\SUC7"-\4 H!0"@% *
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MXNP)K3?$?-7E!#C?8"K8% =A!K4W5E7(-\4;FTONW-+@SC((:(=S=0VD):=
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MU;IT1BR3XCKH3(>XN4WH=5:I KGWK4I7HR2P1T;%V$;$XMXLT@W5T#G'- *
M4!VQHSLN0W&8'$ZZH)2/+VGQ"H2DHJK)P@Y-)9LE>206K=:H$1GW+:E:J[5*
M(VD^4UXKS*;FU)\SU=BVK<=*(=,@6^XMI9N4./.82KC2U+9;D("P-.()<2H
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M[Z@#*W&4HL>80U0;@$)"?]]VU"G8>I V&4WQ,>-8!K>MQ>XLZ/S0=5_++/\
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M>XI8E7VZH96#YDSHY*5\$'8G7PJ.SUZW-I8\6=."S,-T+G2E*4A*0 D#0 ;
M *]65%-]??S%A^_E>PU7FO.\H=OP+(%)5Y<M% * 4 H!0"@% * 4 H!0"@%
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M!UU([5GM/V*[=C;1M8YOF<'<;J5W#*/+\3NMUG8N4!U;#_\ O)"M>4K8D)[
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MPA/-4?L(K67E>[?^U+V?B6>/;_4C&D=4\*X"BUW)%SGDZ-0V4N(*^U1XUH
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M7Y[*,H%+!*D<.J$\.U1UJZ]N9WJ:J8$(6HPR)Q6L6"@% * 4 H!0"@% * 4
MH!0"@% * GF,6OS&'YPZG23) 4==Z4?<C[9KM[6UHC5YL@V;VMPB* 4 H"@9
MGZW(_2+_ !C7BY]YEQT5 "@% * 4 H#D$@@@Z$;B* U5YQG&LB!%_LT*YD[W
M)4=MQSZ33C_"JVW=G;[LFNTBXIYHBCO0[I&\KB.*1FSKKHT[(;3ZP=K:7F.Y
M7YW[/P*_ M\C.MW23IA:G ]!Q.WI>3N<>;5(/K/*6/L5"6]W$LYOW>XRK4%D
MD3!EMJ.PF-&;0Q%1[AAE"6FD^1"  /6K3>+J\RTYH!0"@% * 4 H!0"@% *
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0#D<G;^:W?TWA%,.CV@__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>lc_fig14tumorvolum-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig14tumorvolum-4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$$ &AT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-RXR+6,P,# @-SDN9&5E,V$W-S S+" R,#(R+S X+S$X+3$V.C4P
M.C,P(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.GAM
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240](G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q
M-3 X0S@B('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z-4%",#5!-3E!.#9$
M,3%%14(U,41",S$U,D%!13!$.#$B('AM<$U-.DEN<W1A;F-E240](GAM<"YI
M:60Z-4%",#5!-3A!.#9$,3%%14(U,41",S$U,D%!13!$.#$B('AM<#I#<F5A
M=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@,C8N-2 H36%C:6YT;W-H*2(^
M(#QX;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED
M.C5E-F8V.60U+3,U-3$M-#ED82UB,#(T+3)B8S@T,3AC.#$T82(@<W12968Z
M9&]C=6UE;G1)1#TB>&UP+F1I9#IE930X,60X92UD9&0S+30W,&(M.6)E.2UD
M9#8S,&)A8F1B9C0B+SX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY0<FEN=#PO<F1F.FQI/B \+W)D9CI!;'0^
M(#PO9&,Z=&ET;&4^(#PO<F1F.D1E<V-R:7!T:6]N/B \+W)D9CI21$8^(#PO
M>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T 2%!H;W1O<VAO<" S
M+C  .$))300$       /' %:  ,;)4<< @   @ " #A"24T$)0      $/SA
M'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L A  $ P,# P,$ P,$
M!@0#! 8'!00$!0<(!@8'!@8("@@)"0D)" H*# P,# P*# P-#0P,$1$1$1$4
M%!04%!04%!04 00%!0@'" \*"@\4#@X.%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *M [4# 1$  A$!
M Q$!_\0 X0 !  (" P$!              <(!08" P0) 0$!  (# 0$
M          ,% 0($!@<0   % P(# @<'#0H(# ,&!P ! @,$$04&$@<A$P@Q
M05%A(C(4%75Q@4*SE!8WL5)RTB,SM%4V5Q@X"9&AX6)#<R2U=A?!\9+B4W0E
M5O#1@J*RD],T-94F9H-$Q,)CHU1D&?*$I-1%A481 0 " 0(#! 4)!@0$!P$
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MNT!W
M
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M7*#&N,4S5%EM-R&%&1I,VW4DM)F1\2X& ]
M
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M3<8R.A^H9Q</ ;)D8#=L-_)"P>S8?Q" &;
M
M                                                           :
MWE&WV#9LJ.O+L=MUZ=B?]U>G1FGW6B.M20M234DCJ=2(Z'W@,U;K;;K1!8ME
MIB,P+;%23<:'%;0PPT@NQ*&T$24EXB(!K]]VSV[RB\1\@R/%;3=;Y%TDQ<)L
M)A^01-GJ01K6@S,DF54D?FGQ(!M0#53VSV[/)OGH>*VKYV:^=ZZ]"8],YQ%3
MF\W1JYE.&OSJ<*T ;4   "+>I+Z ]QO8,[XHP&[X=^2%@]FP_B$ ,V
M
M
M                             "+>I+Z ]QO8,[XHP&[X=^2%@]FP_B$
M,V
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M[X=^2%@]FP_B$ ,V
M
M     KOMI^MKOC[.Q?\  0%B                 %>>GSZ6M_\ ^TT3\%4
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M'P,U )I;<;>;0ZTLG&G")2%I,E)4E15(R,N!D9 .0
M                                               KOMI^MKOC[.Q?
M\! 6(                 5YZ?/I:W__ +31/P50"PP
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MJ*VFL-T^^AM%RJGVJ;48"R
M                             KOMI^MKOC[.Q?\  0%B
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MI(6AQ*5MJ)2%%5*DG4C(^\C(!^@
M                               *[[:?K:[X^SL7_ 0%B
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MN(@'H
M          5WVT_6UWQ]G8O^ @+$                 *\]/GTM;_\ ]IHG
MX*H!88                          1;U)?0'N-[!G?%& W?#OR0L'LV'\
M0@!FP
M                                                     %=]M/UM
M=\?9V+_@("Q                 "O/3Y]+6_P#_ &FB?@J@%A@
M                !%O4E] >XWL&=\48#=\._)"P>S8?Q" &;
M
M                                      5WVT_6UWQ]G8O^ @+$
M             *\]/GTM;_\ ]IHGX*H!88
M1;U)?0'N-[!G?%& W?#OR0L'LV'\0@!FP
M
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MV0N(>O5YMS4R:XT@FFS=<J9Z4)X$0#?@
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MBU)MW)61T_BK,!]+0%+_ -I%]%^)>W__ *)\!/'3'^K_ +=^Q8WU# 2P
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MNF,PY$M1KD(U,J<5Q-9-J-)&9]YTI7QCDO&DOG_F6&N+/:*\N?M;&-%:
M                    BWJ2^@/<;V#.^*,!N^'?DA8/9L/XA #-@
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M2DS-)DHC*BB 3.
M            -$W,M\2X1;>RDE*OCKW)M[2*562S+7J_BEP.O<?OB7'.B_\
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MVRI9)["4:$D9T\8#W@
M              .M]]J,RY(?63;#236XM7 DI253,_<(&U:S:8B.<M4QAEV^
MW)_,9R#2VLCCV9E7:W&29D:Z>%?']_N,A);A&BVWEHPXXV]?7>>^>[YD3;:?
MK:[X^SL7_ 1&IUB                 %>>GWZ6M_P#^TT3\%4 L,
M                   (MZDOH#W&]@SOBC ;OAWY(6#V;#^(0 S8
M
M                                      T_(W7,ANS.(0U&49.F3>GD
M_!9(R-+5?"OA^]XQ)7A&JYVE8P8YSVY\J>OO^9MK33;#2&&4DAEM)(;0DJ$E
M*2H1$7B(1J>UIM.L\Y5ZVT_6UWQ]G8O^ @PL0                 KST^?2
MUO\ _P!IHGX*H!88                          1;U)?0'N-[!G?%& W?
M#OR0L'LV'\0@!FP
M                                                           &
M*R*]M6&UNSE)YCYT;BL=IN/K\U)$7'QGXAM6-9=>TV\Y\D5[.V>Z'FQ6RNVB
M IV:KF7B>KTFX/'2IN*XZ>'<FM/=J,VG64F]W$9;Z5^"O"OJ_>SPT<"N^VGZ
MVN^/L[%_P$!8@                !7GI\^EK?\ _M-$_!5 +#
M                "+>I+Z ]QO8,[XHP&[X=^2%@]FP_B$ ,V
M
M                                !V<3[ &F6W_U;D2KVORK':%&S;$G
MYKLCX;WC(O@^]WD8DGW8T[5UF_VN'PX^._&WHCN;F(U* *[[:?K:[X^SL7_
M0%B                 %>>GSZ6M_P#^TT3\%4 L,          ,5?,FQO&(
MZ9>2WB#9HJN"7[C)9B-F9>!3RDEW@,=8-QMOLK>*-C&5VB\R3J9,6^?&E.\*
MU\AIQ2N[P -F             1;U)?0'N-[!G?%& W?#OR0L'LV'\0@!FP
M     >.Z72%9XBILYS0RD])$7%2E'V)27>8FPX;9;=->;FW&YI@IUWG2&IM[
MF6Y3Y(<A/(8,Z<TE)4HB\)I_A%M/E%].%HU4%?[@QS;2:SI\NQN465'FQVY4
M5PG8[I:FUI[#(4UZ329K/"8>DQY*Y*Q:LZQ+N&B0   !\].M#<3<W9O<.T6S
M \YOD*V7BV>L)$-Z5Z0A#_I#K1\LW$FI*3))>36A=P#;NH2?O#T^8CC&YV#;
ME7J[VV?)8A7>SY*<6YM\V3&6^A2%>CMF2#Y2TJ3YQ&9:5$ W#(]U;GNCTI3-
M[\?N=RQ/*[7 >6MFU2E-L)GPY!-.DI"B4EQM=-2=55$E5*ZBJ U7H8S#/-V"
MRF_Y]F%YN[M@?@M6^$N5RXE)"7EK-QMM*>89Z$E11T\0#V;Z]3^8W'=:!T^;
M&/,Q,EE3FK5>,H>0F1Z/)>.CC;"%$I)$PDS4\XI)F1D:4D1IJ83')V%NY8\<
M:V[IYFSEZ$J=9O[]V<?:.69<#<@J+T<V=7\D2"\G@2J\0$5],?5-DF6YI<-D
M]X6V&MPK:[*BPKJPE+2)LBWJ4F1'=;01)2ZDD*6E2")*TI/@E1%K"/\ JWO6
M]FUN8.R-M,WR%S&4VMF]7N*[(1(1;DR9:H:%(4I.OE+<214/5I4?;0R(@GKI
M=ZA(._F#.0[L\F)N%9VBCW^*RKDK>0HM")L<DTHE?PM/WMSAP(T&8=FV]AOB
MMZ=R;/<LTR&YV#&/5/J2URIQJ:;];PUOO<Q24DIW2HJ-:C\DNW4?$!5;?W<O
M=? >HAS;3&MP+_'Q9^1:T);<E)>?:1<4-&Z2'7&U'P-:M&JM/& M-E.S.2&Q
M(LN%[TY?!SER&].MD>Z3X\V,M#*DHJZV45"R1K6A!K2NI:JT5V /;:?G-D?3
M1;+[>[Y=[9FD'''ILNXQ9"HLSUE%C+-9NE32NCB.*5),C 5=Z1\MW0W\RO(+
M'FVY63QX=JMZ)L4[5,9BK-U;Z6SUFIARI4/L 3S-Q7/\0SS;_)<4W/R#*]NI
M]_58\AM%U=:EJ0O3(:U\UIEJK27V3:<)2:I53B95H&G]<N4YUM7 QS*L"S"\
MV>3>ILB+.A-RM<,TMLI6E3;;B5<LR,C\TZ'4!L6V^W^X>XFR-ASRV;L99 SZ
M\6PYK1O3(\BUG,/624KC+C5)LS(B\E=2[>(#6^C+JDS/=._7';;<A2)]]B0U
MW"VWMMIMAQQN.M#;K+Z&B2@U%S$J0M*2[%:JG0!<\!67JVW1WNVMPN1DV$-6
M:VX\B2U =N3ZG)EV)4@CT.M,+;3'0G5Y)DLW%=]./ -FZ/\ )L@S#83'\CRF
MY2+O?)TBYJE3YCBG7EFBX/H21FKL)*2)*4EP(BH7 !.@"GN*[FWCJ.ZB\KP-
MJ^7*R;783#EE%CV&8[;9%QFL2&XAOORHZDNFWJ6XMM"5)31**D9ZJADNE3?/
M(\BS?-]C\YN2[S><0E34V.^R=/I<N# EG$<1(-)));B#-M1+IJ42E5\VH"V
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MN,)-PX5T3J<XJ;(U,2#6>HTFE1ZC00":            1;U)?0'N-[!G?%&
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MO+5=,J*13LY?-D&5?%J)(#Z8@
M          #@]]Y<^Q/Z@"O/0W^K5BG\_=/ZRD +$@   \ETN4:T6^1<9BM+
M$=)J5X3/L))>,SX$,Q&LIL.*V6\4KSE@\0MTDTR,DNJ:7>[47H/^1C?R;95[
M.%#/WJ\2&UI[(=V^RUX8:?#3Z9[9;.-%6  "N^VGZVN^/L[%_P ! 6(
M            5ZZ?3,]VM_ZG6F31/P0P%A0        'X9&9&1'0Z<#[:& K
M19^G')F[;$OF>YKE677ZTQ[A-5CS=[=AQ9=]6YS&9$5]I3"F$*)!);96>ALU
M5X>62@GS&Y-V8Q"U3,Q)J#>V[<P]?4FZA33$E+*52"-TJ(-*%:B-94(Z5[ &
M9:=;>;0\RLG&7$DMMQ)U2I*BJ1D9=I&0#F           "+>I+Z ]QO8,[XH
MP&[X=^2%@]FP_B$ ,V       #PW:TPKU$5#G(-39GJ2I/!:%%V*2?A$^#/;
M%;JJY=SM:;BG1>.'[&HM[91$OZG9[BX]?O:4$E9EX-53+_FBWGS>VG"L:O/U
M_MZG5QO.GJ^O]S=8<2/ C-0XB";CLEI0@NXO\)GWBDO>U[3:W.7I<6*N*L5K
M&D0[QHE    ?.'KBQ_+=T]R++-P#%+_?+=:;24&9.C6>?Z/Z3Z2\X:$+4R6N
MA**IIX<>T!?C <@@Y%B]NDPV9<93,9AF3%N$21!DLO):2:FUMR$(55-:'2I5
M[P$=]4LU3^S65XI;H%PNN1WV J/:[=:X,F<ZXM3J"J?(;6E"4]JC69</" @/
MH&MN0;=IRW'LZQR]8_/ODB Y:EW"US6([W)2^A:2>4UH2I)K3P69=O#O <M\
M>G+.\&WI@=1.R]J.^H;N#=WOF,1S),HI.K^DFRGM<;DI-6LDU6E:E&1&D_)"
M=)75)@:;*I^V6C(Y^8&SK9PM-AN;=T.3IJ3+E8YM(H?!2^8:2[2U=@"'NEOI
MHS"%G]QW]WEC)AY;<)$N=:;$HR6ZS)N*EJ>E/D1J)*M+BDM-U,TZJJHHB 26
MWGL,^I1V\>I+\6++Q5NQ)R([+<B@>LD7%<DVM9Q_-T*^^4T:N%0$M;E;=8SN
MKAMSPC+(_/M=Q;HEU-">COIXMOLJ,CTN-JXI/L/L.J3,C"O?1QMCD6R<C=/#
M\K:76WW"$_%N2&G"CS81L/*0^P=#U527E(29FA7DGQ 5QZC,<S?,NI)_<+%,
M)R6[XI%?M*TS8]FG$3Y6]IGFFR3C23,JH4E)G2I^+B N-?-_L8A+/)K5MQF]
MZRAF*N%$:9QBY1WC:>6APVE.R&D(2@UH2:CXTIP(^P!A<2R+*?T?\HR?<2TW
M6-FV=KO\QG&VH,N5-9-Y"XD.(VPAHUI23331(YA)J1ZC/B8"L_1JQEVR69Y!
M=<^P/+8MMNML3$C2(U@N$HB>;?0YI4EIDU%4B.ATIP 3YN)NS?;_ &R%M7M#
MMWEMNBY/<6HEXR679)MLAP85SF:YSK9O-DK6LG'36M24)02C56H#4>O6#?,^
MM>,8E@N.7J_W.S3I$BY';K5->C,(-E"$)-Y+6A1JKP)"E=AUH WS;# ;!NST
MP6G9G-K9<;1>8%M2S)9N5ODPY4"<RZYR)+)OMH2LR/RBT+\I!FE7!1D @;II
M>WJZ:=QKSA67X;?KAMO.E*8N<ZV6V9/B,26O(:N,933:M;2TT)W3Y1HH=-39
M) ?15AYN0RW(:J;3J4K0:DF@]*BJ54J(C+W#(!5SK>?G95M8]@&)V6[W_)WK
ME#>7%MEMF2D-,LDIU3BW6VC;(N*4E11G4^SM 9CHO=E6+9JS8%D-JNEDRNU.
MW!R7!NENEPJMOS''T+;<>;2A:32ZGL56M>' !KVTVZW4ED'4=D>&9MC:XFW,
M5<Y)+5!..Q"88-7H;K4LTESS?H@N*U$HE&I)))-"#5\(PAWI>ZD<PRC((4S^
MZ;,(4I5GOT"')N#,23(E-2DQ)"(C;KC9ITN-H,TT66@ZU-1)#+])FR^00=Q<
M[WYRVUOV7YT2Y_S7M4]!M34P[C,.4X^\TKRFC,B;0@E>537PH:3,+@@
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M?0'N-[!G?%& W?#OR0L'LV'\0@!FP
M
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M4BIY&C2?'C4BH50D8               %>>GSZ6M_P#^TT3\%4 L,
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M1F1+0=4K*O!1& SH  BWJ2^@/<;V#.^*,!N^'?DA8/9L/XA #-@
M
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M%*3450%C\.I\T;!3L]6PZ?\ 4( 9H
M
M    '![[RY]B?U %>>AO]6K%/Y^Z?UE( 6) :?D;KF17=G$(BC*(C3)O;R>&
MEHC(TM5\*N!_N>,25X1JN=I$8,<Y[<^5/7W_ #-M::;9;0RTDD--I)"$)*A)
M2DJ$1%XB$:GF9F=9YN8,     "N^VAG^EIOB7=ZNQ?A[D$!8@
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MES2V^@D&9MJ-]!-D2BX5</3X:$ ^A%IIZK@T222]':HDC29%Y!<"-)FD_>X
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M,FUM&2]/8DT&9<5'4+R
M     #@]]Y<^Q/Z@"O'0X9%TTXH9\")^Z5/_ /V4@!*]L+YV9"N^N>58[2I3
M%J2?FNO_  WO&1?!][O(Q)/NQHNLW^UP^''QWXV]$=D-S$:E        5WVT
M_6UWQ]G8O^ @+$                 *\]/GTM;_ /\ ::)^"J 6&
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M(E.*2C@1J/C0ANOL5;5I%;3U3$<^_P!+V E 'S3_ &D7TH8E[ _^L? 6.O\
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M[Y /)TWQ9$CKGRAYE)FW$N>5/23+L)LWGVB,_P#EN)(!]+P
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M/9ML25)5*6P3Q$1.+6LTZS26DM":&?$!8X
M                    0!FRY"\JNAR:ZR>TI(_]&1%H_P";0==.3Z%Y=$1M
MZ:=W^+7QNL%DK0N0Y:8*Y5?2E1VE/5[=9H(U5]\<4\WS//$1DM%>6LZ>U[1A
M"        KOMI^MKOC[.Q?\  0%B             '!UYIA!N/N);;+M6LR2
MDO?,9B)GD-:N6X^"VFI3;_#):>U#+GI"R_Y+.LQU4VF:W*LM)O$=JNF\N9QL
MPOT-VUNNKLL6,11N:VIHE..*4;BTI61&=2))5\0])Y?MYQ4GJYS+FR6UE&XL
MT:WNR\Z;/VZM+DXS6IKFQV7%=JF675(1_DD6DO<'C?,*Q7/;1V8Y]UOPKT@
M      #BM:&T*<<42&T$:EK4="(BXF9F?8 _$O,KT:'$JYB>8W11'J1P\HJ=
MI<2X^,!S             1;U)?0'N-[!G?%& W?#OR0L'LV'\0@!FP
M
M                           !P>=:CM+?>63;+:36XM1T2E*2J9F?B!M6
MLVG2.<HVD8^>X,F5?U'ZNMZ4\FW.<NKCZ6S.KCA<#IW%_!QFZNC@]+7=_H*Q
MC^*W.W'EZ(:7T\E:MUL#L^YLN,J*U/=DDU:#<)Y*#AR7(Y&MS2C5JY>K222+
MC3B,3DF4.X\ZO>O32O3KVZZ_8L (GG@        !7?;3];7?'V=B_P" @+$
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MOR0L'LV'\0@!FP
M                                               !I=S=<S&[*Q^&
MLTV""HCN\E!TYKB3J3"#+QEY7\!5ECW8U[5WAK&TQ^+;X[?#'=_F;<;33$0V
M&4$VRVWH;0DJ)2E*:$1%XA$IK6FTZSS5\Z&_U:L4_G[I_64@&JQ(
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M<           "+>I+Z ]QO8,[XHP&[X=^2%@]FP_B$ ,V
M
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M+MT\*^YP >P           $6]27T![C>P9WQ1@-WP[\D+![-A_$( 9L
M
M                          &&R2_(L4(G$(Y]QDJY,"(7%3KRN!<"XT*O
M'^$;5KJ[=IMIS7TY5CC:>Z'5C%A<M+#LNX+Y]\GJYL^0?'RCXDA/\5/_  [A
MFUM6^\W,99BM>%*\*Q];/#17N#WWES[$_J *\]#?ZM6*?S]T_K*0 L2
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M&=\])YND]/*])^Y:Z]G-\CZ[@ ^AEIKZK@UU5]':KKTZO,+MT\*^YP >P
M        $6]27T![C>P9WQ1@-WP[\D+![-A_$( 9L
M
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M&:9FW*%-YOYA;;UBM/BM]$*K8!D=ZB=2>ZTUJ8OTAZ#83>4KRB7RXQ$DE$?
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M\-. #U@           BWJ2^@/<;V#.^*,!N^'?DA8/9L/XA #-@
M
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MV]5'255!T.BO-,/IS8Y<>X66VSXB5HB2HK#["'2HXEMQM*DDHO"1'Q >\
M        $6]27T![C>P9WQ1@-WP[\D+![-A_$( 9L
M
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MUN_YOEVH?VS::3U:;WDEM!:;?C!I,DE4C.#4Z'3A6O'PBLZI7L5B.Q8L:M@
M              %>>GSZ6M__ .TT3\%4 L,         T3<W>/;S9^+;INX-
MV.U1KJXXS!64=^3K6RDE+*C#;AE0C+M 5*SW+^A3=#-+EF^>Y-,NURFM18\=
ME$>[1&HS,5O11/H[*#4:S,U&:Z^ J=X8:+/_ &<N,.GD%N9>N]PMR3DQ+=(1
M>I#;[S9:D(-N01-*J="H[Y'UW !] H3QR8<>0;?)-YI#AM5(]&M)'IJ7 Z5H
M [P           1;U)?0'N-[!G?%& W?#OR0L'LV'\0@!FP
M
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MI+Z ]QO8,[XHP&[X=^2%@]FP_B$ ,V
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M9+(S 9,           $6]27T![C>P9WQ1@-WP[\D+![-A_$( 9L
M
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MT_?OS]$=R@Q_[S/U_P#IXY]W_-;O^;Y=K:Q5+\ 5WVT_6UWQ]G8O^ @+$
M             A;-.I;%\'R:?BUPQ++Y\NWJ0AR9;+*Y)AN:T)<(VG>8G65%
M4J1=H" -H.HW&<9W"W>O,K%<LELY'?(\R/'A6=;\B,EN.:#1*03A<IPS[$GW
M +8[9;G6O=*TR[Q:;/>;.Q#D>BK9OT%5O>6HD)7J;2I2M2?*I4C[0&[@
M   B?=;'-S[SF&#7+;2ZL6=ZT%=7;K(N#3LFW/LNML(1&?8:6V:N8HM25$LC
M1I,RX\##$91E-KEVI6.=1^!,L62I*5?6FCON-*6G@3IO$T3\,ZGP.0R@D_Z0
MP&S;;;3[)8JEK*-L<>LS7IB#.-?+=HEJ6TK@?*DFIP])]AZ%T,!)(
M     "+>I+Z ]QO8,[XHP&[X=^2%@]FP_B$ ,V
M
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M0@N_QF?C,^)CAR9)O:;3SE:8<5<5(I7E#T"-* *[[:?K:[X^SL7_  $!8@
M              !7KI],SW:W_J=:9-$_!# 6%         1SNGO5A6SCEH>S
MN4JWVB[(F\J<EMU\RD0TM+2R2&D+4:G"6K2? JI\8"HFX/[03(\BFGC6Q>*.
MJER5&U%N5Q9.9-<.O V(+!J(C\&M2_&D!^;%;#]7+V2/YW<LM5MRS=GO2[C&
M=98?7*6HRJ:K0T2(R#.G\H2%%X %_HZ'6V&FWW.<^E"4NO:21K614-6DJD53
MXT =@           (MZDOH#W&]@SOBC ;OAWY(6#V;#^(0 S8
M
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M7V?"70!NH              BWJ2^@/<;V#.^*,!N^'?DA8/9L/XA #-@
M
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M $IZ*=X"8              !%O4E] >XWL&=\48#=\._)"P>S8?Q" &;
M
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M9I)?*4K36G"H#)@               KST^?2UO\ _P!IHGX*H!88
M  4?ZB[QU&+WT<E;)X^Y(7C4&(PJ_0(#:Y)M3D<]V#(>=\A]A2B2[RE)5H51
M2=)\3#3<@W6Z_P!O'[EZQQ1^)!**Z4J=&M37I#36@];B.6I1DI)5.J4\.T!]
M!;.:3M, T+-:#C,Z5J,U&HM!4,S/B9GX3 >T           $6]27T![C>P9W
MQ1@-WP[\D+![-A_$( 9L
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M L]@VUNWNV:)R,#QV'82N1MJGG#0:5/&QJ)O6I1F9DG6K27=4_" V\
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M^@/<;V#.^*,!N^'?DA8/9L/XA #-@
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M=\._)"P>S8?Q" &;
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MF'9+0R4>VP&DL1F2XT0@N\SXF9]IF?$SXB>(T?0\.&F&D4I&E:QI#WC*8
M    !3+?!/5%N/O9?<!VDOY8QCN,6ZW34F4OU<J4FY(69O:T(4ZY]T;=:\GR
M$<OC11\0C>_=/_78JQW%$O/7[K$5&=3(MC-_EK<DM&@R4TE+B$),UEY-%*(C
M ?0FTI)%J@I2CEI3':(FS+2:2)!<*=U 'L           !%O4E] >XWL&=\4
M8#=\._)"P>S8?Q" &;
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M*TQ.DQ#:G-<YEEF.TAB.VEIALB2VTVDDH2DN!$1%P(B'B9F9G67<YC
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MK:]->-* -\  $6]27T![C>P9WQ1@-WP[\D+![-A_$( 9L
M                                                           :
MSD5_E(DHQ_'TD_?I!54KM;BM'VN.=O'CP+^ CWK7MGDM-KM:S7Q<O"D?S3W0
M]^/V"-88AM(4;\UX^9,F+XN/.'Q,S,ZG3CP+_",6MJY]UNK9[:\HCE'=#+C5
MQ@   (PWNFIGXI(P:UW*XPLKR$D,VWU$ZAJ>DDN$HU&M:5DAI1)-#E2\I)J(
MC+BHNS;;><GO3/36O.?EVM+6T0/N=MQ-VIQ9C*[Y/:DV[F18DI+1*YS<J6XE
MI*2(^"TZE<5U+PZ1>4\UQ]L2@G%*1+)TXW1)P+C/RV=8;K#E-R?]@*0A:FD>
M<RMYYM1Z5D=%:4EP\)"OWN_\:.FO"/VI*8].,K!BG3        (CSV\S9]QE
MV]"EIA124VAE-:*62>*C(NTZ\"'J]AMZTQ1;[UG@O-=W?)GFGW:]GUJ\])$F
M1!V:QJ8R55LRISC9*+4DS3-=[O=&-A2+[?IGMU9\UR6Q[SJKSC2?HA=R)(3+
MB,2TE1+[:'2(^TB6DE?X1YB]>FTU[I>XQ7ZZ1;OB)]KN&B0      'DNETMM
ME@/W2[RFH5NC)UOR7U$AM">SB9^$^!%WF"++EIBK-KS%8CME5[;S<#"XG4?N
M?E\N\-1\?RJ+8XMDG/$MMMUVWQN2]J-22-LB5V&X1$?A&G7"EI_<&QO;IC)Q
M],6B/;,:+5H6EQ*5H42D*(E)4DZD9'Q(R,ANOHG5B+YE>-8RR;^07:);4$52
M*2\AM2OL4F>I7O$,3,0YL^[PX(UR6BOKEH#N^]FN3JHN"6*[9=)(S3S(49;,
M0C(Z>4^\1:2\>F@UZ^Y2SY[CO.F"E\L^B-(]LNHBW_RHJFJTX- <+L(O6EP2
M2B]]JI>\,>]/H:__ &F?\&"/XK?8[6-A['<'4R\ZO=UR^61ZC1/DK:BD94\Q
MEHRTEP[-5!GH[VU?(<=YUSWOEG_-/#V0D&R8OC>-,DQ8+3$MK=*'Z*RAI2OL
ME)*I^^8VB(A=X-KAP1ICK%?5#+#+I        5YZ?/I:W_\ [31/P50"PP
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M9ICK]LE-6TF)*$M&9M.&W&0LDJ[%:5$= %C\.XXC8#I3_9L/A_\  0 S0
M
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M#OR0L'LV'\0@!FP
M                          :YD.0/Q7D62QH*3D,HO(1VH80?:ZYX"+N(
M_P#'O6O;/)9;7:Q:/$R<,<?3Z(>K'L>8L4=9J6<FYR3YDZ:OBMUP^/?V)*O
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M^(0 S8
M         .J3)CPX[LN6\B/%80IU]]U1(;0V@JJ4I2C(B(B*IF8#6?[T-M/]
M\[%_YG#_ .U /[T-M/\ ?.Q?^9P_^U ;2A:'$)<;42D*(E)4DZD9'Q(R,@'(
M!KN19"[#=;LMF04G(99?<6NU+*3_ )5SP$7:1#>M>V>2RVNUB\3DR<,=?I]$
M/1CN.LV-EQQQPY5UE'KG3E\5N+/C0J]B2[B&+6U1[K=3FG2.%8Y1W,T-7"
M  TG-<V?M4AG&<88*Y9G<"_HT4N+<=L^UY\_@I+M(C[?<'=M]M%HZ[SI2/I]
M$([6TX1S>O"L)8Q9I^=,?.XY/<3YEUNSO%;BSXZ$5\ULC["_@(M-QN9RZ1'"
ML<H9K73UMK'(W:[G.'6[/\7GXG=94V% N!-D[)M<E<*6CE.)=+0ZCB5321&7
M895(P%..IOIOP[ =KEW^UW_)ITHKI;(Q,7.[N2X^F1*2VI7+4@BU$1^2?<8"
M:[?TC8#;KA$N+649BX[#>;D(;=OSYH4II1*(E$22.AF7&AD GX    !K]TR!
MXY)V>PM%+NQ\'%_R,<NS4X?A+P?XA88=M'3XF6>FOTSZE1N=[;K\+#'5?Z*^
MMWV;'V;:M4V2X<R[O<7YCG$^/P4%\%(CS[J<D=,1TUCE"7:;&N&>NT]62>=I
M^KNAF1QK)P>^\N?8G]0!7GH;_5JQ3^?NG]92 %B0     !I>?;D6C!F6(QM.
M73)K@>BT6")Y4J0XHZ$="(S2BO:HR]PC/@-9MHJM_P"98]K$1IU7M\-(YS^[
MTM:Q?;6[Y!=VL[W:6W/OZ#UVG'T'JMUK09U(B34R6Z7"JCJ5>]1D1EB*Z\9<
M&U\MR9LD9]W[U_NT^[3[9^7%+(W>D5WVT_6UWQ]G8O\ @("Q
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M_)"P>S8?Q" &;
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ME] >XWL&=\48#=\._)"P>S8?Q" &;
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M7<1$-XB(7FRV.+:4Z,<>N>V?3+8AEW   KOMI^MKOC[.Q?\  0%B
M                     'X1$7 BH7B\8#]              $6]27T![C>P
M9WQ1@-WP[\D+![-A_$( 9L
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MN) *<=36V6]&.[7.7'+-Y).4VKUI;&CM+EEAP4FZY*2EMWFLK-56U462>PZ
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MT![C>P9WQ1@-WP[\D+![-A_$( 9L
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MT9ON%+SQ<U3)PE3(,> 40FB7K)'(-1JYFI-=1\-)4+B=0D$
M                              $6]27T![C>P9WQ1@-WP[\D+![-A_$(
M 9L
M      &O9#D:K<MNU6IKTS(994C1BXI01_RCA]R2[1O6NO&>2QVNT\2)O>>G
M'7G/U0C'=.P-81M]?]PYS[D^Z6:&_<Y\<M+;<EQ/E&A*M/D5,Z:M)^X0W\19
MT\ZZ)TBGN1RX\?K;1M?C5M>L5DS-9*<EW:!&N##*Z&B.4QE+NDC^$HB7IU?O
M$-;7F7)O/-+YZ],1TU2.(U,  "/<LRZZ7*Z+P7!#)S(%%_M.Z'Q8MS)\#-1E
M6KG@+N]T6.#!6M?%R_#V1^+]R.UIY0V/$<1M>'6LH%O(W9#I\V=.=XOR7S[5
MK5Q/M/@7=^Z8YL^>V:VL_-'<VK71GQSM@    !^&9)(S,Z$7$S/L :S?LDMK
MD25:H#BIEQD-.,MM1$FZ9*6DTU,RX<*\>(L]MM+Q:+VCIK$Z\>"DWN_Q32V.
MD]=[1,:5XHB4DTF:5$9*(Z&1\#(R'KGSV8T9W#8[[^1PN01_<E&ZXHNY"2.M
M?=K3WQP[^T5P6U[5IY52UMS73LX_,F<>,?20       %%-R]VNI+%\FNV*,Y
MU9'?1G#0J1#M/+-K7Y9-I4X:SJE)DE1\>/?WB*U].#R>_P#[BV^WRVPS%YF.
M<UT^N48[;;A;Z;58Q&P[%,KMJ,?AJ<5%C2[>4CE&^ZMYS2HZ*XK6HZ5&OB^A
MQQ_=NWUF>B_\OVKS;2[</VB(QFN:W1G*]Q;JT3TK(4(-,9++O%M$-M?WM'+-
M)5(BKX$I\D2Q6.;T6VV&&N6=Q&MK7XQ,\=(TY5[H_P .24QLM@
M                                            1;U)?0'N-[!G?%&
MW?#OR0L'LV'\0@!FP
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MQVDMZN/ATCKB-'W?;8O"Q5I^&L1[(T9,9=
M                             (MZDOH#W&]@SOBC ;OAWY(6#V;#^(0
MS8
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MO=$0L6,NH
M    !%O4E] >XWL&=\48#=\._)"P>S8?Q" &;
M                                    !K-_R&2F26/X\@I%_>*JE'Q:
MBMGVN.'Q*O@+^ CWK7MGDM-KM:]/BY>%(]MO1#VX_CT:Q,+/6<FXR#US9SG%
MQUP^)\3K0J]A#%K:H-UNK9I[JQRCN9D:N)Y+I:[=>[;,LUXBM3K5/9<BS8;Z
M2<:>8>2:%H6D^!I41F1D K7U ; [+8WLKG%]L6"VB#>(%ID/0IC$8D.M.I+R
M5H4789=P#8MN.G38RZ;>8E<[A@%FD3YMEMTF5(<BI4MQYZ*VM:U&?::E&9F
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M+Q"1Z2M8K&D1I#L!LX/?>7/L3^H KST-_JU8I_/W3^LI "Q(
M                                            "+>I+Z ]QO8,[XHP
M&[X=^2%@]FP_B$ ,V
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M!CE5;BS+4M?PG'%G2JC[S]XN \[DR7S7UGC,I^%([H>61E]OYIQK4V[=9?\
MHXJ=2"^R7V$7C*HZ:;&^FMYBD>G[%7D\TQZ]..)R6_R_:Z?1,LO'&;)19XBN
MUB-]TD4\!N=A']B-^O;XOACKGOGE[$?A;S/\=HQ5[J\;>W['OMV,6:VJYS;'
M/E'Q5)D'S73/PU5P(_<(09=YER<)G2.Z.$.K!Y=@Q3K$:V[YXRS XUB
M    *\=:GT(K]MV;\-0 L.  -'S3=7%L+>1;'EN73)7Z%$L%M3Z1-<6HJI(T
MI\PC_C>\1C6;1"HWOFN';3TS[UYY4KQM^YJ18?N-NB?I&X<U6,8DYQ1B5K<_
MI+S9T,BER"\/>@OW$F-=)GFK?T>[WW'<3X6/_MUYS_Q6^K]B4;!C=BQ:W(M6
M/0&;= ;[&6$TJ?URE'52E>%2C,QO$:/0[?;8L%.C'6*QZ&4&70  #@]]Y<^Q
M/Z@"O/0W^K5BG\_=/ZRD +$@
M                    (MZDOH#W&]@SOBC ;OAWY(6#V;#^(0 S8
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MLNM^=XQ;\KM4:9$M]Q2M;,>YQEPI:2;<4T>MESRDU-!FGN--#+@8#/@
M                                                  BWJ2^@/<;V
M#.^*,!N^'?DA8/9L/XA #-@
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MQJ/4=?>(:9_,(\&*UG6TQQ^MOC\OS9=S-\L^Y6W"/GX?,G,>>>H
M   :S>]Q,%QRJ;UD,"(Z5:LJ?0M[AV_<T&I?_-&)M$*_/YCML/QY*Q\_'V<T
M<93OC9[_ (]>+7@%MO-]N4F))CQI\""Z4=EQ;2B)Q2UDE1$@SKP2-)OK'!1;
MKSS'EQ7KMZWO:8F(FM9TCAS^92D<SY.D#9"*_,W5QEIAA,C3*-QU"T$XDFD-
MK4M1D9&7!)&9'W'3O&].:Z\CI-M[CB(UX_1H^@8ZGVL
M                                                  !%O4E] >XW
ML&=\48#=\._)"P>S8?Q" &;
M              !C,AOL#&;-,OES4:8<-&M9)XJ49F24H36GE*49)+QF)<6*
M<EXK'.6)G2-52LTW%N.99=C>6O168TG$),B78&4ZE)0N4V3*^<9F7,JDO D>
MEKY5BB.,S,N:<LI3@[ZLWVT)AS7&[#=*Z9LXM;B.5]='0G4LUGV:>[P\:E7Y
MO++TM[GO1\N:SV67!&M\WW>5?Q?N[V=LF47I4),#;O$)+L=1ZEWB\F4-IQ1E
MQ<,C/4Y7^*KWA#.VI7\V\>JO%%N-WDW%^J8^R&0^8^<Y"5<QRQR/&7Y]LL2?
M1FZ5J:3>46M1=W%(Q^IPX_RZ?/;C]#FZ9GG+/V+;G#,=,G+=:63ED=3ER"](
M?-1\3/6[J,C^QH.?+N\N3G;@VBD0VD<C=Y9]QA6R.J5.>2RRGO5VF?@27:9^
M(A+BQ6R6Z:QK*#-GIAKU7G2&O:KWE7WO7:; JOE]DI]/B^M2?_"HL=,6VY^_
M?^6/M4^N?>\M<>+^:WV1\N+\RMN/BN Y!)M$T[ N';I4AN[LPSN;L9QIE2BD
M>B]LA2*:N7\*E!79<U\EM;3JM\&WQX:]-(TA\^=Q]WLDO.W^06N3OW<\A8EP
M7&G+(]@B;8W+2HB(VE2R^\DKZ_N$3H93%MY\F@8Q9(374-=;:U&@1&46U&WR
M9:(R6V4))DG_ .5)%-',^%2O> ^B-F>5)M%OD+?.4MZ,RXJ4IHXRG36V1FLV
MCXMFJM=!^;V /:     \\R=!M[)R)\EJ+'+M=?<2T@O^4HR(&E\E:1K:8B/2
MT.\;Y[7697)5?VI\JNE$>VI7-6I7@(V4J3^ZH:3>%-F\\V>/AUQ:>ZOO?L8G
M^]S*[U5.%[=7><A1Z6Y=U-NU,'Q\XC<U5+WR&.J>R'-_5\^7\G;WMZ;>Y'TG
MH/4%D%?2;I9,2C+X$F&RNX2TD=*U-VK9G[AA[TGA^:9N=J8H]$=4_3P?O]QJ
M+L>O-LQON1&947&.3Z'#/MK]Q:K3M[E!T=\G]#\3\_+DR>C72/9#9K'M+MMC
MNA5KQJ$EU'FOOM^E.D?A);YK41^X8VBL0L,'E.TP_#CK\_&?IU;BAM#2$MMI
M)#:2HE"2(B(B[B(ALM(B(Y*D=4&U^*8+C<G<BQ-.1Y,BXPHCUI2:2B&N?(2T
MMQ'#4BFK5I(]/<1$(K8]7D=Y_:^WSY)O69IKSB.7S=R==M-FL5VR)Z3;.;-O
M4E'*?N<K3S.76NAM*2(D),R(S[3/O/L&U:Q"S\L\FP['6:^]:?O3]7<D0;KP
M
M       !%O4E] >XWL&=\48#=\._)"P>S8?Q" &;
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MCI%?5$0RPRZ0    !7CK4^A%?MNS?AJ %AP
M                                            !%O4E] >XWL&=\48
M#=\._)"P>S8?Q" &;
M      :3D&Y]AM$OU1:T.W_(E>2BUVTN<HE?_>+35*"+O[3+P#NQ;*]XZK>[
M7OE';)$-+NYY9DCR8N7SEQ6W_O>&V!57UI/NER2U$DN'E$6KAQ+2.F,F+#^7
M'5/XK?5#NV_E^7-'5>?#IWS\N+'Y>\QM98K?.N&%7O(H,N0;+>-X7".;R#)&
MHG9BN8A:S.E-:E*X]XX<N>UYUF=9=OZO'MXZ=M&G?>><JO;A;AI+.<-;L6W>
M;6:TW*8^5SM%TLB&9US2EM*B9A()U7,4@SU*TF@Z=HGKYAFK&D6<F7+AR6BU
ML<:_>TX1;[%EMG=U[7(O<'"K3M7G6/MW#6;M]OME3"@M<EI3GW9Q+RB0DS+0
MBA'52B\(X\F2V2=;3K+7/N)RZ1$16M>58Y0L*(W*\\V;$M\=4J:ZEEA':M1]
M_@+O,_$0DQX[9)Z:QK*++FIBKU7G2&N'(O65>3"UVNQ*X*E**DE]/\0O@D?A
M_P 0LNG%MOB]^_=V1ZU+UY][\&N/'W_>MZNYGK9:8%HC^C0&B;1VK5VK6?A4
MKM,Q7YL]\LZVE;;?;8\%>FD:?7ZWM$+I &BY[N9CV)62YJCWJU)R=J,\JUP)
ML@]"Y:4&;27DL$MU*#70E&21K-HA7;CS/;8/S+Q'HYS[(XOF?E,K<S+47<[K
M&M:I=YYIS)7I+IK-;YFI2BJFG:8YM:ZZ\7@<&?RO%N8W'BY+6B>KC7MG_E97
M"I^[UDO5C^:\6U-WZ,XQ&MKQ2'#4;IT921D::&2JZ3(^!D=!F)C7M9Q3Y9;=
M1DQY<L9+6UC2O;:?37EQ7Y9V9O-Z;:=S[.KU=GE))4B#!>*!"YAD1J22&R.J
M2/@1^3[PFZ.^7JI\FODG_K9\E_1$],>R&P639?;"P&E</&XKSZ>//FD<UPU>
M&L@UD1^X-HK$.O!Y+L\7PXXF?3[W[=6\,1V(K26(S2&64^:VVDD)+W"*A#9;
MUK%8TB-(=@-@        !KN=96O",6GY.BQW3(U02;/U/8HY3+B\3CB6S-IH
MU(U$C5K7QX)(S 5%W_WCR#=O;U6(6+9_<")<%7"!.)Z=8UH9Y<*0EU95;6X=
M325$^3V@);MO5(_<;C#MY[.;C1O2WFV/2'[$2&F^8HDZUJYW!*:U,_  L"
M
M       BWJ2^@/<;V#.^*,!N^'?DA8/9L/XA #-@
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MX36\-F-.-FW$E(CDI];M(*"HIOR>*%^X G[:7 ^LNS[@6>X[GYW;+M@K)O\
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M'823X\3H99K33FE\J_MNNUR1ER6Z[1RTY1Z?ER6+$KV0
M
M          (MZDOH#W&]@SOBC ;OAWY(6#V;#^(0 S8
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M\CV>*=>CJGOM[W[>#?V(\>*TEB*TAAA'!#3:20@B\1%0B&ZZK6*QI$:0[ ;
M#'7^^6W&+'<LCO+BF;3:8STZ<ZAM;RDL1T&XLR0V2E*,DD?!)&9@*D[W=6FR
M.;[1YCB6/7::_?+O;'XL!A=LFMDMYPBTI-:VB2GW3,!G<!ZR-AK!@N+V*Y7F
M<W<;9:8$*8V5JGK)#\>,VVX6I+)D=%)/B0"T<*7'N$.//BJ-<64TA]A:DJ09
MMN))23-*B)15(^PRJ [P
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M;9LLUX:S4HC,R\14I7QB@\US5F(I'/75ZSR';7BTY9X1II'I2*/.O8@
M
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MGP&6HJ.0TIX]:FY#AI+2@R(]-*T$::(T6$
M
M             !%O4E] >XWL&=\48#=\._)"P>S8?Q" &;
M                '%:T-H-QQ1(0DJJ4HZ$1>,S :?>]U,"L&M,R\LO/H[6(
MAG)77P'RZD1_9&0[*;/+?CII'IX-)O$(TN_4S!6^<'%+*]/EF9D@G3-:S_\
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M+,#C6(
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MEE[98K7:$T@QTH</SGE>4ZKW5'Q')FW.3+\4_8L-OL\6"/<KQ[^WVLB.9V
M
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MP[;)/3Z_9/QI;>47[I(&?Z?G_#^P\:OI]DN"MY-M4E7U\V?N-/F?Q8?T[/\
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MR7F>2+9M(GE#Z#Y)BFFWUF.<_0V;YU8O^.X'RIG[<52]/G5B_P".X'RIG[<
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ME3/VX!\ZL7_'<#Y4S]N RJ%H<0EQM1+;61*2I)U(R/B1D9=I& Y
M     #Y_;+6"7C'7[GENGI-#DGUU<&-14ULW);<UHR\/D.D _-@+#<+OUU[F
M7Q"5*A6*7?G)+Y^:2I$KT9INOA,E*,B\"3\ #Z! (K+IJV#2K6C;RRH61ZB4
MF*E)D=:U(R[*=U %?,SPN\X9>'[?<6%G&UGZ'-TGRGVJ^2I*NRM/.3VD8]QM
M]Q7-76/8X;5FLLQM?@%PS#((CKT11X]%=2]<)#B3)I:&SU<HCX:C7329%V%Q
M$.]W5<5)TGWIY-J5UE9+^Z_;ZI'\W8=2[/N?\(\S^LS?BEU=$=SF6VF %_\
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M6WX[=I<&6S%2EQF0Q"=6VX@R[%)41*(_" F+;#CMIAM>WU%;/P-H!M8
M         C;.MF+%F&5VG<*VW&9C&XMC;7&@Y):R84ZN*Z2DJ8D,R6W6GFZ+
M50E(JDSJ1D ]VV&TF*;4PKFW8"D3+Q?92KCD5_N*R>N-QF+4I1NON)2A/ UJ
M-*$)2DM1F15,S,-[  $8=1O,_N(W"Y*34\5BF\LDE56KE'0RIQK[@#=</K\T
MK":BHH[=$-1&6DZFPBO#A0!F@         !"G3.AQO&<U)Q"D&>=9.HB41IJ
M1W!1D95[2 36          (10AW],!]SEKY)[;,IYNE7+U%?G3TZJ4K0^SM
M3<          (3ZE&W'+7MN3:%+-.XF+*5H2:J)3,,S,Z=A%X0$V
M  #7<_(SP/*"21J4=HGD22(S,S]&<X$1=H#6>GQ*D;%[<H6DTK3CEK)25%0R
M,HK?:1@)(          $*;+H<1N=O@I:%)2O)(1H4I)D2B]4QBX&?: FL
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MI45CMA&E1&DR/T1K@9'Q(P&U
M
M
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M87O;6Z6V7BVY6/))RX8[<3:<-;!DA1/1GV5*0ZWI<0JODJHHCTTX@)5
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MCHE-3 1EM9U*X!O+F]YQ# T2YL2RPBFOWQYOT>,\9O$T2&FW*.F7'5J6A/N
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M4J^"9IH8"<?[[MM_[JO[YO6Q?,3T;TGTO0?-UZ^3R.5V\[F_<M'U_BX@)#
M                'S^Z+;W+R7J9W:R"X*-<VX,3WUJ5Q-).75LR27@))$22
M+P$0#IZ'+U+A]0NZN+I<U0IS<V:Z23JA3UONA-(5_DR5@/H.         Q#.
M+V!C(9F5H@MGD4^,S DW%=5N^B1S6I#*349Z&R4XM1I10E*.IU,!2393;6)?
M.M;.\[Q"(F%@.%S)K*G8Z>7%7=948X;L=HDT(_NBWW5$G@DB+LU) 7R
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M ,20LP''+KS,Q[]HY;9,1SA/=MT"0VD^"F9MI;CJ2LO%4EE[A& ^@H
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M]LRRZ3#Q.=@K1SWK>EQ1NWFXH?1(6W"U)HA%(S:UI6LUI2:M.JFH@^BH
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M'Y PIW<CK_O65VJDO%L+3#DW6XL^7'3-9M;3#4<G"JDW2>.JDUK1M?@ 7F
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MOO6%NKN/9TFK"[7-NT7UFU_W:1.G22^Y-K3Y*Z$EQQ1I,Z>29^<0"]8
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MB S8          QEQQS'KQ(8EW>TPY\N+_W9^5':?<:H>KR%.),T\2KP 9,
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MC%OA2K= LL"+;YR31.B,166V7TFDTF3J$I)*R,CIY1=@#P?W=[?_ .ZEF_\
M+HO_ &8#W?-3%_5?J3U) ]2Z^;ZN]%9]%YE:ZN5HT:J\:T 9<
M
M
M
M                 !PYK7,Y.M/-IJY=2U:>RM.V@#EJ29Z:EJ[:=X#]
M                               !Q4M"*:U$G49)*ITJ9]A "EH334HB
MU'I*ITJ?@+Q@.0#K??8C,KD27$,L-EJ<=<42$)27>9G0B(!S2I*TDM!DI*BJ
ME1<2,C[R ?H       /Q:T-I-:U$E!=JE'0B]\P'[4O"     ZF9$>22SCNH
M>)M:FG#;42M+B#HI)TK0R[R =H
M
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MI]IN#*),*9'43C3K+J24A:%%P,C(P'L
M
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M@$Y@
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M[>V[;V1>47V):%OE;YQ1?0G.1(=6^:'$$Z\1FE;BJ*(R\FG"O$PD,
M
M                             !@LU^:WS0OOSWY'S.]!D>O?2Z\CT'EJ
MYVNG&FBOF\?!Q 11TZ?HW^B7'^X+3RN6WZ7SO6O/]&YKNGD^M_NG(YO-KR?N
M?,U5\JH"=  !YKAR/0)/I/.]'Y2^;Z+SN?IH=>7Z/]UU4[.7Y7@X@*U;#?HD
M_/F?_<=Z?\\^2OUOH^=.GE<TM7I7K#[A]\I]]XU]\!9X
M
0                  ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>lc_fig20prepost-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig20prepost-bw.jpg
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M="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,  X0DE-! 0       \< 5H
M QLE1QP"   "  ( .$))300E       0_.$?B<BWR7@O-&(T!UAWZ__N  Y!
M9&]B90!DP     '_VP"$  0# P,# P0# P0&! ,$!@<%! 0%!P@&!@<&!@@*
M" D)"0D("@H,# P,# H,# T-# P1$1$1$104%!04%!04%!0!! 4%" <(#PH*
M#Q0.#@X4%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%/_  !$( P<#M@,!$0 "$0$#$0'_Q "C  $! 0 " P$!
M        !P@%!@$"! ,) 0$!                     1   0,# @(#" T(
M!P0(! 0'  $" P0%!A$'(1(3-P@Q(A24M)475T'1,M)TU!5U%E9VMAA1<7.S
MT[4V=V&Q0B,S53B!4K(TD6*2PI,DEAFA0Z-4<E.#)8*B1&0U90D1 0$! 0
M               1 4'_V@ , P$  A$#$0 _ -_
M                 $>[3V?Y/MCL[><RP^HBIK]0RTK8)IX6U#$;+.UCTY'\
M%U:JI_0!FS%MP.WQF.(46>XQ!9[GCM= ^KHN6&@9/-'&YS51(5>U_,JM5.7N
MA5D[*W:1N.]5!?;+F%O@M>:8RK%K_!T=%!+ Y58KUCD55C>Q[5;(WF5/R!%Y
MK,JQFW14\]PO5!205<O@]+)454,3)9N[T;%<Y$<[_JIQ _6[Y!8<?IF5E^NE
M':Z-Z\K*BNJ(J:)SEXZ(Z5S450/HM]QH+K2QU]LJH:VAF36&JII&S0O3\K7L
M547_ &*!]0
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MJ.:J?T*G!0/T
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ME<GIYIJ.AO\ 1U$/@U7#"DR*BNYFHJ.:^-'<VKFJFO$#^@
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M#T?A#^EEY.97=\_1-5U<OL =A
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M@
M
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M!Z&JSUF9MYRI/B0#T-5GK,S;SE2?$@'H:K/69FWG*D^) /0U6>LS-O.5)\2
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M"F@
M  "*[M=<FQ_SG>OW8X"U  )=V<^IC%OT=5Y;.!40
M .,M616&^RUT%EN=)<9K9,M)<8Z2>.=U-4-[L4R,558]/]UW$#DP
M                            &7<4ZO,Y_F_#]Z[8!J(          F66
M]=6V_P !R']52@4T
M                17=KKDV/^<[U^ZW 6H !+NSGU,8M^CJO+9P*B
M             ":[ZQ75FWM==K7G,NWJ61S;G5Y##1I<-*>G15=$^%517-<J
MIJU.[II[(&.^S_5[K7'<>*SW_,9,%3/JQNX5OB@M$2NR6)[E21BRI(J4Z.9#
MSN@[FCU7\FH?T.                                     9=Q3J[SG^
M;\/WKM@&H@         "99;UU;<? <A_54H%-
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M\!],,23BM^MVGPR#WX'+PS1SQLFA>V2&1J/CD8J.:YKDU145."HJ >X
M                &7<4ZO,Y_F_#]Z[8!J(          F66==6V_P !R']5
M2@4T
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MT5/DVE[B_P#Z8'>**BI;=204%#"RFH:6-D%-31-1D<4434:QC&IP1K41$1$
M_<                     #+N*=7><_S?A^]=L U$          3++>NK;C
MX#D/ZJE IH
M          BN[77)L?\ .=Z_=C@+4  EW9SZF,6_1U7ELX%1
M                                                &7<4ZN\Y_F_#
M]Z[8!J(          F66==6W'P'(?U5*!30
M                                  !%=VNN38_YSO7[L<!:@ $N[.G4
MQBWZ.J\MG J(
M            R[BG5YG/\WX?O7; -1          $RRSKJVW^ Y#^JI0*:
M                                                          (K
MNUUR;'_.=Z_=C@+4  EW9SZF,6_1U7ELX%1
M                                   &7<4ZO,Y_F_#]Z[8!J(
M    F66]=6W'P'(?U5*!30
M                     !%=VNN38_YSO7[L<!:@ $N[.?4QBWZ.J\MG J(
M                                                           R
M[BG5YG/\WX?O7;"#410         3++>NK;?X#D/ZJE IH
M                                              BN[77)L?\ .=Z_
M=C@+4  EW9SZF,6_1U7ELX%1
M                        &7<4ZN\Y_F_#]Z[8!J(          F66]=6V
M_P !R']52@4T
M            17=KKDV/^<[U^[' 6H !+NSGU,8M^CJO+9P*B
M                             'C5-=->('D                  9=Q
M3J\SG^;\/WKM@&H@         "999UU;<? <A_54H%-
M                                           $5W:ZY-C_ )SO7[K<
M!:@ $N[.?4QBWZ.J\MG J(
M EV_N9WO"\$;+C4R4=_OEQHK#;[FZ-)VT4EQDY'5/1N[U[HV(Y6->J-5_+KK
MW%#,'HQQ37I8EN$5_P"?IFY2VX52WM*Q5U\*\)61467F[[BWE]CEY> &I=AL
MRO><[<45WR61E1?Z2IKK1<*V)B0LJI;7524JU'1-X1NE2-'N8G!'*NG "E@
M               &7<4ZO,Y_F_#]Z[8!J(          F66==6W'P'(?U5*!
M30
M !%=VNN38_YSO7[L<!:@ $N[.?4QBWZ.J\MG J(
M                  ZSG^#6;<;%:[$[XZ:&EJ^1\-;2/Z*KI:F%Z20U%/)H
MO)+$]J.:NG]"ZHJH!GWT$[[N=\F.RG&&4G-T*Y.VCK/E-(>YX0E"J^#=/IQY
M.DZ/F_HX :%P7"K-MYBMNQ&P]*ZWV]BIT]4_IJJHFD<LDT\\FB<\LLCG/>[1
M.*\$1. '8P                #+N*=7><_S?A^]=L U$          3++.N
MK;?X#D/ZJE IH
M             BN[77)L?\YWK]UN M0 "7=G/J8Q;]'5>6S@5$
M                                                  9=Q3J\SG^;
M\/WKM@&H@         "99;UU;<? <A_54H%-
M                                    $5W:ZY-C_G.]?NMP%J  2[LZ
M=3&+?HZKRV<"H@
M             #+N*=7F<_S?A^]=L U$          3++>NK;CX#D/ZJE IH
M
MBN[77)L?\YWK]V. M0 "7=G/J8Q;]'5>6S@5$   Z-N-NSB6V%+1/R%U14W6
MZR.AM%BMD*UESK7QIS2+# U4U9&WOGR.5K&^R[54U#A<'W^PO-\A3$_!+ICF
M2SQ/J+=;<AI/ )*Z*)-95I7(^2.1T>J*]B/YT3ON7E15 J8
M                                         9=Q3J\SG^;\/WKM@&H@
M         "99;UU;;_ <A_54H%-
M                           $5W:ZY-C_ )SO7[L<!:@ $N[.G4QBWZ.J
M\MG J(  !DK=!LM'O[=?EE4957>QT+,2?*G&6CI'2+7P4[UU[YLKF22QM5%5
M%:[E5$U".JY-'-47'$++0-5V5UF1VN?'Z9B*E6CJ.I;+53Q<-8VQTZ2=+*NC
M4:O*J]\B!6WP
M      R[BG5YG/\ -^'[UVP#40         !,LMZZMM_@.0_JJ4"F@
M                                                     "*[M=<F
MQ_SG>OW8X"U  )=V=.IC%OT=5Y;.!40  #K.;[?8=N/:&V/-;3#=K;'*VI@9
M)S,EAJ(_<RPRQN9)&]-53F8Y%T54[@'$X1LSMKMU<:J\8A8F45XK(DII[C--
M45M5T#5YNB;+522O8S5$<K&*B*O%0.^
M                         !EW%.KS.?YOP_>NV :B          )EEG75
MMQ\!R']52@4T
M            17=KKDV/^<[U^[' 6H !+NSIU,8M^CJO+9P*B
M                                                 ,NXIU>9S_-^
M'[UVP#40         !,LMZZMN/@.0_JJ4"F@
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M0_JJ4"F@
M       "*[M=<FQ_SG>OW8X"U  )=V<^IC%OT=5Y;.!40
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M]=6V_P !R']52@4T
M                17=KKDV/^<[U^[' 6H !+NSGU,8M^CJO+9P*B
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M<4ZN\Y_F_#]Z[8!J(          F66]=6V_P'(?U5*!30
M                                            !%=VNN38_P"<[U^[
M' 6H !+NSGU,8M^CJO+9P*B                  (QOGN=D.+2V;"L&\'@S
M+(F5%2MVK&=/!:[;1JQ)JGH-4Z:572-CAB54:KEYG=ZU44)"S<W=W GMRFLR
MJ3-,?MS>EO\ 8;G1T-'+)1,XRSTE12QQ*R:-NKT8_5KT3EX+H!KNVW"ENUOI
M+I1.5]'6PQU-.]45JNBF8CV*J+Q35%[B@?4
M             9=Q3J[SG^;\/WKM@&H7.1B*YRHC43555=$1$]D"8U7:$VFI
ML$O6Y#+^RIQ&Q5LEKJJV".1RR5T7*G0P-<UJRJY7IRN;WJ]W7E15 ^W:O>C!
M=XJ"MJ\0J)VUELD;%=+3<(74E?2ND158LD3M>]>B:M<U53_:!0@      3++
M>NK;?X#D/ZJE IH
M               BN[77)L?\YWK]UN M0 "7=G/J8Q;]'5>6S@5$
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MZ'-YJ3DLLU2Z18FZ2*[G;&YZ<K97,1JJ!7@)EEO75MQ\!R']52@4T
M                                                     17=KKDV
M/^<[U^[' 6H !+NSIU,8M^CJO+9P*B
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MO6G>V.FZ5TBHB<Z.3E1$]C0#1X
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M#B!9D1$X)P0"999UU;<? <A_54H%-
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M30
M !%=VNN38_YSO7[L<!:@ $N[.G4QBWZ.J\MG J(
M                             #/N[W^HC9#]+>?)F@:"        R[BG
M5WG/\WX?O7; -'Y%>H,<L%UR&J8LE+::.HKYF-]TZ.EB=*Y$_I5&@1K8)^5[
MKX-Z1MV::RW-^2RNKL7M[**&7Y,MJJYC('22,YG\6\_%RKQXKKP0/DV4S/<6
MT[F9;L9N9<:;(;A8J.&^V'(:6%E(LMLJGHSH988VM:U8U<UK=/Z>*IHH&@P
M     3++>NK;?X#D/ZJE IH
M                       BN[77)L?\YWK]UN M0 "7=G/J8Q;]'5>6S@5$
M       #I&Y^YUEVOL45RN,$URN]QF2BL-AHD1U9<*UR*Y(H^;1K6M:BOEE>
MJ-8Q%5?810E%-VG;Y::FGJ]P<';9<3>YK+C>K9=67=UN1ZZ-EJ8&T\+EA:JI
MTDD:NY.[HJ :*AFBJ(F3P/;+!*U)(I6*CF.8Y-4<U4X*BIW% _0
M                              9]W>_U$;(?I;SY,T#00       &7<4
MZN\Y_F_#]Z[8!IRKI*>OI9Z&LC;-25,;X:B%Z:M?%(U6N:J?D5%T4#,5JV/[
M1&U\$N+[,[C6I-O(YI)K1:\EHW5%50,F>KU@9,R.3G8BJJHJ\O\ ^'N@4+9K
M9BY8%=+]G.<9$_+=T<IZ)EXO2QI3T\--!_ATM+$G!L;=$XZ)KHG>IH!80
M   3++>NK;?X#D/ZJE IH
M                     BN[77)L?\YWK]V. M0 "7=G/J8Q;]'5>6S@5$
M     #.G:;M]9:;CAFX\T<T^+8[\I4-^EA:LO@$5TCC9'6.8U.;HFNCY)W)K
MRM5%T[J@1G(,OQZNM,]EL%PI[_D-_@EMMCL]GGAK:NKJ*N)T;>1D3UY6-1W/
M)(_1K6IJJ@;0P2S56.83C>.5ZL=76>U4-OJG1*JQK+2T[(GJU5T54U:N@'80
M                                      !GW=[_ %$;(?I;SY,T#00
M      &7<4ZN\Y_F_#]Z[8!HG*,LQK"K1+?\MNU+9;-"J-DK:Z5L$7,NJHU%
M<J<SET71K>*^P!*T[7O9P63HTSZCU7V5@K$;_P!/0: 5C'<FQ[+K5#?,7NE+
M>+/4?X-=0S,J(7*G%4YF*J(Y->+5XI[('*@      F66==6V_P !R']52@4T
M
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MA;*M*CV6EV0(J<ZT;5[W3DY^;DX?D[WE UJ      "99;UU;;_ <A_54H%-
M                                                           $
M5W:ZY-C_ )SO7[L<!:@ $N[.G4QBWZ.J\MG J(
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M%-
M  $5W:ZY-C_G.]?NQP%J  2[LY]3&+?HZKRV<"H@
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MOW;S#?S*<;FPRTW^V4EEL5BKM&W">"G<QZU54Q-%8[O$:U')KHNG<1%4-(@
M     F66]=6V_P !R']52@4T
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M7*JL<CE1')_3W&JBH!<0      3++>NK;CX#D/ZJE IH
M                                            BN[77)L?\YWK]V.
MM0 "7=G/J8Q;]'5>6S@5$
M      SIVU^IB'[067RI -$L]PW\R >P        #/>RO7]OO\.L_DC@-"
M,NXIU>9S_-^'[UVP#N.\6T6;WC+[-NYM!>J6S[F62CEM4M/=(UDMMSMLCEE\
M'FY$5S5:]55KD3_H5$4#KB95VV%C\$^@.'MJ/<+<5N4G0:Z:=)T:3<^GLZ=T
M#L^RVT&78SDM_P!TMU+Y3WW<[)X8:.H2WQK';J"@@T<VFI^9&JY-43F<J)W/
M975RA;0      3++>NK;CX#D/ZJE IH
M                               BN[77)L?\YWK]UN M0 "7=G3J8Q;]
M'5>6S@5$                                             SIVU^IB
M'[067RI -$L]PW\R >P        #/>RO7]OO\.M'DC@-"  ,NXIU>9S_ #?A
M^]=L(-.5=734-/)5ULT=/20M5\U1,](XV-3NJYSE1$3\Y1U--W-JG2="F<8^
MLJ\.5+K1ZZ_^*!^%IPRH3<:X;E09565MFNUJAM]-C:2=):X71O:_PJ+1ZM5[
MD;IJC?97BH'>0      3++>NK;?X#D/ZJE IH
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M3<?:O;NZS77::UT-)<8*=\ZUE/:[O,]&RTL,RJO!R*Y5;K_9T7OFJH&K0
M   3++>NK;?X#D/ZJE IH
M                     BN[77)L?\YWK]V. M0 "7=G3J8Q;]'5>6S@5$
M                                           SIVU^IB'[06;RI -$
ML]PW\R >P        #/>RO7[OO\ #K1Y(X#0@ #+N*=7F<_S?A^]=L(.]=I&
MKV&APZ"'?:*GJK9-*YMGI4;(^YOJE;RKX$E.J3([14YG-5&]SF]@HR(E/V54
M8DDE@W6^0M?\%S*CP'H_]SA)S<NG_6U"MC=G>JV-J,)<W8F.E@L$4J-N-/$V
M1E<RJY?_ .L2?697Z)P5ZJFGN5T"*Z      "999UU;<? <A_54H%-
M                                                      $5W:ZY
M-C_G.]?NQP%J  2[LY]3&+?HZKRV<"H@
M                &=.VOU,0_:"R^5(!HEGN&_F0#V         9[V5Z_M]_
MAUG\D<!H0 !EW%.KS.?YOP_>NV ?/OC60;;]H/#MZ<YL]3=ML:.QU%F^4*:F
M6L2RW5T[I6U<D;4541['<B/1->[IQ1$4.\KVPNS>E+X7].Z7DY.?H_!JWI>Y
MKIR=!S:_T: =)[/CTSG>_<+>;$[%46+;&^6^CMM!+4TZT7RM7P/:Z2M9#HG!
M$:Y.?V>;CWRN1 U.      "99;UU;;_ <A_54H%-
M                                        $5W:ZY-C_G.]?NQP%J
M2[LY]3&+?HZKRV<"H@
M  &=.VOU,0_:"R^5(!HEGN&_F0#V         9[V5Z_=]_AUH\D>!H0 !EW%
M.KS.?YOP_>NV 4'>#>Z3 ;Q9L$Q?%:K.-P\BBEJ*3':1[(6,H8=4?/432(YK
M&*J*U-4T71=53V0CD&Z=ZW$O7R!LULO9Z7/[,U\^;NRNF@IH[15)*Z)D"21L
M8Z627E61CVK[CCR]WE"O[*[QWK-;I?\ ;_<''DQ7=#$^C?=+5 ]9:*>CG_P:
MFE?J[6-=414YG:<./'1 LH      )EEO75MQ\!R']52@4T
M                                              17=KKDV/\ G.]?
MNQP%J  2[LY]3&+?HZKRV<"H@
M         &=.VOU,0_:"R^5(!HEGN&_F0#V         9[V5Z_=]_AUH\D<!
MH0 !EW%.KO.?YOP_>NV <YO)A6YE@W1L6^^T]IILHNU%:I,;R#%JB9M++46^
M299V2T\KU1J/8]>^]G1$T1VJZ!4[?B%IQBYY/GUHMDGTLR>FIZB\T3*ARQU-
M5;J=8X6-1VK6.T_N^9$X]W0"5[%8=N5>-Q<IWWW4M,6,7C(:&GLMDQ6*1)Y:
M2VTSFR<\\B+ISO<U.'!?=:HW@@&AP      3++>NK;CX#D/ZJE IH
M                                                     BN[77)L
M?\YWK]V. M0 "7=G3J8Q;]'5>6S@5$
M               SIVU^IB'[0V7RI -$L]PW\R >P        #/>RO7[OO\
M#K1Y(\#0@ #+N*=7F<_S?A^]=L TW6UE-;Z2>OK96P45+&^>IG>NC(XHFJY[
MG+["(B:J!QN+958,UL5)DV+US+E8:]JOHZZ)'-9(UKE8JHCT:O!S53B@',@
M      3++.NK;CX#D/ZJE IH
M                        BN[77)L?\YWK]V. M0 "7=G/J8Q;]'5>6S@5
M$      'I+*R%CI)%1L;$5SWN5&M:UJ:JJJO!$0"<VWM ;+WB]0X];,WM53=
MJF=:2EB9.B1S3HJIT<<RHD;W.5-&HUZ\R\&Z@4D
M              #.G;7ZF(?M!9?*D T2SW#?S(![         ,][*]?N^_PZ
MT>2. T(  R[BG5YG/\WX?O7; -)WNWPW:SW"U5,$=53U]-/2RTL^J12LFC5C
MF/Y=%Y7(NCM/8 R1A6"]LG:_'J3%+/D&%,Q^F<^.ST5S?4S.IHG/<]L$4JQL
M>]K>;1.D5SM +/M7!VCHKY6+O+4XU/CZTO\ Y!+ VH;4)6=(WW?3(B<G)S?[
M= *^      "999UU;;_ <A_54H%-
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M=6V_P'(?U5*!30
M             !%=VNN38_YSO7[L<!:@ $N[.?4QBWZ.J\MG J(      .(R
MC&+#F=AK\8R>ABN5AN<2P5U%.FK'L=Q[J:*US51'->U4<UR(J*BH!%8^RE8Y
MG1T%[S?)KSB;'?WU@JZFG:RIIVKPIZBIB@9421:=Z].D17)P50+U145+;J6"
MAH8(Z6AIHV04U- QL4,44:<K&,8U$1K6HB(B)P0#]P
M                9T[:_4Q#]H++Y4@&B6>X;^9 /8        !GO97K]WW^
M'6CR1X&A  &7<4ZO,Y_F_#]Z[8!IVIA6HIY8&R/A65CF)+&NCV*Y-.9J^PJ=
MU ,PV?L81X]+7SV'=O-+9+=9GU5R6CK(H/"*B555\LB,C1%>Y5XN[H'SV[L1
MT5G\+^2=V,UH%KYUJZYU+7LA=45+DT6656,17O5$]T[50-%8+BSL)Q.UXLZZ
MUM\=;(EA6[723IJV?5[G\TK_ &53FT_,@'80     F66==6W'P'(?U5*!30
M                                                          !%
M=VNN38_YSO7[L<!:@ $N[.?4QBWZ.J\MG J(
M                    !G3MK]3$/V@LOE2 :*9[AOYD \@        ,][*]
M?N^_PZT>2/ T(  R[BG5WG/\WX?O7; -/RRQPQNEE>UD3$5SWO5&M:UJ:JJJ
MO<1$ CE5VH-JXMM+QNK2U-568O:KE)9(%BIU;-7US%:C&TC7JG.U_-JURJG!
M%5=- .5VAWSQO=Z.YTE%;Z_'\JL3F,O>,WJ'P:OIDF3FBD5NJ\T;T[CO^E$X
M:A40      3++.NK;CX#D/ZJE IH
M                            BN[77)L?\YWK]V. M0 "7=G3J8Q;]'5>
M6S@5$                                 .O9GG6([>69;_FEWI[-:4D
M; R>I<NLDS_<QQ1M1SY'JB*J,C:KM$5=-$4#B<'W?VWW)J*NCPC(:>ZU] UL
ME71(V6GJ61.5$23H9V1O5FJZ<Z-Y=>&NH'=P        &=.VPJ)LO$J\&MO]
MF<Y?81$J4557\R 4]N]6T#6HBYW8M41$_P#\C3>_ \^FO:#Z]6+SC3>_ >FO
M:#Z]6+SC3>_ >FO:#Z]6+SC3>_ >FO:#Z]6+SC3>_ >FO:#Z]6+SC3>_ >FO
M:#Z]6+SC3>_ >FO:#Z]6+SC3>_ >FO:#Z]6+SC3>_ E>P5TMEZWNWPNUFK(;
MA:ZJLM#Z:MI9&S02-2E>BJQ[55%T5%3@!H\ !EW%.KS.?YOP_>NV :(R^T39
M#BM]L%-+T%1=K=5T$,Z]R-]3 Z)KN'Y%=J!AS#\+W)SV3:'8^_8'<L<Q_:VX
M/N.:7:LC6.UUKZ>57T_@TJ)RS=*G-JK5757JON4U MFSU#E>6[_[A[PW/':O
M&<8DHH<6M$-P:L517OH)DZ2J1FB:LUCT8[BFBHB*NB@:1      !,LMZZMM_
M@.0_JJ4"F@
M         "*[M<=Y=CT3N_*=[73^A+6[4"U  )=V<^IC%?Z8JI?^FLG J(
M                              ^*[7>U6.B?<;S74]NM\:HDE7631T\+
M5<NC45\BM:FJKHG$#)>>W>VY?O9=;HE;2WBDL5JH6XA/3U$=7!#!5K*EPG@2
M-RL259F,BEDXO:U&MYD1V@' Y%+)17?$,BMSEBRVDR*U45EK(U_\T]E=5,BJ
MZ9NB\TK)*=9%DB75.5.;3O=0-B9E?'XQB5^R6*%*F6S6ZKN#*=SN1LCJ6!\J
M,5R(NB.5NFN@'%[5YE-N'MWC><5-&RWSWZABKI**-ZRLB=*FO*CU1JJB?ET
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MVM1K^&B::JNKN* 7L      $RR=-=[L 3_\ U.0*GY]:) *:
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M[D[I:^EIZES6/I9I/[6BO:K?Z$U1$YM$#2H      )GDW7?@'S3D']="!3
M                                                          !$
M=^OXOV6^VD/D52!;@ $O[/?5;;_G"]?O:K J
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MW7?@'S3D']="!3
M              !$=^OXOV5^VD/D52!;@ $O[/?5;0?.%Z_>U6!4
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MX*!]@     3/)NN_ /FG(/ZZ$"F
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M4(Y4     )GDW7?@'S3D']="!3
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MY45&_F M@
M         B._7\7[*_;2'R*I MP "7]GOJMM_P X7K][58%0         <5D
M62V#$;3/?<GN=+:+-3)K45U=,RGA9KW$YGJB*JKP1$XJO< X?$-S]OL^EJH,
M+R6W7RIHD1]73T50R66)CNXYS$[Y&JJZ<VFFH';0
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MEF2-:)6))T:)S(U554U_*!:@
M                       !$=^OXOV5^VD/D52!;@ $O[/?5;0?.%Z_>U6!
M4         &4-YW/R'>I]GOK/"+3B]FHKGCUMG5LE,M57SSQSUZPJG*Z5G1M
MA8KT7H^+DTYT Z3D[W6*:U9Q942DRVRW"@CMM?3M1DLD=;614\U+(C-%FBE9
M([6)=>/%-%0#<H           ^>NKJ2V451<:^9E/04D3ZBJJ)%Y61PQ-5[W
MN5>XC6HJJ!F"7?[=;)Y9;SA-NL=DQ"I3FL;,A@K:FY5<"\65,S*:6)L#)4T=
M''WS^5=5_(!7MG]TG[C6ZX4=YMR6;-K!)%3W^UL?TU,O3M5\%52RZ)TE/.U%
M<Q7(CFJCF.35NJA20        '3]V>JS-_F"Z>1R@=9[,_4%MY\RTO\ P@58
M      &=.VOU,0_:"R^5(!HEGN&_F0#V         9[V5Z_M]_AUH\D<!H0
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M"!3
M   !$=^OXOV5^VD/D52!;@ $O[/?5;0?.%Z_>U6!4         $[W.V?L.YD
M=!63UE58\IM"O6SY';%8RL@;*G]Y"])&O9+!)HG/%(U473AHO$#KF&]G>TV#
M):3+,IR"NS"Z6I5DL4%?%34U!0SN3E6I934T;&OG1%5&RR:\B>YT7B!9P
M      "$[&7^^W;<_>^W76YU5=;[1D-+3VJEJ9GRQ4L+J=SE9"URJC&JOL-"
MJUF6/,R[$K[BTDRTS;U;ZJW+4(BJL?A4+HD?HBM5>7FUTUXA&*4R>GP2&'$=
MQH)\;RBRP14=3!+2U,]+5,IV)$RJHIZ>%S)H94;S-TT<Q>\<B*@%Y[...7YM
M1E&X5WMT]GM^3MMU+9+=7,6*N=16IDS4JIXG<8NG=.Y61.[Y&M15]T!>0
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M      $SR;KOP#YIR#^NB I@
M                        B._7\7[*_;2'R*I MP "7]GOJMH/G"]?O:K
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MB2355<Y.=7(W\FJ@:)      !,\FZ[\ ^:<@_KH0*8
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M371 /?LS]06WGS+2_P#"!5@      9T[:_4Q#]H++Y4@&B6>X;^9 /8
M   !GO97K]WW^'6CR1P&A  &7<4ZN\Y_F_#]Z[8!I6[W2CL=JKKU<'+';[=3
MS5E7(B:JV&G8LCUT_H:U0,<1;W;\7V];79]4UM#CNV>X64T]KM6*4].RHN#K
M5TCD66JJ9&KHZ5K5[V-4[J*F@%DVHW+SJJW2S?9[<MM'/?;&UM[L5TMS5CAJ
M+-62:1L>U=/[R+G8S73CQUUTYG!<       3/)NN_ /FG(/ZZ$"F
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M>+W*J-YEU5.]]TY550+D      "9Y-UWX!\TY!_70@4P
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M$;*&L?$JT]13O5S$J&.TY)6*G,Q5[U-0C6       )GDW7?@'S3D']="!3
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M/      !,\FZ[\ ^:<@_KH0*8
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M #6V;B8=:,SM$<L-#=H>E2GG1$FAEC>Z*:%^BJG-'(Q[%5JZ*J<. '90
M SWLKU^[[_#K1Y(X#0@ #+N*=7F<_P WX?O7; -1          $SR;KOP#YI
MR#^NB I@
M        B._7\7[*_;2'R*I MP "7]GOJMH/G"]?O:K J
M       &>.SYUM]H#[34GDK@K0X0      !G_LP?\UNY]NKK_P!P#0
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M:B:\0.\     !GO97K]WW^'6CR1X&A  &7<4ZO,Y_F_#]Z[8!J(
M F>3==^ ?-.0?UT(%,
M                  $1WZ_B_97[:0^15(%N  2_L]]5M!\X7K][58%0
M                  SQV?.MOM ?::D\E<%:'"       ,_]F#_F]W/MU=?^
MX!H         !$=]OXVV4^V#?(:@"W  ,Z=M?J8A^T%E\J0#1+/<-_,@'L
M       SWLKU^[[_  ZT>2/ T(  R[BG5YG/\WX?O7; -1          $SR;
MKOP#YIR#^NA I@
M              B._7\7[*_;2'R*I MP "7]GOJMH/G"]?O:K J
M        !T/=K<5NVV,1W2FM[[OD%RJ66O'K2QR1-J;C4-<YC9)5X1QL:Q\D
MCU[C&KIJO "#0[L;^VJ6*\55;8<D2)W2UV+TE!+0=-"JZOAHJQ\SW)(U.$3I
MF:.7W6@&F<.RRSYUC%KRVP/=)9[M3LJ:5TC>21$=JCF/;JO*]CD5CTUX.10/
MVR;)[!AUCK,ERBX06JQ6]G2UE?5/Y(HVZHB?TJYRJC6M;JYSE1$154#,'9\W
M-PQF[NZ#*RMFMKL_OM-68<MSHZJWLN43*96JD+ZF)C>?5>]C<J/=PT10-:@
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M         "9Y-UWX!\TY!_70@4P
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M&_F0#V         9[V5Z_=]_AUH\D>!H0 !EW%.KO.?YOP_>NV :B
M   )GDW7?@'S3D']=$!3
M                    !$=^OXOV5^VD/D52!;@ $O[/?5;;_G"]?O:K J
M              #/FZO^IK9']%?_ "1 -!@  ' YCAF-9_8*G&,MM\=SLE7R
MK+3R*YKFO8O,R2.1BM?'(Q>+7L<CD]A0)UCG9HV\L%\M^05E3>,EK+0]L]I@
MR&XR7&EI:EGN*AD+D:U96)[A[T=R]U-'<0+&!C[=-4W W7R.@RIBUM@PF6CH
M;%8*E$6B;45=(VJFKIH>+997\Z,A5^K6L35&HY54#BL7Z/;7<#$[WAL3+5#D
M=ZH<:R*TTR=%;JZEN'2-CED@;HUM13N;S12L1KE17-=JU0-?99_"U\^;ZO\
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M7<4ZN\Y_F_#]Z[8!J(          F>3==^ ?-.0?UT0%,
M                                             $1WZ_B_97[:0^15
M(%N  2_L]]5MO^<+U^]JL"H                ,^;J_ZFMD?T5_\D0#08
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M0@4P
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M--SPQ]'!2TL:\6T].SO(^?5[M5<[B[1 I0 "([[?QMLI]L&^0U %N
M S[N]_J(V0_2WGR9H&@@       ,NXIU>9S_ #?A^]=L U$          3/)
MNN_ /FG(/ZZ$"F
M              "([]?Q?LK]M(?(JD"W  )?V>^JV@^<+U^]JL"H
M        ,^;J_P"IG9']%?\ R1 /VWGVLRVHR=FY&WE+%>+C4TD5LR3&)IF4
MDE93TSWNIZFDJ9>\CG@Z1S71R:,E8NFK7-34CIV/;2[CYID%OI<RQ],1P:W5
M-/<;FE16TM?<+G+22MGAI86TCG-AB21C7S2N?SKIR-1-54*U<      #A\L_
MA:^?-]7^I>!)^R!_IRP?X/5>6SA,7 * 9_[,'_-[N?;JZ_\ < T
M B.^W\;;*?;!OD-0!;@       ,^[O?ZB-D/TMY\F:!H(       #+N*=7F<
M_P WX?O7; -1          $SR;KOP#YIR#^NA I@
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M?O7; -1          $SR;KOP#YIR#^NB I@
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M.0?UT(%,
M        $1WZ_B_9;[:0^15(%N  2_L]]5MO^<+U^]JL"H
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MEW%.KS.?YOP_>NV :B          )GDW7?@'S3D']="!3
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M)F@:"        R[BG5WG/\WX?O7; -1          $SR;KOP#YIR#^NA I@
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M-0!;@       ,^[O?ZB-D/TMY\F:!H(       #+N*=7F<_S?A^]=L U$
M       3/)NN_ /FG(/ZZ$"F
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M<@_KH0*8
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MMKJ6XJ^-DLD"=ZRHIW-1T4L:-<O?-=S(H&V    !$=]OXVV4^V#?(:@"W
M     9]W>_U$;(?I;SY,T#00       &7<4ZN\Y_F_#]Z[8!J(
MF>3==^ ?-.0?UT(%,        E=\[2&R6-W:ML=WR^FBN-MDZ"XMAAJJJ*GF
M3W3)9J>&2)KF?VT5_>?VM *5;KC0W:BI[G;*B*LMM7&R>CK*=[989H96HYDD
M;V*K7-<BZHJ*!]0
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MT D6\.2XW?LYV9CL=XH;G+#E['2QT55#4/8U:*H3F<V-[E1-?9 T$
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M&9[_ &&MN].JK_\ 0 V3;*WY2M])7I&L254$4_1JO-R]*Q'\NOLZ:@?6
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MH&@@       ,NXIU>9S_ #?A^]=L U$          3/)NN_ /FG(/ZZ$"F
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MMMSY:*;/L>I[Y);FR-HEJ'2MZ-LRHKT1(WM1=>5.Z!T_\)?9T]7]O_[=1^U
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MKMM*J@?E]MMB4]39;A<JQT=;!15D7.VDDDZ.19DA5')'(Y>;E5&K[E /O_\
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MKG[X#3W9EW,R?=?;NJR;+%IG7.*[5EOC?11.@B=!3I&K%Y'.<J*O,J\0+,
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M"KG0MJJ2>2FF6)7=]T;GQ.<SFX\JIKQ [P  R[BG5YG/\WX?O7; -1
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MJ@=B                1'?K^+]E?MI#Y%4@6X !+^SWU6V_YPO7[VJP*@
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M0VF]_(ZVFM\/6H5RT?2I*BJO(C$Y5:OLZJ!HT
M                                     1'?K^+]E?MI#Y%4@6X !+^S
MWU6T'SA>OWM5@5
M               9=Q3J[SG^;\/WKM@&H@      ?-7T--<Z&IMU:Q):*LBD
MIZF)>X^*5JL<WA^5% A[-F-PJBR4VV5TRRCJ-I*66).]I7MOT]OIY$ECH9)5
M=T2,3E:Q96MYU:G].@1=XXV1,;'&U&QL1&L:G<1$31$"IKDW7?@'S3D']="!
M3
M !$=^OXOV5^VD/D52!;@ $O[/?5;0?.%Z_>U6!4
M                                       !EW%.KO.?YOP_>NV :B
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MKQ&F]X$J4LVB>G:$DRU<9MWH]=C#;<UW0TBQ_**572?\MRZ\W+_\SE[G#7V
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MJ_G5J<W< N-)54]=2PUM)(V:EJ8V302MXM?'(B.:Y/Z%1=0K]@
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M;;VW36[&*-8&U4JU%=532/J*NIG5-.DFFE5SWNT[FJ\/8 [.
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M;M1]&L@M%^D=7)35EUHV4M'.RV\W221.657/8[E7E<C/^@"T@
M
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M[KW-.(=ZSE5_&1M6FO!,;O:HG]*M>%:,"
M
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M_(%5SC_61M7]F[W_ ,,@&C @
M
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ME2*Z.Q[$[GX/'.VBK$=TC:9O3+(Z.%'<59'IPXZ!6A @
5                        '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>lc_fig21prepostfollow-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig21prepostfollow-bw.jpg
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M="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,  X0DE-! 0       \< 5H
M QLE1QP"   "  ( .$))300E       0_.$?B<BWR7@O-&(T!UAWZ__N  Y!
M9&]B90!DP     '_VP"$  0# P,# P0# P0&! ,$!@<%! 0%!P@&!@<&!@@*
M" D)"0D("@H,# P,# H,# T-# P1$1$1$104%!04%!04%!0!! 4%" <(#PH*
M#Q0.#@X4%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%/_  !$( @P#M@,!$0 "$0$#$0'_Q "<  $! 0 # 0$! 0
M        !P8$!0@# 0() 0$!                     1    4" @,'$ <%
M!@0% P4!  $" P0%!A$'(1(3,=,4M58W"$$B,K+2DW24%55UE19V%QA1<[.T
MU#5782,S=SAQL4(T-I:!DD-44F(DI@G1)2:1H8)3A4@1 0$!
M       !$?_:  P# 0 "$0,1 #\ ]_
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MB6RXS;,5LZ:AU$&0Y+?KJWT-D3BCT-QD%KZKI(U5;NMAN!Z3
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MQ*LRWB9N07'<-HDR(U),TIUBW,0%?
M                  >8NG)0:C<66-NTZG4Z54S5<T!4B/#:<?<)C9ODM1DT
M1F2<#[(!O+!Z+F1V6E=:N6U;70W78YXQ)LR1(G+849&DU-%(<6E*L#[(BQ^@
MP$WR M2L/7/TC8DF)(I3E>KTEBG5"0PXR2VWDRT)<;4I):Z4FO6Q3C_^X#SQ
M0,O[AC69%R,NFULQZG=2*F<.7;$":U!LY<7A!OE.;E+BO-I22L%XF>J:^NUL
M- #_ $EI4(J;2X5.2I:DQ([4<E.*VBS)I!(Q4K M8]&D\"Q <L
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MN@77;L.ATZJ4R(Y*AHE&\UK[9PC(FVT&DU+-78E@>&!@/50
M                         \E9N9:4S,7I=673[MMUVM62NV929KCC3Y0T
MOMJDN-DIYK5)*B5JX%K]7]H#69L]'"@,9#WK8.3%$:HU2K?!IO F'G,);T%Y
MMTFC4^XHBUT(-):2+'=^D!*+NJES9_6YEME!;F7U=MRN6Y4J;+N6KUF J!!I
M#5)9-EPF'E=F:\3V9)P,R21=70'(J- N!69G2NE)I$TX]4M4F:6ZF,Z:);I4
MTT:C"M7!Q6MHP1CI ?=ZE7;EY<>1^=;]J5.OVM1K'A6W78%,CJD52F2%Q3(W
M^"GJKPZ_57]'7$>!X8AWM@V#5LY<P<VLR:Y;<NU["OFA(M:E0JPSP:HRM5MM
M!S5Q]U!$;9&@U:=)8;A@(-;]B9J52SJYF37:#/;OS)DK;H]DQ5QI!.26:!-<
M7(V:=76<)3:DZQH(R,B >ONBE953M+*6-4;BCKCW9=\V7<]=;>0;;R9%2<UD
M)62NNQ)HD8DK21X@)S=%0N#*OI95G,"?9U=N"V[IMV-2Z/(MZ&<\U363:(VG
M,#239XMGV:BT&2MP!!*Y1;AH_1"NJ)<5%D4BJO9C;55-J"#:/KS;T8J(B6C6
MQ3KIZT\- "W5>?=6>&;^4<6EV%6[6:RWEG5;MJ%;B<#C1U:K.$2,Z1FEXE&U
MUAH/!23)6&&. >P@                           =36+IMBW5LM7!6H%*
M<D$I3")\IF*IQ*,"4:"=4G$BQ+' !UGQ,RXY843UE$WT ^)F7'+"B>LHF^@'
MQ,RXY843UE$WT ^)F7'+"B>LHF^@'Q,RXY843UE$WT ^)F7'+"B>LHF^@'Q,
MRXY843UE$WT ^)F7'+"B>LHF^@'Q,RXY843UE$WT ^)F7'+"B>LHF^@'Q,RX
MY843UE$WT ^)F7'+"B>LHF^@'Q,RXY843UE$WT ^)F7'+"B>LHF^@'Q,RXY8
M43UE$WT ^)F7'+"B>LHF^@'Q,RXY843UE$WT ^)F7'+"B>LHF^@'Q,RXY843
MUE$WT ^)F7'+"B>LHF^@'Q,RXY843UE$WT ^)F7'+"B>LHF^@'Q,RXY843UE
M$WT ^)F7'+"B>LHF^@'Q,RXY843UE$WT ^)F7'+"B>LHF^@'Q,RXY843UE$W
MT ^)F7'+"B>LHF^@'Q,RXY843UE$WT ^)F7'+"B>LHF^@'Q,RXY843UE$WT
M^)F7'+"B>LHF^@'Q,RXY843UE$WT ^)F7'+"B>LHF^@'Q,RWY843UE$WT!HX
M<R)4(K,Z!(;E0I"$NQY+"TNM.-J+%*D+29DHC+<,C <>JUFCT*)P^N5"-3()
M*2V<J:\W':UUZ$IUW#26)]0L0'2?$S+CEA1/643?0#XF9<<L*)ZRB;Z ?$S+
MCEA1/643?0#XF9<<L*)ZRB;Z ?$S+CEA1/643?0#XF9<<L*)ZRB;Z ?$S+CE
MA1/643?0#XF9<<L*)ZRB;Z ?$S+CEA1/643?0#XF9<<L*)ZRB;Z ?$S+CEA1
M/643?0#XF9<<L*)ZRB;Z ?$S+CEA1/643?0#XF9<<L*)ZRB;Z ?$S+CEA1/6
M43?0#XF9<<L*)ZRB;Z ?$S+CEA1/643?0#XF9<<L*)ZRB;Z ?$S+CEA1/643
M?0#XF9<<L*)ZRB;Z ?$S+CEA1/643?0#XF9<<L*)ZRB;Z ?$S+CEA1/643?0
M#XF9<<L*)ZRB;Z ?$S+CEA1/643?0#XF9<<L*)ZRB;Z ?$S+CEA1/643?0#X
MF9<<L*)ZRB;Z ?$S+CEA1/643?0#XF9<<L*)ZRB;Z ?$S+CEA1/643?0#XF9
M<<L*)ZRB;Z ?$S+CEA1/643?0#XF9<<L*)ZRB;Z ?$S+CEA1/643?0'?4VJ4
MRLPFJE1YK%0ISV.QEQ'4/LKU3-)ZJVS-)X&1D>!@/[FSH5,B/3ZC):AP8Z3<
MD2I"TM,MH+=4M:S(DD7TF8#/?$S+CEA1/643?0#XF9<<L*)ZRB;Z ?$S+CEA
M1/643?0#XF9<<L*)ZRB;Z ?$S+CEA1/643?0#XF9<<L*)ZRB;Z ?$S+CEA1/
M643?0#XF9<<L*)ZRB;Z ?$S+CEA1/643?0#XF9<<L*)ZRB;Z ?$S+CEA1/64
M3?0#XF9<<L*)ZRB;Z ?$S+CEA1/643?0#XF9<<L*)ZRB;Z ?$S+CEA1/643?
M0#XF9<<L*)ZRB;X _GXGY;<L*+ZQB[X ?$_+;EA1?6,7? #XGY;<L*+ZQB[X
M ?$_+;EA1?6,7? #XGY;<L*+ZQB[X PN;+&2F<EI^QUSWO!C4SA;$[:4^JPF
MGMK&,S26LLW"P/'3H ;=K,O+1EIME-X48TMI)"3.HQ<<$EAI_> /[^)^6W+"
MB^L8N^ 'Q/RVY847UC%WP ^)^6W+"B^L8N^ 'Q/RVY847UC%WP ^)^6W+"B^
ML8N^ 'Q/RVY847UC%WP ^)^6W+"B^L8N^ 'Q/RVY847UC%WP ^)^6W+"B^L8
MN^ 'Q/RVY847UC%WP ^)^6W+"B^L8N^ 'Q/RVY847UC%WP!S6+WLR53959C7
M#37J3!4AN;.;F,+CL+<,DH2XX2S2@U&HB(E'IQ =\          )M4:;3JEG
M7$;J,1B6VBUI"D)D-H=))^462Q(ED> *ZM%;74IU5:MK*QBJTVESY%+5.4_3
M(NT?AJV;IDV[UQ)UL=7'=+2 ^VWN/]&X_CU( -O<?Z-Q_'J0 ;>X_P!&X_CU
M( -O<?Z-Q_'J0 ;>X_T;C^/4@ V]Q_HW'\>I !M[C_1N/X]2 #;W'^C<?QZD
M &WN/]&X_CU( -O<?Z-Q_'J0 ;>X_P!&X_CU( -O<?Z-Q_'J0 ;>X_T;C^/4
M@!W5G'0KF;J;-2LZ)1*M2)? IL%QN'*(E*9;?0I+K!&DR-#J=&Z1Z#!&F]E;
M8\R0/%6>Y /96V/,D#Q5GN0#V5MCS) \59[D ]E;8\R0/%6>Y /96V/,D#Q5
MGN0#V5MCS) \59[D ]E;8\R0/%6>Y /96V/,D#Q5GN0#V5MCS) \59[D ]E;
M8\R0/%6>Y /96V/,D#Q5GN0#V5MCS) \59[D ]E;8\R0/%6>Y /96V/,D#Q5
MGN0#V5MCS) \59[D ]E;8\R0/%6>Y /96V/,D#Q5GN0#V5MCS) \59[D ]E;
M8\R0/%6>Y <:I6Q;3=.F+118!*2PZ9'P1D])(/Z4 ,SD$E*,EK$2DB2DJ-$(
MDEH(BV9;@#^LVH\>4FR6)3*'V%W5326TZE+B#(T/[J5$9&"M;[*VQYD@>*L]
MR"'LK;'F2!XJSW(![*VQYD@>*L]R >RML>9('BK/<@'LK;'F2!XJSW(![*VQ
MYD@>*L]R >RML>9('BK/<@'LK;'F2!XJSW(![*VQYD@>*L]R >RML>9('BK/
M<@'LK;'F2!XJSW(![*VQYD@>*L]R >RML>9('BK/<@'LK;'F2!XJSW(![*VQ
MYD@>*L]R >RML>9('BK/<@'LK;'F2!XJSW(![*VQYD@>*L]R >RML>9('BK/
M<@'LK;'F2!XJSW(![*VQYD@>*L]R >RML>9('BK/<@'LK;'F2!XJSW(![*VQ
MYD@>*L]R >RML>9('BK/<@'LK;'F2!XJSW(![*VQYD@>*L]R >RML>9('BK/
M<@'LK;'F2!XJSW(![*VQYD@>*L]R >RML>9('BK/<@'LK;'F2!XJSW(![*VQ
MYD@>*L]R >RML>9('BK/<@/WV6MCS+ \59[D!@^CTVVUEFPVTA+;::K7"2A"
M22DB\KRM!$1$1$ Y6?B4KRANA*R)2389(TJ(C(RX2UH,C ;'V5MCS+ \59[D
M ]E;8\R0/%6>Y /96V/,D#Q5GN0#V5MCS) \59[D ]E;8\R0/%6>Y /96V/,
MD#Q5GN0#V5MCS) \59[D ]E;8\R0/%6>Y /96V/,D#Q5GN0#V5MCS) \59[D
M ]E;8\R0/%6>Y /96V/,D#Q5GN0#V5MCS) \59[D ]E;8\R0/%6>Y /96V/,
MD#Q5GN0#V5MCS) \59[D!]/9NW?-$+Q9KN0#V;MWS1"\6:[D ]F[=\T0O%FN
MY /9NW?-$+Q9KN0#V;MWS1"\6:[D ]F[=\T0O%FNY /9NW?-$+Q9KN0#V;MW
MS1"\6:[D ]F[=\T0O%FNY /9NW?-$+Q9KN0#V;MWS1"\6:[D ]F[=\T0O%FN
MY /9NW?-$+Q9KN0#V;MWS1"\6:[D ]F[=\T0O%FNY /9NW?-$+Q9KN0#V;MW
MS1"\6:[D ]F[=\T0O%FNY /9NW?-$+Q9KN0$WL&F4TLTLW(!0V"@JDT'6C$T
MC9'_ /:VU:488;NG< 5L          8!SGNC>ZLCC%@%,J?\K=OO56OO(#?@
M@ 8EB18Z3W     'PD3(<,DG+D-L$O$D;5:48X;N&L98@/V/+BRTFN(^V^E)
MX*4TM*R(_H/5,P'Q.KTI*S:5.CDX1ZIH-U!*)6.&&&.Z Y@    ##6+_ *ES
M ]-M<6Q &Y                         <2J_E<WP=WM# 87(3F7L7T/$^
MS(!]<T^SL?WKIO:/@J@ @
M      E_1]YM6?2U<XVE .3GUS1W/]0S]Y:!5'!
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M#"Y"<R]B^AXGV9 /KFGV=C^]=-[1\%B@ @
M                   EW1]YM6?2U<XVE .5GUS1W/\ 4,_>6@51P0
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M*YO@[O:& PN0G,O8OH>)]F0#ZYI]G8_O73>T?!5 !
M                          !+NC[S:L^EJYQM* <K/KFCN?ZEG[RT"Q1P
M0                                             2^PN=S-OPF@\5(
M 5           8!SGNC>ZLCC%@%,J?\ *W;[U5K[R WX(
M PUB_P"I<P/3;7%L0!N0                        '$JOY7-\'=[0P&%R
M$YE[%]#Q/LR ?7-/L[']ZZ;VCX*H (                            PN
M8M]U&U54FAVW3FZI=]P*?13&)3IQX+#,1!.2)4IU*5*)MI*D]8A)K<49)3NX
MD'66)F#=$^Y7;*ONF0HM9<AKJE)JM&>=>ITV*TXEIY&I(2AYEYE3B-9*R,E)
M5K)/J *:              )?T?>;5GTM7.-I0#E9]<T=S_4,_>6@51@0
M                                         2^PN=S-OPF@\4H 5
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M              )?T?>;5GTM7.-I0#DY]<T=S_4,_>6@6*."
M                                 "7V%SN9M^$T'BE "H
M# .<]T;W5D<8L IE3_E;M]ZJU]Y ;\$?P\\S'9<D2'$M,-)-QUUPR2A*$EB:
ME&>@B(M)F8#S-5NFU8;%4=9MJV:]<]O1W%-/7!3F&DQG-FHTK5&0\XAQY*<-
MTDECU %XL2_+6S)MF'=UGSDSZ+-(R2LB-#C;J#P6TZVK!2'$'H4E7]QD8#2
M "99N9QQ<KSH5(@4.9==[W0^['MZV:::4/R.#));[BW%XDVVVDR-2C(__P!,
M3(,]8_2"F5:_(F669%CU#+Z\JK'<E4)F9(8GPIZ(Z36ZEJ2Q@G:)2DU:N!Z-
MTR/ C#,4_I37;7Y%:5:.3E>N&D4.IRZ/)J4&5&4E3\%>JX24&G6,\#2K5+Z0
M55\I<WK6SBMYZMVZF1#F4^0J#6J)46]A4*?-;[)E]O$\#^@RT'_:1D1&^
M!AK%_P!2Y@>FVN+8@#<@                        .)5?RN;X.[VA@,+D
M)S+V+Z'B?9D ^N:?9V/[UTWM'P50 0
M               2[H^\VK/I:N<;2@'*SZYH[G^H9^\M JC@@
M                                  E]A<[F;?A-!XI0 J
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M\,Y+)I5&=J<:.X4K4-.@S0O6U_VJQQT@/38   ,-8O\ J7,#TVUQ;$ ;D
M                     !Q*K^5S?!W>T,!A<A.9>Q?0\3[,@'US3[.Q_>NF
M]H^"J "                                             "7='WFU9
M]+5SC:4 Y6?7-'<_U#/WEH%4<$
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M-JSZ6KG&TH!RL^N:.Y_J&?O+0*HX(
M              )?87.YFWX30>*D *@          , YSW1O=61QBP"F5/\
ME;M]ZJU]Y ;\$                8:Q?]2Y@>FVN+8@#<@
M           .)5?RN;X.[VA@,+D)S+V+Z'B?9D ^N:?9V/[UTWM'P50 0
M                                          2[H^\VK/I:N<;2@'*S
MZYH[G^H9^\M L4<$
M $OL+G<S;\)H/%2 &KOR^J#EU;KUR7"IY49+C46)#AM*DS9DR2LFV(T9E'7.
M/.K,DH27]IX$1F P%F=(RVKJFT*FU"AU:W9MP5.JT**5291LF*K1C+:0Y+C:
MU):?<+74T@\=;446.. "R        P#G/=&]U9'&+ *94_Y6[?>JM?>0&_!
M               &&L7_ %+F!Z;:XMB -R                         X
ME5_*YO@[O:& PN0G,O8OH>)]F0#ZYI]G8_O73>T?!5 !
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M,+D)S+V+Z'B?9D ^N:?9V/[UTWM'P50 0
M                  2_H^\VK/I:N<;2@')SZYH[G^H9^\M JC@@
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M<$<<+9G@HVR425;A%] #TB   ##6+_J7,#TVUQ;$ ;D
M       !Q*K^5S?!W>T,!A<A.9>Q?0\3[,@'US3[.Q_>NF]H^"J "
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M)_"$*J#)FI)Q5*).H98'K;N)8 -9E3_E;M]ZJU]Y!6_!
M&&L7_4N8'IMKBV( W(                        #B57\KF^#N]H8#"Y"<
MR]B^AXGV9 /KFGV=C^]=-[1\%4 $
M             $OZ/O-JSZ6KG&TH!R<^N:.Y_J&?O+0*HX(
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M]<T^SL?WKIO:/@J@ @
M   EW1]YM6?2U<XVE .5GUS1W/\ 4,_>6@6*."
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M=T?>;5GTM7.-I0#E9]<T=S_4,_>6@6*."
M     (WFQSMY)^EZOQ4Z L@           )?87.YFWX30>*D .'TC)E!;L2#
M1*Y;#5X*N6MTRATJ@R9"X<9V?+>Q:4\\C2E#9(4O</$R(NKB \VTRS,F*AF
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MY7-\'=[0P&%R$YE[%]#Q/LR ?7-/L[']ZZ;VCX*H (
M                           )?T?>;5GTM7.-I0#DY]<T=S_4,_>6@6*.
M"                                (UFQSMY)^EZOQ4Z LH
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M:M9"B7JGH3IP_: HX   ,-8O^I<P/3;7%L0!N0
M  '$JOY7-\'=[0P&%R$YE[%]#Q/LR ?7-/L[']ZZ;VCX*H (
M                                 )=T?>;5GTM7.-I0#E9]<T=S_4L_
M>6@6*."                                (UFQSMY)^EZOQ4Z LH
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MR ?7-/L[']ZZ;VCX*H (
M     )=T?>;5GTM7.-I0#E9]<T=S_4,_>6@6*."
M           (UFQSMY)^EZOQ4Z LH           )?87.YFWX30>*4 -?=,&
MR+B@N6]>;-,J-/6:'7:95-BZT:DGK(4IIW$CP/26) ,M1,KLA:35X=2MVU+6
MAUR*Z3L"5!AP6Y+;R=Q3:FTDHE%^P!2@       8!SGNC>ZLCC%@%;\$
M                                        <2J_E<WP=WM# 87(3F7L
M7T/$^S(!]<T^SL?WKIO:/@J@ @
M           EW1]YM6?2U<XVE .5GUS1W/\ 4,_>6@51P0
M                 !&LV.=O)/TO5^*G0%E           !+["YW,V_":#Q4
M@!,<Z\FJS=5\5*Z6,M;)N"FG&8-RNW%4ZA#F&F.R1+VJ6$FVE+9%@1X]B6)@
MK)Y496LIO:VZ]2K"RS3$CRCE)JUN5Z=/F-(BJ)+KL=!EJ+4TI:25CH(S+'=(
M![*!       8!SGNC>ZLCC%@%;\$
M            <2J_E<WP=WM# 87(3F7L7T/$^S(!]<T^SL?WKIO:/@J@ @
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M?!W>T,!A<A.9>Q?0\3[,@'US3[.Q_>NF]H^"J "
M                        "7='WFU9]+5SC:4 Y6?7-'<_U#/WEH%BC@@
M                              #SYF5>]GU///*6WX%<AR*S2*U4V:E$
M;>2:F'GJ8ZA#;BNQ2XI76D@U:VMHPQ >@P           2^PN=S-OPF@\4H
M=7TFZ77JMEJVQ28M0J-&:J]-D7A2Z*I::G,MYI_6FLQMF:5FLRU5&E"B-22,
ML=("?/7M:^;&;^75;R98K$BO4%Y4:[*Z[$GP*;'MDV75/09?#$-I<><>-LV2
M2E1ZQ&K6T /4H       , YSW1O=61QBP"M^"
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M0P&%R$YE[%]#Q/LR ?7-/L[']ZZ;VCX*H (
M                    )=T?>;5GTM7.-I0#E9]<T=S_ %#/WEH%4<$
M                           1S-A2BS:R4(C,B.KU?$O_ /*= 6,
M      $OL+G<S;\)H/%* $WD925^]L^\SZI[3799%+X/;J84VW7TP(U2-,-U
M+AJ6\PZEU3)EJ]9AJZQX@-Q;F1-2M^O4^MNYKWU6&X#R7U4NIU..]"D$G_IO
M(1%0:D'U2UB 6        & <Y[HWNK(XQ8!6_!
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M>3'1+J-O2XD-HU?XGGE]:A/TJ,!7@       8!SGNC>ZLCC%@%;\$
M                                     <2J_E<WP=WM# 87(3F7L7T/
M$^S(!]<T^SL?WKIO:/@J@ @
M        EW1]YM6?2U<XVE .5GUS1W/]0S]Y:!8HX(
M              C>;'.WDGZ7J_%3H"R            E]A<[F;?A-!XI0 F?
M217?$NIP897G95M6] JM&J-N.U=$UVN1:PV\26'30TI31MJ<-2,7&C039GK8
M88@.?2<QLW:5=%L4^];XRXE4JMU-FE%#H;-3?J<EQU*E:C))>=0A1D@_WCB2
M;3U3TD0*]&@@      , YSW1O=61QBP"M^"
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MN]H8#"Y"<R]B^AXGV9 /KFGV=C^]=-[1\%4 $
M     ?BE)0DUK,DI26*E'H(B+JF BY=*'+(ZP4$D53R$<G@A7=P,_(>OCJ:^
MWU]?9;3]WMMEL\=.MJ]< M!&1D1D>)'I(R ?H#HKNNZBV11':[77%ICI6AB-
M&CMJ?E2I3QZK4>,RC%3CKBNM0A/]IX$1F02^H=)ZSZ#5XE)NRVKHMOA3?".'
M52EI1$;CI42''5N,O.]:T:D[75(S01XJ(DZ0%J9>9D,MR([B76'4DXTZV9*0
MI"BQ)23+09&6DC(!_8       )=T?>;5GTM7.-I0#E9]<T=S_4,_>6@6*."
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MO;^6^<*H-OR*E(;FVRZZ^JJU"34E$;=092DD')6LT%I/'5W?^ "W
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M6)@CT[:]$3;-LT:VT/')11X,6GID*22#<*(REDEFDC/#6U<<,05VP
M)=T?>;5GTM7.-I0#E9]<T=S_ %#/WEH%BC@@
M       "&YYTQFN7_E30I*E(CU:3<-.><;,B6A$RAR&#4G'1BDEX@).UD+F_
M.:3950I<&)3W6RIDVZVYK;D/@*4$VM]J(1%(VJVRP0TO!*5[JM4![$BQT1(K
M,1HS-MAM+2#5I4:4$22Q_;H ?8        !+["YW,V_":#Q4@!K;XL6W,Q:"
MNV;L8=E4-UUIZ1%9D/1=J;*M9*%K86A9H,^R3K:0''L^Q,N[!2='LFA4NANI
M:2IUF RTU)6T:C(E.J(MHLC,CZY9F U8       , YSW1O=61QBP"M^"
M                                        .)5?RN;X.[VA@,+D)S+V
M+Z'B?9D ^N:?9V/[UTWM'P50 0                               !'"
M_JL/^7I<=F L8           )?T?>;5GTM7.-I0#DY]<T=S_ %#/WEH%BC@@
M                               "-YL<[>2?I>K\5.@+(
M"7V%SN9M^$T'BE #C=(BU[HNRP8T&V8;U51$K%-J-=H$624*15*3#?VLB&T\
M:D$E2\$J+KBQU<"/$R 1VS\KLPIN8EKYD3J*J#?=8N6I7#=]P</;?12;=2RN
M*Q;BTMN&E]2D[)76I_=J2?T: ]=@       P#G/=&]U9'&+ *WX(
M                                    XE5_*YO@[O:& PN0G,O8OH>)
M]F0#ZYI]G8_O73>T?!8H (                                CA?U6'
M_+TN.S 6,           $OZ/O-JSZ6KG&TH!R<^N:.Y_J&?O+0"C@
M                         (WFQSMY)^EZOQ4Z L@           )?87.Y
MFWX30>*4 .OZ2K5:=RX:* W.>MQ-6IR[X8I!N%4'+82]C4$L[ R=THPVFS,E
M;/6 >:<DYMNU:\+4HV3_  E<^W[YN26ZY$;EM4V'8,Y2S)N5MR))G(-,<XR5
MZRR4G$\# >]@       8!SGNC>ZLCC%@%;\$
M                    <2J_E<WP=WM# 87(3F7L7T/$^S(!]<T^SL?WKIO:
M/@J@ @                               ".__P#5A_R]+CLP%B
M     !+^C[S:L^EJYQM* <G/KFCN?ZAG[RT"J."
M           (WFQSMY)^EZOQ4Z L@           )?87.YFWX30>*4 )_P!)
M%&8]JG%N^W<SY]L4FL56DT%N%P* Y2J9PUPF7)LIYY!N;(L#4>*B+7-)8DG<
M#@U5=^6'F5EA3WLWZA>$*Y:F<&H6T4:E-2GFT1G'E3$\'8)7!6S01/%ND2B,
ME@/3P       , YSW1O=61QBP"M^"
M             .)5?RN;X.[VA@,+D)S+V+Z'B?9D ^N:?9V/[UTWM'P50 0
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M(;<0EUG0G#3H,!ZO       !@'.>Z-[JR.,6 5OP0
M                        !Q*K^5S?!W>T,!A<A.9>Q?0\3[,@'US3[.Q_
M>NF]H^"J "     "=9Q924W-RWXU->G+I-:IC_#*/5VFTOFRZ:3;<0XTHR)Q
MIQ!FE:-8NH9&1D QV3?1T3EO<+MX7!6DUNO(CKATQF,P<2'$:?,C>625..+<
M=<U4EK*5@E.@BTF8"[  "-9/(0G,O.E24D1JN&$:C(L,3\EL;H"R@
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M?=>N_>88"R@   EW1]YM6?2U<XVE .5GUS1W/]0S]Y:!5'!
M           $=O7^HC*OT9<OV48!8@             !&^D#_%RH_F%0OLY0
M"R    E]A<[F;?A-!XI0 ^N>EKL7%9"*@JO1+9J-IU"'<](K=4P\G1YU+6:V
M^%D:D_N5ZRFUZ<2UL2Q,L##SED-!7F/=\>'5K[M"H4J@W14LPO(-K/S7I\NL
MS5.$A2N'LL*3$C&^K5-HEZV):YZ2,![8       !@'.>Z-[JR.,6 5OP0
M                                        !Q*K^5S?!W>T,!A<A.9>
MQ?0\3[,@'US3[.Q_>NF]H^"J "           CF4'.3G1[P0N+& %C
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M!]4!W8      P#G/=&]U9'&+ *WX(
M             XE5_*YO@[O:& PN0G,O8OH>)]F0#ZYI]G8_O73>T?!5 !
M         1S*#G*SH]X(7%C "Q@           CMM?U*W[[MT+[:6 L0
M          C5Q_U-V+[KUW[S# 64   $NZ/O-JSZ6KG&TH!RL^N:.Y_J&?O+
M0+%'!                        $=O7^HC*OT9<OV48!8@
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MOWF& L@   )?T?>;5GTM7.-I0#DY]<T=S_4,_>6@6*."
M        ([>O]1&5?HRY?LHP"Q              "-]('^+E1_,*A?9R@%D
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M([#4P5_:0#UH   "7='WFU9]+5SC:4 Y6?7-'<_U#/WEH%BC@@
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M.]1[4CND<MXY-1J$QU4F=+?PU26\\O2K521)2DL$I+<(M(#9
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M;:V6D::B@E)DU&IK2Y4ZO47CE3I.SQ)M*W#))$AM)ZJ$(2E)?1B9F8;0
M!&^D#_%RH_F%0OLY0"R    E]A<[F;?A-!XJ0 R?2*H-H4NV9L@K4B5^Z,R*
MU0;?)BHS)<2"]4$K4U!=E+8<2I#;"=?0S@:SP(\3,!DZOE)EQD_FIEK5H%BT
MLJ%6J@U26*@Q.J:JK!N-QMYYAY#;LA33L4T-*0I*D:R3/6QPT&'J@
M& <Y[HWNK(XQ8!6_!
M '$JOY7-\'=[0P&%R$YE[%]#Q/LR ?7-/L[']ZZ;VCX*H (  ".Y ;N:7\P:
M]_=' 6(              2#+_GYSD^JM;[@^ KX   ([;7]2M^^[="^VE@+$
M              (U<?\ 4W8ONO7?O,,!90   2_H^\VK/I:N<;2@'*SZYH[G
M^H9^\M L48$                        1V]?ZB,J_1ER_91@%B
M       $;Z0/\7*C^85"^SE +(   "7V%SN9M^$T'BE #B](RHT./EXBB5JV
MD7<]=%4@4"C4)V0J V]4YKN,=2I2.N8)LT&YM$8*+# C+'$!/BL:D9/9KV!5
MZ]&JMVTZN.JM^BW)<5<DU>90ZU-9=6AB/&=)#9,O-M*0;Q$;A'U4EH4'IL
M $,SAHT)JH.R(59K$W-2MFVU85'I\YR.4!;24H<>2RT9-E'(\7);LE*B-/6%
M@>! -OFG2[HK%@/4.A,+G5B<Y#CS$Q9:::XJ.3S:I1MO*/K-9M*TZ,58'HQ
M=-E.[#I/M3:T6V7J%<E%<8DSJ:JJ/U>/(3,94J,XQ*E*Q(EDVI"DFA.J9:<=
MT!U-D7#>MPYPF]>MF+LV6S;3R(L==3B57A#:I[)J42HI8(U3+#!6[CHW %K
M                                            <2J_E<WP=WM# 87(
M3F7L7T/$^S(!]<T^SL?WKIO:/@J@ @  ([D!NYI?S!KW]T<!8@
M   !(,O^?G.3ZJU_N#X"O@   CMM?U*W[[MT+[:6 L0              C5Q
M_P!3=B^Z]=^\PP%E   !+^C[S:L^EJYQM* <G/KFCN?ZAG[RT"Q1P0
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M_5:S5'SESY2VTDVWM73(NM;01(0A*22DMPM)XATSG/=&]U9'&+ *WX(
M                                       XE5_*YO@[O:& PN0G,O8O
MH>)]F0#ZYI]G8_O73>T?!5 !   1W(#=S2_F#7O[HX"Q              "0
M9?\ /SG)]5:WW!\!7P   1VVOZE;]]VZ%]M+ 6(              1JX_P"I
MNQ?=>N_>88"R@   EW1]YM6?2U<XVE .7GUS1W/]0S]Y:!8HP(
M              CMZ_U$95^C+E^RC +$              (WT@?XN5'\PJ%]
MG* 60   $OL+G<S;\)H/%2 ' Z2,2EN9>,5BH5:50)-O5>G5JDUV)3W:N4*?
M#=Q:>?B,D:G&,%*2Y@1X$>.![@";618D&_KZ8N&S<PJ)7<J8UT+S%\F4_%RM
MM5^3'4RXPXHE8-Q36MQW56@G.NU#Q[(!ZH       !@'.>Z-[JR.,6 5OP0
M        #,BTGH(                                  <2J_E<WP=WM
M# 87(3F7L7T/$^S(!]<T^SL?WKIO:/@J@ @  ([D!NYI?S!KW]T<!8@
M  -S2>X ;H    "09?\ /SG)]5:_W!\!7P   1VVOZE;]]VZ%]M+ 6(   'X
MI24EK*,DI+=,]! /T   'XE25%BDR47TD>(#]   !&[C_J;L7W7KOWF& L@
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MI=NTZH(8MN1+UED25-FJ0TTXO2I"%:NC<2:C(OH >P
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M=PPGJ.BW:.BLLRJBU%K3BI;<7@,!2%FY*(ED>U4A1(3LDX*/6_8 [P
M & <Y[HWNK(XQ8!6_!         !UU9H%"N.(5/N&F1*M )9.E%GL-RF2<3B
M1*U'4J3B6)X'@ Y%/IU/I,)FG4J(S!I\9.I'B1FTLLMHW=5"$$24E^PB <D
M                              '$JOY7-\'=[0P&%R$YE[%]#Q/LR ?7
M-/L[']ZZ;VCX+% !   1W(#=S2_F#7O[HX"Q        XE2I=-K,%ZF5B&Q4
M*;((DR(<MI#[#A$9*(EMN$I*BQ(CTD ^='H=%MZ&5.H%-BTJGDI3A1(+#<9D
MEK[)6HTE*<3ZIX .>   "09?\_.<GU5K_<'P%?         =;6[>H%RQ4P;C
MI4.KPD+)Y$:H1VI327$D9$LDNI41*(C,L0')I].I](A,TVDQ&8%.C)U(\2*V
MAEAM.[@A"")*2_81 )*7]5A_R]+CLP%>DQH\R.]#F,HD1)"%-/L.I)QMQMPC
M2I"TJ(R-)D>!D>Z ZZA6M;%KMO-6U18%&:D&E4A%.BLQ$N*06"363*4ZQD1X
M%B [8        !+NC[S:L^EJYQM* <K/KFCN?ZAG[RT"J."
M           (EF13*;6L^,LZ36(;-0I4NDW(W*A2FT/L.I)N*HB6VLC2HB,B
M/26Z K-!MJW;6AJI]M4F)1X+CAO.1X##<9M3JB(C6I+:4D:C(B+$].@!V@
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M3SDK<2A]#NRV!XDLUG@>.@!['       !@'.>Z-[JR.,6 5OP0
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M8LBU;PI%P4YY&=U)JM,=D-NS:)!H%$A*J",#/9[6,YKD:B/$E)(S 7L
M  & <Y[HWNK(XQ8!6_!
M   '$JOY7-\'=[0P&%R$YE[%]#Q/LR ?7-/L[']ZZ;VCX*H (  ".Y ;N:7\
MP:]_=' 6(              2#+_GYSD^JM?[@^ KX           (X7]5A_R
M]+CLP%C           !+NC[S:L^EJYQM* <K/KFCN?ZAG[RT"Q1P0
M                !';U_J(RK]&7+]E& 6(              1OI _Q<J/YA
M4+[.4 L@   )?87.YFWX30>*D -K==H6S?-'<M^[J6Q6**ZM#KD&4G7:4MI6
ML@S+1C@8#'T3H]Y)VY5X=>H5CTJ!6:>ZF1"FL,ZKC3J.Q4D\=!D I8
M , YSW1O=61QBP"M^"
M  .)5?RN;X.[VA@,+D)S+V+Z'B?9D ^N:?9V/[UTWM'P50 0  $=R W<TOY@
MU[^Z. L0              D&7_/SG)]5:WW!\!7P           1POZK#_EZ
M7'9@+&           "7]'WFU9]+5SC:4 Y.?7-'<_P!0S]Y:!8HX(
M                 CMZ_P!1&5?HRY?LHP"Q              "-]('^+E1_
M,*A?9R@%D   !+["YW,V_":#Q2@!4          !@'.>Z-[JR.,6 5OP0
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MM7:)9JA0YC+SQI;,R6:4H49J))EUQIQP :L      2#+_GYSD^JM?[@^ KX
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MD6)F>X Z*V+]LJ]3DIM*X(%:7#PX4B#(;?6V2NQ4I*3,R2K_  JPP/J -$
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MH$&?LI,XTZY$\^YK&76%AN .7\-\^_UN/_:U+[L!!^EID]T@:OE;M?;>1?\
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M.OFLQL[J/ERVU'.@S[<F5I]Y25\**5&ELL(2E6MJZAI6>):N./5 40
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MP=WM# 87(3F7L7T/$^S(!]<T^SL?WKIO:/@J@ @
M                        EW1]YM6?2U<XVE .5GUS1W/]0S]Y:!5'!
M3J^<Z+2L.O,6Q.B5:K5]Z)Y17 H=.D5-UF(;AM)==)E)ZB5K)24_M(P&?^9*
MUN2=Y_[;G]P ?,E:W).\_P#;<_N #YDK6Y)WG_MN?W !\R5K<D[S_P!MS^X
M/F2M;DG>?^VY_< )W.S:I\G/"CYB(M.[O9Z!;4VC/&=O3MMPR1,8?01(U,=4
MT(5BKJ'@75 43YDK6Y)WG_MN?W !\R5K<D[S_P!MS^X /F2M;DG>?^VY_< '
MS)6MR3O/_;<_N #YDK6Y)WG_ +;G]P [.UL^K1NJZ:?9[5+K])K-5;D.T\JU
M29-.:>3#03CI)6\1$9I29'@0"I            C>;'.WDGZ7J_%3H"R
M       E]A<[F;?A-!XI0 J           P#G/=&]U9'&+ *WX(
M                                   XE5_*YO@[O:& PN0G,O8OH>)]
MF0#ZYI]G8_O73>T?!5 !
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M H56KE0K[5O73*I=.FU=XI,LHK4:.M*5.$E!'URU'V("P@
M         XE5_*YO@[O:& PN0G,O8OH>)]F0#ZYI]G8_O73>T?!5 !
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M_B 'RM')6=D]GYEPJ;>=2N_RU&N!MM-4(R*+P:&THU-_O'-*]? ]S< >N0
M         1O-CG;R3]+U?BIT!9            2^PN=S-OPF@\5( 5
M     8!SGNC>ZLCC%@%;\$  !'>B_P SE+](5KC:4 L0              CV
M1GYWFW[[SOND0!80                       <2J_E<WP=WM# 87(3F7L7
MT/$^S(!]<T^SL?WKIO:/@J@ @
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MN0G,O8OH>)]F0#ZYI]G8_O73>T?!5 !
M                !+^C[S:L^EJYQM* <K/KFCN?ZAG[RT"J,"
M \:79TH<GJ-TI*;-DU9YVD4>BS+8J-6CL[6&U/D36'<=<CQ4TV2%)<6A)X'N
M8EI >QX\AB6PU*BNH?C/H2ZR\VHEH6VLM9*DJ+$C(R/$C(!]
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M,+D)S+V+Z'B?9D ^N:?9V/[UTWM'P50 0
M                  2[H^\VK/I:N<;2@'*SZYH[G^H9^\M JC@@
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M&>DP%+      $OL+G<S;\)H/%* %0          & <Y[HWNK(XQ8!6_!
M                                        '$JOY7-\'=[0P&%R$YE[
M%]#Q/LR ?7-/L[']ZZ;VCX*H (
M           )?T?>;5GTM7.-I0#DY]<T=S_4,_>6@6*."
M                              "7V%SN9M^$T'BI "H          "0W
MI>UK6#F[3:M=]132J=+MR3%C2'4.K0M],YEPT$;:%:226.D!S/F.R3Y71N\R
MMY /F.R3Y71N\RMY /F.R3Y71N\RMY /F.R3Y71N\RMY /F.R3Y71N\RMY /
MF.R3Y71N\RMY /F.R3Y71N\RMY /F.R3Y71N\RMY /F.R4Y71^\RMY "Z1^2
M)]A>,19%H,T-R%D1END>JT>!EU2W2 /F.R3Y71N\RMY /F.R3Y71N\RMY /F
M.R3Y71N\RMY /F.R3Y71N\RMY /F.R3Y71N\RMY /F.R3Y71N\RMY /F.R3Y
M71N\RMY /F.R3Y71N\RMY /F.R3Y71N\RMY /F.R3Y71N\RMY /F.R3Y71N\
MRMY /F.R3Y71N\RMY /F.R3Y71N\RMY /F.R3Y71N\RMY /F.R3Y71N\RMY
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MLZ-5;:MZV*57CHO K^IJ#<J#$AE+4AELU)8:-F3*U-0G#6I&*E)/$S($>NP
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M5FM8FGFGS-U)-$LS43:"7LVR4>))21'I ;<
M   !U5R^SGD&?[6\#]F]D?E+REL^!['J[7:]9AC](";61\O7D*X_8OR1Y)X*
M[[2ZFMM> :AZ^VVW[W8:NMA_@W<-(#BY;?+?Y</X=>2O:'8.;'4VO"MAJ'M.
M#\)Z[#4[/8_X=W0 VL/X;:MF\!X#JX/>Q6RW/\LK:\'PZNQUM;']O5 <C,?V
M#]DY?Q)X/[)Z[/">&:VRVFT3LNPZ[6U\-75TX@,[E3\$MI/^%/DWAVJGRAP;
M6X;LL>MU]O\ OMGCN?X,?V@*:             _#PP/'<ZN("1V5\N_MN_[#
M>0_;7][J<#U=;' ]MP7_ *>.&.OP?J8XZ,0&THWL%[*U#R/P'V/UZAY3['@>
MMM7.';77ZW#7VFTUM&[U &=@?!?X>3^!>3_AWBQY1UM?@_8L;#::_7]CL-3'
MJ:N&@!0*IP#R9-\JZGDO8.\.VO\ #X/J'M-;]FKCB RE9^&7PR3Y;X#\+^!1
M-GML>!\#Q;X+J?XNRV>SPZ[6U<-(#:-ZNS1J=A@6KCCCAAHW=(#^@
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MPO7UM&KK;37_ .(#O[=\C^0*7[/:OD'@C'DO4UM7@FS3LL-?KL-3##6T@.R
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E<%]F>$RMCP#_ "FWVZ]OLO\ #J[77[#K?H :4        !__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>lc_fig22mannwhitney-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig22mannwhitney-bw.jpg
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M="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,  X0DE-! 0       \< 5H
M QLE1QP"   "  ( .$))300E       0_.$?B<BWR7@O-&(T!UAWZ__N  Y!
M9&]B90!DP     '_VP"$  0# P,# P0# P0&! ,$!@<%! 0%!P@&!@<&!@@*
M" D)"0D("@H,# P,# H,# T-# P1$1$1$104%!04%!04%!0!! 4%" <(#PH*
M#Q0.#@X4%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%/_  !$( >P#M@,!$0 "$0$#$0'_Q "6  $! 0 # 0$!
M        !@<#! 4( @$! 0$                    !$   !@$# 0$'#@H(
M!00!!0   0(#! 4&$1('(1,Q02(4M!4643(SL].4U%5UE39V-U=A<;+2(W-6
MEA<(T4)RDE,T=#6!L5*35)%B0R0EH>&"PJ01 0$!                   1
M ?_:  P# 0 "$0,1 #\ ^_@     !UUSH3<QJN<DM(L'VUO,1%+23RVFC22U
MI09[C2DUI)1D734O5 =@
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M]'OU]B/_ *O7=0'T
M                  S:]2G^.6&*T+<6/WY$??T.16@K200
M                             '%*D(B1G9+A&:&4*6HB[IDDM=" ><Y8
MVK+"I+M:DFFTFXLDR$J422+4]"V:&9%^$!ZC3B76T.H]8M)*3KZBBU(!^@
M                     97S@E*F./MQ$>F<4!EJ6NA]LOJ U0  17+6$3.1
M<!L\/@3&Z^7/<A.-RW4*<0CQ.:Q*/5*3(SU)HTEU[I@,UR+^7*9;/\AN0\A)
M$/)H<R-BE>^T:V*=^]>1*N'3,CW+\:>:;46W;L3N3_6,![\KCGDRDR'(I''N
M1U<#'<TD%87;-E"=D2JVR5%;BO2J\VW4(<[8FD+-J1X*5IU(S)1I <7%O"EE
MQ]>8U;2K9F:U18:WA[K;;2T*=?;G>-^,$:E'HDR\';W=0''C/"5K195BV0O7
M##[./6V6VKS*6EI6\C*7-[2",U&1&R7KS/UW> 6>%8+(Q>]SBWF2FIC65W*;
M>,RE!D;#:84>*3:C49[CU9-6I=XP'XY8P.7G^%2**CG-TV1QY$6RH+A3?:%"
ML(3R76WB06FIZ$I/XE (VV_E^AR;?C6146"(-3A<>/7W<3L24=K"KG&9D1I7
M>3LF,)?5ZNI@*F%QY/BWO)=N<]HV\Z3%3":)"B5%.-6E!,W#U\+51;RVZ= $
M(]_+O8SL?G4,N^::3-P"GP7QAF.I1MS*=3JSE$E:M%-K-Q/Z/77H?4!8XU@>
M6M\A0>1\MGUR[5&,KQN=!J6GVXQO><O&T/-&^M2B3V9$DTJZ[M=.@#/KC^6J
M;*KH$Q#]'=9%3VN13H<'(8"Y=/)A9+-\;4R\E*NT;=942%(>;UZD:32:5= Z
M6=\=IXXX*LFC\0]/%WD&YQ1&.53$&-'R54IANMCQ8Z2,W&T+(FEN/FMQ;1K-
M7_20;IQYA\; <*I<1BJ)SS;'),E\C4?;2W5&[)>/<9GJZ\M;A_V@&11^",X;
MQZ/Q&[D5:OA:+/1-(_%'O2%Z&W.\X)@..=IV!))S1!R$IWF@O6D9Z@/H,
M                                               >;)O:Z,^N,I2W
M'F]"=2RVMW89EJ1*-)&1'^ !^X=S FO>+M+4F1M-9-.MK:4:2Z&9;R+73\ #
MO@       S>]^W'#/D"^\HK05I (
M          #KSXZI<*1&09)6ZVI"35W",RT+70!YS[UO(AN1/-FQ;K:FMYOM
MFA)J3MUZ=3(OQ /5CM&RPTR9ZFVA*#/U=I: .0
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M'L2CM0U.18)MDV:VV2)&[PCU,BZ@-2
M                     !Y-%I_^3_U[_P#_ % +'3SU3>KND>TF ]8
M  &;WOVXX9\@7WE%:"M(!        '"J9$1%7-7(;3";2IQR2:TDTE#>IJ4:
M]=").AZGKT ?MIUI]I#S*TN,N));;B#)25)46I&1ET,C(!^P
M    'X=-Q+:U-));I),T(,]I&HBZ$9Z'IJ8";*TSHR+7'81'WR\Y&?7WL ><
M\Y_9Z%\Y'\& 9IQWE?-MAD=Q&R*F-Z"R2C)J8T5:RP]VG@H8>2VLW4FC^UTT
M5NZZ&%_)RC+HEA!JWL>B^-6/;>+:6)FG_P"N@EKW'XMZA] '<\YYS^ST+YR/
MX, ><\Y_9Z%\Y'\& /.><_L]"^<C^# /:JWK.1$)RWB-PIFY1&PR]XPC:1^"
M>\T-]WU-H#N@                             #+.;_8./_KO0>W+ :F
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M&1O%'>6TE:B+3<9)/373O@/U$IXL61XUO=?D$DT(<D.J=-"3[I)W'TU[X#T
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M8<VNP#%:^R:6Q8Q*>O8EL/>R-OM16TK2OJ?A$HC(^H(I
M $K>_33$OQ67DZ0%4                                   #+.;_8./
M_KO0>W+ :F
M    /X9$HC(RU(^AD?<T <,TM(4@B[G9+_),!.\;_0+'O]"S^2 J0
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M J@                                   99S?[!Q_\ 7>@]N6 U,
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M)NVUK-LW[S)[]UIZYN92&6%O%%:)EAM#,="&VT-H+H24ZF9J,S/4!6
M              E;WZ:8E^*R\G2 J@
M     99S?[!Q_P#7>@]N6 U,
M                   '!-_R4C]4O\DP$[QO] L>_P!"S^2 J0
M              &;WOVXX9\@7WE%:"M(!
M      !*WOTTQ+\5EY.D!5                                    RS
MF_V#C_Z[T'MRP&I@
M           X)O\ DI'ZI?Y)@)WC?Z!8]_H6?R0%2
M   'X.^  ,WO?MQPSY OO**T%:0"
M "5O?IIB7XK+R=("J                              '@S<WPRMOXV*V
M&0UL7)YNAQ*9^8PW-=W]$[&5+)9[OZNB>O> =N_R*@Q6L>NLFM(M/4,:=M.G
MO(C,)-70B-;AI+4SZ$7=/O /.>Y"P*/0P\IDY14L8U8*V0+AV=';AOK/=X+;
MREDA2O!5X)'KT/U '>Q_*,:RR(Y/Q>XA74%IPV'9-=):EM)=21*-"ELJ41*(
ME$>GX0$%S?[!Q_\ 7>@]N6 U,
M                    '!-_R4C]4O\ ),!.\;_0+'O]"S^2 J0
M           'RGBEK44>95%Q+D2X_(=?8Y)+Y5D/%-4END8;DJ:5((R-LV2T
MA>*$@M---G]8!^[ES!+OE*X@XG9RV<B;1=IO[MUV8]83Y,ZL?9:JH#&J"<8C
M;FWTZ$24+:;0VK<:C!7M_P M[L"NN)&.X^<*ZJ$44%^RR6#73*QQFQ:5V'B4
ME,MQPUN*3O>\+:XD]Q++JD$5B?2[^/&/^E/FSQ/S-?\ F7S7XSV_8>-5W^:[
M?P-=NW3LOZVNO30%;$"                                 "5O?IIB7
MXK+R=("J                              'QWDC.*KXO_F%E9"B(>:-9
M59^*O2R1YS3(24<J,FE'^E+IV7BNG3_IZ:@-PY!LN-(=/1YAR4^S.F8G*+Q*
ML0M,I;M_(C=BEAN&DS)Z7HZ?8H-.Y&[>6TO"(,;>P27'Q_&)=G<X_A&09'G\
M_(6:JP9:L8=>[:UTB.BO;2G_ .NY,2UH[X9H0I\U;=Q[=P:SPG>6BKC.L"L9
M,&Y+#["*RWDU9#9KFIBI\4I"V7F(QFT4B*?Z-PT'U2:-4I5J F^5U<K>E&'%
M?(QTL!].*;S:J$N<=SM[=78]JEQ),:]WM-IZ>H ^@P
M                                     <$W_)2/U2_R3 3O&_T"Q[_0
ML_D@*D                        !F][]N.&?(%]Y16@K2 0
M                       2M[]-,2_%9>3I 50
M         FI_'N"6F2Q,RLL;K965P=IQ+EZ*TN6V:--ADZ:=VJ-/ ,^J?ZN@
M#@LN,..;DI!6V*U4XI4Q=I(\8ALN;Y[K265R#W)/]*IM"4&ONF1 $;C#CJ'0
M3<5C8M5M8W9+[6?5)B->*O.$1$2UM[=#46U.BNZ6A: /6QS&,=Q"J:H\6JHM
M/4,ZFW"@LH8:)1Z:J-*"+51Z=5'U/O@(+F_V#C_Z[T'MRP&I@
M                                            X)O^2D?JE_DF G>-
M_H%CW^A9_) 5(                        #-[W[<<,^0+[RBM!6D @
M                              E;WZ:8E^*R\G2 J@
M                     99S?[!Q_P#7>@]N6 U,
M                                   '!-_R4C]4O\DP$[QO] L>_P!"
MS^2 J0                        &;WOVXX9\@7WE%:"M(!
M                      !*WOTTQ+\5EY.D!$<R<LY'QY;4\"EJ6I;$UI3[
MK\E+JB>6E9(\79[/31S0]W77NET[H#6XKRY$5E]QI3#CK:5K87ZY"E$1FD_P
MEW# <P                                #+.;_8./\ Z[T'MRP&I@
M             QGGGD7*,)*FA8ZM$$K'MEO6;C:'>K.TB903A&@C/=N,S(ST
M+IWP%;Q%EEOFF$0[N[;2F>IQYA4AM/9MR$LK-!/)3W")6G73IJ1Z= %R
M                                 X)O^2D?JE_DF G>-_H%CW^A9_)
M5(                        #-[W[<<,^0+[RBM!6D @
M                   E;WZ:8E^*R\G2 J%MMN;3<02C0>Y&XB/11=-2U[A]
M0'Z                                  &6<W^P<?_7>@]N6 U,
M          '3LJJKN8WB=O"8GQ-Q+["4TAYO<7</:LC+4M>Z [###$5EN-&:
M0S':22&F6TDA"$)+0DI26A$1%WB <@
M      #@F_Y*1^J7^28"=XW^@6/?Z%G\D!4@
M,WO?MQPSY OO**T%:0"                                 "5O?IIB7
MXK+R=("J                                   !EG-_L''_ -=Z#VY8
M#4P                                                       <$
MW_)2/U2_R3 3O&_T"Q[_ $+/Y("I                         9O>_;CA
MGR!?>45H*T@$                                 $K>_33$OQ67DZ0%
M4                                   #+.;_8./_KO0>W+ :F
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MXN$\C8OG[4E5 ^YXQ#-)28DELV7T)7KM5M/NI5H>AD8"L
M       &;WOVXX9\@7WE%:"M(!                               >;;
M8_17IQSNJV-8'$7VL4Y3*'NS7ZJ=Y'IW 'I )6]^FF)?BLO)T@*H!FF$<+8_
M@V32\E@S),E;B76X$5[:3<9N0K>X6J2)2S,R(DFKN%ZI]0&E@
M                     ,LYO]@X_P#KO0>W+ :F
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M-?L)D6;"&&)>DJO3NBJ2XO>1:;CU)/0R]4!L((
M           )6]^FF)?BLO)T@*H!T[*VJZ:.4NWFL0(IJ)LGY3J&&]ZNXG<L
MR+4].X [:%H<0EQM1*0HB4E23U(R/J1D9 /Z
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M]W1*2U4H_P 1 .]76,"W@L657);F5\E).1Y+*B6VM)]\C(!V@
M                        <$W_ "4C]4O\DP$[QO\ 0+'O]"S^2 J0
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M:TN2Y<GLT,IUV)0A#;:&TMM--I)*$EH7?,PF.;_8./\ Z[T'MRP&I@
M          ,DYKXPN\]\U6- ^UX]6$ZTN')6;:'&WS2>Y"B)1)61IZZEU(!3
M\687*P+$(]#/DHE3NU>DR%-:]BA;ZMQH;W$1[2_"74]3 6@
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M^\ W8                      9O>_;CAGR!?>45H*T@$
M                   $K>_33$OQ67DZ0%4  ,XY-X@K.2I5?-DV+]=(A(7'
M<-E"'2=C.J)2D:+]:K4NBB_]# 7\"$Q708U?&(RC1&FX[)*/<>QI)(3J9]T]
M" =@                              99S?[!Q_\ 7>@]N6 U,
M       <;[+<EAV.[J;3R%-KT/0]JRT/0_\ B PO#?Y>9&-9C$NYERW*IJIX
MY%<PVVI$EQ:2,FR>,SVD2=>NWUVG> ;P
M          .";_DI'ZI?Y)@)WC?Z!8]_H6?R0%2
M    S>]^W'#/D"^\HK05I (                                 )6]^
MFF)?BLO)T@*H                                   &6<W^P<?_ %WH
M/;E@-3
M !UYRDE$>29D2EH6A!&?52C2?0O5,!/<;_0+'O\ 0L_D@*D
M           !F][]N.&?(%]Y16@K2 0
M9,_S=%8Y01QYYH<-A4E%<JP[0B<\9<02R43.WV(M=-V[_P!W< :/D$.QL**R
M@T\OQ&UDQG6H4SK^B>6@R0OIU+0S[I=P!G?"&&9MAU=;,Y?)W)E/-KA0O&53
M.S-"5$ZYO5W.U,RZ?@U/J K+WZ:8E^*R\G2 J@
M   !P39L.MAR+&PD-Q8$1M;\J4^LFVFF6DFI:UK49$E*2(S,S[A (?$>:^-,
MYEQ(..W7:R[!V4Q7-2(\B&J2N VT\\3)2&V]VC;[;I=]2#W)U21F OP
M!EG-_L''_P!=Z#VY8#4P
M               ?-/.N%9]=YLU8UL"7:TZX[3=;XH9J3&<1KVI*(E%L-2M%
M;^^737H ZM%_,#/QIFEH$U34JDK&(\*PDJ<4F6XX@B0ZXT1> 1$H_!)756G=
M+4!]0$>I:@                        ,WO?MQPSY OO**T%:0"
M                      #H'1TJK4KTZZ,=TE'9)L391XR2---O::;M-.G=
M =\  2M[]-,2_%9>3I 50                          A^9*^FM>+,LK\
M@LO,]._6OE*M3:5(1&21;B=6T@C-:$J(C6C^LG4@&7XKQ[RYD67-VG(#%)6X
M_&R1G,5RZ>;)GO3YL:J:K8Z(Q.MH)B,?9J=7O-2S2I+9>#J8#Z(      &6<
MW^P<?_7>@]N6 U,
M          '!-_R4G]4O\DP&7X5QC@]S3XWEEE4-OW28<9Q;IJ63;CK22V..
M-$9(6HM"ZJ3U[^H#5P                 !\[<T95GM'G<)N#,O8-2IKQ>A
M:Q^!YQCRY3\*:;GC1)9=U>1(3#2TVZIMO8I2M>I[2MXQ]RX>H:MW(6D,7[D2
M.JU89,C;;F*:2;R4&1J(TDO<1=3!'H@   S>]^W'#/D"^\HK05I (
M                          )6]^FF)?BLO)T@*H  =*UN*FCB'/N9S%?"
M)1(.1*<2RWN5W"W+,BU/U '::=:?:0^PM+K#J26VX@R4E25%J1D9=#(R[A@/
MV                     DN4)^/5G'F2S<L9?DXXW7OE8Q(BEMR'VEIV]BV
MI"D&2G3,FT^$74^[H P'!\(9XYR_#YN88 G&*VUF)@8Y*J\IMK;S;/<8<4Q#
ML(TAPF5]HE"D)<8)3:5Z$9:&2@'U6      ,LYO]@X_^N]![<L!J8
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M,,<S2 NSQN<F;$;<-ETR2MM:'"(CVJ0X25%T/4M2Z@/<
M   !*WOTTQ+\5EY.D!5  "!Y4XT1R55P896!UTNO?.0PZ;?;M*WH-"B6WN3K
MT/P3UZ?\0%)B..,8CC59C49]<EFM82PE]W0EK,NIGH70B,SZ%WBZ /:
M                2O)<C%8O'^2OYPT<C$DUTCSO'0E2G'(ZFS)2&R29*[16
MNC>TR/=IH9& QF@I'<?R;C6=R7:9;;Q+%2TXI"R!<%<6FN%QC[!FR5$2A<B8
MIHWD,/N[B2K4O7JU(/I       99S?[!Q_\ 7>@]N6 U,
M                                     !\O<^3L9R#-H,*'<E'N:ULJ
MZP.0TX=>UVJR<3N>;)1I4DU%VFB%%H9:F1D W'!,>B\<X1 I[*R:6B&E3DJ<
MXHF8_:R'#<42-YZ)02E:)U/K_P 0%/*<0[7O.M*);:V5*0M)D:5)-)F1D9=T
MC 3_ !O] L>_T+/Y("I                  'S=S=)Q.3EURUFD>K@2JFA;
MD8<[80Y4A=M.<=6I;2SCNMID,M*2AKQ)25F:G37IIT,K?<9D2I>.4\J= *JF
MOP8SLFL26THKJV4J6P1:%IV9F:-/P B*Y Y1L,1MWJ:DQQ=])KJ=[);I1RDP
MD,5K#AM_HC4VYVKRC0X:6_!+1/51:D _&3\OL4#./VD.H798_D5/8W46<E]+
M#J2KZ\[)#1L+09GVK:3+=N\!7=(!_.(.6OXIPWIAQ:V$:(\64F+!M?.4E!2T
M=IH\V<:/L(BT(EIWH4>XB/P3 =:;<T]MSIBS558Q9[T&COVIS45]M];"_&:X
MMKJ6U&:#U(R\(BZD?J K5@0       !X&69KC>$06K#))I1&'W.Q822%NN.+
MTU,DH;)2CT(M3/3H ]6LLH%S7QK6KD(E5TQM+T:0V>J5MK+4C(!U\@H:W)Z6
M;06[9N5T]HV7TI4:%:'U(TJ+N&DR(R/U0'BX%Q[1<>5TBOI5/O*EN]O*E2UD
MX\XHDDE)'M2E)$DBT(B2 K                8S XQSJ/S"_FCUV2L>6^[(
M(B>=-U<=Q!I1#-D_ )*#T\+7N$1EX0#9@ !*WOTTQ+\5EY.D!5
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M+37KTZ -E
M  8KE7\O51?Y7+R15T["JI[WC=I )I)J-1Z&[V;RE%L)>G75)[>NGX S_E?+
M*KE.;2X[@_C$Q-:Y(0W <;)EF69((D.1S6HNT-*4*VI623T/5(#8^)L9O\3X
MY*IR,]DW=)?:B;R<\68=ZH9W$9ETZJT2>A:Z />XW^@6/?Z%G\D!4@
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MZIJ:OG3%7*R!&A.S*._=F.QF&V5OK.37'N=4A)&L]3,_",^IGZH*U0$
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M<QX=B-=9X-D=?C];%R&5G%&J3;L0V&YKANO*WFM]*"<,U?UM5=>^ VT
M                                               !QR&&I3#L9].]
MAY"FW$'WT++0RZ>J1@,>Q#^7RJQ;*X^0JMWIT*N<4]60%M);4A>AI0;KA&>_
M81]-$IU/J8#5KQZ3'I+*1"8\:F-17W(\;K^E=2VHTHZ?]1EH ^:^",^S2;EU
M?C+LM=A1+BN)DQ%H2:8:&&]6U)4DB-!$K1O:H_"U]4!]1@
M   #Y?R17,*<MN9L)[+VX#]G81;&35+JI=<C'T$:8I5D>1(0EJ61I23CZD[F
MSWFLE'H1%?2-)M\RUVQ;[B/%6-KDMQ+TE1=FG0W7$&I*EG_64E1D9]2,$=\
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M<LQ3/VZ"HN)2^.J>>P36/TD!:E+CO2E)DFXZ\@EN(0<@W2:29(270C ?7(
M    RSF_V#C_ .N]![<L!J8
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MQ6$-2(Z$-,N(2VDDK;0WX*4J+JE*>A%W '?   !F][]N.&?(%]Y16@K2 0
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M2_C3KK/8M$BXGUE>FH=FFFN=2R:WDRD-D:C4A>O@J =KT!=_:W(??C7N !Z
MN_M;D/OQKW  ] 7?VMR'WXU[@ >@+O[6Y#[\:]P /0%W]K<A]^->X 'H"[^U
MN0^_&O< #T!=_:W(??C7N !Z N_M;D/OQKW !A?,>!Y^62QB@%<Y)2]BCS:^
M3BI+C+_7M$K[+82#,R(TK,BZ?UN@#0I+<##:*G5R-G]O6WLMA'C##4PG"-Y*
M2[38E##BC2DST-7<_" J86'1[6$S/@9I>RH$I!.,/M3F5MN-K+4C(R9ZD8#H
M'PIC!R8DU4^R5-KT(:@2%.L*<9;:Z-I2:F#]9_4W:[>\ ]CT!=_:W(??C7N
M!Z N_M;D/OQKW  ] 7?VMR'WXU[@ >@+O[6Y#[\:]P /0%W]K<A]^->X 'H"
M[^UN0^_&O< #T!=_:W(??C7N !Z N_M;D/OQKW  ] 7?VMR'WXU[@ >@+O[6
MY#[\:]P >:5=/QO-\:A-WUI8P[-%@4J/8/H>;/Q=E*D&1);1H9&H!H8   /F
M7)[.OG/9[D.3<A2\8R_%IL^/18XQ(8AQD1XZ"<@J<KG4*.?XYJE9J62NTW]F
MWMV@KZ%QF58SL;IYUQ$*!;28,9Z?!2DT$Q(<92IQHDJ,S+8HS3H9]X$>J
M#-[W[<<,^0+[RBM!6D @                       "6I/IME?ZNL]J= 5(
M   ,J@\(P(7);O(16SRT+DNV#=;V:2,I4A!I7J\2M306IF2=OX#/0@&J@
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MB,NI +_ \6]"\1J\9.1XTN VI+D@D[$J<<6IQ>U/71)*49)_  HP
M     !&Y%]H&$_V;;R=L!9    ^5["35Y1RW)C7&1W%-$>L;6MI;=NRHUOPI
ME0DEOH2U(KEO18ZO#[!7;J5JG51%O(17U#";)F%&:3(7+2VTA)2G5)4XZ24D
M6]2D$E)FKNF9$1"HYP   9O>_;CAGR!?>45H*T@$     $A2\G89D&2R\3J[
M#MKB)O(TFVM+3ILGHZ33AEM6;9]%:?\ #4@%>                 EJ3Z;9
M7^KK/:G0%2                 FLX_V>-\I5WEC0"E
M9)S@^B4[A.)7%F]383E-UYMR2='>5$6\@HKSL>O.0@TJ:1,>0EI:DJ2I1?HR
M,MX":LL%P[A[/\ 5Q:RJEM<EM%U=QC,:4\N)8U!17G7Y3L9Q:R)<,T(<2^G:
M9;C0HSWD0#Z       &6<W^P<?\ UWH/;E@-3
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M\28;C.4R<OJV7DV<@W3;:<=-<=@Y)ZNFRC0MN[KW3/37IH N0
M     $M2?3;*_P!76>U.@*D      051R]B5WFLC!H?C/G-E3S3<E;1%%>>C
M$9NH0LE&>J2(^II(CT/0!>@        )K./]GC?*5=Y8T I0
M    &4_S!V[53Q^\=B>-JQ^:\B';1LM1+?C2&WM>S:89A(<=<?-9$I"4(-1:
M&HO6ZD$'P3@]Q52:_-</K,%5BUVVE$R\J9%U-LEP6S478L.V!K-O:XDB6THT
MD2DZ*3N3T#Z2      &6<W^P<?\ UWH/;E@-3
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MU:(R7$$WT6?]?N]3[H#:@     !EG-_L''_UWH/;E@-3
M                         1R_M58^KSWEK0"Q          'FY!0UF3TT
MRAN6>WK9S?9OMD9I5IJ2B-*BZDI)D2B/U2 36!\58QQZ]+ETYR9,^8DFG)<U
MPG'"92K<3:=J4)(M>I]-3,!;@               C<B^T#"?[-MY.V L@
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MKD*GSFML)E?#GU]E4/JB7%!:1_%;2)()M+R4.L[E%^D;6AQM2%J0I*BT5W=
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M^_V%G*\:8BZR:Y6V*C:GLBZZ'U/5))+O -A!
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M$S.:4RQ^9)CKJ62>?5HEII,=#A$C3P-73T[^H#?P
M                    $<O[56/J\]Y:T L0            $QGN$5V?X\Y0
MV+KD;1Q$F+*9T-;4AK7:O:KHHM#,C2?=(P'E\:<8UW&T.<AB:Y83[!:%RI;J
M$M%M9(R0A"$F9)(MQZ]3U,P%V             C<B^T#"?[-MY.V L@
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M:OQI-I71ILF$KM(CLAE#JVE^J@UD9I/IW@'?      $UG'^SQOE*N\L: 4H
M                         RSF_P!@X_\ KO0>W+ :F
M                          CE_:JQ]7GO+6@%B           ";RG ,0S
M54=>35;<YV)J3#IJ6VXE*C(U(W-J29I/3JDST 9[SMBV12\/J*O#(;JZ6 ]M
MG5->1I6;"4;6=K:-#4A"NZDOP'H>@#UN!Z?*J3"U1<H;?C$J4XNLA2S,WV(Q
MDDMJB,S-)&LE*2@^X7XP&H             (W(OM PG^S;>3M@+(
M  9O>_;CAGR!?>45H*T@$         $O<?3G%_\ 36G_ "C *@
M  !+4GTVRO\ 5UGM3H"I                 36<?[/&^4J[RQH!2@
M                   #+.;_ &#C_P"N]![<L!J8
M                    ".7]JK'U>>\M: 6(
M    "-R+[0,)_LVWD[8"R          &;WOVXX9\@7WE%:"M(!         !
M+W'TYQ?_ $UI_P HP"H             2U)]-LK_ %=9[4Z J0   ?EUUMEM
M;SRTMLMI-;CBS)*4I26IF9GT(B(!/XMG>)9H4KT8M&K X2B3)2@EH4G=KM5H
MM*3-*M.BBZ'ZH"B          $UG'^SQOE*N\L: 4H
M        RSF_V#C_ .N]![<L!J8
M       ".7]JK'U>>\M: 6(           .K9V4"FKY-K:/HBUT-M3TF0X>B
M4-H+4S/^@@$OA?*&(Y[(DPZ&0Z4V*GM5QI32F'%,F>TG$DKNIU/3U2[Y +(
M             1N1?:!A/]FV\G; 60          S>]^W'#/D"^\HK05I (
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M39")<PH[12)3.G9NND@MZT:?U5'J9 .X   ":SC_ &>-\I5WEC0"E
M                   &6<W^P<?_ %WH/;E@-3
M                   1R_M58^KSWEK0"Q          '2M+>JI(OCMS.8KX
M>XD=O*<0RWO5W$[EF1:GIW 'R;R3E.=W^;6N->-RWZNP?3%J:B+X465 =4DV
M'4$DC2X2RT7VFO3U2(@&S<7<+^@%S*OI]J5E-6TJ+$0TT;+;;2U)4I2M5*-2
MU;2+U"_#J UD  ?*6?XMRM+Y3ES($6Q>D.3$+H;*,I91&8I&GLR[0C)#9(Z]
MJ2M->O=U ?5;9.$V@G3)3I)+>:2T(U:=3(@'Z         1N1?:!A/\ 9MO)
MVP%D          ,WO?MQPSY OO**T%:0"     #)\JYNB8QR'&P9=0Y(;6N*
MS+G)=)*TKG:=GV36TS62=2W>$7?T[@#6  !+W'TYQ?\ TUI_RC *@
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M<59.QE/-H<-IPNXI!J(]JOPD [(    ":SC_ &>-\I5WEC0"E
M               &6<W^P<?_ %WH/;E@-3              '6?L($5]F+)E
M,LR9)[8[+CB4..'ZB$F9&K_@ [(                        ".7]JK'U>
M>\M: 6(           /X9$HC2HB-)EH9'U(R,!*4'&>#8O;NWE%3,P[-TEI[
M9)K43:7#U6325*-+9*[^PB]3N *P!Y]U1U&1USM3>0FI]<]IVD=].Y)F74C+
MOD9=XRZD _-#CU)C%<BIH(+5?7-F:DL,IT(U*[JE&>IJ4??-1Z@/2
M   $;D7V@83_ &;;R=L!9      #^$9'J1'J9=#_  'W0#4M33KX1=3+OZ'W
M/^0#^@,WO?MQPSY OO**T%:0"       X)C#DF'(C,O*CNO-K;;D(]>VI:3(
MEI_"DSU(!DW#'%>3<>S[F7>VC4EF:E#+4:,MUQ#JVU&HY+G:$6BS(]-.O=/4
M^X M;QQ#.:XTZX>UMN):J6KU$I3&,S >)Q]S%0\AW$^FKH<F(]%;.5&<D$C;
M(C$LFS66TSVGJHO!5WC :,           "6I/IME?ZNL]J= 5(
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M(C4A+K:2+9O21F6BE:'T/U0&Q@                (W(OM PG^S;>3M@+(
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MR-UMQE+)&?\ 7VK/3O:@-]
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M&&E1MNJ;GOH6VX74T+0N,E23TZ]2 >QYQY+^(JKYP=^#@'G'DOXBJOG!WX.
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M6I/IME?ZNL]J= 5(                ":SC_9XWRE7>6- *4
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M#"?[-MY.V L@         !F][]N.&?(%]Y16@K2 1*T'TSR_\==Y,8"J
M #,B(S,]"+J9F \.@S+%LH>F1\>MHUB] 7LEHCK)1H/4RU_"DS(]%%J7X0'N
M         )C.?]LK_E:L\K; 4X   ):D^FV5_JZSVIT!4@     #Q;7+<9H[
M*#3V]K&A6ED>D**\X2''.NTM"/N$9^"1GW3Z%U >T         F\W(SIXYD6
MI%8UQG^ O'&B 4@                          RSF_P!@X_\ KO0>W+ :
MF                                         CE_:JQ]7GO+6@%B
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MJ_PWP[_P'/?<OW8 _AOAW_@.>^Y?NP!_#?#O_ <]]R_=@#^&^'?^ Y[[E^[
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M=B$()7A'H6IFH]-=>YT :&           "-R+[0,)_LVWD[8"R
M&;WOVXX9\@7WE%:"M(!$K0?3/+_QUWDQ@*H                !,9S_ +97
M_*U9Y6V IP   2U)]-LK_5UGM3H"I      '\6A#B%-N))2%$:5)46I&1]#(
MR,!EUGQ7&Q3&\C>XJBG7Y?9LDW&?-]6]#?:)6IEA;IFEHC+=M]16G7H6@>CP
M[ SJOQ13.>NO.6"I*UPT2W2D2FXII3M2ZXDU:GNW&1&9F1=-0&@@     ":S
MC_9XWRE7>6- *4                          99S?[!Q_]=Z#VY8#4P
M                                      $<O[56/J\]Y:T L0
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MV5N()1MJZ%U29Z& [0  F,Y_VRO^5JSRML!3@   EJ3Z;97^KK/:G0%2
M     ZIV=<4\JLYC!69H[4H7:H[<V_\ J[/7=M_#H A,0YFQ?,\HEXO6LR6G
MFB=5"EO(234I,=6UTT:&:DZ'U3O(M4]?P -%     36<?[/&^4J[RQH!2@
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MEU/N=T!)<8<OPN1Y4ZM56N55I";3()A3J9#;D=2MFY*TI1H:5=%$:?4T :4
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M/>M""7J2_P!'T4 TD    !-9Q_L\;Y2KO+&@%*
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M7Q#7>\V/S #T0Q+XAKO>;'Y@#Q:+^%>32)L6@C4MC(KE]E,;CQXZS;5J9?\
M1U+4C+<6I?A =#D/BNHRS%Y-/2Q8-19*6V\S*1$;)*C:5N[-?9I)6Q7?V_\
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MI^#KKU]< [];_,K9V-M KV,8[8Y4?0X\=U3LIV6;:E)4P@DEN9,T_CTU/O:
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M$)33$:78):>Z*,U*42VE*/<HS5N,^H#V_/><_LFS\Z-^X 'GO.?V39^=&_<
M'2LU9G?-Q8$C'F8,<ID20[*\X(>V(COH=4>PFB-1F2="+4!<
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M,]3-9FG56IEWP':.MKCELSSAL'.CH-EB4;:.U;;/NH2O34D]>X1@.T
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MR6;$EM+J-Q=Q1$HCT,M>Z [$2)%@1FX<%AN-$93L9CLH2VVA)=PDI21$1?B
M<P                    #-[W[<<,^0+[RBM!6D @
M                                                    ,LYO]@X_
M^N]![<L!J8
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M7S1]Z4?]VXWPH ]"^:/O2C_NW&^% .-[$.9V67'E<I1S)M*EF7HW&[B2U_\
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MYORNGD7C-O@:FF\3.)(R9YBU8>2U L3_ $+D4C:0;[J4DM3C:NS(MNB5*W$
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M"2[,@19;\9R$_(9;=<AO[3=96M)*-M>Q2D[DF>T]JC+7N&".P
M                            "2Y'Y&QKBO&5Y=EJWFJ-J1'BR'H[1OJ;
M\9<)LG%((R/8G7<O;J9%W",!V).=4,?)L=Q5*W)$W*(DRPJ94=*78BX\!+*W
M%&ZE6GA$^@T::DH!WJS*\7NI\NJI[N!86D S*?"B2F7Y#!I5L,G6VUJ4C11;
M3W$77H XX698A962*:NR"MEW#C7C#=?'F,.R5,Z:]H32%FHTZ==VF@#VP'D,
MY7B\DY)1[N \<..<V63<IE78Q4J4DWG-%GM;(T++>KIJD_4,!_:[*<8N*I^]
MJ+J!/I(O:>,V464R_%:[%.]S>ZVHT)VI/<K4^A=3 <=?E.)3X#-G575=*K)<
M@XT>9%E,.,.RE:F;:'$*-*G#T/P2/4!S4>2XYDS#LG&[B%<1F%]D^]726I:$
M.::[5*94HB5H>NA@.&JR_$KTIAT=]7695W6P.%,8D%']=[+V:U;/6J]=IW#
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M0@'XG<2\?V41N#-J"=BLT[..-(-]].RLBNMOLMI-+A&2FW&D+0Z1]H2DD>X
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M*+BG"<;O_2*JA.MS&CDG7QUR7W(4 YZNTE>)QEK-ICME>$OLT%ZA:%T 6@
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MVJH=K)C$B2_6+;C=FIEQ1;NQ6:5'X![5&6O=!&S
M
M                                ,]Y7]#>SPOTR\<V^EE1YA\1UU\\[
MU^*]MI_\.N[?J T(                                  0.9>B'\0>.
M?/OC?I+XW:>B_B^OBW;>;G?&?&=.FWL=VS7^MH O@
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>lc_fig23neoantigen-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig23neoantigen-4c.jpg
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M="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,  X0DE-! 0       \< 5H
M QLE1QP"   "  ( .$))300E       0_.$?B<BWR7@O-&(T!UAWZ__N  Y!
M9&]B90!DP     '_VP"$  0# P,# P0# P0&! ,$!@<%! 0%!P@&!@<&!@@*
M" D)"0D("@H,# P,# H,# T-# P1$1$1$104%!04%!04%!0!! 4%" <(#PH*
M#Q0.#@X4%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%/_  !$( >8#M@,!$0 "$0$#$0'_Q #7  $  P # 0$!
M        !08' P0( @$) 0$!  ,! 0               0($!0,&$   !@$#
M 0(&"@P+!P(#!0D  0(#! 4&$1('(1,(,4$B%!464;/3=96U-E8W5V'1,I(C
MDW2TU'87&'&1X4)35)0U598X@;%2LM(S<W(D8D,E@J(T9":AP8/#A*3$1D@1
M 0 ! @($"@8) P0!! ,    !$0(#!"$Q<@5!<;$24I(S4S0549'1,K(3H>&B
MTN)SDQ1482+"@4*"-6/!(Z,&\/$D_]H # ,!  (1 Q$ /P#W\
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M+U$I^=60YLN,J%+DL-/2(3AZK8<<02E-*/IU09[3&<,7=%
M   !GO,?*D?B'%&,IDU;ENV_.9KRBLNI841OH<7OW+2HM"[/P?9&-TT6(9SD
M?>$R"=P2OE7"\>4S8.3SKE1Y1G,1#:2M3:Y3A,DG<DC(B(CT(C46O08S=HJM
M$OPES)?91Q;;YUR' \S:HW'S7816%MHF18[9.*=;9,S/5)ZH/;Y)F706V[1I
M287'C;F7".5UV+>'O27E5:652_.8ZX^A2-VS;N\/W!BQ=4HT 9(
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M:N-\T:Y$PBGS1F$NO:MVE/)A.+2ZMO:XMO0UI(B/[G7P"Q-8)6D5
M    &#9[WFH."\F?LW=QJ1.?[6 UZ1;E-MM__4"09'V:D&?D;^O7J,)OI-&5
M%-YP[P'*''W*,?$\:I&7:=MN*Y';>BO/NVJI)%O2TM!EMVJU;+81GN+4_8&-
MUTQ)$/4L9UQ^.TZZT;#BT)4ME1D:D*4DC-)Z>,O /5BY@%7S[/\ '>-<?5DV
M4..MU27FHRE1VE/K[1X]$^2GKIT\(DS0?/'W(>-\FT*LDQ5QYVK3(<B&J0TI
MA?:LZ;BVJZZ>474(FJS"U"H
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MHE/A5T&7.F(TI10XUQWLKK%WN5(ES8JQQ"7)AJ:=C-$J.T9[W6X1)ZM)T/\
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MR,M,[9GA2:/2P]&(
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MI_?&_P#P/&_O9)]KCC*_@(;PW_I<+I__ *6?Q<,_]J<+#NY4TN0>?,-%JZ[
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M8?0]Q=-2%LG22]Q#V8
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M?&6#\=QGHN&4S%64DR.4^C<X^[M\&]UPU+,B\2=VA>(A8B(*K:*@
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M]= :2Q!B-(CQ6$%HAMEI)(0A)>PDB(B&2.R
M             (G)<9H\PII..Y)#384DPDE+A.&I*'";62TDK8:3T)22/PB3
M%1&X;QSA/'S<QK#*9BG18*0Y-[#>9NJ:(TH-1K4H_)(ST_A"(B!:!17\OP?%
M,^K6JC+ZQJUK67DRFX[QK2E+R"-*5^0I)ZD2C$F*CFQ;$L=PFG;H,6@-UE,R
MI;C41HU&E*W5&I9ZK-1]3/V0B*":%
M
M
M
M
M                                          !55\DX(UE",*=R&"C+
M%F24U)OI[?>9;B1IX"69>!&N[[ E86BU"H
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MG2T-MUEXB(S;=;41*0HM?&7V2Z#*)JBRB@
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M"DRQ[",.J^1.\)(Q:^-95,VXMWYB&5;%K3%4^_V9*+J1*-)$9EUT\ PB*RO
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MI55'F/,E]R;[+_9I5I[))<40EFLN>WQ[,
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MLUT+5Q<;\#\LWW*\3E'EGL:]R%*:LG2;6PJ1+DQT[64DU&+LVT)VI-9GU/\
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M;,2LR]7#U8@
M                                                          /.
M/>)[MCO)]@SF6)OQHV6-,)C38LPC2Q,99U-HR=21FAU&NTC,MIE[&@\[K:LH
MEC<CN\=Y?+E0*C+9YKJ(9DF,[:6Y38\9.FW<AILUJ49)+0NFOV1AS9E:P]B<
M9\?U7&.&U^(5+BGVHA*7)F.))#DF2Z>YUU1%T+<?@+Q)T+4]![1%&"W"@
M          R;O&8+DG(O&[F-XHPU(MESHL@FWW4L([-E1FL]ZB,M2U\ QNBL
M+#A[MN 9/QOQZ[CN6L,Q[55E*EI;CO)D([%Y+9)/<DB+4]I]!+8I!+7QF@
M #C?9:D-+8?0EQAQ*D.MK(E)4A1:&1D?A(R >)\D[J?)F%90[>\,V*?,EK<.
M";,OT;91&G>ILJ6>B'$%KM(]W4BZI'C-DQJ9U=SC[NL9_=YDUE7,<M!Q&)#<
MN7&7*](3K!YHR4A#KJ=4H;Z>5Y1GIT(BUU)%D\*3+V@/9B
M
M
M
M
M
M
M
M
M
M
M
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MQ[&*G5]EQXW"679*_!K7V>S?TW'X1**TD0
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M10+/%;CTU#=-Q!K<:<,VFS;<:U3KX25NZ:"3"M'$
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MO<QP\[/)"B^F8UC95DERO0XU&<.NF.QDN(0ZI:D[R;)1D:CZA)"^"*
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MGW,*P'J!R]];TKX J?<PK ^%8+RR@]J^89"3]@Z*H+_^6%8'YZD<K_7$_P#
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MC;+0ST^Z\(#[I,HQO)2?/'KB#;E&VE).OE,RR:-S4TDOLE*V[M#TU\.@"6
M                $;._O.J_];WM*@%+F<53I<V3,3G^4QDR'5O%&8FLI9:)
MQ1JV-D;!F24ZZ)+7P#I6YV(B(^79-/Z3[7)OW?===,_.Q(KP1-OW7#^R*?\
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MRV)=;AVQ,6SP-CQPS/'JDS/4SA1M3/J9GV21Q,3WYXWT&'[D<23'F]
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MXYH\!S2#$AV\ES%NR56V<!U:VFG=R&65I4VM2DDAU.O4S+0AC*M_&(
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MT39=[WN_[R'1W;XFSC<S>OA,39E:L;^3M1^11O:DC2Q??GC;^%[D<24'F]
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MB4E:%I,C)1?9\!D(/N7_ 'Q6_P#HD?[D ,]X\^EOF+WPHOB2,+.I&J"*
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M_(T>VJ$5GW=_^0\_]8LA^-9 LI#5!%            9?A_TW\H>]^,>UV O
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MH3["B8;(C-:4RB=)9)(RW*+7PBQP#IXQBN38GS1A&'QJN86&U,#(;O$YZ2_
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M7Z6>,?X;S\S0.E@>&Q?^'++D9GQ>#Q8G)#2QS77
M                $?9,R3>ARXK9/+C+4:F=Q(-27$&CH9]-2UUZ@/GSZU_P
MI7X]K[8!Y]:_X4K\>U]L \^M?\*5^/:^V >?6O\ A2OQ[7VP#SZU_P *5^/:
M^V _//K7_"E?CVOM@'GUK_A2OQ[7VP YMH>AG4J,RZE^':Z'X/9 //K7_"E?
MCVOM@'GUK_A2OQ[7VP#SZU_PI7X]K[8 4VT(B(JE1$70B)]K[8!#:F.V+D^4
MQYL78I80T:TN*/11J-1FGH1== &?=W_Y#S_UBR'XUD"RD-4$4
M!E^'_3?RA[WXQ[78"\"-0$4 1N0_W#9_DC_M:AJ9SL,39NY);>3[?#VK>6$5
MQS\A,>_(6?\ E&ONOPN'LPV][^-Q=N[E6<=-R0    !0>;OHFR[WO=_WD.CN
MWQ-G&YF]?"8FS*U8W\G:C\BC>U)&EB^_/&W\+W(XDH/-Z
M                  "#@25UJ7XLB+(4OMW7$K::4XA2'%FI)D:=?$8#M>F6
M_P"J2_[.O[0!Z9;_ *I+_LZ_M 'IEO\ JDO^SK^T >F&OZI+_LZ_M 'IEO\
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MN1F?%X/%B<D-+'-=<
M            !E?=_P#D//\ UBR'XUD"RD-4$4           !E^'_3?RA[W
MXQ[78"\"-0$4 1N0_P!PV?Y(_P"UJ&IG.PQ-F[DEMY/M\/:MY817'/R$Q[\A
M9_Y1K[K\+A[,-O>_C<7;NY5G'3<D     4'F[Z)LN][W?]Y#H[M\39QN9O7P
MF)LRM6-_)VH_(HWM21I8OOSQM_"]R.)*#S>@
M                           #*^//I;YB]\*+XDC"SJ1J@B@    #*W/]
M24;]1Y'QNR+P(U010! YM\D+W\@E>TJ'-WIX3%V+N1TMU^+PMNWEASXI\F*7
M\AC>U)'MDO#X>Q;\,/'/>(Q-N[XI2XW&FR?E:P<QS,N/\PDPI$FCK),Z)8/Q
MDI7V*[1MJ*P:B4I/0UJ'6R5D8F%BX<3$73%LQ7AYM9EQ<_=.'CX6),3-L3,3
M3@YU(AK Y+M
M       ,K[O_ ,AY_P"L60_&L@64AJ@B@           ,OP_Z;^4/>_&/:[
M7@1J B@"-R'^X;/\D?\ :U#4SG88FS=R2V\GV^'M6\L(KCGY"8]^0L_\HU]U
M^%P]F&WO?QN+MW<JSCIN2     *#S=]$V7>][O\ O(='=OB;.-S-Z^$Q-F5J
MQOY.U'Y%&]J2-+%]^>-OX7N1Q)0>;T         '!-EM0(C\U_7L8S:WG-I:
MJVMI-1Z%XST(96V\Z8B.%C=-(JX:>TC7E3 N81+*'8QVID<G$[%]E(03B-R?
M$>A]2%OLFRZ;9UQ-/4QP\2,2R+HU71$^MW1@]
M                97QY]+?,7OA1?$D86=2-4$4 8QR=G.>-YJ>"<?R8-9/J
ML:E9G/FV494U$I$>1YO'@)2EQOLT.J2OMGB,U)3IL+491"/O)N6+AON\-\PX
MW%C,VLRHK[5$::HUQXWGRF2?5IN;4\;*7%J0VDR4ZI))3U41"4TT*Z'9X(Y
MNLZ@Y(W96+%_!HK%-?6Y,U#74/3T'';>=[:N=4:V%-..*:)1[4NI(E)3[*8(
M0F*YUBV=]XE4S%IRIS$'#9$64I4>1&-#I6S/320VV:O ?5.I"TT#=ABH @<V
M^2%[^02O:5#F[T\)B[%W(Z6Z_%X6W;RPY\4^3%+^0QO:DCVR7A\/8M^&'CGO
M$8FW=\4I<;C39ESQ\@D^^U1^?LCI[M[6=F[X9<G>G8QMV?'#31S'6
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M<LO+*=A9LV\BR[T_\1?QC6JVC>G_ (B_C"H$>HH_0
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MG8QMV?'#31S'6
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M8ELSKFRV?H8[IMBW"NMC5%]\1_I=+51R79
M        !E?'GTM\Q>^%%\21A9U(ZG-EEDV*0F\KA<@N8I1-I;A%41:%F]E3
M;!U:C03!+63AK4DM.S26A$DU&?A""77[O^<VF:1KT[;(K*^>BG!=8*VH&L<<
M:CS65/-+;0VXOMD/)T6E9_[ F"&SB*  #*W/]24;]1Y'QNR+P(U010! YM\D
M+W\@E>TJ'-WIX3%V+N1TMU^+PMNWEASXI\F*7\AC>U)'MDO#X>Q;\,/'/>(Q
M-N[XI2XW&FS+GCY!)]]JC\_9'3W;VL[-WPRY.].QC;L^.&FCF.L
M                                               RON__ "'G_K%D
M/QK(%E(:H(H     RM[FJ:R^ZR7%^<.=DXMOM6ZV(:%[%&G<DSFEJE6FJ3]@
M6B5:#C]NN^IX=NY73*E<MLG#K;-M+,UC4S+:\A"W$I5T\!+,14F   #+\/\
MIOY0][\8]KL!>!&H"* (W(?[AL_R1_VM0U,YV&)LW<DMO)]OA[5O+"*XY^0F
M/?D+/_*-?=?A</9AM[W\;B[=W*LXZ;D@                       ,OX-_
MN3)_UHN?;QU=Y>_9L6<CD;K[._\ ,O\ BEJ Y3K@
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M1D"1-7("@
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M;QU=Y>_9L6<CD;K[._\ ,O\ BEJ Y3K@
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MY(68:[;
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MQ735M Z[C@
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MC\I?W'7>^]=^<)'"WSV5GYECZ#<7;7_E8GPKP.Z^?
M  &7\&_W)D_ZT7/MXZN\O?LV+.1R-U]G?^9?\4M0'*=<
M                  &5\>?2WS%[X47Q)&%G4BM<RXKRW89+(L>-HK<QO(L:
M>Q%R:Y8^8>@WI,OM%V79JZNZ-JZ=B7:DI"=.ABP)[B+BUGB[(LHK<<KO16!.
MQJANK:*0;Z9<^.PZB9,-M2E&TXLC90X9_P#<4C=]D29J*3S84*_Y+D8QE]G(
MKL0J\#M,EIU,S'JY*+R-*)M4Q+C*VS<=B,D2D$HU$C>:MO7490.#-.1<L8[J
M-9D<:R-G.Y%-C:[N2W)1'FL-6[T9EZ2M>BC8-Q"UGVII\C4U%U3TE-*<"V]W
M^3%JY6;<=)JHM?88I/BJFR:J=-L:V5Z3B)?;4VN>XXZVZA*=CS9JTUT5_/"5
MAUL7L\ML^\2;F6T$>@D-8;(1$:C6!69/-%;L_A%&3+.SQ>3H?\/0. ;H,5
M        !@> ?2UD'O[>?F\(>6]_&Y3\F[EEZ[F\%G?S[/A;X/5Y
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M1RE_<==[[UWYPD<+?/96?F6/H-Q=M?\ E8GPKN.Z^?
M   &7\&_W)D_ZT7/MXZN\O?LV+.1R-U]G?\ F7_%+4!RG7
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MF\(>6^/&Y3\F[EE[;F\%G?S[/A;Z/5X@
M                      RCNVF:^'Z=]9[GWYERZ^ZKJMQQ5O,U4H_&9Z>$
M64AJXB@    #*VL9X4PK-V$I\PJ,[R3SST7$<EK*492S-V6J#'6X9,=JI!J<
M4PA&Y1==3%TB[8;6XS48S6U^&(CIQ9EDO1?F;G;,*969KWI<W*W[C,U&LU&:
MC,S,]1!ATWAK.GK6ZPK2"[QIDF:-Y];7BY"TS3CD^Q+<J3B$CRE&_'1M?[78
M37\W<1$,JI1,<E<?9IG3F+Y9:X]47-GB%E;%ZG.S5H@V=39-'&:6J0XT:4/H
M)+;IH6VI'W2=? $23"X</X'9X9QM%Q#)G6GY2ES77X41QUR'#8GR'7DP8SCI
MDX;4=#A,H4KKH730M!)G2J!XPK(-/S-RS7US78Q&8^,);;W*7H7F<D]-5FH_
M"?LA.I&RB*     *3R81'64R3ZI.ZKB47B,NV'"WQ[F'^;9_ZN_N7W\7\K$Y
M%V'=<                      9APIH4+,T%T0C+;DDI\1%VB.A#J;Q][#_
M "[.1QMT]G?^9B?$T\<MV0   '&R\T^CM&5I<;,S(EH,E)U(]#ZETZ&6@2.0
M                            !DO'QJ_:-RZYJ?:'>TZ#7XS057#(DZ^Q
MH>@LZAV.>Y-RQAT!NGFRXR)-O!8LXE3*3!N9]>:E*?B5KJE(/SE9))24(6A:
MTI4E*B,PA)17 3N?3XDBSRZ%<U=>BJI:N-"R)9^=NV%>PXB=*2R:W#:0X:FT
MZJ5N=-!N'IJ+)#9QBH  ,K<_U)1OU'D?&[(O C5!%          !@6 ?2WD'
MO[=_F\(>6^/&Y3\F[EE[;F\%G?S[/A;Z/5X@          B:2W7:KLTK:)KS
M":["3HK=O)I*3W'T+0SW> :>5QYQ>?6*<V^;?5PMS,X'RN9IKSK8N]=="6&X
MTP                                    !D_=K^AJB_*;CXWF"RC6!%
M     'E/F*I.-SA2.8EDE"WG%Y(J9Z:;(8]BZME^I;EM1>SDP$+2VR^3KBC8
M>4WO<;U0KRE:9QJ8\+<.%ZK'Z/B[&*O%K;T[0L0D^:W&SLBE&XM2W'";_P#E
MD;BE:-_S"\GQ#&=;*%\$   9-@?TY\O?^#%_S*2+.I&LB*     *3R9_=M+[
M]5WMHX6^/<POS;/_ %=_<OOXOY6)R+L.ZX                      S'A7
M_P#"9K^MUS[8@=3>/O8?Y=G(XNZ?<Q/S<3XFG#ENT    HO#Q$G (!$6A>=6
M?0O?&2-[/=M/%;\,.?N^*8$<=WQ2O0T70
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MS$SAS6FO1,<KY_-9+&RTQ&+;S>=IC3$\E4N-UI
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M&9GH0D0./ ,J@9.U8+@8I;XL45;:7&[JM]%J?-:3,E-%J>\DZ:*/Q:BBY"
M ,K<_P!24;]1Y'QNR+P(U010          9AQ*1'=<E:]?\ ]4R?S=@=7/\
MNX7Y<<LN1N_W\;\R?AM:=M3[!?Q#EU=:D&U/L%_$%2D&U/L%_$%2D&U/L%_$
M%2D&U/L%_$%2D&U/L%_$%2D&U/L%_$%2D&U/L%_$%2D&U/L%_$%2D&U/L%_$
M%2D*;BGRNS3\JB?FC8X60\3F-JWX7>WAX7+;-_QRN8[CA
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ME::]-=-1UL#$^9AVWZN=$3ZXJX^/A_+Q+K-?-F8]4T=P>SQ
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M-O*YJ,>)_MFV;9I,7:_3_5:AJ-T
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M.DR,D]BA1)4EI9%VC9*+4D*+7J,95>Q   &38'].?+W_ (,7_,I(LZD:R(H
M    @<W^1U_[WRO:E#F;T\)B[%W(ZFZO&86W;RN;$_DO2_D,;VI(V,EX?#V+
M>2&OGO$8FW=\4I@;;3
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M)EB7>(.*5W;W?G6'29!NWDPYRVM;9GR&C-*=B/L?P!P#=1BH
M             IF*?*[-/RJ)^:-CAY#Q.8VK?A=[>'A<ML7_ !RN8[C@LQXO
M^5W)WO\ H_,V1U,YV>%L?Y2Y62[7&V_\;6G#ENJ
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MA\/8MY(:^>\1B;=WQ2F!MM,
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MMY7-B?R7I?R&-[4D;&2\/A[%O)#7SWB,3;N^*4P-MI@
M                                   "D\P_19F'O3+]J,;V[_$8>U#G
M;S\+B;-W(G,.^2-![VP_:$#7Q^TNXYY6W@]G;Q0FAXO9DG'WTB<N>_\ 3_%<
M(6=0^.\8J,SA%9,5+LH5M#O:V10R*.O:M[(K-+BB92S$?6A#AJ(U)41Z^3KT
M"!7>'.6YLO)9N&9S:9%)R"6\EJK+(L;8QYIMYJ.J0J,E<5;J%..-$;R.U,MR
M4JV&>ABS"/0 Q4  &5N?ZDHWZCR/C=D7@1J@B@
M  "F8I\KLT_*HGYHV.'D/$YC:M^%WMX>%RVQ?\<KF.XX+,>+_E=R=[_H_,V1
MU,YV>%L?Y2Y62[7&V_\ &UIPY;J@
M#)^[7]#5%^4W'QO,%E&L"*     /+_+.5YUC_,5=-;5D=EB]?*JO-JG%&7)\
M145YF2<]FRC1M5^<N+[ XW;Z-[.J#U)0SB-"-LXECYA%XYQUC/W5NYBF&@[5
M3JTN/$XI2E)0ZM/13B$&E+BBZ&HCZF,9(730A%  !DV!_3GR]_X,7_,I(LZD
M:R(H     @<W^1U_[WRO:E#F;T\)B[%W(ZFZO&86W;RN;$_DO2_D,;VI(V,E
MX?#V+>2&OGO$8FW=\4I@;;3
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MS2'XTZV^VAYE9.,N));;B3)25)46I&1EX2,2VZ+HK&HNB8FDZWV,D
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MFL+-8>%BW6W1?%VJ*>[#UQ,#)XN5Q,7!MOMG#FWWKHFO.GB7P?1/FP
M                                          !2>8?HLS#WIE^U&-[=
M_B,/:ASMY^%Q-F[D3F'?)&@][8?M"!KX_:7<<\K;P>SMXH30\7LR3C[Z1.7/
M?^G^*X0LZA%]YRZJ8F$UE39*J)9VEM$2O&[R=$K$VT1I>K[+,F69=@XC<AQ+
MZ#)2%$GRBW"PDIOA'&BQ>NMX2../V>H>D-OGOM&;I^P6I!I-QQ]#CKGX,DDD
MB<6?A\GQB2K5!   &5N?ZDHWZCR/C=D7@1J@B@
M  "F8I\KLT_*HGYHV.'D/$YC:M^%WMX>%RVQ?\<KF.XX+,>+_E=R=[_H_,V1
MU,YV>%L?Y2Y62[7&V_\ &UIPY;J@  C[[K1V9?\ Y5_VM0U,YV%^S=R-K*=O
M9M6\K@Q8B+&:<B+0O,HWM20R7A\/8MY(99WQ&)MW<LI<;;3
M             !D_=K^AJB_*;CXWF"RC6!%     'F#E2KO;SDZ]C\1U^0KR
MB/7049])HK^'CL=YMY#AP6O_ 'D:2:Y1-$O:\T3>Q&A&YJ?DYQJ8RU/A2KX_
M<Q6%FG'T.1#K,AKJYA+$I:U.,QZAE41E@TJ4LDJ:T6E9I,]Z]RM5:ZC&64-,
M$   9-@?TY\O?^#%_P RDBSJ1K(B@          I5_\ 2+B'_ALO:D#@YK_L
M,#9Q.2'T&4_Z_,<>'RRNH[SY\
M              4GF'Z+,P]Z9?M1C>W?XC#VH<[>?A<39NY$YAWR1H/>V'[0
M@:^/VEW'/*V\'L[>*$T/%[,DX^^D3ESW_I_BN$+.H1G+W#&59YD;UYCEM3Q&
M9^.2<5L(UW6KL=D>6ZIU;T<TO-['#W:'KJ1[2U\ L2BY<5XYG^*T2*/.;JMN
MFX#$6'4/5L-Z&M,>*R31F^;SSV]:MJ3U+3QB2J^"   ,K<_U)1OU'D?&[(O
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M"=$LK0TI:$FDB\"5'_",95/@   R; _ISY>_\&+_ )E)%G4C61%
M !2K_P"D7$/_  V7M2!P<U_V&!LXG)#Z#*?]?F./#Y974=Y\^
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MI-2C/V3,QQ\:(B^Z(],N]A3,V6S/HA+#R>K)^[7]#5%^4W'QO,%E&L"*
M /*6/<'<Q8C?4&0T-9A"[R@EW,B3>N2;%FPN471O&?G[C<0S6:3<2O12EZ*0
M6W0AG6&.EZ<HE7"JJ(K(&XS5X;2#L&X"UNQ4OZ>632W4I6:-? :DD8P9)$
M &38'].?+W_@Q?\ ,I(LZD:R(H          *5?_ $BXA_X;+VI X.:_[# V
M<3DA]!E/^OS''A\LKJ.\^?
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MYIFHKXU>T[A4AUU$1EM@EN';LZJ5V:2U/[)AP(V$10
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M2K_Z1<0_\-E[4@<'-?\ 88&SB<D/H,I_U^8X\/EE=1WGSX
M                                   I/,/T69A[TR_:C&]N_P 1A[4.
M=O/PN)LW<B<P[Y(T'O;#]H0-?'[2[CGE;>#V=O%":'B]F2<??2)RY[_T_P 5
MPA9U#6Q      96Y_J2C?J/(^-V1>!&J"*
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M/H,I_P!?F./#Y974=Y\^
M         *3S#]%F8>],OVHQO;O\1A[4.=O/PN)LW<B<P[Y(T'O;#]H0-?'[
M2[CGE;>#V=O%":'B]F2<??2)RY[_ -/\5PA9U#6Q      96Y_J2C?J/(^-V
M1>!&J"*
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MK/\ 27GOK!P\+,S%EL6Q-MLTC5IMB96X=EQ
M        !2>8?HLS#WIE^U&-[=_B,/:ASMY^%Q-F[D3F'?)&@][8?M"!KX_:
M7<<\K;P>SMXH30\7LR3C[Z1.7/?^G^*X0LZAK8@     ,K<_U)1OU'D?&[(O
M C5!%
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MA-#Q>S)./OI$Y<]_Z?XKA"SJ&MB      RMS_4E&_4>1\;LB\"-4$4
M                                                     !2^7OHN
MS#WIF>U*&]D/$8>U'*YV\_"XNQ=R)O$/DG0^]T3VA U\?M+N.>5MX/9V\4)D
M>+V9/W:_H:HORFX^-Y@LHU@10           &38'].?+W_@Q?\RDBSJ1K(B@
M                        #\/P DJ7Q;\F'/R^?^=.#A;C\-&U=ROH=_>*
M_P"%GP0NH[KY\                                 4GF'Z+,P]Z9?M1
MC>W?XC#VH<[>?A<39NY$YAWR1H/>V'[0@:^/VEW'/*V\'L[>*$T/%[,DX^^D
M3ESW_I_BN$+.H:V(     #*W/]24;]1Y'QNR+P(U010
M                                          %+Y>^B[,/>F9[4H;V0
M\1A[4<KG;S\+B[%W(F\0^2=#[W1/:$#7Q^TNXYY6W@]G;Q0F1XO9D_=K^AJB
M_*;CXWF"RC6!%            9-@?TY\O?\ @Q?\RDBSJ1K(B@
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M;O/$:>G\XR/J70. ;J,5
M                    53DVOG6W'N3U=:PN583*V4S%CMZ&MQQ;9DE*==.I
MF8V\G?;9CV77:(BZ&EG\.[$R]]ML5F;9B/4E<88>BXW3Q)+9M26(,5IYI7W2
M'$,I2I)Z>,C+0>.+,3?=,>F6QA1,61$^B$L/)ZLG[M?T-47Y3<?&\P64:P(H
M           #)L#^G/E[_P &+_F4D6=2-9$4
M ?A^ $E2^+?DPY^7S_SIP<+<?AHVKN5]#O[Q7_"SX(74=U\^
M                     *3S#]%F8>],OVHQO;O\1A[4.=O/PN)LW<B<P[Y(
MT'O;#]H0-?'[2[CGE;>#V=O%":'B]F2<??2)RY[_ -/\5PA9U#6Q  4W-^+<
M)Y%.*O+*TY;T-MZ.T^R^_$=.+*(BD1UN1UMJ6R\22)QI1FE7L"Q-!]SN+\#L
MXUO!G4C#U?>P8M39P5&X45<& 2BC--L$LFV>RW>0IE*5$>AZZI+14=S#<&QK
M Z^178W$4PW,?5,GR'GG94J5*6E*5//OOJ6XXLTI2G52NA$1%T()D4YS_4E&
M_4>1\;LAP(U010
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MX.%N/PT;5W*^AW]XK_A9\$+J.Z^?
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M^=/K?9_RO"_20K >H?.GUOL_Y7A?I(5@/4/G3ZWV?\KPOTD*P'J'SG];[/\
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M[AS%Z7#N6^6:''V76*QEK&EMMOR9$Q9*7#D:_A93CKAET\!JT%G4C<1BH
M                      & CZ:E@4,,X%<@T1S=<?-*E&L][RS6L]3]DS&O
ME\O9@6<RR*1[6SF,SB8]_/Q)K-(CU12$@-AK
M         "/O:6!D=-.H;1"G*VQ97&E-H4:%*:<+:HB4GJ73QD/3#Q+L.Z+K
M=</+%PK<2R;+M5T4ESP(3%;"C5T4ML6(TW'829FHR;:22$D9GX>A>$8W73=,
MS/"SMMBV(B.!V1BR9)Q]](G+GO\ T_Q7"%G4-;$        &.\F<BYU6Y<O"
MN/8U9Z3KL<E9?9RKI+[C3L>.]V#,-E+"VS2MY:5[G5:DA)=$J,91"-"P;)F,
MUPZ@S"*RJ-'OZZ):-Q5JWJ9*8REWLU*(B(S1NVF9%UT&,Z)6)JL
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MC;7#N19=DLM,^^O'F6XA/+991&8::8:U2TTTTVE*4[E'KN49]1)E5U$
M   &*5W=Z:@W=63N3R)6 T5W+RFFQ1<2.E3=I.[<U]M/27;/LI5*?-+:RU,E
M$E:E)21#*H^*?NXU[49RHRO)I^38W"I+#%<6KI#3$==946R4MOD;[:34^^33
M;3+;JR3M2C[DS/4.<E%FX]XJEXC;R\FR;)I.794]7Q:*+9R8[,/S>H@J6XVR
M3;'13BW'%.//*/59[="21:')E6D"                    #X6TTYH:T)49
M>#<1'IK_  @/GS>/_1(^](!4,]Q2BR)6+*M;!NJ]#Y!!MH&ILH\ZF1DNDU&+
MM--3<WGT3Y73H+ M_F\?^B1]Z0@>;Q_Z)'WI 'F\?^B1]Z0!YO'_ *)'WI '
MF\?^B1]Z0!YO'_HD?>D >;Q_Z)'WI 'F\?\ HD?>D >;Q_Z)'WI?: =5F73R
M9$F''<C/2X9I*9';4VMQDW",TDXE)F:=Q%TW>$!6<=QBBKLUS/(X4]$ZRO5U
MJ;.N2;*O,EP(ILMI,D:J(W$GO\O_ &= %GB2*J><@H2X\GS5U4:3V*FW.R?;
MT-3:]NNU:=2U2?4@'9\WC_T2/O2 /-X_]$C[T@#S>/\ T2/O2 /-X_\ 1(^]
M( \WC_T2/O2 /-X_]$C[T@#S>/\ T2/O2 /-X_\ 1(^](!7LRK*2]PZ_I[&6
MS75=G7S*Z99&;24QVY+2V%N;EF2"-&[^<?A\(0.:MCT>*8Q7QY,N.FIJXD6(
MFRDJ::;4AM"&6UJ69D@M_DZ=?"?0!-)8CF9EV*"T_P#A(!^^;Q_Z)'WI 'F\
M?^B1]Z0!YO'_ *)'WI 'F\?^B1]Z0!YO'_HD?>D >;Q_Z)'WI 'F\?\ HD?>
MD ZLV53UW8G8.QHI2'"88-]3;7:.JUT0C>9;E'IT(NH"MV^-T<_/L:R%Z>VQ
M<TT*S9AU'X'=)9L?-R=<VG^$,F^P3]R6GE=1:BR><U/GWHS?'](DSYSYGN;[
M?L-VSM.SUW;-WD[M--1!VO-X_P#1(^]( \WC_P!$C[T@#S>/_1(^]( \WC_T
M2/O2 /-X_P#1(^]( \WC_P!$C[T@#S>/_1(^]( \WC_T2/O2 =2+-IIOG!P7
MHTDX;JH\OL%MN=B^W]TVYM,]JD^-*NI *OQMC>.X1Q_5TM79,VU%6-/J;N5*
M8[-;:GG'EK-;9]F1)-2B,R/Q=19%MBJKYT=J7$[%^*^A+K+[6QQMQM9:I4E2
M=2,C+P&0@YO-X_\ 1(^]( \WC_T2/O2 /-X_]$C[T@#S>/\ T2/O2 /-X_\
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MOF\M^.I.I.L)D(W*09;SW(W%]UU+J [Y8_1E<*R(JR(60*:\W5;%':*8;/\
M1F_MW[>GW.[0!)          "'K<4Q>F:FLU%)7U[5EJ=BW$B,L)DZDHC[8F
MT$2^BE?=:^$P'W%QK'8-.O'851"C8^XEQMRI9C--PU-O:[TFPE)(,E:GN+;U
M\8#MUU;7T\)FMJ8C,"NCIV1X<5M###:=3/1"$$24EJ?B(!V@
M                                'YH7L /T
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M"X-AQ8-SRU&AQFHD=.:R32PPVEELMU;7F9DE!$6I^$S\?A$DAL Q4
M
M
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M=N#DJ>.')#J?3LL\E7.\_*7Z:-MKMB=](I2[T;[+;M+9MTVBR-%$
..               ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>lc_fig27tumor-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig27tumor-4c.jpg
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M Q$!_\0 P0 !  (# 0$! 0            8'! 4( P(!"0$!  (# 0
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MN8M#\6 ;GI9E<:B0B4P3RE+TU-)JU/YJVS_&,B"[P
M                                            <:Y+\6W,2>5\MXRX
M]XUCY2_C$EYM1QW9"WSC,K2V3JTI(B+4UI(]/:8#VQ[XR\VHL[I<-YSXUD87
M&R!U#$&T)3Q$A3BR;2LVWD:.-DM22<4AS5!==#\ %J7G-]SA?Q!5/%690(<?
M#LPB$O#\@8-U+QV"3)"HLDEJ-!J4LC2DT$7SV_\ >/0+P
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MPNPK?(655<9BU0D]">3(;E0O-IX[?3LJ+\*" =O
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M+(S\OT31I,C_ !2 =5X-<OY'A.-Y#*+23;54&>\1>!.2HZ'5>'X5 -^
M                 (ERBQE\OCS)(. M-NYC-@NQ*CO/%'0V])+M=WN&1D1M
M)4;B?E-.GM <X<#_  2X+1X$AGF;&HESG$B6^^^XF5(4AB/J3;+*5,.-I,M$
M=PSTUU7IKT 8]5\,>7<5_$Y5<B<15<./Q<\TU&MJQ4TVULL26O3RDI2Z:UKV
MJ2F4DMW5?EZ$ P6*TN6?CXE7,(N_C_%U:TQ.E)ZMG-0TXE#.XO!:9$ESI_[E
M7R .T@
M         <,VG"?Q3XCSIG?*'$[5.RSD\B0VR[.D,.FJ$ZZATM6W$^51FVDP
M'S:_#?\ $SSSE%"Y\05]5P\+HW>ZJ#6*0;KB5FDW2:0PV2=[A))'<<<\A=4I
M/P,-W\<49S.+7BG@K'R)5U?VQS#9;+4X\1I'I4NJ+V()+CRS/Y&U?( [%@0H
M];!BUT1.R+#:;CL(^1MI)(27\1$ R
M   !Q[S1\-O*53RU^_GX=K!B-E,H]]Q1R5MLI>>4@D.J0;WT2VWTD7=;<-)D
MOSI5J9;0B\W@[XG_ (D,DHD_$*J#B^ T;WJ':JN<8-U\ST)?;1'=D?2+26SN
M.NZ-D9FE/4R4$B^.9L[JCXTX)Q-E";C)+IGT,%I/E9BPFCB-ZI3\QLCD$>OA
MM0KV$8#KFBJ(U!25M#"U]'5Q6(,?7Q[49M+2?]B0&>
M       _%)W)4G4TZD9;B\2U]I (-QCQ'AG$E?8P<39?-^XEKL;>RGOJESI<
ME?X[SZ_,K3J9%X:FH_%2C,)T
M                              ()#XAPV+R?.Y?<:D3,VF14U[4F6^IY
MF'&2E*#1%:/RM;B3YC3U\R_]]6H3L
M       03]T6&N<H_O@F,R)N:-PBK8#LIY3L>%'V[5%&:,M&S42E[C+_ 'U_
M[Q@)V
M
M
M
M
M
M
M                      Y4S)%I%YZ0S6NE.RV1DE)*KY:W[-F?$HEQ$HEP
MF8J63BNPMB)#CKY/$@EK42T]U"-0A,%XD8P^K%9&0GD!XNISF@VU6:IJ;$KB
M 4DU]SYLLF?>FSL>;L_-\I-@+VX7?:9A9VOCEE5A@#5LW^I4>4_(:BK5Z&-Z
MY,9Z2AU:8_JN[H9)4CN=S;T 6)C^27,^\L*"^IVJN9#BQIS2X\SUK;K4IQYK
M0S-EDTJ2ID^FAZD?B DX
M                   (S><B8+C+MFQ?Y# KGJ:&BRM6Y#Z$+C0WG.TVZZ6N
MJ26L]B->JCZ%J V])=U&25,.]H)K-E33VTOPIT59.LNMJ\%)4GH8#.4I*$FM
M9DE"2,U*,]"(B\3,P$5Q3D[CO.ILZMPW**R]GUO6;'KY34A;:==N_1"CU1KT
MWEJG7V@,?*^6^,<&LD4^8Y=54=JXTF2B'/EM,/&RM2DI62%F1[3-*B(_P )-
M46]7?U<2ZI);4^HGM)D0IL=1.,NM++5*T*+H9&7M 9H
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M,O\ ",:O;%;;MA:54&;+<92;;2GI,9#JS0@S,TI-2CT+7H0"0
M                             QYTV/70I-A+4:(D1I<A]24*<43;236H
MR0@E*4>A>"2,S]@#C&^S'C*UY*FY/&R]W]3[.UKLKL*Q[$\D]X/W-'"3$@1U
MR40MIP4N-M25(4@U$M)DG0E&8#HG@"#70N+JM=;9>]TSY%A9RYY0I%4TN;83
MGY,E+,24AMQIE#KBT-I4@O*1'[0'U\0Q69\%\AE3[O7^X+#;V]=_:["N[MTZ
MZ]O< KZ:[AC?*/ ;V#+AHA-55TXM=:;:6DXX52GMFZ;?0F"?[&S?TW^'74!Z
M93CUAD7-EM9XAR74XQ+EXI6NO1O=\:TGKB1I4Q;<EOUGT/I5=U1.*;-1]"U-
M'0S"4\:\BYYE_$F+9A7XW"MKJQ*2S/:;F^ZXAHAR'HR94?N,O&;<@FB=0G3H
ME9=3 2/&,ZR.RRZ1AV4XTBBL&ZU-O'>8L$6+3C*I!QS2>C+)I41EKX&1D G@
M                              J#XC+K"CXYN,%RC,:_#['*X,B/52+)
MXV6W5-&@UI5M\QM*W);>V]=BS 43A;&%91R#B4].8X-^N3N2-6DAG&I:W'H5
M93UI0*NCJ24RV:X[B"<7)Z-(+51$A6I& [5 <Y\N09%]SUBE914%=F=Y78S9
M39F.Y*LF:>+"DRV66YS+ALR3*4IULV=$L+U:UU-/0S#.X MY5%Q-+AT]#)L[
MNFR2YK+C&*]<:.Q5S4SG7'HD)4E]#9Q&-Z2:,G#,TGKH1ZI(+%I>0I\[)X>*
MWN)V6/3;&)*FP'YCL&0PZF"ME+J-8DEXTJ+OH,MR=#Z@)R
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MM<Q;Q*=C]G3IL2L5X[8ST-H;L44KR&):R92LWF4[G$+94\A).MGO3[",+
M                        $+QW[Q,V_P#!I_J7P$T
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M#D2)_('H\FOK263C,**KU2VTM$HM[RNUO>7H:CT2DB"S0
M          !#<>2HN0\T49&25,U&TS+H>C+_ ( )D                  *
MER#B_/8V67>5<7YLSC/ZT=ER_K;*K*XC'-C,(BHEQOY1'-ISLMH0M)[D+VD9
MEJ F7'N$PN/<5B8Q#E/V"VG)$J=9RS(Y$N=.?7)DR'-I$1*<=<6K0NB2Z%X
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M'M0W-/=\CW4BEL(UE':I:QMUV&\W(0A9RIRMJC;-1$>G70P$Z
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MW6C[VU>*$14Q_3+_ )N1&HO^WU^?N 2L   $2B?>;;_85;^=SP$M
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M-4L+4THNU(;:6DB4@R+5!?@Z -Z     KHOOX7^R*/TFH!8H
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MQVWIW*5]%-6(;8>?8DFXCU4X]Y&PI9$1'TT,]0%@
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M9;93'3*D*4IYA2M6R2@R29J,P[( >;S#$EI3,AM#S*M-S;B26D]#U+4CU+Q
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M,,(2VVDC/4]J4D1%U,!&(GWFV_V%6_G<\!+0
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M6A9:D9I6DCT,C\#(!K8GWFV_V%6_G<\!+0
M       !A7%O5X_53+N[EM0*BO97)FS9"B;::9:+<I:E'X$1$ YJX0GUG-5]
M67L"4F=QWQD[)]UH-)H3-RBQ6ZXJ4;:SW=N'%>)#"EMIU<=6I/S '40
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M5BI1$>]*?$@%Q             (GRE]V6:?85I^9N@0W=!_859_1&/JT@-B
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M[*NY%NVK.W>N7ETU8MM^0U'84VGU4XMA%';;29&?751:@)^
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M,99-J-!DAQHU)/:9&D]#Z&6@#VL:^%;5\NJLF4R*Z<RY%EQU_-<9>2:%H/\
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MBR)T@B\_:2?><=4DMN[MI/3IX= %N@   @%_]\&$_8^0?65@"?@
M   (!S-?55/QWD,*?(2U,N:V=75K'4UNR'XRVTD1%X$1J+<H^A"#-GIBC6TN
MEL.G9][>:X:ZS''NB/2WN#Y!3Y'C4&;2RBE1V6T1G3(C2I#K2$DI*DGU(_;_
M  =? 9Q9JY:\U9[$>]V6;:9/AY8TM_UVPD0F40   %4<Z5.,6U34HR>:N%'9
ME+7&<;QUO)S-TVS+\DY"F]D]#/SDE.OAJ V'!,>TB<9546UB>C=:?GIBD=:U
M1J>A^N?.,^JO:2E,93S1H<-LRW$9^;S&8"QP   1*)]YMO\ 85;^=SP$M
M                              1/D;/:WCG&7;^<RY.F.NM0*6GC=95E
M:2SV1H;!:'JMU7X#VI)2CZ),!I^*,"LL7A6&2YB^W/Y,RMQ$[*;!DOH6U((R
M8@1==3*-$0?::U/51[EGU68#8<3_ .@ZW_Q9WY\^ F@
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M2U*;325B5K8<2X1*]7./0S29Z'H F@
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MIZM$LBVF>OF/VD N$            !$N4ONQS3[!M/S-T!O:+^Q*W^BL?5I
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M#ZZJ,S-1@/*BJ*FFY'NH]/ C5[#E+6..-1&6V$*7ZJ<6Y1-DDC/3IJ8"<@
M                             I#)%*YRS61Q_$/?Q/B$I/Z]RD]46]PS
MM<:ID*\#98/:[.\=3V,]/. NY*4I224D24I+0B+H1$7L(!^@
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MGS;<94@VU_2J(S3N2>TR 2X   $2B?>;;_85;^=SP$M
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M2 W>,V[MSR)>2'JN;4J;IJQLF;%#2'%EZJ<>Y':==(T^SJ9=0$_
M                  !Y24R%QWD1'$M2E(43#KB#<0APR/:I2"4DU$1]3+<6
MORD J!_E.\Q&@O\ (<M?BVSL*V=QK':&JB.1IMI;&M*8K+1N2'_.\9GJDD:(
M21K,]J3 2'BC K'%8,_(LO?:L.3,K<1.RNR9(^REQ"3)B#&UU,HL1!]IHC/K
MYEGU68"PP                         !^*/:DU::Z$9Z%XGH Y$O<LSOD
M2UEQ.0N-<UK.-D.;&,/QJ!$=.V9+0R7:6!2FE&TKJ7I8VU)_CN++H Z8P*7
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M]7( 64 B7*7W8YI]@VGYFZ WM%_8E;_16/JT@-@ K[A3[O8WVE>?IF: L$
M4[SG36\B=A^1T=>NTL*23-+T2J<[Z*MJ9')M9NLE*B]LRVEL=)1F75/@I0"6
M<2WWZR8'7V:F&HC_ '9D:3#9KW*8F'XLMUAQM4)YUY;*DJ09*)2SU/S>T!O9
M.(XK,O8^3RZ2 _DD1)(BV[L5E<QI):D1(>4DUEH2E$6A]-Q_*8#XBX9A\%=J
MY"Q^MCKO=Q7:FH;"#FDYNW%)VH+NDK>K7?KKJ?RF RZ2AH\:KT5..UD6IJVS
M4IN% 8;C,)4L]RC)#24IU4?4STZ@-'$^\VW^PJW\[G@):
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M0D.(;A*3(<;]$OO$2S=C;>P\HR+5Q*C(MN@">     *Z+[^%_LBC])J 6*
M        *ZY6_G_'7[70_P RF@+% 1/E+[LLT^PK3\S= ANZ#^PJS^B,?5I
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M=2(:8#][#1,<AMK-U#2E&9&DE&23,NGR -87W\+_ &11^DU +%
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M<:QC$E#EC*)"4ID/DLU%%U+8PGJ6KAFI(=/@
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M=5.*4I1J5KUT(/G%\<H\9Y$O(E#!;@1GZ:L>>;:UT4X4J<DE'J9]="T 6
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M ZYX]R:5E^)0,AFKJER)?=W*Q^Q*XK3)MU;9=J6EMHG.B?-Y"VJU3UTU 2<
M   !71??PO\ 9%'Z34 L4          5URM_/^.OVNA_F4T!8H    " \-?Z
M'_QG(?TY- 3X           %'\_27\>O, SN%?8M33\>E61,M9E/<K(LDK"$
M<=:676FG5;T$>XRV^ "$<)\D7L"UK\*5F'&=O!L[:RG/-T^0S)=LL[67(GJ:
MC,.1B2LVU.[$D:R\B=?$!U.   " 7_WP83]CY!]96 )^          *UY?\
MRO'W[95?U<@!/+F/:RJR1'I)S=;:+(BC37X_K&VS)1&9J9[C6[4M2^>7R@*_
MO,$Y1R"DLJ"?GL H-K%?@R3:Q_:X34EM32]IG/41*T4>FI&,LLJ-BG+$6,S%
M:SRM[;*$MHUQ[KM01)+72P(O8 G=>U-8@QF;&0F7/;:0F5*;:["'72(B4M+>
MY>PE'UV[CT^4880?A3[O8WVE>?IF: L$        !$HGWFV_V%6_G<\!+0
M          'RM:&T[EJ)*>A:J/0M3/0O$!^K6AM*EK424)(U*4H]"(B\3,S
M5SD'/O#>,R?0V.8U[UH9FDJRM<5:SC46OE]-!2^[KT\-@#3_ +Y\JO-R<!XJ
MR6V(C+;-NTQ\8@J0>FBTJL'"D&6AZ^6*?0 .#\2N2$HI5MBV!PW"U05?&E9)
M8(_ ;DE4*.1__DK(!5?+?P53.6[&FNK_ )/MY]S#(X]E(LHL1QI44UFO;#8B
M)BMQSU,]=27N]OAU#JBJKHU/60JB$1E#@,-18Y*TU)IA!-IUT(B\"^0!E@
M                                 ^7%(0VI;AD3:2,UF?AH1=0%7WDO
MA.FQ!K.6Z.GNJ.:MABK735\2P<L),QTF&&8I-(,G'''%$A)$KQ\3+0P$KX^O
M\9R3%XUCB<,ZVK0Z_%<JW(WH'H<N,\MJ1'>CD1=MQMU*DK+Y>I&9=0$G
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MT,!07PWY5SC2M6S4+)Y>/XFM'=2Y=,V3T-<M*M%&PIF#.VJ).O<Z)(^FNNA
M-SSLQR_R7@]5ZO,V,[8@/)F(K:6%:DN8I]&Q$EIM59':42$J/31Q7E69ETU
M2_X4++/^(</MH\VQA5!7,Q,E%!?5-^_(C*90;2G=(;)(0;Q;?*9F>B$G[0'4
M6%_$#42(E@UGKZ8MG%FJ9A2*RHO"B2X9L,N)>0F1%-9:+6XTHC/Q09ET 2;]
M^_&']Z2_\HM?ZH A/(7+F"W4S"G*R5.DMU>21K&P4BHM=&8K426VIQ7\D\"4
MXA/\8";?OWXP_O27_E%K_5 $9S;DS@7*JK9EMC(3!A:OE-76VL?TY:>97=.*
M1)29%YMW3_[!!FP4RQI:'2V'4L^RO-L4Z:\?"6;C/)_"N(5::BAERHT,E&XK
M_P#2K9:UN*T(UK4J*9F9Z%_%T\!G%AKBKRUCL1;W>YMWD^)EG6?V\(;G]^_&
M']Z2_P#*+7^J"920_C+E[ J#%3KK:9-BS/>EU([2ZBU(S9EVTN0RO^:>"VW$
M++\!@)A^_?C#^])?^46O]4 ;_%>0L3S5^3&QR6])>AH2Y(2]#F0R2EPS))D<
MEEHE=2/YNH"4         *.^)IO,)^,UE)0XXG(:"P=D%=ME3MY$ZEYIK=";
M]&X^QM;==U)R2E>YG0C(TZ[TA@XAPMD&*Y/BN6^DK+Q#<=EF=%R'6=>8\2V5
M;VJRX,EN2&&EN*;0U*)2R1KL=(C-)A?X"A^0Z>'R5SO3<6Y6J4[@T/%)F3.U
M<67(@MS+$[%B$V;ZHSC:UI90:E(3N(B4K4![\-9B_18%?0KM=K>1,2RR[Q6M
MDLQY5Q9.0:^:M$8WNPAQQ?;1HVIPR_%+7J ];;D&%*Y&Q?(&<>RA556UMQ&F
M/_JY;$2'9BX)LIT..2CW$RYX$>FG7Q 2W][M!_<F3_\ +=Q_50'XKEZA2DU>
MXLH5H6NU.-7!J/\  1>E 0/EKXEH^"\=WN4TF*Y"Y<064%!*XH+6OKTO/NH9
M2J0^\RVE*$FO=IO2:OFD9&9 .?\ X=_C>Y!R;(K&AY"QZ=E;*HRID%6(U*Y=
MBPIMQ"5)<CLJT4QHO\IXI5H1Z[O*$QYS^,ZTJ..6KCC'%<AJYUE+1$C9+D5*
MY&JVV]KBE]AQTU-NOZM[4H,C+0EF?S= 'G\*7Q89?G5/>P>2ZRSOIU0Y&.)<
MT%+)G&M$@G-S<I%>RI#:DFWJA6U.\C/_ '>H=&M<PT+J34=!E;6AZ:.XS<H,
M_P" CB@/O][M!_<F3_\ +=Q_50$)Y&SR-D#F'JJL=R=\JK)8%G/_ /X[:I[<
M2.AXG'//'+70UIZ)U/\   FW[W:#^Y,G_P"6[C^J@(#RGS3:QZ^''P^+:5*W
MUK]7/M*J57J(DD6UMGUK*$J-6IFK:1FG0OE')ZCN+XHCE[->][3ROTO;[R]Y
MS?U<FFE?'77M]&GZL_C?FB7+Q\_ULK[:PGLNFVW855/-GM.MDDC^D5#96A+B
M3/J73IH>@EV&>V7'K;C$JGF3IV'9[F*XNR+5YM/#MF/V3#][E!_<F3_\MW']
M5'1>60_C'D"'CF'LU-OCN41YR)UJ^IH\=ME'VY=G)D-'JB.HO,VXE7CTUZ]0
M$O\ WNT']R9/_P MW']5 ?O[W*'37W)D^FNG^F[C^J@)\   #"MZBKOZN727
M<-FPJ)[2H\V%)03C+K3A:*2M*M2,C(!@8GAV,8-4^X\2K&:JK[KDA;#!'JM]
MX]5N.+4:E+6K0M5+49Z$1>!$ QHN#8[#S:=GK$",B_L(3%>_*3&92^:6%N+W
M&\2>X9K):4JU/P0GY $E  &KMZ5NWDU$E;RV3J)OO!"4$1DXKT[T?8K7P+1X
MSZ?( V@#65V.8]3S9UE4U,*!8V:R<LI<6,TP])66IDIY:$DIP^I]5&8#[O:I
M%[265(XZIANRBOPUO((C4A,AM39J(CZ&9;M2U 9,.,4.)'B)4:TQVT-$L_$R
M0DDZG_#H QI%%22[./=2JV*_<PTFB)8.,-KDLH5KJ3;II-22/7V&,<L<6\7M
M$:1,Z-@,M&HQ^B;H&9S+3ZWRG3Y=DHUD1;%37E/&@M/8DU:$ SIU=7VC/IK*
M(S,CDHEDS(;0\C<GP/:LC+4AK:L6C28U2XLU\4ZTM-9_"=&0E*4))"")*4EH
ME)="(B]A#9',ZM2BA:1E#V3]]9O/0&JTXVA=LDLO.O$O7QU,W-/X@8;<  :>
M]QZ->OU#[Z]BJB<FP;+8A>\TM.-;#WD>A'W-VI==2(:S6)XPDIEO37EF8U\&
MX&R, 8%U5,7E1.J).G9FLN,*4:4N;36DR)9)61D9I/S%K[2&MJQ:-)[828\E
M\=HM29K,=\<7[35C%+4P:B-H;,)AN.E1))&[MI))J,DZ$1J,M3T]HS%8B-(X
M,9,ELEIM:9F9[Y[99PRT &BQK%X.,^\RA;3]YS79R]K:&MA.Z:-%L(M4HT\N
MORC2M*UX1$+&;<9<VGQ+3;3AK,SHWHW5P!I_<#?ZU?K3ZA?>]W^[/2Z%V]O>
M[V_7QW:] &V<;;=;4TZDEM+(TK0HB-*DF6AD9'XD83#,3,3K'%CU]975,?TE
M7$9A124:^Q&;2RWN5XGM01%J8UK2*QI$:)<N;)EMS7M-I\9G5A7]"W?(KD./
MK8]WSXUDDVR(]ZHJMQ(5K^*KVC9"VX##CU%5$FOV,6#'8L)723+;:0AYWV^=
M9$1J_C,:12L3K$=LI[[C)>D4M:9K7A&LZ1_"'U90DV-=+KUK-M$MER.IQ.AJ
M23J#09EK[2U&Z!YTM:BFIZ^G;<4\W7QF8B'5D1*63#:6R49%TU/;J S@
M             !KL@HJO***SQN[8*33V\5Z!/CF9IWQY+9MN)U+0RU2H^I=2
M 5CC7!!TD^-:VV;WF1V5)6RJ;#I5GZ,W*9B8TEE;S9M1T=Z3L0E/>?W&9%H9
M=3 >EUPC-L)E;>U.>WM%F#-0SC]Y?P2AJ=MH3"C6E<AIYAQI+Z5J<4V^TE*D
M;U%U+P"?X=B5)@F+U6(8XR<>EIXZ(L1M2MZS2GJ:UJ_&6M1FM:O:HS,!O
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ML$[ L[=1DBN6FGU25)0X4M/H2DD[]$1DOI#[?_<[MGDU =2@
M                (>]R1C\/D%GC>T;E5UW.B>MI9<MGMU]ELU[[,21J:5OL
M%M4ZT>BR2HE$1IU,@F       ^5K0VA3CBB0V@C4I2CT(B+J9F9@('AG-7&?
M(%W)Q[$[U,ZUCM*E(:4Q(CHDQ4.=I3\1Q]MM$EI*_*;C"EI_#H9&83X
M                      %6<B\T5O%F:8Y59DU&@81DB51&LE7,:2Y%MMQF
MAN1%5HLHRT)_G*34E"^CA)29* 6DE25))23(TF6I&74C(P'Z     \)DR+70
MY%A.>1'A1&UOR9#A[4-M-)-2UJ,_ DD1F9@*MPOGFIRZ_J*B3CMOC]?E3#TO
M![FU::1&NF(R.ZLVDMN+<94IKZ=M#Z4*6UYB^0!;(
M           _-"UUTZ^&H#]                    ,B,M#ZD?B0
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M<18<#*'DJ<GP:UQ;T9@UK4IMHG%]5J0@TI<47E4LC-/ET ;P
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MQ:81%9-UY:G.VRT@BT::)7;;W:J-*2-1FK4!O@
M
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MQ-Q9^;E62'&1GMZVEK*#I%NM4\^1&<6EJP](XE*6Y3S6SO&DM-=2Z^)A9(
M  ""2.7L-8PVWSA+DI^II9\JGD1H\5UV<Y90Y9P3C-1TEO4XX^1(;(]-=Q&>
MA=0$(;XZY"R"1&Y9K9$3COER:T;-I5H2JUJIM6E2E1(MLV2V>[*809)]2PM)
MH/<A)J1H G?&& /8#46:+*T.ZR7(;)^]R*T[11FGK"4AMI798(U$TTAMIMM"
M=RCT3J9F9F FX                    "ALP4BVY3S*!>9U9X?24.,TUC!D
MPK,J^-%?DR;/O27&W/HG="CMZ]U*DZ%H9=0%?L_$#RE,XZR#,SL\>H+'"*&L
MF3J6[C.^KMY<^"B5ZDMLACTS3^]*8C:6UFIW<A1EIH032=S+GD:ZM,$CM5:L
MRH)EG:V$N9NAURL2C5_KH,IUQQ>C'>=>8A..ZJ2A2'E:=" 9O'_*^7VV&9]*
MR&1#?R_$:\I_H&H2XDAA;]>N6TEYM,B2P\TM2-8[T>2HG6_$DJ+J$.E?$'R#
MC..T6164S'LF/+L:7=QHM:R]%8HY391$]Z:[ZA]2X)*E?3.&EM:5)T+Q\H;2
M\Y8Y3I+2SP2#:4>2WT-=/)*]JXR$/%$M4S3=BMUST]+;TY'I"=:93*)3D=9K
MVFI/G#<\0YQEV=9W[UDY=7SL9F8K3VB:6##<:8<D2)%C&<>BG(<)]LB7%/NI
M<0H]=$:^0E*#2X+R5F]9E1UN29+$MJBVY$O\;,Y3"8ZX,6%#ERF&$.D]H6Y;
M*$M)6G734BW&9:![P^6>2<QOGJ;$[:D@QV8F6VC5@]"<GM2&,>OSK(:4=N4T
M6QQK3NN$9_*D@&NF\]<CX[C5'E]L5+.B9SC*LAI(B&9$9BFD$_7-:S7^\X;\
M1M%BEU]Q*&U%VU::)41I#86?*/*D#)_W9UMYCMO?N65)'1EC<)THK$:ZCV+C
MK$B$W+5I+:*$3S*2D:.-+2:B3XF$PS_.,QB9O$P''KFFQMQG'I.2S,@OXZWX
MTE<9Y,<H[;92(Y-MH/5V2YW%*0A2-"ZFH!7A_$#R+,O)$BMB0)%/3V%'52XD
M)@I$"P][M0W')#-J_,CJ:2YZLSA%Z-?<V%KJ:_(&S^'"YMK*[<CV-M+LV48I
M"=+U4AQXC=/(\A9-W1:C\ZD-(0:O':E)>"2 1?#^4.2&L EV6*R::'2X3AU!
MD\BLGLS)KDU=DS+DR6/6.2U.-(-#!]M:B<42CZZI(!+)7-^:1W7\M0]4/4+.
M5KP]. (:=/(7$H?./WD/=[0Y:M/5)C^GV>FZ[]?, P?WU9[ P.+R'.R3%)L6
M]IV;YBCBMO(F5C:YL-MPM>^LI#+#4A2)3JR9-MU)'IH9I2#DOERV9Y!?K:Z0
M4VGPV[I9;4*I=-,F8J5C][->AOJ0M25DLXS*DH-'3HK0^@#2Y9RURFC#WB1F
M&/O2K_!;G,8TS'XKB956[ :BNH;2;DMTELJ2\M#;ZT)4:TF>WRZ -JUGF757
M(%AB,*XJVLAR&?2UDO-);+SE>E3=$[8*6B&<SLI=?V=IAMMQ"3T4I1K,M##V
MH>6N6,TNWL6H[2A@S*BMO)$V\5 ?EPK&116:(+3T5M,M!H8?)1D[YU[%I42%
M*\0%Y\=92YG& XQF3T=,5^^JX=D[&;5O0VY*82XI"5'H9I(U&1'\@"3
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M[;DBEXP:O9^%-7%<]<8QDM2J*XY,LZU:DRZ]]B6P\A:$L.MR$I(BW;5=?+H
MK' 8O/?'_(_(F#X_,QS+OY9#RZ6FY:?H)<XKN/V77HJH?J64:.PU(<)36AK\
M^J=VT!U7%5)7&95,0AJ8IM)R&FE&XVEPR+<E*C2DU$1^!FDM?D >H
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M<6I1%\IZ@-D
M                                  "/9UF$' <2MLQLHDN= J&#DR(U
M<PJ3)4A)D1FE"?8G7<M1]$I(U'T(!S)G"L\N.)JSD_D#)(&7X!DZZMZZP*-
M8:9BQ+J0RRPJHG-?RHYD13Z%)4XL]ZB5\WH0"W,$X/KJZ<B_Y)@4V69Q3RC;
MH,T7"25N_7L)045VP4I.U<UO0T=Y)>"4JUW:@+@     0?DGD%6$0J^)3P$7
M>97\QFKQ^C.0F-WI#Y+6;KSADHVV&D-....$A7S="+4R <R9%26$KD$I<[$6
MH'(<*4U?9-Q6U-4YCV9Q8B5)1:5:EDRV[-C:[ULO-^924FM.XB48=1\=ER"]
M42+;D=<:/<6L@Y<6@A)2IJHB*2DFH:I)=9+J2+<\]H23<4HD%L)("8
M                   ,&YDV4.HGRZ:"FSMV([KD&N6\45,B0A!FVT;RDK)L
MEJ(D[S2>GB XOD7='/XYO.5;?-;.E^)6#,EI1CJY\COQ[5+ZBB8^U2&X;;T5
MTNVU^04;A*4Z:OG$0=.<4\;1..H-@BJ<D0*>Z6U9-X@:TNUU+,>0:Y;4#IN0
MTXZHUFWNV)5\PDD9@+"     4QS/SI182[&P:BOJ^+R1<2Z^O8.:AQ^+5M6;
MQ-^LF;-&T$A&Y;;;KJ.X>W\74P%=95@G))9UCK63OL7'(%<IV1QGRW'J4M1R
MDH:6M^GOXD;>E##J#<[3[>FW4U(-+FXC"^>.L1N\9KYD[++IR]S*\>*=>2B4
MXF T[M)*8T".HS)F,RDMB/QU_/69J/H$S
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MFUSRG)XBN($?1M*U[F>\QWDDME;S.G>)&A:FI)>70!*P
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MIN*:S-EA3B4I-9-(,FTJ5YM"ZF D@
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M4KK-BWQ6VJ679C=.J%(:>90;KYH6\:DH6A_0D(42S(D]",PN4
M
M                     !$N1\_J^.,7E9#/1ZR8G:S5U#;K;4F?-?<0RS'9
M[AD6JG'$$I77:1[CZ$ YVSIW/9'(&+WN455=AO-5:2RX_M69ST[%;Y#R'"?H
MI:W4,&Q+4AU9-*VEO49FA1Z$0";\&2YG(^9W/+F628L'.J^ 6'R,*B-NMO4C
M+<GU;J)JGS);KSKI$:'$H2UVT^3=JHP%_@
M       "O>6>8,4XEHW)ES([E])BRWJ*E9:D29$QZ(R;FFR,VZI#9'M2MY:2
M0C<6I^ "BLHI>0,DX^ILMS6X_>IQ]?M1K&>WC5>U$NL;F/:+CV5 Y$(W7TQE
MJVK0YN=VIW'N(W$@)9Q)0Y-#Y4EP.99-KDG(>.5[WZGY.\RVB@?HI3B$.O1D
M1VD(8GJ,D-2T/J4X:4I-"C;,P'18
M
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M>_?1._5U2T^[8,HR4;[D-K82F>^:B6ZC<:-Q:I).I@)D
M
M                  .>OB?J^*;>% BY5>MX]GR6'G:.>F/*EDJ"VI)R&K-J
M&A9G5N'HF2;^UHBU/<774-[@#>36+D7)>7W*RFA26(<7%L)@FS*H8BF7FR8E
ME-4@VW9C[A).*AI9=MK:224O<H@N@
M    $6Y(_43]1;W]YOI/U#]*KWW[P_F_8U+3P\V_=M[6SS[]NSSZ *EXUQK&
M*#-<:<RS-;7+,CE5TD^*F;^#*@'#HB02GD:NLMH=L.THDR''ML@V4I^C2G<:
9@Z#                          '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>lc_fig28isotype-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig28isotype-4c.jpg
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M 0,1 ?_$ -P  0 # 0$! 0$!           %!@<(! ," 0D! 0 # 0$! 0
M           !! 4& @,'$  ! P," P($#!(%" 8(!04  0(#! 4&$0<A$@@Q
M$T$B%!A1,M*STU1TM%46-E9A<;'10G*R(W.3E!5UE987-SB2PC/C-('!4F)3
M@R0UD:'BI$5V@D-CH\0EI2;#U%<H":*%1F8Y$0$  0$$! @- P0" P #
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MN3T4"$\
M
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M^543(:BNA262*+56-754T3FX^ Z/#7LWMU37/CA\YBQ.%E
M
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M:NNM-'4U4D,JR3S01OD<J5$B)JYS55>":%O!W%W5=1,TQ,^'Q>5R_P!QS_\
MT;WCC_UA??B;B7P%0?DT7J2WW6YZE/)#G;9/B;B7P%0?DT7J1W6YZE/)!;)\
M3<2^ J#\FB]2.ZW/4IY(+9/B;B7P%0?DT7J1W6YZE/)!;)\3<2^ J#\FB]2.
MZW/4IY(+9/B;B7P%0?DT7J1W6YZE/)!;+&]\K3:K346-EKH:>B;*VI61*>)D
M7-HL>G-RHFNFISN;W=%$T;,1'#P/I1+4=K_X?V#W,GW3C<R_Z>CB>*N%;B^\
M@
M                                      ,3ZN_Y<,_]Q0^_( -3Q'Y*
M6+]'4GK# )D                      !2MP>RV_;3?4::V7]+4R,QZ.M.8
MI\GJ#[1?NE*>+[6I<PG94L3ZI_\ !8I[JJ_66G-9IP4Z^9^G?9G[K[_&GTM!
MV*_A/C7X&;WS*7<#V-.OTRY[[C_[&]XX_P#6&B%YSH     &&=07^*L'VE3]
M6,YC.^&C7S/K0T7:_P#A_8/<R?=.-C+_ *>CB>*N%;B^\@
M
M                       ,3ZN_Y<,_]Q0^_( -3Q'Y*6+]'4GK# )D
M                  !2MP>RV_;3?4::V7]+4R,QZ.M.8I\GJ#[1?NE*>+[6
MI<PG94L3ZI_\%BGNJK]9:<UFG!3KYGZ=]F?NOO\ &GTM!V*_A/C7X&;WS*7<
M#V-.OTRY[[C_ .QO>./_ %AHA><Z     !AG4%_BK!]I4_5C.8SOAHU\SZT-
M%VO_ (?V#W,GW3C8R_Z>CB>*N%;B^\@
M
M        ,3ZN_P"7#/\ W%#[\@ U/$?DI8OT=2>L, F0
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MN&$IH^(
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MP[W&_P!?D,3,_J:^-\Z>"&HF:]
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MBG@AJ)FO0
M                                          Q/J[_EPS_W%#[\@ U/
M$?DI8OT=2>L, F0                      %*W![+;]M-]1IK9?TM3(S'H
MZTYBGR>H/M%^Z4IXOM:ES"=E2F2JM@'.G5/V8G^$K?N(C"S3HZ^9^C?9O_VX
MJ>=IFR/\*<6]R?\ XCS1P78QK]+F?N+_ +&^_P N:%_+CGP       #CKKE_
MQ.#_ &MR_P#ASJ\AX*]7.CQPW3IR_@EAWN-_K\AC9G]37QHIX(:B9KT
M
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M]S7U9Y'WCECF8DD3FOC=Z5[51R+])4/43$\#YS$Q-DOV2@   ..NN7_$X/\
M:W+_ .'.KR'@KU<Z/'#:>GFZVNFV7P^&IKJ>*9M&[FCDF8UR:SR+Q15U,C,J
M*IQ-=D>-%/!#3/S[9/A*E_'Q^J,[W=6B7H_/MD^$J7\?'ZH>[JT2'Y]LGPE2
M_CX_5#W=6B1[()XJF)LT#VRPO35DC'(YJI]!4X*>9BP?0@
M
M              !B?5W_ "X9_P"XH??D &IXC\E+%^CJ3UA@$R
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M]T>1VBEO=O1Z458Q9(4E;R2:(JMXMU73BAJW-[%[1%=/!+S,)$^J
M
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M&ZHFNCD1?&3P+P"$J!B?5W_+AG_N*'WY !J>(_)2Q?HZD]88!,@
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MG^'EA]SKZX\Z/+OIZ.)\ZN%<30>0
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M6*.AIGVVXP)(]M3$]4[R6G:QOBM5?&<G_2$NN,1^2EB_1U)ZPP(3(
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M66XW9\IMC)8[;?*&FN=&RH:C)D@K(FS1I(U%<C7(UR<R:KQ E@
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M8O*LKW\NO@"%Y Q/J[_EPS_W%#[\@ U/$?DI8OT=2>L, F0
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M    !B?5W_+AG_N*'WY !J>(_)2Q?HZD]88!,@
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M/H@>Z\Y%:<NZP=E<HL,RU-DO&(7"NM]0L;XE?!405KV.5LC6N;JB]CD10.M
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M;I_I3?4::V7]+4Q\RB)V;?*F\3XX[0?:+]VXJ8OM:ES!Q9<TIDJ+@
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M[MGE'+W??<J=YR:ZZ<W;IKX /N  ^7<1)*Z=K&I.Y.5TB-3G5J>!5[0/J
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M%*QLD;DT<QZ(YJI]%% _L;&QM1C41K6IHUJ)HB(G9H@'Z
M    #$^KO^7#/_<4/OR #4\1^2EB_1U)ZPP"9
M         %*W![+;]M-]1IK9?TM3(S'HZTYB?R=H/M%^[<4\7VM2YA.QI3)5
M6P          Y&ZY?\)@WX:Y_<4QU&0\->KG1XX;%TT_P.P_W/4>^YC*S3ZF
MOCYD4\$-7T1>TS'I_-$]! &B>@@#1/00!HGH( T3T$ POJ!_QU@1.SNJGZL9
MR^=_NHU\SZT-(VQ^0&/^Y&_54V<O^GHXGBKA6TOO(
M                                                         #$^
MKO\ EPS_ -Q0^_( -3Q'Y*6+]'4GK# )D
M     4K<'LMOVTWU&FME_2U,C,>CK3F)_)V@^T7[MQ3Q?:U+F$[&E,E5;
M       #D;KE_P )@WX:Y_<4QU&0\->KG1XX;%TT_P #L/\ <]1[[F,K-/J:
M^/F13P0U<S'H     #"NH'_'6#\%4_5C.7SO]U&OF?6AI&V/R Q_W(WZJFSE
M_P!/1Q/%7"MI?>0
M                               &)]7?\N&?^XH??D &IXC\E+%^CJ3U
MA@$R                                *5N#V6W[:;ZC36R_I:F1F/1U
MIS$_D[0?:+]VXIXOM:ES"=C2F2JM@         !R-UR_X3!OPUS^XICJ,AX:
M]7.CQPJ.V?5E!MW@MFPQV)27%UJCDC6M;7M@23O)GRZ\BP/TTY]/3%K%91-]
M>S7MV6^3^I$3'@L6SSYJ;YBR_K-G_P"5*VX9^)YOZGAT.DMN,R3<'";/F3:)
M;>EVB=+Y&LG?+'R2/CTY^5FNO+KZ5#G\3<>YO)HMML3$VK25@   ,*Z@?\=8
M/P53]6,Y?._W4:^9]:&D;8_(#'_<C?JJ;.7_ $]'$\5<*VE]Y
M
M      8GU=_RX9_[BA]^0 :GB/R4L7Z.I/6& 3(
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M?]R-^JILY?\ 3T<3Q5PK:7WD
M                        &"[Q[D=0&'Y53VO:S;2++\=DH8ZB>ZR3+&YM
M6Z65KX=.\9Z5K6.[/L@EGW[\^LK_ /0JG_*E]G _B[Y]97_Z%4_Y2OLX'6=
M^>6D@EJHTAJ9(V/FA1=>21S=7-U^@O (>D           8GU=_RX9_[BA]^0
M :GB/R4L7Z.I/6& 3(                                I6X/9;?MIO
MJ--;+^EJ9&8]'6G,3^3M!]HOW;BGB^UJ7,)V-*9*JV            !Q_P!<
MO;@OT[G]2F.JR'IZN=$\,-MZ;_X(X=[EE]\RF/F?U-?'S%/!#4S-2   &%=0
M/^.L'X*I^K&<OG?[J-?,^M#2-L?D!C_N1OU5-G+_ *>CB>*N%;2^\@
M                                                       <+6+(
M.LO.=PLEQ3 MP[37V'&JR2CNN2R6VDBM=/5\SG>1QN=1NEGEC;HU_(Q6M7M=
MHJ.<2^.X%_ZU-L+S9J?,MQK32XI>ZEMOBR^GME'/;J6LE1>ZCK$\B;+"UZII
MWG=N8GH]N@=ST3*B.EACK'MEJV1L;42M31'2(U.9R)X$5>*!#T
M #$^KO\ EPS_ -Q0^_( -3Q'Y*6+]'4GK# )D
M         4K<'LMOVTWU&FME_2U,C,>CK3F)_)V@^T7[MQ3Q?:U+F$[&E,E5
M;             X_ZY>W!?IW/ZE,=5D/3U<Z)X8;;TW_ ,$<.]RR^^93'S/Z
MFOCYBG@AJ9FI   #"NH'_'6#\%4_5C.7SO\ =1KYGUH:1MC\@,?]R-^JILY?
M]/1Q/%7"MI?>0
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MJH]>26GJ&))&]-41='-5%XA#V@8GU=_RX9_[BA]^0 :GB/R4L7Z.I/6& 3(
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MOU5-G+_IZ.)XJX5M+[R
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MF%ZHU-.*Z-50ETUB/R4L7Z.I/6&!"9
M  $-?L?COJ4Z25#H/)U>J<C4=KSHB>'Z1:N,1-U;X+;53$8>+ZSPV6(?]W]/
M[?E_H,+6\)ZL*F[HZTH'(K#'8G4S8YW3]_SZ\[4;IR:=FGTR[A\1-[;X++%/
M$X>+JRR;;5YQCY/V_P#!)]53'Q7:U<;8PO94\26*RT          ''_7+VX+
M].Y_4ICJLAZ>KG1/##;>F_\ @CAWN67WS*8^9_4U\?,4\$-3,U(   85U _X
MZP?@JGZL9R^=_NHU\SZT-(VQ^0&/^Y&_54V<O^GHXGBKA6TOO(
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MF8KJN%JJU[(T5."^!0EN>(_)2Q?H^D]88$)D
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M.75>9[&HY=?#Q EP &)]7?\ +AG_ +BA]^0 :GB/R4L7Z.I/6& 3(
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M?W2Q3:>JHJN6^9=35=70UD21K21,H8Y)'I*JO1R*J1NTY6KX -!  <GU6/\
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MIW/ZE,=5D/3U<Z/'#;>F_P#@CAWN67WS*8^9_4U\?,4\$-3,U(
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MZN:G/KHFG,T/Y=+/?[!U0]/UFRF\NR'(:.PWJ*X7I[.Z=53)352J]6:KIVZ
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MAQREMT5HBMM!3P+:J::2KAI9&L19(HYIE621K7JY&O>NJIQ4(<R4N44?3)U
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MNS5DC4<U=/I*!]@          !B?5W_+AG_N*'WY !J>(_)2Q?HZD]88!,@
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MR?\ .,+]S7#[N ZW(?VU\<<YXX=!]/?\%\,_1[?7'F%F/U-?&BG@AI9GI
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MM>P(2            Q/J[_EPS_W%#[\@ U/$?DI8OT=2>L, F0
M                            !2,_]/;_ />_U37R_I:F/F/1UK!BWR?H
M/P7^=2EBNUJXU["=E3Q)<JK0            '&/7)_SC"_<UP^[@.MR']M?'
M'.>.'0?3W_!?#/T>WUQYA9C]37QHIX(:69Z0              #"NJ'?RY=/
M^+67(+998+U+=:]U ^&IF? V-$A?+S(K&N55\70#7,2N[\AQ:R9#+"E/+=[?
M25\E.U5<V-U5"V56HY=-43FTU F0
M          (#,LUQ;;ZP5.49E=(;18:33OZRH5=.9RZ-8QK$<][W+Z5C&JY?
M @'++.D[I4OV(KNM/4W6FQ2XTSKY)=*JO=3L92S:R\[FOCU;V\&KXW@[0E7-
M@'=#5/N11TN!NJ9\V2=&X[69(E1W+ZE%5&>2=\C8DE5?[+O6-DYM.3Q@.Z @
M           &)]7?\N&?^XH??D &IXC\E+%^CJ3UA@$R
M                       *1G_I[?\ [W^J:^7]+4Q\QZ.M8,6^3]!^"_SJ
M4L5VM7&O83LJ>)+E5:             XRZXT5;QA>B*O_#5_8BK]G!Z!UN0_
MMKXXYT3-DPRC&NI#=K$K#08U8ZZGAM-MB2"DC?0QR.1B*J\7.;JJ\>TT[W++
MB\KFJJ/#/E>;?U9*5\[/>_X3I?U=#ZD^6Y\-HGE3;^K)/.SWO^$Z7]70^I&Y
M\-HGE+?U9)YV>]_PG2_JZ'U(W/AM$\I;^K)/.SWO^$Z7]70^I&Y\-HGE+?U9
M)YV>]_PG2_JZ'U(W/AM$\I;^K)/.SWO^$Z7]70^I&Y\-HGE+?U9)YV>]_P )
MTOZNA]2-SX;1/*6_JR3SL][_ (3I?U=#ZD;GPVB>4M_5DGG9[W_"=+^KH?4C
M<^&T3REOZLD\[/>_X3I?U=#ZD;GPVB>4M_5DGG9[W_"=+^KH?4C<^&T3REOZ
MLD\[/>_X3I?U=#ZD;GPVB>4M_5DGG9[W_"=+^KH?4C<^&T3REOZLD\[/>_X3
MI?U=#ZD;GPVB>4M_5DLQWLW+W.WML-ML&0U=-40V^L2M@:VE2F7G6)\7IHF*
MJ\']A3Q>34S3'N?!/CMJ\1M?JR7^D^S\MSEVLP[\\T+K;<X[110U%$_7F8L,
M+8TUYD14YD:CM%35-=%.6OKN**YIB;;/&]+L?$0^297C6'6W\\99>**QVE'M
MA\NN51'20=Z_TK.>5S4YET71/H 2=-4P5D$552R,FIIV-E@FB<CXY(WIJUS7
M-X*U475%0#Z@ (JAR7'[I<*^T6VZT5;=K4YC+I04U3%-4TCI$U:D\;'*Z-5T
MX<Z)J!4<?WHPO)=S\CVCM:U;LMQ>F967)98%CI%C<L2.2.55U<YJS1ZZM1%U
M\57(B@:&!#9/EF-X7:W7S++K2V:SL>V)]?7RMIX&R2+HQJO>J)JY>P"L6C?3
M9J_5\5JLV>V"MN50J-IZ2*Y4RRRO541&L:KTYG*J\&IQ FLOW$P7 &T;\VR*
MWV!EP61M$ZY5,=,DRPHU7HSG5->7G;K]- (_'=X=JLNKFVS&,ULEVN3U1L=%
M27"GDJ'JO9R1H_F=_P"B@%V  9AF'4-LY@&3_$W,,GBM>3*V%_D#J:LE7EJO
M[)>>&![/&^VX>$#3P                        !REU<45EO.X>Q6/9M(C
M-NZ^^UJWMDSUBI9*B..!*9DSM41$<KWLU54\5S@E_.KFHI;C:MONG;&G0T%5
MG-[HJ:IMM%R1-I['1/355AC3Q(D?R.9P1/O3M/2KH'QZR<3VPQ#8%*2@ME#9
ML@MM3;X<#911,AK6U451$CVP.:G>.1(>\=)Q7P*OC<H'4=A=<7V6W/NZ:75U
M+ M<W332H6)O>)HG^MJ$)$           8GU=_RX9_[BA]^0 :GB/R4L7Z.I
M/6& 3(                                       I&?^GM_^]_JFOE_
M2U,?,>CK6#%OD_0?@O\ .I2Q7:U<:]A.RIXDN55H            #YO@AE5%
MEC;)IZ7F:CM/^DFV1^/(Z/VO'_0;]8;4AY'1^UX_Z#?K#:D/(Z/VO'_0;]8;
M4AY'1^UX_P"@WZPVI#R.C]KQ_P!!OUAM2'D='[7C_H-^L-J0\CH_:\?]!OUA
MM2'D='[7C_H-^L-J0\CH_:\?]!OUAM2'D='[7C_H-^L-J0\CH_:\?]!OUAM2
M'D='[7C_ *#?K#:D/(Z/VO'_ $&_6&U(>1T?M>/^@WZPVI#R.C]KQ_T&_6&U
M(_J4E*UR.;!&US>+51C=45/"G 6R/L0 '(G419F[[[VX;T]LFD;C]HMU=E.5
M30.5%BED@?!0H[AHBM>YNO\ JS!*]]'69UF2;/4V-7Q5;E6!54^*WB"1=9&+
M;W:0:HO%$2)6Q_38H0HMBW9ZC]RMP]RMN\ BL=NHL3OL]'\;+I#(Z.CHHY9(
MX*>.!BN[^ID6-7*]R<C6M75$5S0E9=NMU]W;+NG-L5O5!;*C*;G;IKKAV4VA
MKF4=8R%)%<V>)=-%3NWKP:Q4Y%314<UP&*;06WJ-FWQWD@Q:]8G39?%5VSXW
M5-;353J.9RI-W:T;6,5[41.;G1^FJZ?3('0-AW/K(NH_=+$[TVWT6)8K8*"[
M/N3:9&5O(E/#-(ZHG;JZ1D:22*UJIP3L)$JG5QTY*B*F?T/'T8JI/JPA#,NL
MO+<=SKI7FRK$Z^.Z8]<+E0NHJ^)'(R3NJI\+]$>C7)RO8YJZIVH$O3O1C_2K
M#LW?W5]+A]%=8;3*^W36=+?%<_SFD"I3I M']\>Y95;JG%JIZ?Q=0,RN])=\
MAMO1]1[E4OYRKZZKK([A376-M0L]*YU(E.D[)4=SJZ#NE=SHJK]EQ Z:SOI@
MV5SBR3VM<3MMAN'([R"]6*DAMM;2S]K)6/IVQ\_*[CRR:M7T AGFP/4%26?:
MN[LWPO[*2[X+?YL0K[[5ME>ZKDBU6!SU8CW.D5&R-<Y4U5&<SEU55"5[;U;=
M.;G-:F?T',Y4:GWNJ3BJZ=O<\ AGG75;;?'MYBMS;2PI<WYA:(7UJ1L2=8DA
MJE1BR:<RMU3LUT"8=6!                         4_<O;'#MV\6GQ#-Z
M'RVTS.2:)S'+'/3U#$5&30R)Q8]NJIKV*BJCD5JJ@&>;3])^UFT&1NR^QK<K
MODJ1.IZ2XWNH95/I8I$5KT@2.*)K5<U>17*BNY=41415U";R/IYV^R_=:W[N
M90RINE\M%/3P6RVS2-_-L+Z5[Y&3+$C>9TB.?S>,_EU1/%U U@      &%S]
M5& ?ONIMB[=2UEQR"6H6AJ;I3I$M!!6,B=+)"YRO1[G1\O*_E;P=XO:B@7K=
MG=K#]F,1FS+,IY&T+9&TU)24S4DJJJJD17-AA8YS45RM:YRJYR(B(JJH&(Q]
M9\MF?;[EN/M3D^&X5<I&109/5Q.EIV=\FK'2,6*-414\;1KG.T]*C@EU!15M
M-<*6"NHI65%'4QLGIJB)R/CDBE:CF/:Y."M<BHJ*$/0!B?5W_+AG_N*'WY !
MJ>(_)2Q?HZD]88!,@                                      "D9_Z
M>W_[W^J:^7]+4Q\QZ.M8,6^3]!^"_P ZE+%=K5QKV$[*GB2Y56@
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MGD5M5"Y4:QDBN5=$5>"!+>,1^2EB_1U)ZPP(3(
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M<O,C4YM.W1 /%8=K=M,5JVW#%\-L=EKV\6U=NME)2S)JFG!\4;7)_P!(%M
M1-_QC'<JI8:')K31WBBIYV5<%-<*>.JB941:\DK6RHY$>W5>5R<4U E@
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MF*M+UGS?4
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M%=K5QM3"]E3Q)<K+0
M                                             ,3ZN_Y<,_\ <4/O
MR #4\1^2EB_1U)ZPP"9
M   4C<#T]O\ I2_U37R_I:F/F/1UK!B_R?M_X)/JJ4<5VM7&O87LJ>)+E9:
M
M                           !B?5W_+AG_N*'WY !J>(_)2Q?HZD]88!,
M@                                           *1N!Z>W_ $I?ZIKY
M?TM3'S'HZU@Q?Y/V_P#!)]52CBNUJXU["]E3Q)<K+0
M
M          ,3ZN_Y<,_]Q0^_( -3Q'Y*6+]'4GK# )D
M                          !2-P/3V_Z4O]4U\OZ6ICYCT=;W6#(++1V:
MBIJFLCCGCC1)&+KJBZKP7@?'$8>\JO)F(\#[8?$7=-W3$SX;$C\:<>]OQ_\
M7]8^'=;WJRL=[NNM!\:<>]OQ_P#7]8=UO>K)WNZZT'QIQ[V_'_U_6'=;WJR=
M[NNM"3IJF"L@94TKTDIY$UCD;V*G85ZJ9IFR>%8IJBJ+8X'U/+T
M
M               Q/J[_ )<,_P#<4/OR #4\1^2EB_1U)ZPP"9
M                                  060X\M]=3N2I[CN.?[#GUY]/HI
MZ!<P^(]U;X+;5/$X;WMGALL0O[OW_"'_ +K_ +1;WA_;YU/=W]WF/W?O^$/_
M '2>J&\/[?.;N_N\Q^[]_P (?^Z3U0WA_;YS=W]WF0U_Q];%Y-K4>4>4*]/2
M<G+R:?17774M8?$>]M\%EBIB,/[FSPVVKQBOR>H/P?\ 64R,5VM39PG94\28
M*JT
M                           Q/J[_ )<,_P#<4/OR #4\1^2EB_1U)ZPP
M"9                                                !2MP/_  WZ
M<WU&FME_2U,C,>CK3N*_)Z@_!_UE*>*[6I=PG94\28*JT
M
M         Q/J[_EPS_W%#[\@ U/$?DI8OT=2>L, F0
M                              4K<#_PWZ<WU&FME_2U,C,>CK3N*_)Z
M@_!_UE*>*[6I=PG94\28*JT
M                                               Q/J[_ )<,_P#<
M4/OR #4\1^2EB_1U)ZPP"9
M          !2MP/_  WZ<WU&FME_2U,C,>CK3N*_)Z@_!_UE*>*[6I=PG94\
M28*JT
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M^7#/_<4/OR #4\1^2EB_1U)ZPP"9
M                !2MP/_#?IS?4::V7]+4R,QZ.M.XK\GJ#\'_64IXKM:EW
M"=E3Q)@JK0
M                          #*,CV0HLHWMQC>&[75:B'%*!]';<;EIF24
MZ54BRKY7WKG\)&K(BI][X*QJHJ*@&0==LU#><2PC!K;$E3N+?<DI5QJGB1'5
M3&L:^.65JIQ:SFDC:O'BJHOV/ E_.IB-F7;][#;87B)M;C\U=47BYTKTUBJG
MTW+RI)'KHK4;%(BHOV+U0#:]_L2L^6[+YM9KO3,GIHK-6UE&CFM^\55#3OF@
MD9JB\JL>Q.SP:IX0A"])M]K<BZ=\"N5PE=-5,H)*%9'KS.5EOJ9J2/55_P!2
M)H&S 8GU=_RX9_[BA]^0 :GB/R4L7Z.I/6& 3(
M                          *5N!_X;].;ZC36R_I:F1F/1UIW%?D]0?@_
MZRE/%=K4NX3LJ>),%5:
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M8OBN5/&:H'6V(_)2Q?HZD]88!,@
M               I6X'_ (;].;ZC36R_I:F1F/1UIW%?D]0?@_ZRE/%=K4NX
M3LJ>),%5:                                            'ACO%LF
MKYK3#60276F8V6HH&2L=4QQO]*Y\:+S-:O@54X@>X
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M57P<= \FWNCNM_=:16<DCL9M*N1>U%6&AU1?^@#J,(
M                   &)]7?\N&?^XH??D &IXC\E+%^CJ3UA@$R
M                                        #EGKBVQR_=+"\8M.'4L5
M5645TDJZA)IXZ9B1>3N9Z>5S6ZZN[-2Q=W55Y$Q3Y%:]OJ;N8FK@\/,WK;"W
M5EHVZQ2TW&/NKA06FBI:J+7F1LL,#6.1%3M35."GB]BRJ8>[F;:(E;#Y/L
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M+8VMJI,TGC?.B>.Z..:J<UJKZ"*YRI]-0A_<!_GAW8_\M6GUJA"735+54];
MRII)63T\B:QS1.22-R=FK7-U10A]@
M     &)]7?\ +AG_ +BA]^0 :GB/R4L7Z.I/6& 3(
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M#[\@ U/$?DI8OT=2>L, F0
M                                             5[,\&Q/<*SIC^9V
MN*\65)HZI:*H5Z1K-#JK'*C'-UTU[%X 3T43(6I'&B-C:B-8QJ<K6M:FB(B)
MV(@%=H< Q"V9?=<^H+7%!F-\@BI;M=FJ_O:B"G:QD;'(KE:G*V-B<&IZ5 +*
M                                                #$^KO^7#/_<4
M/OR #4\1^2EB_1U)ZPP"9
M
M                                     ,3ZN_Y<,_\ <4/OR #4\1^2
MEB_1U)ZPP"9
M
M                           ,3ZN_Y<,_]Q0^_( -3Q'Y*6+]'4GK# )D
M
M
M                Q/J[_EPS_P!Q0^_( -3Q'Y*6+]'4GK# )D
M
M
M (;*<KQW";'5Y+E=R@M-AH6\]5753N2-B*J-:B=JN<Y5Y6M:BN<O!$50,;QK
MK.Z>LHOT>/463NI*NHD2&DJ+A25%'2S2.<C6HDTC$:S55[9>0#?0 &)]7?\
M+AG_ +BA]^0 :GB/R4L7Z.I/6& 3(
M
M                                        <E]5'<9QO%LCLY=&/EQB
M[72:\7VBYG)%51TO*D<;T;HNG*V=JKKV/X:!+3.H':?"<GV4RNT/LE#3?FFT
M5E?9)*>FBA=1U-#"Z>)858UO(BJSE<C=$5JJB]H'JZ7,GK\PV"P6^W259[@Z
MWK13S.].];=/)1M<Y?"Y6PHJKX5XA#7@,3ZN^/3AG^GM*'WW !JF)HK<5L;7
M(J.2WTB*B\%14@8!,
M
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M\55\) [7)0
M5[-L'Q;<7':O$\SML5UL%:B=_2R\S51S5U:]CV*U['M7TKF.14 Q''^A[8BQ
M7BDNTU)<KU'0O26CM=VK5J:"-R<6_>FL9S-1?L7N5J^%%0#HUC$8FB=G!$1$
MT1$0#] 8EU>*B=.&?ZKHGD4"<?16L@0#5,05%Q.Q*G9^;J31?]PP"9
M   8;UB*B=-F>JJZ)Y-2)Q]%;A3(@&O8TJ+CMHT[/(J;1?\ =-"4H$
M  &"]:2HG3-G:JNB<EM3CZ*W6D1 -RH?\'3_ ()GW* >@        !@'6NJ-
MZ:<S5>"<]IX__P!WHP-^3@B(!_0        '/O6RJ-Z<,I<Y41$J+0JJO!-$
MNM*!T$          <^=:CFMV!NZN5$1+E9M57AV7*!0F'080         .>>
MM1S6[&52N5$3\\6;BO#LKHE"8=#!          YYZTG-;LHJN5$3\^V7BO#L
MK6*$PZ&"
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M:M7P*![
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M^'L ZVP7%L;PG%+9BV(0I3XS;H>6V1-E=4(D,KG2ZI*]SG/YE<KM5<H0L0
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M-<*JL?%#.]LO=R0U,KEC5ZQ-5%<Q%73@$.@0
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M6-MHNVUOBL\&<4-=2Y18[<G<TLT4:2.2=8&:-;HK4D\5$;K%KIKS*H=CA
M                                                  <V9MTUYC1[
M@7;<[8K/9,%O^1O9)D=KGIFUEMK)TYE696.YD1RJJNT=&_QG.5%;KH$IC9KI
MUK<&RVY;H[B97/G.Z-T@\C6[3Q=S3TE,NG-'3Q\RZ*J-1O-XJ(WQ6M35VI#>
MP        '-N3=-^9X]G%WW V SOXC5V22)/D-@JZ5M=::FI7G5T[6/1Z,<J
MN5W*L;M'.=RN:B\H2E]K^GN]63.W;N;LYA+G6Y3*=]';)^X;26^VP2*]'MIH
M6KIJK7N35&L:G,[Q55>8(;V       !C_4IM!=-[]N$PFT7*GM55^<*:O6JJ
MV/DCY*='HK=(^.J\_ "S;D;68[NKM[5[>94CUH*J&)K*J#1LU/4T^BQSQ*Y%
MT<UR=B\%;JU>"J$N?9NF#?VZV5-NK[OC/4;7\BTLD,= B7*:B1O*E/)*K^96
MJU.14=.YNGV*IP Z=PC#;%M]BEJPS&85I[%9J=M-1QN7F>J(JN<][N',][E<
M]ZZ)JY5"$^      #'>I3:"Z[W;?4^&6>YT]IJXKG37):JLCDEB5E,V1JMTC
MXZKWB*GT@E9MU]I\9WCP6JP7*DD;23+'-2UE.J)/2U<**D<\2N14U35S514T
M5KE3PA##JC8'J8N%F=@5QWR23 I&+1S53;6S\\RT*ZHL;Y]>\57-7E55J%X=
MJJG )=!;;[>8WM7AMLP;%(716:V,5K'RJCIYI9'*^2:5R(B.>]RJY>")X$1$
M1$"%K     "-R"EN%=9;C1VBL2W7>HI9X;?<%8DJ4U3)&YL4W(O!W(Y4=RKV
MZ <BX?TE;ZX)=KQD6,[P4=/DM_?SW>]U%BAK[A/J[G5OE%8Z:1K7.\9R,5.9
M43771-"6U[5X+OCBU_JJ_<W<R+-;')1NAI;9':J>W.BJUEC<V?O(4151&->S
ME7_2U\ 0I67]->;6K/+QN+L)G[\%N632)49'9:BF2LMM35:O5TZ,=SHCE5[G
M<KHW:.<Y6N:B\H2L&RO3S4[?9-=MR<]RB?.-TKU"E)47JIB[F&FI4Y=8J>-7
M.5->1J*[@G*B-:UJ<W,0W8     (S(J2Y5]BN=#9:W\VWFJI*B"W7+D25*6J
MDB<V*;D7@[NW*CN5>W0#D;#>DO?? ;G>+]C&\-'39'D#^\O-[J+'#7W"HU=S
MJU:FL=-(C7.\9R-<G,J(JZZ)H2VS:K!M\,6OM76[G;F1YK99:1T-);8[53VY
MT-6LK')-WD*(JHC$>WE7_2^@!2+[TV9SBN:WC-^GS/?B2[)95J;]CE=1LKK5
M)4N5SG31,<CD8NKE5&]VNFJ\KD;XH$[M3T]W7&\YJ-W-TLMFSG<^:G=14E:Z
M%M+0V^F>KN:.FA:O#5KG)JB,:B.=HW5RJI#>@     \MRMU%=[?5VJY0MJ;=
M70R4M932)JR6"=JLD8[Z#FJJ*!R]:.G3?':Y*JQ;&;JQ6W ZB62>DLF04$=?
M)0.E>YSFP2.9*BIJO,NC6(J\5:J^,I+2=BMB:7:&&^7>YWN?*=P,IG;5Y)DM
M6SD?,]O,K8XF*KE;&USG+Q<JN7T$1K6D*3EO33F]GSR\[A;!Y^_!:[)I?*<C
MLE13-K+;45:J]73M:Y'(BJKW.Y71NT<YRM<U%Y0E8]E.GJ?;S([ON/G63SYO
MNG?(6TM5?:F/NHJ>E3E7N:>-7.5->1J*[AXK4:UK4UU(;J     'DNELH;U;
M:RSW2!M3;+A!+25M-)KR2T\[%CD8[1471S55% Y@M/3MOIM>RIL&R&Z\5NP*
M:22:BLV04$==+0+(]SE;!(YDJ*FJ\RZ-8BKQ5NO%26E;%;%4>S]+>KE7WJ?)
M\]RBH;69-DM6WD?/(U7.:R-BN<K6-5[EXN57*NJ\.5K0H]ZZ:\[Q+-+QFG3Y
MGR84W)9EJ;[C==1LKK6^I>JJZ6%CD>C.+E5&]WJW54:Y&^*@3^U'3U=,9SBK
MW;W/RV;.-T*FG=14U>Z%M+16^F>J\T=+"U=$U1535$8B(YVC?&55#>0@
M
M
M
M
M
M
M
M                                                         # ^
MK[<S,MIMI6Y9@U:R@O?YUI*-9Y((JEJP3-E5[>29KF\58WCH!7H\3ZTDHH[G
M0;G8Q<WOB;/!0U5I;3Q3(YJ.1KI(X.9NNNGU@E:=D]^KGFV17O:_<FPMQ/=[
M'&]]76J-ZOHZRE54_P"(I'.5R\J(]BJWF=XKD<USDUY2%ZS_ 'DVQVM\G3/\
MEH[)-5M[RFI9G/EJ9(T7EYVP0M?)R:HJ<W+IJ!%1=16R<V*/S>'-*"3&(JJ*
M@GK6+*JQ5-0CG1QRQ(SO8U>C'*WG8B*B*!9:3<C":[-:_;FEO,$F<6RG;65M
ME7G;.RG>V-[7HKFHUR<LK%\5R\% DLIRK'\)L-;E&4U\=LQ^W-;)6U\W-W<;
M7O;&W5&HJJKG.:U$1-550*Y?]YML,6Q6UYMD634=NQF]Q,J+/6SJ]KJN*5B2
M-=##R]Z_Q7-<O*S@BIJ P#>;;'=+RE, R6DO<U&U'U5-$KXJF.-5Y>=T,[8Y
M.35=.;ETU O8% S[>W:O:^6"FSW**.S5E2WO(:)ZOGJECUT1_<0,DD1JKV.5
MNB@>)O4)LN_&*?,H\SM\F-U-;%:HZV-SWJVNG8^2."2)K%DC>YD;G(DC&^*F
MO8!SWU@[P6JIRG#]G:#.7XS;*FYJW<FJM[Y8JNBH593OB:^1K?2OCE>[E:KD
M54;S)IP4EY]PNH'"ME]L-OL9V'S*FN<+KC&DK[FV6X5+[)--5^45#WR1L1$;
M4,<Q>Q4[&MT3A ZGP+=;;W=".OFP"_4]]CM;XXZ]U,DC>Z=.CE9KWC&Z\R,=
MHJ>@2A4;OU3=/UCN\ECN6>VUMQB>L4K8.^JH6/1=%:Z>"-\2*B\%\?@!H[,J
MQV7'GY;!<Z:HQB.EDN"W:GD;/2K20M5[Y6R1\R.:U&JJ\H%*3J&V7=3XY5,S
M&A?'ELOD^.L9WKYJJ3RA:3A$V-7L;WS71\\C6MU1>(%_O%WMU@M5=?+Q4-I+
M1;:>:MKZN37DAIJ=BR22.T15T:U%50.4MJ.L;$KAENXM/N/F-LH\8I+QW.!3
M)3R0K/;%DJ$1ZN8QRN\5L6KGZ<=?\A+I6CW!P^OS.X[=T=UBFS6TTS*^XV=J
M/[V&ED[OED55:C51>]C[':^,@0^F:YWB6W5C=DN:W2*SV-DC('5DS7N:DLJZ
M,;I&USM5T] #Q7K=# \=J\:H;W>X*.JS!W)C,<B/7RU=(U\16M5&I]]CXO5$
M\9 *C!U1=/\ 4W_XM0Y_:W759?)VKSR)2.DUY=&U:L2G5%7L<DNB^B!.Y_O?
MM3M;44]'GV44=FKJEO>0T3^\GJECUT1ZPT[))&L5=='.:B+HNG8!/X9G6(;A
MV9F0X5>:6]V=[EC\II).?DD;Q5DC5T=&]$5%Y7M1=%10(?/MX]LMKFTZY]DU
M'9):IO/34LSG25,D:*J<[8(6OD5FJ:<W)IJ!],"W<VWW/AFFP')**^+3<:BG
M@>K*F-O!.9\$K62M:JKHCE9H NV[NV]AR&NQ2]9'1V_(+90+=[A25+G1)!0-
M1%69\CFI&B>,G#FUX]@$C@^?8CN38TR7";FR[V)TTE,VLB9+&U985T>WEE8Q
MW#T=-%\ &0;SX_CUSWBVGN-UW+JL2NU'6JMIQ6!DKH[N]LK%<QKF.1L;GZMA
MD61'(YCN5-/"2TJZ[Q[8V._7C&;UD]%;K[C]$VZWFDJWK#Y/1O6-&R.>]J,7
MF6:-$:URN57)P"$3A?41LMN)>$Q_#LQHKC>W(JQ4+DFI99>7M2)M3''WBHG'
MECU73CV :%=[O:[#;JB[WJM@MUJI&+)5UU9*R"GBC3AS/D>J-:FJ^%0,MM/5
M/T^WN[,LEOSZVK<)7]U$D_?4L+GJNB(V>>-D2ZKV:/X@:X^1&)JO!$XN55T1
M$3M50,@K^JKI[MMV?9*O/[:EPC>L3UB[Z>G1Z+HJ+411.AT1?#SZ :#=\YQ*
MQ8K-G%RN]-'B%/"VJDO43_**7N)'(UKV/AY^='*Y$3EU D;'>[7DEHH;_9*E
MM99KG!'5T%9'KR303-1['IS(BZ*BZ\4 AK3N-A5]RV[X):+Q#59=86-EO%K8
MCTEIV/Y=%<KFHU?3M]*Y>T#"^AW(\CR;;C**S);Q6WFL@R>NIX*BXU$E5)'"
MR"G5(VNE5RHU%551O9Q"6C9+U,;$8A>Y<<R'.+?37F!_=5--'WU4D,B<%9))
M3QR,8Y%],CG(J>$(66DW7VZN&067%;?D5'67[(J)UUL=+2O6=M70L[S6:*6-
M'1JU.ZD^RU\50.=;+UBXD_?;*;1><QML>S--:H),>N#:>3FDN2I3=ZSO6L5[
MM%=/P5NG!-/HDK;DU'AN5]06U^9T6Z51;JRIM'EN/X93-E6"[T4[9IFSLDU1
MC&31Z]ZCV*KVQIIIIP#9,XW+P3;6W1W;/+]26*AG<K*9U7)I),YFBN2*)J.?
M(K45.;D:N@0A\#WTVDW.JI+?@N645WN4;5>M U7T]4K$155S(:AD<CFIIQ5K
M51/"!+7[<[ \7R&UXID5\I[;D%YBEJ+;1U'.WO88$<Z1ZOY>1C6HQRJKW)V
M4^U=46P%ZOD>.6W/;;)=I9.XA;(LT$#Y571&LJ)8VPN5R\&Z2>-X -=
M
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M5QDMJ4\M1(O,][:262G8KE7BKN2-NJKQ50AK@
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M*K%<WBUR+P4):N$
M                                        &5=1=DW$RC:>]8IMC2QU
M&27]&6V:6:I92-@M\ZZ53^9ZHB\T:+%RIQ\?7P: 6?:_!J#;7;_'L$MJH^GL
M5%%2OF;JB2U&BOGET7L[R5SY/\H%N
M
*          /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>lc_fig29control-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig29control-4c.jpg
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M -@  0 " P$! 0$            &!P0%" ," 0D! 0 " P$!
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MZ'T,![Y-EV,87 :M,LMHM-6OOMPVI<YU+#)R'M=B-ZM"(SVGX@-T
M
M T>2YGB&&,,2<OOZZ@C2EFW&>M);,)#BTEJ:4&\I)*,BZZ$ T43FCAZ>Z3$+
MD#')#ZC(DMMV\%2C,^A$1$[J8#?Y+E^+X;5%>Y5;1:BE-QMGXA,=2U')QX]$
M$:U="W>S4P&Y2I*DDI)D:3+4C+J1D8#]
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MT
M        '$7_ (D9-_N?@7=_J_B\G?\ [WL)U\ %:\H1?_#_ &N/+Q>#.NGF
MON;GP(H"[I;QS]A]G>4WZ#M[].YN_%UV^;0!T!Q#QCE65>C4^/>1$K786U7-
M.F9DJ)UV/'4I3]9N/57S%);<;3KY4;4]--"#>>B;D:9G_!M=&MG5.W.*2',?
MDN+UWJ9C(0N,:M?D9<0WK[309@.BP
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M5OV;&(L9M2B_E5JG_@@.P0
M                             <1?^)$IM.(8";NG;*WDFLCZ^4F$Z] &
MHS3E7T!S,.N(E9CE=(M783K<-JMH'H$PY"FS)OMR%,-$VHE:>8W/]T!/_0(6
M65G!<Z?E:GF\;^(R)..%*UU3 0T@WEM;O!DW27M]F[>?M :S_P .Z&^K ,UO
MMIHK[3(5IB(/H6C,=M2C+7\J1?Z '9
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M/J1+=6M22/P+0O8 FP
M                         -/D&)XMEC3+&4T=?>,1E&Y':LXC,Q#:U%M-
M2">0LDF9=-2 :1KB'B9EQ+K.!XZVZD]4K1404J(_P&3(#4<ZL9DKB+(Z/C6G
M59Y1:0SIZV(PMF,EEN878<=W.J0A)--*4I/7Q(B 9/"/&47B#C#'\#84AV37
ML;[*2WKM>GR%&[(61GH>W>HR1KUV$1 +!
M                  85Q6MW51/IW7WXK5A'=B+DQ'.S);2^@T&MIPB/:M)'
MJE7L/J T7'7'F+\68C PG#XRHU)7[S;)Q7<><<>6;BW'5Z$:EJ4?C\FA%H1$
M0"5
M
M
M
M
M
M
M       A=WR[Q?C61LXA?Y?4UN3/FA+=7*EM-/DIW3MDM*E>0UZEL)>F[7H
MF@"%47+_ !=D^2OX?CV755EDT<UDY61I3;CQFSKW"01'HLT:'N)!GMTZ@)J
M                                             ,*=<U%9(AQ+*PC0
MY5BYV*]B0\VTY(>TUV-)69&M6GXJ=3 9H
M     "OY_.7#U5E!X98YM41LF2Y[NNO=EMI4A\SV]I:M=B'->FQ2B5K[ &^S
M'/,-X]JTW.;7D.BK%K[33\UU+1..&1GL;2?F6K0C/:DC/0![XOF&+9K2MY%B
M5O$N:1TU)3.A.I=:)2/G)4:3\JD_C)5H9>T!H<<YFXHR[(7L4QC,:JUR)G?K
M7Q93;CB^V1FOM:'HYM(C-7;-6A>("<@
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M\M@EMFR^^1Z+09&1Z )^
M  ,&ZN:O':B=?7<I$&GK&')<^8Z>C;3#*36M:M-3T(B]@#A;)LYQG/,NXWYL
MR3**R/.D9Q5QL=QM=I%-='B3;<IU4F:RATR:D2W$-/2%KU[:>VWN+30!V%F/
M)#&'NPFTXUD.1MSFC?;DX[6KLV$)(R(B<6A1$DU:ZI^4@&#AO+]-F.2N8C\!
MO\?O4P7+5J/D%8Y7D]$9>;86MM2C42C2MU!&7CU 6&
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MD7;61I4 WLO/<&@5<J\G9-4QJ6%(5!F63T^,W%9EHTW,..J<)"7"UZH4>[\
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MBAJTN-.)-"T**&T1I4E1$9&1]#(RU(!+0
M          !5+'\2T[[#0_K>4 M8
M              59*_B1JOL19?6T !:8
M        "H.2_OJX0_3\B^HI "WP   ?FA$9F1=3\3 ?H
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MWCM=G?TW@)?&Y4Q67C^:Y*U[U\-P&59P;_<PHG.]3,)D2.RG7Z0MBBV&7SC
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M=0%\TUD=Q50K4X<FO.8RA\X,]LF9;/<21['D$I1)6GP46I]0&<
M            *I8_B6G?8:'];R@%K                 *SS;F[%L*N3HGV
M)%A/:VG,**2-K.\B423-:DZJT,CT+_='.S[ZF*W+TS+U7=OZ:W&]Q?-B8K6>
M&NO3YNI.J"^K,FJ(MY3O=ZOEIW-J,M%$9&:5)47L4DR,C(7<>2N2L6KPEY_=
M;7)MLLXLD:6JV0D50                        !5DK^)&J^Q%E];0 %I@
M                             "@\^S'U*8359'ELB%@+>'T;<N>EV3-M
MTRU0H^Y;9*2F/L-Y:2))(2K0UGH0#YE\P<JV3."89BV-U3?+F5T9Y-=Q[=Z2
MW54U>@VT;GDM%WUK4XXEHD)/4E$>IZ=0&;C_ #O95-#R.WRO51JS,>+F&YEX
MQ3.K>@3HDN.J1$>A*?)*R[VQ3>QSJE6FXRUT(-+%Y@YOQA6*93RGB]#"X]R^
M=!KNW429;EO2N6VB8RIWO"4LN)WJ2AWM;=NOM\##HL!4')?WU<(?I^1?44@!
M;X")\@<<XSR75,4V4-ON0XSY2F?=GEL*)TDJ1U-/0RT4?B0M;?<WP6YJ<6];
MS7@J+)_2%Q]+H9S&,.2X60*;UKY,J2MZ.EY)D9$XG;\U6FTS+J6NI:Z:#J8N
M^<L6CGTF.OH31GMKTJ>P3TCY[-R=AO.8[57B\9PES'FI+3KTEM/78R31J-.[
MPW+V[2Z^/0=7<=\8HI_M]-O%P36SQIT+X3Z3.(4J2KW>Q/0R/0YSA:Z?R$1C
MB_U?<>#S*_S[+O:;0RTAELM&VTDA!&9F>B2T+J>IF./,ZH%;>H+"K_D/B2^Q
M#%VV7KR>Y7+BMR7>PT91;&-)<W+T5IY&E:=/'H,#WRG#[RUY?X[S*$AI5'CD
M+(8UJM;A)=2NU;A)8V(T/=J;"]WR *@Y!X7SFUM[RYCXU6Y5 D<@5F6-8_82
MV66)M7#H%USB'3>:=0E7>,M$J0>I$ FMOQY=Y7PN_05N&U?'67U$UN[Q&FKW
MHTF#&M:R2F;%=)R.PPVCO.)-#NC>I)6KJ>H#]HL&Y-Q#AJ?5XZ4%/,.739=K
M?VIN;(<.TO9!KDRDZDK>4-M24,H(CW=M!> #ZXUX?G<:V5OQZU':R#@^UAM3
MHK5NZ4N3$N$FEN6RXR^E?>9EFDI>[<1-N[R)&BB,!N^0^$L5R;CK)L-Q*KK<
M7LKR.T3$^!#9BD4N$\B5%-[L-D:D)>;2:BZ]-= $5:Q#F;/\M@9CF$"IP>UQ
M"EN*_%78$Q5WW+NZ9:8.P6A;+*"CM):\C"]RS-1[E: ,;%\)Y4N^3,2R_+L5
MHL0D8NW._>.^I)QR7LC>FQ3CDCLML,&B/W=)6DE3BDJ)))ZD:C#9<T\.7F>Y
MKBMY0*8;K)"$46?)>7M7(QYJPC6B$-%IU63L9;?^]>67M,!$5<!9RC_-V(ER
M*NHL:.]H^,(C:TLI:9RM]ZRG-O)))$V29*FVFS_H)^0B 9MAQ;R; M,VC5=3
M!LJKD+"8>.R)ZK HSE79555-BH2IE3*N^V\Z^@MZ%D:"U,R 2.YXRRZ;@W!]
M''9CG9X+<8].R-!OZ-HCUM8_#DFRO;YS2MTMA$1;OP (6GBWFA?&"/3:[4U"
M<,2V56YR,F:1J.E2_P!SRU9L[RF&U]'U=[9+\^X!GY+@?--- Y3P7"Z&KNZ#
MDB19V4+(YEG[BJM5;P41GV'XO8<4ZI)M_0J0K:>XM^G4!O,'P+D+!.0J2X;I
MXEEC]GB5#C=[(*>3,BKE4:'MZTM*:,I*%FZ1)-"DGT/I\H;7-\'S![F2ISFE
MK6+C&K+')&&9 R<TH$N!'FSFI*IS6]MQ+VQ"5%VB-*M?: JS)..?4//X2D>G
MR)C=%(KJZ)'K(F9JM.PW.K8#[:F$H@]AQ;,I3:$DXIQPVR42E$HS,@$US3BY
MV7@W/,7+;!BCH<OF*MX5P:C=1'C0ZR$@GI"4%N)"78BC6GQV:_* A&9YCR;F
M%SPDG*J&C@5;F9U<R)-H[@KA5PMN)),YL%MMI';@MMJ4ZXIQ2E%O07@1J4&J
MK/3!E-;61^,7L7C6U*Q)[9YM.RBX*K=JBE^\Z.8\P^VCWDF_)VTZ,=SZ3< E
MF<<2<J65)S'@]140)E5GEHSDM)?KL284E]+E:E4)^,;)FG1$5Q1/)6HCZ%IU
MZ!/J/CK*H%'S3!?:8*5F]K:SL?23Q&E;4RJCPVC=/;Y#-QH]2T/0@%:8'49S
MP]DWP?$H%/EF46F)XLSEF,2+=%5-K)=%7_#4RFEN,.)?A+)&B]A;DK+73S:&
M$T]+C4VVXKR!=L]&>DV^39*X_85AFJOD*?GNH<>A*7U4P:]W;,_80"(0>.N=
MT85A'$<C'*9%!@]Y1R9&5HM#4=E64\]M]*H\(V=S+VQ"3<)UW3RF2==Q;0F"
M^*LR/ACEG"":C_'LOM,JF4B.^7:4Q=R778QN+TT09I7YB]@"/9%PMR'(/+K2
MKBPI$]S(,+R2C@/2^RB:6+P8;4F.MTFU]DU+86E"S29>!GH0#HREDV<VHA2[
MJ FKMWV4.3:U#Z9:8[RDD:VR>2E!.$D^FXDEJ SP            '%K]IDU_
MDN18#D-ME$&XLLGGVW)$M)2V*^KP:A3(=A,U[S222VW-;-A.Z,9NN&:]_LU"
M^_3E)OI?%L*1=/6$B$J;8_NW)NMWQ1V@*8Z5<N6:R)1N*8V'JKJ:=# 6N
M   *I8_B6G?8:'];R@%K                 .>>3."LBOLKE7^-O1W(MFLG
M7V9#AM+9=T(E'KM,E),RW=.I>&@X6ZV%[Y)M7K?2NYOU/@P;:,6:)B:=$3$:
MZQ^U;_'V(EA&*0L>-_WE]G>Y(?(M$J==4:U;2/KM+70AU-MA^5CBKQ?>V_\
MSNYMETTB>$>"$G%ER0                !Y25/HCO*BH)R2E"C9;4>U*ED1
M[2,_81F X6I<]GY=C#-3E.>Y73UV.1+3*N:;QHY-=.K[MTVXD&FAN)0DVD-N
M;W41FB-*R2GY3(@ZVX;G9;9\58?89VA:,NDU45VV)Y':>-Y39'N=1H6UQ1:*
M<3H6BM2T+P 3@   %62OXD:K[$67UM  6F
M    *(YK<;Y$S_".!8ZDO5\UXLNSM@C2HO@-,ZE3$=U!^*)<SMHZ'J1(,!KL
M^OJ;C/U.X[R!FDQ%3A^0X=*Q2/<R/)#8M(]DBP2W(>/R-$XT:MAK,M32?R&
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M?][I9/N<E6U*D[%+VKU0>[4RT\2(9B=&LQJJ+C_![&\NLM1/SS+7&L8R%59
M:^*^1R,U$B2B2\7:\YFMY9&?]'0OPB29\".M==>F5]B),        K[FE^3&
MP":[$EY)">)Z/I(PN(4^Z(C=21DTR:%ZI/\ \X>G1.H#F)-MD2B(TY%SX9:^
M)8RD_P#^E =/<,/RI& 079DO(YKYO224_FD0J^Z/1Y1$3K)(;T27_F_+U3H
ML       52Q_$M.^PT/ZWE +6
M   %3<^W=A18Y62*[([_ !IUV=VU2L9I49!)<3VEGL<96TZ2$:EKOT+J1%[0
M%!%R#EVU+G^:7)1H3T)7^7K!IU_#_8=# =8\>RWI^$4,V3.FV;[\-IQRPM(A
M5\Y]1EU6_&2E!-+/VH)): )*   "K)7\2-5]B++ZV@ +3
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M<!N3&:;[+M.E4:,KK(7M-MA3S9,_.5JDC,.GP
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MV1FXE/XJ7/ZQ)>PE )P   "K)7\2-5]B++ZV@ +3
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M(TVE?7#=1%T(B)@S;W-E^*D]O734!80      JEC^):=]AH?UO* 6L
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M#DO[ZN$/T_(OJ*0 M\
M     %9\3_[<Y0^U[WU77C>W4CIU^-9@T2         "E[C@.P3>7%IQ]R%>
M8+79')<GWM+6IBR(CDU_3O2(WO+:U1G7=-SBFSZJZ@+&P7":+CO%H&(XXAQ-
M7 )9DY(<-Z0\\\M3KSSSA]5N.N+4M:OE/IH70!(@     !5+'\2T[[#0_K>4
M M8               &-8(GKANHJW6F9YE] [(;4ZTE6I?.0E:#/I\BB&MM=
M.CBEQ32+QSQ,UZ])TGSZ3Z$'O+#D6D55I78T[WQ.>S7$90)*>V;R5JW_ -[/
M739X"GDMFIITUZ9TX3^UW]MBV.;G]C)')2;>_7ITTZ/<\*1U4;,FIA*NK"ND
MP-JB4U$AO,.[O89+7(<+3Y?*)Z1DU]J8T\7[W,SWVLU_VZWBWAM$Q]58]+?"
M=S@                !^*22B-*B(TF6AD?4C(P% J].F6UD61B.%\LW.-<5
M23>3^ZK$*%(EQ8\DU*<CPK-Y)OL-EN,F^BC07@?RA=>-8[48CC]9B]!'*+2T
M\5J# CD9JV,,()"2-1ZFH]"ZJ/J9]3 ;):C2A2DI-9D1F22TU,R]A:@.9;SD
M3GK"XM3FV86./L2[.UAP%</18Y2+-,6PE)CH3'L6I*E/2D-J[R]&.UH2O86@
M#IP!5DK^)"J/_P#0BR^MH "TP                '*'-><9@WG<ZI9L)5;7
MUQM)AQXSJV"42FTK[JC09;C4:CT,_ N@\SOL^3YLQK,1#[#^F^[-K.SKDFM;
MVOKK,Q$]>FG3P7KP_D%SDN!U]G>&;D[<ZS[RHM#>;96:$K/Y3Z;3/VF6H[.R
MR6R8HFW%\^_4&TQ;;>6IBZ*]$Z=FL<$Z%UY\  'XHB-)D?@9=?9T <A\'<B<
ME8W@;6*\8\72L_XZHYDV%B^9)LX%$5C!3*=,G#CR]#4:5&I!NH\KFF[1)ZD
MZ=PJYR2_QV+:9;CB\3O7E.E(HW);%@IDD.*2@S?C?1JWI(E]/#70^H"0 /-]
MTH[#KZB,TM(4LR+Q,DEKT ?STQPJ/,^*I')^5<9Y%?3[)<FZRGF&OD,1;.LE
MMR%N$Y4,O/\ ?7'@(2AOZ%*6B[:RTT(P%Z9'!Q[FKFS"L"R22K)>-X6"?OO'
M9-:F8UK,F3&H;$B2VUVR61-:NH3H1$I7AIJ0"'W5K,X'@>H;#<#?>@X]24U7
M?8G#)U;A5,F[0Y&D^[J<4I24]PDO-HUT2KP(!L,_X@PK@S"L,Y/P&*[79M06
MU(BTN4/O*DV\:SDM1IS4W>M1.%([IK/IY3^;M+H Z,S+E/CKCQ^)&SC)8%#(
MG(6Y#;GO)9-U#9D2C3KXD1F0"H;CE#COD7G#AR/@V2P+^17S+]Z:U >)Y3+2
MZ1]"5K(O C4>W^4!T:                                         ^
M'EN-LN.--FZZE*E(:(R2:U$6I)(U="U\.H"HYG,&<5]O54$WBVR:N+LI"JR-
M\5J%DZ4)"7'M5ID&E.U*B/S&6OL$G+':BYY[%EX[8VUK4,3KNG=H;)PU]VK?
M?8E.-$E1DG5R,M;9[B(E>57MZ]1I*2);0890#F?DE/$_'MGF28I3ID<VX\"*
MHS2VN3(62$;S+KL3KN5IU,BT+34;5KK.C2]N6-7(O GJAR=ODE=/E$6(_59U
M<H=FNQFC9=CV$MMF(VMO11D;?T3:5)5J?BK7776>^.-%7'EG7IZW?(K+H
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M:[_U8!;V.S;BQHZ^=D%65)=R&$.3ZE,A$THKRBU4T3[:4I<VGTW)(B,!GO\
M?[#GNVSWG8KL]S79OT\N[3KIKXZ ./,[<R+/2@.0^*+C&_5%%L(3$?,8D!U-
M-$*+)03LD[?<33T-<4G$=M9K4>_9M/Q =,9AQY7YI)BRIEU?5:XC:FD-T=O,
MJFUDLR49N(BN():BTZ&KP 5QC.&0L+]0\2+#M+>T*7A<]Q;EY92;5Q&RU@D1
M-JE+6:"/4]Q)/0^GR +V               !CSGI,>&\_$C',E-H-345*TMJ
M<47@DE+,DEK\IF-;3,1T1JDQ5K:T1:>6.WCIYE89<\S9.5\C+N.#E/O2&H$%
MU<N$M9O/F>Q!J0X1[3,C^=T(<[-,6TF^/P<8>MV%9QQ:-ONN6(B;6]F_".,\
M./UIG0V-XIYFND8JNEJVFS2VZ4F(XTV2"(DH2VPHS(ODT+0A;QVMPFO+'CAP
MMUAPQ$WC-\RTS_#:)GPZRD@L.6   9$9&1EJ1]#(!R%ALSG[A>D1QZJPXRCU
ME:Z^JF@V][-9FQ8,AU;S;"E*;2IQ+9+VH6I)*-.FNH#I+CBZR#(<1A6N4.TS
M]T\IXGW,9E+G59DAU24=IYPB4H]I%O\ D5J0"5@'CT/P <T(XEYWQC";/A7"
M9^-KXWF)FP*G(;)4WXQ75-DMQ3C*HS:#:?=:2ZM#+G=01^4U$0"0WW#67XG.
MP;*N&9E>K(L-Q].&RH&1&\B+9T;9-&VE;T9*EMNMN,DXDR1H9GUT(M##YH^"
M;S(:3DR3RU80WLNY2CLP+!-(ETX%9"@QU,0VXQR"):UMJ6IU:U$DE+TZ=-3#
M4-\6<]9FC$L/Y3M,<_</%9\*RGSJ;WQ=I>*J%$N(V\V^VEIE*U)2N1L49FKY
MFA .C%M-.:=Q"5Z>&XB/^<!4')#33?-7"/;0E&L_(==I$6O_ %%(^0!<0
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M*7&7FU$M"T++5*DJ+4C(R/4C(!Z    JR5_$C5?8BR^MH "TP
M     $/Y ^9C/V@KO^<H5-Q\/VH=ONKCF_"NF MN(    _#UT/:>A^P_P@.(
M>,Y?I;QNBE8_STU1.\TP+":C-Y61QRL94BQ5(<4;K<A3;B%-+0:#039EM+HH
MB7J ZPXQE<<S,-@R.*4P$X0I;Y0"J&DL0]Y.J)[8A*4D1]S=NZ>("7@
M   *@Y+^^KA#]/R+ZBD +?
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M;A->4R>>2TUO>(E:-DM)'YN@"Z %4L?Q+3OL-#^MY0"U@
M $0SS^LQ7]OP_P V\*NX^'[4>MVNZ^&;\*WIJEXM.*
M#QEMF[%?:2\<=2VUI)].FK9FDRW%K[2\0'#N/N9C@KV"8A,XDO;Q_$<=R/&W
MVZJ"B7CET_=N1%1I13]Y,DQ+2RMV4IXB4WNZI48#K'AW$;7 ^+,0PV\D%)MZ
M6KC0YKB%&M!.MH+<A"CTU0V?D0>GS2(!-P   59*_B1JOL19?6T !:8
M           #D_F[-LJ5G4JG3,>@U].ZPY7L,J-KZ0FTN)?,TZ&:M5:I/V%X
M>T>8W^>_S9KKI%>'[7V+]-=V[:-G&3EBULD3S3/3T:Z<OB[>U>W$.16^4X)
MM;L]\[<ZP<@RV]Y#*S03AD737IH9E[2':V>6V3%$VXOGO?\ M,6UWEJ8O=Z)
MT[-8X)T+KSX  /PRU(R(]-?:0#C+@KE/">/./HV(9+QWD[U[72IJ9MRC%Y;Y
MVIKE..(FK4M!N[W4*3N2[YD'Y?FD0#JG \EJ,NQB)>T5;+J:V0IU+4&QA+K9
M*#:<4A1JCK(C21F1F1Z=2Z@)*         J#DO[ZN$/T_(OJ*0 M\
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MZ@                (AGG]9BO[?A_FWA5W'P_:CUNUW7PS?A6]-4O%IQ0
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MR_J^X74_P:F07F J#DO[ZN$/T_(OJ*0 M\
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MG71Y3<ZX;98L'T.H)27'T1]6B6HCU^C\OR )B   "K)7\2-5]B++ZV@ +3
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M"?,UEM21)61^"B,M"\ $V      %4L?Q+3OL-#^MY0"U@
M $0SS^LQ7]OP_P V\*NX^'[4>MVNZ^&;\*WIJEXM.*
M"&9]06F4+HZ(Z.BOL,DRU'ED3(&U2%)BH;-32XK1I4VITG2+JYX>SKU(.548
MNK$:#WEW%?3_ !*"FEE2N64^5*E&S8LD2CBO2I$-QQ4E)'N63BS67B8#L3$W
M+1W&:EVZ37IM5Q6E24TJUNUFXTE_=5N)2HVM/F&9%T ;D   %62OXD:K[$67
MUM  6F                 A_('S,9^T%=_SE"IN/A^U#M]U<<WX5TP%MQ
M  'X9:D9:Z:^TO$!PS6-\B<37O$N)S^,LDO?\K9F1I5;XY!*96VT:YBR&8DA
M#Q.;67%K>)4A+YD:/,KK\T@Z:X"PR]P7C2%4Y,PS!O9DNPMYE5$43D: NUF.
MRRB-*3Y3)DG"0>WR[M=-2Z@+-  %96WIXX4O<J7FEMA=?*R%UY,J0^M+A,/R
M$GJ3KT9*R8=7J9F:G&U&?M 2+.^-,$Y-JFJ7.Z*-=5\=?=C(?)27&7--IJ:=
M;4AQLS+H>Q1:@,G$,#PW :!.+8=2Q:B@(UJ5"CH\CBW"(EJ=-6JG%*(B(U+,
MS,B(O @$7Q;T_<,83DIY?BN&5]9D6JS:F-)6KLFX1I4;#:U*;9U(S3]$E/0]
M/ !90"H.2_OJX0_3\B^HI "WP
M    :S(LAI\3HY^1Y!*1"IJUI4B7)<\$H3["(NIJ49DE*2ZJ49$74QF(U8F=
M(U<[\;8]<<^YJUS=R!$7&PNJ6IOCS&G]#2:4JU]]>3U(S-22,OZ2R+\1"-TM
MIY8TA!6.>>:>'4L[-/OCXM_)9%^IL#2.$I+>]"S1HD &ER>TOJBO1)QZA7D,
MU3J4+A-2F(9I;,C,W-\A24GH9$6A=>HFPTI:=+6Y8\4SZ!!J3E#-[Z;,AQ..
M91%5SOAEJZJVKB*/()#;JM"WZK)+;J%ZI\==/$7LFTQ4B)G)'3&L>S9E:8Y;
M          XOM:!KC_.6<;SN]PN'BU5DUKR#6LS[1J'=7UK/*0Y6-36WBT93
M&=>42I*]R3V(VET =$<&8=;89@+46]7$^,6\^POYD:K5NKHKEQ*<F>[Q3]K3
M1.$DC+H?4RZ +(      %4L?Q+3OL-#^MY0"U@                $0SS^L
MQ7]OP_S;PJ[CX?M1ZW:[KX9OPK>FJ7BTXH                  /*2TI^.\
MPAQ3*W4*0EY'ST&HC(E)_"7B0#B/'L3L\0E4^%Y;48;(NN/*BPKL/PI=Y 2_
ME5Y=+;:7:/QI)H-M)QT*U0\DW#-:MOB1$'5W$F'3N/N,L4PJSEE.L:.MCPI4
ME!F;9NMH+<39J(CV)/RHU(O*1=" 3,   %62OXD:K[$67UM  6F
M        A_('S,9^T%=_SE"IN/A^U#M]U<<WX5TP%MQ    'X>NA[2U/V%^$
M!R/Q7Q[CG*F,+R[E?.+X^29DR8C):5%[)IT5,EJ0MOW%$%IQ'90VE*=I*(]V
MNXCVJ(!TI@6,4>'8Q$H,<F29]1'4ZIF5-F.6+ZC=<4M6K[BE*5HHS(NO3P 2
M4        !4')?WU<(?I^1?44@!;X
M       ^'76F&EO/+2VRVDUN.+,DI2E):F9F?0B(@'+<E<WU69Z<&,MQG@+$
M)1>]O)-3?QRQ;Z[$F6A]LB/V=4H/=T4M.R;W(\*O]Y/@AU%'CQX<=J)$:0Q%
M80EIAAI)(;0V@MJ4I2G0B(B+0B(0K"M\T^^/BW\ED7ZFP-XX2CM[T+-&B0
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M]I$I/4O, ZGX7CY9%XFPR-G/=_>QJHB(M2DF9R">2T1:/&KJ;I)T)S7KNUU
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M\?%OY+(OU-@;QPE';WH6:-$@  *[XP_VSR1]JG?JV .AN_=Q?8_U696(.>P
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ME:3,O'0RZ'[2'5P9HRTBT/$]X[&^SSVPVG68Z^V.IOA.YP
M   \I+WN\=Z1L4[VD*<[;9:K5M(SVI+VF?L <O8E0<L\IX'%YP3R<5#DUI&=
MM:&IC0*UZBKHI&LVXDAQ]A3SFB2VO.FXDT*W=#V@+UXHS&9R#QKBN;6$,H$Z
M]K8\Z3%21DA+KJ"-1HW&9[%'YD:G\TR 3$!6:?4)PVK+?W(3E<<\A.;\*)/:
MD^Z'8ZZ>Z^^]KW;OZ^7M=[?KTTU 68 JR5_$C5?8BR^MH "TP
M  !YOIWL.H_I(47^Z0#CC&N:LZQBNI:>*[&54TT6/"3"-A.UUN,@D:J6?GW*
M(NII47\@\S;O++SZQP['V+%^D=G&"*6UF^G3;7K\$<-/(Z/RNP;MJC"[5I!M
MM3KFIE(;7\Y*7B-9$?X2(QV<UN:M)[;5?/\ 8XIQ9=Q2>-<>2/-T)X+KSJ!1
M/OIMOP8Q7%_^/G )Z   #F>9QEZBR;?=C1.*9#Z24IAMRBFHWJ\2(U;U;=?E
MT,!8_IZR.SRGBRLLKR+70+YN3/AVU;3QCA1(DR',=8=9)HUK\R%(\RB49*/S
M%T,!:(  Y+]2_+6;R8621>*K9VGHN.'H"\SR.(6JY-I/E,1F:B,X?EU;2]WI
M:D[MA[&ST,S(PG?)DC(<_P":*/A2MR6TQ/'F,=D9??SJ!XH=E,(IJ($>,W)V
MJ4TDE&M;FSJHNG3H9!#5\D9CPO4<VXG87<O*EX#5P+O#+B[64JP4U<LK;0U+
M<)*.\3$E!'N/S*29ZF70B#YR''L]X0HL1Y6=Y(R')9[EI41<YJ+F64JGE1;=
MU$>0<.+L2493:W24SL/H1:*U =5+=:;T[BTHU\-QD7\X"H.2'6G.:N$>VM*]
M)^0Z[3(]/^HI'R +B                                   !67IY^YO
M%?R+_P"M/#>_%'C]V$9YUY2O8,R#Q'Q<7O?*63%L)QL_+5PED>^2ZHM=B]NI
MH_HI(U_T25FE>N>#7)>>$<4XXDXMH^)<1CXY5?VB<X?O%Q:K+1Z9,47G<5XF
M22\$)U\J?E/4SUM;66]*16-$[&K=\/-]YEQDEJ;-Q*D=QL]%IW%IJDS(]#+V
M *FD<"19<^%;2L_S%ZTK2=*OEJLH_<8*2DDNDC2(1><DD1ZD?@-^?P0B^7X9
M6-C=(O':ABI<M)URIDUF=A:NH?F.;UFK1:T(;(]NNU/E\!K,ZI(C1MAAD 5W
MQA_MGDC[5._5L =#=^[B^Q_JLRL0<]@         47;^E;![B]R#(5Y-ET.;
MD[ZY%VW!O'XS$C?T)M:$)\S:$Z(0A6NU!$GP(!GX;Z<,<P:;42*/,<S^'4BT
M*@T;]_(<JB;:^:RJ+H2#:_U/ !<H      JEC^):=]AH?UO* 6L
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M\AHMQ),]IF;9]#&W=^WOCB9MT:]2+]5=ZX-W:E,,\T4UUMX^J/,Z '6>'
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MT]@"Q0        %0<E_?5PA^GY%]12 %O@
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M-;CBU'U4MQ:E+6KVJ,S ;\        !4')?WU<(?I^1?44@!;X
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MG6Q)%@^XU!^D2DS-E*MJMI;=VNTS+J87<      *I8_B6G?8:'];R@%K
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MB0TAMP^G0B5JK\74!;0"H.2_OJX0_3\B^HI "WP
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M?8)DK52/I-M*8+SII,B\VJ]"Z:>(#I
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MH.':TVF9GC*O,ZLD:L*\XQ(RN.1S,NAY4[I_[-@?_2.AN_=Q_8_U696&.>P
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M5-9(:(TLN,,]I"C4R1Z,FXM>PO !=8"H.2_OJX0_3\B^HI "WP
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M!MV%H=:EH2GJ^E3:E),G%:J+:HR+70!,@   59*_B1JOL19?6T !:8
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M'UU 62         J#DO[ZN$/T_(OJ*0 M\
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M-I=;,TGJ1FE9&70P'(V+Y;P7QM9<AT?.=7!J<[F7=C(E*M*KWE%K2N+,J[W
MVV'$KCIC;&DLHZDLE:IW*,!<GIH@6M=Q+7,6%:_3UZYEB_CM3-1VYD6C>F.K
M@-/EU/>E@T_.,U;=->H"W0%*7_%_*5+FF295Q!D]551<T]W=OZZ^@O341IT9
M@HQ381L.MEO6VE&]MU*DFI.IZZZ$&UQ+C7+N-:+#L-P*Z@EB=%"L6[SXI&<>
MF3[*4E;S,A*T.$2$^].+==1K\T]I'X&007"^(.?,1R6TRZ1D^)7V47KJ"M,@
MM*NQ<L$P4J(RA1C;FMM,1T>*6VVR(U:&K<9$ Z0 52Q_$M.^PT/ZWE +6
M      8=K5P+NLF4UHRF36SV7(LMA6NBV7DFA:3TT,M2/V#>EYI:+1Q@<R8%
MZ:,*KN6;LGIDN=78HNNG5T%_81+=EI<>03RDD6]+9MET(D[O;TZ'Z3<]ZY;;
M>O1$3?6)\G8VU=3CS#4 :O)?\.V_Z%)_-* :KC/[M\._8E9^J- /'//ZS%?V
M_#_-O"KN/A^U'K=KNOAF_"MZ:I>+3BH%#^^BX^S5;^O3@$]
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M%J?4!+@        %0<E_?5PA^GY%]12 %O@
M    #DCESFBLI\[RUCC^V;M<VN:*IQ:B9KE&\INS<L)I/:.)\I.,I=2:>O\
M6*27]+2>M>CI5KWZ9TXK\X>XYB<6<?U6),;5SFD>\6TI/_GY[Y$IY>O0S(CT
M0C7KL2D16MK*:E>6-$[&K< 5UP/]TN,_D7OUET=#O'_L6^G4S+69MZ@L'Q29
M\"J#>RO+EJ[;%'2I]Y6;O]%;B"4E)_*2=RB_HC?!W=ER1S6]BO;*6N*9Z>$(
MG^YG-O,'TO(-K^XF&O=?W:IU;I[S1_BOO:GIJ7B2C,OE;(6OG[;;?=Q\RW\4
M\/)]/*VYJ4X=,K6PCC'!^.XA1L4J&8;IIVO35%W9;O\ OWEZK,O]77:7L(AS
M,^ZRYIUO.OH16O-N*7"JT5UE_P!['&WY.^_561T,'_7R_P OIEE8HY[
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M^Z8G4M0W%))+\U1=V6]^4>7JHRUZ[==I>PB'C<^ZR9IUO.OH4;7FW%+15:
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M9GBE=B63XGDTBF:1D-95656U'C/,3F+.8RTKN+>;6M!H22MO;,OG'K[#(+N
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MD"ITN_:-O([5ZU;9)%)(7N92Z7D6?@:B]G0!TF
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MZAVWAE-D-#0,5F4Y&[E=RVMQ3MT_%CP''$K6:D)-F*E+9;$F2=2+KIJ8#?@
M    "J6/XEIWV&A_6\H!:P        #\4I*$FI1DE*2U4H^A$1>TP%+X+R7@
M5OR[F4&MOXLB3:(JVJTDJ/9)<ALOI>2RLR)*S29E\T^OLU'9W&TRUV])FL]'
M-KX-=&5TCC, #5Y+_AVW_0I/YI0#5<9_=OAW[$K/U1H!XYX1FYBNA:_]?PS_
M /LWA5W'P_:CUNUW7PS?A6]-4O%IQ4"A_?1<?9JM_7IP">@
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M"DMK94I)F2B42CU,]VNO74!(P        %0<E_?5PA^GY%]12 %O@
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M '("4TM%28W7-4^.UD2HJ6#4;,"O8;BQD&XHUJ-+;24I+<HS4>A=3 ;
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MMQY)GVY*G#(]23T;\?P=1=WU<=[VR5O$Z]73KZ&5N#DL
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M>'/NIPS]CPOS*0$W  $"B??3;?9BN_7YH">@        -1D.5XOB,5J=E=W
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MU'8IML6TF+Y;:VCIBM?6L16M.FT]*@:_TP\B2<_=P:3[JPF*TU-EVJ7DK9*
M^ZMI+R$=%J4HVE[4&DCU+KH74=RW>F*,7S(UZ>C3PI_GUT?T&A16X,./"9,S
M9C-(9;-1ZJVMI)):G\NA#PUIUG5SWN-0             -0         !5?J
M33D2N"<Z3BW=.W.L7J4?^O.'O3[X3>G7?[MW=NGM ;O'?\J/\K8R*$ZC_*3X
M::$D9M%5?#EH/N$]W/+H9&?=[O777?UU 1/TM)<3P[6DQW_W;]_M?W2][[G?
M_=_X@_\ #]W=\^G9V]O=_P";VZ=- %R@     "J6/XEIWV&A_6\H!:P
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M$1%T(B ?8      JEC^):=]AH?UO* 6L       "!YM_C?C?]JS_ *HF )X
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M)@4LZQGS*EATCU(T0GWULF1:]$J2:2^0!<X    "K)7\2-5]B++ZV@ +3
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M FX  @43[Z;;[,5WZ_- 3T               %0<E_?5PA^GY%]12 %O@
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MA2?S2@&JXS^[?#OV)6?JC0"4@ "!0_OHN/LU6_KTX!/0
M        %62OXD:K[$67UM  6F       " \F_W[ ?M5$_4Y@"? ('CGWK9W
M^@4'\TX7<OW%/';U))]V/*X>Y;Y+Y(>Y0O7I5Q/K)%38/QJ^''?=CMQF6'#2
MUL0A1%YDDE1KT\^NOM'LMGM<,8:Z1$ZQT^%>I2O*[;X+6ZYQ%B#CR.VXJO;4
MHM===349*_X7SO\ 2/%;K'6F6U:\(E0O$1,Z)[*_NKWY-7\QBJT0WAS[J<,_
M8\+\RD!-P ! HGWTVWV8KOU^: GH               *@Y+^^KA#]/R+ZBD
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MM;W[VGZG@_[@PXON-MCKX9]J?4V-=P9QO 5W':Q<][Q-R8^ZX9G^%)*2D_\
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M:QRQY_2CF8G@BW"7W4XM^A_](L1,)U*_NKWY-7\Q@(;PY]U.&?L>%^92 FX
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M"8#?@(1EF$V&09[Q_ED:6RS!Q"39R9L9Q*C=?*PKG839-F70C2IS<K=[ $W
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M*XPE:R3U-*37J>@#8X[6NTV/U50^M+K]?#CQ''4$9(4MAI+9J21]=#,N@#9
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M],WC.?XO,1"MZ=N6W.86E^.B6P_&>22#6AQIQ*C(TDI'@H!9(
M       HF_\ 47:1[/)587QU;YCA^%R7X.59)!DPXR&94-.^4U$C/K2[*4R7
M1?;T\WX-#,+AQK(JG+L>J\IH7_>::YBLSH#^AI-3$A!+09I/JD]#ZI/J1]#
M;4!H,WS*AX]Q.VS3)WSC4=-'5)EN)+<LR(R2E"$F9:K6LTH0G7JHR(!6F.<[
MWSV38_1<A<>66#0LP6MG%+29+B34/R$M&\F/*;CGOBO+01FAMS74_+XD>@74
M  ,2TLZ^EK9EQ;R6X557L.2ILQ]1(:9882:W'%J/H24I(S,P%?<,<TTO-E9=
MW%%63JR%3V*JU)62$M.OI[+;[;Q-D9FE*T.I41*Z@+,  %(7W/M^FTR). <=
M66:XOATEZ!DU]$F1(FR9#22Y3$*,\?<EK9(]%DG;YR-*=>FH6WC>05F68_5Y
M/3+4Y56\5F=#6XA33ALR$$M.Y"M#2HB/JD_ P&T 1KD#.J'C3#K;.,F6XFEI
MVDNODPCN/.+<<2RTTVG4B-;CBT-IU,BU/J9%U 5W3\Z9%'R&AIN3..K+!8&6
M24UV-V\B;"L6'9SB%.-1I*8JC5&==2D]B5$>I]/8K0+I ?#JEH:6M"#<6E)F
MELC(C49%J1$9].H"GL5]0E79XQG>39E0R\/3QX^J+D$*6\Q,=)Q#*7MK9QU&
ME2E;TI21'YE&74!B8[Z@+A^_QZKS_CNVP:HS%XHF*W5A)B26GY;C9NM1Y3;"
MC7%>=21]MMPM346GRZ!=X"*\BY998/B4_**R@D9([7)[S];$>8C.^[H(U.N[
MWU)3HVDC49>)^P! ;+U"1RQW I6+XO-R+->1X)6>/XHP^Q'6B,EA,AUV5*=,
MFF6VR62=YZ[E=$D?70)+QARHGD!^_H;:CDXMG6*/,1\BQR8ZU)4Q[XV;T=UJ
M0P9MNM.H(S2M.G@?3P,PL,!6=QRU(H^7\=XKL<8F-Q<J1+52Y-[Q'5$>770S
MER$=DE&ZG86U&JDEJ9].@#VYHYEQKA+$CR>_:>GR7G#9K::%HJ7*6A)N.F@C
MZ$AIM*G77%>5*2^4TD83/';EG(\?J<ACMJ9CVT.//:9<,C6A$II+J4J-)F6I
M$K0] &=*==9C//,,G(>;0I;<=)DE3BDD9D@C49$1J/IJ?0!4V)<^5=OA^;Y?
ME])*Q!K )<B#D$&6ZS+>0Y%CMOJ)"HYFE1GW4H223\RO#Q 8N/<XY.]>4,+/
M>-;3#*#+'DQ,;NI$N+/W2G4&ZRS.CQ]7(BW4I/:2]VBO*K3KH%T (+RWR%.X
MOPV5F<7&Y62PZ[<]:QX3[$=<:$TTMQR2HWU)W)1L(C2C57F\-",!H,IYM75)
MQ*JQ/%9V5YOF-?\ &*W'HSS$1+$%#;:W'I<I\R::0DW$H(^NY70@&TXSY6_?
MRPOL9N\?F8EG>,*C_&\?G.,R22U-0:V'F),=2FGFEDE1;D]2,C(R\-0L4!0%
MEZF)K:+O)\>X]M;[B?&9,B)=YM&E0VB+W%6R4]$A.K)V2RR9'N<29%T/3H1Z
M!*,VYM:I9N/8_@./2L^S#)X"KNKJ:]]B&TFI22?[9(DRC2AIM9K2ELU%YE=/
M'Q#=<7<H1.28=LT]4R\<RK')AUN1XY8FA4F)(-!.(,EM&:'&G$*)3;B>BB\
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M8C,&17*4][JFNF(CF;>]:$]]DST7L(S5NU(P%[@
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MSHV>6$26R=>[[RAQ5B=JZ6PH+31*;::;UWD24D@S,E .S"UT+4]3]I@/T
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M]+N<N9#G'+D->,7U24_))%L4FUAICL1B*-$8*$^HG5[)1%Y^T1&7;Z[@'3H
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M:J<<</JM:S,U'X@-M75=93QBA5,)B!#29J*/%:0PT2E=3/:@B+4_: RP
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M("R0
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M"'^QT:\$::@.LFT=MM+9&:B01)W*/<H]"TU,S\3 ?0
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M/)HV85PPA^W5$>=2^U&>GIVF^VRZ1NMK<3W$ZFCJE1F07N
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M!5$^995U5WNQ*L%H6^9/O+>-/D2A))(UF22(NA )F
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M/><!IPN\B*1[%+/KJE)&L.F4(2VA+:$DE"2)*4ET(B+H1$ _0
M              !A7%O64%5-O+J4W"J*YAR5.F/'M;:892:UK4?R$1:@*=Y=
MYH561\,Q?CR>RWD7)DF-%QG+'V?>J:-&D&1N2269I;>>)L_H&-WG6I.OEZ&$
M$Y I,GQQE&'<\3WL^XCR&0PW79[$A-P;W&KLU;8SKQ0D:$V;BM&9*$ZH4>QP
MC0K106[@'&V75"U/\GYA^_TB(J,FA3(KH\5B'[D2R;E;?I5*FK[BNX^2RZ="
M+V@+-  $9SG/L)X[ICN<ZO(M%5.J[#;\ISMJ<<41GL:2G5:UZ$9Z-D9Z%K[
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MR=(R',[I:9&2Y=9:+L+%YM.QLE'UV,M)+8RR@]J$_*HU*,)\
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M!>8O9.P\2R,BER,/)M)P6+=2OI9D96NK7=01$MI);35YOD)(6"
M                   K"3RDS7\EO\89_3)IZZ^2E.%73SA2*^Y(VR*1$<-2
M$I:DI49[65Z]Q)].NA*"G\KXIJ./KVOXUGL%:^GOD^T56PJ%:S*9C.2OM/2F
M'ZQSJI##AM.'M+HTKKX&I*POOC"ASG&,7*@SV^9R:? D.L5ETAM;<I^L1H4<
MYFXS)4DBU)Q:>A]-34K51A-  !%.0^1,5XQQF7D^5SV8D=AMQ42*MUMN1-D(
M0I:8T9+BD]QYS31*2_T].H#E#/\ F KK(L7]0.$L1[+$9E$K&(MQ9M.R6L)O
MWYB79<R?%90ZI"SCJ2C<G3=L(M_;61J"=<!4M3=9'D;&*..Y'PA)JB;N[2XA
M)2QDN83ICC]A8(2\V1NM]K8RKR]HC(DH(R+<8=,0($&JA,5M9%9A5T5"6HL2
M,VEEEIM!:)0A"")*4D7@1$ R  !%^1<)C\BX7<89*L9M2S;,]GXA6/*CR6E$
M9*29*29:IU(MZ#Z+3JD^A@*>P!,2^H)/I8YNHFG;FGJ6V(3K32RK+NAA[([$
MZ*XDOH7FC)LG$;DJ;<T4CY$A=&"XN]A6)U>+/7,[(%5;1L(MK9:')KK9+4:"
M=6VE!*-"3)LE::F22U,SU,!(0
M
M:NZR&FQ\H*;>?'A/6LI%;5-R74L^]3WDK6U';-7BXLD*VI+J>@#F*K=SOU!5
MG)F-9'8HQ'DO&[VLG8SA<I+<AJD=IR:?C2%/MMH7*8G.DK<YHI*2ZH+30C#)
MS^3FO+-;5X1S?BU7QQ@<62FTS"VL;Z$\FP8K"-9LUR6EI=0A:S0M;SBDFVCI
MU5XA9?IFM+ZWX@J)-W,DV<=M^;&H+BP0IN;/I(\IQN!*?2HB5N<82@]RBU4G
M11ZZZF%N@    /-]AB2T;,EI#S*M-S;B26D]#U+4CU+H9:@/0
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MD]OSN:I+<DU;@[6;42FTJ21I29$9),M#(C+P,O8 ^@    #0M=?;\H
M
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M%_?P&9B+*OQ&QG)7CT66SIVG&XC;3>[MFG<A+JUI(]3T 6@
M
M                             *JLN?,5J^3"XC?JKES-7GX:(,9F&2VI
M,*8VI;D]MWN$GW:/L6E]2]JB4DR2E0# Y6X47?6Q<H\<2O@?-=43:ZRW>=><
MAS&&$&DZZ6R:S1[L\DS)1H22DJT7XZZA&:?BVGYTMI>7\V</LXO;QV8L-EQ5
MJXJ9/6V6LDI**YQIMV,A:4(9[ZEFM*?FDG0@'0<&%#K(4>NKH[<2OB-(CQ(K
M"$M,M,M))*$(0DB)*4D1$1$6A$ ]P
M          !\.MDZVMHS4DEI-)J0HTJ(C+34E%H9'^$@'(-?C5CQ/D=GCGJ%
MM)E_QAFL"1BN.9*_927ZVHAR7W5IK[#N):VO.H-O98.$:B-.PE)21Z!O,0XU
MRKD;$FL*C\MQ\LX$AR3K7GHU>;=U/B5KQ).N<L$N$VMDC0EM<EA&KJ",B/10
M#I^+$B06$183#<:*WKVV&4);;3J9F>B4D1%J9Z@/8
M
M                       :)_,\7C9;%P219M,Y=.A+LX=6YN2Z]$:7VUK;
M,RVJ-)D>J25NT(STT(S <LY/B[Z,Q3QURI:MUO(LV0=EPYS>PPQ%G/OQE*4B
MNGJ;2A*G6>Z;?:/1M]I1$1)<VZAT!QB]S1*3*=Y9BT=>3++$:'&I''Y*WY#6
M[ORUN.$A*&W3-/;9VFI&GF4 L,
M         &LR*X/'Z&RO4P)=JJNC.RBK:ULGYL@V4&OM,-F:=SBM-$IU+4P'
M'. V%;QI;Q.=8<YW+N"+9V=#ADPN:Y)P1%C*[[J78CC[VY"U[4S%;=R%$1H\
MID2PZDQK+./^:,:LW*A+61X>J2]52E3(BE5\U3&WN=HI"-C[)*/;W$DI!J29
M$?0!+*^NKZF#'K*J(S!K8C:68L.*VEEAII!:)0VV@B2E)%X$1: ,D
M
M                                   5AS%F^38\>*X?@YQ6,SSFS555
MUG8H4Y#@,L1W)4J2IM)I[KB&VS)IHU)):S+4]",C"G<XP[D$\MQ'C[DS+2R1
MO(Y$E[ N1H%?'J;['<CKHYRB)348TM/1GVVUI-.GF^:K31*P%D8_P]EU_E%;
MEG.EY5Y>_CC1MXO3P:THM='E+6VM=D\EY;JERS[24HTT0UYC06JN@72
M                                      "+YWR)B'&M0W=9A8E!BR'D
M1(3*&W)$J5*=^8S'892MQUQ6GS4)/Y3T+J H=KU!RHV7VN<44^7EW$I'&AY9
MC)5[D;(</E)1M1*.&II#[T1_0U/;B4:3U-!Z)-(#ZXNAL9WS9?\ *'$KSU5P
MW90VF,I8F0'6(.36[B7^Y(B,2";4V;)&R3T@VR[BC4G16JE .F8T:-"CM1(;
M*(\5E)-LL-))MM"$EH24I21$1%\A /4
M
M           !K[F]I<=AE8W]C&K("G6HY2ICJ&&N](<)II&Y9D6Y:U$E)?*
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M\ZMA$9)U = @
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MVU==3"X@
M                                                   <\\R<I2LC
MQK,,0XIR.7CW,&(.%8_!GHG9L)\&O7W'SA,RFS*2TXVE:FU-$HEFDDGY5]0A
MN/W/(J^6,*RNVQ@LDQ_.ZWX!=Y=CC"WJ"XI'VCE5\V7$=5W(<E@U*0\EY*D*
M:<6E"O*20'0_'''%-Q=2RL<QV7-=H7)S\ZNKYKW?:KFI!DKW2)Y24F.A1*4A
M*C49&H^H"8@                                           C^8YOB
M7']05_FELQ2TQOM12F2C-+?>?/1"=2(_'0_P$1&9]" <]98QE6;\G.Q:?)&(
M.:0(RLJX2RR*HU4]E3NH99LJB8EHS:?23B6U*4DU.;'$N)T2G:89>*<91N6'
MY^;)7DO$U].F?#N4,3JW3@Q[.QK5H<-UJ02==KAG_>HJB-UM1EKN-2C#IE*4
MH+1)$DM3/0BTZJ/4S_TF8#]
M
M    0'FS,<@P#BW),LQ6N5:9% 8;371$MK?^FDOMQR=4VV1J6EGN=U24]32D
MR 4DC/[C@[D]./Y#F>2<E4KM$Y;9LDJGW]=+,[C9QY22@,E[M&>;[ZC85N[:
M4$>I[B 7??X?QMS9C57:3F&;BM>;;L,>OX3BX\V,:R);;\.6R:'65D>A^51=
M2T47L 9/%?'%=Q/A%?@M38S;2NKEOJ8E6;B'9&DEY;QIU;0VDDI-9D1$D!,P
M                                           1;'.2>/\ +[>QH,6R
M:MN+JIU^(P8,II]YDB5M,S2A1F9$KRJ,NA*Z'U 5!S33<H3ZK*,=RBD9SGB>
M^(SBO8\P;63T"T&2V7DPW%FB>3#B6W$DTM+JCUU2:?* B'!_%N-<D4^$<L8_
M,M,(O,=MG'[_ !VN0J-2RK6(E428['A2&TE%3,;/1PHZ4)V*V*3O3N2'6X
M
M                                        BO)L[*:SCO*K'"&?>,NB
M54Q^E9V=U2I;;*E-DELR,EJU+RI,O,>A *!Q/C9Q_CVDYGX"R^SL\]DPT6-@
M=Q8OSH.2.DG63$GL/.*;9>-9+:0IK9V5]/\ 6()?#S+F'E&BI\SX:1B];B>3
MUR"E3+U,U5S6V+3CC$DC;92;,CL*2IM"%[2WI/<>TP%G\;8)6<98)18'3NN/
MU]'%3&1(>_K'5F9K<<41="-:U*5H70M=" 2H
M                   %#<@\R<:9_591P]A^>PZ[/[B),I:R8XF2S"^(K;V&
MPW/[784YJLD&EEU2R,_*1J+0!JKWA#.FLMP"7QBC'<(AX+1R8_QE$5<Q4J;.
M:*.N(<5*F%*CH)'=)UUY2MZ]VTU$>H67PCR#8\G<=5V5V\6/%M5O3(,TX"S>
M@/OUTER*M^(XKJIAU39K1KKIKIJ>FIA88
M
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M*F TB/"A1D$VRRRV6U*$)3H1$1$ S
M
M          %9<X9O-P3&JRP[:VL;L[6)29-=QWO=Y-37VNZ*4]E9D:24T\MK
MJHCTU\# 49S3@/+?&T+$<PJ>2%Y558UDM8Y70LPB,J>C.V"U5O<D6D-+;RV#
M]ZVO)-O73S%U+0POS ,JY6M;253<B8$SCR(K/<:R"NM6+&NEN;DI)+;1I:D-
MF>JE:.-]"+J>ID L0
M !67,7(UA@F)1,OQ]R%*JZ^_JH>5NNF;WN]3)FMQ9:D=M9;7D&XGYW1):F9=
M 'UR;BN;<@3X.%1)2:3C.6RIW+K6*^:;6:C=M*LCDDB-EMU/5]\E;C1Y$Z:F
M9AO\@XQX]RRDK\<R?&X%Q2U*$-UD6>PF04=+24H23:G-5)\J22>A]2\=0$CK
MZ^!4PH]95Q68-;$;2S%AQFTLL--(+1*$-H(DI21>!$6@#)
M
M                           4S)SFPY9O;S#<$D.U^!4Z95=E?(421[K)
M8M&T$:8U4HTK2MQE1D<AU:>VE/E2>[0!"<M:Y:J<)ML1Y#A)Y;XHOH#D-668
MVRVC(XL:0@R1(>KR,VI7;U2M#D56[5.\T@-_Q2F%ZA_39646?-RW&Y+*:BY?
M^EBOR7J64DD2FUN(2K5TV&W3/;T4:D^) +](M"(OD^4
M                           !%.2X>7V. 9#%X^L?AF:JANJHYA(:=(I;
M7G0V9/$I!$X:>T:E$>W=N\2 <[N\'<-\Z\+R^1,0QA%!F>1TLIS2J?DP$(NF
MT+)R/)CMK0TZ2);9H7W&M3TU]NH"4\!47(5UBN#Y]7\LV=OB%I CR[?';R%"
MLGU2#:)+[+=BE++R";>2M'F2OH7R]0'10
M
M               @G)7):,!14UU;2RLGS/(GG8^/8U 4TR])5&;[K[BWGS2V
MRRTDR-QQ9]-R>G4!ROF4=O+).2Y-C-'<4-I%?CKYWX1:D)BR[>L;\Q38;C'1
MW<@_I%1U)*4WJDS)1_2!T9Q'FEOG#I6&,8ZQC_!\. U#Q5<IAR)8SG&MI)>C
MQB-*&(*&R-MI*T;U]%%HGH M<
M         !3?(7(V1RN2*7A3 9+5)D]C'*ZM,CLFDK:8JH[A=QJ R[H4J2YH
M:3(O*TC51]?FA$Z#C&M:=M[KTNY^]0%5V+\"VQJ4;UQBCMBSHX^UV9![VE&;
MA=QV([H1]"+4C(!L_3]0\L8UE_(D3-\7B8_C%Q-8O*Y5=/3.A+MI3>RQ7%)1
M$\EE]:$O]MU">VHS(MVNI!>E?75]3#9KJN(S!KXY;6(D9M+++:===$(01)(M
M3]A ,D
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MK(> X5@#C1VU]1DVMC)4-'OC-5[:TJ)F.ZD^[-6K59K/8G:>\!T>
M
M                                     @&&<55F Y=D5[B\]^%C>2;9
M<O$DI1\.9M35]+-C^UM3J222VTZ),RU_HDD)^
M                       .0:O"\;YWY)SK%_49!D0N1H&Q.)8XU/?;@Q*
MFD)3852T&VE]QU\G%O.+0HT^5!I21*2 N;C^CSV149!Q?S)!8R:@A-HAUN6/
M&TI%[624J+9+C:FI$EHD[7E'T69DHC,]5&%FU=97TM9#IJF.B)5US#42#$:+
M:VU'803;;:2]B4I21$ RP
M
M                                                     '.?J4]R
M_?/B?WKW3O?&_P"R?#_>_P!\^[JC7X5[M]'[OMW>_>\_1]O3\?: Z,
>                                    '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>lc_fig30inoculation-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig30inoculation-4c.jpg
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M -   0 " @,! 0             &!P4( @,$ 0D! 0 " P$
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M++<E23+H9&1ZD [
M                                    &IO*7J9Y>Q[G*PX:XTP>ORB=
M&BL3(R77G&I#B'(J)#IJU<;01)W&1=0'BA^K3E3",PQ['^?>,BQ2FR5\HD*X
MAR.ZEMPUH0:U)W.I6E!K3W$DXE1)/<1'X&%L9ES+<8!SIB& 9'#B)P'.XJXU
M'<H)Q,MJ]9<(C8>,UFA3;A+:0C:@E;W"U/0C 7.
M                                              #5#U^<E_@_B!O#
M8+W;N,VD^4,DGHLJZ(:7I*B_QE&TT9>U*S :E9MR=Q/BK_#&5<.6,B5EG'D=
MB#>(>ANPTS6FE^8<5O66FCCCLE"T]3VN?0 WO]2,BDSKTMY==05IE4UC1LW5
M<_IJ2D(4U,867N/X4F RWI9MYEYZ>^/ITY1KD)JT1-RCU,VX+BXK>I_XC20%
MO@
M                      /SUY.K^3;/UU6<3B.V@TN:*J(YQY]H@G(R64UK
M9NI-)LR.II\/LP&)YLK>;^/<KP#D;U0R(7(.!5-F34:OHGD0FVIBD]\C6V42
M-O49,;]%$:5DC8I22,!;WK\?8=X?PW.Z=[;-KLB@S*F8DC)1(D1'WDF7@9:F
MVVK^0!MQ6RCG5T2:I.Q4EEMXT?T3<02M/Y-0'J
M                                            &OF=>G.QY&]0&.\J
M95<Q)>$XPRVW78JJ,M:UN-)6X2G%J4:#UD+)Q7P=4(2GZ0$WY-X0PGD+ ;_#
M6ZBNJY5M$6S#LF83*7(TI.BV'2V)2HR0XE)J22BW%J6O4!KURKCV4\(>D!?$
M5Q;,Y)DEU/8QK%E0FG&W769TE,CL;%J4I2DI2\A)ETT-"?TAM#Q3AA<><;8M
MA)J2MZDK8T22XCZJY*6R-Y1?0IPU*(!,
M                                                     &J?*7I<
MY*ROFJPYAP#D%G$K"5%CQ&-D9QR0VAJ,AAPC62]IDO;KX ,)(]&O(V?V]4OG
M#EN7EF,53WF$TS+#C7=,]-R=ZG22WN(MIK)"E;>A&7B R'J]JRY"RCB'@"F0
M1KN;?YO91VM"*-4US9LJ<4DM-$]M;^PO::- &VR4I0DD((DI26B4ET(B+V$
M^@
M          ,'<X=BV0VU->WE3&L+;'G7)%)*D()Q<1YTDDIQK7H2O@3\6FI:
M%H S@
M                             #!MX=B[>5NYRBJC_BYZ(FM<N#3K)\FE
M6\F24>NU&XM3)/B8#.
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M16%RED[.)-@2$-2(ZW6&VB<:6APG$J4GX3+:1>)F%\@
M
M
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MU)1$?4@%D\.R)$OB/ 9<MU;\I_'*=U]]U1K<<<7!94I2E*U,U&9ZF9@)J
M
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M)DHB474C+4OT& ^@
M                             ",<D_EUEW]BV7W1P!C>%?R;X\_AFE^X
M,@)R X//,QV7)$AQ+4=I)N.NN&24(0DM5*4H]"(B(M3,P%<?Z0W!/_S(QO\
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M"LT3ZM4>%%5(6IM9,H6;J5))"V5I3H2DK)2M= %\
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M#A"9EV*IPRE;GWB*JIE36)UK*>*I<4_(<**:VFV6RV(0G>:C,U*5TV@-L@
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M6-?*;2]%ELO,J7VDN-N)6DW"_5(R,RW?0 ](
M"$YUR96\?F;MO2W,JM;93(D6E?#\S#92I9MDEQS>G16NG33P,@&9Q;)OQ1$>
ME_)K.E[+G:[%Q&\H\OX25N0G>O5/737W@,Z      *XX>,SBYI]&87OWD!8X
M   *]@*4?.%\DS/:6+U.A?\ Z^P_UP%A                     *>XT_.[
MF[]LQO\ <C0"X0       8Z]OZ3&*F3>Y'8QZJEA)WRI\UU###:3,B+<M9D1
M:F9$7O/H0##81R7@/)$61,P7(H-\S$42)90W26XR:M=O<;/1:25H>TU)ZZ=
M'+-N1\$XW@L66=7\.AB25FU%5,=)"GEIT-1-H+52]NI;MJ3T]H#J>Y0XZ8Q%
MK/7<HK4X6\I*&KWS+9PS6M6PD]PCT)6[X33XD?0P'@QKFOB3,KAC'L5S.IM[
MR22U1X$.4VZ^X32#<6:4I/4]J4FH_H(!/
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M$\MA8?R#Y7.,2L4/^3SVN816RXCK#9N);LX1*-O:Z1&EMV/TW:$HOBZ!<
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MUL6/;S$6%FVV294UIGRR'7"\5$UO<V$?NW& ]@  K?GS\H,J_9F_O#0"R
M     5OP]_FN:?QA>_>0%D    KV A1<WWJS(]IXQ4Z'[/\ /[#_ %@%A
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MTZ& Z^2\SR:@Y=X?QFHG>6H<FE7J+^-VFW/,-5];YEDMZTJ4C:HC/X#+7V]
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MPX)HK[&^,JJJR"-(KWD/3G:ZIFR#F2J^K?F/.P8;SZE*-:V(ZFVC^(]--OL
M6.         C')/Y=9=_8ME]T< 8WA7\F^//X9I?N#("<@        *XSW@7
MB/DZU9O,WQEFRN&6BCE-0])ANN,)/4FW5176NZ@OZ+FX@&7D\6<?RI&+25T;
M#2\)1(:Q9,=3D9N"W+8*,ZEMME:$F2FR(OB(]--2T/J @9>D7T[H;[+>%H:9
MZGVVK"S;1J9$1GHB41:F1%J?B E.9\&<5\@(K"RK'T2I%-'*%6S6)$J%,:BI
M+:3/F8KK3JF]-?@6LRZF?B9@)3BF(XU@U%%QG$:QBHH81**-"C)VH2:S-2E&
M9ZFI2C/52E&9F?B8")YSP1Q5R/<M9%EM 4F\;9\HN?&E2X#ST;77LOJAO,]U
M'^Q<W (OR!Q33XIQ988MQIQW59!C\VS39W^%R''&DRXSIEYE4%2G"2S)3L;4
MQH:4)V_"6[:0"G<6XMI,JSS!U<?<59!@]5C%TQD.297F9/)GJ37-.)CUL,Y<
MF4ZXTM;FJ^VI+9;25U,!N@                   "N\X_,?B_\ ;[;]T20%
MB    K?GS\H,J_9F_O#0"R        5QP\1E%S37_P#W"]^\@+'  '5)C,S(
MST22G?'D(4TZC4TZH61I46I&1EJ1^P!KO7< <0IY8LZ!.-Z5<*DK;.,SYZ?J
MF6],EMK<W>8W'JEELMIGMZ>'4]0V-       !K[SE>8C;YG3<>9ER5^$,2=B
MJE7=/7J>B3)KCBS)AN99(0;<.,LD+(D+=;4^?PI]@!Q3A?I*RV'+K./L.HK#
MY8VR<IJUIG#G>7DI,V7=;=@GW&G"2>UW525>_4!D;WTRXA!EKRCAYU?&F?,Z
M+C6%*:D5KYH,S)F;7:^7=9/4]4I0D_;KTT 7:QWB9;*2:3D;4]TV]=F_3XMN
MO737P =@       *>XT_.[F[]LQO]R- +A  '@N*6KOX2JZWC(E0U&2NVO4M
M%%X*2I)D:3+7Q(Q5MTTVUZ;QF$Q.'"DQ^FQR(<*EB(B1U*WK2G52E*\-5*49
MJ/\ E,8Z=%-48I&()G+)"]  @7*_&+')U+7Q6+:1CV24-@S=8WD,-"'7H5A&
M)24K-IS1+K:DK4EQI1[5%X@(OC'"^70LBM,]S3/G,EY#=J'J+'+1%8Q7P:AA
M_P"-3C4)#CB7'3<)*U+6OJ1;/J@(_GOI\Y%Y!9Q!%URD3Z,8B,'+KYM#'FUM
ME<,FYNGR8WF6D+/:I!(:7N2@T;BZJ4 DS_$6;Y/A]MC'(_(CUU/??BS<?O*:
MM:H)57*AJ-:'$DR^\3NJMNI+T+;J7MU(/-0\-9Q-RZAROEK/RS+\)J<D8[5P
MZEFFBHG/-FR<R23;KQNN$A1]M/PI0?4O$P$KY;XQC<J8U&I_F;U'=U%A%O,=
MO8R$O.P;6 9FR^32S)+A$2E)4A1EJ1^)'U 02!P?R+:<B89R3R)R*B[L,,<F
M^3J(-0BO@J:GQ51EGT?6LG5&9*6M6XM")*4IZF851C,JEQRNR?&\(YP:X\XW
MJI\Y%KB%] C-9'1;GE+D,5[K[Q*2VZ:E''7VG-IJ^'<YJ MOT>4TRC]/>*QI
MD5Z&4A5A.B,22T>\G,GOO1U+_P =I2%E]!D O0                !P>0MQ
MEQMMPVEK2:4NI(C4@S+0E$2B,M2\>I *8C4>;GR3)P]?(MTJOBTT6X2X;%7W
M5//RWV%(4?D]-FUDM"TUU,^H"Z@   5Q_P ?O_N?_P )@+'      %;N_G[%
M_@^3^\V %D    KN3^>U;_"4_P#>4,!8@  TNXYXYX,SVFDWGJ)L&IO-)SYS
M>60+Z\D5K\!],EPFV&8J);*41^UVU,J21I4D]4GIT(-H.,<9X]Q'$V*7B\HY
M8DV\\XP4.8NQ9[SBS4[H\XZ\HSW>);^@"8@       C')/Y=9=_8ME]T< 8W
MA7\F^//X9I?N#("<@        *_S'G'B3CZZ8QS,LOKZ>[D$E:84APS<0ASZ
MJG=A*)I)^Q3FTC 3R/(CRX[4N(ZA^*^A+K#[2B6VMM9;DJ2I.I&1D>I&0#L
M                          !7><?F/Q?^WVW[HD@+$   !6_/GY095^S-
M_>&@%D      #"99C2,MI'J1RTLJ=#RD+.?22UP)J>VHE:(>;^))'IHK3Q(!
M3_!W',>NM;Z_1DV1R5U.17->5=+M7GX$DFEFSWI+"BVNO*(]ZG%=361& OL
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MUM*/=H6NJ7"5[-#+V@+L_P!/7T__ .^;C_U:Y_VP!_IZ^G__ 'S<?^K7/^V
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MP\V7R6FMQ%<'),P80PU4,V,N>VN-7PFXVYI"4,MJ=-*''/B-1J5O,R ;=
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MVTN^4F4M;6,2C(MANMS99[C+Q)"C=223_E/Z.7'Y'7..>+6FN673*]AU&(
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M*/B6L_8D@%(9USQ"GX1DL'^[[/(_F:J<SYB1C<MMEON1G$[UK4>B4IUU4?N
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MJE/I(I/>EU$E;;"ST)7P)5O6@_!U2_H ;;    K?GS\H,J_9F_O#0"R
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M:MLV(AZ;"><FRRVZEUV)-I)I+^0_IHC\=KB8YXK:;8]O^2>I>HZ;$
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MGB^5V'(6=9=)SG/YL%%.U;/PV*R/$K&W>^;$>+&,T)WN:+<4:C,S(O#KJ%J
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M9-1E>)*[:DF@TJ3X(?3^L0"],X_,?B_]OMOW1) 6(   "M^?/R@RK]F;^\-
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M"X_39+E3N!N/YDY]R5+>IXZWI#ZU.N+49'U4I1F9G^D!:8
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M6XR,]5$9@+7       !&.2?RZR[^Q;+[HX QO"OY-\>?PS2_<&0$Y
M  0[,>)^-.0I46=FV*UM[.AD28TJ;&0Z\E!&:MF\RW&C4S/89[?H 2F#!A5D
M-BNK8S4.OBMI9BQ(Z$M,M-(+1*$(01)2DB+0B(M $0R;ASBO,K^/E&58A5V^
M01=A-SY<9#CBB;^H3FI:.$G3X2<)1%[ $0Y/X]GUN#0,>XTPNBO\5BS79%[Q
M_8--,,V$62I;CGE'G?LV)"'5]U"E:)U]I:$1A7_''%%E8\DXADD'C*/Q1@6#
M%936X+CT5^RMK:SC^4(W"BJ<VM,(-1I6XYJ9Z$1;?JAM,
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M0A]+Z6N,*.ZKK%EVZETU++*RHL3G6LF300):%*6AV/#69D1H4HS3N4HB 76
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MPK^3?'G\,TOW!D!.0                                    &I%1_\
MN2]3S^0*_P HXGX66<6KUZL3LD6K5;I>Q1-+;W$I)F7V31^#A@-MP%=YQ^8_
M%_[?;?NB2 L0   &OOJCL^3:W#[EZFCTZ^-D5[2[R1*)]5JE_P R1&3!)<2W
MMT[6FY)G];Z %H<=/\H/ULM7*<:GC6I/Z04T/?[)Q]A=7.^XZ>[=KX'X>P!,
M@'6Z^RSL[SB6^XHFV]ZB3N6KP26OB9^X1,Q',1]MNRR-;,B0F;0_*K!1I90X
MG2:RUIH:]"ZMKU\/_M&G$6VXF<TZ;?\ N_T3R2,DI26B2(B,S/ITZGU,;J'T
M!4/I_P#\RY%_C_)OO8"W@   5/5J4?J4R=)F>TL+HNGLZ6EK_KF M@
M  !I7ZF3Q2+FW)+_ "BVSYB5@*V>)9%DC?7IEI1*\^W'-9&VF>ITV#;,OM-N
MFAZ: )KP;:4N1<W6]]QW)*=B2\.K(^<6,-1KKI.6(<1V#2OZBWT1"<)Y39Z=
M4DKXM0&SX        "GN-/SNYN_;,;_<C0"X0
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MN:MNJ3MVDHC3MZF>NO3J%I         *>XT_.[F[]LQO]R- +A
M                        'DM+.!25DVYM9"(E77,.RYLIP]$-1V$&XXM1
M^Y*4F9@-7_2]63^4\WS#U29,PMO\0/.4F"0WRU.+20UDVI:2U-)*6:";,TZ?
M&ET_!8#:L!7<;\]K+^$H'[RF +$  '%9*-"B0>U9D9)49:D1^P].FH"IRXZY
M1_%7XP/.:SYOY#Y29?(5=KRO?\Q]7S^N_=[==-/8 MDM2(B4>I^T_#J ^@
M           #0[$<UL^/ZZ1CV+^HS!(F/IF2I,&K55FMF&F4^MY3,?[75+1+
M6HTH-2B3KH1Z -L.&,BGY3@[%M9995YK*5(D-JO*-@XL-1-KT)LD&I7Q(_6,
M!8(       (QR3^767?V+9?=' &-X5_)OCS^&:7[@R G(
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MTK[R38:0K<1)-/CIH9_1H%C         *>XT_.[F[]LQO]R- +A
M                      !UOLMR6'([Q;F7D*;<21FG5*RT,M2T,NA^P!1<
M7B?!4\MR\=*%*^31L?AV;$4[.Q-*9CDZ2TIS4Y.IF:&T)T,].GAU,!%O5ID=
MMELW%/31AD@VLFY"DH=O9#?4X=!&6:W7%D1D>BS;6KH?Q(:6D_K$ V,QG':G
M$<>J\7HF"C4U/%9@P62ZFEEA!(3J?M49%JI7M/J R3S1/,N,FI2"<2:#4VHT
M+(E%IJE1=2/W&0"MVN$<>:L?FZ;_ "8[3MHCKF'>33>7':6;B65+WZFV2E*5
MM\-3/W@++                     :U3_4!Z2C5)B/1(\Z49N,N0TXK.<6\
MYJ:5-EO@$E1J/IU5H8"9^F*IN*CBB*S9U+V/P)-C9S<>H9:";F0:67,<=AL2
M"\=Z6U?K&:B29$?AH N(       $8Y)_+K+O[%LONC@#&\*_DWQY_#-+]P9
M3D                                  :7>I+E9!YMD'&?&4]NUY)SBL
MJL-8:@NI7Y!:ILPYA2%)U[:R:=)'CJC<:CTV@-H>+./*CBK *+ J3142GC):
M=D:;52)*S-;[ZBU/0W'%*7IKTUT+H0"8        I#G&U?E(\C$E)545B=U^
MR9[66E/;3:5(->B#09'\.IZ$?CUT'F?RU[WF*TS/3SB,\_#DLJF'$M%-JZ!V
MPN&'&KJR=WON2%+4^MEHMK6\EF>FFJM/H&_^+TVIKZK1]5OGCP1:>*?CKL
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MW*_$HKO54.AB.=LB3["WFVE!F1=>V:O]L,!M.
M"'\AXUFV3UL2)@V:NX1/9?[LF>S71+4WV=BD]HVY?PI^(R5N3UZ: -6,GY'R
MS%[NRHG_ %%W5D[1K-G()M/@,"QA5SB/KIDOQV5(2I'ZY)-1IZD?4M &T?%*
MI[^#5LZ?FB>0#GDJ7&RA$6/ 1(CO'JVDF8OP%L+X3_6U\>H":        C')
M/Y=9=_8ME]T< 8WA7\F^//X9I?N#("<@
M    ,7DF0TV)T%EDN0RT0*2JCN2YTMSP;::2:C,B+4S/V)274SZ%U ?EKZ=/
M3YR!GO*M#FD%QZJQ:).8R=%Q8N$BQD5S<YPFW$MH,U&M]3"T;C^'Q5U3IN#]
M7@   :[<DX1:M<I8370>0,O@5V<V=LBTA1+;ML,-Q:U^<VB(GM'VDDXTDM-3
M^'4@%\4-3\BIX5/YZ79>3:)KS]D[YB8]I^N\[HG<H_:>@#(@(_9R)MO(L<9A
M><JI"&&W6KQ+1*9U4LC-+9F?56G0_P"4:>RUMDVUQFLX^[P2KKU-1D1N ,V7
MT7+5!CH?D[4I<=-$AE.JS21:_H&U6N/?YBY1D@     87*K>WHZ5ZRHZ&3DM
MBVI"6ZF$]&C/N$M1)4HERW66RVD>X]5_H 0#CGF2]Y#N)$%KCRWJ*JOG3:BV
MN9LNK6Q%L*[4G65-LRENK^,B;)3:%)U/7734P%L@ #JE1F)L9Z')3OC2&U-/
M(U,MR'"-*BU(R,M2/V -9*K@;B?^_>[Q;Y KY#78Q3VT.%Y^P-#<Z186#3KQ
M:R==5(8:2>O3X?I/4EM "        %89WGG+6.WQUV&\4/YC2DRVX5RU>UM8
MDW5:[V^S*/?\.A?%X'J CO&^/\F9)RW9<P\AXXSA33>/HQ6FQM$YBTE.M'-\
MZ[)DOQB[9:*226D),]"4KP\5!>(        "GN-/SNYN_;,;_<C0"X0
M                           'YR\Y<[8YSARFUQ1@MB==CV4/5>*9!DTM
M*4-.1XEDY(,XADI1[%N.)(C62=^TBZ)/4!^A5'25F-TM?CU+'3$IZJ,U"@14
M?5;8CH)M"2U]R2(!D                         &IW%7*=/Z?L-_NGY(Q
MZ]8S.FES]DBOJI-@UD/FI;KS<N*^R2TK6\E:243JTFE1;3TTT(+6]-^*WF*<
M:)9OJTZ%ZVM+2[AXT9D?RF%9RW)#$/1.A$:$*(U)(BVFHR,M2,!;8
M(QR3^767?V+9?=' &-X5_)OCS^&:7[@R G(
M       #43ENPG>ICE]CT]XS(<1QGB#S=ERC;1U&27GV5_9UZ%IZ;B46W37^
MLW*V_8=0N_'X$*IYALZFL81$K(&(TT6%$922&F6&9D]"&T)+H24I(B(B 68
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MQ*H<?-H6(Q6S2EIJ1.=*&R\XXI2B01-)<-&F[:9)49'N ?HV
M             C&?81"Y!QUS'IME9TY*=;D1[2CEJ@6$=]D]R%M/)(]#(_8I
M)E] "C\GON9?3_".SN<[QS.<.:2I3</+GFL<OU(;+7M1Y;1+9DN:%_MC6Y1@
M+?XDY*B<M8-7YQ"J9U*Q/-Q)0;-!(>(VE;34DTF9+;5XH7[2]A )P
M",<D_EUEW]BV7W1P!C>%?R;X\_AFE^X,@)R
M      "C/4US)8<:XM$QG"FSG<L9J[\IQ&N9(EO(<>,FURC2?31K<1(W=#<-
M.NJ27H$AX!X<K^%./HN-H<*9D<Q1S\FMS,U+EV3Q$;A[E?$:$?4;U]A;C^)2
MM0]\ C_OQOCTZ?A>I^_V "PP   4QRC;U<?D_C>Q=E([.+3+.7=(3JI;34ZI
MD16=$EU4I3CB/A+J1'N/H-#?^0TZ;=-IX^[+**S*PX#DG)EP[QB0:<6F0UH>
MII<9.]U:U&6]9JUZ&733J1E[]1E29W8O$_1,?;,(Y) PPQ%9;C1FDLQVDDAI
MIM)(0E)="(B+0B(AN5K%8Q')#L$C7GU<'R(7%F4'2_)/P/\ +FOFOG?-_->_
MYM']1VOL=NFSZ_777Z %OX5_>'Y&3_>-\E^9=[_)/P_YKL=C:7]9YOXM^[7Z
MO30!)P     !3_I]_P RY&_Y0,G^]D N    %2U7_.7RC^"J+]YVH"V@
M   <7'$--K==42&T$:EK/H1)26IF?Z &OUT>:TV?3.:N$H%=R5BF7UL*OR&F
MAV<:*_WZM3GEI<.6LULK23;ZTN-&9'KH9:Z_"&7XTQ;D7(.3+'FCDRGC8I.5
M2)Q?'\4C2T6+S,%4LIKS\N0T1-J=6XE!(2WT2DNO7J878         I[C3\[
MN;OVS&_W(T N$                               &GLG_P#=KSQY$O\
M*> ^*)6Z2?C&NL@+4B21_5<:1II^L7;(_8^0"_HWY[67\)0/WE, 6(
M                   C.>XW>99CKM)C^2RL3F/NM&[<5[33LM,=*M7&VC=U
M)"EET[FAFGV (;AWIPXIQ">5\[5N9/ENI*<R?*'UW5FM:?!9.2=R4*^EI" %
ML         (QR3^767?V+9?=' &-X5_)OCS^&:7[@R G(
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MID!<        *?\ 3[_F7(W_ "@9/][(!<    *EJO\ G+Y1_!5%^\[4!;0
M      /AD2B-*BU2?0R/J1D8#5GE3"O3=QE8NW==E[W$V;OFDT,X?+6W)DK,
M_LT+IV4O(=09J^J4=)'KX@)1Z>,SYPR:?:Q.0:MZ1@L5DE4&8VM:G'K>P>W(
M+1VM2\X24&DUJ)PDH+H73XOA"_P        %/<:?G=S=^V8W^Y&@%P@
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MK36]9BM9B8G/-ER0KDK\WN%?[4O?W#+&ZQ6T   "G_5-^0&<?L;/WID!<
M     *?]/O\ F7(W_*!D_P![(!<    *#I,]PR1ZG+]ABZC+<EXY5T<8R4>Q
MRSA3[!U^.E>FTUI2\W[>IGM+51&0WK=COKK]2:ST_P >'-*_!HH      !P>
M:2^RXPHS)+B5(4:3VJ(E%IT,O P%=\></\0<;2GHV$T<"-D#1$Y.G.*\Y;GW
M]3WNR'U./D3AZG]8DG[" 6.          *>XT_.[F[]LQO\ <C0"X0
M                      $9Y"SN@XSPVXSC)GNS44["GW23IW'7#,DM,MD>
MA&MU9I;07O/KT 43Z7,$O\@L+GU*\F,Z9UGA;J*$LC--90'IV$-$9%IW4)1H
M?CVR2>NY:P&S:DDHC2HB-)EH9'U(R,!X2HZ0M"*MBEH>I:,-]#]_U0'O
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MU3N+IJ7@ L?A@TJX>X^4A.Q!XU3&E&IJVEY!G0M3\= $X
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MVA%HHM=="[&W\W2VB:],]4QCV)RW<'DF(       #5CG9J^XTY-/E^NY(QK
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MA/H6I;0V^2HE))1>!EJ7Z# ?0%/<:?G=S=^V8W^Y&@%P@
M             -/\J6OU7\[-X#$4;O!O%TE,O*7T']A;W:3-*(I&7UD(T6WT
M_5)T]?B;,!M\A"&T);;22&T$24I26A$1="(B+P(@'(
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M'0!D@$8Y)_+K+O[%LONC@#&\*_DWQY_#-+]P9 3D
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M8W>.Q!'H1?S]1?N[K;NQ%[3.$KR&L@  %2U7_.7RC^"J+]YVH"V@
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M"%-H%Q8+1K4A"GZAMQPR-9J5\2C,^I@+Y
M!0'JCY9NL0HJSC;CS=(Y;Y!=^5X^RPK1V(PXHFWIBC+ZFTCVMK,R)*M5^#:@
M$\X2XFI>%N.ZO!ZC:Z^PGS%O8$G:J98O$7??/VZ&9$E!'U2A*4]= %A@
M                     "G9E;7'ZE:AHX;!MG@]HHT]I&F[YO Z^'TB1<.U
M.W9M+9IIMTZ:>[00/H#4/@^KYTR##%Y%Q3?TF(\56UA/E8;C-K"<M9,*O5*<
M2:>ZA3.Q*W2<<2T9KV$K:1Z="#9C!H6;0*!N/R!:0KC(R=<-V;61E0HYM&K[
M-)-K6L]2+Q/4!)        1CDG\NLN_L6R^Z. ,;PK^3?'G\,TOW!D!.0
M                        :>Y,XYZM>;TX+"6;O _&,I,G)I39_87-VDS2
MF,E1?6;3HI&J?U.XK=\;1@-P&VVV6T,LH2VTVDD-MH(DI2E):$1$70B(@'(
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M3X)5MZ^\!90       (QR3^767?V+9?=' &-X5_)OCS^&:7[@R G(
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MK[C:$,-&ESX=NNO@9@+&         4]QI^=W-W[9C?[D: 7"
M              -0>1Y#_JCYN8X7IW5GQ#QZ^BQY#G,J,D3K)!J2W )2?Z)D
MIL^I=>ZKQ;1J&W4>/'B1VHL5I#$5A"6F&&DDAM#:"VI2E*="(B(M"(@'8
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M+P 2#T[XSD^+<;-1<K@E3SI]E96T3'$K2ZBHA6,MR0Q!2I'PZ-)7X%]77;[
M%K        C')/Y=9=_8ME]T< 8WA7\F^//X9I?N#("<@
M         -?_ %B\J7G%/#LFQQ2T9J\IM)3-?!>6I'FDM+,U/KC(41[EI26A
MJT^ E;NA[0&N7_T[V+;(\US',+^&[:.PJ^- @Y',4XZJ,MQU2UQ6369I^T3\
M:]O5.A>!+/4/T-  $;/(I5S'4[B#;4MR+8>1L2F=QE*$-_UIHZ$9F6I:?]!#
M2]>=D?\ BQ.+8G/#WIQYO=$Q^+&DV<AYYZ:BT=0\Y&EK)YALT%T)M!EHDO\
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MD9J+KIIT 2,       $8Y)_+K+O[%LONC@#&\*_DWQY_#-+]P9 3D
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MIYXNJ4LSR4_)XQ3S_.&[6=]PW+"P1VE_^;]G;3VB-))02M5*^+PT);5@@
M   'Q2DH2:UF24)(S4HST(B+Q,S 5/E.?<M_,&9'%F#56:X;*C-/P\@+(8\-
M#REZ[B0CLND:2T+11*T,!C>.,1Y+N.4;'F+E"NK\<G%1IQ:CQNLE'8*1$5+*
M:\_)D[$)4LW$I2@D%H2=>A'U,+K         4]QI^=W-W[9C?[D: 7"
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M8 >&TI:B[:CLW$%B>S%DLSHR)+:74MRHJR<9>22B/1;:R)25%U(P'N
M    $8Y)_+K+O[%LONC@#&\*_DWQY_#-+]P9 3D
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MR).])DM2UO.$:=A*+;IXF1^SJ%C         *>XT_.[F[]LQO]R- +A
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M1*T!R7:                    4]QI^=W-W[9C?[D: 7"
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MBQHQ;8[*&B]R$DG_ %"'/M:;<YRZ5:5KRC#M&+, 515_\Y/)_P"#*/\ >=H
MM<                    !3W&GYW<W?MF-_N1H!<(
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M+R/RSL(^7]GRWEM"[?9V[-FG]';TT&(]            (QR3^767?V+9?='
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M8<6<T\@\^U,'D/'K:R6FT@VV:HR%F0F-Y G.ZI4GNZ(T6V3B64>"C^%)::D
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MT 2<                          4]QI^=W-W[9C?[D: 7"
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M:_%]'7/'!&8SC/%?W>F_+O,>5+YCV>YY+N%M[VS7M]W333=\.[;].@P2]0
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MQ%Q5(Y.Y=II&$T3M54W%([60W*V*MJ,I=+&?5VDFV>TC<6I9D7351^\!:_\
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M1])MN+3^@P&2   !C<@Q^ERJFF8]D4)NQI+!OLS83Y;FG6]2/:HBT]I ,D
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MFA>("S@   5K)H+I?J!J\I1"6>.LX=85KMCJGMIFO6D)Y#)EKNW&AM:O#3H
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MTA:5+09_TDD>I?R@.\   '0U.A/R'8K$EIR4QIWV$+2IQ&OAN21ZE_* [P
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M0TMB0VEUEPMJVW")25$?L,CZ& ^,,,1FD,1FD,L-EHAIM)(0DO<1%H1 .P
M<'669".V^VEUO77:M)*+4OH,!TMUU>TLG6HC*'$]4K2VE*B/Z#(@'I   !UO
M1V)!)3(:0ZE"DN()Q)*)*T'JE1:^!E[# =@   //)@09JFE3(K4A3"M[)O-I
M<-"O>G<1Z'T]@#T    Q]Q14F0Q2@W]9%M81*)91IS#<EK<70CV.I46O7QT
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M)&HS\.FIA9X"LN><#O>1L!+&\=-@K(K6IGZREFTWV8$YJ0[\1)4>NU!Z%IU
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M;4KV3=,NMR6[)R9Y'>;R9#2'DE]4M-NFWH VW
M
M
M                                   &%R[*:C"<;LLKOEK;IZIHY$M;
M2#=62",D]$IZGU,!!(/J%X\?F0HELFVQM-DM#5=,R"IFUD-]QPM4I3(>;)HM
MQ=2-:B(_> M4          >*XM85%43[RR6;==61GILMQ*36:68Z#<69)3J9
MF24GT(!PH;JOR2CK,BJ5J=JK>*Q/@N*2;:E1Y3:76U&E6AD9I41Z& \%3F5!
M=9-D.(U[ZW+S%O)?.65-K0EOYDR;[&U:B)*]R$F9[3/3V@,^  'T@
M *NL><\;K6+^0]7SEHQ[(HN*2B0EK5R7--HD.-ZN%]F7=+7717T )IF5_/QC
M&YU[64DO(YT0FS9IJ[:<I\UN);/9NZ?"2C6KZ",!F6'5/,-/+;4RIQ"5J:<T
MWH-1:FE6AF6I>!Z& [     &(RO(8F(XQ=95/:<>A4<&39266"2;JVHC2GE)
M02C26XR3H6ID0#MQZZCY'0560Q$+:B6T.//8;>(B<2W*:2ZE*R(S+<1*ZZ&
M[[2RB4]9-MYZC1!@,.RY*TI-1I:80;BS)):F>A$?0@$7F\@DO&,<RO%J.?DU
M;DCT$F$P4)0ZQ"GH-PI;J732:6T)TW%X]2\.ID$S
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M\ZX)2\>H?JL?S6#=HOZ8Y+\B&X[5,,OL2$H?6X:7M5FE2R/J7TFK4-A@
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M<#2HB-*J.&1D?@9&T6H"F\%Y6R.IXWXJ@\:X=2Q9F<6%Y"33=Z2Q!BKA/O\
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MV124.K,F#/[0G.SMU2DR(U:ZZ!L:VXAUM+K9[FUD2DJ]Y&6I& Y
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MS&4S6ZEQ+BDMI39-I:?WH+HK5*"TU\ $@
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M$8#N
M                                                          %*
M<"?^T7,'U?\ VUF_UW^??U+/]9_W'_>_^QU 76 \%[_Z$LOV5_Q\/ZM0"NO3
M7^1>#_5_]'E]3ZO]:OP 6H
(       __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>lc_fig31backbone-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig31backbone-4c.jpg
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M;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4
M !#\X1^)R+?)>"\T8C0'6'?K_^X #D%D;V)E &3      ?_; (0 ! ,# P,#
M! ,#! 8$ P0&!P4$! 4'" 8&!P8&" H("0D)"0@*"@P,# P,"@P,#0T,#!$1
M$1$1%!04%!04%!04% $$!04(!P@/"@H/% X.#A04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@!;P.V P$1
M  (1 0,1 ?_$ ,D  0 # 0 # 0$            &!P@% @,$ 0D! 0 # 0$
M               ! P0"!1    8! P(" PD("PL(" 8#  $" P0%!A$2!R$3
M,0A!(A11,B.S%76U=C=ALM.T-188.'%"<R1TU)4V5A=W@=%28C,T5(24EE>A
M<I)#4Y-56)&Q@M+B)675X:/#Q$6%)K8G$0$  @(  P0'!P,%         0(1
M R$Q!$%1D1)A<:'1(A0%@;'!X4*2$U)B%3*"LB,S_]H # ,!  (1 Q$ /P#;
MN;YOCG'>-R\LRN4<.EAFVEYU*%.K-3SB6T)2A!&I1FI1>!>'7P(!]>,Y)3YA
M05^3X_(*736C*9,-_::#4A7NI41&DR/HHCZD8#K
M                        (EG_ "9A/%];&MLXL_DNOF/>RQG>P_(W/;%+
MV[8[;BB]5)GJ9 .7@7.'%G)T]ZKPG(6K&SCMF\Y#6S(B/&TDR(UI1)::-1$9
MEJ:==/2 L$                                      0SDGECC_ (CI
MV[S/[IJIAR%J:AMFE;TB0XDMQI:9:2M:].FXR3M3J6XRU <OBWG;B_F1$DL"
MO$S9T%*7)M:^VY%F-(4>FXVGDI-22,]IK1N21]-0%C@
M               *YY+YWXKX?E0(7(=]\CRK-M;\)LHDR4;C;2B2H_WJRZ1:
M&9>.@#I\<\L\=\M5LBUX]OF+J+#6EJ8E"76'V5+(S3W&7T-N))6A[34C16AZ
M>!@)F                              ,I^:W+J^7FN <<3:R??4D>263
MY13U$<Y<I^)'4IIAKMDI.J5GW27JHM"T/W '0\GF6I75Y7QF]'EP#QFR<F4L
M"S:.--;J+):G6DN-&9[5)5JI773X0M &G
M                  &;_-R5LJ-Q@F@]G^73S*O*L]M(SB^UF2NSWB3J?;W[
M=^GH <*L/.Z7S(X1-YI8IW;NWK+"OQ=[%#<3&:=;0:WE3$2$D\K5"C2@]=I&
MKIX*T#5H                                      R)F:(]EY\\,@Y>
MVT[41<:<>Q=B6E)L*G?OE1K;)>J5.DI*C(_?$:4F74D@E=1Q>$(O.#*D-P6>
M;G:DC;2UWD2559;TZJ2C1DSVI,O6^$V$G]J200M$
M            !F7E9I#WG!X,;<0EQ!U^0ZH4DE%T@O'X'KX /10Q8=3YYKV'
MB[+<>#-PAJ5D[$5)(:]N*8V33CJ4Z$3AM]K0SZF2C/TF U"
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MG>9*(C/H2B+4P%F8;G6(<A5*KW"KB/=U"'E15RXBC4V3[:4J4@]2+J1+2?\
M= 2$                                    !"N2>*\1Y6KH-7E[3[L6
MNDE-B^ROKC+2^2%((]R.O@HP'#P;R^<8\>WY931U\A_(6VU,1Y]A*>FN,-N$
M9*)KNJ,DFHC,C5IKH9EKH9@+1
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MCM,3%.D2D=AQ2R2YN(R,MAGT 2,
M
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MJXIFF.9I7M3J&<V^M4:),DP=Z/;(B+!A,AE$EI*E*:6I"M=J@'?
M                                                07&N8./LNRRR
MPJAM#D7U9W^XVIA]IA_V-TF)/LS[B$MO]EPR0[VE*VF Z-AR+A]9F]/QS*LT
M?GE>LR),&J:(W728B-FXMQW81DTDR(]AN:;S(R3KH8#DXQS/Q_F.6V&%8[.D
MR[RL<ELRS]@FMQ"<KW>R^E,IQE+"S2OU?5</7T )^
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MO(::>CM.-QU)<80M"5);6W[Q22,NAI]!EX /> SEY:?M$Y^^NCOWB@&C0
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M1;FW!>3.&L8JLM@<SY;<.NWE;6N0ICZ$LJ:ENF2]=G7P2 VD
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M5BM&I1F:CKXAF9]3,S90 [       S7YX5;>'*_KH1Y+3Z_]XLP&E
M         9<Y3C<BGGEV]4-\G)J#6R4=Z@M,>ATWK,MI_>R9Z#=3JH]I[E;C
M7KIXD N[B5JX9P"I:OD73=JGV@GT9.[$D6Q%[0YL[ZX))8,MNG;V%T1M(^NH
M":@ "(\J_9?FWS!:_B;H"'>5C]7GCWYJ1\8L!;X
M      ,:>93$^(,=Y$HW;+#L;38Y4Z=GD.2Y3-GQ8[S)3H<%YJ*3,AI!R4IE
M>T+-1DEMIM2MJO0&@?+].K;'A[%9513,4%:<=YN/60W'7HB29DNMF['<?^$4
MR\:3>:4OJ:%D LH   &<O.I]E5+]:J3XY8#1H
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M%M*6R\TI25&A9$I.I'X*+4!J,   %$^<K]6G//W&#])10%NXC_-2B^;XGQ"
M'9      '"RS%<5S"K159A71K.I;DL2FX\PB4T4EE9&THM3+J2NA>[KIZ0'=
M               !G3S18K9Y/88.Q2%4VUZ3EBBGQ*ZF.P?:9:$,2O;XIHU0
MI^&U'=+X9.PD/*T,E;24$X\NL:.QQ'2/P[.%:0K%ZPLHRZIQQ^OCMSY[\@H<
M=;Q$X:(V_L?"$2M4'J1>!!:8  B/*OV7YM\P6OXFZ AWE8_5YX]^:D?&+ 6^
M                           #/OF$L2AY-C36:U<RQX@<@693DUM.U>K^
M7U]IN";S;C#ZFB;0IUQA:"+5TM%ZI 6+PI(S.5Q7B[_($=<7*U1-)C+S*(SY
M-)<6F.;S*-$MO*8)M3K:2T0LU)T+0!/0   9R\ZGV54OUJI/CE@-&@
M                   #CY8_[+BMY)^4?D?LU\MSY6V&[[)L96?M&PNJNWIO
MV^G0!C?RZ0Z67>X-<S,$Y*7DTIEN5(S.TDS'L>??>BJ4J6HW'B2;+VNYO<W^
MV3X^(#< #\-*5$:5$1I/H9'X&1@!I)1:*(C+4CT/KU(]2 ?H"A/*K^0^2?[1
M,F^/; 7V                              /1-_S*3^Y+^],!!N"OL6X^
M^KU7^*-@+      8/RKBWD=/(.25C6.1VKV_LW7SY07?QV]J7+B+85TQ<9QT
MGVE08S7LR(K2-JO$MR= &[G6R=;6THU$E:329H4:5$1EIT46AD?W2 42WY8X
M-HU=1L]S2[S-B;32L9I'+0V/:JVNFO(?6KOI;W2).]ML^^]J>B=#(RZ /T_+
M:I^FE/V&;V4KDR1>P\I1G?LL-M]NPK(GL$4O8TH["F41S4@VU%ZQJ,S/P(@^
M:S\J].[BE%C=!E=I22:ZLM*"XMFVXTJ1:U60/G*LF7B?;4E"G7C4M#B.K>IZ
M:]- NZKH:FGJ:^D@Q4(K:N,S!@M*(E]N/&03;:2-6I]$I(@%!^6=*4<A<^I0
MDDI3F;I$E):$1$A7H(!HX   %$^<K]6G//W&#])10%NXC_-2B^;XGQ" '9
M    &=?-QP;E'-^-8[ QK(XM(=1/4])C63KC$.04@D-H6:FDK/NM&1]LMO7>
MKJ1@+SQ6HE8_C%)0SISEI-JX$6#)LWM>[*=C,I:6\O4S]9PTFH^OI =<
M          5KR9QU=9E:4>3X/E18KG&,%,BQ9ZX;-K'5$LTL^T,O1W5(ZGV6
MEH62B-.GI(P'=XUP5GCG$(F,(GNVTI#LJ;8VLA"&G)4ZPD.2I+QMM^H@E.NJ
M-*$]$EH77Q 2T  1'E7[+\V^8+7\3= 0[RL?J\\>_-2/C%@+?
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M7TQ5=Q@C-C8F.V9'V2[G0DI\/ !N4    !0GE5_(?)/]HF3?'M@+[
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MJ<<5IJI:CU,^H#[@   4)Y5?R'R3_:)DWQ[8"^P
M       $ YC_ )G1_G['/IR$ G$W_,I/[DO[TP$&X*^Q;C[ZO5?XHV L
M'$R^XN:#&K&XQ^C=R2YB-DN)1QWFXSLE9J2G:EUWU4Z$9JU/W &,)N'9/DF5
M%+RCB#,YS,^P3:2L?GYU#>@&2I).F?L'12F6U>"2Z:%IJ W4 K^?S3QU67>7
M4,VV)J5@M>U;9.[VUJ9BL/)-24&M)'N=-)$?;21GZQ%X] '&1YC.-E8F_E:U
M63)Q[)FB50.UTEN\5:2FR>8C(@J1W5+=:/NHT+0T:GKT,!XV_F2XIJ,:Q_*S
MGRYU3D<>3.A_)T&3,>9A5ZB1,D26FD&IEN,L]CREEZJM2ZZ& M6)*C3HK$Z&
MZA^');0]'?;,E(<;<22DJ29=#(R/4C 9X\M/VB<_?71W[Q0#1H   *)\Y7ZM
M.>?N,'Z2B@+=Q'^:E%\WQ/B$ .R                       #(/-67\I?U
MB6E1(>GP,-JK""[%7$Q#Y>16U28B'E9!%GZ+_?:)2G(O:)!]ILU+))FDS 7W
MP==Y=D7&5-;9L;KMV\<I*)LF)\G29D)J4ZW#EO12U)EQ]A+;JD%T(U=-/ !8
M8  B/*OV7YM\P6OXFZ AWE8_5YX]^:D?&+ 6^
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MUY7I6KQ,P&I    43YROU:<\_<8/TE% 6[B/\U*+YOB?$( =D
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MQ7S?UU-U1H;3ZROVW4!Q<&X/P/CS))^48ZU,*9*0^Q"B2I;LB%6QID@Y<EB
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M7EI^T3G[ZZ._>* :-   !1/G*_5ISS]Q@_244!;N(_S4HOF^)\0@!V0
M!^*4E!:J,DEJ1:F>G4ST(O[IF _0               9DY+YMX&9Y(_,;F7"
MB=M*I]]$"ULZ4[=OV9J/'DLO,FB.\X:'E/.()+1*VJ;,W-NJ0%]X3E6-YKC$
M#(\0=4[CLI*VX*U1GH1[8SBF%))F0VTM!)4@R+5!=/#IH D   B/*OV7YM\P
M6OXFZ AWE8_5YX]^:D?&+ 6^           "L_+_ /913?PBU^E)0"S
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M           5GY?_ +**;^$6OTI* 68     K'FW\E8?]=,8^DV@%G
M  K[DGB&BY+>K;"3:W&-Y!5)=9AW^-3E5MB464:3?CJ<2E9*:<V),TJ3T,M4
MF1@)/B.*4>#8U68EC<;V6DJ62CQ&=36K:1FI2EJ/JI:U&:UJ/JI1F8#M
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MSM/_ "VO0!M(    !0GE5_(?)/\ :)DWQ[8"^P
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M.(,T.$E:3-*B]522,O20#ZP !$>5?LOS;Y@M?Q-T!#O*Q^KSQ[\U(^,6 M\
M          %9^7_[**;^$6OTI* 68     K'FW\E8?\ 73&/I-H!9P
M **YMY;S[ LNPFEQ?$;"SK;:W9C2YD=<#M6"7(LIPX+/M#J5MO$;:7=ZMJ=J
M3+=U 7="?=DPX\E^.N(^\TAQR*Z:5.-+6DC-"C0:DF:3/0]IF7N />   #.7
MG4^RJE^M5)\<L!HT           %9>83[(,B_P!1_'XX)A9H(1B;QMQU9S'[
M&RQ&EF6$I9NR9<BMB.O.N*\5+6MLU*,_=,P'H+BKB\B,BPF@(C\2^2H?7_\
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M9W(P7-KBAH^:9]+53\GFN(QO^KY^3';ESYZC<C,2EK/<2W%&1*1T4H]R2+<
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MKJ6AG]P^O7Q%.VL5O,1.8AIT7M?7%K1B9A]HJ7@
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M S5X@//R@PEUN'YW6N3'[%R%GF0QEV,Q1+E25-.-)-YY1$1&XO3<LR+Q :%
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M@R ;K      &<O+3]HG/WUT=^\4 T:
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MSVS<546[11Y\<R4:=KS9*425=-=-? P':   !G+SJ?952_6JD^.6 T:
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M1S1-87&<4;,="#6A*^JFU&6K:RZ*3HHO$!9@   (KR3F5'Q_A-MEN2QG9E!
M0TFPCLMI>4;,IYN,HU(69)-">[N<U_:$8"FL)SSR:FIY['G,0JIC5M*0R4IN
M S*7+1),N_'->JNTXKUV%(,D[=-I)+H0:/      &<O+3]HG/WUT=^\4 T:
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MDRIPU1("TFVTMW<25I1H:2,T^J6I -A     *$\JOY#Y)_M$R;X]L!?8
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M"M?.F1_U4TWW,JI-?^^4 T:           "LO,)]D&1?ZC^/QP3"S00
M*S;_ %A)7U,C_2KX"S     '+R5N8]CEPS7N/M3W(4E$5V&23DH>4THD*9)9
MI3W"5H:-QD6H#'7E\XQJ,;R3#9-IPEE-%E\!!)G99*M%O5J991UI=DK8.3H1
M/*-1[":T2:M.NFH#;(    "A/*K^0^2?[1,F^/; 7V
M    *TYVY'D\:<?2[*E:]KS.W=:H\/KDD2ER;JQ/M1TI2KHHD'JZHC\4H,O2
M Z'#O'$;BKCVHP]MWVNR90J3=V1F:ES+24?=E2%*5ZRM[AGMW=2022] #G^7
MO[%L+^;D??J 66  .%E.:8G@\%JRR^YB4M>^Z4=F3.=2RVMY1&HD$I70U&1'
MH0#IR76WJYUYI1+:<84M"RZD:5(,R,OV2 0G@K[%N/OJ]5_BC8"P    >J3)
MC0HSTR8\B/#CH4](D/*)MMMMLC4I:U*,B2E)%J9GX *ED89Y<[/-,<Y,DP*%
M_,<E<0_C-RMQ.M@^TV3B'6$;R;==).U25[#7X:'KH MF6N2W%?<AM)?EH;6J
M.PI7;2MPDF:4FK0]I&?373H R/$X.YES7%^2*7DVLJ6<OSN"LU9FS9NRE(=A
MR6Y%?7-1.P11X3>TR5L6I1GZRMYZ:!U)O#O+EK/F\NR:FIC\DKRVHR9G$DV"
MW(:X--5'4G']M[1$EUTEJ>)7;-*="+TGH')?\N_*]#A]4WC[-3:Y5;8WD^*Y
M0P]+=AQH?YVSU3RE1UFTX;I136;:D;2->A&GQZ!:E[Y6>)LTH\1J\[K';F5B
M%+$H(,M$N5$UCPVTHU-+#J",S-.O7W0$(\H6-T^'9'S7BV/L'&I*?*SAP(ZE
MK=-##+2DI2:W#4I6A%XJ/4!J,           $=S#!,1S^ Q5YC5,V\",\4EA
MA\UDE+Q)4@E%L4D]=JC(!1G,O!/$6.86S8TN)Q(<U=YCT13S2WTJ[$RZAQWT
M:D[X.-.+;5]Q1@+!/RV<&'U_,F#_ .E[\( M%IIMAI#+2=K3:20A)>!)26A$
M \P            %;Y/R;Q3QLYE4R1+A(OZUEFZRJLK"9<MC85V8Z93S"5)6
MLD(4WJI74D:?XNH=_CC.J[DO#*S.*B+(AU5N3KD)J82$O*9;>6TAPR;4LB)P
MD;TEKKH9:D1] &7>)+^W:Y/P?*95K+7:9S*Y :SUF5,><BML8],2F 7L[BS:
MCE&224(VI2>U1D9Z& ZW*RYD#F1_DBVEQ+_!Z65BU2U3561S(EM!>L'S4B0=
M?$,FG>XX^A?:?_RK2=4]-= DO.')'-<"NSG'*CB%RUPTJR;'3EA741A*HSL)
M7=?]E4@W/@]RO4UU5M^Z F/E8_5YX]^:D?&+ 6^           "L_+_]E%-_
M"+7Z4E +,     5CS;^2L/\ KIC'TFT LX       %#<A>:7$L/>N::EK)MY
ME=9-:K:^L[+\=FYF)D,L3(M;(2T\3\B)WD]ULD]#,BU])!8G$>:3.1.-\=S6
MP:C1Y]S&]HE182W'&6'2<4A3)FZ25;VC3VW2,NBR40#/W'W'W).(7N--2\4E
MOQN(HV:OQ9C<B*360O9+-*3"9A:N;DF;>O<-Y*20KH8#RM^..2;7E+L-8P\U
MC]_FN,<ANW[K\=3$&-304%*A/))S?[23S26VR;2I"DJW;B(C =+BOCG)ZWD[
MVNJPVRXXH&8MVQFW<N5VM?=2YTDEP'H!K>4>Y&KKYNJ8;-&_M]?2%;>8S@*+
MQQAE+D36>YAD2RR.HCE79!:G.@_"O'Z_:[:?73IZIZ] &ZP           5E
MYA/L@R+_ %'\?C@F%F@@     5FW^L)*^ID?Z5? 68     CV976/U-.N+D#
MI&W<=RLAUY.$W(GR7F'%E$C^LDU/.(0O8DC(P&0^.>/L>9Y8P6UXXX8R[#%5
MD]Y^_M<J=DE7% 5"D-'M2]+>W/DXMOM;="\=4F75(;=     4)Y5?R'R3_:)
MDWQ[8"^P                    $1NN0(-'FM%@[U3:29^0-NO0["+'2Y ;
M3'_RO>=-Q)H-!&DS]4^BBTU 51C?_P#VGGZQS-SX;C[B53U#C9>+4O)I"2*P
ME%Z%%&;VL)UU+<>])^(#0H"M/+W]BV%_-R/OU ++  $ YCT/#H^I$?\ \^QS
MH9$?_P#.0O= 3B;_ )E)_<E_>F @W!7V+<??5ZK_ !1L!8    *V\P&(9!GO
M#68XCBJ]M_9P31"1O[?>-MQ#JF-QF1%WDH4UU/3UNO0!G_.,F3S/B=!Q)A7$
MN18OEU?.K%0+&SJ4U]?BZ($IE;S[4K730FFU-H)LDFLC]W1)ALD      9R\
MM/VB<_?71W[Q0#1H            "KO,#]GT?ZQXM_\ [!  6B
M     #.?)7E;+*LHFYYC]\A-XBS:R*HQ^ZB,2Z+Y62S'COJE;4%)<;=;BM$2
M.[HVHMQ$?O0%K<38-+X\PB)CEC,:GVIR)MC92(K7LT3VNTENS7D1V2Z-LH6\
M:6T_X) /8CB;C5NUR*\1B]<FWRR,[!R.63"2<FQI"=KS;A^X[_UFFF\^JM3
M>LN'^+RO:7)BQ.M*^QV.S"I9W83OC,1$=MA*"\/@DEHT9D9H_:F0#Z.5?LOS
M;Y@M?Q-T!#O*Q^KSQ[\U(^,6 M\           %9^7_[**;^$6OTI* 68
M  K'FW\E8?\ 73&/I-H!9P       *5S/R]\86>1.Y=#FRL/Y$M9R9-;D=;.
M4S*;GJ:-#WLK#ZEL;I#1*)]*6M7"+<?4M0%D8'A=/QWB-5AE";JJRJ:-MMZ2
MONR'G'%J==>=7H6YQUQ:W%F1$6Y1]" 2(   &<O.I]E5+]:J3XY8#1H
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MO?KLW'KIX@/K  $1Y5^R_-OF"U_$W0$.\K'ZO/'OS4CXQ8"WP
M5GY?_LHIOX1:_2DH!9@    "L>;?R5A_UTQCZ3: 6<       #,?F*J4VG)G
M'4,^3W<1E?**+"-5R%P8L=EJ.Q)87,B.RV#2Y*WOMM=E;BM4K,R1T :4@-+8
M@QF')*ICC;3:%S'-N]XTI(C<5L)*=5>^/:1%[@#Z    9R\ZGV54OUJI/CE@
M-&@           K+S"?9!D7^H_C\<$PLT$     "LV_UA)7U,C_2KX"S
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MY32G''O6(VS-Q9GJGW0%Q  "(\J_9?FWS!:_B;H"'>5C]7GCWYJ1\8L!;X
M         *S\O_V44W\(M?I24 LP    !6/-OY*P_P"NF,?2;0"S@
M9!\SV=8YD[\O#<HGW./\?4YN,Y/)9Q%RS<D.J4DDG$L9*%,1T:?]<@MV[P 6
M[Y=,(XTQO!XV1\7G;*H<FCQG6UW4B2Z\IJ)W6VU$R^>UK7<H_@TI)1;?020%
MP@   SEYU/LJI?K52?'+ :-           !67F$^R#(O]1_'XX)A9H(
M%9M_K"2OJ9'^E7P%F             *$\JOY#Y)_M$R;X]L!?8
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M)F?7=J C/E"=R)_(^:WLNCQ8N3KRLU6T: I3D1N4;2MZ6E+,U&DC\-0&HP
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MWS!:_B;H"'>5C]7GCWYJ1\8L!;X           *S\O\ ]E%-_"+7Z4E +,
M   5CS;^2L/^NF,?2;0"S@       8YS['^0.2^5GY\;.<5N,;J;U_':#!<D
MC6B:YNYA14S%$[&8[2)<AII1N$XXIQLM3V^&A!JS$F<FCXW7,9D[!>R9MK;8
MN5#;C4 W"4>G90\9K)))T+UC\0':   !G+SJ?952_6JD^.6 T:
M "LO,)]D&1?ZC^/QP3"S00     *S;_6$E?4R/\ 2KX"S             %"
M>57\A\D_VB9-\>V OL               ' RS.,.P2O.US*]@T< O>O3WT,;
MS+T()1D:U?XJ2,P%-3?,1D>=L28'E^P:TREUUM:(N7VC?R-CK2U$9)=2[+)+
MDC8?K&VA"=WN]0$8\G7%\_\ -:'RKR.9VF;.'*KL;6^M#K594-OK)2([:4DE
MMQU\WU+66IF@R+4M5$8:K   !\\]V8S!DO5T=,N>VTM<6*XYV$.O)29H0IS:
MO82CT(U;3T\=# 1;C#-9_(&#5F9V=0BA.T;5(9@%+3.V,:F2%*=2VT6ID6II
MTZ>Z ^Y^^F6CRX.,(2Z:#VOVCA?O9KW=G^&K]CH-M=-:1YMGAV_D\RW4VVSY
M=/'OMV1[Y?;54$2L6J4XI4RT=_RTY_UG#U]"?\%/W"%6W?-^'*O<OT=+77/F
MGXK3^J>?Y(MS'_,Z/\_8Y].0AG;$XF_YE)_<E_>F @W!7V+<??5ZK_%&P%@
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M/J[BFGHRUM+23A)22TZIU2HDE^P1ZD ^?RZ_85Q[\QPOBB 6:
M"L^0/ZGJ:IN<YR;'*F]?@/L0[%;-?#L+!R:^XU&8CJ-9:]U2G6D))U:2(C+4
MR3U =KB[)<3RG$FIN&5ATM1%DRX#M,N,U"7#F1'UMR&5-,&IHE$X2C,VU*2>
MNNI@)D  (CRK]E^;?,%K^)N@(=Y6/U>>/?FI'QBP%O@           K/R_\
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M&ZPBO=2VOW4I<40R[8K%YBO+/!OT3>==9OPMCB\"R'S%&9:X+C!%[OYQRO\
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MI"DN):9T]59:EM!#E>83[(,B_P!1_'XX)A9H(     %9M_K"2OJ9'^E7P%F
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MG-\VC<T3<@C9'81XM1R!C&"QL7)[2J=J+F$E<I2XVA$M]:W>ZAY6JDD@B3T
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M?9SA5GBT7@O.8LB?[/L?=@F:$]B2T^>NU)GU)&@"2GYH>0]>GE^S?3^#*_!
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MRRB,3'6XL5M+:$$MU!F71):Z>D!^?U6<8_T*H?Y+A_@@#^JSC'^A5#_)</\
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M'C+-::R@E7<?3;5=U%6M:I"U3XS3*$-DVE224DTF:R<-/0R 6R
M     "%\O8S8YIQ9F>)T^AVUS33H4!*E$VE4EYA:6TJ4?0B4K1)F?H 4IY?:
MO*+ODDLYML8M<8KJ'!*?"'V+N*J$M^UB/&_)5%2HS-;#>TDDYT)6O3T@-/@
M  B7)]-E^18!?T6!6;%/EMC%5%KK22;B6XYNJ)+B]S25+2HFS7L4DC-*M#]
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MH?CH;C2XD9,N4XJ.M9.G$B-K1[5+/1MI2B3U,!;1&2B)23U(^I&7N /T
M                       %+V_+M57\@% FR&K?"73)EQ1P74NUD^&\49R4
MTZM&R9%)YQ#$A;!J5$=VFOX-2E-A=       \'76F&EOOK2TRTDUN.+,DI2E
M):F9F?0B(O$P%*77-+;^3OPJ6*SE6)-5J[$X%2AF;(GU[)J3-G-ONR&F.W$<
M2F.J.DENK<7IZOJ@+CJIT&TK(5G5K)VLFL-283B2-*5,/();9D1D1D1I,NF@
M#ZP                       07DGD:/A5.95C16N63F9JZ.G:2IY;ZJYO?
M)<-#7K*0P75Q*?6,]$)]91 (!PE\J/Y7D4V@N:ZVPEYUM^PF5D=4>LG3IK"9
M!2H3:7'$1Y)&9MSVDJ4VX9MN^H\;R5!?(      KO/N296//G4XG!CWM]&1(
MDVC#LA3#$-F'%]L-M]QIMXVWGV_\@E:2(_?&>A=0K#B6NSRLR&J8KF)**1;I
M29$MA,1NBFX]*A)>9?F(29R$WBG5M&^H]=_51*-HR)(:3
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M'V:&G4](46U<^TFK[TZ=)2VELWY+NA;UFE"4ET(DI(DI(DI(B"3
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MZXYZET/)<'!+2@BL1+2T325[B;B,];+<>0:F9;E<RE:FHKBBV$MQPE%XFGT
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MU"K8C:68D.,VEEAII!:)0VA!$E*4ET(B+0@'T@
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M/XYCM/B=-%H*&-[+5Q"5V6MZW5&IQ:G'%K<<-2UK6M2EK6M1J4HS,SU,!U
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MD\\IUY-<.5+2R6V)&-9$11XQ&1*[39$1$I?K+/59Z;MI!W
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M:*#4KL9!DI.V&DUD3;2DDXVA2U?"?"'JOJ06*
M                                            "I>4.4XN-JID)K59
M#Q];,6Z<QMJM2Y#E77P.U&>EZ,;B6VRZZ:)"4GW$$2E)2>Q1 (5F6%1HMAB"
M>*F,AE9<Q54=?B.61)"W,;C4U=()3A3GFG$M/(>CFM3B74.&Z1H[6BNI!;<K
M#)N09HC(,KD-2J"C6AS%*)HE&RW+V?"3Y>XB)R0DS4B.GWC2=5EJXK5 30
M 'XI24)-:S)*4EJI1]"(B])@(/GN>QJ6J55XQ8U4CD2YB+<Q"EF36&%3G5%H
MA;:5N(-Q!:[]$GZVFA& S[@ZLUS3/8TBDR^3*?7#GKH,Z*/!D6+%2W)*.]'N
MH1(897%F2F7I%9L+O,;32O5.[0-.X5B57@F+5F)4QN+KZQHVFW7S)3KBUJ-Q
MQQ9I));EK4I9[2(M3Z$1= '>                          %:\Q<BMX5C
M^RJNH%5E,KM.ULBV9??JFV^^VUOL7(Y&<:*XMQ+!R%*225++KT,!5F(<>N\B
MY?<W5]3M_(SMA(;O6KAE35@T2TD^[6/-&UM?=9D*:4Q8,R%MHCMMI8TW.&8:
M5@0(57"CUM<PB+7Q&T,18S*20VVTV1)2E*2Z$1$6A /H     5SG?**,?LFL
M9QR*=GE"W8;3ZG&GU54)=@^EF,U/E,)6<=<I1]MDR;<VJ,E+239[@$6PJ&UD
M&0YUA&6X;-KZ#)&$7,VKLXY.06YDK][3V6)K*UM/)=4TU*0;:DJ):EJ-*%$0
M"Y*R W55L2L9=>?9A,MQVWI3JY$A:6DD@E..N&:EK,B]92CU,^I@/K
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M];R&4LMJ6E*6R7L3H>FA="(N@"4@
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MUBN(TN*1G_DZ%$9M;):95]8Q8S41RPGFDB=E/DTDB4MQ6JCU])F [X
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M<L<RNZMJBR+(NW[5517W74IBQBV1#F&IQ;;LXFM$/OH(M2)+>JR;2HPGP
M
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M,:8MY"I#464ZMV6<-)F45*DN:G';0@_@8:3VL)/:1)4:B 3\
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M:;+1"$DE):F?0BT+J?4!Y
M                           #\U+737J74R].A@,^\O<7/UMJK,Z2NL,C
MP2RL&++D?C.N,E_*[\=)(9G,,J,B<<0I+1RHN]+<I#:-W5&BPL; ,>RATEY;
MR.B+^=,MQ;M72QT,O,8]!=0E!0H\DD$MQQ24)5+=)6QQSHA)-I2 GH    "O
M<^Y(KJ#VBBC5MY<RW&W(]C)Q:'\JOU*WFDJ:7):97WD*6ESN-;6U:D6O0M-0
MJ7!N7,?Y:Q'C[ BS*)&O9\2,QG%3;Q'565LW%C]N7$83-:)IU,EQ"TR5EO\
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M1V#KCLIMV4TDEN$PE]2DLLF]N<2TTE""4>NTC 3(
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M*IW0VWF&]C25.?"*V)6[N66X!:X
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M'6'N8E2M)D3+)V;,CQ5S8-E92+5N)(;9(G6X[DA;BB2:S/7US(P$Q
M                !\MG65UU72JBWBM3JN<TN/,AR4)=9>9=2:5H6A1&2DJ(
M]#(P$ Q3B0L<O*^PGY'/O:G'&WF,,JIY-F=8W*1VW-\@B[LI26_@65O*,T-Z
MD>]1FL!9(      I%WDNZS6]1#PRY8H63F3(F.ID1#LEVKE*IQJS<GQBV.1(
M+3Q(80[W6G#<Z^]6V2PZG'.%W?9<;R^M8KXU-?NY!BJJN<4F*9V$9SVCM;6F
ME)CF[*DFVVXG7:LB_:D9A;0
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M@Y9J-26Y:B-:G$-'HV2B;U,TJ,PF(
M     "E.:L4RE%O#Y"QV3.DQ(L-5/=P:UHI-O K)#N^5.HDG[R:M)$T]ZJEJ
M:(C:^$0E*PFV%5<VUC0\GS#'X5?D#!N(H4+04FTKZM:20VT_+<-:C?6G53_;
M5M(U;-5[36H)J                                  *OR?A*ER#*IF0
MQ+!^G@Y&TS%S^IA(0A-_&ADKV9MYXM'&MNXVW5-&1O,F;:^FAD%F,,,16&XT
M9M#,9E"6V66TDA"$(+1*4I+0B(B+0B(![
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M)\\.)89Q#973JR"M4IIF[JF7$/0I4Z+M)LI"=-VTMQ-K-9MJ)"]I!98
M
M
M                  /PS,B,R+4_07N@,N8Q?RN2,IL:[+<=/(,ZLY:JK*\(
MM2--%AN-1']R2>)2%M2I4Q))>8?2DSD&HC;-##)@)OQWQIB+E[0<A\;9C8RL
M%JT6D&NHUN^WUIMR%)CO-Q),E)R$QB=C(<2A+JV34A*F]$^(7:        9$
M9&1EJ1]#(P B(BT+H1
M
M                                           *2YCS[('YT_C7!*^3
M/N(=>Q>965?*5 N44*Y*6G44Z31\/+=0EU*32M!-GH6\G%H(!%L:XGA<D=FV
M;R:9<<=3H3;=1E4&<MJSML=?<6;^/7!J(G74,K(R2^I27TI4MI1I7W#4&D(<
M.)71(]?7QVXD"(VAB+%80EIEIEI))0A"$D24I2DB)*2+0B >X
M
M
M                       0K,L=P[(<CQ;Y3M2J<XK7W9^,OQ)+,>T<99V>
MVLMH<)9O1G$&E$EO8I.AI/U5$A1!+8?L78_^7]KV;>Y_D-NSN=Q7<][TW;]V
M[_&UUZ@/H
M                                                        !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>lc_fig33clinical-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig33clinical-bw.jpg
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M;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4
M !#\X1^)R+?)>"\T8C0'6'?K_^X #D%D;V)E &3      ?_; (0 ! ,# P,#
M! ,#! 8$ P0&!P4$! 4'" 8&!P8&" H("0D)"0@*"@P,# P,"@P,#0T,#!$1
M$1$1%!04%!04%!04% $$!04(!P@/"@H/% X.#A04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@%%@4B P$1
M  (1 0,1 ?_$ *\  0 " @,! 0             '" 4& P0) 0(! 0$! 0
M               ! @,0  $$ 0(# P0)#0L)!08!#0 ! @,$!1$&(1(',1,(
M05$B%&%Q,K+2%E<8.(&10G(C4Y.T%75VEC>AP5)B<[,T=#4V"8*2,],DE-16
M%[%#5949T>&BPU0EM6,F\(.D9?'"HT3$AG<1 0$! 0$!               !
M$3%!(?_:  P# 0 "$0,1 #\ O\                         (:W2J_.5Z
M?)JNGQ?SG#7A[NN%3*$
M
M
M                             (:W3])7I]^CV=]_7"IE"
M
M
M                                                           $
M-;I^DKT^_1[.^_KA4RA
M
M
M                             "&MT_25Z??H]G??UPJ90@
M
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M?)_PJ@/B_2^^3_A5 ?%^E]\G_"J ^+]+[Y/^%4!\7Z7WR?\ "J ^+]+[Y/\
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MW7^$UVBI]8BLB                       Q4::[AF5?)6;I]5Q494B@
M
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M:BZZ<S(Y&^SS-\R!JO0<,@  !#6Z?I*]/OT>SOOZX5,H0
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MK>#F_OI[!%9<@                     Q<7]X)_P"K,]\5&4(H
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M/I .F_43 ]4MIU=Y;:99CQ-N2:*)MR-L4W-7D6-VK6/>FFK>'I ;8
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M\&-2QN[LWNWQ%[*GS>T,EM)];!9ID,>5= Y;".=755C[A[T]'RZKY4 LB$
M                    (=Z6M2[N[,9"RG-:9$][5=VHZ>9>=?;X:&JD3$94
M T7JU7BEVDZ=Z)WM:Q"^)R]J*YW(J)[:.4L2LGT\FDGV=C'2+JYK9(T5?X+)
M7-3]Q!2-G(H                    "'L^QN2ZM4ZEI.:O%+7:C'=BMCB[Y
M$]I7&O$3"94 QV>J0WL)D*EAJ.AEKRM<B_:+HOU%X@1_T7GD?C\G7<JK&R2&
M1OFYI&N1WO4-5(E$RH                    #%Q?W@G_JS/?%1E"*
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M[7S*L'!?90->/1@,@  !#6Z?I*]/OT>SOOZX5,H0
M  A5\[^GG4&:Q8:[\CW%?SN:G_\ ;3NYD<GG[MR<4\R*:[$3-7L06X([-:1L
MU>5J/CE8J.:YJ]BHJ&5<@$1=3]Q,S-JKM/#KZU(R9KK2Q>DBS^YCB14[515U
M=]0U$J2\!BTPN%HXO5%=6B:R1R=BO7B]4]MRJ95D@
M  (CZG4KF%W'CMVTFZIS1ZJO8D\'%&N]A[.'U%-1*DO"9JAG\=#D\?(CX94]
M)NOIQO\ LF/3R.13*LB!I74C=-?"86;'0R(N6R#'0PQ(NKF1/]%\CD\B(FJ)
MYU+(E?CI9A),5MWUJ=BLFR+TF:U>U(432/7V^+O:44C>"*
M       Q<7]X)_ZLSWQ490B@       '5R=UN-QMS(O35E2"6PY/.D3%>O\
MV >=G@UQ;M[=>\AN[,-;8M8^K>S3G/\ 2_VVY*V+GX]JIW[UU\_$-5Z.AD
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M3[]'L[[^N%3*$                      ,-N3;..W/1]4O-5LC-75[+/\
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M-9W(NJ.D9<8BJFFB=KE(5/OC._8!GOZUCOQR($Z^>#']@."_K61_&Y 5/X0
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M^_1[.^_KA4RA
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M=5ME=3Y,PFRKKLE4PDT5:U>2-T==\DK%>B1.?HKD33BO+IYM0-U
M<-O^BS_R;_>J!U<'_9-3[3]]0,@                            !#6Z?
MI*]/OT>SOOZX5,H0
M                                  Q<7]X)_P"K,]\5&4(H
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M-S&Z<2YN<1B1.RE&5U6P]C4T:DG+JU_*G!%>U51.&N@&N;)\)'2G8&ZL9O#
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MD?(Y>Q%X(FB)Y@C<P        '#;_HL_\F_WJ@=7!_V34^T_?4#(
M                     0UNGZ2O3[]'L[[^N%3*$
M                                                           ,
M7%_>"?\ JS/?%1E"*
M                                   <-O\ HL_\F_WJ@=7!_P!DU/M/
MWU R                             $-;I^DKT^_1[.^_KA4RA
M                                 %5$35>")VJ!&.Y.J4C;?Y*VI EN
MPKN[2RK5DYG^:)C>+OMEX>QIQ-8FL8V+K)9;ZVBS1Z^DD;GUXG?@Q\/KEQW4
MK<6#NMQ^\:3M%TYGK&D,Z-_A(B:,>GM?7&&I5IW*N0JQ7:4K9JL[4?%*WL5%
M_P#TXH95S@                               #%Q?W@G_JS/?%1E"*
M
M                <-O^BS_R;_>J!U<'_9-3[3]]0,@
M           !#6Z?I*]/OT>SOOZX5,H0
M           &B]5,[)B=OI4@<K)LBY8G.3@J0M3633V]4;[2EB5R].MIUL'B
M(<E/&CLQ?C;++*Y-5CC>FK8V^9$3W7G46D;J16(W'MVAN7&R8^\Q.945:\Z)
MZ<4FG![5_P"U/*!'W2K)V\?E,CM.^NCHED>QB]C9H7<DB)[#D]+ZAJI$L&5
M                              #%Q?W@G_JS/?%1E"*
M
M     <-O^BS_ ,F_WJ@=7!_V34^T_?4#(
M  0UNGZ2O3[]'L[[^N%3*$
M !%/6F&18<381-8F]^Q?ME1BI]=$4U$J2\78AMXVG:KJBP30QOC5.SE<U%0R
MKM@ (>VL]M_JKD;=5>:NV2T]7)V*UK>ZU_SE->(F$RH
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M[Z@9                             "&MT_25Z??H]G??UPJ90@
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M)I19+Q$8_'3.<R&Y1Q=>1[-.9&RS2,54UU35$7@&IQ-3_ %TT5JI'N7.M?\
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M:>/@=:OV(JM9GNIIWMC8FOG<Y40#AQV8Q.78Z7$WZU^-G![ZLS)VIKYU8JZ
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MB;=V_(VQ5KK-<;[FS87O'M7SM31&M7V434:8V4B@
M            Q<7]X)_ZLSWQ490B@     5S\0W5[<5#,5.DG3:TE/=E^#US
M/9W3F_)>.=JB*S_\M)]CY6IIIQ<CFT0IAM@[6PJK82DW)961RR6<MD_]KMS2
MN]T]SI.9$U7CHB%9UVLOL[:F>A6#*X:I,U45J2,B;!*U%_@21(UR*4UM?1SJ
M=G^EF[,5TZW=DILQT\W%-ZIMK,77\]G&WG>XJ32+[J)ZJC6?P=4TT;S:9L:7
M"(         "*_$G^PK?7YL?[]@%6/#ITRK]6_#;OS:+^5,DF:6[@YG\$BR-
M>E"L2ZKP1'HJQ/7^ Y0U>MG\#W4ZS3ER_1/<KG07Z$D]W!PS^B]CF.5+E71>
MQ6N^ZHWV9/,$K;?'K^R3#_GZ#\5L@B2O"]^P/9']2D_&90B%_%UU[W/B,W6Z
M-].)IJ^<O,A_+%ZFJI;5UQ42"G K?28]Z*CG.;Z6CFHB^Z"R,;M;P$17\0R_
MO_=EIFY[;>]L04&1RQ0R/1%5KY9N997(NO,Y.5->S7M4:CS)KU5\%_4&A7AR
MDF:Z?Y-RRPP.5S*=ZM&Y$F8L3E<D%F-'(O,Q5[6KJYJJT+UZ%8'-X[<N$QVX
M<1*D^+RE:*[3F3[*&=B/8JIY%T7BGD#+S=W!N[>.U/%-N^;8U9U_==[*9'%8
M2!SE<V.UD-8&RHQ?156<ZN1'^BG:[@A5SXFJ#P,V=RP.S?4??UZ]O.ZG>W9X
M8TL1,E=Q5O>3N5\B-5>WT/81"&HOV/E=]>%#KI4Z?YS).N[/RDU>.W&U7)4G
MI7G]W'<BC>J]W)&_7FT_@N;JJ:*%Z]& R  /.OQ<_27PNO#_ &;#_C#RK./0
MQ^0H1M<^2U"QC4U<YTC41$3SJJD11KQS]5-I[BK8+8&WK\.4R&.MOR64GJO;
M+# O=.BCB61JJBO7G<YS47T=$U[0L6:\.&U\CL[HGM#"9:)\&2;5?;L5Y$5K
MXW79I+*,<U>*.:V1$<GD4(@WQ1==]XR;OK]"^DLDL>X+BPULM>INY;2V+:-6
M.K!(BIW>C7(Z61%14UTU;H[4LCI[?\ ].YCVW=][QMR;DLM[RTW'QL="R5R:
MJBRV.9\NB]KM&Z@UH.=QG5#P6;TQ-W&9F3.].<O,Y755YHZ]AD;ONL,L*N<V
M*PC'<T<C%X]O%.9@7J]S]XXE^QW[^HN6UA/R6[-P.;P62LE=;">?15:&5!>F
M_3[??C"W+G-V;XW1+2P.,F:SN8VK,D;['.]E>I"KD9&QC4])ZZJO#W2JJH:X
MEC(?X?\ M):[EPN\<G5OM15BELP03QH].Q5;'W+M-?,X)J?NB.QMR=.>G]3:
M6Z<HF9R=*Q95F0;)+*CZ\LKGQ)]V])NC5TY>*)Y%"*8^+#<]O:'B7Q^Y*K/6
M),/7Q60BJ2/<V&26L]TC&O1J\6JYJ<R>5"K(D+;_ (3-T=8*C.H76[=M^+<>
M;;ZW#BJK6*M.&9.9D;N]YFLT14^Y1L1&=FNNI#4:[ZV-U*\'&[,9NO9N<DR.
MT,C+W2.D18X9I&)SNJ78$<K55S456/;QX*K>56A>K\["WCC.H.SL-O/$(K:&
M9K,LLB<J.?$]?1DB<J<%=&]',=IY4#*F?B'ZQ[\ZG]4$Z$]*K,M:G';_ "9<
MDJ2K#)=O,U6=))6+JV"#1R/1.WE<YVJ:(A8V&E_A^X)<.U,GO.XNX7,UDFKU
MHEIME5.*(QZ\[D1?+SM5?,@-:#L7J%U&\*O56/IIU!OOR&Q;$D2/[Q[Y((Z=
MAW)'>J+)Q8UJHO>1]GHN33F1'!>O0AZHZ)SFKJU6JJ*G8J*@9>670_/=3';M
MSFQNF+UBW/NY/44S,DKT7'4Z\KIIYD7TD;Z*:<_ND^P]-4*TL+/X!*%W'RV,
MAON[9W5,U7RW)*S7UW6%375S72+(Y-?+WFI$UJ7ACWUO?I1UEL=!MZ6I)L58
MGFH0UI'K+%5O0QK+#+7<[BV*=C=.5$37F:[1.(*N_NW<V,V9MC+;KS#E;C,/
M5EN6.7W3FQ-5W*U%[7.7T6IYU"//W:>V.IGC.WME,]N3,/Q&S,7(W5C>:6M5
M2156.M4A56M=+R:J^1W'RN[6M#7$F9_P<[AZ;TG;TZ);PR/QQQ+?6(J,Z1L=
M:;&G,Z.-T2-:JN1.$<C'-?[E=-0FHM\-.Y[F]/%97W7D:[*N0R_Y4MVX(N;N
MVS24Y5?RH[5417:KHO8%O%_>H&]L3TZV;F-Z9M57'XB!9G1-5$?+(JHR*)BK
MPYI'N:QNOE4,J+;3V?U<\9.>R&Z-TYQ^$V!3L=S%%&CY*L;TT=ZO4K\S6N>U
MJM5\LBZ\4[>Q#7&\[F\!46.Q;LCT]W=<^,]1O>U8K[8XHY96(JHUDT/(Z)57
MW+EYM/+YPFME\(G7+<VZ[65Z4]19I)]V8)CY*-RU_2I8:\B0SP3JONI(7*W1
MR^DY%77W.JBNSX\Y)(NDN%?$]S'?&"OQ8JM73U.WY@1#'2KI[U/\2NU<1AKV
M:?MCI-M2!N,C;%SS+?N,5999.[5S$D?Z::O>[E9P1J*O,4XL9T4\+>-Z)[UL
M;KQ.X9LK!;QLV,FJ6J[(WM=+/!,DC9&/TT3NM%:K?+KJ0U8$(X;?]%G_ )-_
MO5 ZN#_LFI]I^^H&0                             AK=/TE>GWZ/9WW
M]<*F4(
M                        8N+^\$_]69[XJ,H10     *&8VX[.=1.J6Y+
M2*M^;<EC&<SEU5*V-^Y1-]I$1/K&HE; 5 #4.J55MG868DYECGHMCO59F\'Q
MS5Y&JUS5[47153@19U>K:>1FR^UL'EK/](OX^I:F^WGA8]W[JF59@
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M(]5^JH1+X #AM_T6?^3?[U0.K@_[)J?:?OJ!D
M      (:W3])7I]^CV=]_7"IE"
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M"
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MBJ\.T)K-=9.CV"ZU;;I[9W!>N8^G3NLR+):"QI(Z2.*6%&N[UCTY=)57L[=
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M3_U9GOBHRA%
M  %5.JW0+J%N_P 16WNIF&BINVQC)\1)9=-8[N?DH3I)-RQ\JZJB=G'B5=6K
M(@                        <-O^BS_P F_P!ZH'5P?]DU/M/WU R
M                        $-;I^DKT^_1[.^_KA4RA
M             #7=\9J3!;;MW*[N6V]$@KN3M;)*NG,GLM35R>T6#5>E6UJ\
M=%-T76))=M*Y*2NX]W"B\JN3^,]47CYA:D28176R&/I96G+0R$+9ZDS5;)&]
M-45%\J>94\BH!$FTW6=E[^GVU+(KZ5IW<HKOLFN3G@>O\;CRK[:FD3(94
M                                      !BXO[P3_U9GOBHRA%
M
M             .&W_19_Y-_O5 ZN#_LFI]I^^H&0
M         AK=/TE>GWZ/9WW]<*F4(                             :)
MU:@DEVJV1FO+#:B?)]JK7LX_5<A8E93IY9BL[.Q2Q*B]U%W,B)]B^-RM<B_6
M%(V<B@$/9U[<AU<I1U?2=7DJLE5O'THM97_6:IKQ$PF5
M                          8N+^\$_P#5F>^*C*$4
M
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M$5?870F&MQ(H                         ,7%_>"?^K,]\5&4(H
M              #CL6*]2%]FU*R"O&FLDLKD8QJ>=7.T1 ,9\:]K_P#C=#_>
MH?A@<]3.X2_+W%#)5;4W;W<$\<CM/::Y5 R
M U7?_4?9_3##19_>N07'8J>PVG%.D,LZK/(Q[VMY86/=[ECEUT RFV-RX;>.
M H;GV]86UA<G%W]*PK'Q*^-55->61&N3BGE0#+
M   #AM_T6?\ DW^]4#JX/^R:GVG[Z@9
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M^QJO$#E1=>*=@  !Q36*]=&K8E9$CEY6K(Y&ZKYDU4#E[>*
M     #AM_P!%G_DW^]4#JX/^R:GVG[Z@9
M  "&MT_25Z??H]G??UPJ90@
M         (>ZHZ/WAAHK/]$5E=%U[-'6'([4U$J83*@!414T7BB@1!TIY6;H
MS4<']&1DO*B=FC;"(W]PU4B7S*@                       !BXO[P3_U9
MGOBHRA%      A3J_P!1-V2[EQO1GI0Z-O4'.0.N9+,2HCX<+BD7E=9>G%%D
M<O"-%]CAJYH'-M'PQ]+MOHM_<./^.FZ;"][D,]N+_;YIYE[7)'*KHVIKV<%7
MSN4#*;G\.G1C=55U>UM&AC['!8K^(B;CK43VJBM<V2NC.**G#F14]@#1=I[C
MWGT0WYBNEO4;+2[AV%N15K[(W?;_ *5#:;HC:%Q_V3G:HD;E[55-."JD=%BR
M          BOQ)_L*WU^;'^_8!"?^'ZB_$G=Z^3\J0_BZ!;U:/=^\MM;#P5O
M<>ZLA%CL548Z1\DKD:YZM3@R-JJBO>Y>#6MXJH10+P=4K^Z/$%D-VU*SH\94
M@R-^VY4U;%Z^YT<4:N[.95>NB>5&KY@U5[^I._L/TQV7E=ZYS5]/&1<S*[%1
M))YY%1D4+%77B]ZHFOD3BO! RI%M?;/7/Q@9&_N3.;B?M[8$$[H8(V=YZDU_
M!5AK5F/9WJL33GEE=_E*O!"\;#N;P6;VV#CY-T=)=Z6[6?QS%L)08QU"U,L?
MI*D$L,KD5_#T6.3TNS4&I9\)W7O)]6,)?VUN]R.WMMYK'2VD:D:W*;UY$E<Q
M$1$D8Y.231$3BU?*H*U7QB=8=Z;?RF!Z4; L2T,MN")LUV[5=W=I[;,RUX*\
M4B*BQ\[FN5[D77L1%1-=1& Q7@(M9&HR]O3?D[\_,B/L-JUEL,C>J:JG?3RH
MZ31?LN5OM UM?3+PT=3^DO4C!YC%;X?FMAQR3,R^-?)/3<Z%\$B1ZUU?+%)I
M(K%]TB\-40HE3Q,V;-3H5O2S4FDKV8JD3HYH7NCD:J68N*.:J*A$4MZ*7NM'
M6#!+T?V=FK&(PT-F;,;IW/-8GDF[N=L<44//S<Z-^Y>C#&Y.=5<KO110U4B[
MK\#.Y,!C)-P]/]YSY#=E-BS)7FB6E+.]J:JD-B.5RL>NGHH[@J]KD[0FMT\(
MGB!S^^9KW37J#8?9W7BXW6,;D+"<MBQ7B<C)H9]4366)5145?2<W7FXM55%B
M:>N?5BET;Z?W=V31-M9-[VTL-1>NC9KTR.5B.TX\C&M=(_3[%NB<50(IST]Z
M/=7/%0VQO[?V[9Z&UYIWQU'2-=,DRQN5'MJ54?'%'$Q?0YOX6J:*J*%XY^H_
MA]ZI>'"E_P!0^F6\+=S"X]S79#N&NK6*[7*C4?+ CY(IHM5]/5.&O%NFJH5:
MGPY]9F=:-A-S%V..ON?&2>I9VM%JD??(WF9-&B\49*WBB>1R.;QTU#-5_P#'
MQFLQB<ML=,5D;5%)JV1[U*TTD*/Y7U].9&.37350L,+TWZP^*?'U=U;FW#+L
MOIIW4=? 8.%9;+YX(&I&Z9T?/$CU>YBKWLJJJ_8MY="G$?\ 4WHOU*\*T^.W
M[LC=<UO".M-KOM0,=6?%*J*YD=J#GDCDCD1')JNJ:\%1-4UB]7HZ1=0(>J'3
MK [VCC;#-DH/]MKL55;%;@<L4[$UX\J/8[EU^QT#* ?%QX@-Q[/O4.EO3F>2
MONK)QLFR5^JG-:ACL.Y(*]?1%5)9>U7)Z36\O+Q=JA9&H[9\"NX<SCF9W?6]
MIZ.[;3$F=#7B6XZ"1R:Z2V'S-5[D5?2Y.'F<O:#46]>)>K'3G;K>B74BY\8<
M-ZU!FMK[C>][WK#"V6%\2.DU<K4[SC&]=8U1-%5KD"Q>#PU_L)V+^;6_SCPR
MASQ0>(3=F'W-5Z-=)5>F\+BP1Y&_51)+,<MO3N:E=%UY9'-<USWZ>BCDY51=
M50LC6</X%=Q[AJ-RO4??LWQBL-1\D4,3\@L3W)JJ/L3S-5ZHO!>5NGF50:U*
MSD.L?@TWMC*^5RDNYNF^354;$KWK5L0QJB2MCCE<[U:RQ%1R<KN5>'%R:H@Z
MO[B,K0SN*HYO%3)8QF2KQ7*<[?<O@G8DC')[;510CS-H]3>H^V.NF\*VSWVL
MON')Y+,83 TY9Y)8X+-NXZ..5D3U6-RQHGHH_P!!.U>"%:SXF*3P0;\W;6?F
M]^]1EGW993O9&/@FOQLE=Z2M6>2>-51%73T6(B>0B:N1MC%SX/;6&PMJ1LUG
M&T:U.:9FO(]]>%L;G-YN.BJW5-0C*@                '#;_HL_P#)O]ZH
M'5P?]DU/M/WU R                             $-;I^DKT^_1[.^_KA
M4RA                                               1[U7V[-D\7
M%EJC5=8QW-WS6^Z6!^BJY/M%37VM2Q*[VQ-\5-PTHJ-V5L6=@8C)8G+IWR-3
M3O&:]NOV2>1181NA%:3OW?%3 T9L=1E;+G;#%8R-B\W<([@LC].Q4^Q3RK[!
M9$KK=*MN2XG$29.VQ66<CRK&UWND@9KRJOLN557VM!2-_(H
M           8N+^\$_\ 5F>^*C*$4     "O_A[2/<&_.LF_+3>;*S[GEP$;
MWKS.CIX=C61L;YD7F37S\J>8"P  "&/%3A8,KT1W%=<JQY#!>KYG%V6\'PVJ
M<S51[5\BJUSV_5 E':^2ES6V<+F)TTFR%"K;D1.SFGA;(O[K@,L
MBOQ)_L*WU^;'^_8!1/H!T"W;U@P>7RFW-VIMZ#'6V5IZRI/]T>^-'H_[D]J=
MBZ<0U:R_5_PD]4]CX"?=TV8BW;B\;&Z7(.B=-ZU6@;IS2=W-S<T;4XN5KM43
MBJ:(JH)5E_!QO7IWN+8EG"[1P4&V\_BWL7.T(Y'3/LJ]O*RWWLBK(]K]%14<
MOW-?1]RK=25K7C]R5JOT]VSBXGJVK=R[I;#473F6O7?R(OL:R:@G4>=+/$1U
M6V-T^P&U]M]([60PM&LGJV1B@OJRUWKG2NG18X'-7O'.5VK55"F-P^=KUS^1
M>]_N^2_X<&-+\+N*WNSQ%Y#=63VED=N8K.PY66:.>I9AJPI:>EEL*231M141
MS41NOF!4I>+CH-O#?U[#=1.GK%M;BPD*5K./C>D5E\44JSPRUW.5$5\;G.U;
MKJO#EXIH0E1UA_&=U;V&D.(ZJ[*6W/ O=2VIHYL/<DY4XJYKXWQN=Y?18U 8
ML3TB\3G3;J];9A<;+-B-T/:YS,-D4:R25&(KG=Q(Q7,DT:G,J:H[3CRZ(H,=
MOQ0_L#WO_4X_QF$(C'P$XFK6Z5YK,,3_ &S(9J6*9^G'NZM>'NVZ^9%D>OU0
MM6K"//:K&W;/CQ=#BON$5C-O[UC/1:OY3HK),BHGG=,Y?;*OC;O\0C(V&P["
MQ*+I5E=DK3T\\D25F-^LCW$6+5=)L14P/3#9^)HM1M>MAZ*)I]D]\#'O=[;G
M.5R^V&6=W+C*N:V[E\/>8DE+(4K%6PQR:HZ.>)S'(J>TH%&/\/V]/'O+>&-:
MJ^K6,97L2-^QYZ]CD:J^SI,X-5W_ /$(_M?8?]6R7\Y6!%S]E5*^/V=MZC3C
M2*I6QE.&"-J:(V..!C6HGM(@919XO*\5CP_;L[UNJQ>HRQKY4>V]!HO[H6,)
MX)'.7H3315U1N2OHU/,G>(O_ &J"]0'4A3<WCR>W)Z2-K9N5\;9/_P!UTG.@
MT1?,L+%0'CT'"*F^/K%5K'33;N8<C4N4<RE>)R^Z[JW6E61J>VL+%7V@L2]X
M:_V$[%_-K?YQX10S'[\W'A_$MN/?>)VU)N[/U,MEY*N*C9-(YJ=Y+7;)RP,>
M[[E&NB<.!6O$^_.UZY_(O>_W?)?\.$Q&W6SJGU=ZU[4K[7RG27(XWU6Y'?KW
MH:>0ED8^-CXU:B.@1-')(NH(N!X;Z^5I]$-FT\W6GIY.M3?!-5M1OAFC2*>5
MC$<R1$<GH(W35.PB*D>'JC5N>,/<DMF-)'TKNXK%9537EE]8DBYD]GED<&KQ
MZ%!D                  '#;_HL_P#)O]ZH'5P?]DU/M/WU R
M                   $-;I^DKT^_1[.^_KA4RA
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M;%"K;^(?)4QBHM>#)NL)WD42,541O+R*]J<&JKDX::%:\7*\4/[ ][_U./\
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MCBE6\>@1$                  !PV_Z+/\ R;_>J!U<'_9-3[3]]0,@
M                        !#6Z?I*]/OT>SOOZX5,H0
M
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M(AG8'AHPVP>JF3ZIU,_:N7LG)?DDQ\L,;(F_E&597(CFKKZ*KP G,
M            .&W_ $6?^3?[U0.K@_[)J?:?OJ!D
M         (:W3])7I]^CV=]_7"IE"
M                                               &+B_O!/\ U9GO
MBHRA%                                  CSKKM7.;WZ2[HVKMN!MG-
MY.M'%3@?(R%KG)/&]=7O5&IZ+57BH&H^%3IQN[I=TTM;:WI3CI99^6LW(XHI
MH["+!+# QKN:)7(B\S'<-0M3B$
M       X;?\ 19_Y-_O5 ZN#_LFI]I^^H&0
M    AK=/TE>GWZ/9WW]<*F4(
M                                          8N+^\$_P#5F>^*C*$4
M
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M>QW%'-<U5147SH$<H    AK=/TE>GWZ/9WW]<*F4(
M                                                           8
M>Y(F/R\-Z7A5GC[B1_D:Y%U37V"HR[7->U',5'-7L5.**17T
M
M     #'9B]'6JR1(O-:F18X8DXN5S^'9]4#L4*ZU:4%=WNHV(CO;\O[H'9
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M&/:R1'HG:[E7SZEJ_09   "&MT_25Z??H]G??UPJ90@
M
M!^)8HYF.BE:CXW<'-<FJ*!C5V_CT5>[[V)J_8LD<B /B_2^^3_A7 /B_2^^3
M_A7 /B_2^^3_ (5P#XOTOOD_X5P#XOTOOD_X5P#XOTOOD_X5P#XOTOOD_P"%
M< ^+]+[Y/^%< ^+]+[Y/^%< ^+]+[Y/^%< ^+]+[Y/\ A7 /B_2^^3_A7 /B
M_2^^3_A7 /B_2^^3_A7 /B_2^^3_ (5P#XOTOOD_X5P#XOTOOD_X5P#XOTOO
MD_X5P#XOTOOD_P"%< ^+]+[Y/^%< ^+]+[Y/^%< ^+]+[Y/^%< ^+]+[Y/\
MA7 /B_2^^3_A7 /B_2^^3_A7 /B_2^^3_A7 /B_2^^3_ (5P#XOTOOD_X5P#
MXOTOOD_X5P#XOTOOD_X5P#XOTOOD_P"%< ^+]+[Y/^%< ^+]+[Y/^%< ^+]+
M[Y/^%< ^+]+[Y/\ A7 /B_2^^3_A7 /B_2^^3_A7 /B_2^^3_A7 /B_2^^3_
M (5P#XOTOOD_X5P#XOTOOD_X5P#XOTOOD_X5P#XOTOOD_P"%< ^+]+[Y/^%<
M ^+]+[Y/^%< ^+]+[Y/^%< ^+]+[Y/\ A7 /B_2^^3_A7 /B_2^^3_A7 /B_
M2^^3_A7 /B_2^^3_ (5P#XOTOOD_X5P#XOTOOD_X5P#XOTOOD_X5P#XOTOOD
M_P"%< ^+]+[Y/^%< ^+]+[Y/^%< ^+]+[Y/^%< ^+]+[Y/\ A7 /B_2^^3_A
M7 /B_2^^3_A7 /B_2^^3_A7 /B_2^^3_ (5P#XOTOOD_X5P#XOTOOD_X5P#X
MOTOOD_X5P#\@4OOD_P"%<!V*F)HTW][#'K-]\>JN=]=0.Z     &@]4NLFQ.
MC^*BR6\KSHYK7,E#&UFI-=LJS3F[N/5J:-U3F>]S6IJB:ZJ@7%<;7^(-MYDS
MFTMCW9JZ>XDFO10O7VV-BD1/\Y0N.+_U",1_R'9_\RC_ .&!B0.C/BWQ_6#?
M,&RJ^U9L3)/7GLI<DNLG1/5V\W+R)"Q5U^V"6+(A  !I/6'*RX/I1O;*UU5+
M%7"9!\+DX*DBUGHQ?J*J*!53_#WQ4+I=]YQR(MAC<=2B7RHQZV)'_75K/K!J
MKPAEYT>(W_\ -'Q;XW<%'[E+):P>5=R\-7Q.CB=_G)#Q\X:G'HN&0#";QVU4
MWEM3-[3O/6.IFZ-C'RRM35T:68W1\Z)PU5JKS)[0%%>CN[-P^$/>>;VIU7PM
MN+:N=?&D.9J1K- LU3G1D\#O1;+&]LGW1J+SM]'T=45H:ZGC<_C6Z+8C#R6]
MOW+6X<NYBK5QD%6>MS2K[E))+#&-:W7W2MYE\R*$Q&_A+Z/;WM;_ ,EURW]1
MEQ3KGK<^,JV(W03V+63<KI;'=O\ 2;$C'O1O,GI<VJ<$XEJZH9 ,1E=U;8P,
M[*V<S=#&69&=Y'#=M0UWN9JJ<R-D<U535--0.C_U%Z??\V8;_P QJ_ZP"+\G
MG\%GO$CL*7!92GDXX<!G&S.I6(K*,5SZ^B.6)SM-?)J%3J$
M
M
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M\!FWVF8ZM'5;*YCZZ-5Z1-:BZ:KIJ!8$(
M
M
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MV=7)Q@HTV\E?O--4YGJD3%T7W3O,&O'I&&0   AK=/TE>GWZ/9WW]<*F4(
M
M
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MNJ(Z:5W%VFJ\K4T:W5=$350RW0    0UNGZ2O3[]'L[[^N%3*$
M
M
M                                   !%?7'KKMGHC@(K^4C=D,]D.=F
M'PL3T9).Z-$YGO>J+W<3=4YG:*NJZ(BA9%1/G,>*KJ/-+8V!AYH<=S*C683#
MK>8Q$\CIIXY_2X>=/:"Y#YRWBLZ<316M_8>:;&ZHCF9O#K1C<B^1LT$<&CN/
M#BOM R+==#NNVV>M^!EO8N-V.S^/Y&YC"RO1[X5DUY7QO1&]Y$[1>5VB+JFB
MHGE)8E4(                  "&MT_25Z??H]G??UPJ90@
M
M
M                                *'[XP-7K)XV$V=NASI=MX>.&):BN
M5O>5J5%+KH4T5%1LDTCN;EX\JKHH:\7HHT:6,IPX_&UHJ="LQ(Z]6NQL4,;&
M]C6,8B(U$\R(&7VY2IY&I-0R%>*W1L,6.Q6G8V6*1CN"M>QZ*CD7S*@%&-G[
M>J='/&TS:FU]8=N9J.9B4VJJ]W6NTG6TA\J\L<\;5;K]BB:AKQ>X,@
M            AK=/TE>GWZ/9WW]<*F4(
M
M
M                 "B_BGP&[^DO6?#^(/:,*R4K"P)=FY5=#'=@B]5=#/RZ
M:1V*Z(S75%5>9."Z!J)6V=XV^CF>H0/W+/:VQE5:B6:UFO+;@:_R]W-68_F;
MYE<QB^P$QR;M\;/1? TII,!:M[FR36_<*M2M+6B<_P G/+:9'RM\ZM:Y?84&
M(F\+V%W?U@ZV9?Q![KK]SCZJSMI2(U6PON30^JQP0<WNF5ZZJU7:ZZ\NNJJH
M6KSAD                  $-;I^DKT^_1[.^_KA4RA
M
M
M                             =;(8['Y>E/C,K5AO8ZTQ8[-2S&V:&1B
M]K7L>BM<GL*@$";@\%O0S.VWW*^/O85TB\SX<9;5D.OET9.V9&^TW1 NOS@/
M!9T,P=MENS1OYI8UYFPY.VKH=?)JRNR%'>T[5 :GS'8['XBC!C,55AHXZJQ(
MJU2M&V&&-B=C6,8B(B>T@1V@                   AK=/TE>GWZ/9WW]<*
MF4(
M
M                                               %3^AN\O%-F.IM
M;']4,??K[)=%;6:6SBJ].))&1N6'[K'$U4]+331RZA;AU]WEXI<+U$L4>D^/
MOV-GMJUGQ2UL57NQK.YJ][]UDAD55U\FO +,1A_U(\=__A.5_P#(*G_# ^'_
M %(\=_\ X3E?_(*G_# ^)/Z![R\4V:ZB5Z'5?'WZ^SW5;+YI;.*KTHTG:S6+
M[K'#&J+KY->(2XM@$                  !#6Z?I*]/OT>SOOZX5,H0
M
M
M                                         $37NN="CURQ_1!V&F?>
MR%=;+<PDS$A:B59;.BQ\O,O"+E]UVJ%Q+(0 A_$=?,?E^M^2Z)LPD\5[&LDD
M?EUF8L+DC@CGX1\O,FJ/T]T%Q, 0                  $-;I^DKT^_1[.^
M_KA4RA
M
M                                                   B/J1XD>F7
M2G<3=K[NL7(LJZO'<1M>JZ=G=3*YK?214XZL4+BI>5Z]=.[?BMPW5R&Q;79M
M*DM>Q,M9R3I(M"Q7T2+754YY&\0N?%A?GM]"O_K,E_N#_A!,?F3QN]"V,<]M
MG*2.:FJ1MHN1SE\R<ST3ZZ@Q$'APS5GJOXJ-U]4,?2EJX-*EB9R2HBNC9,D5
M6M'(K55J2/:Q7Z(J^Y=Q70+>+V!D                  $-;I^DKT^_1[.^
M_KA4RA
M
M                                                   C#?\ X>^E
M/4[.IN3>>&DOYAL#*B3LN6JZ=S$KG-;R0RL;P5R\= NH'N>"W#KUFH6J>'A;
MT7;75+]%V1L^N.L>K2HBM57+)IWW=K_I.SZP74G_ #./#Y_RS-_YED/]>$U^
MXO!YX?(I&R?%:1_+]B_(Y!6K[:>L U*VTMD[2V'C/R/L_#UL-CE=SOAJQHQ7
MO[.:1RZN>[3AS/55",^                   $-;I^DKT^_1[.^_KA4RA
M
M
M                                            5*W]U)ZA;C\5N%Z1
M;1W!8PVVZC:R9J*HD6LJ-@=D++E>]CE1RPJV)/,ODU#7BVH9 *F;)ZC]0]M>
M+'+=)-U;@L9G:]]EA<+%;2+[DDE=,A7<CV,:JN;&U\*ZKQ7V= UXMF&0
M              0UNGZ2O3[]'L[[^N%3*$
M
M
M                   !1/=&;J=*_'*FXMR/2M@<RD"^N2KRLCAOX]*:2JY>
M",9.Q4<[L1J+Y@UXO6US7M1[%1S'(BM<BZHJ+V*BAD541%55T1.*JH%%L#FZ
MG5'QSQYS;4B6L'A$F:Z["O,Q\5#'NK/D1R<%8Z=_(UR<'-5%\H:\7J#(
M              (:W3])7I]^CV=]_7"IE"
M
M
M                    A+Q%^'S'];\)6EIV(\;O/$(],5D)4589(I%175Y^
M5%=R*J:M<B*K%XHBHKD4LJJ="7QH=%84V_CJ>7M86FG=5HXJC,]3;&GN4A>C
M)W,;IV-16Z>9 OQ^KMCQI=9X?R!>J9BIAK:=U99)49@:CHU]UWLBL@<]NG:W
M5VOF4'Q:CPY^'K'=$,-9L7;$>3WIEFM;D\A$BI#%$Q>9M>#F1'<B+Z3G*B*]
M=-431$0EJ;P@                  (:W3])7I]^CV=]_7"IE"
M
M
M                                  !H.U^MO2K>F;CVYM;=%3)YN5LC
MXZ<*2<[FPHKGJBN8B<$37M"X;KZV=*]C9A^W]V;GJXO,QQLF?4F257I'*FK5
M]!CDXI[(3&$^<WT&_P">*'UI_P#5A</G-]!O^>*'UI_]6#&;VIULZ5[XS#-O
M[3W/5RF9D8^5E2%)4>K(DU>OIL:G!/9!C?@@                  (:W3])
M7I]^CV=]_7"IE"
M
M                                                          !"
M/3CPM=.NE^\8M[[=MY67+Q,GC;'<L0RP*EEJM=JUD#'+HB\/2"Z=3O"UTYZL
M;KEWAN:WE8<I+!#6='2L0Q0HR!%1JHU\$BZ\>/I UIWS#^C/_P!?G_\ >ZW_
M  H-/F']&?\ Z_/_ .]UO^%!K<>F/A9Z<])]UQ;PVU;RLN4A@FK-CNV(9859
M.B-<JM9!&NNB</2!J;@@                  (:W3])7I]^CV=]_7"IE"
M
M
M                                          !1R;_$&NQ321)L*%S6
M/<U'?E1W%$71%X55#6./_P!0F]_R!%_YH[_A 8?^H3>_Y B_\T=_P@,/_4)O
M?\@1?^:._P"$!B1^A_BXM=8=_5]E3;4CQ#)ZUBSZXV\ME46NU'<O(L$?;]L$
ML6@"                   AK=/TE>GWZ/9WW]<*F4(
M
M
M                           &"79.S5557;N,55755]2K\57_ " *B=:J
ML?53KOBO#KM:M3P&W*R16]S7J52".Q(]L'KCONC6:Z,B5K6-[%D=J[71-#46
M8VCT/Z4;)H1T,%M/')R-1K[=JO';MRJB:<SYID>]57MTUT\R($U]W9T2Z4[U
MH24,[M/'.1[5:RU6KQU;4:JFFK)H48]%3V]/.@-5MZ&.M=$_$-D^@N2?%D\#
M<CFL[8R4T,27(5D@];1.^:U':/B:YDK->7O&HK41%74M71#(
M      (:W3])7I]^CV=]_7"IE"
M
M
M            H3UMR.9Z">*JIU:?2DM[<S;8Y^5O!)85JMI7(6N71.]9IWK4
M5?*S7@&IQ;/:/77I+O:A'?PF[,<BO:CGT[EB.G;C54XM?#.K')IYT14\RJ$Q
M]W7URZ2[+H27\WNW&^@U7,J5+$=RU(J)JB,A@5[U5?:T\Z@Q4OHOE,OU]\5M
MGJO#1DI[;P3'S\K^/=0MJOIU(GN35.]D55E<U%7L?IP0+>+[!D
M        $-;I^DKT^_1[.^_KA4RA
M
M
M              :YO?8FU.HN GVUO#&QY+%3+S(Q^K9(I414;)%(W1S'IJNC
MFK['8JH!57<7^'Y@K%E\NU=YV:%5SE5E;(5&7'-:OD[R*2#73V6!K7S;W^'Y
MA*]EDNZ=YV;U5KD5];'TV4W.:GD[R62?37[0&K5;&V#M/IQ@8=M[.QL>-Q<2
M\ST9JZ6:541%DED=JY[UT]TY?83@B(&6R                   !#6Z?I*]
M/OT>SOOZX5,H0
M
M                                                          $$
M^(WQ&X[HCCJV-QM:/*;XRD:S4:,JJD$%=%5OK$_*J.5JN16L8U4YE1>*:!9%
M4=X]0_&$S;CNHVX;V3V_M622)D+XV5\:Q/6.$:,@1&S*U?(YS5]L-?%[NC^4
MR.<Z4[,S&6LOMY2_A:-BY;E7FDDFE@8Y[W+Y555U#%0ITBZT]19^OFYNC/4B
MW6NI2993$6H*S*KWOK.;+&Y49Y):[N\TXZ:!;%H0@                  (
M:W3])7I]^CV=]_7"IE"
M
M
M     HU=QU+>GCUDQVYXVV*.+[N2C2F1'1N=2Q3+,*:+Y$D59M UXEKQM_L*
MN?G*A[]P2)*Z$_L7V!^8,;^+,!5:,U(UO^(#B_R:NLZQ1LO(U?*N$DYN;3S1
M\JA?%V R                  "&MT_25Z??H]G??UPJ90@
M
M
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M^CV=]_7"IE"
M
M                                                         @>3
MQ#+>Z]2]!:^U4LIWG<V<O-;1(^Y]12Y*Y:ZP+JB-56(G>>E]4+CN[H\)O0O=
M5R2_/MM,;<F572/Q4\M)BJJZJO<L=W2?Y+$!KBVUX1^A.V;D=^/;JY2U$NL:
MY6Q+;B145%U6%RI$[L^R8H-3;%%%!$R"!C8H(FHR.-B(UC6-31&M1."(B=B!
M'[                   "&MT_25Z??H]G??UPJ90@
M                                  =>[>IXZL^Y>F97K1IJ^61=$3_W
MKY@- R/6+"UI%90J2VVIP25[D@:OM:HYWUT0N)KYCNL>&LR(R_3EJM7@LD;D
MG:GMHB-7ZR*7#6_T;]+)UF7*$[+%:3W,D:ZI[7L*GF4RKL@
M
M                                  %+/$)CK72/KUA?$%@W5\A28M=F
MYL1'8B;=BYH5I.?W2N1W)- J(Q_*J)(WTNU U%D=I=<^DV],?#D,+NS'-65K
M7.IW+$=.W&YR>Y?#,YKD5.S@BIYE5 F-B^/6R/\ F7%?[]6^&$=JANG;&5LI
M3Q>:H7KCD5S:]:U#-(K6]JHUCE71/*!E@                   AK=/TE>G
MWZ/9WW]<*F4(
M    $*Y6QD>I>[/R11E6+#5%<J/[6,B8O*Z94\KGKP9__$UQ$F8;9NW,'"D5
M2C&^33T[,[4EF>OG5SD_[-$)JON8V?MS-PK%=H1M?]A8A:D4S5\Z.:B+]?@-
M$84)LETQW6F.MS++A;:HYS]-&R0.7E233R/8ONO_ 'H7K*;$5%1%1=47L4RT
M
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MO)(O-Y0E60"   !#6Z?I*]/OT>SOOZX5,H0
M                          =#-R2187(RQ?Z5E69S-/X21N5 (\Z,11>J
MYBQHBSK-%&J^5&(Q51/KJIJI$I&5 (QZS11+C\3.J)W[;$D;5\O(Z-55/KM0
MU$K?-NR22X#%RR_Z1]2!SM>W58VF59(
M
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MZKV>[=#HB>RNB!,3%B,QB<_CJ^7P=Z#(XJTWO*URI(V:&1J^5KV*J*$=T
M 0UNGZ2O3[]'L[[^N%3*$
M            'YDC9-&^*1.:.1JM>U?*CDT5 (5V_D'].-WW,7E>9N*LJD;Y
MM%5$8BJL,VB=J:+H[3L^H:ZRFF*:*Q$R:![989$1S)&*CFN1>Q45."F6GV26
M.&-TLSVQQ,17/>]4:UJ)VJJKP0"%MS9-_43==+#X=5?C*RJR.?3@[54[V;[5
M$31OG^J:GQE,\$,=>&.O$G+%$UL;&^9K4T1/K&6G(
M
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MJ+>N]'[RGGP.:=4F?C:N+]7:UT',U&U>#^953B[LT LF$
M                                     #!;GVGC-TU6PW46.Q%KZO:C
MT[QBKY./:U?*BET1TW8_4+;KW1[>OJ^HJZHV"9(VK[*QS>BB^T78F#]D=1-Q
M.;%G[ZLJ(NKFSS(]OMI'#Z*K[8V&)#VOM'&;5K.CIHLMN5$]8MR(G._3R)I[
MEOL(359\@
M                                                       >:&\N
MI]OI%XJ]X[VH8^+*6*URU7;5GD=$Q>_A:Q5YF(JZH&_&\?\ J";K_P"2\?\
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M(   0UNGZ2O3[]'L[[^N%3*$
M
M
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MSWJB<\FB</1:FFJN):L4$   "&MT_25Z??H]G??UPJ90@
M
M
M                                                      !#6Z?I
M*]/OT>SOOZX5,H0
M
M
M #I7<SB,8Y&Y+(5J;G<6ML31Q*J>QSJ@'9AGALPLL5Y&S02M1\<L;D>QS7<4
M5JIJBHH'(                    "&MT_25Z??H]G??UPJ90@
M
M
M                                   *G^*GKMO# Y_&]'>E:RMWCEVQ
M.NW:B(ZU'ZTY6P5J_P#!D?[IS^UK5;RKJJJAJ17CJMX8M\=/NG\W4O?>XH;F
M:DL5X9\:Q9;<W-:<J:R6I')JYOET:Y/,X+J^O0I$7HML%%[%P&.U_P!V8&:K
M?TCR.<Z;^+C<G2VWE+ES;F5CLIBZUVS+8;$Q86Y*MR+*YW%D7/%KY>(7Q=(,
M@                  AK=/TE>GWZ/9WW]<*F4(
M
M
M                        "C\<E?'?X@$S]P*B)95&XR67W'>385K(.77R
MKQC;_&]D->)5\;?["KGYRH>_<$B2NA/[%]@?F#&_BS 56*S<BW-X^Z;L.Y)(
ML.BP79V:*U'U,5(V9%7^*]W=+[(7Q=X,@                  AK=/TE>GW
MZ/9WW]<*F4(
M
M                                                        "L'B
ML\/V<Z@/H=2.GBN;OS!1M9+5B?W,UJ"!ZRQ/@?JW2>%RJK>.KDX(NK6HI957
MNIOB-ZE;OV!-TIZD86.+,03UY9,G+%+2O:U7*OW:!R(U7.[%5J,3V UC.XOQ
M<=34V-@>F'3S Q4\C1Q]?$19&NV7(9"7N(DBYX(D:C6/=IK[E^GD"8L'X3?#
M_FNG;+_4/?S7)OC.Q+%#3E=WLU2K*])9'3/U76:9R-5W'5J)HJZN<B$M6@"
M                  AK=/TE>GWZ/9WW]<*F4(
M
M
M                       #"9;>6T<#?KXK.9['8W*6T:ZK2N6X8+$J2/6-
MJLCD>CG<SD5J:)Q7@!VLI@,%G&HS-8NIDF-X-;<KQ6$1/821K@(@SW7GPZ]*
M,S/M];M&AEX'.BNU\+CUD[E[>UDKZL7(CD7@K>;5%[4"XE'9^]MJ;_PS,_L[
M*P9?$O<L??P*NK)&Z*K)&.1',<B*B\KVHN@1GP                   AK=
M/TE>GWZ/9WW]<*F4(
M
M
M  "D>5J0[\\>D%'(M2;'[;9!+%&_1R<U#');CT3LX6).8->++]>-[S].^DFZ
M=U4Y>YR=>HM?'2)[IMNX]M>)[4\JL=(C_J!(J/X7_#!M3JALVYOSJ$MRQ%>L
MS5L16KS+ BLA]&2P]Z(KG.617-:FNB<JZ\VO MK)=$\9?Z#>*W)=(Z]Z6UMC
M/0O9!WJI]T:E5;U61Z-1$[R-&OA5R(B+J[AQ0%XO6&0
M 0UNGZ2O3[]'L[[^N%3*$
M
M
M      !0[K'E[/0GQ<T>J60IRS[9S<,<\G<HBK)"ZHE"TUBKHBR1JU)>35.U
MNJIJ&IQT/%3XD-J=5MM8C8?3E]F_#8N,NY.=]>2!7/C:K(:S&/1'/57/YG:-
MTU:W15U702+D]'=GR[!Z7[5VC8:C+N-Q\27F)IHEN;6:PB*G;]U>_B&:JS%:
MBWEX^&RT-'U-OI)#/(G'TZ.,?')KIV:3OY/J!KQ=T,@
M AK=/TE>GWZ/9WW]<*F4(
M
M
M      #7-Y[#V?U#Q/Y#WGB(,OC4=WD<<Z*CXY--.>.1BM>QVG#5CD70#2=E
M^&GHQL',Q;AV_MMGY9K.1]2U<GGN+ ]NNCXVSO>UKDUX.Y>9/(H74LKQ33L]
MD(C#I_T"Z>]-=T9#>6WHKDNX\G%+#<NW[3[3W)8E;-*[TOLGO:BN=V_74+J3
MP@                  (:W3])7I]^CV=]_7"IE"
M
M
M                          JKXH/$UGNG.;K=.>G,$<N[[$4<MZ^^/UAU
M;UA?N,,,*HJ/F>FCO2141%;HBJOHED1/1V5XZ]R0IEG97,44G1'-AL92#'OT
M7CQKMD8K/:5B*%^.S_TL\='_ #%D?_/X_P#7 ^)-Z#;%\4.!ZA5\CU5S%RYM
M!M:PR:"QEF76+,YFD2]TCW*NB^73@$N+6!                   0UNGZ2O
M3[]'L[[^N%3*$
M
M                                                          !1
M_(8NMA_'U5L;I8GJF56.YA99T3NW2OQ:P5U37RMGB=&S^.B>4->+P!D
M                 AK=/TE>GWZ/9WW]<*F4(
M                       #7-V[PQ^U*J.F3O[\R*M>HU=%73[)R\>5J>?Z
MQ9$1[#E>J&[];6+1]6@[C&^-6U8M-?L7N]-WU-2_$?9W]6-LM6Y8?+;JLXR:
M.;<;HG;S-]VB>T/BMTV9OZENEOJL[6U<LUO,L*+JR1J=KHU7S>5O;[9+#6X$
M4
M                                                      H5XU=[
M6K.]H=H1[;C?>PD-6]A=U55L1Y"O)-]T>Q',7E<S5J:)VM=Z2*BAJ,#M?QJ]
M:L'C8L=F<)3W!)"U&-OVJ]B&R]&IHBR+"YK'+[/(BKY08SGS[.J'_(^/^M<^
M$#$E]!_%)OCJMU#K[0SNV:>+QTU6S8?;@2RDB.@:CFHG>.5NBA+%K @
M             (:W3])7I]^CV=]_7"IE"
M                  !\<Y&M5SET:U-57V$ A7;U+_J#O6YD\FBR8RLO?.A=
M[ES.;EAB]K1-7>?3V37&4U-:UC48Q$:QJ(C6HFB(B=B(AEI] ASJ/A/BQF*6
MZ,(GJR6)=9&,X-999Z:.1$\CTUYD_P#::B5+.,O1Y/'5,A$FC+43)D3S<[47
M3ZFIE7:
M
M 8#-[YV5MEZQ;BW'C,3*B:K%>N05WZ?:R/:O[@'S";ZV3N61(MN[CQF5F5-4
MBHW8+$FGVL;W+^X!L                     (:W3])7I]^CV=]_7"IE"
M                                           !PVXG359X6<'21O8U
M?9<U4 BKHW89#<S&-E3EM.2*5&KP72-7,<GU%5#52);,J 1QUCMQ,P5*DNG?
MV+22,3RHV%CN9?\ XD0L2MLVA!)6VOB894TD2M&JHO:G,G-I^Z*K-D
M
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MZ?I*]/OT>SOOZX5,H0
M    $/[TP>4VEN%N\,"G^S/D6271-6QR2>[8]$^PD\_D7ZAJ(VS"=3MLY.!O
MKTZ8R[I]T@L<&:^7ED]RJ?64F&NQE.H^T\9"Y[+S;LZ>XKU/NKE7VT]%/JJ,
M-:!BZ67ZF;E3+9.-8L+65&JU->[9$U=4A8OV3G?9K_[D+Q$U(B-1&M31J<$1
M."(B&6GT
M
M"C4EJCB/'[)/NAS6169(XL9--_HTFL8=D5;37RJY>[;_ !U#7B\H9 */2STL
MKX_:TFVE:_U5SH\K-#Q9W]?$21V$54\J<(G?QT\X:\7A#(
M    (:W3])7I]^CV=]_7"IE"
M           _+V,D8Z.1J.8Y%1S7)JBHO:BHH&G9+IAM7(2.ECBDI2.XJE9Z
M-9K]JY'(GU-"ZF.*ATIVM4>V2=)[BM75&3/1&?52-&_]HTQN=>M7J0LK58F0
MUXTY8XHVHUK4\R(A%<H
M
M            "M'BG\.-_JLRIO39+F1[ZQ425WU7O2%MZLQRO8ULBJB-EC<Y
MW(KM$5%T54T:%E5_QWB/\4'2AD>W]VXB6^E32-B[AQ]A9U8WLTLQ.B67M]VY
MSU7SA<C]W_$OXG^J#7X#:&'?0?:^YN=M_'V%L(UW;]WF=+W?VZ*U4\X,B>_"
MSX<<CTM]<WQOES9=]Y:)8&56O29*5>1R/D1\B*J/FD<B<ZM54:B:(JZN"6K,
MA                   0UNGZ2O3[]'L[[^N%3*$
M
M
M                         !U[]^CBZ<^1R=J*ECZS%DL6K$C8H8V)VN>]
MZHUJ)YU4"!]P^,SH5@K;Z<.5MYE\:\KY,94?)%JGFDE6)KD]EBJ@7'S >,WH
M5G+;*<V4MX9\B\K)<G4?'%K[+X5E:U/9<J(#$\8_(T,M2@R6+M0W<=98DE:W
M6D;-#(Q>QS'L545/910CL@                  !#6Z?I*]/OT>SOOZX5,H
M0
M
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M^_1[.^_KA4RA
M
M                                                          4K
MZE\W0_Q9XSJWG:TGQ"W/&D%G)QL<^.M-)4]3E15:BKS,5C)U335S%7EU5%T-
M>+D8O*XS.4(,KAKD.0QEIB25[=61LT,C%[%:]BJBAE^LED\;AJ,V3R]N&ACJ
MS5DL6[4C888V)VJY[U1$3VU IKT[5.MWBYR/53;U>1^P]JQ+##E7,<R*Q-'4
M6I$C5<B>D]SWS-3M1C4YM%4->+J!D                  $-;I^DKT^_1[.
M^_KA4RA
M
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M?H]G??UPJ90@
M
M                                                         (XW
M=URZ?[*WKC.GN9M67[KRZ5UI4:E:6QS+<E=#$BN8FB*YS5X+Y.(7$C*J-17.
M71J<55>"(B!%4]Y^.WI_M_-V,3MS"6]R5:LCHI<I'-'5K2.8NBK!S-D<]OF<
MJ-U\FJ<0N)EZ/=;MF=:</8R.V))8+]%6LR6)MHUMJNLFO(Y4:KFN8[1>5[5\
MG'1> ,20$                  !#6Z?I*]/OT>SOOZX5,H0
M
M
M                                 %)ZS(]Q>/VUZ^G-%AX^:I$[LYJ^
M'9R\%\SY%D0->)Z\3^[Y=F=$-U9&K*L60O0-Q51[5T<C\@]('JU?(K8W/<B^
MP$B'?!YT,V5>Z9_'C=^!J9G*;AFL,I_E&%EF.&A Y:Z(R.5'-:Y[VR*K]-53
ME"VM6V9@Z71OQL+M';.M;;.>@EC;31RJV."Y26XV+CKJC)XDY/XN@/%Z0R
M                "&MT_25Z??H]G??UPJ90@
M
M
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M"IE"
M
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M4(
M
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M>'B,V5/D]IY;:CJN"S3(X\TV%CK"/= JK'W,DGN=/2U7RH!9$(
M
M
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M)8]# R   $-;I^DKT^_1_.^_KA4RA
M
M
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M]X+&Q>#9$7P_;<U1.%C(_CTP*GL(   $-;I^DKT^_1[.^_KA4RA
M
M
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M<P    AK=/TE>GWZ/9WW]<*F4(
M
M
M          'GUXE;NZ^MWB(H]&MO3Z4<4Z*E5A>Y4K-LR0)9MVY4355[N-5:
MO:O*ST4U=Q-1OKO\/S:_Y([MF\;_ .7N[X6EK0^I][Y^YUY^7_\ 7:@U7>+=
M76/I%\:O#OC)I4R&5R->DUE1TBS-DD732DJ<JM2XU\6O#56Z=BJH59/I#X'M
MMX:"MFNJT_Y;S*HV5<%7>L>/@<NB\DLC51\SD7MT5K/)HY.(35L<7B<7@Z$.
M+PU*#'XVLWDKTZL;888VIY&L8B(@9=P                   (:W3])7I]^
MCV=]_7"IE"
M
M                                                      !1KIZF
MOCOW*NFNDF37VO\ 940->+RAE1?>L$<GCWPC7QHY%FQTBHJ=KH\<BM=[:*U/
MK!KQ>@,@                    (:W3])7I]^CV=]_7"IE"
M
M
M                                !13JQX3>L6[NJ6YMZ;:LXVO0RMQ]
MBF]UV6"=(W-:WTD9$NBKIV:AK6J?,W\17_C%#_S6S_J@;'6=X)^O;[*777<6
MZXFFEA<C,LJ:)HGI=SKV!==GYF_B*_\ &*'_ )K9_P!4$V)5\._AUZP=-NI5
M;=&\\A5LX.*I9@?%!?FL/[R9G*Q>1\;47C[(+5P0R                  "
M&MT_25Z??H]G??UPJ90@
M
M
M                             !#6Z?I*]/OT>SOOZX5,H0
M
M
M
MAK=/TE>GWZ/9WW]<*F4(
M
M
M     ".MX==NDVP,T_;N[]RPXS-1QLF?4?#9D<D<J:L76*)[>*>R%Q@?G5^'
M_P#YUK_[M=_X<&'SJ_#_ /\ .M?_ ':[_P .#'9I>)SH+?E;#!OBBQ[ET1;#
M9ZS/JNFB8U/JJ#$H8[)XW,4XLCB;D%_'S)S0VZLK)X7IYVO8JM7ZBA':
M              $-;I^DKT^_1[.^_KA4RA
M
M
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M02?Z1.*Z(J:JUS5!UZ&AD                 (:W3])7I]^CV=]_7"IE"
M
M
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M4(
M
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M@
M
M                                              (AZA>)7I;TPW))
MM3=ENY#EXH8K#F05))H^2=%5NCF\.Q N-5^>QT'_ /$,A_N$H,/GL=!__$,A
M_N$H,;5T]\2W2WJ?N6+:FT[=R;,2Q2V&,GJ20Q\D"<SM7.X=@,2\$
M           !#6Z?I*]/OT>SOOZX5,H0
M
M
M                 $4[]\.72?J7N&3=.[\3-<S,D4==\T=RS WNX45&IR12
M-;V+Y@NM9^9GX?\ _E^S_P"8W?\ 6@UB=Q>"'HME<;+6P<-[ Y)6KW%Z&U+:
M1K_)SQ6'/1S?.B*U?90&HQ\+.W=K]/\ K-FNFV[,0E?JG@F6FXO/P69UKWJ<
MC6O<Q8'.Y$<L+DFC<C>+->9$<WB6KP!D                  $-;I^DKT^_
M1[.^_KA4RA
M
M                                                        =.SE
ML53E6"W>KUYD1%6.65C':+V+HY44#B^,&!_\4I_[Q%\(#IY/>NSL+3DR.6S^
M.I4845TD\]N&-B(U-5XJ[MT\@%(]G;KK=6O&Y6W=M!'OP%3OE2YRN;STZ6-=
M5=,Y%1%1LLBHUO,B+HYNNBAKQ?D,@                  AK=/TE>GWZ/9W
MW]<*F4(
M
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M1>/*U./V2KH@2U* 0                  $-;I^DKT^_1[.^_KA4RA
M
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M&@4WQ5&;-6)MP9R1URQ9D=)K,JN6215U=(]5[>/8;9;(B\J:-]%J=B)P3ZR
M=#)8FIDXU;*U&6-/N=AJ:.:OL^=//J!(_AOWO>I9>ST[RTBNKR))-C&O77NK
M$7I2QMU^Q>W5^GD5%_A*9JQ9HB@                    *17W6J/CRKU-Q
M7)VX>[+%9QL+Y7MKO>N)Y:Z(W5$X3LY4\[T#7B[H9
M   (:W3])7I]^CV=]_7"IE"
M
M                       %4/$M))+U%P]>95]5;0K\B+V>G9FYOKZ(:B5K
MCO=+[94? /J(BKHON5X+[2]H&W>%N25FZ=PUV?T5U-'.\W-'.C6?N.<2K%I#
M*@         !!?BD[_XF8GDU]7_*3>\T[.;N)>77_P"(L2H5Q7)^2Z7=^X[E
MFGUN/[II';  ?-@<_P#UFP7JWN_6H^\T\W=.[S_X=2474,M
M        * ^-K?.-_P"H%3;T>$]7W7M^"I;Q6[JMM\-J-LJK-W3XVLT<C7>G
M&[G1S'<4[51348[:GCRZBX?&Q4-RX2AN&>%J,3(<[Z5B31$3FE[M'L5WG5K&
M@QG_ /U!\]_R-4_\PE_U ,25T*\6V4ZP=0*^RK>V*^*AGK6+/K<5M\ST6NWF
M1J-=$U%U]L)8M,$                  !#6Z?I*]/OT>SOOZX5,H0
M
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M<*F4(
M
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M638]3=N,C]5MHY:N6QRNYW5;L:(KV<W#F:J.:]CO*U4UT75$,U(00
M           $-;I^DKT^_1[.^_KA4RA
M
M
M                H+U?QO\ UI\8^-Z?77/DP.+]5HV&-56IZI6KKD;:(J>Y
M5_.^/F[>SS(&IQ?2K5JT:L-*E"RM3K1MAKUX6I'''%&B-:QC6HB(UJ)HB(&7
M,!B]R;=P^[<#D-M9^LVYA\I ^M<KO35',>FFJ+Y'-7TFN3BUR(J<4 I3X-I;
MVPNM>_ND]R5SX61V&\?<OLX>WW+7HGDYXY7NX>P&JO4&0
M   0UNGZ2O3[]'L[[^N%3*$
M
M
M       "C73[5WCOW*J\523):*O'3_9$0->+RAD  4:Z7</'-N].S63+<.S[
M!JAKQ>4,@                  AK=/TE>GWZ/9WW]<*F4(
M
M
M                               % >J?0+Q#7.LVZ=]=/\;8J07[DDF/
MRE+)UJ4[H)&-:NB]_'(U%3@J+H&M8?\ Z1>-W_Z_/?K)'_Q@/A_TB\;O_P!?
MGOUDC_XP'P_Z1>-W_P"OSWZR1_\ & ^-Z\-O0WK5M#K,S?'47%R-K35+C;F4
ML7JUR9\\[$1JO5DTCW*Y?*H+5W R                  "&MT_25Z??H]G?
M?UPJ90@
M
M
M                !#6Z?I*]/OT>SOOZX5,H0
M
M
M                               !T,SF\-MW'RY;/Y"MB\7 FLUR[*RO
M"SVWR*B :!3\170^]>;CJ^^<5ZRYW(U9)EAB5R\$TED1L?\ \07$EPS16(HY
MX)&RP2M1\4K%1S',<FJ.:J<%14[%"/V   :3N7K!TNV=,ZMN7=V+H7&^[J/L
MQOL)IYXHU<]/\T&.KMSKCTAW9;9C\!O+&6K\J\L55TZ032.7AHQDW(KE]AJ!
M<2 $    !#6Z?I*]/OT>SOOZX5,H0
M
M                                  !I^_NI.W.GE%EC,2.EO3HOJ>.@
MT6>73RZ*NC6(O:YWU-5X 5_R/B0ZA9:=SMOXVM3J(OHM;$^U)I_&D<J-7ZC4
M-8FN;$>)7>V*L,9NC%5[M1RIS<K'U)M/+RNU<Q?:Y1AJP^R]\;?WYBDRN!G5
M[6*C+-61$;/!(J:\LC=5TU\BIJB^13*MC
M                ^.<UK5<Y41J)JJKP1$0#SDSV2W3XP^NR[7Q^0DJ;#QLD
M[Z7+JZ&KBZSD8^VL?!'33JK437L5[6Z\K0UQ/>;\"W2:UMV3'X*UDL?N!L6E
M;+S3^L(Z9$X+-#RM8K57M2/D7S*$U&'A.ZD;JZ=]3+W0'?$SG4GV+-/'PRO5
M[:>3J\SG,B<O_<SM:[1$X*[E5NG,[4M7P#(!HW6/;FX-W=,MQ[:VJ](\_DZR
M5Z3UF6LC7.E9S*LB<43E1VOG[ 1779O@%VK5@CGW[N2YD[ZIK+6Q2,J5FN\W
M>2ME>]/9T9[0:UC.K_@>V[0VQ?W!TQO769;&POM/P]][;$=J.%JN<R)[6,<R
M143T>;F1R\/1UU0:S?@CZR9_>&/RO3K=%I^0M8&".YA[T[E?.M%7I$^&1R\7
M)$Y6=VJZKH[E[&M!8MV&0   AK=/TE>GWZ/9WW]<*F4(
M
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M6#57B#+SH\1G_P":'BXQNX*/W*62U@\J[EX:OC='$[L_A=SQ\^H:G'HN&0
M T#K/U'Q72WIWF=TY*5K;+87UL36<J<UC(3,<D,34\O'TGZ=C$<OD"Q5?P!;
M*R*9'<_4.Q$Z/&+7;A:,CDT2:5\C+$_+[$:1QHOVWL*%J\X9 ,;D=Q;?P\S*
M^6RM.A/(WO&16K$4#W,UTYD1[D54U334#I_'C9?_ #'B_P#?J_PP(KR^8Q&8
M\26P9,1D*V0CBP&<;*ZI/'.C%5]=4YN[<[37R:A4Y!
M
M                                               -4ZG1SS=/-SQU
M]5E7&V5T3M5J1JKD^JU% IQM%S5H6&I[M)M7_5:FAMEGP &L[P5NE)O_ 'FL
MCO\ )X)_V@7JP;)HL)C8K"*D[*L#947MYTC:BZ_5,-.^
M                         "/>NU.2_P!&-^5HFJ^1<'?D:U.U>Z@=)_\
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MCH$:KT;IKIJN@%A @
M
M                     ''/#%9ADKSL22"9KHY8W<4<QR:*B^PJ*!2/>6U\
MCTKWA9QUB)\N%LJKZ,_DFJZZM5%[.\CUY7I^\J&F7/6N5+C$DJS,D:OD141R
M>VB\4*/Q<R%*A&LEJ9K=.R-JHY[O81J =_I7LR_U+WK#D;4"LVWBY&2W7NXQ
M\L:\S*Z+V*Z1?=?Q=5\VLHN:9:
M        =;(T*V5Q]O&76<].[#)6L,_A13-5CD^JB@><_0_<S_#-U\S6T-]N
M=4PEM7XB]=D:J,8WO$EIW=$_[MZ:<?(R157L#5^K]9SJ+L7;FWY-TY?<-"#
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M2    (:W3])7I]^CV=]_7"IE"
M
M                               ,1N3:^!W=C7XG<%)ERF[BU'\'QOTT
MYHWIHYKD\Z*!!N9\*]*2=TNW]P25X55=(+D"3.:GF[R-S-?\PNICGP'A:Q%:
M=L^X\W+>C:NKJU2)*R.T\CI'.D=I[2)[8TQ.>&PF)V[CHL3A*<=''P)]S@A3
M1-5[55>U7+Y7*NJD5WP
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M6IP"   !#6Z?I*]/OT>SOOZX5,H0
M
M    !V<5[ *W=2O$+?=D)=N].D:O=N6*3,<J2ND>G!4KM<BMY4^^.1=?)PXK
M<344V+W4?)2+;O[AN=^JZHC[LRJB^PC%T;]0TC.8#J]U-V-8B7(VWYC%:HU\
M%YZV&.3S-F75['>;5=/84F"T^R-[8;?F#BS>&>J-5>[M57Z=[!,B(JL>B>WJ
MB]BH9:;(
M                                   0UNGZ2O3[]'L[[^N%3*$
M
M                                C'KWN>?;73RVE.18KF6D9CHY&KHY
MK)4<Z54]MC'-^J6)58=M4&5:+;;D_P!IM)S*[RI']BU/^U32,R!^9(XYHW0S
M-1\,B<KV+V*B@9?H3F[&U>IJ;?615QN81U61J]BN:U98'Z>=%16?Y2DJQ;XR
MH
M                           AK=/TE>GWZ/9WW]<*F4(
M
M                       !"?B=QT]K8M*[$BK'1R$;I]/(R6.2-%_SE:GU
M2Q*@K#3,L8JH]B^Y8D;D3R.9P5#2.\  _73:M)F.LN'2JG,VK/WDCTXHC*D3
MG.5?JIR^V2BZ)EH
M                                         0UNGZ2O3[]'L[[^N%3*
M$
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M[T_WF&=CI?\ ,UYO)Y@,X
M                                         0UNGZ2O3[]'L[[^N%3*
M$
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M4,V*L.10
M                         "&MT_25Z??H]G??UPJ90@
M
M                       "N7BJREAL.W,*Q52O*ZQ;D3R+(Q&1QK]1'O\
MKEB5&E6!E6M#6C31D3&M3V].*_54TCE <%X.35J\'(O8J+VH!G_#I>FQ74J]
MA8W+ZI<K3Q/9Y.:!R2,7VT3F3ZI*L?.KW57+[WSEC:.U[#HMLUW.AE=$[E2V
MYBZ/DD<G_=(ON&]B]J]J(B0:+6VKCHFIZRY]B7RKKR,U]A$_?*CCN;3J2,5:
M+W0R^1LB\\:^POE0#BP>5M06OR-D]>=%Y(7/XN:]/L%7RHOV*@;*!K>XUEQV
M0Q^9IN6*Y&]%9*W@J2P*CV.]M +V8JY^4<92R'+R^MP13\OF[UB/T_=,-.V
M                        -#ZG=4,3TWQC)9V^MYNVCO4,<UW*KN7MDD7[
M&-//VJO!/*J45CRW4'JEO:1UF;+34:#UUC@JR.I5T;YFMC7F>GLN5?;+C+IU
M,SU,P,GK>+S]Q[V\58RU)(BZ>>.55:[ZJ%P3ETDZ\)NBY#M?=[&5<]*O=T[K
M$[N*Q(G_ ';V+[B1?)IP<O#@NB+FQ=3D10
M                    0UNGZ2O3[]'L[[^N%3*$
M
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M14XHY%3M NAT]W%)NO96%S\VBV;=9OK*IP19XE6*543R:O:XPTV4
M                                      0UNGZ2O3[]'L[[^N%3*$
M
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MI^DKT^_1[.^_KA4RA
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M2Q-'%K_GJ@'+4O4K\??4;,5J)."R0/;(W7VVJJ =@
M %=>O?2G(V+[NH&U872V$1KLO5A15E1T2(C;#&I[KT4TD1/-S<=7:65*A>CN
MJI*Q&WVK!.G!SVHKHW+Y^'%#2.Q/N;$PL5T<CIW^1D;537VU=HB 9KIST]S?
M53<$5Z_"^MM2J]/6[*:M8K&KJL$*K[I[OLG)[GM7R(LHN;##%7ACKP,2.")J
M,CC:FC6L:FB(B)V(B&6G[
M       $-;I^DKT^_1[.^_KA4RA
M                  !PV[=6C7?:N3,@K1IJ^61R-:GU5 TF]U:VQ4D6.NVQ
M;1%T[R-B,9]19'-7]PN)KL8OJCM;(R-BEDDHO=P1;+41FOV[%<B?5T&&MS8]
MLC6O8Y',<B.:YJZHJ+Q145"*^@
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MHU?\I%&IB1Z]:O3@CJU(605HD1L4,348QK4[$:UJ(B(17*
M                                 $-;I^DKT^_1[.^_KA4RA
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MV%,-/H
M                $-;I^DKT^_1[.^_KA4RA
M                          # ;VGDK[3RTD2JC_5W,U3MTD5&+^XI8-;Z
M/5H8]N6;;43O[%M[9'>Q$UK6I]35?KBI$AD4 B'K!$VME</DH5Y;3HY&*J=O
MW%S7,7ZBN4U$J6X7K)%'(O!7-1RI[*IJ95^P
M                              U/J=A[&>V!N#%U&J^U+4>^&-O%7OA5
M)6M3V7*S0"G&T[+'U)::K]UA>LB)YV/\OU%-LM@  8"U2EW)NO%;<I)SSS31
MU5TXZ/G>FNOVJ<7 7P8QL;&QL31C41K4]A."&&GZ
M                                                   AK=/TE>GW
MZ/9WW]<*F4(
M =++X]F5Q=S&O7E;:A?%S>97(J(OU%X@17TVSR;<RES:N;7U;OION+I%T:RR
MWT',5>STT1.5?_::J1,)E7YDD9$QTLKD9&Q%<][E1&HU.*JJKV(@$+9:W_U$
MWU5J4-7XFKI&V71=%A8[FFE]IWN6^?AYS7&4U]G!.PRT
M                                        JWU<Z+YG!9>;>&QJ[[&-
MF<Z>U1KMYI:SW<7\L:>ZB=VZ(GH^;3B:E3$6P[MC1.2[5>R9O!RQ*BMU3V':
M*A4?';AOY*5E# TI9+DZ\D2-:LLRJO\  C8BZJ!8;H?T;L[4D^-NZF(FX96*
ME*FJH]U5DB:/>]W'[JY%TX>Y37RKPS:J<2*
M                                              0UNGZ2O3[]'L[[
M^N%3*$                                                   &G;
MSV!2W2GK<#FU<LU.7OE35DK4[$D1./#R.3C[994QID,'5K;;?4ZW>6JS.$>J
M,N,1$[.55]-$]LOP?)<#U-W@J09F1U:@JISLE5L$/U8X_2=]4?!(NU=I8[:M
M18:VLUN73UFV]-'/5.Q$3R-3R(2U6P$
M                            #!9796T,Y*MC+X*A=L*NJS35HGR+[;U;
MJOUP.UB=N;?P+5;A,54QR*FCEJP1PJJ>RK&HJ_5 R8
M                                                      !#6Z?I
M*]/OT>SOOZX5,H0
M
M
M                         AK=/TE>GWZ/9WW]<*F4(
M
M
M                                                       0UNGZ
M2O3[]'L[[^N%3*$
M
M
M                         (:W3])7I]^CV=]_7"IE"
M
M
M                                                       $-;I^
MDKT^_1[.^_KA4RA
M      !CLQG<5@*WK65LM@C75(VKQ>]4\C6IQ4#0K76?%12JVOCI9(T7@Z65
MD2K]1$?_ -IK$UDL/U7V[DI&PW&R8][N#9)-'PZ^R]O9]5-"8:WMCV2,:]CD
M<QR(YKFKJBHO%%14(KZ
M
M                                !#6Z?I*]/OT>SOOZX5,H0
M                                           ZF3R$&*Q]G(VET@K1
MND?IVKRIP1/95>" 0[@<+D>I>;M9G,ROCQ4+N5Z,54U7M;!$J]B-1?27M^JN
MIKC*6:&V\!C(4KT<;7BC3_\ )M<Y?;<Y%5?JJ9:83<G3O 9V![Z\#,?D]-8K
M5=J,17>1'L31')^Z74QJO3K/9'#YF;96;56JQSV5T<NO=S,3F5K5_@/;Z3?_
M 'EI$LF5
M
M                     0UNGZ2O3[]'L[[^N%3*$
M                               -,ZI22,VA8:SW,DT+9/M>?F_[40L2
MN;IG!##LO&NB1.:9))953RR.D=KK];04C;2* 0]OMK:G4C$6:JZ6)4J/DT[>
M9LRL37VT30U.(F$RH
M
M                             "&MT_25Z??H]G??UPJ90@
M                                       !B-SX?\O8&[BTT26:/6%5
M[$E8J.9K[&J)J((\Z9;IBQ+YMIYIWJKTF<M-\OHHDBKZ<+E7L7FXM^JAJI$M
M&5=3)Y.AAZ4N0R4[8*L2:N>Y>U?(B)VJJ^1$ B3;3;6^=^R;BFB5F/IO;,C7
M?8-BX01_;*J<Z_5-<1,QE0
M
M                                  $-;I^DKT^_1[.^_KA4RA
M                                             !IF\.GF.W,YUV!R
M4\JJ(CI>7FCE1.SO&^?^,G'VRRIC3X]N=5\,U*N/MR2U6^BSN[$<C$3V._T<
MB%^#D@Z;[NS]IEC=>15L;%['R=_*B>9C6^@WV]1IB4,/AL?@J+,?C8NZKLXJ
MO:Y[E[7.7RJIE7?
M
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M"
M
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M1TU5J^?1S85^H&O'HN&0   AK=/TE>GWZ/9WW]<*F4(
M
M
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M6NYR/YE5.*]F@%EP@
M
M
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MY7Z+Z-6/FAJ:Z]B\TD/[H:O'HN&0   AK="+\Y7I_P"QM[.Z_P"?7"IE"
M
M
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M/VU/56PW([JRJLDS64:U6L7NT7NX(47BD3.9W%>+G*JKIP:TEJ80@   1[U
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M\$&OOS=<9\H._>S3^\EGZ_N0:F0(
M                                 (ZZ^?L4W]^8[W\RX+&R[$_N1MK\
MU4?Q:,(V
M                             A?Q$^XZ5_\ _1=N>^G"Q- 0
M
M                                       8/>>UZF]=IYG:-^:2O2S5
M2:C//!R]ZQD[58KF\R*FJ:^5 ._AL9%A<1C\/ ]TD&/K0U(I)-.=S((TC17:
M(B:JC>('=
M                             -4WSL/';\3;B9&U/5^+6=H[DJ^K*Q.\
MLXU7JR.3G:[[F[G7FTT7V0-K
M
M
M
M
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M[*W!3S'<IS3PP2:3QM7317PO1LC477M<U C:P
M#XJZ(J^;B!!?0_Q+XWK9N/*[=I;=L8>3%U5N23SV(YVN1)FQ<FC&MT7TM==5
M"V)U"
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M-6-M[NF2QK$LZ.6/5)6,7TN1VFGF V\
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M &K#=,.D.S^D-/)XW9C+,./REAMN6O9F6PC)&QI'Z#G)S:*B)[I5"-\"
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M )J:-C;79LG9V"VA%96Y%@Z4&/9:<Q(W2MKL1B.5J*[151.*:A'FGOM=W/\
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M_)F5V3'9KULVM=UJK8G6Q&QU7O$8L:O3F37O5YN9R^0)J1 @
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M%TQV7'31$JMP6,2'E[.7U2/3L#++;MCK2[5SL5S1:C\?;;81W9W:P/1VNOL
M4L_P]_[6W[_5\9[^R&JQO^(%+87>NT(7:^JLQ<[XO-WC["H_]QK 1N./VSX[
MF4*K*&Y\6E!L,:549^2W-2%&IR:+ZHNJ<NGE!\<\FV/'M+&Z*3<V-=&]%:YN
MF,XHJ:*G"F#XSGA.Z#=1.CV?W'>WE'4BI92I!#72I92=5EBE5W%J-331'+Q"
M6HM_Q >.]=G)_P#NR?\ & L7QQK&QXZFQC4:QL$;6M3@B(C$1$0,NT
M                             !67QU_L5K?GRG_,V0L;)X._H^[8_E,A
M^/S@JMGB!V]E?#OU]Q'5O:4/)A,S9=DV0MU;%ZSKRWZCE3L;,UZO3[=>7W(6
M.7QQ;BQ6[6=,]S8.;O\ $Y;%V[E27AJL<SX'(CD371R>Y<WR+J@(O'L77XB[
M:T[?R31T_P!V8&5%O ZR";K=N:>XNM]N(N.BY_=<SKU=)%]O10U7H4&5(/\
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MJ%BYVRXV1;.V]%$U&1LQE)K&)V(UM=B(B>T&6<
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M>FZ#;N)O,RMEZZNBC?6:C:%-CU1$<]J,C<[A[EJJNG,@6K;^)C]@^^?S?_\
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M_B ?WUV=^;)_Q@+%\\?_ $"K_(Q^]0,NP
M        !67QU_L5K?GRG_,V0L;)X._H^[8_E,A^/S@K;>N_2ZOU<Z;97:O*
MQ,PQOKN"G?HG=Y"NBK%Z2]C9$5T3U\C7JH(\K,WN/<%G!XG9.:YFUMJSWF4:
M\K5;-76[(Q]B%VO'1)(U=HO8YS@V]?-A_P!Q]L_FFA^+1AS4$W7#G/"EXDW;
MO;0DL[/REBS:JHQ.5EG&7UUGKL=V=[7<Y-&JO:UBKZ+@UU<&GXF^A-S$MS";
MUHP0*SO'5IUDCMMX:JU:ZM[Q7)V:-:OL:A,4UW]G\OXONN>+P>T:T\.U:+4J
M5IWMT6#'MDY[5Z9.*,5VNC&JO'1C?=*%X]%XZ=?'8EN/J,[NI4KI!!&G8V.)
MG*U/J(@940\ O[0-X_FMGXTT-5?P,J#]3OIU[?\ SC@OYB$->+\!D  >=*?3
MJ_\ ]E_^2&O'HL&5:_&?TK^/'3;XW8R#GW#L[GN>BGIRXUZ)ZTSAV]VC6S)K
MV(UVGN@L<?@PZI-WSTV=LS+2I+G=H(RGRR+JZ;%R(OJSM%[>[1'0JB=C6MU]
MT"J[K\8O!QU[GR,V/FN;&R??10.CX-MXBP])$;&]WH]_7<C.9JZ<6^1KT<%Z
MN/A?$ST,SE"._#O2A41[45U?(.6G.Q5[6N9,C5U3^+JGF4)C7-U>,#HU@I(:
M6$R4FY\O8ECABJXV-S84=*]&HK[$R,C1$UU]%7+[ ,2/U5ZD8[I/LZQO7+TY
MKV-J3UH;,-56),C+,S8N9B/5$<K>;7E54U\X1JVW?%!T+W)698@WC3H2.3TZ
MV4YJ$K%\R]^C6K[;7*GLA<0AXN^NG2;=/3:796W,E6W)N&W;KSUIZ:++#22O
M(CWR]]IR<SF<T2-8Y5T<NO +(EOPC;8S.UNAV$K9R%]:W?ELY**K*BH^.O:D
MUBYD7LYVHDFGF=YPE4EWYFMP[8\3^Z=U[8JON93;^>N95:[$5R.KU'K).C^7
MCW:QHY)%3L;JH:\7JVOXHNB>Y<%#F9-U4\/,Z-'VL9DY$K6X9-/29RN]VJ+Y
M8^9%#.*E=?\ J1:\3?4K;O3SIA#)>PU&62&C8<Q\;;-FPK>^M.:J<S((F,31
M7M14;S.7MT"SXOIA]EXG$[$I]/T:LN%JXMF%>B\'20-@[ARKV\7)JJ^RH9>?
MW2[=64\)'6O,[8WS6F=MN\B4[UB)BKWE5'J^I?A;]FW17<S475$<]/=MY0WU
M<G(^)WH5CL0_,KO.E:B;&LC*E57S7'KIJC$@1O.CE[/31NGET#.*A]/:.?\
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M5U[. ,5D_P 0G^T]@_R&4]_5"Q=#9_\ =+ _FZG_ ## RS0
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MK!IE;E")U>K*MFU7Y(G.YU;I7EC1>/G0+K?(XV11LBC32-B(UJ>9$31 C]
M                                  :SOKI]M#J5A6;>WKCDRF(CG9;9
M766:#2>-KFM=S0/C=P1[DTUTX@=G9VS=M[!V_5VMM.DF/P5-9'5JB22S<JS2
M.E?Z<SGO75SE7BX#.@1+N+PR]#]UYR_N/.[4CL9C)RNLWK#+=V!))G^Z>K(9
MV,17+Q=HWBO%>(74I4*-7%T:N-HQ]U2IQ1UZT2*KN2*%J,8W5RJJZ(B)Q4(Q
MFZMG[7WQB),%NW%5\OB951RUK3$>C7IV/8[@YCDUX.8J+[($)2^"?H1):6PW
M'Y"*)5U]59?E[K3S:NYGZ?Y874O['Z<;(Z;8UV*V3A:^(JR*CIW1(KIIG-31
M%EFD5TCU3R<SET\@1M#FM>US')JUR*BI["@:#L'HITRZ87[>4V-@TQ5Z]$E>
MU*EFU8YXD<CT;I/+(B<4UX(%UOX1H.3Z+=-,SOJ#J5DL&D^]:TM>>#)^LVFJ
MV2HUK8G=TV5(EY4:G:SVPNM^"  ".O\ H5TK^//_ %)_("?'3UGU[\I^M6_Z
M3IR\_==]W79Y.30+J10C\2Q13Q/@G8V6"5JLDC>B.:YKDT5%1>"HJ=J 1ULC
MH+TIZ<9UVY-E8%<3F'PR57SQW+DK703*USF+'-,]BIJQJ^YX*B:!=;AN;:FV
MMYXJ3![KQ5;+XF54<ZK;C;(Q')V.;KQ:Y->#FJBH$0C>\%/0>W9=8AQM^DQR
M\WJ]>_*L::^1.][QVG^4%UM.T?#%T1V7:BOXO:L%G(P.1\5O)22WW->WBUS6
M3N=&U47BBM8B@U)&XMM8#=V(L8'<V.@RN&M<O?TK3$DC<K'(YJZ+V*U4145.
M**$0IE?!CT%R4SIH,-;QJN7564KUA&:^PDSI=/J!=9G9_A5Z([+OQ92CMU,A
MDH'-?!8RLTEU(WL75'-B>O=:HO%%Y-4\@-3.$>?_ $]:U_CPRK'HCFNRN>1S
M535%1:5G5%0->+%;E\('0O<N1DR;L'+BK$SE?-'B[,E:!SE75=(EYF,]J-K4
M":WOIST<Z==*8)8]DX6.E9L-1EK(2.=8N2M1=>5TTJN<C=4UY&Z-U\@-;V$:
MGOOIGL7J7CV8S>^$KY:"+5:\DB.CL0J[M6*:-6R,U\O*[CY0(D@\%'0>&VEE
M^.R$\2*B^J27Y>Z73R*K.5^G^6%U-^V-J;;V7B(L#M3%U\1B(55S*E5B1LYW
M::O=Y7.73BYRJJ^50CLYS"XW<>&R&W\S!ZSB,I7EIWJ_,YG>03L5DC>9BM<F
MK55-6JB@:_L#I?L7I=2MX[8N*3%4[\K;%N-)[%CGE:WD1=;$DBIP\B*!MX&@
MX3HMTSV[O6WU$PV#2MO&])9FM9)+-I_/)=573+W3Y71IS*Y>QG#R!=;\$1!O
M_P ,?1WJ-DY<YF\&M7-V'*^U?QLKZDDSE[72-;K&YR]JO5G,OE4+KN].O#OT
MFZ774RVU\&BYMJ*UF5NROMV8T<FB]VLB\L:JBJBK&UJJG!5T!K)[#Z)],NF6
M3MYC9&"3%9&]#ZM:F2S:GYHN=).7EGED:GI-1>" UOX1%N_?#KT@ZCW)<IN3
M;D29F9>:;)T7R4K,COX4BPN:V1?9D:Y0NM+H^"GH/4F26?&W[S477N;%^9&>
MU]Q[M=/J@U,FS]A[-V!0?C-F82KAJ<JHZ9M6-&OE<U-$=*]=7O5$7@KW*$8C
MJ#T=Z<]4Y:$V^\*F6DQC9647+8LU^[;.K5>G^SRQZZ\C?=:@;E3J5\?4KT*C
M.[J58V001ZJO+'&U&M35555T1/*!S@
M                                              KQT\\,=G8O6C*]
M6G[F9>BR4^2G3$I36)S/RG(YZ)WW?.1>3FT]PFOL!=6'"
M
M              KUMSPS6<#U]M=;';E9/#9MY"Y^14IJQR)D()84;W_?*B\G
M>:Z]WQT"ZL*$
M
M
M
M
M                          X+-VG2:U]RQ%78Y=&NF>V-%7MT17*@')%+
M%/&V:%[9(GHCF2,5'-<B]BHJ<%0#A?D<?%92G);A9;<J(VNZ1J2*KNS1JKKQ
M\@'9    'QSFL:KWJC6-15<Y5T1$3M55 X*M^C>1RTK,5E&:<ZPR-DY=>S7E
M5=-0.P       !^)IHJ\;IIY&Q0L35\CU1K6IYU5>" ?BM;J76++3GCL1HO*
MKXGMD:CD\FK57B!S
M
M
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MJJ:J! OA(Z*[YZ.UMV0[TAJQ.S$E!]):MA+&J5DL(_FT1--.\;IY^(6U9,(
M      BSQ))KT*WUK_X8_P!^T+$4> A$3I-FU1.*Y^=5_P!TJH%JU09
M     "J.U/$#U$S'BCN])+DE)=HP9#)U6-96Y;/<TZ\TD2=YS]O,QNJZ<>(:
MSXM<&0
M
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MS1>VMF\2Y_.ZO.Y.9KFNT171R(BJQVGD5.UJA+$GA
M
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M56RQ]9[VZKZ:1N<B\5]TH6O0L,@
M
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M??OT\\3^<<-^(PAKQ=7J!_<+=/YHR'XM(&53?\/;^SM__P OB_>6PU6&\?\
MMN[#GMG[TB8JTI:LV*DF1/1CGKRK8C15\[TE>K?M5!%PNFF]<7U"V+@]VXF9
MDL&0J1.G8Q458;+6HV:%^G8Z-Z.:O_L#+; (_P"N6:R6WNC^],QB'NBR5;$V
M?5YHUT?&Z1G)WC5\BL1W,B^P%BL?@1V%LS+X+<6[\MCZV2W+5R#*-9;3&3K5
MKI R1'QL>B\KI'/<BOTUT9HGE"U<[*93%[>Q-O,96>.CB,="^S;L2*C8XH8F
MJYSE]A$0,O/KPFYMNY?$[FMQL8L;,O#F<@V-=-6I:G;*B+IYN8-7BX'B1_87
MOK\V2>^:$B*? 1^R;-?GZ?\ %*H6K4AD \\/$BLG37Q78C?MN%R8R:?$9M'H
MU51\5-8X)VIIVN3N%X>R@:G'H12N5,C3KY"A,RS1MQ,GK6(G(Z.2*5J/8]KD
MX*CD5%10RKEXW=XT,%T=DVT^=J9;<]NO7K5D7TU@J2MLS2:?P6JQC%]EZ!8R
M?@QV[<P'0O&3W6.B?FKEO*11O31>YD<V&-=/,YL*/3V%!5>\I;BVSX\V6\NY
M*]>;+P,9(_T6_P#W''-AA75?(KI6H%\>@H9>?/CYW1C,GOK;FV*<K9;N!HS2
MY!&+KW4F0>QS(W>9W)$U^GF<@:B]VTO[JX/\WU/YA@947V,J5O'CD6V%2-7Y
M;,HQ'<-5DI3N:B>VBAKQZ !E03QW8._ANHVT]^5XW>JV:+:K)N*L;;QMATR-
M54[-6S-5//HOF#47=V7NW$[ZVKB=W8.9LV-RU=EF)6JBJQSDT?&[3L?&Y%8]
M/(Y%0,L\!%'B6V[9W1T-WGC*4:RVXZ27HHVZJYWY/E9:<B(G%55L2Z(%B%O
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M-M[7Q&'RO=N8EFA1K5;'=.5.9.>)C7<JZ)J$;.
M
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M*G'1W'SAEYT[EVQM)G5),QX5M[NEW'-/*ZOMRC3R;)H'\>]2M8;5=!)6[?\
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MG>>[[>_-V3YW?]FG5;>QMRKE8IZU9)I%8[OLE7KHYJNU1K845B>10E6G"
H                                                 !__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>lc_fig34liuhugovan-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig34liuhugovan-4c.jpg
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M;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4
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M))-2D=MPS4EMWMGX: K;&OE>G0(LW8;?I++;W;/Q3W$DK0_@U!Y>@
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MXN<8]/9LV$=&U.4;L=Z))46FNXD2W6M3\AD7D(!; (
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MZ0W&CD:4FZ\M+:-RSVI+<HR+4S/0@'<
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MN1I.?SYA/FU5(I:.O0@T(BLN/>D2W%*-1DMQY:6DD9)3M0V1==Q@B6@
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MUF>IZ /13U%905<2DIHR(=5 :3'AQ6M20TTV6B4IUUZ$0#V@
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MGJ1^^/5-4TS$QQ/-5,51A*NBX!P(BTWVG3_^P?\ KC=^NN<W4U?H[?/UR?Y
MX%]O9_C!_P"N'UUSFZCZ.WS]<G^0.!?;V?XP?^N'UUSFZCZ.WS]<G^0.!?;V
M?XP?^N'UUSFZCZ.WS]<L7D7L^4#U++3C$V?#OB0:H+LB8Z\R;B>I(<2H_BJ^
M*9EU+Q]X9+>?JBJ-J(F.AXKR=.'=QB>E$N#N3Y]):*XRS@W&'T/JCUCTHS[C
M$DC\Z(X9^)*/JRK_ &? TC8SN6BJ/$H]/O\ >P96_-,^'7PYO<V2'$=8
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MJ6DTF;AK,MQ*/0]#"]R(DD24EHDNA$7@1 CZ Q.1_P!7?^:U^W(5)9810
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MO!)NH)1D7P:BC*PO^#C_ .Z1^U(0=X       *@P/\_O+W\EQC^AO@JWP0
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MJ=$]#ZZ:@)'"_P"#C_[I'[4A!W@       J# _S^\O?R7&/Z&^"K?!
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M=DE4XK1;;T:6AOW.ZVIM9_HMD.KO2G33+F[OJ[LPV)'%=4
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MA/ZJ'*)1?H(,QWL]W[%-71VPX^4[MZJGI]?Q;2#@.P
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MAMJ,C-1'T\W4AH>)1,X1+G9C=F:R\8W+<T]L=<:$N'MS@
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MI<?Y,UT^V/@VE' =@
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M;&C=? @                            "H,#_ #^\O?R7&/Z&^"K?!
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MW5-,ZW4MW(KIBJ-3,C$R                 "G/9?\ S10_[4N_[UD@2N,
M  %<YG><0U^?8G6YFS#7GTU9%B;DB$N1(2LW227:?2VHFO/]U20%2>T4P_C7
M(>-YK&3M)3;3G<\AOUKY.&7U4+(=[=\[=JJCAI<?.]RY37PT-FXLEF;%8F1U
M;X\AM+S2_=0XDE)/ZI&.%,83@Z\3B[A%
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M",U>):%O9][4B^Q&M8N83LR^C\P[MHN41F[.F)CO8<<3JK]E7^K9,;K\_
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MR?</4O(,UJYM1SN!OG=LY*_A'R5::9YN3ICXK!&9PP
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M:W753:S\%HUZJ;7IYJOJ'U(<?,Y>;-6'%Q2ZEB_%VG'CXX3D:C9
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ME-S)4]E+3,_TQQN0IYUPR6SW%]D^XMSS="]SR +'
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MSKEVBO(  .#W[RY^M5_H :H>P01%Q_EA$6A%?*(B+W"BL@LML@0
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MQ";"LL3H;&N5OKYE=$D1%]E,;<RZPA:#[*/-;U29>8GHGP($9D   %.>R_\
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MJ=HGZA&R9C7G,\S8_P 0G]7_ &_%]^EBZ2]QXLCLEXEZ=YVGP]G03ZF>1?\
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M XQP+"\NR[)L7F.R+[)I*I-\RY*;D);=4\Z\9);2DC;\]Q1:*/W@%C@
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M5*6^]JMQU:EJ2\I2E?*)5YQ@2L4$  !4&!_G]Y>_DN,?T-\%6^"
M   -2?9>21<\<[Z%I_\ +.'^C83#,%EML"
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MLG(D-E+9LO&3I.Z.&HC46NFG0>VJLP
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MA.CLJ.GLY5HS9S#GN.S$MI6E9MI;VEVR(M-$:@+,
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ML>.N%:CCG,\SS2!9RILS-)2IDR-(2V3;"E/NO[6S01&9$;IEYWD(!9P
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M<M_G3G)A^0Z\RQ:N$RVXXI:4$<^9T22C,B\/(*LMKQ$
M                 !3GLO\ YHH?]J7?]ZR0)7& U;YG_P#FN=\7IOC=KU6S
MM_WLM3I_Z!S[VFYPX<;]'W)_2W7=KY=O_C@VD'0?G"I^0.%ORZY.PCD;UUZ#
M^1KA.>KO1N]Z3H\3NG<[B=GAI\10"V
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M='"T/74NGP"C9(0
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M'(7N;C-^FRD$ELM"T(DH2GX"%5LL(@
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MAHH\3=)RS1(<6B0HB?)P^TE+:B5T+RJ(47D(
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ME?#F+7E+ECT)Z9969SF%5[CCK9-&RVWYQN-MF1ZI/IH?P@LKT!
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MX2(!KY[(W)>;<G8?D%IG%F5G/@VQPXSI,,Q]K),-KV[6$((_.49]>H++88$
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M;,IM+C-BN/2QB89:[#13)+1)W-H2I7F-I+59GX K8@$
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M'8CS;"T.;'3'?3(2;1L-M]33X'JDP)7Z
M          *@P/\ /[R]_)<8_H;X*M\$            4!P=Q1F>"\J<IY9D
M4=AJGRN>N33N-/I=6MHY<ATC6E/5)[7$GH8"_P
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M5Y8S#EO$[ZWS)V.[-KK0X,<XK)1T]HF&W.I$9ZGJHP)7V
M                       *@P/\_O+W\EQC^AO@JWP0           !07"'
M+.8YWRERCB60.QUT^)SUQ:A+#!-.$V4N0R6]1&>X]K20%^@
M                      ISV7_S10_[4N_[UD@2\/M23$LX+6P_LI-HTKZC
M#3JS_3T&IF9T0^Q\J48YJJKDHGMF$^XDA'7\9XM%,M#37,+Z_P#BI[G_ -0S
M6ODAQ-\7-O.79_%*9C*Y+73F7C_,LCY[XHRNDJ79F/4#Q*MYZ%MI1'3Z2E9F
MHE*)1^;U\TC%&Q8@
M *6X"_KOF#_'5C_ 1P65E9S9HIL,O[1:MOHM?)<2K]632B3^GH,=R<*9;F0M
M>+F+='+5'K4O[)]8MBBR&U<3KWY4>(VZ?B91F=RONG1KY:-<OKO-UV)NVZ(X
MHF>N?@V'&X^$      !P=(U-+274S29$7U &NOL><?9GQYAF15V:U#E//FVY
MRH[#RVG#4R<=I&XC:6LOC),@66QH(
M      *@P/\ /[R]_)<8_H;X*M\$            :X< <>YIB?+W+V19'4.U
M]-D-DM^FEN+:4F0UZ;*<)220M1EJA:5><1>(*V/!
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M?EI^)+7\& P/I0<1??EI^)+7\& P?#]J'B%*34J;:$E)&I1G26I$1$6IF?\
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M:Z:@K.2,QQ"JO8.'3;V$QDLMM)PJI^0VF6ZG0R29(,]QFK:K;]MH>G@8(D
M   "&2K7 N5:C)<'@7T:R;=COU=XS62FER6&Y*5,K^+NV_9))6AEN(R\2,@'
MV%E/'F%OTO&J\CA1KB+&BP*ZKERVO35MMMI;9)23,C-:TI\W4B-9^ "9
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MN*B0SC\J7D-Q#H%Q5'(333)DF4RQZ)MU)3C2MQ,[=?.VZ:] %N @
M              (=>\J8#C=W^3EQ<):N4DP;T9IF1)[!2E;&?2%,-N)9WG\7
MNJ3J77P 3$  >"UN8-,F(J=W=)TIF!'[##T@^_)5M1O)E"]B-?C.+T0G[(R
M>-C+L?F1:^= E^FPK28Y6PY,1MV2T<EA3J'$K4TE1()*F'$*6O1)*+;KJ9:A
M[[:SB4M9+MY_<]"A-+??[#3DAW8V6I[&F4K6L]/!*$F9^0@'&!<U=G)G0H,I
M#TRL6VU8,)U[C#C[*)"$N)/JDU-N(7I[A@/<
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M$D-.QI"V:^0F*^X33R4+V)<6A.[30]R3+4C(P&8
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MFQ*Q;JW$0ZJ&T4>&TDE'M\\B<DFI"2W=WJ!*U@0
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M['D^HW%HL+!&TR;5Z7+W:*VZDEHBUT E=H(
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M)AOF]Z=(L%)D(>>4@R(W8T XT925[M%K6?B8"_00
M                           !5OM(?F,SG^S5_MT L)KA/_)F._V9"_HZ
M 1G0                                                 !'L]_Y&
MR?\ LF?_ $9P!$?9T_,=@O\ 93/^L%E9X(
M                        "C?9,_-$C^V+?^FN LKR!
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>lc_fig37neisseria-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig37neisseria-bw.jpg
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M="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,  X0DE-! 0       \< 5H
M QLE1QP"   "  ( .$))300E       0_.$?B<BWR7@O-&(T!UAWZ__N  Y!
M9&]B90!DP     '_VP"$  0# P,# P0# P0&! ,$!@<%! 0%!P@&!@<&!@@*
M" D)"0D("@H,# P,# H,# T-# P1$1$1$104%!04%!04%!0!! 4%" <(#PH*
M#Q0.#@X4%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%/_  !$( S0#M@,!$0 "$0$#$0'_Q "K  $  @,! 0$!
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M3\^G?G !Y1C]])^?3OS@ \HQ^^D_/IWYP >48_?2?GT[\X /*,?OI/SZ=^<
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M!LK7&W::-4RYJW>S=1"GP>W83EGV34:-%EW^BM2\ !C&W9%!+R5I;IUD*4S
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M._. %N^[,IQCDZSBM/R/*.X^IYR.Y)D/MFZB<VE*]KSBR)1$9EJ7P@.M0
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M])%KZ0UV0YE"L:'(,;.QA/4R<:JEUD="624JX;V)=VN$6]3R4EH9:]" 4X
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M#[OI -" -" >\>;-B(D-1)+L=J6WV)B&EFA+S)GKVW"+XR=>NA@/#0NG3P\
M#0M==.OP@/S0O@ ?NA>.GAX /S0O@^Z _="UU])^(!H0!H6NOI^$!^:%IIIT
M/Q(!^Z%_T> #\T+773K\(#7W'A4?ZX@?];@#;(BREQG)B&'%PV5H:>DI0HVD
M..=4(4HBT)2M/53XF \S0X1D1MN$9^!&VLC/[Q::F _.NXT:*[A>*-I[^O\
MV=-0!2%^"FED?B230HCT+TZ&6NA?" ]HDN9 D-3Z^0]$EM'N8EQU*:<2K_LN
M)T_Z-0'I8V=I<23FW$Z18S3(D>9ENJ><VI\"(U&>A?<(!BZ?< "29F24EJH^
MB2(M3,SZ$1?? >KL.5'WID1G6.VX;3G=;4@DND6IH,U$1$LBZ[?$!XF:2,B,
MR(SU))'TU^'0!]N,NLFDGFEM*4DEH)Q"D&:%>"B)1%J1^@RZ /D   %K^[7_
M ,5K#_=QS^T&@'6H    #@3)/]L<N_WAM_ZXX UP               ,)K_3
M,O\ \K&_^H\ S0                       8'_ -D1?ZI5_74@,\
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M"WH9'V'2;T[6[U-OH,P&L]VQ*D<L63:OCHQYY"NI*ZIL6R,M2Z'X>/I =:@
M   .!,D_VQR[_>&W_KC@#7                PFO],R_P#RL;_ZCP#-
M                   !@?\ V1%_JE7]=2 SP        &$[_IB'_P"6E?X[
M(#-                          &(U_I29_D(W^,\ RP
M           !B1/\[LO\NC^KM@,L        !Z,R9,8W#BONQS=0;3ILN*;-
M;:O%"MAEJD_@/H ]5V-B["9K'9LA=7'5OCP%/.*C-J/TH:-6Q)_>(!C
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M ,6H"R_=J(BY5GD70BQMPB+_ //V@'6P    #@3)/]L<N_WAM_ZXX UP
M           ,)K_3,O\ \K&_^H\ S0                       8'_ -D1
M?ZI5_74@,\        !A._Z7A_\ EI7^.R S0
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MLRM:A61VL"VKF;6)*4P<1SLOF9));2E*-.I%N3KZ $+N/"H_UQ _ZW &Q
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M $O#_P#+2O\ '9 9H                          Q&O\ 2LS_ "$;_&>
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M;2>B#-?7=U]'P /2'R)D\"E:I(RHFV-&<KX=DN*VNRCPGM=[#4@^J4GK\&I
M$?D7*(J:4F51.Y01E5\)]<5"W'(*T=LXT@S/\HUM_!Z=>OB 0\_MZ^:_)KZZ
MHBP949,*72-P$>S'F6UFX@W&#4>Y:5*,R6:M=.G@ ^&,_P A8C%%),);;=F5
MY&4N(@U1YO<2Z?8T,B0VHTD1H+\'4O2 RX7*.6P%R'6_(OR'ILBTCORH;;[D
M.;,,S><BJ6?Y/=J?3J0#7Q<YR:"JJ=BOL^8I8TR'7O.M=Q7;L#,WU.F9^NHS
M,S(_0 \\LOXM])K6JR*N%24U<Q5UL5TTJ=)MHC4XM9H]4U+6>IF0#[7FM^N
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MM*_QV0&:                          ,1K_2LS_(1O\9X!E@
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M *7A_P#EI7^.R S0                         !B-?Z5F?Y"-_C/ ,L
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MP!K@               837^F9?\ Y6-_]1X!F@
M P/_ +(B_P!4J_KJ0&>         PG?],0__ "TK_'9 9H
M            Q&O]*S/\A&_QG@&6                          ,6"AQV
M=/::0;CSLIIMIM/52EK9:2E)?=,ST ;BZJWJ*XGTC[J)4BM>7&D/QDN*9-QK
M0E[34DCT2?JF9EXD P?1J77T]"UZ?#T ")1F1)2I1GT224J49Z>.FA'KIZ=
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M[O@W>&OW #KTU2HMQ;DZI46XOA3TZE]X!K[C72HU(R_]8@=%$:3\7/0>@#8
M    &A:ZZ=?#4 (B(M"+0B\"(     T(_'[X      M?W:_^*UA_NXY_:#0#
MK4    !P)DG^V.7?[PV_]<< :X               &$U_IF7_P"5C?\ U'@&
M:                       # _^R(O]4J_KJ0&>         PG?],0__+2O
M\=D!F@                         #$:_TK,_R$;_&> 98
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MO\=D!F@                         #$:_TK,_R$;_ !G@&6
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M<< :X               &$U_IF7_ .5C?_4> 9H
M  ,#_P"R(O\ 5*OZZD!G@        ,)W_3$/_P M*_QV0&:
M             ,1K_2LS_(1O\9X!E@                         #$B?Y
MW9?Y=']7; 98    ">0*G'EXUA;<Z PW*RFVE0I^0..NH>BQ8TIEO5HMY-$>
MU9I-2TGH7_2 DIX;C4_*ZVE9Q]VO?.1;(..]$L84"2U#B+=CH6I]UQQYQ+B4
MFXJ.9;VU:D0#"MZG&ZEK)9RL1BKDX_4U*EP7"L(\%RSG2%-R'FNXXEY3'4DM
MZF6N@#&M\:QJ%BC*HU7)E27ZF'.C7D6)+6:YTE:%.)<F=SRB62W''[?;):%;
M=3,P&PDXK0MWT9\L8-%#/B2TU</R-FJ3'DM/-,I<N(9/&\;;:U&CNQE;%&>N
MG30!XQ,4C.LLP9E:F=95TK*U,8_%?D+B295:F,;49C5>\T%O6KU='%DG11F9
M ,6334%9%G7=AC++<]C%T7$C&'G933$6>JP3&;49=SO(0XT?<-I:M=/@U ?#
MM? A+SJ#"9*%42L3K;CR:5J6VS*=7%D-H0:S-1D3BUDC<>I:@*W     :ZX\
M*C_7$#_K< ;$                  6O[M?_ !6L/]W'/[0: =:@    .!,D
M_P!L<N_WAM_ZXX UP               ,)K_ $S+_P#*QO\ ZCP#-
M                !@?_ &1%_JE7]=2 SP        &$[_IB'_Y:5_CL@,T
M                         8C7^E9G^0C?XSP#+
M       &)$_SJR_RZ/ZNV RP    'ZI2E()M:E*:3KM;49FA.[QT2?0M?3IX
M@-K5Y)<5,Q,UM\YAICNP3CSS7*85$D)V.-;5+U2E1=/44D_N@/FXOY]VJ*4@
MFHT2#'3!A08:5-1VHS:C6E&TU*4KUE&K5Q2CU 8!2911CAE(>*$:MYQ2=63!
MK_?=O7;K]W0!Z>T;+S!2_/RO-I1VDR?,.]XF]--A+W;MO_9UT >*77D&V:'7
M$&THW&C2M230L^IJ29'ZJC]*BZF +>?<6ZXZ\XXX_P#YPM:U+4[Z?RAF9FKP
M_"U 9C%Q/CUMC5-N$<:U\LF<M9;WE-0U&MII*U&9I;)1DHTEXZ%\ #
M:ZX\*C_7$#_K< ;$                  6O[M?_ !6L/]W'/[0: =:@
M.!,D_P!L<N_WAM_ZXX UP               ,)K_ $S+_P#*QO\ ZCP#-
M                    !@?_ &1%_JE7]=2 SP        &$[_I>'_Y:5_CL
M@,T                          8C7^E9G^0C?XSP#+
M           &)$_SNR_RZ/ZNV RP                    &NN/"H_UQ _Z
MW &Q                  %K^[7_ ,5K#_=QS^T&@'6H    #A&_HKN5EF5R
M(A0SC.7]NILWGG4.:><<+JE+2B+J7P@,'Z-9)^]@?.'OD #Z-9)^]@?.'OD
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M :J3[O7)+625M>N;0^9?AS'&S)^9LVMKCDK7^;ZZ^L6G3X0&U_9KY1_IN/\
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MZ-9)\%?\X?\ D %G>[I6V5?RM.*P*.1KQQSM^6<6YX3V==V]"-/'T .K@
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ML;Y/Q[CZ\A4;SMK-@4LV'5V3\JSC3)[1*.2MORI,-L)<U033KR7U(T<VZ'H
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MBT C@      AO*^36.'<>7>0U)I19QT,LQ'ED2DM+E/H8[FAZD>PEFHM2TU
M8> /7\'.,LP.XMY600J=BNGPI\\D^<3YUO5UI:D$1&DSZH+3H0"$XUE&;64G
M$,F7?R3:SJTMZ9VF4TVN'!1&WHC.14&6N]HTDI6X_6\#\3 8U3R7:X7.S+Z1
MS[9]JN@1'J6ER]#<:R?L92R;)Q)MD3:8IK/57Y0]$_>,P&M@YWE*L4G5ZLP>
MO[IO+6*Q]ZC<:<MI=8\P1FBJ3M66AN$O:K30R+I\ "U^(KBSO<&C3KFP58V*
M94MAQQ\M)C*&G=&V)?JH_+H3\?U?@\0$Y ?@    #29-X47^O:W_ !G &[(
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MA1%&N$T\Z?7(0B/+E0R:V./()MO4SZ+-)&LE& %AG#A9E]-DP<H38(MCR-B
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MMFP2V\J%M2NNF)66V&TD]4FUJ74O2 T/TEK?XJ=^KYGR0(?22M_BIWZOF?)
M'TDK?XJ=^KYGR0!]):W^*G?J^9\D ?22M_BIWZOF?) ,*XFXWD%5+I+F#-EU
M4]LV9<=4":DE(,R/HI+1&DR,B-*B/4C 1R#BG'U?$\JQ%NE.*G1K1Z<ZBR<F
MO28)&F/W'C;U4VVD]$M_%_P@/EG#^,V+27;(JK/ORDRTICFQ9>5C'8I-,I<1
MHFR)A;I'U4CJ7X.@#WH\;X_H9,F<W M+2PF-(COR[J-/LW?+M'N0TGS#2B2A
M)D7@7H(!X/X?QLZS(:9K+."](L3ND38$:=$E1YQIV;H[K3)&V@B\&R]4O1U
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MUW^,X W>Y73J8!N5\(!JKX3 -ROA -3^$!^IWJ424^*CT+KZ3 1./R3B$B/
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M*==6B]7XY:'ZOB \&L3X??\ /]FFQQSV4:DVFR/"5Y52"W*)_1/Y,R(M3WZ
M,F%@7%]E%:G5V.4<N"^DEL28\.(ZTX@_!25H09&7W2,!D?9KQW]4Z?YA&_$
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M4B,R#3X+G7N_Y]>0:*OP<JUZX1,<QZ9;4#,2':HK5&F4<-[:I*^UIN42MIZ
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MKX4>&3F./&X49I#.XRGLZ;MA%KI]T!TZ     XZE?Z<R/_7MO_770'R
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MZU */&\^RVQ*6N.M;+SCB634V:ENH6O<A2DJUW$9D>H"SP       <M\D_\
M$[*?^] _J+0".      "'<K8Q8YEQ[=8[3[56DE+#L1IPR2EU<9]#W;,U&1%
MO)!D6O34!H\?^F;&67_(,G$Y3*K]RIJ6J1V2P4QF'%1MD3G32:D[4*^(CXQ_
M<+J A*>-,XLJFGX\D5APJ_&Y%]*^D[LALXDOVDAPHJ6$)U7ZRG/RFXO5+Q^
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MYN >P7_#V_;_ ,M'_-P#V"_^G[?^6C_FX![!?^L%O_+1_P W /8+_P"G[?\
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M"UD//QC=7OAM*]8RC$7370NG@"-'[!?_ $_;_P M'_-P#V"_]8+?^6C_ )N
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M=>@#R>S;*(%;DRL=S"5E4$ZZJB1[QU*$H:RBT?;WM0E)01$A#)K,T%KM^_H
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MXW(E*-IPTG^792A#R"^*ATDEN+QZ@)<      )GPG_Q7?_W;?_M!@!TH
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MX3T_<1N_',C\OJ6[3UOA ?IM<RJ-U2J_$C5(22'S-ZPU<21&1$K^;]2(C/Q
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M V_'$EV9DBX;CLTU4&.U2)29,]^4V<NX(YBTK;<+:IQ"5:$X?K;="\ %H@
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MN!UT6PBQ<?O"79H;9ES5^=<F]IA:5MH;D*=WMI2I*3T2?73KJ ]#PO E8_\
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MZ556;,92EQ_,0U[5+:-?K;5$>NBO !*C      &DR7PH?]>UW^,X W?P
M  #]2@UJ)*?%1D1:]/$!#6.3\0>8@R#>?8*?.FU9-OM;'([]6@W92I!;CV(;
M1ZQJZ]/1X@,)',>%'6S[61Y^&S!C1Y[;,J(IM^7#FNDS'?BH)1[T.+,DEJ:=
M/$]" 3&HLDV]<S8E#EP.[N)4.Q9.-*;4A1I,EMF9_!JDR,R474C 9H!T
M 3/A/_BP_P#[MO\ ]H, .E     ' W(=999!;Y-65F85]%72;.\@W%;-C1)Q
M/)>GN_E2)YQ)MN)3ZJ2/IZ?$!'9N 0I&*O87&S6.WCT=BN101GCBN^5DUSG>
M<>>,G$F]WUF9J1T).O3P(!BS..3FQ[&5)Y B2,LL+V!D:[EUN+VC=K6S0VRN
M.3VAMD:C-*241$1)3\(#,Q_C^LIK"CL9N7Q+1^JN;+(YKCOEVUSIU@VAMM:]
M'C))M$G=J1'J?AM *' *BAS6=E#>0TTN%.L)-L:)4:(]:M.RT&2FVIRWC-M"
M5'N2I*-WH^Z UF.<8'C[U:_]H$&4J@BV47&T+8B=N*[:*-2I#A&\?>6>Y9.;
MOC%H733J$LX_QZGP:!8QCOJZ0[:3#G.L0ULPZ^.HT[>W&CF\O8GTJ];KT^ !
M+O:U1^DH?SIC\< ]KU'Z2A_.F/QP'Y[6J/TE#^=,?C@'M:H_24/YTQ^. >UJ
MC])0_G3'XX![6J/TG#^=,?C@-WB]529WC_).$NY1"I$7T2FC+GFZP]_-TO2%
MOH)!NHU[C9*;/UNF[4!(\FX5P>]N.1+R+GL&'+S6*N%5,J5'>8IT6+$>/;NL
MH-\B4[.;C(0M9;#2GIU(",R_XEPBX5E]A&S.K@W][94%A063?ES<IV<9*.4=
MID^^2C-1-.I4M*DGHX9==.I7CDF"Y!E>0-9!;<NT13\?*S^@\V-7Q&9<)ZX:
M7&-V2YYH^[Y9EQ1--M]I+CA(6YKMV@,9G@CC'$IV+77%&80<6O\ &(MA#1-E
MR2MD23L8:H_=<9?E);2M+IE(5VTI):M2,M# 9.#85DG'^/6T"EY3QAS(;"4S
M8NWTF EZ3/E$M:I*[%;MBM;O>2I*$]M2.T2?4(!JKSB&3<TURVOEVJ3D6:6#
M4_D*84=EJ+:PXD=$6-5MM1YC3C$1+:=CII=-UXC/<OJ8"[,*MJ;'L6K*2WR6
M@D38#78W5*8]7 2T@S)IMB*3[I-H0C:@DDL_ $;_ .E^)_IZN^=L?C@'TOQ/
M]/5WSMC\< ^E^)_IZN^=L?C@'TOQ/]/5WSMC\< ^E^)_IZN^=L?C@'TOQ/\
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M/77T -3%XLQ\GFJZRRZ/,PJN<LWJ.B2J*T]'<N$*0X;LGN&;G;):C;]4NO\
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MK5'S"-\F"T^S_ _JM4?,(WR8%/L_P/ZK5'S"-\F!3[/\#^JU1\PC?)@4^S_
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M_5>H^81ODP*SJO&\=HW''J6HA5KKR20ZY#C-1U+2D]2)1MI29D1_""-H
M
M
M
M
M
M
M
M
M
M
M                                                 _-2U-.I;B(C
M,O3H?A_U /T   'X:B26JC(BU(M3Z=3/0@'Z
M                       #Y<<0TA3KJB0V@C4M:C(DI21:F9F?@1 -2C+,
M5=IG,C:O*]>/-&9.VR9;)PD&2B09*?)>PO6,D]5>/0!M6G6I#2'V%I=8=22V
MG4&2D*0HM24DRZ&1EX& B[_)6#1L\C<8O7+*<ZF153X]-M<-U4=!*4:C4230
M1[4J4235NT+70!*P   1S.,]Q'C;'W<IS:T;J*)E:&5RW4K<U<=/1"$H:2M:
ME'\"4G\/@ W5?/AVL"+:5SR9%?-9;DQ)"/BN,O)):%EKZ%),C(!D@
M -)C68XKF4>5+Q.YB746$^J'+>@O(?0U(;(C4VI2#,B41&6I -V
M
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M6(-S=UT:QE1(IK-EHY39.I2G>9JZ)4G74_$!*P
M         5QS_D:<3X4SR],M5L4LQIDO'\M*;..WK]S>XD!_-=Y&7X#QI$X&
MN5.R:CEI.,Y5CDAI)DU'\\XGS#*B49GOW):29%Z4$>GK JRLWYLY@M[[,)V)
MY1(Q*HPJW+&\1H(\JIA0E>SW#:-,YN;):?=4XA&I:-.(W:IZ%T 2S)>3>3Y7
M('+-G#OJW'LEQK'J.@KGK)<)B#&OIY1G9K+$E])DEU7:FI9W.;-WC\)!^XCR
MWR1&XTY+KX?)CC&;U7LZ'$@YP4-B376,M9]Y+%IW%QGR?0T_V"62209)\/C&
M&OIO>%Y&P#BWD.R3E5E?932OUE3[(R:+'>E4MC9[R5**<RXMJ4PKLN]I)IT2
MK9J6W7<&+C'+G-N'N9P]:Y=(R"CAX?+L+-=A854N57W3K1-Q'8I5\F2;;:GW
MFDMEX&1^LDC26@?=M,YTA\9<9HS#.'[JWY8M:.'4UKC"'RAUAJ5(6MXWD*)Y
M]PY#&\U)U)*=NID UN7<Y<A9#0<A\JP>6D885%:N8[A_',1#)O/QDJ2C>MOX
MQ+[:S4EXD*VJ0KJ@B2 O_D+E+.>&_=(Q[+#FN6?(%A K(RKB<92%,S+-OO+?
M<WD9+[9;DH)1>.W77KJ12T3/N1,.Y7QVB;YDE<DT5)0V&9Y3%KG&^V;\" _+
M5!-Y'<-UMPVF]J#ZI2L_429D"M=C?,_,K]AQ?R(7*+-]D>?9%[.E\8PT(\K%
MK/,%'5W&D&KM'\"E))>BDJ)2M%& \\DY YPLL#Y3YMJN3[.HQ:GR]<#%*-#:
M%ID-^<)"4$X9:H:;:=1HV1&A9I/<7I ;W/>9N2\LR#-:NSY-1QC$XUH8;Z8D
M9"6I=U>NQD+<3MU2LT+>-2"0C4DI-'J'JHP&2SR9[P7*V0\+8ACV6GBF57V+
MS+R^F$TGR[C2WI+3,ER,2=JE+9CI6VG0D[E[BT(!L<5R/F&USCE&_1R1+1Q=
MQ,\TQ919"B=?M':&*X2VT.&6C)2'8ZER%$K4]Y%ZP"LN,T<O<:X/PSDF-9RN
M.WR)EBH[&'-QT%%<:ER$QWGY3GQG35L21DHO42I.TR,C ;'..?>:\OR++LIQ
M?*W\<AX]>^QL5HFY=3!A.)C.F2BG-3)#;[KCJ"(R_)+1OU3JDN@"29?S/R9E
M&2\AV4_E%CC)GB^"RS"QME#2W;6[[.CR#:6>KR%/MK;+X^S<C0O%1D=-^ZI-
MRJWX+QC(,SN)5W?W29%@],G+[CA-.R%DR@C/\$FTI,OO@+F
M
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M*TM[;!:N397*TNV,E31I6XXE1+-1;5$2%*46JS1MW_A:@,3WA<.R_*>,7J'
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M2A<M]MA#BTMH4ZM*"4M7Q4D:C+4S]! /8
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M[#)JRMCQ[.4I?=,WD(ZH[AZ[^V7Y/?\ A;=?2 F@
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M$Z*V7!+)LDB9$<LVWI/8B5TUN7&A$AZ2K=VR0I'>W$I6[51'H1 .A0
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M
M    #&AV-?8D^=?+9EE%>7%DFPXEWM2&CT6TO89[5I/XR3ZD R0
M                                        !67/F,VN3\=26JAV$;M5
M+AW4FLMW2CU=E&K'TR784QU7JH:=2CJI7J[B+=ZNH#GV5(MN<[;()F,T&+U-
MK)Q:1BS6+JOZJRDV'M*0P2I\PJY;Z4QJPB4ZQM3W5+/1)IW= ZYQ:E7CF,4N
M/.2ESG*B!%@+FN]''U164M&ZKJ?5>W<?4!M@$$N.7L-IN3L?XC?>>?S/(H\B
M8Q'CH2XU&8C-+=WR5FHC1W";63>A*U,NNA:&83L
M
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MXWJ>7.?EMKDI6X:R2\E"="2VKKUZZ%Z05T<"
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MU.D-I-QQ9FI1DE)%J9@+>
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M_P O>%_Y*=_:,D!=
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MMB6"7F79CA=3%>A6V5Y#D4JRI#LC6C2- 8=U3)=01&;CZ#V-_%ZFL%=%@@
M/P_ _O *8]TS_E[PO_)3O[1D@+H                 4U[S][95'%:X%*_-
MCV^1VU111%U)J38F4V<UWD1=BD'W5,(=2GUB^^ KNHL\PXNA9CET$[3&,(F>
MRX&)U&?N660.*M#<<5,DFS 5+EQF5-:-H0:SW+3O5M(R(!C3?>#Y$?P'.KJ/
M:8]*FU5=':K'*FKOH+S%A:S68+#RSMV6VEH1W5+V)U/<1:^J DV$8C'XX]X*
MOP[%K>XL(\G$)%MFSEO8/V!3)GGF8\28X3RU$B2XHG]>V24[?!)$0"!<BIE9
M?B/)_,,VYM6LDH,@<QOBV+6SWXS$)^OE,P&5M1VE)2Z]+E+7WN\A9FC1):$0
M#ZY&:F91A_)G,%K<6L?*,?R!S&N-(M=/?C,P)-7+9K4+:C-*2AUZ5+-PW^ZE
M>K>B4Z$0#4\J6%METWD;D#):2=<81@%DB@@6$3(7:&36K@I9;F2JF,R@T.3?
M,N]WN2CVJ)"&4$?K:AF\K8S<+R/D+DK)L;8S#CS%XU9&CRIV3/ULA<:OB$5@
MW&9K5I)$I3KAJ64HD&:DDE"=5 .P:-J&S2UK-<TN/7MQ6$1&'34;C;*6TDA*
MC6:E&HDZ$>XS/X0&>
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MA"[7VZWBDIEA2N^F04MJ*[/,C><@M/EW6XFA((R21F9)ZA<H
M      K'E/$.-<ME0V,[R-^H=;C/M-PF+UVF1(C2?4<)UIMYHG4JT-/K$9>)
M -;Q9QSQ#A=JTGCS(7YCL6&Y&C4Q9 _9Q&(JEDM1MQ%/N(3HK\(D^)G\("X
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M/5$J3 2X3#KI&1&9J1HHR(U$9]0%F@
M                                  .9>3<2=R+G&IX^Q"928@4R@E9#
M:RI..U%J[.?*83*29\VUO4Z6JEO:JTVZ'IJ9F F/NRV$^3A=_66<V%9SJ');
M2G=LZF%$K:^3Y4V]KK#,)"$:&E1$HSU5O)1;C(B 72  *%]X[_:;A#_?^O\
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M_+WA?^2G?VC) 70
M                                                YL]ZNJII+%5:
M9->XA['A-K[.*YDAZ.N0^:]5OP9M>LIR'321-J;;;<;4752=2 6/P)>0[WC6
MM>K<)>P"LBJ7%A4+S1M-FRC112&-R&E+:=W;DN+;2I9ZF?PF%F  "A?>._VF
MX0_W_K_ZM( 7T
M  HGWD[#.8U"W5UM-B^18=D*HE$[09 <PIT^VL9)-,,L*9-#2$]4N$ZMQ)H-
M)J(RT(!$.#\:O^+.6CP_)L7QZFE9+2NSH=U6S[>YFS$UKC*%Q$R;1QQ;2&">
M2:F]$I5JDTZF1Z!U*   #\/P/[P"F/=,_P"7O"_\E._M&2 N@
M
M                     !4W+D)%?DO'F3U-5&>R.3DM=1R[5<!J;*:IWT27
MGFT..-K4PDUI2HW$&DR^$!;(#PFSH59$>L+&2U#@1D&[(E2%I:9;;3U-2UK,
MDI(O29F QZ>\I<B@HM,?LHMK6N&:43(#[<EA2D]#(G&E*29EZ>H"E/>._P!I
MN$/]_P"O_JT@!?0
M   "HN<#L+7&L@H+/!$Y%A[5?'L/:CEW#I"3+;DZJVNOFE4=<5"2DE(,]OX/
MP@(+P#16L//K.=D&.V<G(&ZUIE[*<AR^ORFPB0Y!D]'B(8BI0IEJ1M4Z2]GK
M[=3,P'2X  I.H]YK$+?.(V)-T=Y'JK"U?QVJRV3#2U42[:,DU+8;6;G<ZZ&2
M5&V1&9?!U 76?@8"F/=,_P"7O"_\G._M&2 N@
M !6>0>\%P_BV=1.-[W*(T3+9:D-^443AMLNN[>VV^\E)MM*7N+:2U%]W34M0
MLP
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M#/N96<^ET]/A:ZJA>J'*B#<UUQ:6R7W6%H6^5:XMM,>)VM&MWK;E^@NA!T8
M .3J:)S9E//L/->2.-9SV,U<Q</#$IMJ]NNI(CIJ;<L7HZ7'')$I:-#]&TCT
M(M23M"V<G]WC LKOY^2VDV_;L+!9.OHAWEC$CDHDDGU&F7DH06B?!) 5KO=*
M22?=XPE"?BH9F(3KXZ)L))%K_P! "Z0                        '%O)_
MN'*Y YCF9Y&RI,+%KR65C<P7&EKGMNJ,C=;CK)1(-*S+U5*,NWKX*TZ@]]'W
MA>6N&\AQK'< VU%-+A'+=N78S4OS+R'3;..DWTK2GM)2E2NFX]Y>CQ#I7A/+
M[_/>*<4S#*8:8-_;P42)T="%-(W[E))Q*%]4I<2DG"+X% )Z
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M(1:F\E1-H1L<6;NKII>[BOB[?'<>@#^A(
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MX\+YLD\>L8JF7BE1.]DVT];RD3UODKMN.L)(NV2$*/HE6IK(OC)UZ!V>
M                                                       "L\*S
MC*L[RK.VX4>)!PS&9CF.5,AS>Y.DW,-)*EO.)(R0F.A2TMMI+UE:*49ET(!E
M\/9O?YMC<_Z708]?F..6LS'L@:@*4N"Y,@FD^]%-SU^TZVXVXDE^LG70_ !8
M(  H7WCO]IN$/]_Z_P#JT@!?0
M             "K.?\?>R3!8T",Y"=E,W-5,CT5J\4>!=NQ9:'4U3ZU$I.DD
MT[4$I*DFO;N(TZ@*LX.Q+*:[D6IM<PQ^'@,Z)79#%@U*IL23;7;%C;E8^NB&
M?;*+7DZA#?IWKU(DI,B =3    _#\#^\ ICW3/\ E[PO_)3O[1D@+H
M !27-7O3<9\%W59CN5%.G7-BVF2Y$JVFWE1HBEF@GGC=<:(B4:5;4I,U'H?3
MPU"V\>OZC*J.NR2@E)FTMK';F0)3>NUQEY)*2>AZ&70^I'U+P,!L@'".,>XA
MEU)SM%SB1E$5>$UUP5['?;6][7=-N0<A##B3;)!*-1$EQSN'JG4R+7H0=W
M   /"8<HH<@X)).:3:_+$Y\0W=I[-VGHUTU ?SJ]W>_]ZJ7[RBH66.W;L;S#
MOTWB69/%5L120O::$G^1;/4R\MV?C=--4:@/Z.    UM]D-%BU3+OLCL8]53
M04=V9.F.)99;09Z$:E*,BZGZJ2\3/H74!CXKE^,9Q3,Y#B%M%NJ5\U(;FPG4
MNM[T?&0>GQ5%Z4JT,@&Z   !6-W[O?#>19ZQR1<XK%E9@RM#_FU*<)MUYG:3
M;KK!+)IQ:-J=%+0?W?0 LX
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MRT5NZA_1X
M        '/W*>49Y@EC/LK7F/%,4H7G%O5=79TYR)R8_H21(FI<>-.AZJ0T
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M!B2T[(;02MIJ6VE1J26IZ:F7B V8
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M[.9)S>%**312:<GORB&W6W.VI)L_DBCEZR3]7:6G0/Z5
M                I3WALDQM53&X]M\9M,JDV[+UR\Q1NMQIE9 IEM..V;;[
MBT;76%K;-E"/6<7ZOW#"$< 2:IWD)-ED47*IF2Y!1',P7*,RFQ9KDO'&G6B=
M)AF(AI,1:S<8>6VXE3BTJ)1J\2 =1    'X& I?W3/\ E\PS_)SO[1D@+H
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M>DP&Z
M   &FRO%,>S?'YV*Y5 19X_9(2W-@NFI*'$H6EQ.IH-*BT4E*B,C+J0"F<EX
M)]UK#FXCV5UT2G18/IB0//7-@PJ1(69$3;1+F$:U=?!.H"8\=\.\,XK8-YIQ
MY51BFN,O0V;:/.DV"3:-S:ZA"G7WD%Z[>U6WKJG0!.LCR.BQ&CG9)DL]JLHJ
MULWYLZ0K:VV@C(NOB9F9F24I+J9F1%U,!@81GV'\D42<EP>W9N:13JX_FF-Z
M=KS6FYM:'$I6A1$9'M4DCT,C\#(!5'O'?[3<(?[_ -?_ %:0 OH
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MET./)AL3X\M,9I_VB^M:R6E2GFUD:$:$@VT_?5XIT#LGCF\O,FP+&LAR6O\
M9>06E;%EV5?H:>S(>:2I:=JO63U/XJNI>!]0$G
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M7J3O3+9-';4_N)Q&G:0>BEZZ_%(_%7@ R",E$2DGJ1]2,O R ?H
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M<K,>39V;07\YKFF*V76PH#;3W8?/O$Y&(E&HB(TDD^GK& Z!C89R"U7HBO\
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MP7_A@/>/BN;-6;4QW.9#T%%C9S5P#KX:4KA3631$A&LD[B3#6?<2Y\=SP7T
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M[C].O@8":0846MA1JZ"T3$*&TB/&93\5#3220A):^@B(B >X
M                                              YHY[QTLSY4Q^BQ
M*IL+#DJ'1R)Q3V;^5C4"!4.2B:-2W8;;CKCCSI;";07@G570@5/?=XEQWL*L
M*\VKB+=4]S-K;^!D%FY>28UC'[?<;:FN:&ZP:%(6TK0NBO#74$6T  *%]X[_
M &FX0_W_ *_^K2 %]             (?R=QEB?+N(2\*S*.X]42E(>2XPOM2
M&'VCU0ZTO0]%IU/Q(R,C,C(R/0!H^%N"L&X)H9=)AJ9+SEBZE^RLI[B794A;
M:32@E&A#:$I01GM2E!>)^)@-SRQR#%XJX[O^0)D-=@S21R>*$THD*=<<<2RV
MG<9'M(UK3N5H>A==# 4C[JWO76//MM>8UD-"Q4W57'*QCOP%K5&<B]Q#*D*2
MZ9J2XE2T]2/11>@M.H=0@.8/>J]ZV?P%:4>-X]1,VUW:1SL)#T]:T16HI.*:
M2E)-&2E.*4E7I(DD7IUZ!<G&&;U'-'%]-F2ZPFZS(HJ_-5,Q*7T$I#BV'FE;
MD[7$;T*T,T^LGT%X -0YPNQ0O',XJR"=@KQK4ZNJC:3J!U;BM5FNMD&:$&HB
M).L9;6A%T ?*>0L^P]26N3<3.16D9]S*\2[EA ;1U4:Y$)S^=L(0@M5J23R?
MN@-Y0<R\3Y3*@P<>S6FL9]GN\A#8G,*D/&V9$I*6]V_<6OQ=-0'/?O)^^?8<
M*\A1\$QW&V+9V(PS+NI,]UQDE)DD2T-1^WX&2.IN*)1:GIMZ=0Z?PO*(>;XA
M19C7M.,0KZ!&LF&'BT<0B4TEPDJ^Z6[0!]Y;BE%G.-6>(Y-%*;16["HTV,9F
MG<A74C)23(TJ29$I*BZD9:@*UX3]V;C;@B79V6(E-F6]HGL/6%F\AYYN*2]Y
M,-DTVTDDZDDU'MW*,BU,!8OTXPWZ3_0KZ05_TO[??]A>::\]V]-VO9W;_B^M
MX>'7P ;\               %57/ GN_M%89!?850LMZNSK.QEL---IUU<=>=
M<49)27BI2C,!I</XJ]UC+D-VN%8WC%N3';DH=@MLO*06]1-N&DC,R(U-JVF9
M:&:3T\ (N\    _ P%+^Z9_R^89_DYW]HR0%T    \42XKDAV(V^VN4R23>8
M2M)N()1:I-22/4M?1J ]@   1#).5>.,2WHR')ZZ'(;/:N)WTNRB5UZ=AK>Z
M?AZ$ -"OE]^T436#X3D.1FZ@G(L]<4JBL<2?I\S8J9/3_NM*^\ TN69ARK04
MDS+,LGXOQYAL1LERY<GSE]81]RB2DB2WY5E:U*/:E*-WB6FI@*G<Y;X<M<!D
M<G9AR[D>54L*4BKE4==K0]V4\DUMLG AHC.F:DMK<):W]IDD_6Z&0*F_%V3>
MZ[(XWF\L8E4U];CM"MP[6PLH9.6<-]K3U7'7N\ZI:B6CM['%[MQ$77H")IP[
M[PW&G.2;%&$3'_:%7HJ773V?+R296>B7DI)2TJ;,^FI*U(_C$6I:A:@#&L+&
MOJ83UC:RV8-?'3OD2Y3B666T^&JUK,DI+[IF ^*NWJKR$W9TDZ/95KVO:F0W
MD2&%[3-)[7&S4D]#+0]# <*>^]Q9SUFO(]%:87 L;S$6X;;59'JU*,H4]+BC
M>6ZA*BV*7JA1/'TT+37U0':'',#*JO L;KLXEE/S"+71F;N8E6_N3$-D3BC7
MH6X]?%7X1]0$G     ?BUH;0IQQ1)0DC4I2CT(B+J9F9@-#B^3X9DK,M>&6U
M;:QXKRD33JGV)"&WU&>O<[*C(E&9'X^(#?ZEKIZ?@
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M3+\LQ./@T>FB7L!+*)4:7/M4WEPNR:0\<+\DF/"2>QI)]34HS21)Z .F0
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M(JLI2I7LEBH[FYM"SW&@D(8_)N,&6JCU+16[J']'P
M                                        <I\J95&R*WNLSQ)%UC^;
MXQ<L<;XK<5$J&VYD-I.62GZYYB8TZTB/'=,G.^Z7312T_%VF%F>[>FO8P6Q@
M(KIU;D\"[GQLS3:RT64MZ^(T+D/KEMI0AXG$*;4E2&T%MT+:6@"X  !0OO'?
M[3<(?[_U_P#5I "^@           53S-[O'''.K=:>:L26Y]2:BAV5<ZF/))
MIPR-;2E*0XE2#,M=#3T/PTU/4)QA>&X[Q]B];AV*1"@T-4UV8D<C-:M#,U*4
MI2M34I:C-2E'XF8#?      "M^8^#L#YRI8E+F[#_P#Z<ZJ173X3O8E,+<(D
MK)*C2M)I61%N2I)ET+TD1@-WQMQMB?$^)Q,,PR(J+3Q34X9N+[C[S[G5;KJS
MTW+5H6O0BTT(B(B(@$M 43D?NB<+Y3R5]J-K72E73LE$^97MR-M=)EMF1DZZ
MUM-1F9I(UI2LDJ/XQ'J>H7L C.><?8AR7CLK%LTJV;.IE)-.UQ)=UI9^#C+A
M>LVXGQ)23U 4_A/NPL\(2)=SP=;DS:SFR9LX.4M)GQIC;:C-M)2(R&7X^TU*
M49M[B6>W<D]I )HWS$YCBFXG+&.R\.>4>WVTC6RQ]:C5M3I/83^1WZ&HDR6V
M]"\3 6176==<06;.HF,3ZV2G?'F17$/L.)UTU0XV9I46I>@P&4
M     "I_>,3C<GC*14Y+73;M%O/KZZJH:R6=?(L+61)04..<DC(FD*=)*EK5
MT2E)JT,R(@%?\,5-GA?)J,;SNLN*?)K*ID2Z!2LIGY+2S(T=QI,ILT3-IM26
M-[77:9*2H]IEX&'3    !^!@*7]TS_E[PS_)SO[1D@+H   !\)::2XMY*$DZ
MX24K<(B)2B3KM(S\3TU/0!]@/.1(CQ([LN6ZAB*PA3K[[JB0VAM!;E*4I6A$
M1$6IF8#1XIG6&9U&D3,,OX%_%B.=F4[6R6I26G.NB5]M1Z:Z=-?'T *:]\Q/
M*R^''V^*42UR7);:,@36$M5@=4I#A.$R3?KFDUFV3NSKLU_!W -#[BL3E2!Q
M9.A<BPY4&J9F[<7CV+)QI:8VS5[U%)2OM=S^#-9:_&T]70 ]ZOW4;3GRWH\F
MQR^8JKFLC^S9$:>EQ49R*;JW26A31*43B5+5T-.BBTZEIU"[^)>/8W%/'-!Q
M_%F+L&Z2.;2IKJ=BG7'7%O.*).I[4[UJVIU/0M"U,!0WO]X7DN7\1UCN-4[U
MP[3VR)DU$0G79#,<V'6S=2RWJ2TD:B)9F1[2Z^&X!I?<'X^O*OB[(4YSC11:
MRWMFIM6W:,&3LA+#*4FX;#Y:$A*B+M+VEJ>[X"!75U)B&*8T_,E8Y15]1)L%
M$N>] B,Q5OJ+4R-Q32$FH]3/XP(W(      X(QKW&L_J/> 8S65D496%0+GZ
M0,VB77%6C^R3YE+"VS21$XH_5=<W[=-3+4_5 =[@ "'<K8O=YMQOD^)XY9>R
M;RXKWHD*?JI)(<<3IHI2/62E9:H4I/4B/4@'*GN:>[1RYQ#GESE.=$S4U#U<
MJO;KF);<DY;SCR'$N*)A2D$EHFU:&OUM5="TU =N
M                                         *1S7"^.<%Y#QGD9- ],
MR+)\CC5:6D376J^-96,9UI5IY,S4RJ1VF>VI9))1D>NN[J LK!\%QOCNC^C^
M,1ULPER'YTEU]UR3)DS):S<>??>=-2W'%J/JI1_ 1="(@$D  %"^\=_M-PA_
MO_7_ -6D +Z                              'XM"'$*;<22D*(TJ2HM
M2,CZ&1D8"-X_Q_AV)VDZWQFH9J)5DE*)K4+<Q%7LZDKRR%$RE?PK2V2E>DS
M24               %5>\1)HD<:2*ZZII&02KB=7U>/U,&45=+=NI4E"82F9
MAD91EMND3G>/HDDGJ2OBF$.XYQYO!.9DTF9KNL@RZXH#>QG,;ZR:LB.)$6T=
MA7LLLLL%'-I;C*U.;3[Y==4Z;3#H8    _ P%+^Z9_R^89_DYW]HR0%T
M  "!\TX%.Y0XMR? JRP*LL+J)V(TQ>[MI<0XATDN;/6[:]FQ>A'ZJCZ'X .?
M/<T]V;D'A6YR/)\[DQXKME&36Q*>&_YE*TH=)TY#JDZ(+33:V756BE:[?2'7
MX  Y!]\'WI<YX1R2@Q/"($0GYT0K699V#2WT+;[RVBCMH)2"+^#,W%:Z]2TT
M\0'1'$&>/\G<9XUGLF![,DWD,I#T+4U)0X2E-J-!J(C-"C3N1K^"9 )L
M
M              .65\CYM97^27F88>WG'&&%9G,CU[]&E1WM'*ITI2W)<B$I
M)2VB2^9_DS-Q'K&I*BT(@M7@[D=WE"HRG($6#%G21\DGP<>EQFS92JK::86P
M2B41*-9=Q6XUD2M>AD M$  4+[QW^TW"'^_]?_5I "^@
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MTVE\8!VYQZYECN"XXYG:$(S-==&.]0V2224TVD]WHCU2/=KKMZ:^'0!)
M
M             &/$@08'?\C%:C>:=5)D]EM+?=?<TW.+VD6Y:M"U4?4P'S!K
M:ZL2^FMAL0TR7ERI)1VT-$Y(=ZK=7L(MRU:>LH^I@-)GN?8OQIB\S+\OF>3I
MH>U*E)0IUUUUU6UMIIM!&I:UJ/1)%]\]"U,!K>,^5\1Y7K)MAC"Y+,BKD'#M
MJJRCKAV$.01:DA]E?5.XNI'J9']\C(@KSWCO]I>$/]_Z_P#JT@!?0
M                   K;E_@GCKF^NA0<Z@NNO5BU+KK"&Z<>6QW=O<2E9$9
M&E>TMR5),NFOB6H"585A6,\>8S7X?B$!%=05J#1%C(-2SU4HUK6M:S-2EK49
MJ4I1ZF9@-^                   ")\GQ*F9QWE+=Y61;BL:JY<EZML$;XK
MQQ65/()PNAD6Y!'JDR,O$C(P&HXFH,57BN,9U64%?4W=QC=2RXJ WM;9A=A,
MA$5C<9FAE"W5&22\>AJU,M0%A@ #GUKGCD*%R724.48*FEPC*KF5CN..R)6E
M\X[#;[ASG(FFWRJ]/%)ZH(R,S/U=Q5P6&?8+53'JZTRBIA6#![7XDF?&9>;4
M9:D2D+<)1'H>O4@13'NNYY@U1P/B%?:Y/4P9[+<WO19,^,R\C=82%%N0MPC+
M4C(RU+P 6_\ :=QK]<J/]9Q/E0#[3N-?KE1_K.)\J ?:=QK]<J/]9Q/E0#[3
MN-?KE1_K.)\J ?:=QK]<J/\ 6<3Y4 ^TWC;3=],:/:737VG$TU_E0#[3N-?K
ME1_K.)\J ?:=QK]<J/\ 6<3Y4 ^T[C7ZY4?ZSB?*@'VG<:_7*C_6<3Y4 ^T[
MC7ZY4?ZSB?*@!<G<;&>A9C1ZG_\ Y.)\J 'R=QL1F1YC1D9=#+VG$^5 /M.X
MU^N5'^LXGRH!]IW&OURH_P!9Q/E0#[3N-?KE1_K.)\J ?:=QK]<J/]9Q/E0#
M[3N-?KE1_K.)\J ?:;QMIN^F-'MUTU]IQ--?Y4 ^T[C7ZY4?ZSB?*@'VG<:_
M7*C_ %G$^5 /M.XU^N5'^LXGRH!]IW&OURH_UG$^5 /M.XU^N5'^LXGRH!]I
MW&OURH_UG$^5 2=EYJ0TV^PXEUAU)+:=09*0I"BU)23+H9&7@8#[
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M3IN_!T] "TOV?."O[ML:_5,/Y, _9\X*_NVQK]4P_DP#]GS@K^[;&OU3#^3
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MLC2I)Z&1D9:&1@)0
M                  -7D61T6(TDS(\FL&:NCKT=V9.E+)#3:=226IGZ3,R2
MDBZF9Z%U :.HG<<<N5-+EU0Y R>J@2RGTM@DB=*/.8(T;T$HB4VZC<9:&1*+
M4!^8[RMQQEN2VF'XUDL&SR:FW>TJV,Z2W6^VK8O3T+V*/:O89[3Z'H8"8@
M          (=D7*_&^)9-68;DN30:S)[C;[.K9#NQUSN*-"->FB-ZBVHWF6X
M^A:F 7=AQQQ3#N,UO'8.-Q+:2RY=6SA$UYF4:29:-PTD9J7M+:7W &PPW.L1
MY"J#O\*MV+JG2\N,J9%,S;)YHB-2/6(CU(E$?^$!(0            $1*TX\
MY2B9'B'>A9+ K9!5>25JB[[")"=KG9=U+:HTF1:Z&>BBT\2 >4GE#C2DS"#Q
ME*R.!#S&2VV4*B4Z27MJD_DT?O4J4GXB%&2E%IM(]2 3,
M     !0V*^\_2Y3R%$Q-K'9L;%;JPL:3&<R4ZTN)8650DER&R93^4;09:]MQ
M7Q^G0NNT-KS!SXWQ?<L8[5XM-RRZ14RLGN(\)]B*4&B@*V/2E*?/UU:Z[6D%
MJK0^I=-0M'&[^NRK'JK)Z=9N55S#8L(2U$1*-B4VEU&XB,]#VJ+4M0&S
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M7IZ1$FPH^X\1].X:/B?=/0C"]P
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M)K$7EBSB]S(A-UDJSI6UI3&F/L-M-$3CFBM5&G<K34]3ZF1>0
M,*YJHUY46%),4ZB'91GH<A;#BF7B;D(-M1H<1HI*M%=%%U(^H#EW@Z7B'!K/
M.4EV"_4X/C63,L18T9B3*6F-V&8[>Q)[W'-5*(U*U/TJ,P54V?5]A(Y3RW#D
MPWW>0LHY"QG(L5E(B.J)=&PRI7F$2-FU+<=)DES59;3UZ=#T@_H0*@
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MI+16XNAD=7T\-^NJ8%?)D*ER8D9EAZ6OX[RVD$A3BONJ,M3 9H
M /EQMMYM;+R$N-.)-#C:R)25)46AD9'T,C(!2F/XER#AN:\VYI5TS%@[D:JB
M1AT)R6VRB8NMK?+*:6K4^RDED22WZ=/#H J;.^#>8LEO\NK(5- 3C'*\G%[C
M(+1=@CN4,FE)"IC!,[-TG<I'Y)3>A:>/CT#L;PZ
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M%?V,-ZQBME'>4P<>.M*%FI\D&TE6JNB5+(S ;T   #0M=?3\(
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M2PM+C3C3A;DK0M)F2DJ(]2,CZ@/8
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M[7UR2HO'+&!>-M)<>2FVI)I$_6.QDZ$TII"4$:=G4E= [8
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MFNXNQB)D./Q,5ND0R.9C];J42(XM:E[&TFI>PC(]QHWJV&9IU/0!.P
M
M   !A6U-47T)=;>5\:SKG#(W(<UEN2PHTGJ1FAPE)/0_#H TZ>.N/D5BZ5&)
MTR:9QXI;E<5=%**J0E.PG3:[>PUDD]N[373H V$+&,:K:AR@KJ:##H7B6EVK
MCQF6HBTNEHLE,H22#)7X6J>H#7PN.N/JUN4S78G31&IJ$MS6X]=%:2\AM9.)
M2X2&R)9)41*(E>!]0&ZE5=9-DQ)LV$Q(F5ZE.0)#S2''8ZW$[%*:4HC-!J3Z
MIFG34@&6  -0K%,75?)RE5) 5DZ4]M-T<5DYY(V[-I2-G<TVGMTW>'0!\N8C
MBCMZC*7:*O7D[9$ENZ5$85/2DD["(I!H[A$23V_&\.@!-Q'%+*YBY%8T5=+R
M"%M\G;2(C#LQG89J3VWEH-:=#,S+:H!L&:ZOC2Y5A'B,LSYW;\[*;;2AY_LI
MVM]Q9$2E["/1.X^A> #7P,2Q2JMI5_5T5?"O9V[SUG&B,,RW]ZB4KNO(02UZ
MF6I[E>(#*N*2FR& Y57]=%M:QTR-V%.8;DL+-)ZD:FW4J2>A]2U(!Y-XUCC-
M7&I&:B$W2PE(<AUR(S28K*VE]Q"FVB3L2:5>LDTET/J BW+. SN1:&JJ($YN
MO>KKRJNE/.H4X2FZR4F0I!$DR]91)T(_ !(JO#<0HXTZ'24%;6Q+/7VE'APV
M([<G<1I/O);0DG-249'NU\0&7*H:*=3GCTVLB2: VD1SJGF&W(?9;TV-]E23
M1M3M+1.W0M 'E%QG&X-*>-PJ>#&QU2%M*J&8S+<(VW3,UI-A*2;T49GN+;U
M84S ,$L*^!4S\7J9555:^RX+\",['B[M->PVILTMZZ?@$0#9R:2FF/>8EUT6
M0_Y=R%W76&UK\H]IW&=5),^VO0MR/BGZ2 #I*534!A5=%-FJ4A=6V;#>V*IM
M!MH-@MNC9I2>TMFFA= &/!Q7&*NVF7U920(5[8:E/LXT5EF7(W*)1]UY"26O
M4R(_64?4!MP                                               1W
M$\*H\+]N>Q$NI^D-M*R"Q[SANZSIVSNFC7XJ/4+1/H 2(
M
M
M
M
M
M
M
M
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MW3$S+J!M+UO5MDO?'0LTD1J4:20>AJ21DE1FG7KH E(
M           #S9?9D([K#B76SU+>A1*3J70^I /M*DJ+<DR4D_ RZD _0 !A
M5EQ4W3"Y5-/CV,9MQ3+CT1Y#[:74:;D&ILU$2BUZEX@,T!A%<U!VAT96$;VT
M3??.M[S?FB9\-_:UW[?^UIH S0                                 !
M1/O8<P/\3\7R&J%:U9WE*E4^,L1]52$O/)T=D-I3JHS90>J="_A%(+T@.3/=
MORZ)Q!DG+#.(,SWTP\$+(8T6^C+A/R+2G90;RC9,]Q-&Z\ZM)$>O;].I )1Q
M!G4^99XMR%,Y\F6V:SHEA=99QXZT_,A.1(B'I"HK:&]&(BD,H6>YPBT/0T]-
M-2HWC.3\LY/A_"N-P\UM:K(^3,JN[:=9Q9"U2D5T9QF/N66XC6@C0^XA*_5/
M3KX /VPY?Y:XNH^:*6GS.RR&+ R:OQ6DR2Y>*0] =D*FJE/$M>XD&:6.WJ6B
M4J]9)$8#SK,ISQO#^9HB\_L;7#8N+FX^E=\QD5E&N7Y3#;>R5&2EI+$@U/-N
M):4>C9F1^L1 ,+'\BG8#Q_Q'QS0<E2L=Q#D);MQE.8HDF;%5VNC]9"61$4<T
M+49O^GNK2:CV:ZAI,RS_ ".TX.RW#[++Y>48&O.8-/B.56^]3TB%';D/OK6M
MS5Q;;9(C+/QVFKP+<1 )I"Y7S+C+,L[<XYY'G\G8?1X=YV982S3(K8ENX;46
M.;""-324M+4A1(;Z;=R#UVFH!A8[D^33LSX>I,=YOO<RMLQF,V^=4T66[VH9
MLDAY4="B41HW-DZTMH^GJ;S21&D@&PP_DZYY/GQ^0;KG:7A/($[)3ATF ,,R
M9T!$ EMDU&7!C$9J-Q1DCN.)-)D1[M5&9D1\)M'\?YU]X#EF'DTZ5EF!%)<I
MJ%V21KGM&I4=Q+[:")2X,%9LK)M)EHE*"4?0P5X<.<E\H)SK%<I?Y DW3<B#
M+N\YIYU]'LX[U='CNR%JCP&$$4-3+:%:MN&2R61>!= %W>YK0<HY+CM;R]GN
M?VEQ5V*;%%3B\E;KC*#<D]I4AUU:]5GJTLFD;32A)]#+J0(YAL<SA3;/G?D:
M+RC,PO('+HUX[C]2Z;,NV5&D.)C=Q:#2XIE"="T0K1!F:E=-"458EWRMF&69
M13XKR=R?/XL@XKAM9<RG8:CC3;6\D1&I)J5M-/<5JM.K/IVFE*=5*,@T.,<J
MY\CC_B";F6?6U?#S7.K*=<Y!)G.M$515G#CK94Z2B)#&];I]L_4UU/P(!O,U
MYQR6Y+WB.0<;S&>6+0"I\:PM,*6ZW&*1+DH0X_$)*B)*C;C/+-:"U4E?B"-U
M$Q[FRJYGPCB9OF&_<FY=BJ+','GW2?<KT)2XIQ$-*]Q-.&;7;;>,B61F:M3U
MT 0BOYGY5H^(95"6>SVJRXY <Q2#R!9]QR1 J(K2%ONF[JMQ.[N-N$25&:4I
M<))_ 5EUV?WN.Y1RFYC?+-]FV!8'A<HJ6T>FN+0JVM$LPF#-9&27#9?D*4VY
MX^H6TSTZAO\ %I7*^$9G[ODFVY,O;B=FL-RTR6DL9"G(,>F:;3*5JE:CW&4<
MW-ZW-5;D;DGZ $$=RCF&7PFCFUGE'(8MQ;YDJNQK'O-J*(M#AJUW;E:J(C)2
M21_!I2G3;UZ!-N3^4,NCV/O)92C()D5FG5387CL:.\:4-S'GTIDFSH>J-$Q7
MU*(OXPP'<O'M=.J,"QBKLW7'[*'506)KSQ[G5R&XZ$N*4>A=341@B2
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M$GB;C&8S/CRL1J7F+2>5Q9-N0V5)DV*=YE)=(T^NZ6]?K*Z]3 3$
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M#I),XB1*DLDMQ]:"/4D=UU2UDC4M=A*VZ]= $Y
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MXN0J@4V.35VDZ0UD5L5D^Y+DFVV26&#4AN.UU,S4I:M#Z .N0
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M-4U-70UD2FI(;-?4P6DL0X45"6F6FD%HE"$)(B(B^X S
M        5;RCAR[:Q9RB[Y,M,%PJK@K:EL5<UFI;5+<>2:9#\M\EIVDG\F2#
M3XGKN]!A4$*QX1GSDU\?WELG\PM6QM3N21F&5J^!#SL1+:C/_LK,!T%QQBUO
MB-"]5VV53,O0Y,?E5MI9&E<I$%\R4RPMU)Z.F@O_ !-$[M? @$O
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MJO7XP"+R?=^XZD-Y4@H\I@\RN(>0W:V7S0I<VN?3):)![3VM]TE+4GX5*Z_
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MIY"7$&9:'M66I=/O& ]
M         !"LKXIPS.<DJLCS"&J[32M+;KJ6<HGZEM]Q6IRCB*(T+?(O42M>
MNU/@6O4!1=SSG5V\*T3(XKA7?$,"'-L(AO.1')$FGI[!NNLIJ8#C2D(;:4I2
MVFEJ);J4&?JZ] O_ (]PS',$QQ%+B2Y'T<<=<FUT60^Y(;C-2M%DS'[FIH83
MXH;_  =3 2H!^$M)J-!*(UITW)(^I:^&I /T
M                          0;F2IHKSB[*JK)7Y,6DD0'"E2H#"Y<IK:9
M*0XVPVE:G#2LDJV$D]WAX .9^';=C(.7:N#F6:,V-D]<6&54=/!QJZIG9UF=
M64!R5(?LFDI;;:CMFHF63VFXL]Q[4H(!VB TMOEV,T-K3T=Q:1X=QD#JX]+!
M=7H]*=:1O63:?$]J?$_ M2^$@&Z
M     %1>\A=66-\:OV]'8^P+AV?65R,H[3+C56S-FM,N2I'>;<(F$)4?<T(O
MOD A_'TS),>YRAX9+Y,>Y#I['&Y-FY')JO;5 D,R(Z$NR#ALEJV^3A]CUR,C
M)7QBT,!T: XW]\'BWF7.'[:^J:NNR3":FH*+0TB%2W;5B=+>:\S,8BLM*2[(
M(D]M!J7M0UN,D[NH"]K;C7(<^QG%OI#E=YA605L-)6D7"[$X<1V0ZV@EI6;[
M+BUI;-/Y,ST,M3\0$7X.CWN/\I\L8+895=Y148\6/+JWLAE^>DM'80WGWB)9
M(01$:M/!)="(!?0
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MY93[RN(YWF. 6;UJYD\FOQ)#5E#\C]'XT1QMMEILC5L=-2US'G7E%N^(DDZ
MKJ'-\5YZM,DD3<%Y"J\?QE:&DQJN72(GO-K2@B<4;QNH-6Y6JB+3IX CS]V[
M-\JY!XOCY#F<MF;>E864%V5&8**VM$&6Y'0?;29D1F2-05;8(
M                       "#<O-17< M4S<MCX3#VI*1>SV8DJ$EI1[5LR&
M)WY)UMY)FVIL]#5KH74!37NO9 V=K;4&.X33(Q)]LY9<CXI72Z:IL'FE$A+"
MF)[9.*<(E*5JRZMI/4D@.G@   4EQI_S$<Y_]W$_[,>!%V@H
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MI0]O5&>9;8;7V4J+:;>\NA:& [MCF1QVC2A+:30G1M!D:4EH70C+IH7W 'J
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MR+QQ:Y7&QJFPYV$:Y,^KD67LOSKDTW"6W)4O>\AI".VE"2W;CU ?LSECE63
M@\P5EK6-<<S<I8QRDPSR1N2K2K>L_992SF&LEHDK7O>::2C83:2W;CU ;GDG
MFK*',VH<1XQ[!53.3UN-Y7DDAE4ADYTI2G':R&6FU;S3#;CLISP9]5.N\S)(
M:.\Y<Y5D4LSFB@LJZ/QK7Y$U0TN)+A=Z3>0/::*EV6<TW"6TZMY3BV$(;VDE
M!;MVI@.H     $<SV#$G8A<'*@1[%<2(_-AQY<=N8V4N,VIQE9-.)6E2DK(C
M3T\0'EQK:6UWQWB5S?&9W=C3U\NR-37EU'*?C-K=,VB).SUC/U="T\ $H
M!27&G_,1SG_W<3_LQX$7:"@                   (AR7@4;DK&/HI.FN0J
MYV; FS.RA*S>:KY3<OL'N\$N*:22C^ !(K6HJ;V ]57D"/9U<C0GX4UE$B.Y
MM42BW-N$I)Z&1&6I>(")V?#O&EA17=!'QFNJ(]_7OU-A*J8<>#+.+*3HM*76
M6R/Q(E$1ZEJ1:D8"&U7 ]_!1)MI_(UI9YXU6%0XUDTB'"(Z>N-UMQPF(J4$T
MM]XFTI=D.ZK41%X:=0_<B]WEG(,AO9'TOM(.#Y=(C3LQP^,EA+%E)BMMLJ_G
M.WO,MOH:0F0VT9=PM2U(C ?N3>[S&R/(;QY.66==@66/Q9F6X5$0PF-/>A--
M,DE,DT]]AEUMEM#[;2BWI+34B,![Y?P1(R/(+V?3YG8XYC>8,Q8V98_!8C+3
M.:AL%%23$AQ!N1=[!$RYV]=R2]!@,/(_=RA6MQ:.8]E5EBV(Y+ @U&68Q6MQ
MS9G0JMGRK#;3[J%.QB['Y!SM'ZZ.GW0%S5\"'50(M77,(C5\)EN-$C-EM0TR
MRDD(0DO024D1$ R                 '"<O!8]CB.08.QQ(YD7+=U=SI57R
M=70X;M X^]/<=CSU62#-++<9!['8A-GZR#0I)FM0#N:(VZS%8:D*2M]MM"75
MH3L2I:4D1F22\",_0 ]@ !2?O<?\O>7_ 'ZS^U8@)JZT_%+[P*_0
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M5HGLDI:D^HKJ?H ;+*>.<$S:'!K\LQZ#;P:U1KKXTIE*VV%*3L,VT^"?5Z=
M$&R;W>\3<QR/6<;-1<'N:ZYA9-7SHD5+["K*M2M#1R&%*3W&S0M2#(EI/TD8
M#VQ3BC+<:LG<B=S),_*LAM&+#.K-VM:0B? AQE1XU=$92YMBM-$?1S5;AGN-
M1F:@&BPWW>K6@EXW5W^8KO./,'GNVN(XX4%N*ZF6I3BH[DZ4EQ:G_*]Y?:)"
M6R-6BE:Z: /G#?=VLZ"5CM1?9BNZXZPF<]:8CC:8+<5Y,MPW5,.3925J4\<7
MO+[.Q+>JM%*UTT >"_='XXB9)AMG0+G5F/XK+DV#U'[1L7VY,AQ'Y%2%.2C[
M6QU2G%FDM7-32KH9ZA[XW[O%K53*.FN,R79\88E<+R'&<71!;C2"F&\[(8*9
M,2M1O-QW'E+;0EM&X]IJUVD0"^0    %1^\KDMCBG%$^VA7+N/P_.5\:ZN(:
MDHL8]3(E-MS%P37J7F>TI7:]/I3ZQ$ I7!.6^%./^4BB87R:M[C672.R\C9O
MK&3.BHMC?:\HN([,WO=]Q!O'(0D]FU*=?6T(!U_"FQ;*%'L8#R9$&6TB1&?;
M/5#C3J26A23])&1D9 /<  4EQI_S$<Y_]W$_[,>!%V@H
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M(MO>0KIT\.@#[R'A+BS*\H;S/(<:C3LA1Y?N2%K>2T^<,]6#D,(6EE\V_P
MWFU:%H7@1 /W*.$^*\TR:/F&48S&LL@CDRGS#JG2;>*,K>T4AE"TM/[#^+WD
M+T\/ !/@                'RXVV\@VW4)<;/Q0HB41Z'J70P%?\)2LEE<<
MUIYBY*7E#<BP18)L.DQ!%/D=DG$GH9?D>WL(R^)H L(   %"^Y[_ ,%VO]=W
MW]IO@NKZ!                                   1CD#,<;P/%Y.1Y2E
MQZN96RRU#CL'+E2I<AQ+;$>.P1&;CKCBDI0DO3\!:F BN$YU#S6W542>,<AQ
MMI+"Y)6-_5Q8L,S)22[9*0^ZKN*W:D6WT& M!*4H22$$24)(B2DBT(B+P(B
M?H  I+C3_F(YS_[N)_V8\"+M!0
M              !S;2\J<8X=SER)/L<C0Y'R>725"Y[$*6=9 L:N,J,J-,L>
MWY9+BEN)T+N:(\%FD^@#I(   %)^]Q_R]Y?]^L_M6(":NM/Q2^\"OT
M                                         %?\Y2+V)Q!F<G&ICT"]
M:JY"H4J*AU<E*R3U)DF4K63BDZI;4E/JJ,E>@!ROC>6\-X-G."9%QCC>58E%
M:9E%GK[]3;OE+C+BJ)J++:V.^8D^94AQ+R#VHVJ/<K4B!7:F.9!7951P<BJ>
M][-L6B?C>98=BO;#Z>NT\E"T'T\%)($;0  4+[GO_!=K_7=]_:;X+J^@0
M                        !PIRC[]&88-SE.PB!C41_#J*P*LL&7B>.SEZ
M&E+CK*TK)".IGVD]M6I>/CT#NI)[DDK0RU+70^A]0'Z   "H/>9*O;XEL+"S
ML)M.Q63*ZP;N:J$BQG0GXTMM;3[+;CC1$I*R(MY*U(CZ:^ "$\&<E9=DW(3^
M-9'E&16;C-4JQ547V(Q<:)+2W&TM2.\V\IP]=3)*21M/KJ9&0#I4   %)<:?
M\Q'.?_=Q/^S'@1=H*
M      .1Y?%OO$L\=Y#P]5T6+JP2UL)ZHLF19/JL45-A-<ENLJ4<0T&^?<5L
M?-/J:ET-224 Z&X]D\A/0)+&?4=;1JC*;:JV:J>[9$MA*-#-Q;S+)DHC(B+Q
MU 3(  4G[W'_ "]Y?]^L_M6(":NM/Q2^\"N6??6YTY%X8H,93@"$0W+V1)1,
MO'64228\LA!H80ETE();F]2M5)/H@] %A>Z[R9EG+7$%7E^9Q$Q[MQ^1%5):
M;[+4QN.O:F0A'@G=U2>WU=R3TT+H07*
M                T&;9?4X#B=OF-YW3JZ>.J4^B.CN/.;="2VVG4M5K49(2
M1F74_$!#L/SWEJ_N8$;(N*7L:Q^6E:W[9^\KY3L=/;-;9+BLEW#4H]$FDC]7
M7KX +0   !0ON>_\%VO]=WW]IO@NKZ!                            $
M,M.)>,[O+XN>VV+5TO,86PX]PZPE3Y*:Z-J4?@I2-"V*41J3H6AEH F8
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MB-;3C;A)4A:=2Z*+P,C+H9& E(
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M$Y(Y@C8"]BYP,:NY"H=!9I>-R63I$HVU26]NW:[M_ /\GKUW%J8#L@
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M*>-N6<@CVNKCM;32:&S/H2SU7I^#T =C)42TDM/5*B(R/[A@/T
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M>2<"TE^]EUFS*O<A=8-<" XMV''9B$X2%;EI1N=6;BMVB="(B+4P'2@
M                     A/+]=BMKQAE4'-YZJK%7*]Y5E9MG^4C-MEW$O((
MB5JM"DI4E.T]QD1:'KH YOX7A97><E5EAF:,HL*IRTF9/6R7,25C]:[:OUJ8
M*9LY]R4\:?YNA1-,M())N.:GZ" =C    H7W/?\ @NU_KN^_M-\%U?0( /YW
M^\%[TG/N$^\+(Q/&2.%2U$F.Q68Z<1MY-LT^E!DM:U(-Q?>-1I1VE%L\"]8C
M,!_0N,XX[':=>:-EY:$J<9,R4:%*(C-)F7CH?0!Z@
M     -3D^2T>&X_8Y1DLQ%?153*I,Z6YJ:4-H^X1&9F9Z$E)%J9F1%U 5_P[
M[Q'&G.1V3.$2Y!6%5M7*KY[/EY/96>B7D))2R4@S]74E:D?B1:EJ%K  #GC/
MLKF/5]I@7/\ QI:7N)2).^)?8DS)LZR9%;>[C!R68KB)49U&B"6@R6A2R,TG
MMT(!&,):QNNR!$KW=^);R+?OI\E+RC+56E91Q(2W$*=4;<^2IU]9:%M;99W>
MG<1$8#JX   %)<:?\Q'.?_=Q/^S'@1=H*
M                      .+Z?BVVYAR*=R[BF)8;7U[ES,3'J[J7>/.+D5L
MPV5OSX$1YJ&EYQQ@GE-&T?7:I>Y74!V<C?L3W-#<T+>:=23NTZZ:^@!]  "D
M_>X_Y>\O^_6?VK$!-76GXI?>!7Z
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ME6OHV.JU 6''DQYC#<J(\A^,ZDEM/-*);:TGX&E23,C(_N /4
M                                'YJ6NFO4NIE]\!P[18QQ_P!^[D\L
M\/9YE&>2[JQ>L<DB5=D46>VJ6LHSS*(\EE+;9,DVDD[->FO74!V_')!1VB;0
M;;9(22$*U)22TZ$9'UU(!Z  "D_>X_Y>\O\ OUG]JQ 35UI^*7W@5^@
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M*HN*V8JNLXK2U.1U.I;0ZEQE2B(]JDK+U3U-)^D^AF%S@
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M+EMMMZZ_ X>OH 3VNM:RXC)FU$UB?#7\61%=0^T?WE-F9 ,L
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MUSVJ3T/1N83*CT/[@"=0YT*QCIEU\EJ7%7\1]A:76U?>4DS(P'N
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MF6\9P;/,H6?\M\,-9-?UZ6E/Y!B$Y<QF0XT1$UWJN0N,X[V]I%U)WIT/4BT
M7'2\S\;7<]50F\;K;U&U+M1<MNU4U+BM"V=J8EHU*(STT1N 3T
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M3^D&!(D--2'S,]OY)M:B4OKT]4C ;,
M  !7_.-7.N^(LRJ*R7$@SIM8^PS(L5M,Q-7"T-#CCWJ([A:MDM7Q341^@!26
M!8M MN3< L\#X<F<9LXBS,+*;>SA1X;;T=^(MA$&.MM2U35J>43GFCT,DIUU
M/>9 .K0   4+[GO_  7:_P!=WW]IO@NH-R)[B>'\@\LO\B/9#)@TUK)*=>X^
MVPEQ3[^J3<[4@W"[:73(S5JVK0S/;\!$=8MMH9;0TTG:VVDD(27@24EH1 /H
M!@6M'2WK!Q;NMBV44_%B:PW(;_\ E<2H@$&G<"<1S9?M!O&&*V>1FM$JG<?J
M7$N*+;O2<%QDB5]W0!BEQ%?5CCDC%^3,H@O+/HS9/QKR*DB+0B)N<PM9$7CT
M<(S](#Z<JN?ZDF6ZS(L:R1K<CO.7%=+JW]I?&T5">>09G_DBT ?:\ZY3J'2*
M^XU<FPFR(GYV.VL6<9GKH:D1I11'3+TZ=3 ?!\\8? C^9RNMO\3;ZENNZ::T
MWJ2MO\*PV\WU\?C^ "1TO*7&^1=HJ7+*J6\\9I;CIF,ID&I)Z&7:4HED?W#2
M EH    #D_E?WY\3XPY3=X\5CLFU@5;J(^07#3Z6E,.K2E2B88-!]WMDKUM5
MHU/4B^$PZKBR6)D9F9%63D:0A+K+A>"D.$2DF6OPD8#U   !&>0\WJ^-\(O,
MZN6W':ZCBKENL,D1NNFG1*&TZ]"-:C2DC/H6O4!1/NU^]]"Y[R:UQ"=CIX_<
MQ8[EC7&W(.6R]#;<0VI*U&VV:7$FXD_#11:^&G4.G        55S)Q3 S6GM
M;6NBUAY6_"CU[TF]>GMUKE;#E%--E[R4AE39;R-7>1ZQ>G5/0!4ONW3.+D<A
MV-#186Q5YU6UZ_-Y%CEW(R;''8ZG$)6V4I;ZB:=4HB43+K6\B]/PAU> I'E_
MWA5<99"O&J7$Y66SZRF=RK)_+2F82:ZC8=)E3Y&\1DZO7<9-)T/0O'X M^EN
M(%_35U]6K-=;:QF9T-:BVFIB2VEU!F1^!FE1= %0\9_\P_.9_P#8Q/\ LQX$
M7:"@          UMWCU!DL,Z[(JN);0%>,:<PW):U/T[7$J+7[H"!%PC44VB
M^/K^ZPM:#4MN)73%2JPW5'KN7!GE(9,ON() #Y-?/&,&6YJDSZL:01&;9KQ^
MX=69]5:+-^(>WX-S>OW 'HWSAC->9M9Q67&$OI,D&N]@N)A*41%NV38W?C&E
M.OQC=(!B9O[RW"7'RJM&0Y=$4=NK^:'7[K%)-;MIO+.(3I);(^FI^/H(]# 3
MZCS#$\F4IO'+V!;.H:;?<:@RF9#B&GB(T+4EM1FDE$?0S(!N@
M                  !Q'#=>E^U/=X/.HF$\?6LZ;W:?+*I^LRQ%?.F.OR(<
M&0\HX,EJ0I:NS()2G4H7\74D@.UXT=J)':BL%M980EIM)F9Z)01)(M3Z^! /
M12DI2:E&1)(M3,^A$1 --CF88GF#,F1B=[7WL>&Z<>6[62F9:6GD^*%FRI1)
M5]PP%6^]Q_R]Y?\ ?K/[5B FKK3\4OO K]      'RM:&D*==42&T$:EK49$
MDDD6IF9GX$0#BCWS?=ZY1YIR;&<MXY4S?4C$#R"J[S;+*8[BWU.')0;JDH4E
MQ*TDLTJW>H730!?.!\#XY$XPQO$>2ZNNR;)*R U%L+=UA*I!K1J9(;DZ)>VM
M),FD*W$9I20#E3EOWA<=X7Y4?X\P1O)*VFH76V+:5'NG9#+;BT(6LHT&R;E-
M*)LC_#41+/4BVEZP#K6$QSG$KX4RFO\ '\N@R6T2>Y<PI%-,4TXC<E)*A*>:
MU,C+J;!>D!Q)[P_N\>\-G'+$_D3Z,R4UED]%)MR%.:M7*]MAMIHS;0SVWC0D
MR4X@FV=WW-P#N:BYMXN4W'IY^5M0K>,RAN0B_;=II"W$(+<I29R&?6/3<9$9
M@+'8D,2F6Y$5U#T=U)+:=;42T*2HM2-*BU(R,CU(P'H           "F/>-]
MX:H]WS&ZZVF53MW;7+[D:LKVW2CH/LH);CCCII7M2G<DM"29F9_?,@WG!7,U
M-SI@;6:U$)VM6F0[!L*Y]1.J8E,DE1I)Q)$2TFE:5)5M+Q\",!98
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MSG&&^Z1G_(,?..0$RZ+*C-I=E76[$ZEC2EL:)0<Q,AE"#,B)*3-+B241>MJ
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MU;CJ8W82PYJMPTK7NVZ&2>@=,    I+C3_F(YS_[N)_V8\"+M!0
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M![,LLQF6X\=M+4=I)-M--D24(0DM$I2DM"(B(M"(@'V               "
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MK_\ ]'7FU;:<<WF"1Z]R+88]-3/ESC<-QJ7[4WDE1$:2[:D$QL-.IZEHKTF
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MI^/^,,"XLJGJ7 :-BEKY+OF)*&36XXZ[IM)3CCJEK5H70M5:%Z $M
M    !7B."N(T9ZKDY.)POIPMTY*K0R6?\X46AO=HU=KNGX]S9NU];77J L,
M,B,M#ZD?B0"K\1]W;AW!,TE\@8MC#$#)Y9N&4A+CRVF#?(R=\NRM9MM;R,R/
M8DNG0M"Z ,SE;@_C;FB'!B9_4^>76J4NOELNN1I+).FGN)2XV9&:5[2W)5J7
MI\>H"78SC-#AM# QC&(+=;0UC1,083.NQM!&9^*C,S,S,S4I1F9F>IGJ VP
M                 JO(/=RX6R2ZL<EO,92[;V;IRK&4B;/C$Z[M(C<4AF0V
M@CT26IDD!"J#A+W2<T-R+C46NNS/O(6S#O)TG>F.I+;QDE,P]Z$FM*5*+5/K
M%\(#H"O@0ZJ!%JZYE,>OA,MQHL='Q6V64DA""U]"4D1$ R0 !0ON>_\ !=K_
M %W??VF^"ZOH$                                  !4_O'1L:F<56$
M7*9EG#ANRZ\H7T?9:?NGK I;9Q&("74J+S#CQ(2VHM#+QU(M0$*X5N<P8SY6
M-<BV>7UV0NU;LZLQ[)UT\V!-B(=;0J0Q,JV&R-]DU)2ZRL]4[R/UB/H'1H
M *2XT_YB.<_^[B?]F/ B[04
M            43(]Z;$H]G9__@_=O8A6$\M>5LQT.0WF(4YNOFRF6R7W5Q8K
MSA$\\2? E&DE$0"]&W&W6T.M*);2R)2%I/4C2HM2,C+T& ^@ !2?O<?\O>7_
M 'ZS^U8@)JZT_%+[P*_0
M       5[SI6,W/$&8U4BZCX\S,K7F5V\U:VHC)+T+1];?K):7_!N&GJ25'H
M I/BWC;D27R/77EUQ]#X^IL?N["\:E,S(<E:F)U2S6%5P4022DHQK;[ZUN(3
MKM3H1+W:AU<   "A?<]_X+M?Z[OO[3?!=7T"
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MC<>_6RF_6,7Y0 ^T;CWZV4WZQB_* 'VC<>_6RF_6,7Y0 ^T;CWZV4WZQB_*
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MD<+L[DFG6[OM-2T\+207_60+J^00
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MGG/NG<67ZL9/&,4H:5-7>PK.Z(H"/Y[5QR<)^'ZA%T=-2?C>KT 2S]F[@/\
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M$&Y;D>\]Q1ACN8R>5:NS;:F087DT8W'8,SGRFXV[?W5_$[F[33KIH G/V?\
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M^4J:TE.5$C'\AQ^RD4>0T4M:'G(D^+M-22=:]1Q!I6DTK3T/_  L
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MY1V^-3,1RV@1"E3*:<ZU),X5JR;\5Y#K6B3W)(]R--4'T/J M4
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M$_HKRJR:EK\AHI2)M-:1VID"6WKM=8?22T*+4B,M2/P,M2](#8
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M'EN)P\QR7.8L>MR;.LAEY#(IHCY2VX#+R4MM,*?21)<61)-2E)+3J0(N$
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M#17$?(*6OO8C3[$6RC-2VF);2H\EM+R"62'6ED2D+3KHI)]2/H V
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M-G?WGW=>WTW[M=WIU\0&6
M                "I>$OH[[5Y5]@>?[WTVG^V//]KM^T/*0^YY;M?\ @[=F
MF_UOA] *MH$
M    $:G_ $(^F]/[1\E]/?)S/8G=V^>\CN;\UV=>NS7M[]/N )*
%    _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>lc_fig40evxb1-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig40evxb1-4c.jpg
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M ,$  0 " P$! 0$            '" 0%!@$# @D! 0$! 0$! 0$
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M^\!9
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MQS4:US7)IR,9Q/CS&5IN9IF)G\9=_2M:O-0IOJ:Z*:?#1,_A'[]<RLX43^4
M
M              \541-571/54#T#Q7-;W51/V@>@>(J+KHNNG!?V@>@ ,>LK
MJ&W0+57"IBI*9%1JS3O;%&BN71$YGJB<5 UWWNQ3^>V_N:_^+@[GJ^W W(
M   :^YV*QWMU&^\VREN+[=4,K;>ZL@CJ%IZJ+VDT2R-=R2-_=>W14 ]O%DLN
M0T+[7?[=2W6V2Z+)15T$=3 Y4[FL<K7-7_D ^5BQO'<7H_)V,VBBLUOYN?Q2
MW4T5)#S+PUY(6M;K_8!\,AP[$<N9%%E=@MM]C@55@9=*."M;&J]U6I.Q^G<[
MP&SH:"AME)%06VFBHZ&G;R04M/&V*&-OJ-8Q$:B?L0#( A??C\3;+_GJE^K:
M\":        (9W]]MAGSNW_J')U#^S]UQ_%?^Q_C[TS'60X
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M?V?NN/XK_P!C_'WIF.LAP
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M6UX$T        0SO[[;#/G=O_4.3J']G[KC^*_\ 8_Q]Z9CK(<
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MAQ*KFU2"GN?:RJU.948Q&N543O\ !#C:G7%,43/6O/XE=U5S?TT_G-'0W/\
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M<ME-:J&>HEK)::BB9!&ZHJ'<\DBM8B)S.7NJ!M
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MAR]1HIIIIZ(_59_Q6_O+R]O8KJFK_P <_G,S^L)Q.R@
M
M      (@W.WOJ\/RZV[;8-B55G6Y-SHW71+-35,5OIZ6WMD6+MZFKF1S(T<]
M%:U.7]NFK>8/AM]OI=;YG*[7[E874X#GTU(^Y6JCEK(;I0U])&JH]8*N!K&J
M]B)JYG+P1%X\ -=F'4#DT6=W;;O:+;NKW$ON-MA=DM2RX4]HM]%)4L62.'QB
MH8]KY5;Q5O#OHFJM=H'6[/;PV[=FWW9CK558YEN-U?D[)L9N"HZIHJE456+S
M-1$?&]$=R/Y4UY5X 24!"^_'XFV7_/5+]6UX$T        5RZKO?-N/G]GLQ
ME#H_J>5L+&D\P      !'6[^$7S.;/;:.P24\5715B53G53W,;RMC<U-.5C]
M5U5.\?!G+BJ]IB*?TE3?Q_4KG)7M=5[$S%5/1^'[_O#GO(_4=YP6CX./^$/#
MP9S:CX^3I<1H.%>6S]9Y'ZCO."T?!Q_P@\&<VH^/D<1H.%>6S]9Y'ZCO."T?
M!Q_P@\&<VH^/D<1H.%>6S]9Y'ZCO."T?!Q_P@\&<VH^/D<1H.%>6S]9Y'ZCO
M."T?!Q_P@\&<VH^/D<1H.%>6S]9Y'ZCO."T?!Q_P@\&<VH^/D<1H.%>6S]9Y
M'ZCO."T?!Q_P@\&<VH^/D<1H.%>6S]9Y'ZCO."T?!Q_P@\&<VH^/D<1H.%>6
MS]9Y'ZCO."T?!Q_P@\&<VH^/D<1H.%>6S]9Y'ZCO."T?!Q_P@\&<VH^/D<1H
M.%>6S]9Y'ZCO."T?!Q_P@\&<VH^/D<1H.%>6S]9Y'ZCO."T?!Q_P@\&<VH^/
MD<1H.%>6S]9Y'ZCO."T?!Q_P@\&<VH^/D<1H.%>6S]9Y'ZCO."T?!Q_P@\&<
MVH^/D<1H.%>6S]9Y'ZCO."T?!Q_P@\&<VH^/D<1H.%>6S];09C=]^L(LRWN\
M7VWOH^U9!RTT,+Y.:373@ZF:FG#U3POJ\U=4^*JJ.CX_T=+3\OHV=O?M7=W7
MT]'3^,S^G_*4^6Z:2HM])/*O-++#&][M--7.8BJNB>N=NF>F(?SJ^IBFNJ(_
M*)EDGZ>0                                             57CO6_&
MY.^>Z.#XAN7%AN/X1):O$J9UAH;LZ1MRI.U<G/,L;DY7,<O%SM>;O: 8]3O5
MNSBEHWCP'+ZV@J]PMO[ E_L.66VF;%#54U1%S-=-2R\[&2QN<W@B<J\>'#F<
M'EOBZIDVHHMWZ7=NVW-TM@AR=V,W+'**EIG124;:U\#JN![7\&JK4?RMU[_+
MW@SLBZA<UR?$=FZ# XJ/',RW@[9/*US;XQ26QE QBU*Q1O5$ED>Y_P#H-?P<
MG!4U<BH'26"DZE]O]P+#;,DO<.ZFW5\62"ZW=ENI++7V:5K6\DKHX'HV2)RK
MWN9VG-[54;S!/X           JMNC59-!U-6JKV-HV73=*GQ[Q7-J6Z*V*PL
ML$L_:T_:S(J2LJ5FY5:D2.U;IJFG-J&+C-?F<O5%8*CJ!HH;3DLEIKJ;:Z"Q
MN[>Q2> KKBLD\B]LM3V6FC7L:SE[R*K.8.EZ3]9*[>VIJM5NC]Q[Y'4*]-']
MG'V79HOK)J[0#];>ZQ=86\,=+HE--8\?EKT:O!:ED#&QJY/5[-5T]8#NLDW<
MR6PWVML]'M7E=\IJ1Z,CNUNCMZTE0BM1W-$LM9&_3CIX34XH!%N>;AWS,LWV
M@H;IM_D.)009G33MN-[91MII'I;ZYJ0M6FJ9W=HY%5R:HB:-7B!:0
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M?/[/9C*'1_4\K86-)Y@
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M[YMQ\_L]F,H=']3RMA8TGF
M                                               '*;CS;@4V)5E5
MMA3T-;F5.^"6CH+HY8Z6IC9*U9H5>U6\KG1\R,=S(B.TU70#@-N>I+%,MO#<
M'S*CJ, W2CY65&*7W_2=+([71:.H<C65#':>!IHYW>:J<0*O4E#=6U%,R.DS
M).LI+ZQU76R>/>15B6X(LCGNU\5\F+2:\NB=S1/: ?T+         0OOQ^)M
ME_SU2_5M>!-        %<NJ[WS;CY_9[,90Z/ZGE;"QI/,
M
M           (NZ@LXONWVVE7?<=J8+;<)JVWVU;[6Q+/26J&XU<=-)731HB\
MS86OYM%X<VFJ*G!0@ZQ8]:=SL_J=F]QLPM>]V-2V&2_4^24M-2TMRL5:RHBA
M2-E5;GN:UL[9>T8WM.;P4U;R>V#L+98^H'8JYT5#:JR7=K:26>*F\5KG(S*+
M3!*]L:/;+II511HNKDTYM$X(QJ*H%D@        $+[\?B;9?\]4OU;7@30
M     !7+JN]\VX^?V>S&4.C^IY6PL:3S
M                                                         "MV
M*=2=@=+-M;U'V^GPO/6L=25\-TC_ /UV[0N\#MJ>HEYHEBE1>+95Y>]S+Q1
MF7 \4VWQFWS.VVM5HMMLKGI+426.*GCBG>W7E5[X$T=HBKRZKP[P&-G.[VV>
MVU'+6YKE%OM21(J^*R3-DJWZ)KI'3Q\TKU]9K% YC9G=G(]X*N]9'#C,]BVP
MC;!%B=QN3>RKKK(JR+45'9\RHR!$2-(^"Z\5YE75K0EP !XYS6M5SE1&HFJJ
MO!$1 /(Y8YF-EA>V2-W%KV*CFJGK*@'KG-:FKE1J>JJZ >@ (7WX_$VR_P">
MJ7ZMKP)H        KEU7>^;<?/[/9C*'1_4\K86-)Y@
M
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M,90Z/ZGE;"QI/,
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M*       !7+JN]\VX^?V>S&4.C^IY6PL:3S
M
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MA8TGF
M                               "HD6XM%TR[W[@Q;HTE52X'N-707W'
MLO@IY*FF9.D7)-2S]DUSD5BKP1J*YJ)S<O*]%0,#=3=RP]3ESQK9[92.IO\
M&V]4%XR;*/%IJ>@MM!02=HYR.G9&[G5?:KHB+IR-YE=P"Y0        "%]^/
MQ-LO^>J7ZMKP)H        KEU7>^;<?/[/9C*'1_4\K86-)Y@
M
M               KKN%8^INP9)>+UA[[%N/M[<9O&&X+?(V4U93,Y&ZQT\[D
M:QR<S55O:R*B=YG? _6#=2V T%?2X9G&(W#:7)JV=L%-;+I0+#;ZFID5&HE/
M501MC?JJHG,]K$4"Q         "%]^/Q-LO^>J7ZMKP)H        KEU7>^;
M<?/[/9C*'1_4\K86-)Y@
M                                              K[FN5=4&3Y?=<1
MVLQ:VXMC5OF2F7.\CD6;QA.5'.DI*5K=51-=$5T<C5TXJG>#Y8]TJT===[?E
M6]&9WG<K)K=,RKHH:Z9]'9Z6I8J.1T%'"[1-'(G[W*[3BP"PX        "%]
M^/Q-LO\ GJE^K:\":        *Y=5WOFW'S^SV8RAT?U/*V%C2>8
M
M                 1WNCM'0;I5.*U-;?;K978M<V7:%EJJ.P;4.8K5Y)4T7
M_"G*].+45VGM@*R[@4VPE^WHR>QYON=G6 Y0ZK36FFN+;=8Y46-B-?1RK!(Q
MD2I_]5[>.NG "2;!TC8='4VW(;;N=G%RIH9H:VF5;[#/23I$]'M1593Z.8[3
M1='=P"RH        "%]^/Q-LO^>J7ZMKP)H        KEU7>^;<?/[/9C*'1
M_4\K86-)Y@
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MC*'1_4\K86-)Y@
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M:HB:-7B!:0       "N75=[YMQ\_L]F,H=']3RMA8TGF
M
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M3RMA8TGF
M                                  #A+UO7M!CETJK'?\ZL=LO%$_LZ
MN@J[A3PSQ/T1W*]CWHJ+HJ+Q K[U%[N;?[@S8!A>U=ZI<GW/ERBVUMBJ++(E
M5X@R!ZK/,^>+5K6\G![.;VNKG)RMU MZ         A??C\3;+_GJE^K:\":
M       *Y=5WOFW'S^SV8RAT?U/*V%C2>8
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MV%C2>8
M                               0SU48+?\ <+96^V3%Z7Q^^4TE)<Z6
MV+Q2K2@J&3/@T[ZN8UW*W]YVB=\"#LWW4J.JV7$-G<1Q&^6R@GNM'<MQY[M2
MK3T]#;[>[M):57ZJCE<[VJNY-7-8B)JY>4.VZCKO<-R,NQGIYQ*PUM3<TNEJ
MR#(;_P!ERVZV6NFE63G25%]\5&JB(O*G[J:N=H@6A         0OOQ^)ME_S
MU2_5M>!-        %<NJ[WS;CY_9[,90Z/ZGE;"QI/,
M
M                     0OOQ^)ME_SU2_5M>!-        %<NJ[WS;CY_9[
M,90Z/ZGE;"QI/,
M                                              '<XKW /$<UR:M5
M%3U4X@'.:U-7*B)ZJ\ /0 $+[\?B;9?\]4OU;7@30       !7+JN]\VX^?V
M>S&4.C^IY6PL:3S
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M3RMA8TGF
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M/G]GLQE#H_J>5L+&D\P
M                                                   TE[PS#\FF
MCJ<DQ^VWBHA8L4,UPHX*M[(U756M=,QRHFO'1 ,&W[:;<6FM@N5KP^R4-QI7
M=I35=-;:2&:)Z<.9CV1HYJ^NB@9F283AN8LABR[';9?HZ==8&W2C@K4C55UU
M9V['\O<[P&UH+?06JCAM]LI8:*@IV\D%+31MAAC;W=&,8B-:G[$ R (7WX_$
MVR_YZI?JVO F@       "N75=[YMQ\_L]F,H=']3RMA8TGF
M
M                         (7WX_$VR_YZI?JVO F@       "N75=[YMQ
M\_L]F,H=']3RMA8TGF
M                                                        (7WX
M_$VR_P">J7ZMKP)H        KEU7>^;<?/[/9C*'1_4\K86-)Y@
M
M                            "%]^/Q-LO^>J7ZMKP)H        KEU7>
M^;<?/[/9C*'1_4\K86-)Y@
M                                                           "
M%]^/Q-LO^>J7ZMKP)H        KEU7>^;<?/[/9C*'1_4\K86-)Y@
M
M                           03F/4'D,&=7;;O:3;RLW$R#'&0OR2>.N@
MM-OHGU+%DCA6HJ&O:^56IKR<.^B:JUR('6[/;PVS=JW79$M=7CN58Y5K;LEQ
MJXZ>-453HJM\)NB/C>B+R/T37E7AP DD"%]^/Q-LO^>J7ZMKP)H        K
MEU7>^;<?/[/9C*'1_4\K86-)Y@
M
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MMTHFS(C94@K86SQH]$5R([E>FJ(J\0-L
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MFJA_]-&!T       .1W6_P"%V;?,%U_]%*!K=B?^"&VGY4L7U= !(
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MI6JYS8J:FC;%$Q%<JJJ-:U$XKJ!G
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M/\P'XP3J2VCW(R>'#L3NU349#/!+5Q4M1;JZCYH8.+W<]1#&WA^T"60
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MUMAM4B]M/'_EJJC5_JHYKD[@%B0
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M%V+";,W2W6.CAHHGZ(U9'1M\.5R)^](_FD=_F50.B
M
M
M
M
M                                     ?!]91QU45#)41LK9VN?!3.>
MU)7LCTYG-8JZJC=4U5$X ?< !BP7*W55544-+6035M)R^-TT<C'RQ<^O+VC$
M55;KIPU0#*    'QAK*2IDGAIZB.::E>D=3'&]KW1/5J.1KT155JZ*BZ+W@/
ML
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M%3BBHH'H
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M:>__ -RIN/\ ]IH&S
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M^RT[/L]$Y>73AIIW- /J
'      /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>lc_fig41abcess-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig41abcess-4c.jpg
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M'@>;S^W<;_L=]_>D#P/-Y_;N-_V.^_O2!X'F\_MW&_['??WI \#S>?V[C?\
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MT! 0$! 0$! 0$! 0$! 0$! 0$! 00IR9]X3@K_Q;_JJ)!-: @(" @(" @("
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M+<4L.<XY<<3R>E]ML%UB\"NI=\D7B1[@[3?$YKAU ZM<$&9 #0&CH!T 0?J
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M$! 0$! 0$! 0$! 0$!!#&-?>?S[YJ8]\:KT$SH" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(""@GFKY*O&2Y_6X=%4/BQK'G-@;1L<0R:KV!TL
MT@'OBTNV,U[ -1H7%7OL^UKCPQ?3\UOP2A ;'OC>V2-Q9(PAS7-.A!'4$$+N
MI/0GRO<CW7D#CY\5_F=4WJPU'L$M8\[I)X"QKX7R'O> 2QQ[3MU/4E4'N^UK
MAS?EY6C5"4W+BL" @(" @(" @(" @(" @(" @(" @(" @(" @AC&OO/Y]\U,
M>^-5Z"9T! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!0[S6<6
M7JP9M6YY14SY\8OKF335,;2YM-6;0R1DNFNT/(WM<>AU([E>>S[RM\48YG\U
M??"4*]P03U4T=-31/FJ)7!D4,;2][WN.@:UHU))/<%WYF(C64GH=Y9^,[GQQ
M@+FWZ,P7Z]S^WU=([WU/'L#(HG?G  N=Z"[;W+Y_W7=USY?R_IKP0E,ZX[ @
M(" @(" @(" @(" @(" @(" @(" @(" @((8QK[S^??-3'OC5>@F= 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0?$L44\;X9V-DAD!;)&\!S7
M-/0@@]""LQ.@Q%MQ#$[/5&NM%AMU!6NUW5-+2002G7M]>-@/7\*];9\EHTM:
M9CS&:7B" @(" @(" @(" @(" @(" @(" @(" @(" @((8QK[S^??-3'OC5>@
MF= 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 00QC7WG\^^:F/?&J]!,Z @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MHE:YU1<:XMV.J*N4 /DV]=!HUK&CN:T:DGJJ3O-U;<9)O/W>J$&ZK3! 0$!
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M@(" @(" @(" @(*@X'QG7>9&YY?R!R5F-_IJ:AR&Y6&RXG9*]UNI+=36R01
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MZVYQ"<,&\N/"W&N0Q95A.*QVJ_PQ2015C:JMG+8YQM>-L\\C>HZ:[=4$IH"
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MSNIK'0U#2R=PG \2H>PZ%C=OJ,#NKMQ.FFA-3[SOZ7K\JDZ^F?@Q,K:JJHB
M@(" @(""O=\\M]YQR_5V6^7_ #.?CRXW&4U-SQQT+:['*N<^^?[(_I"YP[7,
M!T[&AJ#K-G\\5$QU&:3CJY.;ZL=Q+[K%N'Y3XPYG7O(:T(.M/P5S=RB!3<[<
MDQQ8K)I[9AV%0NH:2I:3JZ.>KE#9GQGH',<TZCL(/5!8/'<>LF)V.AQO&Z&*
MVV.V1-IZ&B@&D<<;>X:ZDDGJ23J3U)U09-!I%5S#QC19JWCFJR>BBSA\L5.V
MQN<[VDRSQMEC;IMTU<QS7#KWH.GE_.W$. WI^.YCEU!9[W&QDLE#4N>)&QRC
M<PD-:>T(.UA',G%_)-?46O!<HHKY<:2'VFIIJ5SB]D.X,WD.:.FYP'\J#IYS
MSSQ!QM=66/-LNH;5>'M:\T#C)-.QLG5KI&0,D,8<.H+].G5!N=@R"QY3:*6_
MXW<*>ZV6N9XE)7T<C9H9&ZZ'1S21J""".T'H>J".[IYE^!K+D$F+W//+7!>8
M93!/&9'NABE:=KF23L:86%IZ.W2#3O02G%+'-&R:%[9(9&A\<C"'-<UPU!!'
M0@A!]H(8QK[S^??-3'OC5>@F= 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 05!YC\IEYN5_K<FXV?!)3W&5U14V.=X@=%-(2YY@>[U"QQ.NQQ;M[!J.RV
M['O-:TBF7P\?ZI1+5<$\GV=7.[0/SIT-CL,;@ZJ9#/'4UDK0?>1B(O8W=V;W
M.]7\D]BV=QWO%6O_ *_S3[C5=^W6ZBM%OI;5;8&TUNH88Z:DIX^C(X86AC&C
MW   J7:TVF9GG*+LJ(\_/,SRQ>\OSBZ8G35<D.)V"H=0QT,;BV.>JIR6RS2@
M>_(>'-9KT#1TZDZWWM.SKBQ1>8_-:-=?4E"$[=<KA:*Z"YVJJEHKA3/$E/54
M[W12QO'86N:005V;5BT:3&L,O2#@'D:LY-XYH[W=-IO='+);KI(P!K9)X UP
MD '0%['L<X#IN)TZ+YYW+:QM\TUCE/&$9:#P7_'+F;]>9\8J%O=P_BX?+X02
MCSS?\H7I^0LXTM=2^ELU)3Q5%X;$XM-3/4#>R.0CMC8S:X-["YW7L:NAV3:5
MZ/FS&LSR]3,*K@EI#FDAP.H(Z$$*SI+W>4OD^\9KC5RQK(JA]9<\=,/LU;*2
MZ66CJ X,:]QU+G1NC(W'J6EOHU5'[SM*XKQ>L:1;\4)6*5?8$'PZ&)TC971M
M,K>C7D N'X"LZC[6 0$! 0$! 0$'R][(F.DD<&1L!<][CHT-'4DD]@"#%8SE
M6.YE:FWS%;E!=K,^6:".OI'>) ^2FD=%(&/'1P#VD;F]#W%!^8[E6.9;23UV
M-7.GNE+2U,U#5/IGAYAJJ9Q9+%(WM8]I'5K@#IH>PA!F$!!6CS 6^WT_.7 -
M?!20Q5]7D-:*JJ9&QLTHCIH0P/>!N=M'0:E!JN59%=++YK<THL>P&3D#([GC
MEGCH+:XT]-1P-B>YTL]35U+7-A8T.:!HT[W$-[4$F\2\K,N.=5_&>:<?,XXY
M)BH?E.GI(I*>KI+C;FR;#)3U5.R,.VN[6=>_KJUP :KY3,>L.6X[FO)>06ZG
MNF3Y;E%W-;75L+9Y11PR"**E;X@.V)@W:,'IT[ - TW%;M-Q79_-7B6(DT-L
MP]SKQCE/%JV.BEO-NFD(A[FMC=&PL:.S1!+/#7#''L_ETQC$ZZPT4])D./TM
M5>)7P1NFFJKG2MFEF,CF[][72'PW:ZLT;MTT"#K>3G(ZFX>7/'9;Y5 FPFOM
MDM9,[:QM+;JF5L9+G: ,CA#6:]@#4$@CG7A$C7ZRL5_[\MWPZ#0^.LFQK+?,
M?GUVQ2\T-]M8QBP0FNM=3%6TXE94UY<PR0N>W< 02->]!/: @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(/.CS(\<W;">1KM=9*=YQ[(:J6XVVM
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M6^TTTKZ8GU&55*SQ&RM!["6-<QVG;TU]Z%7>^8*VP]?C6?=*,KV*D(B @("
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M,-+J$?IY:MY:^6JFD W3/<T $N  &G0-  Z!47=;F^?)-K\_P]2#;%J@@("
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M$! 0$! 0$$,8U]Y_/OFICWQJO03.@(" @(" @(" @(" @(" @(" @(" @("
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MLS6%W]75>>/=8LDZ5MQ;F[[-O-M7JR8YB/3PF/=KHVM;+CB @(" @(" @("
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M+-<BRFW9!9ZRNQ":ON$DL ?2D-JZ>LIW[P][6.;)%,PL'=MU[ MR@(" @("
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M5SIHW&AM5%52UTO78T3L\&-I/9JYSM0/S2>Y<+O=XC;Z3SF8T1E?Y4-$0$!
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MZ=A!ZC9W'?:].F*)U],LZK@T]/!24\5)2Q-AI8&-B@AC :QD; &M:T#H  -
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M9V7Y$Q2D,$,CA)55,KO$J:B0#3?+)H-=!V  -'< N)N=UDW%NJ\_Z,-K6J"
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M\;0>T=I=TT"V" @(" @(" @(""&,:^\_GWS4Q[XU7H)G0$! 0$! 0$! 0$!
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M6W3-8T![(XW LD.I[.IW:,"<T! 0$! 0$! 0$$,8U]Y_/OFICWQJO03.@("
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M%KM=MLEOI[3:*6*AME(P14U)3L$<4;!W-:WHN7>]KS-K3K,L.VH @(" @("
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M:- 0$! 0$! 0$!!#&-?>?S[YJ8]\:KT$SH" @(" @(" @(" @(" @(" @("
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M/@_.M6^[\[4V?9Q?:*6*YV'Y/A?7/CI&ES ZJ945!IF1:[Q -C7>CH$%LD!
M0$! 0$! 0$$,8U]Y_/OFICWQJO03.@(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @CGG',<^P7CVNR+C;&CE640
M21LBM@9+-I$_7?+X4!$DFS3WC#J4%4\*NMEY_JXZ#FOG6LI+G)M%9QC10NQ&
M"*8M]:FDDG#35::]@U=[OH"7_)1A6)6S@[&<KH;'14V3W07!MPO#8&>VS,AN
M-3"QKIB-Y:&,:-NNGN(+)H" @(" @(" @((8QK[S^??-3'OC5>@F= 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0?CWLC8Z21P:QH+G.<=  .
MI))08R@R7'+K4.H[7=Z*MJV:[X*:IBFD;IVZM8XD+UMBO6-9B8CR&47D" @(
M" @(" @(" @(" @(--SKB;C;DRF--G6,T%ZZ;65$\0;51CLTCJ(]LK/ZCP@T
M;C/R\1<0Y3'781F=[9@1CG;-@MQF]MM[99AZLE.]Q:Z+:[UCZKB[O<@FM 0$
M! 0$! 0$!!#&-?>?S[YJ8]\:KT$SH" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(""B?FKY8O=[S.MP"W54E-C-D+(:J")Q8*NK<P/>Z733<UF[
M8UIZ:@N[^EX[/LZTQQDF/S6]T)0KQ2U550U$5913R4U7"X/AGA>Z.1CQV.:Y
MI!!'I"[\Q$QI/))Z'^6SDVX\E8"9;Z_QL@LL_L%;4Z:&=FQKXIG:=-SFG:[T
MN:3WKY_W7:5P9?R_IMQ0E,BY# @(" @(" @(" @(" @(" @(" @(" @(" @(
M(8QK[S^??-3'OC5>@F= 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 04 \U/'5WQGD.NRQM.^3&\C<VIAK&M)CCJM@;+#(X=CBYI>W7M:>FNUV
ME\[/NJY,,4_=7\/2E"!FM<YP:T$N)T '4DE=Q)Z#>5GCR[8)Q[)57Z%]+=L@
MJ/;W44@+9(*=K R%KVGL>0'/([0' '0@JA=WW-<V;2O&*QHA*<EQ&! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 00QC7WG\^^:F/?&J]!,Z @(" @(" @("
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M%E;23QS0.;V[V.!'_"I4M-;1,<X>.XQ5RX[4O^FT3$O0$$D D:$]RO+\WOU
M0$! 0$! 0$! 0$! 0$! 04R\T7!>12Y+4\C8E0RW.W7%K'7BCI6F2>GJ(F!A
ME$;1N=&]K07%NNUVI/0A7#M'<*12,5YTF.242K99L1RC(;BRTV2SUE=<7NV"
MGAA>YP.NGK=-&@=Y=H!WJQY,V.D=5K1$,O0[@/BV7BK!66JXN9)D%QE-==G1
MG<QDKVM:V%KN\1M:!KWNW$=%\_[EO/\ )RZQ^F.$(RE)<Q@0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$$,8U]Y_/OFICWQJO03.@(" @(" @(" @CS-8>8'
MW@.PFHMT=D\)OJU('BB74[MVYKOY-%H9XW'5_P"O319>VV[7&+_]F+]>OART
M1CFF>\T8&*07ZXVP35F[P8((XY9-K--7$;!HW4Z:KG9]QN<.G5,<5L[=VOM.
M^ZOE4OI7G,S,1^+4?]X'DO=K[;3Z::;?98M/P]FJU?\ L<WI]SL__P IV_\
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M" @(" @(" @(" @(" @(" @(" @(" @(""&,:^\_GWS4Q[XU7H)G0$! 0$!
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MIDGIY2Y/<OIC<[2DY(F,E8YZ<X]>GH2BNDJ0@(" @(" @(" @(" @(" @("
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MKUV/:YKVZ]FNW4Z:JB;_ &D[;+T^'./)&4B+GL" @(" @(" @(" @(" @("
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MYCW'ZNRQU8\>/HM&L3,SKI/JC[>2?X88J>&.G@8V*")HCBB8 UK6-&@: .@
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MY1PAM"V7)$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MT+-9+/CMO9:K#006VV1OEECI*2-L,+9*B1TTK@U@ !>][GN]))*#OH" @("
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M'[@&5XPSCACD_E.KR2EQ^X8OSE;+9['<K9?8)[9=/DTO&NZ$2&&9H=M]<@O
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4L'0[@M8@(" @(" @(" @(" @_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>lc_fig42halfmax-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig42halfmax-4c.jpg
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M"B^'+&CDUC<BJBKU Z;
M                          'RJJ6FK:>2DK88ZBEF:K)H)FI)&]J]J.:Y
M%14_2!Q-QO>ZO$O+]YEKO9%2CK*++,I90OIT2)('204\+'1HW1&^'NU9IV:
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MR.1'.7M1J@6T
M                  Y1X8XRO&2<7\\X-?J*ILTF69=DK+=-7T\L".CK((6P
M5+$>U%?&CTW(YNJ+IT \..<V\I8?QG2<4UW$>5U7+%FMS<?H*FDH4FL,\E-#
MZM!5NKT?M\/:UKY-$VZZ^DB=4"Y\ \=5/%'$&*X+7JQUTMU*Z2Y+&NYB5E9*
M^IG:UW[2,?*K$=WH@%)  1;S)?8_'GYA8I]X- M(
M                                                   "+>9+['X\
M_,+%/O!H%I
M                      1;S)?8_'GYA8I]X- M(
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M;S:9-KEG%DC2T?+6&5-KC
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M-7@QO/,8RJ1U/::S=5L17+2RM6*56IWHCNCD_0IIV^]Q9ITK/'R)B8;(=KP
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M:JJJJJKU5RNUW;NN[77J3N&*12.CD^:[^^>V>TY]?Q->.ORY>7H9HW.$
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M8_77P%8QJN37]ESVNT_E[RS]MK:,7'SX/COQ=DQWWNE.=:Q%O7Q^C16R44P
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M/"U(XXXXT1K6,:U$1K6HFB(G8!]0 $6\R7V/QY^86*?>#0+2
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M]X- M(
M    !SC?+5S%BF$V3'\JYBMM'R!>\K\"QY#/88:J.>*JA>E/;V0*Q6LD5Z.D
M25=-J?N]VG505/'OFOHZ::LJN=+;'34['2S2+B]"J-9&BN<O1.Y$ K/$EYGR
M#CG'[S4Y-#F,]7 YS\FIJ7ZOAK5;*]N]M/HWP]--BIHG5-0-U         1;
MS)?8_'GYA8I]X- M(
M               !R_S?Y>N6\^S"S7_&^2JV"SPY#1W..S2QQQPV6*"%T;JN
MD7<JRS,57;&.1NN]>H'MJO+?R]74TU%6^8+(I:*I8Z&IB2A@8KXI$5KVHY)M
M4U1535 +C@6&6GCO#;)A%B61UJL=+'1T\DZHZ61&)Z4CU1$3<]RJYVB(FJ]$
M1 -B         1;S)?8_'GYA8I]X- M(
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MW7:JZH!LX        "+>9+['X\_,+%/O!H%I
M                                   .<?-]:K1EE@P/CRYTL*NS+*Z&
MSPW>='*ZW-E9)XLT"(J-6=S-8HD>BM])>FNB@8W.?))P'+@%QHK)9EL5ZH**
M6:BR'UJHEE9/#$KDDJ&RR.CD8JIK(W:G37;M[@H_EDNUNOG ^#W2U6F&QTD]
M"Y%ME+N2GCFCGD9,Z-'N<Y&R2M?(U%<NB.TU4"L@      UVTYWA]]R6\X?9
M[Q3UN2X^D:WFW0N5TE-XZ:L1ZZ;=5[T1=4[] -B BWF2^Q^//S"Q3[P:!:0
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MV/QY^86*?>#0+2
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M<XJY:CU]OAZ.JYI(]FOTO1U^0#K
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M0#;  $6\R7V/QY^86*?>#0+2
M                       :#RWQ%C7,^-Q8KE=7<:6T1U#:N1EKJ?573.8U
MS49-JQZ/9J[=M5/I(B]P$4P;RS<-9KB]#D>"<@9I68K5>+'03T][GIXE2FE=
M3O1L<E.QR(U\;F_1[NG0#HS#,4HL(QBW8K;ZNLKZ.V1NBBJ[G.M762(Y[GZR
MRN1%<NKM$Z=$T0#.@        (MYDOL?CS\PL4^\&@6D
M                                            0OR>6^X6OR]8K172
MDGH*Z.:[.DI:N)\$S$?=JM[=S)$:Y-6JBIJ@%T          (MYDOL?CS\PL
M4^\&@6D
M      X:RV#S=\>08+AJ4BY?06C+H7V?*X+G5.K;M!(ZHDBI;LGB:MA5K_WK
MY4V-V-;JNFJA5_\ 'GG(_P IL>_\]C_Z0"WX56Y7<<7MM;G%KI[+E<T;G7*V
M4<Z54$+T>Y&HV5.CM6(U5^15T SX        "+>9+['X\_,+%/O!H%I
M                                                      .3N2.+
M:?CZ)V1YQYCLTQNU7.MDBI-]=(D*33;YDAC;&CM$:UJZ=--$ G7UEQ-__7>7
M?]^J?^C [!XBEM<W'%@DLN4U.;6Q8'I3Y17/66IK4;,]%?(YR(JJU46/KU]'
MJ!NH        "+>9+['X\_,+%/O!H%I
M                              .=_-M444]CP'%<@='2X5E676ZT91<)
M&L_=T,C9)%B;,Y-8/%5B-=,QS5:Q'==%4#9>3.%>#W\87JW7K&;/9;!;+=/-
M#<Z>E@I)J!8(G*V>*=C6N:]BINZJN[L=N1510]WEJOMUR7@G!KW>X(Z>YU5N
M3QFQ1-@9(D<KXVS;&(UJ+*UJ2KM1$57:H!50        $6\R7V/QY^86*?>#
M0+2
M  <W\P\X<&WAF0<3\BV*^W:DCE6CN$5/:*J6+QHE1S9()H]%W-=HYCV+_H Y
MMM\OEDN7@07?*N4LLP:BFUI<5KV5<]I:Z%R+X3DB8U=&JFFC%:J?*!W]Q_?\
M?R?#+->\5I):#')Z=&6RBGIG4+X:>G586L\!R(K&MV:-333;IIT V0
M  !%O,E]C\>?F%BGW@T"T@
M                    &+GR;&Z6>2EJKQ0PU,2[989*F%DC7=NCFJY%1>H$
M)\J.1V&CXOK8J^\44,RY)?WM9+50M=M=<951=%?V+VI\O:!T+355-6P1U5'-
M'44LJ;HIX7))&Y/E:YJJB@?4 !^9)(X8WS3/;'%&U7R2/5&M:UJ:JJJO1$1
M/#;+[9+VDJV:Y4MQ2';XRTD\=1LWZ[=WAN=IKHNFH'GN&6XK:*Z.UW6^6^AN
M4VG@T=55P0SOW=FV-[T<NOS(!BN1[%F.2XVMDPJ_MQFX5E1!'77EL?BU4-OW
M:U'JNNK6SN;Z+'N14;KKVZ*@0W@S)*2NY:N%BXOSN]Y_QC2V7QLEJ\AJY;DE
M%>GSHVE92U-2UDRK+&V5TD;46---==W1 Z? BWF2^Q^//S"Q3[P:!:0
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M^/,<P^[U%=>%SS&*E(9;7<Z)GA0U[5>OBU=+#'T1>S=JO<@'6
M                                                       !RYQ-
M:HLAYE\T%@E?LCN<UIHI'::[6U-OJHE73]8&N\+>8_ >&.,:?B[ER6JQWD+!
MO6+;4V5:.HFDK6LGD=!)1NCC5CVR-<U&JY[47Z6NQ4<!3_*9C%^L7&%7?,GH
M9+7>\VOERRNHMLZ*DU.RY2-2)KT71458XVOT7KZ75$75 +L  BWF254L_'NG
M?R%BFO\ Y@T"T@
M                   'RBI::&66>&&..:=46>1C4:Z16IHBN5$U71/E _,M
M#13SQ5,]-%+4P_U,SV-<]G_LN5-4_4!]P  "+>9+['X\_,+%/O!H%I
M
M      1;S)?8_'GYA8I]X- M(
M                                    "+>9+['X\_,+%/O!H%I
M
M       1;S)?8_'GYA8I]X- M(
M                                     "+>9+['X\_,+%/O!H%I
M
M        1;S)?8_'GYA8I]X- M(
M                                   :AR7R%:^,L4GR>YTU17R>-!0V
MVU434?55M?6R)#3T\**J)N>]W?V)JO<!JV%<NY'<LTBX]Y(PJ3"<GN%!+=;$
MC+C!>*.MIJ9S&3L2>!D>R:)9&JZ/:J;>J.TTU"L 1;S)?8_'GYA8I]X- M(
M
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M_J8DVN57:Z!T@!%O,BBK9^/$3_,+%/O!H%I
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ML\D?B+V<!\.7O9Y(_$7LX#X<O>SR1^(O9P'PY>]GDC\1>S@/AR][/)'XB]G
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MI?\ #\7O5NR*D]3K*O);]<Z>/Q(Y=U)7W"6>!^L;G(FYCD71>J=Z(H%-
M                   33GC%;]F?'KK'C=)Z[=%NUDJT@\2.+]Q0W6EJ9G;I
M7-;Z,<;G::ZKIHFJ@4L
M
M
M                                                       $:\QW
M,];PYB=#/:*%LM_R*L9:+5=*Y%CLMOGF5$]8N$_8R-B+O1O:_:O<CE0/CB2X
MIY=<#I:GD+-)KQ>LJN<=17WNI?+5/N%XN:L;I14T2/5(D33:V)FB,3<H%K
M                                          >"]Q7>>S7"''ZB&DOL
ME-,VV555&LU/%5.8J1/DC:YJN8UVBN:CDU0#DRENO+?E.O$%XY.OE3R#Q)E,
MS)LGO[8WOJ;#?*I4225L?5?4Y':(C6HB?S6M?HV4.N;?<*&[4--=+74Q5EMK
M(F5%)5T[VRPRPRM1S'L>U51S7(NJ*@'I                      EO*7.-
MCXBR+%[?EULK(,5R*62EJ,P1$6VV^J_^#%4*FKD\3TE5RZ(UJ;NJ([:&N<AY
M&_)N:<6X2O%-1U_&F68[<[C=Z66-LRUTD2[8F(_M8V-&I,Q\3D=NT77T4 B=
M#B%!Y7.8;-=.45K<FXE\+ZIXXS"X32546*R2O>]U+/!HK&*]%V-J&I]!J;41
M-[6!?N+.1<WY8RJX9;:J*.U\'00OHL?FK87MN5ZJVR)NKXD56^%2HC59&CFZ
MO[>WHT+&                                          !J')7)6*\4
MXK4Y9EE2L5'$J0TE)"GB5=95R:^'34T>J*^5ZIT3L1-7.5&HJH&$XU7/LWPB
MX3\T6.WT3<BEG?2XJC'3.I;-4-1L=+7^)JV2;;JLFC4[=%1%U:@:GQ%Q/GG#
M><77&+#<HKAP#60OK[/0U\KY+C:+A))Z5)3JNNZ!VJOU>O\ [^YT@78
M                #GSS#\A?X/N%!9.3<0@O/EWR:G^K,BOL?BSU-ON$TG[I
M\\3?HPHB-5KV>FC_ $FN1[6M>'-V48SR-PCR%@5919[2T_%$%-64/'7(MRHV
MW6FI*6[L;)'05TD:Z(S1$\"9?01B[FZ,1S8PZ@QO .:<FFEMG-&38QEO&==3
M+ZQ:*&UJCJU7:.BW/>J-8QJ[94<S<NYJ::=H%OIZ>GHZ>*DI(F04L#&Q001-
M1D<<;$VM:UK=$1J(FB(@'U
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MCFHW5RN#K:GIZ>CIXJ2DB9!2P,;%!!$U&1QQL1&M:UK41$:B)HB(!]0
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M(Z:BIHVPTU-"QL<4<4:(UK&,:B(UK431$1-$0#[
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MH!M=/3T])3Q4M+$R"E@8V*"")J,C9&Q-K6M:W1$1$31$0#Z
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M#+E!=ZBU6ZLIZ^>Y5-O<YU/#3MIFHR"#5W[Q5])W<H'5@
M     /PR:*1\D<<C7OA<C)6M5%5CE:CD1R)V+M<B]>Y0.-^2*BL\M^3W"/D"
MK?F_ENY/K9HKM;;M,E7<[3<:I%DE=$UZ^)- J-W_ +M-6Z)V2(U90U3),:Q[
MCRPT> <@U4N8>4C+9HJO",VI9/&K<6K9M70_OVH[]UZ;MKM%16J[I]-BA7+5
MY8+QD<5LI.0>7KSR!Q?3.IZRWXY(V.&GK8HT22'URKBED=51?1<FNFO144#I
MAC&1L;'&U&1L1&L8U-$1$Z(B(G8B ?H
M           )SSIR97\1\:7C.;98JC(*V@8C8:2!JNBB<_5$GJ5:NYL$?;(K
M>O=T15<@3+CU_&W''&MTYZY#RVGRV[YK3LDR#*$UE@JFR:MCM5!2Z:I'&J+$
MV'8C]47>C4;M8&NQ6[+/+#<VY7QW:;EEGEUR96U]?B=+%)+=L>GJ6I)XU+!+
MH]87(OIQOTV]C]JIN<'YK<=A\W_(%DOUYQ6\XWQ/A5-4NM]TN+7VB[7*[5DD
M#D2!&JKVP0I!KO1WTE^7Z(=;-:C&M8WZ+41$U5571/G4#^@
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MF/V_*<8KH[E8;I$E10UL.NU[%547HJ(K7-5%:YKD16N145-4 RX
M              !(,;X(HL(Y<KN1L'O,UCQV_P $JY1AD,376^MN"_U54S5?
MW+D5SG.V-U5>Q4:YR*%?
M  U373O^0#E[+<@Y!\M?(-QS;(+C<<PX"RVM2:[RSJZJKL8K9W(QKV-:FJT?
M8QK6IT31OTT3Q@W;$.*Z?*>0YN<,QR&FS-JJKN-8*1O_ (5:K1,B/9+$Q7.:
M^JD3Z<^O=JFGHHP+1-#%41203QME@E:K)8GHCF.8Y-%:Y%Z*BIVH!\+;;+;9
MJ"GM5HHX:"V4C$BI:*EC;#!%&WL:QC$1K43Y$0#U
M                                              $LY>YDBX\?:\6Q
MJVNRGE3)'I'CF)T[T8^1B+I)4U,G5(::-$<KI'=NB]R/<T.=O,=P7D./Y8OF
M!L$]^J;74L9+G]@L5UFI[K1,;'M6KMU0B>FR!/2\)[-K=NNB1J[PPW'$L%Y$
MS/#:;(>)N=)<JPB[P.B?9LVM5)>XYHWILDIZN9=LK7(BJR1BL_3T ]GEFXDY
MYX>R&\8]E5=8Y^*:I)JVWT%MFJIO4ZV:3<D=&VI8CXXE17+(R1SDUT5J[E<J
MAT^
M          -,SWEGC?C"&"7/<EHK&M2BNIH*AZNJ)6M7171P1H^1S47HKFLT
M0#F"]WNCQG.[KYI> [O!R+B]9&RFY.QF*1*BY4M&W14J:3Q4\:%C$9N6)R(U
M-NNBQZ^$%4X$R'*>1V7/GS*\H93XG=Z>6EQ_#*.I8^UVJW4TJO=-7/71'5OH
MKXCNFQJJB]-&QAC.&\#QY^>U'+7 ^3)2<09')6Q9-B;J25M'47.E<L3*FW^(
MD:1,<_TE<U%;HFUOHNTC#I$
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M+:K52Q45LHHF4]'1T[&Q0Q0Q-1K&,8U$1K6HFB(@'J
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MPZJ
M            !S7SUY?*ROR>W\\<0T='%R_C<K:U]NJHF/H[TR%JMV2-=HC:
MA&>C'+JU>Q-S51CV!Y</RCD_S+WJRWN&DNO&7%.-5$55<H5>M/=[U>Z1VLE(
MCD1%;102(K)%5O[Q45JINZ1!T\
5                         ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>lc_fig45evxb2-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig45evxb2-4c.jpg
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M 0,1 ?_$ ,D  0 # 0$! 0$!           %!@<(! ," 0D! 0 # 0$! 0
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M@F,4%W5ENM+::&"M1_>L\=.BN&_O# @Z L6@&@&@&@,*^97_  TYY_[Q0_\
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MKU$U&]'3O;_IF@:)#2F'81?1*CL[.WIV]NVVWZ:$'WT T T T T T T T T
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M:W;O7"1A*G=]5.T0=G:.YP#Z$Z$GIK?E;9V^/M'RO9Z-:K,KI*EAH,7\F?\
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MI7?KH"7T T T T T T T T T T!QI\E_^*_X_P#^UQ_XY-"3LO0@: : : :
MY+^=(WQ[#O\ ;:O_ +E'KZ/]D[Y_P161Q-L-?5ZE-$:)P,!_URX3_P"-8/\
MU3KASO\ P3_@2EQ/]2=?GYH- - - - - - - - - - - - - - - - - - -
M - - ?"L6J>EF6A=8ZLJ1"\@[E#_ *$C5X./4NK8I-2<7T[E6%%R%M_X0I?]
M$?\ >]>CUXO_ !?K^9YWCR_^2]?R*UD]EOU.!=[N\4[.5B>2'H1L/$L.T?Y-
M]=^-=4_\(:H\_*HM7^<]'_ _&,V6^53&ZVAXH6@9HDEF&^Y(\NT=I'0';?4Y
M-U<?\)ZO4C%HLE_G#1:?DM'X7(7_ .T*7_1'_>]>?UXO_%^OYGH^/+_Y+U_(
MM% M8E'"EPD66M"@3R1CM0M^NPUYUCBY/IV/0K4E%=7%GHU0T.1/DE:<COGR
M7X4M>)9 V+9!44E[%'?5I8[@:<K 6?\ Z/,0C]Z!D\O3NWT)-YXTPOD3&*>[
MT_)&?GD!:\Q"B$MII;4M+&BN)5*T[,)1+W+OW>G;_>="#EFQY[5?'+!>=^*#
M+].XXC5?F<?J6/UI*3*&$5*(@#Y&!W25@OZEO[#L).F^!N/Z?B/A[&\5JNV"
MLHJ/\R^32;)_TZJWJ*DNQ/HC,4#$^U1H0<68W>,4H_D72\^3X[)1\!WS)ZRU
M6&Y/*QH8L@:%8OZL8&\52:0.X8[=GD1Y1;:$G:7)_&V=YO<:"LQ+DNY8-2TD
M#Q5-%;Z6&I2HD9^X2,964@@>.V@//QIQ?R#A5^J+KE?*=TS:W2TK4T5IKZ2"
MFBCF:1'$X:-F)90K*!^XZ YA^,_&?*^8\97BNPOEJLPNUM?+K MGI[72U:"8
M,O=+]=W24=VX]OIMTT!K7Q$N%LQG&,[P"Z4M-09#@-\J8LNR%*AY:>YSN&9K
MA+-4'N5BL+?4#'90H/3<@ 0MVN%;\O<YMUCQZ*2+X[X9<HZ^]7^1#&,@NE(3
M].EI>X!C FY[V'Z'<['Z>X'6FA T T T!\Y*BGA(665(V(W 9@IV_P"70'X_
M-H__ )1%_IK_ )] ?8$$ @[@]01H#^Z : : : : : : : : : XT^2__ !7_
M !__ -KC_P <FA)UGE656#"<?KLIRFM6W6"VJLE;6NKNL:NZQ@E8U9CNS =%
MU*6I!EW_ *6WQW_^[FF_^:UW_P"KZOXI_P#%_P!&!_Z6WQW_ /NYIO\ YK7?
M_J^GBG_Q?]&#4L7RBPYI8*'*,8K5N%AN2&6BK45T61 Q0D+(JL.JD=1K,%'S
M_P"07%O'0>"[WI*V[)N/Z5;-JNJ##<;/VD)&>GI(ZZ]"C NNV6B_+X$.21QW
M\AN7\EY5HK%45>)SX]B44T\MEK*I9&DJW*HLA$A5(R -O%-]O[3KZ7]OQ(4-
MI2ZI<_T*-ZF#:]@%IXUI<BKL]QZDQ&LCM^335D:VJMFZQ15'7M9MT?I_[$_Y
M-<^2X*J3FM8Z<0=17SY!<]\,5E'0\M8U07.CK"337&G84_UPAV=5F@[X@P]>
MUH@W7?;;7ST,'%R$W5)I^O6Y.K6Y>,:^9/&%T,4&24UPQJKDV)-3#^33A6&Z
ML)(-W(/]OTAKFL_:+H\8Z2)ZD8MS;\D,VI^0ZY.-,Q[L/:"E>B-)'3RQ=[0*
M9>LD3-OW[[@^FO4POV^MU+R0_P N)#?X,\_])?G+_P"["?\ ^;TG_>==W^NQ
M_P#A\C5G1'Q+Y5Y Y"R'(Z/,KW)=::BHX):6.2*&,)(\I4D?21#U']NO$_=<
M6JJ,7!::LF+9U;KYTL- - - - - - - - - - - - - - - - - - >6XT,5
MRH:BAF_YN="A/]A/H?\ D/76E<W"2DN1G96IQ<7S/S:K?%:K?3T$/5(4"EO0
MLWJS'_*>NIML=DG)\R*JU7!17(]FLC4: : R#EO@*AY5R?',P7*KSBM_QB&I
M@MM;8I(H9@*P 2'O=&8$KNOB?0G0$EQGQ+>./KK6W*X\B9-F4573BG2BR&K6
MIIX6#A_JQJJ+L_3MW_L.@(GD;XVX)R9R7C')]]DJ8[MC?T :*'Z7XM:E).:B
M%:@,A8A7)WV;JO30%VY+PA^1\*NF%?UFLL-+>(Q35M=;OIBI-*Q^[$ID5@!*
MNZ/T]I(_70$3>.%,#O'$O_4O-1&+#8Z&.WTJQE?R(3!LT=0KE=OK"0?5+D>3
M;]P.Y&@+'@^-38;B5GQ6:ZU-[:T4R4:72O[/RIHHO&/ZI0 %E3M7N]3MN>N^
M@+!H#F>S_$#_ '<I*FV8URUFMDL]54354MOMM;#2P_4J3NY 2(;$^F^A)9*S
MXH<;2\72\3VVLN]JLE;<%NUYN5+5(;E<JA0P(K)I(G61&W!*=@&Z@C8Z A*#
MXA4%IMM/9[/RSR);;11I]&BH**^)3T\$8_ACCCIPJC_(-"#H:WTG]/H*6@^O
M+4_BPQP?DU#?4GE^FH7OD;IW.VV[']3H#TZ : : YDYDPG'^5/D%BF#WN22W
M4]/8*BY5-7!*\536QK4,J4D6Y*+VD-(SA>[;<?IH" YO^-''6%<>W7-\9DJZ
M*MQ^-*N2DJJR6:EK(E=5>%^X]RL^^RLC#K^G70$Y@=GBXLY2P&V8?<:\87R1
M::NLK<9N%2U::*IIJ9:I)8F;8J-F^F>GZ'_D Z>T T T T T T T!E&9_)#B
M3 ,FK,/R6[54604"0RUE+2VVX5HC2I021EGIH)%'<IW]= 7G#,RL&?XY297C
M$TM19:[Z@IY9X)J20_1D:)MXJA(W'DI]5Z^N@)[0'&GR7_XL/C__ +7'_CDT
M).D>:#MQ)FW_ (EKO^X-KLPO_/#_ .R(/\K03L.IU^A]3_)BDM 2=O4Z=3_)
M+2-ZO.4\L?@8+C7)U[K<*XKO-OIH+=<+7"KP-0QQ*L;3_1D#NQ4(TBN^ZJW=
MV?IKPE&A2G*M==B;UU_)+UYFHYK\58\8Q^T9UPC7RW/)K)V7#Z-88:V*Z1;"
M0/"O9],MMU5-BLBG8>6W=YT/W.5DG"WA%_CAH3TZ;%YQ#(>,?ECB<=LS&W&G
MR^Q"07"SK-+3S4D\J_2:II]F'=&2!M]0-V-XL/0MRS5N%/6#X/F6X,P/_JYQ
M/@WD3_=GFZP+?^/KY)M8\PC>I@:GV.WW%IY%!VW FC(++[TW'1O5_P#;LR*^
MJJ6DEO'@5T7,UCDOXW4MFI+5R9\>0*/(K'].XT]NAE:M@KXE^XLD#3-)W/L>
MB[E9%Z#KMW<-/[C*6M=[U3X?P)Z?P73!,[P'Y1X#7XIE= D%_@0)?K"Y[)Z:
M=/%:ND9]V"ACXMZH?!]P?+CNJLQ+%*+X<G],E/4QNFC_ .H/)8>,>;[73Y7P
M_<V9,9R6KI5J'H59MR%8AG103]Z)6W3WQ[@D-Z/4[X^2E],UNOR1MN9!\A<;
MQ?%>4;C:\,IXJ;&VIJ*JHDIY&G@9:FF24O&[,^ZL6[ALVW]G37M?M]D[*4YO
MCJR'P9EVO0(.KO@Q_P#;5EO_ (OIO^[-KYW][[(_Q9,=V=O:^4+C0#0#0#0#
M0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#
M0#0#0'/GR;FX<2GLISZYUUIS&!GFQRML*L]WB7T<@+T,7<!T<CK[3[M 8!'E
M'%-QK*2;D?.,^S:R6^5:F.R5]!(E,[QD,/JCZKEATZ@;$_VZ Z\QGC/%3F]1
MS%'+5UM\O-'"EMCK&V@M]$\,8$=/#L/IE@//K^I'3KN!HV@&@&@&@,>YZYNN
MW"-JIK_#A%=E&/\ TY)+K<Z2H2F@H.V2.*(2ED<_<:39?\F@/5R/SO8>-\#Q
M_+JZV5=RN^5&D@QW&*#:6MJZRMC6185/ILO=LS[']  20"!5\3^2EUGS>RX)
MRGQU=..KAD_?'C=;6U$==1U=0@#& R1QQ]DA#* O7R(!VW&A)&5G'/)UUYTY
M(O. \C6S$;?=*:PBYK24U+?+RD]%22)3I/2U/A3QN'D<,WE(-NWIN0(+[P#G
MF2YUB5WCS%J:?*,4OUSQ6Z7*A4QTM=-:I%3\J)/X1(&&X'3??8#T &JZ XT^
M2_\ Q7_'_P#VN/\ QR:$G2/-'_FDS;_Q+7?]P;79A_\ GA_]D0?Y6 ]!K]!,
MEL#_ &:$L_T!X?R'C3Y </T_&UXIPU=9*"GH+G:I6'Y,34L8ACKJ9]M]B1N&
M \">QMP?+XG+A9C7N:YM_P#P73U*5B66Y7\5<KAXXY'FEN?$ESE8XWD@5F_#
M[FW((&Y"@G[T/JI\TW!(;>RN&7#KAPFMT1L6WFCA>YU-SI^<N#J@4F>TBBNG
M@H2K076!E[C)&%W1Y'0^2]5F4_S>[#%RDEXK>WX]>Q+1.8)G> _*/ :[%<JH
M4@OT"!+[8G/9/33IXK5TC-NP4,?%O5#X/N#Y96U68EBE%\.3^F-=3-L2RW*_
MBIE</''(\TMSXCN<K'&\D"LWX?<VY! W(4$_>A_A]Z;@D-V65PRX=<.$UNB-
MBV\T<+W*JN5-SCP=4K29[2 5TT-"5:"ZP,O<9(PNZ/(Z'R7JLRG^;W88N4DO
M%;V_'KV):)S!,\P'Y18#7XIE= D%_@0)?K"Y[)Z>=/%:ND9MV"ACXMZH?!]P
M?+*VJS$L4HOAR?TPGJ<D9YPM4<99_08UR%>*FCP:X,8;1F,5.:R-8![%DA^H
MG:8]P)$5MU'DH8>OT>/G>2K6$=9+=;%-#1,M^&5ZMN*2Y'A621Y55)&M53V^
M*F$/Y5,R]W=3R+-*KL5/<B_Q_H=]M^:O]YBY],X]/\R>DL7P>M]IBK,JK?Z@
MRY$J14M59)8OILE.KEEG5RV[>7<CKV#L.VY\AK+]ZDVHK3_'\B)V3KY@N- -
M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
M - - - - - <Q<P9AB'%_P A\7S7*&6NIJJPRT$](L3355O_ .D.T5;$K *5
M8]T3!6[UZG;KU M[?+;@E%+MD4@ &Y_Z%5_I_P#DM ;-05M-<J&FN-&W?25D
M4=13OL1W1RJ'4['J-P= >C0#0#0#0&$_,K_AISS_ -YH?_K*ET!G&5'\GF[X
ML4->2;8EHKJFGC;V&K2V1%3_ )053;0DLWS358<1X]N5..V\4>=65K=*O219
M")R0NW7KVC_L#0(T;/>!</SO(ER];C>L6RMJ<4-;><6N,EIJJRD7VQ5)C#"1
M5_A)7NVV&^P&P@M^#8-C/'&,T6(XC1"ALM$&*(6:22221B\DLLCDL\CL2S,Q
M_P"UL- <OUF/?_?"365)HLLQP49ED-,'BHNX1%CV _\ 0#Z+M^NA)C^26_GF
M@^3'"B\[W6W72ZR72 VA[6L2+'3BK02"0100#<MMMT.@/]%KK:[??+;5V>[4
MZU=LKHGIZNFDW[)(I!VLIVVZ$'5H3<6FMT09X?CMPH5*_P"YE -QMO\ =_\
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M9!.W<X5B/&-MNGKH"L\G<'Y%FF&8#)C%Y@L/*''9I*JPW.53-1&>*".*HAE
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M\TW!/=I.F.5#JB__ -%W?KZY'HIERYHX7N=3<Z?G+@VH%)GM(!73P4)5H+K
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M71SCZ^T+ E2DL9_(3M.P/U!OOTU7]QJ5L%?%?I+]'ZX?T(CPX'4VOGRXT T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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M6RL=T6.#_E_ NGJ737*2- - - - - - - - - - - - - - - - - - - -
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M0W2%EW^I&%\7=U]R^V9?W>Y":TTEL31>M/'9M\$IBF5XASMA];9+W1+'<(U
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M.L3F($%MW"DCH/7KJ5N#D/$\JQ'G7$*ZQWRC5+A&"+Y9">V:GE4E5JJ5F\@
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M&VODOW*N-=[C%:+A\%X[&NZ\TD: : : : : : : : : : : : : : : : :
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M+<*H\-I[@]SBI))Y15R1B%F_(D:3;L#-MMOMZZ^4RLAWV.;6FI9+0NNN4D:
M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
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M%U@9>XR1A=T>1T/DO59E/\WNPQ<I)>*WM^/7L2T3F"9W@/RCP&OQ3*Z!(+_
M@2^V)SV3TTZ>*U=(S;L%#'Q;U0^#[@^6=U-F)8I1?#D_IC<Y7Y QGD+@/-<6
MI+O4/<\9QRM_.P^\%/%Z83)-+3$]>T@C=H2=@6)7HW7Z#%LKR822X.2XHH^!
M_HS15E/<*.GKZ1Q)25423P2#T:.50RD?Y0=?&M-/1FA]]0!H!H!H!H!H!H!H
M!H!H!H!H!H!H#+.2_D)QMQ/?Z+&,MJ*T7JOI/ZA3TU!0SUK?C?4:+O/T5;;R
M1O\ L: ]/&?/?&'+=96VO#;NTM[MR_5K+16T\U%6I%N!]3Z4Z*67=@"5WVW&
M^VXT!I6@&@&@,GY8^0.'<37.VXW64-TR+,[O&9[=C6/TIK:]X%)7ZK+W*%0E
M6 Z[G8[#H= >CB3G?#>8'NENL\%PLN46,H+QC5\I_P *Y4XD V<Q]S IOTW!
MW'3N W&X%IY Y Q7C#%*_,\RK10V2@4=[ %Y997/:D42#J\CGHH'^4[*"0!D
MV)?+C!<BR:U8S?,=R/#9<AD$..7#)+?^'1U[R':-8Y!(^S.2 N_0DCKU&A);
M>6^>\-XAJ;79[I2W&^Y9>P[6G&K%3?FW&=$W!D^GW* FX(!)W.QV!V;80?GB
M7G[#N7*ZZ6&W4=RL&7V1%ENF-7ZE-%<(HG( D"=S!DW(!Z[C<;@;C<"J9'\M
M<-M5^O%FQK%\ES6CQN5H<EO6.6\5=OHGCZ2 RM(G<4\N[;QZ="="30:3FGCB
MLXO/,,5Y08&E.:J6O96#QE7^FT+1 %_JB3[?TP-RW0;[C0@S*V_,/#Y9[959
M'AV5XMAU[F6GM.87FVB&TRM*W;&SRI(_8K^JML1MU.PW.A)T8""-QU!]#H0-
M - - - 91S17\#TM%%#S&+7([QEJ2"J0R5[1@G_F?HCZP4MN-U(7?0',]CI<
MEJ+O'-\5:/,+?:3-W5$MYEB3'V _18ZK<=/W,3M^F@.@<$Y2Y"H<[M_%?+]D
MI:3(KM23UEDO=IE$E'6)1KW2AXR>Z-@ 3_\ B]0= ;=H!H!H!H#"?F5_PTYY
M_P"\T/\ ]94N@,YRH?C\W_%BMK@?Z8]HKJ:G=O8*M[9$%'^4EDVT)++\TRLN
M(\>VZ AKO69U95MT2_\ .-(!."5_7IW#_LZ!'2DT4<\4D$J]T4JE'7TW5AL1
MT_NT((G%,4Q_",?H<5Q6A6VX_;4:.BHD9W6-7=I" TC,QW9B>K: Y7K/BU\C
M9ZRIGI_D->(*>6622*$-7D(CN6"]*P#H#MTT),?R7C3D#C7Y,<*47(&?U>>U
MM=<X)J2IK?K]U+&E6BLBF>:8[,3OT(T!_I#H0?*JB6>FF@?<)(C(Q'KLP(.V
M^I6X.#,?R"^\!W^+!LXF>NXXKY7;'LA56/XI+;GH-R%!/WH?53YIN#Y?;-*:
MU6YX$X1R(]4>$N:+#R9QI<IKE#RGQ9,*7.*4"KFAI"K0W2%EW,D8'B[NON7V
MS+^[W5A-:=,MC*B]:>.S;X]>Q*8IE>'\[X?662]T:QU\:@7RQD]LU-,OBM52
MLV[!0QZ'U0^#[@]8E%P92RN>//5;<G],I6/9!?> []#@^<3/7\<5\C-CV0JK
M'\7=MR"!N0H)^]#ZJ?--P?*[2FM5N=$X1R(]4>[FBP\F<9W*>Y0\I\63"ESB
ME JY8J0JT-TA9=S)'MXN[K[E]LR_N]U836G3+8RHO6GCLV^/7L2F*97A_.V'
MUEDO=$L=PC4"^6,GMFIIE\154I;=@H8]#ZH?!]P>L2BX,I97/'GJMN3^BT<6
M5W_4AC+T^75+U&.V6HDIH[K"ID/]+JYD:&:2,;LOTI)"LJC?M'5=QKDS*O-'
M_'<ZL>Y.]27_ '+C_$^_-'"]SJ+G3\Y<&U I,\I *ZHIZ$JT%U@9>XR1A=T>
M1T/DO59E/\WN\W%REIXK>WX]>Q[C1.8+G6 _*/ :[%<JH4@OT"!;[8F/9/33
MIXK5TC-NP4,?%O5#X/N#Y9VU68EBE%\.3^F-S-L2RW*_BKE</&_)$TMSXDN<
MK'&\D"LWX89MR"!N0H)^]#ZJ?--P?+KLKAEPZX<)K=$;%MYHX7N=3<Z?G+@V
MH%)GM(!73P4)5H+K R]QDC"[H\CH?)>JS*?YO=ABY22\5O;\>O8EHG,$SO ?
ME'@-=BN54*07Z! E]L3GLGIIT\5JZ1FW8*&/BWJA\'W!\L[:K,2Q2B^')_3&
MYFV)9;E?Q4RN'CCD>:6Y\27.5CC>2!6;\/N;<@@;D*"?O0^JGS3<$ANNRN&7
M#KAPFMT1L6WFCA>YU5RIN<>#JE:3/:0"NG@H2K076!E[C)&%W1Y'0^2]5F4_
MS>[#%RDEXK>WX]>Q+1Y*KD2P_)3@K*K.:>.AS^ST35M=8Y1]R&JH#]034_?Y
M=DA4Q[^Y.[L;U!;2NJ6)D1?_ &M[_P 2-T:%\9<K.6<-8]-+(9*RU(]HJBW4
MAJ(]L8W_ />C&=<W[E5X[Y?KQ_J3%ZHUW7FDC0#0#0#0#0#0#0#0#0#0#0#0
M#0'%-RY8Q[%?F-G>47FVWF]4UAL-%C="+';Y;BT,T_TJJ7O$9 3R[U&_J=]"
M2[<<6;)>5_D*_/U7BU;AF&V:RM8K)%=X!1W6[32LQ:HF@W++&B2$(6]=EV)\
MNT#1^>Z^X4&/VN2W<JT7$\C5O:]WN--254=6OTG/XZK6.B@_Q[KUZ:$&!-DN
M2[';YF8^#^G_ -%V3_O^A)U[B,LDV*V2:6\1Y#+)04S/?H52.*O8Q*34HL9*
M*LOO 4[=>FA!S[QD%NGS(YFN-=$#66BTV2W6YF&[)2ST\4LG9OZ!F0$[:$GZ
MR2-+5\XL+J+>H@EOV'5T%W,?C]=*:2>2,R;>I!C0 G]% _30']^5B)=,PX*Q
MBO7ZUAN>:TTMPI'ZQ3&F[!&KKZ$$2.-C_;H#Z_.F&(?'^X78 "X6:Z6NNMLW
M\4=0*I8NY3Z@]DC>FA!XL ;^M_,W/+G<T62MM>(VB&W=XW,$=6E//+]/??MW
M=VWV_M/]NA)Z,YACH/FKQ;64:B*IO&.7BCN3QCM:6"FBGFB#D>NS@;;_ -@T
M!=VBXP^)?$ESK(7EIL<H99ZU8JJ?ZU;77&KZK"CL 7DD*A1T\5'<?%2="#G:
M/@[D*7X8O:8K2TV5U]Z7-9,316^H](\RN*,1[;E_I 2?3VWW\-N[IH227-OR
M?P#D_@[)L.Q.QWBMRNNMA>X6.:VS1K:(J0K433U4S*(E2 1DJ49MV"^F_0#J
MCB:JGKN*\&K:ES)4U./VF::1NK,\E%$S$[_J2=""X: : : : YSYHNL<G*UC
ML.'<>V[-.3S:VJ?S;RV])16U9G[1VLP0$R%F[SL1N -R1L!Z?]Z/EY'%V0X!
MBX[%VC05[!1L.@_^,=!H#;J.V4]6;;>[S;:0913TP1JE8TDEIWE0?6CAF(+A
M"VXZ-U&@)70#0#0#0%#YHXX;EOC*_P#'B7$6E[W' @N)A_)$1IZF*HW,??'W
M;_2[?</70$%R+P19N1L#QW%*VZU5KOV)_B3X[E%OVCJZ2MHHEC$R#?VMV[LG
M=_8005!T)*OB?QMOR9Q9<[Y9Y&N'(E=B[228U0U-+%;Z.EJ'V G:.)W#R  $
M'IY $D[#0'0.A T T!QI\E_^*_X__P"UQ_XY-"3LO0@^%:TJ450\ WG6)S$"
M"P+A21T'KUU*W!R%BF58ASMB%=9+Y2*EPC&U[LA/;-32J2JU5*S>0 )Z-ZJ?
M%]P>OV<DX/@?,65SQYZK;\E+Q[(;]P)?H<'SB9Z_CBO=FQW(E5C^+NVY! W(
M4$_>A]5/FFX/E=I36JW.B<(Y$>J/=S18>2^-+E-<H>4^+)A2YQ2@5<T-(5:&
MZ0LNYDC \7=U]R^V9?W>ZL)K3IEL947K3QV;?'KV)3%,KP_G?#ZRR7NC6.OC
M4"^6,GMFIIE\154I;=@H8]#ZH?!]P>L2BX,I97/'EJMN3_N4K'L@OW =^AP?
M.)GK^.*^1FQ[(55C^+NVYW W(4$_>A]5/FFX/E=I36JW.B<(Y$>J/=S18>2^
M,[E/<H>4^+)A2YQ2@5<L5(5:&Z0LNYDC \7=U]R^V9?W>ZL)K3IEL947K3QV
M;?'KV)S!<\QGF/%Z^V7"'\2X/ ]'DUC5NR5(Y?MO+3EMSV;]5W!,;;!OT)B4
M7!\/Y&=E3HFGRU/AAV8Y3\6LHI^.^1)Y+IQ%=G+XQDP5F%(KG?J!N0H[OO0^
MJ'S3<'R\FVJ.5'KAPFMT?3)_T+=S1PO<ZBYT_.7!M0*3/*0"NJ*>A*M!=8&7
MN,D87='D=#Y+U693_-[L,7*27BM[?CU[$M$Y@N=8!\H\!KL5RJA2"_0(%OMB
M<]D]-.GBM72,V[!0Q\6]4/@^X/EG;59B6*47PY/Z8W,VQ++<K^*N5P\<<CS2
MW/B2YRL<;R0*S"C[FW((&Y"@G[T/JI\TW!/=UV5PRX=<.$UNB-BV\T<+W.IN
M=/SEP;4"DSRD KIX*$JT%U@9>XR1A=T>1T/DO59E/\WNPQ<I)>*WM^/7L2T3
MF"9W@/RCP&NQ7*J%(+] @2^V)SV3TTZ>*U=(S;L%#'Q;U0^#[@^6=M5F)8I1
M?#D_IC<S;$LMRSXJ97#QQR/-+<^)+G*QQO) K-^'W-N00-R%!/WH?53YIN"0
MW797#+AUPX36Z(V+;S1PM<:NY4_.'"$Z4V=TJBMJ*:C*O3W>!UW+H%W1W=#Y
M+[9E/\WNPQ<I)>*WM^/7L2T4SX1Y<7N688?41?BM.R7FEHANJPLKF"H0*W4;
M=T0_MZ===W[Q7K&$_P"16)V/KYHN- - - - - - - - - - - - - 85\=\!
MS#&;YRIF&;6W^E7/-,GGK:"E,L4[&V0=PIG)B9P-Q(P"D[].H&A)NNA!#9'B
M.*9A30T666.@OM'3R?6@I[G2PUD<<NQ7O59E8!MB1N- 5L\'\,,"K<=XT0>A
M!L]#MM_\%H"[45%1VVCI[=;J>.DM])&D%+2P(L4,44:A41$4 *J@;  =- <\
M<CX%RWA?,DO-O#-KH\G_ *[;([3EN+5U4E#)*:3;Z%1!-)VJ"%14V)W&QZ-W
M>(D_G'& <O7KDF^<]<JVNAM>4P69K%A6'4U4*B*FBW,S//4(64-(Y*[C<[.V
MX4!1H#SY?@7,_-?#]ENV3VVWX9SCBMZ6_P".4]/-]6D^K0R'Z2.ZR3A/JJ?Y
MW'<JD[ D " R?%?DC\@I+!A/)>(6S!>/Z&Y4]RR>MIKC%7SW!:(]P@IXXV<H
MKD_Q^GKW'M[6 MO*/'W*N+<N4_.?"]OHK_7UUK%BRS%*Z=:,U5/$WU(9X9I"
M%5U[44]=QVC8,&;8#Y<;X#RWE?+DO.G,=KHK!6VFU26;#\1H:E*MH5G)>6:>
M=.Y"S=[H.O\ %U"A1N!E57AORER?DB/D3DOB^BRX6E^_$,;?(:*DL]J?O!^K
M] -)]>;8+]R0^O7;H@4#?GI^:^3^+\GLV04 XJSJ9@F/5ULN:5Y'TOIS)(\U
M-U17=3%(!Y=A) T!EN1T?RQY5PL\/Y/A5KQJFN2P4.49^+I!4QS4:,AEDIZ.
M(F022A""&W'EMX;[J!U39;31V"SV^Q6Y2EOME-#14BL=V$--&L: GIN>U1H0
M>[0#0#0#0'/G,=KY2MO*V.YYQ7BW]5K:.UR4%VJI*B)*:JII9F84LD3,C!D(
M$JRJ?UV_30']?D_Y+JA*\0TQ<#H/ZI%U/_9T!O-NFJZBWTD]? *:NEAC>JI@
MW>(I64%T[OU[3N-] >G0#0#0#0#0#0#0#0#0#0'&GR7_ .+#X_\ ^UQ_XY-"
M3LO0@^<\B1022R,$C169G)V  &Y)/]VI6Y#.+.2^-;E/<X^5.*YA2YO2[U<\
M%*5:&YPD;F2,#=6D9?<OME7]WN^TA):=,MCYRB]:>.S;X]>Q*8IE>'\[X?66
M6]4:QU\:@7RQD]LU-,OBM52LV[!0QZ'U4^#[@]8E%P92RN>//5;<F4K'LAOO
M E^AP;.)GK^.*]V;'<B56/XN[;D$#<A03]Z'U4^:;@^5VE-:K<Z)PCD1ZH]W
M-%AY+XTN4URAY3XLF%+F]*!5S0TA5H;I"R[F2,#Q=W7W+[9E_=[JPFM.F6QE
M1>M/'9M\>O8E,4RO#^=\/K+)>Z-8Z^-0+Y8R>V:FF7Q6JI6;=@H8]#ZH?!]P
M>L2BX,I97/'GJMN3_N4K'\@OW =^AP?.)I*_CBOD9L>R%58_B[MN00-R%!/W
MH?53YIN#Y7:4UJMSHG".1'JCW<T7R^<=4QSFR<I8D(UNJ3QM>Z:!U%/<[?5+
MV23QE?$R=C=W\L@Z^[UI&7#I?_P<T+O\'7+;E^ALL9P'EVQW;B?)E%5<;9!"
M:VBE'TZA8Y$!IZVE<[]!W;=Z^UMU<;'9OG[XSHM\D=GZ:9[F)/JJ6O\  Q7$
M<NRSXJY7#QOR1-)<^);G*QQK)0K,*0,VY! W(4$_>A]4/FFX/EU65PRX=<.$
MUNCJV+;S1PO<ZBYT_.7!M0*3/*0"NJ*>A*M!=8&7N,D87='D=#Y+U693_-[L
M,7*27BM[?CU[$M$Y@N=8#\H\!KL5RJA2"_0(%OMB8]D]-.GBM72,V[!0Q\6]
M4/@^X/EG;59B6*47PY/Z83U,VQ++<K^*N5P\<<CS2W/B2YRL<;R0*S?A]S;D
M$#<A03]Z'U4^:;@[-UV5PRX=<.$UNB-BV\T<+W.IN=/SCP;4"DSVD KIX*$J
MT%U@9>XR1A=T>1T/DO59E/\ -[L,7*27BM[?CU[$M$Y@F=X#\H\!KL5RJA2"
M_0($OMB<]D]-.GBM72,V[!0Q\6]4/@^X/EE;59B6*47PY/Z83U,VQ++<L^*F
M5P\<<CS2W/B2YRL<;R0*S?A]S;D$#<A03]Z'U4^:;@D-V65PRX=<.$UNB-B3
MSD6WCWY/8+GUH$*8]G4'XM94P%133SU/V6F#IXMW"6GE+?Q'R_75Z-;L.=;W
MAQ]>X?!G5VOGBPT T T T T T T T T T T T T T T T T T T T T T T
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MN!_H'@^20YAAUBRB%@RW:A@JG[?19)(P9%_]B^Z_\FOD[J_'8X_AFA/ZQ T
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M'8Z&UXI8: : : : : : : : : : : : : : : : : : : : : : : : : :
M: : : : \UPMUONU'+;KI20UUOJ!VSTE3&LT,B@@[,C@J1N/U&@,$Y5K<>QO
M(K3Q[QOQE8,BY!O$#UP@J:"EBHJ2BC;L,T[!%]S @#N7_P!0$24NX5&?\;TX
MR+E'A_$+C@\++_5JRPTE*:NDB<]ID,;A@RKON?';].X: ZMM55;ZVUT5;:2C
M6NHIXIJ%HE[8S3R(&C*KL-AVD;#0@]>@&@&@&@&@&@&@&@&@&@.-/DO_ ,5_
MQ_\ ]KC_ ,<FA)V7H0?.>1(H9)9&"1HK,SD[  #<DG^[4K<AG%?)?&MRFND?
M*G%<HI<WI=ZN>GI2K0W.$C<R1@;J[LOO7VRK^[W?:0EPZ9;'SE%ZT\=FWQZ]
MB4Q7*L/YWP^LLMZHUCKXU O=D)[9J:9?%:JE9MV"ACT/JI\'W!ZQ*+@REE<\
M>>JV*7CV0W[@2_0X-G,SUW'5<[-CN1*K'\7=MR"!N0H)^[%ZH?--P?*[2FM5
MN=$X1R(]4>[FBP\E\:7*6YP\I\63"ES>E JYX*0JT-TA9=S)&!XN[K[E]LR_
MN]U836G3+8RHO6GCLV^"3Q7*L/YWP^LLMZHUCKXU O=D)[9J:9?%:JE9MV"A
MCT/JI\'W!ZQ*+@REE<\>>JVY/^Y2\>R&_<"7Z'!LXF>OXYKW9L>R%58_B[MN
M00-R%!/WH?53YIN#Y7:4UJMSHG".1'JCW<T6'DOC2Y37*'E/BR84N;TH%7-#
M2%6AND++N9(P/%W=?<OMF7]WNK":TTEL947K3QV;?'KV)[ L_P =Y>QFOH*R
M'\2YFGDH\DL8;MDCCF4Q/+!W[DQG?ION4;HWZ$Q*+B_@RMJ=$D^7(\N&9GE'
MQ<R>FX\Y$GDNG$-V<OB^3!684JR'NZ@;D*.[[T/JA\TW!\O*MICE1<X<)K='
MTREP_0KN=8-E%W^0G(.?\-54=-E&-6W'[S24U JE+I%<(9S.ZLI[)&=44]NQ
M$P)_BVWX\2^*DX6[26G\-/7\B[1MN"YU@'RDP"NQ;*J%(+[ @6^V)CV3TTZ>
M*U=(S;L%#'Q;U0^#[@^2VJS$L4HOAR?TR-S-L1R[*_BKE</&_)$TESXEN<K'
M&LE"LPI S;D$#<A03]Z'U0^:;@^7797#+AUPX36Z(V+;S1PO<ZBYT_.7!M0*
M3/*0"NJ*>A*M!=8&7N,D87='D=#Y+U693_-[L,7*27BM[?CU[$M$Y@F=X#\H
M\!KL5RJA2"_0(%OMB8]D]-.GBM72,V[!0Q\6]4/@^X/EG;59B6*47PY/Z8W,
MVQ++<K^*N5P\<<CS2W/B2YRL<;R0*S"C[FW((&Y"@G[T/JI\TW!(;KLKAEPZ
MX<)K=$;%MYHX7N=3<Z?G+@VH6DSVD KIX*$JT%U@9>XR1A=T>1T/DO59E/\
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MKQWR7ZZ_U+)ZHTC7"2- - - - - - - - - - - - - - - - - - - - -
M- - - - - - - - 9E?.<L,Q/DR+C/,9&L%7<***NL5XKR(K;7EW>.2!)FV5
M)8RH\6/7<==]@0/9R=P_B'+-'1&]_7I+K;B9+3>[=)]&L@+C?97V(9"0"5/_
M ";: SVA^+%FDKJ:KS[,[YF%IMS":GM5SJ"M&&C.X^J.YBRC;J-UT!?<4YHP
M#,<]N/'&&58O%78J#\VYW&@"R6RF(F6!*43*>UI3N6[4\0%/7<$ #1M - -
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M(YJ.@HJ90]153LX[@@_10PWV/KL%828=:,_R_&L$O67Y=Q[BF4TV#YE<L:Y
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M?ZBL25DD=#Y*?&93MZ[=WDU9SFW"_BI>WKV+:?@M^!YW@/RBP&OQ3*Z!(+_
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M0"NJ*>A*M!=8&7N,D87='D=#Y+[9E/\ -[L,7*27BM[?CU[$M$Y@N=8!\I,
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M?ZM'43SU-6*>3]&A2HED1&'Z,%W'Z$: U_0#0#0'&GR7_P"*_P"/_P#M<?\
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MS$L4HOAR?TQN9MB66Y7\5,KAXXY'FEN?$=SE8XWD@5F_#[FW((&Y"@G[T/\
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M'58G8:FW5,U9;YK=224E95'>HFA>!"DDI_G92&;^_0@F= - - - - - - -
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M@G[T/JA\TW!\NNRN&7#KAPFMT1L6SFCA>Z3W.GYRX-J!29Y2 5U13T)5H+K
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M55/2T]?1$DK'54D*P2]G=Y!2R;@-U'H=_77U.'3XJE'77<IN4K7:#K#X+?\
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M=M =^X;:ZZR8AC]EN<@FN5NMM'1UDH/<'GIX$CD;?]=V4G?0@F] - - - -
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M>T@%=/!0E6@NL#+W&2,+NCR.A\EZK,I_F]V&+E)+Q6]OQZ]B6B<P7.\!^4>
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MS;L%#'Q;U0^#[@^65M5F)8I1?#D_IC<S7$LMROXJ97#QQR/-+<^)+G*QQO)
MK-^'W-N00-R%!/WH?X?>FX)#=EE<,N'7#A-;HC8ZEL-@QFWU-QR''8(8VR5X
MJ^NJJ5NZ&JD^GLDX[24)=""67W^IW/77BSG)I1E_VEB<UF!H!H!H!H!H#E+Y
M06"_Y]RIQOQOA>6WC&<FN\-=45M105DE-;Z>TTH^I+/+%"5>:=BOTX5#@?S$
M [@24'FCXWYKQE@]1GMHY<S"\VZQ&*HR&USW.:"HFH#(J3O22AV5)$#=P61&
M!&_7]"!VEB,]'58G8JFWU4U;036ZDDI:RJ.]1-"\"%))3_.RD,W]^A!,Z :
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MXR#M[9%/79NK:XT9UQZ)M2C[HI9G5SBTT^)>PP<!PH0L 613W!6(ZJ#^H!Z
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M^^;_ !_R)FMDP>V8U?J.X7RH_%IZFKBIE@1^QGW<I.S;;+^BG6!N=/: : :
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M=]S[7_)7Z7]NQ/Z:]2[,ZJ4N;W]?J>13A]-S;[5Q7\_[&U?B4O\ J(_]!?\
M-KRCUS^K34Z,&2%%8>A"@$?]K0'UT T T T T T T T T T T T T T T T
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M'MIX9)%1Y#Z;(I(+?\F@/1H!H!H!H#S17&WSU4M#!5PRUL WFIDD5I4'INR
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M]"!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H"E<Q$#B//B3L!CEXW/\
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M)&U1)$& \5:(;?KLZ_KN !U%H0- - - - - - - - - - - - - - - - -
M- - ?&KI*6OI9Z&N@CJ:*IC>&IIID62*6*12KHZ,"&5@2""-B- ?&UVJUV.W
MT]ILM#3VVU4B?3I:&CB2GIXD'7MCCC"JHZ^@&@/9H!H#\R1QRQM%*H>)P5=&
M 965AL00?4'0%2_ZI^+?_N'Q_IZ?_15%_P!ZT!.63'<?QJF>BQRTT=GHY',T
ME/;Z>*DB:0@ N5B506( &^@)/0#0#0%4MW%_&MHO'^\-JPZR4-^[N\7.FMM+
M#5!^OD)4C# ]?4'0%KT T T T!'/C]ADO4>226ND?(H8#20W=J>(UJ4S'N,2
MSE?J!"3N5#;: D= - - 060X3AF6F%LKQVV7UJ?I3FYT5/6F,$[^'UT?;K_9
MH"4M]NM]IHH;;:J2&AMU.O93TE+&L,,:[[[(B *HZ_H- >G0#0#0%9KN../+
MI=OZ_<L2LU9?>X/_ %2HMU+-5]Z[;-]9XR^XV]=] 6;0#0#0'GKZ"BNE%46V
MY4T59;ZN-H:JEG19898G&S(Z,"&5AT((V.@/S;;9;;-04]JL]'!;[92((J6B
MI(D@@BC7T5(XP%4#^P#0'JT T T!6LQX\P;D*DBH<WQZ@OU-3DM3BOITF:)F
MVW,;L.Y-]NO:1OH#Z8C@F&8#0-:\+L-#8:&0AIHK?3QP?48;[-(5 +D;G8L2
M= 6'0#0#0%>ON X+E%7'<,FQBTWJOA4)#57&@IJN9%4[@*\T;, "?T.@)Z**
M*GB2"!%B@B4)%$@"HJ*-@J@=  /0: _>@&@(V;'K!4WJFR2HM5'+D5%$]-1W
M>2GB:MA@EW[XXYRI=4;?JJML= ?"_P"(8GEB0QY38;=?(Z<DTZ7.D@K%C+;;
ME!,C]N^PWVT!(6^W6^T44-MM5)#0VZG7LIZ2EC2&&-=]]D1 %4;G]!H#TZ :
M : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M : : : : : : : PO)_E/AN-YM?,!@Q;+,AON.M"MU-@M(N$,7Y$:RH2R3!@
M"&]64==] 6+C/Y!\;<IW*HQ^QU=3;<MI%,E1C5[IGM]S6-0"7$4FX<#?KV,Q
M'Z[: U+0#0#0#0#0#0#0#0#0%,S3D[&L#ON)8]?%JC<,TKS:K.::'ZL8J!V_
M\\W<.Q?,=>O_ &M 7/0&>X9FV<7_ #W,\:R#"JBPXQ8988[!D4LO?'=$??N9
M%[0/T[O$MV[]K;-H#0M 4'F7E.V<-\?W+.[G12W):-H8*6W4Y[)*BIJ9!'''
MWE6"@D[ENT[ >A/30'NXRO6>9#B=/=N1L>AQ?(ZB1V-GIZD5GTJ<[&+O<= Y
M!\E_3_M: N&@&@&@,]PWERS\C\?W3/<#MU;<XZ$U\%):ZE%HZFKK+>I/T4)+
MA?J-LBL?3?J.FV@)'BW)\IS+!K7D69XU+B615@D_+L50Q:2'Z<K(K'N"L.]5
M#A6 (WT!<= - - - - - - - - - - - - - - - - - - - - - - - - -
M - - - - - - - - - - - - - - - - - <P<*D_P#I8_(!=^A2Q$C]-Q2]
M-"3Y_,2@I;')QCR=952FSZSY9;K=;JN,*)IZ6L$AEIW('<Z'L]IZ ,W\QT"(
M*T8E<?E)RGR+4YSD5TH./,!O$V,6#&;+5-0QRU-(Q6:IJ&7<LQ[=QTW\M@P5
M=B!$T6"Y%Q]\L,!X[K<LNN1\>UMDO4MHI+I52254%/-25*2TLLJ%#*J,H:%S
MU4$ >T'0%N^.F:5'&=-REQ/R)<III.+:JIN]'75DCR3S8W4(U1'(#(>H4#O]
MW3Z@70%G^)=OR&Y85>.5\LGJ)+[R3<Y[W%2SRN\=+; [I1Q11L=D7M+..WU1
ME_LT!0N<K3F66_*_"\(QC*J[%J*[XI.+O76^4I.E$E35/-^.#NJ3R!%C67;=
M-^[]-M 1G+G'%3\5+;;.9^+<GO<E-;KA2TN58[>:UZ^CN5%5N(V)# ;2 ]-]
MCMW=R]I7R G:BTWKY-\TYUC%]R*Y63BCCB2EMT=ALU2U%-<KA4H[--4R*-RB
ME'V7]!V[;'N) _MEI;]\<.><2XXM>0W&^\6<D05<5!;+U.U;46NYT4?>##*=
MB(G)0$#ILQW!*AM 8=21X_<:W(J7Y 9WE/'_ ,BOSJE[->JZ>JI;'"RL#2&E
M:!3&*<=-_)!V^P^FH!>.<>,I;ME'Q_FS?()[QDV2UM/9+[>+-62144\,*H4J
MJ,  1R2++W-*@'=^@VT!V3@F%6SCW%J+$K/4UE7;Z#ZIBJ+G4-65;?6E:5N^
M5]B=BY"_V#8:D@Y,:[W?^M_+]3<:OLM]!$:!?R)=J<_@U)WA'=]L[_JFVH)/
MMQ5\:!RCPSC68Y?GF339S<+3')8KC#<I8Z>UQ*I%)%%"/<J *9"6[F.^Q!ZZ
MD&7\D76Y\K_$3&<^S:NJZK,<;O9QUZJ*H:."K0U2QF:>(#:24(B 2'R[MV]2
M= :#SG<[5PK/A? MLS2^8M@N025M\R[*VFJ;I>11@=BTE.\4;R*)70J2J[#<
M$^/>& S^X<F<3\4W6PY9\=\^R.YW&.X4]/DF'WF.YST5SMTQ(EDWJJ>-$E3]
M&WW\MUVV.\ VFGQ^X_)SF#D:U9A?[I;>->.ZV*QVO&;/5-1+55P#B:JJI$ZO
ML4;L'Z!@ 1LW?(+;BOQ[S'&J[)<%GS.MN_ ]_H1'14%775'^\-KK.]7(I:D1
M]HA.S;CN_4>/N+ 8K\7>+[&O#61<IPW&[Q9':UR:CIJ9*^5;?VBEDB#M3C8%
MP'W[M_=LWJ!J ?JP9YGE7P9P#Q9BV05-GO\ R757"EN>4AWEKZ:WT-;(9?HN
MS!A(RN.U@P("]H(WW$@MG*W!U5\?\*K>7N(,SR"FR3&/I5=TH[O7M<**ZTOU
MD6:.IC95!)![NG3IT .S*!&99%?>9?DA@MNH,ENV*XUEG'E+>+W2VFK>&62A
MJ))9VID;VJ78QJ[]N_:- 3,N(57QIYVXUMF#7^Z5>!\C3U=HO>.7>J>MCCJ*
M=$:.HA9_:V\BG^;Q(W*ML ,WRT8W6\HYQ0_*/)\JQ"]SW&=./;M1R5,./P6G
M=OQ7IC"CJ7'J_>.WIY$/W: [$X.@R>FXRL<.69319K<%1_Q\HMTC3PUM(7)@
MD:5O>X396?\ 4CJ2=R1!H>@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&
M@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@.5)L&^0^"\W\D<A<=XW8KW:
M,T:WK ]UN#T\D:4-.(^B1[>YBV^_]@VT))ZR<-<I<B9_8>1_D#=+8M-B<HK,
M7P?'A*U!#7 @BIJ9IO)Y%*(R@%AOZ%1NK >&[\9\W<4<F9/G7!D-KR/&<ZG%
MPR'%;U,:22GN>Y+5%/-NH[7+,Q\OXMBIV5@!X,7XAYXN'R%Q'FKDRIM<T5-0
M7"DK;7:I&6FM,$M/-'34\(DW>9V:4O+)Z;D@$@#0%3^6F!U.1<V8'9,,N;4&
M2<DT,V-9924Z[M)8*6HAJGJ)-@>BJK[[]2(P >AT!V7;+;16:VT=GMD(I[=;
MX(J2CIU]L<$"".-!O^BJ -"#D3G6RYI>OEUA X\N\%GS.@Q&HKK3-71M+0SR
M0U55WTU4$\A%-&SHS*"R[[CJ-"29O_''R(Y\N=EQ[F.BLF(<86BMBN5VH;-4
MM65=VFINL<88ENR,[GU*[;[[.0NP$]E_%O+F <I7GEG@<VZZP9<D*Y=AEYE:
MFBFJJ92L=53S @*VV^X9AL6;W!ME _6#\2<HYGR=3\R\[3T%ONEDHYJ##\5L
M3F:&W_E(R2U,LS]P:8ACMVENNQW':%T!4[Y@GRN3&;WQ17T6-\E8U<6J8;7F
M61SE:RGIJH%5>H@8$M+%W%D**W:?0L !H"5RKXZ9[:N..(J# KG0W7-.):Q*
M^**[&2&CKV8AY(PZ[LBJP"Q@[>'Z@[: Z P.KS:NQ:AJN1+=16K+G^K^?0VR
M9JBDC E81]DC;D[QA2W]AWT(,%;A#D W3Y&U0IZ3Z/)5&D&*G\D;R2+23PGZ
MP[?MCN=>IT)-BX5Q6[X/Q/A^(W](X[U9K93T=<D+B6,2Q+LP5QT(_OT(.:F^
M-O*9^+S\5BEHO]\#E!O(A_+7Z'XGY'U-_J]NV^WZ;?\ ;Z:$FT\X\2Y1EMVQ
MCDKC&XTUJY3PIYS:VN"LU#74=4A6:CJ.S<@,-^UAZ=S>FX91!5J>S?*KDO(;
M'!FTMOXSPJT5*UMV&-USU%SNC1^V 2 L(X6Z]P+#UZAR!L)&0<9\P\9<FY+R
M5P;#:[_9\W,,V38?>)FI&2X0A@*JFGW"CN[F+JS>K'HWCV 67B?#^:Y\QNG)
M',=^2EDK*845GP"RU,TEGH8PPWFE#'MDG/;T8;[!CY>BJ(,_XPXGYWXSM.2\
M2_AV*Z\:W47R>BR)*B6&XB2XTKBG1H6\1]WL5_$A03LQV&A)^*/XT9O-P7QG
M9Z2XTV/<S<9U$]RL=8S?E4'UIJN25H)BJMO'(OT^XA6V(VV()T!_<IPKY2\Z
MV^+C_D:EL&"8!-)$^2UMGJ'K:ZX0P2I)]&G4NXC5BN_F1_>6'@P%W@XAOUL^
M2./9[::6"'CRR8:,9@^]]^.:*9S'&(B-RH0KY;Z ]W,7&V4YGR9P_E%BB@DM
M.&W>KKKX\LPB=(9TA"&-2#WG[;=!_=H"EWK&?E#BMSR6Q6>DL7*V WZJDJ[4
MN63]M1;DF)_Z-/&_:LL2=-E7??;<=NY70&D?';BFX\-<76["KQ<([A=4GJ:V
MM>E#"DBEJY#(8:<. WTT_M(&YW.PWVT(-5T T T T T T T T T T T T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T!B,
M-FX\I_E#47J[Y)4U?)]5CJQ8_C55331TM':4?::6EG,0BD=W$A8"0L.Y^FV^
MPDV[0@Q:^V? 9?D]BU[K<CG@Y&@QJII[;C"TLC4]1;VFG+U#5 C**RL7'89
M3VCI_:)-IT(&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&
..@&@&@&@&@&@&@&@/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>lc_fig46auclog-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_fig46auclog-4c.jpg
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M Q$$(3$205$%87&!D:&Q(A/PT3)2,Q05!L'A0F)R@L)31)*BLM(C)!;B_]H
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M;XSQ;N2S_FG6ZU^/7NTQPV*T!"T=25=.-%ZH2B4GI@P%!(SEN)M.HZ^""\/
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MCFK!Y,OJ\>J,:F&NGI!M]2YGNA!@DBE"0XXO4$@-M2$=-S.WL02B@(" @("
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MY;2\?VG%<RL=\NKY[BTK4-LN=)6U#QQW$-Q>G!*9:#[7TZ(+(H" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MSM;N05$#%N8=VXO FZMXL[:/U7.8T=HG5(JPR(" @(" @(" @(" @(" @("
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MOR6;7;J\;)?5,Q8^F.*P*Y.X@(" @(" @(" @(" @(" @(" @(" @(" @("
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MKV"SZ?"^C+7;^)9,MXK%8XNGB7[7VVSP7RVR6^'R1QGLCUI[^Z/V]?\ 0_\
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M:MIXJRCFCJ*2<6D@GA)I(S FU8A(7=G9V\'9!VH" @(" @(""&.Y#^1>/_\
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M\0^ QQBPB+?@9ETK6*Q$1RA&RY;9;S>TZVM.L^>7>MG(0$! 0$! 0$! 0$!
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M%!5+ECE[[;/Q_9/L'F..ZYWB\WUCD-H]PH6].X@^QY?6/S%^2VG5!:] 0$!
M0$! 0$! 0$! 0$! 0$!!T0T=)3SU%3!"$=15D)U4HBS%(0 P"Y.WB["S"VOL
M6L5B)F>]TMDM:(K,\*\O)V^]WK9S$$,=SG^#VT_^U>,?SQ3()G0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$$-9+V^6S)+_<;]-?)X)+A.504(P@3 Y^QG<F
MUT5QB\3MCI%>GDSJAS]0ML^\3]D/KF?TOL5]:^]>B&[=]:^ALV[M--.NJU_4
M;?,Z^GLT]NIJF3%^WZVXQD%OO\-[GJ);?*TPPE" B;LSMH[L3Z>*VS>)VR4F
MO3S-4R*G8$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 054YNI^T3+LQJ)\XS"+&
M.2;3_857=K/6RV^YQO&.U@E((S W%GT9S%R9O+KIT01B.)]IM5K!D/<-DM]M
M9,XG;:V^D].8OT<38:9G=M.G1V06HX-NW")XS)B_!U;;ZC'[$X>]T]N,Y"CD
MJMSC).<GG,Y/3+SF[N^WQZ()10$! 0$! 0$$,=R'\B\?_P",#%/YQ!!,Z @(
M" @(" @(" @(" @(" @(" @(""&.YS_![:?_ &KQC^>*9!,Z @(" @(" @("
M @(" @(" @(" @(" @(" @((4_SN_P#)O_?U!-: @(" @(" @(" @(" @("
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M.8T9G[>=QW['K5_^KHO_ $<I;"98W,HP*0=DCBSF#/N82=NK:]-=$') 0$!
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M8=M2=+<?2L=X*H60@(" @(" @P&;9ICG'F+7+,LLK!H;#:HO6JIW;<3ZNP
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MF-)=W@M61 0$! 0$! 05([]#&IQGCFQW:8J;#KIEE+%D$XDX"T+1DWF)M.C
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M)W&ZV7W4YM!&3TK+3Q,S? 1.!.S/XMHWBI-]M>NO]GFX5SUG3^UR6#45($!
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M)$SLZZQBO,:Q6?4(6^T6/_>P]_\ K:C]R_5WZ/O/O$7I>K]=[MF_=INTZZ?
ML?*OKII.OF$TT^2XY5SA34MXHIZF5]L<,53$9D_P"(D[NZS.*\1K,3ZAE%R!
M 0$! 0$! 0$'7//#2P25-0;1P1"YRR$^@B(MJ[O^!9B)F=(8F8B-90;G&<3Y
M).]%1.45EB+R!X%,3?EG\7[T?]/P]/M-I&*-9^U[E'N-Q.2=(Y(,P5W'D7E,
MA?1VN5H=G;QU^JP6<'XV3T>YID_#IZ?>M)@&?-<VCLEZD_\ *+-MI:DO^W,W
MY)/^_P#C_*_#XUN]V71\=.7N3]MN>KX;<TBJH6(@(" @(" @U3DNQ95DV"WJ
MQ83>?L]E-;"(6V\^9O=Y&D G+4&<FU%B'HWM05=^[MWB_MW_ /M*S^MH'W=N
M\7]N_P#]I6?UM!D<>X"[M+??[5<+QS9[]::2LIYZ^B]2K?UZ:*42DCT*-F\X
MLX]4%O$! 0$! 0$! 0?'=A9R)]!;J[OT9F9! //N68K>K=@%%9[[;KA6?;[%
M9/=Z2K@GEV#<0U=@ W=V;7KT03^@(" @(" @(" @(" @(" @(" @XR$0QF0#
MO-F=Q!G9MSLW1M7Z-JL2S$:SQ0K/W*8W2SRTM38[E%4PF4<T1-"Q 8/H0NSR
M>+.VBII\5I$Z367NJ_L[<6B+5R4F)Y<_J=?WG,4_0]P_^P_KBQ^K8_NRV_\
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M^M;;;$,'NGE])OS1 .ORO9J@D#_Y@?;]^_O7]SV_KJ!_\P/M^_?WK^Y[?UU
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M$! 0$! 0$! 0$'PA$Q<#9B F=B%VU9V?Q9V001P_8++0<U\VG1TC!+2W2R#
M3NY-&,UDIY"8&?P\Q%U^!]%VMFO;76>?/T.5<5:Z:1R3PN+J(" @(" @("##
M?9'%/T%;_HD'S$#[(XI^@K?]$@^8@?9'%/T%;_HD'S$#[(XI^@K?]$@^8@]%
M'8+#;I_>;?:Z2DJ6%Q]:"GBB/:7BVX!9]'T09% 0$! 0$! 0$$,=R'\B\?\
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MLBEJ#-HIKB#&.DLIMU9O@06O0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MJM]Y6(PVX=C"ZJ\8P(" @(" @(" @(""&.*O\-7.W]M<?_F&F03.@(" @("
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MS*(__>?_ .8/_'%I_NO\'^9E,'$W^$?'/^-C_P!B2WWOX-O,PNXO%," @("
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ML]0"ZCT(2Z:!'#\.]^E;K9JWEVUP6=_S95].9#5>GX:B<=NCEW?]];\*"8^
M^VC&>$O?;[-7S9-R'>!<;OD]<WYTA,F,XX1(C< (F8C<C(S?3<^C,S!." @(
M" @ICSW_ /\ :_"'_%8_^4U2#N[M0#*.>^ L KA::R3W5ZZOHR;4)A>JIA=C
M9^CMLB,?P$Z"Y""F_:( 8USGS]@=N%H[!27AJJAIA;:$&VKJ@819O!MA /\
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M_M?J@AWECAVEP=^/[Y'FN87\VSO%X6H,AOM1<Z'\Y<0;>\$C;7)OR2]B"UZ
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M9+O6B]4<9TM?/!$4 2N01.(1CH48L6O75!;Q 0$! 0$! 0$!!#'<A_(O'_\
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M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @P[9+;'R5\5WO\
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M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @((4_SN_\F_\
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M"#%SY-C=+,=-57BA@J(GVRPR5,(&)-["$B9V==8Q7F-8K/J$+?:+'_O8>_\
MUM1^Y?J[]'WGWB+TO5^N]VS?NTW:==/@6/E7UTTG7S"::?)<<JYPIJ6\44]3
M*^V.&*IB,R?X!$2=W=9G%>(UF)]0RBY @(" @("#QW:CJ*^VU-'2U14=1,#A
M'4QMJ0._M_TNG7X%TQVBMHF8UAI>LVK,1.BN-WM%?9*^6WW&-XZB-]=?$3%_
M A?VLZ]ABRUR5ZJ\GG+TFDZ2\*Z-$K<5X[=Z8ROL\ITUOG#;'2_[X;V&3/X"
MWY+^+_@\:/Q'/2?@CC,=O<M=GBM'Q3PCWI25&M! 0$! 0$! 0$! 0$! 0$!
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M9[9(RTT("Z$W1UY=JEE 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$,=R'\B\?\ ^,#%/YQ!!,Z @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(.,AM%&<CL[
ML#.3L+.1.S-KT9O%T%5>6^9;!G7ZO[';K%DMNJ7SO%YFJ;Q8ZZVTFD=Q!W%Y
MZ@!!B=ODCKJZ"UB @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(""&.X]W^I< ^/D#%-?[H@@F= 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'&20(HSED?2,&<B?QT9FU?P052Y8Y\X
MEY'?C[',,R'ZRO)9WB]0--[E74^L<5Q!S??401AT;^J06O0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!7WNUYER3BO#+19\"'?R+FM
M>UHL#[1D*+Y+2R@!LXE(Q211@Q=-Q[G\-'"-/NE\]_4WVC_7O>_UE^G[Q[MZ
M]7]6>OIN]W]3WC79KTW^CM_[GH@DSM+YER+E;"[K:<[!@Y$PNN>T9 ^P8RET
MW-%,8!H(F[A)&;#TW [MIKHP6!00QW'_ ,BX!\?(&*?SB""9T! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 04Y[FO[*[INWNCJO_  **
MN]>+=U'UO?(2Z-\.L<?5!<9!3CM?_L?N?[AZ2#R4TER]8XQ^2\GOM2^[\.IE
M_106*R;FSB3#;Q/CV59G:K/>Z80*>@K*H(I@&4&,'(7?5MPNQ-\2"$^=^=>&
M\@M.%167.;/724.;8U<*P8*H#>*CI*\9)IB8== C%MQ%[&02M]Y3@+]HUA^F
MQ?C0/O*<!?M&L7TV+\:!]Y3@+]HUB^FQ?C0/O*<!?M&L7TV+\:!]Y3@+]HUB
M^FQ?C0/O*<!?M&L7TV+\:!]Y3@+]HUB^FQ?C0/O*<!?M&L7TV+\:!]Y3@)^G
MZQK#]-B_&@?>4X"_:-8?IL7XT#[RG 7[1K%]-B_&@?>4X"_:-8OIL7XT#[RG
M 7[1K%]-B_&@?>4X"_:-8OIL7XT#[RG 7[1K%]-B_&@?>4X"_:-8OIL7XT#[
MRG 7[1K%]-B_&@?>4X"_:-8OIL7XT#[RG 7[1K%]-B_&@?>4X"_:-8OIL7XT
M#[RG 7[1K%]-B_&@?>4X"_:-8OIL7XT!NY3@)_\ WC6'Z;%^- ^\KP%^T:Q?
M38_QH'WE. OVC6+Z;%^- ^\IP%^T:Q?38OQH'WE. OVC6+Z;%^- ^\IP%^T:
MQ?38OQH'WE. OVC6+Z;%^- ^\IP%^T:Q?38OQH'WE. OVC6+Z;%^- ^\IP%^
MT:Q?38OQH'WE. OVC6+Z;%^- ^\IP%^T:Q?38OQH'WE. OVC6+Z;%^- ^\IP
M%^T:Q?38OQH'WE. NO\ ^XUAZ?\ #8OQH'WE. OVC6+Z;%^- ^\IP%^T:Q?3
M8OQH'WE. OVC6+Z;%^- ^\IP%^T:Q?38OQH'WE. OVC6+Z;%^- ^\IP%^T:Q
M?38OQH'WE. OVC6+Z;%^- ^\IP%^T:Q?38OQH'WE. OVC6+Z;%^- ^\IP%^T
M:Q?38OQH'WE. OVC6+Z;%^- ^\IP%^T:Q?38OQH'WE. OVC6+Z;%^- ^\IP%
MIK^L:P_38OQH'WE. OVC6+Z;%^- ^\IP%^T:Q?38OQH'WE. OVC6+Z;%^- ^
M\IP%^T:Q?38OQH'WE. OVC6+Z;%^- ^\IP%^T:Q?38OQH'WE. OVC6+Z;%^-
M ^\IP%^T:Q?38OQH'WE. OVC6+Z;%^- ^\IP%^T:Q?38OQH'WE. OVC6+Z;%
M^- ^\IP%^T:Q?38OQH'WE. OVC6+Z;%^- ^\IP%T_P#W&L/7_AL7XT#[RG 7
M[1K%]-B_&@?>4X"_:-8OIL7XT#[RG 7[1K%]-B_&@?>4X"_:-8OIL7XT#[RG
M 7[1K%]-B_&@?>4X"_:-8OIL7XT#[RG 7[1K%]-B_&@?>4X"_:-8OIL7XT#[
MRO 7[1K%]-C_ !H)30$! 0$! 0$! 05+[WL=OMLIL YQQNC*MK.-;P%9<8 U
M_P# Y)89F,]-7],9(! G;P:37P9] W#[Z_;S]DOM3]I7]?T?4^S_ +O-]:>M
MI_$>EMV[M?+OW^G[=^G5!J'9#CE]N%'GW-V2T945;R5>#K:""1GU]SCEFF>0
M-=/S9R5! +Z=6CU\'9!:6ILMFK)GJ*RW4U14$S,4LL,<ANS=&U(A=^B#J;',
M>;PM%%]&B^:@^?9O'?T11?1HOFH'V;QW]$47T:+YJ!]F\=_1%%]&B^:@?9O'
M?T11?1HOFH'V;QW]$47T:+YJ!]F\=_1%%]&B^:@?9O'?T11?1HOFH'V;QW]$
M47T:+YJ#0.=K!8H.$N1YH+71QS1XQ>2"0:>)B$FH)G9V=AZ.WL=!G< QZP2X
M'B\DEJHR,K1;W(GIXG=W>FC_ *E!L7V;QW]$47T:+YJ!]F\=_1%%]&B^:@?9
MO'?T11?1HOFH'V;QW]$47T:+YJ!]F\=_1%%]&B^:@?9O'?T11?1HOFH'V;QW
M]$47T:+YJ!]F\=_1%%]&B^:@?9O'?T11?1HOFH'V;QW]$47T:+YJ!]F\=_1%
M%]&B^:@?9O'?T11?1HOFH(>[E;)9:7 +5)36RDB-\IQD7(:>)G<2N],SM\GP
M=NC_  MT03%]F\=_1%%]&B^:@^?9O'?T11?1HOFH'V;QW]$47T:+YJ!]F\=_
M1%%]&B^:@?9O'?T11?1HOFH'V;QW]$47T:+YJ!]F\=_1%%]&B^:@?9O'?T11
M?1HOFH'V;QW]$47T:+YJ!]F\=_1%%]&B^:@?9O'?T11?1HOFH'V;QW]$47T:
M+YJ!]F\=_1%%]&B^:@AWE&R66+F;@Z&*VT@0S72_M-&U/$PFPV*I=MS;>NC]
M?PH)B^S>._HBB^C1?-0/LWCOZ(HOHT7S4#[-X[^B*+Z-%\U ^S>._HBB^C1?
M-0/LWCOZ(HOHT7S4#[-X[^B*+Z-%\U ^S>._HBB^C1?-0/LWCOZ(HOHT7S4#
M[-X[^B*+Z-%\U ^S>._HBB^C1?-0/LWCOZ(HOHT7S4#[-X[^B*+Z-%\U ^S>
M._HBB^C1?-00Q]1V3[VGNOU;2>[?JZ]3T?0CV;_KS3=IMTUTZ:H)G^S>._HB
MB^C1?-0/LWCOZ(HOHT7S4#[-X[^B*+Z-%\U ^S>._HBB^C1?-0/LWCOZ(HOH
MT7S4#[-X[^B*+Z-%\U ^S>._HBB^C1?-0/LWCOZ(HOHT7S4#[-X[^B*+Z-%\
MU ^S>._HBB^C1?-0/LWCOZ(HOHT7S4#[-X[^B*+Z-%\U ^S>._HBB^C1?-00
M[Q=9+++S-SC#+;:0X8;I8&AC>GB<08K%3.^UMO35^OX4$Q?9O'?T11?1HOFH
M'V;QW]$47T:+YJ!]F\=_1%%]&B^:@?9O'?T11?1HOFH'V;QW]$47T:+YJ!]F
M\=_1%%]&B^:@?9O'?T11?1HOFH'V;QW]$47T:+YJ!]F\=_1%%]&B^:@RB @(
M" @(" @("#C)''-&<,P#)%(+A)&;,0D)-H[.S]'9V01Q]WO@WZT^N?U>6#ZP
MW^KO^KX-F_77=Z>W9KKU^2@D>...&,(80&.*,6".,&81$1;1F9FZ,S,@Y("
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M$%&<<Q*O[V\^R?*\XN]71\+XA<I;-C6-4$OHE4SQ,Q//,[L["3@0&9;7+SL
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MUVY]QM9FU=5<3<KT[6#FS'G.FK:.9AB"Y-3MYIH6;R^HPMO, \I#^<CU!W8
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M')F/<E\N8_)A'%^&S-78QA]2Y>^UE:Q"82U F(%MW #D4D8LXBP .A&:"X:
M@(" @(" @(" @(" @(" @(" @(" @(" @(/+<ZX+7;:RYR0S5,=%!)4%3TD9
M3U$C1 YN$48^8S+301;J[]$$5\$]Q&%\\6VNDLH26K([7(87/':TA]\BB8W&
M.9M-&,";3<[?(/RO['()>04O[RK)>N,,UPGNBPF!BNEAJ M610]6CGIY&-H7
MEV^ R <M-(?CYHV;P9!M?;QP]<\KNT'<MS)60W_/\BACK<9HHR:6@LUNF'?
MT ZD+&P%Y=-?3U=]7D<B06#+ L)+*XLZ?'[?]L88CIX[Y[M&U:T<G0F]5AW/
MTZ:OU9G=O!W0;$@(" @(" @(,7?LEQW%: KKD]VH[-; ?0JRXU$5+"S^.F^4
MA;7XM4&IVWDSAWDZ"MQ6T999,@:Y02T=7:J>N@DFF@G!XY!])CWD+B[L^C(*
MH<;9G>>S+D:JX8Y,.6;AZ_U1UF'Y4;:QTWJNS.YNS:,/41J0;^+/\XS;#U<+
MUT]13UE/%5TDH3TLX#+!/$3'')&;;A(2'5G%V?5G9!2_@BFH,([SN5,"P%Q+
M ZJWM<+A14__ (-1W",J8W =OE;TY*F>)@;Y+/M_(06]M^*XW:KW=,DMMII:
M2_WMH6N]RAB *BJ:F%PB]4V;4MC/HVJ#+H" @(" @(""&.XOG8>%\>MU/9+?
M]>\BY14?5^)V$6(_6J'<1>600\S@#F [!\QF0BVFKD(1!2=KW//(]*V0<O\
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MAVM) U;3QU#"Q,SMHT@EH@]U)1TE!3A24,$=+2Q-I'!" QQBWP"(LS,@[D!
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MV'+<:@E?A[B7?+3WB8"C&NNINQB\3$S.VZ08C87;5HXMQ;7,10760$! 0$!
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MG\8&T3_]7WP!+<'K(VO<%,Y;OJZ.X"]/I^]U.$I=/^^ZH)\X^XRP7BRR?9_
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MXDOMXR?BW"\CR 7&]W6R6^MN#NVURGGI@,ST;PW.^[3V:H-R0$! 0$! 0$!
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M 05$[X+I45]7Q1Q=7W&2TX1FU_:'**Z(MG]CTTU)&(D3^7:WO!2Z%TW )/\
M)03+DG;?PWD>!EQZ6*4%!9XX'BMU11P!'64DNUV&>*?1Y'D9WW$YD^_\O<SN
M@B7L;OU[?$LTXARF;WVLXYO,MIC]34F&DF*4/1T+5W 98)MNOY+[?!F0?,E[
M7,TXYS*JY([6K[38W7UXNUWPZY,Y6BI9RW;8M!-@'5]1C(?(^NPP'RH/-'P)
MSIS?D5MK^YF]VZFP6R3#54V$XZY-!65(=-TY==!=GVN3R&>W<(^GN<D%MXHH
MH(@@@ 8H8A8(XP9A$1%M&9F;HS,W@R#F@(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(""OG<OVT6[F>W19+C4HV3E>R",EDO<9/#Z
M_HOO""<P\S,Q=8I6\T9=6Z:LX:KVX=Q]3F-74<(<Y4C6SEFT.5&4=PC  NK0
MMU8A?R>\,/F<1\LH^<.FK,$MY1VW\%9B\AWW K24\K.TE320?5\Y._M>2C>$
MW?XW=!Z>)^".-.%8[F. VHJ2:[2,=955$IU-0\8?(A&21W)HQ=W=A^%]7U02
M2@(" @(" @(" @(-?S;"<9Y$QFOQ#+Z +C8KB'ISP2="$FZC)&3=0D!_,!CU
M9T%7.#\)YQ[>>6?U24]'/E_!MY]>OMM[,FC&U"SZD1$_E"1R=AD@;I([^I'H
M^]D%PT! 0$! 0$! 0<2,!<1(F8C?:#.^CN^COHWP]&=T'TB86<B=F%FU=WZ,
MS,@^H(^YCX<Q#FS$)\3RR#0FUEM=TB9O>J&JTT:6)W_H&#]#;H_L=@B'M>AY
MZP2]7KA?DRU273#\8A$\=S=STB*G-](::-S\TP.+.XLWF@V[#Z.#,%GT! 0$
M! 0$!!T5M;1VVCJ+C<)XZ6@I(CJ*JJG)HXHH8A<S,R)V81$6=W=_!D%1KGWK
M9)D%TN)\*<57;.\0LLCQW"_QM41#(XMJ_I1Q4\SAJWF'>^]QZN H,W9\ZX&[
MV,>BPG):>IMN26BJCN,N.54C4MQB.F=QD]"46_.Q$+E'+MT)F?5V MI(+04M
M-!1TT-'3!Z=-3@,4(:N^T(V81;5]7Z,R"F/!N7XO@'*/=!R!E%>%MQBW7Z&.
M>8NK',-5<-0 6ZG(9^4!'J[D@DOM\S[F/E_([SR9?*>/'N&:Z%J7$,=J(1>N
MJ/2/5JUY6T)F)MS%U<"Z,#:#O(+$(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @K[W*]LUMYJM\.1XY.%BY5LK"=EO@.4+3
M>B6\(*@XVW,S%UCE'S1EU;5M6<)BP>V9+9<0LUJS&[C?LHI*6.*ZW<(F@&HJ
M!;S&P-_0UT;=XZ-KH@V! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 00-W-\,9-R9
M9K5E& Y#563D+"I3N6/QM4/#0SRLS.8GJ["$KL.@2EY?$#\A.XA6FU<V<J=X
M)V7@N@EIL-C]VDEY&O<$X^K74],; 84D6K/M-G9SB!WW._4FB$MP7[QJPTN+
M8]:\;H9JBIH[32Q45//6RE45)QP P"\DA=2)V;JZ#*(" @(" @(" @(('[RJ
M6_5?;CF@8^Y^M'%335PQ:L94$55$=3X?DM&SD?\ 4,2#.=L-5A]7P1A$F$!%
M%:@ML,=7%%IN&Y +-6^KI_VQY]Y$[^.NO@[(([[F.V@\N+];?$NZQ\SV(FKH
M)Z%V@>YO VNPM-&]X9FTCD?Y?\6>HNS@&\]LW-P\X<=1WBX1#29C9Y?JW)Z$
M6V,-7&+.TH _40E'S,S_ "2W!UVZN%<N*^TC+\PY/R[(^9XIJ+ 8LFKKO2XL
M4SE#=JZ28S"H-A?:\#!)HQ?*/5QZ-NU"^$$$--#'34T8PT\(C'##&+   #:"
M(BVC,S,VC,R#L0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'FH+C;[K2A76NKAK:
M*1S$*FFD&:(BC-XS9C!W9W$A<7Z]'9V0>E!"/<7QORERQ;K)@^&W^FQ_![G4
M''G55YVN)T+"Q,$.GE*,M"$X]1<G<6=_3WL@C_D_LUL,6-V&[<#%]DN3<, "
ML]Q"1XWN'ION)JN5FZS$[DXRNVCZN!-L=M@68Q>+(H<<M<.73TU3E 4L0W>H
MH *.EDJV%FD*(3ZL+EX:_P!!O!!ED! 0$! 0$! 0$'554M-6TTU%60A44=0!
M0U$$HL<<D<C.) 0EJSB3/H[.@HA=K/GO8WG=9E&*T53DG;ID=2TETM4;O)+;
M)3?1O,6NPP;RQREY91TCD?>PDP62A[I^ YL0/-!S>W#;XXO5.@.5ANC'MU]+
MW)_SSR>S1@=OCTZH(C[);1>;S>>4^:9K=)9<7Y O#U%@MLC;=\4=153'+IHS
M.(O.T8D/1R8]/!!;Y 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%1>9^9\OY:R^
M;MW[=YM]S/=%FN:Q$[4MMI6?9-'',&NA-KMDD'KK^;C\^KB$J8?:^'^T_CNW
M8M<\DIK10G(4TU==:E@J*^ND$1FE"%R=V;RCY(AT 6;7KJ3A(F'Y[A?(%N*[
M83?:*^T$9;)I:&8)O3-_ 9!9]P$^FNALSH-B0$! 0$! 0$! 0$! 0$'54TU/
M64\M)5PA44LX%%/!*+'')&;:$)"3.SL[/H[.@A*?L\[<JB_-D)X/3#4L7J/1
MQSU4= YZZL[THRM%I_4,&WXD$VTM+34--#144,=-1TT8PT]/"+1Q1Q1LPB "
M+,PB+-HS-X(.U 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 08^Z4-OR&UW*Q54A'2
M5L$M%6M33%#,(3@X$PR1$)QEH_0A=B;Q9!1G'I<A[#^0)[-?Z<KUV_YE5L5/
MD<4 E74-2PZ TY1BSD<8MYH_ PUDB9B8XT&P<$<0V#N0KK[W"<RL^2/=[E5T
M6+6&261K?16VCD*(&V XN6CZB(/TZ.9,1GJP8;G?C"/M/R2Q\_\ "GJ6RP^_
M16[*\5:4RI)H*C4M!8W)_3DVD+B3OZ<C@0::= O/0UD%QH::X4KN5-5Q!/"3
MMH[A*+&+NWX'0>A 0$! 0$! 0$%?>\/DKDGBKBR'*>.?1@G&YTU/=;C+$,\E
M+3&[D)!'(SQNTD@C";DSZ,?1M7W"&8[=.XO&>?,9]XI]ENS6W +7^P.6I1D_
ME]>#=U. W\'\0?RE['()J0$$.]P/<#CO!N.QR21M=LXNS/%C>-Q.Y35$Q/L:
M21@U(81)]'=NI/Y1Z^ ;#PI6<I7#CJU5W,-/2TN;5#'+44](/IN$!ONB&<&\
MH3,+Z&(=&_#JR"04! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!5ON.R[/<QY+Q;M
MIXVNAX]5Y'2'=\KR.+<TU/:1*0?3B(7$F<FADW,+LY.X#N$7-!@I>!>W_M;O
M-BY2O6=WNRG0N8R4L]9O*\5+#KH\-+",L@L[[CC'4'Z;^FNX)%Q_G/MU[E:&
MOXU:X1W![K$44M@NT$E'-.#>;=3O(S,4@.V\?2/U TW=--4&#R7.,1[-<>QK
M!<8P._WS$IO6J:^\T8^N,4DA/J4LQ"P25!NW\7K&S!IITZ((YO%9R)WLWZR6
M,,8KL+X!LU:%RO-PNC/%6W22)G88HF9F;7:1 WIN0!N<R)R8 07<BCCAC"&(
M6"*,6  %M&$1;1F9O@9D') 0$! 0$! 0$&J<F810\DX!D6"W#:,%\H9J0)2;
M5HIW;=#+I\,<C!(WQL@_.SC;C3,+QA <D\/,5DY^XDKI[+E5AIV9BNE-3D3Q
MR-$WE*;8QT\D1=)_3?\ +TWA=;MW[B,<YWQPC 1M><VL6#(<>-W8XC9]KS0L
M7F*$B\'\0?REUT<@R7/_ #71<'X2V0/;I[O?KE,UNQ^V0QR$$]?(+N#2F#/M
M%M-=/E%X"VO@$9=OW;]D1Y%)SUSU(]VY9NSM/;K=.S%#9H2;R"(=1&81?01;
MI$W1O/J[!:- 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 01A/W&<%T]_^S$V?6<+R
MTOH%%[R+Q#+KIL*=OS3$S]'9S\>B"'>Z*UY#QQG^&=TN(T976FQB/ZHS&W0O
MJ4EFJ"/24=-6T;UI!<^NTGC+3:Q:!A>+;'A?<_SKFW+.25$64X?B;V^VX39:
M@'*BCCJ*?UCFFIY6;4F/=Y)!=O4<M?D#H&:[N^ <&GXYN7*&*4-/BN=X: 72
MCNEJ :%Y@IY!=PD:%A9S9O-#)\L3869]'=D$X<&YE=.0.(<.S&]CI>+K;89:
M\F%@:2H#6.21A;1F:0@<V9OA02"@(" @(" @(""-[AD>+\RXYF>$<>YP-)?Z
M)I+3<+I9S8ZJW51MT)M=-POH0;XR]A,)B8ZB'YXXQ?>Y;M]Y,_5/+E\=FJ'=
MWM5+D4Q5&.UX&[M$\,LXDT03::";/'H?E-P?=H%HJ'O%R# ZR*R=QW'%SPNL
M(O3:^VZ,JVU2E[7'J73H_P#%2S.@U'#.1,&QGN_"_8+?Z.Z\>\TT0QSO1RMI
M37Z)_*TT+Z21R22#T:0&=WJ7^!!-]^[8<5K^:[)S9CMTJ\7O-'*<^045JTBC
MNLFGE>0M= WOY:EMI>L/[T]3<)NGIJ:J$ J80F&,PEC&06-ADC)B VU9]"%V
MU9_8Z#M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%7N]O-LCLF&8Q@6-W#ZFEY!
MNX66XW?5Q]&@+:,H[F=G%C>0-[L_4&(?RD&9J>RC@6; ?L5#86AKQ@<(\I8B
M>[-5:?QY2:LQ>;J\3MZ?L860:MV89'?I[)G? V?F-SKN.:\K2'O#>L$MMG*:
M%X-)&??$)0GMW?\ :S$?DLR#&73MVY0X&S>OY&[7CIJ^R75F&]\>7.39$8"3
MFS4\LA@+L#N_I[I!./5V9S$G%!Y[[C/=!W/%38AR%9(.+.* FBFO\4,XU%QN
M/HFQM$&AF^C.S$.\!!G\S^HXB*"WMCLMKQNRV_'K)3C26>U4T5%04H:[8Z>G
M!HXQ;75WT%FZN@]Z @(" @(" @@OE'N;Q[B+E#'<$S&S5M%C=\IRD/,I6VT$
M4[DP@ LS/O$/^WEJSQ[A?1V?5!$7-_!V3<99,/<GVU.,5?$+U>2XS1MZE)74
MDFDDLL,4;LTD<C-NEB'_ &R/0F0;A#-Q'WV<1O'(S6S++8WF'RR7&R7&0?E#
M\GU::7;\0R"WY,@^0-!X=YAO_%.1EVR=ST,4M&S#38QDE>S5%!4TA/MABFDF
M;;)3GIMBE-M8W_-R::>0)>O'9EP1<\JM686RSSX]<+960W#W>RU#TM).<!^H
M E$[&T8[F9_S'IOT\4%@4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 05>SWOEXS
MQ3(ZK&\9M-TS:>V$37:NLH 5%#Z;Z'LE)_SFU]=2%MGP&Z#LNMSX3[YN/3QF
MSWN:WWFVU,%R"":(8[M;Y ?89>BY[9(SC,HW(#(&<F?7<S,@LC:;<%HM5#:8
MIYZJ.AIXJ4*FKD>>IE&$&!CED+J9EIJ1/XOU05*X4K;=9^ZCN'O5=514-CH(
MZ::X54YM%!$P^<Y#,M&9AVF[NZ#?.(.<LUYLY+N]=B%EBAX"M$,E#'?ZX9(:
MVON8EJTE,W@X:='C(?*.A$3&31H+"H" @(" @(" @P.,YMB69/<VQ6\TMW>S
M59VZY^Z2-+Z%7%\J,]/;\?@_L?H@PG+G'6#<G8-<\<Y!CC&PC&=4]R,PADM\
MD($_O<<Q](RC;5W)_+MU8M1=V04=[;NYP>'[V?&>8W::_P##!U]1;L2SF2GF
M@B@] V;HTNK^[NQ@1!JY0[F?Y+H)*YPX/R?C/)Q[E.VLABN$0O5Y+C5(WJTE
M=22Z22RQ11OI)'(WFEB'_;(]"9!*]EM_&/>+Q;C669CB\\<$50U1#3U.^":*
MIIR8:B.&H!A>6FE<=A..C&S=6$Q\H3K34T%'30TE+&,-+3@,4$(-H(1@S"(L
MS>#,S:,@[4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MCN%6&BQC%+=#:K#;P].DH:8=H SN[N[N^KD1.[D1$[D3]7=W09A 0$! 0$!
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MHP;^@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MRUTU4(X[)3-$&[SR>H$3QD3R0B/IN$DGF?7Q+KM"=$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M! 0$! 0$!! >?]W'&G&7);<=YE372WQ-"!R9$]'(] ,TCL^QFT]20!%VW21
M8L_E]CZ!,F,Y7C.9VJ*^8G=Z2]6F;Y%90S!/'KIKM=P=]I-[1+JWM05"RT?N
MX=X%KS2/^QN.>7Q*BO+^$,%T,P&21_8VDSQ3D9?DRRZ=&07505SX:XHS+ ^X
M;F+)GIPI>.,HEIJN@,B;U*NX3,U5(<0"[Z!"<]1&;GIJ3MMUT?0+&(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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8" @(" @(" @(" @(" @(" @(" @(/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>lg_evaxionaiimmunology-bwlr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_evaxionaiimmunology-bwlr.jpg
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M%!04%!04%!04%!04%/_  !$( #(!W@,!$0 "$0$#$0'_Q ".   !!0$! 0
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M_*X1M/Y,4_\ IYC_  :6:T/D! ;Z:^F@YZ"%;V]Q(XLUA;T /8XTGI3#?))
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B@\OJZ*]_3S3X?]CN_5H$L_BCEX5?M\_K_JT'1_<?NZ#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>pc_fig04aiimmunolo-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pc_fig04aiimmunolo-4c.jpg
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M Q$!_\0 M0 !  $$ P$               <$!08( 0(#"0$!  ,! 0
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M5ZA(@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M7$['9S6!,6(OS6+-.Q6= Z)C&1EI#PYW0\$'@\K3>YX8]<QYK(_,\&R;W?\
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M_H+2=VRMZXD/!_=MKU@LCV' VJ+CT?+3D9:8#^/#_:<!^SE:3OGRI>M)^O\
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MS<ABADK&:=F'WBVS[ B.4&6# S]1=[@]KUX[.OJAEE>;\=YC8_(-+:,I)2.
M_P .WM;R>/89O?>,F^-\SHW\!O ]L-;R.>"3^"#P\;:5Y,U*#&:OG]AQUW2M
M:B%7#24JTL.4N5H6>W7CNE[C$P0LX'\D<R<-Y(X=W!*2($! 0$! 0$! 0$!
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MQH;7B:]SBTO#CPWH/F] @O%:K5I0,JTX8Z]:/I'#"T1L:">>C6@ =4'L@("
M@(" @(" @(" @(" @(,)W_RWX^\95?J-PS<%.PYO=!CV'WKLH^'9 SEY'/\
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M))Y)/4GJ>J(7! 0$! 0$! 0$'E9LUJ5>6W<F97J0,=)//*X1QL8T<N<YSB
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M)6J@@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MX<ACK$=JC98)(+$+A)&]CO0M<WD$+KERQ5" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MRK@?)N)^HI$5<U6:/ZCBGNYDB)Z=[#T[XR?1W'Y'@KNTWFT<VVN&>K140$!
M0$! 0$! 0$! 0$$.XSR+M%_=MPUB[?Q^-Q>L"-T>1=3DD<_WW-:ULC?J /5W
M'R\<K&;W-GT:>LPJO(.\[UH?CIFRW(L>[8ZUPU+<(BE=3FC?,]D4D8]X/;RP
M-=P7'J2$VVNNN422UWR_DC.Z1D]:.V,JW=9V<QPQY&I&^M/2LR-8>)6/?(U\
M9[NCFD$ 'IT',W>S&?D]<\//)[_LU?RQ-H++-&KA68U^5=D9:SY)HF,:7%KO
MY[6EHX_5P%%VOM@Q,97FYF=^JZ?ELI&_&V<O7F9+@IV02QU+M.=D1B#XW3]T
M<CG/<TGOX' ^"MFX1B98_J_EK*[3J.=!BKXCR+K7>,IB[,;WP\Q.+2]K/<#^
MP\=KOGY:[UZ%O-==\S[Q:ZXOV7+8-JW+$;WK6FQ6J+F[&W(/%EU20F 4H3)%
MT$X#B\C^9Z<?P_BINUED^J))C+K<\C9S7?(4&M;'!6=K^6C,&&NUF2-E.58R
M)YK/+GN;\YDXC/:/5OYI[V;8IZYBZ^*=LSVY8"[E-BCJP7J^1LT/8I->(FBJ
M0T_,][RXD\]>G[%.FUL\HVF&=K140$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M=/\ 2C#@J73:?"?:,9E#J[_;L,=!)Z=DK3&[G]C@"JK./7T0<H" @(" @("
M@(" @(" @N>O[#F-6R];.8&T^GDJKNZ*9GQ'Q:X'HYKAT<T]"%,MES$69;Q^
M)/+N)\G8LM(92V:HT'(XWGH1Z>]#SU=&3^]IZ'X%W=IV39S[:X20M5! 0$!
M0$! 0$! 0$!!K=5U2#)^3MYR.R8K)Q82^^O8PN5CHVWM-BG)&\.C[&'GJWH"
M.'!<WKG:Y:Y\1?/,5G/[YXPMP8_7LC'<GRC&XW'NJS?625:IZSR1=O,8<>2T
M.XZ<*W9G;7A&OBN-WUS+^43IFL8['6ZF'Q+XKF=RUZ!]2.,,C:SV8FRAKY)"
M.\'M;V@\=?7AM+MB$N%#M^L,SWFVS;S>(OV-/GP[\99R$-2R^%MAS'#@/B;Z
MCGU'(Y4;3._V3+X9M>SUFYJ>4H0X;*#'8WZ"ACY9:4[;=Z2-S'2R1URT/]MK
M6CYB/[ROGPKCRL7EKQQ=O7JODC1?=BV!GMP9BI6:0Z_CY>(W\LX'<]K#PYKA
M\S/S:U5WT^8G7;XJ4<AJ>#RF>QFS7('OS6'$C<=8$LK!$)@6R#L:X-/>T]KN
MYIZ+6ZRW*F7I)K6&GM"[9K_4666QD('S.=)[5H0F /C#B0TAAXX'3X^O53B&
M736]5PFI5)J&"A?7JV)WVI6/EEFYGEX[W\RN<1W<<GCHHFLG!;E>59 @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("#2O[J/N8<77?&'
MCNYP!W5]CS==W4GJU]2!P_LE>#_H#^)='7I\UR=O;\1I:NARB @(""2/"7CO
M7/*>U2:WEMFKX:_-5G=@Z,C7N=?O-83'&Z1H[8XP?F=U[W@%K!ZD4WMD7ZY-
MKC*5O%^I8W8=)W7[7?($T6J^2Z68&=UZ:V>V.:^(&1-#7>DC"UO3MY+HI>YH
M/"IM<6;3AII,RZ7Q6*:-'OGV\YW:I=\QTN%Q5_"7\58Q\[F/9E;DL;F4A4#7
M'W0V0ESIF_*R/NY/)#3:XVGA&N>NVW_VAIF;S+=<K:F;CQK]:P^\*#/EB=<E
M8R-\S_BYW;&UHYZ !:?.6,S)A0H" @("#UIU;>1MQX_&UY;M^4AL52K&^>9Q
M/H R,%W^1$)LTW[2?,^V".Q>QL&JX]X)]_.2>W/T_"K$'R\_AW!JSO9K&VO3
MM?LG?5_L;T>BULNX['D<Y8X:37HM9C:P=\1S_-D</]IJRO=?AO/Z\^:F37/!
M/AS4R'872L8V8 #ZBY$;\W(^/?:,G7]BSN^U^6NO7K.(D&!K*D+*U1C*U>,<
M,A@:V)C1^36 !4:.Q<YQY<23^)ZH.$! 0$!!V:][?TN(_8>$%)D,;C,LSV\M
M0K9"/CCMMP1SCC_;:5%DO)E@&;\">*LYW.=@QC+#SR9\7*^J>O\ H<NC_P"H
ML[U:U>;U&.P?:C*.Z74MC:_J2VIEHNP\? ":#D?VL65Z/I5YV(@VCQ3Y"T]K
MILW@I_HF=3?I\6ZW'XE\7=V_[0"PVTVG,:3:5AC7-<.6D$>AX_%46=D! 0$!
M 0$%1C\=D,O?K8K%5WV\G=D;!4K1CETDC_0?D/B3Z =4DRAFOD?QC9T/(/IP
MY"OE'5JM>SEZU9W?8QSIVMY$S>.3$7GADOX$=X;RWG3?3U1-LL"6:P@(""XX
M'/9;6<O5SN$LNJ9.F\203,_'T(<#T<UPZ.:>A'0J9;+F(LRWL\3^5,5Y-P?U
M$?;5S]1K6Y7' _H>>GN1\]3&X^GX>A_$]^F_M'-MKA(*T5$! 0$! 0$! 0$!
M 0$!!P'L(:0X<._2>?7IST0<H" @XY'/'/7UX^/"#E 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0:K?==]Q/^#:<_C;2K7;MMV/M
MS&0A=\V/K2MY]MA'I/(T^OJQAY'S%I&W7IGS7-V]F/$:!+J<8@(" @E;P+IN
MB;QMC\%M>;;CL]:@D9J-*U7$N.L94-)B%Q[G-#FAW!97_P"^/0N]&/IO;)X:
M=>LVOEEGFO8[]?2->U7?<'3PGG76\U,Z')X6".@1A*K.(;0^G#& 3S$>R&C_
M +HN ;SUKI/.9PMVVXDO.5%Y-\IZ1Y9\:8',;E3F;YOQ,KL:VWC@R.&[1A#2
M+-LD?(TN<>UC/G$@=V<,=TG76ZWQPC?;7:2V>4%N<^1_N3/?++QV^Y(YSW<?
MARXD\+1BX1(@("#(]+T#=/(N0_IFDX2QE[#2&S2Q-[*L')XYFG?Q&P?M<HMD
MY3KK=N&UWCW['\? V+(>4<XZ[8/#C@\*3#7;Z$"6T\=[_B'"-C1_I+#;M^CI
MU_K_ /TV>U+1M-T*G]!I>"IX2N6]KS4B#9GCGG^9,[F1_7^\XK"[6\NG76:\
M+_Z]3ZJ%A 0$! 0$! 0$! 0$!!RUSF'EI(/Y(,%V[P_X\W3NERN(95R+O_VG
MC>*EGGGGEW8.Q_\ MM*SVZ]:M-K&O^Y_;/M^#$ES4[#=DQS07?3 "OD&@#G_
M '9/9)_L.Y_)<VW39QY:SLE0K8@L4[$M.Y#)6N0DMFKS,='*QP^#F. (6#5T
M0$! 0<()E\<;+JVA:/G-PUR&3*^4AQ4CK6XA[>,JS @VFAI/?#R/YD@^;GM8
M0UO5VVEFLS.6>TMOV8G:VYS=O_K&F4'R9._'8JLM2B2W9R%_*1F"Q,&2]W<T
MESFP0]6@<$]53V\^%L*O>/$F1T?&8I]B[7GS\E$WLY@(G^Y:I1-?V^\./UQ
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M9<5;Q[HXI9#5L81D#(VR]Q >R3Z=G=V\%O)XYZ(97V[K&T4=XQOE'-V:=F#
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M"GBHTJ\\MJ"M%%:G_P!_.QC6R/\ ]9P')_>@J$! 0$! 0$! 0$! 0$! 0$!
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MGWUQ4OK9F(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MZ\30R..*-H:QC&C@!K0.  N)Z+T0$! 05%>L9?G?TC^'YH*\ -  ' 'H$'*
M@(" @(" @(" @(" @(" @(" @(/.6%DS>'>OP=\0@MTD;XG=K_W'X%!T0$!
M08AY*T#'^1]7GP5HMAR,9-C$7W#DU[;1P"2.O8_],@_#KZ@*F^GM,+:W%:(9
M#'WL1?M8K*0.JY*C*^O;KO\ U,EC/!'YCX@_$+SK,.E3HD0$! 0$! 0$&TGV
MH;L98,GH5V3DP<Y'%AQ_@<0V>,<_@XM> /Q<5U=&WPQ[)\MFEU,1 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 00E
M]U?D#_ GB'*1U9?;S&Q'^BT>T\.:VPTFP\<=1VPAX#O@YS5IUS-8]NV-7S&7
M8X! 0$! 0$!!R"6D$'@CJ"/7E!MIK5R'[K/%\^DYB6(>;-,KFSKV4L'M.1I-
M[6%DS^.3R2UDA/\ %V2=>7A87]ES\.F?]DQ\QM%XD\:XSQ-HN.T_'.;-9B!L
MY>^T'_B\A,![TO4#Y>@9&/@QH6&VWM<NG32:S#-U5<0$!!45J_NGO?\ [L?#
M\4%P].@]$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0=)8FRM[7?N/X%!;)(W1/
M+'>OP/XA!U0$! 0:\?<SXZ%NHSR1B8N;=-K*VP,;ZR5OTQ6./QC/R//]TC^Z
MN;NT^6O7M\-8%R-Q 0$! 0$! 09%H>TSZ7M^(V6 GMHV&NL,;ZOKO^29G^TQ
MS@%;7;%RK9F/HQ7GAM016JSQ+7G8V2*1IY:YCQW-(/X$%>DY7H@(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(/GE]
M[.\G8/)E74:TG=C]5JM9(T'EOUUX-FE/3\(_9;^1!75U3$RX>_;-PUF6S 0$
M! 0$! 0$&W_V3^+S-9O^7<M$1%7]W%:RUW(#I".+=D=1SVC^2SU'/?\ @L.W
M;X=/1I_R;GKF=@@("#U@A,S^/X!^H_\ (@N0 :  . /0(.4! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$'E/")F<>CA^DH+:06DM(X(Z$(.$!!TEEB@C=-/(V*
M%G!?(\]K6@D#DD^G4H.+%:O;KSTKL0FJ68WP6J[^K7Q2-+'L</P()"#0;R-I
M5CQ_N&0UJ7N?3B<)\98=_P![2FY,3N?B6_H=_I-*\[?7UN'5K<QBRHL(" @(
M" @("#>3[<]K.R^-:=2=_?>P3W8R;D]?:C = ?V"-S6?[)7=U;9U<V\Q4M+9
M00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!!297)5,+B[N8R#_;H8^O+;M2?W88&&1Y_<UI1%N'Q[VG8+FU[+E]GR!_
MXW,7)[TPYY#76)'2=H_)O/ _)=\F(\RW-RM"E @(" @(" @NFMZ[D]NV+%:K
MA6]^5S5J*C5_!KIG<%[OP:QO+W?D%%N/))FXCZQ:IK&*TK6<3J.$9V8K"UHZ
M=;IP7^V/FD=Q_%(XN>[\RN&W-R]23$Q%X4)$!!RUI<X-;U)Z!!=(HQ$P,'[S
M^)0=T! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 04ER'D>ZT=1^K]GXH*)!B
M/D7=[6@82+-U]?M[$)K#*3:>/<!,+%@]L (+7'L>[Y"YH)!XZ'E!%&4U;R9Y
M%CK6O-6RP>/M*O30P4]1Q4S([=J65[!&R65Q/+R2#P2_M=_ U!/U*O-3IUZ=
MFS)<GKQMBDMS "64L''>_CIW$#YC\3U00Y]RFE#/Z;'M-.+NRNM.,DQ:/F?C
MYB!*.@Y/MN[9!^ [EAW:YF?HTTOG#4)<3H<H" @(" @("">?M5V8XS=KNMRO
MXK9RJ71-Y];-/F1O_LS*NCIN+AEV3PW%78P$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 00=]VVV'5O">9ABD]NYGI(
M<-7Z]2VP2^8?OACD'[UIUS.S'NN-7S*78X! 0$! 0$! 0;7?9!H/]0V7-^2[
ML?\ PV#B_I6(<X$ W;C.Z=[3Z?RX>&?^D6';?&'1T:YMK>!<SM$! 05E*+H9
MG>IZ-_9\2@K$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$#UZ'T06N>+VI
M"W^'U;^Q!27:SKM*S2;,ZL^Q&Z..S'P)(9"/DE:3SPYCN'#\P@U'=I6<V/-Y
M'%XK!9K>O(]"5U+([QM-AU'$8J]"?UTHHW$/,?ROCZGGI\G'1!L7@_)&ESW<
M=IMK;<?D=Y$8J7(87=CK%ZLP-G<QO:&CN>"6CGK\$&8S5Z]J":I<C$M2Q&^"
MS"[T?%*TL>T_M!(0?/C<]8L:9M>7U>QR3C;#HX'N''?7=\\+_P#:C+5YNVN+
MAURYBQJJ1 0$! 0$!!?-+S[]7VW"["PD#'W(9Y0/C$UX]QO^TPN"MK<7*+,Q
M](&/;(QLC"',< YKAU!!Z@A>DY'9 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$&D?WZ[*7Y#4-/C=PV&&QEK+.?4S.$
M$)X_+VY?[5T=,^7)WWB--5T.40$! 0$! 0=7N#&.>>H:">!Z]$0^I'@/2&^/
MO$>LX&2,,R4]89/+$ AQN9#^>\.!^+&N;'_LKBWN:]+KU]=9$D*C00$'9C#(
M]K!ZN*"ZM:&M#1Z#H$'* @(" @(" @(" @(" @(" @(" @(" @(" @(" @I[
M<??%W#]3.O[OB@MZ"#_.V'Q==T>P;7LF<9J-QL-"OI&!D,<V3R[B_M#2!R&N
M8&]_[SZ\<A:?'N"T/+2P:M8T2QHLUV=F3J5H<FRQ;LOP<G\R*XUG,\+>X-+V
M2<-D</7N]26P[B7$N/J3R?WHAK#]U6L"'(X/<Z[.&W(W8N^X#I[L',D#G'\2
MPN;_ +*Y._7SEMUWX:[+F;" @(" @(" @^A/B+.'8O&NMY-S^^;Z-E:=WQ,M
M0FN\G\R8^5Z/7<ZQR[3%9JKJB @(" @(" @(" @(" @(" @(" @(" @(" @P
M'S5O5OQMXPV+<L?$V7(T(8V4FO'<P6+4S*\;W#XM8Z0/(^/'"MK,W"F^WKKE
M'. U&SF/ <>ZW\YE)/(60PS]C9LHO6([$5QT#K4+&-8\1MA8.V,PM9V%G/3D
M\J]O[L?#.3.N?E'%GRYM6[:3X5V]TUJ'8IMMAP^8BQTSJC<B(96\QN:U[(RV
M<!G<'_('$^C5?UDMBGO;)?NF*3[B\1B\+O5K9L%;Q6PZ ZLW+8-LL-ITK;[V
MQU7PS,(:6/<]O>2/D!Y(*S]./NU_DYS\+5Y@W2]L'@G<-CQ\<N*L8QM:;#9K
M&7C+7LLDE@XL5+5<QES.'OC<'!I!!!"G68V1OMG6U0>'8\-N]'5_Z;D,M6VO
M6\9@,WL&2=:R#8[TV0CE]VO-%9=V3LD$3GF1@+0[CM/J$V\(T\X8QD,[K.(^
MX_R!BM^SURAH=3#UK5:M)?O15:]VRRF2^(0R#VWN,DG;V\=7=.JMB^LPKF3>
MYX7'QY@?*/D7P-L=7+97+09!]B:YXXS5BS)7RTM1D;9*QEE8YKW1S=6=TG)+
M7./H&%1;)LG6;77_ &73QAN)\F^"L#K_ +UF':[5L:UDK$<\L=R"S3'O6+GN
MEXD]SZ8>]SS_ +UP:HVF-DZWVU=][Q-;&>=/&>IU+EZ'7L[%FWYNF,C<:R9P
MJ.^G#R)AQV.:/9XXX<.G5)^--I^Z1ZY9^YZMYFJ9?4[ES,ZSF[/^%<]BI+3K
M$&.MMI0V8<A[;W%K>&A[Y>C>>UP_4]/%A<S;PO'VNW+=W1\U)D<M;S5Z+8,C
M7-_(3R6+#X87,;"27N/:"WY@&\-Z]%'9RGJX3>LVP@(" @(" @(/F1]VV?.>
M\YY]C7=U?$LJXR'KZ>S"U\@_=+(]=G7/VO/[KG9""T9"#@^AZ\?G^"(;%8'7
M?%>P:-B]DS/B;;8,=AZT%?:=GPUB1H=)$T!]ML$S&LEB< 7O,76,?J^#CE;9
M<9CIDUNN;*UX>6NDD=& (G/<8VM)(#"XEH!/4\#A:N9U1(@(,T\0ZC_CSRCJ
M>J.C,M6[D(I+S6^OT=7_ (B<_P#0C(5=KB6K:3.TCZN2/[WN>?B>>JX7IJ6[
M>HXRJ^]DK45.E&6-DLV'B*)KI7B-@<YW '<YP:/S*"I<TM):X<$>H*#A!5T8
M^2Z0_#H/^5!6H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(+5*SVY'
M,_ ]/V%!B'D:K@O\+6MASM>>9NJ!VP49:3NRY#9I,<X.B<0X=6ES7!S2WM)Y
M'1!#V'S^]:]DJOE+.8# XVWY L4ZT&"QM6W<S=^*81^TTVF.='"1%Q*>[AA(
M/<.Y!L>]O:]S?7M)'/[$$?>;-=_Q-XPS]2-GN6Z,0RE0?$24C[CN/VQ]X67;
M,ZU?2XK1<$. </0]0N!TN4! 0$! 0$!!N)]J.8-S1,CB'GF3&9!Q8/PBLQM>
M/^LUZ[.B^'/V3RGI=#,0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%BW/4L3
MO>K974<XUSL7EH'5YS&0)&$D.9(PD$!S'!KV\@CD*9<7*-IF81C1T'ROB/%\
MGB6E<Q$T+:K\/2VR5]ADL>+E!CY=2;&0;#(SV,XL=GHXGH0;YF<L_7;UPH<S
M]O<E'6?'&MZ1:KQ0:%EH\[+)D?<#KUF%WO.#C$UW;[LA/)_@;Z \<*9OYN47
MK\23X5M/Q!L++WD'<;7])L;9O4U.$XFZV2UB8<34+(WUIG=C7O?-"'![PSAK
M^WM' /,>W$3Z7S?JQV#[?-AH>+=YT#"3U,?!M]]MG&XN6W8M4<358^)Y:V5T
M0DD>_P!OK\@'Z>IX),^_F57^.^MGU99@=&\GX36=8UBD_!T9,95QV'S.P06+
M<EZ7%8]P[FUF.KL:V1[>X O>0WN/'P46S*TUVDD4$7AG-7_,.X[QLD>-NZ;N
M.*&"M8<2SFRR!C*[!(XF,,)/L$\-<"WN'!Y;U>WC"/2^UMXJ\>$O'6\>*Z>0
MU#+9>KF]'AGDEUB4F49&M"]Y)AF:6",M//<.QWRN[O@0&QMM+Y3IK=?'PJ/'
M_AS'Z)Y!WC=:LK75]HL1V,?2:7<5/<;WVSQT;S+,>X<>C0!^*7;,D3KIBVI0
M+&$\EH)Z=>/P/(_L5&C@1QM+B& %_P"O@#K^W\4'+6,;^EH'H.@XZ#T0<H"
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MN-'N_6N]ILK7F01]SNWL[4$QH@0$! 0$!!'GG>Z['^&MYL-=VN.&N0@CH?\
MB(C#_P"&K:<Q3L_&ODXNYYH@(,L\;ZWKFU[0,1MV<9K6O-I6[=O.2!KQ6->,
M.80QQ'>7.(:&#J>>BKM<3PMI);YX2_4W;[8?%T=ROINNY;R1E;<+JMR]FY34
MQ4K7-+>X0.:T.'7D=U<N;T[7 ]53&UY\-)MUZ\>4 96W1R&2LW<;C8L/0G>7
MP8NO++/#7:?X&23ETA;^'<5JQ4: @(/I7]JN,BQO@/4G,'$N0;;R$WYNGM2
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M\K:O*#QW6S#_ .NC?'_X2TZ_RBFW#?\ 7H.80$! 0$! 0$! 0$! 0$! 0$!
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M6VWAMBNM@(" @(" @(" @(" @(" @(" @(" @(" @(.'.:QI>\AK&@ESB>
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MD=MBPV)@ED:?@]P'+AT^*#RM8+"7IC8NXRI9G(#3+-!'(\M;Z#ES2>!\$%P
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M_KNB8/\ LKE[[PVZVMZY6P@(" @(" @R_P 50?4>2M3C_P#WK4>>/PCF:_\
MY%?3\HKMP^AZ]%RB @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @("#!O,^/=E?$F[T6#F23"7W1C\7QUWR-_RM5M>8IO^-?))
M=SS1 05>+Q63SF2JX;#5)+^6O2"&E2@'=+-*02&L!(Y/ *@DSPVXTKQ_YLU+
M2L-AM)\/8*7)6ZTC]IS.U"K+>EOF>0%@;).WB 1>U[8 (]>@//.-NMOFNO77
M;768GZM=O,. L:SY OXR[B:>"R3Z]2WD<3B7.?C(+EJ$22MIESG'VN3SV\\-
M=W-'0!:ZW,<_9,;88*K*" @^D?VEY=F4\"ZW WJ_%2WL=(?SBLOD'_5D"Y.V
M?N=_3?V1-:R;(?\ )?D+6=0\H:5;RNUP8^+&0WX]APPDGEF=7O0@59'05V2<
MEKQW#OX('4()5Q>4QN;QM7,8>W%>Q5Z,35+<#N^.2-WQ!_(]"#U!Z%!<:I[9
MV_GR$%R0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'61W;&YWX H
M+2@A'RQ'Y%?E<[F8]A.M:?JE.GD,,V#&PWYKD\W FF<^1KRTQ//;VM^;@<@=
M>4&:>*+UG*Z[:R=OZ:U-8NR]NP5,>_$?UB)K6EMR2M(UCVR<DQO)':2T]IX0
M9T@U)^Z>^RQOV+H,//T&*C[Q^#[,SY/\P:N+OO[F_7P@]8-1 0$! 0$!!(O@
M>F;OEK6HP.1'-+.?R$%>23G_ *JTZORBF_#?E>@YA 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!19B@W*XB_BW_HNUIJS
MN?3B:,L/^=(BOC5/#)7FDKS-[98G.CD:?@YIX(_M7H/+>: @K,3>RV-RE*_@
M9IJ^<AF9_39ZKBR=MEY[&&-PZAQ+N 4,V<<MC+F ^WK4JIPOEOR!LVV;]$3'
MFX,%:LS5*5D =\#7'N8\QNY:7%[N2.K6^BQ_=>(Z9ZZS&UMJ$=YU[7,+=JWM
M*S4F>TW+,DEQERS&8+T$D+@V:I;B(';+&2T]S?E>QP</BM);\N?:2<7,8JK(
M$!!O)]BN<=9TG;-9<1_\+RL-Z-O\79D(.TG]G= N;NGEU_U[XL^[:I8.IKWY
M,CM^.MDLYC&[UK.K0[!9?DGNS&*%W-MED(#_ &G1MD?+&"W^7W-';^GX() \
M,;!@,]J4XP-^[E?H[TPR66R5?Z.>]=M<6);+80 &1O+^& #T'[R$BL=V.:[^
MZ04%W]>H0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'A<=VPD?WB
M @M[1RX ^GQ('/3X]$&JKX=XJ[+L>YXG4L[+0VFW<BMYG3\W7OS/Q[^&1B.,
M"5L<T3XVR1O;QPUSF$<'H&QNF#.MU+#-V;W/Z\VJP718<U]@'D]@F<P!IE#.
MT2%O0OY07P D\#U*#1KSGE1F/+&RS-_W=2>/'L'Y4XFQG_K!R\_LN=JZ=)X1
M\LUQ 0$! 0$!!-/VN8\V_)WU7;RVAC[,Y=^!>60C_P!XM^F?N9]G#=5=KG$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M!\CO,&$.N>4]QPW'$=;+W#"../Y,LSI(_P#J.:N[6YCS-YC:L*5E1!ZUK,U.
MU7NUN/J*LL=B'NY ]R%XD;SQUXY:B$^:_P"(O"&_PV-IJ>6HM4J3N?;O:YF8
M(!D:,LKG/?")99XA.T.)[)&1GN;QR.5E=MIXPWFFNWG*/_*=[QY!+BM.\723
MW]8P(GEM;#<';/E,E<+!+,T<-[86-B8R)O:/CZ^IOK+S5-[.->(CY64$!!L=
M]E&QC%>6KFOR%QBV3%30Q-!X'U-%PLM/'X]@D"Q[9X;]%QMCZOH N5W(=\NZ
MKDW;'B]WP>6U_6Y8:,E#+9W8X8K #(Y!+797CG#F^X.9#W  \=#ST""B\,[?
MBLAN&9PD7D.WY!RUVBRY-:DI?2X^K]')VF.LX=.OO$EH''3GGGH@F]!<JS^^
M%I^(^4_N0>R @(" @(" @(" @(" @(" @(" @(" @(" @(" @(""ANOY>U@_
MA')_:4&([]G]?UO3\MD=GOR8W$R5Y*;[-8.=:]RVPQ,;7:T$F4EWR#_D0:X:
M?AV^0<@TXS>[.1V;"]C<'KD,,FH-Q=3D=U_Z1H<V9[3U?%'\KB?F=P>$&VAZ
MGUY_/CCG\^/AR@\;-R#'5;&2M'MK4HI+4SOP9 PR._R!1;@?.6]>FRE^WE+!
M+I[T\MJ1Q]2Z=Y>?\Z\RW+K>")$! 0$! 0$&S/VB8LNM;/FW#Y8XZM.)WXF1
MSY'C]W8Q=71.:Q[&TJZF(@(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(/F[]YVO'"^:K62:SMASU"I?:1Z%\;34?^_F#D
M_M77U7PX.Z8V:]K5B("#@M:[@N )'IR$0Y1(@("#(_'VU2:/O>M[>SGMPV1K
MV9V@]O=7[^R9I/X&-SE%F9A.MQ97UK#XI )8'MD@D ?%(P]S7,>.YI!'J""N
M!ZC#_)NLNVC4Y:]7!4=DS5">&]A<5EBX4GW&.]OF7M<TEH8]Y[2>#QU003%L
MM/3MNPUC=MUJ9K,X"P_^G:+HF.$=*L^TWV97SRPL'+8VD]['=>B#:<C@\ \C
MU!'H0>H/[T%32DX>8SZ.ZC]H05R @(" @(" @(" @(" @(" @(" @(" @("
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M($! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$!!%?W':D=S\,[5C(F=]VI5_J=,#J[W<>18(;^;F,<S_:5]+BL^R9UKY6KM
M><(" @(" @("#9/[+_(#=;\AW-(O2AF+W"$"KW$!K<I2#GQ=3Z>Y&7LX'J0U
M8]LS,M^C;&V/JW[7*[D9^6*DF%A@W76=<QM_=I9*^(=L.5C,E?$T"7O-R8-#
MB&1./5X'3IS\O1!'GC+=61;W(^+/YKR1DLF!6VS8Z\(@UK%5V!TD9@:0!VQR
MEP<\$-['./"#9 @M):>A'0H*FG+VN,3O1W5O[4%<@(" @(" @(" @(" @("
M@(" @(" @(" @(" @X<X-!<[H!U)06N60RO+S\?0?@$'1 0$%+D\G2PF,NYK
M)/$>/QT$ENR\\?[N%I<0.>.IXX'YJ+<3))E\\\_F[FRYS);%D#_QF4LR6Y1_
M=]QW+6#\FMX:/V+S;<W+KDPMZA(@(" @(" @S'Q3KIVKR'KV'<SOKOMLGM-^
M'L5N9I ?VM81^]7TF=HKM<1]#5Z+E$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0=7L9*QT<C0^-X+7L<.06D<$$'X%
M!\BO*>G2:!Y#V/47M+8L9=E94[O5U20^Y7<?]:)S'+NUN9EYF\Q<,05E1 0$
M! 0$!!48_(7\1D*>8Q4[JV5QT\5RC88>'1V*[Q)&X$?@0B/T?5WQOO>/\F:-
MA=WQW#&Y2 .MU@>37N1GLL0GJ2.R0.XY]6\'XKAVUQ</4TV]IE?<MBJ.>Q5_
M!9-CI,;E*\M*Y&QQ8]T,[2QX:YO!!X/0A56:WYW1H]9P'TWF_=X\-X\QLDE?
M!:;KP;4?D:\#C[,DWL@/ED> TN^7U/S.:4$P^*-X=N^MBW)BLABA5>8:#<JQ
MPGM8YI[:UGO( >7-':\@GY@?Q09WR0>1T(]"@N=>83,Y_B'1P_-!ZH" @("
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M(["X&#N'S-HPDB/U].]Q<_\ -O:NWIUQ,N?LOE.RW9B @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @((9^YSQ<?)W
MC&[%CX/=V;!=V3PW:.9)'1-/O0#@<GW8^0&_%X9^"TTVQ67;K[1\OUV//$!
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MC&#^T]3U*\_;:VYKJDPLJJD0$! 0$! 0$&4^.=,M;[N&-UN#N;!/)[EZ9O\
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M;.:GT+,BQTL=4R>\6L#W,'+@UHY/;SZ*VMS,JV8K(59 @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @^:?W7>)O_EOY$ER^+@]O5=H,E^@&#AD
M-KD&S7''0 .=WL'' 8\-'Z2NOKVS'!VZ>M0*M6(@V-\5^%M8UW6(_,WG:1U#
M3(RV3!Z\1Q;RLA'='S'R'%C^.6,Z=X^9Q;'U=EMM;<1OII)/;;AA7F+SSM/E
M>R,>!_1=&IEK,5K-0]E>..+I&Z7M#1(\#TZ=K?1H'7FVNDBF_9=OT1.KLQ 0
M$! (!!!'(/0@^G"(;9?:Y]R$> %/Q?Y$N!F"<1!K6?L.Z4W./#:=EY](2?\
M=2'_ '9^5WR\%N'9IGS'5T]N/VUNZYKFN+7#AP]0N9V.$! 0$#\_B@JHKCF_
M++\P_O?%!6,D9(.6$$(.R @(" @(" @(" @(" @(/&6S'%T)[G_W0@HI;$DO
M0GAO]T?\J#R0$! 0$%JV39,)J&%L[#L-D5<75'S.]9))#^F*)OJZ1QZ-:/\
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!
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M<%!09'[<_&^2DRL<HRD&%S-^/,V\!5R=JMC!DXYFV#9B@C>T1R/>T%_80/B
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M&*;LGO1/M=_<P1ME?7;VQN?QSQ(UO4D(,Y^WRG?HZEFX2'LU3_$>7=I$4@<
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M25UR2<,;<KJI0(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M0"1ST/!^'*#@11 @AC01R00!ZN/)_M/4H,(/CR1_D]_D*:_#)2=B&X+^ANJ
ML$<=IUQL_NF0_P SW''^#CC\^J#-YH8;$3H+$;987CA\<C0YKA^!!Z% ,41
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M!Q^3  MI,,\JU2" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(""U9O6=<V6O]+L6(I9:MP1[5ZO%9: ?P$C7<*9<(LEY1)L7VD^
M#MA+I(\%)A[#O6;%698/[(WF2(?NC5YV;1E>G6HKSOV$X:7O?K.XVJQZED.1
MJQV01\ 9(7P\?M[%>=S._P!?Z5'.9^QORM1<78G)8?*Q?P@335Y3_LR1=O\
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> @(" @(" @(" @(" @(" @(" @(" @(" @("#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>ph_fig25week-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ph_fig25week-4c.jpg
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M="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,  X0DE-! 0       \< 5H
M QLE1QP"   "  ( .$))300E       0_.$?B<BWR7@O-&(T!UAWZ__N  Y!
M9&]B90!DP     '_VP"$  0# P,# P0# P0&! ,$!@<%! 0%!P@&!@<&!@@*
M" D)"0D("@H,# P,# H,# T-# P1$1$1$104%!04%!04%!0!! 4%" <(#PH*
M#Q0.#@X4%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%/_  !$( 80#M@,!$0 "$0$#$0'_Q #8   !! ,! 0
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M.6D5_9+<J(YA%.NY0Z@L :=M&.LA=T!H#0&@- : T!H#0&@- : T!H#0&@-
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M0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@-
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MS)((8%VJ&<]2:=^LA:T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@-
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M0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@-
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MIXP'X<'Q+_=A%_%6+_>NGC ?AP?$O]V$7\58O]ZZ>,!^'!\2_P!V$7\58O\
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MX+Z5>G7KA+P^XS.7R?IYC;E!FI8+:-,M" "TEM'YK)&[]% EHJ^*NT[:%+;
M]<IZ;^E^)@EYWE>+Y"SL\9Q.UY#E_3Q<H3)!?9/,KC;!);UH6ECCFM72],;+
MYGB7J%8:F5]77A?2?T=//KCA-QC,WD;?+6UKGWRTMY#96W&>*WN(@R;7MQ,$
M999[=YS&XE18G5%"_22J%O5#*CXEZ893T:SG)<=C<I99#CT%A&.87]S'%;Y+
MD=Y.OG8FWL@&#QI;;YUD202((]THVNJZ>HA36P: T!H#0&@- : T!H#0&@-
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MUP+J18V0;O>YBK2GI7IV:7 :]OG.52\!O^*VT#2\-AREMF<A,EMO$-]Y$MI
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M2OQ\^\FB\RAZ_I4'B  _-R5/R+V:VR>5CZ0<VS1CN\D'-%4#WB05"=R@NW0
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MP.6QE_-+.&4PNE1(#Y4O>XV@U*BO36LC3$L=A-'<PLZI&*O*0$C4J=P6(U)
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MX-8PPJL;MWP.?FM]@37LW#6E-NYMY[2XEM+E#%<P.T4T;="KH:,#]0C6E:]
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MMC!0BZLF6I:)0/%U'4=C=U&I6950/.V5^4F^V493,XAULLD&(+,@J(9">TD
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M@ W$%U5I5FEZT4H?$-957S+V"X^\,4+-)9RJLUI,ZE#)!(*JU"!]3ZNMQI]
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M]!.1^^.]_<MGKEL+::RHT!H#0&@- :"MWQV?V;^0_LS&?NV+6M1\E-=4&@-
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M,(^7M^70<BS2PVSA954+(QABV!YU)Z$N:;0P'44T&Y LKR1^"1V97$I#'QD
M]:FF[OKV:#EN TX*@T 5@RF@W[C4$=XK^2>[0<$]J654J"ZJ2%+4ZD^+J*@5
MKWZJ*W>J&1CD]0+5%GHD,054C%'VNU"$/RTI4]VK!*F"RMG=8F/&VNV24*NY
M8Q41@_*U 2?EUD-SEV =K=H_)::9E8I""#M?LZD?./U-40MD.*3B9B[0P3.W
MEI'(=A*CI14'4M]?6LA!N;/(V%PLXWQ7,3AHY$/ENDJD4*D4HP-*4).JLJP^
M YWE_4W!' \YOFR=W';/B)Q,5WQ;JM!.&%/G-4,>VNL"".7V%S#/'<W:TOXV
M?'Y04-!=V=$W=@Z21['![SNUJ*;6M*-!]2/Q=W]!.1^^.]_<MGKEL+::RHT!
MH#0&@- :"MWQV?V;^0_LS&?NV+6M1\E-=4&@- : T"OQS'O?Y!$0>.H6/V;V
MZ _]45;ZVO-S[8F'U?V_BEW\KVU6V]*\Y)@\+>X+#P-#>&15@O7;Z-HQ'L)*
M#J7!);V5U\+W73&U?I>+?Z3Q6W:&/8A/04EZUJ>\U]O?KXUVS>IET2) MDI6
M/<N_<2.I77.6^3'J\F=8K<Q2*$4D,H'7M["?_)J:RVYB^N6NWEBCM-Q<&;=X
MZBJT_P";6MY;M\B]V4%U!'-L\3]?K?DZSM+C*;9PVJEY+*4C"B%S4,_3IVD
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MT#V].I.@1,U>QX_'7+JH)4.R0U*K(U>UOSI[?;HBN66X/F\]F+C.3,8Y)?'
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MWOT:@]M>_7CVMSU8RZA?+>"A<"'85+)1C4=NL^$U9\9">V3@Q\1CFN8EBD-
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M*8N9Y;/A,]=XOSH<G?QGW>WO8%5+=I"1'YDBI4*4)V5J:M^3JHEKE=YPWB7
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M5V'4;&<KUZ]@UJ)4P_BWP[\?YY<NH7?/B8U [UA@G0$_*=-EC'\93_-'@?\
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MOWR]O$583;T0>;/0 J7+=.VM>@ZZBGRYMDG]WM T/O4CW4D)VB,W#N6>78
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M'+!4%HYXZ>=!NZ^%Q\PGIV?+HO=$Z8U;:&:3[97EKDKVXD>UL+N +%;V:ED
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M7Z^@VATFH)WN/(1*0A -ZU!(!:N\;E[Z=._0>^<T4+06\.R#JUS'YC26K*]
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MQ61H+J15::-()XFC'10Q9W"4]K:BQ\ZN7Y3)Y6*U?+(MS#%'.T;.$5]D<3E
M=M!X2?"R=?;K<91=K;;ZN_ )_9ZLOX5R/^.NN-523X@O,?XJN:0))L\W*!3T
M'7_-HS0U[N\ZWZ)3^QG&YAB[6;S;>>_>16E\LH"BCPL%D[0Q7\SV_5UEA,O
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M #4]4OO8MO\ :?!Z]E?*=WQ"_P!.WJ1]\F5_=<FD#"Q*A\K8HS!5:XB!9NP
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MI,=<.707P#")HDE/A"N6?<W8P&K6HL/C[E<[R6WBR$MT9V"9&WN+@".2T>K
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M!2VV(Y-#"'EQ]Y*%C:55JRI(QKL;[!U8_*-<^L>G,O2H6QG%[+)74Z1^;''
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MTXQB<A: VD CN(HF%@^X6L&X,M%E9%W&,4H5'SCV:#0;20X9_MND<ONCN#.
MK@1LX&WRCU414Z)\I)T$I>D=W)P_U)Q4D-X(K'/$6%YCD)AMY&E2L$M#X:IM
M 44W-6FE6(5DX=C^.^IO-['/>8_)'SMQ'98EM\M<=(6N%G#O2HD4JX'S?R=5
M''=^G>-Y%>RYK-;ELWDBQ\5I&SFSMY*5B=P&I)*X&X;113VZ"0H[-9;6QL,E
MDFDB$;!;F8'SY9 :;%(J5I\ZM.HK3MU CI"(;B[:VDDN(O+:0V<N[Z25Y%0+
M0FB]!7Q%:]-4-;E/",5F,K;9?(I);9FZNX[LN7""(VYH3.B-5.@Z[JZ!4-S<
MR+)Y]VL=TT9ADN9W4QEFD/5"1\SRZ;2=0,WF+8/&O#E998Y@DZI;&9B(9)6Z
MQN+7Q5*J#T[._5$?<U]:\KEY[K'102X_''8DD=0+J9E395I#O"A5--J]O?JX
M4Q;/!W_(IFCPL4LMA#$WF70C,5M$B)4!Y'910$]=Q_*.KD=*2<;X>5E$UOR?
MD,898HU1OM9:N102F2JM<NO38NT1CVMV:G6J:5_?WN4O)K_(SO<WL[;YIY26
M=CV=2?8.@UJ17/JCZ(_BT_YN^H7[-QOZU<:Y[*W_ (RG^:/ _P"$KW]8CU-1
M\Y]=4&@-!OLKV\QMW#?6$[VUY;L)(9XF*.C#L(([- ZSG./<K5DY3&N)SI.Z
M/D-A /*E;M(N[:+:"6/_ &L0W>U6UG%@YKFVY%PJ\AFC8V]K> R65S XGL;J
M+LJKUV2+W,#1E[P#TT[H?/%_4+$27,3Y."6WN8>US6[CC'S24(!=%/>"" -2
MQ$VXCDEG?PQO;NLT1V>5*I)C^HTK#I^=4ZB%%GMI9O?3'40.&26,A5!/V:D&
MK'ZV@[K(V\CL\H+78/ES3N0H<L>@8]Y.@ZDB6V-8!$#\^0R*#M8$[:-VE13M
MZFN@VO._E+[S6X"59SN\/7LJHZ=O0Z@[^ >IO".#\XM;[EF6BXY9X^*6*TN?
M*>^\Z:8"-HJJ2RT4EJ[32FBPPOB.]4O3C/\ .WY!Z27$&9R5]Y+9G)W<3M;,
M\:!%%BC*OT@5:2/(*>S20K+BV1L\G:176%<)9R*GF6[D5WK4N7 )KM^3MU4.
M*>RA0GS3!'&\9:2HVT(K7QA@0/:=0(EQF<3<+[EC+OWE@@AO)8P3#M[ H=:C
MY*U^KH$Z3$XN-8P4M[>RB.V-F&X)WL 1MJ3WEM U>6^H/',(2LFW-9**OEVM
MO(K1Q5%%\R9"0G0?-!W?4U<"(N0<_P CE2\+74<>/=^MC95A0J /G2D;V^OU
M/MUJ137@:6]E%C812S23L1':V<9:0L"0#102]1TI3\O5,%S^2=K@Q[US2Z&*
M3:K+@[5UGR-Q\A4,1 #3JTW4=RG4RI%SO(Y\PL-C;PIC\%:$^XXN GRXZ]"[
ML>LDK #?*W4_(* )%(NM T!H/J1^+N_H)R/WQWO[EL]<MA;365&@- : T!H#
M05N^.S^S?R']F8S]VQ:UJ/DIKJ@T!H#0;;6[NK&XCN[*>2VNHCNBGA=HY$/9
M564@CZV@<8Y5C\L0O+<4E_*>C92R865_U/5G*JT4IIWR1;C^:UG \/&,5DSN
MXSFX+B1OFX_);<==]2:*"[- Y_Z,U3^9TR$;)X7+X6;R,M8SV4IKM$\;(& -
M*J2*,.G:O35R.'5!H#0 )'4&AT'8N8RR *E_<JJ]% F< ?4ZZF!G]O<W_P!Y
M77ZO)^BTP-<F6RLR-'+?7$B-\Y6E=@?J@G3 Y-4&@- :!5P_&<_GV(P^.GND
M7H\R(1"G0GQRM1$[/LF&ID+0XUQ?#C?R;D"3SKU.+P06^E/;T:Z)6W3L[4:2
MGLU,U'//RZ*S1[?B6-CPD+#:UYN-SDG%*&MRX&ROL@2/Z^F%-EF9V+N2SL26
M8FI)/:2=:'F@- : T!H'WP'^:GJE][%M_M/@]2CN^(7^G;U(^^3*_NN32"-M
M4&@- : T!H/4=XG62-BDB$,CJ:,&'4$$=A&@<\'.\LZ1V^=@MN06D96D>4C\
MV0*IJ0LZ%)A7L_3-9PCOM<_P2:Y$USB<AAWV[?-QMTMT(Z]3Y4=R%VBO8#(:
M#OTQ3!=Q^8XY:@MC/4'*X^0!43WJRD*A:U-%@DD%0#VUZGNU$P4X<YB_*:9_
M5 I<*=SR>Y7[,Y8]BJ4 Z=3_ (:Z8'5+RGA\D9BR?J3G+Y2Q#);6)C1HS3YW
MF;"6':/^?4,$B3/>C\4YEN9>0Y<[=BE5AM1L)HZ'Z8[01U\([=7%,,8_5+A.
M+#187@Z2@*%CN,A>O)+T)ZL$0 G:2*UZ]^F%PT2>M=U Q?#\6PF/D%!%(()9
M72@IN&Z0#?\ GJ?6U<&"3>^L?J)=[UARYQL3@!H\;%%9 T%*EH55B:=Y;3!@
MS+W(7^1E\[(74UW-U^DN)&E;KV]7).KA7/J@T!H-EM;7-Y<1VEI"]Q=3,$A@
MB4O([L:!55022?8-3(DBV]#.7V<*WW/+BP]/\84\[S.47'N=Z\?;6''(LE]+
M6GAV6VT^W6?+X"-IUA2>5+>0RP*["*5EV%T!Z,5J:5'6E=;&&@-!]7?@$_L]
M67\*Y'_'77&JH-\6']HKU _A(?K$6NFHAO6D&@- X<?F<9>!+3DL#.3(C+FK
M?Q7L2J*496(29.SHU&Z=&[M9PASV"9_%V%]E<-?#-8.GD336J^:RP"4OON;8
M^..M*+OHO7M.HAR8[U(Q?(1'#R>T,0=BBWL%28(NC&-=]*$K3LZ #3 E/@.7
MXM9VDPXQ/'?B%B[1HVY41C1?-  -%()[":?)J(>L-S;VC3W%W;$E"/=K]GWQ
MM<=H6*.NXT!)Z]FH/"F$D2YMK>VFCDO3YS1-N0S6\)KNEH20'(.T=X%= JQQ
MP6DLDD3+%?7<23+'O$C"(C='#0=2>TJ:T70;(96BN(Q"4ABFME*(SEJ#J5\R
MOS6![0E?#VZ*+:Y>"&W$]DXA#"#W1V H"U&DBV]"*FH+GHO=HAK77JUQO@'-
ML9E^40S9FVPMW->6V)Q0(DN[Q5I :24JD(W2%C]D*:JPT?77XD;/U<REK<\>
MXTN'MS9FSR%VLJ?;B7SBK"*25* (-M*#JO6K;3320II\"]3<5C\3:8O,7C++
M%)MMKF[=150/+C%$'SE!HSN 1V]^EB)7'*<!D[*:[A=KWR(T5XV\NLTJK2C%
M7JJT'SOK:@2K_P!1!9&5; 08=7*B\N[J6/?L4"A"G<&9J>6K=U- V,QZD<3Q
M\POX9VR.6A1I"DA$1:.;Q$DMT(!Z=GR]FJ&-E?5SE7()(L;Q2S$PF)G5%C]X
MN(I)?"%9MH5=HJ%]@]FKA<&[DN)\I@!N.=Y>VP22CSO)R$@DR.T=5,=M$"Y)
MKTZ*/E&F?@KB?DW"L)3[385L]D4 7W_.FMI44JR64;4J:=KR?6TQ20@9WF7(
M^11):9&]88R%B]OC( +>RA+&IV01A4'U:5^76L*0M4&@-!]$?Q:?\W?4+]FX
MW]:N-<]E;_QE/\T>!_PE>_K$>IJ/G/KJ@T!H#0&@6,-RC,8*.2VM)4EQTS![
MC&W<:7-G*PZ5:&4,M:=-P ;V'4L"JF0X5F9 ,A8S<<NV-??,6S7-F'/86MIF
MWJ!_^3F^HNIU1WXSC_*;6<W?#\G#FI*U5\9=GS^HVJ6M9O+E-*=C1G4R')9^
MIW.>/,(N5<?:=(2?I)8)+*9 >O1PFT@=HJNIB&#FL_6_C%U'NO1=V\S5^CD1
M)UZ"@#,-M:^VFF$P\E]9< BBVM\O?Q1=55XH00JL.VC5IV]FF#!.F]9UA1K/
M#7E]D)"H6*2]'@!?JWT<2 G;W"NK@P:$*<FSU^MY-CLAE9:^'R[5H85KXBID
M8"@%*@DZ(69N*9FY2-KGC$TL[1^66CN KQAFWCHA !5A74RK*TQ'J+@TFN<;
MA,S#;TW74"I'/ X'4G8M6'_4(T'2;OU2&WR>+WC%5*2/<1/2K=A&\D =Y&G0
M)\^2]8K9%C-VN(MJL*&YL;10!T*M5Q^1WZLP$+)CD65CD7.<KQTBL*NLE]YY
M?K3_ +!7'?6FBN"' \40URG+(UMOG>596D\\C$=.BL(T!^JVKD>G,<$QK 8W
M W&6D7LN<S=%%-.RD%J$ 'R-*VF*--QZ@<B:&2UQ;P8.SF&V6#$0I9;Q[&DC
M'F-\NYSI@-AF9V+N2S,:LQZDD]YUI7F@- : T'U(_%W?T$Y'[X[W]RV>N6PM
MIK*C0&@- : T!H*W?'9_9OY#^S,9^[8M:U'R4UU0: T!H#0&@- LXGEG(<+'
M[O87\@LC4/8S4N+1@>W=!*'C-:?F=3 5OY4<7R0(Y!Q6!)6Z&\PDSXZ3VD^4
MPF@J3^9B44[M3 \&-].;[<UKGLAB2 #Y>1L5N5);N$EK)6B_9,8Q7N'=J=1X
MW!X9"QQW*,'>)&/I&-T]F0>X 7D4!;_J5U?(:F]/.6"-)H[2&>&3K%)!>6DP
M<=Q79*20>[IIY#7)Z>\[B7>_&LGL/8PM)F!^H0IKJYB9:/Y$<SKM_D[DZ^SW
M*X_0:9BMW^[_ )P$$DG'K^*+L\V:WDAC'U6D"@?7.F8F6X>GG)EC6>[2TLK0
MG:;FZOK2*-2>S=66O7ZFIY*VCA-A;DC*\MPMK0;RD$LU^YC%:E3:0R)N]BLX
M/U-,HQ:T].<>Q$V2RF:(H5%G;Q8^,@CJ#).T[!E_]$0?R].JL#RS&62E<!QN
MQM'*@>]7V[)W 8 C<//^A!-:_I/0]FF DY7D>>SA_P#:V0GND!JL+N?)7_H1
MBB+V?8J-7 3-4&@- : T!H#0&@?? ?YJ>J7WL6W^T^#U*.[XA?Z=O4C[Y,K^
MZY-((VU0: T!H-MM%'/<0PS3+;12.J/<2!V2-6-"[!%9B%[3M4GV Z"0G]$N
M87.YN-WN$Y1$#13A,S87$[]*C;:22Q777V&"NL^0;^;]-O4+C09N0<4R^,B4
M[3+=V%Q#$3\CL@4U^0ZN8&P05)5A0CH0>T'3(-4&@- : T!H#0 !8A5%6/0
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MA.JF&K44:H- : T!H#0&@- :#ZD?B[OZ"<C]\=[^Y;/7+86TUE1H#0&@- :
MT$*?%?P#EGJ;Z*YCA_"K$9'D%W<V,L%HTT-L&2WN4D<[YW1!103U;5@^>?X#
M_P 3'W'Q_P :XO\ ?6NGE$'X#_Q,?<?'_&N+_?6GE ?@/_$Q]Q\?\:XO]]:>
M4!^ _P#$Q]Q\?\:XO]]:>4!^ _\ $Q]Q\?\ &N+_ 'UIY0'X#_Q,?<?'_&N+
M_?6GE ?@/_$Q]Q\?\:XO]]:>4!^ _P#$Q]Q\?\:XO]]:>4!^ _\ $Q]Q\?\
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MA=?H=3R!_=L\^^[7#_J%U^AT\AMA_%P<ZA2=7YEAF,L>Q"UO<L5;>K5%1T-
M17Y=9VMN/Q663+5_=L\^^[7#_J%U_P"36O)!_=L\^^[7#_J%U^AT\@Y,7\#'
MK?AX6MK'U-QYLV4(UI<0W%U;T *CZ*X21.@/3P].[4S$PZY?@?\ 4^XAE2_S
M_$+V6X<//++BYXI)=H  =X!&:#:*?7UGUROIAA+\#'/I@5=^#>73PQK:Y9%7
MI2H"S#KW]=;S&<-\/P1>HT$,L-O<\&@\U64NN/R$KJ7%"ZF5VVM3I4:F8N&^
M3X-/6D'=9<OXKC2H/E^YXC:8ZJ%\+/$S5H.TFNF88<]Y\&/K_?K1_56QB9H3
M;R^[0W%J&BKT!\E$!^K2NI.]JW&#?O?Q??JYDEVY'U+L[Q0=VVX-]*-U *^,
MGK0:UDP3F_%M^H#,6;FV(9F-68PW523W]FGD//[MGGWW:X?]0NOT.GD/6_%M
M\^:G_P!^F'% !TM[D?\ )J2E>?W;//ONUP_ZA=?H=7R!_=L\^^[7#_J%U^AT
M\@'\6USX?_[KA_U"Z_0Z>0V7'XM[G<]Q-+'S/#(CNS*BV]RH4,:@  =*:SI<
M22KMUK7_ ';//ONUP_ZA=?H=:\D']VSS[[M</^H77Z'3R&W^[<YK&UN\/-\3
M*P :X26UN HD#?-6A.]:4ZG;[*=^I;F$:O[MGGWW:X?]0NOT.KY"S7PI?#QG
M?A^QO)K'-YFTS#9R>TF@:R25!&+9)%8-YH%:E^E/9J6Y&CXNO0'F'KWA.,8O
MB%]C;*;#W=S<W;Y66>)62:)4788(9B35>M0-27 JE_=R>M7_ '_QC]M7_P"\
M=;\XG4?W<GK5_P!_\8_;5_\ O'3SAU9#\7)ZR")MW(.-"XW+Y8%U?;-E#NK_
M )C6M=M/KZSY=?DOHQ_NY/6K_O\ XQ^VK_\ >.M><3J/[N3UJ_[_ .,?MJ__
M 'CIYPZMUK^+H]78KJ&3(YOC\V/5U-U%:7EVEPT5?%Y1EL=F^G9NZ:>1U*.:
M_%O<_C;=QSE^'ND/7RL@ES:L@/V.Z&.<-3\U1:^P:QKM<3R[KMC/0D?W<GK5
M_P!_\8_;5_\ O'6_.)U']W)ZU?\ ?_&/VU?_ +QT\X=68_%R^L?DM7D'&O>=
MZ[![U?>7Y=#NJ?<:[J[:=/;K/EU^2^GS8?W<GK5_W_QC]M7_ .\=:\XG4?W<
MGK5_W_QC]M7_ .\=/.'4#\7)ZT5&[D'& I(J1<WY-.^@-B-/(92?BY/64RR>
M1R#C7D;F\K?=7V_97P[J6-*T[::DVZ=>Y>_1C_=R>M7_ '_QC]M7_P"\=7SA
MU']W)ZU?]_\ &/VU?_O'3SAU9?W<OK)Y1KR#C7G[P%'O-]LV4-37W&M:TZ4U
MGRZ_)?3YL?[N3UJ_[_XQ^VK_ />.M><3J/[N3UJ_[_XQ^VK_ />.GG#J]'XN
M3UG#+OY!QD)4;J75_6E>M*V(U+L0HXO\6]ZDSW3#,<NP=E9;B%DM!=WDNVO0
ME'AMUK3\_J3;HM<M_P#BYO5AKV<XC/8$8P.5MO?KF[6Y9!TW.L-FZ*6/4*':
M@[]:\DZN?^[D]:O^_P#C'[:O_P!XZ><.K8OXN7UA,8#\AXVLV_J?>;XH(]O;
M_P"I5K76?+K\E]/FR_NX?6+[I>-?J]_^\M:\D']W#ZP_=+QK]7O_ -Y:>0N/
M\*_HUR/T,]-[OAO*+ZQO\C/EKC))-C&F> 0SPP1*I,T<3;JQ,3X:=1K%N53?
MJ T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H
M#0&@- :#YF^I'Q4_$M8^M7*O3S@^;]X2VS][B<%BK?%6-S.4BN7BAB7=;N[D
M  58D]YUTQ$'^_#X[CR=.'1S-+GI+-\FD<./PLMO[C$_ER7'O21-;B)''ENY
MEVJ_A-&Z:G0,S-_&/\5W&LO>8'/Y_P"UN9Q\K07MC<XC'1S12+VJRFV_(]HZ
MZN(.#\./XEONMA_BO&_O;3Q@/PX_B6^ZV'^*\;^]M/& _#C^);[K8?XKQO[V
MU?&!1RWQB?%A@?<?MSGO<?MG:19+'^\8C'1^?97%?*F2MMU1]IVMWZF($[\.
M/XEONMA_BO&_O;3$#DX;\4OQB^H-_-C>(9A<E=6T?GW)7&XB&&*,L$4R330I
M&FYF"(&8;F(5:DTTLD"IC_7_ ..?*8_.Y2Q>YDLN,SSV><<X;&(UO=6:^9<0
M['MU=Y(D\<B(K,B^)@!UU,08R?$%\<L?&L?RXR7+8'*O;I83QX;&22R^_.8[
M5O(2W,P2X<%()&C"RMT0L=.@X^:_$S\9_IU+:1<SR?VJ-^)#:.^-Q$L;M 0L
MT8DAA=1)$S!98B=\9-& .K)*&K^''\2WW6P_Q7C?WMJ^,!^''\2WW6P_Q7C?
MWMIXP'X<?Q+?=;#_ !7C?WMIXP'X<?Q+?=;#_%>-_>VGC ?AQ_$M]UL/\5XW
M][:>,!^''\2WW6P_Q7C?WMIXP'X<?Q+?=;#_ !7C?WMIXP'X<?Q+?=;#_%>-
M_>VGC ?AQ_$M]UL/\5XW][:>,!^''\2WW6P_Q7C?WMIXP'X<?Q+?=;#_ !7C
M?WMIXP'X<?Q+?=;#_%>-_>VGC ?AQ_$M]UL/\5XW][:>,!^''\2WW6P_Q7C?
MWMIXP7^^$;U&Y?ZI^CUORWG%^N1STN0O+9KE((;8>5 P"+L@1$Z5/7;KG5,S
MXF_BQS'P_<QQ/&,;QFVS<.2QBY)[FXN9+=D9KB:'8%1&% (ZU^75DR(]X3\<
M/K#ZCSW=MPKTFMLN]@L;WCQY!XXHC.WEPHTLJ(@DE;P11[M\C=$!/32S 4+;
MXQ/7>[P=SR.V]';>3$V4-U=7KC)'SH(,>S+<O+ 5\U!$4(?<@II@,7^\JY3]
MP&/_ &_-_DM7Q!_>5\I^X#'_ +?F_P EIX@_O*N4?<!C_P!OS?Y+3Q#IXO\
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M?^WYO\CIX@_O*^4?<!8?M^;_ ".GB#^\KY1]P%A^WYO\CIXCS^\JY1]P&/\
MV_-_D=/$>_WE?*/N L/V_-_DM/$63^%KXB,E\0>.Y+?Y'!08,X.>U@C2VG>X
M$HN4D8EMZK2FSN]NLV8%@M0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@-
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M$\C]4.6Y[!7CW^)R.4NKJUO'5D$B2R%JQJX#K%4GR@X#"/;N%:ZW R]4&@-
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MC.>H7!8>0<ALH;3)+=W=B[VC*;:Y6SF:);B)5EF\L2 =8S(Q1@5J::E:2)J
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M%XK&X2P@Q6&LX,=B[5!':V-G$EO;Q(.H6..,!5'7L U%=F@- : T!H#0&@-
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MJ0=S5ZZ9$U6\,-D@A@K'#;!(K>%4'E"*G150#:T?:/:#J*\$5'K;,L<P;R7
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M4I3:>[0="Q0S%! IDN8I%(@=R&DCD4!DJM*&E:#L)T&"F[E0QVR)<70!+KO
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M2D75]IZ;@.O3KHAOW?K%Z=PF>%^2X^"2V#2LLDJK^E@*&"@*Z@]H 7\G5P(
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M%Y;[9>D=F)WDGN\?=OC7D5*!$0[U(5@"6"OW]!3ZVLT21%<Q7&,F>>1KR"%
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MNX5U]3N_%<._VMKDK<<YS,MI+93GW=*@L&%0>X_*#KQ\WM==MYMCK'W/V_\
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M!^-YC+V7);&;,8O-75S="YLP"(P:*C1Q%P2C*M/%\TTII@2W-Z]<'S$]IQ[
MR7,68OJHDCQ2VODI3<\,+!@#*Z^'Q^'4P90G\0EV?>K7B[0?:VRO[8,UU/*C
M1M)N-"X2A!A/;XNE=:@9UIZP<HFX_A>(6>:AQL]ENMCG(D-P1Y5*%]VY2:&A
M('L[=,(Y+OU/YS;X_*<5L\C;6F!Y%8?:[/+9Q1F&^CWG=<1AA1"P:C/"!7V
MZ".KK"06(C@@N)9X;9ML<#RE"Y-'W*O5#4]%&X?+U.KE4@<%]%_5?GF+?-8[
M#W38,^?(MY;S+:0S)%\Y8B#L^3:PJI[*:EJ)4^';TQS>,R\_.^3P7./N9K:6
MT@MYVK.Z2'8)9UJ?%04!)#?6TJK%0VT,K;#+<Q04D,LDX2=P%[@%)&WVTZ@=
MFLJRE0PHIE(\J56$4T8Z.AZ44,!2HZL-M13V:(8W/^'P9+@'*O4^]G$-MQFX
MBB@MRP*WOER11S&4]-I'F 0JM/$.H-=44>Y/GAF\M=75S=1W-PL-W<4]V9)(
MW,92-#VJ0 >_ZOLUJ".-;:&@^KOP"?V>K+^%<C_CKKC55M_&0?TL<6^]U/W=
M=:WJBFFMCLM4B:SNV,9:>/RW217VE%J5/AH:@EE^I]?41._I?F+*[XI>XU8(
MY<E%!+<1J7$$C.(_+6C]!T/BH36FL5E9%.(9C@QP>+Y#<129J[Q<.0EN7MA+
M$8Y3^EAB:F2+;M/6AKT[=177MM4E!MI4D9PPMD.Y;A&-"H$;U4@=>G:R]-!F
M8+S<)KB["VQ?80P9*QIVHC #:58;JMVZ#NM<G8QQR;U^V+S43SH+DQQ-'-U5
MG##<S#J/;7Y-!U<:SS\;R\66BQ=EE2C/Y9DE9U41$%O*0$,K4[?"RJ16AT$V
M8;X@/2W-WEKQW*YNWP7(LC$6BQ63E6W:16%/HY&HAW5\()#-W+J8:R^>%WCI
M[WDF9].%X9;SQXF^O;:2]N&'O5M=),X>:619(U65Z53<2"*=-6W$RY[;366W
MM$E^C7"N.V]KB<7!=Q3\QS,@BFCNQ65KI6K[O$6+%0J#Y_5=NJIX<J^'CU7Y
M9+!<3X&TDQIN4:PMI;MK>>%'^<TRH/"2!XV)-.E-3*X2-A_4?XE>)8BYQN4]
M/(L['@F^U_O]M*ZK*(HS]-'U+R0QJGB9EWN33MU.AU1W><ZYIS?&77(<W9^X
M<LDMYEL;2ZC>%C$P+Q0K RFD?2K"N[[(ZHJIC.5Q\=Y"<HL-K</9R,]WC+F
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M?' X14;M\;^WY--=L29]6M_;7DY-IQW,U]6_C7(<AD+2Y3"XH+EX? 9YI \
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MR?)7TI,DHEHJHY^QCC%%55[ ->?-R^SXZZSQJNO.["UL\C&]NNQIMY=.X!2
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MM]LOYT#_ .S/U!W\I^N_D].__P M?QV_Q\_\?S*.NKS#0&@- : T!H#0&@-
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MH!+K&]'*=?G[=ORZF1R7>.N[#PWL36\_A/N\H*2[74.K;6 .T@]#JCFU05U
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M*11=S("BUV[Q\[J-$7=SV>]+^2VV+L^37]C,,I])B87FVS#<BU\4;50BO6I
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MYA(&U6F9![=3/P4AY_.C*M;V5E$;3 X\-'C;$MN*JY&Z20B@:62@,C@"M
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M"A$]Q).I [MLI8:F(!N=<BE%+A[.Y![?><=8SU^O) QTP,!S"^J2^/Q+U_\
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MY0H<DGH$J=3(;^J#0&@-!]#/Q:/_ +F]1OV3BOUNZUSV%\-84: T!H#0&@-
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M_%J6P3C'/[S?4RW^/A\NG9Y4,S5K\OF?E:\]WSM=?A)_7/\ HWX])5Z-5D:
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M@- : T!H#0&@DKTY_H_]8/O<QW^T^'U!/'J]^!Q_O4YK_*W_ '@?RH^W=_\
M;C[7_:OW+WWWA_.]W\WQ^7OKLW]::DRAG/\ @*[NG^\FE!\W[44[/SW7296L
M?^!;_P"I7_P?3J@_X%O_ *E?_!].H]/X"M%I_O)K0UI]J*]O?7_DTZJ\_P"!
M;_ZE?_!].J).]-?]T_N7_P#QK_?[]IO>#Y_\FO<OM=[Q05\_9]!NI2N_N[=3
MIZX1)/\ _P 6][A_WG^]>[^='[S_ +Q/Y'?;&GEMMW>Y_P">;>WLZUUFYST:
MGS-WEW]W%Y,WF>5[YMZ_:+[<[MWYS;]#_P FG4]4/9?\ ?S1[G_+S93_ /,?
M==E?_P!;\5=:F0EC\!;K_25V?_L?5ZH/^!;_ .I7_P 'TZ@_X%O_ *E?_!].
MHRC_  %=Z[O]Y&WOW?:C;V=^WKJ7.%G=E!^ GN7S/]X]*]?,^U5/K^7U_(U;
MD/KC']W=[Q'[_P#R@[&_][^^^77NW>Y?E=WMUGJ4]LE^!U[PO\@O=O(\/_NS
M[2^_?-\7E_RC\=?J?6U)D<&<_D)Y$OVT_P!_?VBV&GVO^UGVI\J@[/M?]#MV
MT^=W:LQ\D1!=_@0^\2>_?[SO>Z_2^=]J?,K^>W=:_5UH:?\ @6_^I7_P?3J/
M3^ K7I_O)[!V?:C_ )=.H\_X%O\ ZE?_  ?3J#_@6_\ J5_\'TZCW_@6H/Z2
M:]?^YZZ=5>?\"W_U*_\ @^G5!_P+?_4K_P"#Z=1?_P"$_P#W=?[F\?\ [K/M
MO_(_WR]]W_E#Y'O_ )WG'S=WNWT>W=\VG=V]=<ZTQ]8OP8?Y26?^^[[0?RG]
MQ3W'[<T]X^U_G2[-OYSS/-I\M=.HC_\ X _);;_(SRMR[^RFZC;?RJZSZ_-K
MKAC_ .'[_J9^5K75D?\ A^_ZF?E:=59K^ )Y4OE?R-\JB^=V=E>GY>LWO,]U
MF<,/_#]_U,_*UKJR/_#]_P!3/RM.JC_P_NM/Y&=G?34H/_#]_P!3/RM7J#_P
M_?\ 4S\K3J#_ ,/VO_\ IGY6ER#_ ,/W_4S\K0ZL#_=]_P"I_P"7H=6M/[OO
MS4\O^2._<-OZ9VUZ?)J7MU)G(_\ #\WM7^1^ZIK\^E?\&J=6U?[OW_4VOR_\
M^AU9?^'[_J9^5IU&4GX 7FOY_P#(SSMQW]E=W?7Z^LZ]NG9;G/5C_P"'[_J9
M^5K75D?^'[_J9^5IU&4GX &X>9_(W=M6E:?-VC;^5K.OR:N?5C_X?O\ J9^5
MK75!_P"'[_J9^5IU1F_X GEP^=_(W9M/D]GS-[5I_P!;=K,[W#5RP_\ #]_U
M,_*UKJ@_\/W_ %,_*TZB8?17_<9]K\M_N.^U'VM\^/[;_:3YGG[#Y?F?+MK3
M6.F?FMSCY)1UID: T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- :
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KX%7\E_4'[3?RT^U'VFM/Y1>?[OYGN7V[QWE^13IYGO/N]=WV&ZFG5'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>ph_fig26evx2evx3-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ph_fig26evx2evx3-4clr.jpg
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M;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4
M !#\X1^)R+?)>"\T8C0'6'?K_^X #D%D;V)E &3      ?_; (0 ! ,# P,#
M! ,#! 8$ P0&!P4$! 4'" 8&!P8&" H("0D)"0@*"@P,# P,"@P,#0T,#!$1
M$1$1%!04%!04%!04% $$!04(!P@/"@H/% X.#A04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@!^@.V P$1
M  (1 0,1 ?_$ -,  0 " @,! 0             &!P4( 0,$ @D! 0 " P$!
M               $!0$#!@('$  !! $"! ('!0,( PH)"0D!  (#! 41!B$Q
M$@=!$U%A<2(R% B!D4(C%:%28K'!<H*2,R06HD,)LE/3--0E5A<8&?#1X6-S
MDY255\+2LT2D-55U-H.CPU2T129&-Q$!  (! @0#!08% P,"!P$!  $" Q$$
M(3$2!4%187&!(C(3D:&QP=$4\.%"4@;Q(Q5B@C-R-)*BLD-3)$06-?_:  P#
M 0 "$0,1 #\ W^0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!8U!9! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0-=$'&H/M*P /'3]JR.4! 0$!!QJ@
MYUU0 =1J@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MB L,FIU6!RL@@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M#FN!\01P*J9B8X2MHG7D^UAD0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MI[+5!)F,A><-37K,C:?0Z9^I_8U7_=[?!6OG*B[576\SY0S_ '$[<#)LESV
MA R6A=;I- #; '-S1X2?[KVJOV>]FDQ6T\%AO-GUQU5YHQMK>QMX.WL[<$IZ
M)(7Q8V[*2"R1@U;#*3Q'$:-<?85+S;72\9,<>/&/SC\T7%N=:3CO/LG\I6;V
M]MFUM2B'?WE?KKNU]+''3]A51NJZ9;+7;6UQPQN(<ZIW&S=1Q]RQ6;,P:<-3
MTD_RE;LD]6WIZ2TXXBN>WK#'=WL/#;QU+(Q1@9"%YB$GBZ(M+BP_:-0I?:LT
MQ>:^")W3%6:Q;3BJ:2[E,O6QV&=*Z6"CULI0G0!H?Q))//0#AZE>6PUK:;QX
M\U/&6;5BDSPCP7YV\KMJ;0QT+6!FH>3PXN)>>)]JY+>:SEEU&TT^E&CR8;2Q
MOW-V".$$3(FGT'W1_,I&;AMJ1ZH^'CN;SZ0Y[@%]B'%XIGQ7;;00/0WAK^U9
MV'";7\H-_P 8K7SE">X>_OG>K;.W9":+-(+5J+4NF=\/E1:<V^!(^+D%9;#9
M=/\ N9.?./3UE7;[>=?^W3E^/I"0]N^W;<,V+.9V,.R[AK6K'0MK-/B? R:?
MV?!0]_O_ *GP4^7\?Y)NRV/T_CO\WX?S0[O!4^2W7'?C 'S5:.;^O XM_F"D
M]MMKCF$?N$=.2++D?FJ];;S<Y.X"(5663KXE[ 0/M)T5#7%KDZ/'5=3DTIU>
MC [ H2/JV=P6SU6LF]SFOY_E:Z_M/\BG;_)QC''*J%L<?"<D\[(KWFJT2['V
M&#_G-@<R7I'.L[EU?UN7VJ=VB;1K']/YH7=8KPG^K\DC[3Y:7([695E<728V
M1U8$\28N#F:^P'3[%#[GCZ<VL?U<4SMN3JQ:?V\$[56LQ 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 04GWN<X97&-_"*LKA[>M7_ &OE91=SYQ[&
M3R&-GPN%VWO/$L DI5:[+S&\ Z,L !('IU+7>T*/CM&2U\5O&9T;\M?IUKDK
M'*.*RZ=JKF,=%;A_,IW(NKI=P!:\:$$?L*J[5FEM)YPLZS%ZZ^$H9@K+]L7\
MQM^R[2"..2[0<?W6M+B ?Z('W%6F:D9ZTR1[)56&\X;7I/MA"^SE;YG<MJZ\
M<*U5S@?XYWZ?R:JQ[K;IQ17SG\$'M=>K+-O3\5Z: +EO1TR.;NV=C=VTA%:_
M)NQ _*76#5\9/@?WFGQ:I.WW%L-M8Y(^?!7+725,1G=G;#,.>^%K6R#H+G-,
ME2Q&#KP=PT/W$*^GZ6ZISX_9HI(^IM;\N'VZLMG^Y57<%?'%^.DJW:-EECW7
MMDC+6_$ >!U.G!:L.QMCM/&.,/>;>UR5CA/"7.Z>[%W-U)<7B:GR5:R#%)+(
M?-G>QW M8UHT;K]I6,';HI/5>7K/OYM'36'.![39/(X6Q=R$AH7Y6@XVJ_PT
MXDSCF.H< .8YKW;N=:7B(XU\?Y/%>VVO69GA;PC]6)Q>>W5VXORT)Z_0Q[@9
MJ=@$Q2:#0.CD'\K?N4W+AQ;RL6B??'Z(>++EVEIB8^W]69=W,JVMP4\[:Q\K
M!4A=$*\<C7ZO=KQ#CIPXJ-';IKBFD6YRW_OZVR1>U9X0\>Y^Y.6W3$,11I?*
MUY7@^7&3/9D(/ #I T^P+;M^WTP3U6G6?LAKW&_OFCIK72/ME(-B]KWQ319C
M=,0ZV$25<:3U:.YA\W@2/W/O4'>]RB?@Q_;^B;L^W]/Q7CW?JMS14*]1W?5
MY':&8JL&KS7?(WVQ?F#_ '*D[:\5RUF?"4?<TZL5HCR4]LW<#L9MG/48#_C[
MTD#*L8^+29I8]P]@_E5WNL'5DK/A'-2[;-TX[1"Z=JX5N P=7'=($[6]=DCQ
ME?Q=]W)4.?)]2\RO,./Z=(A&^.[]W:#W\)A3_5?+K^W5P^X*P_\ ;X/^J_X*
M[_W&;_IHKC:337[EP1Q\&MO6F#^B0_57&YG7:Z^D*O!\.ZT]6P@ 'M7(NK<H
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(. =3HL#E
M9'R>7O<5@:_;_)F[C3-?H1YU-FAY=.C/_&NFVD:;?7VN=W4__L<?1.K@_P C
M;RCR$8+-OYD]%@#X(Y2>/#PT/O#U$JMI_OXM-/BK]Z?;_8RZZ_#9-\YC(LUB
M[&/?IK*W6)QX],@XM=]Z@X<LX[Q:$W-CC)2:J[OYN0]M\OCK1Z;]'IHO:>#M
M'R!K?V:C[%<TP1^ZI:/EMQ5%L\_MKUM\U>#M[+U"S%9.ZX<)[+8FGTB)G']K
MEX[O;7)6/*'KM-=*6G3Q6@"/#DJ-=JWW_P!M8\VZ3,X)C8LN>-FMP;'9]?H#
M_7X^*M-IO9Q_#;C7\%;NMG%_BKPG\4)VGOO*;(DFPN4H/EK>9UR5Y/RK,3SH
M#IU<' Z>/WJQW&TC/\=9XJ_!NYPSTVC@R\G<7 '>,&XXH[3:ORKJ]F(QCS/,
MX]/2 [0CEXJ/^SO]*:<-=>"1^\Q_5BWAHQ&\M_V=Y"##8RBZ*H90Z./^\M32
M<0T -Y#CR"D;;:1@UO:>/W(^XW?UM*U?=[M7N*E@X,K'^?D "^WCH^,D;/P]
M!'Q.'XA]RW8NY8YOTSR\)_5JR]OR13JCGXQ^CU[3[JS82G'BLO4-NK![D<\)
MZ)F#7B'M=H"1]B\;KMGU+3:LZ:O6V[E].L5M&NC(87N-M[&7\UDIV67OORA]
M>-D0+N@:\'$N '-:L^PRWK2L:?##9@WV.EK6G7XIX(WNK>62WKD:];&4Y(0
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M<STNT)^Q0LFWOB^:."9CSTR?++/+0WB @(" @(" @(" @(" @(" @(" @("
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MQE8:058F1,]?2--?M/%<U>W7:9GQ='2O36(>Q>7H0$! 0$! 0$! 0$! 0$!
M0- L:0*@[N[5E=*W=-!A<P-;%DFL'O-Z?@FX>@>ZX^'!=#VO=1'^W;W?HH.Y
M[:>&2L>W]6/Q&[I=V-H;>W#D(Z-:(#SK+G=!M]/!H+CP#M/3P/-;LNTC;]63
M''5/X-&/=3GF*7F*Q^*W))\7@L4V8EM?'5V ,#="-#R#=.9/[5ST5OEOISM+
MH)M3%3RB$/CKW]Z6ADLP30VS7/57KN/EF7^(D_M=]@]*L^JNVCII\5YY^BLB
MMMU/5?6M(Y1YLY8WCLS",%5^4JP1Q#ICKPN#^D#PZ8P=%"KM<^3C%9G5.MNL
M&/A-HC17.[NXT6?$F.I2RU<400]S6'KFX'XN((;ZOO5SM^VS2-;<;?@J,_<>
MN=*\(_%@NVV>QVW<])=RLQ@K25G0AP:7CK+VD:]/APYK9OL%\U=*QK,->TST
MPSK?E*^\9E<;EZWS>+MQW("="^)X< ?01S!]JYK)COCG2T:3ZNCI>MXUK.L/
M<#J-5XU>W* @(" @(" @(" @(" @(" @QF9SV&P+:7ZS:;6;D[<6,I![7.\V
MW9U\N(=(/%W2>?!>+7K737QX#QX? ;)QN4NR8#&8NIFHND9!U&"O%99YPZVB
M7RFAPZQ[PZN?->:TI$STQ&K+/K:P(" @Q>9VWMW<3(X]P8FGE60DNA;>KQ60
MPGF6^8UVFOJ7BV.MOFB)'OK5JU.".K3A97JPM#(H(FB.-C1R#6M  'L7J(B.
M$#M600$!!PX:CBL"L.\=RL_"5:3+$9LBVU\E8/!D#0QPZBWF -5=]HK,9)G3
MP4O=9B:1$3XHUL'?U?;%9N,O@/H2RNDD<P?F1.=I[P'X@=.(YJ9O]K]6>JO-
M%V6YG%'3/RK6K[JVGEV/@BRE2=D@Z7Q/>UO4#X$/T7/SARTXZ3"]C+COPUA%
M+%'(["N.S&!ZKVV)W=5VD'=9BU_$T\>7@[[#Z5/B\;F.FW"\<I\T*:SMYZJ\
M:3SCR3BE?Q6X\7YU<MM4;#2R2-PUY\V/;X$*MM%L=M.4PL(FMZZ\XE ;%]W:
M[(F%[S;VS=ZI*];J!L0R\]&@GD?3R^U6=:?NZZQ&EHY^L*ZU_P!K.D\:_@A.
M%K9+N+O;YVXW\CS&6+O3\$->(^Y$#Z3ITC[2K#),;;!TQS0L<3N,W5+80<1I
MR"YB'1.0.&B#E9! 0$! 0$! 0$! 0$! 0$'7+'%/%)!,T/BD:62-/(M<-"$Z
MM)U8F(F-):]N&4[9[Q]V,OAC<[RVDZ-L49'>!](_8X+K]*[W!Z_A+E)FVTS^
MGXPL3#%O<&]^M7) <'3=TU<=U#J+QS,H'+U^GPX*GS:;2O3'SSSG]%IBB=W;
MJM\D<H_5+\UGL?@*7S%LZ'3I@KMTZWN'(-'H]:KL&*V:VE5CFRUQ5ULC&-V]
M=W-;9N#=4>L0(=1QIX-:SF"X'P]7CXJ?ES5PU^GC]]D#%AMFM]3)R\*I+D]Q
M8/#0.DO788A&/[D/:9#Z & ZJ!CP9,DZ5A/R9\>.-;2I+?NZG[I,,C7Q,HUI
M#\M6:0907MT+G'QUT\. 71[?:1AYQK,\W/[C=?6CT\(6%VHR55VU:^/^9B^=
MCDFTK%[?,#2\D>[KKHJ??X[1DF=)T6^RR5G'$:\86 T=/_B5;"P?2R" @("
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M=';O)X&45H=Q9/&.K2M8]_RC;<L6C@UY:7= =KH2W73P4K)2U\<QXS##YR&
MW0-A5,)MW)QXO=%&K49!<+?-KF:JUG4QX+23')TEI.FH!UT\%BU+?3TK.DP(
MY1VQN_<^X,-D-VXK'[?P>W[#LE'C<?/\V^]E.@QQSO<(X@QD8<YS1Q=KSX+5
M&.][1-HBL5X\/&1:*FL" @(" @((WOO:-7>^V[>"L.$<KP):=C_>K,?%C_9X
M'U$J)NMO&?'-)&M7;W=V2[5;PM8W.QOBH/D%7.5>9C<SX)V@<PT'7A\3"N3V
M6:VTS]%^7*7J>/%LI>VMMK<,#+T,;&FRULL-ZH0.MKAJUP+>#@0==5] P[N^
M/E.L(>7:X\GAI+&-J[SVWPJ2#.8UO*&0Z3M:/ :\?NU4J;X,W/X+?<BQ7/AY
M?'7[U796[_F[N!#+! Z,6;-:$1.]YP$&@<3IZ.DJ]QX_V^VF)GE$_>I;W_<9
MXM$>,<&PXXKCG7/I9! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'&FA]2P-=,5
M>GVIOZ>5]<V)X+-F 5P>DO=.2&Z$@\R0NHO6,VWCCIP<W2TXL\\-5EG!;RW4
M==P71B<8[_\ M]3^\+3X.(/\I/L53&7%B^6.JWG*T^GER_-/37RAF'TML;%Q
M,N3?&V..LW^_DTDGD=R:QI/XB>  6N+9=S:*Z\_L>YKBV]9MI^JGZ-3+=S-V
M236-612D/MO;\->HTZ-C:?WB. ])U*Z.]J;/#PY^'K+GJUON\O'W^D-@:U:"
ME6AJ5&".O QL4,;>0:T: +D;6FTS,\Y=96L5B(CE#T+R]" @(" @(" @(" @
M(" @$@<T!!QP*P(EOO9E?=E >5TPYBJ":5DC@?$QO/[KOV'BIFUW,X;>D\T3
M<[>,M?7P5+MC>6<V-9L8BS"'5FRD6*,^H,,HYEA'+J^X\U=Y]K3<QU1S\U/A
MW%\$],K$O]V,73Q\CQ5D&:Z1Y5!W%I<X<"Z1O -',^*K\?:\EK<_A\TV_<Z5
MKRGJ\D%V+@+^\=RNSF4UEI5Y_F;D[A[LM@'J;$/2!X^@:!6N]SUV^+HKSF-(
M](\U9M,-L^7KGE'&?5?C/'TZKE'4OI 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 08#>&VH=U86;&/<([ (EJ3D:AD[/A)]1Y'U*1M\\X;Q:$?<88RTFLJ6P.
MY-Q=M\G9QMVJ3$\ZV,?*2&EPX"6%XU''TC@1S5]DP8MU7JK/%1X\^3;6Z;1P
M<[G[@YG<-7Y/S?EJ<P_/KP@M!&O!A)XN!\5OVNQQXOBTUEHW&^R9.$3I'DL/
MMILV+"T1F;7ES9BVP-'0YKVUX3Q\L%I(ZCS>1[%3]PW<Y;=,<*Q]ZVV&TC%7
MJ_JG[EAMX#3T<U5<EJY0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%8=
MW.UL.]:/ZOB&-BW529I"[@UMJ(<?)>?3^XX\CPY'A3=P[?&>.JOS1]_\?QZ9
MB5+;'[I;KV/_ ,P2,9/C8)'L_3[P+'02:GJC#^!9[W@> *Y_;;_/@F,>FND\
MI>]-4KO_ %.8++UQ@<97DQF9N!T4UR=S'U83RZ62@C5SOPD@ +M^U[K!FRQ&
M3X?17;W)DKBF:1JF/:7:$\<G^:<C&6-+#'C(Y!HXM?P=,0>6HX-U\.*Z/NFZ
MB?\ :K[_ -%;VS:\?JS[EN+GE^(" @(" @(" @(" @(" @(" @(" @(" @("
M"G^[>S[/S(W7C8W/C+6MR3(Q[[#'\$PTXZ <'>C@5=[#<1I].WN_13;_ &\Z
M]=7&#[P^7C8JV5JF?*,TC;:#@V&1HX![^9#O2!S3)VS6_P ,_"Q3N,13C'Q0
MB^;S>X.X>9K8^%@> \MIU8P1&TGXI7Z^@>)Y!6N+#BVE)M/OG\E7ES9=S>*P
MNO:VVJ6UL5'CJPZYG>_;LZ>]+*>9/J')H\ N8W.YMGMU3_HZ3;[>N&G3'O\
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M<%'N[UC+U5;!XBY^I8JE?_\ YF"*4Z>E[03^U<S>O3:8\G14MU5B7M7E[$!
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M^T,MQ;GLX/M'M.+.XRJ]T<>6ONG<ZWY9T=)#6@#7-CUUZ7/?JX<2UO)&4X[
M?7!ANZ6YJNP][X4;8W3?>8,79AE=+1LV!J?(<) U\,CM-&!Q<''AJ'%H)AMN
M@(" @(" @^7C70::Z\/2-"DBD][]OLA@[KMP[9;(:(>9G10:B>J_B2Y@;Q+/
M'U>Q=-L]]7+7Z>7GZ\I_FYO=[*V.?J8^7IX,3A=T4<C+Y.[,A>8UQ'3:A>7Q
MD>/F-XD'UM"E9L%J1KBK7V?HBXLU;_\ EM;VPLS'[&V9DZK;-:9V0K/T/FMG
M#VGQX].FA]2HLF\SQ.DQTS[%WBV>"8UB>J/:RL.Q=I0:!N+B<1S+^IY_:2HD
M[K-/]27&VQ1_2J[O#5QN/OXRG0K15@VO++*(6AFH+M&ZZ>PJX[9-K=4S*I[C
M$5TTT6QLZ)]?:N'BE^,5(2=?XF@_SJDS3KDM[5QAC2D>QG%J;A 0$! 0$! 0
M$! 0</8V1KF/:',<"US7#4$'@004'Y__ %0_30=@22=Q^W5>5NTWS>=EL96#
MNO%3%W6+,!9[S8.KF/\ 5'B/=^&5CR:\)0<V+IXQR6U],'U.Q[ZBK=O^X%ID
M6]H6!F+RCR&1Y6-@X ^ L@?$W_6?$..H7C)CTXPVXLO5PGG^+:=:$D0$! 0$
M!!PL#0SNS'';[_Y*MEG'Y*7*T89SKTD5G-A;P/A[IYKFMQ$6SS$^;TV9M_3M
ML"=SGP.O57NUT\N=K@/[;'']JL;=MQ3/#6/>QJ\T'82/'=1Q&Z<A6U/4T.'5
MIX<V/8H^3M6LZQ>T,ZH;NG/9?8DCJE/N'+E<C$0!CH0Z8MU_WQ[B]C-/03KZ
ME5;BV7;<LVL^3U$Q*),D[A=Y<Q7HOF=>%/@)7 14JK7<#))T #K(_K'P42O[
MC>VBLSJ:Z-G]D;,QFQL##A<?^8_7S;EMP ?/.[XGNTY#P:/ +L=MMJ8*=-6M
M)%+T!9! 0$!!X,Y>EQF%R62@:U\].K/8C8_7I+HHW/ .FAT)'%!^<%/_ &B/
M>R^\Q4MH;?M3-:7.9!6R,C@T<-=&VR0.*#V_]OOZ@/\ H%B/_8<I_P I1E>F
M(^HGN[F?ICS/>J# 8F#=V#R$K;6(FK7657XRO)&V1[6&<2=;6R%Y=YG3HT\/
M!!FOI*^I/,_4!1W-%NBEC\=G<%-6=%!C1,R.2I::\!Q;/+*XEKXW D'3B.",
M);]3O>NWV)[9NW;B:U6[G[=ZOCL75O=9@=)+U22.>V-\;W!L4;_A<..B"N.W
M7?/Z@.Y'83</=O#8' .S^/N/_1<*VO=,=W'T& W--;/492XN$/2[BZ,MT)*,
MO!]+'UB97O5O"_LC?6/QV)S,M?YO;SL:V=C+'D FQ"\3RRDO#?S&])'NM=KR
M1A]_51]863[)[LQVR=C8_'9;.,K_ #FX#DFS/CKMF ->)@@EB(D<W61W43[I
M;Z> ; ]H\KW"SVP\7G>Y]*EC-UY-AMR8K'1S11U*\NAABD$\DK_-#-#+QX.)
M;IP03A!K%]2?UA8?L=EF;-P.)&X=[.A99M12RF&G2CFXQB4M#G/D>WWA&WI]
MT@EW$ A4NS?]H=F:^Y*V*[M;+CQ&(LE@DO8_YB.>LR1V@F=7L]1D8/'H<#IR
MZCP1EN'W#[I[0[9["M]Q=P7 _;\$4<M4U2V62X^P!Y$=<:@/=)J.GCII[Q(:
M"48:26_]HKW!L36,GANW=,;8@EZ72336IGL;J-!)8C:R-KCJ/P>*,MK?I^^H
MG:?U 8&W>P]>3$[AQ3FLS&!L/;+)")=?+DCD:&B2)_20'=+2"""T<"3"XD!
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M]U[PAO3XRYAYL9&S&1QS2^=)9KS N;+)$.G2)WXN>B#<W_O$NQ7_ .&[D_\
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M>[CYNIXD/Y_L7,]PPVQY-9G6+<OT=)L,U;X](C28YIRJQ9" @(" @(" @("
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M<>?'@>9*L-GN)R5X\X>5[*Q! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
MH(AW W<[:N(!J]+LM=)BIA_%K=!JZ0CQ#1R])4S:;?ZU]/#Q0]UG^E7UE6.S
M^W][>39\WE;<D-.5SBVPX>9-9EU]YWO?A!\?N5ONMW&'2E--?P_FJMOM)RZW
MOR_'^2<U]A[CQ,0KX+<)@K-XMA,98W4^) UU5=;=8[_/3BL*[:]/EMP=\='N
M;4<YOS]:XP#AJ&ZZ_P!9H6:WVL\ZS#S:NZB/AF-7U^K]PJATGQ,-@#F6<?\
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M2YNOL7,=ZP<(R1[&82OM-W-Q.9VI#3SE^&IF<-&VO;^8D;'YL31I'*TN(UU
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M0#@%S&XW%\]NJWV.CV^WIAKI7[6<Z6GPY*.DN4! 0$! 0$! 0$! 0$! 0$!
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M<$:C18%%=WL=/C]TU\Q'_=W8HW1O\!-5(!;]W25T7;KQ;'-)4&_K-<D6A/\
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M1H^,_%'(WXF.]8*Y[+BG'::ROL62,E>J&46IM$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0%@4QW\[RQ]NL2,%@W"7>>5B=\OXMIUSJTV'^O7A&WQ=QY#C
M WFX^G72.<BE.Q'8V3?_ )F\MVOL1;>\UQI 'IGOS]1,DQ>X$] =^+\3M>/!
M5^VVDY/BOR9U;$[H[4;%DV9>Q<$-;!N@@DDJYV70OJ3M80V>225WO-:>+FO=
MTD*PGM^"_":_9S):+?3;W)S';+O:,+D\DRWA=PWG87.21S"6O/9,ACKW&2 E
MK@).3QSC>0NLW&VI]"LTK%8K'".7!KB7Z9*C>Q 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 049W8W'-D\V-OUW?X+'EO6P'026G@?%_0!T]NJZCM>"*X_J3'
M&?P<SW+/-[_3CE'X^J>[,V=@,=A PB#)6++0;MSA(US^?2P^#6^"J=WN\M\F
MO&L1RA:;7:XJT\+3/.6&W;VII6ZLMS;Q=#D8P7LJO=U12>/0">+3Z.*][?N-
MZSI?C#SGV-;1K7A+ ]L][OQ-ANU\T\QT7O,=.2;@:\VNAB=KR:3R]!4C>[3K
MCZE.?BT;/<S6?IVX1X?HNM@(&A^]42[?2 @(" @(" @(" @(" @(" @ZW<-2
M= /$GT+ H#>F?N[VW+'B\7K+2BE^5QD33PDD)Z73.U^WCX-"Z_9X*[;%U7YZ
M:S^CE-WFMN,O13E$Z1Y3ZK+QLVV>WN)CQ;K#9;W!]KRAUS33D<7']T:\@>05
M%>,N[OU:</#RB%S2V+:TZ=>/CZR\@R.^=U$MQ=<8+$NX&W+QF(]+?'^R/M2<
M>'#\T]5O+P9C)FS?+'3'WH1W,VK7V[%BYFV9K=NX9F6IISU%Y: X$#PYJQV&
MXG)-HF-(X*_?8(QQ6=9F>*W-DRRS[1PTLQUD-2($GGH&@#]@5)N(B,EHCS76
MWF9QUF?)GEH;Q 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!3'>V27]0Q47^I;
M!,]OHZRX _L"Z3L\?#:?8Y[NTSK2/:F.-V?@LKMO$ET7DV&U(2VU >B34L!U
M)Y'B?%5E]YDIEMQUXSPE84VF.^*O#P=#XMZ[8:75)/US&,_U3P3.&CP'XONU
M7J;X,W&?@M]SST9\4\/BK][Q9+/;6WYB9,'E"<7E->JL;(Z?*L#@TA^FFG@X
M'3@L4Q9-O;JKQAFV7'GKTSPE">WF>M;3W0[$WST5+DORER,G5K+ /2R0'ESX
M$^@JQW>*,V+KCG'X(&TR3BR]$\I_%?XXD_<N<="Y0$! 0$! 0$! 0$! 0$!
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M:1D;CQ>7/)<='\3XJ=M\ELF"9MS8GF_4=G5TCJXNT'4?6N;>GTL@@(" @("
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M!!&R-I]3&AO\RYF9UF9=%$:1H[UAZ$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M%P./E^SSG:R?T0Q:NX9NN_3'@S#:95K(@(" @(" @(" @(" @(" @(" @("
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MVW!;(QWMRB1'CWC[5ME\D[QQ/F'A_P ;BT_M:Z+=^TS<^F?L8ZH2?%9W"9Z
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MS772.3,9)K/5$<4MD[G[ZR!,-21C'._#5K>8_C[>M1H[=MZ\_OE(GN&XGE^
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MDK:VU.;&W\5,>;Z<#C[?+"ILL:7F/5<8[=58GT95:VP(!X'B$  #@.2 @("
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M>;:N^NP>5RNVK ?8O.K8V_CI'!MNG+/('.;*WGIHQW2X>ZX<EMW.:ML,^O\
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M\?9Y#(WMZ]P]R=Q;VRMD6,;1PWZ/1S#,U>@DGFKLM%PT9"U[!(]^K= \M:T
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MUUDD<0;$K?4T 1@^)ZO0M&SQ_P!2R_R/>1.F&.?.S<0 #DK-Q+E 0$! 0$!
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M(:L8(TI"1WG+.3=WGRX?8KR[DZ(^JW(9G)3,K8C;&$?-=M2G2.*-E8=3W.\
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M'Q.CA^:=)$^-\0D Z^CR]=2W3VK3N<T3,=/'U6?9>W9,6*WU:Z=7AXZ>KI[
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M"#X$H.0-.:#E 0$'RYO5S)T] 0<]( T'@@=(UU^]!R!H-$! 0$! 0$! 0$!
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MC?3[/+R;2JX<&(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M4Z<UF<'"NDZ35NIW28MEF](M&;G''SUC2?18RDJ80$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
60$! 0$! 0$! 0$! 0$! 0$! 0$'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>ph_fig35bacterial-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ph_fig35bacterial-4c.jpg
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M>'!A8VME="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,  X0DE-! 0
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MO"WZ*=>M?-^_[6NWW%J5KQY3G6..8]NGEYO3]OO3;;BTSP5ULG$<DB1^V*,
M/(8R$@!>R]$)$5$OTMZ)7E^\_P#)ICV<':[?]&O/Q:DI+SENX=T1.*>BJ@WO
M9/Z:IS>968K$-O!RTB' <QTQS_,7U(B9,.ZII^1.0JB*OV]/C5W:W[4IT3/R
MRK7VHM;JCC"V/&CFJYR>DT&23-161$6'>!@VC*V[@%]Y2ZIU+T^%>U^Q?[7?
MOU8_U*QPG&(QSCGGUO/?<(W=NO3GY9GXK0R>.C9:!(QLP5*+*;)IU!517B2?
M!4]%KV]Z1>LUGA+A[>Y-+1:.,.5%PL=EZ1##'Q0C09#CLAB2VXX4=TW%$^YP
M7JBH*&AHGN5;IQM7BYV]9C$:3SY<GOHWIF(GJG,QICGZOACXJKR3I!DI,E@_
MU9.*"$VJJ%T2RAR5$O9$]53K7'O.N8>AVX^2(EB%)DR#)2<577%4N2)[B-4M
MU7U].E83,RV16(2J+M),-8Z-FA^='%D#D>$O1P5'UY/(7MLGVBI=;5<KOS$1
MU:Q7DYUNUS-IIIU<_P"7I#ISPY&TN5BY.=UH2<G2'2^<D2 :!\.\@N=I.TJH
M@72_VJOK7KOMM=F:S>G'GGCZGAONUM^MXIN<(C3&<:<]>:8[7NNHZ-!:R>Y9
MR#@<<^ZD=F5DI#<5LWE%30!)Q412XB2V3K9*[#A(<?U&^!@Z+Y'UY5M?ID6"
M_P"(EH/$OJ7\ C:_D7!]?LF O_%0>)?5!]/HWOY#PUDZ=)%_^(:#-P?U$^$]
MFS,+7L!NV-R&:R+J,0H3#A$XZZ2*J"/MM=;?;06=0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!05^GA'Q4.U3=V'5H0[1D$?27.$3%"*8VK4AU&D
M-&A>=!5%QX 1PD5;EU6@VK'C71XRZRK.%CBNFQWX>KW0B^1CRHZ17@#D2W0V
MDX%SOTH(YA?IW\+:Y.+)8/38$*<2RN+S:.JH!D&3CR&VT)Q4;:-MPQ[06!+W
M1$7K0;;/^'O&VT:SB=.SVOQY>NX$&F<+%Y.M.0VV&T: 6'VC%T$X(@K8_<GK
M>@Q,UX+\1[!A<)KV5U+'NX;6^7X%%: HR14<_P 8($P0%P=7JZ"DHN+U-"6@
M\-O\4XU_P[L/BC08T37X>3Q\Z%BV$0VX<=Z>1NF5@0B$5<<(K"G2_1/A08^H
M^ _%NL8K)0HVL0&IFP8U,3LKS".<9,9QOB^RWR*[+#A*I*VSP%>BJET2@V^W
M^&O&6^XW%XG;M<BY.#A [6($^XTY&9[:-*T#K)@YVR$1$V^7$K)R1;4&7+\6
M>/IF0UO*NZ]";GZ@/;UEZ.W\M\BT@\$:;1E0'M(GHV2*"?90:[6_!WB74,ED
MLOKFHXZ#.RS;L>:2-=UOY:01$ZPTTZIMLLN*2\VF1$"^*4'E@? OB#68&9QF
M$U" Q!V!E8F7:<$Y/>BE_P#8<GS,@:1;*+8*(BJ(J(BI0;/"^*/'VNQ'X.'P
M4>/$E8MO7Y3:JX]W<4QW>$8U=,U(4[SB=>MEM?TH/.9X@\;3](A^.)>NQ7-*
MQR@6/Q7O%(SC1$8NLNB2.@XBD7ZP30_<77JM!L<+X^TW7=5/2,%AXT#4W&78
MSV+9!1;<;DBH.]Q;\C)Q%7F9$I%\5H-'L7@WQ1MF,PF'V'6(LW'ZY&"!A&U5
MUHX\)H!;&/W&G!,V>(HBMF2B5NJ+0?6S>$/%&XR<3+V74\=.>P<88&+3M*RV
MU!#[D56V2 '& _09<$@'KQ1+K093/B+QQ'R&NY5C7HK>1U2$6*P$D>YSCP";
M)I8_W_UC?$B1!=Y(EU5.JT&EQ'TZ^%<"<YS#Z="B'DHTR!-4%>7G#R0=N3'&
M[B\&C%53MA81NO%$O0;;;/#?C/><1BL%M>N1<CC,&",X<%5QEV*RC:,JTV\R
M8.(V0(@F'/B=DY(MDH,;.>"O$.R/X:3F=.QDAS7V6XF)$6>PTW$8-'&XQMLJ
M .L :<A9=$@1;J@]5H+"LEK6Z>EOA:@_:!0*!0:S8L["UC 979,GS_#</#D9
M&9VDY.=B(T3SG$>ERXBMDO05[HGGS5=YR4?$KB,WK4R?C?QS$+L<)(+,_&B@
M*X_'>!QULD;1QLC$B$D0D6UJ"38'RGXWVE[Y?6MNPV7D6?7LP<A'D'QBV[I(
M@&J\01452]+*B^BT&@SWU!>)<)IN:WEC986<P> =9C9%,))8GOB_)=[338@V
MXEU-;J/7W()*E[4&\E>6O&$$<.<W<L)&#8!1S!D[D8P),;)5%#94C3F*DG%"
M3IRZ7O08F\>5]:U&!FFXDW'97;\/'.46JKE(<&:0-@#ID:R3%&@%MP7%</VV
M5/M2@S<GY2\>:_.:P^S;3A\)G3B_/'BY^1BLR 9XH2DHDXG3ULOZ5E5+HBT'
M[JOD#'[7M&X:O#BNM/:A)A1I$HR F9/XA#;FMFUQ55X\'$3K_10?N)\I>-\_
MF6==P>VX?)9Z0RLF/C8<^._(<9&ZD0@!JJV054D3JB)>@^4\K^,RQN1S(;AA
M3Q.'%HLM.#(QC8B_,J0M(\:&J 3B@2 )>Y52R)0:?8?._BW68VIY#(;##<Q&
MZ2G(>$RL:0R[!)604G'#>YH(M@2(V1)?B9(*I02,?(6C'M?[BCL>,7<T#N+@
M$F,K/0>/<_Q/+G?A[^-K\?=Z4$7PWG#2BU2#LN[Y3%:<].64K>/G9B"^JM19
MAP^X#K+B@XBD"<N%^"KQ+JBT%C0YL7(1F9L%YN3"DM@]&DLF+K3K+HH0&!BJ
MH0DBW146RI0>] H% H% H% H% H% H% H% H% H% H% H.>OK*C,SO%.+@2>
M:Q9>SX.-)!LS:4F7I/ QY J*ET5?1:#*7Z,?IUOTU>2B?8F9S'^F4'Y_<Q^G
M7_5>3_;.7_TR@?W,?IV_U7D_VSE_],H,$?H?^GD50APD]"3JBIEIZ*G_ .-6
M75(Q\K]'?TW8/'2LOEX,R#BH+1R9LV1FY[3+++0\C,S)]$041+JJTZI%0>(O
MI\T?RAY#QGDW4\)/UKPSJLI'M<?FS)CV2V.?&>0TEH,EPOEX@$V*#Q%#.UE6
MZJC<S([!\GXUG):3EP,7$DM,*Y$D1F%DR6745.)M"*B7)/BHDBVK!$N+#F9?
M(2 6>"S$:>6%W'C)R09BO(FP-M.9*E[J5O1;%>LF+7SL-/BY%R 4-U#1U6P/
M@5B1%]>ET3UZ]>E$)- PF'F,MQ<^Y(BR6S<B1P$5_5*:=^X72Q(BJ@^[IZK\
M4HE=_A7PK.UK)!M^;?<CS@0VXD2S:J39HEG%(2+BA"JHH?>_-\8F4Q"_JADA
MOE"&,S49*(#JNM&#K1LV10(5^\1*HJ(? E%;UP/OU.KM)G7,3$QCE_+Q=+[=
M?IWHX.?(H9#)NQE>%'PE*H-J2<G%0/9R4[C:WHEUZV]*^7UK?<F,Z]3U]IK2
M)QIAAIBL@,A&SC*-E1>9=&U2ZV555;(BVJO]&^>#;]6N.+?QL1 E@W#G,OAD
MGD5ADUN*B31< 2Z]$157T_HKH[>S2V*WB>J=(^$*=MVU=:S&(7!XY\=IJ@ED
MIIE^+/AVW&1-#; 45?BB)>_1?R5[W[+]FGM(Z[S\\Z8Y1_%YSO\ O_K_ "Q^
MF%A5ZER%!_4JP;$'"YR-\PS*A$\A2FK-L\%X*@F:*A<[IR +$*^Z]J\Y]YB8
MBMHSEZ[_ ->F)M>DXQ.-.?IXSZE!CB\M.26U(8 Y+;*2%41LH<K&(D:DB*I<
MO^<J+\:\Q-)G,8X:O73NTKB8G3.&##P^320?<ANM$TA<A).)W;L1(%UNI(B?
M#TK7&W;/!MOO4QQA,L?H\7;9"8G"L.CLQ6?-'31@#1P4><0B/DBV1?:J>GQO
M>K].W^M/36/F\W,OWL[$=5YCHX>/DZB\;:!"\>X,L7%?<D.OGWY)FOM[BIU0
M43I9/2_JM>P[+M([>G3$YR\)]P[ZW=;G5,8QP;W/:QKFTQFH>RX>#F8;+B/L
MQ\E%:F- ZB**&(O"2(2(JIR3KUJ^YC1CXE\5BEAT;7D^/3$PD_\ RJ#U'Q=X
MS&_#3,$-_6V+AI_^50>H^./'H*BAJ>&&R63CCHJ=/_[=!2GFW7=?P?DWP2N$
MQ,+&D]M9HZ4.,S'(D&(:HBJV(JJ=?2@Z2H% H% H% H% H% H% H% H% H%
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M+!<<=;:)YE;@IHT8*2(J_=*X_DH-[$B1H$9J'#:"/#CM@S'CL@C;3338\0
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M=_\ TU&?F5.R\^''E;AZ\_APM>_3UJY]:O1U\L9<[Z-NOHYYPV5;FDH% H%
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M<G+RS-')1HG>= 7FT54&XW$53UH.G8^PX&9++'P\I#D3Q4D**S(:<>16_O7
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M/V)7G=CY[6W.4Z1ZH_C.7JNX_P!.E=KG&MO\T_PC$>],:N*!0*!0*#0[-N.
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M"IMO\6^0]@W@-FPGD_(Z_KXG$(M:CQD<CJ,?CW1Y]X/\;9;^WI?XU(@O@/\
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MF.F-=-;<(1;S]G<$QJ+6+.)-:V')SU_']GB$XY$^5$2 6^U((3Y\Q #%!!;
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M7^A*[_VWZD;T5QF/AYY>7^[QL3VTVBV)X1'CY8=5U[)X$H% H% H% H% H%
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M"@H?ZL_Y=X'^+M=_;PH+XH% H% H% H% H% H% H% H% H% H% H% H% H%
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MNVB7=&R+>R6"&L[?F]HTS7]VS>63/[$[X[\J/?C,F,V"2$A3R;CF48@X"*
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MI-DHEVG>*(2(O03$A%,8%DU J'S#BY92<5)@IV@E]R++<LJM%9.0]U+<;]+
MI+^2I%52<&XGRLAUYIH)#8F8'<'$6]E7@MOM3_\ 90375?'47:W6I$L":A-*
MA29K#O,)*IT5L5Z<2%43X>E!=&:8DMX&6SC'?EI+<8ACO*J^S@/K=$5;HB5
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M!0*"A_/?\Q_!/\6.?L#U!?% H% H% H% H% H% H% H% H% H% H% H% H%
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ME]OMCP505%$C1?L4*[T3P5Y PFX8+9=G_!22+N^Q[AE(^,<=6*+6<PP1&4C
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M#!&XS(\&P3X)^7[55>JK7T':VJ[5(I6,1#S-[S>9F>,LBMK H% H% H% H%
MH% H% H% H% H% H,/)XK&YF(>/RT-B? <LKD66T#[)**W2X.(HK94NG2@R6
MF@9 6FT06P1! !1!$1%+(B(G1$2@^Z!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!01'R3K>V[;JTC :;M"Z?DYI(T_G6HJ3)+40D5'1CHKK7
M;=+H@N\KAU4?=94F!]^.?'.J>*]4AZ=IT3Y7%1;FXX:H<F5)-$[DB0Y9%<=<
M5/<5K(EA%!%!%($KH/AYYMALG7B0&@2YF2V1$2@A^<\B8N'!C/85 RTN8_\
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MH*+R3JOV+UH(WKGC;%Z].*83Y9#CR^4&6 F3%RNG ENO1.GY?6@FM H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H-#N>)7-ZW.QR"X9.!R%ME4$R4%Y(B7_-
M0<];#%#'M1U@BC,ALR$P;)3[2 EE%1+_ !9?:*]:D:*-/E_-LOM<>Y'7F"%]
MVR?>OROZI>Z^M2+'\?Y/#;%M4599NLY9LW9$-6406R0A13:3](13C>RWO^3X
MP+YJ!"=YW69K3L.%CH*RYLE%=N75L6VU7ERMU3HE[_T4%89K>LI/S4B8DN3C
MI#3308^&)6; B#]<2@O&W)>G(KJ(_EJ1F8[R+N.0)\8^1CI\BG?4'6A3N,HB
M<D54N1"G6RHEUZ?GH+#T/:LGGG,E&RS8"]%<$H[C(D@$PXEQ5%LB=45%2_N]
M?LJ!-J!08S,^'(<-IB0TZZT7!UL'!(@.W+B2(JV6W6U!DT"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@HG;=#RY[3E,N$8RQ[SH2Q>;40:[5E5]3M
MZ$GV*BJJ=?6I$/@XN"D]/D2DS$)WBQP:%VZB263BB^B^[[]K6^V@O?4-+B8,
M5R4QIIS/OBB/R0!!$42Z)P&R<55+<_M6H$OH(GO^+&9A3GH:]S&"Y(%GD@ Z
MB(EP4E^ZO3VK_P "T'-^4>#)//Y%D2 ?;R A7VA]W[W6]E^-2/K%X^3*$CAD
MV$I$Y-]XD 2"ZVXWZ*JEZ5(O[Q2WLH:\2[$/%#-"@J=N\K5K*KG1%O=+)RZV
MK$3R@IW8=MW*/L$YMLFHN/CJ3#4,R1%<;LJHX2*OY?T5NO2@J]C--L1FDC$<
M>2V#@.N@9-F^XXJD1+;HBWLO+UZ(E2)+B<QE\@RCT'.RUS<MMR/(:,R).0BG
M BYE?BJCQ3BM^OI07MJY90\%"7,MDUDD:%'Q.W)5MZJ@^B_D7K]O6H&WH% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H%!\.M \V;3B<FW!4#'[1)+*E!IL
M=I^NXF>>3QD$(LPTXD;=T2W%!M:]O1/^7UH-Y0*#RD,-RF'([R7:=$FW$]+B
M267K057G_&[N%QO+5P=G2B18PLN*/LC)R-/A9215MR+KZ=/C0?FC:++E$N0V
M-DF8HE[<7)9 24["2%R&UD1;6XHEENGVT%M4"@JGRW$/%M1LMCFKR,@[\I+#
MBJHXICQ!16_L/\WWOZ*D4P]B)I T^S%<5H^0FHKS$2;54*Z].G2]Z#?8W3<C
MG'HT''/''R16-6#!0:%L5LKR'=$)4^]_Q4'26(B/0,9$A2'UE/QV0;=D%>[A
MBEE);_;4#-H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H,+*8G'YF-\GDF!D1^2&@EZB8]1(22RB2?!4H*WVKQID9DP'=?..UCAM_F+
MG($0C%>ZY[>/N*R7Z];_ )+4$VU36(6M8X8\?F4AQ$.2Z\XKQJXJ)R1"6W1%
M3[*#?T"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&%ELOC,% ?RN9FQ
M\=BXP\Y4Z:\$:.T-T1%-QQ4$4NJ)U6@^3S6):G1<6[.C-Y2<VX]!@D\"2'VF
M>/<-IM5Y&(<AY$**B72_K09] H% H%!AQLKC9DR9CHLQA[(XY6TR$-IT#?CJ
M^'<;1X!52#F/N'DB73JE!F4&'/RN-Q:Q4R4QB&LU\(</YET&>]*=OP9;YJG-
MPK+Q >JVH,#7MNUW:W<PS@)PS7<!D'<-EQ$' [&0CB!.,KW!'DHH8^X;CU]:
M#=T"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@IOZK&WWOI]WAJ,P<
MIXXK"#'; G"-%F,7'B"*2W2][?"@HW8\'Y/T??X>D:[$E9#(Z?J6W.>,=B42
MD'(A3F8OR4)Q3YBLJ"3;C(<NC@=E53KU#22\X(:ULY^&]@W'*X@-)RCV^R<V
M]DS<C;*B,?(N-%(%":R)N=Y)(1R1OMHBHGMO06MJ>N[7K7E-[2]1V?,Q8&R:
M F?D9+.F_GFV=C&>S'^;0)9H*.FVX7=9 P$K)[4XI0>'G&'Y)TOQQ"<VO?\
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MU?9=1#!WM\.YS1%YW6H$\H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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%% H/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>tb_fig02milestones-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_fig02milestones-4c.jpg
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M Q$!_\0 DP !  (# 0$!              4& P0' @$( 0$! 0$
M        ! $"$   !@$" P0(!0,$ @$# P4  0(#! 4&$1(A$P>3%546,4%1
MT2*2%%3A,M)3E&$C"$(S)!=Q@5*10S2AL6)S@B5%)A$!   & P$! 0$
M      &1 E(#%%&A$Z)3!$'_V@ , P$  A$#$0 _ /W\
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MMI#["S(TF;;J24DS)1$9:D?H,!G
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M1S4[3+^X@MIJUT] "\@
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M1&K0O1J WP
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M&Z68UAN5-16K:BB(@+."^N2TM+&J2<WK;:,MQ<=NWA[0'0P
M
M
M               $?%HJ2%,<L(59$C3WC4;TIEAMMY9K/<K<M*24>I\3U,!(
M
M
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M(&O7?$[DLO&I'RI#WHL@:]=\7WN6R\9D?*D9[T60->N^*:$BT
M
M
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MLDJ+_P!D PM95CS^32,-:L&UY/$B(LI-86[FHANK-M#I\--IJ+3T@)@
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M;:4<W#*);JDD1;E]YVB=RM/2>B=./J(!UP
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M2 XUT[=LL+?E_P"/E6V\S6Y 4'(<+>W&KZ;&K8B<N64N$C:@XCR7TM$I6_\
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M5IQG$K6,Q'I&840FY,>RI(LPFW'S:YQ):=D;VU)4E1Z:+U(]"#L0
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MN!FD^):^@^(#!>X3B632ZV?D%/&LIU.OFU4F2V3CL5S5)FME1\4*/:6JD\3
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M[0$U!IZJMDSYE?"9BRK1XI5D\RVE"Y#Z6T,DXZ9$1J42&T(U/U)(@&Z
M
M
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MFY1Q&1YH@?L2>Q4&I5S"9N4<1D^^9X/[$KL5#-6KF$S<HXC)-"1:
M
M
M
M
M                                                         .*5
M747J5?6V?5D(\9@EAEF54T]8*F-MR%N1&I3:EJ)?]LCYR4'H2N)&9>H!,?\
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MN+(K'9-?=*7\$BVA*;<EP$)TT-;,9]E]7'T*,O4 Z2
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M4Z'P,@'Z?0:E(2I2=JC(C-)Z'H?LU(!]
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MO<VIC89)3M;)6W4]3#K@
M                                              AKS$\<R236S+VN
M:G2J9\IE4Z[J:HTDN!.MZ&6U9%PW>G34O09@)D
M                                 &"7#B6$9R%/CMRH;Q;7H[Z$N-+3
M[%)41D9?^0'V+%C08[<2(TEF,T6UII!:)2GV$0#,
M
M
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M<,]Z;(.M>J^I,B18
M
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M(MBT]DM=':FSZYLS4ZPQ(/1M3FA:)WZ?"1GJ9<=- $P
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MFHJ"9.VL(T I*^5'^J>;9YCA_P"E&\RW'_0@&Z
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M$6U?N:&GKK>R;W-R9EO6*?4_+6R39-H0X3Y(0E*SVI;+AQ =8
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M/3^POEK=M)%#7N//NJ-;CJ383RW%J5J:E+1M6HS])GJ Z.
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MA#3:34HR0E)&HSX@+$                   "I7'37$+[(V\NLHKYY(S&.
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M@
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MHU*5Z3,]3X@-D
M
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M1(L
M
M
M
M
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MEI+5)D9<# :9=0<,.=D=85NS]?B+*9.2L:+W067&C>0MWX>!*;2:T^TB/3T
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MJM2ST+7@23W::IW!?
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M+(28%]7G+*5';>1);+GS'GTFEQO@9;7"]1<0'2P
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MVM:FE1\>!:@/T6
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MYIN!%95(<*.PT:7=S:FM."=B$_#KQ,.M
M                          ",AX[C]=;6%_7U,.)>V_**ULV([34N64=.
MQKGO)22W-B?A1O,]I>@!)@
M                                                 QOL,2F7(TEI
M#T=U)H=:<22T+2HM#)23U(R,O48!'CL1641HK2&8[1;6VFTDA"4EZ")):$1
M,@
M
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M(U8WU3/+[_C$[M?P#8A93(U8WU3/+[_C$[M?P#8A93(U8WU3/+[_ (Q.[7\
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M_ -B%E,C5C?5,\OO^,3NU_ -B%E,C5C?5,\OO^,3NU_ -B%E,C5C?5,\OO\
MC$[M?P#8A93(U8WU3/+[_C$[M?P#8A93(U8WU3/+[_C$[M?P#8A93(U8WU3/
M+[_C$[M?P#8A93(U8WU3/+[_ (Q.[7\ V(64R-6-]4SR^_XQ.[7\ V(64R-6
M-]4SR^_XQ.[7\ V(64R-6-]4SR^_XQ.[7\ V(64R-6-]4SR^_P",3NU_ -B%
ME,C5C?5,\OO^,3NU_ -B%E,C5C?5,\OO^,3NU_ -B%E,C5C?5,\OO^,3NU_
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MJ3(D6
M
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M%>/0/++S=K2T<^M6XS81;.;%7-?7+92DD.QUMQ7"29:['%;U<3(!VT
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MAR_!CAR<&JHSNUIZ-]$U)BJ^GT-,PK"4;L99*2O3@A.U1:@*]F^9YA5(ZM9
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M?)YN3X!(7:7";JQJ[R[JW9)/')6EJ'9/MQT+<7HXK1DFS2ITMZD;5'Z0'6
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M5IM41 /T&   "BO=&^F[[MN^JDVNWZU.W2FY4MKZM:T[3-XD/))1[3V\?5P
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MT)_\$ D0
M
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M[='N#QQW]'OE_/M[[UM_!G.V;&>6._IU[9+(S@F1(L
M
M
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MP,
M
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M24J-"R)2B(!W
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M.=0YF6M'4N54;';5%;#^H4?/E1W84>8W)4V9%RR=2^2D(/XMFAJT,]""_
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MCUU#]"@
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M536%+<7!6@EJ4VZ>B%);V::J2D.X@
M                        \<IK?S-B=^NN[0M=3(BUU_\ !: /8
M
M                   ^:E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0
M#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :
ME[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O
M: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0
M#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :
ME[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O
M: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0
M#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :
ME[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0#4O: :E[0$*K
M$Z):E+5',U*,S,^8OTG_ /W"R']>6'^HH_Q8H_YW%\\HT/VQ]HY^H-S+RS1P
M\=Q/*-#]L?:.?J#<R\FCAX[B>4:'[8^T<_4&YEY-'#QW$\HT/VQ]HY^H-S+R
M:.'CN)Y1H?MC[1S]0;F7DT</'<3RC0_;'VCGZ@W,O)HX>.XGE&A^V/M'/U!N
M9>31P\=Q/*-#]L?:.?J#<R\FCAX[B>4:'[8^T<_4&YEY-'#QW$\HT/VQ]HY^
MH-S+R:.'CN)Y1H?MC[1S]0;F7DT</'<3RC0_;'VCGZ@W,O)HX>.XGE&A^V/M
M'/U!N9>31P\=Q/*-#]L?:.?J#<R\FCAX[B>4:'[8^T<_4&YEY-'#QW$\HT/V
MQ]HY^H-S+R:.'CN)Y1H?MC[1S]0;F7DT</'<3RC0_;'VCGZ@W,O)HX>.XGE&
MA^V/M'/U!N9>31P\=Q/*-#]L?:.?J#<R\FCAX[B>4:'[8^T<_4&YEY-'#QW$
M\HT/VQ]HY^H-S+R:.'CN)Y1H?MC[1S]0;F7DT</'<3RC0_;'VCGZ@W,O)HX>
M.XGE&A^V/M'/U!N9>31P\=Q/*-#]L?:.?J#<R\FCAX[B>4:'[8^T<_4&YEY-
M'#QW$\HT/VQ]HY^H-S+R:.'CN)Y1H?MC[1S]0;F7DT</'<3RC0_;'VCGZ@W,
MO)HX>.XGE&A^V/M'/U!N9>31P\=Q/*-#]L?:.?J#<R\FCAX[B>4:'[8^T<_4
M&YEY-'#QW$\HT/VQ]HY^H-S+R:.'CN)Y1H?MC[1S]0;F7DT</'<3RC0_;'VC
MGZ@W,O)HX>.XGE&A^V/M'/U!N9>31P\=Q/*-#]L?:.?J#<R\FCAX[B>4:'[8
M^T<_4&YEY-'#QW$\HT/VQ]HY^H-S+R:.'CN)Y1H?MC[1S]0;F7DT</'<3RC0
M_;'VCGZ@W,O)HX>.XGE&A^V/M'/U!N9>31P\=Q/*-#]L?:.?J#<R\FCAX[B>
M4:'[8^T<_4&YEY-'#QW$\HT/VQ]HY^H-S+R:.'CN)Y1H?MC[1S]0;F7DT</'
M<3RC0_;'VCGZ@W,O)HX>.XGE&A^V/M'/U!N9>31P\=Q/*-#]L?:.?J#<R\FC
MAX[B>4:'[8^T<_4&YEY-'#QW$\HT/VQ]HY^H-S+R:.'CN)Y1H?MC[1S]0;F7
MDT</'<3RC0_;'VCGZ@W,O)HX>.XGE&A^V/M'/U!N9>31P\=Q/*-#]L?:.?J#
M<R\FCAX[B>4:'[8^T<_4&YEY-'#QW$\HT/VQ]HY^H-S+R:.'CN)Y1H?MC[1S
M]0;F7DT</'<3RC0_;'VCGZ@W,O)HX>.XGE&A^V/M'/U!N9>31P\=Q/*-#]L?
M:.?J#<R\FCAX[B>4:'[8^T<_4&YEY-'#QW$\HT/VQ]HY^H-S+R:.'CN)Y1H?
MMC[1S]0;F7DT</'<3RC0_;'VCGZ@W,O)HX>.XGE&A^V/M'/U!N9>31P\=Q/*
M-#]L?:.?J#<R\FCAX[B>4:'[8^T<_4&YEY-'#QW$\HT/VQ]HY^H-S+R:.'CN
M)Y1H?MC[1S]0;F7DT</'<3RC0_;'VCGZ@W,O)HX>.XGE&A^V/M'/U!N9>31P
M\=Q/*-#]L?:.?J#<R\FCAX[B>4:'[8^T<_4&YEY-'#QW$\HT/VQ]HY^H-S+R
M:.'CN)Y1H?MC[1S]0;F7DT</'<3RC0_;'VCGZ@W,O)HX>.XGE&A^V/M'/U!N
M9>31P\=Q/*-#]L?:.?J#<R\FCAX[B>4:'[8^T<_4&YEY-'#QW$\HT/VQ]HY^
MH-S+R:.'CN)Y1H?MC[1S]0;F7DT</'<3RC0_;'VCGZ@W,O)HX>.XGE&A^V/M
M'/U!N9>31P\=Q/*-#]L?:.?J#<R\FCAX[B>4:'[8^T<_4&YEY-'#QW$\HT/V
MQ]HY^H-S+R:.'CN)Y1H?MC[1S]0;F7DT</'<3RC0_;'VCGZ@W,O)HX>.XGE&
MA^V/M'/U!N9>31P\=Q/*-#]L?:.?J#<R\FCAX[B>4:'[8^T<_4&YEY-'#QW$
M\HT/VQ]HY^H-S+R:.'CN)Y1H?MC[1S]0;F7DT</'<3RC0_;'VCGZ@W,O)HX>
M.XGE&A^V/M'/U!N9>31P\=Q/*-#]L?:.?J#<R\FCAX[B>4:'[8^T<_4&YEY-
M'#QW$\HT/VQ]HY^H-S+R:.'CN)Y1H?MC[1S]0;F7DT</'<3RC0_;'VCGZ@W,
MO)HX>.XGE&A^V/M'/U!N9>31P\=Q/*-#]L?:.?J#<R\FCAX[B>4:'[8^T<_4
M&YEY-'#QW$\HT/VQ]HY^H-S+R:.'CN)Y1H?MC[1S]0;F7DT</'<3RC0_;'VC
MGZ@W,O)HX>.XGE&A^V/M'/U!N9>31P\=Q/*-#]L?:.?J#<R\FCAX[B>4:'[8
M^T<_4&YEY-'#QW$\HT/VQ]HY^H-S+R:.'CN)Y1H?MC[1S]0;F7DT</'<63RO
M2_L*[1?ZASM9.76GBX[BF!*L
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M\)[C(_0 E &%N7%=D/1&GVURHQ(.0RE1&MLG2,T;TD>I;B(]-?2 S
M Q*DQT2&HBW4)E/)6XTR:B):T-&DEJ)/I,DFM.I^K4O: R@*U39O47F79)A4
M1F4W<8LW >L5OLFTPMNT0ZMA3"S/^X7]E9*,BX&6@"R@ ",H;@[VO^O.OFUA
M\Z1'^ELFBCR/^,\MGF;"4KX'-F]M6OQ(,CX:@),   &A>6T>@IK"\E-//Q:V
M,[,>9BMF\^MMA!K43;:>*E&1<$EZ0&'&,A@9;C5/E543A5=Y"C6<'G)V._3S
M&DO-[TD9Z*VK+4M> "5  %:PK.:?.XEI,IFY+2*BTF4<UN8UR'$S*Y?+>(DZ
MG\.OH/U@+*      ,4>2Q+CM2XKB7XSR$NLO-F2T+0LM4J2HN!D9<2,O2 T<
M=N3R&EA71U\VI.8WS.[K1DHTUGB9;7FB4K:KAZ-Q@),          0^5Y) P
M[&;?*[1M]VLI8CT^:B*WSG^1&0;CAH1J6IDDC/T@-BKN8-M1PLA86;=9.B-3
MVG']&S2P\V3I&OCHG1)\>/ !N,/LR66Y,=Q+L=Y*7&G4&2D*0LM4J29<#(R/
M4@&M;V]=0UDNYMGRCUL)M3TEXTJ6:4)]B4$I2E'Z$I21J4? B,P%*H.M&$W<
M3(I$M<S'9&*,%-OX&00WJR7&A*0I:))M.EJII9(5M4C7T:'H? !M1.J^)OPK
M67*^MKGZ:-&GS*Z9#>;G'$L-2BNM1TI4MPGEI4VA*"-7,2:#22BT 9<"ZFXY
MU#5:Q*MJ=77E$ZTS=4-S$<K[*(<A!N,*<8=+78Z@C4VM)FE1$>A\# ;^*9YC
M.:RKZ+C<OZWRW8*I[-Y*3)HIC;:'5H;4?YR3S"2:BX;M2 60  5S-LUJ<"J&
M;RZ:DN0'IL.N-41KG&V]8R$1F5.<4DE!N.(2:C/UD L8
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MU:Q%JUD3ZBCMJUVLC3);LYV.5C51Y$@D./K6OEJ?-:B3NVI5N(M/0 [
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M * /#<2*TV;+3#:&34;AMI0DD[U'N-6A%IJ9\=0'MMIIHC)I"4$?I))$7_[
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MT,!:^GF=9'E63YE06T&$F!BDJ-!8N:YQY;$YV5%:F'L):=J>4EU+;B2<49+
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MK1!:DDM# =Q
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M %F
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*>*_IUZ9K.X/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>tb_fig18tumor-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_fig18tumor-4c.jpg
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M;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4
M !#\X1^)R+?)>"\T8C0'6'?K_^X #D%D;V)E &3      ?_; (0 ! ,# P,#
M! ,#! 8$ P0&!P4$! 4'" 8&!P8&" H("0D)"0@*"@P,# P,"@P,#0T,#!$1
M$1$1%!04%!04%!04% $$!04(!P@/"@H/% X.#A04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@!A@.T P$1
M  (1 0,1 ?_$ )L  0 " P$! 0             %!@,$!P$"" $! 0$! 0$
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M-3S"MMI:A-@XIRA9-_(2F8(.( 6"KLH/=*^I&CM86"%J*UW(&8<Y\X(,3_\
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MRWG63><MLAMHHB$ D(;Q'.RXJ+E7I%:"*L'^R>E[D+-UNA-P+-=+=IV79X:
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M;QQX1HUDWF#KC1A@HH:*G:%$5%4-;3?K;&O&NM1:4N-N.WQ;<U9I%JWHN-7
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MW*.V>9$4''(HD^(DB=E-N!*B*'0*!05_75^E:5T3J/5$)EN3+LELF7)F,\1
MVZ4-@WD B%%5$+)ABB;*#D>G?]D&6';8'J-!8L\2^:0MVN+5<8+AOMDW<'6(
MQ6\FB'>+(%Z0T+:AB+J%_*J8*%WC>N'IW)G,VP;@XW/)B?+F,/-$TL-JSOG&
MFK(SX(*L.MF#F7-EPS?@5"4-*[>ME@?]+M8^H>BR&Z.:4@O3'(4E#80C"&$]
ME"P3%!>8<;<$D]A;<"140,;_ /L'Z?6R#.>O$IT)UF@<_>HT-AV8K.X"*Y,
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MOI)IG66H2U-<Y5Q8N3EG?TX]R4I8X';)CB.OM=D<PJXHIB8$A)AL5*")N/\
MK[Z=W&/=H"L2HUHO5KM]@FVMA].4\LM#;C<5@&W!/+D1PB$T[:'@0DA)C0;"
M>AVC68>HK9;Y-SMUIU+,8NDV#"FFRVU-8)HC=9+!317U9'?B1D)[=FU:#19_
MUQ],1MMGLLR+*N-FL0W$+;!FR%=!L;R,D)8YT1'<K@RW!(-YE7 ,450%4"U6
MKT\MEIT.WH%NXW"5:6F AC*F.MR):QF\$%HR-I0,,@[LA-M<P8H6;%:"M!_K
M]H.-;AM=N>NENB#9H.G$2'/=:/D;7-.?'[>TLPN..#CC@K9*"IEV4%4G?Z^7
MFTWBR.>G6HALEEL39+ CSHL:ZKS,FZ.W*23J2F2)057,&MRXV8%MS;$6@ZGH
M/T\L/IQ;Y%GTT<D+*Y(?E1+:^[O6(22G2?<:C)E11;5PR)!(BPQV+ALH+90*
M#A?I'KJ]WW1NO9.I+X3UTAZKU%8;$XZK+3HMP")(S#:"(H1B(J6U%)<,5QH.
M7:9]8/4==/Z3-W4;EUDZL].[UJ6\F;<;?6>?:F<T>X"K;8Y6GS7<[MP5#./9
M_F10MGI+ZDZ^U'ZA>FUGOTZ0MMO7IHQJ6Y,.<J0S+HX[&%9?]$<P(2.G@WV1
M3\NR@_3- H% H*/>O2?2>H-37G55UYIZ??M/N:1N3"/D$8[2\9F3: *(J%F<
M-4-"Q3,M! 6S_7K0MK",C<JZOOQ+E!O+4F1,5Q[G+9;2M,=5+(F(C&+)EPVT
M'D/_ %V]/8$5B-&6>+D)NQMVV4LG,]$/2ZNK;W&54%1#;1]T2S(J&A*A(M!.
M:)](-%^GUQ8N6F&7XSD>SQ]/-LF\3C7)17W90JJ%M)TG7W3-Q5Q526@UIGHK
MHN?J&=J61SBSKA.*[O-)(5&$N2VXK4$D R[#;C&0-[<J*N;#,B*@1]H_UY].
M+',M$VW1Y39V4;>L5I7\S9RK/"=MT*6X*CVGV8[Q-B70O94D4A14#%;?]=?3
MVU!;&XA7%&K2=A.(!RU),=*O//V]"[.U -\U)/YO;T4&.'_KAZ?0HTZ,,B[O
MK<7K9)ER)5P<D2#=LDQZ=$(G74(R4'7CVD2JHX(O102ET]"]!W;73_J/*;EI
MJR1)AR2EA(5$%N%&<AK&$5%<(\AIQ1DM?A<V*NU$H/;-Z(:0L<+2ENC2;D]#
MT1..XZ:;DRU=6-G9..,?,HYC9!MP@ 3551%_$M!-6'TWTWIV_P"HM40$D+?M
M4@RU=YINX.&W%5Y64Q;0.TVCQ +A8N94$<V I04^U_ZV^G5IR''>NSLINXVB
M\MRW[@ZZ\,^P-NM1G<R]*JV\0.XHN=.G;MH)W6?HMH;7U_+46I&9+\IZWQ[-
M-C@^0195NBSAN(QWF\%10)\!4\,%(4RJN5510CO_ ,!T1YS>[\<BYO7#4,>5
M!NG,R^:9<AS9G.NL*T^#@*WG5002%<&UR=&& 8XG^N_IY;K=?++;O,(ECU'9
M8VGKO;&YAE'=8A1AA-/_ -1"(9","+2N"6!"FU%7;0;3WH3HE^4],-VX\P_,
M9N+A)*5,9$>T'8Q7\/1RAD"^]=O30;FC?1O2.@KLW=],G-BFEKMUFE15?SQY
M3-F8Y:&Z\*CBKS3*(UG$DQ%$S(N%!T&@4$7J2PPM5:>NNF;F3HVV\Q'[?,6.
M>Z=W$ILFG$ TQ45427!4Z*#GK/\ KMZ:I;'+;,CR[@?E5OT]#GRY1G+AVNSO
M-R8;$8Q04;1MYH'L4'$S%,ZDB(E!F7T!]/'2@+.CR)X0)LZ[*$EU#21<+LKZ
MS)#Q" DJOI(,7 $A;(4%%# !P"5B^D^G&/3:3Z5/2KA+TM)@%:%63(0Y06\F
M]T+ .B X"#?8%512PZ55=M!\VCT@TC92U&U&64Y:]5M;N]VA]Y#A/.G$""Z_
MDRHJ.O,@(NKFRETX8[:#YM_H[HVSW;2]ZL@2;;-TG:!TW!6.^N5^SMY%"+*W
MB&K@B0(:%BA9L>UM6@F?3_0MC]-=)6_1>FUD+9;:KRQ>;=60]_[+[D@\SA;5
M[;A8?9LH+-0*"G^JFN"]-?3S4.O!@I<UL,59BP%=Y??()"BCO,CF5<%V+D6@
MY#?_ /:9ZUL78H&F&)CUKO.K+*JE<D!IP='6I;LX\A#'/#?-B3:!_(6"J2I0
M:9^O6HK]J27%9;"WZ=8O?I_$@#"=!+@K>K49DN#*5UIYL@47=V:-Y5RCV215
MS($YIW7VM)?^KVJ=?/W=3UA:HFK9,.ZDRP6!66;/"-BWDW:H(1P#:.WI7%:#
MZD>N5[L%AT[&F6X)-QNNBTU!!ODLC2'.NT>UO3W8B\NV2-N9&-]@:AG BR;0
M5%"9>]8;QIWT3T?ZLZ@ML:=%GL6:7JUZ$\X#<&!==T+TUH$:<-U&=Z)FRF&S
M-VNSC0:UW]?TT_KJ'HNZVAEQUQMPYR09B29;"I:95W!%81M%0B"*K0MN*!F1
M9AQ%-H:,'_8*]W*)I-(>FX)777,>1==+,G=P"/*M\6%%G.-..JSBS,1))-;H
MPRYFC+-EH*Y*_P!CKKI*W7V0-K<U L.Y:WD.G<)[4=68FD9T9HF&-Q$[0F$K
M!E#[0Y>V1]-!-ZY_V-EZ?N^KM.VFU1';C8['?[K!D.2]\B2=/P8LY0DM-BF5
M7!E8;I'-X&3MHB&BB$78_774$?64W3LX$N-\N9:3M\$#DM-6./)O-HG7)UYM
M0C[\ (8A9D,G,Q9<F5$*@D(7^T*3[MI=EC3.2SZC/23?,.S<LIDM:M3"83<J
MR@EN"AEG7>=L20AH/T-0*!05#U2UNOIMZ>ZAUVD)+EY#$*:L%7>7WR J(H[S
M(YEQQZ<JT%#;];M6+J*;I5-#K*OMIAQY]TBQ+BTK8LW,);D(FWY(, 0_^L#+
MY8)E<=%!S(*K05V9_M!):L+%\A:=9>!FP7?4EX8E2GK?(C+I^>Q!F6]67XV9
M)0J]^$\!S#AM0D6@VKC_ +/!"9U'.9TV;L*T,:G=MX.ODR^\YHQR*$L9 [HM
MPCW-)N%7,O9[2=I*#;A?[$2CGMPKIIQ(,6/JR3HR\WAN2<N#%E-I#*,1*VSO
M$23SB-@9MHV+H92),XK07#TB]4Y'JK;7K\U8GK78'@WMIF/. 9.Y)$B*\PZV
MF! \R<?%Q-H]M$0E(2H.D4"@4"@4"@_.T[_:/R4]1R+SIC+:[''U ZP[$F*^
M\\>FKTQ9G-X!, C0.E)!U"S%D$2QQV4$O+]?[E:KV-CO6E3ARH*6HKRBR$,W
M&K[>SLD1V"  2NB2BDE1/*2 N3#/C01\'_9=RXE=F8-BB2I,"X:?M\=6;F+L
M9S_)+H_:47F&F# MPZQG,F\P$A945%'%0K5R_P!CM3W_ $\5VM4)BS6MW1&J
M]13=U(SW%J;IVXI;%Y1XV#:_$A.-;QDL<>TG9[06JX_[!7K3R7.1*TA+FZ:T
M[ E3+I=T>Q?5J%:(UQ:D*@LHUEEN248:[:*B@9JB)V1#6UE_LE>]$VQ)]ST>
M"JS:Y]^D(MP1M'K=;KA"AB]%P9<SC)&:+C2.*!)E5"3H6@Z)HSU,/4^N=6:'
MN%L6SW/3;@FQ'?,B=EV]UPFV9S2H&Z-EU0).PXI-FBMN(A)0="H%!1_4[7TC
MT_MUADQ+<W<Y5_OULTVPT[(6*VV[=GMP#I&C;JJ@$J*HH.*IT4',]+?[/?Y1
M"LUPB:4D&T_86-37YB-(!]^+!??FQS<811!'Q9.$N?# EW@((J6*4&@7^UHC
MI.X7T]/LLW&%%MES"*]/0678M[LC]\CM-GNLQR!;8W+K8!V<R.X[O&@E(?\
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MAV32%NE19T"S18LV#'Y*%(8A(VXQ$X#9"VB@U_;'L_93CGY,')'7M*7Y^/\
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MGAIQS\F#DCKVDY^/_<^4YX:<<_)@Y(Z]I.?C_P!SY3GAIQS\F#DCKVDY^/\
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MMDN5I-H.$K@K["[2;:<<_)@Y(Z]I?9:7T&48(9:=@%$;"0RW'6V@K8M32SR
M$=U@@O%VG138:[2QIQS\F#DCKVE3XOHMZ>1=<2->[F0Y>I+[DAU2%T0(78G(
MK&,0$0.,C. BR8*FQ-NQ*<<_)@Y(Z]I6Q-'^GJ0H]M_QFW>71(Y0HL1;:VK+
M45PD,V0#=94;(A0B!$P541>E*<<_)@Y(Z]I2<&%IZV2)$NW0&XLN6N,I]F*0
M..+BJ]HD!%7:JEM]JJO2JTXY^3!R1U[2W^?C_P!SY3GAIQS\F#DCKVDY^/\
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M7P4IC?P5SMY]/0<EJ:(; ""])(YBJ?\ &5*DQC<B<K>6Q6'0H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H/#,0%3,D$!VD1+
M@B)]JK08%G04:1Y9+2,JJBCF<<N*=*8XX;*#,+C9MHZ!(31(A":*BBHJF**B
M^Z@\;>9=;WK3@FUM[8DBCLZ=J4'T)"8H0*A"28B2;45%]U!X1@&5#)!4ERCB
MN&*^Y*#YYAC!TMZ&5E<KRYDP!41"P+W+@J+MH,E H,(S(AM$^,ALF1)6R<0Q
M44,5RJ*KCABBI@J4'BSH2,I(62TC!8H+N<<BY=BX+CALPH,R$*BA(J**IBBI
MT8+08GYD2,N$F0VRJ[41PQ#9_P JE!FH% H,92&!?"*3H))<$G&V5)$<( 5$
M(D'I5$4AQ7[4H,E H% H% H% H% H% H% H% H%!XJHB*JK@B;55:#&W)CO"
M!LO X#N.[("0D+#IRJB[<,*#+0*!0*!0*!0*!0*!0>(0DF(JBHO0J;>B@]H%
M H% H% H%!\.O,L(*O."VAD+8*9(**9K@(ICTJJ[$2@^Z!0*##S<3FN1W[?/
M;O?<MG'>[K'+GR8XY<=F.&&-!Z4B. (Z3H"VI(VAJ2(.<BRH./O4EPP]]!EH
M% H% H% H%!B.3&::<?<> &6L=ZX1(@CATYE5<$PH/I76D=1A3%'R%3%O%,Z
M@*HBDB=."*J;:#Y"1'<;!UMT":=7!HQ)%$E]PJB[>B@RT"@4"@4"@4"@4"@4
M'(=;?X;,]4M+QRG2+?K.WRX\Q9;*35-R*3;S0P0R 3*MOJ2D^)+@(IF+M9%0
M.O4"@4"@4' [?"O0ZM]5-1VNVQ[J=CNSEPM,!UN6D]^6S8(>Y"*XC@-[HY".
M@0B*H1Y\=M!H/^I_J$]9&KK:+Y%F1GK9?KQ$DA9)@*16MN$Y'B/ _NB0U=.0
MR2 V)*F")_4 EH-V]^J6MK(=RB#(69)MMV?"(Z-H?)J=;VW+8:AF94T0@;F/
MB.[3$T;SXID-%"/L>JM3:>O#>EK$06N#=-1WZ5'ESX,R8S+<2^N;V"&Z'%HB
MC%OFB(A1<V8<0 DH/T=0*!0*!0?DZR>?M>H#4FWLRWA__3;GOF(8RPN)6J0Q
MNU<-QW%CRX")''!RX$@HC:HYTA^L:!0*!0*"G^JC,:3Z=:DB35=2+)A.1WBC
M*:/B#V#:DTH8DCB9L05-J%@M!R&!(UI(U'Z9P]6<\#FE]1S=/F^8.BS>&FK3
M-5J['E4A)IP%BBA.;$D&:)T)0;-NU9>-(V>YMQ3?MUHN.M=0PY&H'XLBXA;0
M<)YV&:L;2)EY] ;$D7(F9!14S"J!WRWE(.!%.82'+)EM7S%LF$)Q13,J-F1$
M"*O\I$JIT*M!LT"@4"@YQZJH?F/IXXUOMZWJN(I*QO=C)1)8FKB-[,FU$7/V
M<</;A051J)>KYZDW]OU T[,CZ>EZ;))F6<LB"K,.Y.N,-M!'450R;[3F':+H
M+LY4H.A>F%A#3^C(,=(Z1')I/7-V&BN*+!3W2D(R*.D1"C0F+>7V9:"X4"@4
M%?UVR<C1&I([31R'7K7-:;8:%7''#<CF(@(BBJJJJX(B)0?G:%Z8O6#3WIW?
MI$65+?N-TTD_?+(W ,6+:S9;7(CO/.QQ0U1Q3=RR'33;@ X=F@Z1Z;VS5MBN
MNJYEHLPP/3R[W]95IM5T><AR(4(8K#<R1'C(T\HMR)(//-1S5KISX#O,$#1]
M)W&X?H[%T5*LEQB7 +;=5F09-ND1P; WGU035P$%2=1Q% !4B)%Z*"TZ7MT]
M/1W2-L&WS?-8MGM<=8;3ZVR5'D,1FVRSF:BH;LD5#%4+W92Z*"$UK9-5E%T(
M-[+SJXPM8P)R/08QDL2 VV\"D\X*)FRH6!O;MM%S?A2@U+EI5_1A:@G6:-+O
M4-R5#D3VI0&;1D4IU\5,615V0$;FC?>(4(S$&FDV 5!(>H.K?4"-IW3UQT[:
M[E#O\^ 4^7;8\)+@TU)#E7#B/J($2.9#>1L4R">4L311$2"NRM7^K%OE3IK:
M7.XP'9-W1V(%J!#A6V)?HK,9Z,(LB3KJVYZ0Z &I*[ND)!545""+O6GKJ_\
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MCR#VCRIV4Z:#R3>[1#NL"QRIK3-WN@ON6Z$9(CKX14$GE;'I5 0Q4O=C0;]
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M6P/IP$1PQZ-E!S6!Z'ZRM5F@V^(W;W(C4&R1+W91GRHL>ZNP8$N#-<<?!DS
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MWK"R:KN3DVY _HXFC2WQ,<7%=<-HQ,AR)@X*H^3SF==Z3J+@.6@O5 H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M _?3ERN<6%CRV#P!^^G+E<XL+'EL'@#]].7*YQ86/+8/ '[Z<N5SBPL>6P>
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MKDRK@+9**B]-G;Q77W>RF)XO.$F&"8DM!8*!0*!0*!0*!0*!0*")_P 9LO\
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M%1P4)456R3WT%ZU+K6\Z)LVG .V.Z@NUV20R9/O,6\Q=B6Z1<5WV4%!%(8Q
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M>8&B(IH!.H#S:"N5&@)-N.-!?+;KZYV!84+7]T".3$F2DEQL >=-L-V( \;
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M4*F<T_F7K]]*%3.>U,RX+T[??2A4SGTYEQZ.GV4H5>*JJN*KBJ]*K5'E H%
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M/:4$7-E[6&&VI6%I^$Q50H% H% H% H% H->?/AVN#(N5P>&/!B-D](?/'*
M F*K@F*K]B(F*]";:DR1"*C:PT]-8M3\60XXM[WGED98TAN4Z+*X.&K#C8.
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M#Q()DJ9A11QK-)6L+-Z<Z8N6EK ^S>Y R;]=KC-O=U)I?Z(2KBZKA-M[$3*
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MW.3RCE$WV_P_[.:WF.'_ ,-W_P UFDU6OX25:0H% H% H% H-&]-N/6>>RU
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M$DWJZMS9W,'$;;!6;<S<G(+;I"B"BH.3M=&Q%7''93:AJO:I@JI[JZ,% H%
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M(NY+WA[MNW^.WII2"LL4K3]@FR')DVUQ)$MY$%U]U@#<-!%03$E157LDH_\
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M#:9D2((_Q55P3_FE1[BB&C:JF]5%) Q3,HHJ(JHG3@BKTTJ/$<;41-#%0/!
M)"11)5Z$14V+T>RE1]4"@4"@4&W;?_O-?Q7_ ,+7/_7_ )EU_P O^H66O/>@
MJ!_C+^*UZD/+G]O*(4"@Y6*JCD\)*O+IT-:2"O@_UE3D2B)DQ]NYW^3'+V:X
M?EVA<]"I>!T=94O^=+LD=-^CO_:@YRW6?';FW>3-CMQZ:ZX_ISR_:PUIDH%
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MRB. GE$MX*(;("6 A@*KCMK431B85/\ R77TB* L.SV25);Z/K;<QD*6H)#
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M H% H/E&VQ,G1 4=-$0W$%$(D3H15Z5PH/J@4"@4"@4"@4"@4"@8KU]- H%
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M"ZRWV+E!?;$TDLH>.[<!'0/([N]Z3:JBX9A'M+_\>UT5:I0&ZVMR&5Q;FL'
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MMM&\P[I&1!1RJR(D@9MBJX9+M6KK*;+F2XDJHF"*N.">RNC#R@4"@4&W;?\
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M[-8TAK:5CK;)0*!0*#4N=NC7: _;9BFD62.1W=&K9Y<4782;4Z*DQ4B:(_\
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M;D>0R0Q]RUG2%VE/---1VFX[ "TPR MM- F @ (@B*)[$1$P2MQ#+[H% H%
MH% H(/\ Q*S;F2R@O"LFX%>5>%XD>;GFF"O-'_(N&S!-F%8TAK:2-H_3D.7&
MF180M%$1G<,"1;A'(K9-,.JVJX*XV!$(FNW;[]M72#:7S/T;8+HVPW/8-[<.
MNOJ:N$ANE((#=%U4_$)JV&*?_%$3HII!M*>55)5)=JKM5:TR4"@4"@V[;_\
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2G_I,ZS^'3_.(VC\K!7Q/N?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>tb_fig20trae-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_fig20trae-4clr.jpg
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M<L:/K(ZK<W/QRW=N]LWE_7_[B=,CGC1L!PT
M
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M'F_56D+2W38:9330;FHA?BM,+A+??=8<;YJ/W.D?+WMJ_IMV .G@
M
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MO)UGY!.:E3-A31:9,#<,E(5%D.OFYO[?4C)S9LV?H N
M
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M*/>,!WP
M
M                         8!W%>1F1N*VEZ?]IW]/_:.](L^F)G5=U%X3
MO"&D3IB9U7=1>$[PAI$Z8F=5W47A.\(:1.F)G5=U%X3O"&D3IB9U7=1>$[PA
MI$Z8F=5W47A.\(:1.F)G-=U%X3O"&D3IB9U7=1>$[PAI$Z8F=5W47A.\(:1.
MF)G-=U%X3O"&D3IB9S7=1>$[PAI$Z8F=5W47A.\(:1.F)G5=U%X3O"&D3IB9
MU7=1>$[PAI$Z8F=5W47A.\(:1.F)G-=U%X3O"&D3IB9S7=1>$[PAI$Z8F=5W
M47A.\(:1.F)G-=U%X3O"&D3IB9S7=1>$[PAI$Z8F=5W47A.\(:1.F)G5=U%X
M3O"&D3IB9U7=1>$[PAI$Z8F=5W47A.\(:1.F)G-=U%X3O"&D3IB9S7=1>$[P
MAI$Z8F<UW47A.\(:1.F)G5=U%X3O"&D3IB9U7=1>$[PAI$Z8F=5W47A.\(:1
M.F)G5=U%X3O"&D3IB9U7=1>$[PAI$Z8F=5W47A.\(:1.F)G-=U%X3O"&D3IB
M9S7=1>$[PAI$Z8F=5W47A.\(:1.F)G-=U%X3O"&D3IB9U7=1>$[PAI$Z8F=5
MW47A.\(:1.F)G5=U%X3O"&D3IB9U7=1>$[PAI$Z8F=5W47A.\(:1.F)G5=U%
MX3O"&D3IB9U7=1>$[PAI$Z8F=5W47A.\(:1.F)G-=U%X3O"&D3IB9U7=1>$[
MPAI$Z8F=5W47A.\(:1.F)G5=U%X3O"&D3IB9U7=1>$[PAI$Z8F<UW47A.\(:
M1.F)G-=U%X3O"&D3IB9U7=1>$[PAI$Z8F<UW47A.\(:1.F)G-=U%X3O"&D3I
MB9U7=1>$[PAI$Z8F<UW47A.\(:1.F)G5=U%X3O"&D3IB9S7=1>$[PAI$Z8F=
M5W47A.\(:1.F)G5=U%X3O"&D3IB9U7=1>$[PAI$Z8F=5W47A.\(:1.F)G5=U
M%X3O"&D3IB9U7=1>$[PAI$Z8F=5W47A.\(:1.F)G-=U%X3O"&D3IB9U7=1>$
M[PAI$Z8F=5W47A.\(:1.F)G5=U%X3O"&D3IB9U7=1>$[PAI$Z8F<UW47A.\(
M:1.F)G5=U%X3O"&D3IB9S7=1>$[PAI$Z8F=5W47A.\(:1.F)G5=U%X3O"&D3
MIB9S7=1>$[PAI$Z8F=5W47A.\(:1.F)G-=U%X3O"&D3IB9U7=1>$[PAI$Z8F
M=5W47A.\(:1.F)G5=U%X3O"&D3IB9U7=1>$[PAI$Z8F<UW47A.\(:1.F)G5=
MU%X3O"&D3IB9U7=1>$[PAI$Z8F=5W47A.\(:1.F)G5=U%X3O"&D3IB9U7=1>
M$[PAI$Z8F=5W47A.\(:1.F)G5=U%X3O"&D3IB9S7=1>$[PAI$Z8F<UW47A.\
M(:1.F)G5=U%X3O"&D3IB9S7=1>$[PAI$Z8F=5W47A.\(:1.F)G5=U%X3O"&D
M3IB9U7=1>$[PAI$Z8F=5W47A.\(:1.F)G-=U%X3O"&D3IBG.(&YO\Q>[MW=O
M*<^OU_Z1-8G3%G#EH
M
M                                         @S(C(C/89_0O]0$@
M
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MBDRLB:9:V.2)$A:2_P!#_3:5^I(R'6X[3;Z^8\A"4N+_ .I1$1&?_P!3!'J
M
M                                                 /Q1J_SIIC6W
MD[36IBUS!K=(Z:U9$J:>A3,3'DR&D$XFQM)S6W:3)K)+$5*C_HVK,BWM@*[O
M_(MAFVT;0:;G;<@U'JBBK;MXC)*4052TOJ-1JVIW5+:0VK>]#)6S]016OY >
M6=/0[J#X<>U;$TDJWC*L-77DB2B,]&HR/EJC1%*__P!<LSY:#3ZMM[SFS;N@
M*0UYTT]"\.^.="TFM(-1<:G@_AS]52I1$BIJX1<J8\E]T_W32]&HZ#,S-P]X
M_1/K1>OXPZ[TZU_'*#<R[LIT72K=H=[+4ZJ7(8;C2I$@N<9;5&OD&A9%L]2,
MMA"#D.G/)\#R)YQTAJC_ .0&8,_6E7J"L@T$*6AUNCCN-QT4Z5M;RD*GO&XX
M^X2_^?\ M[/V"JSXL.7H*\+QSKC5A0]/PI59>:SD53UC);6F&VO\2'^XG'OR
MK5QM<Z6TT1);88/U-*]H@[!Y6L83FLO!NN=.NHEOSM0'619C1[[;U/>5C[CR
MMB=AJ29,M+2H_1)^HJ.XB   *?K_ ,8Z1\E1(C&I([R)M<X;]5;U[[L&RAN*
M+=6;$IA27$$M)[JT[=U7ZEZ%L"O,?Q]\:,Z,OM$N0I4J#J@D)U!9S)C\FUFD
MRI*F^;,=4ITR1ND2$D>Z1?0O4]H;;7?B+2'D&PKKNU_-K]15;;D>'=TTU^MG
MIC/>KC"G6%)-;2C_ ';BMNP_4MFT]H:1'\=/%L?2[^DX,"5"KW+=>HXLJ/-D
M(GP[1U"$+?C2C6;K9J2C8K]WJ1GM^H#UK?X^>,*^GOZ5VODV4;53<=&H7[&;
M)E2ICL12UM/N/K7S">2:_P!KB%$9;$[-FP!N]$^+=-Z%G3;> _8VE]8-MQI-
MQ=SY%G,_%8_[;"%OJ/<;2>U6ZDBVJ/:>T!5M4?QN\?ZKUC8Z\FS;Z%J:T;1'
ME2ZRXEPO_':2E*64DTLMUO\ :2MPO3>]?J"NKP(;== BU[*W'&8C+;#;CRS=
M=4EI))(UK5M-2C(O51^IF",@
M
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M=3H:ECK=<?3*E-)8D27U++^E#"$QVD&I9G^Y:CVF0#J8
M
M
M  P#5=[3V-1=W;Z;7'-NS#'?F[/W9&_>=*)BN?&'FY[L;][THF(Y\8>;GNQO
MWO2B8CGQAYN>[&_>=*)B.?&'FY[LC?O>E$Q'/C#S<]V3O7O2B8CGQAYN>[&_
M>=*)B.?&'FY[L;][THF(Y\8>;GNR-^]Z43$<^,/-SW9._>=*)B.?&'FY[LC?
MO>E$Q7/C#S<]V3OWO2B8CGQAYN>[&_>]*)B.?&'FY[L;][THF*Y\8>;GNQOW
MO2B8CGQAYN>[&_>]*)B.?&'FY[L;]YTHF(Y\8>;GNQOWO2B8CGQAYN>[(W[W
MI1,1SXP\W/=D[][THF(Y\8>;GNQOWO2B8CGQAYN>[(W[WI1,1SXP\W/=D[][
MTHF(Y\8>;GNR-^]Z43$<^,/-SW8W[WI1,1SXP\W/=D[][THF(Y\8>;GNQOWO
M2B8CGQAYN>[&_>]*)B.?&'FY[L;]YTHF*Y\8>;GNQOWG2B8CGQAYN>[&_>]*
M)B.?&'FY[L;][THF(Y\8>;GNQOWO2B8CGQAYN>[&_>]*)B.?&'FY[L;]YTHF
M(Y\8>;GNR-^]Z43$<^,/-SW9._>]*)B.?&'FY[LC?O>E$Q'/C#S<]V-^]Z43
M$<^,/-SW8W[WI1,1SXP\W/=C?O>E$Q'/C#S<]V-^]Z43$<^,/-SW8W[WI1,1
MSXP\W/=D[][THF(Y\8>;GNQO7O2B8CGQAYN>[&_>]*)B.?&'FY[L;]YTHF(Y
M\8>;GNQO7O2B8CGQAYN>[&_>]*)BN?&'FY[LC?O>E$Q'/C#S<]V3OWG2B8CG
MQAYN>[(W[WI1,1SXP\W/=D[U[THF(Y\8>;GNQOWO2B8CGQAYN>[&_>]*)B.?
M&'FY[L;]YTHF(Y\8>;GNQOWO2B8CGQAYN>[(W[WI1,1SXP\W/=D[]YTHF(Y\
M8>;GNQOWG2B8CGQAYN>[(W[WI1,1SXP\W/=C?O>E$Q'/C#S<]V-^]Z43$<^,
M/-SW9._>]*)B.?&'FY[LC?O>E$Q'/C#S<]V3OWO2B8CGQAYN>[&_>]*)B.?&
M'FY[L;][THF(Y\8>;GNQOWO2B8CGQAYN>[&_>]*)B.?&'FY[LC?O>E$Q'/C#
MS<]V3OWO2B8CGQAYN>[&_>]*)B.?&'FY[LC?O>C$Q7/C#S<]V3O7O2B8CGQA
MYN>[&_>]*)B.?&'FY[L;][THF(Y\8>;GNQO7O2B8CGQAYN>[&_>=*)B.?&'F
MY[LC?O>E$Q'/C#S<]V-^]Z43$<^,/-SW9.]>]*)B.?&'FY[L;]YTHF(Y\8>;
MGNQOWG2B8CGQAYN>[&_>]*)B.?&'FY[L;][THF(Y\8>;GNQOWO2B8CGQAYN>
M[&_>]*)B.?&'FY[L;]YTHF(Y\8>;GNR-^]Z43$<^,/-SW9._>]*)B.?&'FY[
MLC?O>E$Q'/C#S<]V-^]Z43%<^,/-SW9._>]*)B.?&'FY[L;][THF(Y\8>;GN
MQOWO2B8CGQAYN>[&_>]*)B.?&'FY[L;][THF(Y\8>;GNQOWO2B8CGQAYN>[(
MW[WI1,1SXP\W/=D[]WN_]F-O[?IS%[-GL#S<]6; <-
M
M                                                          &A
MU;K32F@ZA=[K"VCT]6@S23\E>Z:UDDU;C2"VK<69$9DAM)J/9] 'QH_76C]?
MU><:-N8MS7D:4NKBN$I;2U))1(>;/8MI>PR/<<2E6S] %A  &JB:CI9U[8Z:
MB2TN7E0W'?L89$HE--S"4;*C,R))[Q(5]#_0!M=H#G^K/-WBO0UL[1ZIU+'@
M649##LULVWWD142U\ME4EUEM;;!+5_3SE)_U^GJ OY&2B)23VI/U(R^AD D
M
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M5E9P'CVN1S4VD^4L_P#J1_2?_H S@
M
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M)+>Z@B+=3M/8GZ%M ?-124M!$.!0UT6K@FM3IQH+#<9KF+]5*W&DI+>/]3V
M)F4U/82XD^?7QI4ZO4:X$I]EMUZ.M7U4TM1&I!GL^J3(!G
M
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M\BN^1)LQR9*C5R*;3E6I"&X=5$/=5(-A*2]7'U)3O.'ZD@B07[=NT+H
M
M
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M=W\Z7]=N]S2V_P#I_3]!-K072\6P'#0
M
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MJ>ANY5'^6W8MSD+..M*&^9RT)-J0LU?NB[%+1_J8#-8\L>-9&F6=9MZIKO\
M:S\G\!%LN0AN.4LU&GDK4O9N.;2_I7L,!G:.\@:+\@PY$[1EU&N(T-PF)9QE
M'OLNFDE$EQ"B)23,CVEO)]?T 60
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MD?\ <2D]JG4,J2DEJ+T1Z;01UD
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M2MXHS"I;KIMMD?Z(V;?U,P%Z
M
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MU^A!-7V(
M
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M9=HW-CUI2TKL"=0E*_R6VUN;[2E&A7HK;]01^A@
M
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MXEM&U%IR'K2ZJO'&I'94R7HV+^/^(U+FDI;ALO*;-Y#)O*YQQTKW-[T]$GL
M;*7_ !^B.W=K:0-4V4&#J+3K>E]2U*$1EQYS4: _ C/F:F]]MQI+ZED2%;IJ
M^I;-NTLUB_\ B6JY'C5C,)&SQH;9URMB-LKE5RZXN=Z>FU"]_P#;L]01T(
M
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MLP
M
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M GE2'W\.99=NQCK^$)0)Y4A]_#F67;L8Z_A"4">5(??PYEEV[&.OX0EC_O\
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/>S9_Z\H/X3RI#_?^/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>tb_fig32inoculatnew-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_fig32inoculatnew-4clr.jpg
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M 0,1 ?_$ )0  0 " @,!               %!@0' 0(#" $! 0$!
M          $# A    8! P$%!@4# @0% @<   $" P0%!A$2!R$QT1,4%4%1
M(I*3"&$RTE150B,6<8&14C,78D,D-!BA@K'A8T7%)B<1 0 " 04! 0 # 0
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M'^LL9-0
M
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M3\1[]-" 86'\J<<\@29</"\GK[N9!U\W'AOI<=01'H:MO0S3KTW$6@"W@
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MMPM=%Z_*KM!7WRTO>6XC(TF1&1EV=2UZ"H]
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M:F9NU9,59H+53Z"5HE/P_%TZD I)YES9R)A6=?<!3<C?XG7XE/F,T^%I9;7
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M: SXAI>GO)5NW^#HM)FGXE::G[3#[2%0
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M2&X;TM*MQ/.Q4.$RM>I:ZFCJ?:'P;72C:>O:?9_L*.P
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MI_L*))? /'2&<$B5T1ZL@\=3#L<>B0G20V<A1%N.1N2I3FXRW*/<1F?M ;/
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M=;*N9KDXX,99&2FHQ*))(29'I[3T ;?(M '(
M                            !V]H#C:GW$ Y   !QH1GKIU -"+L(!R
M
M
M
M
M
M
M
M
M
M
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MB*ZDEM/M*2XVM*NPTJ29D9'[R,![
M                H4_DZ+6\HU'&$RDL6I-[&DRJN^-#?IKQPFB=?:)6_?O0
M1EJ6SVB"FR/N5QAF4_.+';MWCV+8^BRL\1';.H1+)\HRE_\ 4\0V$NGX:GB1
MIN 3F9\TP\9R=_#Z+&+G,;ZOB-V5S'HVFG4P8KQJ\/Q%.N((W7"2:FVD]5$
MNN&Y=1YUBU7E^./*?I;=DI$1:TFVX1&9DI"T'U2M"B-*D^PR,42*+>K<AN6"
M)K"H#._Q9:74&RCPM27N61[2VF1[M3Z /*=D%'5Q6IUG9184)\TI8DR7VF6G
M#66J20M:B)6I=2T,!E1YT*6X\U%DM/.QS2F0VVM*U-J6DE))9),]IFDR,M?8
M UG=<[T51DM]B\7&<EO)>-*81<R::M\['95)9*0@C-+I+,S0K7H@0<W/W#\7
M4N"U7)#UFN1B%K8-5!38[1J5%E.FHE)E-K-"VO#-!^(1IW)]QBBU7G(&/T%U
MBM'*4Z])S*0[%IGHR4NL&IB.<DU+62BT2:"^%1:Z@(^YY:PRAY&HN+;&2XWE
M60QW)<!!((V"0WOVI<<W%M6YX:R;3IUT 7D
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MA>%X1,EL,NWIJ ^D_MOV_P#8GC\T[=OHL739IM_+[-.@HVD
M                                  #2G(!H3]P_#:-Q$I47*=I:]>D)
MG73_ $$&CW,OQV+]J4_AV1+0?*+4B1BYXFHC*S<M';=2D&EC3<I*D*)XG--F
MGM ;0H<PQGBSFCDQCD.W8HRN*[';.IF3U>"U,C5T!420;*SZ+6AU)D:$_%UZ
M$ M7VPP9D3AFDD3&7(Q6<FRM8L9Y)MN-Q;">_(8U2K0RW-K2O3\05H^!FN&X
MA]M7)^#Y%:Q*_+*^5DT"30.N(3-6]+D.J:-#!_&M"R<2HEI2:=.NO0P1FUT7
MCVPY'HH/.APU8RQ@](OCYF_6AND-Q4=)6*T>*9,G((R;_-\1(TT]@$K7]IC>
M+MW?+I86:EXI_D315#BC6K6,48B3L4[\9MEV-&K^C3V! DL0SC#,0YEYL_RC
M(JZE4N;2.M(GRV8[BT(JD[C0AQ1*5IK_ $D U.4.-DBW<I5#/_M]GW,%0[1Q
MIC2FVY\,XSL63))ITB/PY*B49:E\6FH"9-JWP7FKBOARZ-^15T%Q8V.#W+ZM
MY/X\[7/$45Q9]3>@K+PM3_,WM/H I616F8Y]$SCE[&L&M[*4_>1;C"LOBNPD
M0H];A[JFVM&W7">4ETDR#<VIT4:BTUTZA]OXAD\#,\9I\JJG$N5MS"8GQE(4
M2R)+Z"5MU+VI,S2?XD*)P                                  >3K"7
MM2625(/\R%%N(_\ 8P!EAJ.6UE"6T'UVH222_P#IH ZNQFGEH<=0A:VCW,J4
MDE*09^U)F73_ & '8S;Z#:>2EUH^IH<22R/3LU(]0'9QA#K:FG4I6VLMJT*(
MC29>XR/H [--(9;2TVE*&TEHA"2)*2(O81%T(!W
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M .*VL@U$1J!61F84!A.QB)&;0RRVG771"$$24EJ?81 ,P
M
M
M             !QH0 1$780#D
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MZ5]<2=[^>8<^;G_QZOJM]X=*^N).]_/,'FY_\>KZK?>'2OKB3O?SS#CS<_\
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MK>66,FH  &A &A                            :$  &A &A    :$
M                    !H0    !H0!H0!H0!H0!H0           &A &A &
MA &A &A                        :$ :$       !H0!H0    !H0
M!H0        !H0    !H0
M
M
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M#ZD*,X
M
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MA"B9
M
M                                   !4<PXUQ+.[3'K;)X:ITC%Y?J5
M.TIQ:6$2RTVN+;29)69:%IN 6X
M
M
M
M
M
M
M
M
M
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M1$KL,R+J6OL >P                                #KN/733VZ:@.P
M      .#,R(S+J?N "5J9EIIH Y
M        =5*TT]Y@.2/4M>S\ '(       .NX]=-.GO =@
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M+R6C*.ZII#]G$=)!$TM2.OAE\.X@1]$(/5/;K^(H[
M           #YGY>SS/\*YSA6V/.R+##Z#%DVV6XPT9K\>N78JCR);*-=/&C
M)-+OO4A)D(.SW,[>,9]RKF,F?*O,'K:'%YN/5L5S>T^_;I<2R49*NA')6I!&
MK_<^P/HL4+E/E7%\CQJMYAQFLK*7,I2*NIL*&4]*5!LWR-3,6<3I$1FYH:2<
M:/;N 6SE+D6SPE-%1XS5E>9WEDM=?CM:ZX;,7>PV;S[\ETB,TM,H+<K;\1]A
M -<9-R;FIT'('&?)=9#ILW3B=G?4=G12'7:Z9 994VZ;9N[76WF5F6Y*BZEU
M+\0CJ'F#EG#>-\2SO)</B?\ :EFOK&+)U,U;V1LPW&6F4V+C>G@J0I2B<-HE
M&O:?4P$MDO/.=L\@WV)890U$]O&%PDN4UI8JA7]VU+;)Y;M2VHB:6A"#Z;E'
MN,@&1FW/-^QF=KAF"_XU"?QUAAVZFYI:%6(>ERVR>1#AMMJW*6E!EXCBO@2H
M]H# 7]R60Y)5<?/\:8W&M;O-7[BME5LZ5X2(-A3-I-S5]O5*V4J-2C475:-N
MWJ8"XTO+\^!8\ATW(\:'5V."0V+HUP77#9EU3\0WC>;\;11FAU"VCT]NA=I@
M*S7\S\K9*WBF,8OC-47(US3)RF^38R7VZBJJ93JD1$*-O<\N0ZG;J@B^$]3[
M.P*9R!S=R_98-R; 8J8N(9)@TNCBS7FI;RW_  [!;9N.QG4)T4EQ1I\/<1?V
ME*U^(!>+O(9U)R7QK,Y-K(",K:JLEF3K.GF3C@PHT./XJO"8<VD\:VR^(W4&
M:3_*"L!7/'*,'&6.7[C#8+'"LA3<A:&Y3AY*Q42%$AJ>XRHB9,OB2XIE*MVT
M_P#<$3$[E'F"_P \S+#>,\=HYT7%&ZZ2FVMY<AEN0BRB>90RE#)&?B+_ *5]
M$)+\W: B;+[E+&9AN!W>.5U=3VN:R)T*5*RF6N-3U,JJU2\S)?929FMQ9&EG
MLW -N\:Y)DV4XRQ9Y?2%0WI.NL2(K+Z)<1\FC^"3%>09[V'DF2VS/KI_Q%%Q
M                           !2>5<%3R7ATK#E6!U92I$*3YU+1/FGR4I
MJ3MV&I'YO#VZZ]-=1 S_  <LX?Q-Y5@J"6+W\3(R031.^8.$VZCP/S)V[O%U
MW]=-.P45%SAJZB5]TC&<WF45U9Y5-S"/.C,)7'+SZ4I5!E1E+VR6-$]=33UT
M/IH((=O[;FG,+R6CL,G</)\FMHF12+V%!8AQ8]A7FV;!L0$*-LD%X9>(1KU7
MU,SU 2MIQ#F3]I59M39T57R?'KO1[R\35,N5]K$)TW6_%@F[HVMLS^!27/P[
M.PK6_+/$D3%N/*JKEW4ZVR3+\\I9F2Y424L3793KBFTN,H;(TLI9222:1U).
M@(V=3\09$_FM3F').:N9@K&4/IQJM37LUL9EZ4WX3DF032E^,]X>J"/X2+4S
MT 5F3]N.2)Q:WXVI>29E9Q79(E)B4*8#+LV(W+-2SCHFJ62SCDM6NS:2C3JC
M=UU 6%[A:VB6N#Y%BV7*J+[$*AK');CL!N7&L:U*FEK2;2G$FTM1M_"I*CVZ
M^W0!,XYQ6UCF(YMB+5HM]K,9]S8%*-@DJB%=(V>&2=Y^)X7_ #:EN_ !6SX)
MN*A.+V^#9DY0YICE%'Q>7:.06YD*RKHNAH)^(M:=JT*U4A1.:EKIU!7B?VZ1
ME4"8DC)Y4S+)F30,OR')Y3"%.SI5<K5MA+*5)2RT2/@;2DSV%[P^(][/A+*X
MUEDA<?<A2<4Q?+Y3UA>4_D&9SC4N86DEZ#(6M)L*>[3^%6U74O< H_(V,89P
MY:<>(QB]L>/9=;6OT-9EJX96]*]#)7C*A6J#4DR<<<5XS3O0MV[\- ]?M^8;
MD9KRUGLZY?R?$)S4",_EMA'\M'L7X<=PYWEV=-I1F2,FTI3JDB]I@,+@[$,F
MQS@/*,JP./(=S#,5/*Q!B8LDOPZA#JXU6@S<(B23#2U/D78 ^BY&.2IN"O8A
M/LERILNI752KAQ)*<<==CFRN0I&I$9FHS7MU_ 44&PX3D+Q# :FBR=ZGR_CE
MEMJBR5$9MY#FD4HCZ7XJU:*;>07Q(W]/>(("1]NEM;,\@NY'G3EI>\@UD&MG
M3SKFV$13@*-25,LH=TV:="09ZEU,U'J V'B'&Z<8SC),T*S.4>0PJJ"<(V2;
M)GTA@V-^_<>[Q-=VFTMOX@J_BH                         *CREBDO.N
M.\DPZ!(;B3;N ]"8DODI33:W4Z$I9(ZZ?Z -7\O?;TKDK#,7K*VS:J\PQIF'
M".T-*_ EP6O".1%>)!;S;4II+K9'^5:?Q,14O?<<<C4><WN<<1W=5$7EK<<L
MBILBCO/14RX;1,M3(RXII62]GPJ0OX3/K_H1;>*^.T<;8R]6/63MU=V4Z5=7
MMN^DFSE64]6]YQ+:>B$="2E/L(A1K$N%N4J"EM^-<&R^M@<5W3LHTN38CSU[
M51;%:ER8T-25$RM)FM?AK=+<G=T["$&3)X0S#&<RI<JXJOH%5$QO%XN)UU-;
M,.R&)C4=]QU7FU,FA1%\25I6U\6_7IH8#)K>&\]9JLLOY>9LQ^7<OD1),RWA
MPD.5+,>M2:&*]$9\E*7&4@S2Z:_B5NU]G4J K_MFEVU5G+.93:JHE9@B 4>J
MQ&(MBF@2JESQ6)B6))JWO+7_ -4M")2-4^WH^"<P7AW,*W+JS),L/$J^)2-N
M)C0<1I6X;D^0X@VR?F//(-;9H+XB;8,D[C_ !9\'XJ;I.&&^(\K>9LX[L2P@
MV3T=*O"6U8OON? 3A:D:4NEV_P!1= %>XYX#.DX^RK$N1+-.16N9(\C<6D<E
M-J.NBQ4PH32/$+7<RTG773\QGV@BJ91P=S?E_'S?&-WG%,K'*I44JR<S"D-S
M[!JO=0;#=@>XT))*$%N\$M5J+K[05L5KCO+JKEG),SIK2N7B&;1HK60UTQE[
MU!AZNAJBL*B.-JV&2M24LG"]^@(I>/\  6:X118)98;D->SR1B%6_0SES67G
M:6SK9$E4DV74H-+R/#6HEH6GKKJ788?!Z6? &4W^-9E+R'(8<ODS.950Y93V
MV%M542%22VGV8<5'5S:26S^-9ZJ4>I_B&R,UP:=E&;X!E4:6S'B8A,L)4QAT
MEFZ\F;#5&3X1IZ$I*CW'N :XK^#L^D9WCN0Y5?TTV/B\]5@QD]?7JA939M$2
MD(B3W6S)E3.U1)<T(S422]Y@/H5L]4ZZ:=3%'<
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M-4Y?B'%A-K4I28[78@E'K[14;&                             -"
M  =%M-.D1.(2LDF2DDHB/11=AEK[2 =P#0@  T(  -"  'F_'8E,KCR6D/,.
M%M<:<22T*+W&1ZD8 B.PVP49MI"(R4[$LI21()&FFTDETTT]@#NE*4I)*2)*
M4EHE)%H1$7L(!R :$                                     :$  &A
M    :$  &A &A  !H78                                  &A    :
M$ :$  &A      !H0   &A &@
M
M
M
M
M
M
M
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M.$2DGJD^WV )KQ#UTVF X-PRTU3IJ [)69F7PZ$?M =@
M               0;N88VSD[.%O6++>5R8BK*-4J5H^Y#0OPU.H(RT,B5VZ'
MK^ #O$RJ@G7]EBT.<V]D-0U'D6=>G7Q6&IA*-E2M2TT7M/30P$P1Z^PR <&O
MXC3IU 1U[?5^-TMCD%NM3-751G9LUTDFLTL,(-:S)*=3/0B[" >E3;P[NI@W
M=<HW*VRC,S8CID:34Q(0EQ!F1]2U2HNA@,PG#,M=I@'B&>NB3/0 \3W)U]AZ
M 'B&7:DR]P!XGL))Z^X!'W>05&-5<B[OY;==41=GF)D@]K2/$6EM.X_9JI1)
M+_4!@V&95=9E--A\AF6JUO6I+\-UJ,XY$0B&DEK)Y]);&S,C^$E'U 3WB'_R
MGI[P G#/L28!XFO0D]?: )<U5MTT,!W                           !I
M7[K26?"=R3!).2<VG\$G-?#-SU.-LWZ==NO;IU$D4F1&S.)SQBTKE1JE;M9U
M%>Q<4/%"<2VI]#"79/J)RDD\I'A(_LZ? 2_Q,%4KC#SF:57$'$5E>2Z3#)>-
M65_*9K9"X,JVF1K%QE,3S#9DLFVDJ\9:&S(U>WL!&;D&999QI!Y0X[QG)IDF
M@I)^.0:W)Y[OGIE$SD:_"F-JD+U-1L$6YHW#U;W=?8 N4^B5PER1Q_%PB_M[
MEC,79L"\QRVL'+3SC3$1<E,]OQ34;3B%H(E*1H@R5IH0#7J\>5F/VXY+SC>9
M[;,9Q:UMK(G.E/4BK8(E.L^D^0,_")LTD3.U2=^XR/4!OYJ_LL3^V^)DU)&*
M1;U&&QYL*.HMY>,Q7(6G5/M))EJ9"BAXG@E;44O'_)S?*-I&R6]=KG[2?8SU
MS*^^79();D%,1:R;3N,]&?"3JWM]IEJ(*Y0<8MY>7-F1OY'=5DZKRN\50-U4
M]Z$Q"EQH[3OF?#:,B=6M6TE>(2BVIT(%0]CG.<<G2.,\=FPK6]K['#&\DMJ>
M@M&*&18V)2/*K6](<<94MI!(\3P65$K<K<?PD",*=8\FMX#-P^9;6-#'A9]0
M5&/3SMX]G>0HDU7]^)*D0W5DI3*OR)=^+:HB5KH"KU;\;O8_R_CG&E1E^1,X
M)F%9.L<@K7+)YZ0[(J309&U*<-3K)/F[_?)I1;B+0MH"JY/;Y-A=+R3QY6Y#
M9O5F(9-B9T,^1+=78,PKMU"W8BI&[Q%M)V&2=RCZ*,C!'KR4UD%7F.7YMD>1
M79T%=;,E3YKBEHW*C8TPWX2%0;"E\1!'\2C\92B4:DKU_ RK=CF%44S[K<UM
MC?FG*@5%5<QMDZ0EI3\C>E6]HEZ+:T_*TK5"3[" 4?%<3RY?VZ1.9:S*+VUS
MZK5Z_%C2)[SD7R%-8/*=@I9W:*2XPE>[?N4I6@(V_P >Y*KECENSSJEFNKX_
MQJGAU52TV\LHTJTM4(G2G5H2>Q2X[2FV#UUVJ,_: WH*
M             #6?W#J-'!^>J+M*FE&7R@/EOD53W%O#TGC28;AX/F46FN<
M?6M3I1;#S,-^PJE*,OA3U5)C?@:DZF9"*W$_1GS'S'R!C67Y%:UE-A2*V/18
M]4SW*PS3-BD^NQ<-DTJ<5O5L09ZH21:&0(MGVY9-=Y%A5G$NK=60ECM_:8_6
MY$YH;EC!KW"2R^XI/PK7H>U2T]%;=>W44:=J*R5R%Q5E?.N1Y[;4F>5SMN_"
M\G8+BU] JI=<0S!5#)7AJ)1(3XI.I-2]_3M(SBO.H1*Y<YAPMW*[F7C<C)^-
M(%G<U=:^<"38O%,=4;"'4&3B&RU\92&SW&G\"!'O)=S.MK.6N(<0SE9P<9G4
M:<<N[FR0Q)05D1/2J7U)PS-+JB0:&5'\2=VTP$/-S.^XUP;DFMQB9D5)DT)-
M,A[$LADM62Z-FUD^6=L(-BMUTG6W25T-2B2VO178 L6%0<_PGE'#8M54W='2
MWRY,/)(64Y- NBLF6F?$*7&:3(6X4AM6BE*83L-)Z: J#Q7$\S5]OC?,U9E5
MY;9_5NNW<&%)G/+A^0I;)];D)+.[19.LH7O->IJZ)[ 1:;GDBZRJXSCF#"'W
MY6-<=8@2*"N;<6<25>6L8ISKSK2#-#AQ630VI)ZZ*,P53>3,65B' 57R91\D
MWTC*<@54/64YVU==8N%V#K2W&6F2426MAFHV_!T-*4F2M>H@V%A&$4L?[A.9
MK]F1.394AUDZ$GS\CP3=M*MQUWQ6=^UQ*5*_M)61DV71.@J*/QM97O)D'B+C
M3*<GLX6.6.+3<BL7V)KK%C>3F)ZXZ8:YAK\4T,H_O+2A6XR_ NA7GF5UDV+8
M[S+QC09793:7$I&,.X[?.2EO6-8_;3F$/052B/<YX1?&DE'J23VJ!&RGL6D\
M1\O<=M46274^!FBK2OR>)<3G9[,E^+"5):F$ETS)MQ*R^+P]$[>FA *)QZB^
MQG-,2MLUR&[*XOKB1"8S6NM&[[$LE0^M_P &$I@EEY-6B$I:T;^%2#_V#[%0
M9F1Z]NIBCL                              /E_EK";7,_N!0K%YAUN<
M8]A3=WBE@1Z)3/C6RD^"[[#9D(6IETC_ *5:^S00:X?Y?LY3W-7)^+[J3(CI
ML2K+%$A&KM--<D.PIYN)5IJ<4S4I)]GY5 -DW>/?]DLPXRGX7E]O;O9C=QZ.
M^J;BP<M&[6)+0I;D]"7%'X;C&A+WM:(VJT/\0N'/%I:R+OCSCQB[?QRAS>VD
M0KVXA.>7F&S#C'(;ALO_ /E*DJ+9N+XM.A=H#6F5QG^.K_/N**&WGW.&67'E
MOD,BLLY;EB]53HY*91L>=-3B6Y"5?]-:OS=2 0LVA<P;[?\ &.<:#D*UDYO!
M@5#\5QR>;E7.\8V6CJ2@I/PMA$9MDE"=Y&DS/\ S.56<C8R[+\UOKN[_ ,8K
M50G*O(L2MFG',1-#23=8GTOBH)S56JG%JW;D'V KWRN7EG)7*F7T[]5D&2T6
M+LU<>EBXY>QL>:83/B%).P<2MUI;SCIJU;5U;0DMIEJ PZ]WD/D%CA3&,MR:
M?62;.9E,&TM:.R:7)L*VN83X/BR(:UM*=4E.Q:TZF2B49:&8(L^1YK,X"R7D
M2B=E2YM==4+.0<?-S)+DI16C*45CT-LW3,S-3RV7]J3[#48#%JL,M;7.L6X,
MS7)[=FIH,1:R&:U&L78\NZO)<M293CDI"B=<:85KL;2KI_H UUF]2MW%^?L?
ML<KL\GK<3L\9*HERI[BULDI;:%QW5(425FUXAH7N+JI)&KXB ;CS14WBW/N/
M<?Q.982:F!1998)K)<V3,\[(CP_,-)D&XM2G=%_DW:[?Z= 50+&'-HN!87W)
MPL^MIO)KT>)=+DKGK75S)$MY!+JBKR/P?"(E&REM"=Z33KKT!%VK<%<Y6Y<Y
M1AY/D%] IZQ% J!25MG(A,QIDVL\5QW1HR^-"BT27Y===R3 4^'/Y$Y%XPXZ
M1)LI&1/1)UY!R+'HMRFANL@8K'%,L/LOZH-PX^TEO()1;]2,S!6\OM[LXUC@
M;C,6YM[A%7:3ZQ:,D:2W;UZXSNAP)*TJ7XJF-=I.[OB(R[.P$;8%
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MB1NT+V ,?#N#^+L!MCO<5Q]N)<$TJ,S->?DS76&%_F;85*==\%)]ADWMU+H
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M0#0B[
M
M
M
M
M
M                                                 =261EJ1&9?Z
M>X!R1ZEK_P#B Y     <$HCUT]@#D!U-9),B/V@!+(ST+M =@   -= '7<6N
MGM =@'!F22U/L ",C+4@''B)/H6IZ=NA .2/4M0 E$9Z>T@')GH6I@.I+(_8
M>GO =@    '7>7X]>P!V(]0     ST+4!PE1*+4@'(      :D
M
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MFZB0XM1.-H:TVFI1'\.H#ZU1V?[BCL
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M=C3(SB7F'6U%T4A:#-*DG[#(Q1E::  #@R(P'(  ::@!%IT --0
M  0$G#<?F9=!SF7$)[):R(]7UTM2E&3$>2HENDA&NTE+VD1JTUTZ=@"?
M    /\.T!!XCB-#@U&QC>-1O)T\=;SK,?<IS:N2ZM]P]RC,^JUJ,!.
M
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MFA"B6
M
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MTDE"4E["(M"(@'H
M
M
M
M
M                                                     ,1ZQA1Y
MD>"_)9:ER]_E8ZW$I==\,B-?AH,]5;2/56A= &6   #$BV,*:[(8BR69#L1?
M@RFV7$N*9=(B/8X23,TJT,CT5U 98   ,>;-C5\=R9-?;C0V4FM^0^M+;2$I
M[34M1D1%_J ]6G$/-H=;42VW$DI"TF2DJ29:D9&70R,!W       !P?0C,!C
M0K&%8D\<&4S**.ZJ.^;#B72;>;_,VO:9[5IUZI/J0#*
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M6I=3 >$"Q@6D8I=;*9F134I"7XSB7FS4A1I41*09EJ1D9'[C 9(
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M-<Q(:F0$7"4^#*;D+<43BB,R-QHT:%KH1^T%?3)="T%0
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M_#=T"1 )YQS)'%MH3\2&KF>#DQX$U!2A7DG;AZ228[_A[]Q-*C*\?\W7:?L
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MHG2(ZGV2)UUQ92&SV&3AFE)D?9T ?0 J               TXGK]U*^IE_\
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M\.E.9;X"\HH+:=CUM+B)-J/*?K7"1YA#9Z[/$2I*C3V$K73H"-GB@
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M>O0%0C_VRT+KCU*UE%['XLE23FRN.FGT)JEK6X;RV2<V^.F.MSXE,)7M_P!
M&PJ3CVLH<[N\Z@O.)D74&!6*KB0A,5ABL)1-^$22(RU)6AEV%[ 1WX_P.%Q]
M$N(5?*>F(NKB;>OKD$DC0]/4DUMHVD7PIV]->H"YB@             Z):2E
MQ3B4I):]-ZB+12MO9J?MT =P
M                     !T0VE!F:4DG<9J5M+34S]IZ=H#N  //PD>(;B4I
M):M-RR(MQZ=FI@/0    !T6VE:DK-)&M&NU1EU+7H>A^S4!W
M
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MCT+V>\2?RM$_\=1^U)C[]9I=@R:@
M
M
&    #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>tm233400d4_ex8-2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm233400d4_ex8-2img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T (L# 2(  A$! Q$!_\0
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M)N!W$8SQU[5=T;Q7I6O73V]C)*TB)O8/$5&,X[_6LX_$;PX&(^T3Y!P?W#4
M9?BWP7=7>LP:EI$8(EE5KJ$/MRP/W^>.G^>37=W2-):3(HRS(P ]\53TC7=-
MUV!Y=.N5F5" XP05)]0:R[WQYH-E=R6S3RRO$<2&&(LJ'W- !X$TJ\T;PTEI
M?P^5.)78KN#<'IR*B31[X?$E]6,'^A&T\L2;A][CC&<UKPZ_IESH\NJV]R);
M.(,7=5.1@9(QUS6,/B/X<(R)[C_OPU '645A+XNTEM#DU@2R_8TD\MF,9SNR
M!T_$5JV-];:E9QW=I*LL$@RK+_GK0!8HK/L-:LM2O+VTMG9I;-_+F!4@ \]/
M7H:T* ,#QCK2Z'X=GF!_?S#R80#SO8'G\.OX5Q,-E9^$+G0M3MKZVF<?Z/?+
M'*"3O).[KT&?_'177:UX=N-?\163WHB.D6BEO*W$M*Y]1CIT[]O>EU#P+H5Q
MI]Q#;Z;;PSO&PCD4$%6QP?SH I_$X_\ %',?^F\?]:SM%N)O!.KPZ5>2&32M
M1(>VF)P(6/\ "<_AG\#ZU>U'PYK>I^ X-(N)(&OXG7+F0[652<<XZXQ^5=%J
M>BP:QH3:;=J,-& &QDHP'##Z4 <5X2_Y%3Q5_P!=9_\ T"MWP#;PR^![ 20Q
MN&$@.Y0<_.U5_#7A6_T?PUJVG7#PM-=%_+9&..4VC/''-5-*TCQOI&E1:;:R
MZ4D,8(5VW,PR2<]/?TH 31H(]&^*%_IUBH2TN+82M$GW4; /3\_^^JS-%UFX
MTK7/$"P:)<:D)+QB6A&=F"W!X-=?X:\,/H\]SJ%_=F\U.Z_ULV, #T'Z?D*Q
MK70_%FD:GJ<^F'33%>7!E_?,Q.,G'0>] '2>']4FU6&:6?2)M.9&"A9A@N,=
M1P*\_P#!OBK2-"TN[M]0BF:1KEG!2'<,8 Z_A7=Z+_PD_P!L?^VO[/\ L^SY
M?LV[=NR/7MC-4_"?AJ;2M#O=.U-895N)W8JIW*4( P>!Z4 9G@Z)M2\0ZQK=
MK;26>FW*+'$C+MWMW8#IV/YU1TZ35O RW5E=:&^H6<DA<75N,E@?[W!_7'>N
MD\/:)J6A_;]/$ZG3F9FLI-VYX<]BI'/)]>WO5*.T\=::'ABO+#48SG9+/E77
MW./_ *] "_VEI6I_#W5)M(@%O"(90\.P*4?&3D#ZYK&\-^)KRR\.V5M'X6O+
MM(TP)T'ROR>1\M;>F>$KNQ\*ZM92SQ2ZAJ&]G=<A-Q& .GU[=ZJZ9IWC?2=-
M@L+<Z0885VJ7+$XSGF@!_C>X:Z^'+W#VK6KR-$S0N.4.X<&LW1YIO VH6D$[
MF31=45761N!;R$#.3T[C\.>U;>K:/X@UWPA<6%\;(7[S*4,1(38"#SQUZUMS
MZ/#?^'ETJ]4,A@6-L=B .1]#0!SG@LAO%'BM@00;L$$=^7KMJY'P3X6O/#,N
MHK<RQ2QS,OE.A.2!GJ.W45UU !1110 4444 %%%% !1110 4444 %%%% !11
-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>tm233400d4_ex8-2img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm233400d4_ex8-2img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !A &0# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH *0L!]?2HI)\/Y4?S2XSCT]S3DCQ\S'+GJ: 'T4M%
M!111F@ I*BN+J&TB,L[A$'<]ZJBZN;K!MH/+C8?ZV8?R7K^>*=G8"\6"C)(
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;%N "EHHJEL 4444P"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>tm2334005d4_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2334005d4_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !" )@# 2(  A$! Q$!_\0
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M</NXZ\&N^HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>tm2334005d4_ex5-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2334005d4_ex5-1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  5 "T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BL'6[7Q
M)/>(VCZA;6]N(P&25027R<G[A[8[UF_V=XY_Z#-C_P!\#_XW6,JK3MRO^OF=
MD,+&45)U8KR;=_R.PHKC_P"SO'/_ $&;'_O@?_&Z/[.\<_\ 09L?^^!_\;I>
MV?\ (_P_S+^IP_Y_0^]__(G845RMI8>,DO(&NM6LWMQ(IE14&63/('[L=O>N
AJK2$W+=->ISUJ2IM)24O3_AD%%%%68!1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>tm2334005d4_ex5-1img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2334005d4_ex5-1img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !F 'D# 2(  A$! Q$!_\0
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JX;"SMVW0VT,;>JH :LT44VV]P"BBBD 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
